PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dizon, DS				Dizon, Don S.			PARP inhibitors for targeted treatment in ovarian cancer	LANCET			English	Editorial Material							MAINTENANCE THERAPY		[Dizon, Don S.] Brown Univ, Alpert Med Sch, Womens Canc, Lifespan Canc Inst,Med Oncol,Rhode Isl Hosp,Med, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Dizon, DS (corresponding author), Brown Univ, Alpert Med Sch, Womens Canc, Lifespan Canc Inst,Med Oncol,Rhode Isl Hosp,Med, Providence, RI 02903 USA.	don.dizon@Lifespan.org	Dizon, Don Steven/I-3634-2019	Dizon, Don Steven/0000-0001-6541-9580	Pfizer; FujiBio; Teva Pharmaceuticals	Pfizer(Pfizer); FujiBio; Teva Pharmaceuticals(Teva Pharmaceutical Industries)	I have received consulting fees from Pfizer in the therapeutic area of biosimilars and FujiBio in the area of novel chemotherapy agents, and conference speakers' fees from Teva Pharmaceuticals.	Coleman RL, 2017, LANCET; FDA, 2016, FDA GRANTS ACC APPR; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Pujade-Lauraine E, 2017, SOC GYN ONC ANN M WO; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; US Food and Drug Administration, FDA APPR LYNP TREAT; US Food and Drug Administration, NIR ZEJULA PROD INF; US Food and Drug Administration, FDA APPR OL TABL MAI	10	21	23	2	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	2017	390	10106					1929	1930		10.1016/S0140-6736(17)32418-2	http://dx.doi.org/10.1016/S0140-6736(17)32418-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK9HW	28916370				2023-01-03	WOS:000413823200013
J	Sulmasy, LS; Mueller, PS				Sulmasy, Lois Snyder; Mueller, Paul S.		Amer Coll Phys	Ethics and the Legalization of Physician-Assisted Suicide: An American College of Physicians Position Paper	ANNALS OF INTERNAL MEDICINE			English	Review							PALLIATIVE CARE; MENTAL-DISORDERS; TERMINALLY-ILL; UNITED-STATES; OREGON DEATH; AFFECT RATES; DIGNITY ACT; OF-LIFE; EUTHANASIA; END	Calls to legalize physician-assisted suicide have increased and public interest in the subject has grown in recent years despite ethical prohibitions. Many people have concerns about how they will die and the emphasis by medicine and society on intervention and cure has sometimes come at the expense of good end-of-life care. Some have advocated strongly, on the basis of autonomy, that physician-assisted suicide should be a legal option at the end of life. As a proponent of patient-centered care, the American College of Physicians (ACP) is attentive to all voices, including those who speak of the desire to control when and how life will end. However, the ACP believes that the ethical arguments against legalizing physician-assisted suicide remain the most compelling. On the basis of substantive ethics, clinical practice, policy, and other concerns articulated in this position paper, the ACP does not support legalization of physician-physician relationship, affects trust in the relationship and in the profession, and fundamentally alters the medical profession's role in society. Furthermore, the principles at stake in this debate also underlie medicine's responsibilities regarding other issues and the physician's duties to provide care based on clinical judgment, evidence, and ethics. Society's focus at the end of life should be on efforts to address suffering and the needs of patients and families, including improving access to effective hospice and palliative care. The ACP remains committed to improving care for patients throughout and at the end of life.	[Sulmasy, Lois Snyder; Mueller, Paul S.; Amer Coll Phys] Amer Coll Physicians, Philadelphia, PA USA; [Sulmasy, Lois Snyder] Amer Coll Physicians, Ctr Eth & Professionalism, 190 N Independence Mall West, Philadelphia, PA 19106 USA; [Mueller, Paul S.] Mayo Clin, Gonda Bldg 17,200 First St Southwest, Rochester, MN 55905 USA	American College of Physicians; American College of Physicians; Mayo Clinic	Sulmasy, LS (corresponding author), Amer Coll Physicians, Ctr Eth & Professionalism, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	lsnyder@acponline.org						Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Ankuda CK, 2017, ANN FAM MED, V15, P63, DOI 10.1370/afm.2002; Appelbaum PS, 2016, JAMA PSYCHIAT, V73, P325, DOI 10.1001/jamapsychiatry.2015.2890; British Medical Association, 2014, END LIF CAR PHYS ASS; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Callahan D., 1997, PHYSICIAN ASSISTED S; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Cook D, 2015, ANN INTERN MED, V163, P271, DOI 10.7326/M15-0502; Curry TA, 2016, JAMA-J AM MED ASSOC, V315, P261, DOI 10.1001/jama.2015.13326; De Lima L, 2017, J PALLIAT MED, V20, P8, DOI 10.1089/jpm.2016.0290; Death with Dignity, 2022, YOUR STAT; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Disability Rights & Defense Fund, 2017, NATL DISABILITY ORG; Drum CE, 2010, DISABIL HEALTH J, V3, P3, DOI 10.1016/j.dhjo.2009.10.001; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Field MJ, 1997, APPROACHING DEATH IM; Fohr S A, 1998, J Palliat Med, V1, P315, DOI 10.1089/jpm.1998.1.315; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gerst-Emerson K, 2015, AM J PUBLIC HEALTH, V105, P1013, DOI 10.2105/AJPH.2014.302427; GERT B, 1994, HASTINGS CENT REP, V24, P13, DOI 10.2307/3562837; Golden M, 2010, DISABIL HEALTH J, V3, P16, DOI 10.1016/j.dhjo.2009.08.006; Groff AC, 2016, NEW ENGL J MED, V375, P1610, DOI 10.1056/NEJMp1607206; Hippocrates, 1923, HIPPOCRATES 1, P289; Hippocrates, 1923, HIPPOCRATES 2, P193; INGELFINGER FJ, 1980, NEW ENGL J MED, V303, P1507, DOI 10.1056/NEJM198012253032604; Johnson KS, 2013, J PALLIAT MED, V16, P1329, DOI 10.1089/jpm.2013.9468; Jones DA, 2015, SOUTH MED J, V108, P599, DOI 10.14423/SMJ.0000000000000349; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; Kearney MK, 2009, JAMA-J AM MED ASSOC, V301, P1155, DOI 10.1001/jama.2009.352; Kellehear, 2014, INNER LIFE DYING PER; Kelley AS, 2015, NEW ENGL J MED, V373, P747, DOI 10.1056/NEJMra1404684; Kheriaty A, 2015, SOUTH MED J, V108, P605, DOI 10.14423/SMJ.0000000000000346; Kim SYH, 2016, JAMA PSYCHIAT, V73, P362, DOI 10.1001/jamapsychiatry.2015.2887; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lampert R, 2010, HEART RHYTHM, V7, P1008, DOI 10.1016/j.hrthm.2010.04.033; Lerner BH, 2015, JAMA INTERN MED, V175, P1640, DOI 10.1001/jamainternmed.2015.4086; Loggers ET, 2013, NEW ENGL J MED, V368, P1417, DOI 10.1056/NEJMsa1213398; Mattlin B., 2012, NY TIMES, pA31; McKenzie KC, 2016, NEW ENGL J MED, V374, P2107, DOI 10.1056/NEJMp1601820; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; Monforte-Royo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037117; Mueller PS, 2010, MAYO CLIN PROC, V85, P791, DOI 10.4065/mcp.2010.0113; National Cancer Institute, 2006, ED PALL END LIF CAR; Norden Carl, 2016, Ann Intern Med, V165, P525, DOI 10.7326/M16-1243; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Panke JT, 2016, J PAIN SYMPTOM MANAG, V52, P313, DOI 10.1016/j.jpainsymman.2016.02.010; Payne R, 2016, J PALLIAT MED, V19, P131, DOI 10.1089/jpm.2015.0475; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; PELLEGRINO ED, 1995, ANN INTERN MED, V122, P377, DOI 10.7326/0003-4819-122-5-199503010-00010; Pereira J, 2011, CURR ONCOL, V18, pE38; Phillips RS, 2000, J AM GERIATR SOC, V48, pS1, DOI 10.1111/j.1532-5415.2000.tb03118.x; Prokopetz JJZ, 2012, NEW ENGL J MED, V367, P97, DOI 10.1056/NEJMp1205283; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2016, JAMA-J AM MED ASSOC, V315, P245, DOI 10.1001/jama.2015.16210; Robinson S, 2017, J PAIN SYMPTOM MANAG, V53, P243, DOI 10.1016/j.jpainsymman.2016.08.013; Rosenfeld B, 2014, SOC SCI MED, V111, P35, DOI 10.1016/j.socscimed.2014.03.027; Rosenthal DI, 2016, NEW ENGL J MED, V375, P1813, DOI 10.1056/NEJMp1609055; Salem T, 1999, HASTINGS CENT REP, V29, P30, DOI 10.2307/3528193; Scofield Giles R, 1995, Seattle Univ Law Rev, V18, P473; Snijdewind MC, 2015, JAMA INTERN MED, V175, P1633, DOI 10.1001/jamainternmed.2015.3978; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Snyder L, 2012, ANN INTERN MED, V156, DOI 10.7326/0003-4819-156-1-201201031-00001; Srivastava R, 2016, NEW ENGL J MED, V374, P2309, DOI 10.1056/NEJMp1603934; Stevens KR, 2006, ISSUES LAW MED, V21, P187; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; Sulmasy DP, 1998, J LAW MED ETHICS, V26, P55, DOI 10.1111/j.1748-720X.1998.tb01906.x; Unger KM, 2016, J PAIN SYMPTOM MANAG, V52, P305, DOI 10.1016/j.jpainsymman.2016.03.004; Verghese A, 2016, HEALTH AFFAIR, V35, P1924, DOI 10.1377/HLTHAFF.2016.0837; Wilson KG, 2016, BMJ SUPPORT PALLIAT, V6, P170, DOI 10.1136/bmjspcare-2013-000604; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Yang YT, 2016, JAMA-J AM MED ASSOC, V315, P247, DOI 10.1001/jama.2015.16194; Yuill K., 2015, ASSISTED SUICIDE LIB	75	50	50	1	98	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					576	+		10.7326/M17-0938	http://dx.doi.org/10.7326/M17-0938			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ9JM	28975242				2023-01-03	WOS:000413092700018
J	Yarnell, CJ; Fu, LD; Manuel, D; Tanuseputro, P; Stukel, T; Pinto, R; Scales, DC; Laupacis, A; Fowler, RA				Yarnell, Christopher J.; Fu, Longdi; Manuel, Doug; Tanuseputro, Peter; Stukel, Therese; Pinto, Ruxandra; Scales, Damon C.; Laupacis, Andreas; Fowler, Robert A.			Association Between Immigrant Status and End-of-Life Care in Ontario, Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PALLIATIVE CARE; RACIAL DISPARITIES; ETHNIC-DIFFERENCES; OLDER-ADULTS; DEATH; PERSPECTIVES; PREFERENCES; PRIORITIES; OUTCOMES; HOSPICE	IMPORTANCE People who immigrate face unique health literacy, communication, and system navigation challenges, and theymay have diverse preferences that influence end-of-life care. OBJECTIVE To examine end-of-life care provided to immigrants to Canada in the last 6 months of their life. DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study (April 1, 2004, to March 31, 2015) included 967 013 decedents in Ontario, Canada, using validated linkages between health and immigration databases to identify immigrant (since 1985) and long-standing resident cohorts. EXPOSURES All decedents who immigrated to Canada between 1985 and 2015 were classified as recent immigrants, with subgroup analyses assessing the association of time since immigration, and region of birth, with end-of-life care. MAIN OUTCOMES AND MEASURES Location of death and intensity of care received in the last 6 months of life. Analysis included modified Poisson regression with generalized estimating equations, adjusting for age, sex, socioeconomic position, causes of death, urban and rural residence, and preexisting comorbidities. RESULTS Among 967 013 decedents of whom 47 514 (5%) immigrated since 1985, sex, socioeconomic status, urban (vs rural) residence, and causes of death were similar, while long-standing residents were older than immigrant decedents (median [interquartile range] age, 75 [58-84] vs 80 [68-87] years). Recent immigrant decedents were overall more likely to die in intensive care (15.6% vs 10.0%; difference, 5.6%; 95% CI, 5.2%-5.9%) after adjusting for differences in age, sex, income, geography, and cause of death (relative risk, 1.30;95% CI, 1.27-1.32). In their last 6 months of life, recent immigrant decedents experienced more intensive care admissions (24.9% vs 19.2%; difference, 5.7%; 95% CI, 5.3%-6.1%), hospital admissions (72.1% vs 68.2%; difference, 3.9%; 95% CI, 3.5%-4.3%), mechanical ventilation (21.5% vs 13.6%; difference, 7.9%; 95% CI, 7.5%-8.3%), dialysis (5.5% vs 3.4%; difference, 2.1%; 95% CI, 1.9%-2.3%), percutaneous feeding tube placement (5.5% vs 3.0%; difference, 2.5%; 95% CI, 2.3%-2.8%), and tracheostomy (2.3% vs 1.1%; difference, 1.2%; 95% CI, 1.1%-1.4%). Relative risk of dying in intensive care for recent immigrants compared with long-standing residents varied according to recent immigrant region of birth from 0.84 (95% CI, 0.74-0.95) among those born in Northern and Western Europe to 1.96 (95% CI, 1.89-2.05) among those born in South Asia. CONCLUSIONS AND RELEVANCE Among decedents in Ontario, Canada, recent immigrants were significantly more likely to receive aggressive care and to die in an intensive care unit compared with other residents. Further research is needed to understand the mechanisms behind this association.	[Yarnell, Christopher J.; Scales, Damon C.; Laupacis, Andreas; Fowler, Robert A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Fu, Longdi; Manuel, Doug; Stukel, Therese; Scales, Damon C.; Laupacis, Andreas; Fowler, Robert A.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Manuel, Doug] Univ Ottawa, Ottawa, ON, Canada; [Tanuseputro, Peter] Bruyere Res Inst, Ottawa, ON, Canada; [Stukel, Therese; Fowler, Robert A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Pinto, Ruxandra; Scales, Damon C.; Laupacis, Andreas] Sunnybrook Hlth Sci Ctr, Programme Trauma Emergency & Crit Care, Toronto, ON, Canada; [Scales, Damon C.; Fowler, Robert A.] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada; [Scales, Damon C.; Fowler, Robert A.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Laupacis, Andreas] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Ottawa; University of Ottawa; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Fowler, RA (corresponding author), Univ Toronto, Sunnybrook Hosp, 2075 Bayview Ave,D478, Toronto, ON M4N 3M5, Canada.	rob.fowler@sunnybrook.ca	; Manuel, Doug/D-7100-2014	Yarnell, Christopher/0000-0001-5657-9398; Tanuseputro, Peter/0000-0002-4409-0795; Stukel, Therese/0000-0002-2951-1360; Manuel, Doug/0000-0003-0912-0845	Canadian Institutes of Health Research; Heart and Stroke Foundation of Ontario; Canadian Frailty Network Center of Excellence; University of Toronto Integrating Challenge Fund; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-term Care	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Canadian Frailty Network Center of Excellence; University of Toronto Integrating Challenge Fund; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-term Care(Ministry of Health and Long-Term Care, Ontario)	The study was funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Ontario, the Canadian Frailty Network Center of Excellence, and the University of Toronto Integrating Challenge Fund. This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-term Care.	Adames HY, 2014, PALLIAT SUPPORT CARE, V12, P149, DOI 10.1017/S147895151300028X; Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Baicker K, 2005, PERSPECT BIOL MED, V48, pS42; Bosma H, 2010, PALLIATIVE MED, V24, P510, DOI 10.1177/0269216309351380; Central Intelligence Agency, WORLD FACTB COUNTR C; Chiu M, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0375-3; Cruz-Oliver DM, 2014, AM J HOSP PALLIAT ME, V31, P87, DOI 10.1177/1049909113480841; Dobbs D, 2015, J AM GERIATR SOC, V63, P565, DOI 10.1111/jgs.13309; Ebrahim S, 2011, J PALLIAT CARE, V27, P170, DOI 10.1177/082585971102700214; Frost DW, 2011, CRIT CARE MED, V39, P1174, DOI 10.1097/CCM.0b013e31820eacf2; Fuller-Thomson E, 2011, CAN J PUBLIC HEALTH, V102, P273, DOI 10.1007/BF03404048; Garrido MM, 2014, CANCER-AM CANCER SOC, V120, P3981, DOI 10.1002/cncr.28970; Glazier RH, 2012, COMPARISON PRIMARY C, P41; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Heyland DK, 2010, CAN MED ASSOC J, V182, pE747, DOI 10.1503/cmaj.100131; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Higginson IJ, 2014, PALLIATIVE MED, V28, P101, DOI 10.1177/0269216313488989; Jonnalagadda S, 2012, CHEST, V142, P1251, DOI 10.1378/chest.12-0330; Juurlink D, 2006, CANADIAN I HLTH INFO; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Lackan NA, 2009, MED CARE, V47, P138, DOI 10.1097/MLR.0b013e3181844dba; Mack JW, 2010, ARCH INTERN MED, V170, P1533, DOI 10.1001/archinternmed.2010.322; Moss KO, 2014, OMEGA-J DEATH DYING, V69, P271, DOI 10.2190/OM.69.3.c; Phua J, 2015, JAMA INTERN MED, V175, P363, DOI 10.1001/jamainternmed.2014.7386; Sanmartin Claudia, 2006, Healthc Policy, V1, P103; Sharma RK, 2012, J GEN INTERN MED, V27, P311, DOI 10.1007/s11606-011-1890-7; Smith AK, 2009, JAMA-J AM MED ASSOC, V301, P1047, DOI 10.1001/jama.2009.308; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Statistics Canada, 2017, POP DWELL COUNT HIGH; Tu JV, CIRCULATION; Unroe KT, 2012, AM HEART J, V163, P987, DOI 10.1016/j.ahj.2012.03.006; Volandes AE, 2008, J PALLIAT MED, V11, P754, DOI 10.1089/jpm.2007.0224; White DB, 2016, JAMA-J AM MED ASSOC, V315, P2086, DOI 10.1001/jama.2016.5351; who, WHO DEF PALL CAR; Wright AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058663; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183	36	59	59	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2017	318	15					1479	1488		10.1001/jama.2017.14418	http://dx.doi.org/10.1001/jama.2017.14418			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK0RM	28973088	Green Published, Bronze			2023-01-03	WOS:000413187300020
J	Futier, E; Lefrant, JY; Guinot, PG; Godet, T; Lorne, E; Cuvillon, P; Bertran, S; Leone, M; Pastene, B; Piriou, V; Molliex, S; Albanese, J; Julia, JM; Tavernier, B; Imhoff, E; Bazin, JE; Constantin, JM; Pereira, B; Jaber, S				Futier, Emmanuel; Lefrant, Jean-Yves; Guinot, Pierre-Gregoire; Godet, Thomas; Lorne, Emmanuel; Cuvillon, Philippe; Bertran, Sebastien; Leone, Marc; Pastene, Bruno; Piriou, Vincent; Molliex, Serge; Albanese, Jacques; Julia, Jean-Michel; Tavernier, Benoit; Imhoff, Etienne; Bazin, Jean-Etienne; Constantin, Jean-Michel; Pereira, Bruno; Jaber, Samir		INPRESS Study Grp	Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE KIDNEY INJURY; INFLAMMATORY RESPONSE SYNDROME; INTERNATIONAL CONSENSUS CONFERENCE; GOAL-DIRECTED THERAPY; ACUTE-RENAL-FAILURE; NONCARDIAC SURGERY; INTRAOPERATIVE HYPOTENSION; COGNITIVE DYSFUNCTION; MYOCARDIAL INJURY; GENERAL-SURGERY	IMPORTANCE Perioperative hypotension is associated with an increase in postoperative morbidity and mortality, but the appropriate management strategy remains uncertain. OBJECTIVE To evaluate whether an individualized blood pressure management strategy tailored to individual patient physiology could reduce postoperative organ dysfunction. DESIGN, SETTING, AND PARTICIPANTS The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) study was a multicenter, randomized, parallel-group clinical trial conducted in 9 French university and nonuniversity hospitals. Adult patients (n = 298) at increased risk of postoperative complications with a preoperative acute kidney injury risk index of class III or higher (indicating moderate to high risk of postoperative kidney injury) undergoing major surgery lasting 2 hours or longer under general anesthesia were enrolled from December 4, 2012, through August 28, 2016 (last follow-up, September 28, 2016). INTERVENTIONS Individualized management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the reference value (ie, patient's resting SBP) or standard management strategy of treating SBP less than 80mmHg or lower than 40% from the reference value during and for 4 hours following surgery. MAIN OUTCOMES AND MEASURES The primary outcomewas a composite of systemic inflammatory response syndrome and dysfunction of at least 1 organ system of the renal, respiratory, cardiovascular, coagulation, and neurologic systems by day 7 after surgery. Secondary outcomes included the individual components of the primary outcome, durations of ICU and hospital stay, adverse events, and all-cause mortality at 30 days after surgery. RESULTS Among 298 patients who were randomized, 292 patients completed the trial (mean [SD] age, 70 [7] years; 44 [15.1%] women) and were included in the modified intention-to-treat analysis. The primary outcome event occurred in 56 of 147 patients (38.1%) assigned to the individualized treatment strategy vs 75 of 145 patients (51.7%) assigned to the standard treatment strategy (relative risk, 0.73; 95% CI, 0.56 to 0.94; P =.02; absolute risk difference, -14%, 95% CI, -25% to -2%). Sixty-eight patients (46.3%) in the individualized treatment group and 92 (63.4%) in the standard treatment group had postoperative organ dysfunction by day 30 (adjusted hazard ratio, 0.66; 95% CI, 0.52 to 0.84; P =.001). There were no significant between-group differences in severe adverse events or 30-day mortality. CONCLUSIONS AND RELEVANCE Among patients predominantly undergoing abdominal surgery who were at increased postoperative risk, management targeting an individualized systolic blood pressure, compared with standard management, reduced the risk of postoperative organ dysfunction.	[Futier, Emmanuel; Godet, Thomas; Bazin, Jean-Etienne; Constantin, Jean-Michel] Univ Clermont Auvergne, Ctr Natl Rech Sci, INSERM, CHU Clermont Ferrand, Clermont Ferrand, France; [Lefrant, Jean-Yves; Cuvillon, Philippe; Bertran, Sebastien] CHU Nimes, Sect Anesthesie, Nimes, France; [Lefrant, Jean-Yves; Cuvillon, Philippe; Bertran, Sebastien] CHU Nimes, Dept Anesthesie & Reanimat, Nimes, France; [Guinot, Pierre-Gregoire; Lorne, Emmanuel] CHU Amiens, Dept Anesthesie & Reanimat, Amiens, France; [Leone, Marc; Pastene, Bruno] Univ Aix Marseille, Hop Nord, AP HM, Serv Anesthesie & Reanimat, Marseille, France; [Piriou, Vincent; Imhoff, Etienne] Univ Claude Bernard Lyon 1, Serv Anesthesie Reanimat, Hosp Civils Lyon, Ctr Hosp Lyon Sud, Lyon, France; [Molliex, Serge] CHU St Etienne, Dept Anesthesie Reanimat, St Etienne, France; [Albanese, Jacques] Hop Conception, AP HM, Serv Anesthesie & Reanimat, Marseille, France; [Julia, Jean-Michel] Clin Parc, Anesthesie & Reanimat, Castelnau Le Lez, France; [Tavernier, Benoit] CHU Lille, Pole Anesthesie Reanimat, Lille, France; [Pereira, Bruno] CHU Clermont Ferrand, Biostat Unit, Direct Rech Clin, Clermont Ferrand, France; [Jaber, Samir] Ctr Hosp Univ Montpellier, Dept Anesthesie & Reanimat B, Hop St Eloi, Montpellier, France; [Jaber, Samir] INSERM, U 1046, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CHU Clermont Ferrand; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU de St Etienne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite de Lille - ISITE; CHU Lille; CHU Clermont Ferrand; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Futier, E (corresponding author), Hop Estaing, Dept Med Perioperatoire, Anesthesie Reanimat, 1 Pl Lucie Aubrac, F-63003 Clermont Ferrand, France.	efutier@chu-clermontferrand.fr	Albanese, Jacques/AAS-7466-2021; Guinot, Pierre/AAO-5722-2021; Leone, Marc/P-4835-2016; Piriou, Vincent/AFV-4922-2022	Guinot, Pierre/0000-0002-7019-9727; Leone, Marc/0000-0002-3097-758X; piriou, vincent/0000-0001-6900-1480; Lorne, Emmanuel/0000-0001-6409-5449	University Hospital of Clermont-Ferrand; Aguettant	University Hospital of Clermont-Ferrand; Aguettant	This study was funded by the University Hospital of Clermont-Ferrand and was supported in part by a grant from Aguettant.	Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bihorac A, 2009, ANN SURG, V249, P851, DOI 10.1097/SLA.0b013e3181a40a0b; Bijker JB, 2007, ANESTHESIOLOGY, V107, P213, DOI 10.1097/01.anes.0000270724.40897.8e; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Dalfino L, 2011, CRIT CARE, V15, DOI 10.1186/cc10284; Devereaux PJ, 2014, NEW ENGL J MED, V370, P1504, DOI 10.1056/NEJMoa1401106; Fleisher LA, 2014, CIRCULATION, V130, pE278, DOI 10.1161/CIR.0000000000000106; Glick D, 2015, MILLERS ANESTHESIA, P346; Haga Y, 1997, CRIT CARE MED, V25, P1994, DOI 10.1097/00003246-199712000-00016; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Hiltebrand LB, 2011, ANESTHESIOLOGY, V114, P557, DOI 10.1097/ALN.0b013e31820bfc81; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Jaber S, 2016, JAMA-J AM MED ASSOC, V315, P1345, DOI 10.1001/jama.2016.2706; Kheterpal S, 2009, ANESTHESIOLOGY, V110, P505, DOI 10.1097/ALN.0b013e3181979440; Levy Mitchell M, 2003, Intensive Care Med, V29, P530; Mets B, 2016, ANESTH ANALG, V122, P1707, DOI 10.1213/ANE.0000000000001239; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Monk TG, 2015, ANESTHESIOLOGY, V123, P307, DOI 10.1097/ALN.0000000000000756; Moore LJ, 2010, ARCH SURG-CHICAGO, V145, P695, DOI 10.1001/archsurg.2010.107; O'Connor ME, 2016, INTENS CARE MED, V42, P521, DOI 10.1007/s00134-015-4157-7; Palmer BF, 2002, NEW ENGL J MED, V347, P1256, DOI 10.1056/NEJMra020676; Pearse R, 2005, CRIT CARE, V9, pR687, DOI 10.1186/cc3887; PITTET D, 1995, INTENS CARE MED, V21, P302, DOI 10.1007/BF01705408; Salmasi V, 2017, ANESTHESIOLOGY, V126, P47, DOI 10.1097/ALN.0000000000001432; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; Sun LY, 2015, ANESTHESIOLOGY, V123, P515, DOI 10.1097/ALN.0000000000000765; Talmor M, 1999, ARCH SURG-CHICAGO, V134, P81, DOI 10.1001/archsurg.134.1.81; Thiele RH, 2011, ANESTH ANALG, V113, P284, DOI 10.1213/ANE.0b013e3182124c0e; Vallet B, 2013, Ann Fr Anesth Reanim, V32, P454, DOI 10.1016/j.annfar.2013.04.013; van Waes JAR, 2016, ANESTHESIOLOGY, V124, P35, DOI 10.1097/ALN.0000000000000922; Vincent JL, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0932-7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wakeam E, 2015, JAMA SURG, V150, P65, DOI 10.1001/jamasurg.2014.1795; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	39	351	362	4	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2017	318	14					1346	1357		10.1001/jama.2017.14172	http://dx.doi.org/10.1001/jama.2017.14172			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ6BP	28973220	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000412838900018
J	Jasinska-Konior, K; Pochylczuk, K; Czajka, E; Michalik, M; Romanowska-Dixon, B; Swakon, J; Urbanska, K; Elas, M				Jasinska-Konior, Katarzyna; Pochylczuk, Katarzyna; Czajka, Elibieta; Michalik, Marta; Romanowska-Dixon, Boiena; Swakon, Jan; Urbanska, Krystyna; Elas, Martyna			Proton beam irradiation inhibits the migration of melanoma cells	PLOS ONE			English	Article							RELATIVE BIOLOGICAL EFFECTIVENESS; UVEAL MELANOMA; SURVIVAL; RADIOTHERAPY; PROGRESSION; EXPRESSION; FIBROBLASTS; APOPTOSIS; SYSTEM; DAMAGE	Purpose In recent years experimental data have indicated that low-energy proton beam radiation might induce a difference in cellular migration in comparison to photons. We therefore set out to compare the effect of proton beam irradiation and X-rays on the survival and long-term migratory properties of two cell lines: uveal melanoma Mel270 and skin melanoma BLM. Materials and methods Cells treated with either proton beam or X-rays were analyzed for their survival using clonogenic assay and MTT test. Long-term migratory properties were assessed with time-lapse monitoring of individual cell movements, wound test and transpore migration, while the expression of the related proteins was measured with western blot. Results Exposure to proton beam and X-rays led to similar survival but the quality of the cell colonies was markedly different. More paraclones with a low proliferative activity and fewer highly-proliferative holoclones were found after proton beam irradiation in comparison to X-rays. At 20 or 40 days post-irradiation, migratory capacity was decreased more by proton beam than by X-rays. The beta-1-integrin level was decreased in Mel270 cells after both types of radiation, while vimentin, a marker of EMT, was increased in BLM cells only. Conclusions We conclude that proton beam irradiation induced long-term inhibition of cellular motility, as well as changes in the level of beta-1 integrin and vimentin. If confirmed, the change in the quality, but not in the number of colonies after proton beam irradiation might favor tumor growth inhibition after fractionated proton therapy.	[Jasinska-Konior, Katarzyna; Pochylczuk, Katarzyna; Czajka, Elibieta; Urbanska, Krystyna; Elas, Martyna] Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland; [Michalik, Marta] Fac Biochem Biophys & Biotechnol, Dept Cell Biol, Krakow, Poland; [Romanowska-Dixon, Boiena] Jagiellonian Univ, Med Coll, Dept Ophthalmol & Ophthalm Oncol, Krakow, Poland; [Swakon, Jan] PAS, Inst Nucl Phys, Krakow, Poland	Jagiellonian University; Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University; Polish Academy of Sciences; Institute of Nuclear Physics - Polish Academy of Sciences	Elas, M (corresponding author), Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland.	martyna.elas@uj.edu.pl	Swakoń, Jan/M-5808-2018; Elas, Martyna/E-3584-2017	Swakoń, Jan/0000-0001-9262-7326; Elas, Martyna/0000-0001-6296-2844; Jasinska-Konior, Katarzyna/0000-0003-3795-1590; Urbanska, Krystyna/0000-0001-9643-4740	National Science Centre, Cracow, Poland [2012/07/B/NZ4/01657]; Ministry of Science and Higher Education	National Science Centre, Cracow, Poland(National Science Centre, Poland); Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	This project was supported by grant 2012/07/B/NZ4/01657 from National Science Centre, Cracow, Poland (https://www.ncn.gov.pl/?languag=en). Faculty of Biochemistry, Biophysics and Biotechnology of Jagiellonian University is a partner of the Leading National Research Center (KNOW) supported by the Ministry of Science and Higher Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agemy L, 2008, PROSTATE, V68, P530, DOI 10.1002/pros.20702; Antoccia A, 2009, J RADIAT RES, V50, P457, DOI 10.1269/jrr.09008; Aypar U, 2011, MUTAT RES-FUND MOL M, V707, P24, DOI 10.1016/j.mrfmmm.2010.12.003; Beaver CM, 2014, CLONOGENICITY HOLOCL, V9; Boberek M, 2014, ROM REP PHYS, V66, P5; Burotto M, 2014, MAPK PATHWAY ACROSS, DOI [10.1002/cncr.28864, DOI 10.1002/CNCR.28864]; Chang PY, 2007, RADIAT ENVIRON BIOPH, V46, P187, DOI 10.1007/s00411-006-0087-7; Chaudhary P, 2016, INT J RAD ONCOL BIOL, V95; Chaudhary P, 2014, INT J RADIAT ONCOL, V90, P27, DOI 10.1016/j.ijrobp.2014.05.010; Chen PW, 1997, CLIN EXP METASTAS, V15, P509, DOI 10.1023/A:1018479011340; Damato B, 2010, BRIT J CANCER, V103, P285, DOI 10.1038/sj.bjc.6605765; Dasu A, 2013, MED PHYS, V40, DOI 10.1118/1.4769417; Dendale R, 2006, INT J RADIAT ONCOL, V65, P780, DOI 10.1016/j.ijrobp.2006.01.020; Dhillon AS, 2007, MAP KINASE SIGNALLIN, P3279; Dogrusoz M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20212; Durante M, 2016, REP PROG PHYS, V79, DOI 10.1088/0034-4885/79/9/096702; Egger E, 2001, INT J RADIAT ONCOL, V51, P138, DOI 10.1016/S0360-3016(01)01560-7; Fokas E, 2009, BBA-REV CANCER, V1796, P216, DOI 10.1016/j.bbcan.2009.07.005; Frese MC, 2011, INT J RAD ONCOL BIOL; Friedrich T, 2012, INT J RADIAT BIOL, V88, P103, DOI 10.3109/09553002.2011.611213; Galanty A, 2008, CELL MOL BIOL LETT, V13, P585, DOI 10.2478/s11658-008-0013-x; Gerelchuluun A, 2011, INT J RADIAT BIOL, V87, P57, DOI 10.3109/09553002.2010.518201; Girdhani S, 2013, RADIAT RES, V179, P257, DOI 10.1667/RR2839.1; Green LM, 2001, RADIAT RES, V155, P32, DOI 10.1667/0033-7587(2001)155[0032:ROTFCT]2.0.CO;2; Grosse N, 2014, INT J RADIAT ONCOL, V88, P175, DOI 10.1016/j.ijrobp.2013.09.041; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; IAEA, 2000, IAEA TECHN REP SER, V398, P1; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Kawamoto A, 2012, ONCOL REP, V27, P51, DOI 10.3892/or.2011.1485; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Komiya Yuko, 2008, Organogenesis, V4, P68; Kruger N J, 1994, Methods Mol Biol, V32, P9; Lane AM, 2015, JAMA OPHTHALMOL, V133, P792, DOI 10.1001/jamaophthalmol.2015.0887; Li FZ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00031; Lindberg U, 2008, SEMIN CANCER BIOL, V18, P2, DOI 10.1016/j.semcancer.2007.10.002; Madeja Z, 2001, BIOCHEM CELL BIOL, V79, P425, DOI 10.1139/bcb-79-4-425; McNamara AL, 2015, PHYS MED BIOL, V60, P8399, DOI 10.1088/0031-9155/60/21/8399; Moncharmont C, 2012, CANCER LETT, V322, P139, DOI 10.1016/j.canlet.2012.03.024; Ogata T, 2005, CANCER RES, V65, P113; Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2; Paganetti H, 2013, SEMIN RADIAT ONCOL, V23, P77, DOI 10.1016/j.semradonc.2012.11.002; Petrovic I, 2006, INT J RADIAT BIOL, V82, P251, DOI 10.1080/09553000600669859; Petrovic I, 2010, INT J RADIAT BIOL, V86, P742, DOI 10.3109/09553002.2010.481322; Rietschel P, 2005, J CLIN ONCOL, V23, P8076, DOI 10.1200/JCO.2005.02.6534; Sage E., 2016, FREE RADIC BIOL MED; Shay G, 2015, MATRIX BIOL, V44-46, P200, DOI 10.1016/j.matbio.2015.01.019; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Todorovic D, 2008, J MICROSC-OXFORD, V232, P517, DOI 10.1111/j.1365-2818.2008.02151.x; Tommasino F, 2015, CANCERS, V7, P353, DOI 10.3390/cancers7010353; Underwood T, 2016, INT J RADIAT ONCOL, V95, P56, DOI 10.1016/j.ijrobp.2015.10.006; VANMUIJEN GNP, 1989, ANTICANCER RES, V9, P879; Wedenberg M, 2013, MODEL RELATIVE BIOL; Zheng Q, 2015, HUM EXP TOXICOL, P4	53	11	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2017	12	10							e0186002	10.1371/journal.pone.0186002	http://dx.doi.org/10.1371/journal.pone.0186002			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ3JE	29016654	Green Published, Green Submitted, gold			2023-01-03	WOS:000412627400047
J	Linder, JA; Meeker, D; Fox, CR; Friedberg, MW; Persell, SD; Goldstein, NJ; Doctor, JN				Linder, Jeffrey A.; Meeker, Daniella; Fox, Craig R.; Friedberg, Mark W.; Persell, Stephen D.; Goldstein, Noah J.; Doctor, Jason N.			Effects of Behavioral Interventions on Inappropriate Antibiotic Prescribing in Primary Care 12 Months After Stopping Interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Linder, Jeffrey A.; Persell, Stephen D.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Meeker, Daniella; Doctor, Jason N.] Univ Southern Calif, Los Angeles, CA 90089 USA; [Fox, Craig R.; Goldstein, Noah J.] Univ Calif Los Angeles, Los Angeles, CA USA; [Friedberg, Mark W.] RAND Corp, Boston, MA USA	Northwestern University; Feinberg School of Medicine; University of Southern California; University of California System; University of California Los Angeles; RAND Corporation	Doctor, JN (corresponding author), Univ Southern Calif, Sch Pharm, Leonard D Schaeffer Ctr Hlth Policy & Econ, 635 Downey Way,Verna & Peter Dauterive Hall, Los Angeles, CA 90089 USA.	jdoctor@usc.edu	Meeker, Daniella/AAV-5953-2020; Linder, Jeffrey/AAF-3424-2021; Friedberg, Mark William/Y-2607-2019	Meeker, Daniella/0000-0002-1034-7628; Linder, Jeffrey/0000-0003-2217-184X; Friedberg, Mark William/0000-0002-7907-8358	American Recovery and Reinvestment Act of 2009 from the National Institutes of Health [RC4 AG039115, R01 HS19913-01]; National Institute on Aging and Agency for Healthcare Research and Quality; Patient-Centered Outcomes Research Institute [CDRN-1306-04819]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS019913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [RC4AG039115] Funding Source: NIH RePORTER	American Recovery and Reinvestment Act of 2009 from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging and Agency for Healthcare Research and Quality; Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants RC4 AG039115 (Dr Doctor) and R01 HS19913-01 (Dr Ohno-Machado) of the American Recovery and Reinvestment Act of 2009 from the National Institutes of Health and National Institute on Aging and Agency for Healthcare Research and Quality. Data for the project was collected by the University of Southern California's Medical Information Network for Experimental Research, which participates in the Patient-Centered Scalable National Network for Effectiveness Research supported by contract CDRN-1306-04819 (Dr Ohno-Machado) from the Patient-Centered Outcomes Research Institute.	Allcott H, 2014, AM ECON REV, V104, P3003, DOI 10.1257/aer.104.10.3003; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Gerber JS, 2014, JAMA-J AM MED ASSOC, V312, P2569, DOI 10.1001/jama.2014.14042; Meeker D, 2016, JAMA-J AM MED ASSOC, V315, P562, DOI 10.1001/jama.2016.0275; Persell SD, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-290	5	77	77	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2017	318	14					1391	1392		10.1001/jama.2017.11152	http://dx.doi.org/10.1001/jama.2017.11152			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ6BP	29049577	Green Published			2023-01-03	WOS:000412838900024
J	Dyer, C				Dyer, Clare			Man with advanced MND loses challenge for an assisted death	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		[Anonymous], 2017, QUEEN APPL N DOUGLAS; BMA, 2016, END OF LIF CAR PHYS; DYER C, 2014, BMJ-BRIT MED J, V348, P72702, DOI DOI 10.1136/BMJ.G4290	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 6	2017	359								j4631	10.1136/bmj.j4631	http://dx.doi.org/10.1136/bmj.j4631			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ5XH	28986394				2023-01-03	WOS:000412826400004
J	Sashourpour, M; Zahri, S; Radjabian, T; Ruf, V; Pan-Montojo, F; Morshedi, D				Sashourpour, Mandyeh; Zahri, Saber; Radjabian, Tayebeh; Ruf, Viktoria; Pan-Montojo, Francisco; Morshedi, Dina			A study on the modulation of alpha-synuclein fibrillation by Scutellaria pinnatifida extracts and its neuroprotective properties	PLOS ONE			English	Article							NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; APOPTOSIS INDUCTION; ALZHEIMERS-DISEASE; OLIGOMER FORMATION; PARKINSON-DISEASE; GROWTH-INHIBITION; ANTIOXIDANT; FLAVONOIDS; BAICALEIN	Aggregation of alpha-synuclein (alpha-SN) is a key pathogenic event in Parkinson's disease (PD) leading to dopaminergic degeneration. The identification of natural compounds inhibiting alpha-SN aggregation may have a major role in treating PD. Different Scutellaria species are known as valuable medicinal plants, primarily due to their high flavonoid levels. Scutellaria pinnatifida (S. pinnatifida) is endemic to Iran; however, the knowledge of its pharmaceutical properties is limited. Here we report that S. pinnatifida extracts have an anti-fibrillation effect on alpha-SN aggregation and neuroprotective properties on PC12 and primary dopaminergic neurons. Treatment during alpha-SN fibril formation with S. pinnatifida extracts showed that the extractions performed with dichloromethane (DCMEx) and n-butanol (BuOHEx) strongly inhibited alpha-SN fibrillation. TLC-based analysis revealed that S. pinnatifida contains a great amount of flavonoids with high antioxidant properties as shown using a radical scavenging assay. Further analysis using HPLC and Mass spectroscopy on the DCMEx revealed the presence of baicalein in this extract. We then selected the more efficient extracts based on cell viability and ROS scavenging on PC12 cells and tested their neuroprotective properties on primary dopaminergic neurons. Our results showed the extracts strongly protected against alpha-SN oligomers. Surprisingly, they also neutralized the severe toxicity of paraquat. Therefore, S. pinnatifida may be a potential valuable medicinal herb for further studies related to the treatment of PD.	[Sashourpour, Mandyeh; Zahri, Saber] Mohaghegh Ardabili Univ, Dept Biol, Fac Sci, Ardebil, Iran; [Sashourpour, Mandyeh; Morshedi, Dina] NIGEB, Dept Ind & Environm Biotechnol, Tehran, Iran; [Radjabian, Tayebeh] Shahed Univ, Fac Basic Sci, Dept Biol, Tehran, Iran; [Ruf, Viktoria] Ludwig Maximilians Univ Munchen, Ctr Neuropathol & Prion Res, Munich, Germany; [Pan-Montojo, Francisco] LMU, Univ Hosp, Dept Neurol, Munich, Germany; [Pan-Montojo, Francisco] Munich Cluster Syst Neurol SyNergy, Munich, Germany	University of Mohaghegh Ardabili; Shahed University; University of Munich; University of Munich; University of Munich	Zahri, S (corresponding author), Mohaghegh Ardabili Univ, Dept Biol, Fac Sci, Ardebil, Iran.; Morshedi, D (corresponding author), NIGEB, Dept Ind & Environm Biotechnol, Tehran, Iran.; Pan-Montojo, F (corresponding author), LMU, Univ Hosp, Dept Neurol, Munich, Germany.; Pan-Montojo, F (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.	Zahri@uma.ac.ir; francisco.pan-montoio@med.uni-muenchen.de; morsheci@nigeb.ac.ir	Zahri, Saber/AAD-3707-2022; Radjabian, Tayebeh/W-1658-2019	Radjabian, Tayebeh/0000-0001-8280-9409; Morshedi, Dina/0000-0002-0751-8772	Iranian Ministry of Science and Technology; Deutsche Forschungsgesellschaft (DFG) through Munich Excellence Cluster for Systems Neurology; Ministry of Science, Research and Technology of Iran	Iranian Ministry of Science and Technology; Deutsche Forschungsgesellschaft (DFG) through Munich Excellence Cluster for Systems Neurology(German Research Foundation (DFG)); Ministry of Science, Research and Technology of Iran	This project was funded by the Iranian Ministry of Science and Technology (Grant given to SZ) and the Deutsche Forschungsgesellschaft (DFG) through the Munich Excellence Cluster for Systems Neurology (Grant given to F.P-M). MS received a travel grant from the Ministry of Science, Research and Technology of Iran to perform an internship in Munich.; This project was funded by the Iranian Ministry of Science and Technology (Grant given to SZ) and the Deutsche Forschungsgesellschaft (DFG) through the Munich Excellence Cluster for Systems Neurology (Grant given to F.P-M). MS received a travel grant from the Ministry of Science, Research and Technology of Iran to perform an internship in Munich. The authors would like to acknowledge Mr. Farhang Aliakbari for helping in the protein expression and purification and Mr. Esmaeil Eskandary for helping to find the IUCN protection list.	Alves G, 2005, NEUROLOGY, V65, P1436, DOI 10.1212/01.wnl.0000183359.50822.f2; Bader B, 2011, BIOCHEM BIOPH RES CO, V411, P190, DOI 10.1016/j.bbrc.2011.06.135; Bhattacharjee N, 2016, NEUROCHEM INT, V101, P48, DOI 10.1016/j.neuint.2016.10.001; Bieschke J, 2010, P NATL ACAD SCI USA, V107, P7710, DOI 10.1073/pnas.0910723107; Bodles AM, 2001, J NEUROCHEM, V78, P384, DOI 10.1046/j.1471-4159.2001.00408.x; Boozari M, 2015, ENVIRON TOXICOL PHAR, V39, P307, DOI 10.1016/j.etap.2014.12.002; BORS W, 1990, RADICAL CHEM FLAVONO, P165; Bueler H, 2009, EXP NEUROL, V218, P235, DOI 10.1016/j.expneurol.2009.03.006; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Dorsey ER, 2007, NEUROLOGY, V68, P384, DOI 10.1212/01.wnl.0000247740.47667.03; Feng J, 2010, J PHARMACEUT BIOMED, V53, P591, DOI 10.1016/j.jpba.2010.04.002; Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Ghahreman A., 1999, BIODIVERSITY PLANT S; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hong DP, 2008, J MOL BIOL, V383, P214, DOI 10.1016/j.jmb.2008.08.039; Hu Q, 2016, BBA-MOL BASIS DIS, V1862, P1883, DOI 10.1016/j.bbadis.2016.07.008; Huang CJ, 2005, PROTEIN EXPRES PURIF, V42, P173, DOI 10.1016/j.pep.2005.02.014; Huang KC, 2010, PHARM CHINESE HERBS; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Jameson D. M., 2014, INTRO FLUORESCENCE; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim DH, 2006, MECH AGEING DEV, V127, P719, DOI 10.1016/j.mad.2006.05.002; Kim DO, 2003, FOOD CHEM, V81, P321, DOI 10.1016/S0308-8146(02)00423-5; Krenna L, 2003, FLAVONOIDS ACHILLEA; LAMAISON JL, 1990, PHARM ACTA HELV, V65, P315; Lamer-Zarawska E, 2010, ADV CLIN EXP MED, V19, P419; Lee HH, 2003, BRAIN RES, V986, P103, DOI 10.1016/S0006-8993(03)03197-4; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lindstrom V, 2017, MOL CELL NEUROSCI, V82, P143, DOI 10.1016/j.mcn.2017.04.009; Lu JH, 2011, CHEMBIOCHEM, V12, P615, DOI 10.1002/cbic.201000604; Masuda M, 2006, BIOCHEMISTRY-US, V45, P6085, DOI 10.1021/bi0600749; Meng X, 2010, EFFECTS VARIOUS FLAV; Meng XY, 2010, PARKINSONS DIS-US, V2010, DOI 10.4061/2010/650794; Meng XY, 2009, BIOCHEMISTRY-US, V48, P8206, DOI 10.1021/bi900506b; Mohammadi A AJ, 2012, NATURAL PRODUCTS M S, V4, P102; Motaez M, 2015, AVICENNA J PHYTOMEDI, V5, P553; Mousavi SNM, 2015, IRAN J PHARM RES, V14, P215; Murphy DD, 2000, J NEUROSCI, V20, P5214; Mustafa RA, 2010, J FOOD SCI, V75, pC28, DOI 10.1111/j.1750-3841.2009.01401.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012; Niranjan R, 2014, MOL NEUROBIOL, V49, P28, DOI 10.1007/s12035-013-8483-x; Paillusson S., 2017, ACTA NEUROPATHOL; Palhano FL, 2013, J AM CHEM SOC, V135, P7503, DOI 10.1021/ja3115696; Piao HZ, 2004, ARCH PHARM RES, V27, P930, DOI 10.1007/BF02975846; Poblocka-Olech L, 2016, ACTA PHARMACEUT, V66, P543, DOI 10.1515/acph-2016-0038; Roberts HL, 2015, BIOMOLECULES, V5, P282, DOI 10.3390/biom5020282; Sauvage Severine, 2010, Oriental Pharmacy and Experimental Medicine, V10, P304; Sereikaite J, 2006, ACTA BIOCHIM POL, V53, P87; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Smallwood I.M., 2012, HDB ORG SOLVENT PROP; Souri E., 2010, IJPR, V3, P55, DOI [10.22037/IJPR.2010.298, DOI 10.22037/IJPR.2010.298]; Suk K, 2005, NEUROSIGNALS, V14, P23, DOI 10.1159/000085383; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Taebnia N, 2016, LANGMUIR, V32, P13394, DOI 10.1021/acs.langmuir.6b02935; Tai MC, 2005, CNS DRUG REV, V11, P141; Toyoda Y, 2014, BIOL OPEN; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Uversky VN, 2015, CURR PROTEIN PEPT SC, V16, P682, DOI 10.2174/138920371608150828114357; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Winner B, 2011, P NATL ACAD SCI USA, V108, P4194, DOI 10.1073/pnas.1100976108	63	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0184483	10.1371/journal.pone.0184483	http://dx.doi.org/10.1371/journal.pone.0184483			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957336	Green Published, gold, Green Submitted			2023-01-03	WOS:000411985200014
J	Zhao, SP; Li, R; Dai, W; Yu, BL; Chen, LZ; Huang, XS				Zhao, Shui-ping; Li, Rong; Dai, Wen; Yu, Bi-lian; Chen, Lu-zhu; Huang, Xian-sheng			Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPAR alpha signaling pathway	PLOS ONE			English	Article							ACTIVATED RECEPTOR-ALPHA; DENSITY-LIPOPROTEIN RECEPTOR; CORONARY-HEART-DISEASE; HMG-COA REDUCTASE; CARDIOVASCULAR-DISEASE; DYSLIPIDEMIA; ATORVASTATIN; CHOLESTEROL; MECHANISMS; EXPRESSION	Xuezhikang (XZK), an extract of Chinese red yeast rice, is recommended as an optimal choice for patients with coronary heart disease (CHD) with markedly elevated triglyceride (TG) levels. This study was designed to compare the hypotriglyceridemic effects between XZK and simvastatin. The role of apolipoprotein A5 (apoA5), a key regulator of TG metabolism and a target gene of peroxisome proliferator-activated receptor a (PPAR alpha), was to be identified in XZK-related hypotriglyceridemic actions. For these goals, hypertriglyceridemia of rats was induced by a high-fructose diet. In order to investigate the hypotriglyceridemic effects of XZK and simvastatin on these animals based on an equivalent low-density lipoprotein cholesterol (LDL-C) lowering power, we titrated their doses (XZK 80 mg/kg/d versus simvastatin 1 mg/kg/d) according to plasma LDL-C reduction of rats. Similarly, we titrated the target doses of the two agents (XZK 500 mu g/ml versus simvastatin 10 mu M) according to hepatocyte LDL receptor expressions, and then compared the effects of the two agents on TG and apoA5 of hepatocytes in vitro. Our results showed that XZK (80 mg/kg/d) had higher hypotriglyceridemic performance than simvastatin (1 mg/kg/d) on these animals albeit their equivalent LDL-C lowering power. Higher plasma apoA5 levels and hepatic apoA5 expressions were observed in rats treated with XZK (80 mg/kg/d) than simvastatin (1 mg/kg/d). Further, XZK (80 mg/kg/d) contributed to higher hepatic PPARa expressions of rats than simvastatin (1 mg/kg/d). Although the two agents led to an equivalent up-regulation of LDL receptors of hepatocytes, more TG reduction and apoA5 elevation were detected in hepatocytes treated with XZK (500 mu g/ml) than simvastatin (10 mu M). However, PPARa knockdown eliminated the above effects of XZK on hepatocytes. Therefore, our study indicates that XZK has greater hypotriglyceridemic performance than simvastatin in the setting of an equivalent LDL-C lowering power, which is attributed to more apoA5 up-regulation by this agent via the PPARa signaling pathway.	[Zhao, Shui-ping; Dai, Wen; Yu, Bi-lian; Chen, Lu-zhu; Huang, Xian-sheng] Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China; [Li, Rong] Cent S Univ, Xiangya Hosp 2, Dept Stomatol, Changsha, Hunan, Peoples R China	Central South University; Central South University	Huang, XS (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China.	initialhxs@163.com						Baroukh N, 2004, ARTERIOSCL THROM VAS, V24, P1297, DOI 10.1161/01.ATV.0000130463.68272.1d; Brautbar A, 2011, ATHEROSCLEROSIS, V219, P737, DOI 10.1016/j.atherosclerosis.2011.08.015; Carroll MD, 2012, JAMA-J AM MED ASSOC, V308, P1545, DOI 10.1001/jama.2012.13260; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; Critchley J, 2004, CIRCULATION, V110, P1236, DOI 10.1161/01.CIR.0000140668.91896.AE; Grosskopf I, 2005, ARTERIOSCL THROM VAS, V25, P2573, DOI 10.1161/01.ATV.0000186189.26141.12; Henneman P, 2007, ATHEROSCLEROSIS, V193, P129, DOI 10.1016/j.atherosclerosis.2006.05.030; Huang XS, 2009, BRIT J PHARMACOL, V158, P706, DOI 10.1111/j.1476-5381.2009.00350.x; KASIM SE, 1992, J LIPID RES, V33, P1; Miller M, 2008, J AM COLL CARDIOL, V51, P724, DOI 10.1016/j.jacc.2007.10.038; Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726; Moriarty PM, 2014, J CLIN LIPIDOL, V8, P568, DOI 10.1016/j.jacl.2014.09.002; Nilsson SK, 2007, BIOCHEMISTRY-US, V46, P3896, DOI 10.1021/bi7000533; Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Qiu J, 2007, NATURE, V448, P126, DOI 10.1038/448126a; REIHNER E, 1990, NEW ENGL J MED, V323, P224, DOI 10.1056/NEJM199007263230403; Roglans N, 2002, J PHARMACOL EXP THER, V302, P232, DOI 10.1124/jpet.302.1.232; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Tai ES, 2008, CURR OPIN LIPIDOL, V19, P349, DOI 10.1097/MOL.0b013e328304b681; Talmud PJ, 2002, HUM MOL GENET; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Yashiro T, 2012, ATHEROSCLEROSIS, V220, P369, DOI 10.1016/j.atherosclerosis.2011.11.006; Zhao SP, 2014, ATHEROSCLEROSIS, V235, P463, DOI 10.1016/j.atherosclerosis.2014.05.916; Zhao SP, 2004, CIRCULATION, V110, P915, DOI 10.1161/01.CIR.0000139985.81163.CE	29	12	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0184949	10.1371/journal.pone.0184949	http://dx.doi.org/10.1371/journal.pone.0184949			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH7CN	28934253	Green Published, Green Submitted, gold			2023-01-03	WOS:000411339900063
J	Kanazawa, Y; Nakamura, K; Ishii, T; Aso, T; Yamazaki, H; Omori, K				Kanazawa, Yuji; Nakamura, Kimihiro; Ishii, Toru; Aso, Toshihiko; Yamazaki, Hiroshi; Omori, Koichi			Phonological memory in sign language relies on the visuomotor neural system outside the left hemisphere language network	PLOS ONE			English	Article							VERBAL WORKING-MEMORY; SPOKEN LANGUAGE; PREMOTOR CORTEX; FRONTAL-CORTEX; DEAF SIGNERS; FMRI; PET; PARIETAL; SPEECH; AREAS	Sign language is an essential medium for everyday social interaction for deaf people and plays a critical role in verbal learning. In particular, language development in those people should heavily rely on the verbal short-term memory (STM) via sign language. Most previous studies compared neural activations during signed language processing in deaf signers and those during spoken language processing in hearing speakers. For sign language users, it thus remains unclear how visuospatial inputs are converted into the verbal STM operating in the left-hemisphere language network. Using functional magnetic resonance imaging, the present study investigated neural activation while bilinguals of spoken and signed language were engaged in a sequence memory span task. On each trial, participants viewed a nonsense syllable sequence presented either as written letters or as fingerspelling (4-7 syllables in length) and then held the syllable sequence for 12 s. Behavioral analysis revealed that participants relied on phonological memory while holding verbal information regardless of the type of input modality. At the neural level, this maintenance stage broadly activated the left-hemisphere language network, including the inferior frontal gyrus, supplementary motor area, superior temporal gyrus and inferior parietal lobule, for both letter and fingerspelling conditions. Interestingly, while most participants reported that they relied on phonological memory during maintenance, direct comparisons between letters and fingers revealed strikingly different patterns of neural activation during the same period. Namely, the effortful maintenance of fingerspelling inputs relative to letter inputs activated the left superior parietal lobule and dorsal premotor area, i.e., brain regions known to play a role in visuomotor analysis of hand/arm movements. These findings suggest that the dorsal visuomotor neural system subserves verbal learning via sign language by relaying gestural inputs to the classical left-hemisphere language network.	[Kanazawa, Yuji; Nakamura, Kimihiro; Ishii, Toru; Aso, Toshihiko] Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Kyoto, Japan; [Kanazawa, Yuji; Yamazaki, Hiroshi; Omori, Koichi] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan; [Nakamura, Kimihiro] Univ Tsukuba, Fac Human Sci, Tsukuba, Ibaraki, Japan	Kyoto University; Kyoto University; University of Tsukuba	Nakamura, K (corresponding author), Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Kyoto, Japan.; Nakamura, K (corresponding author), Univ Tsukuba, Fac Human Sci, Tsukuba, Ibaraki, Japan.	kimihiro@human.tsukuba.ac.jp	Omori, Koichi/AAU-9017-2021; YAMAZAKI, HIROSHI/AAR-5628-2021; Aso, Toshihiko/C-2798-2018	Omori, Koichi/0000-0003-3404-5461; YAMAZAKI, HIROSHI/0000-0003-0301-6350; Aso, Toshihiko/0000-0003-4814-089X	Japan Society of Logopedics and Phoniatrics; JSPS Kakenhi [16KT0005]; Grants-in-Aid for Scientific Research [16KT0005, 15H05871] Funding Source: KAKEN	Japan Society of Logopedics and Phoniatrics(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); JSPS Kakenhi(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by research grants from the Japan Society of Logopedics and Phoniatrics (to YK) and JSPS Kakenhi (16KT0005 to KN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Masataka Nakayama (Department of Education, Kyoto University) for his assistance in devising the behavioral tasks. This work was supported by research grants from the Japan Society of Logopedics and Phoniatrics (to YK) and JSPS Kakenhi (16KT0005 to KN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amano S, 2000, JAPANESE NTT DATABAS; Amiez C, 2012, NEUROIMAGE, V59, P3723, DOI 10.1016/j.neuroimage.2011.10.058; Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; Bavelier D, 2008, CEREB CORTEX, V18, P2263, DOI 10.1093/cercor/bhm248; BELLUGI U, 1972, COGNITION, V1, P173, DOI 10.1016/0010-0277(72)90018-2; Blasi V, 2002, NEURON, V36, P159, DOI 10.1016/S0896-6273(02)00936-4; Buccino G, 2001, EUR J NEUROSCI, V13, P400, DOI 10.1046/j.1460-9568.2001.01385.x; Buchsbaum B, 2005, BRAIN LANG, V95, P265, DOI 10.1016/j.bandl.2005.01.009; Cai Q, 2010, CEREB CORTEX, V20, P1153, DOI 10.1093/cercor/bhp175; Christophel TB, 2015, NEUROIMAGE, V106, P198, DOI 10.1016/j.neuroimage.2014.11.018; Corina DP, 2006, CORTEX, V42, P529, DOI 10.1016/S0010-9452(08)70393-9; Cornelissen PL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005359; Crottaz-Herbette S, 2004, NEUROIMAGE, V21, P340, DOI 10.1016/j.neuroimage.2003.09.019; Ellis AW, 2009, PHILOS T R SOC B, V364, P3675, DOI 10.1098/rstb.2009.0187; Emmorey K, 2005, NEUROIMAGE, V24, P832, DOI 10.1016/j.neuroimage.2004.10.008; Emmorey K, 2007, NEUROIMAGE, V36, P202, DOI 10.1016/j.neuroimage.2007.02.040; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; HANSON VL, 1984, J EXP CHILD PSYCHOL, V37, P378, DOI 10.1016/0022-0965(84)90010-9; Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832; Hickok G, 2003, J COGNITIVE NEUROSCI, V15, P673, DOI 10.1162/089892903322307393; Hoshi E, 2007, CURR OPIN NEUROBIOL, V17, P234, DOI 10.1016/j.conb.2007.02.003; Jobard G, 2003, NEUROIMAGE, V20, P693, DOI 10.1016/S1053-8119(03)00343-4; Klein M, 2015, CEREB CORTEX, V25, P1715, DOI 10.1093/cercor/bht350; Lacadie CM, 2008, NEUROIMAGE, V42, P717, DOI 10.1016/j.neuroimage.2008.04.240; Laurienti PJ, 2002, J COGNITIVE NEUROSCI, V14, P420, DOI 10.1162/089892902317361930; Levanen S, 2001, CEREB CORTEX, V11, P506, DOI 10.1093/cercor/11.6.506; MacSweeney M, 2002, J COGNITIVE NEUROSCI, V14, P1064, DOI 10.1162/089892902320474517; Montgomery KJ, 2007, SOC COGN AFFECT NEUR, V2, P114, DOI 10.1093/scan/nsm004; Nakayama M, 2015, J EXP PSYCHOL LEARN, V41, P1570, DOI 10.1037/a0038825; Newman AJ, 2015, P NATL ACAD SCI USA, V112, P11684, DOI 10.1073/pnas.1510527112; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Price CJ, 2012, NEUROIMAGE, V62, P816, DOI 10.1016/j.neuroimage.2012.04.062; Price CJ, 2011, TRENDS COGN SCI, V15, P246, DOI 10.1016/j.tics.2011.04.001; Raboyeau G, 2010, NEUROIMAGE, V49, P2850, DOI 10.1016/j.neuroimage.2009.10.007; Rizzolatti G, 2002, CURR OPIN NEUROBIOL, V12, P149, DOI 10.1016/S0959-4388(02)00308-2; Ronnberg J, 2004, COGNITIVE BRAIN RES, V20, P165, DOI 10.1016/j.cogbrainres.2004.03.002; Ruchkin DS, 1997, COGNITIVE BRAIN RES, V6, P95, DOI 10.1016/S0926-6410(97)00021-9; Schubotz RI, 2003, NEUROIMAGE, V20, pS120, DOI 10.1016/j.neuroimage.2003.09.014; Schumacher EH, 1996, NEUROIMAGE, V3, P79, DOI 10.1006/nimg.1996.0009; Sehyr ZS, 2016, J DEAF STUD DEAF ED; Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x; Tamaoka K, 2004, BEHAV RES METH INS C, V36, P531, DOI 10.3758/BF03195600; Tanaka S, 2001, NEUROREPORT, V12, P1171, DOI 10.1097/00001756-200105080-00024; Tanida Y, 2014, MOD RHEUMATOL, P1; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wheat KL, 2010, J NEUROSCI, V30, P5229, DOI 10.1523/JNEUROSCI.4448-09.2010; Wilson M, 1997, MEM COGNITION, V25, P313, DOI 10.3758/BF03211287; Xu JQ, 2013, NEUROIMAGE, V83, P991, DOI 10.1016/j.neuroimage.2013.07.055	49	6	6	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0177599	10.1371/journal.pone.0177599	http://dx.doi.org/10.1371/journal.pone.0177599			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FH6UK	28931014	Green Published, gold, Green Submitted			2023-01-03	WOS:000411314700002
J	Saigi, M; Oliva, M; Aliste, L; Calvo, M; Hormigo, G; Serra, O; Boladeras, A; Farran, L; Robles, J; Creus, G; Paules, MJ; Gornals, JB; de Lama, E; Borras, JM; Sala, N; Galan, M				Saigi, Maria; Oliva, Marc; Aliste, Luisa; Calvo, Mariona; Hormigo, Gloria; Serra, Olbia; Boladeras, Anna; Farran, Leandre; Robles, Javier; Creus, Gloria; Jose Paules, Ma; Gornals, Joan B.; de lama, Eugenia; Ma Borras, Josep; Sala, Nuria; Galan, Maica			Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre	PLOS ONE			English	Article							NEOADJUVANT RADIOCHEMOTHERAPY; ESOPHAGOGASTRIC JUNCTION; CANCER; ADENOCARCINOMA; SURVIVAL; SURGERY; CHEMOTHERAPY; MORTALITY; PATTERNS	Background Locally advanced esophageal carcinoma (LAEC) represents less than 30% of all diagnosed esophageal carcinoma worldwide. The standard of care for resectable tumours consists of preoperative chemoradiotherapy (CRT) followed by surgery. Despite the curative intent, the prognosis is still poor mainly due to relapse. A multidisciplinary approach is required in order to optimize the therapeutic strategy and follow-up. Differences in outcomes between the two main histological subtypes, adenocarcinoma (ADC) and squamous cell carcinoma (SCC), have been reported. Nevertheless, the heterogeneity in trials design and data available have hampered the achievement of clear conclusions. The purpose of this study is to report the outcomes from a cohort of patients with LAEC treated with a multidisciplinary approach and to remark the differences observed between the two main histologic subtypes and their clinical implications. Methods We retrospectively reviewed 100 patients diagnosed with LAEC that were treated with pre-operative CRT at our institution and integrated centres. Histopathological characteristics and toxicities during treatment were recorded. Patterns of recurrence at the first relapse were analysed. Survival curves were plotted using the Kaplan Meier method and multivariate Cox proportional hazards models were used. Results Among the patients who received preoperative CRT, 83% underwent surgery. The median overall survival (mOS) was 31.7 months, 26.9 months for ADC and 45.5 for SCC (p-value = 0.33). In the multivariate Cox regression analysis, ypN+ was the only factor that negatively influenced in OS (OR = 4.1, p-value = 0.022). Patterns of recurrence differed according to histologic subtype. Distant relapse was more frequent in ADC (62%), whereas locoregional relapse was higher in SCC (50%) (p-value = 0.027). Second line therapeutic strategies could be offered to 50% of those patients who relapsed. Conclusions Differences in outcomes and recurrence pattern could be observed between the two main histologic subtypes of LAEC. A better molecular characterization, adapted therapeutic regimens and follow up strategies should be adopted in order to improve survival of these patients.	[Saigi, Maria; Oliva, Marc; Calvo, Mariona; Hormigo, Gloria; Serra, Olbia; Galan, Maica] Hosp Llobregat, IDIBELL, Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain; [Saigi, Maria; Oliva, Marc; Calvo, Mariona; Hormigo, Gloria; Serra, Olbia; Boladeras, Anna; Farran, Leandre; Robles, Javier; Creus, Gloria; Jose Paules, Ma; Gornals, Joan B.; de lama, Eugenia; Galan, Maica] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Gastroesophageal Tumours Funct Unit UTEG,Inst Cat, Barcelona, Spain; [Aliste, Luisa] Hosp Llobregat, Dept Hlth, Evaluat Unit, Canc Plan, Barcelona, Spain; [Boladeras, Anna] Hosp Llobregat, IDIBELL, Inst Catala Oncol, Dept Radiat Oncol, Barcelona, Spain; [Farran, Leandre] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Digest Surg Dept, Barcelona, Spain; [Robles, Javier] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Nucl Med Dept,Inst Diagnost Imatge, Barcelona, Spain; [Creus, Gloria] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Clin Nutr Unit, Barcelona, Spain; [Jose Paules, Ma] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Pathol Dept, Barcelona, Spain; [Gornals, Joan B.] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Gastroenterol Dept, Barcelona, Spain; [de lama, Eugenia] Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Radiol Dept, Barcelona, Spain; [Ma Borras, Josep] Univ Barcelona, Hosp Llobregat, IDIBELL, Dept Clin Sci, Barcelona, Spain; [Sala, Nuria] IDIBELL, ICO, Canc Epidemiol Res Program, Unit Nutr & Canc, Barcelona, Spain; [Sala, Nuria] IDIBELL, ICO, Translat Res Lab, Barcelona, Spain	Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Saigi, M (corresponding author), Hosp Llobregat, IDIBELL, Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain.; Saigi, M (corresponding author), Hosp Univ Bellvitge, Hosp Llobregat, IDIBELL, Gastroesophageal Tumours Funct Unit UTEG,Inst Cat, Barcelona, Spain.	msaigi@iconcologia.net	Galan, Maica/AHC-9182-2022; Sala, Nuria/G-8471-2015	Sala, Nuria/0000-0003-3585-7613; Borras, Josep M/0000-0001-7330-6308; PAULES, MARIA JOSE/0000-0002-0842-3994; Oliva Bernal, Marc/0000-0001-5352-8130; Saigi, Maria/0000-0001-5815-5388	Fondo de investigaciones Sanitarias del Institute de Salud Carlos III, Spanish Ministry of Health; European Regional Development Funds (ERDF/FEDER) [ISCIII PI16/00599]	Fondo de investigaciones Sanitarias del Institute de Salud Carlos III, Spanish Ministry of Health; European Regional Development Funds (ERDF/FEDER)	This work was supported by Fondo de investigaciones Sanitarias del Institute de Salud Carlos III, Spanish Ministry of Health. Cofounded by European Regional Development Funds (ERDF/FEDER) 'a way to build Europe'. http://www.isciii.es/, ISCIII PI16/00599.	Bang YJ, 2010, LANCET, V376, P1302; Bollschweiler E, 2009, ANN ONCOL, V20, P231, DOI 10.1093/annonc/mdn622; Burtness Barbara, 2014, Am Soc Clin Oncol Educ Book, pe172, DOI 10.14694/EdBook_AM.2014.34.e172; Castro C, 2014, ANN ONCOL, V25, P283, DOI 10.1093/annonc/mdt486; Cheung P, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160251; Davies AR, 2014, J CLIN ONCOL, P1; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Teixidor LF, 2013, CIR ESPAN, V91, P517, DOI 10.1016/j.ciresp.2012.12.005; Galan M, 2015, CLIN TRANSL ONCOL, V17, P247, DOI 10.1007/s12094-014-1221-7; Gebski V, 2007, LANCET ONCOL, V8, P226, DOI 10.1016/S1470-2045(07)70039-6; Hermann RM, 2006, DIS ESOPHAGUS, V19, P329, DOI 10.1111/j.1442-2050.2006.00589.x; Kawaguchi Y, 2007, BRIT J CANCER, V97, P494, DOI 10.1038/sj.bjc.6603885; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kubo A, 2010, NUTR RES REV, V23, P230, DOI 10.1017/S0954422410000132; Oppedijk V, 2014, J CLIN ONCOL, V32, P385, DOI 10.1200/JCO.2013.51.2186; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Secrier M, 2016, NAT GENET, V48, P1131, DOI 10.1038/ng.3659; Shaheen N, 2002, JAMA-J AM MED ASSOC, V287, P1972, DOI 10.1001/jama.287.15.1972; Siewert JR, 2005, J SURG ONCOL, V90, P139, DOI 10.1002/jso.20218; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Stahl M, 2005, J CLIN ONCOL, V23, P2310, DOI 10.1200/JCO.2005.00.034; Stahl M, 2013, ANN ONCOL, V24, P51, DOI 10.1093/annonc/mdt342; Stahl M, 2009, J CLIN ONCOL, V27, P851, DOI 10.1200/JCO.2008.17.0506; Tepper J, 2008, J CLIN ONCOL, V26, P1086, DOI 10.1200/JCO.2007.12.9593; Thallinger CMR, 2011, J CLIN ONCOL, V29, P4709, DOI 10.1200/JCO.2011.36.7599; Thies S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00262; Uemura Norihisa, 2014, World J Gastrointest Pathophysiol, V5, P322, DOI 10.4291/wjgp.v5.i3.322; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088	31	3	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0184737	10.1371/journal.pone.0184737	http://dx.doi.org/10.1371/journal.pone.0184737			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931046	Green Published, Green Submitted, gold			2023-01-03	WOS:000411314700032
J	Laub, KR; Marek, M; Stanchev, LD; Herrera, SA; Kanashova, T; Bourmaud, A; Dittmar, G; Pomorski, TG				laub, Katrine Rude; Marek, Magdalena; Stanchev, Lyubomir Dimitrov; Herrera, Sara Abad; Kanashova, Tamara; Bourmaud, Adele; Dittmar, Gunnar; Pomorski, Thomas Guenther			Purification and characterisation of the yeast plasma membrane ATP binding cassette transporter Pdr11p	PLOS ONE			English	Article							MULTIDRUG-RESISTANCE; STEROL UPTAKE; NUCLEOTIDE-BINDING; ABC TRANSPORTERS; P-GLYCOPROTEIN; HYDROLYSIS; CHOLESTEROL; PROTEINS; LIPIDS; CELLS	The ATP binding cassette (ABC) transporters Pdr11p and its paralog Aus1p are expressed under anaerobic growth conditions at the plasma membrane of the yeast Saccharomyces cerevisiae and are required for sterol uptake. However, the precise mechanism by which these ABC transporters facilitate sterol movement is unknown. In this study, an overexpression and purification procedure was developed with the aim to characterise the Pdr11p transporter. Engineering of Pdr11p variants fused at the C terminus with green fluorescent protein (Pdr11p-GFP) and containing a FLAG tag at the N terminus facilitated expression analysis and one-step purification, respectively. The detergent-solubilised and purified protein displayed a stable ATPase activity with a broad pH optimum near 7.4. Mutagenesis of the conserved lysine to methionine (K788M) in the Walker A motif abolished ATP hydrolysis. Remarkably, and in contrast to Aus1p, ATPase activity of Pdr11p was insensitive to orthovanadate and not specifically stimulated by phosphatidylserine upon reconstitution into lipo-somes. Our results highlight distinct differences between Pdr11p and Aus1p and create an experimental basis for further biochemical studies of both ABC transporters to elucidate their function.	[laub, Katrine Rude; Marek, Magdalena; Stanchev, Lyubomir Dimitrov; Herrera, Sara Abad; Pomorski, Thomas Guenther] Univ Copenhagen, Dept Plant & Environm Sci, Frederiksberg C, Denmark; [Stanchev, Lyubomir Dimitrov; Herrera, Sara Abad; Pomorski, Thomas Guenther] Ruhr Univ Bochum, Dept Mol Biochem, Bochum, Germany; [Kanashova, Tamara; Dittmar, Gunnar] Max Delbruck Ctr Mol Med, Mass Spectrometry Core Unit, Berlin, Germany; [Bourmaud, Adele; Dittmar, Gunnar] Luxembourg Inst Hlth, Proteome & Genome Res Lab, Strassen, Luxembourg; [Marek, Magdalena] Univ Lausanne, Dept Fundamental Microbiol, Lausanne, Switzerland	University of Copenhagen; Ruhr University Bochum; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Luxembourg Institute of Health; University of Lausanne	Pomorski, TG (corresponding author), Univ Copenhagen, Dept Plant & Environm Sci, Frederiksberg C, Denmark.; Pomorski, TG (corresponding author), Ruhr Univ Bochum, Dept Mol Biochem, Bochum, Germany.	tgp@plen.ku.dk	Pomorski, Thomas Günther/G-4804-2014; Dittmar, Gunnar/C-6333-2019	Pomorski, Thomas Günther/0000-0002-4889-0829; Dittmar, Gunnar/0000-0003-3647-8623; Bourmaud, Adele/0000-0002-0557-3639; Stanchev, Lyubomir Dimitrov/0000-0002-0338-8210	Research Centre 'bioSYNergy' at University of Copenhagen - UCPH; Villium Fonden [022868]; FNR [FNR/P09/01]; Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health	Research Centre 'bioSYNergy' at University of Copenhagen - UCPH; Villium Fonden; FNR(Luxembourg National Research Fund); Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health	This work was supported by the Research Centre 'bioSYNergy' at University of Copenhagen funded by the UCPH Excellence Program for Interdisciplinary Research and the Villium Fonden (grant 022868 to TGP). AB was supported by FNR grant FNR/P09/01. TK was funded by the Helmholtz Virtual Institute of Complex Molecular Systems in Environmental Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertsen L, 2011, APPL ENVIRON MICROB, V77, P1033, DOI 10.1128/AEM.01361-10; Alimardani P, 2004, BIOCHEM J, V381, P195, DOI 10.1042/BJ20040297; Aye ILMH, 2009, CHEM-BIOL INTERACT, V180, P327, DOI 10.1016/j.cbi.2009.04.012; Benabdelhak H, 2005, BIOCHEM J, V386, P489, DOI 10.1042/BJ20041282; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Georgiev AG, 2011, TRAFFIC, V12, P1341, DOI 10.1111/j.1600-0854.2011.01234.x; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hirayama H, 2013, J LIPID RES, V54, P496, DOI 10.1194/jlr.M033209; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Jensen NB, 2014, FEMS YEAST RES, V14, P238, DOI 10.1111/1567-1364.12118; Ketchum CJ, 2001, J BIOL CHEM, V276, P29007, DOI 10.1074/jbc.M100810200; Kohut P, 2011, BIOCHEM BIOPH RES CO, V404, P233, DOI 10.1016/j.bbrc.2010.11.099; Lamping E, 2007, EUKARYOT CELL, V6, P1150, DOI 10.1128/EC.00091-07; Lamping E, 2010, FUNGAL GENET BIOL, V47, P127, DOI 10.1016/j.fgb.2009.10.007; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; Li YF, 2004, J BIOL CHEM, V279, P45226, DOI 10.1074/jbc.M407600200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Marek M, 2014, FEMS YEAST RES, V14, P1223, DOI 10.1111/1567-1364.12219; Marek M, 2011, J BIOL CHEM, V286, P21835, DOI 10.1074/jbc.M111.244525; MEAD DJ, 1986, MOL GEN GENET, V205, P417, DOI 10.1007/BF00338076; Nagi M, 2013, MOL MICROBIOL, V88, P371, DOI 10.1111/mmi.12189; Nakayama H, 2007, J ANTIMICROB CHEMOTH, V60, P1264, DOI 10.1093/jac/dkm321; Neumann J, 2017, BBA-BIOMEMBRANES, V1859, P605, DOI 10.1016/j.bbamem.2016.09.023; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Phillips MC, 2014, J BIOL CHEM, V289, P24020, DOI 10.1074/jbc.R114.583658; Prasad R, 2012, ANNU REV MICROBIOL, V66, P39, DOI 10.1146/annurev-micro-092611-150111; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Reiner S, 2006, MOL BIOL CELL, V17, P90, DOI 10.1091/mbc.e05-06-0515; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Takahashi K, 2006, J BIOL CHEM, V281, P10760, DOI 10.1074/jbc.M513783200; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; Wang ZL, 2006, BIOCHEMISTRY-US, V45, P9929, DOI 10.1021/bi0608055; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; Xu P, 2009, J CELL SCI, V122, P2866, DOI 10.1242/jcs.047423	41	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2017	12	9							e0184236	10.1371/journal.pone.0184236	http://dx.doi.org/10.1371/journal.pone.0184236			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH3OQ	28922409	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000411059300013
J	Robinson, JC; Whaley, CM; Brown, TT				Robinson, James C.; Whaley, Christopher M.; Brown, Timothy T.			Association of Reference Pricing with Drug Selection and Spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICANCER DRUGS; HEALTH-CARE; PRICES; CHOICES; COMPLICATIONS; CONSUMERS; SURGERY; MARKET; TESTS	BACKGROUND In the United States, prices for therapeutically similar drugs vary widely, which has prompted efforts by public and private insurers to steer patients toward the lower-priced options. Under reference pricing, the insurer or employer establishes a maximum contribution it will make toward the price of a drug or procedure, and the patient pays the remainder. METHODS We used difference-in-differences multivariable regression methods to analyze changes in prescriptions and pricing for 1302 drugs in 78 therapeutic classes in the United States, before and after implementation of reference pricing by an alliance of private employers. We assessed trends for the study group relative to those for an employee group that was not subject to reference pricing. The study included 1,122,741 prescriptions that were reimbursed during the period from 2010 through 2014. RESULTS Implementation of reference pricing was associated with a higher percentage of prescriptions that were filled for the lowest-priced reference drug within its therapeutic class (difference in probability, 7.0 percentage points; 95% confidence interval [CI], 4.0 to 9.9), a lower average price paid per prescription (-13.9%; 95% CI, -23.8 to -2.7), and a higher rate of copayment by patients (5.2%; 95% CI, 0.2 to 10.4) than in the comparison group. During the first 18 months after implementation, spending for employers was $1.34 million lower and the amount of copayments for employees was $0.12 million higher than in the comparison group. CONCLUSIONS Implementation of reference pricing was associated with significant changes in drug selection and spending for a population of patients covered by employment-based insurance in the United States.	[Robinson, James C.; Whaley, Christopher M.; Brown, Timothy T.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Whaley, Christopher M.] RAND, Santa Monica, CA USA	University of California System; University of California Berkeley; RAND Corporation	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	james.robinson@berkeley.edu		Robinson, James/0000-0003-0056-3017	Agency for Healthcare Research and Quality; Genentech Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS022098] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Genentech Foundation(Roche HoldingGenentech); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Funded by the Agency for Healthcare Research and Quality and the Genentech Foundation.	Acosta A, 2014, COCHRANE DB SYST REV, V10; Aitken M, 2016, HEALTH AFFAIR, V35, P1595, DOI 10.1377/hlthaff.2015.1636; [Anonymous], 2016, EST MED D; Bennette CS, 2016, HEALTH AFFAIR, V35, P805, DOI 10.1377/hlthaff.2015.1145; Chandra A, 2010, AM ECON REV, V100, P193, DOI 10.1257/aer.100.1.193; Dafny LS, 2016, NEW ENGL J MED, V375, P2013, DOI 10.1056/NEJMp1607378; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Government Accountability Office, 2016, GEN DRUGS MED D; Hauptman PJ, 2017, JAMA INTERN MED, V177, P126, DOI 10.1001/jamainternmed.2016.6955; Howard DH, 2015, J ECON PERSPECT, V29, P139, DOI 10.1257/jep.29.1.139; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Lee Joy Li-Yueh, 2012, Am J Manag Care, V18, pe429; Robinson JC, 2017, HEALTH AFFAIR, V36, P524, DOI 10.1377/hlthaff.2016.1256; Robinson JC, 2016, MED CARE, V55, P1050, DOI 10.1097/MLR.0000000000000605; Robinson JC, 2016, JAMA INTERN MED, V176, P1353, DOI 10.1001/jamainternmed.2016.2492; Robinson JC, 2015, JAMA INTERN MED, V175, P1783, DOI 10.1001/jamainternmed.2015.4588; Robinson JC, 2015, J BONE JOINT SURG AM, V97A, P1473, DOI 10.2106/JBJS.O.00240; Robinson JC, 2015, HEALTH AFFAIR, V34, P415, DOI 10.1377/hlthaff.2014.1198; Robinson JC, 2013, HEALTH AFFAIR, V32, P1392, DOI 10.1377/hlthaff.2013.0188; Ubel PA, 2016, ANN INTERN MED, V165, P878, DOI 10.7326/M16-1334	21	18	18	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2017	377	7					658	665		10.1056/NEJMsa1700087	http://dx.doi.org/10.1056/NEJMsa1700087			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD7FG	28813219	Green Accepted, Bronze			2023-01-03	WOS:000407691400008
J	Abecia, L; Jimenez, E; Martinez-Fernandez, G; Martin-Garcia, AI; Ramos-Morales, E; Pinloche, E; Denman, SE; Newbold, CJ; Yanez-Ruiz, DR				Abecia, Leticia; Jimenez, Elisabeth; Martinez-Fernandez, Gonzalo; Ignacio Martin-Garcia, A.; Ramos-Morales, Eva; Pinloche, Eric; Denman, Stuart E.; Newbold, C. Jamie; Yanez-Ruiz, David R.			Natural and artificial feeding management before weaning promote different rumen microbial colonization but not differences in gene expression levels at the rumen epithelium of newborn goats	PLOS ONE			English	Article							TOLL-LIKE-RECEPTORS; PATHOGEN RECOGNITION; BACTERIAL COMMUNITY; SODIUM-BUTYRATE; GUT MICROBIOTA; IMMUNE-SYSTEM; DAIRY CALVES; EARLY-LIFE; PROTOZOA; DIET	The aim of this work was to evaluate the effect of feeding management during the first month of life (natural with the mother, NAT, or artificial with milk replacer, ART) on the rumen microbial colonization and the host innate immune response. Thirty pregnant goats carrying two fetuses were used. At birth one kid was taken immediately away from the doe and fed milk replacer (ART) while the other remained with the mother (NAT). Kids from groups received colostrum during first 2 days of life. Groups of four kids (from ART and NAT experimental groups) were slaughtered at 1, 3, 7, 14, 21 and 28 days of life. On the sampling day, after slaughtering, the rumen content was sampled and epithelial rumen tissue was collected. Pyrosequencing analyses of the bacterial community structure on samples collected at 3, 7, 14 and 28 days showed that both systems promoted significantly different colonization patterns (P = 0.001). Diversity indices increased with age and were higher in NAT feeding system. Lower mRNA abundance was detected in TLR2, TLR8 and TLR10 in days 3 and 5 compared to the other days (7, 14, 21 and 28). Only TLR5 showed a significantly different level of expression according to the feeding system, presenting higher mRNA abundances in ART kids. PGLYRP1 showed significantly higher abundance levels in days 3, 5 and 7, and then experienced a decline independently of the feeding system. These observations confirmed a highly diverse microbial colonisation from the first day of life in the undeveloped rumen, and show that the colonization pattern substantially differs between preruminants reared under natural or artificial milk feeding systems. However, the rumen epithelial immune development does not differentially respond to distinct microbial colonization patterns.	[Abecia, Leticia; Jimenez, Elisabeth; Martinez-Fernandez, Gonzalo; Ignacio Martin-Garcia, A.; Ramos-Morales, Eva; Yanez-Ruiz, David R.] CSIC, Estac Expt Zaidin, Granada, Spain; [Martinez-Fernandez, Gonzalo; Denman, Stuart E.] CSIRO, Agr & Food Flagship Queensland Biosci Precinct, St Lucia, Qld, Australia; [Ramos-Morales, Eva; Pinloche, Eric; Newbold, C. Jamie] Aberystwyth Univ, IBERS, Aberystwyth, Dyfed, Wales	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS)	Yanez-Ruiz, DR (corresponding author), CSIC, Estac Expt Zaidin, Granada, Spain.	david.yanez@eez.csic.es	Yanez-Ruiz, David/Q-4963-2019; Abecia, Leticia/N-6885-2019; Ramos-Morales, Eva/ABD-3707-2021; Martín-García, Ignacio A/ADF-1356-2022; Denman, Stuart E/A-5823-2011; Fernandez, Gonzalo Martinez/K-1589-2015	Abecia, Leticia/0000-0003-4097-8903; Ramos-Morales, Eva/0000-0002-7056-9097; Martín-García, Ignacio A/0000-0002-5366-3938; Denman, Stuart E/0000-0002-9910-3709; Fernandez, Gonzalo Martinez/0000-0002-6177-0186	MINECO [AGL2011-27218, BFU2014-57964-R]	MINECO(Spanish Government)	This research has been funded by MINECO (www.mineco.gob.es): grants AGL2011-27218 and BFU2014-57964-R.; This research has been funded by MINECO (grants AGL2011-27218 and BFU2014-57964-R).	Abecia L, 2014, ANIM PROD SCI, V54, P1449, DOI 10.1071/AN14337; Abecia L, 2013, J ANIM SCI, V91, P4832, DOI 10.2527/jas.2012-6142; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexander M., 1971, MICROBIAL ECOLOGY; ANDERSON KL, 1987, J DAIRY SCI, V70, P1000, DOI 10.3168/jds.S0022-0302(87)80105-4; Belanche A, 2014, FEMS MICROBIOL ECOL, V90, P663, DOI 10.1111/1574-6941.12423; Bragg L, 2012, NAT METHODS, V9, P425, DOI 10.1038/nmeth.1990; Brossard L, 2004, REPROD NUTR DEV, V44, P195, DOI 10.1051/rnd:2004023; BUSH LJ, 1980, J DAIRY SCI, V63, P672, DOI 10.3168/jds.S0022-0302(80)82989-4; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chang ZL, 2008, CHINESE SCI BULL, V53, P1121, DOI 10.1007/s11434-008-0184-x; Chessel D., 2004, R NEWS, V4, P5; DENISE SK, 1989, J DAIRY SCI, V72, P552, DOI 10.3168/jds.S0022-0302(89)79140-2; Dziarski R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-232; EADIE JM, 1959, NATURE, V183, P624, DOI 10.1038/183624a0; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Faber S. N., 2005, Professional Animal Scientist, V21, P420; FONTY G, 1987, J GEN MICROBIOL, V133, P1835; Fonty G, 2007, COMMUNAUTES MICROBIE, P71; Galef BG, 2001, ANIM BEHAV, V61, P3, DOI 10.1006/anbe.2000.1557; Gazzinelli RT, 2004, NATURE REV IMMUNOL, V6, P895; Gorka P, 2011, J DAIRY SCI, V94, P5578, DOI 10.3168/jds.2011-4166; Guan Y, 2010, J IMMUNOL, V184, P5094, DOI 10.4049/jimmunol.0901888; GUIDRY AJ, 1980, VET IMMUNOL IMMUNOP, V1, P329, DOI 10.1016/0165-2427(80)90012-4; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heinrichs J, 2005, ADV DAIRY TECHNOL, V17, P179; Henderson G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14567; Hernandez-Sanabria E, 2012, APPL ENVIRON MICROB, V78, P1203, DOI 10.1128/AEM.05114-11; Jami E, 2013, ISME J, V7, P1069, DOI 10.1038/ismej.2013.2; Jami E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033306; Jiao JZ, 2015, APPL ENVIRON MICROB, V81, P3502, DOI 10.1128/AEM.00203-15; Kaetzel CS, 2014, IMMUNOL LETT, V162, P10, DOI 10.1016/j.imlet.2014.05.008; Kato SI, 2011, J ENDOCRINOL, V211, P241, DOI 10.1530/JOE-11-0299; Kowalski ZM, 2015, J DAIRY SCI, V98, P3284, DOI 10.3168/jds.2014-8688; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P84, DOI 10.1016/S0005-2728(01)00230-4; LASCELLES AK, 1979, J DAIRY SCI, V62, P154, DOI 10.3168/jds.S0022-0302(79)83216-6; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Lilius EM, 2001, CURR OPIN INFECT DIS, V14, P295, DOI 10.1097/00001432-200106000-00008; Malmuthuge N, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00036; Malmuthuge N, 2014, APPL ENVIRON MICROB, V80, P2021, DOI 10.1128/AEM.03864-13; Malmuthuge N, 2012, VET IMMUNOL IMMUNOP, V146, P18, DOI 10.1016/j.vetimm.2012.01.010; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Meale SJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00582; MINATO H, 1992, J GEN APPL MICROBIOL, V38, P447, DOI 10.2323/jgam.38.447; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Oksanen J., 2020, VEGAN COMMUNITY ECOL, DOI DOI 10.4135/9781412971874.N145; Osanai A, 2011, INFECT IMMUN, V79, P858, DOI 10.1128/IAI.00466-10; Rey M, 2014, J APPL MICROBIOL, V116, P245, DOI 10.1111/jam.12405; Sekirov I, 2009, J PHYSIOL-LONDON, V587, P4159, DOI 10.1113/jphysiol.2009.172742; Sharpe ME, 1975, DIGESTION METABOLISM; Skillman LC, 2004, ANAEROBE, V10, P277, DOI 10.1016/j.anaerobe.2004.05.003; Snoeck V, 2006, VET RES, V37, P455, DOI 10.1051/vetres:2006010; Steele MA, 2016, J DAIRY SCI, V99, P4955, DOI 10.3168/jds.2015-10351; Stevenson DM, 2007, APPL MICROBIOL BIOT, V75, P165, DOI 10.1007/s00253-006-0802-y; Subharat S, 2015, VET IMMUNOL IMMUNOP, V164, P201, DOI 10.1016/j.vetimm.2015.02.008; Teran R, 2011, CLIN IMMUNOL, V138, P299, DOI 10.1016/j.clim.2010.12.011; Van dA, 2011, FEMS MICROBIOL REV, V35, P681; Vieira AD, 2012, J DAIRY SCI, V95, P5149, DOI 10.3168/jds.2011-5073; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang W, 2016, SCI REP-UK, V6, DOI 10.1038/srep19511; Williams A.G., 1992, RUMEN PROTOZOA; Yanez-Ruiz DR, 2007, BRIT J NUTR, V97, P938, DOI 10.1017/S0007114507675187; Yanez-Ruiz DR, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01133; Yanez-Ruiz DR, 2010, FEMS MICROBIOL ECOL, V72, P272, DOI 10.1111/j.1574-6941.2010.00852.x; ZIOLECKI A, 1961, J APPL BACTERIOL, V24, P148, DOI 10.1111/j.1365-2672.1961.tb00247.x	67	33	40	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2017	12	8							e0182235	10.1371/journal.pone.0182235	http://dx.doi.org/10.1371/journal.pone.0182235			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD6XW	28813529	Green Published, Green Submitted, gold			2023-01-03	WOS:000407672200024
J	Huybrechts, KF; Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Rough, K; Mogun, H; Kerzner, LS; Davis, JM; Stover, M; Bartels, D; Cottral, J; Patorno, E				Huybrechts, Krista F.; Bateman, Brian T.; Desai, Rishi J.; Hernandez-Diaz, Sonia; Rough, Kathryn; Mogun, Helen; Kerzner, Leslie S.; Davis, Jonathan M.; Stover, Megan; Bartels, Devan; Cottral, Jennifer; Patorno, Elisabetta			Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ABSTINENCE SYNDROME; UNITED-STATES; GABAPENTIN; PREGNANCY; ADJUSTMENT; METHADONE	OBJECTIVES To assess the impact of in utero co-exposure to psychotropic medications and opioids on the incidence and severity of neonatal drug withdrawal. DESIGN Observational cohort study. SETTING Nationwide sample of pregnancies in publicly insured women in the US, nested in the Medicaid Analytic eXtract (2000-10). PARTICIPANTS 201 275 pregnant women with public insurance who were exposed to opioids around the time of delivery and their liveborn infants. INTERVENTIONS In utero exposure to psychotropic medications, in particular antidepressants, atypical antipsychotics, benzodiazepines, gabapentin, and non-benzodiazepine hypnotics (Z drugs), with prescriptions filled within the same time window as prescriptions for opioids. MAIN OUTCOME MEASURE Diagnosis of neonatal drug withdrawal in infants exposed in utero to opioids and psychotropic medications compared with opioids alone. RESULTS The absolute risk for neonatal drug withdrawal ranged from 1.0% in infants exposed in utero to prescription opioids alone to 11.4% for those exposed to opioids co-prescribed with gabapentin. Among neonates exposed in utero to prescription opioids, the relative risk adjusted for propensity score was 1.34 (95% confidence interval 1.22 to 1.47) with concomitant exposure to antidepressants, 1.49 (1.35 to 1.63) with benzodiazepines, 1.61 (1.26 to 2.06) with gabapentin, 1.20 (0.95 to 1.51) with antipsychotics, and 1.01 (0.88 to 1.15) with Z drugs. In utero exposure to two or more psychotropic medications along with opioids was associated with a twofold increased risk of withdrawal (2.05, 1.77 to 2.37). The severity of the withdrawal seemed increased in neonates exposed to both opioids and psychotropic medications compared with opioids alone. CONCLUSIONS During pregnancy, the use of psychotropic medications in addition to prescription opioids is common, despite a lack of safety data. The current findings suggest that these drugs could further increase the risk and severity of neonatal drug withdrawal.	[Huybrechts, Krista F.; Bateman, Brian T.; Desai, Rishi J.; Rough, Kathryn; Mogun, Helen; Patorno, Elisabetta] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Huybrechts, Krista F.; Bateman, Brian T.; Desai, Rishi J.; Rough, Kathryn; Mogun, Helen; Kerzner, Leslie S.; Bartels, Devan; Cottral, Jennifer; Patorno, Elisabetta] Harvard Med Sch, Boston, MA USA; [Bateman, Brian T.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Hernandez-Diaz, Sonia; Rough, Kathryn] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Kerzner, Leslie S.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Davis, Jonathan M.] Tufts Med Ctr, Floating Hosp, Dept Pediat, Boston, MA USA; [Davis, Jonathan M.] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA; [Stover, Megan] Tufts Med Ctr, Dept Obstet & Gynecol, Boston, MA USA; [Stover, Megan] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Bartels, Devan; Cottral, Jennifer] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Floating Hospital For Children; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Harvard University; Massachusetts General Hospital	Huybrechts, KF (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.	khuybrechts@bwh.harvard.edu	Desai, Rishi/AAH-8988-2021		National Institute of Mental Health [R01 MH100216, K01MH099141]; National Institute of Child Health and Human Development [K08HD075831]; National Institute of Drug Abuse [R01DA032889-04, R21DA041706-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD075831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH099141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA041706] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by an R01 grant (R01 MH100216) from the National Institute of Mental Health. KFH was supported by a career development grant K01MH099141 from the National Institute of Mental Health. BTB was supported by a career development grant K08HD075831 from the National Institute of Child Health and Human Development. JMD was supported by R01 (R01DA032889-04) and R21 (R21DA041706-01) grants from the National Institute of Drug Abuse. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	[Anonymous], 2013, OBSTET GYNECOL, V122, P957, DOI 10.1097/AOG.0b013e3182a603bb; [Anonymous], 2016, CLIN PHARM DATABASE; Bateman BT, 2014, ANESTHESIOLOGY, V120, P1216, DOI 10.1097/ALN.0000000000000172; Carrasco M, 2015, PEDIATR NEUROL, V53, P445, DOI 10.1016/j.pediatrneurol.2015.06.023; Desai RJ, 2017, EPIDEMIOLOGY, V28, P249, DOI 10.1097/EDE.0000000000000595; Desai RJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2102; Desai RJ, 2014, OBSTET GYNECOL, V123, P997, DOI 10.1097/AOG.0000000000000208; Dryden C, 2009, BJOG-INT J OBSTET GY, V116, P665, DOI 10.1111/j.1471-0528.2008.02073.x; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; FDA Drug Safety Communication, 2011, ANT DRUG LAB UPD US; FINNEGAN LP, 1975, ADDICT DIS, V2, P141; Hanley GE, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-242; Hudak ML, 2012, PEDIATRICS, V129, pE540, DOI 10.1542/peds.2011-3212; Hwang CS, 2016, AM J PREV MED, V51, P151, DOI 10.1016/j.amepre.2016.02.014; Jansson LM, 2012, DRUG ALCOHOL DEPEN, V122, P213, DOI 10.1016/j.drugalcdep.2011.10.003; Loudin S, 2017, J PEDIATR-US, V181, P286, DOI 10.1016/j.jpeds.2016.11.004; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Mercadante S, 2013, CURR MED RES OPIN, V29, P661, DOI 10.1185/03007995.2013.791617; Mersfelder TL, 2016, ANN PHARMACOTHER, V50, P229, DOI 10.1177/1060028015620800; Norton JW, 2001, CLIN NEUROPHARMACOL, V24, P245, DOI 10.1097/00002826-200107000-00011; Patrick SW, 2015, J PERINATOL, V35, P650, DOI 10.1038/jp.2015.36; Patrick SW, 2012, JAMA-J AM MED ASSOC, V307, P1934, DOI 10.1001/jama.2012.3951; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Raffaeli G, 2017, PHARMACOTHERAPY, V37, P814, DOI 10.1002/phar.1954; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; van Amsterdam Jan, 2015, Curr Drug Abuse Rev, V8, P3; Volkow ND, 2014, AM ADDICTION OPIOIDS; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Wachman EM, 2011, J ADDICT MED, V5, P293, DOI 10.1097/ADM.0b013e3182266a3a	29	84	85	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	2017	358								j3326	10.1136/bmj.j3326	http://dx.doi.org/10.1136/bmj.j3326			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD0CG	28768628	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000407206800002
J	Rockendorf, N; Meckelein, B; Scherf, KA; Schalk, K; Koehler, P; Frey, A				Roeckendorf, Niels; Meckelein, Barbara; Scherf, Katharina A.; Schalk, Kathrin; Koehler, Peter; Frey, Andreas			Identification of novel antibody-reactive detection sites for comprehensive gluten monitoring	PLOS ONE			English	Article							CELIAC-DISEASE; MONOCLONAL-ANTIBODIES; GLIADIN; PEPTIDES	Certain cereals like wheat, rye or barley contain gluten, a protein mixture that can trigger celiac disease (CD). To make gluten-free diets available for affected individuals the gluten content of foodstuff must be monitored. For this purpose, antibody-based assays exist which rely on the recognition of certain linear gluten sequence motifs. Yet, not all CD-active gluten constituents and fragments formed during food processing/fermentation may be covered by those tests. In this study, we therefore assayed the coverage of reportedly CD-active gluten components by currently available detection antibodies and determined the antibody-inducing capacity of wheat gluten constituents in order to provide novel diagnostic targets for comprehensive gluten quantitation. Immunizations of outbred mice with purified gliadins and glutenins were conducted and the linear target recognition profile of the sera was recorded using synthetic peptide arrays that covered the sequence space of gluten constituents present in those preparations. The resulting murine immunorecognition profile of gluten demonstrated that further linear binding sites beyond those recognized by the monoclonal antibodies alpha 20, R5 and G12 exist and may be exploitable as diagnostic targets. We conclude that the safety of foodstuffs for CD patients can be further improved by complementing current tests with antibodies directed against additional CD-active gluten components. Currently unrepresented linear gluten detection sites in glutenins and alpha-gliadins suggest sequences QQQYPS, PQQSFP, QPGQGQQG and QQPPFS as novel targets for antibody generation.	[Roeckendorf, Niels; Meckelein, Barbara; Frey, Andreas] Res Ctr Borstel, Div Mucosal Immunol & Diagnost, Prior Area Asthma & Allergy, Borstel, Germany; [Scherf, Katharina A.; Schalk, Kathrin; Koehler, Peter] Leibniz Inst, Deutsch Forsch Anstalt Lebensmittelchem, Freising Weihenstephan, Germany; [Koehler, Peter] Biotask AG, Esslingen, Germany	Forschungszentrum Borstel; Leibniz-Institute for Food Systems Biology at the Technical University of Munich	Frey, A (corresponding author), Res Ctr Borstel, Div Mucosal Immunol & Diagnost, Prior Area Asthma & Allergy, Borstel, Germany.	afrey@fz-borstel.de	Scherf, Katharina/AAM-7029-2020; SCHERF, Katharina/B-8141-2019	Scherf, Katharina/0000-0001-8315-5400; SCHERF, Katharina/0000-0001-8315-5400	German Ministry for Education and Research [13GW0042A, 13GW0042B]; Open Access Fund of the Leibniz Association	German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Open Access Fund of the Leibniz Association	This work was supported by the German Ministry for Education and Research, 13GW0042A, to Dr. Andreas Frey and the German Ministry for Education and Research, 13GW0042B, to Prof. Peter Koehler. The publication of this article was funded by the Open Access Fund of the Leibniz Association.	[Anonymous], DET CRUD PROT GRAIN; [Anonymous], DET MOIST CONT CER C; [Anonymous], DET ASH CER CER PROD; Blandino A, 2003, FOOD RES INT, V36, P527, DOI 10.1016/S0963-9969(03)00009-7; Briant DJ, 2009, METHODS MOL BIOL, V570, P175, DOI 10.1007/978-1-60327-394-7_6; Bugyi Z, 2013, QUAL ASSUR SAF CROP, V5, P79, DOI 10.3920/QAS2012.0174; Catassi C, 2015, DIGEST DIS, V33, P141, DOI 10.1159/000369518; CICLITIRA PJ, 1984, CLIN SCI, V66, P357, DOI 10.1042/cs0660357; FDA, 2013, FED REG; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Frey A, 2000, J IMMUNOL METHODS, V233, P47, DOI 10.1016/S0022-1759(99)00166-0; Frey A, 1999, VACCINE, V17, P3007, DOI 10.1016/S0264-410X(99)00163-2; Goodman RE, 2016, MOL NUTR FOOD RES; Hovhannisyan Z, 2008, NATURE, V456, P534, DOI 10.1038/nature07524; Howdle PD, 2006, EUR J GASTROEN HEPAT, V18, P703, DOI 10.1097/01.meg.0000221847.09792.34; Kahlenberg F, 2006, EUR FOOD RES TECHNOL, V222, P78, DOI 10.1007/s00217-005-0100-4; KENDALL MJ, 1972, LANCET, V2, P1065; Koenig A, 2015, FOOD CHEM, V168, P176, DOI 10.1016/j.foodchem.2014.07.040; Kok MS, 2012, BMC BIOPHYS, V5, DOI 10.1186/2046-1682-5-10; Lagrain B, 2012, J CEREAL SCI, V56, P726, DOI 10.1016/j.jcs.2012.08.003; Martinez-Esteso MJ, 2016, J PROTEOMICS, V147, P156, DOI 10.1016/j.jprot.2016.03.015; Mitea C, 2008, AM J CLIN NUTR, V88, P1057, DOI 10.1093/ajcn/88.4.1057; Moron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002294; Osman AA, 2001, EUR J GASTROEN HEPAT, V13, P1189, DOI 10.1097/00042737-200110000-00011; Pahlavan A, 2016, FOOD CHEM, V208, P264, DOI 10.1016/j.foodchem.2016.03.092; Pflaum T, 2013, J AGR FOOD CHEM, V61, P6485, DOI 10.1021/jf4012906; Rzychon M, 2017, FOOD CHEM, V234, P144, DOI 10.1016/j.foodchem.2017.04.092; Schalk K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172819; Scherf KA, 2016, J AGR FOOD CHEM, V64, P7622, DOI 10.1021/acs.jafc.6b02512; Scherf KA, 2016, EUR FOOD RES TECHNOL, V242, P1837, DOI 10.1007/s00217-016-2683-3; Scherf KA, 2016, J CEREAL SCI, V67, P2, DOI 10.1016/j.jcs.2015.07.008; Scherf KA, 2016, J CEREAL SCI, V67, P112, DOI 10.1016/j.jcs.2015.08.006; Sollid LM, 2012, IMMUNOGENETICS, V64, P455, DOI 10.1007/s00251-012-0599-z; Stepniak D, 2005, IMMUNOGENETICS, V57, P8, DOI 10.1007/s00251-005-0780-8; Stern M, 2001, EUR J GASTROEN HEPAT, V13, P741, DOI 10.1097/00042737-200106000-00023; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; Tye-Din JA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001012; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; Winkler DFH, 2009, METHODS MOL BIOL, V570, P157, DOI 10.1007/978-1-60327-394-7_5	39	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2017	12	7							e0181566	10.1371/journal.pone.0181566	http://dx.doi.org/10.1371/journal.pone.0181566			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3TH	28759621	Green Published, Green Submitted, gold			2023-01-03	WOS:000406761600020
J	Qin, G; Lo, JW; Marlow, N; Calvert, SA; Greenough, A; Peacock, JL				Qin, Gordon; Lo, Jessica W.; Marlow, Neil; Calvert, Sandy A.; Greenough, Anne; Peacock, Janet L.			Postnatal dexamethasone, respiratory and neurodevelopmental outcomes at two years in babies born extremely preterm	PLOS ONE			English	Article							CHRONIC LUNG-DISEASE; FREQUENCY OSCILLATORY VENTILATION; CONTROLLED-TRIAL; FOLLOW-UP; AGE; CORTICOSTEROIDS; PREVENTION; THERAPY; INFANTS	Importance Postnatal dexamethasone is associated with reduction in bronchopulmonary dysplasia. There remains, however, concern that its short-term benefits are accompanied by long-term adverse effects e.g. poorer neurodevelopmental outcomes. Objective Our aim was to determine the effects of administration of postnatal dexamethasone on respiratory and neurodevelopmental outcome at two years of age after adjusting for neonatal and infant risk factors. Materials and methods The study included 412 infants born at 23-28 weeks of gestation, 29% had received postnatal dexamethasone. Two outcomes were examined, respiratory hospital admissions in the past 12 months and neurodevelopmental impairment. Logistic regression, adjusted for sex, birthweight z-score, gestation, maternal smoking, oxygen dependency at 36 weeks, airleak, patent ductus arteriosus, pulmonary haemorrhage, major ultrasound abnormality, mode of ventilation and age at assessment, was undertaken. Results After adjustment, postnatal dexamethasone was associated with significantly increased proportions of both respiratory hospital readmission: (0.35 vs 0.15, difference = 0.20; 95% CI: 0.08, 0.31) and neurodevelopmental impairment (0.59 vs 0.45, difference = 0.14; 95% CI: 0.02, 0.26). Conclusions Postnatal dexamethasone use in extremely preterm infants is associated with increased risks of respiratory hospital admissions and neurodevelopmental impairment. These associations were not explained by excess neonatal morbidities.	[Qin, Gordon; Lo, Jessica W.; Peacock, Janet L.] Kings Coll London, Div Hlth & Social Care Res, London, England; [Qin, Gordon] Queen Alexandra Hosp, Portsmouth, Hants, England; [Lo, Jessica W.; Greenough, Anne] Univ New South Wales, UNSW Med, Sch Psychiat, Randwick, NSW, Australia; [Marlow, Neil] UCL, Inst Womens Hlth, London, England; [Calvert, Sandy A.] St Georges Univ London, Dept Child Hlth, London, England; [Greenough, Anne] Kings Coll London, Div Asthma Allergy & Lung Biol, London, England	University of London; King's College London; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of New South Wales Sydney; University of London; University College London; St Georges University London; University of London; King's College London	Peacock, JL (corresponding author), Kings Coll London, Div Hlth & Social Care Res, London, England.	janet.peacock@kcl.ac.uk	Marlow, Neil/D-2918-2009	Marlow, Neil/0000-0001-5890-2953; Peacock, Janet/0000-0002-0310-2518; Greenough, Anne/0000-0002-8672-5349	Medical Research Council; National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London; MRC [G1002276] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B, G1002276] Funding Source: researchfish; National Institute for Health Research [NF-SI-0616-10093] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	The original UKOS Study was funded by the Medical Research Council (1997). This secondary analysis was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health. JLP is an NIHR Senior Investigator.	Baud O, 1999, ARCH DIS CHILD-FETAL, V80, pF159; Baud O, 2004, ARCH DIS CHILD-FETAL, V89, P96, DOI 10.1136/adc.2003.028696; Doyle LW, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001146.pub4; Gross SJ, 2005, PEDIATRICS, V115, P681, DOI 10.1542/peds.2004-0956; Halliday HL, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001145.pub2, 10.1002/14651858.CD001146.pub2]; Johnson AH, 2002, NEW ENGL J MED, V347, P633, DOI 10.1056/NEJMoa020432; JONES R, 1991, PEDIATRICS, V88, P421; Jones RAK, 2005, PEDIATRICS, V116, P379, DOI 10.1542/peds.2004-1819; Khalife N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081394; Marlow N, 2006, ARCH DIS CHILD-FETAL, V91, P320, DOI 10.1136/adc.2005.079632; Mieskonen S, 2003, ACTA PAEDIATR, V92, P896, DOI 10.1080/08035250310003451; Nixon PA, 2007, J PEDIATR-US, V150, P345, DOI 10.1016/j.jpeds.2006.12.013; Smith LJ, 2011, J PAEDIATR CHILD H, V47, P448, DOI 10.1111/j.1440-1754.2010.01992.x; Tschanz SA, 1997, PEDIATR PULM, P247; Vyas J, 1997, ARCH DIS CHILD-FETAL, V77, pF147, DOI 10.1136/fn.77.2.F147; Wilson-Costello D, 2009, PEDIATRICS, V123, pe430, DOI 10.1542/peds.2008-1928; Yeh TF, 2004, NEW ENGL J MED, V350, P1304, DOI 10.1056/NEJMoa032089	17	14	15	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2017	12	7							e0181176	10.1371/journal.pone.0181176	http://dx.doi.org/10.1371/journal.pone.0181176			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3UH	28723921	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000406067800038
J	Fuller, BM; Carpenter, CR				Fuller, Brian M.; Carpenter, Christopher R.			Pooled RCTs: Early goal-directed therapy does not reduce mortality more than usual care in early septic shock	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SEVERE SEPSIS; RESUSCITATION; TRIAL		[Fuller, Brian M.; Carpenter, Christopher R.] Washington Univ, St Louis, MO 63130 USA	Washington University (WUSTL)	Fuller, BM (corresponding author), Washington Univ, St Louis, MO 63130 USA.		Carpenter, Christopher R./E-3720-2013	Carpenter, Christopher R./0000-0002-2603-7157				Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Nguyen HB, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1288-3; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	6	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 18	2017	167	2					JC6	JC6		10.7326/ACPJC-2017-167-2-006	http://dx.doi.org/10.7326/ACPJC-2017-167-2-006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA6SD	28715828				2023-01-03	WOS:000405573400007
J	Al-Saffar, NMS; Agliano, A; Marshall, LV; Jackson, LE; Balarajah, G; Sidhu, J; Clarke, PA; Jones, C; Workman, P; Pearson, ADJ; Leach, MO				Al-Saffar, Nada M. S.; Agliano, Alice; Marshall, Lynley V.; Jackson, L. Elizabeth; Balarajah, Geetha; Sidhu, Jasmin; Clarke, Paul A.; Jones, Chris; Workman, Paul; Pearson, Andrew D. J.; Leach, Martin O.			In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells	PLOS ONE			English	Article							BREAST-CANCER CELLS; HIGH-GRADE GLIOMA; BRAIN-TUMORS; CLINICAL-TRIALS; CHILDREN; ADULT; PATHWAY; AGENTS; AKT; PHOSPHOCHOLINE	Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor. Our aim is to assess whether this combination results in metabolic changes that are detectable by nuclear magnetic resonance (NMR) spectroscopy, potentially providing metabolic biomarkers for PI3K inhibition and TMZ combination treatment. Using two genetically distinct paediatric glioblastoma cell lines, SF188 and KNS42, in vitro H-1-NMR analysis following treatment with the dual pan-Class I PI3K/mTOR inhibitor PI-103 resulted in a decrease in lactate and phosphocholine (PC) levels (P<0.02) relative to control. In contrast, treatment with TMZ caused an increase in glycerolphosphocholine (GPC) levels (P <= 0.05). Combination of PI-103 with TMZ showed metabolic effects of both agents including a decrease in the levels of lactate and PC (P<0.02) while an increase in GPC (P<0.05). We also report a decrease in the protein expression levels of HK2, LDHA and CHKA providing likely mechanisms for the depletion of lactate and PC, respectively. Our results show that our in vitro NMR-detected changes in lactate and choline metabolites may have potential as non-invasive biomarkers for monitoring response to combination of PI3K/mTOR inhibitors with TMZ during clinical trials in children with glioblastoma, subject to further in vivo validation.	[Al-Saffar, Nada M. S.; Agliano, Alice; Jackson, L. Elizabeth; Balarajah, Geetha; Sidhu, Jasmin; Leach, Martin O.] Inst Canc Res, Div Radiotherapy & Imaging, Canc Res UK Canc Imaging Ctr, London, England; [Al-Saffar, Nada M. S.; Agliano, Alice; Marshall, Lynley V.; Jackson, L. Elizabeth; Balarajah, Geetha; Sidhu, Jasmin; Jones, Chris; Pearson, Andrew D. J.; Leach, Martin O.] Royal Marsden NHS Fdn Trust, London, England; [Marshall, Lynley V.; Jones, Chris; Pearson, Andrew D. J.] Inst Canc Res, Div Canc Therapeut, London, England; [Marshall, Lynley V.; Jones, Chris] Inst Canc Res, Div Mol Pathol, London, England; [Marshall, Lynley V.; Pearson, Andrew D. J.] Inst Canc Res, Div Clin Studies, London, England; [Clarke, Paul A.; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, Div Canc Therapeut, London, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Al-Saffar, NMS (corresponding author), Inst Canc Res, Div Radiotherapy & Imaging, Canc Res UK Canc Imaging Ctr, London, England.; Al-Saffar, NMS (corresponding author), Royal Marsden NHS Fdn Trust, London, England.	Nada.Al-Saffar@icr.ac.uk	leach, martin o/C-2248-2008; Jones, Chris/ABE-6059-2021	leach, martin o/0000-0002-0756-5368; Jones, Chris/0000-0001-8118-2296; Al-Saffar, Nada/0000-0002-1292-0889; Clarke, Paul/0000-0001-9342-1290	Brain Tumour Charity [6/54]; Oak Foundation [OCay-04-169]; Cancer Research UK; EPSRC Cancer Imaging Centre; MRC; Department of Health (England) [C1060/A10334, C1060/6916]; Cancer Research UK Life Chair and Programme Grant within a Cancer Research UK ICR Core Award [C347/A15403]; Cancer Research UK [C309/A2187, C309/A8274]; National Health Service; Cancer Research UK [16464] Funding Source: researchfish; The Brain Tumour Charity [6/54] Funding Source: researchfish	Brain Tumour Charity; Oak Foundation; Cancer Research UK(Cancer Research UK); EPSRC Cancer Imaging Centre(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health (England); Cancer Research UK Life Chair and Programme Grant within a Cancer Research UK ICR Core Award; Cancer Research UK(Cancer Research UK); National Health Service; Cancer Research UK(Cancer Research UK); The Brain Tumour Charity	This work was supported by The Brain Tumour Charity grant 6/54 for N.M.S.A, GB and AA; The Oak Foundation grant OCay-04-169 for LVM; Cancer Research UK and EPSRC Cancer Imaging Centre in association with the MRC and Department of Health (England) grant C1060/A10334, C1060/6916 for MOL, NMSA, LEJ and TE; Cancer Research UK Life Chair and Programme Grant included within a Cancer Research UK ICR Core Award (C347/A15403) to AP; Cancer Research UK (C309/A2187, C309/A8274) to PW and PAC. PW is a Cancer Research UK Life Fellow; MOL is an NIHR senior investigator. The Institute of Cancer Research co-authors acknowledge National Health Service funding to the Biomedical Research Centre. The funders had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript.	Aboagye EO, 1999, CANCER RES, V59, P80; Agnihotri S, 2014, CANCER DISCOV, V4, P1198, DOI 10.1158/2159-8290.CD-14-0157; Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Al-Saffar NMS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103835; Al-Saffar NMS, 2010, CANCER RES, V70, P5507, DOI 10.1158/0008-5472.CAN-09-4476; Arias-Mendoza F, 2013, ACAD RADIOL, V20, P1122, DOI 10.1016/j.acra.2013.04.013; Bartels U, 2011, CURR ONCOL, V18, pE19; Bax DA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005209; Beloueche-Babari M, 2006, MOL CANCER THER, V5, P187, DOI 10.1158/1535-7163.MCT-03-0220; Beloueche-Babari M, 2010, BRIT J CANCER, V102, P1, DOI 10.1038/sj.bjc.6605457; Beloueche-Babari M, 2011, CELL CYCLE, V10, P2883, DOI 10.4161/cc.10.17.17192; Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426; Broniscer A, 2006, J NEURO-ONCOL, V76, P313, DOI 10.1007/s11060-005-7409-5; Bulik M, 2013, CLIN NEUROL NEUROSUR, V115, P146, DOI 10.1016/j.clineuro.2012.11.002; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Caporali S, 2008, MOL PHARMACOL, V74, P173, DOI 10.1124/mol.107.044743; Chaumeil MM, 2015, BRAIN PATHOL, V25, P769, DOI 10.1111/bpa.12310; Chaumeil MM, 2012, NEUROIMAGE, V59, P193, DOI 10.1016/j.neuroimage.2011.07.034; Chung YL, 2003, J NATL CANCER I, V95, P1624, DOI 10.1093/jnci/djg084; Clarke PA, 2012, J CLIN ONCOL, V30, P331, DOI 10.1200/JCO.2011.38.7167; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; De Salvo M, 2011, INT J RADIAT BIOL, V87, P518, DOI 10.3109/09553002.2011.556173; Gadian DG, 1995, INFORMATION AVAILABL, P29; Figueiras RG, 2011, RADIOGRAPHICS, V31, P2059, DOI 10.1148/rg.317115108; Gaspar N, 2010, CANCER RES, V70, P9243, DOI 10.1158/0008-5472.CAN-10-1250; Glunde K, 2015, EXPERT REV MOL DIAGN, V15, P735, DOI 10.1586/14737159.2015.1039515; Gutte H, 2015, AM J NUCL MED MOLEC, V5, P548; Hargrave Darren R, 2007, Expert Rev Neurother, V7, P1029, DOI 10.1586/14737175.7.8.1029; Harris LM, 2015, NMR BIOMED, V28, P338, DOI 10.1002/nbm.3255; Hourani R, 2006, J MAGN RESON IMAGING, V23, P99, DOI 10.1002/jmri.20480; Jones C., 2016, NEUROONCOL; Jones C, 2012, NAT REV CLIN ONCOL, V9, P400, DOI 10.1038/nrclinonc.2012.87; Kurhanewicz J, 2011, NEOPLASIA, V13, P81, DOI 10.1593/neo.101102; Kwak EL, 2007, CLIN CANCER RES, V13, P5232, DOI 10.1158/1078-0432.CCR-07-1385; Lee SC, 2013, NMR BIOMED, V26, P106, DOI 10.1002/nbm.2825; McKnight TR, 2004, SEMIN ONCOL, V31, P605, DOI 10.1053/j.seminoncol.2004.07.003; Moller-Hartmann W, 2002, NEURORADIOLOGY, V44, P371, DOI 10.1007/s00234-001-0760-0; Murphy PS, 2004, BRIT J CANCER, V90, P781, DOI 10.1038/sj.bjc.6601593; Nelson SJ, 2011, NMR BIOMED, V24, P734, DOI 10.1002/nbm.1669; Novaka J, 2014, EUR J RADIOL, V83, pE106, DOI 10.1016/j.ejrad.2013.11.009; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Peet AC, 2012, NAT REV CLIN ONCOL, V9, P700, DOI 10.1038/nrclinonc.2012.187; Radoul M, 2016, MOL CANCER THER, V15, P1113, DOI 10.1158/1535-7163.MCT-15-0769; Ruggiero A, 2006, J NEURO-ONCOL, V77, P89, DOI 10.1007/s11060-005-9011-2; Shuttleworth SJ, 2011, CURR MED CHEM, V18, P2686; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Su JS, 2012, NMR BIOMED, V25, P379, DOI 10.1002/nbm.1764; Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210; Venkatesh HS, 2012, NEURO-ONCOLOGY, V14, P315, DOI 10.1093/neuonc/nor209; Workman P, 2006, JNCI-J NATL CANCER I, V98, P580, DOI 10.1093/jnci/djj162; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yu ZY, 2015, CANCER LETT, V367, P58, DOI 10.1016/j.canlet.2015.07.007	54	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2017	12	7							e0180263	10.1371/journal.pone.0180263	http://dx.doi.org/10.1371/journal.pone.0180263			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA7TL	28704425	gold, Green Submitted, Green Published			2023-01-03	WOS:000405649700034
J	Mohamed, S; Johnson, GR; Chen, P; Hicks, PB; Davis, LL; Yoon, J; Gleason, TC; Vertrees, JE; Weingart, K; Tal, I; Scrymgeour, A; Lawrence, DD; Planeta, B; Thase, ME; Huang, GD; Zisook, S				Mohamed, Somaia; Johnson, Gary R.; Chen, Peijun; Hicks, Paul B.; Davis, Lori L.; Yoon, Jean; Gleason, Theresa C.; Vertrees, Julia E.; Weingart, Kimberly; Tal, Ilanit; Scrymgeour, Alexandra; Lawrence, David D.; Planeta, Beata; Thase, Michael E.; Huang, Grant D.; Zisook, Sidney		VAST-D Investigators	Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTPATIENTS; GUIDELINES; OUTCOMES; FAILURE; SSRIS; MOOD; SR	IMPORTANCE Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. OBJECTIVE To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. DESIGN, SETTING, AND PARTICIPANTS From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study. Patients were randomly assigned (1:1:1) to 1 of 3 treatments and evaluated for up to 36 weeks. INTERVENTIONS Switch to a different antidepressant, bupropion (switch group, n=511); augment current treatment with bupropion (augment-bupropion group, n=506); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, n=505) for 12 weeks (acute treatment phase) and up to 36 weeks for longer-term follow-up (continuation phase). MAIN OUTCOMES AND MEASURES The primary outcome was remission during the acute treatment phase (16-item Quick Inventory of Depressive Symptomatology-Clinician Rated [QIDS-C-16] score <= 5 at 2 consecutive visits). Secondary outcomes included response (>= 50% reduction in QIDS-C-16 score or improvement on the Clinical Global Impression Improvement scale), relapse, and adverse effects. RESULTS Among 1522 randomized patients (mean age, 54.4 years; men, 1296 [85.2%]), 1137 (74.7%) completed the acute treatment phase. Remission rates at 12 weeks were 22.3% (n=114) for the switch group, 26.9% (n=136)for the augment-bupropion group, and 28.9% (n=146) for the augment-aripiprazole group. The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P=.02), but other remission comparisons were not significant. Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]). No significant treatment differences were observed for relapse. Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n=124] vs 16.6% in the augment-aripiprazole group [n=84]; and 22.5% in augment-bupropion group [n=114]). Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain. CONCLUSIONS and Relevance Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy. Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.	[Mohamed, Somaia] VA Connecticut Healthcare Syst, Vet Affairs VA New England Mental Illness Res Edu, 950 Campbell Ave,Mailstop 182, West Haven, CT 06516 USA; [Mohamed, Somaia] Yale Univ, Sch Med, West Haven, CT 06516 USA; [Johnson, Gary R.; Lawrence, David D.; Planeta, Beata] VA Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, 950 Campbell Ave,Mailstop 182, West Haven, CT 06516 USA; [Chen, Peijun] Louis Stokes VA Med Ctr, Cleveland, OH USA; [Chen, Peijun] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Hicks, Paul B.] Cent Texas Vet Healthcare Syst, Temple, TX USA; [Hicks, Paul B.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Psychiat & Behav Sci, Temple, TX USA; [Davis, Lori L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA; [Davis, Lori L.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; [Yoon, Jean] VA Palo Alto, Hlth Econ Resource Ctr, Menlo Pk, CA USA; [Gleason, Theresa C.] Off Res & Dev, Dept Vet Affairs, Washington, DC USA; [Vertrees, Julia E.; Scrymgeour, Alexandra] Clin Res Pharm Coordinating Ctr, Cooperat Studies Program, Albuquerque, NM USA; [Weingart, Kimberly; Tal, Ilanit; Zisook, Sidney] VA San Diego Healthcare Syst, San Diego, CA USA; [Weingart, Kimberly; Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA; [Thase, Michael E.] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Huang, Grant D.] Off Res & Dev, Dept Vet Affairs, Cooperat Studies Program, Cent Off, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Mohamed, S (corresponding author), VA Connecticut Healthcare Syst, 950 Campbell Ave,Mailstop 182, West Haven, CT 06516 USA.	somaia.mohamed@va.gov	Hicks, Paul/AAW-7599-2021; Hicks, Paul/AAF-6121-2021	Hicks, Paul/0000-0002-3921-9056	Veterans Affairs Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Veterans Affairs Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by the Veterans Affairs Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development, which participated in the design and oversaw the conduct of the study including data collection and management and analysis. Bristol-Myers Squibb provided aripiprazole for use in this study.	Adams JR, 2006, COMMUNITY MENT HLT J, V42, P87, DOI 10.1007/s10597-005-9005-8; American Psychiatric Association, 2010, PRACTICE GUIDELINE T, V3rd; Arbaizar B, 2009, GEN HOSP PSYCHIAT, V31, P478, DOI 10.1016/j.genhosppsych.2009.05.005; Barrett E, 2004, OBES RES, V12, P362; Center for Behavioral Health Statistics and Quality, KEY SUBST US MENT HL; Cleare A, 2015, J PSYCHOPHARMACOL, V29, P459, DOI 10.1177/0269881115581093; Fava M, 2008, AM J PSYCHIAT, V165, P342, DOI 10.1176/appi.ajp.2007.06111868; Goldberg JF, 2015, DEPRESS ANXIETY, V32, P605, DOI 10.1002/da.22378; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; Han C, 2015, J PSYCHIATR RES, V66-67, P84, DOI 10.1016/j.jpsychires.2015.04.020; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Israel JA, 2006, J PSYCHOPHARMACOL, V20, P5, DOI 10.1177/1359786806064306; Kennedy SH, 2016, CAN J PSYCHIAT, V61, P540, DOI 10.1177/0706743716659417; Kolovos S, 2017, J AFFECT DISORDERS, V210, P72, DOI 10.1016/j.jad.2016.12.013; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Management of MDD Working Group, CLIN PRACT GUID MAN; Mohamed S, 2015, PSYCHIAT RES, V229, P760, DOI 10.1016/j.psychres.2015.08.005; Mohamed S, 2009, J CLIN PSYCHIAT, V70, P906, DOI 10.4088/JCP.08m04450; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Rush AJ, 2009, CNS DRUGS, V23, P627, DOI 10.2165/00023210-200923080-00001; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Rush AJ, 2006, NEW ENGL J MED, V354, P1231, DOI 10.1056/NEJMoa052963; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P41; Trivedi MH, 2009, J CLIN PSYCHIAT, V70, P26, DOI 10.4088/JCP.8133su1c.04; Trivedi MH, 2006, NEW ENGL J MED, V354, P1243, DOI 10.1056/NEJMoa052964; Wisniewski Stephen R, 2006, J Psychiatr Pract, V12, P71, DOI 10.1097/00131746-200603000-00002; Zisook S, 2016, J AFFECT DISORDERS, V206, P232, DOI 10.1016/j.jad.2016.07.023	30	82	83	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2017	318	2					132	145		10.1001/jama.2017.8036	http://dx.doi.org/10.1001/jama.2017.8036			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA1HS	28697253	Green Published			2023-01-03	WOS:000405190800015
J	Kehayas, V; Holtmaat, A				Kehayas, Vassilis; Holtmaat, Anthony			Rejuvenating brain plasticity	SCIENCE			English	Editorial Material							AUDITORY-CORTEX; NUCLEUS BASALIS; CRITICAL PERIOD; MEMORY; SYSTEM		[Kehayas, Vassilis; Holtmaat, Anthony] Univ Geneva, Dept Basic Neurosci, Geneva, Switzerland	University of Geneva	Holtmaat, A (corresponding author), Univ Geneva, Dept Basic Neurosci, Geneva, Switzerland.	anthony.holtmaat@unige.ch	Kehayas, Vassilis/I-1154-2019	Kehayas, Vassilis/0000-0002-8759-2808; Holtmaat, Anthony/0000-0002-7577-0769	Swiss National Science Foundation [31003A-153448, CRSIII-154453]; International Foundation for Research in Paraplegia	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); International Foundation for Research in Paraplegia	Financial support to V.K. and A.H. is provided by the Swiss National Science Foundation (31003A-153448; CRSIII-154453) and the International Foundation for Research in Paraplegia.	Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; Blundon JA, 2017, SCIENCE, V356, P1352, DOI 10.1126/science.aaf4612; Blundon JA, 2011, J NEUROSCI, V31, P16012, DOI 10.1523/JNEUROSCI.3281-11.2011; Chun SK, 2013, J NEUROSCI, V33, P7345, DOI 10.1523/JNEUROSCI.4500-12.2013; Feldman DE, 2009, ANNU REV NEUROSCI, V32, P33, DOI 10.1146/annurev.neuro.051508.135516; Froemke RC, 2007, NATURE, V450, P425, DOI 10.1038/nature06289; Holtmaat A, 2009, NAT REV NEUROSCI, V10, P647, DOI 10.1038/nrn2699; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; King AJ, 2009, NAT NEUROSCI, V12, P698, DOI 10.1038/nn.2308; Kullmann DM, 2012, NEURON, V75, P951, DOI 10.1016/j.neuron.2012.07.030; Kuroda S, 2001, CHEM PHARM BULL, V49, P988, DOI 10.1248/cpb.49.988; Miller LM, 2001, NEURON, V32, P151, DOI 10.1016/S0896-6273(01)00445-7; Nakahara H, 2004, P NATL ACAD SCI USA, V101, P7170, DOI 10.1073/pnas.0401196101; Stepanyants A, 2002, NEURON, V34, P275, DOI 10.1016/S0896-6273(02)00652-9; Zhang LI, 2001, NAT NEUROSCI, V4, P1123, DOI 10.1038/nn745	15	4	4	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2017	356	6345					1335	1336		10.1126/science.aan8374	http://dx.doi.org/10.1126/science.aan8374			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EY9XE	28663458				2023-01-03	WOS:000404351500019
J	Ma, Y; Wang, YH; Xu, ZH; Wang, YJ; Fallon, JK; Liu, F				Ma, Yan; Wang, Yuhua; Xu, Zhenghong; Wang, Yongjun; Fallon, John K.; Liu, Feng			Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp	PLOS ONE			English	Article							TUMOR MICROENVIRONMENT; DRUG-RESISTANCE; MULTIDRUG-RESISTANCE; CHEMOTHERAPY; GLYCOPROTEIN; CELLS; INHIBITION; SECRETION; EFFICACY; IMPROVES	We conducted a prospective, meaningful study of extreme low dose of 5-fluorouracil (5FU) as a metronomic agent targeting cancer associated fibroblasts (CAFs) to reverse Multidrug resistance (MDR) by sensitizing cancer associated fibroblasts and down-regulating P-glycoprotein (P-gp). The combination of 5FU and Taxol inhibited resistant KB-8-5 tumor growth by 79% and H460/Tax-R tumor growth by 55%. The inhibition was significant for both tumor types compared with Taxol treatment alone (p<0.001 and p = 0.0067, respectively). Nevertheless, the low -dose 5FU (2.2 mg/kg compared to the therapeutic dose of 50-150 mg/kg) showed negligible tumor inhibitory effect. The tumor growth inhibition study on resistant tumors demonstrated that the continuous administration of low dose 5FU with Taxol significantly inhibited the tumor growth. The treatment overcomes drug resistance in tumors by down -regulating multi -drug resistance transporter protein (P-gp), and more importantly, by eliminating CAFs recruited by resistant tumors. Compared with traditional metronomic chemotherapy, 5FU as metronomic agent targeting CAFs can avoid the disadvantages resulted from the concomitant administration of antiangiogenetic drug. The approach has good translational potential for clinical trials when treating stroma-rich drug resistant tumors.	[Ma, Yan; Wang, Yuhua; Xu, Zhenghong; Wang, Yongjun; Fallon, John K.; Liu, Feng] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA; [Ma, Yan] Guangzhou Univ Chinese Med, Sch Chinese Mat Med, Guangzhou, Guangdong, Peoples R China; [Wang, Yongjun] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Guangzhou University of Chinese Medicine; Shenyang Pharmaceutical University	Ma, Y; Wang, YH (corresponding author), Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.; Ma, Y (corresponding author), Guangzhou Univ Chinese Med, Sch Chinese Mat Med, Guangzhou, Guangdong, Peoples R China.	mygzhtcm@163.com; yhw_albert@163.com		Fallon, John/0000-0003-1848-0121	National Cancer Institute National Institutes of Health [5R01CA149387]; National Nature Science Foundation of China [81403109]; Science and Technology Planning Project of Guangdong Province [2014A020210021]; NATIONAL CANCER INSTITUTE [R01CA149387] Funding Source: NIH RePORTER	National Cancer Institute National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by: 1. National Cancer Institute National Institutes of Health (5R01CA149387), Feng Liu; 2. National Nature Science Foundation of China (81403109), Yan Ma; 3. Science and Technology Planning Project of Guangdong Province (2014A020210021), Yan Ma.	Benasso M, 1997, SEMIN ONCOL, V24, pS46; Binkhathlan Z, 2013, CURR CANCER DRUG TAR, V13, P326, DOI 10.2174/15680096113139990076; Blansfield JA, 2008, CLIN CANCER RES, V14, P270, DOI 10.1158/1078-0432.CCR-07-1562; Brenda PN, 2000, CLIN BREAST CANCER, V1, P136; Browder T, 2000, CANCER RES, V60, P1878; Callaghan R, 2014, DRUG METAB DISPOS, V42, P623, DOI 10.1124/dmd.113.056176; Cristiane CD, 2000, FOOD CHEM TOXICOL, V48, P3120; Cruz JJ, 2008, CANCER TREAT REV, V34, P268, DOI 10.1016/j.ctrv.2007.12.004; Han EKH, 2000, EUR J CANCER, V36, P1565, DOI 10.1016/S0959-8049(00)00145-3; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Johnson LM, 2013, CANCER BIOL THER, V14, P90, DOI 10.4161/cbt.22636; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; PIWNICAWORMS D, 1993, CANCER RES, V53, P977; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Yan M, 2014, MOL PHARM, V11, P2623	19	10	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180023	10.1371/journal.pone.0180023	http://dx.doi.org/10.1371/journal.pone.0180023			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662182	Green Published, gold, Green Submitted			2023-01-03	WOS:000404608300089
J	Riaz, N; Havel, JJ; Makarov, V; Desrichard, A; Urba, WJ; Sims, JS; Hodi, FS; Martin-Algarra, S; Mandal, R; Sharfman, WH; Bhatia, S; Hwu, WJ; Gajewski, TF; Slingluff, CL; Chowell, D; Kendall, SM; Chang, H; Shah, R; Kuo, FS; Morris, LGT; Sidhom, JW; Schneck, JP; Horak, CE; Weinhold, N; Chan, TA				Riaz, Nadeem; Havel, Jonathan J.; Makarov, Vladimir; Desrichard, Alexis; Urba, Walter J.; Sims, Jennifer S.; Hodi, F. Stephen; Martin-Algarra, Salvador; Mandal, Rajarsi; Sharfman, William H.; Bhatia, Shailender; Hwu, Wen-Jen; Gajewski, Thomas F.; Slingluff, Craig L., Jr.; Chowell, Diego; Kendall, Sviatoslav M.; Chang, Han; Shah, Rachna; Kuo, Fengshen; Morris, Luc G. T.; Sidhom, John-William; Schneck, Jonathan P.; Horak, Christine E.; Weinhold, Nils; Chan, Timothy A.			Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab	CELL			English	Article							IMMUNE CHECKPOINT BLOCKADE; SOMATIC POINT MUTATIONS; CELL LUNG-CANCER; METASTATIC MELANOMA; PD-1 BLOCKADE; CTLA-4 BLOCKADE; THERAPY; NEOANTIGENS; EXPRESSION; CARCINOMA	The mechanisms by which immune checkpoint blockade modulates tumor evolution during therapy are unclear. We assessed genomic changes in tumors from 68 patients with advanced melanoma, who progressed on ipilimumab or were ipilimumabnaive, before and after nivolumab initiation (CA209-038 study). Tumors were analyzed by whole-exome, transcriptome, and/or T cell receptor (TCR) sequencing. In responding patients, mutation and neoantigen load were reduced from baseline, and analysis of intratumoral heterogeneity during therapy demonstrated differential clonal evolution within tumors and putative selection against neoantigenic mutations on-therapy. Transcriptome analyses before and during nivolumab therapy revealed increases in distinct immune cell subsets, activation of specific transcriptional networks, and upregulation of immune checkpoint genes that were more pronounced in patients with response. Temporal changes in intratumoral TCR repertoire revealed expansion of T cell clones in the setting of neoantigen loss. Comprehensive genomic profiling data in this study provide insight into nivolumab's mechanism of action.	[Riaz, Nadeem; Havel, Jonathan J.; Makarov, Vladimir; Desrichard, Alexis; Sims, Jennifer S.; Chowell, Diego; Kendall, Sviatoslav M.; Shah, Rachna; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Riaz, Nadeem; Weinhold, Nils; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Riaz, Nadeem; Makarov, Vladimir; Sims, Jennifer S.; Chowell, Diego; Kendall, Sviatoslav M.; Kuo, Fengshen; Morris, Luc G. T.; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA; [Urba, Walter J.] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR 97213 USA; [Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Martin-Algarra, Salvador] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Med Oncol, Pamplona 31008, Spain; [Mandal, Rajarsi; Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Sharfman, William H.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Bhatia, Shailender] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98105 USA; [Hwu, Wen-Jen] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Gajewski, Thomas F.] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Slingluff, Craig L., Jr.] Univ Virginia, Sch Med, Dept Surg, Charlottesville, VA 22908 USA; [Slingluff, Craig L., Jr.] Univ Virginia, Sch Med, Canc Ctr, Charlottesville, VA 22908 USA; [Chang, Han; Horak, Christine E.] Bristol Myers Squibb, Princeton, NJ 08648 USA; [Sidhom, John-William; Schneck, Jonathan P.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; University of Navarra; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; University of Chicago; University of Virginia; University of Virginia; Bristol-Myers Squibb; Johns Hopkins University	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Weinhold, N; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA.	weinholn@mskcc.org; chant@mskcc.org	Martín-Algarra, Salvador/CAF-3626-2022; Shah, Rachna/AAY-1788-2021; Chan, Timothy A/ABD-5850-2021	Martín-Algarra, Salvador/0000-0002-3109-8026; Shah, Rachna/0000-0002-3639-7113; Riaz, Nadeem/0000-0001-9873-5862; Havel, Jonathan/0000-0003-0951-510X; Sidhom, John-William/0000-0002-5575-0285	Bristol-Myers Squibb; Pershing Square Sohn Cancer Research Foundation; PaineWebber Chair; Stand Up 2 Cancer; Memorial Sloan Kettering Cancer Center [5P30 CA008748-50]; STARR Cancer Consortium; Abraxis; Amgen; Bionomics; EMD Serono; Immune Design; Immunogen; Merck; NantKwest; OncoSec; Genentech; Incyte; Ono; Seattle Genetics; AbbVie; Aduro; Bayer; Jounce Therapeutics; stock shareholder of Jounce Therapeutics; Novartis; GlaxoSmithKline; MedImmune; Castle Biosciences; Polynoma; Green Peptide; eTheRNA; NATIONAL CANCER INSTITUTE [R01CA205426, P30CA016672, R01CA177828, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE024774] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Pershing Square Sohn Cancer Research Foundation(Pershing Square Sohn Cancer Research Alliance); PaineWebber Chair; Stand Up 2 Cancer; Memorial Sloan Kettering Cancer Center; STARR Cancer Consortium; Abraxis; Amgen(Amgen); Bionomics; EMD Serono; Immune Design; Immunogen; Merck(Merck & Company); NantKwest; OncoSec; Genentech(Roche HoldingGenentech); Incyte; Ono; Seattle Genetics; AbbVie(AbbVie); Aduro; Bayer(Bayer AG); Jounce Therapeutics; stock shareholder of Jounce Therapeutics; Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Castle Biosciences; Polynoma; Green Peptide; eTheRNA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We first thank each patient and their families for participation in this study. This work was funded by Bristol-Myers Squibb, the Pershing Square Sohn Cancer Research Foundation (T.A.C.), the PaineWebber Chair (T.A.C.), Stand Up 2 Cancer (T.A.C.), the Memorial Sloan Kettering Cancer Center (core grant 5P30 CA008748-50), and the STARR Cancer Consortium (T.A.C.). S.B. reports grants from Abraxis, Amgen, Bionomics, Bristol-Myers Squibb, EMD Serono, Immune Design, Immunogen, Merck, NantKwest, and OncoSec, and personal fees from Genentech. T.A.C. is a co-founder of Gritstone Oncology and reports research grants from Bristol-Myers Squibb. H.C. and C.E.H. are full-time employees and stock shareholders of Bristol-Myers Squibb. T.F.G. reports grants from Bristol-Myers Squibb, Incyte, Merck, Ono, Genentech, and Seattle Genetics, personal fees from AbbVie, Aduro, Bayer, Jounce Therapeutics, Merck, and Genentech, and is a stock shareholder of Jounce Therapeutics. J.J.H. reports that spouse is a full-time employee of Regeneron Pharmaceuticals. F.S.H. reports grants from Bristol-Myers Squibb and personal fees from Bristol-Myers Squibb, EMD Serono, Genentech, Merck, and Novartis. W.-J.H. reports grants from Bristol-Myers Squibb, GlaxoSmithKline, MedImmune, and Merck, and personal fees from Merck. F.K. and V.M. report grants from Bristol-Myers Squibb. S.M.-A. reports personal fees from Bristol-Myers Squibb and Merck. L.G.T.M. reports personal fees from Merck. N.R. reports grants from Bristol-Myers Squibb, and personal fees from MedImmune. J.P.S. reports grants and personal fees from, and is a stock shareholder of, NexImmune. W.H.S. reports grants from Bristol-Myers Squibb and Merck and personal fees from Bristol-Myers Squibb, Castle Biosciences, Merck, and Novartis. C.L.S. reports grants from Merck and Polynoma, personal fees from Immatics, and is a patent holder for the University of Virginia. W.J.U. reports grants and personal fees from Bristol-Myers Squibb and MedImmune and personal fees from Green Peptide and eTheRNA. Medical writing and editorial assistance provided by Amrita Dervan, MSc, and Jay Rathi, MA, of Spark Medica (US), funded by Bristol-Myers Squibb.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Arnaud-Haond S, 2007, MOL ECOL, V16, P5115, DOI 10.1111/j.1365-294X.2007.03535.x; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Dako, 2016, PD L1 IHC 28 8 PHARM; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Emerson R, 2013, J IMMUNOL METHODS, V391, P14, DOI 10.1016/j.jim.2013.02.002; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; HODI FS, 2016, CANCER RES S14, V76; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Larkin J., 2017, J CLIN ONCOL; Larson DE, 2012, BIOINFORMATICS, V28, P311, DOI 10.1093/bioinformatics/btr665; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Morris LGT, 2016, ONCOTARGET, V7, P10051, DOI 10.18632/oncotarget.7067; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677; Riaz N, 2016, INT IMMUNOL, V28, P411, DOI 10.1093/intimm/dxw019; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Salerno EP, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1240857; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Sims JS, 2016, P NATL ACAD SCI USA, V113, pE3529, DOI 10.1073/pnas.1601012113; Six A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00413; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Sweis RF, 2016, CANCER IMMUNOL RES, V4, P563, DOI 10.1158/2326-6066.CIR-15-0274; Taube JM, 2015, CLIN CANCER RES, V21, P3969, DOI 10.1158/1078-0432.CCR-15-0244; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Verdegaal EME, 2016, NATURE, V536, P91, DOI 10.1038/nature18945; Wang JG, 2016, NAT GENET, V48, P768, DOI 10.1038/ng.3590; Weber J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw378.1; Weber J, 2016, CANCER IMMUNOL RES, V4, P345, DOI 10.1158/2326-6066.CIR-15-0193; Wei L, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1779-7; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Yau C, 2013, BIOINFORMATICS, V29, P2482, DOI 10.1093/bioinformatics/btt416; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zarnitsyna VI, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00485	70	923	946	16	174	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 2	2017	171	4					934	+		10.1016/j.cell.2017.09.028	http://dx.doi.org/10.1016/j.cell.2017.09.028			21	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FL5DE	29033130	Green Accepted, Bronze			2023-01-03	WOS:000414250900020
J	Sarabia, JM; Moya-Ramon, M; Hernandez-Davo, JL; Fernandez-Fernandez, J; Sabido, R				Sarabia, J. M.; Moya-Ramon, M.; Hernandez-Davo, J. L.; Fernandez-Fernandez, J.; Sabido, R.			The effects of training with loads that maximise power output and individualised repetitions vs. traditional power training	PLOS ONE			English	Article							BENCH PRESS STRENGTH; RESISTANCE EXERCISE; HORMONAL RESPONSES; BALLISTIC-POWER; PERFORMANCE; ADAPTATIONS; INTENSITY; VELOCITY; FAILURE; GAINS	Background It has been suggested that strength training effects (i.e. neural or structural) vary, depending on the total repetitions performed and velocity loss in each training set. Purpose The aim of this study is to compare the effects of two training programmes (i.e. one with loads that maximise power output and individualised repetitions, and the other following traditional power training). Methods Twenty-five males were divided into three groups (optimum power [OP = 10], traditional training [TT = 9] and control group [CG = 6]). The training load used for OP was individualised using loads that maximised power output (41.7%-5.8 of one repetition maximum [1RM]) and repetitions at maximum power (4 to 9 repetitions, or 'reps'). Volume (sets x repetitions) was the same for both experimental groups, while intensity for TT was that needed to perform only 50% of the maximum number of possible repetitions (i.e. 61.1%-66.6% of 1RM). The training programme ran over 11 weeks (2 sessions per week; 4-5 sets per session; 3-minute rests between sets), with pre-, intermediate and post-tests which included: anthropometry, 1RM, peak power output (PPO) with 30%, 40% and 50% of 1RM in the bench press throw, and salivary testosterone (ST) and cortisol (SC) concentrations. Rate of perceived exertion (RPE) and power output were recorded in all sessions. Results Following the intermediate test, PPO was increased in the OP group for each load (10.9%- 13.2%). Following the post-test, both experimental groups had increased 1RM (11.8%-13.8%) and PPO for each load (14.1%-19.6%). Significant decreases in PPO were found for the TT group during all sets (4.9%-15.4%), along with significantly higher RPE (37%). Conclusion OP appears to be a more efficient method of training, with less neuromuscular fatigue and lower RPE.	[Sarabia, J. M.; Moya-Ramon, M.; Hernandez-Davo, J. L.; Fernandez-Fernandez, J.; Sabido, R.] Univ Miguel Hernandez Elche, Sports Res Ctr, Elche, Spain; [Fernandez-Fernandez, J.] Univ Leon, Fac Phys Act & Sports Sci, Leon, Spain	Universidad Miguel Hernandez de Elche; Universidad de Leon	Sarabia, JM (corresponding author), Univ Miguel Hernandez Elche, Sports Res Ctr, Elche, Spain.	jsarabia@goumh.es	Hernandez, Jose/AAS-6643-2021; Fernandez-Fernandez, Jaime/AAO-9270-2020; MOYA, MANUEL/F-7172-2016; Sarabia, Jose M/F-4014-2016; Sabido, Rafael/AAO-5763-2021	MOYA, MANUEL/0000-0002-2291-5899; Sarabia, Jose M/0000-0002-1917-6634; Sabido, Rafael/0000-0003-0158-9075; Hernandez-Davo, Jose Luis/0000-0001-5785-4697; Fernandez-Fernandez, Jaime/0000-0002-5284-303X				Ahtlainen JP, 2003, INT J SPORTS MED, V24, P410; Argus CK, 2014, J STRENGTH COND RES, V28, P240, DOI 10.1519/JSC.0b013e318295d1c9; Bautista IJ, 2014, J HUM KINET, V44, P161, DOI 10.2478/hukin-2014-0122; Casey A, 1996, AM J PHYSIOL-ENDOC M, V271, pE38, DOI 10.1152/ajpendo.1996.271.1.E38; Cohen J., 2013, STAT POWER ANAL BEHA; Cormie P, 2011, SPORTS MED, V41, P17, DOI 10.2165/11537690-000000000-00000; Cormie P, 2010, MED SCI SPORT EXER, V42, P1582, DOI 10.1249/MSS.0b013e3181d2013a; Cormie P, 2010, MED SCI SPORT EXER, V42, P1566, DOI 10.1249/MSS.0b013e3181cf818d; Crewther B, 2006, SPORTS MED, V36, P215, DOI 10.2165/00007256-200636030-00004; Drinkwater EJ, 2005, J STRENGTH COND RES, V19, P382; Filaire E, 2009, PSYCHONEUROENDOCRINO, V34, P150, DOI 10.1016/j.psyneuen.2008.08.022; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Folland JP, 2002, BRIT J SPORT MED, V36, P370, DOI 10.1136/bjsm.36.5.370; Fry AC, 2004, SPORTS MED, V34, P663, DOI 10.2165/00007256-200434100-00004; Gonzalez-Badillo JJ, 2010, INT J SPORTS MED, V31, P347, DOI 10.1055/s-0030-1248333; Gonzalez-Badillo JJ, 2006, J STRENGTH COND RES, V20, P73; Gorostiaga EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040621; HAKKINEN K, 1991, EUR J APPL PHYSIOL O, V63, P194, DOI 10.1007/BF00233847; HAKKINEN K, 1988, J APPL PHYSIOL, V65, P2406, DOI 10.1152/jappl.1988.65.6.2406; Harris NK, 2008, J STRENGTH COND RES, V22, P1742, DOI 10.1519/JSC.0b013e318187458a; Davo JLH, 2016, J STRENGTH COND RES, V30, P1265, DOI 10.1519/JSC.0000000000001214; HICKSON RC, 1994, J APPL PHYSIOL, V76, P663, DOI 10.1152/jappl.1994.76.2.663; Izquierdo M, 2006, J APPL PHYSIOL, V100, P1647, DOI 10.1152/japplphysiol.01400.2005; Izquierdo M, 2002, EUR J APPL PHYSIOL, V87, P264, DOI 10.1007/s00421-002-0628-y; Izquierdo-Gabarren M, 2010, MED SCI SPORT EXER, V42, P1191, DOI 10.1249/MSS.0b013e3181c67eec; Gonzalez-Badillo JJ, 2010, J STRENGTH COND RES, V24, P3443, DOI 10.1519/JSC.0b013e3181bac37d; Kaneko M, 1983, SCAND J SPORTS SCI, V5, P50; Kawamori N, 2004, J STRENGTH COND RES, V18, P675; Kraemer WJ, 2005, SPORTS MED, V35, P339, DOI 10.2165/00007256-200535040-00004; Legaz-Arrese A, 2007, J SPORT MED PHYS FIT, V47, P427; Loturco I, 2013, J SPORT SCI MED, V12, P109; Marques MC, 2014, J STRENGTH COND RES, V28, P2366, DOI 10.1519/JSC.0000000000000390; Marx JO, 2001, MED SCI SPORT EXER, V33, P635, DOI 10.1097/00005768-200104000-00019; MAYHEW JL, 1995, J SPORT MED PHYS FIT, V35, P108; McBride JM, 2002, J STRENGTH COND RES, V16, P75, DOI 10.1519/00124278-200202000-00011; McGuigan MR, 2012, INT J SPORT PHYSIOL, V7, P2, DOI 10.1123/ijspp.7.1.2; McKinnon NB, 2017, AGEING RES REV, V35, P147, DOI 10.1016/j.arr.2016.09.003; Picerno P, 2016, EUR J APPL PHYSIOL, V116, P2035, DOI 10.1007/s00421-016-3457-0; Rhea MR, 2004, J STRENGTH COND RES, V18, P918, DOI 10.1519/00124278-200411000-00040; Robertson RJ, 2003, MED SCI SPORT EXER, V35, P333, DOI 10.1249/01.MSS.0000048831.15016.2A; Romero-Arenas S, 2017, J STRENGTH CONDITION; Sanborn K, 2000, J STRENGTH COND RES, V14, P328; Sanchez-Medina L, 2011, MED SCI SPORT EXER, V43, P1725, DOI 10.1249/MSS.0b013e318213f880; Spassov A, 1988, STRENGTH CON J, V10, P58; Stone MH, 2003, J STRENGTH COND RES, V17, P140; Verkhoshansky Y, 1989, NSCA J, V11, P58; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; WILSON GJ, 1993, MED SCI SPORT EXER, V25, P1279; Wilson JM, 2012, J STRENGTH COND RES, V26, P1724, DOI 10.1519/JSC.0b013e318234eb6f; Zaras N, 2013, J SPORT SCI MED, V12, P130	50	18	18	7	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2017	12	10							e0186601	10.1371/journal.pone.0186601	http://dx.doi.org/10.1371/journal.pone.0186601			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK2MA	29053725	gold, Green Published, Green Submitted			2023-01-03	WOS:000413315100026
J	Abrahams, MI; Peres, CA; Costa, HCM				Abrahams, Mark I.; Peres, Carlos A.; Costa, Hugo C. M.			Measuring local depletion of terrestrial game vertebrates by central-place hunters in rural Amazonia	PLOS ONE			English	Article							MANU NATIONAL-PARK; INDIGENOUS PEOPLES; MBARACAYU RESERVE; TROPICAL FORESTS; TAYASSU-PECARI; BRINGING HOME; BIOKO ISLAND; SUSTAINABILITY; CONSERVATION; POPULATION	The degree to which terrestrial vertebrate populations are depleted in tropical forests occupied by human communities has been the subject of an intense polarising debate that has important conservation implications. Conservation ecologists and practitioners are divided over the extent to which community-based subsistence offtake is compatible with ecologically functional populations of tropical forest game species. To quantify depletion envelopes of forest vertebrates around human communities, we deployed a total of 383 camera trap stations and 78 quantitative interviews to survey the peri-community areas controlled by 60 semi-subsistence communities over a combined area of over 3.2 million hectares in the Medio Jurua and Uatuma regions of Central-Western Brazilian Amazonia. Our results largely conform with prior evidence that hunting large-bodied vertebrates reduces wildlife populations near settlements, such that they are only found at a distance to settlements where they are hunted less frequently. Camera trap data suggest that a select few harvest-sensitive species, including lowland tapir, are either repelled or depleted by human communities. Nocturnal and cathemeral species were detected relatively more frequently in disturbed areas close to communities, but individual species did not necessarily shift their activity patterns. Group biomass of all species was depressed in the wider neighbourhood of urban areas rather than communities. Interview data suggest that species traits, especially group size and body mass, mediate these relationships. Large-bodied, large-group-living species are detected farther from communities as reported by experienced informants. Long-established communities in our study regions have not "emptied" the surrounding forest. Low human population density and low hunting offtake due to abundant sources of alternative aquatic protein, suggest that these communities represent a best-case scenario for sustainable hunting of wildlife for food, thereby providing a conservative assessment of game depletion. Given this 'best-case' camera trap and interview-based evidence for hunting depletion, regions with higher human population densities, external trade in wildlife and limited access to alternative protein will likely exhibit more severe depletion.	[Abrahams, Mark I.; Peres, Carlos A.] Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England; [Costa, Hugo C. M.] Univ Estadual Santa Cruz, PPG Ecol & Conservacao Biodiversidade, Ilheus, Brazil; [Abrahams, Mark I.] Bristol Zool Soc, Field Conservat & Sci Dept, Bristol, Avon, England	University of East Anglia; Universidade Estadual de Santa Cruz	Abrahams, MI (corresponding author), Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England.; Abrahams, MI (corresponding author), Bristol Zool Soc, Field Conservat & Sci Dept, Bristol, Avon, England.	mabrahams@bristolzoo.org.uk	Peres, Carlos A./ABE-8361-2020; Peres, Carlos Augusto/N-8275-2019; Peres, Carlos A./B-1276-2013	Peres, Carlos A./0000-0002-1588-8765; Peres, Carlos A./0000-0002-1588-8765; abrahams, mark/0000-0002-6424-187X	School of Environmental Science at University of East Anglia; Darwin Initiative for the Survival of Species grant; Explorers Club; Idea Wild; Rufford Foundation Small Grants; Smithsonian Manson School of Conservation partial scholarship award	School of Environmental Science at University of East Anglia; Darwin Initiative for the Survival of Species grant; Explorers Club; Idea Wild; Rufford Foundation Small Grants; Smithsonian Manson School of Conservation partial scholarship award	The PhD studentship of MIA was funded by the School of Environmental Science at University of East Anglia (https://wm.uea.ac.uk/environmental-sciences). Fieldwork and equipment funding were provided by a Darwin Initiative for the Survival of Species grant (http://www.darwininitiative.org.uk/ DEFRA no. 20-001) to CAP; the Explorers Club (https://explorers.org/); Idea Wild (http://Aqww.ideawild.org/); the Rufford Foundation Small Grants (http://www.rufford.org/12231-1) and the Smithsonian Manson School of Conservation partial scholarship award (http//smconservation.gmu.edu/ MCCS 0501) to HCMC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahams MI, J WILDLIFE MANAGEMEN; ALCORN JB, 1993, CONSERV BIOL, V7, P424, DOI 10.1046/j.1523-1739.1993.07020424.x; Altrichter M, 2005, BIOL CONSERV, V126, P351, DOI 10.1016/j.biocon.2005.06.024; ALVARD MS, 1993, HUM ECOL, V21, P355, DOI 10.1007/BF00891140; Alvard MS, 1997, CONSERV BIOL, V11, P977, DOI 10.1046/j.1523-1739.1997.96047.x; Antunes AP, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600936; Baptista L. F., 1997, HDB BIRDS WORLD, V4, P60; Bar-Oz G, 2011, P NATL ACAD SCI USA, V108, P7345, DOI 10.1073/pnas.1017647108; Becher H, 1996, AMAZONIA MAN CULTURE; Bennett EL, 2000, BIOL RESOURCE MANAGE, P305; Berkes F, 2000, ECOL APPL, V10, P1251, DOI 10.2307/2641280; Berkes F., 1995, Biodiversity conservation: problems and policies. Papers from the Biodiversity Programme, Beijer International Institute of Ecological Economics, Royal Swedish Academy of Sciences., P281; BODMER RE, 1990, J TROP ECOL, V6, P191, DOI 10.1017/S0266467400004314; Bodmer RE, 1997, CONSERV BIOL, V11, P460, DOI 10.1046/j.1523-1739.1997.96022.x; Borner J., 2013, PROMOTING FOREST STE; Bowen-Jones E, 1999, ORYX, V33, P233, DOI 10.1046/j.1365-3008.1999.00066.x; Branch TA, 2013, TRENDS ECOL EVOL, V28, P409, DOI 10.1016/j.tree.2013.03.003; Brandon K., 1998, PARKS PERIL PEOPLE P; Burnham K. P., 2002, MODEL SELECTION MULT, V172, DOI 10.1016/j.ecolmodel.2003.11.004; Carboneras C., 1992, HDB BIRDS WORLD; Cincotta RP, 2000, NATURE, V404, P990, DOI 10.1038/35010105; Clayton L, 1997, ECOL APPL, V7, P642, DOI 10.1890/1051-0761(1997)007[0642:BHTBAS]2.0.CO;2; Corlett RT, 2007, BIOTROPICA, V39, P292, DOI 10.1111/j.1744-7429.2007.00271.x; da Silva Maria N.F., 2005, Neotropical Primates, V13, P31, DOI 10.1896/1413-4705.13.2.31; Datta A, 2008, BIOL CONSERV, V141, P1429, DOI 10.1016/j.biocon.2008.02.022; Denevan WM, 1996, ANN ASSOC AM GEOGR, V86, P654, DOI 10.1111/j.1467-8306.1996.tb01771.x; Dunning Jr JB, 1992, CRC HDB AVIAN BODY M; EMMONS LH, 1984, BIOTROPICA, V16, P210, DOI 10.2307/2388054; Emmons LH, 1997, NEOTROPICAL RAINFORE, P2; Endo W, 2016, BIOL CONSERV, V201, P129, DOI 10.1016/j.biocon.2016.07.006; Fa JE, 2002, CONSERV BIOL, V16, P232, DOI 10.1046/j.1523-1739.2002.00275.x; Fa JE, 2000, CONSERV BIOL, V14, P1602, DOI 10.1111/j.1523-1739.2000.99067.x; Fragoso J.M.V., 1991, P154; Fragoso JMV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152659; Garcia-Fernandez C, 2008, FOREST ECOL MANAG, V256, P1468, DOI 10.1016/j.foreco.2008.04.029; Gaston KJ, 2000, NATURE, V405, P220, DOI 10.1038/35012228; Geisler C, 2003, INT SOC SCI J, V55, P69, DOI 10.1111/1468-2451.5501007; Golden CD, 2009, ORYX, V43, P386, DOI 10.1017/S0030605309000131; Gompper ME, 2006, WILDLIFE SOC B, V34, P1142, DOI 10.2193/0091-7648(2006)34[1142:ACONTT]2.0.CO;2; Vega MG, 2013, CONSERV BIOL, V27, P576, DOI 10.1111/cobi.12067; Hanson MA, 2012, SCIENCE, V335, P851, DOI [10.1126/science.1215904, 10.1126/science.1244693]; Harrison RD, 2013, ECOL LETT, V16, P687, DOI 10.1111/ele.12102; Harrison RD, 2011, BIOSCIENCE, V61, P919, DOI 10.1525/bio.2011.61.11.11; Hart John A., 2000, P106; HAWKES K, 1982, AM ETHNOL, V9, P379, DOI 10.1525/ae.1982.9.2.02a00100; Hill K, 2003, CONSERV BIOL, V17, P1312, DOI 10.1046/j.1523-1739.2003.01135.x; Hill K, 2000, BIOL RESOURCE MANAGE, P79; Holt Flora L, 2004, OCCASIONAL PAPER, P87; Instituto Nacional de Pesquisas Espaciais [INPE], 2009, MON FLOR AM BRAS STA; Jerozolimski A, 2003, BIOL CONSERV, V111, P415, DOI 10.1016/S0006-3207(02)00310-5; JOHNS AD, 1985, AM J PRIMATOL, V8, P31, DOI 10.1002/ajp.1350080104; Kern DC, 2007, AMAZONIAN DARK EARTH; Kramer R, 1997, LAST STAND PROTECTED; Lahm S., 2001, WHY CONSERVATION SHO; Leendertz SAJ, 2017, MAMMAL REV, V47, P98, DOI 10.1111/mam.12082; Lehner B, 2013, HYDROL PROCESS, V27, P2171, DOI 10.1002/hyp.9740; Leuwenberg FT, 2013, HUNTING SUSTAINABILI, P375; Levi T, 2009, J APPL ECOL, V46, P804, DOI 10.1111/j.1365-2664.2009.01661.x; LOW BS, 1993, POPUL ENVIRON, V15, P7, DOI 10.1007/BF02207996; Madhusudan MD, 2002, AMBIO, V31, P49, DOI 10.1639/0044-7447(2002)031[0049:LHATCO]2.0.CO;2; Martin P. S., 1967, P75; Martinez D., 1996, SIERRA MAGAZINE SIER, V81; MCDONALD DR, 1977, ANTHROPOS, V72, P734; MCGRATH DG, 1993, HUM ECOL, V21, P167, DOI 10.1007/BF00889358; Milner-Gulland EJ, 2003, TRENDS ECOL EVOL, V18, P351, DOI 10.1016/S0169-5347(03)00123-X; Milner-Gulland EJ, 2001, TRENDS ECOL EVOL, V16, P686, DOI 10.1016/S0169-5347(01)02278-9; Mitlermeier R.A., 1987, Monographs in Primatology, V9, P109; Muller-Landau HC, 2007, BIOTROPICA, V39, P372, DOI 10.1111/j.1744-7429.2007.00290.x; Munari DP, 2011, MAMMALIAN BIOL Z SAU, V76; NEPAL SK, 1995, ENVIRON MANAGE, V19, P853, DOI 10.1007/BF02471937; Nichols JD, 2010, ANIM CONSERV, V13, P344, DOI 10.1111/j.1469-1795.2010.00382.x; NORTONGRIFFITHS M, 1995, ECOL ECON, V12, P125, DOI 10.1016/0921-8009(94)00041-S; Noss A, 2000, BIOL RESOURCE MANAGE, P282; Novaro AJ, 2000, CONSERV BIOL, V14, P713, DOI 10.1046/j.1523-1739.2000.98452.x; Nowak R., 1999, WALKERS MAMMALS WORL; Ntiamoa-Baidu Y., 2008, J STUDY RELIG NATURE, V2; Nuno A, 2015, BIOL CONSERV, V189, P5, DOI 10.1016/j.biocon.2014.09.047; O'Donnell KP, 2010, ANIM CONSERV, V13, P526, DOI 10.1111/j.1469-1795.2010.00377.x; OBrien T., 2010, WILDLIFE PICTURE IND; Ohl-Schacherer J, 2007, CONSERV BIOL, V21, P1174, DOI 10.1111/j.1523-1739.2007.00759.x; Oliveira-Santos LGR, 2010, MAMM BIOL, V75, P219, DOI 10.1016/j.mambio.2009.05.006; Parry L, 2015, ECOL SOC, V20, DOI 10.5751/ES-07601-200315; Parry L, 2010, POPUL ENVIRON, V32, P137, DOI 10.1007/s11111-010-0127-8; Peres CA, 2000, CONSERV BIOL, V14, P240, DOI 10.1046/j.1523-1739.2000.98485.x; PERES CA, 1995, CONSERV BIOL, V9, P34, DOI 10.1046/j.1523-1739.1995.09010034.x; Peres CA, 2003, CONSERV BIOL, V17, P521, DOI 10.1046/j.1523-1739.2003.01413.x; Peres CA, 1996, BIOL CONSERV, V77, P115, DOI 10.1016/0006-3207(96)00010-9; PERES CA, 1990, BIOL CONSERV, V54, P47, DOI 10.1016/0006-3207(90)90041-M; Peres CA, 2001, CONSERV BIOL, V15, P1490, DOI 10.1046/j.1523-1739.2001.01089.x; Peres CA, 2000, OECOLOGIA, V122, P175, DOI 10.1007/PL00008845; Peres CA, 2008, HUMAN EXPLOITATION B, P287; Peres CA, 2011, TROPICAL FOREST COMM, P349; Peres CA, 2007, BIOTROPICA, V39, P304, DOI 10.1111/j.1744-7429.2007.00272.x; Peres CA, 2011, CONSERV BIOL, V25, P1124, DOI 10.1111/j.1523-1739.2011.01770.x; Porter-Bolland L, 2012, FOREST ECOL MANAG, V268, P6, DOI 10.1016/j.foreco.2011.05.034; Radar na Amazo A nia (RADAMBRASIL), 1976, LEVANTAMENTO RECURSO; Read JM, 2010, J LAT AM GEOGR, V9, P213, DOI 10.1353/lag.2010.0030; REDFORD KH, 1992, BIOSCIENCE, V42, P412, DOI 10.2307/1311860; Renno CD, 2008, REMOTE SENS ENVIRON, V112, P3469, DOI 10.1016/j.rse.2008.03.018; Reyna-Hurtado R, 2010, ORYX, V44, P89, DOI 10.1017/S0030605309990664; Ripple WJ, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.160498; Robinson J.G., 1991, P415; Robinson John G., 1994, Oryx, V28, P249, DOI 10.1017/S0030605300028647; Ruggiero R., 1990, PACHYDERM, V13, P42; Rushton J, 2005, ODI WILDLIFE POLICY, V11; Schwartzman S, 2000, CONSERV BIOL, V14, P1351, DOI 10.1046/j.1523-1739.2000.99329.x; Sequin ES, 2003, CAN J ZOOL, V81, P2015, DOI 10.1139/Z03-204; Siren A, 2004, CONSERV BIOL, V18, P1315, DOI 10.1111/j.1523-1739.2004.00024.x; Sollmann R, 2013, BIOL CONSERV, V159, P405, DOI 10.1016/j.biocon.2012.12.025; Sreekar R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117920; Steinmetz R, 2013, BIOL CONSERV, V163, P68, DOI 10.1016/j.biocon.2012.12.016; Struebig MJ, 2007, ORYX, V41, P390, DOI 10.1017/S0030605307000310; Thurfjell H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178082; van Vliet N, 2008, ORYX, V42, P392, DOI 10.1017/S0030605308000288; Van Vliet N, 2010, CONSERV BIOL, V24, P1327, DOI 10.1111/j.1523-1739.2010.01484.x; Veloso HP, FITOGEOGRAFIA BRASIL; Wilkie DS, 2011, ANN NY ACAD SCI, V1223, P120, DOI 10.1111/j.1749-6632.2010.05908.x; Wilkie DS, 1999, BIODIVERS CONSERV, V8, P927, DOI 10.1023/A:1008877309871; Wright SJ, 2003, PERSPECT PLANT ECOL, V6, P73, DOI 10.1078/1433-8319-00043; Zuur Alain F., 2009, P1	120	23	24	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2017	12	10							e0186653	10.1371/journal.pone.0186653	http://dx.doi.org/10.1371/journal.pone.0186653			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK0KA	29040340	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000413167500068
J	Zschaeck, S; Blumke, B; Wust, P; Kaul, D; Bahra, M; Riess, H; Klein, F; Sinn, M; Pelzer, U; Budach, V; Ghadjar, P				Zschaeck, Sebastian; Bluemke, Bibiana; Wust, Peter; Kaul, David; Bahra, Marcus; Riess, Hanno; Klein, Fritz; Sinn, Marianne; Pelzer, Uwe; Budach, Volker; Ghadjar, Pirus			Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients	PLOS ONE			English	Article							INDUCTION CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; DUCTAL ADENOCARCINOMA; RADIATION-THERAPY; PHASE-II; CHEMORADIOTHERAPY; GEMCITABINE; CONCURRENT; SURVIVAL; TRIAL	Purpose The role of radiotherapy for unresectable pancreatic cancer is controversial. A benefit of additional radiotherapy is supported by some observations. A dose-effect relationship was recently found by dose escalation employing image guided and intensity modulated radiotherapy. Methods We retrospectively evaluated 28 consecutive patients, all with history of extensive prior therapies for unresectable locally advanced/recurrent pancreatic cancer (LAPC/LRPC). Treatment was delivered by helical tomotherapy after daily position verification with computed tomography. Dose to the planned target volume (PTV) was 51 Gy, while the dose to the macroscopic tumor was escalated by a simultaneous integrated boost to a median cumulative dose of 66 Gy (60-66 Gy). Concomitant chemotherapy consisted mainly of capecitabine (n = 23). Results 10 of 28 patients presented acute toxicities > grade 2, one patient succumbed to gastrointestinal bleeding after treatment. No correlations of toxicities and dose volume histograms (DVH) of retrospectively delineated small bowel loops were observed, although average small bowel volume receiving >= 20 Gy was 374 ml. DVH analyses revealed a correlation of splenic parameters and acute toxicity: Vomiting, anorexia, dehydration, hematologic toxicity, fatigue, combined gastro-intestinal toxicity wit R-values between 0.392 and 0.561 (all p-values > 0.05). Only one patient developed late toxicities > grade 2. With an average follow-up time in surviving patients of 14 months median overall survival time was 19 months and median time to local recurrence 13 months. In 8 patients with available imaging of local recurrence: 5 in field recurrences, 2 marginal recurrences and one lymph node recurrence outside the high dose radiation field were observed. In univariate analysis only Delta CA-19-9 during radiotherapy was associated with local control (p = 0.029) and overall survival (p = 0.049). Conclusion Dose escalated normo-fractionated radiotherapy for LAPC/LRPC seems feasible and suitable to prolong local control and in consequence long-term survival. However, in-field local progression is still frequently observed and possibilities to increase the local effectiveness should be evaluated. Exposure of the spleen was predictive for acute toxicity and should be further investigated.	[Zschaeck, Sebastian; Bluemke, Bibiana; Wust, Peter; Kaul, David; Budach, Volker; Ghadjar, Pirus] Charite, Dept Radiat Oncol, Berlin, Germany; [Bahra, Marcus; Klein, Fritz] Charite, Dept Gen Visceral & Transplantat Surg, Berlin, Germany; [Riess, Hanno; Sinn, Marianne; Pelzer, Uwe] Charite, Dept Hematol Oncol Tumorimmunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Zschaeck, S (corresponding author), Charite, Dept Radiat Oncol, Berlin, Germany.	Sebastian.Zschaeck@charite.de	Ghadjar, Pirus/V-5616-2019; Pelzer, Uwe/AAX-1957-2020	Pelzer, Uwe/0000-0001-9213-2737; Zschaeck, Sebastian/0000-0003-3109-0662; Ghadjar, Pirus/0000-0002-2747-165X; Budach, Volker/0000-0002-2191-9871				Akimoto M, 2017, INT J RAD ONCOLOGY B; Bahra M, 2015, PANCREAS, V44, P930, DOI 10.1097/MPA.0000000000000365; Ben-Josef E, 2012, INT J RADIAT ONCOL, V84, P1166, DOI 10.1016/j.ijrobp.2012.02.051; Chadha AS, 2016, INT J RAD ONCOLOGY B; Chadha AS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156910; Chauffert B, 2008, ANN ONCOL, V19, P1592, DOI 10.1093/annonc/mdn281; Chung SY, 2017, RADIOTHERAPY ONCOLOG; Diener MK, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006053.pub3, 10.1002/14651858.CD006053.pub4]; Fiore M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45845; Hammel P, 2016, JAMA-J AM MED ASSOC, V315, P1844, DOI 10.1001/jama.2016.4324; Huguet F, 2014, CLIN ONCOL-UK, V26, P560, DOI 10.1016/j.clon.2014.06.002; Huguet F, 2007, J CLIN ONCOL, V25, P326, DOI 10.1200/JCO.2006.07.5663; Jin L, 2016, CURR ONCOL, V23, pE41, DOI 10.3747/co.23.2771; Kavanagh BD, 2010, INT J RADIAT ONCOL, V76, pS101, DOI 10.1016/j.ijrobp.2009.05.071; Kelly P, 2013, INT J RADIAT ONCOL, V85, pE143, DOI 10.1016/j.ijrobp.2012.09.035; Kishi T, 2016, RADIOTHER ONCOL, V120, P217, DOI 10.1016/j.radonc.2016.07.012; KLAASSEN DJ, 1985, J CLIN ONCOL, V3, P373, DOI 10.1200/JCO.1985.3.3.373; Koom WS, 2009, INT J RADIAT ONCOL, V73, P1148, DOI 10.1016/j.ijrobp.2008.06.1483; Krishnan S, 2007, CANCER-AM CANCER SOC, V110, P47, DOI 10.1002/cncr.22735; Krishnan S, 2016, INT J RADIAT ONCOL, V94, P755, DOI 10.1016/j.ijrobp.2015.12.003; Lee KJ, 2016, GUT LIVER, V10, P303, DOI 10.5009/gnl15186; Lens E, 2016, RADIOTHER ONCOL, V121, P268, DOI 10.1016/j.radonc.2016.09.012; Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904; Maluta S, 2011, STRAHLENTHER ONKOL, V187, P619, DOI 10.1007/s00066-011-2226-6; Micke O, 2003, INT J RADIAT ONCOL, V57, P90, DOI 10.1016/S0360-3016(03)00524-8; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Park JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052481; Rutter CE, 2015, CANCER-AM CANCER SOC, V121, P4141, DOI 10.1002/cncr.29652; Sinn M, 2014, THESCIENTIFICWORLDJO, V2014; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Sperti C, 2015, WORLD J GASTRO ONCOL, V7, P375, DOI 10.4251/wjgo.v7.i12.375; Sun WJ, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-28; Thomas RM, 2012, J GASTROINTEST SURG, V16, P1696, DOI 10.1007/s11605-012-1912-8; Trip AK, 2015, RADIOTHER ONCOL, V116, P239, DOI 10.1016/j.radonc.2015.07.036; Uesaka K, 2016, LANCET, V388, P248, DOI 10.1016/S0140-6736(16)30583-9; Vainshtein JM, 2013, INT J RADIAT ONCOL, V86, P96, DOI 10.1016/j.ijrobp.2012.11.020; Verma V, 2017, RADIOTHER ONCOL, V122, P464, DOI 10.1016/j.radonc.2016.12.030; Wang LS, 2015, PRACT RADIAT ONCOL, V5, pE457, DOI 10.1016/j.prro.2015.04.004; Xu BH, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0566-6	40	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2017	12	10							e0186341	10.1371/journal.pone.0186341	http://dx.doi.org/10.1371/journal.pone.0186341			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ6DU	29023527	Green Submitted, gold, Green Published			2023-01-03	WOS:000412845100109
J	Tiwari, P; Kutum, R; Sethi, T; Shrivastava, A; Girase, B; Aggarwal, S; Patil, R; Agarwal, D; Gautam, P; Agrawal, A; Dash, D; Ghosh, S; Juvekar, S; Mukerji, M; Prasher, B				Tiwari, Pradeep; Kutum, Rintu; Sethi, Tavpritesh; Shrivastava, Ankita; Girase, Bhushan; Aggarwal, Shilpi; Patil, Rutuja; Agarwal, Dhiraj; Gautam, Pramod; Agrawal, Anurag; Dash, Debasis; Ghosh, Saurabh; Juvekar, Sanjay; Mukerji, Mitali; Prasher, Bhavana			Recapitulation of Ayurveda constitution types by machine learning of phenotypic traits	PLOS ONE			English	Article							REGRESSION; REGULARIZATION; SELECTION; MEDICINE; MODELS; AREA	In Ayurveda system of medicine individuals are classified into seven constitution types, "Prakriti", for assessing disease susceptibility and drug responsiveness. Prakriti evaluation involves clinical examination including questions about physiological and behavioural traits. A need was felt to develop models for accurately predicting Prakriti classes that have been shown to exhibit molecular differences. The present study was carried out on data of phenotypic attributes in 147 healthy individuals of three extreme Prakriti types, from a genetically homogeneous population of Western India. Unsupervised and supervised machine learning approaches were used to infer inherent structure of the data, and for feature selection and building classification models for Prakriti respectively. These models were validated in a North Indian population. Unsupervised clustering led to emergence of three natural clusters corresponding to three extreme Prakriti classes. The supervised modelling approaches could classify individuals, with distinct Prakriti types, in the training and validation sets. This study is the first to demonstrate that Prakriti types are distinct verifiable clusters within a multidimensional space of multiple interrelated phenotypic traits. It also provides a computational framework for predicting Prakriti classes from phenotypic attributes. This approach may be useful in precision medicine for stratification of endophenotypes in healthy and diseased populations.	[Tiwari, Pradeep; Sethi, Tavpritesh; Aggarwal, Shilpi; Gautam, Pramod; Agrawal, Anurag; Mukerji, Mitali; Prasher, Bhavana] CSIR, Genom & Mol Med, Inst Genom & Integrat Biol, New Delhi, India; [Tiwari, Pradeep; Kutum, Rintu; Mukerji, Mitali; Prasher, Bhavana] CSIR, TRISUTRA Translat Res & Innovat Sci Ayurgen, Ayurgen Unit, Inst Genom & Integrat Biol, New Delhi, India; [Tiwari, Pradeep; Kutum, Rintu; Agrawal, Anurag; Dash, Debasis; Mukerji, Mitali; Prasher, Bhavana] CSIR, Acad Sci & Innovat Res AcSIR, IGIB, Delhi, India; [Kutum, Rintu; Dash, Debasis] CSIR, GN Ramachandran Knowledge Ctr Genome Informat, Inst Genom & Integrat Biol, New Delhi, India; [Shrivastava, Ankita; Girase, Bhushan; Patil, Rutuja; Agarwal, Dhiraj; Juvekar, Sanjay] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India; [Ghosh, Saurabh] Indian Stat Inst, Human Genet Unit, Kolkata, India; [Sethi, Tavpritesh] Indraprastha Inst Informat Technol, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Academy of Scientific & Innovative Research (AcSIR); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Indian Statistical Institute; Indian Statistical Institute Kolkata; Indraprastha Institute of Information Technology Delhi	Mukerji, M; Prasher, B (corresponding author), CSIR, Genom & Mol Med, Inst Genom & Integrat Biol, New Delhi, India.; Mukerji, M; Prasher, B (corresponding author), CSIR, TRISUTRA Translat Res & Innovat Sci Ayurgen, Ayurgen Unit, Inst Genom & Integrat Biol, New Delhi, India.; Mukerji, M; Prasher, B (corresponding author), CSIR, Acad Sci & Innovat Res AcSIR, IGIB, Delhi, India.; Juvekar, S (corresponding author), KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India.	sanjay.juvekar@gmail.com; mitali@igib.res.in; Bhavana.p@igib.res.in	Agrawal, Anurag/GZL-5821-2022; Patil, Rutuja/O-9996-2018; Tiwari, Dr. Pradeep/V-8314-2018; Dash, Debasis/F-3137-2012	Patil, Rutuja/0000-0001-6390-4363; Mukerji, Mitali/0000-0003-0697-5055; Girase, Bhushan/0000-0001-7105-3730; Tiwari, Dr. Pradeep/0000-0003-0387-9236; Agrawal, Anurag/0000-0002-0340-5252; Sethi, Tavpritesh/0000-0002-4776-7941; Kutum, Rintu/0000-0001-8667-6199; Dash, Debasis/0000-0002-5647-3785	CSIR [MLP901]; DBT-BINC fellowship; Council of Scientific & Industrial Research [MLP901]	CSIR(Council of Scientific & Industrial Research (CSIR) - India); DBT-BINC fellowship; Council of Scientific & Industrial Research(Council of Scientific & Industrial Research (CSIR) - India)	Funding from CSIR (MLP901) and DBT-BINC fellowship to PT are acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Authors acknowledge all field staffs and study population from KEMHRC-VADU. Authors also acknowledge Binuja Varma, Amruta Vasudevan for help in genotyping experiments and Ankita Narang in genotype analysis. Indian Genome Variation Consortium (IGVC) is also acknowledged for genotype data for diverse Indian population. Project funding MLP901 from Council of Scientific & Industrial Research (http://www.csir.res.in and DBT-BINC fellowship to PT are acknowledged. CSIR-IGIB is acknowledged for infrastructure support including the data centre.	Aggarwal S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0542-9; Aggarwal S, 2010, P NATL ACAD SCI USA, V107, P18961, DOI 10.1073/pnas.1006108107; Bradley AP, 1997, PATTERN RECOGN, V30, P1145, DOI 10.1016/S0031-3203(96)00142-2; Brahmachari SK, 2005, HUM GENET, V118, P1, DOI 10.1007/s00439-005-0009-9; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Dance A, 2016, NATURE, V537, pS52, DOI 10.1038/537S52a; FARRAR DE, 1967, REV ECON STAT, V49, P92, DOI 10.2307/1937887; Flores M, 2013, PERS MED, V10, P565, DOI 10.2217/pme.13.57; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Govindaraj P, 2015, SCI REP-UK, V5, DOI 10.1038/srep15786; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie T., 2009, UNSUPERVISED LEARNIN, P485; Hood L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/nrclinonc.2010.227; Juyal RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045752; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; Kaufman L., 1990, FINDING GROUPS DATA, P68, DOI [DOI 10.1002/9780470316801.CH2, 10.1002/9780470316801.ch2]; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11; Leboyer M, 1998, TRENDS NEUROSCI, V21, P102, DOI 10.1016/S0166-2236(97)01187-9; Maechler M, 2012, R PACKAGE VERSION; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Prasher B, 2016, J ETHNOPHARMACOL; Prasher B, 2016, J GENET, V95, P209, DOI 10.1007/s12041-015-0607-9; Prasher B, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-48; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; R Core Team, 2021, R LANG ENV STAT COMP; Roenneberg T, 2003, J BIOL RHYTHM, V18, P80, DOI 10.1177/0748730402239679; Rotti H, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0506-0; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sethi TP, 2011, ACS CHEM BIOL, V6, P875, DOI 10.1021/cb2003016; Sharma P, 1999, SUSRUTA SAMHITA ENGL; Shi T, 2005, MODERN PATHOL, V18, P547, DOI 10.1038/modpathol.3800322; SLINKER BK, 1985, AM J PHYSIOL, V249, pR1, DOI 10.1152/ajpregu.1985.249.1.R1; Tian Q, 2012, J INTERN MED, V271, P111, DOI 10.1111/j.1365-2796.2011.02498.x; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Van der Laan MJ, 2003, J STAT COMPUT SIM, V73, P575, DOI 10.1080/0094965031000136012; Wittmann M, 2006, CHRONOBIOL INT, V23, P497, DOI 10.1080/07420520500545979; Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	40	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2017	12	10							e0185380	10.1371/journal.pone.0185380	http://dx.doi.org/10.1371/journal.pone.0185380			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI9WM	28981546	Green Submitted, Green Published, gold			2023-01-03	WOS:000412360300037
J	Aveni, E; Bauer, B; Ramelet, AS; Decosterd, I; Ballabeni, P; Bonvin, E; Rodondi, PY				Aveni, Eleonore; Bauer, Brent; Ramelet, Anne-Sylvie; Decosterd, Isabelle; Ballabeni, Pierluigi; Bonvin, Eric; Rodondi, Pierre-Yves			Healthcare professionals' sources of knowledge of complementary medicine in an academic center	PLOS ONE			English	Article							THEORY-PRACTICE GAP; ALTERNATIVE MEDICINE; INTERPROFESSIONAL EDUCATION; PHYSICIANS ATTITUDES; THERAPIES; NURSES; COMMUNICATION; PAIN	Background Complementary medicine ( CM) is utilized in a growing number of academic centers despite the debate concerning its value, risks and benefits. Healthcare professionals often feel uncomfortable discussing CM with patients, and little is known about their sources of knowledge in the field of CM. Objective To assess healthcare professionals' sources of knowledge and attitude toward CM in an academic hospital. Design and participants The cross-sectional web-based survey took place from October to December 2013. A total of 4,925 healthcare professionals working at Lausanne University Hospital, Switzerland, were invited to answer the questionnaire. Main measures Factors influencing healthcare professionals' opinion toward CM, knowledge and communication about CM. Key results The questionnaire was answered by 1,247 healthcare professionals. The three key factors influencing professionals' opinion toward CM were personal experience, clinical experience and evidence demonstrating the physiological mechanism of CM. Personal experience was more associated with nurses' and midwives' opinion compared to physicians' (80.8% vs 57.1%, OR = 3.08, [95% CI: 2.35-4.05], P<0.001 and 85.3% vs 57.1%, OR = 3.83, [95% CI: 1.95-7.53], P<0.001, respectively) as well as with professionals trained in CM compared tonon-trained professionals (86.0% vs 73.2%, OR = 2.60, [95% CI: 1.92-3.53], P<0.001). Physicians relied more on randomized controlled clinical trials compared to nurses (81.3% vs 62.9%, OR = 0.43, [95% CI: 0.33-0.57], P<0.001). A majority of the respondents (82.5%) agreed that they lacked knowledge about CM and 65.0% noted that it was the patient who initially started the discussion about CM. Conclusions Different professionals used different strategies to forge opinions regarding CM: physicians relied more on scientific evidence, while nurses and midwives were more influenced by personal experience. Regardless of preferred information source, most respondents did not feel prepared to address patient questions regarding CM. Enhancing interprofessional education opportunities is an important strategy to help providers become empowered to discuss CM with patients. This in turn will help patients making informed decisions in their healthcare.	[Aveni, Eleonore; Ballabeni, Pierluigi; Rodondi, Pierre-Yves] Lausanne Univ Hosp, Inst Social & Prevent Med, Lausanne, Switzerland; [Bauer, Brent] Mayo Clin, Div Gen Internal Med, Rochester, MN USA; [Ramelet, Anne-Sylvie] Lausanne Univ, IUFRS, Inst Higher Educ & Res Healthcare, Lausanne, Switzerland; [Decosterd, Isabelle] Lausanne Univ Hosp, Dept Anesthesiol, Pain Ctr, Lausanne, Switzerland; [Bonvin, Eric] Lausanne Univ Hosp, Dept Psychiat, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Mayo Clinic; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Aveni, E (corresponding author), Lausanne Univ Hosp, Inst Social & Prevent Med, Lausanne, Switzerland.	eleonore.aveni@chuv.ch	Ramelet, Anne-Sylvie/G-8451-2013; Rodondi, Pierre-Yves/AAU-3708-2020	Ramelet, Anne-Sylvie/0000-0001-8809-2920; Ballabeni, Pierluigi/0000-0002-1572-7179; Rodondi, Pierre-Yves/0000-0003-2007-2995; Bonvin, Eric/0000-0001-7995-2490	Lebherz-Cornelius Celsius Foundation	Lebherz-Cornelius Celsius Foundation	This study was supported by a grant from the Lebherz-Cornelius Celsius Foundation. The authors who received the funding: PYR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Association of American Medical Colleges (AAMS), 1998, LEARN OBJ MED STUD E; Aveni E, 2016, EXPLORE-NY, V12, P341, DOI 10.1016/j.explore.2016.06.001; Blue AV, 2010, J INTERPROF CARE, V24, P204, DOI 10.3109/13561820903442887; Brock D, 2013, POSTGRAD MED J, V89, P642, DOI [10.1136/postgradmedj-2012-000952rep, 10.1136/bmjqs-2012-000952]; Brooke Joanne, 2015, Nurse Educ Today, V35, pe6, DOI 10.1016/j.nedt.2015.02.026; Chen L, 2010, PAIN MED, V11, P530, DOI 10.1111/j.1526-4637.2010.00815.x; Chen XW, 2011, CURR MED CHEM, V18, P4836, DOI 10.2174/092986711797535317; Clarke TC, 2015, NATL HLTH STAT REPOR, P1; Condon C, 2016, PHYSIOTHERAPY, V102, P10, DOI 10.1016/j.physio.2015.06.003; Coulter ID, 2008, HOSP BASED INTEGRATI; Coulter ID, 2004, MAINSTREAMING COMPLE, P103; Cowen VS, 2015, AM J PREV MED, V49, pS257, DOI 10.1016/j.amepre.2015.07.035; Dawes Martin, 2005, BMC Med Educ, V5, P1; Estabrooks CA, 2005, QUAL HEALTH RES, V15, P460, DOI 10.1177/1049732304273702; Forsman H, 2012, INT J NURS STUD, V49, P1155, DOI 10.1016/j.ijnurstu.2012.04.002; Geisler C, 2015, J AM ASSOC NURSE PRA, V27, P380, DOI 10.1002/2327-6924.12190; Hall Amanda, 2004, Health Info Libr J, V21, P102, DOI 10.1111/j.1471-1842.2004.00506.x; Hall H, 2017, INT J NURS STUD, V69, P47, DOI 10.1016/j.ijnurstu.2017.01.008; Hatlevik IK, 2012, J ADV NURS, V68, P868; Hollenberg DB, 2011, J COMPLEMENT INTEGR; HUMPHREYS BL, 1994, B MED LIBR ASSOC, V82, P18; Institute of Medicine (US), 2005, COMM US COMPL ALT ME; Interprofessional Education Collaborative Expert Panel, 2011, COR COMP INT COLL PR; Jong MC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-4; Jung B, 2016, EXPLORE; Kadar GE, 2015, J INTERPROF CARE, V29, P377, DOI 10.3109/13561820.2014.967337; Klein SD, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0141985, 10.1371/journal.pone.0144676]; Labriola D, 1999, ONCOLOGY-NY, V13, P1003; Lin V, 2015, HEALTH EXPECT, V18, P2651, DOI 10.1111/hex.12239; Nematollahi R, 2012, INT NURS REV, V59, P194, DOI 10.1111/j.1466-7657.2011.00949.x; Ott M, 2015, TRACE ELEM ELECTROLY, V32, P74; Patterson C, 2008, INTEGR MED INSIGHTS, V3; Reeves S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002213.pub3; Robinson A, 2004, COMPLEMENT THER MED, V12, P90, DOI 10.1016/j.ctim.2004.09.006; Scully NJ, 2011, COLLEGIAN, V18, P93, DOI 10.1016/j.colegn.2010.04.002; Silverman J, 2012, SKILLS COMMUNICATING; Straus SE, 2009, CAN MED ASSOC J, V181, P165, DOI 10.1503/cmaj.081229; SUDMAN S, 1985, EVALUATION REV, V9, P349, DOI 10.1177/0193841X8500900306; Templeman K, 2011, COMPLEMENT THER MED, V19, P84, DOI 10.1016/j.ctim.2011.02.003; Thompson Carl, 2004, Evid Based Nurs, V7, P68; Trimborn A, 2013, ANN ONCOL, V24, P2641, DOI 10.1093/annonc/mdt299; VanGeest JB, 2007, EVAL HEALTH PROF, V30, P303, DOI 10.1177/0163278707307899; Vaucher C, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0120-5; Verloo H, 2017, J EVAL CLIN PRACT, V23, P139, DOI 10.1111/jep.12653; Wahner-Roedler DL, 2006, EVID-BASED COMPL ALT, V3, P495, DOI 10.1093/ecam/nel036; Wahner-Roedler DL, 2014, COMPLEMENT THER CLIN, V20, P54, DOI 10.1016/j.ctcp.2013.09.003; Widmer M, 2006, FORSCH KOMP KLAS NAT, V13, P356, DOI 10.1159/000097254; Winslow LC, 2002, ARCH INTERN MED, V162, P1176; World Health Organization, TRADITIONAL MED; Youngblut J M, 2001, AACN Clin Issues, V12, P468, DOI 10.1097/00044067-200111000-00003	50	17	17	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2017	12	9							e0184979	10.1371/journal.pone.0184979	http://dx.doi.org/10.1371/journal.pone.0184979			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI5MG	28961256	gold, Green Published, Green Submitted			2023-01-03	WOS:000412027700013
J	Carson, JL; Triulzi, DJ; Ness, PM				Carson, Jeffrey L.; Triulzi, Darrell J.; Ness, Paul M.			Indications for and Adverse Effects of Red-Cell Transfusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LUNG INJURY; RESTRICTIVE TRANSFUSION; UNITED-STATES; BLOOD-DONORS; CIRCULATORY OVERLOAD; TRANSMITTED MALARIA; BABESIA-MICROTI; GUIDELINES; MANAGEMENT; RISK	Approximately 11 million units of red cells are transfused annually in the United States, making red-cell transfusion one of the most common medical interventions. Red cells are typically administered as a concentrate, called packed red cells, with a preservative solution (hematocrit, 60%) that allows up to 42 days of refrigerated storage. On average, transfusion of 1 unit of red cells, which has a volume of 350 ml, results in a hemoglobin increment of 1 g per deciliter in an adult with stable blood volume. In this review, we describe the evidence underlying current transfusion guidelines, trends in use, the infectious and noninfectious risks of transfusion, and ongoing research. We describe the effects of transfusion in adults who have cardiovascular disease or gastrointestinal bleeding, who are critically ill, or who are undergoing orthopedic surgery, as well as the effects in children. Discussions of the safety of transfusion in resource-poor countries and the efficacy of transfusion in premature infants, pregnant women, and patients with hemorrhagic shock or congenital anemias are beyond the scope of this review.	[Carson, Jeffrey L.] Rutgers Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, New Brunswick, NJ USA; [Triulzi, Darrell J.] Univ Pittsburgh, Dept Pathol, Div Transfus Med, Pittsburgh, PA USA; [Ness, Paul M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Transfus Med, Baltimore, MD 21205 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University	Carson, JL (corresponding author), Rutgers Robert Wood Johnson Med Sch, 125 Paterson St, New Brunswick, NJ 08901 USA.	jeffrey.carson@rutgers.edu			Terumo BCT; Carmell; Fresenius Kabi; Cerus Corporation; New Health Sciences	Terumo BCT; Carmell; Fresenius Kabi; Cerus Corporation; New Health Sciences	Dr. Carson reports receiving grant support from Terumo BCT; Dr. Triulzi, receiving advisory board fees from Carmell and Fresenius Kabi and fees for serving on a data and safety monitoring board from Cerus Corporation; Dr. Ness, receiving fees for serving as scientific advisor from Terumo BCT and New Health Sciences. No other potential conflict of interest relevant to this article was reported.	Aberle-Grasse J, 1999, TRANSFUSION, V39, P206, DOI 10.1046/j.1537-2995.1999.39299154737.x; Abuchowski A, 2016, ADV EXP MED BIOL, V876, P461, DOI 10.1007/978-1-4939-3023-4_58; Alayash AI, 2014, TRENDS BIOTECHNOL, V32, P177, DOI 10.1016/j.tibtech.2014.02.006; Alexander J, 2016, JAMA-J AM MED ASSOC, V316, P2038, DOI 10.1001/jama.2016.12870; Allain JP, 2016, LANCET, V387, P1753, DOI 10.1016/S0140-6736(16)00581-X; Amer Soc Anesthesiologists, 2015, ANESTHESIOLOGY, V122, P241, DOI 10.1097/ALN.0000000000000463; [Anonymous], 2013, NCCN CLIN PRACT GUID; [Anonymous], TRANSF DON FAT NOT P; [Anonymous], 2009, BLOOD SAF SURV; [Anonymous], 2014, TRANSF ASS CIRC OV T; [Anonymous], 2016, COLL TEST US BLOOD B; [Anonymous], 2012, PAT BLOOD MAN GUID; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; Blajchman Morris A., 2001, Transfusion Medicine Reviews, V15, P1, DOI 10.1053/tmrv.2001.19946; Bloch EM, 2016, TRANSFUSION, V56, P1875, DOI 10.1111/trf.13617; Brecher ME, 2005, CLIN MICROBIOL REV, V18, P195, DOI 10.1128/CMR.18.1.195-204.2005; Busch MP, 2005, NEW ENGL J MED, V353, P460, DOI 10.1056/NEJMoa044029; Cantey PT, 2012, TRANSFUSION, V52, P1922, DOI 10.1111/j.1537-2995.2012.03581.x; Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Carson JL, 2015, LANCET, V385, P1183, DOI 10.1016/S0140-6736(14)62286-8; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 2016, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD002042; Chung KW, 2016, TRANSFUSION, V56, P2184, DOI 10.1111/trf.13644; Cohn SM, 2007, J TRAUMA, V62, P44, DOI 10.1097/TA.0b013e31802eb817; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; Davenport R. D., 2016, ROSSIS PRINCIPLES TR, P642; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dhabangi A, 2016, JAMA PEDIATR, V170, P995, DOI 10.1001/jamapediatrics.2016.1254; Dhabangi A, 2015, JAMA-J AM MED ASSOC, V314, P2514, DOI 10.1001/jama.2015.13977; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Ellingson KD, 2017, TRANSFUSION, V57, P1588, DOI 10.1111/trf.14165; Elmer J, 2013, J EMERG MED, V44, P829, DOI 10.1016/j.jemermed.2012.11.025; Fang DC, 2016, TRANSFUS MED REV, V30, P132, DOI 10.1016/j.tmrv.2016.04.002; fda, FAT REP FDA FOLL BLO; Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038; Goodnough LT, 2012, ANESTHESIOLOGY, V116, P1367, DOI 10.1097/ALN.0b013e318254d1a3; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hoffbrand AV, 2012, BLOOD, V120, P3657, DOI 10.1182/blood-2012-05-370098; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Hoofnagle JH, 2012, NEW ENGL J MED, V367, P1237, DOI 10.1056/NEJMra1204512; Jairath V, 2015, LANCET, V386, P137, DOI 10.1016/S0140-6736(14)61999-1; Katz LM, 2017, ARCH PATHOL LAB MED, V141, P85, DOI 10.5858/arpa.2016-0430-RA; Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, 2012, KIDNEY INT SUPPL, V2, P279, DOI DOI 10.1038/kisup.2012.37; Killick SB, 2014, BRIT J HAEMATOL, V164, P503, DOI 10.1111/bjh.12694; Kleinman S, 2004, TRANSFUSION, V44, P1774, DOI 10.1111/j.0041-1132.2004.04347.x; Kohn L, 2000, Jt Comm J Qual Improv, V26, P227; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Leahy MF, 2017, TRANSFUSION, V57, P1347, DOI 10.1111/trf.14006; McCullough J, 2004, BLOOD, V104, P1534, DOI 10.1182/blood-2003-12-4443; Migliaccio AR, 2012, BLOOD REV, V26, P81, DOI 10.1016/j.blre.2011.11.002; Minino Arialdi M, 2011, Natl Vital Stat Rep, V59, P1; Moritz ED, 2016, NEW ENGL J MED, V375, P2236, DOI 10.1056/NEJMoa1600897; Muller MCA, 2015, TRANSFUSION, V55, P164, DOI 10.1111/trf.12816; Mungai M, 2001, NEW ENGL J MED, V344, P1973, DOI 10.1056/NEJM200106283442603; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Narick C, 2012, TRANSFUSION, V52, P160, DOI 10.1111/j.1537-2995.2011.03247.x; National Institute for Health and Care Excellence (NICE), 2015, BLOOD TRANSFUSION; National Weather Service, 2017, DANG IS LIGHTN; NESS PM, 1994, ARCH PATHOL LAB MED, V118, P337; Petersen LR, 2010, TRANSFUS MED REV, V24, P15, DOI 10.1016/j.tmrv.2009.09.002; PlaneCrashInfo. com, 2017, CAUS FAT ACC DEC; Prowse CV, 2013, VOX SANG, V104, P183, DOI 10.1111/j.1423-0410.2012.01662.x; Qaseem A, 2013, ANN INTERN MED, V159, P770, DOI 10.7326/0003-4819-159-11-201312030-00009; Retter A, 2013, BRIT J HAEMATOL, V160, P445, DOI 10.1111/bjh.12143; Roubinian NH, 2017, VOX SANG, V112, P56, DOI 10.1111/vox.12466; Roubinian NH, 2015, INT J CLIN TRANSFUS, V3, P17; Shander A, 2014, TRANSFUSION, V54, P2688, DOI 10.1111/trf.12565; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x; Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644; Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51; Toy P, 2012, BLOOD, V119, P1757, DOI 10.1182/blood-2011-08-370932; Vamvakas EC, ROSSIS PRINCIPLES TR; Van Remoortel H, 2016, TRANSFUSION, V56, P472, DOI 10.1111/trf.13385; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Whitaker B, 2016, TRANSFUSION, V56, P2173, DOI 10.1111/trf.13676; Zou SM, 2010, TRANSFUSION, V50, P1495, DOI 10.1111/j.1537-2995.2010.02622.x	80	124	128	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	2017	377	13					1261	1272		10.1056/NEJMra1612789	http://dx.doi.org/10.1056/NEJMra1612789			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FI3DU	28953438				2023-01-03	WOS:000411838100009
J	Hofmann, R; James, SK; Jernberg, T; Lindahl, B; Erlinge, D; Witt, N; Arefalk, G; Frick, M; Alfredsson, J; Nilsson, L; Ravn-Fischer, A; Omerovic, E; Kellerth, T; Sparv, D; Ekelund, U; Linder, R; Ekstrom, M; Lauermann, J; Haaga, U; Pernow, J; Ostlund, O; Herlitz, J; Svensson, L				Hofmann, Robin; James, Stefan K.; Jernberg, Tomas; Lindahl, Bertil; Erlinge, David; Witt, Nils; Arefalk, Gabriel; Frick, Mats; Alfredsson, Joakim; Nilsson, Lennart; Ravn-Fischer, Annica; Omerovic, Elmir; Kellerth, Thomas; Sparv, David; Ekelund, Ulf; Linder, Rickard; Ekstrom, Mattias; Lauermann, Jorg; Haaga, Urban; Pernow, John; Ostlund, Ollie; Herlitz, Johan; Svensson, Leif		DETO2X-SWEDEHEART Investigators	Oxygen Therapy in Suspected Acute Myocardial Infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEST-PAIN; INHALATION; SIZE	BACKGROUND The clinical effect of routine oxygen therapy in patients with suspected acute myocardial infarction who do not have hypoxemia at baseline is uncertain. METHODS In this registry-based randomized clinical trial, we used nationwide Swedish registries for patient enrollment and data collection. Patients with suspected myocardial infarction and an oxygen saturation of 90% or higher were randomly assigned to receive either supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open face mask) or ambient air. RESULTS A total of 6629 patients were enrolled. The median duration of oxygen therapy was 11.6 hours, and the median oxygen saturation at the end of the treatment period was 99% among patients assigned to oxygen and 97% among patients assigned to ambient air. Hypoxemia developed in 62 patients (1.9%) in the oxygen group, as compared with 254 patients (7.7%) in the ambient-air group. The median of the highest troponin level during hospitalization was 946.5 ng per liter in the oxygen group and 983.0 ng per liter in the ambient-air group. The primary end point of death from any cause within 1 year after randomization occurred in 5.0% of patients (166 of 3311) assigned to oxygen and in 5.1% of patients (168 of 3318) assigned to ambient air (hazard ratio, 0.97; 95% confidence interval [CI], 0.79 to 1.21; P = 0.80). Rehospitalization with myocardial infarction within 1 year occurred in 126 patients (3.8%) assigned to oxygen and in 111 patients (3.3%) assigned to ambient air (hazard ratio, 1.13; 95% CI, 0.88 to 1.46; P = 0.33). The results were consistent across all predefined subgroups. CONCLUSIONS Routine use of supplemental oxygen in patients with suspected myocardial infarction who did not have hypoxemia was not found to reduce 1-year all-cause mortality.	[Hofmann, Robin; Witt, Nils; Frick, Mats] Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, Div Cardiol, Sjukhusbacken 10, S-11883 Stockholm, Sweden; [Svensson, Leif] Soder Sjukhuset, Karolinska Inst, Ctr Resuscitat Sci, Stockholm, Sweden; [Jernberg, Tomas; Linder, Rickard; Ekstrom, Mattias] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Cardiol, Stockholm, Sweden; [James, Stefan K.; Lindahl, Bertil; Arefalk, Gabriel] Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden; [James, Stefan K.; Ostlund, Ollie] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Erlinge, David; Sparv, David] Lund Univ, Dept Clin Sci, Cardiol, Lund, Sweden; [Ekelund, Ulf] Lund Univ, Dept Clin Sci, Emergency Med, Lund, Sweden; [Alfredsson, Joakim; Nilsson, Lennart] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Alfredsson, Joakim; Nilsson, Lennart] Linkoping Univ, Dept Cardiol, Linkoping, Sweden; [Ravn-Fischer, Annica; Omerovic, Elmir; Herlitz, Johan] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden; [Kellerth, Thomas] Orebro Univ Hosp, Dept Cardiol, Orebro, Sweden; [Lauermann, Jorg] Ryhov Hosp, Dept Internal Med, Div Cardiol, Jonkoping, Sweden; [Haaga, Urban] Karlstad Cent Hosp, Dept Cardiol, Karlstad, Sweden; [Pernow, John] Karolinska Univ Hosp, Dept Cardiol, Solna, Sweden; [Pernow, John; Svensson, Leif] Karolinska Inst, Dept Med, Solna, Sweden; [Herlitz, Johan] Univ Boras, Dept Hlth Sci, Boras, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Danderyds Hospital; Karolinska Institutet; Uppsala University; Uppsala University; Lund University; Lund University; Linkoping University; Linkoping University; Sahlgrenska University Hospital; Orebro University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Boras	Hofmann, R (corresponding author), Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, Div Cardiol, Sjukhusbacken 10, S-11883 Stockholm, Sweden.	robin.hofmann@sll.se	Hofmann, Robin/C-1138-2013; James, Stefan K/J-4554-2014; Ekström, Mattias/HGU-3873-2022	Hofmann, Robin/0000-0002-8907-895X; Ekström, Mattias/0000-0001-9448-8403; Ostlund, Ollie/0000-0001-8028-2308; Pernow, John/0000-0003-4766-0922; Jernberg, Tomas/0000-0003-1695-379X	Swedish Heart-Lung Foundation; Swedish Research Council; Swedish Foundation for Strategic Research; AstraZeneca; Merck Sharp Dohme; Aspen; Roche; BioMerieux; Philips; Thermofisher; the Medicines Company	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); AstraZeneca(AstraZeneca); Merck Sharp Dohme(Merck & Company); Aspen; Roche(Roche Holding); BioMerieux; Philips; Thermofisher; the Medicines Company	Supported by the Swedish Heart-Lung Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research.; Dr. Jernberg reports receiving lecture fees and consulting fees from AstraZeneca, consulting fees from Merck Sharp & Dohme, and lecture fees from Aspen; Dr. Lindahl, receiving fees for serving on a steering committee, paid to his university, from Roche, research support and advisory board fees, paid to his university, from BioMerieux, and advisory board fees, paid to his university, from Philips and Thermofisher; and Dr. Erlinge, receiving lecture fees and advisory board fees from AstraZeneca and the Medicines Company. No other potential conflict of interest relevant to this article was reported.	Cabello JB, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007160.pub4; Hofmann R, 2014, AM HEART J, V167, P322, DOI 10.1016/j.ahj.2013.09.022; Jernberg T, 2010, HEART, V96, P1617, DOI 10.1136/hrt.2010.198804; KELLY RF, 1995, AM HEART J, V130, P957, DOI 10.1016/0002-8703(95)90194-9; Khoshnood A, 2016, EUR J EMERG MED; MADIAS JE, 1976, CIRCULATION, V53, P411, DOI 10.1161/01.CIR.53.3.411; MAROKO PR, 1975, CIRCULATION, V52, P360, DOI 10.1161/01.CIR.52.3.360; Montori VM, 2001, CAN MED ASSOC J, V165, P1339; Moradkhan R, 2010, J AM COLL CARDIOL, V56, P1013, DOI 10.1016/j.jacc.2010.04.052; Thang ND, 2012, AM J EMERG MED, V30, P1788, DOI 10.1016/j.ajem.2012.02.014; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Sepehrvand N, 2016, JACC-HEART FAIL, V4, P783, DOI 10.1016/j.jchf.2016.03.026; Steele C., 1900, BMJ-BRIT MED J, V2, P1568; Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Thang ND, 2013, INT J CARDIOL, V166, P141, DOI 10.1016/j.ijcard.2011.10.014; Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184; Zweier JL, 2006, CARDIOVASC RES, V70, P181, DOI 10.1016/j.cardiores.2006.02.025	20	197	210	3	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 28	2017	377	13					1240	1249		10.1056/NEJMoa1706222	http://dx.doi.org/10.1056/NEJMoa1706222			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FI3DU	28844200	Green Published, Bronze			2023-01-03	WOS:000411838100007
J	Kang'''', N; Cauraugh, JH				Kang, Nyeonju; Cauraugh, James H.			Does non-invasive brain stimulation reduce essential tremor? A systematic review and meta-analysis	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST STIMULATION; MOTOR CORTEX; PERIPHERAL STIMULATION; REPEATED SESSIONS; RTMS; EXCITABILITY; CONNECTIVITY; IMPROVEMENT; PREVALENCE	Essential tremor (ET) is the most common age-related disease leading to abnormal tremulous behaviors in the upper and lower extremities. Non-invasive brain stimulation (NIBS) may be an effective ET therapy by modulating the oscillating network of the brain. The current systematic review and meta-analysis examined the effects of NIBS interventions on tremor symptoms in ET patients. Our comprehensive search identified eight studies that used 1 Hz of rTMS, cTBS, or ctDCS protocols. Twenty total comparisons from the eight qualified studies were statistically synthesized, and the meta-analytic findings revealed that NIBS techniques reduced tremulous behaviors in individuals with ET. Moreover, the four moderator variable analyses demonstrated that the positive therapeutic effects of NIBS appeared across the following subgroups: (a) tremor assessment (clinical test vs. quantitative tremor assessment), (b) stimulation site (cerebellum vs. motor cortex), (c) session number (single session vs. multiple sessions), and (d) sustained positive treatment effect (posttest vs. retention test). This comprehensive systematic review and meta-analysis provided evidence that support positive treatment effects of NIBS techniques on ET motor therapy.	[Kang, Nyeonju] Univ Florida, Lab Rehabil Neurosci, Dept Appl Physiol & Kinesiol, Gainesville, FL USA; [Kang, Nyeonju; Cauraugh, James H.] Univ Florida, Motor Behav Lab, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Kang, Nyeonju] Incheon Natl Univ, Div Sport Sci, Incheon, South Korea	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Incheon National University	Cauraugh, JH (corresponding author), Univ Florida, Motor Behav Lab, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA.	cauraugh@ufl.edu	Kang, Nyeonju/AAX-1879-2021	KANG, NYEONJU/0000-0003-4440-4413	University of Florida Open Access Publishing Fund	University of Florida Open Access Publishing Fund	Publication of this article was funded in part by the University of Florida Open Access Publishing Fund.	Avanzino L, 2009, EUR J NEUROSCI, V30, P1971, DOI 10.1111/j.1460-9568.2009.06984.x; Badran BW, 2016, BRAIN STIMUL, V9, P945, DOI 10.1016/j.brs.2016.08.003; BAIN PG, 1994, BRAIN, V117, P805, DOI 10.1093/brain/117.4.805; Baumer T, 2003, NEUROIMAGE, V20, P550, DOI 10.1016/S1053-8119(03)00310-0; Blobaum P, 2006, J MED LIBR ASSOC, V94, P477; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Bologna M, 2015, CEREBELLUM, V14, P133, DOI 10.1007/s12311-014-0621-0; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; Borenstein M, 2013, PREV SCI, V14, P134, DOI 10.1007/s11121-013-0377-7; Borich M, 2009, RESTOR NEUROL NEUROS, V27, P55, DOI 10.3233/RNN-2009-0461; Chalah MA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00440; Chen R, 2012, CLIN NEUROPHYSIOL, V123, P850, DOI 10.1016/j.clinph.2011.09.015; Chuang WL, 2014, MOVEMENT DISORD, V29, P501, DOI 10.1002/mds.25809; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Dupuis MJM, 2010, MOVEMENT DISORD, V25, P2884, DOI 10.1002/mds.23328; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Elble RJ, 2009, CURR NEUROL NEUROSCI, V9, P273, DOI 10.1007/s11910-009-0041-6; Ferrucci Roberta, 2016, Cerebellum Ataxias, V3, P16, DOI 10.1186/s40673-016-0054-2; Gironell A, 2002, ARCH NEUROL-CHICAGO, V59, P413, DOI 10.1001/archneur.59.3.413; Gironell A, 2015, TREMOR OTHER HYPERK, V5, DOI 10.7916/D8DV1HQC; Grimaldi G, 2008, TREATMENT PATHOGENES; Hellriegel H, 2012, CLIN NEUROPHYSIOL, V123, P1010, DOI 10.1016/j.clinph.2011.08.033; Helmich RC, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0378-8; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Lindenberg R, 2012, NEUROREHAB NEURAL RE, V26, P479, DOI 10.1177/1545968311427568; Louis ED, 2000, ARCH NEUROL-CHICAGO, V57, P1194, DOI 10.1001/archneur.57.8.1194; Louis ED, 2001, MOVEMENT DISORD, V16, P914, DOI 10.1002/mds.1184; Louis Elan D, 2011, Front Neurol, V2, P91, DOI 10.3389/fneur.2011.00091; Louis ED, 2010, MOVEMENT DISORD, V25, P534, DOI 10.1002/mds.22838; Louis ED, 2009, NEUROEPIDEMIOLOGY, V32, P208, DOI 10.1159/000195691; Lu R., 2017, BRAIN STIMUL, V10, P513, DOI [10.1016/j.brs.2017.01.499, DOI 10.1016/J.BRS.2017.01.499]; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nettekoven C, 2014, J NEUROSCI, V34, P6849, DOI 10.1523/JNEUROSCI.4993-13.2014; Ni Z, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0045-x; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Obeso I, 2016, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00486; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Pinto AD, 2003, NEUROLOGY, V60, P1985, DOI 10.1212/01.WNL.0000065890.75790.29; Popa T, 2013, BRAIN STIMUL, V6, P175, DOI 10.1016/j.brs.2012.04.009; Raethjen J, 2012, CLIN NEUROPHYSIOL, V123, P61, DOI 10.1016/j.clinph.2011.09.024; Rosenthal R, 2001, ANNU REV PSYCHOL, V52, P59, DOI 10.1146/annurev.psych.52.1.59; Sandvik U, 2012, NEUROSURGERY, V70, P840, DOI 10.1227/NEU.0b013e318236a809; Shih LC, 2017, TREMOR OTHER HYPERK, V7, DOI 10.7916/D8G44W01; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Vanneste S, 2013, BRAIN STIMUL, V6, P155, DOI 10.1016/j.brs.2012.03.019; Yilmaz NH, 2016, NEUROLOGIST, V21, P28, DOI 10.1097/NRL.0000000000000070; Zhang K, 2010, J NEUROSURG, V112, P1271, DOI 10.3171/2009.10.JNS09371	51	14	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185462	10.1371/journal.pone.0185462	http://dx.doi.org/10.1371/journal.pone.0185462			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957367	Green Submitted, Green Published, gold			2023-01-03	WOS:000411985200063
J	Kennedy, AE; Kandalam, S; Olivares-Navarrete, R; Dickinson, AJG				Kennedy, Allyson E.; Kandalam, Suraj; Olivares-Navarrete, Rene; Dickinson, Amanda J. G.			E-cigarette aerosol exposure can cause craniofacial defects in Xenopus laevis embryos and mammalian neural crest cells	PLOS ONE			English	Article							PROPYLENE-GLYCOL; OROFACIAL DEVELOPMENT; MATERNAL SMOKING; CLEFT-LIP; NICOTINE; BUTTER; MODEL; MALFORMATIONS; METABOLISM; DIACETYL	Since electronic cigarette (ECIG) introduction to American markets in 2007, vaping has surged in popularity. Many, including women of reproductive age, also believe that ECIG use is safer than traditional tobacco cigarettes and is not hazardous when pregnant. However, there are few studies investigating the effects of ECIG exposure on the developing embryo and nothing is known about potential effects on craniofacial development. Therefore, we have tested the effects of several aerosolized e-cigarette liquids (e-cigAM) in an in vivo craniofacial model, Xenopus laevis, as well as a mammalian neural crest cell line. Results demonstrate that e-cigAM exposure during embryonic development induces a variety of defects, including median facial clefts and midface hypoplasia in two of e-cigAMs tested e-cigAMs. Detailed quantitative analyses of the facial morphology revealed that nicotine is not the main factor in inducing craniofacial defects, but can exacerbate the effects of the other e-liquid components. Additionally, while two different e-cigAMs can have very similar consequences on facial appearances, there are subtle differences that could be due to the differences in e-cigAM components. Further assessment of embryos exposed to these particular e-cigAMs revealed cranial cartilage and muscle defects and a reduction in the blood supply to the face. Finally, the expression of markers for vascular and cartilage differentiation was reduced in a mammalian neural crest cell line corroborating the in vivo effects. Our work is the first to show that ECIG use could pose a potential hazard to the developing embryo and cause craniofacial birth defects. This emphasizes the need for more testing and regulation of this new popular product.	[Kennedy, Allyson E.; Dickinson, Amanda J. G.] Virginia Commonwealth Univ, Dept Biol, Richmond, VA 23284 USA; [Kandalam, Suraj; Olivares-Navarrete, Rene] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University	Dickinson, AJG (corresponding author), Virginia Commonwealth Univ, Dept Biol, Richmond, VA 23284 USA.	ajdickinson@vou.edu		Dickinson, Amanda/0000-0002-1427-9140	NIDCR [5R56DE026024-02]; NIH National Institute of Dental and Craniofacial Research [5R56DE026024-02]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R56DE026024] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by NIDCR 5R56DE026024-02 to Olivares-Navarrete and Dickinson co-PIs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was funded by a Grant awarded by the NIH National Institute of Dental and Craniofacial Research (Grant number: 5R56DE026024-02) to Rene Olivares-Navarrete and Amanda Dickinson. The authors would also like to acknowledge Chesapeake Tschaenn and Deborah Howton for specimen collection and frog husbandry (Dickinson lab). Finally we would like to especially thank Alison Breland and Tom Eissenberg for their insight into the human use of ECIGs and the needs for testing these products in embryos.	Adams DS, 2016, J PHYSIOL-LONDON, V594, P3245, DOI 10.1113/JP271930; Ashford K, 2016, NURS RES, V65, P408, DOI 10.1097/NNR.0000000000000176; Bahl V, 2012, REPROD TOXICOL, V34, P529, DOI 10.1016/j.reprotox.2012.08.001; Bailey RL, 2015, AM J IND MED, V58, P1235, DOI 10.1002/ajim.22533; Martelli DRB, 2015, BRAZ J OTORHINOLAR, V81, P514, DOI 10.1016/j.bjorl.2015.07.011; Bnait KS, 1995, EXP TOXICOL PATHOL, V47, P453, DOI 10.1016/S0940-2993(11)80327-1; Brass DM, 2017, AM J RESP CELL MOL B; Breland A, 2017, ANN NY ACAD SCI, V1394, P5, DOI 10.1111/nyas.12977; Breland AB, 2014, J ADDICT MED, V8, P223, DOI 10.1097/ADM.0000000000000049; Bruin JE, 2010, TOXICOL SCI, V116, P364, DOI 10.1093/toxsci/kfq103; Burstyn I, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-18; Cavalcanti ZD, 2012, J BRAS PNEUMOL, V38, P395, DOI 10.1590/S1806-37132012000300016; Conlon F, 2011, BENZIDINE PEROXIDASE; Curwin BD, 2015, J EXPO SCI ENV EPID, V25, P324, DOI 10.1038/jes.2014.52; DARLINGTON RB, 1973, REV EDUC RES, V43, P433, DOI 10.3102/00346543043004433; Deniz E, 2017, SCI REP-UK, V7, DOI 10.1038/srep42506; Devotta A, 2016, DEV BIOL, V415, P371, DOI 10.1016/j.ydbio.2016.02.010; Dickinson AJG, 2016, SEMIN CELL DEV BIOL, V51, P53, DOI 10.1016/j.semcdb.2016.03.005; Dickinson AJG, 2016, SEMIN CELL DEV BIOL, V51, P54, DOI 10.1016/j.semcdb.2016.01.016; Dubey A, 2017, CURR PATHOBIOL REP, V5, P79, DOI 10.1007/s40139-017-0128-8; FDA, 2017, VAP E CIG OTH EL NIC; Fowles JR, 2013, CRIT REV TOXICOL, V43, P363, DOI 10.3109/10408444.2013.792328; Gouignard N, 2016, DIS MODEL MECH, V9, P607, DOI 10.1242/dmm.024661; Griffin JN, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005018; Gunnerbeck A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084715; Hanken J, 2005, J ANAT, V207, P437, DOI 10.1111/j.1469-7580.2005.00481.x; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; Holden VK, 2016, CURR OPIN PULM MED, V22, P158, DOI 10.1097/MCP.0000000000000250; Honein MA, 2014, BIRTH DEFECTS RES A, V100, P822, DOI 10.1002/bdra.23274; Huerta TR, 2017, AM J PREV MED, V52, P339, DOI 10.1016/j.amepre.2016.10.017; Jensen RP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42549; JOSCHKO MA, 1991, NEUROTOXICOL TERATOL, V13, P307, DOI 10.1016/0892-0362(91)90076-9; Kang P, 2003, Orthod Craniofac Res, V6, P129, DOI 10.1034/j.1600-0544.2003.02236.x; Kennedy AE, 2014, JOVE-J VIS EXP, DOI 10.3791/52062; Kennedy AE, 2014, ANAT REC, V297, P834, DOI 10.1002/ar.22864; Kienhuis AS, 2015, TOB INDUC DIS, V13, DOI 10.1186/s12971-015-0038-7; Klingenberg CP, 2011, MOL ECOL RESOUR, V11, P353, DOI 10.1111/j.1755-0998.2010.02924.x; Kreiss K, 2002, NEW ENGL J MED, V347, P330, DOI 10.1056/NEJMoa020300; Lauterstein DE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040417; Levine AJ, 2003, DEV BIOL, V254, P50, DOI 10.1016/S0012-1606(02)00029-5; Mark KS, 2015, J ADDICT MED, V9, P266, DOI 10.1097/ADM.0000000000000128; Massarsky A, 2017, ZEBRAFISH, V14, P216, DOI 10.1089/zeb.2016.1400; MCCARTHY M, 2014, BMJ-BRIT MED J, V349, DOI DOI 10.1136/BMJ.G5154; McMillen RC, 2015, NICOTINE TOB RES, V17, P1195, DOI 10.1093/ntr/ntu213; Oncken C, 2017, NICOTINE TOB RES, V19, P585, DOI 10.1093/ntr/ntw225; Palpant NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126259; Pankow JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173055; Peace MR, 2016, J ANAL TOXICOL, V40, P403, DOI 10.1093/jat/bkw037; Pu J, 2017, PERSPECT PUBLIC HEAL; Rigler MW, 2010, INT J OCCUP ENV HEAL, V16, P291; Rinon A, 2007, DEVELOPMENT, V134, P3065, DOI 10.1242/dev.002501; Rom O, 2015, ANN NY ACAD SCI, V1340, P65, DOI 10.1111/nyas.12609; Rowell TR, 2017, AM J PHYSIOL-LUNG C, V313, pL52, DOI 10.1152/ajplung.00392.2016; Schmidt J, 2013, J ANAT, V222, P134, DOI 10.1111/j.1469-7580.2012.01541.x; [Services DoHaH Administration FaD], 2016, RESTR SAL DISTR TOB; Shen X, 2004, INT J PHARMACEUT, V275, P249, DOI 10.1016/j.ijpharm.2004.02.005; Shi M, 2007, AM J HUM GENET, V80, P76, DOI 10.1086/510518; Singh T, 2016, TOBACCO USE AMONOG M; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; Spindle TR, 2015, NICOTINE TOB RES, V17, P142, DOI 10.1093/ntr/ntu186; Tahir R, 2014, MECH DEVELOP, V133, P91, DOI 10.1016/j.mod.2014.05.004; TAYLOR DJ, 1985, BIOCHEM J, V225, P315, DOI 10.1042/bj2250315; Tierney PA, 2016, TOB CONTROL, V25, pE10, DOI 10.1136/tobaccocontrol-2014-052175; van Rooij IALM, 2001, EPIDEMIOLOGY, V12, P502, DOI 10.1097/00001648-200109000-00007; Wagner NJ, 2017, MATERN CHILD HLTH J, V21, P1655, DOI 10.1007/s10995-016-2257-9; Wahl SE, 2015, DEV BIOL, V405, P108, DOI 10.1016/j.ydbio.2015.07.001; Warkman AS, 2007, SEMIN CELL DEV BIOL, V18, P46, DOI 10.1016/j.semcdb.2006.11.010; Werley MS, 2011, TOXICOLOGY, V287, P76, DOI 10.1016/j.tox.2011.05.015; Wheeler GN, 2012, GENESIS, V50, P207, DOI 10.1002/dvg.22009; Wickstrom R, 2007, CURR NEUROPHARMACOL, V5, P213, DOI 10.2174/157015907781695955; Wyszynski DF, 1997, CLEFT PALATE-CRAN J, V34, P206, DOI 10.1597/1545-1569(1997)034<0206:MCSAOC>2.3.CO;2; Xu YQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147184; Yildirim M, 2012, J DENT RES, V91, P556, DOI 10.1177/0022034512444928; Yingst JM, 2017, NICOTINE TOB RES; Zaccone EJ, 2015, TOXICOL APPL PHARM, V289, P542, DOI 10.1016/j.taap.2015.10.004; Zhao ZY, 2005, BIRTH DEFECTS RES B, V74, P383, DOI 10.1002/bdrb.20052; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670; Ziermann JM, 2014, J EXP ZOOL PART B, V322, P586, DOI 10.1002/jez.b.22566	78	29	31	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185729	10.1371/journal.pone.0185729	http://dx.doi.org/10.1371/journal.pone.0185729			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957438	Green Submitted, Green Published, gold			2023-01-03	WOS:000411985200111
J	Grinberg-Bleyer, Y; Oh, H; Desrichard, A; Bhatt, DM; Caron, R; Chan, TA; Schmid, RM; Klein, U; Hayden, MS; Ghosh, S				Grinberg-Bleyer, Yenkel; Oh, Hyunju; Desrichard, Alexis; Bhatt, Dev M.; Caron, Rachel; Chan, Timothy A.; Schmid, Roland M.; Klein, Ulf; Hayden, Matthew S.; Ghosh, Sankar			NF-kappa B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer	CELL			English	Article							TRANSCRIPTION FACTOR; TUMOR-IMMUNITY; NUCLEAR-FACTOR; MICE LACKING; PENTOXIFYLLINE; MELANOMA; EXPRESSION; ANTITUMOR; PD-1; INFLAMMATION	Regulatory T cells (Tregs) play a pivotal role in the inhibition of anti-tumor immune responses. Understanding the mechanisms governing Treg homeostasis may therefore be important for development of effective tumor immunotherapy. We have recently demonstrated a key role for the canonical nuclear factor kappa B (NF-kappa B) subunits, p65 and c-Rel, in Treg identity and function. In this report, we show that NF-kappa B c-Rel ablation specifically impairs the generation and maintenance of the activated Treg (aTreg) subset, which is known to be enriched at sites of tumors. Using mouse models, we demonstrate that melanoma growth is drastically reduced in mice lacking c-Rel, but not p65, in Tregs. Moreover, chemical inhibition of c-Rel function delayed melanoma growth by impairing aTreg-mediated immunosuppression and potentiated the effects of anti-PD-1 immunotherapy. Our studies therefore establish inhibition of NF-kappa B c-Rel as a viable therapeutic approach for enhancing checkpoint-targeting immunotherapy protocols.	[Grinberg-Bleyer, Yenkel; Oh, Hyunju; Bhatt, Dev M.; Caron, Rachel; Klein, Ulf; Hayden, Matthew S.; Ghosh, Sankar] Columbia Univ, Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA; [Desrichard, Alexis; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Schmid, Roland M.] Tech Univ Munich, Med Klin 2, Klinikum Rechts Isar, Munich, Germany; [Klein, Ulf] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Coll Phys & Surg, New York, NY 10032 USA; [Klein, Ulf] Columbia Univ, Dept Pathol & Cell Biol, Coll Phys & Surg, New York, NY 10032 USA; [Hayden, Matthew S.] Dartmouth Hitchcock Med Ctr, Sect Dermatol, Dept Surg, Lebanon, NH 03756 USA; [Klein, Ulf] Univ Leeds, Sect Expt Haematol, Leeds Inst Canc & Pathol, Leeds LS2 9JT, W Yorkshire, England	Columbia University; Memorial Sloan Kettering Cancer Center; Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Columbia University; Columbia University; Dartmouth College; University of Leeds	Ghosh, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA.	sg2715@cumc.columbia.edu	Chan, Timothy A/ABD-5850-2021	Grinberg-Bleyer, Yenkel/0000-0002-3515-8305; Bhatt, Dev/0000-0003-3616-3701; Hayden, Matthew/0000-0003-1670-6430; Caron, Rachel/0000-0003-1421-4256	Cancer Research Institute; NIH [R01-AI068977]; Herbert Irving Cancer Center at Columbia University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443, R01AI068977] Funding Source: NIH RePORTER	Cancer Research Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Herbert Irving Cancer Center at Columbia University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Lekha Nair, Alice Lepelley, Thomas S. Postler, John J. Seeley, Crystal Bussey, Gaelle H. Martin, Christian Schindler, Thomas M. Enzler, and Gary K. Schwartz for technical help and constructive discussions on the project. Y.G.B. was supported by a postdoctoral fellowship from the Cancer Research Institute. This work was supported by grants from the NIH (R01-AI068977) and the Herbert Irving Cancer Center at Columbia University and institutional support from Columbia University to S.G.	Algul H, 2007, J CLIN INVEST, V117, P1490, DOI 10.1172/JCI29882; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Boissonnas A, 2010, IMMUNITY, V32, P266, DOI 10.1016/j.immuni.2009.11.015; Bravo-Cuellar A, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-13; Chen SH, 2015, CANCER IMMUNOL RES, V3, P149, DOI 10.1158/2326-6066.CIR-14-0118; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Darrasse-Jeze G, 2009, J CLIN INVEST, V119, P2648, DOI 10.1172/JCI36628; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Deree J, 2007, SURGERY, V142, P276, DOI 10.1016/j.surg.2007.04.008; Dias S, 2017, IMMUNITY, V46, P78, DOI 10.1016/j.immuni.2016.12.017; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Donkor MK, 2011, IMMUNITY, V35, P123, DOI 10.1016/j.immuni.2011.04.019; Dua P, 2007, INT J CANCER, V121, P1600, DOI 10.1002/ijc.22843; EDWARD M, 1991, INT J CANCER, V49, P711, DOI 10.1002/ijc.2910490514; FINGERT HJ, 1988, CANCER RES, V48, P4375; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Godec J, 2016, IMMUNITY, V44, P194, DOI 10.1016/j.immuni.2015.12.006; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Heise N, 2014, J EXP MED, V211, P2103, DOI 10.1084/jem.20132613; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Isomura I, 2009, J EXP MED, V206, P3001, DOI 10.1084/jem.20091411; Jandus C, 2008, CANCER IMMUNOL IMMUN, V57, P1795, DOI 10.1007/s00262-008-0507-4; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Kamran MZ, 2013, BIOMED PHARMACOTHER, V67, P399, DOI 10.1016/j.biopha.2013.03.020; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Luo CT, 2016, NATURE, V529, P532, DOI 10.1038/nature16486; Messina N, 2016, J AUTOIMMUN, V70, P52, DOI 10.1016/j.jaut.2016.03.017; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Nakagawa H, 2016, P NATL ACAD SCI USA, V113, P6248, DOI 10.1073/pnas.1604765113; Neo WH, 2014, J BIOL CHEM, V289, P31693, DOI 10.1074/jbc.M114.574517; Nishikawa H, 2010, INT J CANCER, V127, P759, DOI 10.1002/ijc.25429; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Oh H, 2017, IMMUNITY, V47, P450, DOI 10.1016/j.immuni.2017.08.010; Ouyang WM, 2012, NATURE, V491, P554, DOI 10.1038/nature11581; Ouyang ZX, 2016, TUMOR BIOL, V37, P77, DOI 10.1007/s13277-015-4315-0; Pinzani M, 1996, BRIT J PHARMACOL, V119, P1117, DOI 10.1111/j.1476-5381.1996.tb16012.x; Ratheesh A, 2007, CANCER BIOL THER, V6, P1743, DOI 10.4161/cbt.6.11.4833; Rosenblum MD, 2011, NATURE, V480, P538, DOI 10.1038/nature10664; Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006; Samstein RM, 2012, CELL, V151, P153, DOI 10.1016/j.cell.2012.06.053; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shono Y, 2014, CANCER DISCOV, V4, P578, DOI 10.1158/2159-8290.CD-13-0585; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Suresh R, 2002, J IMMUNOL, V169, P4262, DOI 10.4049/jimmunol.169.8.4262; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Vahl JC, 2014, IMMUNITY, V41, P722, DOI 10.1016/j.immuni.2014.10.012	53	172	176	1	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 7	2017	170	6					1096	1108		10.1016/j.cell.2017.08.004	http://dx.doi.org/10.1016/j.cell.2017.08.004			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FG1ED	28886380	Green Accepted, Bronze			2023-01-03	WOS:000409536000008
J	Lam, C; Chen, PL; Kang, JH; Cheng, KF; Chen, RJ; Hung, KS				Lam, Carlos; Chen, Ping-Ling; Kang, Jiunn-Horng; Cheng, Kuang-Fu; Chen, Ray-Jade; Hung, Kuo-Sheng			Risk factors for 14-day rehospitalization following trauma with new traumatic spinal cord injury diagnosis: A 10-year nationwide study in Taiwan	PLOS ONE			English	Article							CERVICAL-SPINE; BLUNT TRAUMA; NEUROLOGICAL DETERIORATION; ASSOCIATION; SURGERY; MANAGEMENT; INSTABILITY; CLEARANCE; SECONDARY; ETIOLOGY	Objectives Fourteen-day rehospitalization with new traumatic spinal cord injury (tSCI) diagnosis is used as an indicator for the diagnostic quality of the first hospitalization. In this nationwide population-based cohort study, we identified risk factors for this indicator. Methods We conducted a nested case-control study by using the data of patients who received a first hospitalization for trauma between 2001 and 2011. The data were retrieved from Taiwan's National Health Insurance Research Database. Variables including demographic and trauma characteristics were compared between patients diagnosed with tSCI at the first hospitalization and those receiving a 14-day rehospitalization with new tSCI diagnosis. Results Of the 23 617 tSCI patients, 997 had 14-day rehospitalization with new tSCI diagnosis (incidence rate, 4.22%). The risk of 14-day rehospitalization with new tSCI diagnosis was significantly lower in patients with severe (injury severity score [ISS] = 16-24; odds ratio [OR], 0.17; 95% confidence interval [CI], 0.13-0.21) and profound (ISS > 24; OR, 0.11; 95% CI, 0.07-0.18) injuries. Interhospital transfer (OR, 8.20; 95% CI, 6.48-10.38) was a significant risk factor, along with injuries at the thoracic (OR, 1.62; 95% CI, 1.21-2.18), lumbar (OR, 1.30; 95% CI, 1.02-1.65), and multiple (OR, 3.23; 95% CI, 1.86-5.61) levels. Brain (OR, 2.82), chest (OR, 2.99), and abdominal (OR, 2.74) injuries were also identified as risk factors. In addition, the risk was higher in patients treated at the orthopedic department (OR, 2.26; 95% CI, 1.78-2.87) and those of other surgical disciplines (OR, 1.89; 95% CI, 1.57-2.28) than in those treated at the neurosurgery department. Conclusions Delayed tSCI diagnoses are not uncommon, particularly among trauma patients with ISSs < 16 or those who are transferred from lower-level hospitals. Further validation and implementation of evidence-based decision rules is essential for improving the diagnostic quality of traumatic thoracolumbar SCI.	[Lam, Carlos] Taipei Med Univ, Wan Fang Hosp, Dept Emergency & Crit Care Med, Emergency Dept, Taipei, Taiwan; [Lam, Carlos; Chen, Ping-Ling; Hung, Kuo-Sheng] Taipei Med Univ, Coll Publ Hlth, Grad Inst Injury Prevent & Control, Taipei, Taiwan; [Lam, Carlos] Taipei Med Univ, Coll Med, Sch Med, Dept Emergency Med, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Taipei Med Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Coll Med, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan; [Cheng, Kuang-Fu] Taipei Med Univ, Coll Management, Biostat Ctr, Taipei, Taiwan; [Chen, Ray-Jade] Taipei Med Univ, Sch Med, Dept Surg, Coll Med, Taipei, Taiwan; [Chen, Ray-Jade] Taipei Med Univ Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan; [Hung, Kuo-Sheng] Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan	Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital	Hung, KS (corresponding author), Taipei Med Univ, Coll Publ Hlth, Grad Inst Injury Prevent & Control, Taipei, Taiwan.; Chen, RJ (corresponding author), Taipei Med Univ, Sch Med, Dept Surg, Coll Med, Taipei, Taiwan.; Chen, RJ (corresponding author), Taipei Med Univ Hosp, Div Gen Surg, Dept Surg, Taipei, Taiwan.; Hung, KS (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Neurosurg, Taipei, Taiwan.	rayjchen@tmu.edu.tw; kshung25@gmail.com	Chen, Ray/GRJ-6736-2022	Lam, Carlos/0000-0002-8051-7485	Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan [E1020766]	Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan	This research was supported by grants from the Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan (Grant number E1020766). PLC received the funding. The funder's website is http://www.hpa.gov.tw/Bhpnet/Web/Index/Index.aspx. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson S, 1996, ACAD EMERG MED, V3, P832, DOI 10.1111/j.1553-2712.1996.tb03527.x; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; BICKNELL JM, 1992, AM J EMERG MED, V10, P336, DOI 10.1016/0735-6757(92)90015-P; Biering-Sorensen F, 2003, J SPINAL CORD MED S1, V26, pS50, DOI [DOI 10.1080/10790268.2003.11754575, 10.1080/10790268.2003.11754575]; Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014; Cason B, 2016, J TRAUMA ACUTE CARE, V80, P125, DOI 10.1097/TA.0000000000000884; Cirera E, 2014, INJURY PREV, V20, P401, DOI 10.1136/injuryprev-2014-041199; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; Delfini R, 1999, SURG NEUROL, V51, P588, DOI 10.1016/S0090-3019(99)00020-8; Diaz JJ, 2007, J TRAUMA, V63, P709, DOI 10.1097/TA.0b013e318142d2db; Dvorak MF, 2015, J NEUROTRAUM, V32, P645, DOI 10.1089/neu.2014.3632; Flabouris A, 2001, INJURY, V32, P569, DOI 10.1016/S0020-1383(01)00071-7; Furlan JC, 2011, J NEUROTRAUM, V28, P1371, DOI 10.1089/neu.2009.1147; Gabbe BJ, 2005, ACAD EMERG MED, V12, P318, DOI 10.1197/j.aem.2004.12.002; Goldfield NI, 2008, HEALTH CARE FINANC R, V30, P75; Grossman MD, 1999, J TRAUMA, V47, P684, DOI 10.1097/00005373-199910000-00012; Harris JH, 2002, J TRAUMA, V53, P392, DOI 10.1097/00005373-200208000-00041; Hicks CW, 2014, JAMA SURG, V149, P642, DOI 10.1001/jamasurg.2014.166; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Inaba K, 2015, J TRAUMA ACUTE CARE, V78, P459, DOI 10.1097/TA.0000000000000560; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Lekovic GP, 2007, NEUROSURGERY, V60, P516, DOI 10.1227/01.NEU.0000255337.80285.39; Levi AD, 2006, SPINE, V31, P451, DOI 10.1097/01.brs.0000199927.78531.b5; McCormack RA, 2012, SPINE, V37, P1260, DOI 10.1097/BRS.0b013e318245f561; Middleton PM, 2012, INJURY, V43, P480, DOI 10.1016/j.injury.2011.12.010; Nance ML., NATL TRAUMA DATA BAN; National Health Insurance Administration Ministry of Health and Welfare, HEALTHC QUAL IND GLO; National Health Insurance Administration Ministry of Health and Welfare, NHIA ORG CHART; O'Connor E, 2009, EMERG MED AUSTRALAS, V21, P94, DOI 10.1111/j.1742-6723.2009.01164.x; Poonnoose PM, 2002, J TRAUMA, V53, P314, DOI 10.1097/00005373-200208000-00021; Quigley RS, 2015, SPINE, V40, P851, DOI 10.1097/BRS.0000000000000878; RAVICHANDRAN G, 1982, BRIT MED J, V284, P953, DOI 10.1136/bmj.284.6320.953; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; SCHNEIDER RC, 1954, J NEUROSURG, V11, P546, DOI 10.3171/jns.1954.11.6.0546; Sears JM, 2014, INJURY, V45, P16, DOI 10.1016/j.injury.2012.12.024; Shah VM, 2007, SPINE, V32, pE168, DOI 10.1097/01.brs.0000257355.27053.4c; Sixta S, 2012, J TRAUMA ACUTE CARE, V73, pS326, DOI 10.1097/TA.0b013e31827559b8; Stein DM, 2012, NEUROCRIT CARE, V17, P102, DOI 10.1007/s12028-012-9759-0; Stephan K, 2015, SPINE J, V15, P1994, DOI 10.1016/j.spinee.2015.04.041; Todd NV, 2015, BONE JOINT J, V97B, P527, DOI 10.1302/0301-620X.97B4.34328; TOSCANO J, 1988, PARAPLEGIA, V26, P143, DOI 10.1038/sc.1988.23; Wu JC, 2012, J NEUROTRAUM, V29, P889, DOI 10.1089/neu.2011.1777; Yang NP, 2008, INJURY, V39, P443, DOI 10.1016/j.injury.2007.12.007; Yang TY, 2015, SPINE, V40, P147, DOI 10.1097/BRS.0000000000000704	45	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2017	12	9							e0184253	10.1371/journal.pone.0184253	http://dx.doi.org/10.1371/journal.pone.0184253			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF3ON	28863195	Green Submitted, Green Published, gold			2023-01-03	WOS:000408816900043
J	Chien, TJ; Hsu, CH; Liu, CY; Fang, CJ				Chien, Tsai-Ju; Hsu, Chung-Hua; Liu, Chia-Yu; Fang, Ching-Ju			Effect of acupuncture on hot flush and menopause symptoms in breast cancer-A systematic review and meta-analysis	PLOS ONE			English	Review							POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; AUTONOMIC DYSFUNCTION; SLEEP DISTURBANCES; APPLIED RELAXATION; BODY-TEMPERATURE; CONTROLLED-TRIAL; FLASHES; ELECTROACUPUNCTURE; SURVIVORS	Background Many breast cancer patients suffer from hot flush and medical menopause as side effects of treatment. Some patients undergo acupuncture, rather than hormone therapy, to relieve these symptoms, but the efficacy of acupuncture is uncertain. This meta-analysis evaluated the efficacy of acupuncture on hot flush and menopause symptoms in women with breast cancer. Methods A literature search was performed, following the PRISMA Statement and without language restrictions, of 7 databases from inception through March 2017. All selected studies were randomized clinical trials (RCTs) that examined the effect of needle acupuncture on hot flush and menopause symptoms in patients with breast cancer. The methodological quality of these trials was assessed using Cochrane criteria, and meta-analysis software (RevMan 5.2) was used to analyze the data. Results We examined 844 breast cancer patients (average age: 58 years-old) from 13 RCTs. The trials had medium-to-high quality, based on the modified Jadad scale. The meta-analysis showed that acupuncture had no significant effect on the frequency and the severity of hot flush (p = 0.34; p = 0.33), but significantly ameliorated menopause symptoms (p = 0.009). None of the studies reported severe adverse events. Conclusions Acupuncture significantly alleviated menopause symptoms, but had no effect on hot flush. Breast cancer patients concerned about the adverse effects of hormone therapy should consider acupuncture. Further large-scale studies that also measure biomarkers or cytokines may help to elucidate the mechanism by which acupuncture alleviates menopause symptoms in patients with breast cancer.	[Chien, Tsai-Ju; Hsu, Chung-Hua; Liu, Chia-Yu] Natl Yang Ming Univ, Inst Tradit Med, Taipei, Taiwan; [Chien, Tsai-Ju] Taipei City Hosp, Div Hematooncol, Branch Zhong Xing, Dept Internal Med, Taipei, Taiwan; [Chien, Tsai-Ju; Hsu, Chung-Hua; Liu, Chia-Yu] Taipei City Hosp, Branch Linsen Chinese Med & Kunming, Taipei, Taiwan; [Hsu, Chung-Hua] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan; [Fang, Ching-Ju] Natl Cheng Kung Univ, Med Lib, Tainan, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; Taipei City Hospital; China Medical University Taiwan; National Cheng Kung University	Chien, TJ (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, Taipei, Taiwan.; Chien, TJ (corresponding author), Taipei City Hosp, Div Hematooncol, Branch Zhong Xing, Dept Internal Med, Taipei, Taiwan.; Chien, TJ (corresponding author), Taipei City Hosp, Branch Linsen Chinese Med & Kunming, Taipei, Taiwan.	chientsaiju@gmail.com	Fang, Ching-Ju/B-4221-2009	Fang, Ching-Ju/0000-0002-7892-8840; Chien, Tsai Ju/0000-0001-9646-5272				AKSEL S, 1976, AM J OBSTET GYNECOL, V126, P165, DOI 10.1016/0002-9378(76)90270-2; Albertazzi Paola, 2006, Treat Endocrinol, V5, P101, DOI 10.2165/00024677-200605020-00004; ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Andrikoula M, 2009, CLIMACTERIC, V12, P3, DOI 10.1080/13697130802556296; Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352; Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015; Borud E, 2010, AUTON NEUROSCI-BASIC, V157, P57, DOI 10.1016/j.autneu.2010.04.004; Borud E, 2010, MATURITAS, V66, P131, DOI 10.1016/j.maturitas.2009.12.010; Chiu HY, 2016, OBSTET GYNECOL, V127, P507, DOI 10.1097/AOG.0000000000001268; Cho SH, 2009, MENOPAUSE, V16, P1065, DOI 10.1097/gme.0b013e3181a48abd; Conti FF, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-185; COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737; Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774; Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z; Filshie Jacqueline, 2005, Acupunct Med, V23, P171; Freedman RR, 2014, J STEROID BIOCHEM, V142, P115, DOI 10.1016/j.jsbmb.2013.08.010; Freedman RR, 1999, AM J OBSTET GYNECOL, V181, P66, DOI 10.1016/S0002-9378(99)70437-0; Freedman RR, 2005, SEMIN REPROD MED, V23, P117, DOI 10.1055/s-2005-869479; FREEDMAN RR, 1995, J CLIN ENDOCR METAB, V80, P2354, DOI 10.1210/jc.80.8.2354; Freedman RR, 2001, AM J HUM BIOL, V13, P453, DOI 10.1002/ajhb.1077; Freedman RR, 2007, TREATMENT POSTMENOPA, P187; Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709; Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8; Gao Z, 2013, J TRADIT CHIN MED, V33, P1; Gorodeski EZ, 2012, MENOPAUSE, V19, P382, DOI 10.1097/gme.0b013e31824c7a3b; Hervik J, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-141; Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holmberg L, 2008, JNCI-J NATL CANCER I, V100, P475, DOI 10.1093/jnci/djn058; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jayasena CN, 2015, SCI REP-UK, V5, DOI 10.1038/srep08466; Johns C, 2016, BREAST CANCER RES TR, V156, P415, DOI 10.1007/s10549-016-3765-4; Joshi N, 2009, ACUPUNCTURE ELECTRO, V34, P165, DOI 10.3727/036012909803861022; Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Loaiza LA, 2002, AUTON NEUROSCI-BASIC, V97, P103, DOI 10.1016/S1566-0702(02)00051-6; Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412; Mao JJ, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.SABCS14-PD4-7; Moher D, 2009, PLOS MED, V6; Morrow PKH, 2011, ONCOLOGIST, V16, P1658, DOI 10.1634/theoncologist.2011-0174; Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050; Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797; Otte JL, 2011, CLIN NURSE SPEC, V25, P228, DOI 10.1097/NUR.0b013e318229950b; Otte JL, 2010, J PAIN SYMPTOM MANAG, V39, P535, DOI 10.1016/j.jpainsymman.2009.07.004; Philp Hazel A, 2003, Altern Med Rev, V8, P284; Rance NE, 2013, FRONT NEUROENDOCRIN, V34, P211, DOI 10.1016/j.yfrne.2013.07.003; Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3; Schenck-Gustafsson K, 2011, MATURITAS, V68, P94, DOI 10.1016/j.maturitas.2010.10.005; Schneider H P, 2000, Climacteric, V3, P50, DOI 10.3109/13697130009167599; Seib C, 2014, J WOMENS HEALTH, V23, P151, DOI 10.1089/jwh.2013.4472; Olid AS, 2013, MED ACUPUNCT, V25, P386, DOI 10.1089/acu.2013.0976; Sturdee DW, 2008, MATURITAS, V60, P42, DOI 10.1016/j.maturitas.2008.02.006; Thurston RC, 2008, MENOPAUSE, V15, P841, DOI 10.1097/gme.0b013e318168f09b; Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150; Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55; Wang JD, 2002, AUTON NEUROSCI-BASIC, V100, P90, DOI 10.1016/S1566-0702(02)00150-9; Zhang Wei, 2015, Zhen Ci Yan Jiu, V40, P388	58	34	35	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2017	12	8							e0180918	10.1371/journal.pone.0180918	http://dx.doi.org/10.1371/journal.pone.0180918			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2ZB	28829776	Green Published, gold, Green Submitted			2023-01-03	WOS:000408085100004
J	Youk, J; Kim, YS; Lim, JA; Shin, DY; Koh, Y; Lee, ST; Kim, I				Youk, Jeonghwan; Kim, Young-Sook; Lim, Jung-Ah; Shin, Dong-Yeop; Koh, Youngil; Lee, Soon-Tae; Kim, Inho			Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies	PLOS ONE			English	Article							CISPLATIN NEUROTOXICITY; SENSORY NEUROPATHY; TRIAL; PAIN; MICE; TAXOL; RATS; CARBOPLATIN; PREDICTORS; PACLITAXEL	Objective To investigate whether the depletion of nerve growth factor (NGF) is associated with the development of chemotherapy-induced peripheral neuropathy (CIPN) in patients with hematologic malignancy. Methods We prospectively enrolled hematologic cancer patients who had a plan to receive bortezomib, thalidomide, or vincristine. Baseline NGF levels were measured within one week before the start date of chemotherapy. Follow-up NGF levels were measured after four months from the start date of chemotherapy or the date when CIPN was initially diagnosed. Results Baseline and follow-up NGF pairs were measured in 45 patients (male/female = 27/18, median age = 63 years old). CIPN has developed in 28 patients. In the CIPN group, the level of NGF was significantly decreased after chemotherapy compared to the baseline (Delta NGF = -3.52 +/- 5.72; p-value = 0.003), while the NGF level of the no-CIPN group was not changed after chemotherapy. The differences in Delta NGF levels between the CIPN and no-CIPN group were more profound when analyzed in the subgroup of newly diagnosed multiple myeloma patients (Delta NGF = -4.14 +/- 4.87 pg/ml for the CIPN group and +2.52 +/- 8.39 pg/ml for the no-CIPN group; p-value = 0.043). Conclusions This study shows that the depletion of NGF occurs during the development of CIPN, suggesting pathogenesis based on the role of NGF and therapeutic implications.	[Youk, Jeonghwan; Shin, Dong-Yeop; Koh, Youngil; Kim, Inho] Seoul Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea; [Kim, Young-Sook; Lim, Jung-Ah; Lee, Soon-Tae] Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea; [Kim, Inho] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Kim, I (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea.; Lee, ST (corresponding author), Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea.; Kim, I (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea.	slee@snuh.org; ihkimmd@snu.ac.kr		Lee, Soon-Tae/0000-0003-4767-7564	National Research Foundation of Korea(NRF) grants - Ministry of Science, ICT & Future Planning, Republic of Korea [2016R1C1B2011815, 2016M3C7A1914002]; SNUH Research Fund [0420150850]	National Research Foundation of Korea(NRF) grants - Ministry of Science, ICT & Future Planning, Republic of Korea; SNUH Research Fund	This work was supported by the National Research Foundation of Korea(NRF) grants funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (2016R1C1B2011815, 2016M3C7A1914002). S.-T. Lee was supported by the SNUH Research Fund (0420150850). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aloe L, 2000, AUTON NEUROSCI-BASIC, V86, P84, DOI 10.1016/S1566-0702(00)00247-2; Aloe L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-239; ANAND P, 1991, LANCET, V337, P1253, DOI 10.1016/0140-6736(91)92921-N; Anand P, 1996, NAT MED, V2, P703, DOI 10.1038/nm0696-703; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; APFEL SC, 1991, ANN NEUROL, V29, P87, DOI 10.1002/ana.410290115; APFEL SC, 1992, ANN NEUROL, V31, P76, DOI 10.1002/ana.410310114; Apfel SC, 2002, INT REV NEUROBIOL, P50; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Cavaletti G, 2004, ANN ONCOL, V15, P1439, DOI 10.1093/annonc/mdh348; CAVALETTI G, 1995, EXP NEUROL, V133, P64, DOI 10.1006/exnr.1995.1008; Cavaletti G, 1998, ANN ONCOL, V9, P443, DOI 10.1023/A:1008231925889; Cavaletti G, 2002, NEUROSCI LETT, V322, P103, DOI 10.1016/S0304-3940(02)00091-5; Chang DS, 2016, J PAIN RES, V9, P373, DOI 10.2147/JPR.S89061; Chaudhry V, 2008, J PERIPHER NERV SYST, V13, P275, DOI 10.1111/j.1529-8027.2008.00193.x; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Contreras PC, 1997, BRAIN RES, V774, P20, DOI 10.1016/S0006-8993(97)81682-4; De Santis S, 2000, CLIN CANCER RES, V6, P90; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Ferdousi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139394; Friesland A, 2014, NEUROTOXICOLOGY, V45, P81, DOI 10.1016/j.neuro.2014.09.005; Gary Pittenger AV, 2003, EXPT DIAB RES, V4, P271; GREGG RW, 1992, J CLIN ONCOL, V10, P795, DOI 10.1200/JCO.1992.10.5.795; Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Lauria G, 2012, CURR OPIN NEUROL, V25, P542, DOI 10.1097/WCO.0b013e32835804c5; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; Ocean AJ, 2004, SUPPORT CARE CANCER, V12, P619, DOI 10.1007/s00520-004-0657-7; Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204; Pignata S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-5; Richardson Paul G, 2003, Cancer Control, V10, P361; SAHENK Z, 1994, ARCH NEUROL-CHICAGO, V51, P726, DOI 10.1001/archneur.1994.00540190110024; SCHMIDT Y, 1995, EXP NEUROL, V132, P16, DOI 10.1016/0014-4886(95)90054-3; Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020; Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813; Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951; Tredici G, 1999, EXP NEUROL, V159, P551, DOI 10.1006/exnr.1999.7174; Ugolini G, 2007, P NATL ACAD SCI USA, V104, P2985, DOI 10.1073/pnas.0611253104; Wild KD, 2007, J PHARMACOL EXP THER, V322, P282, DOI 10.1124/jpet.106.116236	40	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2017	12	8							e0183491	10.1371/journal.pone.0183491	http://dx.doi.org/10.1371/journal.pone.0183491			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2TT	28827818	Green Submitted, Green Published, gold			2023-01-03	WOS:000408069300025
J	Arends, M; Biegstraaten, M; Hughes, DA; Mehta, A; Elliott, PM; Oder, D; Watkinson, OT; Vaz, FM; van Kuilenburg, AABP; Wanner, C; Hollak, CEM				Arends, Maarten; Biegstraaten, Marieke; Hughes, Derralynn A.; Mehta, Atul; Elliott, Perry M.; Oder, Daniel; Watkinson, Oliver T.; Vaz, Frederic M.; van Kuilenburg, Andre A. B. P.; Wanner, Christoph; Hollak, Carla E. M.			Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors	PLOS ONE			English	Article							AGALSIDASE-BETA THERAPY; MAGNETIC-RESONANCE; CLINICAL MANIFESTATIONS; UNCERTAIN DIAGNOSIS; ALPHA-GALACTOSIDASE; QUANTIFICATION; PROGRESSION; CONSENSUS; IMPACT; KIDNEY	Despite enzyme replacement therapy, disease progression is observed in patients with Fabry disease. Identification of factors that predict disease progression is needed to refine guidelines on initiation and cessation of enzyme replacement therapy. To study the association of potential biochemical and clinical prognostic factors with the disease course (clinical events, progression of cardiac and renal disease) we retrospectively evaluated 293 treated patients from three international centers of excellence. As expected, age, sex and phenotype were important predictors of event rate. Clinical events before enzyme replacement therapy, cardiac mass and eGFR at baseline predicted an increased event rate. eGFR was the most important predictor: hazard ratios increased from 2 at eGFR <90 ml/min/1.73m(2) to 4 at eGFR <30, compared to patients with an eGFR >90. In addition, men with classical disease and a baseline eGFR <60 ml/min/1.73m(2) had a faster yearly decline (-2.0 ml/min/1.73m(2)) than those with a baseline eGFR of >60. Proteinuria was a further independent risk factor for decline in eGFR. Increased cardiac mass at baseline was associated with the most robust decrease in cardiac mass during treatment, while presence of cardiac fibrosis predicted a stronger increase in cardiac mass (3.36 gram/m(2)/year). Of other cardiovascular risk factors, hypertension significantly predicted the risk for clinical events. In conclusion, besides increasing age, male sex and classical phenotype, faster disease progression while on enzyme replacement therapy is predicted by renal function, proteinuria and to a lesser extent cardiac fibrosis and hypertension.	[Arends, Maarten; Biegstraaten, Marieke; Hollak, Carla E. M.] Acad Med Ctr, Dept Endocrinol & Metab, Amsterdam, Netherlands; [Hughes, Derralynn A.; Mehta, Atul] Royal Free London NHS Fdn Trust, Dept Haematol, London, England; [Hughes, Derralynn A.; Mehta, Atul; Elliott, Perry M.; Watkinson, Oliver T.] UCL, London, England; [Elliott, Perry M.; Watkinson, Oliver T.] St Bartholomews Hosp, Dept Cardiol, London, England; [Oder, Daniel; Wanner, Christoph] Univ Hosp Wuerzburg, CHFC, Div Cardiol & Nephrol, Dept Internal Med 1, Wurzburg, Germany; [Oder, Daniel; Wanner, Christoph] Univ Hosp Wuerzburg, Fabry Ctr Interdisciplinary Therapy FAZIT, Div Cardiol & Nephrol, Dept Internal Med 1, Wurzburg, Germany; [Vaz, Frederic M.; van Kuilenburg, Andre A. B. P.] Acad Med Ctr, Lab Genet Metab Dis, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; University of London; Queen Mary University London; University of Wurzburg; University of Wurzburg; University of Amsterdam; Academic Medical Center Amsterdam	Arends, M (corresponding author), Acad Med Ctr, Dept Endocrinol & Metab, Amsterdam, Netherlands.	m.arends@amc.uva.nl	Mehta, Atul/GPC-7364-2022; Mehta, Atul/AAF-3559-2022; Elliott, Perry/AAR-3430-2020; Mehta, Atul/AFI-0044-2022; hughes, derralynn/J-8012-2013	Elliott, Perry/0000-0003-3383-3984; hughes, derralynn/0000-0003-4531-9173; Vaz, Frederic/0000-0002-9048-1041; Hollak, Carla/0000-0003-0464-1078; van Kuilenburg, Andre/0000-0002-7989-4910	Ministry of Health (ZonMw) of the Netherlands [836011009]; Bundesministerium fur Bildung und Forschung of the Federal Republic of Germany (BMBF) [01EO1504 MO2]	Ministry of Health (ZonMw) of the Netherlands; Bundesministerium fur Bildung und Forschung of the Federal Republic of Germany (BMBF)(Federal Ministry of Education & Research (BMBF))	This study was supported by a grant (project number: 836011009) from the Ministry of Health (ZonMw) of the Netherlands. Researchers worked independently from the funders. The funding source had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit an article for publication. The collection of data at University Hospital Wuerzburg has been supported by the Bundesministerium fur Bildung und Forschung of the Federal Republic of Germany (BMBF 01EO1504 MO2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts JM, 2008, P NATL ACAD SCI USA, V105, P2812, DOI 10.1073/pnas.0712309105; Arends M, 2017, J AM SOC NEPHROL, V28, P1631, DOI 10.1681/ASN.2016090964; Arends M, 2016, MOL GENET METAB, V117, P194, DOI 10.1016/j.ymgme.2015.11.014; Banikazemi M, 2007, ANN INTERN MED, V146, P77, DOI 10.7326/0003-4819-146-2-200701160-00148; Biegstraaten M, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0253-6; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; Buechner S, 2008, J NEUROL NEUROSUR PS, V79, P1249, DOI 10.1136/jnnp.2008.143693; Cartwright DJ, 2004, J INHERIT METAB DIS, V27, P791, DOI 10.1023/B:BOLI.0000045841.27968.06; Desnick RJ, 2013, OMMBID ONL MET MOL B; Elliott PM, 2006, HEART, V92, P357, DOI 10.1136/hrt.2004.054015; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Fellgiebel A, 2014, CEREBROVASC DIS, V38, P448, DOI 10.1159/000369293; Germain DP, 2007, J AM SOC NEPHROL, V18, P1547, DOI 10.1681/ASN.2006080816; Germain DP, 2015, J MED GENET, V52, P353, DOI 10.1136/jmedgenet-2014-102797; Gold H, 2013, CLIN CHEM, V59, P547, DOI 10.1373/clinchem.2012.192138; Gommans DHF, 2016, NETH HEART J, V24, P326, DOI 10.1007/s12471-016-0805-y; Hollak CEM, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-16; Hughes DA, 2016, CURR OPIN CARDIOL, V31, P434, DOI 10.1097/HCO.0000000000000308; Jardim LB, 2006, ARQ NEURO-PSIQUIAT, V64, P711, DOI 10.1590/S0004-282X2006000500002; Kampmann C, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0338-2; Kawel-Boehm N, 2015, J CARDIOVASC MAGN R, V17, DOI 10.1186/s12968-015-0111-7; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013, KIDNEY INT SUPPL, V3, P1, DOI [DOI 10.1038/KISUP.2012.73, 10.1038/kisup.2012.73]; KINT J A, 1970, Science (Washington D C), V167, P1268, DOI 10.1126/science.167.3922.1268; Kramer J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140627; Kramer J, 2014, AM J CARDIOL, V114, P895, DOI 10.1016/j.amjcard.2014.06.019; Kruger R, 2012, J CHROMATOGR B, V883, P128, DOI 10.1016/j.jchromb.2011.11.020; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lenders M, 2016, NEPHROLOGY DIALYSIS; MacDermot KD, 2001, J MED GENET, V38, P750, DOI 10.1136/jmg.38.11.750; MacDermot KD, 2001, J MED GENET, V38, P769, DOI 10.1136/jmg.38.11.769; Rombach SM, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-47; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Schiffmann R, 2017, KIDNEY INT, V91, P284, DOI 10.1016/j.kint.2016.10.004; Sirrs SM, 2014, MOL GENET METAB, V111, P499, DOI 10.1016/j.ymgme.2014.01.014; Smid BE, 2014, INT J CARDIOL, V177, P400, DOI 10.1016/j.ijcard.2014.09.001; van Breemen MJ, 2011, BBA-MOL BASIS DIS, V1812, P70, DOI 10.1016/j.bbadis.2010.09.007; van der Tol L, 2014, JIMD REP, V17, P83, DOI 10.1007/8904_2014_342; Vogel-Claussen J, 2006, J COMPUT ASSIST TOMO, V30, P426, DOI 10.1097/00004728-200605000-00013; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; Wanner C, 2010, CLIN J AM SOC NEPHRO, V5, P2220, DOI 10.2215/CJN.04340510; Warnock DG, 2015, J MED GENET, V52, P860, DOI 10.1136/jmedgenet-2015-103471; Warnock DG, 2012, NEPHROL DIAL TRANSPL, V27, P1042, DOI 10.1093/ndt/gfr420; Weidemann F, 2005, EUR HEART J, V26, P1221, DOI 10.1093/eurheartj/ehi143; Weidemann F, 2013, J INTERN MED, V274, P331, DOI 10.1111/joim.12077; Weidemann F, 2009, CIRCULATION, V119, P524, DOI 10.1161/CIRCULATIONAHA.108.794529; Wijburg FA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124987; Zon MW, 2013, TREATM PAT FABR DIS	47	59	61	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0182379	10.1371/journal.pone.0182379	http://dx.doi.org/10.1371/journal.pone.0182379			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3VC	28763515	Green Published, Green Submitted, gold			2023-01-03	WOS:000406766500063
J	Wacker, D; Stevens, RC; Roth, BL				Wacker, Daniel; Stevens, Raymond C.; Roth, Bryan L.			How Ligands Illuminate GPCR Molecular Pharmacology	CELL			English	Review							PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; STRUCTURE-BASED DISCOVERY; TERNARY COMPLEX MODEL; KAPPA-OPIOID RECEPTOR; CRYO-EM STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; FUNCTIONAL SELECTIVITY; STRUCTURAL BASIS	G protein-coupled receptors (GPCRs), which are modulated by a variety of endogenous and synthetic ligands, represent the largest family of druggable targets in the human genome. Recent structural and molecular studies have both transformed and expanded classical concepts of receptor pharmacology and have begun to illuminate the distinct mechanisms by which structurally, chemically, and functionally diverse ligands modulate GPCR function. These molecular insights into ligand engagement and action have enabled new computational methods and accelerated the discovery of novel ligands and tool compounds, especially for understudied and orphan GPCRs. These advances promise to streamline the development of GPCR-targeted medications.	[Wacker, Daniel; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27514 USA; [Wacker, Daniel; Roth, Bryan L.] Univ North Carolina Chapel Hill, Sch Med, Div Chem Biol & Med Chem, Chapel Hill, NC 27514 USA; [Stevens, Raymond C.] Univ Southern Calif, Bridge Inst, Dept Biol Sci, Los Angeles, CA 90089 USA; [Stevens, Raymond C.] Univ Southern Calif, Bridge Inst, Dept Chem, Los Angeles, CA 90089 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Southern California; University of Southern California	Roth, BL (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Dept Pharmacol, Chapel Hill, NC 27514 USA.; Roth, BL (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Div Chem Biol & Med Chem, Chapel Hill, NC 27514 USA.	bryan_roth@med.unc.edu	Roth, Bryan L/F-3928-2010; Roth, Bryan/ABE-7032-2020; Stevens, Raymond/K-7272-2015	Roth, Bryan/0000-0002-0561-6520; Stevens, Raymond/0000-0002-4522-8725	National Institute of Health [RO1MH112205, UO1MH104974, U19MH82441, PO1DA035764]; Michael Hooker Distinguished Professorship; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK116195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH112205, U01MH104974, U19MH082441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA035764] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michael Hooker Distinguished Professorship; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This review was supported by grants from the National Institute of Health (RO1MH112205; UO1MH104974; U19MH82441; and PO1DA035764) and the Michael Hooker Distinguished Professorship to BLR.	Airan RD, 2009, NATURE, V458, P1025, DOI 10.1038/nature07926; Aitken M, 2009, HEALTH AFFAIR, V28, pW151, DOI 10.1377/hlthaff.28.1.w151; Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5744, DOI 10.1111/bph.13348; Allen JA, 2011, P NATL ACAD SCI USA, V108, P18488, DOI 10.1073/pnas.1104807108; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Bortolato A., 2016, NATURE, V533, P277; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Carlsson J, 2011, NAT CHEM BIOL, V7, P769, DOI 10.1038/nchembio.662; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; Changeux JP, 2016, CELL, V166, P1084, DOI 10.1016/j.cell.2016.08.015; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Christopher JA, 2015, J MED CHEM, V58, P6653, DOI 10.1021/acs.jmedchem.5b00892; Christopoulos A, 2014, PHARMACOL REV, V66, P918, DOI 10.1124/pr.114.008862; Clark AJ, 1926, J PHYSIOL-LONDON, V61, P547, DOI 10.1113/jphysiol.1926.sp002315; Congreve M, 2012, J MED CHEM, V55, P1898, DOI 10.1021/jm201376w; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DeWire SM, 2011, CIRC RES, V109, P205, DOI 10.1161/CIRCRESAHA.110.231308; Dillon GM, 2011, BEHAV PHARMACOL, V22, P91, DOI 10.1097/FBP.0b013e3283423d7e; Dror RO, 2011, P NATL ACAD SCI USA, V108, P13118, DOI 10.1073/pnas.1104614108; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fedele J.M., 2016, SET NAT BIOTECHNOL; Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944; Foord D.E., 2009, J MED CHEM, V52; Gimpl G, 2016, CHEM PHYS LIPIDS, V199, P61, DOI 10.1016/j.chemphyslip.2016.04.006; Hamann J, 2015, PHARMACOL REV, V67, P338, DOI 10.1124/pr.114.009647; Herenbrink CK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10842; Hollenstein K, 2013, NATURE, V499, P438, DOI 10.1038/nature12357; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Huang XP, 2015, NATURE, V527, P477, DOI 10.1038/nature15699; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Kang YY, 2015, NATURE, V523, P561, DOI 10.1038/nature14656; Katritch V, 2014, TRENDS BIOCHEM SCI, V39, P233, DOI 10.1016/j.tibs.2014.03.002; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; KENAKIN T, 1989, J PHARMACOL EXP THER, V250, P944; Kenakin T, 2012, ACS CHEM NEUROSCI, V3, P193, DOI 10.1021/cn200111m; Kolb P, 2009, P NATL ACAD SCI USA, V106, P6843, DOI 10.1073/pnas.0812657106; Krupnick Jr O.B., 1996, NATURE; Kruse AC, 2013, NATURE, V504, P101, DOI 10.1038/nature12735; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lafferty-Whyte K, 2017, NAT REV DRUG DISCOV, V16, P10, DOI 10.1038/nrd.2016.263; Lagerstrom R., 2003, MOL PHARM; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Lanzafame A, 1997, J PHARMACOL EXP THER, V282, P278; Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Liang YL, 2017, NATURE, V546, P118, DOI 10.1038/nature22327; Liu JJ, 2012, SCIENCE, V335, P1106, DOI 10.1126/science.1215802; Liu W, 2012, SCIENCE, V337, P232, DOI 10.1126/science.1219218; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Manglik A, 2015, CELL, V161, P1101, DOI 10.1016/j.cell.2015.04.043; Mason JS, 2012, TRENDS PHARMACOL SCI, V33, P249, DOI 10.1016/j.tips.2012.02.005; McAlear SD, 2010, ADV EXP MED BIOL, V664, P263, DOI 10.1007/978-1-4419-1399-9_30; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Ngo T, 2017, NAT CHEM BIOL, V13, P235, DOI [10.1038/NCHEMBIO.2266, 10.1038/nchembio.2266]; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; O'Connor C, 2015, P NATL ACAD SCI USA, V112, P11852, DOI 10.1073/pnas.1510117112; Oswald C, 2016, NATURE, V540, P462, DOI 10.1038/nature20606; Paek J, 2017, CELL, V169, P338, DOI 10.1016/j.cell.2017.03.028; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rahmeh R, 2012, P NATL ACAD SCI USA, V109, P6733, DOI 10.1073/pnas.1201093109; Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478; Rasmussen S. G., NATURE, V477, P549; Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648; Ring AM, 2013, NATURE, V502, P575, DOI 10.1038/nature12572; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Roth BL, 2015, J BIOL CHEM, V290, P19471, DOI 10.1074/jbc.R115.654764; Roth BL, 2007, NEW ENGL J MED, V356, P6, DOI 10.1056/NEJMp068265; Rothman RB, 2000, CIRCULATION, V102, P2836; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Shihoya W, 2016, NATURE, V537, P363, DOI 10.1038/nature19319; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smit MJ, 2007, ANNU REV PHARMACOL, V47, P53, DOI 10.1146/annurev.pharmtox.47.120505.105126; Staus DP, 2016, NATURE, V535, P448, DOI 10.1038/nature18636; Tesmer JJG, 2016, NAT REV MOL CELL BIO, V17, P439, DOI 10.1038/nrm.2016.36; Thomsen ARB, 2016, CELL, V166, P907, DOI 10.1016/j.cell.2016.07.004; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Urs NM, 2016, P NATL ACAD SCI USA, V113, pE8178, DOI 10.1073/pnas.1614347113; van der Westhuizen ET, 2015, J PHARMACOL EXP THER, V353, P246, DOI 10.1124/jpet.114.221606; Vass M, 2016, CURR OPIN PHARMACOL, V30, P59, DOI 10.1016/j.coph.2016.07.007; Vemuri T., 2016, CRYSTAL STRUCTURE HU, V167, p[750, e714]; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; Wacker D, 2017, CELL, V168, P377, DOI 10.1016/j.cell.2016.12.033; Wacker D, 2013, SCIENCE, V340, P615, DOI 10.1126/science.1232808; Wacker D, 2010, J AM CHEM SOC, V132, P11443, DOI 10.1021/ja105108q; Wang C, 2013, SCIENCE, V340, P610, DOI 10.1126/science.1232807; Wardman JH, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac8035; White JF, 2012, NATURE, V490, P508, DOI 10.1038/nature11558; White KL, 2015, J PHARMACOL EXP THER, V352, P98, DOI 10.1124/jpet.114.216820; Yamashita S.M., 2013, PHARM EXP THER, V344, P708; Zhang DD, 2015, NATURE, V520, P317, DOI 10.1038/nature14287; Zhang Y, 2017, NATURE, V546, P248, DOI 10.1038/nature22394	105	294	297	18	145	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 27	2017	170	3					414	427		10.1016/j.cell.2017.07.009	http://dx.doi.org/10.1016/j.cell.2017.07.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FB9ME	28753422	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000406462400003
J	Ott, PA; Hu, ZT; Keskin, DB; Shukla, SA; Sun, J; Bozym, DJ; Zhang, WD; Luoma, A; Giobbie-Hurder, A; Peter, L; Chen, C; Olive, O; Carter, TA; Li, SQ; Lieb, DJ; Eisenhaure, T; Gjini, E; Stevens, J; Lane, WJ; Javeri, I; Nellaiappan, K; Salazar, AM; Daley, H; Seaman, M; Buchbinder, EI; Yoon, CH; Harden, M; Lennon, N; Gabriel, S; Rodig, SJ; Barouch, DH; Aster, JC; Getz, G; Wucherpfennig, K; Neuberg, D; Ritz, J; Lander, ES; Fritsch, EF; Hacohen, N; Wu, CJ				Ott, Patrick A.; Hu, Zhuting; Keskin, Derin B.; Shukla, Sachet A.; Sun, Jing; Bozym, David J.; Zhang, Wandi; Luoma, Adrienne; Giobbie-Hurder, Anita; Peter, Lauren; Chen, Christina; Olive, Oriol; Carter, Todd A.; Li, Shuqiang; Lieb, David J.; Eisenhaure, Thomas; Gjini, Evisa; Stevens, Jonathan; Lane, William J.; Javeri, Indu; Nellaiappan, Kaliappanadar; Salazar, Andres M.; Daley, Heather; Seaman, Michael; Buchbinder, Elizabeth I.; Yoon, Charles H.; Harden, Maegan; Lennon, Niall; Gabriel, Stacey; Rodig, Scott J.; Barouch, Dan H.; Aster, Jon C.; Getz, Gad; Wucherpfennig, Kai; Neuberg, Donna; Ritz, Jerome; Lander, Eric S.; Fritsch, Edward F.; Hacohen, Nir; Wu, Catherine J.			An immunogenic personal neoantigen vaccine for patients with melanoma	NATURE			English	Article							CD4(+) T-CELLS; SEQUENCING DATA; CANCER-IMMUNOTHERAPY; IMMUNE-RESPONSES; EXPRESSION; PREDICTION; MOLECULES; EPITOPES; ANTIGENS; PEPTIDE	Effective anti-tumour immunity in humans has been associated with the presence of T cells directed at cancer neoantigens(1), a class of HLA-bound peptides that arise from tumour-specific mutations. They are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. Although neoantigens were long-envisioned as optimal targets for an anti-tumour immune response(2), their systematic discovery and evaluation only became feasible with the recent availability of massively parallel sequencing for detection of all coding mutations within tumours, and of machine learning approaches to reliably predict those mutated peptides with high-affinity binding of autologous human leukocyte antigen (HLA) molecules. We hypothesized that vaccination with neoantigens can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. Here we demonstrate the feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens. Vaccine-induced polyfunctional CD4(+) and CD8(+) T cells targeted 58 (60%) and 15 (16%) of the 97 unique neoantigens used across patients, respectively. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour. Of six vaccinated patients, four had no recurrence at 25 months after vaccination, while two with recurrent disease were subsequently treated with anti-PD-1 (anti-programmed cell death-1) therapy and experienced complete tumour regression, with expansion of the repertoire of neoantigen-specific T cells. These data provide a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies.	[Ott, Patrick A.; Hu, Zhuting; Keskin, Derin B.; Shukla, Sachet A.; Sun, Jing; Bozym, David J.; Zhang, Wandi; Chen, Christina; Olive, Oriol; Daley, Heather; Buchbinder, Elizabeth I.; Ritz, Jerome; Fritsch, Edward F.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Ott, Patrick A.; Buchbinder, Elizabeth I.; Ritz, Jerome; Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; [Ott, Patrick A.; Keskin, Derin B.; Buchbinder, Elizabeth I.; Yoon, Charles H.; Barouch, Dan H.; Aster, Jon C.; Getz, Gad; Wucherpfennig, Kai; Ritz, Jerome; Lander, Eric S.; Hacohen, Nir; Wu, Catherine J.] Harvard Med Sch, Boston, MA 02215 USA; [Keskin, Derin B.; Shukla, Sachet A.; Carter, Todd A.; Li, Shuqiang; Lieb, David J.; Eisenhaure, Thomas; Harden, Maegan; Lennon, Niall; Gabriel, Stacey; Getz, Gad; Lander, Eric S.; Fritsch, Edward F.; Hacohen, Nir; Wu, Catherine J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Luoma, Adrienne; Wucherpfennig, Kai] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA; [Giobbie-Hurder, Anita; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Peter, Lauren; Seaman, Michael; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Peter, Lauren; Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Gjini, Evisa; Rodig, Scott J.] Dana Farber Canc Inst, CIO, Boston, MA 02215 USA; [Stevens, Jonathan; Lane, William J.; Rodig, Scott J.; Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; [Javeri, Indu; Nellaiappan, Kaliappanadar] CuriRx Inc, Wilmington, MA 01887 USA; [Salazar, Andres M.] Oncovir Inc, 3203 Cleveland Ave NW, Washington, DC 20008 USA; [Yoon, Charles H.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02215 USA; [Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02214 USA; [Hacohen, Nir] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02214 USA; [Fritsch, Edward F.] Neon Therapeut Inc, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Wu, CJ (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Wu, CJ (corresponding author), Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.; Wu, CJ (corresponding author), Harvard Med Sch, Boston, MA 02215 USA.; Wu, CJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.	cwu@partners.org	Giobbie-Hurder, Anita/AAU-6193-2021; Barouch, Dan/Y-3918-2019; Rodig, Scott/Y-3889-2019; Ritz, Jerome/C-7929-2009	Ritz, Jerome/0000-0001-5526-4669; Peter, Lauren/0000-0002-2105-7503	Broad Institute SPARC program; National Institutes of Health [NCI-1RO1CA155010-02, NHLBI-5R01HL103532-03, NCI-SPORE-2P50CA101942-11A1, NCI-R50 RCA211482A]; Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund; Faircloth Family Research Fund; DFCI Center for Cancer Immunotherapy Research fellowship; NATIONAL CANCER INSTITUTE [P50CA101942, R01CA155010, T32CA207021, R50CA211482] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL103532] Funding Source: NIH RePORTER	Broad Institute SPARC program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund; Faircloth Family Research Fund; DFCI Center for Cancer Immunotherapy Research fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank J. Russell and the Dana-Farber Cancer Institute (DFCI) Center for Immuno-Oncology (CIO) staff; M. Copersino (Regulatory Affairs), B. Meyers, C. Harvey, and S. Bartel (Clinical Pharmacy); A. Lako (CIO), M. Bowden (Center for Molecular Oncologic Pathology); O. Sturtevant, H. Negre, S. Y. Kim, M. A. Kelley (Cell Manipulation Core Facility) and the Pasquarello Tissue Bank (all at DFCI); T. Bowman (DFHCC Specialized Histopathology Core Laboratory); the Broad Institute's Biological Samples, Genetic Analysis, and Genome Sequencing Platforms; S. Hodi, G. Dranoff, M. Rajasagi, U. Burkhardt, S. Sarkizova, J. Fan, and P. Bachireddy for discussions; J. Petricciani and M. Krane for regulatory advice; B. McDonough (CSBio) and S. Thorne (CuriRx) for peptide development. This research was made possible by a gift from the Blavatnik Family Foundation, and was supported by grants from the Broad Institute SPARC program and the National Institutes of Health (NCI-1RO1CA155010-02 (to C.J.W.), NHLBI-5R01HL103532-03 (to C.J.W.), NCI-SPORE-2P50CA101942-11A1 (to D.B.K.); NCI-R50 RCA211482A (to S. S.)), from the Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund (to P. A. O.), the Faircloth Family Research Fund (to P. A. O.), and the DFCI Center for Cancer Immunotherapy Research fellowship (to Z.H.). C.J.W. is a scholar of the Leukemia and Lymphoma Society.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Cai A, 2012, CLIN CANCER RES, V18, P5761, DOI 10.1158/1078-0432.CCR-12-1182; Call MJ, 2009, J IMMUNOL, V182, P6342, DOI 10.4049/jimmunol.0803464; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fisher S, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r1; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Haabeth OA, 2016, LEUKEMIA, V30, P1216, DOI 10.1038/leu.2015.278; Hacohen N, 2013, CANCER IMMUNOL RES, V1, P11, DOI 10.1158/2326-6066.CIR-13-0022; Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8; Hirschhorn-Cymerman D, 2012, J EXP MED, V209, P2113, DOI 10.1084/jem.20120532; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kharchenko PV, 2014, NAT METHODS, V11, P740, DOI [10.1038/NMETH.2967, 10.1038/nmeth.2967]; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433; Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202; Lundegaard C, 2011, J IMMUNOL METHODS, V374, P26, DOI 10.1016/j.jim.2010.10.011; Martin SD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155189; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Prickett TD, 2016, CANCER IMMUNOL RES, V4, P669, DOI 10.1158/2326-6066.CIR-15-0215; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roemer MGM, 2016, CANCER IMMUNOL RES, V4, P910, DOI 10.1158/2326-6066.CIR-16-0201; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Stephen TL, 2017, IMMUNITY, V46, P51, DOI 10.1016/j.immuni.2016.12.015; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521	45	1442	1538	33	800	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 13	2017	547	7662					217	+		10.1038/nature22991	http://dx.doi.org/10.1038/nature22991			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA3AX	28678778	Green Accepted			2023-01-03	WOS:000405314500039
J	Hudak, R; Szekely, EG; Kovacs, KR; Nagy, A; Hofgart, G; Berenyi, E; Csiba, L; Kappelmayer, J; Bagoly, Z				Hudak, Renata; Szekely, Edina G.; Kovacs, Katalin R.; Nagy, Attila; Hofgart, Gergely; Berenyi, Ervin; Csiba, Laslo; Kappelmayer, Janos; Bagoly, Zsuzsa			Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis	PLOS ONE			English	Article							ASSAYS; HEMOPHILIA; HEMORRHAGE; MANAGEMENT; RISK	Thrombolysis by intravenous recombinant tissue plasminogen activator (rt-PA) is an effective therapy in acute ischemic stroke (AIS). Thrombin generation test (TGT) is a global hemostasis test providing information about the speed and amount of generated thrombin in plasma. Here we aimed to find out whether results of this test before the initiation of thrombolysis might predict outcomes. Study population included 120 consecutive AIS patients, all within 4.5 hours of their symptom onset, who underwent thrombolysis by rt-PA. Blood samples were collected from all patients upon admission and TGT was performed using platelet poor plasma. Clinical data of patients including the NIHSS were registered at admission, day 1 and 7 after therapy. The ASPECT score was assessed using CT images taken before and 24 hours after thrombolysis. Long-term functional outcome was defined 3 months after the event by the modified Rankin Scale. Endogenous Thrombin Potential (ETP) and Peak Thrombin were significantly lower in patients with cardioembolic IS. Symptomatic intracranial hemorrhage (SICH) was found in 6 patients and was significantly associated with low ETP and Peak Thrombin levels. A multiple logistic regression model revealed that an ETP result in the lower quartile is an independent predictor of mortality within the first two weeks (OR: 6.03; 95% CI: 1.2-30.16, p< 0.05) and three months after the event (OR: 5.28; 95% CI: 1.27-21.86, p< 0.05). Low levels of ETP and Peak Thrombin parameters increase the risk of therapy associated SICH. A low ETP result is an independent predictor of short-and longterm mortality following thrombolysis.	[Hudak, Renata; Kappelmayer, Janos] Univ Debrecen, Fac Med, Dept Lab Med, Debrecen, Hungary; [Szekely, Edina G.; Bagoly, Zsuzsa] Univ Debrecen, Fac Med, Dept Lab Med, Div Clin Lab Sci, Debrecen, Hungary; [Kovacs, Katalin R.; Hofgart, Gergely; Csiba, Laslo] Univ Debrecen, Fac Med, Dept Neurol, Debrecen, Hungary; [Nagy, Attila] Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary; [Berenyi, Ervin] Univ Debrecen, Fac Med, Dept Radiol, Debrecen, Hungary	University of Debrecen; University of Debrecen; University of Debrecen; University of Debrecen; University of Debrecen	Bagoly, Z (corresponding author), Univ Debrecen, Fac Med, Dept Lab Med, Div Clin Lab Sci, Debrecen, Hungary.	bagoly@med.unideb.hu	Bagoly, Zsolt/K-6365-2018; Bagoly, Zsuzsa/AAB-3553-2020	Bagoly, Zsolt/0000-0002-2679-7594; Bagoly, Zsuzsa/0000-0001-5314-5607; Nagy, Attila/0000-0002-0554-7350	National Research, Development and Innovation Fund (OTKA) [K109712, PD111929]; National Development Agency [TAMOP 4.2.2.A-11/1/KONV-2012-0045]; European Union; European Regional Development Fund [GINOP-2.3.2-15-2016-00043]; Janos Bolyai fellowship; European Social Fund [TAMOP -4.2.4.A/2-11/1-2012-0001]	National Research, Development and Innovation Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); National Development Agency; European Union(European Commission); European Regional Development Fund(European Commission); Janos Bolyai fellowship(Hungarian Academy of Sciences); European Social Fund(European Social Fund (ESF))	This work was supported by grants from the National Research, Development and Innovation Fund (OTKA K109712, PD111929), the National Development Agency (TAMOP 4.2.2.A-11/1/KONV-2012-0045) and by the European Union and the European Regional Development Fund, GINOP-2.3.2-15-2016-00043. ZB is the recipient of Janos Bolyai fellowship and Lajos Szodoray Prize. RH was supported by the European Social Fund in the frame of TAMOP -4.2.4.A/2-11/1-2012-0001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscrip	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Aviv RI, 2007, AM J NEURORADIOL, V28, P1975, DOI 10.3174/ajnr.A0689; Ay Y, 2013, CLIN APPL THROMB-HEM, V19, P389, DOI 10.1177/1076029612438611; Bosch Y, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-154; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brummel-Ziedins KE, 2014, CURR OPIN HEMATOL, V21, P395, DOI 10.1097/MOH.0000000000000074; Carcaillon L, 2011, ARTERIOSCL THROM VAS, V31, P1445, DOI 10.1161/ATVBAHA.111.223453; Castoldi E, 2011, THROMB RES, V127, pS21, DOI 10.1016/S0049-3848(11)70007-X; Cocho D, 2006, STROKE, V37, P996, DOI 10.1161/01.STR.0000206461.71624.50; Fugate Jennifer E, 2010, Front Neurol, V1, P139, DOI 10.3389/fneur.2010.00139; Gerotziafas GT, 2005, THROMB J, V3, DOI 10.1186/1477-9560-3-16; Gissel M, 2010, THROMB RES, V126, P262, DOI 10.1016/j.thromres.2010.07.002; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Haidl H, 2006, THROMB HAEMOSTASIS, V95, P772, DOI 10.1160/TH05-10-0685; Hemker HC, 2006, THROMB HAEMOSTASIS, V96, P553, DOI 10.1160/TH06-07-0408; Hemker HC, 2013, THROMB RES, V131, P3, DOI 10.1016/j.thromres.2012.10.011; Lance MD, 2015, THROMB J, V13, DOI 10.1186/1477-9560-13-1; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Perrin J, 2015, THROMB RES, V136, P125, DOI 10.1016/j.thromres.2014.12.015; Rooth E, 2013, SCAND J CLIN LAB INV, V73, P576, DOI 10.3109/00365513.2013.826817; Seet RCS, 2012, CEREBROVASC DIS, V34, P106, DOI 10.1159/000339675; Smid M, 2011, J THROMB HAEMOST, V9, P450, DOI 10.1111/j.1538-7836.2010.04162.x; Young G, 2013, BLOOD, V121, P1944, DOI 10.1182/blood-2012-08-378935	25	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0180477	10.1371/journal.pone.0180477	http://dx.doi.org/10.1371/journal.pone.0180477			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28692682	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000405544800045
J	Heiskanen, K; Ahonen, R; Kanerva, R; Karttunen, P; Timonen, J				Heiskanen, Kati; Ahonen, Riitta; Kanerva, Risto; Karttunen, Pekka; Timonen, Johanna			The reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland	PLOS ONE			English	Article							DRUG SHORTAGES; IMPACT	The aim of this study was to explore the reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. The study took the form of semi-structured interviews. Forty-one pharmaceutical companies and pharmaceutical wholesalers were invited to participate in the study. The pharmaceutical companies were the member organizations of Pharma Industry Finland (PIF) (N = 30) and the Finnish Generic Pharmaceutical Association (FGPA) (N = 7). One company which is a central player in the pharmaceutical market in Finland but does not belong to PIF or FGPA was also invited. The pharmaceutical wholesalers were those with a nationwide distribution network (N = 3). A total of 30 interviews were conducted between March and June 2016. The data were subjected to qualitative thematic analysis. The most common reasons behind medicine shortages in Finland were the small size of the pharmaceutical market (29/30), sudden or fluctuating demand (28/30), small stock sizes (25/30), long delivery time (23/30) and a long or complex production chain (23/30). The reasons for the medicine shortages were supply-related more often than demand-related. However, the reasons were often complex and there was more than one reason behind a shortage. Supply-related reasons behind shortages commonly interfaced with the country-specific characteristics of Finland, whereas demand-related reasons were commonly associated with the predictability and attractiveness of the market. Some reasons, such as raw material shortages, were considered global and thus had similar effects on other countries.	[Heiskanen, Kati; Ahonen, Riitta; Timonen, Johanna] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm Social Pharm, Kuopio Campus, Kuopio, Finland; [Kanerva, Risto] Espoo I Tapiola Pharm, Espoo, Finland; [Karttunen, Pekka] Siilinjarvi I Pharm, Siilinjarvi, Finland	University of Eastern Finland	Heiskanen, K (corresponding author), Univ Eastern Finland, Fac Hlth Sci, Sch Pharm Social Pharm, Kuopio Campus, Kuopio, Finland.	kati.heiskanen@uef.fi	Sarnola, Kati/AAR-5493-2021	Sarnola, Kati/0000-0003-1300-7482	Association of Finnish Pharmacies	Association of Finnish Pharmacies	Association of Finnish Pharmacies : The funder provided support in the form of research grant for author[KH], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of the author is articulated in the 'author contributions' section.	[Anonymous], 2008, TENDERING PHARM EU M; Association of Finnish Pharmacies, 2015, ANN REV; Baumer AM, 2004, AM J HEALTH-SYST PH, V61, P2015, DOI 10.1093/ajhp/61.19.2015; Becker DJ, 2013, J ONCOL PRACT, V9, pE122, DOI 10.1200/JOP.2012.000799; Besancon L, 2013, INT PHARM FEDERATION; Bogaert P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125691; Canadian Pharmacists Association, 2010, CAN DRUG SHORT SURV; Claus B., 2015, J PHARM BELG, V1, P24; Creese A, WHOEDMPAR20045; De Weerdt E, 2015, REGUL TOXICOL PHARM, V71, P251, DOI 10.1016/j.yrtph.2015.01.005; Dylst P, 2011, HEALTH POLICY, V101, P146, DOI 10.1016/j.healthpol.2011.03.004; EAHP, EAHP POL BRIEF MED S; EFPIA, 2016, PHARM IND FIG; Erginel E, 2014, EUROPEAN COMMISSION; European Federation of Pharmaceutical Industries and Associations, 2014, EFPIA GOOD PRACT REV; European Healthcare Distribution Association (GIRP), MED SHORT EUR THEIR; European Medicines Agency, EUR MED REG NETW; European Medicines Agency, SHORT CAT; Finnish Medicines Agency, SAAT; Finnish Medicines Agency, REP QUANT BE STOCK M; Finnish Medicines Agency and Social Insurance Institution, 2015, FINN STAT MED STAT P, P56; Gloor C, EVALUATION MED SHORT; Guest G., 2012, APPL THEMATIC ANAL, P11; Hawley KL, 2016, ACAD EMERG MED, V23, P63, DOI 10.1111/acem.12838; Heiskanen K, 2015, HEALTH POLICY, V119, P232, DOI 10.1016/j.healthpol.2014.11.001; Hennink M, 2016, QUAL HEALTH RES, V27, P1; Hunnisett-Dritz D, 2012, AM J HEALTH-SYST PH, V69, P1416, DOI 10.2146/ajhp120113; Institute for Safe Medication Practices [ISMP], 2010, ISMP MED SAFETY ALER, V15, P4; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; McLaughlin M, 2013, J MANAGE CARE PHARM, V19, P783, DOI 10.18553/jmcp.2013.19.9.783; Ministry of Social Affairs and Health, REF PRIC SYST; Ministry social Affairs and Health, SOC WELF HLTH CAR SY; Morrison A, 2011, DRUG SUPPLY DISRUPTI, P17; Pauwels K, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-438; Pelkonen E., 2010, LAAKKEISTA TERVEYTTA, P28; Pharma Industry Finland, OUR ACT; Pharma Industry Finland, MED CAR HOSP MED; Pharma Industry Finland, PHARM MAN FINL; Pharma Industry Finland, 2015, PHARM SAL FINL 2015; Rinnakkaislaaketeollisuusry, RINN TIET SIV; Silverman D, 2013, DOING QUALITATIVE RE, P297; Smith F, COMMUNICATION, V1; Tan YX, 2016, INT J CLIN PHARM-NET, V38, P1133, DOI 10.1007/s11096-016-0342-1; Timonen J, 2013, J PHARM HEALTH SERV, V4, P165, DOI 10.1111/jphs.12021; Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048; Wiedenmayer K., 2004, ACCESS MED MED SUPPL	46	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2017	12	6							e0179479	10.1371/journal.pone.0179479	http://dx.doi.org/10.1371/journal.pone.0179479			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JT	28658307	Green Submitted, gold, Green Published			2023-01-03	WOS:000404607900027
J	Garon, EB				Garon, Edward B.			Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CELL LUNG-CANCER; DOCETAXEL; PEMBROLIZUMAB; NIVOLUMAB		[Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Garon, EB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.							Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Rebelatto MC, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0545-8; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Shaverdian N, 2017, LANCET ONCOL; SPIGEL DR, 2015, J CLIN ONCOL, V33; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011	12	24	24	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 22	2017	376	25					2483	2485		10.1056/NEJMe1705692	http://dx.doi.org/10.1056/NEJMe1705692			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY2BW	28636845				2023-01-03	WOS:000403774400013
J	Asela, I; Noyong, M; Simon, U; Andrades-Lagos, J; Campanini-Salinas, J; Vasquez-Velasquez, D; Kogan, M; Yutronic, N; Sierpe, R				Asela, I.; Noyong, M.; Simon, U.; Andrades-Lagos, J.; Campanini-Salinas, J.; Vasquez-Velasquez, D.; Kogan, M.; Yutronic, N.; Sierpe, R.			Gold nanoparticles stabilized with beta cyclodextrin-2-amino-4-(4-chlorophenyl)thiazole complex: A novel system for drug transport	PLOS ONE			English	Article							BETA-CYCLODEXTRIN; INCLUSION COMPLEXES; ORGANOPHOSPHORUS PESTICIDES; 2,4-DISUBSTITUTED THIAZOLES; PHOTODEGRADATION RATES; ANTIBACTERIAL ACTIVITY; DELIVERY-SYSTEMS; ANTIBIOTICS; ABSORPTION; AGENTS	While 2-amino-4-(4-chlorophenyl)thiazole (AT) drug and thiazole derivatives have several biological applications, these compounds present some drawbacks, such as low aqueous solubility and instability. A new complex of beta CD-AT has been synthesized to increase AT solubility and has been used as a substrate for the deposit of solid-state AuNPs via magnetron sputtering, thus forming the beta CD-AT-AuNPs ternary system, which is stable in solution. Complex formation has been confirmed through powder X-ray diffraction and 1D and 2D nuclear magnetic resonance. Importantly, the amine and sulfide groups of AT remained exposed and can interact with the surfaces of the AuNPs. The complex association constant (970 M-1) has been determined using phase solubility analysis. AuNPs formation (32 nm average diameter) has been studied by UV-Visible spectroscopy, transmission/scanning electron microscopy and energy-dispersive X-ray analysis. The in vitro permeability assays show that effective permeability of AT increased using beta CD. In contrast, the ternary system did not have the capacity to diffuse through the membrane. Nevertheless, the antibacterial assays have demonstrated that AT is transferred from beta CD-AT-AuNPs, being available to exert its antibacterial activity. In conclusion, this novel beta CD-AT-AuNPs ternary system is a promising alternative to improve the delivery of AT drugs in therapy.	[Asela, I.; Yutronic, N.; Sierpe, R.] Univ Chile, Fac Ciencias, Dept Quim, Santiago, Chile; [Noyong, M.; Simon, U.] Rhein Westfal TH Aachen, Inst Inorgan Chem, Aachen, Germany; [Andrades-Lagos, J.; Campanini-Salinas, J.; Vasquez-Velasquez, D.; Kogan, M.; Sierpe, R.] Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Farmacol & Toxicol, Santiago, Chile; [Kogan, M.; Sierpe, R.] Univ Chile, Adv Ctr Chron Dis ACCDiS, Santiago, Chile; [Kogan, M.; Sierpe, R.] Pontificia Univ Catolica Chile, Santiago, Chile	Universidad de Chile; RWTH Aachen University; Universidad de Chile; Universidad de Chile; Pontificia Universidad Catolica de Chile	Yutronic, N; Sierpe, R (corresponding author), Univ Chile, Fac Ciencias, Dept Quim, Santiago, Chile.; Kogan, M; Sierpe, R (corresponding author), Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Farmacol & Toxicol, Santiago, Chile.; Kogan, M; Sierpe, R (corresponding author), Univ Chile, Adv Ctr Chron Dis ACCDiS, Santiago, Chile.; Kogan, M; Sierpe, R (corresponding author), Pontificia Univ Catolica Chile, Santiago, Chile.	mkogan@ciq.uchile.cl; nyutroni@uchile.cl; rsierpe@ciq.uchile.cl	Noyong, Michael/I-6207-2016; Campanini-Salinas, Javier./CPX-2835-2022; Simon, Ulrich/K-7737-2013; Velásquez, David R. Vásquez/I-2010-2013	Noyong, Michael/0000-0002-3148-1084; Campanini-Salinas, Javier./0000-0002-7358-409X; Simon, Ulrich/0000-0002-6118-0573; Velásquez, David R. Vásquez/0000-0003-0635-4857	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [21130628, 21130643, 1170929, 1160114]; Fondo de Financiamiento de Centros Investigacion en Areas Prioritarias (FONDAP) [15130011]	Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Fondo de Financiamiento de Centros Investigacion en Areas Prioritarias (FONDAP)	This work was supported by Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT), number 21130628 (JA), 21130643 (JC), 1170929 (MK), and 1160114 (NY); http://www.conicyt.cl/fondecyt/. It was also supported by Fondo de Financiamiento de Centros Investigacion en Areas Prioritarias (FONDAP), number 15130011; http://www.conicyt.cl/fondap/.	Abadeer NS, 2016, J PHYS CHEM C, V120, P4691, DOI 10.1021/acs.jpcc.5b11232; Alexander CM, 2012, BIOCONJUGATE CHEM, V23, P2061, DOI 10.1021/bc3002634; Alvarez-Lorenzo C, 2006, BIOTECHNOL ANN REV, V12, P225, DOI 10.1016/S1387-2656(06)12007-4; ATTIOUI F, 1994, BIOL CELL, V82, P161, DOI 10.1016/S0248-4900(94)80018-9; Brewster ME, 2007, INT J PHARMACEUT, V342, P250, DOI 10.1016/j.ijpharm.2007.04.029; Burygin GL, 2009, NANOSCALE RES LETT, V4, P794, DOI 10.1007/s11671-009-9316-8; Caira MR, 2001, REV ROUM CHIM, V46, P371; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; Chen H, 2014, OPT LETT, V39, P5822, DOI 10.1364/OL.39.005822; Chen M, 2006, CHEMOSPHERE, V63, P522, DOI 10.1016/j.chemosphere.2005.08.033; Chen YZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150877; Connors KA, 1997, CHEM REV, V97, P1325, DOI 10.1021/cr960371r; CREIGHTON JA, 1991, J CHEM SOC FARADAY T, V87, P3881, DOI 10.1039/ft9918703881; Dang Z, 2011, CURR ORG CHEM, V15, P848, DOI 10.2174/138527211794518899; Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; Das B, 2006, J MOL CATAL A-CHEM, V252, P235, DOI 10.1016/j.molcata.2006.02.065; De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596; Fang LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146292; Feng XL, 2010, ACS APPL MATER INTER, V2, P2429, DOI 10.1021/am100435k; Gibson JD, 2007, J AM CHEM SOC, V129, P11653, DOI 10.1021/ja075181k; Herrera B, 2013, J COLLOID INTERF SCI, V389, P42, DOI 10.1016/j.jcis.2012.08.027; Higuchi T., 1965, ADV ANAL CHEM INSTRU, V4, P117; Hinde E, 2017, NAT NANOTECHNOL, V12, P81, DOI [10.1038/nnano.2016.160, 10.1038/NNANO.2016.160]; Holla BS, 2003, EUR J MED CHEM, V38, P313, DOI 10.1016/S0223-5234(02)01447-2; Huang XH, 2010, J ADV RES, V1, P13, DOI 10.1016/j.jare.2010.02.002; KAMIYA M, 1994, CHEMOSPHERE, V28, P1961, DOI 10.1016/0045-6535(94)90146-5; KAMIYA M, 1995, ENVIRON INT, V21, P299, DOI 10.1016/0160-4120(95)00026-H; Kamiya M, 2001, CHEMOSPHERE, V42, P251, DOI 10.1016/S0045-6535(00)00085-0; Kansy M, 1998, J MED CHEM, V41, P1007, DOI 10.1021/jm970530e; Karegoudar P, 2008, EUR J MED CHEM, V43, P261, DOI 10.1016/j.ejmech.2007.03.014; Kogan MJ, 2007, NANOMEDICINE-UK, V2, P287, DOI 10.2217/17435889.2.3.287; Lepretre S, 2009, BIOMATERIALS, V30, P6086, DOI 10.1016/j.biomaterials.2009.07.045; Loftsson T, 2007, J PHARM SCI-US, V96, P2532, DOI 10.1002/jps.20992; Loftsson T, 2010, J PHARM PHARMACOL, V62, P1607, DOI 10.1111/j.2042-7158.2010.01030.x; Manolikar MK, 2003, CHEMOSPHERE, V51, P811, DOI 10.1016/S0045-6535(03)00099-7; Morillo E, 2001, CHEMOSPHERE, V44, P1065, DOI 10.1016/S0045-6535(00)00346-5; Moser F, 2016, BIOPHYS J, V110, P947, DOI 10.1016/j.bpj.2016.01.004; Okamoto T, 2003, J PHYS CHEM B, V107, P10321, DOI 10.1021/jp0345371; Ottaviani G, 2006, J MED CHEM, V49, P3948, DOI 10.1021/jm060230+; Paciotti GF, 2016, BIOCONJUGATE CHEM, V27, P2646, DOI 10.1021/acs.bioconjchem.6b00405; Padukka Indra, 2000, Journal of Food Composition and Analysis, V13, P59, DOI 10.1006/jfca.1999.0820; Pajatsch M, 1998, J BACTERIOL, V180, P2630, DOI 10.1128/JB.180.10.2630-2635.1998; Peng X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118274; Pessine F., 2014, MAGNETIC RESONANCE S, P237; Pinto-Alphandary H, 2000, INT J ANTIMICROB AG, V13, P155, DOI 10.1016/S0924-8579(99)00121-1; Premakumari C, 2014, ARAB J CHEM, V7, P385, DOI 10.1016/j.arabjc.2013.10.024; Rai A, 2010, J MATER CHEM, V20, P6789, DOI 10.1039/c0jm00817f; Rao VM, 2003, J PHARM SCI, V92, P927, DOI 10.1002/jps.10341; Saenger WR, 1998, CHEM REV, V98, P1787, DOI 10.1021/cr9700181; Saha B, 2007, NANOSCALE RES LETT, V2, P614, DOI 10.1007/s11671-007-9104-2; Saikosin R, 2002, J INCL PHENOM MACRO, V44, P191, DOI 10.1023/A:1023099925658; Schmid G., 2006, ENCY INORG CHEM; Schnurch M, 2011, BIOORG MED CHEM LETT, V21, P2149, DOI 10.1016/j.bmcl.2011.01.123; Shi Y, 2013, INORG CHEM, V52, P9418, DOI 10.1021/ic400989v; Shulman M, 2012, PLOS ONE, V7; Siddiqui HL, 2007, CHEM PHARM BULL, V55, P1014, DOI 10.1248/cpb.55.1014; Sierpe R, 2017, CARBOHYDR POLYM; Sierpe R, 2015, ACS APPL MATER INTER, V7, P15177, DOI 10.1021/acsami.5b00186; Silva CO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165419; Sperling RA, 2010, PHILOS T R SOC A, V368, P1333, DOI 10.1098/rsta.2009.0273; Su KH, 2003, NANO LETT, V3, P1087, DOI 10.1021/nl034197f; SZENTE L, 1981, ACTA CHIM HUNG, V107, P195; Thatiparti TR, 2010, MACROMOL BIOSCI, V10, P82, DOI 10.1002/mabi.200900204; Tiwari G, 2010, J PHARM BIOALLIED SC, V2, P72, DOI 10.4103/0975-7406.67003; Venkatachalam TK, 2001, BIOORG MED CHEM LETT, V11, P523, DOI 10.1016/S0960-894X(01)00011-7; Wang SH, 2010, J NANOBIOTECHNOL, V8, DOI 10.1186/1477-3155-8-33; Wayne P.A, 2015, M100S25 CLSI; Wikler M.A., 2009, METHODS DILUTION ANT, V8; Wulf V, 2016, J PHYS CHEM LETT, V7, P4951, DOI 10.1021/acs.jpclett.6b02165; Yokoo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141946	70	7	7	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2017	12	10							e0185652	10.1371/journal.pone.0185652	http://dx.doi.org/10.1371/journal.pone.0185652			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ4ZX	29020065	Green Submitted, Green Published, gold			2023-01-03	WOS:000412754400038
J	Nakazatol, Y; Kurane, R; Hirose, S; Watanabe, A; Shimoyama, H				Nakazatol, Yuichi; Kurane, Riichi; Hirose, Satoru; Watanabe, Akihisa; Shimoyama, Hiromi			Aging and death-associated changes in serum albumin variability over the course of chronic hemodialysis treatment	PLOS ONE			English	Article							BLOOD-PRESSURE VARIABILITY; CHRONIC KIDNEY-DISEASE; INTRAINDIVIDUAL VARIATION; HEMOGLOBIN VARIABILITY; DIALYSIS PATIENTS; NUTRITIONAL PARAMETERS; BIOLOGICAL VARIATION; ALL-CAUSE; FRAILTY; MORTALITY	Background Several epidemiological studies have demonstrated associations between variability in a number of biological parameters and adverse outcomes. As the variability may reflect impaired homeostatic regulation, we assessed albumin variability over time in chronic hemodialysis (HD) patients. Methods Data from 1346 subjects who received chronic HD treatment from May 2001 to February 2015 were analyzed according to three phases of HD treatment: post-HD initiation, during maintenance HD treatment, and before death. The serum albumin values were grouped according to the time interval from HD initiation or death, and the yearly trends for both the albumin levels and the intra-individual albumin variability (quantified by the residual coefficient of variation: Alb-rCV) were examined. The HD initiation and death-associated changes were also analyzed using generalized additive mixed models. Furthermore, the long-term trend throughout the maintenance treatment period was evaluated separately using linear regression models. Results Albumin levels and variability showed distinctive changes during each of the 3 periods. After HD initiation, albumin variability decreased and reached a nadir within a year. During the subsequent maintenance treatment period (interquartile range = 5.2-11.0 years), the log Alb-rCV showed a significant upward trend (mean slope: 0.011 +/- 0.035/year), and its overall mean was -1.49 +/- 0.08 (equivalent to an Alb-rCV of 3.22%). During the 1-2 years before death, this upward trend clearly accelerated, and the mean log Alb-rCV in the last year of life was -1.36 +/- 0.17. The albumin levels and variability were negatively correlated with each other and exhibited exactly opposite movements throughout the course of chronic HD treatment. Different from the albumin levels, albumin variability was not dependent on chronological age but was independently associated with an individual's aging and death process. Conclusion The observed upward trend in albumin variability seems to be consistent with a presumed aging-related decline in homeostatic capacity.	[Nakazatol, Yuichi] Hakuyukai Med Corp, Yuai Nisshin Clin, Div Nephrol, Saitama, Saitama, Japan; [Kurane, Riichi; Shimoyama, Hiromi] Hakuyukai Med Corp, Yuai Clin, Div Nephrol, Saitama, Saitama, Japan; [Hirose, Satoru] Hakuyukai Med Corp, Yuai Mihashi Clin, Div Nephrol, Saitama, Saitama, Japan; [Watanabe, Akihisa] Hakuyukai Med Corp, Yuai Nakagawa Clin, Div Nephrol, Saitama, Saitama, Japan		Nakazatol, Y (corresponding author), Hakuyukai Med Corp, Yuai Nisshin Clin, Div Nephrol, Saitama, Saitama, Japan.	nkzt@hakuyukai.jp	Barretti, Pasqual/K-4156-2012	Barretti, Pasqual/0000-0003-4979-4836; Nakazato, Yuichi/0000-0001-7541-3799				Arbeev KG, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00003; Boudville NC, 2009, CLIN J AM SOC NEPHRO, V4, P1176, DOI 10.2215/CJN.04920908; Broers NJH, 2015, NEPHROL DIAL TRANSPL, V30, P676, DOI 10.1093/ndt/gfu367; Cohen AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122541; Corte Z, 2015, ANN CLIN BIOCHEM, V52, P53, DOI 10.1177/0004563214545116; Dalrymple LS, 2013, CLIN J AM SOC NEPHRO, V8, P2091, DOI 10.2215/CJN.02870313; Dalrymple LS, 2013, J RENAL NUTR, V23, P91, DOI 10.1053/j.jrn.2012.03.001; Danielski M, 2003, AM J KIDNEY DIS, V42, P286, DOI 10.1016/S0272-6386(03)00653-X; den Hoedt CH, 2014, CLIN J AM SOC NEPHRO, V9, P318, DOI 10.2215/CJN.04470413; Fedarko NS, 2011, CLIN GERIATR MED, V27, P27, DOI 10.1016/j.cger.2010.08.006; Ferrucci L, 2008, MECH AGEING DEV, V129, P677, DOI 10.1016/j.mad.2008.09.007; Flythe JE, 2013, AM J KIDNEY DIS, V61, P966, DOI 10.1053/j.ajkd.2012.12.023; FRASER CG, 1989, CLIN CHEM, V35, P783; Fried LP, 2009, J GERONTOL A-BIOL, V64, P1049, DOI 10.1093/gerona/glp076; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Friedman AN, 2010, J AM SOC NEPHROL, V21, P223, DOI 10.1681/ASN.2009020213; Gama-Axelsson T, 2012, CLIN J AM SOC NEPHRO, V7, P1446, DOI 10.2215/CJN.10251011; Goldwasser P, 1999, KIDNEY INT, V56, P2260, DOI 10.1046/j.1523-1755.1999.00768.x; Gorostidi M, 2015, J HYPERTENS, V33, pE40, DOI 10.1097/01.hjh.0000467455.93515.1e; HOLZEL WGE, 1987, CLIN CHEM, V33, P1133; HOLZEL WGE, 1987, CLIN CHEM, V33, P670; HOLZEL WGE, 1987, CLIN CHEM, V33, P57; Isaia G, 2009, AGING CLIN EXP RES, V21, P453, DOI 10.1007/BF03327448; Kainz A, 2010, NEPHROL DIAL TRANSPL, V25, P3701, DOI 10.1093/ndt/gfq287; Kalantar-Zadeh K, 2005, NEPHROL DIAL TRANSPL, V20, P1880, DOI 10.1093/ndt/gfh941; Kalyani RR, 2012, J GERONTOL A-BIOL, V67, P1300, DOI 10.1093/gerona/glr141; Kotanko P, 2009, BLOOD PURIFICAT, V27, P38, DOI 10.1159/000167007; Leavey SF, 2000, KIDNEY INT, V58, P2119; Li Q, 2015, AGING CELL, V14, P1103, DOI 10.1111/acel.12402; Lloyd D, 2001, ScientificWorldJournal, V1, P133; Ma WY, 2012, J DIABETES COMPLICAT, V26, P296, DOI 10.1016/j.jdiacomp.2012.03.028; Mendez CE, 2013, DIABETES CARE, V36, P4091, DOI 10.2337/dc12-2430; Michelis R, 2010, BIOCHEM BIOPH RES CO, V401, P137, DOI 10.1016/j.bbrc.2010.09.027; MORGAN DB, 1983, ANN CLIN BIOCHEM, V20, P257, DOI 10.1177/000456328302000501; Nakazato Y, 2015, CLIN EXP NEPHROL, V19, P1165, DOI 10.1007/s10157-015-1108-0; Ram N., 2015, HDB INTRAINDIVIDUAL, P16; Ramsay DS, 2014, PSYCHOL REV, V121, P225, DOI 10.1037/a0035942; Ricos C, 2007, ANN CLIN BIOCHEM, V44, P343, DOI 10.1258/000456307780945633; Ricos C, 2009, BIOCHEM MEDICA, V19, P250; Rocco MV, 2004, KIDNEY INT, V65, P2321, DOI 10.1111/j.1523-1755.2004.00647.x; Selvarajah V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086514; Usvyat LA, 2013, KIDNEY INT, V84, P149, DOI 10.1038/ki.2013.73; Varadhan R, 2008, MECH AGEING DEV, V129, P666, DOI 10.1016/j.mad.2008.09.013; Varadhan R, 2009, J GERONTOL A-BIOL, V64, P682, DOI 10.1093/gerona/glp013; Webb AJS, 2014, STROKE, V45, P2967, DOI 10.1161/STROKEAHA.114.005982; Whittle J, 2016, CLIN J AM SOC NEPHRO, V11, P471, DOI 10.2215/CJN.04660415; Wilhelm-Leen ER, 2009, AM J MED, V122, P664, DOI 10.1016/j.amjmed.2009.01.026; Wood S, 2016, PACKAGE GAMM4; Yang W, 2007, J AM SOC NEPHROL, V18, P3164, DOI 10.1681/ASN.2007010058	49	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2017	12	9							e0185216	10.1371/journal.pone.0185216	http://dx.doi.org/10.1371/journal.pone.0185216			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI4WR	28953942	Green Published, gold, Green Submitted			2023-01-03	WOS:000411980300044
J	Ambrisko, TD; Schramel, JP; Auer, U; Moens, YPS				Ambrisko, Tamas D.; Schramel, Johannes P.; Auer, Ulrike; Moens, Yves P. S.			Impact of four different recumbencies on the distribution of ventilation in conscious or anaesthetized spontaneously breathing beagle dogs: An electrical impedance tomography study	PLOS ONE			English	Article							SPATIAL-DISTRIBUTION; COMPUTED-TOMOGRAPHY; LUNG VENTILATION; PERFUSION; CONSOLIDATION; RECRUITMENT; NEED; EIT	The aim was to examine the effects of recumbency and anaesthesia on distribution of ventilation in beagle dogs using Electrical Impedance Tomography (EIT). Nine healthy beagle dogs, aging 3.7 +/- 1.7 (mean +/- SD) years and weighing 16.3 +/- 1.6 kg, received a series of treatments in a fixed order on a single occasion. Conscious dogs were positioned in right lateral recumbency (RLR) and equipped with 32 EIT electrodes around the thorax. Following five minutes of equilibration, two minutes of EIT recordings were made in each recumbency in the following order: RLR, dorsal (DR), left (LLR) and sternal (SR). The dogs were then positioned in RLR, premedicated (medetomidine 0.01, midazolam 0.1, butorphanol 0.1 mg kg(-1) iv) and pre-oxygenated. Fifteen minutes later anaesthesia was induced with 1 mg kg(-1) propofol iv and maintained with propofol infusion (0.1 +/- 0.2 mg kg(-1) minute(-1) iv). After induction, the animals were intubated and allowed to breathe spontaneously (FIO2 = 1). Recordings of EIT were performed again in four recumbencies similarly to conscious state. Centre of ventilation (COV) and global inhomogeneity (GI) index were calculated from the functional EIT images. Repeated-measures ANOVA and Bonferroni tests were used for statistical analysis (p < 0.05). None of the variables changed in the conscious state. During anaesthesia left-toright COV increased from 46.8 +/- 2.8% in DR to 49.8 +/- 2.9% in SR indicating a right shift, and ventral-to-dorsal COV increased from 49.8 +/- 1.7% in DR to 51.8 +/- 1.1% in LLR indicating a dorsal shift in distribution of ventilation. Recumbency affected distribution of ventilation in anaesthetized but not in conscious dogs. This can be related to loss of respiratory muscle tone (e.g. diaphragm) and changes in thoracic shape. Changing position of thoraco-abdominal organs under the EIT belt should be considered as alternative explanation of these findings.	[Ambrisko, Tamas D.; Schramel, Johannes P.; Auer, Ulrike; Moens, Yves P. S.] Univ Vet Med, Dept Compan Anim & Horses, Anaesthesiol & Perioperat Intens Care Med, Vienna, Austria	University of Veterinary Medicine Vienna	Ambrisko, TD (corresponding author), Univ Vet Med, Dept Compan Anim & Horses, Anaesthesiol & Perioperat Intens Care Med, Vienna, Austria.	tambrisko@hotmail.com		Ulrike, Auer/0000-0003-0390-2678	Gesellschaft zur Forderung Kynologischer Forschung e.V., Weilerswist, Germany	Gesellschaft zur Forderung Kynologischer Forschung e.V., Weilerswist, Germany	This work was supported by the Gesellschaft zur Forderung Kynologischer Forschung e.V., Weilerswist, Germany (http://gkf-boon.de/index.php/startserte.html). Funding was acquired by TDA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Gesellschaft zur Forderung Kynologischer Forschung e.V., Weilerswist, Germany. The authors thank Dr. Martina Mosing for providing a CT image of a beagle dog that was used to create an EIT mesh for dogs. Preliminary results were presented as an Abstract at the 12th World Congress of Veterinary Anaesthesiology, Kyoto, Japan, 1st- 4th September 2015. None of the authors has any financial or personal relationships that could inappropriately influence or bias the content of the paper.	Adler A, 1998, J APPL PHYSIOL, V84, P726, DOI 10.1152/jappl.1998.84.2.726; Adler A, 1996, IEEE T BIO-MED ENG, V43, P414, DOI 10.1109/10.486261; Adler A, 1997, J APPL PHYSIOL, V83, P1762, DOI 10.1152/jappl.1997.83.5.1762; Adler A, 2012, PHYSIOL MEAS, V33, P679, DOI 10.1088/0967-3334/33/5/679; Adler A, 2009, PHYSIOL MEAS, V30, pS35, DOI 10.1088/0967-3334/30/6/S03; Ambrisko TD, 2016, PHYSIOL MEAS, V37, P175, DOI 10.1088/0967-3334/37/2/175; BEYDON L, 1992, CHEST, V102, P1697, DOI 10.1378/chest.102.6.1697; Bloomfield FH, 1999, PEDIATR RADIOL, V29, P459, DOI 10.1007/s002470050617; Chang H, 2002, J APPL PHYSIOL, V92, P745, DOI 10.1152/japplphysiol.00377.2001; Costa ELV, 2008, CRIT CARE MED, V36, P1230, DOI 10.1097/CCM.0b013e31816a0380; Costa ELV, 2009, CURR OPIN CRIT CARE, V15, P18, DOI 10.1097/MCC.0b013e3283220e8c; De Monte V, 2013, AM J VET RES, V74, P25, DOI 10.2460/ajvr.74.1.25; Frerichs I, 2006, AM J RESP CRIT CARE, V174, P772, DOI 10.1164/rccm.200512-1942OC; Gloning S, 2017, TIERAERZTL PRAX K H, V45, P15, DOI 10.15654/TPK-150569; Gomez-Laberge C, 2011, PHYSIOL MEAS, V32, DOI 10.1088/0967-3334/32/7/S13; Hoareau GL, 2011, J VET EMERG CRIT CAR, V21, P226, DOI 10.1111/j.1476-4431.2011.00635.x; Leonhardt S, 2012, INTENS CARE MED, V38, P1917, DOI 10.1007/s00134-012-2684-z; Luepschen H, 2007, PHYSIOL MEAS, V28, pS247, DOI 10.1088/0967-3334/28/7/S18; Marcucci C, 2001, J APPL PHYSIOL, V90, P421, DOI 10.1152/jappl.2001.90.2.421; Mosing M, 2016, VET ANAESTH ANALG; Newell JC, 1996, IEEE T BIO-MED ENG, V43, P133, DOI 10.1109/10.481982; Rocchi A., 2014, AVA C NOTT ASS VET A; Rooney D, 2009, PHYSIOL MEAS, V30, P1075, DOI 10.1088/0967-3334/30/10/008; Schibler A, 2009, PEDIATR PULM, V44, P851, DOI 10.1002/ppul.21000; Tusman G, 2010, BEST PRACT RES-CLIN, V24, P183, DOI 10.1016/j.bpa.2010.02.006; WEST JB, 1960, J APPL PHYSIOL, V15, P405, DOI 10.1152/jappl.1960.15.3.405; Zhao ZQ, 2009, INTENS CARE MED, V35, P1900, DOI 10.1007/s00134-009-1589-y	27	7	7	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2017	12	9							e0183340	10.1371/journal.pone.0183340	http://dx.doi.org/10.1371/journal.pone.0183340			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH3OQ	28922361	Green Published, Green Submitted, gold			2023-01-03	WOS:000411059300004
J	Leslie, M				Leslie, Mitch			Zebrafish larvae could help to personalize cancer treatments	SCIENCE			English	News Item																			0	8	8	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 25	2017	357	6353					745	745		10.1126/science.357.6353.745	http://dx.doi.org/10.1126/science.357.6353.745			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE6OD	28839055				2023-01-03	WOS:000408327900019
J	Kuryk, L; Vassilev, L; Ranki, T; Hemminki, A; Karioja-Kallio, A; Levalampi, O; Vuolanto, A; Cerullo, V; Pesonen, S				Kuryk, Lukasz; Vassilev, Lotta; Ranki, Tuuli; Hemminki, Akseli; Karioja-Kallio, Aila; Levalampi, Onerva; Vuolanto, Antti; Cerullo, Vincenzo; Pesonen, Sari			Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102-Support for clinical studies on advanced cancer treatment	PLOS ONE			English	Article							REPLICATION-SELECTIVE ADENOVIRUS; GENE DELIVERY; THERAPY; TUMORS; CHEMOTHERAPY; VIROTHERAPY; INFUSION; ONYX-015; VIRUS	The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administration and dosage differs from the clinical protocol and in more detail, investigate bio-distribution and toxicological profile of ONCOS-102 treatment in animal model. The study was carried out in 300 hamsters divided into nine test groups-three bio-distribution groups and six groups for analysis of toxicity. Hamsters received ONCOS-102 by intracardial, intraperitoneal or subcutaneous injections. Additionally, one group was administered twice a week with intraperitoneal injections of Cyclophosphamide. The control animals were administered with NaCl solution without ONCOS-102 in the same volume and the same way. No adverse effects of repeated administration of ONCOS-102 including body weight, food consumption, hematology and clinical chemistry parameters, histopathology and bio-accumulation were observed in the course of 6-month administration and following 3-month recovery period. All obtained findings indicate the treatment clinically safe.	[Kuryk, Lukasz; Vassilev, Lotta; Ranki, Tuuli; Vuolanto, Antti; Pesonen, Sari] Targovax Oy, Helsinki, Finland; [Kuryk, Lukasz; Cerullo, Vincenzo] Univ Helsinki, Fac Pharm, ImmunoViroTherapy Lab, Div Pharmaceut Biosci, Helsinki, Finland; [Kuryk, Lukasz; Cerullo, Vincenzo] Univ Helsinki, Fac Pharm, Ctr Drug Res, Helsinki, Finland; [Kuryk, Lukasz] Natl Inst Hyg, Natl Inst Publ Hlth, Dept Virol, Warsaw, Poland; [Hemminki, Akseli] Univ Helsinki, Dept Pathol, Canc Gene Therapy Grp, Fac Med, Helsinki, Finland; [Hemminki, Akseli] HUCH, Dept Oncol, Helsinki, Finland; [Hemminki, Akseli] TILT Biotherapeut Ltd, Helsinki, Finland; [Karioja-Kallio, Aila; Levalampi, Onerva] Univ Helsinki, Fac Med, Helsinki, Finland	University of Helsinki; University of Helsinki; National Institute of Hygiene (NIH); National Institute of Public Health (NIPH); University of Helsinki; University of Helsinki	Kuryk, L (corresponding author), Targovax Oy, Helsinki, Finland.; Kuryk, L (corresponding author), Univ Helsinki, Fac Pharm, ImmunoViroTherapy Lab, Div Pharmaceut Biosci, Helsinki, Finland.; Kuryk, L (corresponding author), Univ Helsinki, Fac Pharm, Ctr Drug Res, Helsinki, Finland.; Kuryk, L (corresponding author), Natl Inst Hyg, Natl Inst Publ Hlth, Dept Virol, Warsaw, Poland.	lukasz.kuryk@targovax.com	Kuryk, Lukasz/D-9596-2018; Cerullo, Vincenzo/B-9075-2015	Kuryk, Lukasz/0000-0003-1887-6361; Cerullo, Vincenzo/0000-0003-4901-3796	Marie Curie Innovative Training Network (ITN) grant [FP7-290002]	Marie Curie Innovative Training Network (ITN) grant	Marie Curie Innovative Training Network (ITN) grant, ADVance (FP7-290002) provided support in the form of salary for author LK. Targovax Oy provided support in the form of salaries for authors LK, TR, AV, SP, LV. Targovax Oy had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript by supervising, monitoring, funding the study and manuscript preparation. The specific roles of these authors are articulated in the 'author contributions' section.	Diaconu I, 2012, CANCER RES, V72, P2327, DOI 10.1158/0008-5472.CAN-11-2975; Dranoff G, 2002, IMMUNOL REV, V188, P147, DOI 10.1034/j.1600-065X.2002.18813.x; Freytag SO, 2007, MOL THER, V15, P1042, DOI 10.1038/sj.mt.6300162; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; Kicielinski KP, 2014, MOL THER, V22, P1056, DOI 10.1038/mt.2014.21; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Koski A, 2010, MOL THER, V18, P1874, DOI 10.1038/mt.2010.161; Koski A, 2009, J GENE MED, V11, P966, DOI 10.1002/jgm.1373; Liikanen I, 2013, MOL THER, V21, P1212, DOI 10.1038/mt.2013.51; Lubaroff DM, 2009, CLIN CANCER RES, V15, P7375, DOI 10.1158/1078-0432.CCR-09-1910; Nemunaitis J, 2001, GENE THER, V8, P746, DOI 10.1038/sj.gt.3301424; Nguyen A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00145; Pesonen S, 2010, GENE THER, V17, P892, DOI 10.1038/gt.2010.17; Pesonen S, 2011, MOL PHARMACEUT, V8, P12, DOI 10.1021/mp100219n; Ranki T, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.958937; Sarkioja M, 2008, GENE THER, V15, P921, DOI 10.1038/gt.2008.56; Siurala M, 2015, INT J CANCER, V136, P945, DOI 10.1002/ijc.29048; Thomas MA, 2006, CANCER RES, V66, P1270, DOI 10.1158/0008-5472.CAN-05-3497; Touchefeu Y, 2011, RADIOTHER ONCOL, V99, P262, DOI 10.1016/j.radonc.2011.05.078; Turnbull S, 2015, VIRUSES-BASEL, V7, P6291, DOI 10.3390/v7122938; van de Laar L, 2012, BLOOD, V119, P3383, DOI 10.1182/blood-2011-11-370130; Vassilev L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1017702; Vile RG, 2014, MOL THER, V22, P1881, DOI 10.1038/mt.2014.188; Woller N, 2015, Z GASTROENTEROLOGIE, V53; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9; Yamamoto M, 2010, MOL THER, V18, P243, DOI 10.1038/mt.2009.266	26	28	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0182715	10.1371/journal.pone.0182715	http://dx.doi.org/10.1371/journal.pone.0182715			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28796812	Green Submitted, Green Published, gold			2023-01-03	WOS:000407396200087
J	Jaja-Chimedza, A; Graf, BL; Simmler, C; Kim, Y; Kuhn, P; Pauli, GF; Raskin, I				Jaja-Chimedza, Asha; Graf, Brittany L.; Simmler, Charlotte; Kim, Youjin; Kuhn, Peter; Pauli, Guido F.; Raskin, Ilya			Biochemical characterization and anti-inflammatory properties of an isothiocyanate-enriched moringa (Moringa oleifera) seed extract	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION PROFILES; STRUCTURAL INFLUENCE; ANTITUMOR PROMOTER; NF-KB; CURCUMIN; ANTIOXIDANT; NRF2; ACTIVATION; L.	Moringa oleifera Lam. is a tropical plant, used for centuries as food and traditional medicine. The aim of this study was to develop, validate and biochemically characterize an isothiocyanate- enriched moringa seed extract (MSE), and to compare the anti-inflammatory effects of MSE-containing moringa isothiocyanate-1 (MIC-1) with a curcuminoid-enriched turmeric extract (CTE), and a material further enriched in its primary phytochemical, curcumin (curcumin- enriched material; CEM). MSE was prepared by incubating ground moringa seeds with water to allow myrosinase-catalyzed enzymatic formation of bioactive MIC-1, the predominant isothiocyanate in moringa seeds. Optimization of the extraction process yielded an extract of 38.9% MIC-1. Phytochemical analysis of MSE revealed the presence of acetylated isothiocyanates, phenolic glycosides unique to moringa, flavonoids, fats and fatty acids, proteins and carbohydrates. MSE showed a reduction in the carrageenan-induced rat paw edema (33% at 500 mg/kg MIC-1) comparable to aspirin (27% at 300 mg/kg), whereas CTE did not have any significant effect. In vitro, MIC-1 at 1 mu M significantly reduced the production of nitric oxide (NO) and at 5 mu M, the gene expression of LPS-inducible nitric oxide synthase (iNOS) and interleukins 1 beta and 6 (IL-1 beta and IL-6), whereas CEM did not show any significant activity at all concentrations tested. MIC-1 (10 mu M) was also more effective at upregulating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) target genes NAD(P) H: quinone oxidoreductase 1 (NQO1), glutathione S-transferase pi 1 (GSTP1), and heme oxygenase 1 (HO1) than the CEM. Thus, in contrast to CTE and CEM, MSE and its major isothiocyanate MIC-1 displayed strong anti-inflammatory and antioxidant properties in vivo and in vitro, making them promising botanical leads for the mitigation of inflammatory-mediated chronic disorders.	[Jaja-Chimedza, Asha; Graf, Brittany L.; Kim, Youjin; Kuhn, Peter; Raskin, Ilya] Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA; [Simmler, Charlotte; Pauli, Guido F.] Univ Illinois, Ctr Nat Prod Technol, Dept Med Chem & Pharmacognosy, Chicago, IL USA; [Kim, Youjin] Nutrasorb LLC, Freehold, NJ USA	Rutgers State University New Brunswick; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Jaja-Chimedza, A (corresponding author), Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA.	jaja@sebs.rutgers.edu	Pauli, Guido F/C-1159-2009	Simmler, Charlotte/0000-0002-6923-2630; Jaja-Chimedza, Asha/0000-0001-5631-1893	National Center For Complementary & Integrative Health; Office of Dietary Supplements of the National Institutes of Health funds the Botanical Research Center of Pennington Biomedical Research Center [P50AT002776, 5T32AT004094]; Department of Plant Biology in the School of Environmental and Biological Sciences (SEBS) of Rutgers University; New Jersey Agricultural Experiment Station at Rutgers University; National Institutes of Health/Small Business Innovative Research [5R43AT008628-02]; Tropical Research Ecological Exchange Institute, Key West, FL; National Center for Complementary and Integrative Health [U41 AT008706]; Office of Dietary Supplement/National Institutes of Health; NIH [GM068944]; National Center for Complementary & Integrative Health [T32AT004094, P50AT002776, R43AT008628] Funding Source: NIH RePORTER	National Center For Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Dietary Supplements of the National Institutes of Health funds the Botanical Research Center of Pennington Biomedical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Plant Biology in the School of Environmental and Biological Sciences (SEBS) of Rutgers University; New Jersey Agricultural Experiment Station at Rutgers University; National Institutes of Health/Small Business Innovative Research; Tropical Research Ecological Exchange Institute, Key West, FL; National Center for Complementary and Integrative Health; Office of Dietary Supplement/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This publication was supported by the National Center For Complementary & Integrative Health and the Office of Dietary Supplements of the National Institutes of Health under Award Number P50AT002776 and 5T32AT004094 which funds the Botanical Research Center of Pennington Biomedical Research Center and the Department of Plant Biology in the School of Environmental and Biological Sciences (SEBS) of Rutgers University and the New Jersey Agricultural Experiment Station at Rutgers University (AJ, BLG, PK and IR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. YK was supported by National Institutes of Health/Small Business Innovative Research grant 5R43AT008628-02. BLG was also supported by funding from the Tropical Research Ecological Exchange Institute, Key West, FL. The authors CS and GFP were supported by grants U41 AT008706 from National Center for Complementary and Integrative Health and Office of Dietary Supplement/National Institutes of Health. CS and GFP also acknowledge NIH grant GM068944 support for the purchase of the Bruker AVANCE 900 MHz spectrometer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldieri E, 2003, FEBS LETT, V552, P141, DOI 10.1016/S0014-5793(03)00905-0; Amaglo NK, 2010, FOOD CHEM, V122, P1047, DOI 10.1016/j.foodchem.2010.03.073; Anandakumar Senthilkumar, 2014, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V43, P612; [Anonymous], INT J PHARM PHARM SC; Anwar F, 2007, PHYTOTHER RES, V21, P17, DOI 10.1002/ptr.2023; Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a; Bak MJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/409321; Bennett RN, 2003, J AGR FOOD CHEM, V51, P3546, DOI 10.1021/jf0211480; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; Brunelli D, 2010, BIOCHEM PHARMACOL, V79, P1141, DOI 10.1016/j.bcp.2009.12.008; Buadonpri W, 2009, J HEALTH RES, V23, P10; Chainani-Wu N, 2003, J ALTERN COMPLEM MED, V9, P161, DOI 10.1089/107555303321223035; Cheenpracha S, 2010, BIOORGAN MED CHEM, V18, P6598, DOI 10.1016/j.bmc.2010.03.057; Chen PH, 2015, J PHARMACEUT BIOMED, V115, P260, DOI 10.1016/j.jpba.2015.07.014; Das L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124000; Dayal B, 2013, ACS SYM SER, V1129, P203; Fahey J., 2005, TREES LIFE J; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Gao W, 2017, MAGN RESON CHEM, V55, P239, DOI 10.1002/mrc.4425; Gonzalez-Reyes S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/801418; Guevara AP, 1999, MUTAT RES-GEN TOX EN, V440, P181, DOI 10.1016/S1383-5718(99)00025-X; Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Jurenka JS, 2009, ALTERN MED REV, V14, P141; Karim Nurul Ashikin Abd, 2016, Asian Pac J Cancer Prev, V17, P3675; Kobayashi E, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/529219; Kobayashi Y, 2010, J LEUKOCYTE BIOL, V88, P1157, DOI 10.1189/jlb.0310149; La Marca M, 2012, FOOD CHEM TOXICOL, V50, P2822, DOI 10.1016/j.fct.2012.05.044; Maldini M, 2014, J MASS SPECTROM, V49, P900, DOI 10.1002/jms.3437; McCarson KE, 2012, CURR PROTOC PHARM; Menon VP, 2007, ADV EXP MED BIOL, V595, P105; MUKHOPADHYAY A, 1982, AGENTS ACTIONS, V12, P508, DOI 10.1007/BF01965935; Murakami A, 2007, INT J CANCER, V121, P2357, DOI 10.1002/ijc.23161; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975; Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079; Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5; Park EJ, 2011, NUTR CANCER, V63, P971, DOI 10.1080/01635581.2011.589960; Pauli GF, 2014, J MED CHEM, V57, P9220, DOI 10.1021/jm500734a; Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007; Phansalkar RS, 2017, J NAT PROD, V80, P634, DOI 10.1021/acs.jnatprod.6b00923; Pierson JT, 2014, FOOD CHEM, V149, P253, DOI 10.1016/j.foodchem.2013.10.108; Prawan A, 2008, PHARM RES-DORDR, V25, P836, DOI 10.1007/s11095-007-9370-9; Rajan TS, 2016, FITOTERAPIA, V112, P104, DOI 10.1016/j.fitote.2016.05.008; Razis AFA, 2014, ASIAN PAC J CANCER P, V15, P8571, DOI 10.7314/APJCP.2014.15.20.8571; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Saini RK, 2016, 3 BIOTECH, V6, DOI 10.1007/s13205-016-0526-3; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670; Smith T, 2016, HERBALGRAM, P67; SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Traka M, 2009, PHYTOCHEM REV, V8, P269, DOI 10.1007/s11101-008-9103-7; Tumer TB, 2015, J AGR FOOD CHEM, V63, P1505, DOI 10.1021/jf505014n; Volpe D. A., 2007, CLIN RES REGUL AFF, V24, P39, DOI DOI 10.1080/10601330701273669; Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014; Waterman C, 2015, MOL NUTR FOOD RES, V59, P1013, DOI 10.1002/mnfr.201400679; Waterman C, 2014, PHYTOCHEMISTRY, V103, P114, DOI 10.1016/j.phytochem.2014.03.028; Yates MS, 2009, CARCINOGENESIS, V30, P1024, DOI 10.1093/carcin/bgp100	61	77	78	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2017	12	8							e0182658	10.1371/journal.pone.0182658	http://dx.doi.org/10.1371/journal.pone.0182658			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC9EU	28792522	Green Published, Green Submitted, gold			2023-01-03	WOS:000407144700031
J	Lindley, RI; Anderson, CS; Billot, L; Forster, A; Hackett, ML; Harvey, LA; Jan, S; Li, Q; Liu, HM; Langhorne, P; Maulik, PK; Murthy, GVS; Walker, MF; Pandian, JD; Alim, M; Felix, C; Gandhi, DBC; Syrigapu, A; Tugnawat, DK; Verma, SJ; Shamanna, BR; Hankey, G; Thrift, A; Bernhardt, J; Mehndiratta, MM; Jeyaseelan, L; Donnelly, P; Byrne, D; Steley, S; Santhosh, V; Chilappagari, S; Mysore, J; Roy, J; Padma, MV; John, L; Aaron, S; Borah, NC; Vijaya, P; Kaul, S; Khurana, D; Sylaja, PN; Halprashanth, DS; Madhusudhan, BK; Nambiar, V; Sureshbabu, S; Khanna, MC; Narang, GS; Chakraborty, D; Chakraborty, SS; Biswas, B; Kaura, S; Koundal, H; Singh, P; Andrias, A; Thambu, DS; Ramya, I; George, J; Prabhakar, AT; Kirubakaran, P; Anbalagan, P; Ghose, M; Bordoloi, K; Gohain, P; Reddy, NM; Reddy, KV; Rao, TNM; Alladi, S; Jalapu, VRR; Manchireddy, K; Rajan, A; Mehta, S; Katoch, C; Das, B; Jangir, A; Kaur, T; Sreedharan, S; Sivasambath, S; Dinesh, S; Shibi, BS; Thangaraj, A; Karunanithi, A; Sulaiman, SMS; Dehingia, K; Das, K; Nandini, C; Thomas, NJ; Dhanya, TS; Thomas, N; Krishna, R; Aneesh, V; Krishna, R; Khullar, S; Thouman, S; Sebastian, I				Lindley, Richard I.; Anderson, Craig S.; Billot, Laurent; Forster, Anne; Hackett, Maree L.; Harvey, Lisa A.; Jan, Stephen; Li, Qiang; Liu, Hueiming; Langhorne, Peter; Maulik, Pallab K.; Murthy, Gudlavalleti Venkata Satyanarayana; Walker, Marion F.; Pandian, Jeyaraj D.; Alim, M.; Felix, C.; Gandhi, D. B. C.; Syrigapu, A.; Tugnawat, D. K.; Verma, S. J.; Shamanna, B. R.; Hankey, G.; Thrift, A.; Bernhardt, J.; Mehndiratta, M. M.; Jeyaseelan, L.; Donnelly, P.; Byrne, D.; Steley, S.; Santhosh, V.; Chilappagari, S.; Mysore, J.; Roy, J.; Padma, M. V.; John, L.; Aaron, S.; Borah, N. C.; Vijaya, P.; Kaul, S.; Khurana, D.; Sylaja, P. N.; Halprashanth, D. S.; Madhusudhan, B. K.; Nambiar, V.; Sureshbabu, S.; Khanna, M. C.; Narang, G. S.; Chakraborty, D.; Chakraborty, S. S.; Biswas, B.; Kaura, S.; Koundal, H.; Singh, P.; Andrias, A.; Thambu, D. S.; Ramya, I.; George, J.; Prabhakar, A. T.; Kirubakaran, P.; Anbalagan, P.; Ghose, M.; Bordoloi, K.; Gohain, P.; Reddy, N. M.; Reddy, K. V.; Rao, T. N. M.; Alladi, S.; Jalapu, V. R. R.; Manchireddy, K.; Rajan, A.; Mehta, S.; Katoch, C.; Das, B.; Jangir, A.; Kaur, T.; Sreedharan, S.; Sivasambath, S.; Dinesh, S.; Shibi, B. S.; Thangaraj, A.; Karunanithi, A.; Sulaiman, S. M. S.; Dehingia, K.; Das, K.; Nandini, C.; Thomas, N. J.; Dhanya, T. S.; Thomas, N.; Krishna, R.; Aneesh, V.; Krishna, R.; Khullar, S.; Thouman, S.; Sebastian, I.		ATTEND Collaborative Grp	Family-led rehabilitation after stroke in India (ATTEND): a randomised controlled trial	LANCET			English	Article							LOW-INCOME; CARE; CAREGIVERS; SERVICES; BURDEN; HEALTH	Background Most people with stroke in India have no access to organised rehabilitation services. The effectiveness of training family members to provide stroke rehabilitation is uncertain. Our primary objective was to determine whether family-led stroke rehabilitation, initiated in hospital and continued at home, would be superior to usual care in a low-resource setting. Methods The Family-led Rehabilitation after Stroke in India (ATTEND) trial was a prospectively randomised open trial with blinded end point done across 14 hospitals in India. Patients aged 18 years or older who had had a stroke within the past month, had residual disability and reasonable expectation of survival, and who had an informal family nominated caregiver were randomly assigned to intervention or usual care by site coordinators using a secure web based system with minimisation by site and stroke severity. The family members of participants in the intervention group received additional structured rehabilitation training-including information provision, joint goal setting, carer training, and task-specific training-that was started in hospital and continued at home for up to 2 months. The primary outcome was death or dependency at 6 months, defined by scores 3-6 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) as assessed by masked observers. Analyses were by intention to treat. This trial is registered with Clinical Trials Registry-India (CTRI/2013/04/003557), Australian New Zealand Clinical Trials Registry (ACTRN12613000078752), and Universal Trial Number (U1111-1138-6707). Findings Between Jan 13, 2014, and Feb 12, 2016, 1250 patients were randomly assigned to intervention (n=623) or control (n=627) groups. 33 patients were lost to follow-up (14 intervention, 19 control) and five patients withdrew (two intervention, three control). At 6 months, 285 (47%) of 607 patients in the intervention group and 287 (47%) of 605 controls were dead or dependent (odds ratio 0.98, 95% CI 0.78-1.23, p=0.87). 72 (12%) patients in the intervention group and 86 (14%) in the control group died (p=0.27), and we observed no difference in rehospitalisation (89 [14%] patients in the intervention group vs 82 [13%] in the control group; p=0.56). We also found no difference in total nonfatal events (112 events in 82 [13%] intervention patients vs 110 events in 79 [13%] control patients; p=0.80). Interpretation Although task shifting is an attractive solution for health-care sustainability, our results do not support investment in new stroke rehabilitation services that shift tasks to family caregivers, unless new evidence emerges. A future avenue of research should be to investigate the effects of task shifting to health-care assistants or team-based community care.	[Lindley, Richard I.] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia; [Lindley, Richard I.] Univ Sydney, Sydney Med Sch, Westmead Hosp, Discipline Med, Sydney, NSW, Australia; [Anderson, Craig S.] Univ New South Wales, George Inst Global Hlth, Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Anderson, Craig S.] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Billot, Laurent; Hackett, Maree L.; Jan, Stephen] Univ New South Wales, Fac Med, George Inst Global Hlth, Sydney, NSW, Australia; [Forster, Anne] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England; [Hackett, Maree L.] Univ Cent Lancashire, Preston, Lancs, England; [Harvey, Lisa A.] Univ Sydney, Sydney, NSW, Australia; [Li, Qiang; Liu, Hueiming; Donnelly, P.; Byrne, D.; Steley, S.; Mysore, J.] George Inst Global Hlth, Sydney, NSW, Australia; [Langhorne, Peter] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Maulik, Pallab K.; Alim, M.; Felix, C.; Chilappagari, S.] George Inst Global Hlth India, Delhi, India; [Maulik, Pallab K.] Univ Oxford, George Inst Global Hlth, Oxford, England; [Murthy, Gudlavalleti Venkata Satyanarayana; Syrigapu, A.; Tugnawat, D. K.] Indian Inst Publ Hlth, Hyderabad, Andhra Pradesh, India; [Walker, Marion F.] Univ Nottingham, Nottingham, Notts, England; [Pandian, Jeyaraj D.; Gandhi, D. B. C.; Verma, S. J.] Christian Med Coll & Hosp Ludhiana, Ludhiana, Punjab, India; [Shamanna, B. R.] Univ Hyderabad, Hyderabad, Andhra Pradesh, India; [Hankey, G.] Univ Western Australia, Nedlands, WA, Australia; [Thrift, A.] Monash Univ, Melbourne, Vic, Australia; [Bernhardt, J.] Univ Melbourne, Melbourne, Vic, Australia; [Mehndiratta, M. M.] Janakpuri Super Special Hosp, New Delhi, India; [Jeyaseelan, L.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Santhosh, V.] George Inst Global Hlth, Bangalore, Karnataka, India; [Khanna, M. C.; Narang, G. S.] Christian Med Coll & Hosp, Ludhiana, Punjab, India; [Roy, J.; Chakraborty, D.; Chakraborty, S. S.; Biswas, B.] Apollo Gleneagles Hosp, Kolkata, W Bengal, India; [Padma, M. V.; Kaura, S.; Koundal, H.] All India Inst Med Sci, Delhi, India; [John, L.; Singh, P.; Andrias, A.] Baptist Christian Hosp, Tezpur, Assam, India; [Aaron, S.; Thambu, D. S.; Ramya, I.; George, J.; Prabhakar, A. T.; Kirubakaran, P.; Anbalagan, P.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Borah, N. C.; Ghose, M.; Bordoloi, K.; Gohain, P.] GNRC Hosp, Dispur, Assam, India; [Vijaya, P.; Reddy, N. M.; Reddy, K. V.; Rao, T. N. M.] Lalitha Super Specialty Hosp, Guntur, Andhra Pradesh, India; [Kaul, S.; Alladi, S.; Jalapu, V. R. R.; Manchireddy, K.; Rajan, A.] Nizam Inst Med Sci, Hyderabad, Andhra Pradesh, India; [Khurana, D.; Mehta, S.; Katoch, C.; Das, B.; Jangir, A.; Kaur, T.] Postgrad Inst Med Educ & Res, Chandigarh, India; [Sylaja, P. N.; Sreedharan, S.; Sivasambath, S.; Dinesh, S.; Shibi, B. S.] Sree Chitra Tirunal Inst Med Sci & Technol, Thiruvananthapuram, Kerala, India; [Halprashanth, D. S.; Thangaraj, A.; Karunanithi, A.; Sulaiman, S. M. S.] Global Hosp, Madras, Tamil Nadu, India; [Madhusudhan, B. K.; Dehingia, K.; Das, K.; Nandini, C.; Thomas, N. J.] BGS Global Hosp, Bangalore, Karnataka, India; [Nambiar, V.; Dhanya, T. S.; Thomas, N.; Krishna, R.; Aneesh, V.; Krishna, R.] Amrita Inst Med Sci, Kochi, Kerala, India; [Sureshbabu, S.; Khullar, S.; Thouman, S.; Sebastian, I.] St Stephens Hosp, Delhi, India	George Institute for Global Health; University of Sydney; University of Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of New South Wales Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Leeds; University of Central Lancashire; University of Sydney; George Institute for Global Health; University of Sydney; University of Glasgow; University of Oxford; University of Nottingham; University of Hyderabad; University of Western Australia; Monash University; University of Melbourne; Christian Medical College & Hospital (CMCH) Vellore; All India Institute of Medical Sciences (AIIMS) New Delhi; Christian Medical College & Hospital (CMCH) Vellore; Nizam's Institute of Medical Sciences; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; St. Stephen's Hospital	Lindley, RI (corresponding author), George Inst Global Hlth, POB M201, Camperdown, NSW 2050, Australia.; Lindley, RI (corresponding author), Univ Sydney, POB M201, Camperdown, NSW 2050, Australia.	rlindley@georgeinstitute.org.au	Jan, Stephen/AAG-3333-2021; Sebastian, Ivy/HDO-4802-2022; Lindley, Richard/B-8148-2013; Thrift, Amanda/I-6251-2012; SREEDHARAN, SAPNA ERAT/AAF-7589-2021; Hankey, Graeme J/H-4968-2014; Billot, Laurent/Y-1241-2019; Fazli, Ghazal/AAE-8320-2022; Pandian, Jeyaraj Durai/AAV-5591-2020; Hackett, Maree L/O-8752-2016; Gandhi, Dorcas/AAO-3740-2021; Mohammed, Alim/L-2831-2018; Bernhardt, Julie/F-9538-2015	Lindley, Richard/0000-0002-0104-5679; Thrift, Amanda/0000-0001-8533-4170; SREEDHARAN, SAPNA ERAT/0000-0003-0633-4899; Hankey, Graeme J/0000-0002-6044-7328; Billot, Laurent/0000-0002-4975-9793; Hackett, Maree L/0000-0003-1211-9087; Mohammed, Alim/0000-0002-1802-2203; Bernhardt, Julie/0000-0002-2787-8484; Thouman, Dr. Singlai/0000-0003-4568-8059; Maulik, Pallab Kumar/0000-0001-6835-6175; Gandhi, Dorcas B C/0000-0002-9616-7870; Jan, Stephen/0000-0003-2839-1405; Alladi, Suvarna/0000-0002-0372-9572; Pandian, Jeyaraj/0000-0003-0028-1968; Harvey, Lisa A/0000-0002-4365-0236; Forster, Anne/0000-0001-7466-4414	National Health and Medical Research Council of Australia; National Institute for Health Research [NF-SI-0512-10092] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institute for Health Research(National Institute for Health Research (NIHR))	The National Health and Medical Research Council of Australia.	Alim M, 2016, TRIALS, V17, DOI 10.1186/s13063-015-1129-8; Billot L, 2017, INT J STROKE, V12, P208, DOI 10.1177/1747493016674956; Chisholm D, 2007, LANCET, V370, P1241, DOI 10.1016/S0140-6736(07)61242-2; Dieleman JL, 2016, LANCET, V387, P2521, DOI 10.1016/S0140-6736(16)30167-2; Early Supported Discharge Trialists, 2012, COCHRANE DB SYST REV, V9; Eaton J, 2011, LANCET, V378, P1592, DOI 10.1016/S0140-6736(11)60891-X; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Forster A, 2013, LANCET, V382, P2069, DOI 10.1016/S0140-6736(13)61603-7; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Govindarajan V, 2013, HARVARD BUS REV, V91, P117; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hassett L, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012074; Howard G, 2012, STROKE, V43, P664, DOI 10.1161/STROKEAHA.111.632935; Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK; Joshi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103754; Kalkonde YV, 2015, STROKE, V46, P1764, DOI 10.1161/STROKEAHA.115.008918; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Langhorne P, 2012, LANCET NEUROL, V11, P341, DOI 10.1016/S1474-4422(12)70024-8; LINDLEY RI, 1994, CEREBROVASC DIS, V4, P314, DOI 10.1159/000108501; Liu HM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012027; MAHONEY F I, 1965, Md State Med J, V14, P61; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Pandian JD, 2015, INT J STROKE; Pandian JD, INCIDENCE SHORT TERM; Pandian JD, 2013, J STROKE, V15, P128, DOI 10.5853/jos.2013.15.3.128; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organization, 2008, TASK SHIFT RAT RED T; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	76	77	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	2017	390	10094					588	599		10.1016/S0140-6736(17)31447-2	http://dx.doi.org/10.1016/S0140-6736(17)31447-2			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC5BM	28666682	Green Accepted, Green Submitted			2023-01-03	WOS:000406855800023
J	Gianotti, N; Poli, A; Galli, L; Franzin, M; Tadini, P; Galizzi, N; Carbone, A; Merli, M; Muccini, C; Oltolini, C; Andolina, A; Spagnuolo, V; Lazzarin, A; Castagna, A				Gianotti, Nicola; Poli, Andrea; Galli, Laura; Franzin, Michela; Tadini, Patrizia; Galizzi, Nadia; Carbone, Alessia; Merli, Marco; Muccini, Camilla; Oltolini, Chiara; Andolina, Andrea; Spagnuolo, Vincenzo; Lazzarin, Adriano; Castagna, Antonella			Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients	PLOS ONE			English	Article							FIXED-DOSE COMBINATION; NEVIRAPINE GPO-VIR(R); FOLLOW-UP; THERAPY; LAMIVUDINE; STAVUDINE; COHORT; CAMEROON; DRUGS; INDIA	Background Aim of this study was to evaluate the efficacy and the safety of switching from branded to generic antiretrovirals in patients with HIV-RNA < 50 copies/mL. Methods Matched-cohort study of patients followed at a single clinical center. Since September 2014, all patients with HIV-RNA < 50 copies/mL who were receiving branded lamivudine or zidovudine/lamivudine or efavirenz were switched to the generic compound (switchers) and matched, in a ratio 1: 1, for age (+/- 5 years), gender, anti-HCV antibodies, nadir and (+/- 50 cells/mu L) baseline CD4+ count (+/- 100 cells/mu L), duration of antiretroviral therapy (+/- 1 year), with patients with HIV-RNA < 50 copies/mL, on treatment with unavailable generic compounds (non-switchers). Incidence rates (IR) of different outcomes were calculated and compared by Poisson regression model. A confirmed HIV-RNA >= 50 copies/mL defined virological failure; any change in the antiretroviral regimen was defined as treatment discontinuation. Results Four hundred forty patients were switched to generic compounds (268 [61%] on lamivudine, 65 [15%] on zidovudine/lamivudine, 87 [20%] on efavirenz and 20 [4%] on efavirenz and either lamivudine or zidovudine/lamivudine). Over a median follow-up of 15.0 (12.1-15.7) months, virological failure occurred in four switchers (IR: 0.07 [0.02-0.18]/100-person months of follow-up [PMFU]) and in ten non-switchers (IR: 0.20 [0.10-0.35]/100PMFU) (p = 0.0003), while treatment discontinuation occurred in 118 switchers (IR: 2.05 [1.70-2.44]/100-PMFU) and in 128 non-switchers (IR: 2.37 [1.99-2.81]/100-PMFU) (p = 0.699). Conclusions After more than one year of follow-up, we found no evidence of increased risk of reduced efficacy or increased toxicity after switching from branded to generic lamivudine or zidovudine/lamivudine or efavirenz.	[Gianotti, Nicola; Poli, Andrea; Galli, Laura; Galizzi, Nadia; Carbone, Alessia; Merli, Marco; Muccini, Camilla; Oltolini, Chiara; Andolina, Andrea; Spagnuolo, Vincenzo; Lazzarin, Adriano; Castagna, Antonella] Ist Sci San Raffaele, Infect Dis, Milan, Italy; [Franzin, Michela; Tadini, Patrizia] Ist Sci San Raffaele, Pharm, Milan, Italy; [Galizzi, Nadia; Muccini, Camilla; Andolina, Andrea; Spagnuolo, Vincenzo; Castagna, Antonella] Univ Vita Salute San Raffaele, Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University	Gianotti, N (corresponding author), Ist Sci San Raffaele, Infect Dis, Milan, Italy.	gianotti.nicola@hsr.it	Oltolini, Chiara/AAN-1920-2020; Castagna, Antonella/K-3280-2018; Muccini, Camilla/AAN-5180-2020; Galli, Laura/B-1161-2016; LAZZARIN, Adriano/K-3607-2018	Castagna, Antonella/0000-0002-8338-9714; LAZZARIN, Adriano/0000-0003-2551-7754; Spagnuolo, Vincenzo/0000-0002-9656-7217; Gianotti, Nicola/0000-0002-7182-5080; Muccini, Camilla/0000-0002-0900-5639; Galli, Laura/0000-0001-8046-0290; Merli, Marco/0000-0001-5081-8669				[Anonymous], 2006, 40 WHO EXP COMM SPEC, V937; Bartlett John A, 2007, J Int Assoc Physicians AIDS Care (Chic), V6, P15, DOI 10.1177/1545109707299856; Bourgeois A, 2005, ANTIVIR THER, V10, P335; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Cooperativecom, 2016, FLASHBACKS RURAL ELE; Dentali F, 2011, PHARMACOTHERAPY, V31, P386, DOI 10.1592/phco.31.4.386; Desakorn V, 2011, SE ASIAN J TROP MED, V42, P1414; Di Biagio A, 2016, JAIDS-J ACQ IMM DEF, V71, P263, DOI 10.1097/QAI.0000000000000849; Doyle T, 2012, CLIN INFECT DIS, V54, P724, DOI 10.1093/cid/cir936; European Medicines Agency, 2010, GUID INV BIOEQ; Ford N, 2012, INT J EPIDEMIOL, V41, P460, DOI 10.1093/ije/dys032; Getahun Aneley, 2006, Journal of the Medical Association of Thailand, V89, P1472; Gianotti N, 2013, CLIN MICROBIOL INFEC, V19, pE542, DOI 10.1111/1469-0691.12266; Gianotti N, 2015, CLIN MICROBIOL INFEC, V21; Goemaere E, 2002, JAMA-J AM MED ASSOC, V287, P841; Kiertiburanakul Sasisopin, 2007, Journal of the Medical Association of Thailand, V90, P237; Kumarasamy N, 2005, CLIN INFECT DIS, V41, P1525, DOI 10.1086/497267; Kumarasamy N, 2005, AIDS, V19, P625, DOI 10.1097/01.aids.0000163940.85940.03; Laurent C, 2004, LANCET, V364, P29, DOI 10.1016/S0140-6736(04)16586-0; Li TS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003918; Manosuthi Weerawat, 2007, AIDS Res Ther, V4, P6, DOI 10.1186/1742-6405-4-6; Manzoli L, 2016, EUR J EPIDEMIOL, V31, P351, DOI 10.1007/s10654-015-0104-8; Pujari SN, 2004, JAIDS-J ACQ IMM DEF, V37, P1566, DOI 10.1097/00126334-200412150-00005; Stringer JSA, 2012, INT J EPIDEMIOL, V41, P448, DOI 10.1093/ije/dys022; Tansuphasawadikul Somboon, 2011, Journal of the Medical Association of Thailand, V94, P172; van den Bergh JPW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078153	26	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0182007	10.1371/journal.pone.0182007	http://dx.doi.org/10.1371/journal.pone.0182007			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3VC	28763473	gold, Green Published, Green Submitted			2023-01-03	WOS:000406766500033
J	Humphreys, K				Humphreys, Keith			Avoiding globalisation of the prescription opioid epidemic	LANCET			English	Editorial Material							UNITED-STATES; DRUG		[Humphreys, Keith] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94550 USA; [Humphreys, Keith] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94035 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Humphreys, K (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94550 USA.; Humphreys, K (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94035 USA.	knh@stanford.edu			US Veterans Health Services Research and Development Service; Stanford Neurosciences Institute	US Veterans Health Services Research and Development Service; Stanford Neurosciences Institute	I have received grants from the US Veterans Health Services Research and Development Service and Stanford Neurosciences Institute. I declare no other competing interests. This Comment is an expression of personal opinion that does not necessarily reflect the official views of the funders. I am grateful to Benedikt Fischer, David Juurlink, Kristy Nielsen, and Peter Reuter for their suggestions on this Comment.	Balko R., 2012, HUFFINGTON POST; Clark K, 2017, COMMUNICATION; Fischer B, 2017, DRUG ALC REV; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Humphreys K, 2015, HEALTH AFFAIR, V34, P1624, DOI 10.1377/hlthaff.2015.0934; Lamas D, 2012, NEW ENGL J MED, V366, P199, DOI 10.1056/NEJMp1113622; Lembke A, 2016, DOCTORS WERE DUPED P; Lembke A, 2016, AM FAM PHYSICIAN, V93, P982; Lopez G., 2017, VOX             0420; Meier Barry, 2007, NY TIMES; National Institute on Drug Abuse, 2022, OV DEATH RAT; Ostrowksi J., 1989, THINKING DRUG LEGALI; Quinones S., 2015, DREAMLAND TRUE TALE; Robbins R., 2016, STAT NEWS       0309; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ryan H., 2016, LOS ANGELES TIMES; United Nations International Narcotics Control Board, 2016, NARC DRUGS EST WORLD; US Centers for Disease Control and Prevention, 2016, PRESCR OP OV DAT; US Food and Drug Administration, 2017, FDA REQ REM OP ER RI; Whyte LE, 2016, ASSOCIATED PRES 1215; Zeller S., 2017, COMMONWEALTH	21	68	68	2	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 29	2017	390	10093					437	439		10.1016/S0140-6736(17)31918-9	http://dx.doi.org/10.1016/S0140-6736(17)31918-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB9MO	28792397				2023-01-03	WOS:000406463400008
J	You, JHS; Tam, LP; Lee, NLS				You, Joyce H. S.; Tam, Lok-pui; Lee, Nelson L. S.			Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting	PLOS ONE			English	Article							HONG-KONG; ADULTS; OSELTAMIVIR; INFECTION; MORTALITY; ILLNESS; VACCINE	Background Early initiation of antiviral therapy in elderly patients with influenza is associated with reduced risk of extra clinic visit, hospitalization and death. This study examined the costeffectiveness of molecular POCT for detection of influenza viruses in Hong Kong elderly patients with influenza-like illness (ILI) in the outpatient clinics. Methods A decision analytic model was used to simulate outcomes of a hypothetical cohort of elderly patients presented with ILI at outpatient clinics during peak season of influenza with two diagnostic approaches: Rapid molecular assay (POCT-PCR group) and clinical judgement with no POCT. Outcome measures included influenza-associated direct medical cost, hospitalization and mortality rates, quality-adjusted life year loss (QALY loss), and incremental cost per QALY saved (ICER). Results In base-case analysis, POCT-PCR group was expected to reduce hospitalization (1.38% versus 2.85%) and mortality rate (0.08% versus 0.16%) and save 0.00112 QALYs at higher cost (by USD33.2 per ILI patient), comparing with clinical judgement group. The ICER of POCTPCR was 29,582 USD/QALY saved. One-way sensitivity analyses found ICER sensitive to: Hospitalization rate without prompt antiviral therapy; odds ratio of hospitalization with prompt therapy; influenza prevalence; patient age and mortality rate of hospitalized patients. POCTPCR was cost-effective in 60.6% and 99.4% of 10,000 Monte Carlo simulations at willingnessto- pay threshold of 1x and 3x gross domestic product per capita of Hong Kong, respectively. Conclusions Molecular POCT for influenza detection in elderly patients with ILI at outpatient clinics during peak influenza season appeared to be cost-effective in Hong Kong.	[You, Joyce H. S.; Tam, Lok-pui] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China; [Lee, Nelson L. S.] Chinese Univ Hong Kong, Dept Med & Therapeut, Div Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	You, JHS (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Hong Kong, Peoples R China.	joyceyou@cuhk.edu.hk	Lee, Nelson/B-6418-2008; You, Joyce H. S./C-2984-2008	Lee, Nelson/0000-0002-0783-6607; You, Joyce H. S./0000-0002-5763-7403				[Anonymous], HONG KONG LIF TABL 2; [Anonymous], GUID CLIN US RT PCR; Brendish NJ, 2017, LANCET RESP MED, V5, P401, DOI [10.1016/s2213-2600(17)30120-0, 10.1016/S2213-2600(17)30120-0]; Census and Statistics Department The Government of Hong Kong SAR, PROJ MID YEAR POP AG; Centers for Disease Control and Prevention, INFL ANT MED SUMM CL; Centre for Health Protection Department of Health, DET INFL VIR RESP SP; Chan D, 2013, COMMUNICABLE DIS WAT, V10, P74; Chan YK, 2017, ANTIVIR THER, V22, P173, DOI 10.3851/IMP3102; Chowell G, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-97; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Jefferson T, 2014, COCHRANE DB SYST REV, DOI [10.1590/1516-3180.20141324T2, 10.1002/14651858.CD008965.pub4]; Jefferson T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2545; Lee BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011284; Lee N, 2010, THORAX, V65, P510, DOI 10.1136/thx.2009.130799; Lee N, 2007, ANTIVIR THER, V12, P501; Lee N, 2011, J INFECT DIS, V203, P1739, DOI 10.1093/infdis/jir187; Ng S, 2010, CLIN INFECT DIS, V50, P707, DOI 10.1086/650458; Nie SP, 2014, J CLIN MICROBIOL, V52, P3339, DOI 10.1128/JCM.01132-14; Petrie JG, 2011, J INFECT DIS, V203, P1309, DOI 10.1093/infdis/jir015; Soto M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146620; Stein J, 2005, ANN EMERG MED, V46, P412, DOI 10.1016/j.annemergmed.2005.05.020; Wang CB, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001070; WHO, 2002, REDUCING RISKS PROMO; Wu P, 2012, J INFECT DIS, V206, P1862, DOI 10.1093/infdis/jis628; You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9	25	22	22	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							0182091	10.1371/journal.pone.0182091	http://dx.doi.org/10.1371/journal.pone.0182091			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1CT	28750092	Green Submitted, Green Published, gold			2023-01-03	WOS:000406575700133
J	Deng, PY; Li, X; Wei, Y; Liu, J; Chen, M; Xu, YM; Dong, B; Zhu, LQ; Cheri, LM				Deng, Peiying; Li, Xue; Wei, Yi; Liu, Juan; Chen, Meng; Xu, Yamei; Dong, Bin; Zhu, Lingqun; Chai, Limin			The herbal decoction modified Danggui Buxue Tang attenuates immune-mediated bone marrow failure by regulating the differentiation of T lymphocytes in an immune-induced aplastic anemia mouse model	PLOS ONE			English	Article							RADIX-ASTRAGALI; NITRIC-OXIDE; CELLS; PATHOPHYSIOLOGY; MECHANISMS; EXPRESSION; RESPONSES; GAMMA; HETEROGENEITY; RHIZOMA	Angelicae Sinensis, Radix Astragali and Rhizoma Coptidis are all herbs of modified Danggui Buxue Tang (DGBX) and are extensively applied herbs in traditional Chinese medicine for the treatment of anemia and inflammation. In this study, immune-induced AA mice were used as an animal model, and the immunosuppressive agent, Ciclosporin A (CsA), was used as a positive control. Multiple pro-inflammatory cytokines were examined by bead based multiplex flow cytometry. The T-cell subsets were assessed using a fluorescence activated cell sorter (FACS). Western blot analysis was used to estimate the protein expression levels of specific transcription factors for T helper cells (Th1, Th2 and Th17) and key molecules of the Janus-activated kinase (Jak)/signal transducer and activator of transcription (Stat3) signaling pathway. DGBX treatment could significantly increase the production of whole blood cells in peripheral blood (PB); inhibit the expansion of Th1 and Th17 cells; increase the differentiation of Th2 and Tregs cells; regulate the expression levels of T-bet, GATA-3, RORy and proinflammatory cytokines; and decrease the expression levels of key molecules in the Jak/Stat signaling pathway. These results indicate that DGBX can regulate the differentiation of T lymphocytes, resulting in immunosuppressive and hematogenic functions on AA mice. DGBX might be a good candidate for inclusion in a randomized study for AA with more data on the possible side effects and doses used in humans. Ultimately, it may be used for applications of traditional medicine against AA in modern complementary and alternative immunosuppressive therapeutics.	[Deng, Peiying; Li, Xue; Wei, Yi; Dong, Bin; Zhu, Lingqun; Chai, Limin] Beijing Univ Chinese Med, Minist Educ, Key Lab Chinese Internal Med, Beijing, Peoples R China; [Deng, Peiying; Li, Xue; Wei, Yi; Dong, Bin; Zhu, Lingqun; Chai, Limin] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China; [Liu, Juan; Xu, Yamei] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Hematol & Oncol, Beijing, Peoples R China; [Chen, Meng] Beijing Univ Chinese Med, Sch Preclin Med, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Cheri, LM (corresponding author), Beijing Univ Chinese Med, Minist Educ, Key Lab Chinese Internal Med, Beijing, Peoples R China.; Cheri, LM (corresponding author), Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China.	liminchai@hotmail.com			National Natural Science Foundation of China [81373583]; Fundamental Research Funds for Beijing University of Chinese medicine [2015-JYB-XJQ002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for Beijing University of Chinese medicine	This work was supported by National Natural Science Foundation of China 81373583 (http://wwtiv.nsfc.gov.cri), Fundamental Research Funds for Beijing University of Chinese medicine 2015-JYB-XJQ002 (http./Armwbum.eduLn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad W, 2016, FOOD FUNCT, V7, P1380, DOI [10.1039/c5fo01531f, 10.1039/C5FO01531F]; [Anonymous], 2006, [No title captured]; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Bettelli E, 2007, CURR OPIN IMMUNOL, V19, P652, DOI 10.1016/j.coi.2007.07.020; Bin Dong JL, 2014, J BEIJING U TRADITIO, V37; Bloom ML, 2004, EXP HEMATOL, V32, P1163, DOI 10.1016/j.exphem.2004.08.006; Brodsky RA, 2005, LANCET, V365, P1647, DOI 10.1016/S0140-6736(05)66515-4; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Chen Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep11638; Choi YY, 2013, J ETHNOPHARMACOL, V149, P506, DOI 10.1016/j.jep.2013.07.008; de Latour RP, 2010, BLOOD, V116, P4175, DOI 10.1182/blood-2010-01-266098; Fagerlie SR, 2004, J IMMUNOL, V173, P3863, DOI 10.4049/jimmunol.173.6.3863; Gao QT, 2006, PLANTA MED, V72, P1227, DOI 10.1055/s-2006-947186; Giannakoulas NC, 2004, BRIT J HAEMATOL, V124, P97, DOI 10.1046/j.1365-2141.2003.04729.x; Gong AGW, 2016, PLANTA MED, V82, P418, DOI 10.1055/s-0035-1558332; Hoyer KK, 2009, BLOOD, V113, P389, DOI 10.1182/blood-2008-04-153346; Iizuka N, 2000, CANCER LETT, V158, P35, DOI 10.1016/S0304-3835(00)00496-1; Ishikawa S, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7262054; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Juan Liu CZ, 2013, J BEIJING U TRADITIO, V36; Kordasti S, 2012, BLOOD, V119, P2033, DOI 10.1182/blood-2011-08-368308; Kotsianidis I, 2009, LEUKEMIA, V23, P510, DOI 10.1038/leu.2008.333; Li J., 2016, STEM CELLS INT, V2016, P6, DOI DOI 10.1016/J.ENGGE0.2016.03.006; Liu TT, 2015, SCI REP-UK, V5, DOI 10.1038/srep13982; Miyara M, 2011, IMMUNOL CELL BIOL, V89, P346, DOI 10.1038/icb.2010.137; Munoz J, 2014, ONCOLOGIST, V19, P536, DOI 10.1634/theoncologist.2013-0407; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; Perez-Diez A, 2007, BLOOD, V109, P5346, DOI 10.1182/blood-2006-10-051318; Qiu CL, 2014, CELL PHYSIOL BIOCHEM, V33, P784, DOI 10.1159/000358652; Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179; Remppis A, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/194896; Shi J, 2012, BLOOD, V120, P1624, DOI 10.1182/blood-2011-11-390708; Shin JS, 2016, J PHARMACOL EXP THER, V358, P20, DOI 10.1124/jpet.115.231043; Solomou EE, 2007, BLOOD, V110, P1603, DOI 10.1182/blood-2007-01-066258; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Yan Y, 2013, J PHARMACEUT BIOMED, V80, P192, DOI 10.1016/j.jpba.2013.03.008; Yang M, 2009, J ETHNOPHARMACOL, V124, P87, DOI 10.1016/j.jep.2009.04.007; Young NS, 2008, CURR OPIN HEMATOL, V15, P162, DOI 10.1097/MOH.0b013e3282fa7470; Young NS, 2010, BIOL BLOOD MARROW TR, V16, pS119, DOI 10.1016/j.bbmt.2009.09.013; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Zeng WH, 2001, J CLIN INVEST, V108, P765, DOI 10.1172/JCI12687; Zeng Y, 2015, CLIN EXP IMMUNOL, V180, P361, DOI 10.1111/cei.12605; Zhang B, 2016, J CLIN INVEST, V126, P975, DOI 10.1172/JCI79196; Zhou B, 2014, J CLIN INVEST, V124, P553, DOI 10.1172/JCI69804; Zhou K, 2016, INFLAMMATION, V39, P1558, DOI 10.1007/s10753-016-0391-6; Zierau O, 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/	49	15	14	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2017	12	7							e0180417	10.1371/journal.pone.0180417	http://dx.doi.org/10.1371/journal.pone.0180417			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA3HX	28683082	Green Published, Green Submitted, gold			2023-01-03	WOS:000405335200033
J	De Pasquale, C; Conti, D; Pistorio, ML; Fatuzzo, P; Veroux, M; Di Nuovo, S				De Pasquale, Concetta; Conti, Daniela; Pistorio, Maria Luisa; Fatuzzo, Pasquale; Veroux, Massimiliano; Di Nuovo, Santo			Comparison of the CBA-H and SF-36 for the screening of the psychological and behavioural variables in chronic dialysis patients	PLOS ONE			English	Article							QUALITY-OF-LIFE; HEMODIALYSIS-PATIENTS; RENAL-FAILURE; DISEASE; SYMPTOMS; PATTERN	The aim of the study was to perform an analysis of the emotional reactions, perception of stressful life and behavioural changes related to Haemodialysis (HD) in order to identify those variables that can improve lifestyle and the adherence to treatment. Some psychometric assessment, such as the Cognitive Behavioural Assessment, Hospital Form, (CBA-H) and the Health Survey (SF-36), which provides two indexes: the Physical Component Score (PCS) and the Mental Component Score (MCS), are suitable to assess a patient's psychological and behavioural style and their health-related quality of life. The study involved 37 Italian out-patients with end-stage renal disease under HD therapy. We calculated the Spearman correlation between variables of CBA-H, SF-36, age and time on HD. We also performed a multivariate linear regression using the CBA-H variables as predictors and PCS and MCS as dependent variables. From the CBA-H, 95% of participants self-reported psychological characteristics comparable to Type A personality, which identifies an anxious, hyperactive and hostile subject. Physical limitations were found to be directly proportional to the time on dialysis (r(s) = -0.42). The condition of perceived stress worsens the state of mental health (r(s) = -0.68) and general health perception (r(s) = -0.44). The condition of vital exhaustion correlates both the PCS and the MCS (p<0.01) with possible outcomes of physical and mental illness. The psychological wellbeing of a dialyzed patient could be due to the combination of several factors, including life parameters, the positive perception of psychosocial outcomes, and the perceived quality of life. A multidisciplinary team (neurologists, psychiatrists, psychologists, and nurses) is essential to plan effective psychological and psychotherapeutic interventions to improve a mind-body integration.	[De Pasquale, Concetta; Pistorio, Maria Luisa; Veroux, Massimiliano] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Vasc Surg & Organ Transplant Unit, Catania, Italy; [De Pasquale, Concetta; Di Nuovo, Santo] Univ Catania, Dept Educ Sci, Catania, Italy; [Conti, Daniela] Sheffield Hallam Univ, Fac Arts Comp Engn & Sci, Sheffield, S Yorkshire, England; [Fatuzzo, Pasquale] Univ Catania, Dept Med & Paediat Sci, Catania, Italy	University of Catania; University of Catania; Sheffield Hallam University; University of Catania	Conti, D (corresponding author), Sheffield Hallam Univ, Fac Arts Comp Engn & Sci, Sheffield, S Yorkshire, England.	d.conti@shu.ac.uk	Conti, Daniela/J-5197-2019; Di Nuovo, Santo/K-7760-2019; de pasquale, concetta/AAG-8431-2020; Veroux, Massimiliano/K-4821-2018	Conti, Daniela/0000-0001-5308-7961; Di Nuovo, Santo/0000-0001-6086-7624; de pasquale, concetta/0000-0003-4692-0980; Veroux, Massimiliano/0000-0002-2780-6421	European Union's H research and innovation program under the MSCA-Individual Fellowship [703489]	European Union's H research and innovation program under the MSCA-Individual Fellowship	The work of Daniela Conti was partially supported by the European Union's H2020 research and innovation program under the MSCA-Individual Fellowship grant agreement no. 703489. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAM HS, 1971, AM J PSYCHIAT, V127, P1199, DOI 10.1176/ajp.127.9.1199; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th; Balestroni G, 2015, MONALDI ARCH CHEST D, V74; De Pasquale C, 2014, TRANSPL P, P2199; De Pasquale C, 2016, TRANSPL P, P319; De Pasquale C, 2011, TRANSPL P, P1045; De Pasquale C, 2012, TRANSPL P, P1876; Fornaro M, 2013, J AFFECT DISORDERS, V148, P375, DOI 10.1016/j.jad.2013.01.002; FRIEDMAN M, 1959, JAMA-J AM MED ASSOC, V169, P1286, DOI 10.1001/jama.1959.03000290012005; Friedman M, 1974, TYPE BEHAV YOUR HEAR, P26; Friedman M., 1996, TYPE BEHAV ITS DIAGN; Fujisawa M, 2000, UROLOGY, V56, P201, DOI 10.1016/S0090-4295(00)00623-3; Ghadam MS, 2016, GLOB J HLTH SCI, V8, P121; Lahousen T, 2016, NORD J PSYCHIAT, V70, P24, DOI 10.3109/08039488.2015.1041156; Lee SY, 2004, J PSYCHOSOM RES, V57, P5, DOI 10.1016/S0022-3999(03)00528-2; LEVY NB, 1979, PSYCHOTHER PSYCHOSOM, V31, P260, DOI 10.1159/000287338; LIVESLEY WJ, 1982, J PSYCHOSOM RES, V26, P581, DOI 10.1016/0022-3999(82)90072-1; Masoud Rayyani., 2014, ASIAN J NURSING ED R, V4, P165; Petticrew MP, 2012, AM J PUBLIC HEALTH, V102, P2018, DOI 10.2105/AJPH.2012.300816; Poorgholami Farzad, 2015, Glob J Health Sci, V8, P165, DOI 10.5539/gjhs.v8n7p165; Poppe C, 2013, NEPHROL DIAL TRANSPL, V28, P116, DOI 10.1093/ndt/gfs151; Prihodova L, 2014, TRANSPLANTATION, V97, P1139, DOI 10.1097/01.TP.0000441092.24593.1e; Sanavio E, 2013, PSYCHO COMMUNITY HEA, V2, P362, DOI DOI 10.5964/PCH.V2I3.61; SENSKY T, 1993, PSYCHOTHER PSYCHOSOM, V59, P56, DOI 10.1159/000288649; Soponaru C, 2016, ARCH MED SCI D CIVIL, P16; van Dijk S, 2012, PSYCHOSOM MED, V74, P854, DOI 10.1097/PSY.0b013e31826aff0b; WARE JE, 2000, HLTH SURVEY MANUAL I; WILLIAMS RB, 1980, PSYCHOSOM MED, V42, P539, DOI 10.1097/00006842-198011000-00002; WRIGHT RG, 1966, ANN INTERN MED, V64, P611, DOI 10.7326/0003-4819-64-3-611; Zotti AM, 2010, CBA H COGNITIVE BEHA	30	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2017	12	6							e0180077	10.1371/journal.pone.0180077	http://dx.doi.org/10.1371/journal.pone.0180077			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EZ3KB	28666025	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000404608700060
J	Garcia-Recio, M; Cladera, A; Bento, L; Dominguez, J; de Gracia, SR; Sartori, F; Del Campo, R; Garcia, L; Ballester, C; Gines, J; Bargay, J; Sampol, A; Gutierrez, A				Garcia-Recio, Marta; Cladera, Antonia; Bento, Leyre; Dominguez, Julia; de Gracia, Silvia Ruiz; Sartori, Francesca; Del Campo, Raquel; Garcia, Lucia; Ballester, Carmen; Gines, Jordi; Bargay, Joan; Sampol, Antonia; Gutierrez, Antonio			Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience	PLOS ONE			English	Article							B-CELL LYMPHOMA; PRIMARY CNS LYMPHOMA; NON-HODGKIN-LYMPHOMA; HIGH-RISK PATIENTS; RITUXIMAB ERA; THERAPY; TRIAL; METHOTREXATE; LEUKEMIA; RELAPSE	Central nervous system (CNS) lymphomatosis is a fatal complication of aggressive non-Hodgkin lymphoma (NHL). In lymphoblastic or Burkitt lymphoma, without specific CNS prophylaxis the risk of CNS relapse is 20-30%. DLBCL has a lower risk of relapse (around 5%) but several factors increase its incidence. There is no consensus or trials to conclude which is the best CNS prophylaxis. Best results seem to be associated with the use of intravenous (iv) high-dose methotrexate (HDMTX) but with a significant toxicity. Other options are the administration of intrathecal (IT) MTX, cytarabine or liposomal cytarabine (ITLC). Our aim is to analyze the experience of the centers of the Balearic Lymphoma Group (BLG) about the toxicity and efficacy of ITLC in the prophylaxis and therapy of CNS lymphomatosis. We retrospectively reviewed cases from 2005 to 2015 (n = 58) treated with ITLC. Our toxicity results were: 33% headache, 20% neurological deficits, 11% nausea, 9% dizziness, 4% vomiting, 4% fever, 2% transient blindness and 2% photophobia. In the prophylactic cohort (n = 26) with a median follow-up of 55 months (17-81) only 3 CNS relapses (11%) were observed (testicular DLBCL, Burkitt and plasmablastic lymphoma, with a cumulative incidence of 8%, 14% and 20% respectively). In the treatment cohort (n = 32), CSF complete clearance was obtained in 77% cases. Median OS was 6 months (0-16). Death causes were lymphoma progression (19 patients, 79%), treatment toxicity (2 patients) and nonrelated (3 patients, 12%). Toxicity profile was good especially when concomitant dexamethasone was administered. In the prophylactic cohort the incidence of CNS relapse in DLBCL group was similar to previously reported for HDMTX and much better than IT MTX. A high number of ITLC injections was associated with better rates of CSF clearance, clinical responses, PFS and lower relapses. Survival is still poor in CNS lymphomatosis and new therapeutic approaches are still needed.	[Garcia-Recio, Marta; Bento, Leyre; de Gracia, Silvia Ruiz; Sartori, Francesca; Garcia, Lucia; Ballester, Carmen; Sampol, Antonia; Gutierrez, Antonio] Son Espases Univ Hosp, Hematol Dept, Palma de Mallorca, Balearic Island, Spain; [Cladera, Antonia; Dominguez, Julia; Del Campo, Raquel; Bargay, Joan] Hosp Son Llatzer, Hematol Dept, Palma de Mallorca, Balearic Island, Spain; [Gines, Jordi] Son Espases Univ Hosp, Pharm Dept, Palma de Mallorca, Balearic Island, Spain	Hospital Universitari Son Espases; Hospital Universitari Son Llatzer; Hospital Universitari Son Espases	Gutierrez, A (corresponding author), Son Espases Univ Hosp, Hematol Dept, Palma de Mallorca, Balearic Island, Spain.	antoniom.gutierrez@ssib.es	Gutiérrez, Antonio/AAL-9381-2021; Llàtzer, Son/ABG-1829-2020; garcia, lucia/GXV-8296-2022	Llàtzer, Son/0000-0002-6739-3916; 				Abramson JS, 2010, CANCER-AM CANCER SOC, V116, P4283, DOI 10.1002/cncr.25278; Bassan R, 2015, HAEMATOLOGICA, V100, P786, DOI 10.3324/haematol.2014.123273; Bhojwani D, 2008, LEUKEMIA LYMPHOMA, V49, P1427, DOI 10.1080/10428190802220527; Boehme V, 2009, BLOOD, V113, P3896, DOI 10.1182/blood-2008-10-182253; Chamberlain MC, 2016, J NEURO-ONCOL, V126, P545, DOI 10.1007/s11060-015-1994-8; Cheah CY, 2014, BRIT J CANCER, V111, P1072, DOI 10.1038/bjc.2014.405; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Corazzelli G, 2012, BRIT J HAEMATOL, V156, P234, DOI 10.1111/j.1365-2141.2011.08947.x; Doolittle ND, 2008, BLOOD, V111, P1085, DOI 10.1182/blood-2007-07-101402; Ferreri AJM, 2009, HEMATOL ONCOL, V27, P61, DOI 10.1002/hon.881; Gonzalez-Barca E, 2016, ANN HEMATOL, V95, P893, DOI 10.1007/s00277-016-2648-4; Guirguis HR, 2012, BRIT J HAEMATOL, V159, P39, DOI 10.1111/j.1365-2141.2012.09247.x; HRYNIUK WM, 1969, J CLIN INVEST, V48, P2140, DOI 10.1172/JCI106181; Jahn F, 2015, ONCOLOGY-BASEL, V89, P137, DOI 10.1159/000380913; Jun GT, 2009, COMMON TERMINOLOGY C, P829; Jurczak W, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0520-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Krawczyk K, 2013, POL ARCH MED WEWN, V123, P589, DOI 10.20452/pamw.1968; Kumar A, 2012, CANCER-AM CANCER SOC, V118, P2944, DOI 10.1002/cncr.26588; Kumiega Beata, 2013, Przegl Lek, V70, P187; McMillan A, 2013, BRIT J HAEMATOL, V163, P168, DOI 10.1111/bjh.12509; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pui CH, 2009, SEMIN ONCOL, V36, pS2, DOI 10.1053/j.seminoncol.2009.05.002; Schuitema I, 2015, J INT NEUROPSYCH SOC, V21, P1; Siegal T, 2012, BLOOD REV, V26, P97, DOI 10.1016/j.blre.2011.12.001	25	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2017	12	6							e0179595	10.1371/journal.pone.0179595	http://dx.doi.org/10.1371/journal.pone.0179595			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3KB	28665999	Green Published, Green Submitted, gold			2023-01-03	WOS:000404608700036
J	Prats-Sanchez, L; Martinez-Domeno, A; Camps-Renom, P; Delgado-Mederos, R; Guisado-Alonso, D; Marin, R; Dorado, L; Rudilosso, S; Gomez-Gonzalez, A; Purroy, F; Gomez-Choco, M; Canovas, D; Cocho, D; Garces, M; Abilleira, S; Martin-Fabregas, J				Prats-Sanchez, Luis; Martinez-Domeno, Alejandro; Camps-Renom, Pol; Delgado-Mederos, Raquel; Guisado-Alonso, Daniel; Marin, Rebeca; Dorado, Laura; Rudilosso, Salvatore; Gomez-Gonzalez, Alejandra; Purroy, Francisco; Gomez-Choco, Manuel; Canovas, David; Cocho, Dolores; Garces, Moises; Abilleira, Sonia; Martin-Fabregas, Joan			Risk factors are different for deep and lobar remote hemorrhages after intravenous thrombolysis	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; WHITE-MATTER LESIONS; INTRACEREBRAL HEMORRHAGE; CEREBRAL MICROBLEEDS; SAFE IMPLEMENTATION; THERAPY; CLASSIFICATION; PATHOGENESIS	Background and purpose Remote parenchymal haemorrhage (rPH) after intravenous thrombolysis is defined as hemorrhages that appear in brain regions without visible ischemic damage, remote from the area of ischemia causing the initial stroke symptom. The pathophysiology of rPH is not clear and may be explained by different underlying mechanisms. We hypothesized that rPH may have different risk factors according to the bleeding location. We report the variables that we found associated with deep and lobar rPH after intravenous thrombolysis. Methods This is a descriptive study of patients with ischemic stroke who were treated with intravenous thrombolysis. These patients were included in a multicenter prospective registry. We collected demographic, clinical and radiological data. We evaluated the number and distribution of cerebral microbleeds (CMB) from Magnetic Resonance Imaging. We excluded patients treated endovascularly, patients with parenchymal hemorrhage without concomitant rPH and stroke mimics. We compared the variables from patients with deep or lobar rPH with those with no intracranial hemorrhage. Results We studied 934 patients (mean age 73.9 +/- 12.6 years) and 52.8% were men. We observed rPH in 34 patients (3.6%); 9 (0.9%) were deep and 25 (2.7%) lobar. No hemorrhage was observed in 900 (96.6%) patients. Deep rPH were associated with hypertensive episodes within first 24 hours after intravenous thrombolysis (77.7% vs 23.3%, p<0.001). Lobar rPH were associated with the presence of CMB (53.8% vs 7.9%, p<0.001), multiple (>1) CMB (30.7% vs 4.4%, p = 0.003), lobar CMB (53.8% vs 3.0%, p<0.001) and severe leukoaraiosis (76.9% vs 42%, p = 0.02). Conclusions A high blood pressure within the first 24 hours after intravenous thrombolysis is associated with deep rPH, whereas lobar rPH are associated with imaging markers of amyloid deposition. Thus, our results suggest that deep and lobar rPH after intravenous thrombolysis may have different mechanisms.	[Prats-Sanchez, Luis; Martinez-Domeno, Alejandro; Camps-Renom, Pol; Delgado-Mederos, Raquel; Guisado-Alonso, Daniel; Marin, Rebeca; Martin-Fabregas, Joan] Hosp Santa Creu & Sant Pau, Serv Neurol, Biomed Res Inst, IIB St Pau, Barcelona, Spain; [Dorado, Laura] Hosp Badalona Germans Trias & Pujol, Dept Neurol, Badalona, Spain; [Rudilosso, Salvatore] Hosp Clin Barcelona, Dept Neurol, Barcelona, Spain; [Gomez-Gonzalez, Alejandra] Hosp del Mar, Dept Neurol, Barcelona, Spain; [Purroy, Francisco] Hosp Arnau Vilanova, Dept Neurol, Lleida, Spain; [Gomez-Choco, Manuel] Hosp Moises Broggi, Dept Neurol, St Joan Desp, Spain; [Canovas, David] Hosp Univ Sabadell Corp Sanitaria Parc Taul, Dept Neurol, Sabadell, Spain; [Cocho, Dolores] Univ Granollers, Hosp Gen, Dept Neurol, Granollers, Spain; [Garces, Moises] Hosp Verge de la Cinta, Dept Neurol, Tortosa, Spain; [Abilleira, Sonia] Stroke Programme Agcy Hlth Qual & Assessment Cata, Barcelona, Spain; [Martin-Fabregas, Joan] Univ Autonoma Barcelona, Med Dept, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Hospital of Santa Creu i Sant Pau; Hospital Germans Trias i Pujol; University of Barcelona; Hospital Clinic de Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University Hospital Arnau de Vilanova; Autonomous University of Barcelona	Prats-Sanchez, L (corresponding author), Hosp Santa Creu & Sant Pau, Serv Neurol, Biomed Res Inst, IIB St Pau, Barcelona, Spain.	lpratss@santpau.cat	Purroy, Francisco/D-4538-2009; Gomez-Choco, Manuel/AAA-1958-2021; Rudilosso, Salvatore/B-9265-2018; Guisado-Alonso, Daniel/F-3399-2018	Purroy, Francisco/0000-0002-1808-5968; Gomez-Choco, Manuel/0000-0002-4191-7574; Rudilosso, Salvatore/0000-0002-8775-6884; Martinez-Domeno, Alejandro/0000-0002-9933-3192; Marti-Fabregas, Joan/0000-0001-9229-8649; Cocho, Dolores/0000-0003-2151-6068; Prats Sanchez, Luis Antonio/0000-0002-3192-4631; Abilleira, Sonia/0000-0002-5587-128X; Guisado-Alonso, Daniel/0000-0002-5799-3184; CAMPS-RENOM, POL/0000-0001-6587-6271; GARCES REDONDO, MOISES/0000-0002-1756-5492	Ministery of Health-Institute de Salud Carlos III: RETICS (Redes tematicas de Investigacion Cooperativa) INVICTUS [RD012/0014]; FEDER (Fondo Europeo de Desarrollo Regional)	Ministery of Health-Institute de Salud Carlos III: RETICS (Redes tematicas de Investigacion Cooperativa) INVICTUS; FEDER (Fondo Europeo de Desarrollo Regional)(European Commission)	This work was supported by Ministery of Health-Institute de Salud Carlos III: RETICS (Redes tematicas de Investigacion Cooperativa) INVICTUS RD012/0014, FEDER (Fondo Europeo de Desarrollo Regional). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Ahmed N, 2009, STROKE, V40, P2442, DOI 10.1161/STROKEAHA.109.548602; Charidimou A, 2015, NEUROLOGY, V85, P927, DOI 10.1212/WNL.0000000000001923; Charidimou A, 2015, BRAIN, V138, P2126, DOI 10.1093/brain/awv162; Chen YW, 2006, NEUROLOGY, V67, P83, DOI 10.1212/01.wnl.0000223613.57229.24; Craig SAA, ENHANCED CONTROL HYP; Curtze S, 2016, ANN NEUROL, V80, P593, DOI 10.1002/ana.24760; Derex L, 2008, J NEUROL NEUROSUR PS, V79, P1093, DOI 10.1136/jnnp.2007.133371; Greenberg SM, 2014, LANCET NEUROL, V13, P419, DOI 10.1016/S1474-4422(14)70003-1; Jeon SB, 2009, NEUROLOGY, V73, P1638, DOI 10.1212/WNL.0b013e3181bd110f; Kapeller P, 2003, STROKE, V34, P441, DOI 10.1161/01.STR.0000049766.26453.E9; Kidwell CS, 2002, STROKE, V33, P95, DOI 10.1161/hs0102.101792; Kimura K, 2013, STROKE, V44, P2776, DOI 10.1161/STROKEAHA.113.001778; Ly JV, 2010, ANN NEUROL, V68, P959, DOI 10.1002/ana.22072; Marti-Fabregas J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156992; Matosevic B, 2013, NEUROLOGY, V80, P1216, DOI 10.1212/WNL.0b013e3182897015; Mazya MV, 2014, STROKE, V45, P1657, DOI 10.1161/STROKEAHA.114.004923; Meretoja A, 2012, STROKE, V43, P2592, DOI 10.1161/STROKEAHA.112.661603; Pantoni L, 2014, CEREBROVASC DIS, V37, P5, DOI 10.1159/000356796; Prats-Sanchez L, 2016, STROKE, V47, P2003, DOI 10.1161/STROKEAHA.116.013952; Ruecker M, 2012, NEUROLOGY, V79, P31, DOI 10.1212/WNL.0b013e31825dcdf0; Shoamanesh A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00203; SLOAN MA, 1995, NEUROLOGY, V45, P649, DOI 10.1212/WNL.45.4.649; Trouillas P, 2006, STROKE, V37, P556, DOI 10.1161/01.STR.0000196942.84707.71; Tsivgoulis G, 2016, JAMA NEUROL, V73, P675, DOI 10.1001/jamaneurol.2016.0292	24	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2017	12	6							e0178284	10.1371/journal.pone.0178284	http://dx.doi.org/10.1371/journal.pone.0178284			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY6ZV	28640874	gold, Green Published, Green Submitted			2023-01-03	WOS:000404135800004
J	Wouters, H; Scheper, J; Koning, H; Brouwer, C; Twisk, JW; van der Meer, H; Boersma, F; Zuidema, SU; Taxis, K				Wouters, Hans; Scheper, Jessica; Koning, Hedi; Brouwer, Chris; Twisk, Jos W.; van der Meer, Helene; Boersma, Froukje; Zuidema, Sytse U.; Taxis, Katja			Discontinuing Inappropriate Medication Use in Nursing Home Residents A Cluster Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; OLDER-PEOPLE; ALZHEIMERS-DISEASE; BEERS CRITERIA; SCREENING TOOL; ALERT DOCTORS; DEMENTIA; ADULTS; RISK; HOSPITALIZATION	Background: Inappropriate prescribing is a well-known clinical problem in nursing home residents, but few interventions have focused on reducing inappropriate medication use. Objective: To examine successful discontinuation of inappropriate medication use and to improve prescribing in nursing home residents. Design: Pragmatic cluster randomized controlled trial, with clustering by elder care physicians and their wards. Setting: 59 Dutch nursing home wards for long-term care. Patients: Residents with a life expectancy greater than 4 weeks who consented to treatment with medication. Intervention: Multidisciplinary Multistep Medication Review (3MR) consisting of an assessment of the patient perspective, medical history, critical appraisal of medications, a meeting between the treating elder care physician and the pharmacist, and implementation of medication changes. Measurements: Successful discontinuation of use of at least 1 inappropriate drug (that is, without relapse or severe withdrawal symptoms) and clinical outcomes (neuropsychiatric symptoms, cognitive function, and quality of life) after 4 months of follow-up. Results: Nineteen elder care physicians (33 wards) performed the 3MR, and 16 elder care physicians (26 wards) followed standard procedures. A total of 426 nursing home residents (233 in the intervention group and 193 in the control group) were followed for an average of 144 days (SD, 21). In an analysis of all participants, use of at least 1 inappropriate medication was successfully discontinued for 91 (39.1%) residents in the intervention group versus 57 (29.5%) in the control group (adjusted relative risk, 1.37 [95% CI, 1.02 to 1.75]). Clinical outcomes did not deteriorate between baseline and follow-up. Limitations: The 3MR was done only once. Some withdrawal symptoms or relapses may have been missed. Conclusion: The 3MR is effective in discontinuing inappropriate medication use in frail nursing home residents without a decline in their well-being. Primary Funding Source: Netherlands Organisation for Health Research and Development. Annals.org	[Scheper, Jessica; Koning, Hedi; Brouwer, Chris; van der Meer, Helene; Taxis, Katja] Univ Groningen, Dept PharmacoTherapy Epidemiol & Econ PTEE, Groningen Res Inst Pharm, Fac Sci & Engn, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands; [Wouters, Hans; Boersma, Froukje; Zuidema, Sytse U.] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Bldg 50,POB 196, NL-9700 AD Groningen, Netherlands; [Twisk, Jos W.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Biostat, De Boelelaan 1089a, Amsterdam, Netherlands	University of Groningen; University of Groningen; Vrije Universiteit Amsterdam	Wouters, H (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice & Elderly Care Med, Bldg 50,POB 196, NL-9700 AD Groningen, Netherlands.	j.wouters@umcg.nl; k.taxis@rug.nl	Taxis, Katja/ABE-2637-2021	Taxis, Katja/0000-0001-8539-2004; van der Meer, Helene/0000-0002-3329-3271	Netherlands Organisation for Health Research and Development	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	Netherlands Organisation for Health Research and Development.	Alldred DP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009095.pub3; Bahri O, 2015, J AM GERIATR SOC, V63, P71, DOI 10.1111/jgs.13200; Ballard C, 2005, BMJ-BRIT MED J, V330, P874, DOI 10.1136/bmj.38369.459988.8F; Ballard C, 2008, PLOS MED, V5, P587, DOI 10.1371/journal.pmed.0050076; Bergh S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1566; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Callisaya ML, 2014, J AM GERIATR SOC, V62, P1527, DOI 10.1111/jgs.12925; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Davidoff AJ, 2015, J AM GERIATR SOC, V63, P486, DOI 10.1111/jgs.13320; Devanand DP, 2012, NEW ENGL J MED, V367, P1497, DOI 10.1056/NEJMoa1114058; Farrell B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122246; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frankenthal D, 2014, J AM GERIATR SOC, V62, P1658, DOI 10.1111/jgs.12993; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2007, J CLIN PHARM THER, V32, P113, DOI 10.1111/j.1365-2710.2007.00793.x; Gray SL, 2003, J AM GERIATR SOC, V51, P1563, DOI 10.1046/j.1532-5415.2003.51502.x; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hilmer SN, 2007, ARCH INTERN MED, V167, P781, DOI 10.1001/archinte.167.8.781; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Iyer S, 2008, DRUG AGING, V25, P1021, DOI 10.2165/0002512-200825120-00004; Jansen J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2893; Loganathan M, 2011, AGE AGEING, V40, P150, DOI 10.1093/ageing/afq161; Patterson SM, 2010, J AM GERIATR SOC, V58, P44, DOI 10.1111/j.1532-5415.2009.02617.x; Perri M, 2005, ANN PHARMACOTHER, V39, P405, DOI 10.1345/aph.1E230; Qato DM, 2016, JAMA INTERN MED, V176, P473, DOI 10.1001/jamainternmed.2015.8581; Reeve E, 2015, BRIT J CLIN PHARMACO, V80, P1254, DOI 10.1111/bcp.12732; Ruggiero C, 2010, DRUG AGING, V27, P747, DOI 10.2165/11538240-000000000-00000; Saxton J, 2005, AM J GERIAT PSYCHIAT, V13, P999, DOI 10.1176/appi.ajgp.13.11.999; Scholzel-Dorenbos CJM, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-118; Wallerstedt SM, 2014, BRIT J CLIN PHARMACO, V78, P488, DOI 10.1111/bcp.12351; Wouters H, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006082; Zuidema SU, 2011, INT PSYCHOGERIATR, V23, P1632, DOI 10.1017/S1041610211001438	33	59	61	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2017	167	9					609	+		10.7326/M16-2729	http://dx.doi.org/10.7326/M16-2729			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM1DV	29052691	Green Published			2023-01-03	WOS:000414714700002
J	Caram-Deelder, C; Kreuger, AL; Evers, D; de Vooght, KMK; de Kerkhof, DV; Visser, O; Pequeriaux, NCV; Hudig, F; Zwaginga, JJ; van der Bom, JG; Middelburg, RA				Caram-Deelder, Camila; Kreuger, Aukje L.; Evers, Dorothea; de Vooght, Karen M. K.; de Kerkhof, Daan van; Visser, Otto; Pequeriaux, Nathalie C. V.; Hudig, Francisca; Zwaginga, Jaap Jan; van der Bom, Johanna G.; Middelburg, Rutger A.			Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LUNG INJURY; CARDIAC-SURGERY; SEX; SURVIVAL; CELLS	IMPORTANCE Transfusion of red blood cells from female donors has been associated with increased mortality in male recipients. OBJECTIVE To quantify the association between red blood cell transfusion from female donors with and without a history of pregnancy and mortality of red blood cell recipients. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of first-time transfusion recipients at 6 major Dutch hospitals enrolled from May 30, 2005, to September 1, 2015; the final follow-up date was September 1, 2015. The primary analysis was the no-donor-mixture cohort (ie, either all red blood cell transfusions exclusively from male donors, or all exclusively from female donors without a history of pregnancy, or all exclusively from female donors with a history of pregnancy). The association between mortality and exposure to transfusions from ever-pregnant or never-pregnant female donors was analyzed using life tables and time-varying Cox proportional hazards models. EXPOSURES Red blood cell transfusions from ever-pregnant or never-pregnant female donors, compared with red blood cell transfusions from male donors. MAIN OUTCOMES AND MEASURES All-cause mortality during follow-up. RESULTS The cohort for the primary analyses consisted of 31 118 patients (median age, 65 [interquartile range, 42-77] years; 52% female) who received 59 320 red blood cell transfusions exclusively from 1 of 3 types of donors (88% male; 6% ever-pregnant female; and 6% never-pregnant female). The number of deaths in this cohort was 3969 (13% mortality). For male recipients of red blood cell transfusions, all-cause mortality rates after a red blood cell transfusion from an ever-pregnant female donor vs male donor were 101 vs 80 deaths per 1000 person-years (time-dependent "per transfusion" hazard ratio [HR] for death, 1.13 [95% CI, 1.01-1.26]). For receipt of transfusion from a never-pregnant female donor vs male donor, mortality rates were 78 vs 80 deaths per 1000 person-years (HR, 0.93 [95% CI, 0.81-1.06]). Among female recipients of red blood cell transfusions, mortality rates for an ever-pregnant female donor vs male donor were 74 vs 62 per 1000 person-years (HR, 0.99 [95% CI, 0.87 to 1.13]); for a never-pregnant female donor vs male donor, mortality rates were 74 vs 62 per 1000 person-years (HR, 1.01 [95% CI, 0.88-1.15]). CONCLUSIONS AND RELEVANCE Among patients who received red blood cell transfusions, receipt of a transfusion from an ever-pregnant female donor, compared with a male donor, was associated with increased all-cause mortality among male recipients but not among female recipients. Transfusions from never-pregnant female donors were not associated with increased mortality among male or female recipients. Further research is needed to replicate these findings, determine their clinical significance, and identify the underlying mechanism.	[Caram-Deelder, Camila; Kreuger, Aukje L.; Evers, Dorothea; Zwaginga, Jaap Jan; van der Bom, Johanna G.; Middelburg, Rutger A.] Sanquin Res, Ctr Clin Transfus Res, Leiden, Netherlands; [Caram-Deelder, Camila; Kreuger, Aukje L.; van der Bom, Johanna G.; Middelburg, Rutger A.] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands; [Evers, Dorothea; Zwaginga, Jaap Jan] Leiden Univ, Dept Immunohaematol & Blood Transfus, Med Ctr, Leiden, Netherlands; [de Vooght, Karen M. K.] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands; [de Kerkhof, Daan van] Catharina Hosp, Dept Clin Chem & Haematol, Eindhoven, Netherlands; [Visser, Otto] Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands; [Pequeriaux, Nathalie C. V.] Jeroen Bosch Hosp, Dept Clin Chem & Haematol, Shertogenbosch, Netherlands; [Hudig, Francisca] Haga Teaching Hosp, LabWest, The Hague, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Catharina Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Jeroen Bosch Ziekenhuis; Haga Hospital	Middelburg, RA (corresponding author), Plesmanlaan 1a, NL-2333 BZ Leiden, Netherlands.	r.a.middelburg@lumc.nl	Evers, Dorothea/W-4035-2017; Middelburg, Rutger/N-9134-2017; van der Bom, Johanna G./G-1965-2018	Middelburg, Rutger/0000-0002-6545-7277; Caram-Deelder, Camila/0000-0003-3161-5684; van der Bom, Johanna G./0000-0001-9095-2475	Dutch Ministry of Health, Welfare and Sports [PPOC-11-005]	Dutch Ministry of Health, Welfare and Sports	This study was funded by the Dutch Ministry of Health, Welfare and Sports (grant PPOC-11-005).	Bandyopadhyay S, 2017, BLOOD TRANSFUS-ITALY, V15, P158, DOI 10.2450/2017.0349-16; Barty RL, 2015, AABB ANN M 2015 OCT; Bjursten H, 2016, J THORAC CARDIOV SUR, V152, P223, DOI 10.1016/j.jtcvs.2015.12.022; Chasse M, 2016, JAMA INTERN MED, V176, P1307, DOI 10.1001/jamainternmed.2016.3324; Chasse M, 2016, TRANSFUS MED REV, V30, P69, DOI 10.1016/j.tmrv.2016.01.002; Desmarets M, 2016, TRANSFUSION, V56, P1213, DOI 10.1111/trf.13537; Evers D, 2016, LANCET HAEMATOL, V3, pE284, DOI 10.1016/S2352-3026(16)30019-9; Middelburg RA, 2011, VOX SANG, V101, P221, DOI 10.1111/j.1423-0410.2011.01487.x; Middelburg RA, 2011, VOX SANG, V100, P327, DOI 10.1111/j.1423-0410.2010.01420.x; Middelburg RA, 2011, TRANSFUSION, V51, P2111, DOI 10.1111/j.1537-2995.2011.03118.x; Middelburg RA, 2010, TRANSFUSION, V50, P2447, DOI 10.1111/j.1537-2995.2010.02715.x; Pfuntner A., 2011, MOST FREQUENT PROCED; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Stata Statistical Software, 2015, VERS 14 1; Toy P, 2005, CRIT CARE MED, V33, P721, DOI 10.1097/01.CCM.0000159849.94750.51; West FB, 2013, EXPERT REV HEMATOL, V6, P265, DOI [10.1586/EHM.13.31, 10.1586/ehm.13.31]; Zalpuri S, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001150	17	34	34	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2017	318	15					1471	1478		10.1001/jama.2017.14825	http://dx.doi.org/10.1001/jama.2017.14825			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK0RM	29049654	Green Published			2023-01-03	WOS:000413187300019
J	Ding, L; Wo, LK; Du, ZY; Tang, LH; Song, ZY; Dou, XB				Ding, Lei; Wo, Like; Du, Zhongyan; Tang, Lihua; Song, Zhenyuan; Dou, Xiaobing			Danshen protects against early-stage alcoholic liver disease in mice via inducing PPAR alpha activation and subsequent 4-HNE degradation	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; GLUTATHIONE S-TRANSFERASES; LIPID-METABOLISM; OXIDATIVE STRESS; RECEPTORS PPARS; INJURY; CELLS; CONTRIBUTES; INHIBITION; MODULATION	Alcoholic liver disease (ALD) is a type of chronic liver disease caused by long-term heavy ethanol consumption. Danshen is one of the most commonly used substances in traditional Chinese medicine and has been widely used for the treatment of various diseases, and most frequently, the ALD. The current study aims to determine the potential beneficial effect of Danshen administration on ALD and to clarify the underlying molecular mechanisms. Danshen administration improved liver pathologies of ALD, attenuated alcohol-induced increment of hepatic 4-Hydroxynonenal (4-HNE) formation, and prevented hepatic Peroxisome proliferators activated receptor alpha (PPAR alpha) suppression in response to chronic alcohol consumption. Cell culture studies revealed that both hepatoprotective effect and increased intracellular 4-HNE clearance instigated by Danshen supplementation are PPAR alpha-dependent. In conclusion, Danshen administration can protect against ALD via inducing PPAR alpha activation and subsequent 4-HNE degradation.	[Ding, Lei; Tang, Lihua; Dou, Xiaobing] Zhejiang Chinese Med Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China; [Wo, Like] Zhejiang Prov Hosp Tradit Chinese Med, Hangzhou, Zhejiang, Peoples R China; [Du, Zhongyan] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China; [Song, Zhenyuan] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dou, XB (corresponding author), Zhejiang Chinese Med Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China.; Song, ZY (corresponding author), Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA.	song2008@uic.edu; xbdou77@gmail.com			Natural Science Foundation of China [81473393, 81470845]; National Science Fund for Distinguished Young Scholars [LR15H030003]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	This work was supported by the Natural Science Foundation of China [grant numbers 81473393 to XD, 81470845 to ZS], http://www.nsfc.gov.cn/; and the National Science Fund for Distinguished Young Scholars [grant number LR15H030003 to XD], http://www.nsfc.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balogh LM, 2011, DRUG METAB REV, V43, P165, DOI 10.3109/03602532.2011.558092; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; CHAIT A, 1972, LANCET, V2, P62; Cheng JZ, 2001, BIOCHEM BIOPH RES CO, V282, P1268, DOI 10.1006/bbrc.2001.4707; Cheng TO, 2006, INT J CARDIOL, V113, P437, DOI 10.1016/j.ijcard.2005.10.026; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Demozay D, 2008, DIABETES, V57, P1216, DOI 10.2337/db07-0389; Dey A, 2006, HEPATOLOGY, V43, pS63, DOI 10.1002/hep.20957; Donohue TM, 2007, WORLD J GASTROENTERO, V13, P4974; Dou XB, 2012, AM J PATHOL, V181, P1702, DOI 10.1016/j.ajpath.2012.08.004; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; Fischer M, 2003, J BIOL CHEM, V278, P27997, DOI 10.1074/jbc.M302140200; Gallagher EP, 2007, TOXICOL IN VITRO, V21, P1365, DOI 10.1016/j.tiv.2007.04.004; Gloerich J, 2006, MOL GENET METAB, V89, P111, DOI 10.1016/j.ymgme.2006.05.009; Guo XH, 2009, CHINESE MED CLIN, V9, P13; Han BK, 2008, EUROPEAN J PHARM, V601, P30; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Katunga LA, 2015, MOL METAB, V4, P493, DOI 10.1016/j.molmet.2015.04.001; Kharbanda KK, 2009, MOL CELL BIOCHEM, V327, P75, DOI 10.1007/s11010-009-0044-2; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1002/hep.1840130211; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krengel U, FEBS LETT; Li HH, 2014, ALCOHOL CLIN EXP RES, V38, P1520, DOI 10.1111/acer.12424; LIEBER CS, 1970, SCIENCE, V170, P78, DOI 10.1126/science.170.3953.78; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Miyamura M, 2016, YAKUGAKU ZASSHI, V136, P579, DOI 10.1248/yakushi.15-00264-3; Petersen DR, 2005, ALCOHOL, V35, P243, DOI 10.1016/j.alcohol.2005.03.013; Reichard JF, 2000, BIOCH BIOPHYSICA ACT, V1487; Ronis MJJ, 2015, AM J PHYSIOL-GASTR L, V308, pG403, DOI 10.1152/ajpgi.00154.2014; Rouach H, 1997, HEPATOLOGY, V25, P351; Sampey BP, 2007, J BIOL CHEM, V282, P1925, DOI 10.1074/jbc.M610602200; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Shearn CT, 2012, FREE RADICAL BIO MED, V53, P1, DOI 10.1016/j.freeradbiomed.2012.04.021; Singhal SS, 2015, TOXICOL APPL PHARM, V289, P361, DOI 10.1016/j.taap.2015.10.006; SINGHAL SS, 1995, INVEST OPHTH VIS SCI, V36, P142; Smathers RL, 2011, CHEM-BIOL INTERACT, V192, P107, DOI 10.1016/j.cbi.2011.02.021; Song ZY, 2004, HEPATOLOGY, V40, P989, DOI 10.1002/hep.20412; Wu D, 2009, SEM LIV DIS; Zhang Y, 2012, PHARM RES-DORDR, V29, P1595, DOI 10.1007/s11095-012-0670-3	39	15	16	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2017	12	10							e0186357	10.1371/journal.pone.0186357	http://dx.doi.org/10.1371/journal.pone.0186357			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ4ZX	29020055	Green Published, gold, Green Submitted			2023-01-03	WOS:000412754400094
J	Piao, L; Fang, YH; Kubler, MM; Donnino, MW; Sharp, WW				Piao, Lin; Fang, Yong-Hu; Kubler, Manfred M.; Donnino, Michael W.; Sharp, Willard W.			Enhanced pyruvate dehydrogenase activity improves cardiac outcomes in a murine model of cardiac arrest	PLOS ONE			English	Article							GLUCOSE-OXIDATION; INDUCED HYPOTHERMIA; MILD HYPOTHERMIA; DICHLOROACETATE; RESUSCITATION; REPERFUSION; INHIBITION; METABOLISM; ISCHEMIA; SURVIVAL	Rationale Post-ischemic changes in cellular metabolism alter myocardial and neurological function. Pyruvate dehydrogenase (PDH), the limiting step in mitochondrial glucose oxidation, is inhibited by increased expression of PDH kinase (PDK) during ischemia/reperfusion injury. This results in decreased utilization of glucose to generate cellular ATP. Post-cardiac arrest (CA) hypothermia improves outcomes and alters metabolism, but its influence on PDH and PDK activity following CA are unknown. We hypothesized that therapeutic hypothermia (TH) following CA is associated with the inhibition of PDK activity and increased PDH activity. We further hypothesized that an inhibitor of PDK activity, dichloroacetate (DCA), would improve PDH activity and post-CA outcomes. Methods and results Anesthetized and ventilated adult female C57BL/6 wild-type mice underwent a 12-minute KCl-induced CA followed by cardiopulmonary resuscitation. Compared to normothermic (37 E C) CA controls, administering TH (30 degrees C) improved overall survival (72-hour survival rate: 62.5% vs. 28.6%, P<0.001), post-resuscitation myocardial function (ejection fraction: 50.9 +/- 3.1% vs. 27.2 +/- 2.0%, P<0.001; aorta systolic pressure: 132.7 +/- 7.3 vs. 72.3 +/- 3.0 mmHg, P<0.001), and neurological scores at 72-hour post CA (9.5 +/- 1.3 vs. 5.4 +/- 1.3, P<0.05). In both heart and brain, CA increased lactate concentrations (1.9-fold and 3.1-fold increase, respectively, P<0.01), decreased PDH enzyme activity (24% and 50% reduction, respectively, P<0.01), and increased PDK protein expressions (1.2-fold and 1.9-fold, respectively, P<0.01). In contrast, post-CA treatment with TH normalized lactate concentrations (P<0.01 and P<0.05) and PDK expressions (P<0.001 and P<0.05), while increasing PDH activity (P<0.01 and P<0.01) in both the heart and brain. Additionally, treatment with DCA (0.2 mg/g body weight) 30 min prior to CA improved both myocardial hemodynamics 2 hours post-CA (aortic systolic pressure: 123 +/- 3 vs. 96 +/- 4 mmHg, P<0.001) and 72-hour survival rates (50% vs. 19%, P<0.05) in normothermic animals. Conclusions Enhanced PDH activity in the setting of TH or DCA administration is associated with improved post-CA resuscitation outcomes. PDH is a promising therapeutic target for improving post-CA outcomes.	[Piao, Lin; Fang, Yong-Hu; Kubler, Manfred M.; Sharp, Willard W.] Univ Chicago, Sect Emergency Med, Chicago, IL 60637 USA; [Piao, Lin; Fang, Yong-Hu; Kubler, Manfred M.; Sharp, Willard W.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Internal Med, Boston, MA 02215 USA	University of Chicago; University of Chicago; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Sharp, WW (corresponding author), Univ Chicago, Sect Emergency Med, Chicago, IL 60637 USA.; Sharp, WW (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	wsharp@medicine.bsd.uchicago.edu	Sharp, Willard/AAB-9972-2020	Sharp, Willard/0000-0002-7175-3523	NIH [R01HL133675]; University of Chicago Women's Board; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL133675] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago Women's Board; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by funding from NIH grant R01HL133675 and from the University of Chicago Women's Board.; This work was supported by funding from NIH grant R01HL133675 and from the University of Chicago Women's Board.	Azam MA, 2015, AM J PHYSIOL-HEART C, V309, pH1543, DOI 10.1152/ajpheart.00404.2015; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Fang YH, 2012, J MOL MED, V90, P31, DOI 10.1007/s00109-011-0804-9; Fiskum G, 2008, ANN NY ACAD SCI, V1147, P129, DOI 10.1196/annals.1427.026; Gilbert NF, 2002, ANN THORAC SURG, V74, P1208, DOI 10.1016/S0003-4975(02)03873-0; GINSHAW SL, 1988, ANN EMERG MED, V17, P473, DOI 10.1016/S0196-0644(88)80239-7; Gorecka M, 2016, IRISH IR J MED SCI; Holzer M, 2002, NEW ENGL J MED, V346, P549; Huang CH, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0516-3; Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7; Korvald C, 2000, AM J PHYSIOL-HEART C, V278, pH1345, DOI 10.1152/ajpheart.2000.278.4.H1345; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LEWANDOWSKI ED, 1995, CIRCULATION, V91, P2071, DOI 10.1161/01.CIR.91.7.2071; Li J, 2015, AM J PHYSIOL-HEART C, V308, pH1414, DOI 10.1152/ajpheart.00748.2014; Makino J, 2005, CRIT CARE, V9, pR357, DOI 10.1186/cc3714; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Masoud WGT, 2014, CARDIOVASC RES, V101, P30, DOI 10.1093/cvr/cvt216; Ning XH, 2007, AM J PHYSIOL-HEART C, V293, pH2119, DOI 10.1152/ajpheart.00123.2007; Piao L, 2013, J MOL MED, V91, P333, DOI 10.1007/s00109-012-0982-0; Piao L, 2010, J MOL MED, V88, P1011, DOI 10.1007/s00109-010-0679-1; PULSINELLI WA, 1982, ANN NEUROL, V11, P499, DOI 10.1002/ana.410110510; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Shao ZH, 2010, AM J PHYSIOL-HEART C, V298, pH2164, DOI 10.1152/ajpheart.00994.2009; Sharp Willard W, 2015, Crit Care Med, V43, pe38, DOI 10.1097/CCM.0000000000000817; SHEU KFR, 1985, ANN NEUROL, V17, P444; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Sun WQ, 2015, LIFE SCI, V121, P97, DOI 10.1016/j.lfs.2014.11.030; Sun YY, 2016, ONCOTARGET, V7, P31708, DOI 10.18632/oncotarget.9150; Taniguchi M, 2001, AM J PHYSIOL-HEART C, V280, pH1762, DOI 10.1152/ajpheart.2001.280.4.H1762; Ussher JR, 2012, CARDIOVASC RES, V94, P359, DOI 10.1093/cvr/cvs129; Weinberg Guy L, 2007, Expert Rev Cardiovasc Ther, V5, P135, DOI 10.1586/14779072.5.2.135; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; Zhang XW, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1133-0; Zhao DH, 2008, RESUSCITATION, V77, P242, DOI 10.1016/j.resuscitation.2007.10.015; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	39	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0185046	10.1371/journal.pone.0185046	http://dx.doi.org/10.1371/journal.pone.0185046			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH7CN	28934276	Green Published, Green Submitted, gold			2023-01-03	WOS:000411339900080
J	Kim, Y; Wu, AG; Jaja-Chimedza, A; Graf, BL; Waterman, C; Verzi, MP; Raskin, I				Kim, Youjin; Wu, Alex G.; Jaja-Chimedza, Asha; Graf, Brittany L.; Waterman, Carrie; Verzi, Michael P.; Raskin, Ilya			Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; DEXTRAN SULFATE SODIUM; MOUSE MODEL; PHENETHYL ISOTHIOCYANATE; OXIDATIVE STRESS; CLINICAL-ASPECTS; GENE-EXPRESSION; OLEIFERA LEAVES; SULFORAPHANE	Moringa (Moringa oleifera Lam.) seed extract (MSE) has anti-inflammatory and antioxidant activities. We investigated the effects of MSE enriched in moringa isothiocyanate-1 (MIC-1), its putative bioactive, on ulcerative colitis (UC) and its anti-inflammatory/antioxidant mechanism likely mediated through Nrf2-signaling pathway. Dextran sulfate sodium (DSS)-induced acute (n = 8/group; 3% DSS for 5 d) and chronic (n = 6/group; cyclic rotations of 2.5% DSS/water for 30 d) UC was induced in mice that were assigned to 4 experimental groups: healthy control (water/vehicle), disease control (DSS/vehicle), MSE treatment (DSS/MSE), or 5-aminosalicyic acid (5-ASA) treatment (positive control; DSS/5-ASA). Following UC induction, water (vehicle), 150 mg/kg MSE, or 50 mg/kg 5-ASA were orally administered for 1 or 2 wks. Disease activity index (DAI), spleen/colon sizes, and colonic histopathology were measured. From colon and/or fecal samples, pro-inflammatory biomarkers, tight-junction proteins, and Nrf2-mediated enzymes were analyzed at protein and/or gene expression levels. Compared to disease control, MSE decreased DAI scores, and showed an increase in colon lengths and decrease in colon weight/length ratios in both UC models. MSE also reduced colonic inflammation/damage and histopathological scores (modestly) in acute UC. MSE decreased colonic secretions of pro-inflammatory keratinocyte-derived cytokine (KC), tumor necrosis factor (TNF)-alpha, nitric oxide (NO), and myeloperoxidase (MPO) in acute and chronic UC; reduced fecal lipocalin-2 in acute UC; downregulated gene expression of pro-inflammatory interleukin (IL)-1, IL-6, TNF-alpha, and inducible nitric oxide synthase (iNOS) in acute UC; upregulated expression of claudin-1 and ZO-1 in acute and chronic UC; and upregulated GSTP1,an Nrf2-mediated phase II detoxifying enzyme, in chronic UC. MSE was effective in mitigating UC symptoms and reducing UC-induced colonic pathologies, likely by suppressing proinflammatory biomarkers and increasing tight-junction proteins. This effect is consistent with Nrf2-mediated anti-inflammatory/antioxidant signaling pathway documented for other isothiocyanates similar to MIC-1. Therefore, MSE, enriched with MIC-1, may be useful in prevention and treatment of UC.	[Kim, Youjin] Nutrasorb LLC, Freehold, NJ 07728 USA; [Kim, Youjin; Jaja-Chimedza, Asha; Graf, Brittany L.; Raskin, Ilya] Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA; [Wu, Alex G.; Verzi, Michael P.] Rutgers State Univ, Dept Genet, Piscataway Township, NJ USA; [Wu, Alex G.; Verzi, Michael P.] Rutgers State Univ, Human Genet Inst New Jersey, Piscataway Township, NJ USA; [Waterman, Carrie] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of California System; University of California Davis	Kim, Y (corresponding author), Nutrasorb LLC, Freehold, NJ 07728 USA.; Kim, Y (corresponding author), Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA.	youjin@nutrasorb.com			National Institute of Health National Center for Complementary and Integrative Health (NIH-NCCIH) [5R43AT008628-02]; NIH-NCCIH [P50 AT002776-06]; NIH Office of Dietary Supplements (NIH-ODS); Botanical Dietary Supplements Research Center (BDSRC) of Pennington Biomedical Research Center; NIH training grant [T32: 5T32AT004094]; FOGARTY INTERNATIONAL CENTER [K01TW009987] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT004094, P50AT002776, R43AT008628] Funding Source: NIH RePORTER	National Institute of Health National Center for Complementary and Integrative Health (NIH-NCCIH); NIH-NCCIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Office of Dietary Supplements (NIH-ODS); Botanical Dietary Supplements Research Center (BDSRC) of Pennington Biomedical Research Center; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	YK salary was paid by a SBIR grant # 5R43AT008628-02 from the National Institute of Health National Center for Complementary and Integrative Health (NIH-NCCIH), funding Nutrasorb, LLC. IR receives consulting income from Nutrasorb, LLC. IR was partially funded by a grant # 2-P50 AT002776-06 from the NIH-NCCIH and NIH Office of Dietary Supplements (NIH-ODS), funding the Botanical Dietary Supplements Research Center (BDSRC) of Pennington Biomedical Research Center, and AJ by an NIH training grant (# T32: 5T32AT004094). The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; Bennett RN, 2003, J AGR FOOD CHEM, V51, P3546, DOI 10.1021/jf0211480; Boddupalli Sekhar, 2012, Frontiers in Genetics, V3, P7, DOI 10.3389/fgene.2012.00007; Boyanapalli SSS, 2014, CHEM RES TOXICOL, V27, P2036, DOI 10.1021/tx500234h; Brunelli D, 2010, BIOCHEM PHARMACOL, V79, P1141, DOI 10.1016/j.bcp.2009.12.008; Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104; Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328; Cheenpracha S, 2010, BIOORGAN MED CHEM, V18, P6598, DOI 10.1016/j.bmc.2010.03.057; Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8; Choi K, 2011, GASTROENTEROLOGY, V141, P1293, DOI 10.1053/j.gastro.2011.06.074; Edalat M, 2004, HISTOCHEM CELL BIOL, V122, P151, DOI 10.1007/s00418-004-0688-7; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Fahey J., 2005, TREES LIFE J; Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193; Frink M, 2007, SHOCK, V28, P576, DOI 10.1097/shk.0b013e31814b8e0d; Fuentes Francisco, 2015, Curr Pharmacol Rep, V1, P179; Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216, DOI 10.1152/ajpgi.2001.281.1.G216; Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002; Ho E, 2013, REDOX BIOL, V1, P483, DOI 10.1016/j.redox.2013.07.006; HOLLANDER D, 1986, ANN INTERN MED, V105, P883, DOI 10.7326/0003-4819-105-6-883; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Islam MS, 2008, BRIT J PHARMACOL, V154, P812, DOI 10.1038/bjp.2008.137; Jaja-Chimedza A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182658; Jones DT, 2008, AM J GASTROENTEROL, V103, P2382, DOI 10.1111/j.1572-0241.2008.01999.x; Jurenka JS, 2009, ALTERN MED REV, V14, P141; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678; Laroui H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032084; Lean QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128453; Leone A, 2015, INT J MOL SCI, V16, P12791, DOI 10.3390/ijms160612791; Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017; Lirk Philipp, 2002, Current Drug Targets - Inflammation and Allergy, V1, P89, DOI 10.2174/1568010023344913; Lu M, 2016, MED RES REV, P1; Maillard M. H., 2010, INFLAMM BOWEL DIS, P119; Mbikay M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00024; Mikhailov TA, 2009, WORLD J GASTROENTERO, V15, P270, DOI 10.3748/wjg.15.270; Murphy CT, 2010, CLIN EXP IMMUNOL, V162, P188, DOI 10.1111/j.1365-2249.2010.04234.x; Murthy S, 2002, INFLAMM RES, V51, P522, DOI 10.1007/PL00012423; Muzes G, 2012, WORLD J GASTROENTERO, V18, P5848, DOI 10.3748/wjg.v18.i41.5848; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nikolaus S, 2007, GASTROENTEROLOGY, V133, P1670, DOI 10.1053/j.gastro.2007.09.001; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Poritz LS, 2007, J SURG RES, V140, P12, DOI 10.1016/j.jss.2006.07.050; Rutgeerts P, 2009, GASTROENTEROLOGY, V136, P1182, DOI 10.1053/j.gastro.2009.02.001; Saxena Arpit, 2014, J Tradit Complement Med, V4, P203, DOI 10.4103/2225-4110.139111; Schulze HA, 2008, GENES IMMUN, V9, P240, DOI 10.1038/gene.2008.11; Stallhofer J, 2015, INFLAMM BOWEL DIS, V21, P2327, DOI 10.1097/MIB.0000000000000515; Theiss AL, 2007, FASEB J, V21, P197, DOI 10.1096/fj.06-6801com; Tumer TB, 2015, J AGR FOOD CHEM, V63, P1505, DOI 10.1021/jf505014n; Vijay-Kumar M, 2007, J CLIN INVEST, V117, P3909, DOI 10.1172/JCI33084; Wagner AE, 2013, J NUTR BIOCHEM, V24, P2085, DOI 10.1016/j.jnutbio.2013.07.009; Waterman C, 2015, MOL NUTR FOOD RES, V59, P1013, DOI 10.1002/mnfr.201400679; Waterman C, 2014, PHYTOCHEMISTRY, V103, P114, DOI 10.1016/j.phytochem.2014.03.028; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41	55	38	39	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2017	12	9							e0184709	10.1371/journal.pone.0184709	http://dx.doi.org/10.1371/journal.pone.0184709			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH3OQ	28922365	Green Submitted, gold, Green Published			2023-01-03	WOS:000411059300023
J	Maddocks, M; Lovell, N; Booth, S; Man, WDC; Higginson, IJ				Maddocks, Matthew; Lovell, Natasha; Booth, Sara; Man, William D-C; Higginson, Irene J.			Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease	LANCET			English	Article							OF-LIFE CARE; REFRACTORY CHRONIC COUGH; END-STAGE COPD; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; LUNG-CANCER; DOUBLE-BLIND; RESPIRATORY-DISEASES; EXERCISE CAPACITY; SELF-MANAGEMENT	People with advanced chronic obstructive pulmonary disease (COPD) have distressing physical and psychological symptoms, often have limited understanding of their disease, and infrequently discuss end-of-life issues in routine clinical care. These are strong indicators for expert multidisciplinary palliative care, which incorporates assessment and management of symptoms and concerns, patient and caregiver education, and sensitive communication to elicit preferences for care towards the end of life. The unpredictable course of COPD and the difficulty of predicting survival are barriers to timely referral and receipt of palliative care. Early integration of palliative care with respiratory, primary care, and rehabilitation services, with referral on the basis of the complexity of symptoms and concerns, rather than prognosis, can improve patient and caregiver outcomes. Models of integrated working in COPD could include: services triggered by troublesome symptoms such as refractory breathlessness; short-term palliative care; and, in settings with limited access to palliative care, consultation only in specific circumstances or for the most complex patients.	[Maddocks, Matthew; Lovell, Natasha; Higginson, Irene J.] Kings Coll London, Cicely Saunders Inst Palliat Care Policy & Rehabi, London, England; [Booth, Sara] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Palliat Med, Cambridge, England; [Booth, Sara] Univ Cambridge, Dept Oncol, Cambridge, England; [Man, William D-C] Royal Brompton & Harefield NHS Fdn Trust, Harefield Hosp, Harefield Pulm Rehabil & Muscle Res Lab, London, England	University of London; King's College London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Higginson, IJ (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London SE5 9PJ, England.	irene.higginson@kcl.ac.uk	Harding, Richard/G-9729-2012; Lovell, Natasha/F-8536-2016; Higginson, Irene Julie/C-7309-2012	Higginson, Irene Julie/0000-0002-3687-1313; Lovell, Natasha/0000-0001-6594-799X; Maddocks, Matthew/0000-0002-0189-0952; Man, William/0000-0002-3782-659X	Cicely Saunders International; National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLARHC) South London at King's College Hospital NHS Foundation Trust; NIHR Health Services & Delivery Research grant [NIHR HSDR 16/02/18]; NIHR CLARHC South London; NIHR CLAHRC for Northwest London Breathlessness Theme; MRC [G1002113] Funding Source: UKRI; Marie Curie [MCCC-RP-15-A18859] Funding Source: researchfish; Medical Research Council [G1002113] Funding Source: researchfish; National Institute for Health Research [NIHR-CTF-2013-02-009, 16/02/18, CDF-2017-10-009, PB-PG-0213-30003, CTF-01-12-04, PDF-2011-04-048, ACF-2011-17-019] Funding Source: researchfish	Cicely Saunders International; National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLARHC) South London at King's College Hospital NHS Foundation Trust; NIHR Health Services & Delivery Research grant; NIHR CLARHC South London; NIHR CLAHRC for Northwest London Breathlessness Theme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Marie Curie(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by Cicely Saunders International and the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLARHC) South London at King's College Hospital NHS Foundation Trust. Cicely Saunders International support NL and funded much of the work on breathlessness upon which text in this review is based. MM is supported by an NIHR Health Services & Delivery Research grant (NIHR HSDR 16/02/18) and NIHR CLARHC South London. WD-CM is part funded by NIHR CLAHRC for Northwest London Breathlessness Theme. IJH is an NIHR Emeritus Senior Investigator. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We thank Surinder Birring (King's College Hospital) for feedback on text relating to cough.	Abdulqawi R, 2015, LANCET, V385, P1198, DOI 10.1016/S0140-6736(14)61255-1; Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; Ahmadi Z, 2016, INT J CHRONIC OBSTR, V11, P2651, DOI 10.2147/COPD.S112484; Albert RK, 2016, NEW ENGL J MED, V375, P1617, DOI 10.1056/NEJMoa1604344; Ali Zohal Mohammad, 2013, Glob J Health Sci, V5, P150, DOI 10.5539/gjhs.v5n3p150; Andreassen P, 2017, BMJ SUPPORT PALLIAT, V7, P335, DOI 10.1136/bmjspcare-2015-000886; [Anonymous], 2017, LANCET, V389, P574, DOI 10.1016/S0140-6736(17)30327-6; Au DH, 2012, CHEST, V141, P726, DOI 10.1378/chest.11-0362; Back AL, 2006, J CLIN ONCOL, V24, P4209, DOI 10.1200/JCO.2006.06.007; Baltzan MA, 2011, CHRON RESP DIS, V8, P119, DOI 10.1177/1479972310396737; Barnes H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011008.pub2; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bausewein C, 2010, J PALLIAT MED, V13, P1109, DOI 10.1089/jpm.2010.0068; Beernaert K, 2013, RESP MED, V107, P1731, DOI 10.1016/j.rmed.2013.06.003; Benzo RP, 2016, ANN AM THORAC SOC, V13, P10, DOI 10.1513/AnnalsATS.201508-490OC; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Birring SS, 2017, PULM PHARMACOL THER, V47, P84, DOI 10.1016/j.pupt.2017.04.001; Blinderman CD, 2009, J PAIN SYMPTOM MANAG, V38, P115, DOI 10.1016/j.jpainsymman.2008.07.006; Booth Sara, 2006, Palliat Support Care, V4, P287; Breslin E, 1998, CHEST, V114, P958, DOI 10.1378/chest.114.4.958; Brighton LJ, 2016, POSTGRAD MED J, V92, P466, DOI 10.1136/postgradmedj-2015-133368; Buckingham S, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.20; Budhiraja R, 2012, SLEEP, V35, P369, DOI 10.5665/sleep.1698; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Cherny NI., 2015, OXFORD TXB PALLIATIV, V6; Chin C, 2016, POSTGRAD MED J, V92, P393, DOI 10.1136/postgradmedj-2015-133578; Chochinov HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147607; Chochinov HM, 2011, LANCET ONCOL, V12, P753, DOI 10.1016/S1470-2045(11)70153-X; Chochinov HM, 2002, LANCET, V360, P2026, DOI 10.1016/S0140-6736(02)12022-8; Claessens MT, 2000, J AM GERIATR SOC; Cohen J, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0017-y; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Coventry PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060532; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; Curtis JR, 2008, J PALLIAT MED, V11, P610, DOI 10.1089/jpm.2007.0209; Curtis JR, 2004, EUR RESPIR J, V24, P200, DOI 10.1183/09031936.04.00010104; Disler RT, 2014, J PAIN SYMPTOM MANAG, V48, P1182, DOI 10.1016/j.jpainsymman.2014.03.009; Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC; Donesky-Cuenco D, 2009, J ALTERN COMPLEM MED, V15, P225, DOI 10.1089/acm.2008.0389; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Edmonds P, 2001, PALLIATIVE MED, V15, P287, DOI 10.1191/026921601678320278; Ekstrom M, 2018, THORAX, V73, P88, DOI 10.1136/thoraxjnl-2016-209868; Farquhar M., 2016, PALLIATIVE CARE RESP; Farquhar M, 2017, CURR OPIN SUPPORT PA, V11, P165, DOI 10.1097/SPC.0000000000000281; Farquhar M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177081; Farquhar MC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1304-6; Ferreira IM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000998.pub3; Fishman A, 2003, NEW ENGL J MED, V348, P2059; FLENLEY DC, 1981, LANCET, V1, P681; Furness S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008934.pub2; Galbraith S, 2010, J PAIN SYMPTOM MANAG, V39, P831, DOI 10.1016/j.jpainsymman.2009.09.024; Giacomini M, 2012, Ont Health Technol Assess Ser, V12, P1; Global Initiative for Chronic Obstructive Lung Disease, 2016, GLOBAL STRATEGY DIAG; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gott M, 2009, PALLIATIVE MED, V23, P642, DOI 10.1177/0269216309106790; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; Guidelines and audit implementation network (GAIN), 2011, GEN PALL CAR GUID MA; Gysels M H, 2009, Chron Respir Dis, V6, P133, DOI 10.1177/1479972309102810; Gysels M, 2008, J PAIN SYMPTOM MANAG, V36, P451, DOI 10.1016/j.jpainsymman.2007.11.008; Gysels Marjolein, 2007, Palliat Support Care, V5, P281; Gysels M, 2015, EUR RESPIR J, V46, P1515, DOI 10.1183/13993003.00751-2015; Habraken JM, 2008, BRIT J GEN PRACT, V58, P844, DOI 10.3399/bjgp08X376186; HajGhanbari B, 2012, RESP MED, V106, P998, DOI 10.1016/j.rmed.2012.03.004; Han MLK, 2016, LANCET RESP MED, V4, P473, DOI 10.1016/S2213-2600(16)00094-1; Hanania NA, 2011, AM J RESP CRIT CARE, V183, P604, DOI 10.1164/rccm.201003-0472OC; Harrington SE, 2017, CURR OPIN PULM MED, V23, P154, DOI 10.1097/MCP.0000000000000358; Hearn J, 1999, QUAL HEALTH CARE, V8, P219, DOI 10.1136/qshc.8.4.219; Heffner JE, 1996, AM J RESP CRIT CARE, V154, P1735, DOI 10.1164/ajrccm.154.6.8970363; Higginson IJ, 2017, BMC MED, V15, DOI 10.1186/s12916-016-0776-2; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Holland AE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008250.pub2; Houben CHM, 2017, CHEST, V151, P1081, DOI 10.1016/j.chest.2016.12.003; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; Howard C, 2014, NPJ PRIM CARE RESP M, V24, DOI 10.1038/npjpcrm.2014.76; Hui D, 2016, NAT REV CLIN ONCOL, V13, P159, DOI 10.1038/nrclinonc.2015.201; Hui D, 2015, ANN PALLIAT MED, V4, P89, DOI 10.3978/j.issn.2224-5820.2015.04.01; Hui D, 2015, ONCOLOGIST, V20, P77, DOI 10.1634/theoncologist.2014-0312; Jacobsen J, 2011, J PALLIAT MED, V14, P459, DOI 10.1089/jpm.2010.0382; Janssen DJA, 2012, J AM MED DIR ASSOC, V13, P394, DOI 10.1016/j.jamda.2011.04.017; Janssen DJA, 2011, CHEST, V139, P1081, DOI 10.1378/chest.10-1753; Janssen DJA, 2012, PATIENT EDUC COUNS, V86, P19, DOI 10.1016/j.pec.2011.01.007; Jones S, 2016, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD009419.PUB3; Kahraman H, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-66; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kendall M, 2015, J PAIN SYMPTOM MANAG, V50, P216, DOI 10.1016/j.jpainsymman.2015.02.017; Khakban A, 2017, AM J RESP CRIT CARE, V195, P287, DOI 10.1164/rccm.201606-1162PP; Knauft E, 2005, CHEST, V127, P2188, DOI 10.1378/chest.127.6.2188; Kunik ME, 2008, PSYCHOL MED, V38, P385, DOI 10.1017/S0033291707001687; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Laveneziana P, 2012, EUR RESPIR J, V40, P522, DOI 10.1183/09031936.00041212; Levack WM, 2013, N Z J PHYS, V42, P170; Levack WMM, 2015, COCHRANE DB SYST REV, V9; Lewko A, 2012, CURR RESPIR MED REV, V8, P370, DOI 10.2174/157339812803832476; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lu XM, 2016, INT J CHRONIC OBSTR, V11, P675, DOI 10.2147/COPD.S98082; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Maddocks M, 2016, THORAX, V71, P988, DOI 10.1136/thoraxjnl-2016-208460; Maddocks M, 2016, LANCET RESP MED, V4, P27, DOI [10.1016/S2213-2600(15)00503-2, 10.1016/S2213-2600(16)00093-X]; Martinez M, 2017, PALLIATIVE MED, V31, P492, DOI 10.1177/0269216316665562; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; McGarvey L, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000148; Meharry R, 2016, EUROP RESP J; Mikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824; Mitchell SAFC, 2017, THORAX, V72, P129, DOI 10.1136/thoraxjnl-2016-208843; Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009; Momen N, 2012, THORAX, V67, P777, DOI 10.1136/thoraxjnl-2012-201835; Mucke M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006788.pub3; Mullerova H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085540; Murphy PB, 2017, JAMA-J AM MED ASSOC, V317, P2177, DOI 10.1001/jama.2017.4451; Murray CJL, 2015, LANCET, V386, P2145, DOI 10.1016/S0140-6736(15)61340-X; Nakken N, 2015, EUR RESPIR REV, V24, P498, DOI 10.1183/16000617.00010114; Ngai SPC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009953.pub2; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Norden J, 2015, EUR J CLIN NUTR, V69, P256, DOI 10.1038/ejcn.2014.76; Ospina MB, 2017, THORAX, V72, P31, DOI 10.1136/thoraxjnl-2016-208820; Patel K, 2012, RESPIROLOGY, V17, P72, DOI 10.1111/j.1440-1843.2011.02087.x; Payne C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008427.pub2; Philip J, 2018, PALLIAT SUPPORT CARE, V16, P452, DOI 10.1017/S147895151700044X; Pilling S, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4108; Pinnock Hilary, 2011, BMJ Support Palliat Care, V1, P174, DOI 10.1136/bmjspcare.d142rep; Puhan MA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005305.pub4; Puhan MA, 2009, LANCET, V374, P704, DOI 10.1016/S0140-6736(09)61301-5; Rayner L, 2010, COCHRANE DB SYST REV, V3, DOI DOI 10.001002/14651858.CD14007503; Rea H, 2004, INTERN MED J, V34, P608, DOI 10.1111/j.1445-5994.2004.00672.x; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; Rocker GM, 2013, CLIN INVEST MED, V36, pE114; Rush B, 2017, CHEST, V151, P41, DOI 10.1016/j.chest.2016.06.023; Ryan NM, 2012, LANCET, V380, P1583, DOI 10.1016/S0140-6736(12)60776-4; Seymour JM, 2010, EUR RESPIR J, V36, P81, DOI 10.1183/09031936.00104909; Simon ST, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub3; Simon ST, 2016, J PAIN SYMPTOM MANAG, V52, P228, DOI 10.1016/j.jpainsymman.2016.02.016; Singer AE, 2015, ANN INTERN MED, V162, P175, DOI 10.7326/M13-1609; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Slater G, 2012, J THORAC DIS, V4, P608, DOI 10.3978/j.issn.2072-1439.2012.10.07; Smith SMS, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000042; Solomon BK, 2016, J PAIN SYMPTOM MANAG, V51, P529, DOI 10.1016/j.jpainsymman.2015.11.007; Spathis A, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0024-z; Spruit MA, 2017, LANCET RESP MED, V5, P542, DOI 10.1016/S2213-2600(17)30158-3; Steiner MC, 2015, THORAX, V70, P805, DOI 10.1136/thoraxjnl-2015-206948; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinweg M, 2017, UNTIMELY MEDITATIONS, P1, DOI 10.1136/thoraxjnl-2016-209376; Struik FM, 2013, COCHRANE DB SYST REV, V6; Sullivan MD, 2010, PAIN, V149, P345, DOI 10.1016/j.pain.2010.02.037; Tawakol A, 2017, LANCET, V389, P834, DOI 10.1016/S0140-6736(16)31714-7; Teno JM, 2015, J PALLIAT MED, V18, P662, DOI 10.1089/jpm.2015.0039; Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841; Twycross R, 2014, PALLIATIVE CARE FORM; Usmani ZA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010673.pub2; Usmani ZA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008483.pub2; van Dam van Isselt Eleonore F, 2014, BMJ Open, V4, pe005898, DOI 10.1136/bmjopen-2014-005898; Vanfleteren LEGW, 2016, LANCET RESP MED, V4, P911, DOI 10.1016/S2213-2600(16)00097-7; Verma JY, 2018, CHRON RESP DIS, V15, P5, DOI 10.1177/1479972317712720; Vertigan AE, 2016, CHEST, V149, P639, DOI 10.1378/chest.15-1271; Vozoris NT, 2016, EUR RESPIR J, V48, P683, DOI 10.1183/13993003.01967-2015; Wachterman MW, 2016, JAMA INTERN MED, V176, P1095, DOI 10.1001/jamainternmed.2016.1200; Weisberg J, 2002, CHEST, V121, P1070, DOI 10.1378/chest.121.4.1070; Wildman MJ, 2009, QJM-INT J MED, V102, P389, DOI 10.1093/qjmed/hcp036; Wildman MJ, 2007, BRIT MED J, V335, P1132, DOI 10.1136/bmj.39371.524271.55; Willgoss TG, 2013, RESP CARE, V58, P858, DOI 10.4187/respcare.01862; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wysham NG, 2015, ANN AM THORAC SOC, V12, P1294, DOI 10.1513/AnnalsATS.201503-180OC; Yin HL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006836; Yoong J, 2013, JAMA INTERN MED, V173, P283, DOI 10.1001/jamainternmed.2013.1874; Yorke J, 2015, SUPPORT CARE CANCER, V23, P3373, DOI 10.1007/s00520-015-2810-x; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	166	112	113	3	40	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	2017	390	10098					988	1002		10.1016/S0140-6736(17)32127-X	http://dx.doi.org/10.1016/S0140-6736(17)32127-X			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF2SE	28872031	Green Submitted			2023-01-03	WOS:000408746300028
J	Hu, XY; Wu, RH; Logue, M; Blondel, C; Lai, LYW; Stuart, B; Flower, A; Fei, YT; Moore, M; Shepherd, J; Liu, JP; Lewith, G				Hu, Xiao-Yang; Wu, Ruo-Han; Logue, Martin; Blondel, Clara; Lai, Lily Yuen Wan; Stuart, Beth; Flower, Andrew; Fei, Yu-Tong; Moore, Michael; Shepherd, Jonathan; Liu, Jian-Ping; Lewith, George			Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis	PLOS ONE			English	Review							DOUBLE-BLIND; COMMON COLD; FIXED COMBINATION; HERBAL MEDICINE; ANTIBIOTIC USE; EXTRACT; DRUG; PHARMACOKINETICS; DERIVATIVES; PILOT	Introduction Antimicrobial resistance (AMR) is a substantial threat to public health. Safe and effective alternatives are required to reduce unnecessary antibiotic prescribing. Andrographis Paniculata (A. Paniculata, Chuan Xin Lien) has traditionally been used in Indian and Chinese herbal medicine for cough, cold and influenza, suggesting a role in respiratory tract infections (RTIs). This systematic review aimed to evaluate the clinical effectiveness and safety of A. Paniculata for symptoms of acute RTIs (ARTIs). Materials and methods English and Chinese databases were searched from their inception to March 2016 for randomised controlled trials (RCTs) evaluating oral A. Paniculata without language barriers (Protocol ID: CRD42016035679). The primary outcomes were improvement in ARTI symptoms and adverse events (AEs). A random effects model was used to pool the mean differences and risk ratio with 95% CI reported. Methodological quality was evaluated using the Cochrane risk of bias tool; two reviewers independently screened eligibility and extracted data. Results Thirty-three RCTs (7175 patients) were included. Most trials evaluated A. Paniculata (as a monotherapy and as a herbal mixture) provided commercially but seldom reported manufacturing or quality control details. A. Paniculata improved cough (n = 596, standardised mean difference SMD:-0.39, 95% confidence interval CI [-0.67,-0.10]) and sore throat (n = 314, SMD: -1.13, 95% CI [-1.37, -0.89]) when compared with placebo. A. Paniculata (alone or plus usual care) has a statistically significant effect in improving overall symptoms of ARTIs when compared to placebo, usual care, and other herbal therapies. Evidence also suggested that A. Paniculata (alone or plus usual care) shortened the duration of cough, sore throat and sick leave/time to resolution when compared versus usual care. No major AEs were reported and minor AEs were mainly gastrointestinal. The methodological quality of included trials was overall poor. Conclusions A. Paniculata appears beneficial and safe for relieving ARTI symptoms and shortening time to symptom resolution. However, these findings should be interpreted cautiously owing to poor study quality and heterogeneity. Well-designed trials evaluating the effectiveness and potential to reduce antibiotic use of A. Paniculata are warranted.	[Hu, Xiao-Yang; Logue, Martin; Lai, Lily Yuen Wan; Stuart, Beth; Flower, Andrew; Moore, Michael; Lewith, George] Aldermoor Hlth Ctr, Primary Care & Populat Sci, Southampton, Hants, England; [Wu, Ruo-Han; Fei, Yu-Tong; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Blondel, Clara] AgroParisTech, Paris Inst Technol Life Food & Environm Sci, Paris, France; [Shepherd, Jonathan] Univ Southampton, SHTAC, Fac Med, Southampton, Hants, England	Beijing University of Chinese Medicine; AgroParisTech; University of Southampton	Hu, XY (corresponding author), Aldermoor Hlth Ctr, Primary Care & Populat Sci, Southampton, Hants, England.	X.Hu@saton.ac.uk	Moore, Michael/C-3447-2011; Hu, Xiao-Yang/AGD-5115-2022	Moore, Michael/0000-0002-5127-4509; Hu, Xiao-Yang/0000-0002-3143-7999; Liu, Jianping/0000-0002-0320-061X; Stuart, Beth/0000-0001-5432-7437	National Institute for Health Research School for Primary Care Research (NIHR SPCR)	National Institute for Health Research School for Primary Care Research (NIHR SPCR)	This paper presents independent research funded by the National Institute for Health Research School for Primary Care Research (NIHR SPCR). The views expressed are those of the author(s) and not necessarily those of the NIHR, the NHS or the Department of Health.	Agency EM, 2014, ASS REP ANDR PAN NEE; Ahovuo-Saloranta A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000243.pub3; Amroyan E, 1999, PHYTOMEDICINE, V6, P27, DOI 10.1016/S0944-7113(99)80031-2; [Anonymous], 2008, PRESCR ANT SELF LIM, V69, P1; [Anonymous], 2014, REVMAN RM VERS 5 3; [Anonymous], 1997, GUIDING PRINCIPLE CL, P71; Arnold SR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003539.pub2; Arroll B, 2005, RESP MED, V99, P255, DOI 10.1016/j.rmed.2004.11.004; Bent S, 1999, AM J MED, V107, P62, DOI 10.1016/S0002-9343(99)00167-9; Butler CC, 2011, EUR RESPIR J, V38, P119, DOI 10.1183/09031936.00133910; Caceres DD, 1999, PHYTOMEDICINE, V6, P217, DOI 10.1016/S0944-7113(99)80012-9; Calabrese C, 2000, PHYTOTHER RES, V14, P333, DOI 10.1002/1099-1573(200008)14:5&lt;333::AID-PTR584&gt;3.0.CO;2-D; Carlet J, 2011, LANCET, V378, P369, DOI 10.1016/S0140-6736(11)60401-7; Chen JX, 2009, BIOL PHARM BULL, V32, P1385, DOI 10.1248/bpb.32.1385; Chien CF, 2010, CHEM-BIOL INTERACT, V184, P458, DOI 10.1016/j.cbi.2010.01.017; Cohen J., 2013, STAT POWER ANAL BEHA; Collaboration TC, 2011, COCHRANE HDB SYSTEMA; Coon JT, 2004, PLANTA MED, V70, P293, DOI 10.1055/s-2004-818938; Doh, 2013, UK 5 YEAR ANT RES ST; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fan L, 2008, CLIN PHARMACOL THER, V83, P471, DOI 10.1038/sj.clpt.6100318; Fong YK, 2012, J ETHNOPHARMACOL, V141, P742, DOI 10.1016/j.jep.2011.08.042; Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Harnden A, 2007, ARCH DIS CHILD, V92, P594, DOI 10.1136/adc.2007.116665; Hopstaken RM, 2005, J CLIN EPIDEMIOL, V58, P175, DOI 10.1016/j.jclinepi.2004.08.004; ICH, CLIN SAF DAT MAN DEF; Jiang LH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004559.pub4; Julia Fashner KE, 2012, AM FAM PHYSICIAN, P153; Julian P.T.H., 2011, MANUAL COCHRANE REVI; Kenealy T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000247.pub3; Kulichenko L. L., 2003, Journal of Herbal Pharmacotherapy, V3, P77, DOI 10.1080/J157v03n01_04; Little P, 2014, BMJ-BRIT MED J, P348; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Liu Jin-Feng, 2012, HEILONGJIANG MED PHA, P42; Melchior J, 2000, PHYTOMEDICINE, V7, P341, DOI 10.1016/S0944-7113(00)80053-7; Melchior J, 1997, PHYTOMEDICINE, V3, P315, DOI 10.1016/S0944-7113(97)80002-5; Muluye Rekik A, 2014, J Tradit Complement Med, V4, P93, DOI 10.4103/2225-4110.126635; Murad MH., 2015, USERSGUIDE MEDICAL L; Organisation WH, EV THR ANT RES OPT A; Poolsup N, 2004, J CLIN PHARM THER, V29, P37, DOI 10.1046/j.1365-2710.2003.00534.x; PURI A, 1993, J NAT PROD, V56, P995, DOI 10.1021/np50097a002; Reveiz L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004783.pub5; Saxena RC, 2010, PHYTOMEDICINE, V17, P178, DOI 10.1016/j.phymed.2009.12.001; Shakhova E. G., 2003, Vestnik Otorinolaringologii, P48; Shen YC, 2002, BRIT J PHARMACOL, V135, P399, DOI 10.1038/sj.bjp.0704493; Simasek M, 2007, AM FAM PHYSICIAN, V75, P515; Smith Richard, 2013, BMJ, V346, pf1493, DOI 10.1136/bmj.f1493; Smith SM, 2014, JAMA-J AM MED ASSOC, V312, P2678, DOI 10.1001/jama.2014.12839; Smith SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub4; Spasov AA, 2004, PHYTOTHER RES, V18, P47, DOI 10.1002/ptr.1359; Spinks Anneliese, 2013, Cochrane Database Syst Rev, pCD000023, DOI 10.1002/14651858.CD000023.pub4; Suebsasana S, 2009, ARCH PHARM RES, V32, P1191, DOI 10.1007/s12272-009-1902-x; Tan Z-H, 2011, J YOUJIANG MED COLL, P768; TGA, 2015, SAF REV ANDR PAN AN; THAMLIKITKUL V, 1991, Journal of the Medical Association of Thailand, V74, P437; Venekamp RP, 2015, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000219.PUB4, 10.1002/14651858.CD000219.pub4]; Wagner L, 2015, FORSCH KOMPLEMENTMED, V22, P359, DOI 10.1159/000442111; WHO, 2003, INT CLASSIFICATION P, V2nd; Wu TX, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-46; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Xiao YH, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001556; Yale SH, 2004, ARCH INTERN MED, V164, P1237, DOI 10.1001/archinte.164.11.1237; Yi S, 2009, BASIC CLIN PHARMACOL, V105, P249, DOI 10.1111/j.1742-7843.2009.00423.x; Yu B, 2014, CHIN J INTEGR MED, V20, P540, DOI 10.1007/s11655-014-1860-0; Zhang X, 2007, COCHRANE DATABASE SY	67	39	39	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2017	12	8							e0181780	10.1371/journal.pone.0181780	http://dx.doi.org/10.1371/journal.pone.0181780			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC6IS	28783743	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000406944300013
J	Weier, N; Thursky, K; Zaidi, STR				Weier, Naomi; Thursky, Karin; Zaidi, Syed Tabish R.			Antimicrobial knowledge and confidence amongst final year medical students in Australia	PLOS ONE			English	Article							ANTIBIOTIC-RESISTANCE; JUNIOR DOCTORS; PRESCRIBING ERRORS; PERCEPTIONS; STEWARDSHIP; CURRICULUM; PHARMACOTHERAPY; ATTITUDES; EDUCATION; INTERNS	Introduction Inappropriate use of antimicrobials is one of the major modifiable contributors to antimicrobial resistance. There is currently no validated survey tool available to assess knowledge and confidence of medical students in infectious diseases (ID) compared to other diseases states, and little is known about this topic. Materials and methods A cross-sectional survey of final year medical students attending universities around Australia was conducted between August and September, 2015. A survey unique from other published studies was developed to survey satisfaction in education, confidence and knowledge in ID, and how this compared to these factors in cardiovascular diseases. Results Reliability and validity was demonstrated in the survey tool used. Students were more likely to rate university education as sufficient for cardiovascular diseases (91.3%) compared to ID (72.5%), and were more confident in their knowledge of cardiovascular diseases compared to ID (74.38% vs. 53.76%). Students tended to answer more cardiovascular disease related clinical questions correctly (mean score 78%), compared to questions on antimicrobial use (mean score 45%). Conclusions Poor knowledge and confidence amongst final year medical students in Australia were observed in ID. Antimicrobial stewardship agenda should include the provision of additional training in antimicrobial prescribing to the future medical workforce.	[Weier, Naomi; Zaidi, Syed Tabish R.] Univ Tasmania, Div Pharm, Sch Med, Hobart, Tas, Australia; [Thursky, Karin] Doherty Inst, Melbourne, Vic, Australia; [Thursky, Karin] Royal Melbourne Hosp, Parkville, Vic, Australia	University of Tasmania; Royal Melbourne Hospital	Zaidi, STR (corresponding author), Univ Tasmania, Div Pharm, Sch Med, Hobart, Tas, Australia.	tabish.razizaidi@utas.edu.au	thursky, karin/AAV-4524-2021; Zaidi, Syed Tabish R./J-7336-2014	Weier, Naomi/0000-0001-9832-1846; thursky, karin/0000-0002-7400-232X; Zaidi, Syed Tabish R./0000-0002-2031-1055				Abbo LM, 2013, CLIN INFECT DIS, V57, P631, DOI 10.1093/cid/cit370; Ajemigbitse AA, 2013, ANN AFR MED, V12, P223, DOI 10.4103/1596-3519.122691; Akat PB, 2012, J PHARMACOL PHARMACO, V3, P56, DOI 10.4103/0976-500X.92519; Akici A, 2005, EUR J CLIN PHARMACOL, V61, P643, DOI 10.1007/s00228-005-0960-3; Australian Commission on Safety and Quality in Health Care (ACSQHC), 2014, ANT PRESCR PRACT AUS; Avent ML, 2014, AUST HEALTH REV, V38, P557, DOI 10.1071/AH13137; Broom A, 2014, SOC SCI MED, V110, P81, DOI 10.1016/j.socscimed.2014.03.030; Charani E, 2011, CLIN INFECT DIS, V53, P651, DOI 10.1093/cid/cir445; Coombes ID, 2008, MED J AUSTRALIA, V188, P89, DOI 10.5694/j.1326-5377.2008.tb01529.x; Dartnell J., 2001, AUS PRESCR, V2001, P2; De Clercq L, 2001, Educ Health (Abingdon), V14, P417; DeVellis R. F., 2012, SCALE DEV THEORY APP; Dyar OJ, 2014, J ANTIMICROB CHEMOTH, V69, P842, DOI 10.1093/jac/dkt440; Gupta Kanchan, 2014, Int J Appl Basic Med Res, V4, P90, DOI 10.4103/2229-516X.136786; Henning RH, 1994, GUIDE GOOD PRESCRIBI; Illing JC, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-34; Ingram PR, 2012, INTERN MED J, V42, P719, DOI 10.1111/j.1445-5994.2012.02809.x; Levy SB, 2002, J ANTIMICROB CHEMOTH, V49, P25, DOI 10.1093/jac/49.1.25; Martin AA, 2007, MED J AUSTRALIA, V186, P346, DOI 10.5694/j.1326-5377.2007.tb00934.x; Maxwell S, 2003, BRIT J CLIN PHARMACO, V55, P496, DOI 10.1046/j.1365-2125.2003.01878.x; Minen MT, 2010, MICROB DRUG RESIST, V16, P285, DOI 10.1089/mdr.2010.0009; Monrouxe L., 2014, PREPARED ARE UK MED; Pearson SA, 2002, MED EDUC, V36, P781, DOI 10.1046/j.1365-2923.2002.01267.x; Piddock LJV, 2012, LANCET INFECT DIS, V12, P249, DOI 10.1016/S1473-3099(11)70316-4; Pulcini C, 2011, CLIN MICROBIOL INFEC, V17, P80, DOI 10.1111/j.1469-0691.2010.03179.x; Pulcini C, 2013, VIRULENCE, V4, P192, DOI 10.4161/viru.23706; Rolfe IE, 2004, MED EDUC, V38, P778, DOI 10.1111/j.1365-2929.2004.01891.x; Slight SP, 2013, BRIT J GEN PRACT, V63, pE713, DOI 10.3399/bjgp13X673739; Srvinivasan A, 2004, ARCH INTERN MED, V164, P1451; Starmer K, 2013, EMERG MED AUSTRALAS, V25, P147, DOI 10.1111/1742-6723.12061; Stone S, 2000, ANN EMERG MED, V36, P320, DOI 10.1067/mem.2000.109341; T Dornan, 2009, DEPTH INVESTIGATION; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; The Department of Health, 2010, MED GRAD AUSTR GOV D; Vasundara K, 2010, INDIAN J PHARMACOL, V42, P420, DOI 10.4103/0253-7613.71901; Vollebregt JA, 2006, BRIT J CLIN PHARMACO, V61, P345, DOI 10.1111/j.1365-2125.2005.02571.x	36	26	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2017	12	8							e0182460	10.1371/journal.pone.0182460	http://dx.doi.org/10.1371/journal.pone.0182460			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC5AR	28771549	Green Accepted, Green Published, gold			2023-01-03	WOS:000406853600119
J	Suzuki, T; Espana, MU; Nunes, MA; Zhurov, V; Dermauw, W; Osakabe, M; Van Leeuwen, T; Grbic, M; Grbic, V				Suzuki, Takeshi; Espana, Maria Urizarna; Nunes, Maria Andreia; Zhurov, Vladimir; Dermauw, Wannes; Osakabe, Masahiro; Van Leeuwen, Thomas; Grbic, Miodrag; Grbic, Vojislava			Protocols for the delivery of small molecules to the two-spotted spider mite, Tetranychus urticae	PLOS ONE			English	Article							GREEN PEACH APHID; RNA INTERFERENCE; INDOLE GLUCOSINOLATE; BEMISIA-TABACI; HONEY-BEE; GENE; DSRNA; DIET; IMPROVEMENT; ELEGANS	The two-spotted spider mite, Tetranychus urticae, is a chelicerate herbivore with an extremely wide host range and an extraordinary ability to develop pesticide resistance. Due to its responsiveness to natural and synthetic xenobiotics, the spider mite is becoming a prime pest herbivore model for studies of the evolution of host range, plant-herbivore interactions and mechanisms of xenobiotic resistance. The spider mite genome has been sequenced and its transcriptional responses to developmental and various biotic and abiotic cues have been documented. However, to identify biological and evolutionary roles of T. urticae genes and proteins, it is necessary to develop methods for the efficient manipulation of mite gene function or protein activity. Here, we describe protocols developed for the delivery of small molecules into spider mites. Starting with mite maintenance and the preparation of the experimental mite populations of developmentally synchronized larvae and adults, we describe 3 methods for delivery of small molecules including artificial diet, leaf coating, and soaking. The presented results define critical steps in these methods and demonstrate that they can successfully deliver tracer dyes into mites. Described protocols provide guidelines for high-throughput setups for delivery of experimental compounds that could be used in reverse genetics platforms to modulate gene expression or protein activity, or for screens focused on discovery of new molecules for mite control. In addition, described protocols could be adapted for other Tetranychidae and related species of economic importance such as Varroa, dust and poultry mites.	[Suzuki, Takeshi; Espana, Maria Urizarna; Nunes, Maria Andreia; Zhurov, Vladimir; Grbic, Miodrag; Grbic, Vojislava] Univ Western Ontario, Dept Biol, London, ON, Canada; [Dermauw, Wannes; Van Leeuwen, Thomas] Univ Ghent, Fac Biosci Engn, Dept Crop Protect, Lab Agrozool, Ghent, Belgium; [Osakabe, Masahiro] Kyoto Univ, Grad Sch Agr, Lab Ecol Informat, Kyoto, Japan; [Van Leeuwen, Thomas] Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Dept Evolutionary Biol, Amsterdam, Netherlands; [Grbic, Miodrag] Univ La Rioja, Logrono, Spain; [Suzuki, Takeshi] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, Koganei, Tokyo, Japan; [Nunes, Maria Andreia] Inst Agron Campinas, Ctr Citricultura Sylvio Moreira, Cordeiropolis, SP, Brazil	Western University (University of Western Ontario); Ghent University; Kyoto University; University of Amsterdam; Universidad de La Rioja; Tokyo University of Agriculture & Technology; Instituto Agronomico de Campinas (IAC)	Grbic, M; Grbic, V (corresponding author), Univ Western Ontario, Dept Biol, London, ON, Canada.; Grbic, M (corresponding author), Univ La Rioja, Logrono, Spain.	mgrbic@uwo.ca; vgrbic@uwo.ca	Suzuki, Takeshi/F-7548-2012; Osakabe, Masahiro/H-8587-2019; Grbic, Miodrag/AID-4825-2022; Dermauw, Wannes/H-1583-2015	Suzuki, Takeshi/0000-0002-7930-1425; Osakabe, Masahiro/0000-0002-2246-3431; Dermauw, Wannes/0000-0003-4612-8969; Van Leeuwen, Thomas/0000-0003-4651-830X; Grbic, Vojislava/0000-0001-6570-8796; Zhurov, Vladimir/0000-0002-7120-4655	Ontario Research FundResearch Excellence Round 8 [RE08-067]; Postdoctoral Fellowship for Research Abroad - Japan Society for the Promotion of Science (JSPS); National Counsel of Technological and Scientific Development (CNPq/Brazil); Grants-in-Aid for Scientific Research [16K18661] Funding Source: KAKEN	Ontario Research FundResearch Excellence Round 8; Postdoctoral Fellowship for Research Abroad - Japan Society for the Promotion of Science (JSPS); National Counsel of Technological and Scientific Development (CNPq/Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Development of described protocols was supported by the Ontario Research Fund Research Excellence Round 8 (RE08-067) (to MG and VG). TS has been supported by the Postdoctoral Fellowship for Research Abroad funded by the Japan Society for the Promotion of Science (JSPS) and MAN by the National Counsel of Technological and Scientific Development (CNPq/Brazil). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aronstein K, 2006, J APICULT RES, V45, P20, DOI 10.1080/00218839.2006.11101307; Baum JA, 2007, NAT BIOTECHNOL, V25, P1322, DOI 10.1038/nbt1359; Bensoussan N, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01105; Bosse TC, 1996, PHYSIOL ENTOMOL, V21, P188, DOI 10.1111/j.1365-3032.1996.tb00854.x; Campbell EM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-73; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Cazaux M, 2014, JOVE-J VIS EXP, DOI 10.3791/51738; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Conte D, 2015, CURR PROTOC MOL BIOL, V109; EKKA I, 1971, J INSECT PHYSIOL, V17, P1393, DOI 10.1016/0022-1910(71)90148-X; Ekka I., 1969, REARING 2 SPOTTED SP; FEBVAY G, 1988, CAN J ZOOL, V66, P2449, DOI 10.1139/z88-362; Ghanim M, 2007, INSECT BIOCHEM MOLEC, V37, P732, DOI 10.1016/j.ibmb.2007.04.006; Gotoh T, 2008, INT J ACAROL, V34, P393, DOI 10.1080/17088180809434783; Grbic M, 2011, NATURE, V479, P487, DOI 10.1038/nature10640; HARE JD, 1988, ENTOMOL EXP APPL, V47, P137, DOI 10.1007/BF00367479; Ikegami Y, 2000, APPL ENTOMOL ZOOL, V35, P339, DOI 10.1303/aez.2000.339; Jonckheere W, 2016, MOL CELL PROTEOMICS, V15, P3594, DOI 10.1074/mcp.M116.058081; Khila A, 2007, DEV GENES EVOL, V217, P241, DOI 10.1007/s00427-007-0132-9; Kim JH, 2008, PLANT J, V54, P1015, DOI 10.1111/j.1365-313X.2008.03476.x; Kim JH, 2007, PLANT J, V49, P1008, DOI 10.1111/j.1365-313X.2006.03019.x; Kim YH, 2015, PESTIC BIOCHEM PHYS, V120, P109, DOI 10.1016/j.pestbp.2015.01.002; Kola VSR, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00119; Kranthi K.R., 2005, INSECTICIDE RESISTAN; Kwon DH, 2016, PESTIC BIOCHEM PHYS, V130, P1, DOI 10.1016/j.pestbp.2015.11.005; Kwon DH, 2013, PESTIC BIOCHEM PHYS, V105, P69, DOI 10.1016/j.pestbp.2012.12.001; Li JJ, 2015, PEST MANAG SCI, V71, P1175, DOI 10.1002/ps.3903; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Migeon A., 2006, SPIDER MITES WEB COM; PROSSER WA, 1992, J INSECT PHYSIOL, V38, P93, DOI 10.1016/0022-1910(92)90037-E; Protocols CSH, 2006, COLD SPRING HARBOR P, V2006; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sterck L, 2012, NAT METHODS, V9, P1041, DOI 10.1038/nmeth.2242; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Ubara M, 2015, ENVIRON ENTOMOL, V44, P1210, DOI 10.1093/ee/nvv080; Van Leeuwen T, 2015, PESTIC BIOCHEM PHYS, V121, P12, DOI 10.1016/j.pestbp.2014.12.009; Van Leeuwen T, 2012, P NATL ACAD SCI USA, V109, P4407, DOI 10.1073/pnas.1200068109; VANDERGEEST LPS, 1983, ENTOMOL EXP APPL, V33, P297, DOI 10.1111/j.1570-7458.1983.tb03272.x; Wang YB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018644; Whyard S, 2009, INSECT BIOCHEM MOLEC, V39, P824, DOI 10.1016/j.ibmb.2009.09.007; Wuriyanghan H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027736; Yu N, 2013, INSECT SCI, V20, P4, DOI 10.1111/j.1744-7917.2012.01534.x	43	25	25	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180658	10.1371/journal.pone.0180658	http://dx.doi.org/10.1371/journal.pone.0180658			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686745	Green Published, gold, Green Submitted			2023-01-03	WOS:000405464100088
J	Aoun, M; Koubar, SH; Antoun, L; Tamim, H; Makki, M; Chelala, D				Aoun, Mabel; Koubar, Sahar H.; Antoun, Leony; Tamim, Hani; Makki, Maha; Chelala, Dania			Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; DIALYSIS OUTCOMES; PRIMARY PREVENTION; PRACTICE PATTERNS; RISK; ANTIPLATELET; STROKE; CLOPIDOGREL; MORTALITY	There is so far no international consensus concerning the prescription of antithrombotic agents in hemodialysis patients. It is not clear yet why they cause more bleeding in some patients and are beneficial in others. We therefore tried to find out what triggers bleeding in this population. This is an observational before-and-after study that included all patients undergoing hemodialysis in our center between 2005 and 2015. We divided the study into two phases: phase one (125 patients) where aspirin was used without restrictions and phase two (110 patients) where aspirin was avoided in severe hypertension and primary prevention. We aimed to assess the differential occurrence of intracerebral hemorrhage between the two phases and the cardiovascular mortality of patients whether on aspirin or not. Bleeding events occurred in 12.8% of patients in phase one and 13.6% in phase two (p = 0.85). Seven out of 125 patients (6%) in phase one experienced intracerebral hemorrhage and none in phase two. Intracerebral hemorrhage was significantly increased in those with the combination of aspirin and severe hypertension (p = 0.003). Aspirin and acenocoumadin were significantly associated with total bleeding (OR = 3.81 and 4.85 with p = 0.005 and 0.001 respectively). Cardiovascular mortality did not differ between phase one and two whether patients were on aspirin or not (p = 0.45 and 0.31 respectively). Minimizing aspirin use in hemodialysis patients with severe hypertension reduced intracerebral bleeding without a significant difference in cardiovascular mortality.	[Aoun, Mabel] St George Hosp, Dept Nephrol, Ajaltoun, Lebanon; [Aoun, Mabel; Chelala, Dania] St Joseph Univ, Dept Nephrol, Beirut, Lebanon; [Koubar, Sahar H.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Nephrol, Beirut, Lebanon; [Antoun, Leony] Holy Spirit Univ, Dept Internal Med, Kaslik, Lebanon; [Tamim, Hani; Makki, Maha] Amer Univ Beirut, Biostat Unit, Clin Res Inst, Med Ctr, Beirut, Lebanon	American University of Beirut; American University of Beirut	Aoun, M (corresponding author), St George Hosp, Dept Nephrol, Ajaltoun, Lebanon.; Aoun, M (corresponding author), St Joseph Univ, Dept Nephrol, Beirut, Lebanon.	aounmabel@yahoo.fr	Aoun, Mabel/ADU-1246-2022					Bagai A, 2016, CIRCULATION, V133, P2094, DOI 10.1161/CIRCULATIONAHA.115.021158; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Brandenburg VM, 2017, NEPHROL DIAL TRANSPL, V32, P126, DOI 10.1093/ndt/gfv438; Chan KE, 2009, J AM SOC NEPHROL, V20, P872, DOI 10.1681/ASN.2008080824; Chen CY, 2014, INT J STROKE, V9, P580, DOI 10.1111/ijs.12254; De Berardis G, 2012, JAMA-J AM MED ASSOC, V307, P2286, DOI 10.1001/jama.2012.5034; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Dember LM, 2008, JAMA-J AM MED ASSOC, V299, P2164, DOI 10.1001/jama.299.18.2164; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Ethier J, 2007, AM J KIDNEY DIS, V50, P602, DOI 10.1053/j.ajkd.2007.07.007; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Guirguis-Blake JM, 2016, ANN INTERN MED, V164, P804, DOI 10.7326/M15-2113; Hart RG, 2005, STROKE, V36, P1588, DOI 10.1161/01.STR.0000170642.39876.f2; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; Hiremath S, 2009, CLIN J AM SOC NEPHRO, V4, P1347, DOI 10.2215/CJN.00810209; Holden RM, 2008, CLIN J AM SOC NEPHRO, V3, P105, DOI 10.2215/CJN.01810407; Htun P, 2011, J AM SOC NEPHROL, V22, P627, DOI 10.1681/ASN.2010020220; January CT, 2014, CIRCULATION, V130, pE199, DOI [10.1161/CIR.0000000000000041, 10.1161/CIR.0000000000000142, 10.1016/j.jacc.2014.03.021, 10.1016/j.jacc.2014.03.022]; Kaufman JS, 2003, J AM SOC NEPHROL, V14, P2313, DOI 10.1097/01.ASN.0000081661.10246.33; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Liu J, 2016, HEMODIAL INT, V20, P548, DOI 10.1111/hdi.12409; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Matthys F, 2014, EUR J PREV CARDIOL, V21, P354, DOI 10.1177/2047487312472077; Miller LM, 2006, CAN J CARDIOL, V22, P755, DOI 10.1016/S0828-282X(06)70291-4; Perry HM, 2000, JAMA-J AM MED ASSOC, V284, P465, DOI 10.1001/jama.284.4.465; Robinson BM, 2012, KIDNEY INT, V82, P570, DOI 10.1038/ki.2012.136; Sakamoto N, 2014, WORLD NEUROSURG, V81, P538, DOI 10.1016/j.wneu.2013.10.033; Saran R, 2002, AM J KIDNEY DIS, V40, P1255, DOI 10.1053/ajkd.2002.36895; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Sood MM, 2013, KIDNEY INT, V84, P600, DOI 10.1038/ki.2013.170; Tordoir J, 2007, NEPHROL DIAL TRANSPL, V22, P88, DOI 10.1093/ndt/gfm021; Wasse H, 2003, KIDNEY INT, V64, P1455, DOI 10.1046/j.1523-1755.2003.00225.x; Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477	33	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2017	12	10							e0185847	10.1371/journal.pone.0185847	http://dx.doi.org/10.1371/journal.pone.0185847			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI5MY	28968454	gold, Green Submitted, Green Published			2023-01-03	WOS:000412029600059
J	Shin, HW; Ju, BJ; Jang, YK; You, HS; Kang, H; Park, JY				Shin, Hye Won; Ju, Bum Jun; Jang, Yoo Kyung; You, Hae Seun; Kang, Hyun; Park, Ji Yong			Effect of tramadol as an adjuvant to local anesthetics for brachial plexus block: A systematic review and meta-analysis	PLOS ONE			English	Article							NERVE BLOCK; POSTOPERATIVE ANALGESIA; PERIPHERAL-NERVE; MOTOR BLOCKADE; PAIN; LEVOBUPIVACAINE; ROPIVACAINE; 0.5-PERCENT; DEXAMETHASONE; MEPIVACAINE	Background Tramadol, a 4-phenyl-piperidine analog of codeine, has a unique action in that it has a central opioidergic, noradrenergic, serotonergic analgesic, and peripheral local anesthetic (LA) effect. Many studies have reported contradictory findings regarding the peripheral analgesic effect of tramadol as an adjuvant to LA in brachial plexus block (BPB). This meta-analysis aimed to evaluate the effects of tramadol as an adjunct to LA in BPB during shoulder or upper extremity surgery. Methods We searched the PubMed, EMBASE, Cochrane, KoreaMed databases, and Google Scholar for eligible randomized controlled trials (RCTs) that compared BPB with LA alone and BPB with LA and tramadol. Primary outcomes were the effects of tramadol as an adjuvant on duration of sensory block, motor block, and analgesia. Secondary outcomes were the effects of tramadol as an adjuvant on time to onset of sensory block and motor block and on adverse effects. We performed the meta-analysis using Review Manager 5.3 software. Results We identified 16 RCTs with 751 patients. BPB with tramadol prolonged the duration of sensory block (mean difference [MD], -61.5 min; 95% CI, -95.5 to -27.6; P = 0.0004), motor block (MD, -65.6 min; 95% CI, -101.5 to -29.7; P = 0.0003), and analgesia (MD, -125.5 min; 95% CI, -175.8 to -75.3; P < 0.0001) compared with BPB without tramadol. Tramadol also shortened the time to onset of sensory block (MD, 2.1 min; 95% CI, 1.1 to 3.1; P < 0.0001) and motor block (MD, 1.2 min; 95% CI, 0.2 to 2.1; P = 0.010). In subgroup analysis, the duration of sensory block, motor block, and analgesia was prolonged for BPB with tramadol 100 mg (P < 0.05) but not for BPB with tramadol 50 mg. The quality of evidence was high for duration of analgesia according to the GRADE system. Adverse effects were comparable between the studies. Conclusions In upper extremity surgery performed under BPB, use of tramadol 100 mg as an adjuvant to LA appears to prolong the duration of sensory block, motor block, and analgesia, and shorten the time to onset of sensory and motor blocks without altering adverse effects.	[Shin, Hye Won; Ju, Bum Jun; Jang, Yoo Kyung; You, Hae Seun; Park, Ji Yong] Korea Univ, Dept Anesthesiol & Pain Med, Coll Med, Anam Hosp, Seoul, South Korea; [Kang, Hyun] Chung Ang Univ Hosp, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea	Korea University; Korea University Medicine (KU Medicine); Chung Ang University; Chung Ang University Hospital	Shin, HW (corresponding author), Korea Univ, Dept Anesthesiol & Pain Med, Coll Med, Anam Hosp, Seoul, South Korea.	drhwshin@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880; Jang, Yookyung/0000-0002-3491-1430				Abdallah FW, 2013, BRIT J ANAESTH, V110, P915, DOI 10.1093/bja/aet066; Alemanno F, 2012, MINERVA ANESTESIOL, V78, P291; Altunkaya H, 2003, BRIT J ANAESTH, V90, P320, DOI 10.1093/bja/aeg079; Antonucci S, 2001, Minerva Anestesiol, V67, P23; Arcioni R, 2002, ANESTH ANALG, V94, P1553, DOI 10.1097/00000539-200206000-00033; Broch O, 2005, ANASTH INTENSIV NOTF, V40, P526, DOI 10.1055/s-2005-870205; Budd K, 1999, BRIT J ANAESTH, V82, P493, DOI 10.1093/bja/82.4.493; Chattopadhyay S, 2007, J ANAESTHESIOL CLIN, V23, P187; Choi S, 2014, BRIT J ANAESTH, V112, P427, DOI 10.1093/bja/aet417; Dikmen B, 2009, TURK J MED SCI, V39, P733, DOI 10.3906/sag-0903-8; Fanelli G, 2001, ACTA ANAESTH SCAND, V45, P590, DOI 10.1034/j.1399-6576.2001.045005590.x; Geze S, 2012, EUR J GEN MED, V9, P118, DOI [DOI 10.29333/EJGM/82475, 10.29333/ejgm/82475]; Gormley WP, 1996, BRIT J ANAESTH, V76, P802, DOI 10.1093/bja/76.6.802; Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kaabachi O, 2009, ANESTH ANALG, V108, P367, DOI 10.1213/ane.0b013e31818e0c6b; Kapral S, 1999, ANESTH ANALG, V88, P853, DOI 10.1097/00000539-199904000-00032; KAYSER V, 1992, EUR J PHARMACOL, V224, P83, DOI 10.1016/0014-2999(92)94822-D; Kesimci E, 2007, ACTA ANAESTH SCAND, V51, P736, DOI 10.1111/j.1399-6576.2007.01308.x; Khosa AH, 2015, PAK J MED HEALTH SCI, V9, P1120; Kirksey MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137312; Knezevic NN, 2015, PAIN PHYSICIAN, V18, P1; Madhusudhana R, 2011, INT J BIOL MED RES, V2, P1061; Mannion S, 2005, BRIT J ANAESTH, V94, P352, DOI 10.1093/bja/aei057; Mert T, 2003, PHARMACOLOGY, V69, P68, DOI 10.1159/000072358; Mukherjee K, 2014, J RES PHARM PRACT, V3, P123, DOI 10.4103/2279-042X.145387; Nagpal Vishal, 2015, J Anaesthesiol Clin Pharmacol, V31, P191, DOI 10.4103/0970-9185.155147; Omar AM, 2011, EGYPT J ANAESTH, V27, P101, DOI 10.1016/j.egja.2011.04.002; Park CH, 2013, KOREAN J PAIN, V26, P265, DOI 10.3344/kjp.2013.26.3.265; Popping DM, 2009, ANESTHESIOLOGY, V111, P406, DOI 10.1097/ALN.0b013e3181aae897; Robaux S, 2004, ANESTH ANALG, V98, P1172, DOI 10.1213/01.ANE.0000108966.84797.72; Saryazdi Hamid, 2015, Adv Biomed Res, V4, P232, DOI 10.4103/2277-9175.167901; Scott LJ, 2000, DRUGS, V60, P139, DOI 10.2165/00003495-200060010-00008; Senel AC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/686287; Sousa AM, 2012, BRAZ J MED BIOL RES, V45, P147, DOI 10.1590/S0100-879X2011007500164; Trabelsi W, 2013, ANALG RESUSC CURR RE, V2, P2; Yalcin P, 2005, PHARMACOL BIOCHEM BE, V80, P69, DOI 10.1016/j.pbb.2004.10.020; Yurtlu BS, 2012, TURK J MED SCI, V42, P55, DOI 10.3906/sag-1010-1250	38	9	9	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2017	12	9							e0184649	10.1371/journal.pone.0184649	http://dx.doi.org/10.1371/journal.pone.0184649			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4WR	28953949	gold, Green Submitted, Green Published			2023-01-03	WOS:000411980300020
J	Mahasa, KJ; Eladdadi, A; de Pillis, L; Ouifki, R				Mahasa, Khaphetsi Joseph; Eladdadi, Amina; de Pillis, Lisette; Ouifki, Rachid			Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach	PLOS ONE			English	Article							VESICULAR STOMATITIS-VIRUS; NEWCASTLE-DISEASE-VIRUS; SELECTIVE REPLICATION; ANTITUMOR IMMUNITY; CANCER-TREATMENT; CELLS; IMMUNOTHERAPY; INNATE; SUPPRESSION; ADENOVIRUS	In the present paper, we address by means of mathematical modeling the following main question: How can oncolytic virus infection of some normal cells in the vicinity of tumor cells enhance oncolytic virotherapy? We formulate a mathematical model describing the interactions between the oncolytic virus, the tumor cells, the normal cells, and the antitumoral and antiviral immune responses. The model consists of a system of delay differential equations with one (discrete) delay. We derive the model's basic reproductive number within tumor and normal cell populations and use their ratio as a metric for virus tumor-specificity. Numerical simulations are performed for different values of the basic reproduction numbers and their ratios to investigate potential trade-offs between tumor reduction and normal cells losses. A fundamental feature unravelled by the model simulations is its great sensitivity to parameters that account for most variation in the early or late stages of oncolytic virotherapy. From a clinical point of view, our findings indicate that designing an oncolytic virus that is not 100% tumor-specific can increase virus particles, which in turn, can further infect tumor cells. Moreover, our findings indicate that when infected tissues can be regenerated, oncolytic viral infection of normal cells could improve cancer treatment.	[Mahasa, Khaphetsi Joseph] Univ Stellenbosch, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa; [Eladdadi, Amina] Coll St Rose, Albany, NY USA; [de Pillis, Lisette] Harvey Mudd Coll, Claremont, CA 91711 USA; [Ouifki, Rachid] Univ Pretoria, Dept Math & Appl Math, Pretoria, South Africa	National Research Foundation - South Africa; Stellenbosch University; Claremont Colleges; Harvey Mudd College; University of Pretoria	Mahasa, KJ (corresponding author), Univ Stellenbosch, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa.	mahasa@aims.ac.za	Ouifki, Rachid/A-4064-2017	Ouifki, Rachid/0000-0001-7697-1792; dePillis, Lisette/0000-0002-9839-3636; Mahasa, Khaphetsi Joseph/0000-0003-0017-3780	Society for Mathematical Biology (SMB)	Society for Mathematical Biology (SMB)	We thank Prof. Peter Hinow and the anonymous referee for their helpful comments and suggestions that helped in the revision of this paper. KJ Mahasa would like to acknowledge and thank the Society for Mathematical Biology (SMB) for granting him the SMB Landahl-Busenberg Award to present this research at the SMB2017 annual meeting in Salt Lake City in Utah, USA.	Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Alkayyal AA, 2016, J TAIBAH UNIV MED SC, V11, P187, DOI 10.1016/j.jtumed.2016.04.002; Alvarez-Breckenridge CA, 2015, CURR OPIN VIROL, V13, P25, DOI 10.1016/j.coviro.2015.03.015; Baba A. I., 2007, COMP ONCOLOGY, P119; Bajzer Z, 2008, J THEOR BIOL, V252, P109, DOI 10.1016/j.jtbi.2008.01.016; Bridle BW, 2010, MOL THER, V18, P1430, DOI 10.1038/mt.2010.98; Bridle BW, 2009, MOL THER, V17, P1814, DOI 10.1038/mt.2009.154; Carolan LA, 2016, J VIROL, V90, P2838, DOI 10.1128/JVI.02797-15; Cassady KA, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8020043; Chang W, 2003, ANAL IMMUNOTHERAPY C; Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015; Crittenden MR, 2005, IMMUNOLOGY, V114, P11, DOI 10.1111/j.1365-2567.2004.02001.x; Crivelli JJ, 2012, J BIOL DYNAM, V6, P104, DOI 10.1080/17513758.2011.613486; de Pillis LG, 2005, CANCER RES, V65, P7950, DOI 10.1158/0008-5472.CAN-05-0564; de Pillis LG, 2003, COMPUTATIONAL FLUID AND SOLID MECHANICS 2003, VOLS 1 AND 2, PROCEEDINGS, P1661; de Pillis L, 2013, DISCRETE CONT DYN-B, V18, P915, DOI 10.3934/dcdsb.2013.18.915; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233; Downs-Canner S, 2016, MOL THER, V24, P1492, DOI 10.1038/mt.2016.101; Eftimie R, 2016, B MATH BIOL, V78, P2091, DOI 10.1007/s11538-016-0214-9; Eftimie R, 2011, B MATH BIOL, V73, P2932, DOI 10.1007/s11538-011-9653-5; Eftimie R, 2011, B MATH BIOL, V73, P2, DOI 10.1007/s11538-010-9526-3; El-Shemi AG, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0353-8; Enderling H, 2014, CURR PHARM DESIGN, V20, P4934; Fiola C, 2006, INT J CANCER, V119, P328, DOI 10.1002/ijc.21821; Friedman A, 2006, CANCER RES, V66, P2314, DOI 10.1158/0008-5472.CAN-05-2661; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Greiner J, 2006, BLOOD, V108, P4109, DOI 10.1182/blood-2006-01-023127; Guo ZS, 2008, BBA-REV CANCER, V1785, P217, DOI 10.1016/j.bbcan.2008.02.001; Hastie E, 2012, J GEN VIROL, V93, P2529, DOI 10.1099/vir.0.046672-0; Hoeller C, 2016, CANCER IMMUNOL IMMUN, V65, P1015, DOI 10.1007/s00262-016-1860-3; Jha BK, 2013, MOL THER, V21, P1749, DOI 10.1038/mt.2013.112; Kaufman HL, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-11; Kim PS, 2015, MATH BIOSCI ENG, V12, P841, DOI 10.3934/mbe.2015.12.841; Kirschner D, 1998, J MATH BIOL, V37, P235, DOI 10.1007/s002850050127; Krishnamurthy S, 2006, J VIROL, V80, P5145, DOI 10.1128/JVI.02618-05; Ku-Carrillo RA, 2016, APPL MATH MODEL, V40, P4908, DOI 10.1016/j.apm.2015.12.018; Kwon OJ, 2011, J CONTROL RELEASE, V155, P317, DOI 10.1016/j.jconrel.2011.06.014; Lemay CG, 2012, MOL THER, V20, P1791, DOI 10.1038/mt.2012.128; Leveille S, 2011, J VIROL, V85, P12160, DOI 10.1128/JVI.05703-11; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Macnamara C, 2015, J THEOR BIOL, V377, P1, DOI 10.1016/j.jtbi.2015.04.004; Marchini A, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8010009; Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011; Matveeva OV, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.17; Melen GJ, 2016, CANCER LETT, V371, P161, DOI 10.1016/j.canlet.2015.11.036; Miller AC, 2014, VIRUS ADAPT TREAT, V6, P11; Msaouel P, 2012, CURR PHARM BIOTECHNO, V13, P1732, DOI 10.2174/138920112800958896; Msaouel P, 2009, CURR OPIN MOL THER, V11, P43; Okamoto KW, 2014, J THEOR BIOL, V358, P166, DOI 10.1016/j.jtbi.2014.04.030; Paiva LR, 2009, CANCER RES, V69, P1205, DOI 10.1158/0008-5472.CAN-08-2173; Parato KA, 2012, MOL THER, V20, P749, DOI 10.1038/mt.2011.276; Prestwich RJ, 2009, HUM GENE THER, V20, P1119, DOI 10.1089/hum.2009.135; Ribacka C, 2008, CURR GENE THER, V8, P88, DOI 10.2174/156652308784049372; Rommelfanger DM, 2012, GENE THER, V19, P543, DOI 10.1038/gt.2011.132; Ruf B, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.18; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Smith TT, 2014, ONCOLYTIC VIROTHER, V3, P21, DOI 10.2147/OV.S52749; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Tong AW, 2012, CURR PHARM BIOTECHNO, V13, P1750; Turnbull S, 2015, VIRUSES-BASEL, V7, P6291, DOI 10.3390/v7122938; Vaha-Koskela M, 2014, BIOMEDICINES, V2, P163, DOI 10.3390/biomedicines2020163; Wein LM, 2003, CANCER RES, V63, P1317; Wiesel M, 2009, APMIS, V117, P356, DOI 10.1111/j.1600-0463.2009.02459.x; Willmon C, 2009, MOL THER, V17, P1667, DOI 10.1038/mt.2009.194; Wodarz D, 2001, CANCER RES, V61, P3501; Wodarz D, 2014, J VIROL, V88, P13240, DOI 10.1128/JVI.02096-14; Wodarz D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004271; Woller N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00188; Wollmann G, 2010, J VIROL, V84, P1563, DOI 10.1128/JVI.02040-09; Workenhe ST, 2015, FUTURE ONCOL, V11, P675, DOI 10.2217/fon.14.254; Workenhe ST, 2014, MOL THER, V22, P251, DOI 10.1038/mt.2013.220; Wu JT, 2001, B MATH BIOL, V63, P731, DOI 10.1006/bulm.2001.0245; Yarbro CH, 2011, CANC NURSING	74	24	25	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0184347	10.1371/journal.pone.0184347	http://dx.doi.org/10.1371/journal.pone.0184347			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH7CN	28934210	gold, Green Published			2023-01-03	WOS:000411339900026
J	Pattison, S; Mitchell, C; Lade, S; Leong, T; Busuttil, RA; Boussioutas, A				Pattison, Sharon; Mitchell, Catherine; Lade, Stephen; Leong, Trevor; Busuttil, Rita A.; Boussioutas, Alex			Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer	PLOS ONE			English	Article							GENE-EXPRESSION; CARCINOMA; SURGERY; ADENOCARCINOMA; MUTATIONS; SUBTYPES; TRENDS; RHOA	Background Survival from gastric cancer remains poor, particularly in Western populations. Previous pre-clinical and subgroup analyses of clinical trials have suggested differing benefits from fluoropyrimidine-based chemotherapeutics for diffuse and intestinal gastric cancer. This analysis examines patterns of relapse with and without adjuvant chemotherapy after curative resection for gastric cancer in these subtypes to explore the Lauren classification as a predictive marker of benefit for fluoropyrimidine-based adjuvant chemotherapy. Patients and methods Gastric cancer patients enrolled in an ongoing tissue banking study were analysed, 164 patients who would currently be considered for adjuvant therapy after curative resection were included in the analysis. Patients who did and did not receive adjuvant chemotherapy were compared. The primary end point was relapse free survival. Results Approximately 50% of patients received adjuvant chemotherapy, the majority receiving a fluoropyrimidine-based regimen. The comparison of Kaplan-Meier curves for patients who did and did not receive adjuvant chemotherapy are different between patients with intestinal and diffuse gastric cancer, and suggest that there may be a benefit in intestinal gastric cancer. The hazard ratio for adjuvant chemotherapy for intestinal gastric cancer was 0.56, (95% CI 0.27-1.17), suggesting a trend towards benefit that was lacking in diffuse gastric cancer patients (1.26, 95% CI 0.70-2.38). The patterns of relapse after adjuvant chemotherapy also differed between diffuse and intestinal gastric cancer. More than 50% of diffuse gastric cancer patients who received adjuvant chemotherapy relapsed within 12 months of surgery despite similar surgical parameters. Conclusions Lauren classification is prognostic in gastric cancer. This analysis adds further evidence that it may also be predictive of benefit for fluoropyrimidine-based chemotherapeutics, with lower chemosensitivity seen in diffuse gastric cancer. Treating diffuse and intestinal gastric cancer as separate entities, with identification of efficacious treatments for diffuse gastric cancer will help in improving outcomes from gastric cancer.	[Pattison, Sharon] Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand; [Mitchell, Catherine; Lade, Stephen] Peter MacCallum Canc Ctr, Dept Pathol, Parkville, Vic, Australia; [Lade, Stephen; Busuttil, Rita A.; Boussioutas, Alex] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Leong, Trevor] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Parkville, Vic, Australia; [Leong, Trevor] Univ Melbourne, Dept Pathol, Parkville, Vic, Australia; [Busuttil, Rita A.; Boussioutas, Alex] Peter MacCallum Canc Ctr, Upper Gastrointestinal Translat Res Lab, Parkville, Vic, Australia; [Busuttil, Rita A.; Boussioutas, Alex] Univ Melbourne, Dept Med, Parkville, Vic, Australia	University of Otago; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne	Boussioutas, A (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia.; Boussioutas, A (corresponding author), Peter MacCallum Canc Ctr, Upper Gastrointestinal Translat Res Lab, Parkville, Vic, Australia.; Boussioutas, A (corresponding author), Univ Melbourne, Dept Med, Parkville, Vic, Australia.	alex.boussioutas@petermac.org		Pattison, Sharon/0000-0003-2188-3423; Boussioutas, Alex/0000-0002-8109-6897	National Health and Medical Research Council (NHMRC) [ID288714, ID454584]; Cancer Australia [ID570996]; Peter Mac Foundation grant [APP1030980]; NHMRC post-graduate scholarship [APP1039393]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Australia; Peter Mac Foundation grant; NHMRC post-graduate scholarship(National Health and Medical Research Council (NHMRC) of Australia)	Collection and curation of the study cohort has been funded through a number of grants National Health and Medical Research Council (NHMRC) project grants (2004-2006 ID288714; 2007-2009 ID454584); 2009-2011 Cancer Australia ID570996; 2012-2014 Peter Mac Foundation grant ID APP1030980. S Pattison was supported a NHMRC post-graduate scholarship APP1039393. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bittoni A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078544; Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1; Boussioutas A, 2003, CANCER RES, V63, P2569; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Faria GR, 2013, INT J SURG, V11, P472, DOI 10.1016/j.ijsu.2013.04.004; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Henson DE, 2004, ARCH PATHOL LAB MED, V128, P765; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kim Jin-Pok, 1998, Gastric Cancer, V1, P125, DOI 10.1007/s101200050006; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAUREN PA, 1993, CANCER-AM CANCER SOC, V71, P2926, DOI 10.1002/1097-0142(19930515)71:10<2926::AID-CNCR2820711007>3.0.CO;2-X; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Marrelli D, 2011, BRIT J SURG, V98, P1273, DOI 10.1002/bjs.7528; Park SH, 2015, J CLIN ONCOL, V33, P3130, DOI 10.1200/JCO.2014.58.3930; Pattison S, 2016, ANZ J SURG, V86, P469, DOI 10.1111/ans.12915; Qiu MZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-58; Smalley SR, 2012, J CLIN ONCOL, V30, P2327, DOI 10.1200/JCO.2011.36.7136; Smyth E, 2016, J CLIN ONCOL; Tan IB, 2011, GASTROENTEROLOGY, V141, P476, DOI 10.1053/j.gastro.2011.04.042; Therneau T.M.A., 2015, R TOP DOC; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356	25	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2017	12	9							e0183891	10.1371/journal.pone.0183891	http://dx.doi.org/10.1371/journal.pone.0183891			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH3OQ	28922362	gold, Green Published			2023-01-03	WOS:000411059300008
J	McCombie, L; Leslie, W; Taylor, R; Kennon, B; Sattar, N; Lean, MEJ				McCombie, Louise; Leslie, Wilma; Taylor, Roy; Kennon, Brian; Sattar, Naveed; Lean, Mike E. J.			Beating type 2 diabetes into remission	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							BARIATRIC SURGERY; MAINTENANCE; ASSOCIATION; WEIGHT; DIET		[McCombie, Louise; Leslie, Wilma; Lean, Mike E. J.] Univ Glasgow, Sch Med, Human Nutr Sect, Glasgow G31 2ER, Lanark, Scotland; [Taylor, Roy] Univ Newcastle, Magnet Resonance Ctr, Campus Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England; [Kennon, Brian] Queen Elizabeth Univ Hosp, Diabet Ctr, Glasgow, Lanark, Scotland; [Sattar, Naveed] Univ Glasgow, Biomed Res Ctr, Glasgow, Lanark, Scotland	University of Glasgow; Newcastle University - UK; Queen Elizabeth University Hospital (QEUH); University of Dundee; University of Glasgow	McCombie, L (corresponding author), Univ Glasgow, Sch Med, Human Nutr Sect, Glasgow G31 2ER, Lanark, Scotland.	louise.mccombie@glasgow.ac.uk			Diabetes UK	Diabetes UK(Diabetes UK)	We have read and understand BMJ policy on declarations of interest and declare that with the exception of BK all authors are involved in the Diabetes UK funded Diabetes Remission Clinical Trial. LMcC and MEJL provide consultancy to Counterweight.	American Diabetes Association, LIV DIAB HLTH INS; [Anonymous], 2017, ANT MED US EUR; Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041; Buse JB, 2009, DIABETES CARE, V32, P2133, DOI 10.2337/dc09-9036; Casagrande SS, 2012, DIABETES CARE, V35, P2243, DOI 10.2337/dc12-0257; Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET; Dall TM, 2010, HEALTH AFFAIR, V29, DOI 10.1377/hlthaff.2009.0155; Diabetes UK, 2014, COST DIAB REP; General Medical Services, 2016, QUAL OUTC FRAM QOF G; Gregg EW, 2012, JAMA-J AM MED ASSOC, V308, P2489, DOI 10.1001/jama.2012.67929; Johansson K, 2014, AM J CLIN NUTR, V99, P14, DOI 10.3945/ajcn.113.070052; Karter AJ, 2014, DIABETES CARE, V37, P3188, DOI 10.2337/dc14-0874; Lean M, 2013, BRIT J GEN PRACT, V63, pE115, DOI 10.3399/bjgp13X663073; Leslie WS, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0406-2; Lim EL, 2011, DIABETOLOGIA, V54, P2506, DOI 10.1007/s00125-011-2204-7; Logue J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c154; Mingrone G, 2015, LANCET, V386, P964, DOI 10.1016/S0140-6736(15)00075-6; Rehackova L, 2017, DIABETIC MED, V34, P1554, DOI 10.1111/dme.13426; Romeo S, 2012, DIABETES CARE, V35, P2613, DOI 10.2337/dc12-0193; Steven S, 2016, DIABETES CARE, V39, P808, DOI 10.2337/dc15-1942; Tancredi M, 2015, NEW ENGL J MED, V373, P1720, DOI 10.1056/NEJMoa1504347; Wright AK, 2017, DIABETES CARE, V40, P338, DOI 10.2337/dc16-1616; Zoungas S, 2017, LANCET DIABETES ENDO, V5, P431, DOI 10.1016/S2213-8587(17)30104-3	23	44	44	2	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2017	358								j4030	10.1136/bmj.j4030	http://dx.doi.org/10.1136/bmj.j4030			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH6NB	28903916	Green Published, Green Accepted			2023-01-03	WOS:000411292600005
J	Ramos-Morales, E; de la Fuente, G; Nash, RJ; Braganca, R; Duval, S; Bouillon, ME; Lahmann, M; Newbold, CJ				Ramos-Morales, Eva; de la Fuente, Gabriel; Nash, Robert J.; Braganca, Radek; Duval, Stephane; Bouillon, Marc E.; Lahmann, Martina; Newbold, C. Jamie			Improving the antiprotozoal effect of saponins in the rumen by combination with glycosidase inhibiting iminosugars or by modification of their chemical structure	PLOS ONE			English	Article							STEVIA-REBAUDIANA; BACTERIAL PROTEIN; HEDERA-HELIX; TEA SAPONIN; FERMENTATION; BERTONI	The antiprotozoal effect of saponins is transitory, as when saponins are deglycosylated to sapogenins by rumen microorganisms they become inactive. We hypothesised that the combination of saponins with glycosidase-inhibiting iminosugars might potentially increase the effectiveness of saponins over time by preventing their deglycosylation in the rumen. Alternatively, modifying the structure of the saponins by substituting the sugar moiety with other small polar residues might maintain their activity as the sugar substitute would not be enzymatically cleaved. The aim of this in vitro study was to evaluate the acute antiprotozoal effect and the stability of this effect over a 24 h incubation period using ivy saponins, a stevia extract rich in iminosugars, ivy saponins with stevia extract, and a chemically modified ivy saponin, hederagenin bis-succinate (HBS). The effects on fermentation parameters and rumen bacterial communities were also studied. Ivy saponins with stevia and HBS had a greater antiprotozoal effect than ivy saponins, and this effect was maintained after 24 h of incubation (P<0.001). The combination of ivy and stevia extracts was more effective in shifting the fermentation pattern towards higher propionate (+39%) and lower butyrate (-32%) and lower ammonia concentration (-64%) than the extracts incubated separately. HBS caused a decrease in butyrate (-45%) and an increase in propionate (+43%) molar proportions. However, the decrease in ammonia concentration (-42%) observed in the presence of HBS was less than that caused by ivy saponins, either alone or with stevia. Whereas HBS and stevia impacted on bacterial population in terms of community structure, only HBS had an effect in terms of biodiversity (P<0.05). It was concluded that ivy saponins with stevia and the modified saponin HBS had a strong antiprotozoal effect, although they differed in their effects on fermentation parameters and bacteria communities. Ivy saponins combined with an iminosugar-rich stevia extract and/or HBS should be evaluated to determine their antiprotozoal effect in vivo.	[Ramos-Morales, Eva; de la Fuente, Gabriel; Newbold, C. Jamie] Aberystwyth Univ, Inst Biol Environm & Rural Sci, Aberystwyth, Dyfed, Wales; [Nash, Robert J.] PhytoQuest Ltd, Aberystwyth, Dyfed, Wales; [Braganca, Radek] Bangor Univ, BioComposites Ctr, Bangor, Gwynedd, Wales; [Duval, Stephane] DSM Nutr Prod Ltd, Ctr Rech Nutr Anim, St Louis, France; [Bouillon, Marc E.; Lahmann, Martina] Bangor Univ, Sch Chem, Bangor, Gwynedd, Wales; [de la Fuente, Gabriel] Univ Lleida, Dept Ciencia Anim, Lleida, Spain; [Newbold, C. Jamie] Scotlands Rural Coll, Edinburgh, Midlothian, Scotland	Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS); Aberystwyth University; Bangor University; DSM NV; Bangor University; Universitat de Lleida; Scotland's Rural College	Ramos-Morales, E; Newbold, CJ (corresponding author), Aberystwyth Univ, Inst Biol Environm & Rural Sci, Aberystwyth, Dyfed, Wales.; Newbold, CJ (corresponding author), Scotlands Rural Coll, Edinburgh, Midlothian, Scotland.	evr1@aber.ac.uk; Jamie.Newbold@sruc.ac.uk	Nash, Robert/ABE-3575-2020; Ramos-Morales, Eva/ABD-3707-2021; de la Fuente Oliver, Gabriel/M-6981-2019; de la Fuente Oliver, Gabriel/B-3793-2015; Lahmann, Martina/A-3090-2010	Ramos-Morales, Eva/0000-0002-7056-9097; de la Fuente Oliver, Gabriel/0000-0003-0083-776X; de la Fuente Oliver, Gabriel/0000-0003-0083-776X; Lahmann, Martina/0000-0002-8513-1952; Nash, Robert/0000-0002-3272-640X	Innovate UK project "Ivy for ruminants" [101091]; Biotechnology and Biological Sciences Research Council, UK [BB/J0013/1]; BBSRC [BBS/E/W/10964A01B] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/W/10964A01B] Funding Source: researchfish	Innovate UK project "Ivy for ruminants"(UK Research & Innovation (UKRI)Innovate UK); Biotechnology and Biological Sciences Research Council, UK(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was financed by the Innovate UK project "Ivy for ruminants" Ref: 101091. SD (DSM Nutritional Products Ltd.) and RN (PhytoQuest Ltd.) were part of the project consortium and they contributed to the conceptualization of the project as well as to the funding acquisition and revision of the manuscript (as described in the author's contributions section). The before mentioned institutions did not provide any further funding. CJN acknowledges the support of the Biotechnology and Biological Sciences Research Council, UK via grant number BB/J0013/1.	Asano N, 2003, CURR TOP MED CHEM, V3, P471, DOI 10.2174/1568026033452438; Atteh JO, 2008, J ANIM PHYSIOL AN N, V92, P640, DOI 10.1111/j.1439-0396.2007.00760.x; Belanche A, 2012, J ANIM SCI, V90, P4495, DOI 10.2527/jas.2012-5118; Belanche A, 2016, J SCI FOOD AGR, V96, P3069, DOI 10.1002/jsfa.7481; Belanche A, 2016, FEMS MICROBIOL ECOL, V92, DOI 10.1093/femsec/fiv160; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; De la Fuente Gabriel, 2006, Zootaxa, V1377, P47; Debnath M, 2008, J MED PLANTS RES, V2, P45; Dehority BA, 1993, LABORATORY MANUAL FO; Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725; Ghias Uddin, 2011, Middle East Journal of Scientific Research, V8, P198; Guo YQ, 2008, LETT APPL MICROBIOL, V47, P421, DOI 10.1111/j.1472-765X.2008.02459.x; Hill TCJ, 2003, FEMS MICROBIOL ECOL, V43, P1, DOI 10.1111/j.1574-6941.2003.tb01040.x; Hongoh Y, 2003, FEMS MICROBIOL LETT, V221, P299, DOI 10.1016/S0378-1097(03)00218-0; Hu WL, 2005, ANIM FEED SCI TECH, V120, P333, DOI 10.1016/j.anifeedsci.2005.02.029; Jayanegara A, 2014, ASIAN AUSTRAL J ANIM, V27, P1426, DOI 10.5713/ajas.2014.14086; KOHDA H, 1976, PHYTOCHEMISTRY, V15, P981, DOI 10.1016/S0031-9422(00)84384-8; Lutsenko Y., 2010, Herba Polonica, V56, P83; Menke K.H., 1988, ANIMAL RES DEV, V28, P7, DOI DOI 10.1016/S0301-6226(01)00298-6.PALMQUIST; Michalik A, 2010, PHYTOCHEM LETT, V3, P136, DOI 10.1016/j.phytol.2010.04.004; Morgavi DP, 2004, FOOD ADDIT CONTAM A, V21, P871, DOI [10.1080/02652030400002188, 10.1080/0265-2030400002188]; Moss AR, 2000, ANN ZOOTECH, V49, P231, DOI 10.1051/animres:2000119; NASH RJ, 1986, J CHROMATOGR, V366, P431, DOI 10.1016/S0021-9673(01)93497-1; Nash RJ, 2011, FUTURE MED CHEM, V3, P1513, DOI [10.4155/FMC.11.117, 10.4155/fmc.11.117]; Newbold CJ, 2010, IN VITRO SCREENING OF PLANT RESOURCES FOR EXTRA-NUTRITIONAL ATTRIBUTES IN RUMINANTS: NUCLEAR AND RELATED METHODOLOGIES, P47, DOI 10.1007/978-90-481-3297-3_4; Newbold CJ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01313; Newbold CJ, 1997, BRIT J NUTR, V78, P237, DOI 10.1079/BJN19970143; Parvu M, 2015, NOT BOT HORTI AGROBO, V43, P53, DOI 10.15835/nbha4319644; Patra AK, 2009, NUTR RES REV, V22, P204, DOI 10.1017/S0954422409990163; Patra K. A., 2009, ANTON LEEUW INT J G, V96, P363, DOI [10.1007/s10482-009-9364-1, DOI 10.1007/S10482-009-9364-1]; Pielartzik H, 1985, METHODEN DER ORGANIS, P656; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; Ramos-Morales E, 2016, UK patent application number, Patent No. [1620438.0, 1620438]; Ramos-Morales E, 2016, Patent PCT/ EP, Patent No. 2016062383; Ramos-Morales E, 2014, VITRO EFFECT OF THE, P116; Ramos-Morales E, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00399; Seymour WM, 2005, ANIM FEED SCI TECH, V119, P155, DOI 10.1016/j.anifeedsci.2004.10.001; Skrivanova E, 2010, VET MICROBIOL, V144, P334, DOI 10.1016/j.vetmic.2010.01.013; STEWART CS, 1985, J GEN MICROBIOL, V131, P427; Sumit Ghosh, 2008, International Journal of Integrative Biology, V2, P27; Tedeschi LO, 2000, P CORN NUTR C FEED M; Tomita T, 1997, MICROBIOL IMMUNOL, V41, P1005, DOI 10.1111/j.1348-0421.1997.tb01961.x; Torres M, 2015, Compend. cienc. vet, V5, P32, DOI 10.18004/compend.cienc.vet.2015.05.02.32-37; Wallace RJ, 2007, J LIPID RES, V48, P2247, DOI 10.1194/jlr.M700271-JLR200; WALLACE RJ, 1987, BRIT J NUTR, V58, P313, DOI 10.1079/BJN19870098; Wang LS, 2014, ANIM FEED SCI TECH, V187, P104, DOI 10.1016/j.anifeedsci.2013.10.014; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; Williams A.G., 1992, RUMEN PROTOZOA; Wina E, 2005, J AGR FOOD CHEM, V53, P8093, DOI 10.1021/jf048053d	50	10	10	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0184517	10.1371/journal.pone.0184517	http://dx.doi.org/10.1371/journal.pone.0184517			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG2YO	28886130	Green Published, gold, Green Submitted			2023-01-03	WOS:000410001100145
J	Barcena, C; Lopez-Otin, C				Barcena, Clea; Lopez-Otin, Carlos			A fruitful liaison of ZSCAN10 and ROS on the road to rejuvenation	NATURE CELL BIOLOGY			English	Editorial Material							METABOLIC-REGULATION; STEM-CELLS; ACTIVATION	Induced pluripotent stem cells derived from aged donors (A-iPSCs) usually show genomic instability that affects their utility and raises concerns about their safety. Now, a study highlights the importance of ZSCAN10-dependent recovery of glutathione-ROS homeostasis in counteracting the genomic defects in A-iPSCs.	[Barcena, Clea; Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.	clo@uniovi.es	Barcena, Clea/AAB-4606-2020; López-Otín, Carlos/AAB-2106-2020	Barcena, Clea/0000-0002-7452-2536; López-Otín, Carlos/0000-0001-6964-1904				Chandel NS, 2016, NAT CELL BIOL, V18, P823, DOI 10.1038/ncb3385; Cheteh EH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.225; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Kang EJ, 2016, CELL STEM CELL, V18, P625, DOI 10.1016/j.stem.2016.02.005; Kilpinen H, 2017, NATURE, V546, P370, DOI 10.1038/nature22403; Li TS, 2010, STEM CELLS, V28, P1178, DOI 10.1002/stem.438; Lo Sardo V, 2017, NAT BIOTECHNOL, V35, P69, DOI 10.1038/nbt.3749; Neves J, 2017, CELL STEM CELL, V20, P161, DOI 10.1016/j.stem.2017.01.008; Skamagki M, 2017, NAT CELL BIOL, V19, P1037, DOI 10.1038/ncb3598; Soria-Valles C, 2015, NAT CELL BIOL, V17, P1004, DOI 10.1038/ncb3207; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Yu HB, 2009, J BIOL CHEM, V284, P31327, DOI 10.1074/jbc.M109.016162; Zhang W, 2006, NUCLEIC ACIDS RES, V34, P4780, DOI 10.1093/nar/gkl631; Zhou G, 2016, CELL REP, V15, P919, DOI 10.1016/j.celrep.2016.03.084	15	1	1	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2017	19	9					1012	1013		10.1038/ncb3602	http://dx.doi.org/10.1038/ncb3602			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FF1RC	28855729				2023-01-03	WOS:000408675600005
J	Letai, A				Letai, Anthony			Functional precision cancer medicine-moving beyond pure genomics	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; DRUG-SENSITIVITY; TARGETED THERAPY; RESISTANCE; DEATH; INHIBITOR; MUTATIONS; ONCOLOGY; STRATEGY; PATIENT	The essential job of precision medicine is to match the right drugs to the right patients. In cancer, precision medicine has been nearly synonymous with genomics. However, sobering recent studies have generally shown that most patients with cancer who receive genomic testing do not benefit from a genomic precision medicine strategy. Although some call the entire project of precision cancer medicine into question, I suggest instead that the tools employed must be broadened. Instead of relying exclusively on big data measurements of initial conditions, we should also acquire highly actionable functional information by perturbing-for example, with cancer therapies-viable primary tumor cells from patients with cancer.	[Letai, Anthony] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Letai, A (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	anthony_letai@dfci.harvard.edu	He, Liye/C-8843-2015	He, Liye/0000-0002-6632-2112	National Institutes of Health [R01CA205967]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	I would like to acknowledge P. Bhola for assistance with Figure 1 and the entire Letai laboratory for conversations over years that have stimulated ideas contained in this article. I also gratefully acknowledge funding from National Institutes of Health grant R01CA205967.	Andre F, 2014, ANN ONCOL, V25, P2295, DOI 10.1093/annonc/mdu478; Armand P, 2016, J CLIN ONCOL, V34, P1, DOI [DOI 10.1200/JC0.2016.67.3467, 10.1200/JC0.2016.67.3467]; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Carr TH, 2016, NAT REV CANCER, V16, P319, DOI 10.1038/nrc.2016.35; Cermak N, 2016, NAT BIOTECHNOL, V34, P1052, DOI 10.1038/nbt.3666; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Etchin J, 2016, LEUKEMIA, V30, P190, DOI 10.1038/leu.2015.194; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fojo T, 2016, SEMIN ONCOL, V43, P9, DOI 10.1053/j.seminoncol.2016.01.005; Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015; Frismantas V, 2017, BLOOD, V129, pE26, DOI 10.1182/blood-2016-09-738070; Halfter K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1491-7; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jain N, 2016, BLOOD REV, V30, P233, DOI 10.1016/j.blre.2015.12.002; Jonas O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010564; KERN DH, 1990, J NATL CANCER I, V82, P582, DOI 10.1093/jnci/82.7.582; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lopez-Chavez A, 2015, J CLIN ONCOL, V33, P1000, DOI 10.1200/JCO.2014.58.2007; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Meric-Bernstam F, 2015, JNCI-J NATL CANCER I, V107, P107; Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165; Montero J, 2015, CELL, V160, P977, DOI 10.1016/j.cell.2015.01.042; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Pietarinen PO, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.30; Prasad V, 2016, NATURE, V537, pS63, DOI 10.1038/537S63a; Prasad V, 2016, LANCET ONCOL, V17, pE81, DOI 10.1016/S1470-2045(15)00620-8; Prasad V, 2015, MAYO CLIN PROC, V90, P1639, DOI 10.1016/j.mayocp.2015.08.017; Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Ryan J, 2016, BIOL CHEM, V397, P671, DOI 10.1515/hsz-2016-0107; Samson DJ, 2004, J CLIN ONCOL, V22, P3618, DOI 10.1200/JCO.2004.04.077; Schwaederle M, 2015, J CLIN ONCOL, V33, P3817, DOI 10.1200/JCO.2015.61.5997; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Stevens MM, 2016, NAT BIOTECHNOL, V34, P1161, DOI 10.1038/nbt.3697; Swanton C, 2016, ANN ONCOL, V27, P1443, DOI 10.1093/annonc/mdw192; Tannock IF, 2016, NEW ENGL J MED, V375, P1289, DOI 10.1056/NEJMsb1607705; Vo TT, 2012, CELL, V151, P344, DOI 10.1016/j.cell.2012.08.038; Townsend EC, 2016, CANCER CELL, V29, P574, DOI 10.1016/j.ccell.2016.03.008; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Tsimberidou AM, 2015, LANCET ONCOL, V16, pE579, DOI 10.1016/S1470-2045(15)00397-6; Tsimberidou AM, 2014, CLIN CANCER RES, V20, P4827, DOI 10.1158/1078-0432.CCR-14-0603; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Vasan N, 2014, ONCOLOGIST, V19, P453, DOI 10.1634/theoncologist.2013-0377; Voss MH, 2014, CLIN CANCER RES, V20, P1955, DOI 10.1158/1078-0432.CCR-13-2345; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; West H, 2016, JAMA ONCOL, V2, P717, DOI 10.1001/jamaoncol.2016.0075; Wu SC, 2015, CANCER CELL, V28, P29, DOI 10.1016/j.ccell.2015.06.005; Yadav B, 2014, SCI REP-UK, V4, DOI 10.1038/srep05193; Younes A, 2016, LANCET ONCOL, V17, P1283, DOI 10.1016/S1470-2045(16)30167-X; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533	64	163	167	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2017	23	9					1028	1035		10.1038/nm.4389	http://dx.doi.org/10.1038/nm.4389			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FG2XO	28886003				2023-01-03	WOS:000409996200009
J	Fu, SP; Hong, H; Lu, SF; Hu, CJ; Xu, HX; Li, Q; Yu, ML; Ou, C; Meng, JZ; Wang, TL; Hennighausen, L; Zhu, BM				Fu, Shu-Ping; Hong, Hao; Lu, Sheng-Feng; Hu, Chen-Jun; Xu, Hou-Xi; Li, Qian; Yu, Mei-Ling; Ou, Chen; Meng, Jian-Zhong; Wang, Tian-Lin; Hennighausen, Lothar; Zhu, Bing-Mei			Genome-wide regulation of electro-acupuncture on the neural Stat5-loss-induced obese mice	PLOS ONE			English	Article							SIGNAL TRANSDUCER; GROWTH-HORMONE; ACUPUNCTURE; ACTIVATOR; DIFFERENTIATION; TRANSCRIPTION; GENETICS; PROTEIN; BURDEN; LIVER	Acupuncture is reported to be effective in treating obesity related illnesses, but its mechanism is still unclear. To investigate this mechanism we applied electro-acupuncture (EA) in a mouse model of obesity and used RNA-seq to identify molecular consequences. Deletion of the transcription factor STAT5 from neurons (Stat5NKO) led to obesity. Acupuncture, in turn, reduced body weight and the ratio of epididymal white adipose tissue (Epi-WAT) to body weight, and it also decreased plasma concentrations of glucose, triglyceride, and cholesterol. In addition, EA increased cold endurance of Stat5NKO obese mice. EA reversed altered gene expressions in the hypothalamus and Epi-WAT, especially in the hypothalamus in Stat5NKO obese mice. This study provides, for the first time, insight into genomic networks of obesity and their modulation by electro-acupuncture, which in turn reveals potential mechanisms that explain acupuncture-induced weight-loss.	[Fu, Shu-Ping; Hong, Hao; Lu, Sheng-Feng; Xu, Hou-Xi; Li, Qian; Yu, Mei-Ling; Ou, Chen; Meng, Jian-Zhong; Wang, Tian-Lin] Nanjing Univ Chinese Med, Minist Educ, Key Lab Acupuncture & Med Res, Nanjing, Jiangsu, Peoples R China; [Hu, Chen-Jun] Nanjing Univ Chinese Med, Sch Informat Technol, Nanjing, Jiangsu, Peoples R China; [Hennighausen, Lothar] NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; [Zhu, Bing-Mei] Sichuan Univ, West China Hosp, Regenerat Med Res Ctr, Chengdu, Sichuan, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Sichuan University	Zhu, BM (corresponding author), Sichuan Univ, West China Hosp, Regenerat Med Res Ctr, Chengdu, Sichuan, Peoples R China.	zhubm64@hotmail.com		Hennighausen, Lothar/0000-0001-8319-9841	National Natural Science Foundation of China [81574063, 81403479, 81273838]; Natural Science Foundation of the Jiangsu Province of China [BK20130956]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of the Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Natural Science Foundation of China (No. 81574063, 81403479, 81273838), the Natural Science Foundation of the Jiangsu Province of China (No. BK20130956).	Abdi H, 2012, THESCIENTIFICWORLDJO, V2012, DOI DOI 10.1100/2012/603539; Baik M, 2016, J NUTR BIOCHEM, V29, P56, DOI 10.1016/j.jnutbio.2015.10.018; Baugh JE, 2007, OBESITY, V15, P583, DOI 10.1038/oby.2007.500; Belivani M, 2013, ACUPUNCT MED, V31, P88, DOI 10.1136/acupmed-2012-010247; Brestoff JR, 2015, NATURE, V519, P242, DOI 10.1038/nature14115; Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552; Cave BJ, 2005, NEUROREPORT, V16, P1423, DOI 10.1097/01.wnr.0000176516.19347.6f; Cho SH, 2009, INT J OBESITY, V33, P183, DOI 10.1038/ijo.2008.269; Choowanthanapakorn M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17366; Coll AP, 2004, J CLIN ENDOCR METAB, V89, P2557, DOI 10.1210/jc.2004-0428; Crujeiras A. B., 2015, LIFE SCI; Cui Y, 2007, HEPATOLOGY, V46, P504, DOI 10.1002/hep.21713; Darbandi S, 2013, ALTERN THER HEALTH M, V19, P24; Garretson JT, 2015, J NEUROSCI, V35, P4571, DOI 10.1523/JNEUROSCI.2129-14.2015; Gaudet AD, 2016, SCI REP-UK, V6, DOI 10.1038/srep22862; Gong M, 2015, ACUPUNCT MED; Gong MR, 2012, AM J CHINESE MED, V40, P511, DOI 10.1142/S0192415X12500395; Gortmaker SL, 2011, LANCET, V378, P838, DOI 10.1016/S0140-6736(11)60815-5; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Herrera BM, 2011, MATURITAS, V69, P41, DOI 10.1016/j.maturitas.2011.02.018; Kelly T, 2008, INT J OBESITY, V32, P1431, DOI 10.1038/ijo.2008.102; Lee JY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001639; LIN JH, 1991, AM J CHINESE MED, V19, P9, DOI 10.1142/S0192415X9100003X; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Meister B, 2000, Vitam Horm, V59, P265, DOI 10.1016/S0083-6729(00)59010-4; O'Rahilly S, 2009, NATURE, V462, P307, DOI 10.1038/nature08532; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Pischon T, 2008, NEW ENGL J MED, V359, P2105, DOI 10.1056/NEJMoa0801891; Schmid PM, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-48; Shang CA, 2003, MOL ENDOCRINOL, V17, P2494, DOI 10.1210/me.2003-0139; Shen WX, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-501; Teucher B, 2010, MATURITAS, V65, P112, DOI 10.1016/j.maturitas.2009.11.018; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Wang F, 2011, PEPTIDES, V32, P2394, DOI 10.1016/j.peptides.2011.10.019; Wang Q, 2012, AM J CHINESE MED, V40, P1157, DOI 10.1142/S0192415X12500851; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; Wen CK, 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/473978; White UA, 2010, MOL CELL ENDOCRINOL, V318, P10, DOI 10.1016/j.mce.2009.08.023; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054; Yu JB, 2014, MED SCI MONITOR, V20, P406, DOI 10.12659/MSM.890111	42	11	12	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2017	12	8							e0181948	10.1371/journal.pone.0181948	http://dx.doi.org/10.1371/journal.pone.0181948			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD5CP	28806763	gold, Green Submitted, Green Published			2023-01-03	WOS:000407548800010
J	Messina, S; Solaro, C; Righini, I; Bergamaschi, R; Bonavita, S; Bossio, RB; Morra, VB; Costantino, G; Cavalla, P; Centonze, D; Comi, G; Cottone, S; Danni, MC; Francia, A; Gajofatto, A; Gasperini, C; Zaffaroni, M; Petrucci, L; Signoriello, E; Maniscalco, GT; Spinicci, G; Matta, M; Mirabella, M; Peda, G; Castelli, L; Rovaris, M; Sessa, E; Spitaleri, D; Paolicelli, D; Granata, A; Zappia, M; Patti, F				Messina, Silvia; Solaro, Claudio; Righini, Isabella; Bergamaschi, Roberto; Bonavita, Simona; Bossio, Roberto Bruno; Morra, Vincenzo Brescia; Costantino, Gianfranco; Cavalla, Paola; Centonze, Diego; Comi, Giancarlo; Cottone, Salvatore; Danni, Maura Chiara; Francia, Ada; Gajofatto, Alberto; Gasperini, Claudio; Zaffaroni, Mauro; Petrucci, Loredana; Signoriello, Elisabetta; Maniscalco, Giorgia Teresa; Spinicci, Gabriella; Matta, Manuela; Mirabella, Massimiliano; Peda, Graziella; Castelli, Letizia; Rovaris, Marco; Sessa, Edoardo; Spitaleri, Daniele; Paolicelli, Damiano; Granata, Alfredo; Zappia, Mario; Patti, Francesco		SAFE Study Grp	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)	PLOS ONE			English	Article							CANNABIS-BASED MEDICINE; DOUBLE-BLIND; SYMPTOMS; MANAGEMENT; IMPACT	Background The approval of Sativex for the management of multiple sclerosis (MS) spasticity opened a new opportunity to many patients. In Italy, the healthcare payer can be fully reimbursed by the involved pharma company with the cost of treatment for patients not responding after a 4 week (28 days) trial period (Payment by Results, PbR), and 50% reimbursed with the cost of 6 weeks (42 days) treatment for other patients discontinuing (Cost Sharing, CS). The aim of our study was to describe the Sativex discontinuation profile from a large population of spasticity treated Italian MS patients. Methods We collected data of patients from 30 MS centres across the country starting Sativex between January 2014 and February 2015. Data were collected from the mandatory Italian Medicines Agency (AIFA) web-registry. Predictors of treatment discontinuation were assessed using a multivariate Cox proportional regression analysis. Results During the observation period 631 out of 1597 (39.5%) patients discontinued Sativex. The Kaplan-Meier estimates curve showed that 333 patients (20.8%) discontinued treatment at 4 weeks while 422 patients (26.4%) discontinued at 6 weeks. We found after adjusted modeling that a higher NRS score at T1 (adjHR 2.23, 95% 2.07-2.41, p<0.001) and a lower baseline NRS score (adjHR 0.51 95% CI 0.46-0.56, p<0.001) were predictive of treatment discontinuation. Conclusion These data show that the first 6 weeks are useful in identifying those patients in which Sativex could be effective, thus avoiding the cost of longer term evaluation.	[Messina, Silvia; Zappia, Mario; Patti, Francesco] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Catania, Italy; [Solaro, Claudio] Dept Head & Neck, Neurol Unit, ASL3, Genoa, Italy; [Righini, Isabella] Univ Florence, Dept NEUROFARBA, Florence, Italy; [Bergamaschi, Roberto] Neurol Inst C Mondino, Dept Neurol, Pavia, Italy; [Bonavita, Simona] II Univ Naples, Clin Neurol 1, Naples, Italy; [Bossio, Roberto Bruno] Neurol Operating Unit, Cosenza, Italy; [Bossio, Roberto Bruno] Multiple Sclerosis Ctr, Prov Hlth Author Cosenza, Cosenza, Italy; [Morra, Vincenzo Brescia] Univ Federico II, Multiple Sclerosis Ctr, Naples, Italy; [Costantino, Gianfranco] Foggia Hosp, Demyelinating Dis Ctr, Foggia, Italy; [Cavalla, Paola] Cittadella Salute & Sci Torino, AOU, Turin, Italy; [Centonze, Diego] Univ Tor Vegata, Neurosci Dept, Rome, Italy; [Centonze, Diego] IRCCS, Neuromed, Unit Neurol & Neurorehabil, Pozzilli, IS, Italy; [Centonze, Diego] Osped San Raffaele, Dept Neurol, Milan, Italy; [Cottone, Salvatore] Villa Sofia Cervello Hosp, Neuroimmunol Unit, Palermo, Italy; [Danni, Maura Chiara] Ancona Hosp, Neurol Clin, Ancona, Italy; [Francia, Ada] Psich Sapienza Univ, Dept Neurol, Multiple Sclerosis Ctr, Rome, Italy; [Gajofatto, Alberto] Univ Verona, Dept Neurosci, Biomed & Movement Multiple Sclerosis Ctr, Verona, Italy; [Gasperini, Claudio] San Camillo Hosp, Neurol Div, Rome, Italy; [Zaffaroni, Mauro] Sant Antonio Abate Hosp, Multiple Sclerosis Ctr, Gallarate, Italy; [Petrucci, Loredana] Univ Hosp Pisa, Multiple Sclerosis Ctr, Pisa, Italy; [Signoriello, Elisabetta] Univ Naples 2, Multiple Sclerosis Ctr, Naples, Italy; [Maniscalco, Giorgia Teresa] Cardarelli Hosp, Multiple Sclerosis Ctr, Naples, Italy; [Spinicci, Gabriella] Univ Cagliari, Dept Med Sci, Cagliari, Italy; [Matta, Manuela] San Luigi Gonzaga Hosp, Multiple Sclerosis Ctr CRESM, Orbassano, Italy; [Mirabella, Massimiliano] Cattol Univ, Multiple Sclerosis Ctr, Rome, Italy; [Peda, Graziella] Vaio Hosp, Multiple Sclerosis Ctr, Fidenza, Italy; [Castelli, Letizia] S Andrea Hosp, Multiple Sclerosis Ctr, Rome, Italy; [Rovaris, Marco] IRCCS, Don Gnocchi Fdn, Multiple Sclerosis Ctr, Milan, Italy; [Sessa, Edoardo] IRCCS, Bonino Pulejo Ctr, Multiple Sclerosis Ctr, Messina, Italy; [Spitaleri, Daniele] San G Moscati Hosp, Multiple Sclerosis Ctr, Avellino, Italy; [Paolicelli, Damiano] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy; [Granata, Alfredo] Magna Graecia Univ Catanzaro, Inst Neurol, Dept Med Sci, Catanzaro, Italy	University of Catania; University of Florence; IRCCS Fondazione Casimiro Mondino; Universita della Campania Vanvitelli; University of Naples Federico II; A.O.U. Citta della Salute e della Scienza di Torino; IRCCS Neuromed; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Verona; University of Pisa; Azienda Ospedaliero Universitaria Pisana; Universita della Campania Vanvitelli; Antonio Cardarelli Hospital; University of Cagliari; Azienda Ospedaliero-Universitaria San Luigi Gonzaga; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Fondazione Don Carlo Gnocchi Onlus; San Giuseppe Moscati Hospital; Universita degli Studi di Bari Aldo Moro; Magna Graecia University of Catanzaro	Patti, F (corresponding author), Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Catania, Italy.	patti@unict.it	Sessa, Edoardo/AAB-8544-2020; Solaro, Claudio Marcello/AAL-2402-2021; MIRABELLA, Massimiliano/AAC-4016-2020; Signoriello, Elisabetta/ABG-1289-2020; Castelli, Letizia/AAC-2441-2019; Rovaris, Marco/AAA-6040-2020; Centonze, Diego/J-7767-2016; Bonavita, Simona/AGN-5124-2022; Messina, Silvia/ABC-8780-2020; Castelli, Letizia/AAL-7701-2020; Zappia, Mario/AAB-7800-2019; Signoriello, Elisabetta/AAL-9069-2021	Solaro, Claudio Marcello/0000-0002-6713-4623; MIRABELLA, Massimiliano/0000-0002-7783-114X; Signoriello, Elisabetta/0000-0001-5753-6752; Rovaris, Marco/0000-0001-9691-1957; Centonze, Diego/0000-0002-8390-8545; Bonavita, Simona/0000-0002-8561-9720; patti, francesco/0000-0002-6923-0846				Arroyo R, 2014, J COMP EFFECT RES, V3, P435, DOI [10.2217/CER.14.30, 10.2217/cer.14.30]; Arroyo R, 2011, EXPERT REV PHARM OUT, V11, P205, DOI [10.1586/ERP.11.6, 10.1586/erp.11.6]; Beard S., 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7400; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; Collin C, 2010, NEUROL RES, V32, P451, DOI 10.1179/016164109X12590518685660; Farrar JT, 2008, CLIN THER, V30, P974, DOI 10.1016/j.clinthera.2008.05.011; Garrison LP, 2013, VALUE HEALTH, V16, P703, DOI 10.1016/j.jval.2013.04.011; Meuth SG, 2015, EXPERT REV NEUROTHER, V15, P909, DOI 10.1586/14737175.2015.1067607; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Oreja-Guevara C., 2015, CLIN EXP PHARM, V5, DOI [10.4172/2161-1459.1000184, DOI 10.4172/2161-1459.1000184]; Otero-Romero S, 2016, MULT SCLER J, V22, P1386, DOI 10.1177/1352458516643600; Patti F, 2016, J NEUROL NEUROSUR PS, V87, P944, DOI 10.1136/jnnp-2015-312591; Patti F, 2014, NEUROEPIDEMIOLOGY, V42, P211, DOI 10.1159/000360423; Pozzilli C, 2014, EUR NEUROL, V71, P1, DOI 10.1159/000357739; Shakespeare D T, 2001, Cochrane Database Syst Rev, pCD001332, DOI 10.1002/14651858.CD001332; Slof J, 2015, EXPERT REV PHARM OUT, V15, P379, DOI 10.1586/14737167.2015.1025759; Wade DT, 2006, MULT SCLER J, V12, P639, DOI 10.1177/1352458505070618; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa	18	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0180651	10.1371/journal.pone.0180651	http://dx.doi.org/10.1371/journal.pone.0180651			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3VC	28763462	Green Published, Green Submitted, gold			2023-01-03	WOS:000406766500006
J	Mate-Munoz, JL; Lougedo, JH; Barba, M; Garcia-Fernandez, P; Garnacho-Castano, MV; Dominguez, R				Luis Mate-Munoz, Jose; Lougedo, Juan H.; Barba, Manuel; Garcia-Fernandez, Pablo; Garnacho-Castano, Manuel V.; Dominguez, Raul			Muscular fatigue in response to different modalities of CrossFit sessions	PLOS ONE			English	Article							SHORTENING CYCLE EXERCISE; CREATINE SUPPLEMENTATION; AEROBIC FITNESS; PERFORMANCE; LACTATE; FORCE; POWER; COORDINATION; ENDURANCE; RECOVERY	Background CrossFit is a new strength and conditioning regimen involving short intense daily workouts called workouts of the day (WOD). This study assesses muscular fatigue levels induced by the three modalities of CrossFit WOD; gymnastics (G), metabolic conditioning (M) and weightlifting (W). Material and methods 34 healthy subjects undertook three WOD (one per week): a G WOD consisting of completing the highest number of sets of 5 pull-ups, 10 push-ups and 15 air squats in 20 min; an M WOD, in which the maximum number of double skipping rope jumps was executed in 8 sets (20 s), resting (10 s) between sets; and finally, a W WOD in which the maximum number of power cleans was executed in 5 min, lifting a load equivalent to 40% of the individual's 1RM. Before and after each WOD, blood lactate concentrations were measured. Also, before, during, and after each WOD, muscular fatigue was assessed in a countermovement jump test (CMJ). Results Significant reductions were produced in the mechanical variables jump height, average power and maximum velocity in response to G; and in jump height, mean and peak power, maximum velocity and maximum force in response to W (P<0.01). However, in M, significant reductions in mechanical variables were observed between pre- and mid session (after sets 2, 4, 6 and 8), but not between pre- and post session. Conclusions Muscular fatigue, reflected by reduced CMJ variables, was produced following the G and W sessions, while recovery of this fatigue was observed at the end of M, likely attributable to rest intervals allowing for the recovery of phosphocreatine stores. Our findings also suggest that the high intensity and volume of exercise in G and W WODs could lead to reduced muscular-tendon stiffness causing a loss of jump ability, related here to a longer isometric phase during the CMJ.	[Luis Mate-Munoz, Jose; Lougedo, Juan H.; Barba, Manuel; Garcia-Fernandez, Pablo; Dominguez, Raul] Alfonso X Sabio Univ, Dept Phys Act & Sport Sci, Madrid, Spain; [Garnacho-Castano, Manuel V.] Pompeu Fabra Univ, Coll Hlth Sci, TecnoCampus, Barcelona, Spain	Pompeu Fabra University	Mate-Munoz, JL (corresponding author), Alfonso X Sabio Univ, Dept Phys Act & Sport Sci, Madrid, Spain.	jmatmuo@uax.es	Domínguez, Raúl/AAX-1068-2021; Garnacho-Castaño, Manuel Vicente/AAE-4620-2020	Garnacho-Castaño, Manuel Vicente/0000-0003-3180-4629; Dominguez, Raul/0000-0002-6891-391X; Garcia Fernandez, Pablo/0000-0002-6604-9136; Mate-Munoz, Jose Luis/0000-0003-3282-1455				Abdessemed D, 1999, INT J SPORTS MED, V20, P368, DOI 10.1055/s-2007-971146; Bobbert M F, 2001, Exerc Sport Sci Rev, V29, P95, DOI 10.1097/00003677-200107000-00002; Bompa TO, 1999, HUMAN KINETICS; BOSCO C, 1979, EUR J APPL PHYSIOL O, V41, P275, DOI 10.1007/BF00429744; Bosquet L, 2010, J SPORT SCI MED, V9, P459; Brown LE, 2003, J STRENGTH COND RES, V17, P88; Butcher SJ, 2015, OPEN ACCESS J SPORTS, V6, P241, DOI 10.2147/OAJSM.S88265; Cooper R, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-33; Dong-Hoon Yoo，, 2015, [Exercise Science, 운동과학], V24, P109, DOI 10.15857/ksep.2015.24.2.117; Farley CT, 1999, J BIOMECH, V32, P267, DOI 10.1016/S0021-9290(98)00170-5; Garnacho-Castano MV, 2015, J STRENGTH COND RES, V29, P2867, DOI 10.1519/JSC.0000000000000956; Garnacho-Castano MV, 2015, J SPORT SCI MED, V14, P128; Glassman G, 2007, E VAL CROSSFIT NEWSL, V56, P1; Goins J, 2014, MED SCI SPORT EXER, V46, P270, DOI 10.1249/01.mss.0000493998.84691.5d; Gorostiaga EM, 2010, J STRENGTH COND RES, V24, P1138, DOI 10.1519/JSC.0b013e3181cf769f; Gutierrez M, 2006, BIOMECANICA DEPORTIV; Hadeed MJ, 2011, MED SCI SPORT EXER, V43, P224, DOI 10.1249/01.MSS.0000400606.24620.bc; Hak PT, 2013, J STRENGTH IN PRESS; Horita T, 2003, EUR J APPL PHYSIOL, V88, P527, DOI 10.1007/s00421-002-0716-z; Ishikawa M, 2006, EUR J APPL PHYSIOL, V97, P298, DOI 10.1007/s00421-006-0180-2; Ishikawa M, 2006, J ELECTROMYOGR KINES, V16, P423, DOI 10.1016/j.jelekin.2005.08.006; Joondeph SA, 2013, RETINAL DETACHMENT D; Khamoui AV, 2011, J STRENGTH COND RES, V25, P198, DOI 10.1519/JSC.0b013e3181b94a7b; Kliszczewicz B, 2014, J SPORT HUMAN PERF, P1, DOI DOI 10.12922/JSHP.V2I2.38; Kliszczewicz B, 2015, J HUM KINET, V47, P81, DOI 10.1515/hukin-2015-0064; Korhonen MT, 2006, J APPL PHYSIOL, V101, P906, DOI 10.1152/japplphysiol.00299.2006; Mc Naughton LR, 2002, INT J SPORTS MED, V23, P130, DOI 10.1055/s-2002-20133; McCully KK, 2002, CAN J APPL PHYSIOL, V27, P70, DOI 10.1139/h02-005; McLean S.R., 2004, INT J APPL SPORTS SC, V16, P22; Millet GY, 2004, SPORTS MED, V34, P105, DOI 10.2165/00007256-200434020-00004; Moreira Reis AJL, 2014, APUNTS MED SPORT, V49, P53; Murray DP, 2007, J STRENGTH COND RES, V21, P870; Pereira Gleber, 2014, Motriz: rev. educ. fis., V20, P303, DOI 10.1590/S1980-65742014000300009; Perez M, 2003, BRIT J SPORT MED, V37, P140, DOI 10.1136/bjsm.37.2.140; Rodacki ALF, 2002, MED SCI SPORT EXER, V34, P105, DOI 10.1097/00005768-200201000-00017; Rodacki ALF, 2001, MED SCI SPORT EXER, V33, P1157; Romero D., 2010, PREVENCION LESIONES; Sanchez-Medina L, 2011, MED SCI SPORT EXER, V43, P1725, DOI 10.1249/MSS.0b013e318213f880; Skare OC, 2001, SCAND J MED SCI SPOR, V11, P96, DOI 10.1034/j.1600-0838.2001.011002096.x; Smilios I, 2010, J STRENGTH COND RES, V24, P2122, DOI 10.1519/JSC.0b013e3181a5bc44; Smith MM, 2013, J STRENGTH COND RES, V27, P3159, DOI 10.1519/JSC.0b013e318289e59f; Tabata I, 1996, MED SCI SPORT EXER, V28, P1327, DOI 10.1097/00005768-199610000-00018; Tibana RA, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00260; Tomlin DL, 2001, SPORTS MED, V31, P1, DOI 10.2165/00007256-200131010-00001; Weisenthal BM, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114531177	45	54	58	2	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2017	12	7							e0181855	10.1371/journal.pone.0181855	http://dx.doi.org/10.1371/journal.pone.0181855			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1ED	28753624	Green Submitted, gold, Green Published			2023-01-03	WOS:000406579300029
J	Tiruvoipati, R; Botha, J; Fletcher, J; Gangopadhyay, H; Majumdar, M; Vij, S; Paul, E; Pilcher, D				Tiruvoipati, Ravindranath; Botha, John; Fletcher, Jason; Gangopadhyay, Himangsu; Majumdar, Mainak; Vij, Sanjiv; Paul, Eldho; Pilcher, David		Australia & New Zealand Intensive	Intensive care discharge delay is associated with increased hospital length of stay: A multicentre prospective observational study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; AFTER-HOURS DISCHARGE; MORTALITY; DELIRIUM; ADMISSION; UNIT; RISK	Background Some patients experience a delayed discharge from the intensive care unit (ICU) where the intended and actual discharge times do not coincide. The clinical implications of this remain unclear. Objective To determine the incidence and duration of delayed ICU discharge, identify the reasons for delay and evaluate the clinical consequences. Methods Prospective multi-centre observational study involving five ICUs over a 3-month period. Delay in discharge was defined as > 6 hours from the planned discharge time. The primary outcome measure was hospital length stay after ICU discharge decision. Secondary outcome measures included ICU discharge after-hours, incidence of delirium, survival to hospital discharge, discharge destination, the incidence of ICU acquired infections, revocation of ICU discharge decision, unplanned readmissions to ICU within 72 hours, review of patients admitting team after ICU discharge decision. Results A total of 955 out of 1118 patients discharged were included in analysis. 49.9% of the patients discharge was delayed. The most common reason (74%) for delay in discharge was non-availability of ward bed. The median duration of the delay was 24 hours. On univariable analysis, the duration of hospital stay from the time of ICU discharge decision was significantly higher in patients who had ICU discharge delay (Median days-5 vs 6; p = 0.003). After-hours discharge was higher in patients whose discharge was delayed (34% Vs 10%; p< 0.001). There was no statistically significant difference in the other secondary outcomes analysed. Multivariable analysis adjusting for known confounders revealed delayed ICU discharge was independently associated with increased hospital length of stay. Conclusion Half of all ICU patients experienced a delay in ICU discharge. Delayed discharge was associated with increased hospital length of stay.	[Tiruvoipati, Ravindranath; Botha, John] Frankston Hosp, Dept Intens Care Med, Frankston, Vic, Australia; [Tiruvoipati, Ravindranath; Botha, John] Monash Univ, Sch Publ Hlth, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia; [Fletcher, Jason] Bendigo Hosp, Bendigo, Vic, Australia; [Gangopadhyay, Himangsu] Box Hill Hosp, Box Hill, Vic, Australia; [Majumdar, Mainak] Maroondah Hosp, Ringwood, Vic, Australia; [Vij, Sanjiv] Dandenong Hosp, Dandenong, Vic, Australia; [Paul, Eldho; Pilcher, David] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Paul, Eldho] Alfred Hosp, Clin Haematol Dept, Melbourne, Vic, Australia; [Pilcher, David] Alfred Hosp, Dept Intens Care Med, Melbourne, Vic, Australia	Frankston Hospital; Monash University; Box Hill Hospital; Monash University; Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health	Tiruvoipati, R (corresponding author), Frankston Hosp, Dept Intens Care Med, Frankston, Vic, Australia.; Tiruvoipati, R (corresponding author), Monash Univ, Sch Publ Hlth, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia.	travindranath@hotmail.com	Tiruvoipati, Ravindranath/Q-9365-2019; litton, edward/C-5384-2017; Deane, Adam/D-7842-2013; Cooper, D. James/G-7961-2013; Udy, Andrew/G-2538-2010	litton, edward/0000-0002-5125-6829; French, Craig/0000-0003-1363-9711; Tiruvoipati, Ravindranath/0000-0003-3800-902X; Saxena, Manoj/0000-0002-0385-6731; Paul, Eldho/0000-0003-1263-7255; Mitchell, Imogen/0000-0001-6013-4922; Deane, Adam/0000-0002-7620-5577; Pilcher, David/0000-0002-8939-7985; Cooper, D. James/0000-0002-5872-9051; Young, Paul/0000-0002-3428-3083; Udy, Andrew/0000-0002-6284-2022	Australia and New Zealand Intensive Care Society (ANZICS) Safety and Quality Outcomes grant	Australia and New Zealand Intensive Care Society (ANZICS) Safety and Quality Outcomes grant	This study was funded by the Australia and New Zealand Intensive Care Society (ANZICS) Safety and Quality Outcomes grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, INTENSIVE CARE CLIN; Bhonagiri D, 2011, MED J AUSTRALIA, V194, P287, DOI 10.5694/j.1326-5377.2011.tb02976.x; Cardoso LTQ, 2011, CRIT CARE, V15, DOI 10.1186/cc9975; Drouot X, 2008, SLEEP MED REV, V12, P391, DOI 10.1016/j.smrv.2007.11.004; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Gantner D, 2014, INTENS CARE MED, V40, P1528, DOI 10.1007/s00134-014-3438-x; Girard TD, 2008, CRIT CARE, V12, DOI 10.1186/cc6149; Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6; Harris S, 2015, LANCET, V385, P40; Levin PD, 2003, J CRIT CARE, V18, P206, DOI 10.1016/j.jcrc.2003.10.003; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Luetz A, 2010, CRIT CARE MED, V38, P409, DOI 10.1097/CCM.0b013e3181cabb42; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pilcher DV, 2007, ANAESTH INTENS CARE, V35, P477, DOI 10.1177/0310057X0703500403; Salgado CD, 2005, CRIT CARE MED, V33, P2373, DOI 10.1097/01.CCM.0000181727.04501.F3; Santamaria JD, 2015, AM J RESP CRIT CARE, V191, P1033, DOI 10.1164/rccm.201412-2208OC; Simchen E, 2007, CRIT CARE MED, V35, P449, DOI 10.1097/01.CCM.0000253407.89594.15; Van Rompaey B, 2008, CRIT CARE, V12, DOI 10.1186/cc6790; Williams Teresa, 2004, Aust Health Rev, V28, P87; Williams TA, 2010, AUST CRIT CARE, V23, P141, DOI 10.1016/j.aucc.2010.02.003; Zaal IJ, 2015, CRIT CARE MED, V43, P40, DOI 10.1097/CCM.0000000000000625	21	22	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							e181827	10.1371/journal.pone.0181827	http://dx.doi.org/10.1371/journal.pone.0181827			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1CT	28750010	Green Published, gold			2023-01-03	WOS:000406575700085
J	Sharpe, AL; Varela, E; Beckstead, MJ				Sharpe, Amanda L.; Varela, Erika; Beckstead, Michael J.			Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA/2J mice without causing excessive sedation	PLOS ONE			English	Article							DOPAMINE; PSYCHOSTIMULANT; ACTIVATION; STRIATUM; RAT	Methamphetamine (METH) is a psychostimulant that exhibits significant abuse potential. Although METH addiction is a major health and societal concern, no drug is currently approved for its therapeutic management. METH activates the central dopaminergic "reward" circuitry, and with repeated use increases levels of the neuromodulatory peptide neurotensin in the nucleus accumbens and ventral tegmental area. Previous studies in rats suggest that neurotensin agonism decreases METH self-administration, but these studies did not examine the effect of neurotensin agonism on the pattern of self-administration or open field locomotion. In our studies, we established intravenous METH self-administration in male, DBA/2J mice (fixed ratio 3, 2 hr sessions) and examined the effect of pretreatment with the NTS1 receptor agonist PD149163 on METH self-administration behavior. Locomotion following PD149163 was also measured up to 2 hours after injection on a rotarod and in an open field. Pretreatment with PD149163 (0.05 and 0.10 mg/kg, s.c.) significantly decreased METH self-administration. The pattern of responding suggested that PD149163 decreased motivation to self-administer METH initially in the session with more normal intake in the second hour of access. Voluntary movement in the open-field was significantly decreased by both 0.05 and 0.10 mg/kg (s.c.) PD149163 from 10-120 minutes after injection, but rotarod performance suggested that PD149163 did not cause frank sedation. These results suggest that a systemically delivered NTS1 receptor agonist decreases METH self-administration in mice. The pattern of self-administration suggests that PD149163 may acutely decrease motivation to self-administer METH before the drug is experienced, but cannot rule out that depression of voluntary movement plays a role in the decreased self-administration.	[Sharpe, Amanda L.] Univ Incarnate Word, Feik Sch Pharm, Dept Pharmaceut Sci, San Antonio, TX 78209 USA; [Sharpe, Amanda L.; Varela, Erika; Beckstead, Michael J.] UT Hlth, Dept Cellular & Integrat Physiol, San Antonio, TX 78229 USA; [Beckstead, Michael J.] UT Hlth, Ctr Biomed Neurosci, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sharpe, AL (corresponding author), Univ Incarnate Word, Feik Sch Pharm, Dept Pharmaceut Sci, San Antonio, TX 78209 USA.; Sharpe, AL (corresponding author), UT Hlth, Dept Cellular & Integrat Physiol, San Antonio, TX 78229 USA.	sharpe@uiwtx.edu		Sharpe, Amanda/0000-0003-3971-5946	National Institutes of Health [K01 DA21699, R01 DA32701]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA032701, K01DA021699] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	These studies were funded by National Institutes of Health grants K01 DA21699 and R01 DA32701 to MJB. The funder had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript.	Binder EB, 2001, PHARMACOL REV, V53, P453; Boules Mona, 2013, Front Endocrinol (Lausanne), V4, P36, DOI 10.3389/fendo.2013.00036; Boules M, 2011, NEUROPEPTIDES, V45, P9, DOI 10.1016/j.npep.2010.09.003; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CASTEL MN, 1994, EUR J NEUROSCI, V6, P646, DOI 10.1111/j.1460-9568.1994.tb00310.x; Cooke JH, 2009, OBESITY, V17, P1135, DOI 10.1038/oby.2008.652; DEUTCH AY, 1992, ANN NY ACAD SCI, V668, P232, DOI 10.1111/j.1749-6632.1992.tb27353.x; Feifel D, 2008, PSYCHOPHARMACOLOGY, V200, P197, DOI 10.1007/s00213-008-1197-5; Frankel PS, 2011, J PHARMACOL EXP THER, V336, P809, DOI 10.1124/jpet.110.176610; Fuxe K, 2014, PROG BRAIN RES, V211, P113, DOI 10.1016/B978-0-444-63425-2.00005-2; Geisler S, 2006, EUR J NEUROSCI, V24, P116, DOI 10.1111/j.1460-9568.2006.04928.x; Grimond-Billa SK, 2007, PSYCHOPHARMACOLOGIA, V22, P290; Hanson GR, 2012, NEUROSCIENCE, V203, P99, DOI 10.1016/j.neuroscience.2011.12.037; Hanson GR, 2013, J PHARMACOL EXP THER, V346, P173, DOI 10.1124/jpet.113.205310; HAWKINS MF, 1986, PHYSIOL BEHAV, V36, P1, DOI 10.1016/0031-9384(86)90064-8; HAWKINS MF, 1986, PHARMACOL BIOCHEM BE, V24, P1195, DOI 10.1016/0091-3057(86)90170-X; Holly EN, 2011, EUR NEUROPSYCHOPHARM, V21, P526, DOI 10.1016/j.euroneuro.2010.12.004; LEE TF, 1987, AM J PHYSIOL, V252, pE102, DOI 10.1152/ajpendo.1987.252.1.E102; LEVINE AS, 1983, PHARMACOL BIOCHEM BE, V19, P23, DOI 10.1016/0091-3057(83)90305-2; LUTTINGER D, 1982, EUR J PHARMACOL, V81, P499, DOI 10.1016/0014-2999(82)90116-9; MEISENBERG G, 1985, PHARMACOL BIOCHEM BE, V22, P189, DOI 10.1016/0091-3057(85)90376-4; Prus AJ, 2014, DRUG DEVELOP RES, V75, P47, DOI 10.1002/ddr.21171; Richelson E, 2003, LIFE SCI, V73, P679, DOI 10.1016/S0024-3205(03)00388-6; Sharpe AL, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu073; Sulzer D, 2005, PROG NEUROBIOL, V75, P406, DOI 10.1016/j.pneurobio.2005.04.003; Vadnie CA, 2014, NEUROPHARMACOLOGY, V85, P482, DOI 10.1016/j.neuropharm.2014.05.046; Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022	27	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180710	10.1371/journal.pone.0180710	http://dx.doi.org/10.1371/journal.pone.0180710			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686721	Green Submitted, Green Published, gold			2023-01-03	WOS:000405464100093
J	Jedrusik, P; Symonides, B; Wojciechowska, E; Gryglas, A; Gaciong, Z				Jedrusik, Piotr; Symonides, Bartosz; Wojciechowska, Ewa; Gryglas, Adam; Gaciong, Zbigniew			Diagnostic value of potassium level in a spot urine sample as an index of 24-hour urinary potassium excretion in unselected patients hospitalized in a hypertension unit	PLOS ONE			English	Article							DAILY SALT INTAKE; SODIUM-EXCRETION; PRIMARY ALDOSTERONISM; POPULATION; COLLECTIONS; VALIDATION; CREATININE	Background Primary hyperaldosteronism may be associated with elevated 24-hour urinary potassium excretion. We evaluated the diagnostic value of spot urine (SU) potassium as an index of 24-hour urinary potassium excretion. Methods We measured SU and 24-hour urinary collection potassium and creatinine in 382 patients. Correlations between SU and 24-hour collections were assessed for potassium levels and potassium/creatinine ratios. We used the PAHO formula to estimate 24-hour urinary potassium excretion based on SU potassium level. The agreement between estimated and measured 24-hour urinary potassium excretion was evaluated using the Bland-Altman method. To evaluate diagnostic performance of SU potassium, we calculated areas under the curve (AUC) for SU potassium/creatinine ratio and 24-hour urinary potassium excretion estimated using the PAHO formula. Results Strongest correlation between SU and 24-hour collection was found for potassium/creatinine ratio (r = 0.69, P<0.001). The PAHO formula underestimated 24-hour urinary potassium excretion by mean 8.3 +/- 18 mmol/d (95% limits of agreement-28 to +44 mmol/d). Diagnostic performance of SU potassium/creatinine ratio was borderline good only if 24-hour urinary potassium excretion was largely elevated (AUC 0.802 for 120 mmol K+/24 h) but poor with lower values (AUC 0.696 for 100 mmol K+/24 h, 0.636 for 80 mmol K+/24 h, 0.675 for 40 mmol K+/24 h). Diagnostic performance of 24-hour urinary potassium excretion estimated by the PAHO formula was excellent with values above 120 mmol/d and good with lower values (AUC 0.941 for 120 mmol K+/24 h, 0.819 for 100 mmol K+/24 h, 0.823 for 80 mmol K+/24 h, 0.836 for 40 mmol K+/24 h). Conclusions Spot urine potassium/creatinine ratio might be a marker of increased 24-hour urinary potassium excretion and a potentially useful screening test when reliable 24-hour urine collection is not available. The PAHO formula allowed estimation of the 24-hour urinary potassium excretion based on SU measurements with reasonable clinical accuracy.	[Jedrusik, Piotr; Symonides, Bartosz; Wojciechowska, Ewa; Gryglas, Adam; Gaciong, Zbigniew] Med Univ Warsaw, Dept Internal Med Hypertens & Vasc Dis, Warsaw, Poland	Medical University of Warsaw	Jedrusik, P (corresponding author), Med Univ Warsaw, Dept Internal Med Hypertens & Vasc Dis, Warsaw, Poland.	pjedrusik@wum.edu.pl	Symonides, Bartosz/N-1883-2018	Symonides, Bartosz/0000-0002-5933-609X; Jedrusik, Piotr/0000-0003-0037-6035				BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brown IJ, 2013, AM J EPIDEMIOL, V177, P1180, DOI 10.1093/aje/kwt066; Chernecky CC, 2008, LAB TESTS DIAGNOSTIC, P399; Doenyas-Barak K, 2015, NEPHRON, V130, P35, DOI 10.1159/000430105; Funder JW, 2016, J CLIN ENDOCR METAB, V101, P1889, DOI 10.1210/jc.2015-4061; Han WZ, 2015, AM J HYPERTENS, V28, P1368, DOI 10.1093/ajh/hpv037; Hong YH, 2010, UROLOGY, V75, P1294, DOI 10.1016/j.urology.2009.08.061; Huang L., 2014, J HYPERTENS S1, V32, P110; Ix JH, 2011, CLIN J AM SOC NEPHRO, V6, P184, DOI 10.2215/CJN.05030610; Ji C, 2014, NUTR METAB CARDIOVAS, V24, P140, DOI 10.1016/j.numecd.2013.06.011; Ji C, 2012, REV PANAM SALUD PUBL, V32, P307, DOI 10.1590/S1020-49892012001000010; KAMEL KS, 1990, AM J NEPHROL, V10, P89, DOI 10.1159/000168062; Kawamura M, 2006, HYPERTENS RES, V29, P397, DOI 10.1291/hypres.29.397; Kawamura M, 2012, HYPERTENS RES, V35, P611, DOI 10.1038/hr.2012.6; KAWASAKI T, 1993, CLIN EXP PHARMACOL P, V20, P7, DOI 10.1111/j.1440-1681.1993.tb01496.x; Koo H, 2015, ANN LAB MED, V35, P238, DOI 10.3343/alm.2015.35.2.238; Lerchl K, 2015, HYPERTENSION, V66, P850, DOI 10.1161/HYPERTENSIONAHA.115.05851; Mann SJ, 2010, J CLIN HYPERTENS, V12, P174, DOI 10.1111/j.1751-7176.2009.00241.x; Martin Helen, 2011, Clin Biochem Rev, V32, P97; McLean R, 2014, J HUM HYPERTENS, V28, P657, DOI 10.1038/jhh.2014.10; McLean RM, 2014, NUTRIENTS, V6, P4651, DOI 10.3390/nu6114651; Mizehoun-Adissoda C, 2016, J CLIN HYPERTENS, V18, P634, DOI 10.1111/jch.12722; Mulatero P, 2004, J CLIN ENDOCR METAB, V89, P1045, DOI 10.1210/jc.2003-031337; Organization WH, 2010, DIS PREV POP WID DIE; Palmer BF, 2015, CLIN J AM SOC NEPHRO, V10, P1050, DOI 10.2215/CJN.08580813; Rodby RA, 2016, AM J KIDNEY DIS, V68, P836, DOI 10.1053/j.ajkd.2016.06.025; Stern N., 2018, MANUAL ENDOCRINOLOGY, V5th, P202; Tanaka T, 2002, J HUM HYPERTENS, V16, P97, DOI 10.1038/sj.jhh.1001307; van Huysduynen EJCH, 2014, PUBLIC HEALTH NUTR, V17, P2505, DOI 10.1017/S1368980014001177; Wang CY, 2013, J NUTR, V143, P1276, DOI 10.3945/jn.113.175927; Woywodt A, 2001, NEPHROL DIAL TRANSPL, V16, P1066, DOI 10.1093/ndt/16.5.1066	32	7	7	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180117	10.1371/journal.pone.0180117	http://dx.doi.org/10.1371/journal.pone.0180117			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662194	Green Published, gold, Green Submitted			2023-01-03	WOS:000404608300105
J	Zuckerman, RB; Maddox, KEJ; Sheingold, SH; Chen, LM; Epstein, AM				Zuckerman, Rachael B.; Maddox, Karen E. Joynt; Sheingold, Steven H.; Chen, Lena M.; Epstein, Arnold M.			Effect of a Hospital-wide Measure on the Readmissions Reduction Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SAFETY-NET HOSPITALS; PENALTIES; RATES	BACKGROUND The Hospital Readmissions Reduction Program penalizes hospitals that have high 30-day readmission rates across specific conditions. There is support for changing to a hospital-wide readmission measure to broaden hospital eligibility and provide incentives for improvement across more conditions. METHODS We used Medicare claims from 2011 through 2013 to evaluate the number of hospitals that were eligible for penalties, in that they met a volume threshold of 25 admissions over a 3-year period for a specific condition or 25 admissions over a 1-year period for the cohorts included in the hospital-wide measure. We estimated the expected effects that changing from the condition-specific readmission measures to a hospital-wide measure would have on average penalties for safety-net hospitals (i.e., hospitals that treat a large proportion of low-income patients) and other hospitals. RESULTS Our sample included 6,807,899 admissions for the hospital-wide measure and 4,392,658 admissions for the condition-specific measures. Of 3443 hospitals, 688 were considered to be safety-net hospitals. Changing to the hospital-wide measure would result in 76 more hospitals being eligible to receive penalties. The hospital-wide measure would increase penalties (mean [+/- SE] Medicare payment reductions across all hospitals) from 0.42 +/- 0.01% to 0.89 +/- 0.01% of Medicare base diagnosis-related- group payments. It would also increase the disparity in penalties between safety-net hospitals and other hospitals from -0.03 +/- 0.02 to 0.41 +/- 0.06 percentage points. CONCLUSIONS A transition to a hospital-wide readmission measure would only modestly increase the number of hospitals eligible for penalties and would substantially increase the penalties for safety-net hospitals.	[Zuckerman, Rachael B.; Maddox, Karen E. Joynt; Sheingold, Steven H.; Chen, Lena M.] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA; [Maddox, Karen E. Joynt; Epstein, Arnold M.] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Maddox, Karen E. Joynt; Epstein, Arnold M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Chen, Lena M.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Dept Internal Med, Div Internal Med, Ann Arbor, MI 48109 USA; [Chen, Lena M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Epstein, AM (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.; Epstein, AM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	aepstein@hsph.harvard.edu			Department of Health and Human Services	Department of Health and Human Services	Supported by the Department of Health and Human Services, where all of the authors were employed at the time the research was initiated. This research received no external sources of support.	[Anonymous], 2012, ENDORSEMENT SUMMARY; [Anonymous], 2013, MED HLTH CAR DEL SYS; [Anonymous], 2015, BUDG BRIEF FISC YEAR; [Anonymous], 2016, BUDG BRIEF FISC 2017; [Anonymous], 2016, SOCIOECONOMIC STATUS; Berenson J, 2012, HIGHER READMISSIONS; Carey K, 2016, HEALTH AFFAIR, V35, P1918, DOI 10.1377/hlthaff.2016.0537; Carey K, 2015, HEALTH AFFAIR, V34, P978, DOI 10.1377/hlthaff.2014.1408; Conover M., 2012, HOSP WIDE ALL CAUSE; Department of Health and Human Services Centers for Medicare & Medicaid Services, 2012, FED REGISTER, V77, P53258; Dorsey KB, 2014, MEASURES UPDATES SPE; Gilman M, 2015, ANN INTERN MED, V163, P427, DOI 10.7326/M14-2813; Gilman M, 2014, HEALTH AFFAIR, V33, P1314, DOI 10.1377/hlthaff.2014.0138; Horwitz LI, 2014, MEASURE UPDATES SPEC; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Medicare Payment Advisory Commission (MedPAC), 2013, MED HLTH CAR DEL SYS, P89; Rosen AK, 2016, MED CARE, V54, P155, DOI 10.1097/MLR.0000000000000455; Sheingold SH, 2016, HEALTH AFFAIR, V35, P124, DOI 10.1377/hlthaff.2015.0534; Suter LG, 2014, PROCEDURE SPECIFIC R; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	21	29	29	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 19	2017	377	16					1551	1558		10.1056/NEJMsa1701791	http://dx.doi.org/10.1056/NEJMsa1701791			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK1LU	29045205	Bronze			2023-01-03	WOS:000413243900008
J	Haider, S; Grabovac, I; Winzer, E; Kapan, A; Schindler, KE; Lackinger, C; Titze, S; Dorner, TE				Haider, Sandra; Grabovac, Igor; Winzer, Eva; Kapan, Ali; Schindler, Karin Emmi; Lackinger, Christian; Titze, Sylvia; Dorner, Thomas Ernst			Change in inflammatory parameters in prefrail and frail persons obtaining physical training and nutritional support provided by lay volunteers: A randomized controlled trial	PLOS ONE			English	Article							C-REACTIVE PROTEIN; BIOELECTRICAL-IMPEDANCE ANALYSIS; APPENDICULAR SKELETAL-MUSCLE; NECROSIS-FACTOR-ALPHA; OLDER-ADULTS; BODY-COMPOSITION; GRIP STRENGTH; INTERLEUKIN-6; EXERCISE; MARKERS	The aim of the study was to compare the effects of home visits with physical training and nutritional support on inflammatory parameters to home visits with social support alone within a randomized controlled trial. Prefrail and frail persons received home visits from lay volunteers twice a week for 12 weeks. Participants in the physical training and nutritional intervention group (PTN, n = 35) conducted two sets of six strength exercises and received nutritional support. The social support group (SoSu, n = 23) received visits only. TNF-alpha, IL-6, CRP, and total leukocyte count were assessed at baseline and after 12 weeks. Changes over time within groups were analyzed with paired t-tests; differences between groups were analyzed with ANCOVA for repeated measurements. In the PTN group, IL-6 and CRP remained stable, whereas in the SoSu group, IL-6 increased significantly from a median value of 2.6 pg/l (min-max = 2.0-10.2) to 3.0 pg/l (min-max = 2.0-20.8), and CRP rose from 0.2 mg/dl (min-max = 0.1-0.9) to 0.3 mg/dl (min-max = 0.1-3.0) after 12 weeks. In CRP, a significant difference between groups was found. TNF-a and total leukocyte count did not change in either the PTN group or the SoSu group. Persons showing an increase in physical performance (OR 4.54; 95% CI = 1.33-15.45) were more likely to have constant or decreased IL-6 values than persons who showed no improvement. In conclusion, in non-robust older adults, a physical training and nutritional support program provided by lay volunteers can delay a further increase in some inflammatory parameters.	[Haider, Sandra; Grabovac, Igor; Winzer, Eva; Kapan, Ali; Dorner, Thomas Ernst] Med Univ Vienna, Dept Social & Prevent Med, Ctr Publ Hlth, Vienna, Austria; [Schindler, Karin Emmi] Med Univ Vienna, Div Endocrinol & Metab, Dept Internal Med 3, Vienna, Austria; [Lackinger, Christian] SPORTUNION, Dept Hlth Promot & Prevent, Vienna, Austria; [Titze, Sylvia] Karl Franzens Univ Graz, Inst Sport Sci, Graz, Austria	Medical University of Vienna; Medical University of Vienna; University of Graz	Grabovac, I (corresponding author), Med Univ Vienna, Dept Social & Prevent Med, Ctr Publ Hlth, Vienna, Austria.	igor.grabovac@meduniwien.ac.at	Grabovac, Igor/F-9210-2017	Grabovac, Igor/0000-0001-9605-1467; Kapan, Ali/0000-0002-4007-0973; Winzer, Eva/0000-0002-5547-8517; Haider, Sandra/0000-0002-3612-7332	Vienna Science and Technology Fund [LS12-039]	Vienna Science and Technology Fund	This work was supported by the 'Vienna Science and Technology Fund' (grant number: LS12-039). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleman H, 2011, AGE AGEING, V40, P469, DOI 10.1093/ageing/afr040; Basu A, 2006, ARTERIOSCL THROM VAS, V26, P995, DOI 10.1161/01.ATV.0000214295.86079.d1; Bauer J, 2013, J AM MED DIR ASSOC, V14, P542, DOI 10.1016/j.jamda.2013.05.021; Biesalski HK, 2007, CURR OPIN CLIN NUTR, V10, P724, DOI 10.1097/MCO.0b013e3282f0cef2; Bonnefoy M, 2015, J NUTR HEALTH AGING, V19, P250, DOI 10.1007/s12603-014-0568-3; Cesari M, 2006, AM J CLIN NUTR, V83, P1142, DOI 10.1093/ajcn/83.5.1142; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen XJ, 2014, CLIN INTERV AGING, V9, P433, DOI 10.2147/CIA.S45300; Colbert LH, 2004, J AM GERIATR SOC, V52, P1098, DOI 10.1111/j.1532-5415.2004.52307.x; Dale O, 1996, ACTA ANAESTH SCAND, V40, P771, DOI 10.1111/j.1399-6576.1996.tb04530.x; Das B. I. A., 2009, DATA INPUT; DeRijk R, 1997, J CLIN ENDOCR METAB, V82, P2182, DOI 10.1210/jc.82.7.2182; Dorner TE, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1232; Espinoza S. E., 2007, CLIN GERIATR MED, V15, P37; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ford ES, 2002, EPIDEMIOLOGY, V13, P561, DOI 10.1097/00001648-200209000-00012; Forti LN, 2014, AGE, V36, DOI 10.1007/s11357-014-9704-6; Geffken DF, 2001, AM J EPIDEMIOL, V153, P242, DOI 10.1093/aje/153.3.242; Genton L, 2001, GERONTOLOGY, V47, P315, DOI 10.1159/000052821; Gonzalez R, 2011, CRIT REV FOOD SCI, V51, P331, DOI 10.1080/10408390903584094; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Haider S, 2016, PLOS ONE; Haider S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169613; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hubbard RE, 2008, EUR J CLIN PHARMACOL, V64, P895, DOI 10.1007/s00228-008-0499-1; Hubbard RE, 2009, J CELL MOL MED, V13, P3103, DOI 10.1111/j.1582-4934.2009.00733.x; Jialal I, 2004, HYPERTENSION, V44, P6, DOI 10.1161/01.HYP.0000130484.20501.df; Kaiser MJ, 2009, J NUTR HEALTH AGING, V13, P782, DOI 10.1007/s12603-009-0214-7; Kasapis C, 2005, J AM COLL CARDIOL, V45, P1563, DOI 10.1016/j.jacc.2004.12.077; Kyle UG, 2001, NUTRITION, V17, P248, DOI 10.1016/S0899-9007(00)00553-0; Lambert CP, 1985, J APPL PHYSIOL, V105, P473, DOI DOI 10.1152/JAPPLPHYSIOL.00006.2008; Legrand D, 2013, ARCH GERONTOL GERIAT, V57, P345, DOI 10.1016/j.archger.2013.06.003; Leng S, 2002, J AM GERIATR SOC, V50, P1268, DOI 10.1046/j.1532-5415.2002.50315.x; Leng SX, 2007, J AM GERIATR SOC, V55, P864, DOI 10.1111/j.1532-5415.2007.01186.x; Leong DP, 2016, J CACHEXIA SARCOPENI, V7, P535, DOI 10.1002/jcsm.12112; Medina-Remon A, 2016, BR J CLIN PHARM; Ng TP, 2015, AM J MED, V128, P1225, DOI 10.1016/j.amjmed.2015.06.017; Nicklas BJ, 2008, J AM GERIATR SOC, V56, P2045, DOI 10.1111/j.1532-5415.2008.01994.x; Nicklas BJ, 2009, EXERC SPORT SCI REV, V37, P165, DOI 10.1097/JES.0b013e3181b7b3d9; Nicklas BJ, 2004, AM J CLIN NUTR, V79, P544; Norman K, 2012, CLIN NUTR, V31, P854, DOI 10.1016/j.clnu.2012.05.008; Penninx BWJH, 2004, J AM GERIATR SOC, V52, P1105, DOI 10.1111/j.1532-5415.2004.52308.x; PODOR TJ, 1989, ANN NY ACAD SCI, V557, P374; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Puts MTE, 2005, CLIN ENDOCRINOL, V63, P403, DOI 10.1111/j.1365-2265.2005.02355.x; Roberts HC, 2011, AGE AGEING, V40, P423, DOI 10.1093/ageing/afr051; Rolland Y, 2011, MED CLIN N AM, V95, P427, DOI 10.1016/j.mcna.2011.02.008; Romero-Arenas S, 2013, AGING DIS, V4, P256, DOI 10.14336/AD.2013.0400256; Romero-Ortuno R, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-57; Rost NS, 2001, STROKE, V32, P2575, DOI 10.1161/hs1101.098151; Schaap LA, 2009, J GERONTOL A-BIOL, V64, P1183, DOI 10.1093/gerona/glp097; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Segen J.C, 2011, SEGENS MED DICT; Sergi G, 2015, CLIN NUTR, V34, P667, DOI 10.1016/j.clnu.2014.07.010; Shrivastava AK, 2015, ALLERGOL IMMUNOPATH, V43, P81, DOI 10.1016/j.aller.2013.11.003; Soysal P, 2017, MATURITAS, V99, P66, DOI 10.1016/j.maturitas.2017.01.006; Soysal P, 2016, AGEING RES REV, V31, P1, DOI 10.1016/j.arr.2016.08.006; Taaffe DR, 2000, J GERONTOL A-BIOL, V55, pM709, DOI 10.1093/gerona/55.12.M709; Thomas L, 2008, DIAGNOSTIK; Ticinesi A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040186; University of Harvard, 2013, HLTH EAT PLAT; Velissaris Dimitrios, 2017, J Clin Med Res, V9, P461, DOI 10.14740/jocmr2959w; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; Yao X, 2011, CLIN GERIATR MED, V27, P79, DOI 10.1016/j.cger.2010.08.002; Zhang SY, 2014, CLIN EPIDEMIOL, V6, P227, DOI 10.2147/CLEP.S56554	65	14	14	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2017	12	10							e0185879	10.1371/journal.pone.0185879	http://dx.doi.org/10.1371/journal.pone.0185879			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ6DU	29023536	Green Published, gold, Green Submitted			2023-01-03	WOS:000412845100036
J	Stokes, A; Berry, KM; Mchiza, Z; Parker, WA; Labadarios, D; Chola, L; Hongoro, C; Zuma, K; Brennan, AT; Rockers, PC; Rosen, S				Stokes, Andrew; Berry, Kaitlyn M.; Mchiza, Zandile; Parker, Whadi-ah; Labadarios, Demetre; Chola, Lumbwe; Hongoro, Charles; Zuma, Khangelani; Brennan, Alana T.; Rockers, Peter C.; Rosen, Sydney			Prevalence and unmet need for diabetes care across the care continuum in a national sample of South African adults: Evidence from the SANHANES-1, 2011-2012	PLOS ONE			English	Article							THERAPY; CASCADE	South Africa faces an epidemic of chronic non-communicable diseases (NCDs), yet national surveillance is limited due to the lack of recent data. We used data from the first comprehensive national survey on NCDs-the South African National Health and Nutrition Examination Survey (SANHANES-1 (2011-2012))-to evaluate the prevalence of and health system response to diabetes through a diabetes care cascade. We defined diabetes as a Hemoglobin A1c equal to or above 6.5% or currently on treatment for diabetes. We constructed a diabetes care cascade by categorizing the population with diabetes into those who were unscreened, screened but undiagnosed, diagnosed but untreated, treated but uncontrolled, and treated and controlled. We then used multivariable logistic regression models to explore factors associated with diagnosed and undiagnosed diabetes. The age-standardized prevalence of diabetes in South Africans aged 15+ was 10.1%. Prevalence rates were higher among the non-white population and among women. Among individuals with diabetes, a total of 45.4% were unscreened, 14.7% were screened but undiagnosed, 2.3% were diagnosed but untreated, 18.1% were treated but uncontrolled, and 19.4% were treated and controlled, suggesting that 80.6% of the diabetic population had unmet need for care. The diabetes care cascade revealed significant losses from lack of screening, between screening and diagnosis, and between treatment and control. These results point to significant unmet need for diabetes care in South Africa. Additionally, this analysis provides a benchmark for evaluating efforts to manage the rising burden of diabetes in South Africa.	[Stokes, Andrew; Berry, Kaitlyn M.; Brennan, Alana T.; Rockers, Peter C.; Rosen, Sydney] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA; [Mchiza, Zandile; Parker, Whadi-ah; Labadarios, Demetre; Chola, Lumbwe; Hongoro, Charles; Zuma, Khangelani] Human Sci Res Council, Populat Hlth Hlth Syst & Innovat, Cape Town, South Africa; [Brennan, Alana T.; Rosen, Sydney] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Hlth Econ & Epidemiol Res Off,Dept Internal Med, Johannesburg, South Africa	Boston University; Human Sciences Research Council-South Africa; University of Witwatersrand	Stokes, A (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA.	acstokes@bu.edu	Chola, Lumbwe/AFX-3377-2022	Parker, Whadi-ah/0000-0001-8308-8447; Berry, Kaitlyn/0000-0002-2928-6773; Hongoro, Charles/0000-0002-9715-4940; Rosen, Sydney/0000-0002-6560-2964; Brennan, Alana/0000-0002-7746-0668; Zuma, Khangelani/0000-0003-4492-5083; Chola, Lumbwe/0000-0001-6488-2813; Stokes, Andrew/0000-0002-8502-3636				Ali MK, 2014, ANN INTERN MED, V161, P681, DOI 10.7326/M14-0019; Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc12-S064, 10.2337/dc09-S062, 10.2337/dc11-S011]; [Anonymous], 2016, DIABETES CARE, V39, pS1, DOI 10.2337/dc16-S001; [Anonymous], 2015, IDF DIABETES ATLAS; Booysen BL, 2015, S AFRICAN FAM PRACT, P57; Bradshaw D, 2007, JEMDSA, V12, P65, DOI 10.1080/22201009.2007.10872159; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP ES; Clouse K, 2013, J ACQ IMMUN DEF SYND, V62, P22, DOI DOI 10.1097/QAI.0B013E318273AC48.PATIENT; Department of Health; Republic of South Africa, 2013, STRAT PLAN PREV CONT; Fox MP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002268; Fox MP, 2015, JAIDS-J ACQ IMM DEF, V69, P98, DOI 10.1097/QAI.0000000000000553; Gardner EM, 2014, LANCET INFECT DIS, V14, P5, DOI 10.1016/S1473-3099(13)70272-X; Harris B, 2011, J PUBLIC HEALTH POL, V32, pS102, DOI 10.1057/jphp.2011.35; Hu FB, 2011, DIABETES CARE, V34, P1249, DOI 10.2337/dc11-0442; International Diabetes Federation, 2011, IDF DIABETES ATLAS, DOI [10.1007/978-90-481-3271-3, DOI 10.1007/978-90-481-3271-3]; International Diabetes Federation, 2012, DIAB AT A GLANC, DOI [10.1080/03071845709419205, DOI 10.1080/03071845709419205]; Isaacs A, 2015, S AFRICAN FAM PRACT, P6190; Labadarios D, 2014, SAMJ S AFR MED J, V104, P675, DOI [10.7196/SAMJ.8842, 10.7196/samj.8842]; Matsebula V, 2016, SOCIOECONOMIC CORREL; McLaren Z, 2013, DISTANCE BARRIER HLT; Mendenhall E, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2615-3; Miller CM, 2010, TROP MED INT HEALTH, V15, P48, DOI 10.1111/j.1365-3156.2010.02514.x; Moodley L, 2007, S AFRICAN FAM PRACT, P49; Peer N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043336; Perlman DC, 2017, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00296; Rosen S, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002015, 10.1371/journal.pmed.1002106]; Rowe KA, 2005, INT J TUBERC LUNG D, V9, P263; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Shisana O, 2014, S AFRICAN NATL HLTH; Shisana O., 2013, S AFRICAN NATL HLTH; Statistics South Africa, 2014, PRETORIA, V3, P1; United Nations Department of Economic and Social Affairs, 2014, NON TRADITIONAL REF; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	33	38	38	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2017	12	10							e0184264	10.1371/journal.pone.0184264	http://dx.doi.org/10.1371/journal.pone.0184264			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI5MY	28968435	gold, Green Submitted, Green Published			2023-01-03	WOS:000412029600006
J	Dowell, AC; Cobby, E; Wen, KS; Devall, AJ; During, V; Anderson, J; James, ND; Cheng, KK; Zeegers, MP; Bryan, RT; Taylor, GS				Dowell, Alexander C.; Cobby, Ellen; Wen, Kaisheng; Devall, Adam J.; During, Vinnie; Anderson, Jane; James, Nicholas D.; Cheng, Kar K.; Zeegers, Maurice P.; Bryan, Richard T.; Taylor, Graham S.			Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer	PLOS ONE			English	Article							BACILLUS-CALMETTE-GUERIN; CARCINOMA IN-SITU; IL-17; RECURRENCE; EXPRESSION; CYTOKINES; PROGRESSION; PROGNOSIS; SURVIVAL; THERAPY	The tumour immune microenvironment is considered to influence cancer behaviour and outcome. Using a panel of markers for innate and adaptive immune cells we set out to characterise and understand the bladder tumour microenvironment of 114 patients from a prospective multicentre cohort of newly-diagnosed bladder cancer patients, followed-up for 4.33 +/- 1.71 years. We found IL-17-positive cells were significantly increased in primary and concomitant carcinoma in situ (CIS), p<0.0001, a highly malignant lesion which is the most significant single risk factor for disease progression. Further characterisation of the tumour immunophenotype identified IL-17+ cells as predominantly mast cells rather than T-cells, in contrast to most other tumour types. Expression of the IL-17-receptor in bladder tumours, and functional effects and gene expression changes induced by IL-17 in bladder tumour cells in vitro suggest a role in tumour behaviour. Finally, we assessed the effects of IL-17 in the context of patient outcome, following intravesical BCG immunotherapy which is the standard of care; higher numbers of IL-17+ cells were associated with improved event-free survival (p = 0.0449, HR 0.2918, 95% CI 0.08762-0.9721) in patients with primary and concomitant CIS (n = 41), we propose a model of IL-17+ Mast cells mechanism of action. Thus, in the context of bladder CIS, IL-17+ mast cells predict favourable outcome following BCG immunotherapy indicative of a novel mechanism of BCG immunotherapy in UBC and could form the basis of a stratified approach to treatment.	[Dowell, Alexander C.; Taylor, Graham S.] Univ Birmingham, Inst Immunol & Immunotherapy, Vincent Dr, Birmingham, W Midlands, England; [Cobby, Ellen] Royal Shrewsbury Hosp, Shrewsbury, Salop, England; [Wen, Kaisheng; During, Vinnie; Anderson, Jane; James, Nicholas D.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Devall, Adam J.] Univ Birmingham, Inst Appl Hlth Res, Birmingham Clin Trials Unit, Public Hlth Bldg, Edgbaston, England; [Cheng, Kar K.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England; [Zeegers, Maurice P.] Maastricht Univ, Nutr & Translat Res Metab Sch NUTRIM, Maastricht, Netherlands; [Zeegers, Maurice P.] Maastricht Univ, Care & Publ Hlth Res Inst, Sch CAPHRI, Maastricht, Netherlands; [Zeegers, Maurice P.; Bryan, Richard T.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); University of Birmingham	Bryan, RT (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England.	r.t.bryan@bham.ac.uk	Bryan, Richard T/AAJ-9325-2021; Cheng, Kar/AAL-8899-2021; Devall, Adam/AAC-9646-2022	Bryan, Richard T/0000-0003-2853-4293; Cheng, Kar/0000-0002-1516-1857; Zeegers, Maurice/0000-0002-2387-083X; Dowell, Alexander/0000-0002-1909-7047; Taylor, Graham/0000-0002-4807-2797	Birmingham Cancer Research UK Centre Development Fund [DF-21/TC/0710]	Birmingham Cancer Research UK Centre Development Fund	This work was supported by the Birmingham Cancer Research UK Centre Development Fund DF-21/TC/0710. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abol-Enein H, 2005, EUR UROL, V48, P202, DOI 10.1016/j.eururo.2005.04.006; Amicarella F, 2015, GUT; Antoni S., 2016, EUR UROL; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Bryan RT, 2013, BJU INT, V112, P169, DOI 10.1111/bju.12032; Chavan S, 2014, EUR UROL, V66, P59, DOI 10.1016/j.eururo.2013.10.001; Chen X, 2010, LUNG CANCER, V69, P348, DOI 10.1016/j.lungcan.2009.11.013; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; de Boer OJ, 2010, J PATHOL, V220, P499, DOI 10.1002/path.2667; Di Pierro GB, 2012, CURR GENOMICS, V13, P395, DOI 10.2174/138920212801619232; Goebell PJ, 2010, UROL ONCOL-SEMIN ORI, V28, P409, DOI 10.1016/j.urolonc.2010.04.003; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Hanada T, 2000, INT J UROL, V7, P263, DOI 10.1046/j.1442-2042.2000.00190.x; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; Hueber AJ, 2010, J IMMUNOL, V184, P3336, DOI 10.4049/jimmunol.0903566; Kamat AM, 2016, EUR UROL, V69, P197, DOI 10.1016/j.eururo.2015.06.023; Keijsers RRMC, 2014, EXP DERMATOL, V23, P799, DOI 10.1111/exd.12487; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lin LC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028984; Lin Y, 2015, CLIN TRANSL ONCOL, V17, P50, DOI 10.1007/s12094-014-1197-3; Liu XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106834; Liu XX, 2014, FUTURE ONCOL, V10, P1443, DOI [10.2217/fon.14.79, 10.2217/FON.14.79]; Liu YB, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0174-8; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Mrabet-Dahbi S, 2009, EXP DERMATOL, V18, P437, DOI 10.1111/j.1600-0625.2009.00878.x; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Nakae S, 2005, P NATL ACAD SCI USA, V102, P6467, DOI 10.1073/pnas.0501912102; Noordenbos T, 2016, J LEUKOCYTE BIOL, V100, P453, DOI 10.1189/jlb.3HI1215-542R; Noordenbos T, 2012, ARTHRITIS RHEUM-US, V64, P99, DOI 10.1002/art.33396; Otto W, 2012, WORLD J UROL, V30, P875, DOI 10.1007/s00345-012-0974-2; RILEY GF, 1995, MED CARE, V33, P828, DOI 10.1097/00005650-199508000-00007; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Sibilano R, 2012, J IMMUNOL, V189, P120, DOI 10.4049/jimmunol.1200009; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Suurmond J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3466; Sylvester RJ, 2005, UROLOGY, V66, P90, DOI 10.1016/j.urology.2005.06.135; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Sylvester RJ, 2005, J UROLOGY, V174, P86, DOI 10.1097/01.ju.0000162059.64886.1c; Takeuchi A, 2011, EUR J IMMUNOL, V41, P246, DOI 10.1002/eji.201040773; Thalmann GN, 2000, J UROLOGY, V164, P2129, DOI 10.1016/S0022-5347(05)66983-2; Thalmann GN, 1997, J UROLOGY, V158, P1340, DOI 10.1016/S0022-5347(01)64210-1; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; Wallace DMA, 2002, BJU INT, V89, P868, DOI 10.1046/j.1464-410X.2002.02776.x; Wang B, 2013, CANCER IMMUNOL IMMUN, V62, P1575, DOI 10.1007/s00262-013-1460-4; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Winerdal ME, 2011, BJU INT, V108, P1672, DOI 10.1111/j.1464-410X.2010.10020.x; Zeegers MP, 2010, BJU INT, V105, P784, DOI 10.1111/j.1464-410X.2009.08849.x; Zhu XW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2195; Zuiverloon TCM, 2016, EUR UROL, V69, P201, DOI 10.1016/j.eururo.2015.07.010; Zuiverloon TCM, 2012, EUR UROL, V61, P128, DOI 10.1016/j.eururo.2011.09.026; Zuniga LA, 2013, IMMUNOL REV, V252, P78, DOI 10.1111/imr.12036	57	18	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0184841	10.1371/journal.pone.0184841	http://dx.doi.org/10.1371/journal.pone.0184841			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931051	Green Published, Green Submitted, gold			2023-01-03	WOS:000411314700038
J	Mouzouvi, CRA; Umerska, A; Bigot, AAK; Saulnier, P				Mouzouvi, Celia R. A.; Umerska, Anita; Bigot, Andre A. K.; Saulnier, Patrick			Surface active properties of lipid nanocapsules	PLOS ONE			English	Article							AIR-WATER-INTERFACE; DROP TENSIOMETER; KINETICS; REORGANIZATION; ADSORPTION; NANOCARRIERS; TRANSITION; STABILITY; LIPOSOMES; DESIGN	Lipid nanocapsules (LNCs) are biomimetic nanocarriers used for the encapsulation of a broad variety of active ingredients. Similar to surface active compounds, LNCs contain both hydrophilic and hydrophobic parts in their structure. Moreover, the components of LNCs, macrogol 15 hydroxystearate (MHS) and lecithin, are known for their surface active properties. Therefore, the aim of this paper was to investigate the capability of the LNCs to decrease surface tension using two techniques: drop tensiometry and the Wilhelmy plate method. LNCs with diameters ranging from 30 to 100 nm were successfully obtained using a phase inversion technique. The LNCs' properties, such as size and zeta potential, depend on the composition. LNCs exhibit a lower limiting surface tension compared to MHS (34.8-35.0 mN/m and 37.7-38.8 mN/m, respectively), as confirmed by both drop tensiometry and the Wilhelmy plate method. LNCs have exhibited a saturated interfacial concentration (SIC) that was 10-fold higher than the critical micellar concentration (CMC) of MHS or the SIC of binary and ternary mixtures of LNC ingredients. The SIC of the LNC formulations depended on the mass mixing ratio of the MHS/triglycerides but not on the presence of lecithin. The CMC/SIC values measured by the Wilhelmy plate method were higher than those obtained using drop tensiometry because of the longer duration of the tensiometry measurement. In conclusion, the surfactantlike properties of the LNCs offer new possibilities for medical and pharmaceutical applications.	[Mouzouvi, Celia R. A.; Umerska, Anita; Saulnier, Patrick] Univ Bretagne Loire, CNRS 6021, Univ Angers, Micro & Nanomed Biomimet MINT,INSERM U1066, Angers, France; [Mouzouvi, Celia R. A.] Univ Abomey Calavi, Lab Pharm Galen & Technol Pharmaceut, UFR Pharm, FSS, Cotonou, Benin; [Bigot, Andre A. K.] Univ Abomey Calavi, Unite Immunol, Fac Sci Sante, Cotonou, Benin	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; University of Abomey Calavi; University of Abomey Calavi	Umerska, A (corresponding author), Univ Bretagne Loire, CNRS 6021, Univ Angers, Micro & Nanomed Biomimet MINT,INSERM U1066, Angers, France.	anitaumerska@yahoo.fr		Saulnier, Patrick/0000-0002-6408-3533; Umerska, Anita/0000-0002-4981-8247	'Service de Cooperation et d'Action Culturelle' of the French Embassy in Benin; Z-cube (Italy); Ministere de l'Enseignement Superieur et de la Recherche Scientifique du Benin	'Service de Cooperation et d'Action Culturelle' of the French Embassy in Benin; Z-cube (Italy); Ministere de l'Enseignement Superieur et de la Recherche Scientifique du Benin	This study was funded by 'Service de Cooperation et d'Action Culturelle' of the French Embassy in Benin, by Z-cube (Italy) and by Ministere de l'Enseignement Superieur et de la Recherche Scientifique du Benin.r This study was funded by 'Service de Cooperation et d'Action Culturelle' of the French Embassy in Benin, by Z-cube (Italy) and by Ministere de l'Enseignement Superieur et de la Recherche Scientifique du Benin.	Adamson A.W., 1997, PHYS CHEM SURFACES, Vsixth; Berry JD, 2015, J COLLOID INTERF SCI, V454, P226, DOI 10.1016/j.jcis.2015.05.012; Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0; Biresaw G., 2014, SURFACTANT SCI TECHN, P299; Blute I, 2009, COLLOID SURFACE A, V337, P127, DOI 10.1016/j.colsurfa.2008.12.009; Czajka A, 2015, LANGMUIR, V31, P8205, DOI 10.1021/acs.langmuir.5b00336; Du K, 2010, LANGMUIR, V26, P12518, DOI 10.1021/la100497h; Dulieu C, 2005, PHARM RES-DORDR, V22, P285, DOI 10.1007/s11095-004-1196-0; Fan H, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051610; Fathi-Azarbayjani A, 2009, J PHARM PHARM SCI, V12, P218, DOI 10.18433/J32P40; Florence A. T., 2006, PHYSICOCHEMICAL PRIN; Gugliotti M, 1998, BIOCHEM EDUC, V26, P233, DOI 10.1016/S0307-4412(98)00091-0; Heurtault B, 2003, COLLOID SURFACE B, V30, P225, DOI 10.1016/S0927-7765(03)00096-1; Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668; Hirsjavi S, 2012, INT J PHARMACEUT, V434, P460, DOI 10.1016/j.ijpharm.2012.06.019; Hsu CT, 1997, LANGMUIR, V13, P6204, DOI 10.1021/la970613y; Hureaux J, 2009, INT J PHARMACEUT, V379, P266, DOI 10.1016/j.ijpharm.2009.05.033; Hureaux J, 2009, EUR J PHARM BIOPHARM, V73, P239, DOI 10.1016/j.ejpb.2009.06.013; Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026; Ivanova T, 2014, COLLOID POLYM SCI, V292, P1307, DOI 10.1007/s00396-014-3180-5; Kutuzov S, 2007, PHYS CHEM CHEM PHYS, V9, P6351, DOI 10.1039/b710060b; LABOURDENNE S, 1994, CHEM PHYS LIPIDS, V71, P163, DOI 10.1016/0009-3084(94)90068-X; Lamprecht A, 2004, INT J PHARM, V278, P407, DOI 10.1016/j.ijpharm.2004.03.018; Lemkadem B., 1999, COLLOID SURFACE B, V17, P1; Luo M, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/37/375109; Matougui N, 2016, INT J PHARMACEUT, V502, P80, DOI 10.1016/j.ijpharm.2016.02.019; Miles GD, 1944, J PHYS CHEM-US, V48, P57, DOI 10.1021/j150433a007; Minkov I, 2005, COLLOID SURFACE B, V45, P24, DOI 10.1016/j.colsurfb.2005.07.002; Minkov I, 2005, COLLOID SURFACE B, V45, P14, DOI 10.1016/j.colsurfb.2005.03.009; Minkov I, 2005, COLLOID SURFACE B, V44, P197, DOI 10.1016/j.colsurfb.2005.07.001; OKUBO T, 1995, J COLLOID INTERF SCI, V171, P55, DOI 10.1006/jcis.1995.1150; Paillard A, 2010, BIOMATERIALS, V31, P7542, DOI 10.1016/j.biomaterials.2010.06.024; PANAIOTOV I, 1995, COLLOID SURFACE A, V102, P159, DOI 10.1016/0927-7757(95)03253-A; Petelska AD, 2002, BBA-BIOMEMBRANES, V1567, P79, DOI 10.1016/S0005-2736(02)00582-5; RANEVA V, 1995, COLLOID POLYM SCI, V273, P150, DOI 10.1007/BF00654012; Schreier S, 2000, BBA-BIOMEMBRANES, V1508, P210, DOI 10.1016/S0304-4157(00)00012-5; SHINODA K, 1964, J PHYS CHEM-US, V68, P3485, DOI 10.1021/j100794a007; SHINODA K, 1962, J PHYS CHEM-US, V66, P577, DOI 10.1021/j100810a001; Umerska A, 2016, EUR J PHARM BIOPHARM, V108, P100, DOI 10.1016/j.ejpb.2016.09.001; Umerska A, 2017, CARBOHYD POLYM, V156, P276, DOI 10.1016/j.carbpol.2016.09.035; Umerska A, 2016, INT J PHARMACEUT, V506, P191, DOI 10.1016/j.ijpharm.2016.04.028; Umerska A, 2015, INT J PHARMACEUT, V493, P224, DOI 10.1016/j.ijpharm.2015.07.008; Umerska A, 2014, J BIOMED NANOTECHNOL, V10, P3658, DOI 10.1166/jbn.2014.1878; Vafaei S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/18/185702; Valcourt C, 2016, INT J PHARMACEUT, V498, P23, DOI 10.1016/j.ijpharm.2015.11.042; Vonarbourg A, 2005, ELECTROPHORESIS, V26, P2066, DOI 10.1002/elps.200410145	46	21	21	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0179211	10.1371/journal.pone.0179211	http://dx.doi.org/10.1371/journal.pone.0179211			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28796777	Green Published, Green Submitted, gold			2023-01-03	WOS:000407396200001
J	Punchik, B; Komarov, R; Gavrikov, D; Semenov, A; Freud, T; Kagan, E; Goldberg, Y; Press, Y				Punchik, Boris; Komarov, Roman; Gavrikov, Dmitry; Semenov, Anna; Freud, Tamar; Kagan, Ella; Goldberg, Yury; Press, Yan			Can home care for homebound patients with chronic heart failure reduce hospitalizations and costs?	PLOS ONE			English	Article							DISEASE MANAGEMENT PROGRAMS; TRANSITIONAL CARE; EPIDEMIOLOGY; READMISSIONS; STRATEGIES; MULTIDISCIPLINARY; INTERVENTION; RISK	Background Congestive heart failure (CHF), a common problem in adults, is associated with multiple hospitalizations, high mortality rates and high costs. Purpose To evaluate whether home care for homebound patients with CHF reduces healthcare service utilization and overall costs. Methods A retrospective study of healthcare utilization among homebound patients who received home care for CHF from 2012-1015. The outcome measures were number of hospital admissions per month, total number of hospitalization days and days for CHF only, emergency room visits, and overall costs. A comparison was conducted between the 6-month period prior to entry into home care and the time in home care. Results Over the study period 196 patients were treated by home care for CHF with a mean age of 79.4 +/- 9.5 years. 113 (57.7%) were women. Compared to the six months prior to home care, there were statistically significant decreases in hospitalizations (46.3%), in the number of total in-hospital days (28.7%), in the number of in-hospital days for CHF (66.7%), in emergency room visits (47%), and in overall costs (23.9%). Conclusion Home care for homebound adults with CHF can reduce healthcare utilization and healthcare costs.	[Punchik, Boris; Gavrikov, Dmitry; Semenov, Anna; Kagan, Ella; Goldberg, Yury; Press, Yan] Yasski Clin, Home Care Unit, Clalit Hlth Serv, Beer Sheva, Israel; [Punchik, Boris; Kagan, Ella] Ben Gurion Univ Negev, Div Hlth Community, Unit Community Geriatr, Beer Sheva, Israel; [Komarov, Roman; Gavrikov, Dmitry; Semenov, Anna] Clalit Hlth Serv, Kenion Ha Negev Towers, Beer Sheva, Israel; [Freud, Tamar; Press, Yan] Ben Gurion Univ Negev, Dept Family Med, Siaal Family Med & Primary Care Res Ctr, Fac Hlth Sci, Beer Sheva, Israel	Clalit Health Services; Ben Gurion University; Clalit Health Services; Ben Gurion University	Press, Y (corresponding author), Yasski Clin, Home Care Unit, Clalit Hlth Serv, Beer Sheva, Israel.; Press, Y (corresponding author), Ben Gurion Univ Negev, Dept Family Med, Siaal Family Med & Primary Care Res Ctr, Fac Hlth Sci, Beer Sheva, Israel.	yanpr@clalit.org.il	Freud, Tamar/D-7276-2016; Komarov, Roman/AAB-7631-2020	Punchik, Boris/0000-0002-1346-9874	Israel Association of Family Physicians	Israel Association of Family Physicians	This work was supported by the Israel Association of Family Physicians (htlp //www. woncaeurope.org/content/israel-association-family-physicians). There is no grant number. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Bradley EH, 2013, CIRC-CARDIOVASC QUAL, V6, P444, DOI 10.1161/CIRCOUTCOMES.111.000101; Brannstrom M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Community- based care for the specialized management of heart failure, 2009, ONT HLTH TECHNOL ASS, V9, P1; Curtis LH, 2008, ARCH INTERN MED, V168, P418, DOI 10.1001/archinternmed.2007.80; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Eastwood CA, 2014, CAN J CARDIOL, V30, P612, DOI 10.1016/j.cjca.2014.02.017; Eilat-Tsanani S, 2016, EUR J CARDIOVASC NUR, V15, pE78, DOI 10.1177/1474515115602677; Feltner C, 2014, ANN INTERN MED, V160, P774, DOI 10.7326/M14-0083; Fergenbaum Jennifer, 2015, J Cardiovasc Nurs, V30, pS44, DOI 10.1097/JCN.0000000000000235; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Jeon YH, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-77; Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064; Kimmelstiel C, 2004, CIRCULATION, V110, P1450, DOI 10.1161/01.CIR.0000141562.22216.00; Maru S, 2015, INT J CARDIOL, V201, P368, DOI 10.1016/j.ijcard.2015.08.066; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Norton C, 2011, PROG CARDIOVASC DIS, V54, P78, DOI 10.1016/j.pcad.2011.04.002; Ponikowski P, 2014, ESC HEART FAIL, V1, P4, DOI 10.1002/ehf2.12005; Psotka MA, 2013, HEART FAIL CLIN, V9, P303, DOI 10.1016/j.hfc.2013.04.005; Roger VL, 2013, CIRC RES, V113, P646, DOI 10.1161/CIRCRESAHA.113.300268; Savard LA, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-194; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; Takeda A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002752.pub3; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DIAGN DIS H, P253, DOI DOI 10.3378/027.083.0506; Thomas R, 2013, HEART, V99, P233, DOI 10.1136/heartjnl-2012-302313; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Young JB, 2004, MED CLIN N AM, V88, P1135, DOI 10.1016/j.mcna.2004.06.001; Zhang B, 2013, J NEUROSCI, V33, P2639, DOI 10.1523/JNEUROSCI.4377-12.2013	32	8	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2017	12	7							e0182148	10.1371/journal.pone.0182148	http://dx.doi.org/10.1371/journal.pone.0182148			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1ED	28753675	gold, Green Submitted, Green Published			2023-01-03	WOS:000406579300052
J	Moon, RY; Hauck, FR; Colson, ER; Kellams, AL; Geller, NL; Heeren, T; Kerr, SM; Drake, EE; Tanabe, K; McClain, M; Corwin, MJ				Moon, Rachel Y.; Hauck, Fern R.; Colson, Eve R.; Kellams, Ann L.; Geller, Nicole L.; Heeren, Timothy; Kerr, Stephen M.; Drake, Emily E.; Tanabe, Kawai; McClain, Mary; Corwin, Michael J.			The Effect of Nursing Quality Improvement and Mobile Health Interventions on Infant Sleep Practices A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; EDUCATIONAL INTERVENTION; CHILDREN PROGRAM; POSITION; SUDDEN; TRENDS; WOMEN; RISK; CARE; DECISIONS	IMPORTANCE Inadequate adherence to recommendations known to reduce the risk of sudden unexpected infant death has contributed to a slowing in the decline of these deaths. OBJECTIVE To assess the effectiveness of 2 interventions separately and combined to promote infant safe sleep practices compared with control interventions. DESIGN, SETTING, AND PARTICIPANTS Four-group cluster randomized clinical trial of mothers of healthy term newborns who were recruited between March 2015 and May 2016 at 16 US hospitals with more than 100 births annually. Data collection ended in October 2016. INTERVENTIONS All participants were beneficiaries of a nursing quality improvement campaign in infant safe sleep practices (intervention) or breastfeeding (control), and then received a 60-day mobile health program, in which mothers received frequent emails or text messages containing short videos with educational content about infant safe sleep practices (intervention) or breastfeeding (control) and queries about infant care practices. MAIN OUTCOMES AND MEASURES The primary outcome was maternal self-reported adherence to 4 infant safe sleep practices of sleep position (supine), sleep location (room sharing without bed sharing), soft bedding use (none), and pacifier use (any); data were collected by maternal survey when the infant was aged 60 to 240 days. RESULTS Of the 1600 mothers who were randomized to 1 of 4 groups (400 per group), 1263 completed the survey (78.9%). The mean (SD) maternal age was 28.1 years (5.8 years) and 32.8% of respondents were non-Hispanic white, 32.3% Hispanic, 27.2% non-Hispanic black, and 7.7% other race/ethnicity. The mean (SD) infant age was 11.2 weeks (4.4 weeks) and 51.2% were female. In the adjusted analyses, mothers receiving the safe sleep mobile health intervention had higher prevalence of placing their infants supine compared with mothers receiving the control mobile health intervention (89.1% vs 80.2%, respectively; adjusted risk difference, 8.9%[95% CI, 5.3%-11.7%]), room sharing without bed sharing (82.8% vs 70.4%; adjusted risk difference, 12.4%[95% CI, 9.3%-15.1%]), no soft bedding use (79.4% vs 67.6%; adjusted risk difference, 11.8%[95% CI, 8.1%-15.2%]), and any pacifier use (68.5% vs 59.8%; adjusted risk difference, 8.7%[95% CI, 3.9%-13.1%]). The independent effect of the nursing quality improvement intervention was not significant for all outcomes. Interactions between the 2 interventions were only significant for the supine sleep position. CONCLUSIONS AND RELEVANCE Among mothers of healthy term newborns, a mobile health intervention, but not a nursing quality improvement intervention, improved adherence to infant safe sleep practices compared with control interventions. Whether widespread implementation is feasible or if it reduces sudden and unexpected infant death rates remains to be studied.	[Moon, Rachel Y.; Kellams, Ann L.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Hauck, Fern R.; Tanabe, Kawai] Univ Virginia, Sch Med, Dept Family Med, Charlottesville, VA 22908 USA; [Colson, Eve R.] Yale Univ, Dept Pediat, New Haven, CT 06520 USA; [Geller, Nicole L.; Kerr, Stephen M.; McClain, Mary; Corwin, Michael J.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA; [Heeren, Timothy] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Drake, Emily E.] Univ Virginia, Sch Nursing, Dept Family Community & Mental Hlth Syst, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; Yale University; Boston University; Boston University; University of Virginia	Moon, RY (corresponding author), Univ Virginia, Div Gen Pediat, Dept Pediat, POB 800386, Charlottesville, VA 22908 USA.	rym4z@virginia.edu	Drake, Emily/AAT-7282-2021	Drake, Emily/0000-0002-1395-2911; Corwin, Michael/0000-0002-6591-209X	National Institute of Child Health and Human Development [1R01HD072815-01]; CJ Foundation for SIDS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072815] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); CJ Foundation for SIDS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was funded by grant 1R01HD072815-01 from the National Institute of Child Health and Human Development and funding from the CJ Foundation for SIDS.	Bartick M, 2010, J HUM LACT, V26, P405, DOI 10.1177/0890334410379797; Cole-Lewis H, 2010, EPIDEMIOL REV, V32, P56, DOI 10.1093/epirev/mxq004; Colson ER, 2005, AMBUL PEDIATR, V5, P349, DOI 10.1367/A04-220R1.1; Colson ER, 2002, ARCH PEDIAT ADOL MED, V156, P717, DOI 10.1001/archpedi.156.7.717; Colson ER, 2006, PEDIATRICS, V118, pE243, DOI 10.1542/peds.2005-2517; Colson ER, 2013, JAMA PEDIATR, V167, P1032, DOI 10.1001/jamapediatrics.2013.2560; Colson ER, 2009, ARCH PEDIAT ADOL MED, V163, P1122, DOI 10.1001/archpediatrics.2009.234; Corwin MJ, 2003, PEDIATRICS, V111, P52, DOI 10.1542/peds.111.1.52; Degan Viviane V, 2004, J Dent Child (Chic), V71, P148; Eisenberg SR, 2015, PEDIATRICS, V136, pE315, DOI 10.1542/peds.2015-0551; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Hauck FR, 2008, PEDIATRICS, V122, pS113, DOI 10.1542/peds.2008-1315o; Hauck FR, 2015, J COMMUN HEALTH, V40, P457, DOI 10.1007/s10900-014-9957-0; Hauck FR, 2005, PEDIATRICS, V116, pE716, DOI 10.1542/peds.2004-2631; Hauck FR, 2002, PEDIATRICS, V110, P772, DOI 10.1542/peds.110.4.772; Haughton J, 2010, J HUM LACT, V26, P266, DOI 10.1177/0890334410365067; Hwang SS, 2016, MATERN CHILD HLTH J, V20, P1956, DOI 10.1007/s10995-016-2011-3; Joyner BL, 2016, J IMMIGR MINOR HEALT, V18, P402, DOI 10.1007/s10903-015-0206-0; Joyner BL, 2010, J NATL MED ASSOC, V102, P881, DOI 10.1016/S0027-9684(15)30706-9; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; MacGregor Elizabeth, 2010, Community Pract, V83, P30; Mathews A, 2016, J PEDIAT, V175, P79; Moon RY, 2008, PEDIATRICS, V122, P788, DOI 10.1542/peds.2007-3010; Moon RY, 2004, PEDIATRICS, V113, P542, DOI 10.1542/peds.113.3.542; Oden RP, 2010, J NATL MED ASSOC, V102, P870, DOI 10.1016/S0027-9684(15)30705-7; Perrine CG, 2012, PEDIATRICS, V130, P54, DOI 10.1542/peds.2011-3633; Philipp BL, 2001, PEDIATRICS, V108, P677, DOI 10.1542/peds.108.3.677; Rojjanasrirat W, 2010, J CLIN NURS, V19, P2014, DOI 10.1111/j.1365-2702.2009.03152.x; Shapiro-Mendoza CK, 2015, PEDIATRICS, V135, P10, DOI 10.1542/peds.2014-1793; Shapiro-Mendoza CK, 2006, AM J EPIDEMIOL, V163, P762, DOI 10.1093/aje/kwj117; Issler RMS, 2009, BIRTH-ISS PERINAT C, V36, P115, DOI 10.1111/j.1523-536X.2009.00308.x; Smith LA, 2016, ACAD PEDIATR, V16, P540, DOI 10.1016/j.acap.2016.01.021; Viswanath K., 2008, HLTH BEHAV HLTH ED T; Whalen B, 2010, CURR OPIN PEDIATR, V22, P655, DOI 10.1097/MOP.0b013e32833c8996	34	36	38	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2017	318	4					351	359		10.1001/jama.2017.8982	http://dx.doi.org/10.1001/jama.2017.8982			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BS	28742913	Green Accepted			2023-01-03	WOS:000406296700015
J	Dai, YK; Zhang, YZ; Li, DY; Ye, JT; Zeng, LF; Wang, Q; Hu, L				Dai, Yun-kai; Zhang, Yun-zhan; Li, Dan-yan; Ye, Jin-tong; Zeng, Ling-feng; Wang, Qi; Hu, Ling			The efficacy of Jianpi Yiqi therapy for chronic atrophic gastritis: A systematic review and meta-analysis	PLOS ONE			English	Review							HELICOBACTER-PYLORI ERADICATION; CANCER; ASSOCIATION; QUALITY; LESIONS; RISK	Jianpi Yiqi therapy (JYT) is a classical therapy in treating chronic atrophic gastritis (CAG), but the clinical effects of it are still contentious. The purpose of this article is to evaluate the efficacy and safety of JYT for CAG. Seven electronic databases including PubMed, Embase, Springer Link, CNKI (China National Knowledge Infrastructure), VIP (Chinese Scientific Journals Database), Wan-fang database, and CBM (Chinese Biomedicine Database) were searched from their inception to November 1, 2016. 13 randomized controlled trials (RCTs) with a total of 1119 participants were identified for analysis. Meta-analyses demonstrated that both JYT (RR 1.41; 95% CI 1.27, 1.57; P < 0.00001) and JYT + western medicine (RR 1.27; 95% CI 1.17, 1.38; P < 0.00001) were more efficacious than only western medicine. Furthermore, JYT had potential improvement on traditional Chinese medicine (TCM) symptoms scores such as stomachache, stomach distention, belching, fatigue, et al. In addition, no serious adverse events were reported in the selected trials. The Cochrane Collaboration's risk of bias tool was evaluated for the weaknesses of methodological quality, while the quality level of Grades of Recommendations Assessment Development and Evaluation (GRADE) evidence classification indicated "Very low". This meta-analysis indicates that JYT may have potential effects on the treatment of patients with CAG. However, due to limitations of methodological quality and small sample size of the included studies, further standardized research of rigorous design should be needed.	[Dai, Yun-kai; Zhang, Yun-zhan; Li, Dan-yan; Ye, Jin-tong; Hu, Ling] Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Zeng, Ling-feng; Wang, Qi] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou, Guangdong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Hu, L (corresponding author), Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.; Wang, Q (corresponding author), Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou, Guangdong, Peoples R China.	wqitcm@qq.com; drhuling@163.com	hu, ling/GWC-1104-2022	Wang, Qi/0000-0001-7626-676X	National Natural Science Foundation of China [81373563]; Guangzhou University of Chinese Medicine [2016KYTD07]; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine [64]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou University of Chinese Medicine; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine	This study was supported by National Natural Science Foundation of China, no. 81373563; Innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) no. 7, no. 2016KYTD07; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) no. 64. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by National Natural Science Foundation of China, No. 81373563; Innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) No. 7, No. 2016KYTD07; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) No. 64.	[Anonymous], 2010, J TRADITIONAL CHINES, V51, P749; Centanni M, 1999, ARCH INTERN MED, V159, P1726, DOI 10.1001/archinte.159.15.1726; Chen XB, 2010, SHANXI TCM, V26, P24; de Vries AC, 2008, GASTROENTEROLOGY, V134, P945, DOI 10.1053/j.gastro.2008.01.071; den Hollander WJ, 2012, EXPERT OPIN PHARMACO, V13, P2625, DOI 10.1517/14656566.2012.747510; Fuccio L, 2009, ANN INTERN MED, V151, P121, DOI 10.7326/0003-4819-151-2-200907210-00009; Guo YL., 2013, CHIN J EXP TRADIT ME, V19, P292; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Kuipers EJ, 1997, SCAND J GASTROENTERO, V32, P28; Li YP, 2014, CLIN J CHINESE MED, V6, P126; Liang MH, 2016, CHINESE ARCH TRADITI, V34, P1704; Liu DX, 2013, CHINA J CHINESE MED, V28, P745; Liu Ming, 2012, Zhongguo Zhong Yao Za Zhi, V37, P3361; Lu RX, 2014, MED RES ED, V31, P30; Lu WM, 1998, CHINESE J INTEGRATED, V18, P721; Ma XY, 2015, J PRACTICAL TRADITIO, V29, P124; Matos JI, 2013, EUR J GASTROEN HEPAT, V25, P1431, DOI 10.1097/MEG.0b013e328364b53e; Neumann WL, 2013, NAT REV GASTRO HEPAT, V10, P529, DOI 10.1038/nrgastro.2013.101; Park Yo Han, 2015, J Cancer Prev, V20, P25, DOI 10.15430/JCP.2015.20.1.25; Peng GS, 2015, J PRACTICAL TRADITIO, V29, P52; Simren M, 2006, CLIN GASTROENTEROL H, V4, P187, DOI 10.1016/S1542-3565(05)00981-X; Sun TT, 2011, EXPERT REV ANTICANC, V11, P1509, DOI [10.1586/ERA.11.124, 10.1586/era.11.124]; Sun WF, 2001, J ANHUI TCM COLL, V20, P13; Thou Jia-he, 2015, Zhongguo Zhong Xi Yi Jie He Za Zhi, V35, P406; Valle J, 1996, SCAND J GASTROENTERO, V31, P546, DOI 10.3109/00365529609009126; VILLAKO K, 1991, SCAND J GASTROENTERO, V26, P135, DOI 10.3109/00365529109104000; Wang JZ, 2013, J PRACTICAL TRADITIO, V27, P81; Wang YY, 2015, J CHANGCHUN U CHINES, V31, P361; Wang ZX, 2015, HENAN TRADITIONAL CH, V35, P2794; Xu JW, 2016, SHAANXI J TRADITIONA, V37, P142; Xue FB, 2001, WORLD J GASTROENTERO, V7, P801, DOI 10.3748/wjg.v7.i6.801; Zabaleta Jovanny, 2012, Methods Mol Biol, V863, P411, DOI 10.1007/978-1-61779-612-8_26; Zhang CG, 2014, J PRACTICAL TRADITIO, V28, P56; Zhang ZH, 2013, J LIAONING U TCM, V15, P245; Zheng X.Y., 2002, CHINESE HERBAL MED N, P124	35	18	19	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2017	12	7							e0181906	10.1371/journal.pone.0181906	http://dx.doi.org/10.1371/journal.pone.0181906			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8BB	28738092	Green Published, Green Submitted, gold			2023-01-03	WOS:000406362700087
J	Clark, LV; Pesola, F; Thomas, JM; Vergara-Williamson, M; Beynon, M; White, PD				Clark, Lucy V.; Pesola, Francesca; Thomas, Janice M.; Vergara-Williamson, Mario; Beynon, Michelle; White, Peter D.			Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial	LANCET			English	Article							VALIDITY; MODELS	Background Graded exercise therapy is an effective and safe treatment for chronic fatigue syndrome, but it is therapist intensive and availability is limited. We aimed to test the efficacy and safety of graded exercise delivered as guided self-help. Methods In this pragmatic randomised controlled trial, we recruited adult patients (18 years and older) who met the UK National Institute for Health and Care Excellence criteria for chronic fatigue syndrome from two secondary-care clinics in the UK. Patients were randomly assigned to receive specialist medical care (SMC) alone (control group) or SMC with additional guided graded exercise self-help (GES). Block randomisation (randomly varying block sizes) was done at the level of the individual with a computer-generated sequence and was stratified by centre, depression score, and severity of physical disability. Patients and physiotherapists were necessarily unmasked from intervention assignment; the statistician was masked from intervention assignment. SMC was delivered by specialist doctors but was not standardised; GES consisted of a self-help booklet describing a six-step graded exercise programme that would take roughly 12 weeks to complete, and up to four guidance sessions with a physiotherapist over 8 weeks (maximum 90 min in total). Primary outcomes were fatigue (measured by the Chalder Fatigue Questionnaire) and physical function (assessed by the Short Form-36 physical function subscale); both were self-rated by patients at 12 weeks after randomisation and analysed in all randomised patients with outcome data at follow-up (ie, by modified intention to treat). We recorded adverse events, including serious adverse reactions to trial interventions. We used multiple linear regression analysis to compare SMC with GES, adjusting for baseline and stratification factors. This trial is registered at ISRCTN, number ISRCTN22975026. Findings Between May 15, 2012, and Dec 24, 2014, we recruited 211 eligible patients, of whom 107 were assigned to the GES group and 104 to the control group. At 12 weeks, compared with the control group, mean fatigue score was 19.1 (SD 7.6) in the GES group and 22.9 (6.9) in the control group (adjusted difference -4.2 points, 95% CI -6.1 to -2.3, p<0.0001; effect size 0.53) and mean physical function score was 55.7 (23.3) in the GES group and 50.8 (25.3) in the control group (adjusted difference 6.3 points, 1.8 to 10.8, p=0.006; 0.20). No serious adverse reactions were recorded and other safety measures did not differ between the groups, after allowing for missing data. Interpretation GES is a safe intervention that might reduce fatigue and, to a lesser extent, physical disability for patients with chronic fatigue syndrome. These findings need confirmation and extension to other health-care settings. Funding UK National Institute for Health Research Research for Patient Benefit Programme and the Sue Estermann Fund. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.	[Clark, Lucy V.; Beynon, Michelle; White, Peter D.] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Ctr Psychiat, Charterhouse Sq, London EC1M 6BQ, England; [Pesola, Francesca] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England; [Thomas, Janice M.] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Vice Principal Hlth Off, London, England; [Vergara-Williamson, Mario] Kent & Medway Natl Hlth Serv & Social Care Partne, Chron Fatigue Syndrome Myalg Encephalopathy Serv, Maidstone, Kent, England	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London	Clark, LV (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Ctr Psychiat, Charterhouse Sq, London EC1M 6BQ, England.	l.clark@qmul.ac.uk		Clark, Lucy/0000-0001-7162-0512; Beynon, Michelle/0000-0002-2628-2187	UK National Institute for Health Research Research for Patient Benefit Programme; Sue Estermann Fund	UK National Institute for Health Research Research for Patient Benefit Programme; Sue Estermann Fund	UK National Institute for Health Research Research for Patient Benefit Programme and the Sue Estermann Fund.	Action for ME, 2008, ME 2008 WHAT PROGR; [Anonymous], 2014, ME TIM DEL IN FIND A; Baldwin SA, 2011, PSYCHOL METHODS, V16, P149, DOI 10.1037/a0023464; Cairns R, 2005, OCCUP MED-OXFORD, V55, P20, DOI 10.1093/occmed/kqi013; Chalder T, 1997, BRIT J HEALTH PSYCH, V2, P189, DOI 10.1111/j.2044-8287.1997.tb00535.x; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Clark L.V., 2011, GRADED EXERCISE THER; Clark LV, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.5395; Collin SM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001417; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Guy W., 1976, ASSESSMENT MANUAL PS, P217; Johnson DR, 2011, J MARRIAGE FAM, V73, P926, DOI 10.1111/j.1741-3737.2011.00861.x; Knoop H, 2008, BRIT J PSYCHIAT, V193, P340, DOI 10.1192/bjp.bp.108.051292; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Larun L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003200.pub4; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; Reeves WC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-25; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Tummers M, 2012, PSYCHOL MED, V42, P2205, DOI 10.1017/S0033291712000232; White PD, 2011, LANCET, V377, P823, DOI 10.1016/S0140-6736(11)60096-2; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Williams J.B.W., 2002, STRUCTURED CLIN INTE; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	41	44	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2017	390	10092					363	373		10.1016/S0140-6736(16)32589-2	http://dx.doi.org/10.1016/S0140-6736(16)32589-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB1NU	28648402	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000405911300025
J	Unnanuntana, A; Jarusriwanna, A; Songcharoen, P				Unnanuntana, Aasis; Jarusriwanna, Atthakorn; Songcharoen, Panupan			Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax (R)) for osteoporosis treatment	PLOS ONE			English	Article							FEMORAL-NECK FRACTURES; QUALITY-OF-LIFE; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; MEDICAL LITERATURE; USERS GUIDES; BONE-DENSITY; DOUBLE-BLIND; WOMEN; BISPHOSPHONATES	Introduction Although the same efficacy and tolerability are anticipated due to both drugs containing the same active ingredients, comparative studies between brand and generic alendronate are limited. Accordingly, the objective of this study was to compare efficacy and safety between brand alendronate and a recently introduced generic alendronate drug. Methods A total of 140 postmenopausal women or men aged older than 50 years who met the indications for osteoporosis treatment were randomized to receive either generic (Bonmax r) or brand alendronate (Fosamax r) 70 mg/week over a 12-month period during the May 2014 to June 2015 study period. Endpoints included bone mineral density (BMD) changes at the lumbar spine, total hip, and femoral neck; percentage of patients with predefined levels of change in total hip and lumbar spine BMD at 12 months; and, changes in biochemical bone markers at 3, 6, and 12 months. Tolerability was evaluated by patient self-reporting of adverse experiences. Results At 12 months post-treatment, BMD significantly increased at all sites in both groups. There were no differences in BMD percentage changes or the number of patients with stable or increased BMD after 1 year between groups. No significant differences in the amount of biochemical bone marker reduction or incidence of adverse events were observed between groups. Conclusions Generic and brand alendronate produced similar gains in BMD and reduction in bone turnover markers. Both medicadoitions were also equally well-tolerated. Based on these	[Unnanuntana, Aasis; Jarusriwanna, Atthakorn; Songcharoen, Panupan] Mahidol Univ, Siriraj Hosp, Dept Orthopaed Surg, Fac Med, Bangkok, Thailand	Mahidol University	Unnanuntana, A (corresponding author), Mahidol Univ, Siriraj Hosp, Dept Orthopaed Surg, Fac Med, Bangkok, Thailand.	uaasis@gmail.com	Jarusriwanna, Atthakorn/AAC-6568-2021	Jarusriwanna, Atthakorn/0000-0002-3919-8195	Medical Association of Thailand (Prasert Prasarttong-Osoth) Research Fund	Medical Association of Thailand (Prasert Prasarttong-Osoth) Research Fund	This study was partially supported by the Medical Association of Thailand (Prasert Prasarttong-Osoth) Research Fund. There was no additional external funding received for this study.	Baim S, 2005, J CLIN DENSITOM, V8, P371, DOI 10.1385/JCD:8:4:371; Biswas PN, 2003, OSTEOPOROSIS INT, V14, P507, DOI 10.1007/s00198-003-1399-y; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897; Bonnick SL, 2001, J CLIN DENSITOM, V4, P105, DOI 10.1385/JCD:4:2:105; Brown JP, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-550; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002-9343(01)01124-X; Dansereau RJ, 2009, CURR MED RES OPIN, V25, P449, DOI [10.1185/03007990802648903, 10.1185/03007990802648903 ]; Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698; Greenspan SL, 2000, J CLIN ENDOCR METAB, V85, P3537, DOI 10.1210/jc.85.10.3537; Grima DT, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-68; Hassler N, 2015, OSTEOPOROSIS INT, V26, P339, DOI 10.1007/s00198-014-2929-5; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; Lai PSM, 2012, CURR MED RES OPIN, V28, P1347, DOI 10.1185/03007995.2012.708326; Lietzan EK, 2004, FOOD DRUG LAW J, V59, P287; McAlister FA, 1999, JAMA-J AM MED ASSOC, V282, P1371, DOI 10.1001/jama.282.14.1371; Office of the Surgeon General (US), 2004, BON HLTH OST REP SUR; Orwoll ES, 2010, J BONE MINER RES, V25, P2239, DOI 10.1002/jbmr.119; Paggiosi MA, 2014, OSTEOPOROSIS INT, V25, P2729, DOI 10.1007/s00198-014-2817-z; Papaioannou A, 2009, OSTEOPOROSIS INT, V20, P703, DOI 10.1007/s00198-008-0743-7; Pongchaiyakul Chatlert, 2012, Journal of the Medical Association of Thailand, V95, P1528; Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141; Sanderson J, 2016, BONE, V89, P52, DOI 10.1016/j.bone.2016.05.013; Savaridas T, 2013, BONE JOINT J, V95B, P1263, DOI 10.1302/0301-620X.95B9.31562; Strom O, 2012, OSTEOPOROSIS INT, V23, P2201, DOI 10.1007/s00198-011-1850-4; Tarride JE, 2012, OSTEOPOROSIS INT, V23, P2591, DOI 10.1007/s00198-012-1931-z; Tidermark J, 2003, QUAL LIFE RES, V12, P1069, DOI 10.1023/A:1026193812514; Tidermark J, 2002, QUAL LIFE RES, V11, P473, DOI 10.1023/A:1015632114068; van den Bergh JPW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078153; Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198-010-1501-1; Watts N, 1999, INT J CLIN PRACT, P51	33	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0180325	10.1371/journal.pone.0180325	http://dx.doi.org/10.1371/journal.pone.0180325			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678853	Green Submitted, gold, Green Published			2023-01-03	WOS:000405272200053
J	Kronborg, L; Bandholm, T; Palm, H; Kehlet, H; Kristensen, T				Kronborg, Lise; Bandholm, Thomas; Palm, Henrik; Kehlet, Henrik; Kristensen, Tange			Effectiveness of acute in-hospital physiotherapy with knee-extension strength training in reducing strength deficits in patients with a hip fracture: A randomised controlled trial	PLOS ONE			English	Article							INTERTESTER RELIABILITY; BASIC MOBILITY; OLDER-PEOPLE; SURGERY; PAIN; EXPERIENCES; MORTALITY; DISCHARGE; EXERCISE; EFFICACY	Question Is acute in-hospital physiotherapy with additional progressive knee-extension strength training (ST) of the fractured limb more effective in reducing knee-extension strength deficit at follow-up compared to physiotherapy without strength training in patients with a hip fracture? Design Assessor blinded, randomised controlled trial with intention-to-treat analysis. Participants 90 patients with a hip fracture admitted to an acute orthopaedic Hip Fracture Unit at a university hospital between October 2013 and May 2015. Intervention Daily physiotherapy with or without progressive knee-extension strength training (10RM), 3 x 10 repetitions, of the fractured limb using ankle weight cuffs conducted by ward physical therapists during hospital stay. Outcome measures Primary outcome was the change in maximal isometric knee-extension strength in the fractured limb in percentage of the non-fractured limb from inclusion to postoperative day 10 or discharge (follow-up). Secondary outcome was Timed Up and Go test measured early after surgery and at follow-up. Results In the intention-to-treat analysis of between-group differences, the primary outcome improved 8.1% (95% CI -2.3; 18.4) by additional strength training from baseline to follow-up. In the per-protocol analysis of non-missing data, significant between-group improvements by 10.5% (95% CI 0.3; 20.7) were found in favour of additional ST. No significant between-group differences were found in any secondary outcome. Conclusion Physiotherapy with addition of 5 sessions of ST yielded no additional improvements compared to physiotherapy without strength training in reducing the knee-extension strength deficit at follow-up in patients with a hip fracture. It is debatable whether larger improvements than the observed 8-10% can be expected given that only five exercise sessions, on average, were completed. In fragile patients with a hip fracture in the acute phase, where the ability to participate in functional exercise is compromised, we still consider early strength training a possibility to improve outcomes of clinical importance, given the results of the per-protocol analysis. The present data provides an important basis and call for future investigations including longer term interventions.	[Kronborg, Lise; Bandholm, Thomas; Kristensen, Tange] Copenhagen Univ Hosp, Dept Physio & Occupat Therapy, Phys Med & Rehabil Res Copenhagen PMR C, Hvidovre, Denmark; [Bandholm, Thomas] Copenhagen Univ Hosp, Clin Res Ctr, Hvidovre, Denmark; [Bandholm, Thomas; Palm, Henrik; Kristensen, Tange] Copenhagen Univ Hosp, Dept Orthopaed Surg, Hvidovre, Denmark; [Kehlet, Henrik] Univ Copenhagen, Rigshosp, Sect Surg Pathophysiol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen	Kronborg, L (corresponding author), Copenhagen Univ Hosp, Dept Physio & Occupat Therapy, Phys Med & Rehabil Res Copenhagen PMR C, Hvidovre, Denmark.	lisekronborg@hotmail.com	Bandholm, Thomas/AAZ-8632-2020; Kristensen, Morten/L-3527-2019	Bandholm, Thomas/0000-0001-6884-1971; Kristensen, Morten/0000-0001-5868-4677; Kehlet, Henrik/0000-0002-2209-1711	IMK Foundation; Research Foundation of the Capital Region; Foundation of Hvidovre Hospital; UCSF Lundbeck Foundation [FP15/2013]	IMK Foundation; Research Foundation of the Capital Region; Foundation of Hvidovre Hospital; UCSF Lundbeck Foundation	The study was funded by grants from The IMK Foundation (LK), The Research Foundation of the Capital Region (MTK), https:// www.regionh.dk/til-fagfolk/forskning-ogi nnovation/Finansiering/Soeg-regionens-midler/ Sider/Forskningsprojekter.aspx. The Research Foundation of the Danish Physical Therapy Organisation (LK), https://fysio.dk/fafo/fonde/ danske-fysioterapeuters-fond-for-forskningu ddannelse-og-praksisudvikling/#.VsRHSfnhAsM. The Research Foundation of Hvidovre Hospital (LK), and The UCSF Lundbeck Foundation (LK), http://www.lundbeckfoundation.com/ grant number FP15/2013. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ariza-Vega P, 2015, ARCH PHYS MED REHAB, V96, P1215, DOI 10.1016/j.apmr.2015.01.023; Ariza-Vega P, 2014, DISABIL REHABIL, V36, P685, DOI 10.3109/09638288.2013.813081; Beaupre LA, 2013, BEST PRACT RES CL RH, V27, P771, DOI 10.1016/j.berh.2014.01.001; Bech RD, 2015, PAIN RES TREAT, V2015, DOI 10.1155/2015/676212; Bloch ML, 2016, J GERIATR PHYS THER; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Christensen R, 2012, INT J SPORTS PHYS TH, V7, P504; Cummings SR, 2014, JAMA-J AM MED ASSOC, V311, P2061, DOI 10.1001/jama.2014.3033; Davenport SJ, 2014, PHYSIOTHER RES INT; de Camargo OP, 2011, SAO PAULO MED J, V129, P435, DOI [10.1590/S1516-31802011000600012, 10.1002/14651858.CD001704.pub4]; Diong J, 2015, BR J SPORTS MED; Egan M, 2008, CLIN REHABIL, V22, P272, DOI 10.1177/0269215507081573; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Foss NB, 2009, BRIT J ANAESTH, V102, P111, DOI 10.1093/bja/aen345; Foss NB, 2005, ANESTHESIOLOGY, V102, P1197, DOI 10.1097/00000542-200506000-00020; Graham JE, 2010, PHYS THER, V90, P1591, DOI 10.2522/ptj.20100018; Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003-4819-152-6-201003160-00008; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Katoh M, 2014, J PHYS THER SCI, V26, P15, DOI 10.1589/jpts.26.15; Kehlet H, 2009, CURR OPIN CRIT CARE, V15, P355, DOI 10.1097/MCC.0b013e32832fbbe7; Kempen GIJM, 2008, AGE AGEING, V37, P45, DOI 10.1093/ageing/afm157; Kristensen MT, 2009, CLIN BIOMECH, V24, P218, DOI 10.1016/j.clinbiomech.2008.10.003; Kristensen MT, 2013, PM&R, V5, P135, DOI 10.1016/j.pmrj.2012.10.006; Kristensen MT, 2012, DAN MED J, V59; Kristensen MT, 2011, J AM GERIATR SOC, V59, P565, DOI 10.1111/j.1532-5415.2010.03293.x; Kristensen MT, 2009, CLIN REHABIL, V23, P1116, DOI 10.1177/0269215509342330; Kronborg L, 2016, J AGING PHYS ACTIV, P1; Kronborg L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093332; Manini TM, 2007, J AM GERIATR SOC, V55, P451, DOI 10.1111/j.1532-5415.2007.01087.x; Milte R, 2013, J REHABIL MED, V45, P81, DOI 10.2340/16501977-1054; Mitchell SL, 2001, CLIN REHABIL, V15, P282, DOI 10.1191/026921501676849095; Overgaard J, 2013, WORLD J ORTHOP, V4, P248, DOI 10.5312/wjo.v4.i4.248; Peterson MD, 2010, AGEING RES REV, V9, P226, DOI 10.1016/j.arr.2010.03.004; Rapp K, 2013, J BONE MINER RES, V28, P821, DOI 10.1002/jbmr.1809; Rosell PAE, 2003, INJURY, V34, P529, DOI 10.1016/S0020-1383(02)00414-X; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Sherrington C, 2003, AUST J PHYSIOTHER, V49, P15, DOI 10.1016/S0004-9514(14)60184-7; Suetta C, 2004, J AM GERIATR SOC, V52, P2016, DOI 10.1111/j.1532-5415.2004.52557.x; Valenzuela T, 2012, J AM MED DIR ASSOC, V13, P418, DOI 10.1016/j.jamda.2011.11.001; Yau DT, 2012, CALCIF TISSUE INT; Ziden L, 2008, CLIN REHABIL, V22, P801, DOI 10.1177/0269215508090204; Ziden L, 2010, DISABIL REHABIL, V32, P103, DOI 10.3109/09638280903009263	44	24	24	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0179867	10.1371/journal.pone.0179867	http://dx.doi.org/10.1371/journal.pone.0179867			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EZ3JX	28662153	Green Published, Green Submitted, gold			2023-01-03	WOS:000404608300060
J	Wang, JS; Fogerty, RL; Horwitz, LI				Wang, Jessica S.; Fogerty, Robert L.; Horwitz, Leora I.			Effect of therapeutic interchange on medication reconciliation during hospitalization and upon discharge in a geriatric population	PLOS ONE			English	Article							ADMISSION; SUBSTITUTION; ERRORS; CARE; DISCREPANCIES; PROGRAM; TRANSITIONS; INHIBITORS; HISTORIES; ORDERS	Background Therapeutic interchange of a same class medication for an outpatient medication is a widespread practice during hospitalization in response to limited hospital formularies. However, therapeutic interchange may increase risk of medication errors. The objective was to characterize the prevalence and safety of therapeutic interchange. Methods and findings Secondary analysis of a transitions of care study. We included patients over age 64 admitted to a tertiary care hospital between 2009-2010 with heart failure, pneumonia, or acute coronary syndrome who were taking a medication in any of six commonly-interchanged classes on admission: proton pump inhibitors (PPIs), histamine H-2-receptor antagonists (H2 blockers), hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled corticosteroids (ICS). There was limited electronic medication reconciliation support available. Main measures were presence and accuracy of therapeutic interchange during hospitalization, and rate of medication reconciliation errors on discharge. We examined charts of 303 patients taking 555 medications at time of admission in the six medication classes of interest. A total of 244 (44.0%) of medications were therapeutically interchanged to an approved formulary drug at admission, affecting 64% of the study patients. Among the therapeutically interchanged drugs, we identified 78 (32.0%) suspected medication conversion errors. The discharge medication reconciliation error rate was 11.5% among the 244 therapeutically interchanged medications, compared with 4.2% among the 311 unchanged medications (relative risk [RR] 2.75, 95% confidence interval [CI] 1.45-5.19). Conclusions Therapeutic interchange was prevalent among hospitalized patients in this study and elevates the risk for potential medication errors during and after hospitalization. Improved electronic systems for managing therapeutic interchange and medication reconciliation may be valuable.	[Wang, Jessica S.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; [Fogerty, Robert L.] Yale Sch Med, Dept Internal Med, Sect Gen Internal Med, New Haven, CT USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY 10003 USA; [Horwitz, Leora I.] NYU Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY 10016 USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY 10003 USA	University of California System; University of California San Francisco; Yale University; New York University; NYU Langone Medical Center; New York University	Horwitz, LI (corresponding author), NYU, Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY 10003 USA.; Horwitz, LI (corresponding author), NYU Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY 10016 USA.; Horwitz, LI (corresponding author), NYU, Sch Med, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY 10003 USA.	Leora.Horwitz@nyumc.org	Horwitz, Leora/ABD-1292-2020	Fogerty, Robert/0000-0001-9119-7707	CTSA from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024139]; NIH road map for Medical Research; Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine [P30AG021342 NIH/NIA]; John A. Hartford Foundation; American Federation for Aging Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG021342] Funding Source: NIH RePORTER	CTSA from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH road map for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine; John A. Hartford Foundation; American Federation for Aging Research; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This publication was made possible by CTSA Grant Number UL1 RR024139 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH road map for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. This work was also supported by the Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine (#P30AG021342 NIH/NIA) and The John A. Hartford Foundation and the American Federation for Aging Research. No funding source had any role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the John A. Hartford Foundation, or the American Federation for Aging Research.	Amidon PB, 2000, AM J MANAG CARE, V6, P593; Chong PH, 2002, ANN PHARMACOTHER, V36, P1907, DOI 10.1345/aph.1C116; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; DOERING PL, 1982, AM J HOSP PHARM, V39, P1028, DOI 10.1093/ajhp/39.6.1028; Galt KA, 2001, P T J, V26, P151; Glaholt Sarah, 2014, P T, V39, P267; Gleason KM, 2004, AM J HEALTH-SYST PH, V61, P1689, DOI 10.1093/ajhp/61.16.1689; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Grimes TC, 2011, BRIT J CLIN PHARMACO, V71, P449, DOI 10.1111/j.1365-2125.2010.03834.x; Grossman JM, HOSP EXPERIENCES USI; Himmel W, 1996, EUR J CLIN PHARMACOL, V50, P253, DOI 10.1007/s002280050103; Holmes DR, 2011, J AM COLL CARDIOL, V58, P1287, DOI 10.1016/j.jacc.2011.06.001; Institute for Safe Medication Practices Canada, MED REC 2016; KORMAN L, 1995, AM J HEALTH-SYST PH, V52, P1078, DOI 10.1093/ajhp/52.10.1078; Kramer JS, 2007, AM J HEALTH-SYST PH, V64, P404, DOI 10.2146/ajhp060506; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Office of the National Coordinator for Health Information Technology, HOSP AD MEAN US STAG; Pedersen CA, 2011, AM J HEALTH-SYST PH, V68, P669, DOI [10.2146/ajhp100711, 10.2146/ajhp090596]; Pippins JR, 2008, J GEN INTERN MED, V23, P1414, DOI 10.1007/s11606-008-0687-9; Reeder TA, 2008, AM J HEALTH-SYST PH, V65, P857, DOI 10.2146/ajhp070292; Schachtner JM, 2002, AM J HEALTH-SYST PH, V59, P529, DOI 10.1093/ajhp/59.6.529; Schneeweiss S, 2006, CLIN PHARMACOL THER, V79, P379, DOI 10.1016/j.clpt.2005.12.304; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Sodorff MM, 2002, PHARMACOTHERAPY, V22, P500, DOI 10.1592/phco.22.7.500.33677; Tam VC, 2005, CAN MED ASSOC J, V173, P510, DOI 10.1503/cmaj.045311; Taylor AJ, 2001, PHARMACOTHERAPY, V21, P1130, DOI 10.1592/phco.21.13.1130.34616; Usher-Smith J, 2008, INT J CLIN PRACT, V62, P480, DOI 10.1111/j.1742-1241.2007.01690.x; Vira T, 2006, QUAL SAF HEALTH CARE, V15, P122, DOI 10.1136/qshc.2005.015347; Wohlauer MV, 2012, ACAD MED, V87, P411, DOI 10.1097/ACM.0b013e318248e766; Wong JD, 2008, ANN PHARMACOTHER, V42, P1373, DOI 10.1345/aph.1L190; Ziaeian B, 2012, J GEN INTERN MED, V27, P1513, DOI 10.1007/s11606-012-2168-4	31	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0186075	10.1371/journal.pone.0186075	http://dx.doi.org/10.1371/journal.pone.0186075			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0UN	29049325	gold, Green Published, Green Submitted			2023-01-03	WOS:000413195900039
J	Carrasco, JM; Garcia, M; Navas, A; Olza, I; Gomez-Baceiredo, B; Pujol, F; Garralda, E; Centeno, C				Miguel Carrasco, Jose; Garcia, Miriam; Navas, Alejandro; Olza, Ines; Gomez-Baceiredo, Beatriz; Pujol, Francesc; Garralda, Eduardo; Centeno, Carlos			What does the media say about palliative care? A descriptive study of news coverage in written media in Spain	PLOS ONE			English	Article							COMMUNICATION; PERSPECTIVE; COUNTRIES; BARRIERS; EUROPE	Introduction The goal of palliative care (PC) is to improve the quality of life of terminal stage patients and their families. The subject frequently appears in the mass-media and this helps create a socially accepted identity. The aim of this study is to describe and analyse PC related news items appeared in the Spanish written media. Methodology A descriptive cross-sectional study was designed. Considering diffusion, scope and the range in editorial policy criteria, four printed newspapers (PN) were selected, together with four exclusively digital media sources (DM). Through Mynews, a newspaper content depository, and the search tool for each DM website, articles published between 2009 and 2014 which included the terms "palliative care" and "palliative medicine" were sought. A questionnaire was created to characterise each article identified and a descriptive analysis was undertaken. Results A total of 627 articles were identified, of which 359 (57%) were published in PN (42% in the printed editions -PE- 16% in their online editions -OE-) and 268 (43%) in DM. In general, they appeared mainly in sections concerning Health (23%), Culture and Society (18%) and General/Home News (15%). In PE, just 2% were found in the Health section and nearly 70% in Culture and Society and General/Home News. Most of the articles were informative in nature and contained socio-political messages (90%). Statements by PC professionals were found in 35% of the articles and by politicians in 32%. The most frequent content was related to facing end of life (74%) and patient quality of life (70%). Conclusions The Spanish written media reflects the socio-political interest aroused by PC. Nevertheless, messages circulating about PC do not describe professional practice, or the contribution of the same for patients. Content more in line with the clinical practice might help contribute to the development of this new area of medicine.	[Miguel Carrasco, Jose; Garralda, Eduardo; Centeno, Carlos] Univ Navarra, Inst Culture & Soc, ATLANTES Res Program, Pamplona, Spain; [Miguel Carrasco, Jose; Garralda, Eduardo; Centeno, Carlos] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain; [Garcia, Miriam] Errea Comunicac, Pamplona, Spain; [Navas, Alejandro] Univ Navarra, Sch Commun, Publ Commun Dept, Pamplona, Spain; [Olza, Ines] Univ Navarra, Inst Culture & Soc, GRADUN, Pamplona, Spain; [Gomez-Baceiredo, Beatriz] Univ Navarra, Sch Commun, Journalism Projects Dept, Pamplona, Spain; [Pujol, Francesc] Univ Navarra, Sch Econ & Business Adm, Dept Econ, Pamplona, Spain	University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra	Carrasco, JM (corresponding author), Univ Navarra, Inst Culture & Soc, ATLANTES Res Program, Pamplona, Spain.; Carrasco, JM (corresponding author), Navarra Inst Hlth Res IdiSNA, Pamplona, Spain.	jmcarrascog@unay.es	Gomez, Beatriz/AAF-1391-2021; Pujol, Francesc/Z-4767-2019; Centeno, Carlos/H-3430-2013; Carrasco, Jose Miguel/I-3482-2015	Gomez, Beatriz/0000-0001-5332-0698; Pujol, Francesc/0000-0002-0368-0529; Centeno, Carlos/0000-0003-3395-7039; Carrasco, Jose Miguel/0000-0002-3847-8312	Institute for Culture and Society (ICS) of the University Navarra	Institute for Culture and Society (ICS) of the University Navarra	Support for this work was received from the Institute for Culture and Society (ICS) of the University Navarra. One of the authors [MG] is employed by a commercial company [Errea Comunicacion], but the company did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Aguiar F, 2013, ADV APPL SOCIOLOGY, V3, P124; Akintola O, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0051-6; Akiyama M, 2016, SUPPORT CARE CANCER, V24, P347, DOI 10.1007/s00520-015-2788-4; [Anonymous], 2011, ASOCIACION INVESTIGA; Centeno C, 2015, PALLIATIVE MED, P31; Conde Fernando, 2009, ANALISIS SOCIOLOGICO; Daw JR, 2013, HEALTH POLICY, V110, P67, DOI 10.1016/j.healthpol.2013.01.006; De Leon E, 2014, J MED INTERNET RES, V16, P119, DOI 10.2196/jmir.2837; Duran M.A., 2004, REV ESP INVESTIG SOC, V106, P9; Gempeler F. E., 2015, REV COLOMB ANESTESIO, V43, P142; Habermas J, 1981, HIST CRITICA OPINION; Husemann S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1742-1; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; Lynch T, 2010, PALLIATIVE MED, V24, P812, DOI 10.1177/0269216310368578; Lynch T, 2009, J PAIN SYMPTOM MANAG, V37, P305, DOI 10.1016/j.jpainsymman.2008.03.011; McIlfatrick S, 2014, PALLIATIVE MED, V28, P273, DOI 10.1177/0269216313502372; McIlfatrick S, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-34; Muszbek K, 2007, J PAIN SYMPTOM MANAG, V33, P605, DOI 10.1016/j.jpainsymman.2007.02.027; Naugle DA, 2014, J HEALTH COMMUN, V19, P190, DOI 10.1080/10810730.2014.918217; Norton SA, 2013, RES NURS HEALTH, V36, P582, DOI 10.1002/nur.21563; Oliver D, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4846; Parry R, 2014, BMJ SUPPORT PALLIAT, V4, P331, DOI 10.1136/bmjspcare-2014-000649; Pastrana T, 2015, J PALLIAT MED, V18, P429, DOI 10.1089/jpm.2014.0120; Rodriguez Diaz R, 2004, OBSERVATORIO EUROPEO; StataCorp, 2011, STAT STAT SOFTW REL; Taiwo R., 2007, PERSPECTIVES MEDIA D; Van den Berg R, 2011, EUR J GEN PRACT, V17, P14, DOI 10.3109/13814788.2010.549224; Vega T, 2011, GAC SANIT, V25, P205, DOI 10.1016/j.gaceta.2011.02.005; World Health Organization, 2013, EUR HLTH REP 2012 CH; World Health Organization-WHO, 2014, DEF PALL CAR; World Palliative Care Alliance World Health Organization, 2014, GLOBAL ATLAS PALLIAT; Wurz A, 2013, J HEALTH COMMUN, V18, P1566, DOI 10.1080/10810730.2013.840698; 2013, WORLD HLTH REP 2013, P1	34	13	15	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2017	12	10							e0184806	10.1371/journal.pone.0184806	http://dx.doi.org/10.1371/journal.pone.0184806			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI5MY	28968433	Green Published, Green Submitted, gold			2023-01-03	WOS:000412029600010
J	Byun, SJ; Bae, WH; Jung, SM; Lee, SW; Park, YB; Song, JJ				Byun, Se Jin; Bae, William Han; Jung, Seung Min; Lee, Sang-Won; Park, Yong-Beom; Song, Jason Jungsik			Fever as an initial manifestation of spondyloarthritis: A retrospective study	PLOS ONE			English	Article							SOCIETY CLASSIFICATION CRITERIA; ANKYLOSING-SPONDYLITIS; CLINICAL-ASPECTS; DOUBLE-BLIND; ARTHRITIS; EFFICACY	Objectives: We aimed to evaluate a wide spectrum of clinical features of adult patients with spondyloarthritis (SpA) whose initial manifestation was fever, using the Assessment of SpondyloArthritis international Society (ASAS) classification criteria. Methods: We retrospectively collected the electronic medical records of hospitalized SpA patients who initially presented to the Severance Hospital (Seoul, Korea) with fever from January 2010 to May 2016. As a control group, we also recruited one-hundred consecutive patients who were diagnosed with SpA in our outpatient clinic. Clinical features and laboratory findings were compared in two patient groups. Results: There were 26 patients who had fever as initial presentation of SpA (reactive arthritis 50%, undifferentiated SpA 26.9%, ankylosing spondylitis 15.4%, enteropathic arthritis 3.8%, psoriatic arthritis 3.8%). Peripheral SpA was more common in febrile SpA patients than in control SpA patients (65.4% vs 24.0%, p<0.001). Febrile SpA patients were less frequently HLA-B27 positive than control SpA patients (52.2% vs 77.0%, p<0.05). At baseline, systemic inflammatory markers were significantly higher in the febrile SpA patients (white blood cell count, 11.57 vs 7.81 cells/mu L, p<0.001; erythrocyte sedimentation rate, 69.2 vs 41.0 mm/h, p<0.001; C-reactive protein, 109.6 vs 15.3 mg/L, p<0.001). The proportion of patients treated with systemic steroids was significantly higher in febrile SpA patients (57.7% vs. 11.0%, p<0.001). The proportion of patients who visited rheumatology specialty was significantly lower in febrile SpA patients than in control SpA patients (7.7% vs 59.0%, p<0.001). Conclusion: Various subgroups of SpA can be presented with fever as an initial manifestation. Febrile SpA patients demonstrated higher systemic inflammation and a lower chance to visit rheumatology in early stage. When evaluating febrile patients with any clinical features of SpA, clinicians are advised to consider performing SpA-focused evaluation including HLA-B27 or a simple sacroiliac joint radiograph.	[Byun, Se Jin; Bae, William Han; Jung, Seung Min; Lee, Sang-Won; Park, Yong-Beom; Song, Jason Jungsik] Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; [Song, Jason Jungsik] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Song, JJ (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea.; Song, JJ (corresponding author), Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea.	JSKSONG@yuhs.ac		Jung, Seung Min/0000-0003-3465-2181; Song, Jason/0000-0003-0662-7704; Lee, Sang-Won/0000-0002-8038-3341	Basic Science Research Program through National Research Foundation of Korea [2015R1C1A1A01053140]; Ministry of Education, Science, and Technology	Basic Science Research Program through National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the Basic Science Research Program (2015R1C1A1A01053140) through the National Research Foundation of Korea, and funded by the Ministry of Education, Science, and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baeten D, 2013, ARTHRITIS RHEUM-US, V65, P12, DOI 10.1002/art.37829; Behar VM, 2016, JOINT BONE SPINE; Carter JD, 2009, RHEUM DIS CLIN N AM, V35, P21, DOI 10.1016/j.rdc.2009.03.010; Courcoul A, 2017, JOINT BONE SPINE; Danve A, 2015, CLIN RHEUMATOL, V34, P987, DOI 10.1007/s10067-015-2958-2; del Rio-Martinez P, 2016, SEMINARS ARTHRITIS R; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; Fauci AS, 2015, HARRISONS PRINCIPLES, V1; Guo RR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128979; Haibel H, 2014, ANN RHEUM DIS, V73, P243, DOI 10.1136/annrheumdis-2012-203055; Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002; Inman RD, 1999, J RHEUMATOL, V26, P1219; Maugars Y, 1996, BRIT J RHEUMATOL, V35, P767; Pato E, 2000, J RHEUMATOL, V27, P2198; Rudwaleit M, 2011, ANN RHEUM DIS, V70, P25, DOI 10.1136/ard.2010.133645; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; Seo MR, 2015, CLIN RHEUMATOL, V34, P1397, DOI 10.1007/s10067-014-2768-y; Stolwijk C, 2013, ANN RHEUMATIC DIS; Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972; van der Heijde D, 2011, ANN RHEUM DIS, V70, P905, DOI 10.1136/ard.2011.151563; van Tubergen A, 2015, NAT REV RHEUMATOL, V11, P110, DOI 10.1038/nrrheum.2014.181; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Ward MM, 2016, ARTHRITIS RHEUMATOL, V68, P282, DOI 10.1002/art.39298; ZELICKSON BD, 1991, ARCH DERMATOL, V127, P1339, DOI 10.1001/archderm.127.9.1339; Zochling J, 2010, BEST PRACT RES CL RH, V24, P747, DOI 10.1016/j.berh.2011.02.002	25	3	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184323	10.1371/journal.pone.0184323	http://dx.doi.org/10.1371/journal.pone.0184323			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0VR	28910361	Green Submitted, Green Published, gold			2023-01-03	WOS:000410859200041
J	Mwau, M; Bwana, P; Kithinji, L; Ogollah, F; Ochieng, S; Akinyi, C; Adhiambo, M; Ogumbo, F; Sirengo, M; Boeke, C				Mwau, Matilu; Bwana, Priska; Kithinji, Lucy; Ogollah, Francis; Ochieng, Samuel; Akinyi, Catherine; Adhiambo, Maureen; Ogumbo, Fred; Sirengo, Martin; Boeke, Caroline			Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years	PLOS ONE			English	Article							EARLY INFANT DIAGNOSIS; RANDOMIZED CONTROLLED-TRIAL; HEALTH SYSTEM; PREVENTION; WOMEN; RISK; CARE; INFECTION; DELIVERY; COMMUNITY	Objective To describe factors associated with mother-to-child HIV transmission (MTCT) in Kenya and identify opportunities to increase testing/care coverage. Design Cross-sectional analysis of national early infant diagnosis (EID) database. Methods 365,841 Kenyan infants were tested for HIV from January 2007-July 2015 and results, demographics, and treatment information were entered into a national database. HIV risk factors were assessed using multivariable logistic regression. Results 11.1% of infants tested HIV positive in 2007 - 2010 and 6.9% in 2014 - 2015. Greater odds of infection were observed in females (OR: 1.08; 95% CI: 1.05 - 1.11), older children (18 - 24 months vs. 6 weeks-2 months: 4.26; 95% CI: 3.87 - 4.69), infants whose mothers received no PMTCT intervention (vs. HAART OR: 1.92; 95% CI: 1.79 - 2.06), infants receiving no prophylaxis (vs. nevirapine for 6 weeks OR: 2.76; 95% CI: 2.51 - 3.05), and infants mixed breastfed (vs. exclusive breastfeeding OR: 1.39; 95% CI: 1.30 - 1.49). In 2014 - 2015, 9.1% of infants had mothers who were not on treatment during pregnancy, 9.8% were not on prophylaxis, and 7.0% were mixed breastfed. Infants exposed to all three risky practices had a sevenfold higher odds of HIV infection compared to those exposed to recommended practices. The highest yield of HIV-positive infants were found through targeted testing of symptomatic infants in pediatric/outpatient departments (>15%); still, most infected infants were identified through PMTCT programs. Conclusion Despite impressive gains in Kenya's PMTCT program, some HIV-infected infants present late and are not benefitting from PMTCT best practices. Efforts to identify these early and enforce evidence-based practice for PMTCT should be scaled up. Infant testing should be expanded in pediatric/outpatient departments, given high yields in these portals.	[Mwau, Matilu; Akinyi, Catherine; Adhiambo, Maureen; Ogumbo, Fred] Kenya Govt Med Res Ctr, Ctr Infect & Parasit Dis Control Res, Busia, Kenya; [Mwau, Matilu; Bwana, Priska; Kithinji, Lucy; Ogollah, Francis; Ochieng, Samuel] Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi, Kenya; [Sirengo, Martin] Minist Hlth, Natl AIDS & STIs Control Program, Nairobi, Kenya; [Boeke, Caroline] Clinton Hlth Access Initiat, Boston, MA USA	Kenya Medical Research Institute; Kenya Medical Research Institute	Mwau, M (corresponding author), Kenya Govt Med Res Ctr, Ctr Infect & Parasit Dis Control Res, Busia, Kenya.; Mwau, M (corresponding author), Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi, Kenya.	mmwau@kemri.org	Ogumbo, Fredrick/AAO-6964-2021	Ogumbo, Fredrick/0000-0002-5699-5591	Centers for Disease Control and Prevention (CDC); USAID/PEPFAR; UNITAID; Hewlett-Packard	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); USAID/PEPFAR(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); UNITAID; Hewlett-Packard	The authors wish to thank the Centers for Disease Control and Prevention (CDC), USAID/PEPFAR, and UNITAID for funding HIV diagnostics in Kenya. The IT infrastructure was funded by Hewlett-Packard. None of the funders had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors wish to thank the Centers for Disease Control and Prevention (CDC), USAID/PEPFAR, and UNITAID for funding HIV diagnostics in Kenya, as well as the Clinton Health Access Initiative for technical support.	Ambia J, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20309; [Anonymous], 2000, BMJ, V320, P14681; [Anonymous], 2016, THAIL IS 1 COUNTR AS; [Anonymous], 2014, KENYA AIDS RESP PROG; Becquet R, 2008, PREV MED, V47, P27, DOI 10.1016/j.ypmed.2007.11.014; Biggar RJ, 2006, JAIDS-J ACQ IMM DEF, V41, P509, DOI 10.1097/01.qai.0000191283.85578.46; Bosire R, 2016, BREASTFEED MED, V11, P56, DOI 10.1089/bfm.2015.0071; Brahmbhatt H, 2009, J PEDIAT INF DIS-GER, V4, P275, DOI 10.3233/JPI-2009-0168; Chang J, 2014, J VIROL METHODS, V204, P25, DOI 10.1016/j.jviromet.2014.03.010; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Dillabaugh LL, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/602120; Finocchario-Kessler S, 2014, AIDS, V28, pS313, DOI 10.1097/QAD.0000000000000332; Fowler MG, 2008, PLOS MED, V5, P359, DOI 10.1371/journal.pmed.0050063; Galli L, 2005, JAIDS-J ACQ IMM DEF, V40, P479, DOI 10.1097/01.qai.0000164247.49098.0e; Goggin K, 2016, AIDS BEHAV, V20, P2141, DOI 10.1007/s10461-016-1404-z; Goldstein M, 2013, AM ECON J-APPL ECON, V5, P58, DOI 10.1257/app.5.2.58; Hassan AS, 2012, AIDS BEHAV, V16, P5, DOI 10.1007/s10461-010-9877-7; IATT, 2016, INT TASK TEAM PREV T; Jennings L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1131; Kageha S, 2012, J TROP PEDIATRICS, V58, P247, DOI 10.1093/tropej/fmr076; Kinuthia J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0467-6; KNBS, 2014, KENYA DEM HLTH SURV; Lofgren SM, 2009, AIDS, V23, P2459, DOI 10.1097/QAD.0b013e328331f702; Lowther K, 2016, AIDS CARE, V28, P60, DOI 10.1080/09540121.2016.1146214; Luque-Fernandez MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056088; Ministry of Health Government of Kenya, 2012, GUIDELINES PREVENTIO, V4th ed; Mushamiri I, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1358-5; NASCOP, 2015, KENYA HIV TEST SERV; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Obermeyer CM, 2013, TROP MED INT HEALTH, V18, P1110, DOI 10.1111/tmi.12155; Odeny BM, 2016, BREASTFEED MED, V11, P252, DOI 10.1089/bfm.2016.0014; Okanda JO, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-280; Onono M, 2015, AIDS PATIENT CARE ST, V29, P204, DOI 10.1089/apc.2014.0181; Piwoz EG, 2005, AIDS, V19, P1719, DOI 10.1097/01.aids.0000184745.12338.21; Rustagi AS, 2016, J ACQUIR IMMUNE DEFI; Sharma M, 2015, NATURE, V528, pS77, DOI 10.1038/nature16044; Tao Z, 2010, J BIOL CHEM, V285, P17725, DOI 10.1074/jbc.M110.121798; Turan JM, 2015, JAIDS-J ACQ IMM DEF, V69, pe172, DOI 10.1097/QAI.0000000000000678; UNAIDS/WHO, 2013, UNAIDS REP GLOB AIDS; Wise J, 2001, BRIT MED J, V322, P511; World Health Organization, 2016, CONS GUID US ANT DRU	41	14	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2017	12	8							e0183860	10.1371/journal.pone.0183860	http://dx.doi.org/10.1371/journal.pone.0183860			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE9SU	28850581	gold, Green Published, Green Submitted			2023-01-03	WOS:000408544200035
J	Farley, JE; Ndjeka, N; Kelly, AM; Whitehouse, E; Lachman, S; Budhathoki, C; Lowensen, K; Bergren, E; Mabuza, H; Mlandu, N; van der Walt, M				Farley, Jason E.; Ndjeka, Norbert; Kelly, Ana M.; Whitehouse, Erin; Lachman, Simmi; Budhathoki, Chakra; Lowensen, Kelly; Bergren, Ellie; Mabuza, Hloniphile; Mlandu, Ntombasekhaya; van der Walt, Martie			Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant tuberculosis in South Africa	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; MDR-TB; OUTCOMES; DOCTORS	Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) in South Africa remain close to 50%. Lack of access to timely, decentralized care is a contributing factor. We evaluated MDR-TB treatment outcomes from a clinical cohort with task-sharing between a clinical nurse practitioner (CNP) and a medical officer (MO). Methods We completed a retrospective evaluation of outcomes from a prospective, programmatically-based MDR-TB cohort who were enrolled and received care between 2012 and 2015 at a peri-urban hospital in KwaZulu-Natal, South Africa. Treatment was provided by either by a CNP or MO. Findings The cohort included 197 participants with a median age of 33 years, 51% female, and 74% co-infected with HIV. The CNP initiated 123 participants on treatment. Overall MDR-TB treatment success rate in this cohort was 57.9%, significantly higher than the South African national average of 45% in 2012 (p<0.0001) and similar to the provincal average of 60% (p = NS). There were no significant differences by provider type: treatment success was 61% for patients initiated by the CNP and 52.7% for those initiated by the MO. Interpretation Clinics that adopted a task sharing approach for MDR-TB demonstrated greater treatment success rates than the national average. Task-sharing between the CNP and MO did not adversely impact treatment outcome with similar success rates noted. Task-sharing is a feasible option for South Africa to support decentralization without compromising patient outcomes. Models that allow sharing of responsibility for MDR-TB may optimize the use of human resources and improve access to care.	[Farley, Jason E.; Whitehouse, Erin; Budhathoki, Chakra; Lowensen, Kelly; Bergren, Ellie] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA; [Ndjeka, Norbert] Republ South Africa Dept Hlth, Pretoria, South Africa; [Kelly, Ana M.] Columbia Univ, Sch Nursing, New York, NY USA; [Lachman, Simmi] Murchison Dist Hosp, Port Shepstone, South Africa; [Mabuza, Hloniphile] Ctr Dis Control & Prevent, Atlanta, GA USA; [Mlandu, Ntombasekhaya] JHHESA, Pretoria, South Africa; [van der Walt, Martie] MRC, Pretoria, South Africa	Johns Hopkins University; Columbia University; Centers for Disease Control & Prevention - USA	Farley, JE (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.	jfarley1@jhu.edu	Ndjeka, Norbert/AAX-7260-2021; van der Walt, Martie/CAH-0101-2022; Budhathoki, Chakra/AAC-3180-2021	Ndjeka, Norbert/0000-0001-6200-1592; van der Walt, Martie/0000-0001-9987-3167; Budhathoki, Chakra/0000-0002-1886-7847; Farley, Jason/0000-0002-6896-0134; Whitehouse, Erin/0000-0002-5158-0282	Johns Hopkins University; Medical Research Council; National Department of Health from Centers for Disease Control and Prevention; President's Emergency Plan for AIDS Relief (PEPFAR) through Centers for Disease Control and Prevention (CDC) [5U2GPS00206205]; National Institutes of Health [T32, 5T32NR013454-04]; National Institute of Nursing Research of the National Institutes of Health [5T32NR012704-05]	Johns Hopkins University(Johns Hopkins University); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Department of Health from Centers for Disease Control and Prevention; President's Emergency Plan for AIDS Relief (PEPFAR) through Centers for Disease Control and Prevention (CDC)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Nursing Research of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Funding for this study was provided by separate cooperative agreements between Johns Hopkins University, the Medical Research Council, and the National Department of Health from the Centers for Disease Control and Prevention. This publication has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of grant 5U2GPS00206205. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. AK was supported by a National Institutes of Health T32 "Training in interdisciplinary research to prevent infections (TIR1)" (5T32NR013454-04) grant during the writing of this report. EW was supported by the National Institute of Nursing Research of the National Institutes of Health under award number (5T32NR012704-05) during the writing of this report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Allison PD, 2005, SURVIVAL ANAL USING; Brennan AT, 2011, AIDS, V25, P2027, DOI 10.1097/QAD.0b013e32834b6480; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Cameron D, 2012, SAMJ S AFR MED J, V102, P98, DOI 10.7196/SAMJ.5195; Cohen R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-23; Emdin CA, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18445; Fairall L, 2012, LANCET, V380, P889, DOI 10.1016/S0140-6736(12)60730-2; Farley JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111702; Farley JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020436; Gielen SC, 2014, INT J NURS STUD, V51, P1048, DOI 10.1016/j.ijnurstu.2013.12.003; Iwu EN, 2014, AIDS CARE, V26, P42, DOI 10.1080/09540121.2013.793278; Kredo T, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007331.pub3; Long L, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001055; Loveday M, 2015, INT J TUBERC LUNG D, V19, P163, DOI 10.5588/ijtld.14.0369; Loveday M, 2012, INT J TUBERC LUNG D, V16, P209, DOI 10.5588/ijtld.11.0401; McGuire M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074090; Republic of South Africa Department of Health, 2011, MULT RES TUB POL FRA; Republic of South Africa Department of Health, 2013, MAN DRUG RES TUB POL; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; The South African National AIDS Council, 2011, NAT STRAT PLAN NSP H; Turashvili M, 2014, MED SANS FRONTIERES; Van der Walt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058817; van Rensburg HCJ, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-26; Walsh A, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-272; WHO, 2015, END TB STRAT GLOB ST; World Health Organization, 2016, GLOBAL TUBERCULOSIS; World Health Organization, 2008, TASK SHIFT RAT RED T	28	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2017	12	8							e0182780	10.1371/journal.pone.0182780	http://dx.doi.org/10.1371/journal.pone.0182780			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC6IS	28783758	gold, Green Published, Green Submitted			2023-01-03	WOS:000406944300054
J	Chotun, N; Preiser, W; van Rensburg, CJ; Fernandez, P; Theron, GB; Glebe, D; Andersson, MI				Chotun, Nafiisah; Preiser, Wolfgang; van Rensburg, Christoffel Johannes; Fernandez, Pedro; Theron, Gerhard Barnard; Glebe, Dieter; Andersson, Monique Ingrid			Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; WESTERN CAPE; TENOFOVIR; METAANALYSIS; THERAPY; INFANTS; ANTIGEN; GAMBIA; SAFETY; TESTS	Background & aims Elimination of HIV and syphilis mother-to-child transmission (MTCT) has received much attention but little consideration has been given to the possibility of elimination of HBV MTCT. In sub-Saharan Africa, HBV vertical transmission continues to be reported and it remains an important public health problem. This study aimed to assess the feasibility of screening pregnant women for HBV using a point-of-care (POC) test and implementing interventions to prevent HBV MTCT. Methods In this observational prospective cohort study, HIV-uninfected pregnant women who consented to testing were screened for HBV using a rapid POC test for HBsAg. Positive results were laboratory-confirmed and tested for HBV DNA and serological markers. Women with viral loads >= 20 000 IU/ml received tenofovir (TDF) treatment and all infants received birth-dose HBV vaccine. Two blood samples collected six months apart from HBV-exposed infants within their first year of life were tested for HBV DNA. Results Of 144 women who were approached, 134 consented to participating (93% acceptance rate of HBV POC test). Six women tested positive for HBsAg (4.5%; 95% CI 0.99%-8.01%), all confirmed by laboratory testing. Two mothers, M1 and M4, were treated with TDF during their third trimester of pregnancy. Six HBV-exposed infants received the HBV vaccine within 24 hours of birth, of whom two were lost to follow-up and four (including the two born to M1 and M4) had undetectable levels of HBV DNA when tested at the two time points. Conclusion We found that HBV screening using POC testing fulfilled the criteria considered necessary for implementation. It has acceptable performance, is inexpensive, reliable, and was well accepted by the study participants. Screening pregnant women as part of the HBV MTCT prevention strategy is therefore feasible in a South African clinical setting.	[Chotun, Nafiisah; Preiser, Wolfgang; Andersson, Monique Ingrid] Stellenbosch Univ, Div Med Virol, Dept Pathol, Fac Med & Hlth Sci, Cape Town, South Africa; [Preiser, Wolfgang] Tygerberg Hosp, NHLS, Tygerberg, South Africa; [van Rensburg, Christoffel Johannes] Stellenbosch Univ, Div Gastroenterol & Hepatol, Dept Med, Cape Town, South Africa; [Fernandez, Pedro] Stellenbosch Univ, Div Urol, Dept Surg Sci, Cape Town, South Africa; [Theron, Gerhard Barnard] Stellenbosch Univ, Dept Obstet & Gynaecol, Cape Town, South Africa; [Glebe, Dieter] Justus Liebig Univ Giessen, Inst Med Virol, Natl Reference Ctr Hepatitis B&D Viruses, German Ctr Infect Res DZIF, Giessen, Germany; [Andersson, Monique Ingrid] Oxford Univ Hosp NHS Fdn Trust, Oxford, England	Stellenbosch University; University of Cape Town; Tygerberg Hospital; Stellenbosch University; Stellenbosch University; Stellenbosch University; German Center for Infection Research; Justus Liebig University Giessen; Oxford University Hospitals NHS Foundation Trust	Chotun, N (corresponding author), Stellenbosch Univ, Div Med Virol, Dept Pathol, Fac Med & Hlth Sci, Cape Town, South Africa.	nafiisahc@sun.ac.za	Preiser, Wolfgang/J-4875-2016; Chotun, Nafiisah/AAP-4773-2020	Preiser, Wolfgang/0000-0002-0254-7910; Chotun, Nafiisah/0000-0003-1729-7915	Gilead Forderprogramm Infektiologie, "Piloting of rapid test-based screening for hepatitis B in pregnancy in South Africa"	Gilead Forderprogramm Infektiologie, "Piloting of rapid test-based screening for hepatitis B in pregnancy in South Africa"	This work was supported by the Gilead Forderprogramm Infektiologie, "Piloting of rapid test-based screening for hepatitis B in pregnancy in South Africa" to DG, MIA, and WP. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aly HAA, 2015, WHO TECH REP SER, V994, P1; Andermann A, 2008, B WORLD HEALTH ORGAN, V86, P317, DOI 10.2471/BLT.07.050112; Andersson MI, 2013, VACCINE, V31, P5579, DOI 10.1016/j.vaccine.2013.08.028; Andersson MI, 2015, LANCET GLOB HEALTH, V3, pE358, DOI 10.1016/S2214-109X(15)00056-X; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; Brown RS, 2016, HEPATOLOGY, V63, P319, DOI 10.1002/hep.28302; Chotun N, 2015, VACCINE, V33, P4618, DOI 10.1016/j.vaccine.2015.06.076; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Hipgrave DB, 2006, B WORLD HEALTH ORGAN, V84, P65, DOI 10.2471/BLT.04.017426; Keane E, 2016, ALIMENT PHARM THER, V44, P1005, DOI 10.1111/apt.13795; le Roux SM, 2017, AIDS, V31, P97, DOI 10.1097/QAD.0000000000001302; Lukhwareni A, 2009, J MED VIROL, V81, P406, DOI 10.1002/jmv.21418; Mofenson LM, 2017, AIDS, V31, P213, DOI 10.1097/QAD.0000000000001313; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nayagam S, 2016, LANCET GLOB HEALTH, V4, pE568, DOI 10.1016/S2214-109X(16)30101-2; Njai HF, 2015, J CLIN MICROBIOL, V53, P1156, DOI 10.1128/JCM.02980-14; Pan CQ, 2016, NEW ENGL J MED, V374, P2324, DOI 10.1056/NEJMoa1508660; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X; Servant-Delmas A, 2015, J CLIN MICROBIOL, V53, P3954, DOI 10.1128/JCM.02117-15; Shivkumar S, 2012, AM J GASTROENTEROL, V107, P1306, DOI 10.1038/ajg.2012.141; Solomon MM, 2016, JAIDS-J ACQ IMM DEF, V71, P281, DOI 10.1097/QAI.0000000000000857; Terrault NA, 2016, HEPATOLOGY, V63, P261, DOI 10.1002/hep.28156; Wanyenze RK, 2008, B WORLD HEALTH ORGAN, V86, P302, DOI 10.2471/BLT.07.042580; Wen WH, 2013, J HEPATOL, V59, P24, DOI 10.1016/j.jhep.2013.02.015; World Health Organization, 2015, GUIDELINES PREVENTIO, P166; World Health Organization, 2017, WHO GUID HEP B C TES; World Health Organization Publication, 2010, VACCINE, V28, P589, DOI DOI 10.1016/J.VACCINE.2009.10.110	28	19	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2017	12	7							e0181267	10.1371/journal.pone.0181267	http://dx.doi.org/10.1371/journal.pone.0181267			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC2BU	28732085	Green Submitted, Green Published, gold			2023-01-03	WOS:000406643100030
J	Wu, XK; Stener-Victorin, E; Kuang, HY; Ma, HL; Gao, JS; Xie, LZ; Hou, LH; Hu, ZX; Shao, XG; Ge, J; Zhang, JF; Xue, HY; Xu, XF; Liang, RN; Ma, HX; Yang, HW; Li, WL; Huang, DM; Sun, Y; Hao, CF; Du, SM; Yang, ZW; Wang, X; Yan, Y; Chen, XH; Fu, P; Ding, CF; Gao, YQ; Zhou, ZM; Wang, CC; Wu, TX; Liu, JP; Ng, EHY; Legro, RS; Zhang, HP				Wu, Xiao-Ke; Stener-Victorin, Elisabet; Kuang, Hong-Ying; Ma, Hong-Li; Gao, Jing-Shu; Xie, Liang-Zhen; Hou, Li-Hui; Hu, Zhen-Xing; Shao, Xiao-Guang; Ge, Jun; Zhang, Jin-Feng; Xue, Hui-Ying; Xu, Xiao-Feng; Liang, Rui-Ning; Ma, Hong-Xia; Yang, Hong-Wei; Li, Wei-Li; Huang, Dong-Mei; Sun, Yun; Hao, Cui-Fang; Du, Shao-Min; Yang, Zheng-Wang; Wang, Xin; Yan, Ying; Chen, Xiu-Hua; Fu, Ping; Ding, Cai-Fei; Gao, Ya-Qin; Zhou, Zhong-Ming; Wang, Chi Chiu; Wu, Tai-Xiang; Liu, Jian-Ping; Ng, Ernest H. Y.; Legro, Richard S.; Zhang, Heping		PCOSAct Study Grp	Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFERTILITY; MEDICINE; COMPLEMENTARY; HIRSUTISM; COMMUNITY; LETROZOLE; OVULATION; IMPACTS; COHORT	IMPORTANCE Acupuncture is used to induce ovulation in some women with polycystic ovary syndrome, without supporting clinical evidence. OBJECTIVE To assess whether active acupuncture, either alone or combined with clomiphene, increases the likelihood of live births among women with polycystic ovary syndrome. DESIGN, SETTING, AND PARTICIPANTS A double-blind (clomiphene vs placebo), single-blind (active vs control acupuncture) factorial trial was conducted at 21 sites (27 hospitals) in mainland China between July 6, 2012, and November 18, 2014, with 10 months of pregnancy follow-up until October 7, 2015. Chinese women with polycystic ovary syndrome were randomized in a 1:1:1:1 ratio to 4 groups. INTERVENTIONS Active or control acupuncture administered twice a week for 30 minutes per treatment and clomiphene or placebo administered for 5 days per cycle, for up to 4 cycles. The active acupuncture group received deep needle insertion with combined manual and low-frequency electrical stimulation; the control acupuncture group received superficial needle insertion, no manual stimulation, and mock electricity. MAIN OUTCOMES AND MEASURES The primary outcome was live birth. Secondary outcomes included adverse events. RESULTS Among the 1000 randomized women (mean [SD] age, 27.9 [3.3] years; mean [SD] body mass index, 24.2 [4.3]), 250 were randomized to each group; a total of 926 women (92.6%) completed the trial. Live births occurred in 69 of 235 women (29.4%) in the active acupuncture plus clomiphene group, 66 of 236 (28.0%) in the control acupuncture plus clomiphene group, 31 of 223 (13.9%) in the active acupuncture plus placebo group, and 39 of 232 (16.8%) in the control acupuncture plus placebo group. There was no significant interaction between active acupuncture and clomiphene (P = .39), so main effects were evaluated. The live birth rate was significantly higher in the women treated with clomiphene than with placebo (135 of 471 [28.7%] vs 70 of 455 [15.4%], respectively; difference, 13.3%; 95% CI, 8.0% to 18.5%) and not significantly different between women treated with active vs control acupuncture (100 of 458 [21.8%] vs 105 of 468 [22.4%], respectively; difference, -0.6%; 95% CI, -5.9% to 4.7%). Diarrhea and bruising were more common in patients receiving active acupuncture than control acupuncture (diarrhea: 25 of 500 [5.0%] vs 8 of 500 [1.6%], respectively; difference, 3.4%; 95% CI, 1.2% to 5.6%; bruising: 37 of 500 [7.4%] vs 9 of 500 [1.8%], respectively; difference, 5.6%; 95% CI, 3.0% to 8.2%). CONCLUSIONS AND RELEVANCE Among Chinese women with polycystic ovary syndrome, the use of acupuncture with or without clomiphene, compared with control acupuncture and placebo, did not increase live births. This finding does not support acupuncture as an infertility treatment in such women.	[Wu, Xiao-Ke; Stener-Victorin, Elisabet; Kuang, Hong-Ying; Ma, Hong-Li; Gao, Jing-Shu; Xie, Liang-Zhen; Hou, Li-Hui; Legro, Richard S.] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China; [Wu, Xiao-Ke] World Federat Chinese Med Societies, Comm Reprod Med, Beijing, Peoples R China; [Stener-Victorin, Elisabet] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; [Hu, Zhen-Xing] Xuzhou Maternal & Childrens Hosp, Outpatient Dept, Xuzhou, Peoples R China; [Shao, Xiao-Guang] Dalian Maternal & Childrens Ctr, Ctr Reprod Med, Dalian, Peoples R China; [Ge, Jun] Tanggu Dist Maternal & Childrens Hosp, Dept Infertil, Tianjin, Peoples R China; [Zhang, Jin-Feng] Shanxi Prov Hosp Chinese Med, Dept Obstet & Gynecol, Taiyuan, Peoples R China; Huaian Maternal & Childrens Hosp, Ctr Reprod Med, Huaian, Peoples R China; [Xu, Xiao-Feng] Suzhou City Hosp Chinese Med, Dept Gynecol, Suzhou, Peoples R China; [Liang, Rui-Ning] Jiangxi Univ Chinese Med, Hosp 2, Dept Gynecol, Nanchang, Jiangxi, Peoples R China; [Ma, Hong-Xia] Guangzhou Med Univ, Affiliated Hosp 1, Dept Chinese Med, Guangzhou, Guangdong, Peoples R China; [Yang, Hong-Wei] Liwan Dist Hosp Chinese Med, Dept Infertil, Guangzhou, Guangdong, Peoples R China; [Li, Wei-Li] Anhui Univ Chinese Med, Affiliated Hosp, Dept Obstet & Gynecol, Hefei, Peoples R China; [Huang, Dong-Mei] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst Integrated Tradit andWestern Med, Wuhan, Peoples R China; [Sun, Yun] Wenzhou City Hosp Chinese Med, Dept Gynecol, Wenzhou, Peoples R China; [Hao, Cui-Fang] Yuhuangding Hosp, Ctr Reprod Med, Yantai, Peoples R China; [Du, Shao-Min] Daqing Longnan Hosp, Dept Obstet & Gynecol, Daqing, Peoples R China; [Yang, Zheng-Wang] Hunan Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Changsha, Hunan, Peoples R China; [Wang, Xin] Liaoning Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Shenyang, Peoples R China; [Yan, Ying] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Gynecol, Tianjin, Peoples R China; [Chen, Xiu-Hua] Guangdong Prov Hosp Chinese Med, Dept Tradit Technol, Guangzhou, Guangdong, Peoples R China; [Fu, Ping] Hangzhou City Hosp Chinese Med, Dept Gynecol, Hangzhou, Zhejiang, Peoples R China; [Ding, Cai-Fei] Zhejiang Prov Hosp Integrat Med, Ctr Reprod Med, Hangzhou, Zhejiang, Peoples R China; [Gao, Ya-Qin] Daqing Oilfield Gen Hosp, Ctr Reprod Med, Daqing, Peoples R China; [Zhou, Zhong-Ming] Hubei Prov Hosp Chinese Med, Dept Obstet & Gynecol, Wuhan, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Wang, Chi Chiu] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, Tai-Xiang] Chinese Clin Trial Registry, Shenzhen, Peoples R China; [Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Ng, Ernest H. Y.] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Legro, Richard S.] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA USA; [Zhang, Heping] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA	Heilongjiang University of Chinese Medicine; Karolinska Institutet; Jiangxi University of Traditional Chinese Medicine; Guangzhou Medical University; Anhui University of Chinese Medicine; Huazhong University of Science & Technology; Hunan University of Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Beijing University of Chinese Medicine; University of Hong Kong; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Yale University	Wu, XK (corresponding author), Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin 150040, Peoples R China.	xiaokewu2002@vip.sina.com	Stener-Victorin, Elisabet/W-6322-2018; Wang, Ronald/C-6541-2014; Liangzhen, Xie/AAR-4319-2020; Zhang, He/GXN-0028-2022; Xie, Liangzhen/L-6087-2016	Stener-Victorin, Elisabet/0000-0002-3424-1502; Wang, Ronald/0000-0002-3928-7278; Liangzhen, Xie/0000-0003-1375-1666; Xie, Liangzhen/0000-0003-1375-1666; Hou, Lihui/0000-0003-0269-7801; Legro, Richard/0000-0001-9927-7584; Ng, Ernest/0000-0002-7688-4557; Liu, Jianping/0000-0002-0320-061X	National Public Welfare Projects for Chinese Medicine [201107005, 200807002]; Heilongjiang Province Foundation for Outstanding Youths [JC200804]; Intervention for PCOS Based on Traditional Chinese Medicine Theory-TianGui Disorder [2011TD006]; First Affiliated Hospital, Heilongjiang University of Chinese Medicine from National Clinical Trial Base in Chinese Medicine Special Projects [JDZX2012036, 2015B009]; National Key Discipline of Chinese Medicine in Gynecology; Heilongjiang Province "Longjiang Scholar" Program; Chinese "Thousand Talents Plan" scholarship; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; Novo Nordisk Fonden [NNF16OC0020744, NNF17OC0026724, NNF15OC0015902] Funding Source: researchfish	National Public Welfare Projects for Chinese Medicine; Heilongjiang Province Foundation for Outstanding Youths; Intervention for PCOS Based on Traditional Chinese Medicine Theory-TianGui Disorder; First Affiliated Hospital, Heilongjiang University of Chinese Medicine from National Clinical Trial Base in Chinese Medicine Special Projects; National Key Discipline of Chinese Medicine in Gynecology; Heilongjiang Province "Longjiang Scholar" Program; Chinese "Thousand Talents Plan" scholarship; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Novo Nordisk Fonden(Novo Nordisk Foundation)	This work was supported by grants 201107005 and 200807002 from the National Public Welfare Projects for Chinese Medicine, JC200804 from the Heilongjiang Province Foundation for Outstanding Youths, 2011TD006 from the Intervention for PCOS Based on Traditional Chinese Medicine Theory-TianGui Disorder, and JDZX2012036 and 2015B009 from 2009 through 2016 at the First Affiliated Hospital, Heilongjiang University of Chinese Medicine from the National Clinical Trial Base in Chinese Medicine Special Projects, by the National Key Discipline of Chinese Medicine in Gynecology from 2009 through 2016, by the Heilongjiang Province "Longjiang Scholar" Program (Drs X.-K. Wu, Stener-Victorin, and Legro), and by the Chinese "Thousand Talents Plan" scholarship (Drs Legro and H. Zhang).	Birkeflet O, 2012, ACUPUNCT MED, V30, P12, DOI 10.1136/acupmed-2011-010089; Bovey M, 2010, FERTIL STERIL, V94, P2569, DOI 10.1016/j.fertnstert.2010.03.072; Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004; Chen ZJ, 2012, ZHONGHUA FU CHAN KE, V47, P74, DOI DOI 10.3760/CMA.J.ISSN.0529-567X.2012.01.022; Harbin Consensus Conference Workshop Group, 2014, FERTIL STERIL, V102, pe15; Hu M, 2015, P NATL ACAD SCI USA, V112, P14348, DOI 10.1073/pnas.1507514112; Jedel E, 2011, AM J PHYSIOL-ENDOC M, V300, pE37, DOI 10.1152/ajpendo.00495.2010; Johansson J, 2013, AM J PHYSIOL-ENDOC M, V304, pE934, DOI 10.1152/ajpendo.00039.2013; Kar Sujata, 2015, J Hum Reprod Sci, V8, P197, DOI 10.4103/0974-1208.170373; Kuang HY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/527303; Legro RS, 2007, NEW ENGL J MED, V356, P551, DOI 10.1056/NEJMoa063971; Legro RS, 2006, FERTIL STERIL, V86, P914, DOI 10.1016/j.fertnstert.2006.03.037; Legro RS, 2014, HUM REPROD, V29, P2075, DOI 10.1093/humrep/deu218; Legro RS, 2014, FERTIL STERIL, V102, P952, DOI 10.1016/j.fertnstert.2014.08.002; Legro RS, 2014, NEW ENGL J MED, V371, P119, DOI 10.1056/NEJMoa1313517; Legro RS, 2012, CONTEMP CLIN TRIALS, V33, P470, DOI 10.1016/j.cct.2011.12.005; Li R, 2013, HUM REPROD, V28, P2562, DOI 10.1093/humrep/det262; Li R, 2012, EUR J OBSTET GYN R B, V163, P165, DOI 10.1016/j.ejogrb.2012.03.023; Li YA, 2011, FERTIL STERIL, V96, P452, DOI 10.1016/j.fertnstert.2011.05.072; Lim CED, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007689.pub4; MacPherson H, 2016, J ALTERN COMPLEM MED, V22, P101, DOI 10.1089/acm.2015.0184; Park JJ, 2010, J ALTERN COMPLEM MED, V16, P193, DOI 10.1089/acm.2008.0600; Pastore LM, 2011, J CLIN ENDOCR METAB, V96, P3143, DOI 10.1210/jc.2011-1126; Read SC, 2014, J ALTERN COMPLEM MED, V20, P686, DOI 10.1089/acm.2013.0329; Schlaff WD, 2011, FERTIL STERIL, V96, P15, DOI 10.1016/j.fertnstert.2011.05.069; Smith CA, 2014, COMPLEMENT THER MED, V22, P710, DOI 10.1016/j.ctim.2014.06.001; Smith JF, 2010, FERTIL STERIL, V93, P2169, DOI 10.1016/j.fertnstert.2010.02.054; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Tarlatzis BC, 2008, FERTIL STERIL, V89, P505, DOI 10.1016/j.fertnstert.2007.09.041; Wu XK, 2016, FERTIL STERIL, V106, P757, DOI 10.1016/j.fertnstert.2016.05.022; Wu XK, 2015, LANCET, V386, P70; Wu XK, 2016, Fertil Steril, V106, pe1; Zain MM, 2009, FERTIL STERIL, V91, P514, DOI 10.1016/j.fertnstert.2007.12.002; Zhao XM, 2011, FERTIL STERIL, V96, P792, DOI 10.1016/j.fertnstert.2011.06.040; Zhou Beifan, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P5	35	99	132	9	144	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2017	317	24					2502	2514		10.1001/jama.2017.7217	http://dx.doi.org/10.1001/jama.2017.7217			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY6PV	28655015	Green Published, Bronze			2023-01-03	WOS:000404106600020
J	Topalian, SL				Topalian, Suzanne L.			Targeting Immune Checkpoints in Cancer Therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PD-1 BLOCKADE		[Topalian, Suzanne L.] Johns Hopkins Univ, Sch Med, Dept Surg, 1550 Orleans St,CRB2,Room 508, Baltimore, MD 21287 USA; [Topalian, Suzanne L.] Johns Hopkins Bloomberg Kimmel Inst Canc Immunoth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Topalian, SL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, 1550 Orleans St,CRB2,Room 508, Baltimore, MD 21287 USA.	stopali1@jhmi.edu			Bristol-Myers Squibb; Potenza Therapeutics; Compugen	Bristol-Myers Squibb(Bristol-Myers Squibb); Potenza Therapeutics; Compugen	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Topalian receives research grants from Bristol-Myers Squibb, and is a consultant for and owns stock from Five Prime Therapeutics. An immediate family member is a consultant for Amgen, MedImmune/AstraZeneca, Merck, and Pfizer; receives research grants, consulting fees, and stock options from Potenza Therapeutics; receives stock options from Jounce Therapeutics; receives research grants and stock options from Compugen; and receives patent royalties through his institution from Bristol-Myers Squibb and Potenza.	Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690	8	82	86	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2017	318	17					1647	1648		10.1001/jama.2017.14155	http://dx.doi.org/10.1001/jama.2017.14155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM0CW	28885639				2023-01-03	WOS:000414627500009
J	Fragala, MS; Bi, CX; Chaump, M; Kaufman, HW; Kroll, MH				Fragala, Maren S.; Bi, Caixia; Chaump, Michael; Kaufman, Harvey W.; Kroll, Martin H.			Associations of aerobic and strength exercise with clinical laboratory test values	PLOS ONE			English	Article							C-REACTIVE PROTEIN; GLOMERULAR-FILTRATION-RATE; SERUM URIC-ACID; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; IRON STATUS; PARAMETERS; ENDURANCE; ALBUMIN	Objectives Physical exercise may affect levels of blood-based biomarkers. However, exercise status is seldom considered in the interpretation of laboratory results. This study reports the associations between habitual exercise participation and clinical laboratory test results. Methods The effects of days per week of aerobic and strength exercise participation on laboratory test results for 26 biomarkers in young adults aged 18 to 34 years (n = 80,111) were evaluated using percentile distribution analyses and multivariate regression. Results In both men and women, more days per week of either aerobic or strength exercise were significantly associated with lower levels of glucose, hemoglobin A1c, LDL cholesterol, total cholesterol, triglycerides, estimated glomerular filtration rate, globulin, and C-reactive protein, and significantly higher levels of HDL cholesterol, creatinine, iron, and percent saturation (all p <.05). Type of exercise or gender influenced the observed relationships with exercise frequency for total cholesterol, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, uric acid, bilirubin, and iron binding capacity. Conclusions Physical exercise shifted the distribution of results into the direction suggestive of better health. Reported relationships may help clinicians and patients to better understand and interpret laboratory results in athletic populations and possibly re-evaluate interpretation of reference intervals for physically active populations.	[Fragala, Maren S.; Bi, Caixia; Chaump, Michael; Kaufman, Harvey W.; Kroll, Martin H.] Quest Diagnost, 3 Giralda Farms, Madison, NJ 07940 USA		Fragala, MS (corresponding author), Quest Diagnost, 3 Giralda Farms, Madison, NJ 07940 USA.	Maren.S.Fragala@questdiagnostics.com			Quest Diagnostics	Quest Diagnostics	Quest Diagnostics provided support in the form of salaries for MSF, CB, MC, HWK, and MHK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banfi G, 2008, J SPORT MED PHYS FIT, V48, P479; Banfi G, 2012, ADV CLIN CHEM, V56, P1, DOI 10.1016/B978-0-12-394317-0.00015-7; Banfi G, 2009, SPORTS MED, V39, P331, DOI 10.2165/00007256-200939040-00005; Bruinvels G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149881; Busher J. T. Serum, 1990, CLIN METHODS HIST PH; Ceriotti Ferruccio, 2007, Clin Biochem Rev, V28, P115; Colombini A, 2014, J SPORT MED PHYS FIT, V54, P658; Constantini N, 2006, MIL MED, V171, P866, DOI 10.7205/MILMED.171.9.866; de Ferranti S, 2002, CLIN CHIM ACTA, V317, P1, DOI 10.1016/S0009-8981(01)00797-5; DODDS WN, 1984, INJURY, V16, P94, DOI 10.1016/S0020-1383(84)80006-6; Du Toit C, 2007, J SCI MED SPORT, V10, P351, DOI 10.1016/j.jsams.2007.01.001; Dubnov G, 2004, INT J SPORT NUTR EXE, V14, P30, DOI 10.1123/ijsnem.14.1.30; EDWARDS JG, 1994, BIOCHEM BIOPH RES CO, V199, P1482, DOI 10.1006/bbrc.1994.1398; EHN L, 1980, MED SCI SPORT EXER, V12, P61; Emdin M, 2005, CIRCULATION, V112, P2078, DOI 10.1161/CIRCULATIONAHA.105.571919; Fallon KE, 1999, BRIT J SPORT MED, V33, P264, DOI 10.1136/bjsm.33.4.264; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; FRIDAY KE, 1993, J CLIN ENDOCR METAB, V77, P1605, DOI 10.1210/jc.77.6.1605; Froiland K, 2004, INT J SPORT NUTR EXE, V14, P104, DOI 10.1123/ijsnem.14.1.104; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GREEN HJ, 1988, MED SCI SPORT EXER, V20, P55, DOI 10.1249/00005768-198802000-00008; GRIMSTON SK, 1993, J CLIN ENDOCR METAB, V76, P867, DOI 10.1210/jc.76.4.867; Gullu S, 2004, EUR J ENDOCRINOL, V150, P655, DOI 10.1530/eje.0.1500655; Hampl, 1996, Endocr Regul, V30, P57; Haskell W L, 1984, Exerc Sport Sci Rev, V12, P205; Hawkins MS, 2011, MED SCI SPORT EXER, V43, P1457, DOI 10.1249/MSS.0b013e31820c0130; Hinton PS, 2000, J APPL PHYSIOL, V88, P1103, DOI 10.1152/jappl.2000.88.3.1103; Huang C, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-258; JAMES WPT, 1968, J CLIN INVEST, V47, P1958, DOI 10.1172/JCI105885; Karamizrak SO, 1996, BRIT J SPORT MED, V30, P15, DOI 10.1136/bjsm.30.1.15; KRAMER BK, 1988, CLIN CHEM, V34, P2516; Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L; Lidegaard LP, 2015, DIABETOLOGIA, V58, P2709, DOI 10.1007/s00125-015-3738-x; Lippi G, 2004, CLIN CHEM LAB MED, V42, P644, DOI 10.1515/CCLM.2004.110; Lippi G, 2008, INT J SPORTS MED, V29, P948, DOI 10.1055/s-2008-1038745; Lippi G, 2011, EUR J INTERN MED, V22, pE36, DOI 10.1016/j.ejim.2011.02.007; LJUNGHALL S, 1984, EUR J CLIN INVEST, V14, P469, DOI 10.1111/j.1365-2362.1984.tb01215.x; MCLAREN DS, 1965, AM J CLIN NUTR, V17, P152, DOI 10.1093/ajcn/17.3.152; Meyer T, 2011, INT J SPORTS MED, V32, P875, DOI 10.1055/s-0031-1280776; Mora S, 2007, CIRCULATION, V116, P2110, DOI 10.1161/CIRCULATIONAHA.107.729939; NIEMAN DC, 1989, INT J SPORTS MED, V10, P124, DOI 10.1055/s-2007-1024887; NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661; NYMAN MT, 1991, ANN CHIR GYNAECOL, V80, P289; Perseghin G, 2009, EUR J ENDOCRINOL, V161, P871, DOI 10.1530/EJE-09-0569; Pettersson J, 2008, BRIT J CLIN PHARMACO, V65, P253, DOI 10.1111/j.1365-2125.2007.03001.x; Plaisance EP, 2006, SPORTS MED, V36, P443, DOI 10.2165/00007256-200636050-00006; Puglisi MJ, 2008, J NUTR, V138, P2293, DOI 10.3945/jn.108.097188; Richter EA, 2013, PHYSIOL REV, V93, P993, DOI 10.1152/physrev.00038.2012; ROCKER L, 1976, EUR J APPL PHYSIOL O, V36, P57, DOI 10.1007/BF00421634; Roepstorff C, 2002, AM J PHYSIOL-ENDOC M, V282, pE435, DOI 10.1152/ajpendo.00266.2001; Rudberg A, 2000, CALCIFIED TISSUE INT, V66, P342, DOI 10.1007/s002230010071; SCHOBERSBERGER W, 1990, EUR J APPL PHYSIOL O, V60, P163, DOI 10.1007/BF00839152; Schumacher YO, 2002, MED SCI SPORT EXER, V34, P869; Tice JA, 2003, AM J MED, V114, P199, DOI 10.1016/S0002-9343(02)01497-3; Waring WS, 2003, CLIN SCI, V105, P425, DOI 10.1042/CS20030149; Whitfield JB, 2001, CRIT REV CL LAB SCI, V38, P263, DOI 10.1080/20014091084227; WILLIS WT, 1987, J APPL PHYSIOL, V62, P2442, DOI 10.1152/jappl.1987.62.6.2442; Witard OC, 2011, MED SCI SPORT EXER, V43, P598, DOI 10.1249/MSS.0b013e3181f684c9; Zarzeczny R, 1996, J PHYSIOL PHARMACOL, V47, P503	59	22	25	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2017	12	10							e0180840	10.1371/journal.pone.0180840	http://dx.doi.org/10.1371/journal.pone.0180840			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK3RE	29059178	Green Published, Green Submitted, gold			2023-01-03	WOS:000413403000001
J	van Samkar, G; Hermanns, H; Lirk, P; Hollmann, MW; Stevens, MF				van Samkar, Ganapathy; Hermanns, Henning; Lirk, Philipp; Hollmann, Markus W.; Stevens, Markus F.			Influence on number of top-ups after implementing patient controlled epidural analgesia: A cohort study	PLOS ONE			English	Article							POSTOPERATIVE PAIN MANAGEMENT; LABOR ANALGESIA; SURGICAL-PATIENTS; MAJOR SURGERY; METAANALYSIS; INFUSION; EXPERIENCE	Postoperative epidural analgesia often needs rate readjustment using top-ups. Patient-controlled epidural analgesia (PCEA) is said to reduce the requirement of epidural top-ups when compared to continuous epidural analgesia (CEA). We compared CEA and PCEA in major thoracic and abdominal surgery, in a cohort study. The primary endpoint was the required number of epidural top-ups. Secondary endpoints were pain scores, side effects and workload differences. We analysed 199 patients with CEA and 187 with PCEA. Both groups had similar pain scores. The total number of top-ups was 75 in 57 patients (CEA) versus 20 top-ups in 18 patients (PCEA). (p = 0.0001) Sedation tended to occur more frequently in patients with CEA versus PCEA, 5.5% vs 1.6% (p = 0.05). Implementation of PCEA led to a decreased number of top-ups, fewer side-effects and decreased use of the postoperative care unit.	[van Samkar, Ganapathy; Hermanns, Henning; Lirk, Philipp; Hollmann, Markus W.; Stevens, Markus F.] Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Lirk, Philipp] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA	University of Amsterdam; Academic Medical Center Amsterdam; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Hollmann, MW (corresponding author), Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands.	m.w.hollmann@amc.uva.nl		Stevens, Markus Florian/0000-0002-0032-860X; Hermanns, Henning/0000-0002-4297-495X; Hollmann, Markus/0000-0001-8248-0244	Academic Medical Center, Amsterdam, The Netherlands [SH102002, 201015b]; B. Braun Medical B.V. (Oss, The Netherlands)	Academic Medical Center, Amsterdam, The Netherlands(Netherlands Government); B. Braun Medical B.V. (Oss, The Netherlands)	The study was funded by an internal developmental grant (project code SH102002; grant number 201015b) of the Academic Medical Center, Amsterdam, The Netherlands to MS. We would like to acknowledge B. Braun Medical B.V. (Oss, The Netherlands) for giving financial support of 750 Euros as a contribution to the costs of publication. B. Braun Medical was not involved in any part of the research, including design, analysis, or writing of the manuscript.	Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; Capogna G, 2013, CURR OPIN ANESTHESIO, V26, P261, DOI 10.1097/ACO.0b013e328360b069; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Golster M, 2014, EUROPEAN J ANAESTHES; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Kainzwaldner V, 2013, ANAESTHESIST, V62, P453, DOI 10.1007/s00101-013-2177-7; Kim SH, 2013, KOREAN J PAIN, V26, P39, DOI 10.3344/kjp.2013.26.1.39; Lim Y, 2006, ANAESTHESIA, V61, P339, DOI 10.1111/j.1365-2044.2006.04535.x; Lopard E, 2006, ANN FR ANESTH, V25, P593, DOI 10.1016/j.annfar.2006.02.012; Loubert C, 2011, ANAESTHESIA, V66, P191, DOI 10.1111/j.1365-2044.2010.06616.x; Nightingale JJ, 2007, BRIT J ANAESTH, V98, P380, DOI 10.1093/bja/ael367; Popping DM, 2008, BRIT J ANAESTH, V101, P832, DOI 10.1093/bja/aen300; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Schuster M, 2004, ANESTH ANALG, V98, P708; Sia AT, 2013, ANAESTHESIA, V68, P267, DOI 10.1111/anae.12093; Stienstra R, 2000, Curr Opin Anaesthesiol, V13, P253, DOI 10.1097/00001503-200006000-00002; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x	20	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2017	12	10							e0186225	10.1371/journal.pone.0186225	http://dx.doi.org/10.1371/journal.pone.0186225			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0KG	29045482	Green Submitted, gold, Green Published			2023-01-03	WOS:000413168100044
J	Hedberg, K; New, C				Hedberg, Katrina; New, Craig			Oregon's Death With Dignity Act: 20 Years of Experience to Inform the Debate	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIFE; END; AID	Twenty years ago, Oregon voters approved the Death With Dignity Act, making Oregon the first state in the United States to allow physicians to prescribe medications to be self-administered by terminally ill patients to hasten their death. This report summarizes the experience in Oregon, including the numbers and types of participating patients and providers. These data should inform the ongoing policy debate as additional jurisdictions consider such legislation.	[Hedberg, Katrina; New, Craig] Oregon Hlth Author, 800 Northeast Oregon St,Suite 225, Portland, OR USA; [Hedberg, Katrina] Oregon Publ Hlth Div, 800 Northeast Oregon St,Suite 930, Portland, OR 97232 USA		Hedberg, K (corresponding author), Oregon Publ Hlth Div, 800 Northeast Oregon St,Suite 930, Portland, OR 97232 USA.	Katrina.hedberg@state.or.us						Cain Cindy L, 2016, Policy Brief UCLA Cent Health Policy Res, P1; Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Ganzini L, 2009, ARCH INTERN MED, V169, P489, DOI 10.1001/archinternmed.2008.579; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; Gostin LO, 2016, JAMA-J AM MED ASSOC, V315, P249, DOI 10.1001/jama.2015.16586; Oregon Health Authority, 2017, DEATH DIGN ACT ANN R; Silveira MJ, 2000, JAMA-J AM MED ASSOC, V284, P2483, DOI 10.1001/jama.284.19.2483; Sulmasy LS, 2017, ANN INTERN MED, V167, P576, DOI 10.7326/M17-0938; van der Heide A, 2017, NEW ENGL J MED, V377, P492, DOI 10.1056/NEJMc1705630	9	30	30	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					579	+		10.7326/M17-2300	http://dx.doi.org/10.7326/M17-2300			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ9JM	28975232				2023-01-03	WOS:000413092700019
J	Inambao, M; Kilembe, W; Canary, LA; Czaicki, NL; Kakungu-Simpungwe, M; Chavuma, R; Wall, KM; Tichacek, A; Pulerwitz, J; Thior, I; Chomba, E; Allen, SA				Inambao, Mubiana; Kilembe, William; Canary, Lauren A.; Czaicki, Nancy L.; Kakungu-Simpungwe, Matilda; Chavuma, Roy; Wall, Kristin M.; Tichacek, Amanda; Pulerwitz, Julie; Thior, Ibou; Chomba, Elwyn; Allen, Susan A.			Transitioning couple's voluntary HIV counseling and testing (CVCT) from stand-alone weekend services into routine antenatal and VCT services in government clinics in Zambia's two largest cities	PLOS ONE			English	Article							MALE INVOLVEMENT; CARE; TRANSMISSION; BARRIERS; RWANDA	Introduction Most HIV infections in Africa are acquired by married/cohabiting adults and WHO recommends couple's voluntary HIV counseling and testing (CVCT) for prevention. The handover from NGO-sponsored weekend CVCT to government-sponsored services in routine weekday antenatal care (ANC) and individual voluntary testing and counseling (VCT) services in Zambia's two largest cities from 2009-2015 is described. Methods Government clinic counselors were trained to provide CVCT, and along with community health workers they promoted CVCT services in their clinic and surrounding areas. When client volume exceeded the capacity of on-duty staff in ANC and VCT, non-governmental organization (NGO) subsidies were offered for overtime pay. Results Implementation of routine CVCT services varied greatly by clinic and city. The 12 highest volume clinics were examined further, while 13 clinics had CVCT numbers that were too low to warrant further investigation. In Lusaka, the proportion of pregnant women whose partners were tested rose from 2.6% in 2009 to a peak of 26.2% in 2012 and 24.8% in 2015. Corresponding reports in Ndola were 2.0% in 2009, 17.0% in 2012 and 14.5% in 2015. Obstacles to CVCT included: limited space and staffing, competing priorities, record keeping not adapted for couples, and few resources for promotion and increasing male involvement. Conflicting training models for 'partner testing' with men and women separately vs. CVCT with joint post-test counseling led to confusion in reporting to district health authorities. Discussion A focused and sustained effort will be required to reach a meaningful number of couples with CVCT to prevent heterosexual and perinatal HIV transmission. Establishing targets and timelines, funding for dedicated and appropriately trained staff, adoption of standardized data recording instruments with couple-level indicators, and expansion of community and clinic-based promotions using proven models are recommended.	[Inambao, Mubiana; Kilembe, William; Canary, Lauren A.; Czaicki, Nancy L.; Wall, Kristin M.; Tichacek, Amanda; Allen, Susan A.] Emory Univ, Dept Pathol & Lab Med, Rwanda Zambia HIV Res Grp, Sch Med, Atlanta, GA 30322 USA; [Inambao, Mubiana; Kilembe, William; Canary, Lauren A.; Czaicki, Nancy L.; Wall, Kristin M.; Tichacek, Amanda; Allen, Susan A.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Inambao, Mubiana] Zambia Emory HIV Res Project ZEHRP, Ndola, Zambia; [Kilembe, William] Zambia Emory HIV Res Project ZEHRP, Lusaka, Zambia; [Kakungu-Simpungwe, Matilda; Chavuma, Roy] MCDMCH, DHMT, Lusaka, Zambia; [Wall, Kristin M.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Pulerwitz, Julie; Thior, Ibou] PATH, Washington, DC USA; [Chomba, Elwyn] MCDMCH, Lusaka, Zambia	Emory University; Emory University; Rollins School Public Health; Emory University; Rollins School Public Health	Allen, SA (corresponding author), Emory Univ, Dept Pathol & Lab Med, Rwanda Zambia HIV Res Grp, Sch Med, Atlanta, GA 30322 USA.; Allen, SA (corresponding author), Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.	sallen5@emory.edu		, Mubiana/0000-0002-1474-652X; Canary, Lauren/0000-0002-4297-2102	Canadian Government through Foreign Affairs, Trade and Development Canada (DFATD); AIDS International Training and Research Program Fogarty International Center [D43 TW001042]; American people through the United States Agency for International Development (USAID)	Canadian Government through Foreign Affairs, Trade and Development Canada (DFATD); AIDS International Training and Research Program Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); American people through the United States Agency for International Development (USAID)(United States Agency for International Development (USAID))	This document was produced under Arise Enhancing HIV Prevention Programs for At Risk Populations, through financial support provided by the Canadian Government through Foreign Affairs, Trade and Development Canada (DFATD) with technical support from PATH (CID.1450-08863-SUB). Arise implements innovative HIV prevention initiatives for vulnerable communities, with a focus on determining costeffectiveness through rigorous evaluations; AIDS International Training and Research Program Fogarty International Center (D43 TW001042); the Emory Center for AIDS Research (P30 AI050409); the National Institutes of Mental Health (MH95503); Emory Rollins School of Public Health Global Field Experience (GEE) Fund; and the International AIDS Vaccine Initiative. This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents do not necessarily reflect the views of USAID or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-349; [Anonymous], 2010, GLOBAL REPORT UNAIDS; Audet CM, 2016, QUAL HEALTH RES, V26, P1721, DOI 10.1177/1049732315580302; Audet CM, 2016, AIDS BEHAV, V20, P2090, DOI 10.1007/s10461-016-1341-x; Bakari JP, 2000, ANN NY ACAD SCI, V918, P64; Boeras DI, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-18; Brent RJ, 2010, HEALTH ECON, V19, P154, DOI 10.1002/hec.1457; Brou H, 2007, PLOS MED, V4, P1912, DOI 10.1371/journal.pmed.0040342; Byamugisha R, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-43; Byamugisha R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-12; Chomba E, 2008, JAIDS-J ACQ IMM DEF, V47, P108, DOI 10.1097/QAI.0b013e31815b2d67; COLEBUNDERS R, 1993, LANCET, V342, P601, DOI 10.1016/0140-6736(93)91417-K; Conkling M, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-10; Crankshaw TL, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18832; Dunkle KL, 2008, LANCET, V371, P2183, DOI 10.1016/S0140-6736(08)60953-8; Karamagi CAS, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-284; Kelley AL, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3424-z; Kelley AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019573; Lambdin BH, 2011, HEALTH AFFAIR, V30, P1488, DOI 10.1377/hlthaff.2009.0994; Lingappa JR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001411; Matovu JKB, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1720-y; McKenna SL, 1997, AIDS, V11, pS103; Mohlala BKF, 2011, AIDS, V25, P1535, DOI 10.1097/QAD.0b013e328348fb85; Morfaw F, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-5; Musheke M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3396-z; Musheke M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-97; Nannozi V, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4043-z; Odong J, 2015, UGANDA COUPLES HIV T; Prevention CfDCa, COUPL HIV COUNS TEST; SAHARA, 2009, DEV HARM MIN STAND G; Sweat M, 2000, LANCET, V356, P113, DOI 10.1016/S0140-6736(00)02447-8; Wall K, 2012, AIDS, V26, P217, DOI 10.1097/QAD.0b013e32834dc593; Wall KM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001171; World Health Organization, 2012, GUID OR PREEXP PROPH; Zambia, 2008, ZAMB NAT PROT GUID I; Zambia, 2007, DEM HLTH SURV; Zambia Central Statistical Office, 2014, ZAMB DEM HLTH SURV	37	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2017	12	10							e0185142	10.1371/journal.pone.0185142	http://dx.doi.org/10.1371/journal.pone.0185142			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ8YP	29036208	Green Published, Green Submitted, gold			2023-01-03	WOS:000413054800004
J	Citrin, DE				Citrin, Deborah E.			Recent Developments in Radiotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CELL LUNG-CANCER; MODULATED RADIATION-THERAPY; ELECTIVE NODAL IRRADIATION; INVOLVED-FIELD RADIATION; CALRETICULIN EXPOSURE; LOCAL RADIATION; STAGE-I; PHYSIOLOGICAL FRAILTY; BREAST RADIOTHERAPY; SECRETORY PHENOTYPE	It is estimated that 470,000 patients receive radiotherapy each year in the United States. 1 As many as half of patients with cancer will receive radiotherapy. 2 Improvements in diagnosis, therapy, and supportive care have led to increasing numbers of cancer survivors. 3 In response, the emphasis of radiation oncology has expanded beyond cure to include reducing side effects, particularly late effects, which may substantially affect a patient's quality of life. Radiotherapy is used to treat benign and malignant diseases and can be used alone or in combination with chemotherapy, surgery, or both. For primary tumors or metastatic deposits, palliative radiotherapy is often used to reduce pain or mass effect (due to spinal cord compression, brain metastases, or airway obstruction). Therapeutic radiation can be delivered from outside the patient, known as external-beam radiation therapy, or EBRT (see the Glossary in the Supplementary Appendix, available with the full text of this article at NEJM.org), by implanting radioactive sources in cavities or tissues (brachytherapy), or through systemic administration of radiopharmaceutical agents. Multiple technological and biologic advances have fundamentally altered the field of radiation oncology since it was last reviewed in the Journal.(4)	[Citrin, Deborah E.] NCI, Radiat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Citrin, DE (corresponding author), NCI, Radiat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.	citrind@mail.nih.gov		Citrin, Deborah/0000-0002-4391-2734	NATIONAL CANCER INSTITUTE [ZIABC010850] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Cancer Society, 2012, CANC TREATM SURV FAC; Anscher MS, 2006, INT J RADIAT ONCOL, V65, P876, DOI 10.1016/j.ijrobp.2006.02.051; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arora M, 2016, JAMA ONCOL, V2, P1277, DOI 10.1001/jamaoncol.2016.0855; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244; Basch E, 2010, NEW ENGL J MED, V362, P865, DOI 10.1056/NEJMp0911494; Bradley J, 2004, INT J RADIAT ONCOL, V59, P78, DOI 10.1016/j.ijrobp.2003.10.044; Brown JM, 2014, INT J RADIAT ONCOL, V88, P254, DOI 10.1016/j.ijrobp.2013.07.022; Cancer Moonshot Blue Ribbon Panel, 2016, CANC MOONSH BLUE RIB; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chang JY, 2015, LANCET ONCOL, V16, P630, DOI 10.1016/S1470-2045(15)70168-3; CHEE CA, 1974, BRIT J RADIOL, V47, P37, DOI 10.1259/0007-1285-47-553-37; Chung EJ, 2016, INT J RADIAT ONCOL, V96, P857, DOI 10.1016/j.ijrobp.2016.07.026; Chung EJ, 2016, INT J RADIAT ONCOL, V94, P1163, DOI 10.1016/j.ijrobp.2015.11.044; Citrin DE, 2013, JNCI-J NATL CANCER I, V105, P1474, DOI 10.1093/jnci/djt212; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davis BJ, 2012, BRACHYTHERAPY, V11, P6, DOI 10.1016/j.brachy.2011.07.005; DEMARIA S, 2012, FRONT ONCOL, V2; Demaria S, 2015, JAMA ONCOL, V1, P1325, DOI 10.1001/jamaoncol.2015.2756; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; DeVita V.T.J., 2014, DEVITA HELLMAN ROSEN, Vtenth; Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265; Dueck AC, 2015, JAMA ONCOL, V1, P1051, DOI 10.1001/jamaoncol.2015.2639; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Gameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719; Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518; Gulley JL, 2005, CLIN CANCER RES, V11, P3353, DOI 10.1158/1078-0432.CCR-04-2062; Hall E, 2000, RADIOBIOLOGY RADIOLO; Hasmim M, 2013, J IMMUNOL, V191, P5802, DOI 10.4049/jimmunol.1302140; Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3; Hiniker SM, 2012, TRANSL ONCOL, V5, P404, DOI 10.1593/tlo.12280; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lawton CA, 2008, INT J RADIAT ONCOL, V70, P437, DOI 10.1016/j.ijrobp.2007.06.050; Lechleider RJ, 2008, CLIN CANCER RES, V14, P5284, DOI 10.1158/1078-0432.CCR-07-5162; Leroy R, 2016, INT J RADIAT ONCOL, V95, P267, DOI 10.1016/j.ijrobp.2015.10.025; Li RJ, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0698-3; Li XL, 2012, RADIOTHER ONCOL, V102, P246, DOI 10.1016/j.radonc.2011.10.016; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; Michalski JM, 2013, INT J RADIAT ONCOL, V87, P932, DOI 10.1016/j.ijrobp.2013.07.041; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Ness KK, 2013, J CLIN ONCOL, V31, P4496, DOI 10.1200/JCO.2013.52.2268; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; Nyman J, 2016, RADIOTHER ONCOL, V121, P1, DOI 10.1016/j.radonc.2016.08.015; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ojerholm E, 2017, PEDIAT BLOOD CANC; ORDER SE, 1977, CANCER, V39, P737, DOI 10.1002/1097-0142(197702)39:2+<737::AID-CNCR2820390708>3.0.CO;2-M; Osa EOO, 2014, INT J RADIAT ONCOL, V89, P899, DOI 10.1016/j.ijrobp.2014.03.036; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Paulson ES, 2016, RADIOTHER ONCOL, V121, P187, DOI 10.1016/j.radonc.2016.09.018; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Potter R, 2006, RADIOTHER ONCOL, V78, P67, DOI 10.1016/j.radonc.2005.11.014; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Rosenzweig KE, 2007, J CLIN ONCOL, V25, P5557, DOI 10.1200/JCO.2007.13.2191; Sadak KT, 2013, NAT REV UROL, V10, P15, DOI 10.1038/nrurol.2012.218; Schaapveld M, 2015, NEW ENGL J MED, V373, P2499, DOI 10.1056/NEJMoa1505949; Specht L, 2014, INT J RADIAT ONCOL, V89, P854, DOI 10.1016/j.ijrobp.2013.05.005; Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511; Wang JB, 2012, CLIN LUNG CANCER, V13, P81, DOI 10.1016/j.cllc.2011.08.002; Yamoah K, 2016, ONCOTARGETS THER, V9, P5721, DOI 10.2147/OTT.S100518; Yeboa DN, 2016, SEMIN RADIAT ONCOL, V26, P71, DOI 10.1016/j.semradonc.2015.09.003; Yuan SH, 2007, AM J CLIN ONCOL-CANC, V30, P239, DOI 10.1097/01.coc.0000256691.27796.24	68	196	208	33	96	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2017	377	11					1065	1075		10.1056/NEJMra1608986	http://dx.doi.org/10.1056/NEJMra1608986			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG6YC	28902591				2023-01-03	WOS:000410545200009
J	Keener, A				Keener, Amanda			Uncovering cancer: How enlisting T cells can boost the power of immunotherapy	NATURE MEDICINE			English	News Item							CHECKPOINT BLOCKADE; ANTITUMOR; EXPOSURE; TUMORS											Charych DH, 2016, CLIN CANCER RES, V22, P680, DOI 10.1158/1078-0432.CCR-15-1631; Klarquist J, 2014, J IMMUNOL, V193, P6124, DOI 10.4049/jimmunol.1401869; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Yamazaki T, 2016, CELL DEATH DIFFER, V23, P1004, DOI 10.1038/cdd.2016.35; Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154	7	1	1	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2017	23	9					1006	1008		10.1038/nm0917-1006	http://dx.doi.org/10.1038/nm0917-1006			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FG2XO	28886004				2023-01-03	WOS:000409996200002
J	Xiang, Y; Lai, FN; He, GF; Li, YP; Yang, LL; Shen, W; Huo, HQ; Zhu, J; Dai, HY; Zhang, YG				Xiang, Ya; Lai, Fangnong; He, Guifang; Li, Yapeng; Yang, Leilei; Shen, Wei; Huo, Heqiang; Zhu, Jun; Dai, Hongyi; Zhang, Yugang			Alleviation of Rosup-induced oxidative stress in porcine granulosa cells by anthocyanins from red-fleshed apples	PLOS ONE			English	Article							GLUTATHIONE-REDUCTASE; ANTIOXIDANT; APOPTOSIS; ZEARALENONE; PIGMENTS; NECROSIS; COLOR	Anthocyanins are the polyphenolic phytochemicals which have been shown to scavenge free radicals. In this study, we investigated the effects of anthocyanins extracted from red-fleshed apples (Malus sieversii) on reducing oxidative damage by Rosup in porcine granulosa cells (GCs) by measuring intracellular reactive oxygen species (ROS), content of glutathione (GSH), activities of superoxide dismutase (SOD1), catalase (CAT) and glutathione peroxidase (GPX1) and the gene expression of SOD1, CAT, GPX1. Apoptosis was determined with TdT-mediated dUTP-biotin nick end labeling (TUNEL) and apoptosis-related proteins were quantified with Western blotting. The results indicate that Rosup increases oxidative stress by inducing reactive oxygen species production in porcine GCs and the oxidative stress could be reduced by anthocyanins. The gene expression of SOD1, CAT, GPX1 and the activities of these enzymes were increased when GCs were treated with anthocyanins and Rosup for 6 hours. Anthocyanins inhibit Rosup-induced apoptosis by increasing expression of antiapoptotic protein Bcl-2 and suppressing the expression of proapoptotic protein Bax. Collectively, anthocyanins from red-fleshed apples reduce oxidative stress and inhibit apoptosis in porcine GCs in vitro. This approach indicates that antioxidants might be developed from red-fleshed apples.	[Xiang, Ya; Zhu, Jun; Dai, Hongyi; Zhang, Yugang] Qingdao Agr Univ, Coll Hort, Qingdao, Peoples R China; [Xiang, Ya; Dai, Hongyi; Zhang, Yugang] Qingdao Agr Univ, Qingdao Key Lab Genet Dev & Breeding Hort Plants, Qingdao, Peoples R China; [Lai, Fangnong; He, Guifang; Li, Yapeng; Yang, Leilei; Shen, Wei] Qingdao Agr Univ, Key Lab Anim Reprod & Germplasm Enhancement Univ, Qingdao, Peoples R China; [Yang, Leilei; Shen, Wei] Qingdao Agr Univ, Coll Anim Sci & Technol, Qingdao, Peoples R China; [Huo, Heqiang] Univ Florida, Midflorida Res & Educ Ctr, Apopka, FL USA	Qingdao Agricultural University; Qingdao Agricultural University; Qingdao Agricultural University; Qingdao Agricultural University; State University System of Florida; University of Florida	Zhang, YG (corresponding author), Qingdao Agr Univ, Coll Hort, Qingdao, Peoples R China.; Zhang, YG (corresponding author), Qingdao Agr Univ, Qingdao Key Lab Genet Dev & Breeding Hort Plants, Qingdao, Peoples R China.	ygzhang@qau.edu.cn	Yang, Lei-Lei/AAM-4080-2021	Yang, Lei-Lei/0000-0002-5082-2075; zhang, yu gang/0000-0002-2726-2153	National Natural Science Foundation of China [31372032]; China Agriculture Research System Foundation [CARS-27]; Shandong Provincial Improved Variety Engineering System Foundation; Taishan Scholar Constructive Foundation; "12th Five-Year" National Science and technology support program [2013BAD02601]; Qingdao Scientific Research Foundation [15-9-2-99-nsh, 15-10-2-2-nsh]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Agriculture Research System Foundation; Shandong Provincial Improved Variety Engineering System Foundation; Taishan Scholar Constructive Foundation; "12th Five-Year" National Science and technology support program; Qingdao Scientific Research Foundation	This work was supported by the National Natural Science Foundation of China (Grant No. 31372032), China Agriculture Research System Foundation (Grant No. CARS-27), Shandong Provincial Improved Variety Engineering System Foundation, Taishan Scholar Constructive Foundation and Qingdao Scientific Research Foundation (Grant No. 15-9-2-99-nsh, 15-10-2-2-nsh), "12th Five-Year" National Science and technology support program (2013BAD02601). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bianco L, 2016, PLANT J, V86, P62, DOI 10.1111/tpj.13145; Carlisi D, 2014, ONCOL REP, V32, P167, DOI 10.3892/or.2014.3212; Chagne D, 2013, PLANT PHYSIOL, V161, P225, DOI 10.1104/pp.112.206771; Chaudhary N, 2014, INT J HLTH SCI RES, V4, P216; Denis MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053725; Duda M, 2011, REPROD BIOL, V11, P117, DOI 10.1016/S1642-431X(12)60049-7; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Gonzalez-Talice J, 2013, SCI HORTIC-AMSTERDAM, V151, P83, DOI 10.1016/j.scienta.2012.12.007; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; He JA, 2010, ANNU REV FOOD SCI T, V1, P163, DOI 10.1146/annurev.food.080708.100754; Hole PS, 2013, BLOOD, V122, P3322, DOI 10.1182/blood-2013-04-491944; Huang WJ, 2016, BIOMED REP, V4, P519, DOI 10.3892/br.2016.630; Huang ZL, 2009, LWT-FOOD SCI TECHNOL, V42, P819, DOI 10.1016/j.lwt.2008.11.005; Igarashi K, 2000, BIOSCI BIOTECH BIOCH, V64, P1600, DOI 10.1271/bbb.64.1600; Jang H, 2013, WORLD J MENS HEALTH, V31, P239, DOI 10.5534/wjmh.2013.31.3.239; Jang H, 2012, REPROD FERT DEVELOP, V24, P649, DOI 10.1071/RD11174; Jhin C, 2014, INT J MOL SCI, V15, P14715, DOI 10.3390/ijms150814715; Jones DP, 2008, AM J PHYSIOL-CELL PH, V295, pC849, DOI 10.1152/ajpcell.00283.2008; Knollema S, 1996, J COMP NEUROL, V373, P157, DOI 10.1002/(SICI)1096-9861(19960916)373:2<157::AID-CNE1>3.0.CO;2-2; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Ma T, 2016, FOOD CHEM, V194, P296, DOI 10.1016/j.foodchem.2015.07.110; Marin DE, 2013, FOOD CHEM TOXICOL, V58, P408, DOI 10.1016/j.fct.2013.05.033; McMahon BK, 2012, J AM CHEM SOC, V134, P10725, DOI 10.1021/ja300887k; Nems A, 2015, FOOD CHEM, V172, P175, DOI 10.1016/j.foodchem.2014.09.033; Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874; Park HB, 2010, J ORTHOP RES, V28, P1162, DOI 10.1002/jor.21097; Qin XC, 2015, INT J PHOTOENERGY, V2015, DOI 10.1155/2015/471364; Raghvendra VS, 2011, INT J PHARM SCI REV, V6, P28; Sakatani M, 2007, J REPROD DEVELOP, V53, P605, DOI 10.1262/jrd.18124; Sari P, 2012, FOOD CHEM, V132, P1908, DOI 10.1016/j.foodchem.2011.12.025; Seeram NP, 2002, J AGR FOOD CHEM, V50, P5308, DOI 10.1021/jf025671q; Sousa A, 2016, FOOD CHEM, V192, P142, DOI 10.1016/j.foodchem.2015.06.108; Streit E, 2012, TOXINS, V4, P788, DOI 10.3390/toxins4100788; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tedesco I, 2001, J NUTR BIOCHEM, V12, P505, DOI 10.1016/S0955-2863(01)00164-4; TSUDA T, 1994, J AGR FOOD CHEM, V42, P2407, DOI 10.1021/jf00047a009; Whitaker BD, 2008, REPROD FERT DEVELOP, V20, P694, DOI 10.1071/RD08037; [项亚 Xiang Ya], 2016, [植物生理学报, Plant Physiology Journal], V52, P1353; You J, 2010, THERIOGENOLOGY, V74, P777, DOI 10.1016/j.theriogenology.2010.04.002; ZHANG YC, 2016, INT J FUTUR GENER CO, V9, P1, DOI DOI 10.17660/EJHS.2016/81.5.3; Zheng J, 2011, FOOD CHEM, V126, P859, DOI 10.1016/j.foodchem.2010.11.052; Zhu L, 2012, J CELL PHYSIOL, V227, P1814, DOI 10.1002/jcp.22906; Zienolddiny S, 2000, CARCINOGENESIS, V21, P1521, DOI 10.1093/carcin/21.8.1521	43	16	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2017	12	8							e0184033	10.1371/journal.pone.0184033	http://dx.doi.org/10.1371/journal.pone.0184033			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE9SU	28850606	Green Published, gold, Green Submitted			2023-01-03	WOS:000408544200053
J	Ding, SB; Jiang, JJ; Zhang, GF; Bu, YJ; Zhang, GH; Zhao, XM				Ding, Shibin; Jiang, Jinjin; Zhang, Guofu; Bu, Yongjun; Zhang, Guanghui; Zhao, Xiangmei			Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats	PLOS ONE			English	Article							ER STRESS; GLUCOSE-HOMEOSTASIS; AUTOPHAGY; LIVER; SIRT1; EXPRESSION; DISEASE; MICE; SUPPLEMENTATION; INFLAMMATION	Background Studies have demonstrated that resveratrol ( a natural polyphenol) and caloric restriction activate Sirtuin-1 (SIRT1) and induce autophagy. Furthermore, autophagy is induced by the SIRT1-FoxO signaling pathway and was recently shown to be a critical protective mechanism against non-alcoholic fatty liver disease (NAFLD) development. We aimed to compare the effects of resveratrol and caloric restriction on hepatic lipid metabolism and elucidate the mechanism by which resveratrol supplementation and caloric restriction alleviate hepatosteatosis by examining the molecular interplay between SIRT1 and autophagy. Methods and results Eight-week-old male Wistar rats (40) were divided into four groups: the STD group, which was fed a standard chow diet; the HFD group, which was fed a high-fat diet; HFD-RES group, which was fed a high-fat diet plus resveratrol (200 mg/kg. bw); and the HFD-CR group, which was fed a high-fat diet in portions containing 70% of the mean intake of the HFD group rats. The groups were maintained for 18 weeks. Metabolic parameters, Oil Red O and hematoxylin-eosin staining of the liver, and the mRNA and protein expression of SIRT1, autophagy markers and endoplasmic reticulum(ER) stress-associated genes in the liver were assessed after the 18-week treatment. We found that resveratrol (200 mg/kg bw) and caloric restriction (30%) partially prevented hepatic steatosis and hepatocyte ballooning, increased the expression of SIRT1 and autophagy markers while decreasing ER stress markers in the liver and alleviated lipid metabolism disorder. Moreover, caloric restriction provided superior protection against HFD-induced hepatic fatty accumulation compared with resveratrol and the effects were associated with decreased total energy intake and body weight. Conclusion We conclude that the SIRT1-autophagy pathway and decreased ER stress are universally required for the protective effects of moderate caloric restriction (30%) and resveratrol (a pharmacological SIRT1 activator) supplementation against HFD-induced hepatic steatosis.	[Ding, Shibin; Zhang, Guofu; Bu, Yongjun; Zhang, Guanghui; Zhao, Xiangmei] Xinxiang Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Xinxiang, Henan, Peoples R China; [Ding, Shibin] Xinxiang Med Univ, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang, Henan, Peoples R China; [Jiang, Jinjin] Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China	Xinxiang Medical University; Xinxiang Medical University; Capital Medical University	Ding, SB (corresponding author), Xinxiang Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Xinxiang, Henan, Peoples R China.; Ding, SB (corresponding author), Xinxiang Med Univ, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang, Henan, Peoples R China.	dingshibin@163.com			Key Scientific Research Project of Universities in Henan Province [16A330002]; Scientific Research Fund of Xinxiang Medical University [2014QN107]	Key Scientific Research Project of Universities in Henan Province; Scientific Research Fund of Xinxiang Medical University	This work was supported by the Key Scientific Research Project of Universities in Henan Province (16A330002) and Scientific Research Fund of Xinxiang Medical University (2014QN107).	Abd El-Haleim EA, 2016, WORLD J GASTROENTERO, V22, P2931, DOI 10.3748/wjg.v22.i10.2931; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beaudeux JL, 2010, CURR OPIN CLIN NUTR, V13, P729, DOI 10.1097/MCO.0b013e32833ef291; Catta-Preta M, 2011, VIRCHOWS ARCH, V459, P477, DOI 10.1007/s00428-011-1147-1; Chen Q, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-56; Colak Y, 2011, MED SCI MONITOR, V17, pHY5, DOI 10.12659/MSM.881749; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cui MX, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/852754; Day C P, 2005, Gastroenterology, V129, P375, DOI 10.1053/j.gastro.2005.05.041; Ding SB, 2014, J ENDOCRINOL, V221, P167, DOI 10.1530/JOE-13-0386; Ezquerro S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39942; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Fischer-Posovszky P, 2010, AM J CLIN NUTR, V92, P5, DOI 10.3945/ajcn.2009.28435; Gonzalez-Rodriguez A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.162; Heeboll S, 2016, J GASTROEN HEPATOL, V31, P668, DOI 10.1111/jgh.13151; Heeboll S, 2015, PHARMACOL RES, V95-96, P34, DOI 10.1016/j.phrs.2015.03.005; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ji GY, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0139-6; Jove M, 2014, AGING CELL, V13, P828, DOI 10.1111/acel.12241; Kessoku T, 2016, SCI REP-UK, V6, DOI 10.1038/srep22251; Kim KE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30111; Kruse R, 2015, DIABETOLOGIA, V58, P2087, DOI 10.1007/s00125-015-3654-0; la Porte C, 2010, CLIN PHARMACOKINET, V49, P449, DOI 10.2165/11531820-000000000-00000; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Loison C, 2002, BRIT J NUTR, V87, P199, DOI [10.1079/BJNBJN2002521, 10.1079/BJN2002521]; Mansur AP, 2017, INT J CARDIOL, V227, P788, DOI 10.1016/j.ijcard.2016.10.058; Marino G, 2014, AUTOPHAGY, V10, P1879, DOI 10.4161/auto.36413; Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Andrade JMO, 2014, NUTRITION, V30, P915, DOI 10.1016/j.nut.2013.11.016; Pan QR, 2015, NUTR RES, V35, P576, DOI 10.1016/j.nutres.2015.05.006; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975; Poulsen MM, 2013, ANN NY ACAD SCI, V1290, P74, DOI 10.1111/nyas.12141; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rodriguez A, 2012, DIABETOLOGIA, V55, P3038, DOI 10.1007/s00125-012-2671-5; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Tauriainen E, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/525094; Tian YL, 2016, MOL CELL BIOCHEM, V422, P75, DOI 10.1007/s11010-016-2807-x; Tsutsumi A, 2011, BIOCHEM BIOPH RES CO, V404, P339, DOI 10.1016/j.bbrc.2010.11.120; Ueno T, 2017, NAT REV GASTRO HEPAT, V14, P170, DOI 10.1038/nrgastro.2016.185; Xu JQ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030271; Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4; Zhang Q, 2015, INT J BIOL SCI, V11, P559, DOI 10.7150/ijbs.10690; Zhang XQ, 2014, WORLD J GASTROENTERO, V20, P1768, DOI 10.3748/wjg.v20.i7.1768; Zhang Y, 2015, MOL NUTR FOOD RES, V59, P1443, DOI 10.1002/mnfr.201500016	49	105	107	4	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2017	12	8							e0183541	10.1371/journal.pone.0183541	http://dx.doi.org/10.1371/journal.pone.0183541			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD9QG	28817690	Green Published, Green Submitted, gold			2023-01-03	WOS:000407856600150
J	Wan, WT; Jiang, BP; Sun, L; Xu, LJ; Xiao, PG				Wan, Wenting; Jiang, Baoping; Sun, Le; Xu, Lijia; Xiao, Peigen			Metabolomics reveals that vine tea (Ampelopsis grossedentata)prevents high-fat-diet-induced metabolism disorder by improving glucose homeostasis in rats	PLOS ONE			English	Article							AMPELOPSIS-GROSSEDENTATA; DIHYDROMYRICETIN; CHOLINE; PLASMA; SERUM; OBESE	Background Vine tea (VT), derived from Ampelopsis grossedentata (Hand.-Mazz.) W.T. Wang, is an alternative tea that has been consumed widely in south China for hundreds of years. It has been shown that drinking VT on a daily basis improves hyperlipidemia and hyperglycemia. However, little is known about the preventive functions of VT for metabolic dysregulation and the potential pathological mechanisms involved. This paper elucidates the preventive effects of VT on the dysregulation of lipid and glucose metabolism using rats maintained on a high-fat-diet (HFD) in an attempt to explain the potential mechanisms involved. Methods Sprague Dawley (SD) rats were divided into five groups: a group given normal rat chow and water (control group); a group given an HFD and water (HFD group); a group given an HFD and Pioglitazone (PIO group), 5 mg/kg; and groups given an HFD and one of two doses of VT: 500 mg/L or 2000 mg/L. After 8 weeks, changes in food intake, tea consumption, body weight, serum and hepatic biochemical parameters were determined. Moreover, liver samples were isolated for pathology histology and liquid chromatography-mass spectrometry (LC-MS)-based metabolomic research. Results VT reduced the serum levels of glucose and total cholesterol, decreased glucose area under the curve in the insulin tolerance test and visibly impaired hepatic lipid accumulation. Metabolomics showed that VT treatment modulated the contents of metabolic intermediates linked to glucose metabolism (including gluconeogenesis and glycolysis), the TCA cycle, purine metabolism and amino acid metabolism. Conclusion The current results demonstrate that VT may prevent metabolic impairments induced by the consumption of an HFD. These effects may be caused by improved energy-related metabolism (including gluconeogenesis, glycolysis and TCA cycle), purine metabolism and amino acid metabolism, and reduced lipid levels in the HFD-fed rats.	[Wan, Wenting; Jiang, Baoping; Sun, Le; Xu, Lijia; Xiao, Peigen] Chinese Acad Med Sci, Inst Med Plant Dev, Beijing, Peoples R China; [Wan, Wenting; Jiang, Baoping; Sun, Le; Xu, Lijia; Xiao, Peigen] Peking Union Med Coll, Beijing, Peoples R China; [Wan, Wenting; Jiang, Baoping; Sun, Le; Xu, Lijia; Xiao, Peigen] Minist Educ, Key Lab Bioact Subst & Resources Utilizat Chinese, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medicinal Plant Development - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Xu, LJ (corresponding author), Chinese Acad Med Sci, Inst Med Plant Dev, Beijing, Peoples R China.; Xu, LJ (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.; Xu, LJ (corresponding author), Minist Educ, Key Lab Bioact Subst & Resources Utilizat Chinese, Beijing, Peoples R China.	xulijia@hotmail.com			National Natural Science Foundation of P. R. China [81274188, 81573576]	National Natural Science Foundation of P. R. China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of P. R. China. No.81274188. (LJX) https://isisn.nsfc.gov.cn/egrantindex/funcindex/prisearch-list, and National Natural Science Foundation of P. R. China. No.81573576. (LJX) https://isisn.nsfc.gov.cn/egrantindex/funcindex/prisearch-list.	Baldwin W, 2011, DIABETES, V60, P1258, DOI 10.2337/db10-0916; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Chen J, 2016, BIOORGAN MED CHEM, V24, P1488, DOI 10.1016/j.bmc.2016.02.018; Chen SH, 2015, PHARMACOL RES, V99, P74, DOI 10.1016/j.phrs.2015.05.009; Chen YuQiong, 2007, Journal of Tea Science, V27, P221; Doi M, 2007, AM J PHYSIOL-ENDOC M, V292, pE1683, DOI 10.1152/ajpendo.00609.2006; Friedrich N, 2012, J ENDOCRINOL, V215, P29, DOI 10.1530/JOE-12-0120; Gustavo DP, 2013, J NUTR BIOCH, V24, P809; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Hijmans BS, 2014, BIOCHIMIE, V96, P121, DOI 10.1016/j.biochi.2013.06.007; Hinder LM, 2013, J ENDOCRINOL, V216, P1, DOI 10.1530/JOE-12-0356; IbuYuez E., 2014, COMPREHENSIVE ANAL C, V64, P395; Jiang BP, 2015, ENDOCRINOLOGY, V156, P2006, DOI 10.1210/en.2015-1015; Kobayashi T, 2007, METABOLISM, V56, P439, DOI 10.1016/j.metabol.2006.09.022; Lamharzi N, 2004, DIABETES, V53, P3217, DOI 10.2337/diabetes.53.12.3217; Langenberg C, 2011, NAT MED, V17, P418, DOI 10.1038/nm0411-418; Li Lei O, 2010, Mol Endocrinol, V24, P657, DOI 10.1210/me.2009-0152; Li Y.S., 2006, J HUBEI I NATL MED E, V23, P7; Li ZK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127355; Lin SH, 2011, MOL BIOSYST, V7, P1537, DOI 10.1039/c0mb00246a; Lu JY, 2012, J PROTEOME RES, V11, P4705, DOI 10.1021/pr300523x; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Patterson AD, 2011, J BIOL CHEM, V286, P19511, DOI 10.1074/jbc.M111.221739; Penry JT, 2008, INT J SPORT NUTR EXE, V18, P191, DOI 10.1123/ijsnem.18.2.191; Phypers B, 2006, BJA EDUC, V6, P128, DOI 10.1093/bjaceaccp/mkl018; Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200; Roberts LD, 2014, LANCET DIABETES ENDO, V2, P65, DOI 10.1016/S2213-8587(13)70143-8; Sansbury BE, 2014, CIRC-HEART FAIL, V7, P634, DOI 10.1161/CIRCHEARTFAILURE.114.001151; Suhre K, 2014, J ENDOCRINOL, V221, pR75, DOI 10.1530/JOE-14-0024; Waldram A, 2009, J PROTEOME RES, V8, P2361, DOI 10.1021/pr8009885; [王家胜 Wang Jiasheng], 2014, [中成药, Chinese Traditional Patent Medicine], V36, P145; World Health Organization, 2005, PREVENTING CHRONIC D; Xu LJ, 2011, MODERN CHINESE MED, V14, P62; Ye LY, 2015, FOOD CHEM, V172, P416, DOI 10.1016/j.foodchem.2014.09.090; Yuan Q, 2014, NEIMONOGOL J TRADITI, P126	35	23	25	3	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2017	12	8							e0182830	10.1371/journal.pone.0182830	http://dx.doi.org/10.1371/journal.pone.0182830			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD6XW	28813453	Green Published, gold, Green Submitted			2023-01-03	WOS:000407672200042
J	Goodman, CW; Brett, AS				Goodman, Christopher W.; Brett, Allan S.			Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Goodman, Christopher W.; Brett, Allan S.] Univ South Carolina, Sch Med, Dept Med, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia	Goodman, CW (corresponding author), Univ South Carolina, Sch Med, Dept Med, Columbia, SC 29208 USA.		Goodman, Christopher/AAJ-3784-2021	Goodman, Christopher/0000-0003-4863-6342				[Anonymous], 2017, MED US SPEND US REV; Dowell D, 2016, JAMA-J AM MED ASSOC, V2016, P1624, DOI DOI 10.1001/JAMA.2016.1464; Evoy KE, 2017, DRUGS, V77, P403, DOI 10.1007/s40265-017-0700-x; Mathieson S, 2017, NEW ENGL J MED, V376, P1111, DOI 10.1056/NEJMoa1614292; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008	5	183	184	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2017	377	5					411	414		10.1056/NEJMp1704633	http://dx.doi.org/10.1056/NEJMp1704633			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC3NW	28767350	Bronze			2023-01-03	WOS:000406747100002
J	Henke, A; Thuss-Patience, P; Behzadi, A; Henke, O				Henke, Antje; Thuss-Patience, Peter; Behzadi, Asita; Henke, Oliver			End-of-life care for immigrants in Germany. An epidemiological appraisal of Berlin	PLOS ONE			English	Article							PALLIATIVE CARE; HEALTH-CARE; DISEASES; HOSPICE; TURKISH	Background Since the late 1950' s, a steadily increasing immigrant population in Germany is resulting in a subpopulation of aging immigrants. The German health care system needs to adjust its services-linguistically, culturally, and medically-for this subpopulation of patients. Immigrants make up over 20% of the population in Germany, yet the majority receive inadequate medical care. As many of the labor immigrants of the 1960s and 1970s are in need of hospice and palliative care (HPC), little is known about this specialized care for immigrants. This epidemiological study presents utilization of HPC facilities in Berlin with a focus on different immigrant groups. Methods A validated questionnaire was used to collect data from patients at 34 HPC institutions in Berlin over 20 months. All newly admitted patients were recruited. Anonymized data were coded and analyzed by using SPSS and compared with the population statistics of Berlin. Results 4118 questionnaires were completed and included in the analysis. At 11.4% the proportion of immigrants accessing HPC was significantly (p<0,001) below their proportion in the general Berlin population. This difference was especially seen in the age groups of 51-60 (21.46% immigrants in Berlin population, 17.7% immigrants in HPC population) and 61-70 years (16,9% vs. 13,1%). The largest ethnic groups are Turks, Russians, and Poles, with a different weighting than in the general population: Turkish immigrants were 24% of all Berlin immigrants, but only 13.6% of the study immigrant population (OR: 0.23, 95% CI: 0.18-0.29, p<0.001). Russian and Polish immigrants account for 5.6% and 9.2% in the population, but 11.5% and 24.8% in the study population respectively (Russian: OR 0.88, 95% CI: 0.66-1.16; Polish: OR 1.17, 95% CI: 0.97-1.42). Palliative care wards (PC) were used most often (16.7% immigrants of all PC patients); outpatient hospice services were used least often by immigrants (11.4%). Median age at first admission to HPC was younger in immigrants than non-immigrants: 61-70 vs. 71-80, p = 0.03. Conclusions Immigrants are underrepresented in Berlin's HPC and immigrants on average make use of care at a younger age than non-immigrants. In this regard, Turkish immigrants in particular have the poorest utilization of HPC. These results should prompt research on Turkish immigrants, regarding access barriers, since they represent the largest immigrant group. This may be due to a lack of cultural sensitivity of the care-providers and a lack of knowledge about HPC among immigrants. In the comparison of the kinds of institutions, immigrants are less likely to access outpatient hospice services compared to PC. Apparently, PC appear to be a smaller hurdle for utilization. These results show a non-existent, but oft-cited "healthy immigrant effect" of the first generation of work immigrants, now entering old age. These findings correspond with studies suggesting increased health concerns in immigrants. Focused research is needed to promote efforts in providing adequate and fair access to HPC for all people in Berlin.	[Henke, Antje; Thuss-Patience, Peter; Behzadi, Asita; Henke, Oliver] Charite, Div Palliat Med, Dept Hematol & Oncol, Virchow Campus, Berlin, Germany; [Henke, Antje] Charite, Berlin Sch Publ Hlth, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Henke, O (corresponding author), Charite, Div Palliat Med, Dept Hematol & Oncol, Virchow Campus, Berlin, Germany.	oliver.henke@charite.de	Henke, Oliver/HGA-7260-2022	Behzadi, Asita/0000-0002-8568-0644	Foundation Paula-Kubitscheck-Vogel from Ravenburg, Germany	Foundation Paula-Kubitscheck-Vogel from Ravenburg, Germany	The study poject "Immigrants in End-Of-Life Care in Berlin 2013-2016", was supported by the Foundation Paula-Kubitscheck-Vogel from Ravenburg, Germany with 24,000 Euros. This epidemiologic study was part of the project, https://www.pkv-stiftung.det/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberer M, 2016, DEUT MED WOCHENSCHR, V141, pE8, DOI 10.1055/s-0041-106907; Anderson P, 2008, SOZIALREFERAT LANDES, P40; [Anonymous], 2012, 18 BUND MIGR FLUCHTL, V18; Borde T, 2002, GESUNDHEITSWESEN, V64, P476, DOI 10.1055/s-2002-33775; Bozorgmehr K, 2016, BUNDESGESUNDHEITSBLA, V59, P545, DOI 10.1007/s00103-016-2329-4; Bundesamt Statistisches, 2015, BEV ERW; Bundesamt Statistisches, 2014, BEV ERW; Crawley LaVera M, 2005, J Palliat Med, V8 Suppl 1, pS58; David M, 2006, EUR J EMERG MED, V13, P352, DOI 10.1097/01.mej.0000228451.15103.89; de Graaff FM, 2012, ETHNIC HEALTH, V17, P363, DOI 10.1080/13557858.2011.645152; Domnich A, 2012, EPIDEMIOL BIOSTAT PU, V9, DOI 10.2427/7532; Evans N, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-141; Henke O, 2012, Z PALLIATMEDIZIN, V13, P191, DOI 10.1055/s-0032-1305060; Henke O, 2015, Z PALLIATMEDIZIN, V16, P254, DOI 10.1055/s-0035-1552726; Jansky M, 2017, BUNDESGESUNDHEITSBLA, V60, P89, DOI 10.1007/s00103-016-2476-7; Koffman J, 2007, PALLIATIVE MED, V21, P145, DOI 10.1177/0269216306074639; Kohls M., 2012, 12 BUND MIGR FLUCHTL, V12; Lampert T, 2005, ARMUTS UND REICHTUMS, P127; Paal P, 2017, PLOS ONE, V12; Razum O., 2006, MIGRATION MORTALITAT, P255; Schenk L, 2006, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V49, P853, DOI 10.1007/s00103-006-0018-4; Schenk L., 2008, ALTER GESUNDHEIT KRA, P156; Schimany P, 2012, 18 BUND MIGR FLUCHTL, V18; Selby P, 1996, BRIT J CANCER, V74, pS54; Stich A, 2016, INTERNIST, V57, P409, DOI 10.1007/s00108-016-0057-3; Tezcan-Guntekin H, 2015, DTSCH ARZTEBL, V112; TNS Infratest Sozialforschung, 2011, TNS INFR SOZ; Woellert F, 2009, UNGENUTZTE POTENZIAL	28	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0182033	10.1371/journal.pone.0182033	http://dx.doi.org/10.1371/journal.pone.0182033			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3VC	28763469	Green Published, gold, Green Submitted			2023-01-03	WOS:000406766500035
J	Campbell, KT; Hadley, DJ; Kukis, DL; Silva, EA				Campbell, Kevin T.; Hadley, Dustin J.; Kukis, David L.; Silva, Eduardo A.			Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-WEIGHT DISTRIBUTION; LYMPHATIC VASCULATURE; COVALENT INCORPORATION; MYOCARDIAL-INFARCTION; COLLAGEN MATRICES; TYROSINE KINASES; TUMOR-GROWTH; IN-VIVO; ANGIOGENESIS	Lymphatic dysfunction is associated with the progression of many cardiovascular disorders due to their role in maintaining tissue fluid homeostasis. Promoting new lymphatic vessels (lymphangiogenesis) is a promising strategy to reverse these cardiovascular disorders via restoring lymphatic function. Vascular endothelial growth factor (VEGF) members VEGF-C and VEGF-D are both potent candidates for stimulating lymphangiogenesis, though maintaining spatial and temporal control of these factors represents a challenge to developing efficient therapeutic lymphangiogenic applications. Injectable alginate hydrogels have been useful for the controlled delivery of many angiogenic factors, including VEGF-A, to stimulate new blood vasculature. However, the utility of these tunable hydrogels for delivering lymphangiogenic factors has never been closely examined. Thus, the objective of this study was to utilize ionically cross-linked alginate hydrogels to deliver VEGF-C and VEGF-D for potential lymphangiogenic applications. We demonstrated that lymphatic endothelial cells (LECs) are sensitive to temporal presentation of VEGF-C and VEGF-D but with different responses between the factors. The greatest LEC mitogenic and sprouting response was observed for constant concentrations of VEGF-C and a high initial concentration that gradually decreased over time for VEGF-D. Additionally, alginate hydrogels provided sustained release of radiolabeled VEGF-C and VEGF-D. Finally, VEGF-C and VEGF-D released from these hydrogels promoted a similar number of LEC sprouts as exogenously added growth factors and new vasculature in vivo via a chick chorioallantoic membrane (CAM) assay. Overall, these findings demonstrate that alginate hydrogels can provide sustained and bioactive release of VEGF-C and VEGF-D which could have applications for therapeutic lymphangiogenesis.	[Campbell, Kevin T.; Hadley, Dustin J.; Silva, Eduardo A.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Kukis, David L.] Univ Calif Davis, Ctr Mol & Genom Imaging, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Silva, EA (corresponding author), Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.	esilva@ucdavis.edu	Silva, Eduardo A./M-2711-2015	Silva, Eduardo A./0000-0003-3173-7622	American Heart Association [15BGIA25730057]; Center for Molecular and Genomic Imaging at UC Davis; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL086350] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Center for Molecular and Genomic Imaging at UC Davis; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by a grant from the American Heart Association (15BGIA25730057) and by pilot funding from the Center for Molecular and Genomic Imaging at UC Davis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the American Heart Association (15BGIA25730057) and the Center for Molecular and Genomic Imaging at UC Davis for the funding support.	Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Anderson EM, 2015, J VASC RES, V52, P62, DOI 10.1159/000382129; Boontheekul T, 2005, BIOMATERIALS, V26, P2455, DOI 10.1016/j.biomaterials.2004.06.044; Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106; Bouhadir KH, 2001, BIOTECHNOL PROGR, V17, P945, DOI 10.1021/bp010070p; Bronckaers A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071104; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cimpean AM, 2010, CLIN EXP MED, V10, P169, DOI 10.1007/s10238-009-0085-6; Cui Yingjie, 2010, Pathophysiology, V17, P307, DOI 10.1016/j.pathophys.2009.07.006; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Goldman J, 2007, FASEB J, V21, P1003, DOI 10.1096/fj.06-6656com; Hao XJ, 2007, CARDIOVASC RES, V75, P178, DOI 10.1016/j.cardiores.2007.03.028; Henri O, 2016, CIRCULATION, V133, P1484, DOI 10.1161/CIRCULATIONAHA.115.020143; Hwang JH, 2011, BIOMATERIALS, V32, P4415, DOI 10.1016/j.biomaterials.2011.02.051; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Kearney CJ, 2013, NAT MATER, V12, P1004, DOI [10.1038/NMAT3758, 10.1038/nmat3758]; Kim IG, 2013, J VASC RES, V50, P124, DOI 10.1159/000343699; Kim S, 2016, BIOMATERIALS, V78, P115, DOI 10.1016/j.biomaterials.2015.11.019; Koch S, 2006, J MATER SCI-MATER M, V17, P735, DOI 10.1007/s10856-006-9684-x; Kong HJ, 2004, BIOMACROMOLECULES, V5, P1720, DOI 10.1021/bm049879r; Li JY, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.71; Lim HY, 2013, CELL METAB, V17, P671, DOI 10.1016/j.cmet.2013.04.002; Ludwig LL, 1997, CARDIOVASC RES, V33, P164, DOI 10.1016/S0008-6363(96)00177-0; Madrigal J.L., 2016, ANN BIOMED ENG; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Martel C, 2013, J CLIN INVEST, V123, P1571, DOI 10.1172/JCI63685; Nakano T, 2005, HUM PATHOL, V36, P330, DOI 10.1016/j.humpath.2005.01.001; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Randolph GJ, 2014, J CLIN INVEST, V124, P929, DOI 10.1172/JCI71610; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003; Schulz MMP, 2012, P NATL ACAD SCI USA, V109, pE2665, DOI 10.1073/pnas.1206036109; Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x; Silva EA, 2008, P NATL ACAD SCI USA, V105, P14347, DOI 10.1073/pnas.0803873105; Silva EA, 2010, BIOMATERIALS, V31, P1235, DOI 10.1016/j.biomaterials.2009.10.052; Singh S, 2012, J BIOMED MATER RES A, V100A, P720, DOI 10.1002/jbm.a.34010; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Steffens GCM, 2004, TISSUE ENG, V10, P1502, DOI 10.1089/ten.2004.10.1502; Venturoli D, 2005, AM J PHYSIOL-RENAL, V288, pF605, DOI 10.1152/ajprenal.00171.2004; Williams PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123437; Wong C, 2003, THROMB HAEMOSTASIS, V89, P573, DOI 10.1055/s-0037-1613389; Zheng W, 2011, BLOOD, V118, P1154, DOI 10.1182/blood-2010-11-317800	50	31	31	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2017	12	7							e0181484	10.1371/journal.pone.0181484	http://dx.doi.org/10.1371/journal.pone.0181484			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3UH	28723974	Green Published, Green Submitted, gold			2023-01-03	WOS:000406067800054
J	Pitkanen, M; Kallioniemi, E; Julkunen, P				Pitkanen, Minna; Kallioniemi, Elisa; Julkunen, Petro			Effect of inter-train interval on the induction of repetition suppression of motor-evoked potentials using transcranial magnetic stimulation	PLOS ONE			English	Article							CORTEX EXCITABILITY; HABITUATION; INHIBITION; TMS; RESPONSES	Repetition suppression (RS) is evident as a weakened response to repeated stimuli after the initial response. RS has been demonstrated in motor-evoked potentials (MEPs) induced with transcranial magnetic stimulation (TMS). Here, we investigated the effect of inter-train interval (ITI) on the induction of RS of MEPs with the attempt to optimize the investigative protocols. Trains of TMS pulses, targeted to the primary motor cortex by neuronavigation, were applied at a stimulation intensity of 120% of the resting motor threshold. The stimulus trains included either four or twenty pulses with an inter-stimulus interval (ISI) of 1 s. The ITI was here defined as the interval between the last pulse in a train and the first pulse in the next train; the ITIs used here were 1, 3, 4, 6, 7, 12, and 17 s. RS was observed with all ITIs except with the ITI of 1 s, in which the ITI was equal to ISI. RS was more pronounced with longer ITIs. Shorter ITIs may not allow sufficient time for a return to baseline. RS may reflect a startle-like response to the first pulse of a train followed by habituation. Longer ITIs may allow more recovery time and in turn demonstrate greater RS. Our results indicate that RS can be studied with confidence at relatively short ITIs of 6 s and above.	[Pitkanen, Minna; Kallioniemi, Elisa; Julkunen, Petro] Kuopio Univ Hosp, Dept Clin Neurophysiol, Kuopio, Finland; [Pitkanen, Minna] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland; [Kallioniemi, Elisa] Kuopio Univ Hosp, Dept Clin Radiol, Kuopio, Finland; [Julkunen, Petro] Univ Eastern Finland, Dept Appl Phys, Kuopio, Finland	Kuopio University Hospital; University of Eastern Finland; Aalto University; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Pitkanen, M (corresponding author), Kuopio Univ Hosp, Dept Clin Neurophysiol, Kuopio, Finland.; Pitkanen, M (corresponding author), Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, Espoo, Finland.	minna.pitk@gmail.com	Julkunen, Petro/AAS-5293-2020; Kallioniemi, Elisa/J-5000-2019	Kallioniemi, Elisa/0000-0001-6706-2837; Julkunen, Petro/0000-0002-0461-1058; Pitkanen, Minna/0000-0003-1716-3909	Finnish Cultural Foundation, Helsinki, Finland; Cancer Society of Finland, Helsinki, Finland; Paivikki and Sakari Sohlberg Foundation, Helsinki, Finland; Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (Kuopio, Finland) [5041726, 5041730, 5041749]	Finnish Cultural Foundation, Helsinki, Finland(Finnish Cultural Foundation); Cancer Society of Finland, Helsinki, Finland; Paivikki and Sakari Sohlberg Foundation, Helsinki, Finland; Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (Kuopio, Finland)	The work was supported by the Finnish Cultural Foundation, Helsinki, Finland, http://skr.fi/en (Received by MP); the Cancer Society of Finland, Helsinki, Finland, https://www.cancersociety.fi/ (Received by EK and PJ); and Paivikki and Sakari Sohlberg Foundation, Helsinki, Finland, http://www.pss-saatio.fi/english.htm (Received by EK). In addition, the authors (EK, PJ) acknowledge the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (projects 5041726, 5041730 and 5041749, Kuopio, Finland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awiszus F, 2003, SUPPL CLIN NEUROPHYS, V56, P13; Awiszus F, MOTOR THRESHOLD ASSE; BARKER AT, 1985, LANCET, V1, P1106; Cash RFH, 2017, BRAIN STIMUL, P1; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; FRUHSTOR.H, 1970, ELECTROEN CLIN NEURO, V28, P153, DOI 10.1016/0013-4694(70)90183-5; FRUHSTORFER H, 1971, ELECTROEN CLIN NEURO, V30, P306, DOI 10.1016/0013-4694(71)90113-1; GEYER MA, 1982, PSYCHOPHYSIOLOGY, V19, P1, DOI 10.1111/j.1469-8986.1982.tb02589.x; Giles AC, 2009, NEUROBIOL LEARN MEM, V92, P139, DOI 10.1016/j.nlm.2008.08.004; Giovannini MG, 2001, NEUROSCIENCE, V106, P43, DOI 10.1016/S0306-4522(01)00266-4; Grill-Spector K, 2006, TRENDS COGN SCI, V10, P14, DOI 10.1016/j.tics.2005.11.006; Hamilton AFD, 2009, HUM BRAIN MAPP, V30, P2898, DOI 10.1002/hbm.20717; Hohlefeld FU, 2011, NEUROREPORT, V22, P141, DOI 10.1097/WNR.0b013e3283436d84; Julkunen P, 2012, BRAIN STIMUL, V5, P526, DOI 10.1016/j.brs.2011.07.006; Kallioniemi E, 2015, NEUROSCIENCE, V310, P504, DOI 10.1016/j.neuroscience.2015.09.056; Kim H, 2017, HUM BRAIN MAPP, V38, P1894, DOI 10.1002/hbm.23492; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lofberg O, 2014, NEUROSCIENCE, V274, P403, DOI 10.1016/j.neuroscience.2014.05.060; Lofberg O, 2013, NEUROSCIENCE, V243, P40, DOI 10.1016/j.neuroscience.2013.03.060; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Rankin CH, 2009, NEUROBIOL LEARN MEM, V92, P135, DOI 10.1016/j.nlm.2008.09.012; RITTER W, 1968, ELECTROEN CLIN NEURO, V25, P550, DOI 10.1016/0013-4694(68)90234-4; Saisanen L, 2008, J CLIN NEUROPHYSIOL, V25, P367, DOI 10.1097/WNP.0b013e31818e7944; Sakai K, 1997, EXP BRAIN RES, V113, P24, DOI 10.1007/BF02454139; SCHOENEN J, 1995, EUR J NEUROL, V2, P115, DOI 10.1111/j.1468-1331.1995.tb00103.x; SOININEN HS, 1995, PHYSIOL BEHAV, V57, P927, DOI 10.1016/0031-9384(94)00393-J; Vaalto S, 2011, HUM BRAIN MAPP, V32, P1692, DOI 10.1002/hbm.21137; Volz LJ, 2015, CEREB CORTEX, V25, P2346, DOI 10.1093/cercor/bhu032; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wiggs CL, 1998, CURR OPIN NEUROBIOL, V8, P227, DOI 10.1016/S0959-4388(98)80144-X; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306	33	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2017	12	7							e0181663	10.1371/journal.pone.0181663	http://dx.doi.org/10.1371/journal.pone.0181663			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3UH	28723977	gold, Green Published, Green Submitted			2023-01-03	WOS:000406067800065
J	Clark, RSB; Empey, PE; Bay, H; Rosario, BL; Poloyac, SM; Kochanek, PM; Nolin, TD; Au, AK; Horvat, CM; Wisniewski, SR; Bell, MJ				Clark, Robert S. B.; Empey, Philip E.; Bay, Hulya; Rosario, Bedda L.; Poloyac, Samuel M.; Kochanek, Patrick M.; Nolin, Thomas D.; Au, Alicia K.; Horvat, Christopher M.; Wisniewski, Stephen R.; Bell, Michael J.			Phase I randomized clinical trial of Nacetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children	PLOS ONE			English	Article							N-ACETYLCYSTEINE; DOUBLE-BLIND; PHARMACOKINETICS; EFFICACY; GLUTATHIONE; SYSTEMS	Background There are no therapies shown to improve outcome after severe traumatic brain injury (TBI) in humans, a leading cause of morbidity and mortality. We sought to verify brain exposure of the systemically administered antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probenecid, and identify adverse effects of this drug combination after severe TBI in children. Methods IRB-approved, randomized, double- blind, placebo controlled Phase I study in children 2 to 18 years-of-age admitted to a Pediatric Intensive Care Unit after severe TBI (Glasgow Coma Scale [GCS] score <= 8) requiring an externalized ventricular drain for measurement of intracranial pressure (ICP). Patients were recruited from November 2011-August 2013. Fourteen patients (n = 7/group) were randomly assigned after obtaining informed consent to receive probenecid (25 mg/kg load, then 10 mg/kg/dose q6hx11 doses) and NAC (140 mg/kg load, then 70 mg/kg/dose q4hx17 doses), or placebos via naso/orogastric tube. Serum and CSF samples were drawn pre-bolus and 1-96 h after randomization and drug concentrations were measured via UPLC-MS/MS. Glasgow Outcome Scale (GOS) score was assessed at 3 months. Results There were no adverse events attributable to drug treatment. One patient in the placebo group was withdrawn due to adverse effects. In the treatment group, NAC concentrations ranged from 16,977.3 +/- 2,212.3 to 16,786.1 +/- 3,285.3 in serum and from 269.3 +/- 113.0 to 467.9 +/- 262.7 ng/mL in CSF, at 24 to 72 h post-bolus, respectively; and probenecid concentrations ranged from 75.4.3 +/- 10.0 to 52.9 +/- 25.8 in serum and 5.4 +/- 1.0 to 4.6 +/- 2.1 mu g/mL in CSF, at 24 to 72 h post-bolus, respectively (mean +/- SEM). Temperature, mean arterial pressure, ICP, use of ICP-directed therapies, surveillance serum brain injury biomarkers, and GOS at 3 months were not different between groups. Conclusions Treatment resulted in detectable concentrations of NAC and probenecid in CSF and was not associated with undesirable effects after TBI in children.	[Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Clark, Robert S. B.; Bay, Hulya; Kochanek, Patrick M.; Au, Alicia K.; Horvat, Christopher M.; Bell, Michael J.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; [Clark, Robert S. B.; Empey, Philip E.; Kochanek, Patrick M.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA; [Empey, Philip E.; Poloyac, Samuel M.; Nolin, Thomas D.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA USA; [Bay, Hulya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Rosario, Bedda L.; Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Childrens Natl Hlth Syst, Dept Pediat, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Children's National Health System	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Clark, RSB (corresponding author), UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.; Clark, RSB (corresponding author), Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Nolin, Thomas/AAB-7311-2020; Empey, Philip/L-9604-2019	Nolin, Thomas/0000-0003-4339-1382; Empey, Philip/0000-0001-7474-2339	NIH [R01NS069247]; NCATS [KL2TR000146, U01NS081041]; Children's Hospital of Pittsburgh of UPMC Scientific Program and Brain Care Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040686] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Children's Hospital of Pittsburgh of UPMC Scientific Program and Brain Care Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by NIH grants R01NS069247 (RSBC, PEE, MJB, PMK), NCATS KL2TR000146 (PEE), and U01NS081041 (MJB, SRW, PMK); and the Children's Hospital of Pittsburgh of UPMC Scientific Program and Brain Care Institute. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of there port.	Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berk M, 2014, J CLIN PSYCHIAT, V75, P628, DOI 10.4088/JCP.13m08454; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; BURNELL JM, 1951, J CLIN INVEST, V30, P697, DOI 10.1172/JCI102482; Du LN, 2016, J NEUROTRAUM, V33, P1913, DOI 10.1089/neu.2015.4342; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010; Hagos FT, 2016, XENOBIOTICA, P1; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Katz M, 2015, PARKINSONISM RELAT D, V21, P500, DOI 10.1016/j.parkreldis.2015.02.020; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Levin SW, 2014, LANCET NEUROL, V13, P777, DOI 10.1016/S1474-4422(14)70142-5; Maeda K, 2014, EUR J PHARM SCI, V59, P94, DOI 10.1016/j.ejps.2014.04.004; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Nigam SK, 2015, PHYSIOL REV, V95, P83, DOI 10.1152/physrev.00025.2013; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; SELEN A, 1982, J PHARM SCI, V71, P1238, DOI 10.1002/jps.2600711114; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wiest DB, 2014, J PEDIATR-US, V165, P672, DOI 10.1016/j.jpeds.2014.06.044; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304	28	28	29	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180280	10.1371/journal.pone.0180280	http://dx.doi.org/10.1371/journal.pone.0180280			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686657	Green Submitted, Green Published, gold			2023-01-03	WOS:000405464100047
J	Kussmaul, WG				Kussmaul, William G.			The Slippery Slope of Legalization of Physician-Assisted Suicide	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kussmaul, William G.] 5 Arrowhead Trail, Media, PA 19063 USA		Kussmaul, WG (corresponding author), 5 Arrowhead Trail, Media, PA 19063 USA.	w.kussmaul@verizon.net						Marsh Laura, 2016, NEW REPUBLIC; Stahl RY, 2017, NEW ENGL J MED, V376, P1380, DOI 10.1056/NEJMsb1612472; Sulmasy LS, 2017, ANN INTERN MED, V167, P576, DOI 10.7326/M17-0938	3	3	3	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					595	596		10.7326/M17-2072	http://dx.doi.org/10.7326/M17-2072			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ9JM	28975201				2023-01-03	WOS:000413092700025
J	Marcantonio, ER				Marcantonio, Edward R.			Delirium in Hospitalized Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONFUSION ASSESSMENT METHOD; MECHANICALLY VENTILATED PATIENTS; POSTOPERATIVE DELIRIUM; ELDERLY-PATIENTS; HIP FRACTURE; REDUCING DELIRIUM; PREDICTIVE MODEL; VALIDATION; MORTALITY; RISK	A 75-year-old man is admitted for scheduled major abdominal surgery. He is functionally independent, with mild forgetfulness. His intraoperative course is uneventful, but on postoperative day 2, severe confusion and agitation develop. What is going on? How would you manage this patient's care? Could his condition have been prevented?	[Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Marcantonio, Edward R.] Harvard Med Sch, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Marcantonio, ER (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,CO 216, Boston, MA 02215 USA.	emarcant@bidmc.harvard.edu	Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	NATIONAL INSTITUTE ON AGING [R01AG051658, R01AG030618, K24AG035075] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG051658, K24 AG035075, R01 AG030618] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association DSM-5 Task Force, 2013, DIAGN STAT MAN MENT, V5th; Bellelli G, 2014, AGE AGEING, V43, P496, DOI 10.1093/ageing/afu021; Bergmann MA, 2005, J AM GERIATR SOC, V53, P1817, DOI 10.1111/j.1532-5415.2005.53519.x; Bjorkelund KB, 2010, ACTA ANAESTH SCAND, V54, P678, DOI 10.1111/j.1399-6576.2010.02232.x; Cole MG, 2009, AGE AGEING, V38, P19, DOI 10.1093/ageing/afn253; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fick DM, 2015, J HOSP MED, V10, P645, DOI 10.1002/jhm.2418; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; Gleason LJ, 2015, JAMA SURG, V150, P1134, DOI 10.1001/jamasurg.2015.2606; Hager DN, 2013, CRIT CARE MED, V41, P1435, DOI 10.1097/CCM.0b013e31827ca949; Han JH, 2013, ANN EMERG MED, V62, P457, DOI 10.1016/j.annemergmed.2013.05.003; Hatta K, 2014, JAMA PSYCHIAT, V71, P397, DOI 10.1001/jamapsychiatry.2013.3320; Hshieh TT, 2015, JAMA INTERN MED, V175, P512, DOI 10.1001/jamainternmed.2014.7779; Inouye SK, 2007, ARCH INTERN MED, V167, P1406, DOI 10.1001/archinte.167.13.1406; Inouye SK, 2016, ALZHEIMERS DEMENT, V12, P766, DOI 10.1016/j.jalz.2016.03.005; Inouye SK, 2015, J AM GERIATR SOC, V63, P142, DOI 10.1111/jgs.13281; Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Inouye SK, 2001, ARCH INTERN MED, V161, P2467, DOI 10.1001/archinte.161.20.2467; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Kennedy M, 2014, J AM GERIATR SOC, V62, P462, DOI 10.1111/jgs.12692; Kiely DK, 2007, J GERONTOL A-BIOL, V62, P174, DOI 10.1093/gerona/62.2.174; Kiely DK, 2004, J GERONTOL A-BIOL, V59, P344; Lynch EP, 1998, ANESTH ANALG, V86, P781; Marcantonio ER, 2014, ANN INTERN MED, V161, P554, DOI 10.7326/M14-0865; Marcantonio ER, 2012, JAMA-J AM MED ASSOC, V308, P73, DOI 10.1001/jama.2012.6857; Marcantonio ER, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-11-201106070-01006; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7; McDowell JA, 1998, J AM GERIATR SOC, V46, P700, DOI 10.1111/j.1532-5415.1998.tb03803.x; Mikhailoyich A, 2015, J AM GERIATR SOC, V63, P843, DOI 10.1111/jgs.13406; Neufeld KJ, 2016, J AM GERIATR SOC, V64, P705, DOI 10.1111/jgs.14076; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Rudolph JL, 2009, CIRCULATION, V119, P229, DOI 10.1161/CIRCULATIONAHA.108.795260; Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923; Siddiqi N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005563.pub3; Sieber FE, 2010, MAYO CLIN PROC, V85, P18, DOI 10.4065/mcp.2009.0469; Wei LA, 2008, J AM GERIATR SOC, V56, P823, DOI 10.1111/j.1532-5415.2008.01674.x; Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013; Wong CL, 2010, JAMA-J AM MED ASSOC, V304, P779, DOI 10.1001/jama.2010.1182; Yang FM, 2009, PSYCHOSOMATICS, V50, P248, DOI 10.1176/appi.psy.50.3.248; Young J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3704	48	366	386	7	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	2017	377	15					1456	1466		10.1056/NEJMcp1605501	http://dx.doi.org/10.1056/NEJMcp1605501			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ4ZP	29020579	Bronze, Green Accepted			2023-01-03	WOS:000412753100010
J	Eloot, S; Van Biesen, W; Roels, S; Delrue, W; Schepers, E; Dhondt, A; Vanholder, R; Glorieux, G				Eloot, Sunny; Van Biesen, Wim; Roels, Sanne; Delrue, Willem; Schepers, Eva; Dhondt, Annemieke; Vanholder, Raymond; Glorieux, Griet			Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; P-CRESOL; ASYMMETRICAL DIMETHYLARGININE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; SYNBIOTIC TREATMENT; RENAL-FAILURE; MORTALITY; SOLUTES; TRIAL	Background and aim Numerous outcome studies and interventional trials in hemodialysis (HD) patients are based on uremic toxin concentrations determined at one single or a limited number of time points. The reliability of these studies however entirely depends on how representative these cross-sectional concentrations are. We therefore investigated the variability of predialysis concentrations of uremic toxins over time. Methods Prospectively collected predialysis serum samples of the midweek session of week 0, 1, 2, 3, 4, 8, 12, and 16 were analyzed for a panel of uremic toxins in stable chronic HD patients (N = 18) while maintaining dialyzer type and dialysis mode during the study period. Results Concentrations of the analyzed uremic toxins varied substantially between individuals, but also within stable HD patients (intra-patient variability). For urea, creatinine, beta-2-micro-globulin, and some protein-bound uremic toxins, Intra-class Correlation Coefficient (ICC) was higher than 0.7. However, for phosphorus, uric acid, symmetric and asymmetric dimethylarginine, and the protein-bound toxins hippuric acid and indoxyl sulfate, ICC values were below 0.7, implying a concentration variability within the individual patient even exceeding 65% of the observed inter-patient variability. Conclusion Intra-patient variability may affect the interpretation of the association between a single concentration of certain uremic toxins and outcomes. When performing future outcome and interventional studies with uremic toxins other than described here, one should quantify their intra-patient variability and take into account that for solutes with a large intra-patient variability associations could be missed.	[Eloot, Sunny; Van Biesen, Wim; Delrue, Willem; Schepers, Eva; Dhondt, Annemieke; Vanholder, Raymond; Glorieux, Griet] Ghent Univ Hosp, Dept Nephrol, Ghent, Belgium; [Roels, Sanne] Univ Ghent, Dept Data Anal, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Eloot, S (corresponding author), Ghent Univ Hosp, Dept Nephrol, Ghent, Belgium.	sunny.eloot@ugent.be			Belgian Fund for Research Flanders (FWO Vlaanderen) [G0A4614N]	Belgian Fund for Research Flanders (FWO Vlaanderen)	This study was financially supported by the Belgian Fund for Research Flanders (FWO Vlaanderen, project number G0A4614N).	Bammens B, 2006, KIDNEY INT, V69, P1081, DOI 10.1038/sj.ki.5000115; Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609; Crespo-Salgado J, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0195-9; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Deltombe O, 2017, ANAL METHODS-UK, V9, P1935, DOI 10.1039/c7ay00054e; Dou L, 2015, J AM SOC NEPHROL, V26, P876, DOI 10.1681/ASN.2013121283; Eloot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076838; Fagugli RM, 2002, AM J KIDNEY DIS, V40, P339, DOI 10.1053/ajkd.2002.34518; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; Guida B, 2014, NUTR METAB CARDIOVAS, V24, P1043, DOI 10.1016/j.numecd.2014.04.007; Kielstein JT, 2004, CIRCULATION, V109, P172, DOI 10.1161/01.CIR.0000105764.22626.B1; Liabeuf S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067168; Liabeuf S, 2012, KIDNEY INT, V82, P1297, DOI 10.1038/ki.2012.301; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; Lu TM, 2011, CLIN J AM SOC NEPHRO, V6, P1566, DOI 10.2215/CJN.08490910; Meert N, 2012, NEPHROL DIAL TRANSPL, V27, P2388, DOI 10.1093/ndt/gfr672; Meert N, 2010, ARTIF ORGANS, V34, P580, DOI 10.1111/j.1525-1594.2010.01005.x; Meert N, 2009, J NEPHROL, V22, P352; Nakabayashi I, 2011, NEPHROL DIAL TRANSPL, V26, P1094, DOI 10.1093/ndt/gfq624; Nakazato Y, 2015, CLIN EXP NEPHROL, V19, P1165, DOI 10.1007/s10157-015-1108-0; Nazzal L, 2017, NEPHROL DIAL TRANSPL; Poesen R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140820; Raj DSC, 2000, NEPHROL DIAL TRANSPL, V15, P58, DOI 10.1093/ndt/15.1.58; Rossi M, 2016, CLIN J AM SOC NEPHRO, V11, P223, DOI 10.2215/CJN.05240515; Santoro A, 2008, AM J KIDNEY DIS, V52, P507, DOI 10.1053/j.ajkd.2008.05.011; Shafi T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126048; Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974; Vanholder R, 2001, INT J ARTIF ORGANS, V24, P695, DOI 10.1177/039139880102401004; Vanholder R, 1999, J AM SOC NEPHROL, V10, P1815; Yilmaz MI, 2008, J AM SOC NEPHROL, V19, P388, DOI 10.1681/ASN.2007040461; Zewinger S, 2017, EUR HEART J, V38, P1597, DOI 10.1093/eurheartj/ehx118; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8; Zoccali C, 2006, J AM SOC NEPHROL, V17, P1466, DOI 10.1681/ASN.2005090949	34	21	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2017	12	10							e0186010	10.1371/journal.pone.0186010	http://dx.doi.org/10.1371/journal.pone.0186010			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ3JE	29016645	gold, Green Published, Green Submitted			2023-01-03	WOS:000412627400048
J	Cangialosi, A; Yoon, C; Liu, J; Huang, Q; Guo, JK; Nguyen, TD; Gracias, DH; Schulman, R				Cangialosi, Angelo; Yoon, ChangKyu; Liu, Jiayu; Huang, Qi; Guo, Jingkai; Nguyen, Thao D.; Gracias, David H.; Schulman, Rebecca			DNA sequence-directed shape change of photopatterned hydrogels via high-degree swelling	SCIENCE			English	Article							NANOPARTICLE SUPERLATTICES; HYBRIDIZATION; RESPONSES	Shape-changing hydrogels that can bend, twist, or actuate in response to external stimuli are critical to soft robots, programmable matter, and smart medicine. Shape change in hydrogels has been induced by global cues, including temperature, light, or pH. Here we demonstrate that specific DNA molecules can induce 100-fold volumetric hydrogel expansion by successive extension of cross-links. We photopattern up to centimeter-sized gels containing multiple domains that undergo different shape changes in response to different DNA sequences. Experiments and simulations suggest a simple design rule for controlled shape change. Because DNA molecules can be coupled to molecular sensors, amplifiers, and logic circuits, this strategy introduces the possibility of building soft devices that respond to diverse biochemical inputs and autonomously implement chemical control programs.	[Cangialosi, Angelo; Huang, Qi; Gracias, David H.; Schulman, Rebecca] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Yoon, ChangKyu; Nguyen, Thao D.; Gracias, David H.] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; [Liu, Jiayu; Guo, Jingkai; Nguyen, Thao D.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; [Schulman, Rebecca] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Gracias, DH; Schulman, R (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.; Gracias, DH (corresponding author), Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA.; Schulman, R (corresponding author), Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.	dgracias@jhu.edu; rschulm3@jhu.edu	Gracias, David/A-1942-2010; Nguyen, Thao/A-3391-2010	Gracias, David/0000-0003-2735-4725; Schulman, Rebecca/0000-0003-4555-3162; Nguyen, Thao/0000-0002-0312-1583; Yoon, ChangKyu/0000-0003-3716-4853	U.S. Army Research Office [W911NF-15-1-0490]; U.S. Department of Energy [221874]	U.S. Army Research Office; U.S. Department of Energy(United States Department of Energy (DOE))	We thank D. Scalise, J. Fern, J. Zenk, H. R. Kwag, A. M. Mohammed, D. Wirtz, and M. McCaffrey for discussions and technical assistance. We acknowledge funding from U.S. Army Research Office award W911NF-15-1-0490 and U.S. Department of Energy award 221874 for some materials characterization. All data are included in the article and supplementary materials. We declare no conflict of interest.	ALON U, 2006, INTRO SYSTEMS BIOL; Flory PJ, 1943, J CHEM PHYS, V11, P512, DOI 10.1063/1.1723791; Freund LB, 1999, APPL PHYS LETT, V74, P1987, DOI 10.1063/1.123722; Gracias DH, 2013, CURR OPIN CHEM ENG, V2, P112, DOI 10.1016/j.coche.2012.10.003; Hawkes E, 2010, P NATL ACAD SCI USA, V107, P12441, DOI 10.1073/pnas.0914069107; Hu YW, 2016, J AM CHEM SOC, V138, P16112, DOI 10.1021/jacs.6b10458; Huang FJ, 2015, SMALL, V11, P5800, DOI 10.1002/smll.201501826; Ikeda M, 2014, NAT CHEM, V6, P511, DOI [10.1038/NCHEM.1937, 10.1038/nchem.1937]; Ilievski F, 2011, ANGEW CHEM INT EDIT, V50, P1890, DOI 10.1002/anie.201006464; Jeon SJ, 2017, ACCOUNTS CHEM RES, V50, P161, DOI 10.1021/acs.accounts.6b00570; Kahn JS, 2017, ACCOUNTS CHEM RES, V50, P680, DOI 10.1021/acs.accounts.6b00542; Kim Y, 2016, SCIENCE, V351, P579, DOI 10.1126/science.aad2212; Liedl T, 2007, SMALL, V3, P1688, DOI 10.1002/smll.200700366; Lin DC, 2005, J MATER RES, V20, P1456, DOI 10.1557/JMR.2005.0186; Liu Y, 2012, SOFT MATTER, V8, P1764, DOI 10.1039/c1sm06564e; Maye MM, 2010, NAT NANOTECHNOL, V5, P116, DOI [10.1038/NNANO.2009.378, 10.1038/nnano.2009.378]; Murakami Y, 2005, BIOMACROMOLECULES, V6, P2927, DOI 10.1021/bm0504330; Nagahara S, 1996, POLYM GELS NETW, V4, P111, DOI 10.1016/0966-7822(96)00001-9; Postma SGJ, 2017, ANGEW CHEM INT EDIT, V56, P1794, DOI 10.1002/anie.201610875; Qian L, 2011, SCIENCE, V332, P1196, DOI 10.1126/science.1200520; Rus D, 2015, NATURE, V521, P467, DOI 10.1038/nature14543; Shim TS, 2017, NAT NANOTECHNOL, V12, P41, DOI [10.1038/NNANO.2016.192, 10.1038/nnano.2016.192]; Venkataraman S, 2007, NAT NANOTECHNOL, V2, P490, DOI 10.1038/nnano.2007.225; Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a; Zarzar LD, 2014, ACCOUNTS CHEM RES, V47, P530, DOI 10.1021/ar4001923; Zhang DY, 2011, NAT CHEM, V3, P103, DOI 10.1038/NCHEM.957; ZHANG Y, 2006, J APPL PHYS, V99, DOI DOI 10.1063/1.2178400; Zhang YG, 2015, NAT MATER, V14, P840, DOI [10.1038/nmat4296, 10.1038/NMAT4296]; Zhou WZ, 2014, ANALYST, V139, P2627, DOI 10.1039/c4an00132j	29	236	245	33	416	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	2017	357	6356					1126	1129		10.1126/science.aan3925	http://dx.doi.org/10.1126/science.aan3925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG7XX	28912239				2023-01-03	WOS:000410639800038
J	Piotrowski, JS; Li, SC; Deshpande, R; Simpkins, SW; Nelson, J; Yashiroda, Y; Barber, JM; Safizadeh, H; Wilson, E; Okada, H; Gebre, AA; Kubo, K; Torres, NP; LeBlanc, MA; Andrusiak, K; Okamoto, R; Yoshimura, M; DeRango-Adem, E; Van Leeuwen, J; Shirahige, K; Baryshnikova, A; Brown, GW; Hirano, H; Costanzo, M; Andrews, B; Ohya, Y; Osada, H; Yoshida, M; Myers, CL; Boone, C				Piotrowski, Jeff S.; Li, Sheena C.; Deshpande, Raamesh; Simpkins, Scott W.; Nelson, Justin; Yashiroda, Yoko; Barber, Jacqueline M.; Safizadeh, Hamid; Wilson, Erin; Okada, Hiroki; Gebre, Abraham A.; Kubo, Karen; Torres, Nikko P.; LeBlanc, Marissa A.; Andrusiak, Kerry; Okamoto, Reika; Yoshimura, Mami; DeRango-Adem, Eva; Van Leeuwen, Jolanda; Shirahige, Katsuhiko; Baryshnikova, Anastasia; Brown, Grant W.; Hirano, Hiroyuki; Costanzo, Michael; Andrews, Brenda; Ohya, Yoshikazu; Osada, Hiroyuki; Yoshida, Minoru; Myers, Chad L.; Boone, Charles			Functional annotation of chemical libraries across diverse biological processes	NATURE CHEMICAL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; DRUG DISCOVERY; IN-VITRO; BIOACTIVE COMPOUNDS; O-DEMETHYLATION; HIGH-THROUGHPUT; SMALL MOLECULES; BUDDING YEAST; CELL-CYCLE; BLEOMYCIN	Chemical-genetic approaches offer the potential for unbiased functional annotation of chemical libraries. Mutations can alter the response of cells in the presence of a compound, revealing chemical-genetic interactions that can elucidate a compound's mode of action. We developed a highly parallel, unbiased yeast chemical-genetic screening system involving three key components. First, in a drug-sensitive genetic background, we constructed an optimized diagnostic mutant collection that is predictive for all major yeast biological processes. Second, we implemented a multiplexed (768-plex) barcode-sequencing protocol, enabling the assembly of thousands of chemical-genetic profiles. Finally, based on comparison of the chemical-genetic profiles with a compendium of genome-wide genetic interaction profiles, we predicted compound functionality. Applying this high-throughput approach, we screened seven different compound libraries and annotated their functional diversity. We further validated biological process predictions, prioritized a diverse set of compounds, and identified compounds that appear to have dual modes of action.	[Piotrowski, Jeff S.; Li, Sheena C.; Yashiroda, Yoko; Barber, Jacqueline M.; LeBlanc, Marissa A.; Okamoto, Reika; Yoshimura, Mami; Hirano, Hiroyuki; Osada, Hiroyuki; Yoshida, Minoru; Boone, Charles] RIKEN, Ctr Sustainable Resource Sci, Wako, Saitama, Japan; [Deshpande, Raamesh; Safizadeh, Hamid; Wilson, Erin; Myers, Chad L.] Univ Minnesota Twin Cities, Dept Comp Sci & Engn, Minneapolis, MN USA; [Simpkins, Scott W.; Nelson, Justin; Myers, Chad L.] Univ Minnesota Twin Cities, Bioinformat & Computat Biol Program, Minneapolis, MN USA; [Safizadeh, Hamid] Univ Minnesota Twin Cities, Dept Elect & Comp Engn, Minneapolis, MN USA; [Okada, Hiroki; Gebre, Abraham A.; Kubo, Karen; Ohya, Yoshikazu] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba, Japan; [Torres, Nikko P.; Andrusiak, Kerry; DeRango-Adem, Eva; Van Leeuwen, Jolanda; Brown, Grant W.; Costanzo, Michael; Andrews, Brenda; Boone, Charles] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Shirahige, Katsuhiko] Univ Tokyo, Inst Mol & Cellular Biosci, Ctr Epigenet Dis, Bunkyo Ku, Tokyo, Japan; [Baryshnikova, Anastasia] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Brown, Grant W.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Piotrowski, Jeff S.] Yuman Therapeut, Cambridge, MA USA; [Baryshnikova, Anastasia] Calico Life Sci, San Francisco, CA USA	RIKEN; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Tokyo; University of Toronto; University of Tokyo; Princeton University; University of Toronto	Osada, H; Yoshida, M; Boone, C (corresponding author), RIKEN, Ctr Sustainable Resource Sci, Wako, Saitama, Japan.; Myers, CL (corresponding author), Univ Minnesota Twin Cities, Dept Comp Sci & Engn, Minneapolis, MN USA.; Myers, CL (corresponding author), Univ Minnesota Twin Cities, Bioinformat & Computat Biol Program, Minneapolis, MN USA.; Boone, C (corresponding author), Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.	hisyo@riken.jp; yoshidam@riken.jp; chadm@umn.edu; charlie.boone@utoronto.ca	Osada, Hiroyuki/AAY-6254-2020; Hirano, Hiroyuki/C-7496-2017; Ohya, Yoshikazu/AAW-2200-2021; Osada, Hiroyuki/N-4305-2014; Yoshida, Minoru/C-8049-2014; Li, Sheena/C-9298-2017	Hirano, Hiroyuki/0000-0002-0761-5548; Ohya, Yoshikazu/0000-0003-0837-1239; Yoshida, Minoru/0000-0002-4376-5674; Brown, Grant/0000-0002-9002-5003; Simpkins, Scott/0000-0002-5997-2838; Li, Sheena/0000-0002-5759-8117; Shirahige, Katsuhiko/0000-0002-7862-1144; van Leeuwen, Jolanda/0000-0003-3991-518X; Okada, Hiroki/0000-0001-8428-2559	RIKEN Strategic Programs for RD; RIKEN Foreign Postdoctoral Fellowship; NSF Graduate Research Fellowship [00039202]; NIH Biotechnology training grant [T32GM008347]; University of Minnesota; National Institutes of Health [1R01HG005084-01A1, 1R01GM104975-01, R01HG005853]; National Science Foundation [DBI 0953881]; JSPS KAKENHI Grant [15H04483, 15H04402, 26221204]; Canadian Institutes of Health Research [FDN-143264, FDN-143265]; Canadian Institute for Advanced Research Genetic Networks Program; Ministry of Education, Culture, Sports, Science and Technology, Japan [24370002]; Lewis Sigler fellowship at Princeton University; Canadian Cancer Society Research Institute impact grant [702310]; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST); NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG005084, R01HG005853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008347, R01GM104975] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [17H06411, 15H05976, 15H04402] Funding Source: KAKEN	RIKEN Strategic Programs for RD; RIKEN Foreign Postdoctoral Fellowship; NSF Graduate Research Fellowship(National Science Foundation (NSF)); NIH Biotechnology training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Minnesota(University of Minnesota System); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Institute for Advanced Research Genetic Networks Program; Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Lewis Sigler fellowship at Princeton University; Canadian Cancer Society Research Institute impact grant; Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by RIKEN Strategic Programs for R&D. J.S.P. and S.C.L. were funded by a RIKEN Foreign Postdoctoral Fellowship. S.W.S. is supported by an NSF Graduate Research Fellowship (00039202), an NIH Biotechnology training grant (T32GM008347), and a one-year BICB fellowship from the University of Minnesota. H.O. is a research fellow of the Japan Society for the Promotion of Science (JSPS). R.D., J.N., E.W., and C.L.M. are supported by National Institutes of Health Grants 1R01HG005084-01A1, 1R01GM104975-01, and R01HG005853 and National Science Foundation Grant DBI 0953881. C.B. and Y.O. are supported by JSPS KAKENHI Grant Numbers 15H04483. C.B. and B.A. were supported by the Canadian Institutes of Health Research, grants FDN-143264 and FDN-143265, respectively. C.L.M., C.B., M.C., J.L., and B.A. are supported by the Canadian Institute for Advanced Research Genetic Networks Program. Y.O. is supported by Ministry of Education, Culture, Sports, Science and Technology, Japan Grant for Scientific Research 24370002 and JSPS KAKENHI Grant Numbers 15H04402. M. Yoshida is supported by JSPS KAKENHI Grant Number 26221204. A.B. is supported by a Lewis Sigler fellowship at Princeton University. G.W.B. and N.P.T. are supported by Canadian Cancer Society Research Institute impact grant 702310. K.S. is supported by The Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST). We thank Astellas Pharma, Inc. (Tokyo, Japan) for their kind gift of micafungin. We thank T. Saito for help with NPDepo compound access. Sequencing was provided by RIKEN Center for Life Science Technologies, Division of Genomic Technologies, Genome Network Analysis Support Facility (GeNAS) RIKEN CLST and the University of Chicago.	Abdel-Rahman SM, 1999, DRUG METAB DISPOS, V27, P770; Andrusiak K, 2012, THESIS; Bamford MJ, 2005, BIOORG MED CHEM LETT, V15, P3402, DOI 10.1016/j.bmcl.2005.05.021; Baryshnikova A, 2016, CELL SYST, V2, P412, DOI 10.1016/j.cels.2016.04.014; Bokulich NA, 2013, NAT METHODS, V10, P57, DOI [10.1038/nmeth.2276, 10.1038/NMETH.2276]; Borgelt C., 2005, P 1 INT WORKSHOP OPE, P6, DOI DOI 10.1145/1133905.1133908; Clemons PA, 2004, CURR OPIN CHEM BIOL, V8, P334, DOI 10.1016/j.cbpa.2004.04.002; Costanzo M, 2016, SCIENCE, V353, DOI 10.1126/science.aaf1420; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; Dalke A., 2008, CHEM CENT J, V2, DOI DOI 10.1186/1752-153X-2-5; Deshpande R., 2017, EFFICIENT STRATEGIES; Desta Z, 2000, DRUG METAB DISPOS, V28, P789; Disbrow GL, 2005, CANCER RES, V65, P10854, DOI 10.1158/0008-5472.CAN-05-1216; Dranchak P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057888; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; EKIMOTO H, 1985, J ANTIBIOT, V38, P1077, DOI 10.7164/antibiotics.38.1077; Geysen HM, 2003, NAT REV DRUG DISCOV, V2, P222, DOI 10.1038/nrd10335; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goodrich SK, 2014, FUTURE ONCOL, V10, P647, DOI [10.2217/FON.13.228, 10.2217/fon.13.228]; Grollman A P, 1980, Adv Enzyme Regul, V18, P67, DOI 10.1016/0065-2571(80)90009-6; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; HAY J, 1991, ARCH TOXICOL, V65, P81, DOI 10.1007/BF02034932; Hoepfner D, 2014, MICROBIOL RES, V169, P107, DOI 10.1016/j.micres.2013.11.004; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jeong S, 2009, ANTIMICROB AGENTS CH, V53, P541, DOI 10.1128/AAC.01123-08; KANOFSKY JR, 1986, J BIOL CHEM, V261, P3546; Kato N, 2012, CURR OPIN CHEM BIOL, V16, P101, DOI 10.1016/j.cbpa.2012.02.016; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Koh JLY, 2015, G3-GENES GENOM GENET, V5, P1223, DOI 10.1534/g3.115.017830; Laugesen S, 2005, CLIN PHARMACOL THER, V77, P312, DOI 10.1016/j.clpt.2004.11.002; Lee AY, 2014, SCIENCE, V344, P208, DOI 10.1126/science.1250217; Li W, 2005, PLOS GENET, V1, P329, DOI 10.1371/journal.pgen.0010036; Li Y, 2001, BIOORG MED CHEM LETT, V11, P5, DOI 10.1016/S0960-894X(00)00578-3; Mahe Y, 1996, J BIOL CHEM, V271, P25167, DOI 10.1074/jbc.271.41.25167; Medina-Franco JL, 2013, DRUG DISCOV TODAY, V18, P495, DOI 10.1016/j.drudis.2013.01.008; MOORE CW, 1992, ANTIMICROB AGENTS CH, V36, P2497, DOI 10.1128/AAC.36.11.2497; Myers CL, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-187; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; O'Neill PM, 2010, MOLECULES, V15, P1705, DOI 10.3390/molecules15031705; Ohya Y, 2005, P NATL ACAD SCI USA, V102, P19015, DOI 10.1073/pnas.0509436102; Okada H, 2014, MOL BIOL CELL, V25, P222, DOI 10.1091/mbc.E13-07-0396; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Parsons AB, 2006, CELL, V126, P611, DOI 10.1016/j.cell.2006.06.040; Peters JU, 2009, CHEMMEDCHEM, V4, P680, DOI 10.1002/cmdc.200800411; Piotrowski JS, 2015, P NATL ACAD SCI USA, V112, pE1490, DOI 10.1073/pnas.1410400112; PODDEVIN B, 1991, BIOCHEM PHARMACOL, V42, pS67, DOI 10.1016/0006-2952(91)90394-K; Roemer T, 2013, NAT CHEM BIOL, V9, P222, DOI [10.1038/NCHEMBIO.1205, 10.1038/nchembio.1205]; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Sidorova JM, 2003, MUTAT RES-FUND MOL M, V532, P5, DOI 10.1016/j.mrfmmm.2003.08.006; Smith AM, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq368; Steinbeck C, 2003, J CHEM INF COMP SCI, V43, P493, DOI 10.1021/ci025584y; Steinbrueck Lisa, 2010, Cancer Genomics & Proteomics, V7, P337; SUN IL, 1985, BIOCHEM PHARMACOL, V34, P617, DOI 10.1016/0006-2952(85)90254-0; Sundberg SA, 2000, CURR OPIN BIOTECH, V11, P47, DOI 10.1016/S0958-1669(99)00051-8; Vancutsem PM, 1996, VET HUM TOXICOL, V38, P254; Wang XT, 2013, GENOME BIOL EVOL, V5, P1291, DOI 10.1093/gbe/evt092; Xia WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088983; Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707; Yu L, 2006, MOL BIOL CELL, V17, P4736, DOI 10.1091/mbc.E06-04-0368	60	55	55	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2017	13	9					982	+		10.1038/NCHEMBIO.2436	http://dx.doi.org/10.1038/NCHEMBIO.2436			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE0SK	28759014	Green Accepted, Green Submitted			2023-01-03	WOS:000407929800015
J	Lostao, L; Geyer, S; Albaladejo, R; Moreno-Lostao, A; Santos, JM; Regidor, E				Lostao, Lourdes; Geyer, Siegfried; Albaladejo, Romana; Moreno-Lostao, Almudena; Santos, Juana M.; Regidor, Enrique			Socioeconomic position and health services use in Germany and Spain during the Great Recession	PLOS ONE			English	Article							ECONOMIC-CRISIS; MEDICAL-CARE; COUNTRIES; REFORMS; INCOME	Objective The relationship of socioeconomic position with the use of health services may have changed with the emergence of the economic crisis. This study shows that relationship before and during the economic crisis, in Germany and in Spain. Methods Data from the 2006 and 2011 Socio-Economic Panel carried out in Germany, and from the 2006 and 2011 National Health Surveys carried out in Spain were used. The health services investigated were physician consultations and hospitalization. The measures of socioeconomic position used were education and household income. The magnitude of the relationship between socioeconomic position and the use of each health services was estimated by calculating the percentage ratio by binary regression. Results In Germany, in both periods, after adjusting for age, sex, type of health insurance and need for care, subjects belonging to the lower educational categories had a lower frequency of physician consultations, while those belonging to the lower income categories had a higher frequency of hospitalization. In the model comparing the two lower socioeconomic categories to the two higher categories, the percentage ratio for physician consultation by education was 0.97 (95% CI 0.96-0.98) in 2006 and 0.96 (95% CI 0.95-0.97) in 2011, and the percentage ratio for hospitalization by income was 1.14 (95% CI 1.05-1.25) in 2006 and 1.12 (95% CI 1.03-1.21) in 2011. In Spain, no significant socioeconomic differences were observed in either period in the frequency of use of these health services in the fully adjusted model. Conclusion The results suggest that the economic crisis did not alter accessibility to the health system in either country, given that the socioeconomic pattern in the use of these health services was similar before and during the crisis in both countries.	[Lostao, Lourdes] Univ Publ Navarra, Med Sociol, Dept Sociol, Pamplona, Spain; [Geyer, Siegfried] Hannover Med Sch, Med Sociol Unit, Hannover, Germany; [Albaladejo, Romana; Santos, Juana M.; Regidor, Enrique] Univ Complutense Madrid, Dept Prevent Med & Publ Hlth, Madrid, Spain; [Moreno-Lostao, Almudena; Santos, Juana M.; Regidor, Enrique] Univ Navarra, Pamplona, Spain; [Santos, Juana M.; Regidor, Enrique] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain; [Regidor, Enrique] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, Madrid, Spain	Universidad Publica de Navarra; Hannover Medical School; Complutense University of Madrid; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Hospital Clinico San Carlos	Lostao, L (corresponding author), Univ Publ Navarra, Med Sociol, Dept Sociol, Pamplona, Spain.	llostao@unavarra.es	Lostao, Lourdes/ABH-2196-2020; Moreno, Almudena/AAZ-1141-2020	Lostao, Lourdes/0000-0003-0891-0685; 	Ministerio de Economia y Competividad (ES) [CSO2013-40877-P]	Ministerio de Economia y Competividad (ES)	This work was supported by the Ministerio de Economia y Competividad (ES), www.mineco.gob.es, no. CSO2013-40877-P.	Cylus J, 2012, HEALTH SERV RES, V47, P2204, DOI 10.1111/j.1475-6773.2012.01428.x; Dubois H, IMPACTS CRISIS ACCES; Eurostat, DAT SOC COND HLTH CA; Geyer S, 2002, J EPIDEMIOL COMMUN H, V56, P109, DOI 10.1136/jech.56.2.109; Giovanella L, 2014, CAD SAUDE PUBLICA, V30, P2263, DOI 10.1590/0102-311X00021314; Gruber S, 2010, J PUBLIC HEALTH-HEID, V18, P351, DOI 10.1007/s10389-010-0321-2; Haisken-DeNew J.P., 2005, DTC DESKTOP COMPANIO; Hoebel J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155982; Instituto Nacional de Estad o A stica. Society, HLTH NAT HLTH SURV; Karanikolos M, 2013, LANCET, V381, P1323, DOI 10.1016/S0140-6736(13)60102-6; Kroll LE, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-271; Lostao L, 2011, HEALTH PLACE, V17, P830, DOI 10.1016/j.healthplace.2011.03.006; Lusardi A, 2015, SOC SCI QUART, V96, P202, DOI 10.1111/ssqu.12076; Mladovsky P., 2012, HLTH POLICY RESPONSE; Morris S, 2005, SOC SCI MED, V60, P1251, DOI 10.1016/j.socscimed.2004.07.016; OECD, 1982, OECD LIST SOC IND; OECD, 2013, HLTH GLANC 2013 OECD, DOI [10.1787/health_glance-2013-49-en, DOI 10.1787/HEALTH_GLANCE-2013-49-EN]; Organization for Economic Co-Operation and Development (OECD), OECD STAT HLTH CAR U; Quesnel-Vallee A, 2007, INT J EPIDEMIOL, V36, P1161, DOI 10.1093/ije/dym236; Regidor E, 2014, J EPIDEMIOL COMMUN H, V68, P280, DOI 10.1136/jech-2013-202944; Regidor E, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-183; Regidor Enrique, 2006, Gac Sanit, V20, P352, DOI 10.1157/13093202; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; Ruckert IM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-232; Stirbu I, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-288; Sutton M, 2002, ALLOCATION RESOURCES; Van der Heyden JHA, 2003, HEALTH POLICY, V65, P153, DOI 10.1016/S0168-8510(02)00213-0; van Doorslaer E, 2006, CAN MED ASSOC J, V174, P177, DOI 10.1503/cmaj.050584; Van Doorslaer E, 2004, 14 OECD; *WHO, EUR HLTH ALL DAT HFA; World Bank, DATA; World Health Organization, EUR HLTH ALL DAT PUB	32	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2017	12	8							e0183325	10.1371/journal.pone.0183325	http://dx.doi.org/10.1371/journal.pone.0183325			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FF1XX	28854226	Green Published, gold, Green Submitted			2023-01-03	WOS:000408693600037
J	Baker, M				Baker, Monya			CHECK YOUR CHEMISTRY	NATURE			English	Editorial Material							DISCOVERY; INHIBITOR											Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a; Bisson J, 2016, J MED CHEM, V59, P1671, DOI 10.1021/acs.jmedchem.5b01009; Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306; Davis BJ, 2013, BIOORG MED CHEM LETT, V23, P2844, DOI 10.1016/j.bmcl.2013.03.028; Greco GE, 2016, DNA REPAIR, V43, P18, DOI 10.1016/j.dnarep.2016.04.004; Hermann JC, 2013, ACS MED CHEM LETT, V4, P197, DOI 10.1021/ml3003296; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Irwin JJ, 2015, J MED CHEM, V58, P7076, DOI 10.1021/acs.jmedchem.5b01105; Levinson NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029828; Shortt J, 2014, CELL REP, V7, P1009, DOI 10.1016/j.celrep.2014.04.008; Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054	12	11	11	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	2017	548	7668					485	488		10.1038/548485a	http://dx.doi.org/10.1038/548485a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE5VI	28836600	Bronze			2023-01-03	WOS:000408279000045
J	Bernard, G				Bernard, Gordon			HISTORY OF MEDICINE Acute Lung Failure - Our Evolving Understanding of ARDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OUTCOMES		[Bernard, Gordon] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA	Vanderbilt University	Bernard, G (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.							BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; The ARDS Definition Task Force, 2012, JAMA, V307, P2526	5	14	14	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2017	377	6					507	509		10.1056/NEJMp1706595	http://dx.doi.org/10.1056/NEJMp1706595			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD0EM	28792872				2023-01-03	WOS:000407212600002
J	McDaid, A; Logette, E; Buchillier, V; Muriset, M; Suchon, P; Pache, TD; Tanackovic, G; Kutalik, Z; Michaud, J				McDaid, Aaron; Logette, Emmanuelle; Buchillier, Valerie; Muriset, Maude; Suchon, Pierre; Pache, Thierry Daniel; Tanackovic, Goranka; Kutalik, Zoltan; Michaud, Joelle			Risk prediction of developing venous thrombosis in combined oral contraceptive users	PLOS ONE			English	Article							ASSOCIATION; THROMBOEMBOLISM; SUSCEPTIBILITY; VARIANTS; MIGRAINE; GENETICS; UPDATE	Background Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. Methods and findings Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69-0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. Conclusion We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use.	[McDaid, Aaron; Kutalik, Zoltan] Univ Hosp Lausanne, Inst Social & Prevent Med, Lausanne, Switzerland; [McDaid, Aaron; Kutalik, Zoltan] SIB, Lausanne, Switzerland; [Logette, Emmanuelle; Buchillier, Valerie; Muriset, Maude; Pache, Thierry Daniel; Tanackovic, Goranka; Michaud, Joelle] Gene Predictis SA, EPFL Innovat Pk, CH-1015 Lausanne, Switzerland; [Suchon, Pierre] Alx Marseille Univ, INSERM, INRA, NORT, Marseille, France; [Suchon, Pierre] Hop la Timone, AP HM, Serv Hematol Biol, Marseille, France	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute of Bioinformatics; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Michaud, J (corresponding author), Gene Predictis SA, EPFL Innovat Pk, CH-1015 Lausanne, Switzerland.	jam@genepredictis.com	Colaus, PsyColaus/K-6607-2013; Kutalik, Zoltan/HHZ-5697-2022	Kutalik, Zoltan/0000-0001-8285-7523; Suchon, Pierre/0000-0001-8845-9163	Canton de Vaud, Service de promotion economique et du commerce; Gene Predictis SA	Canton de Vaud, Service de promotion economique et du commerce; Gene Predictis SA	This study was funded by Canton de Vaud, Service de promotion economique et du commerce (https://www.vd.ch/themes/economie/developpement-econornique/prornotioneconomique/): EL, VB, MM, GT, JM. This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. It was also funded by Gene Predictis SA: AM, ZK. Authors EL, VB, MM, GT and JM are employed by Gene Predictis SA. TDP is President of the Board of directors of Gene Predictis SA. Gene Predictis SA provided support in the form of salaries for authors (EL, VB, MM, GT and JM) but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	[Anonymous], 2011, INT J GYNECOL OBSTET, V112, P252, DOI 10.1016/j.ijgo.2010.12.003; Anttila V, 2013, NAT GENET, V45, P912, DOI 10.1038/ng.2676; Auton A., 2015, NATURE, V7571, P68, DOI [10.1038/nature15393, DOI 10.1038/NATURE15393]; Bruzelius M, 2015, J THROMB HAEMOST, V13, P219, DOI 10.1111/jth.12808; Cushman Mary, 2005, Hematology Am Soc Hematol Educ Program, P452; de Haan HG, 2012, BLOOD, V120, P656, DOI 10.1182/blood-2011-12-397752; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Firmann M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-6; Heit JA, 2012, J THROMB HAEMOST, V10, P1521, DOI 10.1111/j.1538-7836.2012.04810.x; Kutalik Z, 2011, BIOSTATISTICS, V12, P1, DOI 10.1093/biostatistics/kxq039; Li Y, 2009, J THROMB HAEMOST, V7, P1802, DOI 10.1111/j.1538-7836.2009.03544.x; Millar DS, 2000, HUM GENET, V106, P646, DOI 10.1007/s004390050038; Morange PE, 2015, THROMB HAEMOSTASIS, V114, P910, DOI 10.1160/TH15-05-0410; Morange PE, 2011, BLOOD, V117, P3692, DOI 10.1182/blood-2010-11-319053; Peng KP, 2016, HEADACHE, V56, P1290, DOI 10.1111/head.12885; Rosendaal FR, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0108-y; Rosendaal FR, 2009, J THROMB HAEMOST, V7, P301, DOI 10.1111/j.1538-7836.2009.03394.x; Sacco S, 2015, CEPHALALGIA, V35, P146, DOI 10.1177/0333102414559551; Saposnik B, 2004, BLOOD, V103, P1311, DOI 10.1182/blood-2003-07-2520; Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607; Suchon P, 2017, CLIN GENET, V91, P131, DOI 10.1111/cge.12833; Suchon P, 2016, THROMB HAEMOSTASIS, V115, P135, DOI 10.1160/TH15-01-0045; Vinogradova Y, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2135; Wang B, 2004, DRUG METAB DISPOS, V32, P1209, DOI 10.1124/dmd.104.000182	24	18	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							e0182041	10.1371/journal.pone.0182041	http://dx.doi.org/10.1371/journal.pone.0182041			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1CT	28750087	Green Published, gold, Green Submitted			2023-01-03	WOS:000406575700120
J	Banshodani, M; Kawanishi, H; Fukuma, S; Moriishi, M; Shintaku, S; Tsuchiya, S				Banshodani, Masataka; Kawanishi, Hideki; Fukuma, Shingo; Moriishi, Misaki; Shintaku, Sadanori; Tsuchiya, Shinichiro			The impact of hemodialysis schedules on the day of the week of hospitalization for cardiovascular and infectious diseases, over a period of 20 years	PLOS ONE			English	Article							GENERALIZED ESTIMATING EQUATIONS; NOCTURNAL HEMODIALYSIS; CONVENTIONAL HEMODIALYSIS; INTERDIALYTIC INTERVALS; FREQUENT HEMODIALYSIS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; BLOOD-PRESSURE; HEART-RATE; LONG-TERM	There have been no studies as yet that have evaluated how hemodialysis (HD) schedules affect the day of the week of hospitalization for cardiovascular diseases (CVDs) and infectious diseases (IDs), over a period of time. Herein, we performed a retrospective observational cohort study (1995 -2014) evaluating 11,111 hospitalizations in 1,953 patients with end-stage renal disease, receiving HD 3 times a week (following either a Monday-Wednesday-Friday [MWF] schedule or a Tuesday-Thursday-Saturday [TTS] schedule) or receiving frequent HD (FHD) at least 4 times a week. Overall, hospitalization rates for CVDs and IDs were the highest on Monday in the MWF schedule and Tuesday in the TTS schedule compared to the average rates for all the days of the week. When generalized estimating equations (GEEs) were used in conjunction with robust variance estimators of each type of CVD, the risk for pulmonary edema was found to be significantly higher on Sunday and Monday in the MWF schedule and Monday and Tuesday in the TTS schedule. For both cerebrovascular and ischemic heart disease, the risks were significantly higher on Tuesday in the MWF schedule and Wednesday in the TTS schedule. Moreover, there were significant differences in the day of the week risks among the various CVD types. On trend analysis, the overall hospitalization rate for CVDs on the first HD day did not decrease (P = 0.2); however, the hospitalization rate for IDs on the first HD day significantly decreased (P = 0.02) over a span of 20 years. When GEEs were used in the case of FHD patients with severe heart failure, the hospitalization rate on the first HD day (Monday) significantly decreased after FHD initiation (P = 0.04). It was found that HD schedules affected the day of the week of hospitalization for CVDs. FHD may lower the day of the week risk.	[Banshodani, Masataka; Kawanishi, Hideki; Moriishi, Misaki; Shintaku, Sadanori; Tsuchiya, Shinichiro] Tsuchiya Gen Hosp, Akane Fdn, Dept Artificial Organs, Hiroshima, Japan; [Kawanishi, Hideki] Hiroshima Univ, Fac Med, Hiroshima, Japan; [Fukuma, Shingo] Kyoto Univ, Grad Sch Med, Human Hlth Sci, Kyoto, Japan	Hiroshima University; Kyoto University	Kawanishi, H (corresponding author), Tsuchiya Gen Hosp, Akane Fdn, Dept Artificial Organs, Hiroshima, Japan.; Kawanishi, H (corresponding author), Hiroshima Univ, Fac Med, Hiroshima, Japan.	h-kawanishi@tsuchiya-hp.jp		Fukuma, Shingo/0000-0002-8379-8761				Bleyer AJ, 2006, KIDNEY INT, V69, P2268, DOI 10.1038/sj.ki.5000446; Bleyer AJ, 1999, KIDNEY INT, V55, P1553, DOI 10.1046/j.1523-1755.1999.00391.x; Bonomini V, 1972, Proc Eur Dial Transplant Assoc, V9, P44; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; Chan C, 2002, NEPHROL DIAL TRANSPL, V17, P1518, DOI 10.1093/ndt/17.8.1518; Chan CT, 2014, NEPHROL DIAL TRANSPL, V29, P168, DOI 10.1093/ndt/gft212; Chan CT, 2013, CLIN J AM SOC NEPHRO, V8, P2106, DOI 10.2215/CJN.03280313; Chan CT, 2005, KIDNEY INT, V68, P338, DOI 10.1111/j.1523-1755.2005.00411.x; Chan CT, 2004, KIDNEY INT, V65, P661, DOI 10.1111/j.1523-1755.2004.00384.x; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Collins AJ, 2015, KIDNEY INT SUPPL, V5, P2, DOI 10.1038/kisup.2015.2; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Dalrymple LS, 2010, AM J KIDNEY DIS, V56, P522, DOI 10.1053/j.ajkd.2010.04.016; Flythe JE, 2011, KIDNEY INT, V79, P250, DOI 10.1038/ki.2010.383; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Foley RN, 2011, NEW ENGL J MED, V365, P1099, DOI 10.1056/NEJMoa1103313; Fotheringham J, 2015, KIDNEY INT, V88, P569, DOI 10.1038/ki.2015.141; Hanafusa N, 2011, KIDNEY INT S, V5, P15; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Johansen KL, 2009, KIDNEY INT, V76, P984, DOI 10.1038/ki.2009.291; KALANTARZADEH K, 2009, CIRCULATION, V119, P671, DOI [DOI 10.1097/01.ASN.0000043141.67989.39, DOI 10.1161/CIRCULATI0NAHA.108.807362]; Kjellstrand CM, 1978, KIDNEY INT S, pS120; Krishnasamy R, 2013, AM J KIDNEY DIS, V61, P96, DOI 10.1053/j.ajkd.2012.07.008; Liu FJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169203; Obokata M, 2015, AM HEART J, V169, P523, DOI 10.1016/j.ahj.2015.02.003; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Susantitaphong P, 2012, AM J KIDNEY DIS, V59, P689, DOI 10.1053/j.ajkd.2011.12.020; TESCHAN PE, 1960, ANN INTERN MED, V53, P992, DOI 10.7326/0003-4819-53-5-992; Ting GO, 2003, AM J KIDNEY DIS, V42, P1020, DOI 10.1016/j.ajkd.2003.07.020; Tsilonis K, 2016, AM J KIDNEY DIS, V68, P772, DOI 10.1053/j.ajkd.2016.06.017; Wong MMY, 2017, AM J KIDNEY DIS, V69, P367, DOI 10.1053/j.ajkd.2016.08.030; Woods JD, 1999, KIDNEY INT, V55, P2467, DOI 10.1046/j.1523-1755.1999.00493.x; Zager PG, 1998, KIDNEY INT, V54, P561, DOI 10.1046/j.1523-1755.1998.00005.x; Zhang H, 2012, KIDNEY INT, V81, P1108, DOI 10.1038/ki.2011.481; Zimmerman DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097135	37	5	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0180577	10.1371/journal.pone.0180577	http://dx.doi.org/10.1371/journal.pone.0180577			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28700621	Green Submitted, gold, Green Published			2023-01-03	WOS:000405544800056
J	Hightow-Weidman, L; LeGrand, S; Choi, SK; Egger, J; Hurt, CB; Muessig, KE				Hightow-Weidman, Lisa; LeGrand, Sara; Choi, Seul Ki; Egger, Joseph; Hurt, Christopher B.; Muessig, Kathryn E.			Exploring the HIV continuum of care among young black MSM	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY USE; MARIJUANA USE; MEDICATION ADHERENCE; INFECTED PATIENTS; SUBSTANCE-ABUSE; UNITED-STATES; WHITE MEN; DRUG-USE; SEX; DISPARITIES	Background HIV disproportionately impacts young, black men who have sex with men (YBMSM) who experience disparities across the HIV care continuum. A more nuanced understanding of facilitators and barriers to engagement in care, missed visits, antiretroviral uptake, adherence and viral suppression could improve care and intervention design. Methods A randomized controlled trial of an online intervention, healthMpowerment, enrolled 465 YBMSM (18-30 years); 193 identified as HIV-positive. Bivariable and multivariable analyses of baseline data explored predictors of: engagement in care, missed visits, antiretroviral uptake, self-reported adherence, and viral suppression. Results Mean age was 24.9 years; most identified as gay (71.0%) and were receiving HIV care (89.1%). Among those in care, 52.1% reported no missed visits in the past 12 months, 41 (24.6%) reported one missed visit, and 39 (23.4%) reported two or more. Having insurance (prevalence odds ratio [POR] 4.5; 95% CI: 1.3, 15.8) and provider self-efficacy (POR 20.1; 95% CI: 6.1, 64.1) were associated with being in care. Those with a college degree (POR 9.1; 95% CI: 1.9, 45.2) and no recent marijuana (POR 2.6; 95% CI: 1.2, 5.6) or methamphetamine use (POR 5.4; 95% CI: 1.0, 28.5) were less likely to miss visits. Most (n = 153, 84.1%) had been prescribed antiretroviral therapy. A majority of participants (70.8%) reported >= 90% adherence; those with depressive symptoms had 4.7 times the odds of reporting adherence <90% (95% CI: 1.65, 13.37). Of participants who reported viral load testing in the past six months, 65% (n = 102) reported an undetectable viral load. Disclosure to sex partners was associated with viral suppression (POR 6.0; 95% CI: 1.6, 22.4). Conclusions Multi-level facilitators and barriers to engagement across the continuum of care were identified in this sample of YBMSM. Understanding the distinct needs of YBMSM at each stage of the continuum and addressing them through tailored approaches is critical for long term success in care.	[Hightow-Weidman, Lisa; Hurt, Christopher B.] Univ North Carolina Chapel Hill, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27599 USA; [LeGrand, Sara; Egger, Joseph] Duke Univ, Duke Global Hlth Inst, Durham, NC USA; [Choi, Seul Ki; Muessig, Kathryn E.] Univ North Carolina Chapel Hill, Gillings Sch Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Hightow-Weidman, L (corresponding author), Univ North Carolina Chapel Hill, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27599 USA.	lisa_hightow@med.unc.edu	Muessig, Kate/P-1242-2018; LeGrand, Sara/AAB-2613-2021	Hightow-Weidman, Lisa/0000-0002-2421-923X; Choi, Seul Ki/0000-0003-0405-7787	NIH [R01MH093275-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069423, P30AI064518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH093275] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	NIH R01MH093275-01	Allshouse AA, 2015, JAIDS-J ACQ IMM DEF, V69, P187, DOI 10.1097/QAI.0000000000000562; [Anonymous], 2016, NSDUH SER H, V51; Berg MB, 2005, AIDS CARE, V17, P902, DOI 10.1080/09540120500101658; Bouris A., 2013, J AIDS CLIN RES, V4; Buttram ME, 2015, J RACIAL ETHN HEALTH, V2, P1, DOI 10.1007/s40615-014-0042-2; Centers for Disease Control and Prevention, 2015, 2013 HIV SURV SUPPL, V20; Centers for Disease Control and Prevention (CDC), 2014, MMWR-MORBID MORTAL W, V63; Chibanda D, 2016, J AFFECT DISORDERS, V198, P50, DOI 10.1016/j.jad.2016.03.006; Conserve DF, 2015, AIDS BEHAV, V19, P1763, DOI 10.1007/s10461-015-1006-1; D'Souza G, 2012, JAIDS-J ACQ IMM DEF, V61, P618, DOI 10.1097/QAI.0b013e318273ab3a; Dyer TP, 2012, J URBAN HEALTH, V89, P697, DOI 10.1007/s11524-012-9674-x; Eaton LA, 2014, SEX HEALTH, V11, P244, DOI 10.1071/SH14022; Edwards M, 2014, J ASSOC NURSE AIDS C, V25, P243, DOI 10.1016/j.jana.2013.05.004; Giordano TP, 2004, HIV CLIN TRIALS, V5, P74, DOI 10.1310/JFXH-G3X2-EYM6-D6UG; Gonzalez JS, 2011, JAIDS-J ACQ IMM DEF, V58, P181, DOI [10.1097/QAI.0B013E31822D490A, 10.1097/QAI.0b013e31822d490a]; Harper GW, 2013, AIDS BEHAV, V17, P213, DOI 10.1007/s10461-011-0071-3; Hausmann LRM, 2011, MED CARE, V49, P626, DOI 10.1097/MLR.0b013e318215d93c; Hendershot CS, 2009, JAIDS-J ACQ IMM DEF, V52, P180, DOI 10.1097/QAI.0b013e3181b18b6e; Hightow-Weidman LB, 2015, HEALTH EDUC BEHAV, V42, P493, DOI 10.1177/1090198114562043; Hightow-Weidman LB, 2011, AIDS EDUC PREV, V23, P1, DOI 10.1521/aeap.2011.23.1.1; Hoots BE, 2017, J INFECT DIS; Howe CJ, 2010, AIDS RES HUM RETROV, V26, P875, DOI 10.1089/aid.2009.0282; Hussen SA, 2015, AIDS PATIENT CARE ST, V29, P77, DOI 10.1089/apc.2014.0117; Kahana SY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151106; Kahana SY, 2015, JAIDS-J ACQ IMM DEF, V68, P169, DOI 10.1097/QAI.0000000000000408; Kalichman SC, 2016, AIDS PATIENT CARE ST, V30, P221, DOI 10.1089/apc.2015.0333; Kapogiannis B, 2015, 8 INT AIDS SOC C HIV; Lubben J, 2006, GERONTOLOGIST, V46, P503, DOI 10.1093/geront/46.4.503; Magnus M, 2010, JAIDS-J ACQ IMM DEF, V53, P529, DOI 10.1097/QAI.0b013e3181b56404; Maksut JL, 2016, J BEHAV MED, V39, P665, DOI 10.1007/s10865-016-9734-x; Malta M, 2010, AIDS BEHAV, V14, P731, DOI 10.1007/s10461-008-9489-7; Markin S, 2016, US UNINSURED RATE 11; Marks G, 2009, AIDS BEHAV, V13, P682, DOI 10.1007/s10461-008-9380-6; Maulsby C, 2014, AIDS BEHAV, V18, P10, DOI 10.1007/s10461-013-0476-2; Maurer DM, 2012, AM FAM PHYSICIAN, V85, P139; Mayer KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087298; Millett GA, 2007, AIDS, V21, P2083, DOI 10.1097/QAD.0b013e3282e9a64b; Millett GA, 2012, LANCET, V380, P341, DOI 10.1016/S0140-6736(12)60899-X; Mimiaga MJ, 2013, AM J PUBLIC HEALTH, V103, P1457, DOI 10.2105/AJPH.2012.301162; Morgan E, 2016, SUBST USE MISUSE, V51, P1751, DOI 10.1080/10826084.2016.1197265; Mugavero MJ, 2014, CLIN INFECT DIS, V59, P1471, DOI 10.1093/cid/ciu603; Mugavero MJ, 2010, AIDS PATIENT CARE ST, V24, P607, DOI 10.1089/apc.2010.0086; Mugavero MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P100, DOI 10.1097/QAI.0b013e31818d5c37; Murphy DA, 2005, ARCH PEDIAT ADOL MED, V159, P764, DOI 10.1001/archpedi.159.8.764; Mustanski B, 2007, ANN BEHAV MED, V34, P37, DOI 10.1007/BF02879919; O'Neil Conar R, 2012, J Int Assoc Physicians AIDS Care (Chic), V11, P134, DOI 10.1177/1545109711423976; Oster AM, 2011, AIDS, V25, P1103, DOI 10.1097/QAD.0b013e3283471efa; Pence BW, 2005, JAIDS-J ACQ IMM DEF, V40, P434, DOI 10.1097/01.qai.0000177512.30576.9c; Petroll AE, 2011, SEX TRANSM DIS, V38, P63, DOI 10.1097/OLQ.0b013e3181ebd50f; Quinn K, 2016, AIDS CARE, V28, P866, DOI 10.1080/09540121.2016.1153596; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramo DE, 2012, PSYCHOL ADDICT BEHAV, V26, P801, DOI 10.1037/a0026201; Ramo DE, 2011, HEALTH PSYCHOL, V30, P693, DOI 10.1037/a0023443; Rosenberg ES, 2014, LANCET HIV, V1, pE112, DOI 10.1016/S2352-3018(14)00011-3; Sam TS, 2015, AIDS BEHAV, V19, P2049, DOI 10.1007/s10461-015-1064-4; Samet JH, 2004, ALCOHOL CLIN EXP RES, V28, P572, DOI 10.1097/01.ALC.0000122103.74491.78; Schneider JA, 2017, AIDS, V31, P159, DOI 10.1097/QAD.0000000000001269; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Shively M., 2002, AIDS BEHAV, V6, P371, DOI DOI 10.1023/A:1021156914683; Simoni JM, 2006, AIDS BEHAV, V10, P227, DOI 10.1007/s10461-006-9078-6; Solowij N, 2012, PSYCHOPHARMACOLOGY, V219, P575, DOI 10.1007/s00213-011-2486-y; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Weber R, 2015, HIV MED, V16, P137, DOI 10.1111/hiv.12184; Whetten K, 2005, AIDS PATIENT CARE ST, V19, P89, DOI 10.1089/apc.2005.19.89	64	49	49	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0179688	10.1371/journal.pone.0179688	http://dx.doi.org/10.1371/journal.pone.0179688			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EZ3JX	28662170	Green Published, gold, Green Submitted			2023-01-03	WOS:000404608300041
J	Uematsu, H; Yamashita, K; Kunisawa, S; Otsubo, T; Imanaka, Y				Uematsu, Hironori; Yamashita, Kazuto; Kunisawa, Susumu; Otsubo, Tetsuya; Imanaka, Yuichi			Prediction of pneumonia hospitalization in adults using health checkup data	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; RISK-FACTORS; BENZODIAZEPINES; PERFORMANCE; FRAMEWORK; MORTALITY; EFFICACY	Objectives Community-acquired pneumonia is a common cause of hospitalization, and pneumococcal vaccinations are recommended for high-risk individuals. Although risk factors for pneumonia have been identified, there are currently no pneumonia hospitalization prediction models based on the risk profiles of healthy subjects. This study aimed to develop a predictive model for pneumonia hospitalization in adults to accurately identify high-risk individuals to facilitate the efficient prevention of pneumonia. Methods We conducted a retrospective database analysis using health checkup data and health insurance claims data for residents of Kyoto prefecture, Japan, between April 2010 and March 2015. We chose adults who had undergone health checkups in the first year of the study period, and tracked pneumonia hospitalizations over the next 5 years. Subjects were randomly divided into training and test sets. The outcome measure was pneumonia hospitalization, and candidate predictors were obtained from the health checkup data. The prediction model was developed and internally validated using a LASSO logistic regression analysis. Lastly, we compared the new model with comparative models. Results The study sample comprised 54,907 people who had undergone health checkups. Among these, 921 were hospitalized for pneumonia during the study period. The c-statistic for the prediction model in the test set was 0.71 (95% confidence interval: 0.69-0.73). In contrast, a comparative model with only age and comorbidities as predictors had a lower c-statistic of 0.55 (95% confidence interval: 0.54-0.56). Conclusions Our predictive model for pneumonia hospitalization performed better than comparative models, and may be useful for supporting the development of pneumonia prevention measures.	[Uematsu, Hironori; Yamashita, Kazuto; Kunisawa, Susumu; Otsubo, Tetsuya; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Kyoto, Japan	Kyoto University	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Kyoto, Japan.	imanaka-y@umin.net	Otsubo, Tetsuya/HCH-1434-2022; KUNISAWA, Susumu/HCH-1094-2022; Yuichi, Imanaka/GYR-2098-2022	Yuichi, Imanaka/0000-0003-4613-2159	Ministry of Health, Labour and Welfare of Japan [H27-iryo-ippan-005, H27-shinkogyosei-shitei-005, H29-shinkogyosei-shitei-005]; Japan Society for the Promotion of Science [[A]16H02634]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported in part by Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H27-iryo-ippan-005, H27-shinkogyosei-shitei-005, H29-shinkogyosei-shitei-005; http://sci-hub.io/http://www.mhlw.go.jp), and a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. ([A]16H02634; http://sci-hub.io/https://www.jsps.go.jp/j-grantsinaid) YI received this funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almario CV, 2015, EUR J GASTROEN HEPAT, V27, P1259, DOI 10.1097/MEG.0000000000000444; Almirall J, 2008, EUR RESPIR J, V31, P1274, DOI 10.1183/09031936.00095807; Brown JS, 2012, CLIN MED, V12, P538, DOI 10.7861/clinmedicine.12-6-538; Chien YF, 2015, J CRIT CARE, V30, P506, DOI 10.1016/j.jcrc.2015.01.001; Chong IG, 2005, CHEMOMETR INTELL LAB, V78, P103, DOI 10.1016/j.chemolab.2004.12.011; Debray TPA, 2015, J CLIN EPIDEMIOL, V68, P280, DOI 10.1016/j.jclinepi.2014.06.018; Diao WQ, 2016, VACCINE, V34, P1496, DOI 10.1016/j.vaccine.2016.02.023; Dublin S, 2011, J AM GERIATR SOC, V59, P1899, DOI 10.1111/j.1532-5415.2011.03586.x; Friedman J, GLMNET LASSO ELASTIC; Huss A, 2009, CAN MED ASSOC J, V180, P48, DOI 10.1503/cmaj.080734; Ishida T., 2011, EFFICACY OF PNEUMOCO; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Miller ER, 2016, VACCINE, V34, P2841, DOI 10.1016/j.vaccine.2016.04.021; Ministry of Health, 2007, LAB WELF JAP STAND P; Ministry of Health, 2007, LAB WERLF JAP STAND; Obiora E, 2013, THORAX, V68, P163, DOI 10.1136/thoraxjnl-2012-202374; Orimo Hajime, 2006, Nihon Ronen Igakkai Zasshi, V43, P27; Remington LT, 2014, CURR OPIN PULM MED, V20, P215, DOI 10.1097/MCP.0000000000000052; Rossi RG, 2004, INT J TUBERC LUNG D, V8, P528; Schierenberg A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149895; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Taneja C, 2010, J HOSP MED, V5, P528, DOI 10.1002/jhm.704; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Torres A, 2013, THORAX, V68, P1057, DOI 10.1136/thoraxjnl-2013-204282; Uematsu H, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-203; van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4; Whiteside J, 2006, CLIN INQUIRIES	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180159	10.1371/journal.pone.0180159	http://dx.doi.org/10.1371/journal.pone.0180159			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662167	Green Submitted, Green Published, gold			2023-01-03	WOS:000404608300115
J	Horton, R				Horton, Richard			A milestone for palliative care and pain relief	LANCET			English	Editorial Material									[Horton, Richard] The Lancet, London EC2Y 5AS, England		Horton, R (corresponding author), The Lancet, London EC2Y 5AS, England.	richard.horton@lancet.com	Harding, Richard/G-9729-2012					Barber RM, 2017, LANCET, V390, P231, DOI [10.1016/S0140-6736(17)30818-8, 10.1016/s0140-6736(17)30818-8]; Knaul FM, 2017, LANCET	2	6	6	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2018	391	10128					1338	1339		10.1016/S0140-6736(17)32560-6	http://dx.doi.org/10.1016/S0140-6736(17)32560-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB8RK	29032991				2023-01-03	WOS:000429342800007
J	de Vries, EM; Oosterman, JE; Eggink, HM; de Goede, P; Sen, S; Foppen, E; Boudzovitch-Surovtseva, O; Boelen, A; Romijn, JA; LaFleur, SE; Kalsbeek, A				de Vries, E. M.; Oosterman, J. E.; Eggink, H. M.; de Goede, P.; Sen, S.; Foppen, E.; Boudzovitch-Surovtseva, O.; Boelen, A.; Romijn, J. A.; LaFleur, S. E.; Kalsbeek, A.			Effects of meal composition and meal timing on the expression of genes involved in hepatic drug metabolism in rats	PLOS ONE			English	Article							HIGH-SUGAR DIET; HIGH-FAT DIET; CIRCADIAN CLOCK; NUCLEAR RECEPTORS; CYTOCHROME-P450 GENES; MOUSE; RHYTHM; LIVER; IDENTIFICATION; ACETAMINOPHEN	Introduction With chronotherapy, drug administration is synchronized with daily rhythms in drug clearance and pharmacokinetics. Daily rhythms in gene expression are centrally mastered by the suprachiasmatic nucleus of the hypothalamus as well as by tissue clocks containing similar molecular mechanisms in peripheral organs. The central timing system is sensitive to changes in the external environment such as those of the light-dark cycle, meal timing and meal composition. We investigated how changes in diet composition and meal timing would affect the daily hepatic expression rhythms of the nuclear receptors PXR and CAR and of enzymes involved in P450 mediated drug metabolism, as such changes could have consequences for the practice of chronotherapy. Materials and methods Rats were subjected to either a regular chow or a free choice high-fat-high-sugar (fcHFHS) diet. These diets were provided ad libitum, or restricted to either the light phase or the dark phase. In a second experiment, rats had access to chow either ad libitum or in 6 meals equally distributed over 24 hours. Results Pxr, Alas1 and Por displayed significant day-night rhythms under ad libitum chow fed conditions, which for Pxr was disrupted under fcHFHS diet conditions. Although no daily rhythms were detected in expression of CAR, Cyp2b2 and Cyp3a2, the fcHFHS diet did affect basal expression of these genes. In chow fed rats, dark phase feeding induced a diurnal rhythm in Cyp2b2 expression while light phase feeding induced a diurnal rhythm in Car expression and completely shifted the peak expression of Pxr, Car, Cyp2b2, Alas1 and Por. The 6-meals-a-day feeding only abolished the Pxr rhythm but not the rhythms of the other genes. Conclusion We conclude that although nuclear receptors and enzymes involved in the regulation of hepatic drug metabolism are sensitive to meal composition, changes in meal timing are mainly effectuated via changes in the molecular clock.	[de Vries, E. M.; Romijn, J. A.] Acad Med Ctr, Dept Med, Amsterdam, Netherlands; [Oosterman, J. E.; Eggink, H. M.; de Goede, P.; Boudzovitch-Surovtseva, O.; Boelen, A.; LaFleur, S. E.; Kalsbeek, A.] Acad Med Ctr, Dept Endocrinol & Metab, Amsterdam, Netherlands; [Sen, S.; Foppen, E.; Kalsbeek, A.] Netherlands Inst Neurosci, Hypothalam Integrat Mech, Amsterdam, Netherlands; [LaFleur, S. E.] Netherlands Inst Neurosci, Metab & Reward Grp, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	de Vries, EM (corresponding author), Acad Med Ctr, Dept Med, Amsterdam, Netherlands.	e.m.devries@amc.uva.nl	Kalsbeek, Andries/H-3076-2019	Kalsbeek, Andries/0000-0001-9606-8453	Technology Foundation STW [12195]; AMC PhD Scholarship	Technology Foundation STW(Technologiestichting STW); AMC PhD Scholarship	This work was supported by the Technology Foundation STW grant "Feeding OnTime" (#12195) for SEF and AK and an AMC PhD Scholarship for JOE.	Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chiba T, 2016, J PHARM PHARMACOL, V68, P1567, DOI 10.1111/jphp.12646; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Froy O, 2009, CURR DRUG METAB, V10, P104, DOI 10.2174/138920009787522179; Gachon F, 2006, CELL METAB, V4, P25, DOI 10.1016/j.cmet.2006.04.015; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Ghoneim RH, 2015, BRIT J NUTR, V113, P507, DOI 10.1017/S0007114514003717; Ghose R, 2011, LIFE SCI, V89, P57, DOI 10.1016/j.lfs.2011.05.005; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Hughes ME, 2010, J BIOL RHYTHM, V25, P372, DOI 10.1177/0748730410379711; Johnson BP, 2014, P NATL ACAD SCI USA, V111, P18757, DOI 10.1073/pnas.1421708111; Kaasik K, 2004, NATURE, V430, P467, DOI 10.1038/nature02724; Knutsson A, 2003, OCCUP MED-OXFORD, V53, P103, DOI 10.1093/occmed/kqg048; Kumar GN, 2001, MED RES REV, V21, P397, DOI 10.1002/med.1016; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; la Fleur SE, 2007, INT J OBESITY, V31, P1286, DOI 10.1038/sj.ijo.0803570; la Fleur SE, 2014, INT J OBESITY, V38, P643, DOI 10.1038/ijo.2013.159; la Fleur SE, 2011, INT J OBESITY, V35, P595, DOI 10.1038/ijo.2010.164; Lammers LA, 2015, DRUG METAB DISPOS, V43, P819, DOI 10.1124/dmd.114.062299; Lu YF, 2013, CHRONOBIOL INT, V30, P1135, DOI 10.3109/07420528.2013.805762; Martignoni M, 2006, EXPERT OPIN DRUG MET, V2, P875, DOI 10.1517/17425255.2.6.875; Matsunaga N, 2004, J PHARMACOL EXP THER, V311, P594, DOI 10.1124/jpet.104.069062; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; Murray M, 2006, CURR DRUG METAB, V7, P67, DOI 10.2174/138920006774832569; OHDO S, 1991, CHRONOBIOL INT, V8, P35, DOI 10.3109/07420529109063917; Ohdo S, 2010, ADV DRUG DELIVER REV, V62, P859, DOI 10.1016/j.addr.2010.01.006; Oishi K, 2003, J BIOL CHEM, V278, P41519, DOI 10.1074/jbc.M304564200; Oosterman JE, 2015, AM J PHYSIOL-REG I, V308, pR337, DOI 10.1152/ajpregu.00322.2014; Opperhuizen AL, 2016, EUR J NEUROSCI, V44, P2795, DOI 10.1111/ejn.13377; Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; SONAWANE B R, 1983, Drug-Nutrient Interactions, V2, P7; STEPHAN FK, 1972, PHYSIOL BEHAV, V8, P315, DOI 10.1016/0031-9384(72)90379-4; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Su Y, 2016, MOL CELL ENDOCRINOL, V422, P125, DOI 10.1016/j.mce.2015.12.011; Takiguchi T, 2007, PHARMACOGENET GENOM, V17, P1047, DOI 10.1097/FPC.0b013e3282f12a61; Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504; Wieneke N, 2007, FEBS LETT, V581, P5617, DOI 10.1016/j.febslet.2007.11.011; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101	40	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2017	12	10							e0185520	10.1371/journal.pone.0185520	http://dx.doi.org/10.1371/journal.pone.0185520			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI5MY	28968417	Green Published, gold, Green Submitted			2023-01-03	WOS:000412029600023
J	Kato, K; Kanosue, K				Kato, Kouki; Kanosue, Kazuyuki			Corticospinal excitability for hand muscles during motor imagery of foot changes with imagined force level	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; VOLUNTARY MOVEMENT; EVOKED-POTENTIALS; CORTICAL PLASTICITY; FOREARM MUSCLES; MENTAL PRACTICE; FUNCTIONAL MRI; CONTRACTION; FACILITATION; MODULATION	The object of this study was to clarify whether corticospinal excitability controlling hand muscles changes concurrently with increases in the imagined contraction level of foot dorsiflexion. Twelve participants performed actual and imagined dorsiflexion of their right foot at three different EMG levels (10, 40 or 80% of the maximum voluntary contraction). During isometric actual-or imagined-dorsiflexion, transcranial magnetic stimulation (TMS) was delivered to the right hand area of the left primary motor cortex. Motor evoked potentials (MEPs) were recorded from the right extensor carpi radialis (ECR) and flexor carpi radialis (FCR). During actual contraction, MEP amplitudes of ECR and FCR increased with an increased EMG level of dorsiflexion. Similarly, during imagery contraction, MEP amplitudes of ECR and FCR increased with the intensity of imagery contraction. Furthermore, a correlation between MEP amplitude during actual contraction and imagery contraction was observed for both ECR and FCR. Motor imagery of foot contraction induced an enhancement of corticospinal excitability for hand muscles that was dependent on the imagined contraction levels, just as what was observed when there was an actual contraction.	[Kato, Kouki; Kanosue, Kazuyuki] Waseda Univ, Fac Sport Sci, Tokorozawa, Saitama, Japan	Waseda University	Kato, K (corresponding author), Waseda Univ, Fac Sport Sci, Tokorozawa, Saitama, Japan.	kato.k@aoni.waseda.jp		Kato, Kouki/0000-0002-4922-3120	JSPS KAKENHI [15K16494, JP26242065]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI grant numbers 15K16494 to K Kato and JP26242065 to K Kanosue.; The authors thank Dr. Larry Crawshaw for English editing. This work was supported by JSPS KAKENHI Grant Numbers 15K16494 to K Kato and JP26242065 to K Kanosue. All authors declare no conflicts of interest.	Allami N, 2008, EXP BRAIN RES, V184, P105, DOI 10.1007/s00221-007-1086-x; Allison T, 1996, EVOKED POTENTIAL, V100, P126, DOI 10.1016/0013-4694(95)00226-X; Baldissera F, 2002, J PHYSIOL-LONDON, V539, P903, DOI 10.1113/jphysiol.2001.013282; Borroni P, 2004, BRAIN RES, V1022, P117, DOI 10.1016/j.brainres.2004.07.003; BROWN P, 1991, BRAIN, V114, P2333, DOI 10.1093/brain/114.5.2333; Byblow WD, 2007, J NEUROPHYSIOL, V98, P414, DOI 10.1152/jn.00325.2007; Cauda F, 2011, HUM BRAIN MAPP, V32, P1566, DOI 10.1002/hbm.21132; Dai TH, 2001, EXP BRAIN RES, V140, P290, DOI 10.1007/s002210100815; DECETY J, 1989, BEHAV BRAIN RES, V34, P35, DOI 10.1016/S0166-4328(89)80088-9; DELWAIDE PJ, 1981, BRAIN, V104, P701, DOI 10.1093/brain/104.4.701; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Fourkas AD, 2006, BEHAV BRAIN RES, V168, P190, DOI 10.1016/j.bbr.2005.10.015; Guillot A, 2009, HUM BRAIN MAPP, V30, P2157, DOI 10.1002/hbm.20658; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; Holmes P, 2008, J MOTOR BEHAV, V40, P433, DOI 10.3200/JMBR.40.5.433-445; Hortobagyi T, 2003, J NEUROPHYSIOL, V90, P2451, DOI 10.1152/jn.01001.2002; Huang X, 2017, MOL PSYCHIATR, V22, P1274, DOI 10.1038/mp.2017.143; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; Isaac AR., 1992, SPORT PSYCHOL, V6, P192, DOI [10.1123/tsp.6.2.192, DOI 10.1123/TSP.6.2.192, DOI 10.1123/tsp.6.2.192]; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; Jendr?ssik, 1883, DTSCH ARCH KLIN MED, V33, P177; Kasai T, 1997, BRAIN RES, V744, P147, DOI 10.1016/S0006-8993(96)01101-8; Kato K, 2015, PHYSL REP, V3, P1; Kato K, 2016, FRONT HUM NEUROSCI, V10, DOI [10.3389/fnhum.2016.00131, 10.3389/fnhum.2016.00218]; Kato K, 2016, NEUROSCI LETT, V633, P252, DOI 10.1016/j.neulet.2016.09.019; Kato K, 2015, NEUROSCI RES, V92, P39, DOI 10.1016/j.neures.2014.10.013; Kato K, 2014, EXP BRAIN RES, V232, P181, DOI 10.1007/s00221-013-3730-y; KAWAKITA H, 1991, J ELECTROMYOGR KINES, V1, P96, DOI 10.1016/1050-6411(91)90003-N; Lotze M, 2006, J PHYSIOL-PARIS, V99, P386, DOI 10.1016/j.jphysparis.2006.03.012; Makary MM, 2017, NEUROREPORT, V28, P610, DOI 10.1097/WNR.0000000000000809; Marconi B, 2007, CLIN NEUROPHYSIOL, V118, P2468, DOI 10.1016/j.clinph.2007.08.021; Mizuguchi N, 2012, J PHYS FIT SPORT MED, V1, P103, DOI 10.7600/jpfsm.1.103; Mizuguchi N, 2013, EXP BRAIN RES, V230, P243, DOI 10.1007/s00221-013-3649-3; Mizuguchi N, 2009, EXP BRAIN RES, V196, P529, DOI 10.1007/s00221-009-1875-5; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Perez MA, 2009, CORTEX, V45, P1065, DOI 10.1016/j.cortex.2008.12.006; Roberts R, 2008, J SPORT EXERCISE PSY, V30, P200, DOI 10.1123/jsep.30.2.200; Shen Y, 2017, BIOL PSYCHIAT, V81, pE49, DOI 10.1016/j.biopsych.2016.06.013; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Stedman A, 1998, MUSCLE NERVE, V21, P1033, DOI 10.1002/(SICI)1097-4598(199808)21:8<1033::AID-MUS7>3.0.CO;2-9; Stein RB Zehr, 1999, EXP BRAIN RES, V159, P382; Stinear CM, 2004, EXP BRAIN RES, V157, P351, DOI 10.1007/s00221-004-1851-z; Takada Y, 2000, J NEUROPHYSIOL, V83, P2063, DOI 10.1152/jn.2000.83.4.2063; Tazoe T, 2007, CLIN NEUROPHYSIOL, V118, P1204, DOI 10.1016/j.clinph.2007.03.005; Tazoe T, 2009, EUR J NEUROSCI, V30, P1297, DOI 10.1111/j.1460-9568.2009.06895.x; TOULOUSE P, 1980, ARCH PHYS MED REHAB, V61, P511; van Duinen H, 2008, HUM BRAIN MAPP, V29, P281, DOI 10.1002/hbm.20388; WERNER W, 1991, EXP BRAIN RES, V86, P293; Yazawa S, 1999, BRAIN, V122, P1357, DOI 10.1093/brain/122.7.1357	53	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185547	10.1371/journal.pone.0185547	http://dx.doi.org/10.1371/journal.pone.0185547			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI4YC	28957398	Green Published, Green Submitted, gold			2023-01-03	WOS:000411985200083
J	Kitagawa, M; Sada, KE; Hinamoto, N; Kimachi, M; Yamamoto, Y; Onishi, Y; Fukuhara, S				Kitagawa, Masashi; Sada, Ken-ei; Hinamoto, Norikazu; Kimachi, Miho; Yamamoto, Yosuke; Onishi, Yoshihiro; Fukuhara, Shunichi			Shorter dialysis session length was not associated with lower mental health and physical functioning in elderly hemodialysis patients: Results from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS)	PLOS ONE			English	Article							QUALITY-OF-LIFE; SHORT-FORM 12; NOCTURNAL HEMODIALYSIS; 3 TIMES; MORTALITY; DISEASE; PREDICTORS; TRIALS	Background Health-related quality of life (HRQOL) is often prioritized over long-term survival in elderly patients. Although a longer dialysis session length (DSL) has been shown to reduce mortality, its effects on improving the HRQOL are unknown. Methods Using data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS), patients aged >= 65 years on maintenance hemodialysis were enrolled. DSL was categorized as short (<210 minutes), medium (210-240 minutes), or long (>240 minutes). The primary outcomes were changes in mental health (Delta MH) and physical functioning (Delta PF) scores assessed using the Japanese version of SF-12, in one year. The differences in the Delta MH and Delta PF among the three groups were assessed via regression (beta) coefficients derived using a linear regression model. Results Of 1,187 patients at baseline, 319 (26.9%) had a short length, 686 (57.8%) a medium length, and 182 (15.3%) a long length. We assessed the.MH data from 793 patients and the Delta PF data from 738. No significant differences in the.MH were noted for the short or long groups compared with the medium group (score difference: 0.26, 95% confidence interval [CI]: -4.17 to 4.69 for short; score difference: -1.15, 95% CI: -6.17 to 3.86 for long). Similarly, no significant differences were noted for these groups versus the medium group in.PF either (score difference: -1.43, 95% CI: -6.73 to 3.87 for short; score difference: -1.71, 95% CI: -7.63 to 4.22 for long). Conclusions A shorter DSL might have no adverse effects on MH or PF for elderly patients.	[Kitagawa, Masashi; Sada, Ken-ei; Hinamoto, Norikazu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Nephrol Rheumatol Endocrinol & Metab, Okayama, Okayama, Japan; [Kimachi, Miho; Yamamoto, Yosuke; Fukuhara, Shunichi] Kyoto Univ, Sch Publ Hlth, Grad Sch Med, Dept Healthcare Epidemiol, Kyoto, Kyoto, Japan; [Onishi, Yoshihiro] iHope Int, Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Kyoto, Japan; [Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima, Fukushima, Japan	Okayama University; Kyoto University; Fukushima Medical University	Kitagawa, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Nephrol Rheumatol Endocrinol & Metab, Okayama, Okayama, Japan.	masa4_n_r@yahoo.co.jp	YAMAMOTO, Yosuke/HCH-0666-2022	Sada, Ken-ei/0000-0003-1020-0818	Amgen; Kyowa Hakko Kirin; Sanofi/Genzyme; Abbott; Baxter; Vifor Fresenius Renal Pharma	Amgen(Amgen); Kyowa Hakko Kirin(Kyowa Kirin Ltd); Sanofi/Genzyme; Abbott(Abbott Laboratories); Baxter; Vifor Fresenius Renal Pharma	The JDOPPS is Japanese part of The DOPPS. The DOPPS is administered by the Arbor Research Collaborative for Health and is supported by scientific research grants from Amgen (since 1996), Kyowa Hakko Kirin (since 1999, in Japan), Sanofi/Genzyme (since 2009), Abbott (since 2009), Baxter (since 2011), and Vifor Fresenius Renal Pharma (since 2011), without restrictions on publications. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The present study is supported by scientific research grants from Kyowa Hakko Kirin without restrictions.	Bohlke M, 2008, SAO PAULO MED J, V126, P252, DOI 10.1590/S1516-31802008000500002; Brunelli SM, 2010, KIDNEY INT, V77, P630, DOI 10.1038/ki.2009.523; Davison SN, 2015, KIDNEY INT, V88, P447, DOI 10.1038/ki.2015.110; Flythe JE, 2013, KIDNEY INT, V83, P104, DOI 10.1038/ki.2012.346; Fukuhara S, 2003, KIDNEY INT, V64, P1903, DOI 10.1046/j.1523-1755.2003.00289.x; Fukuhara S., 2004, MANUAL SF 36V2 JAPAN; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Hall YN, 2012, CLIN J AM SOC NEPHRO, V7, P782, DOI 10.2215/CJN.10601011; Hamuro A, 2016, J OBSTET GYNAECOL RE, V42, P707, DOI 10.1111/jog.12952; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Heidenheim AP, 2003, AM J KIDNEY DIS, V42, pS36, DOI 10.1016/S0272-6386(03)00536-5; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; Honda M, 2015, ANN SURG ONCOL, V22, pS848, DOI 10.1245/s10434-015-4696-8; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; Inoue M, 2017, CLIN RHEUMATOL, V36, P1053, DOI 10.1007/s10067-017-3545-5; Jaber BL, 2010, AM J KIDNEY DIS, V56, P531, DOI 10.1053/j.ajkd.2010.04.019; Kato S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123022; Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P252, DOI 10.2215/CJN.07231009; Liu JN, 2010, KIDNEY INT, V77, P141, DOI 10.1038/ki.2009.413; Loosman WL, 2015, NEPHROL DIAL TRANSPL, V30, P1170, DOI 10.1093/ndt/gfv066; Manns BJ, 2009, KIDNEY INT, V75, P542, DOI 10.1038/ki.2008.639; Marshall MR, 2005, KIDNEY INT, V67, P1944, DOI 10.1111/j.1523-1755.2005.00293.x; McPhatter LL, 1999, ADV RENAL REPLACE TH, V6, P358, DOI 10.1016/S1073-4449(99)70048-8; Osthus TBH, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-46; Parker SL, 2012, J NEUROSURG-SPINE, V16, P61, DOI 10.3171/2011.8.SPINE1194; Perl J, 2016, NEPHROL DIAL TRANSPL; Perl J, 2017, NEPHROL DIAL TRANSPL, V32, P521, DOI 10.1093/ndt/gfw233; Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005; Saran R, 2006, KIDNEY INT, V69, P1222, DOI 10.1038/sj.ki.5000186; Shinzato T, 1997, NEPHROL DIAL TRANSPL, V12, P884, DOI 10.1093/ndt/12.5.884; Singh J, 2010, J AM ACAD ORTHOP SUR, V18, P72; Tentori F, 2012, NEPHROL DIAL TRANSPL, V27, P4180, DOI 10.1093/ndt/gfs021; Unruh ML, 2013, AM J KIDNEY DIS, V61, P748, DOI 10.1053/j.ajkd.2012.11.047; Vilagut G, 2013, VALUE HEALTH, V16, P564, DOI 10.1016/j.jval.2013.01.006; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Yoshida M, 2016, NEUROUROL URODYN	37	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184019	10.1371/journal.pone.0184019	http://dx.doi.org/10.1371/journal.pone.0184019			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG0EG	28877202	Green Submitted, Green Published, gold			2023-01-03	WOS:000409391200054
J	Azpiazu, D; Gonzalez-Parra, E; Ortiz, A; Egido, J; Villa-Bellosta, R				Azpiazu, Daniel; Gonzalez-Parra, Emilio; Ortiz, Alberto; Egido, Jesus; Villa-Bellosta, Ricardo			Impact of post-dialysis calcium level on ex vivo rat aortic wall calcification	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; VASCULAR CALCIFICATION; TISSUE CALCIFICATION; PARATHYROID-HORMONE; MORTALITY RISK; HEMODIALYSIS; ACETAZOLAMIDE; ASSOCIATION; PHOSPHORUS; DEPOSITION	Objectives Vascular calcification is a frequent complication in chronic haemodialysis patients and is associated with adverse outcomes. Serum calcium and phosphate levels and imbalances in calcification regulators are thought to contribute to the process. In this regard, the dialysate calcium concentration is a modifiable tool for modulating the risk of vascular calcification. We explored pre-and post-dialysis phosphate and calcium concentrations in stable chronic haemodialysis patients treated by dialysis with the KDIGO-suggested 1.5 mmol/L calcium dialysate to investigate the effects on ex vivo calcification of rat aortic rings. Approach and results At the end of haemodialysis, mean serum calcium levels were increased in 88% of paired pre-/post-dialysis samples, while mean serum phosphate and parathyroid hormone levels were decreased. Rat aortic ring cultures grown at the same calcium and phosphate concentrations revealed that pre-and post-dialysis resulted in a similar degree of calcification. By contrast, haemodialysis with unchanged serum calcium resulted in a 5-fold reduction in calcium deposition. Conclusion Dialysis with the widely prescribed 1.5 mmol/L calcium dose results in persistent high serum calcification potential in a sizable proportion of patients, driven by increased post-dialysis calcium concentration. This could potentially be mitigated by individualising dialysate calcium dosage based on pre-dialysis serum calcium levels.	[Azpiazu, Daniel; Gonzalez-Parra, Emilio; Ortiz, Alberto; Egido, Jesus; Villa-Bellosta, Ricardo] FJD, FIIS, Madrid, Spain		Villa-Bellosta, R (corresponding author), FJD, FIIS, Madrid, Spain.	ricardo.villa@fjd.es	ortiz, alberto/Y-7582-2018	ortiz, alberto/0000-0002-9805-9523; Villa-Bellosta, Ricardo/0000-0002-1680-552X	Spanish Ministerio de Economia y Competitividad (MINECO) [SAF-2014-60699-JIN]; Foundation SENEFRO (Spanish Nephrology Society)	Spanish Ministerio de Economia y Competitividad (MINECO); Foundation SENEFRO (Spanish Nephrology Society)	This study was supported by grant SAF-2014-60699-JIN from the Spanish Ministerio de Economia y Competitividad (MINECO) to RVB and grant from Foundation SENEFRO (Spanish Nephrology Society). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basile C, 2015, CLIN KIDNEY J, V8, P393, DOI 10.1093/ckj/sfv038; Basile C, 2012, AM J KIDNEY DIS, V59, P92, DOI 10.1053/j.ajkd.2011.08.033; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; de Solis AJ, 2009, J NEPHROL, V22, P647; Finer G, 2014, AM J MED GENET A, V164, P1545, DOI 10.1002/ajmg.a.36476; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gonzalez-Parra E, 2014, BLOOD PURIFICAT, V38, P224, DOI 10.1159/000366126; Gotch FA, 2010, KIDNEY INT, V78, P343, DOI 10.1038/ki.2010.157; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Leibrock CB, 2016, J MOL MED, V94, P95, DOI 10.1007/s00109-015-1331-x; Locatelli F, 2015, CLIN KIDNEY J, V8, P580, DOI 10.1093/ckj/sfv057; Mendoza FJ, 2008, KIDNEY INT, V73, P407, DOI 10.1038/sj.ki.5002646; O'Neill WC, 2007, KIDNEY INT, V72, P792, DOI 10.1038/sj.ki.5002412; Ok E, 2016, J AM SOC NEPHROL, V27, P2475, DOI 10.1681/ASN.2015030268; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; Villa-Bellosta R, 2015, CURR CARDIOL REV, V11, P341, DOI 10.2174/1573403X11666150805120505; Villa-Bellosta R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159858; Villa-Bellosta R, 2015, METHODS MOL BIOL, V1339, P119, DOI 10.1007/978-1-4939-2929-0_8; Villa-Bellosta R, 2013, CIRC J, V77, P2145, DOI 10.1253/circj.CJ-13-0016; Villa-Bellosta R, 2011, AM J PHYSIOL-CELL PH, V300, pC210, DOI 10.1152/ajpcell.00229.2010	21	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2017	12	8							e0183730	10.1371/journal.pone.0183730	http://dx.doi.org/10.1371/journal.pone.0183730			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE6YW	28832652	Green Published, Green Submitted, gold			2023-01-03	WOS:000408355800097
J	Matossian, MD; Elliott, S; Hoang, VT; Burks, HE; Phamduy, TB; Chrisey, DB; Zuercher, WJ; Drewry, DH; Wells, C; Collins-Burow, B; Burow, ME				Matossian, Margarite D.; Elliott, Steven; Hoang, Van T.; Burks, Hope E.; Phamduy, Theresa B.; Chrisey, Douglas B.; Zuercher, William J.; Drewry, David H.; Wells, Carrow; Collins-Burow, Bridgette; Burow, Matthew E.			Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH; EMT; PROGRESSION; EXPRESSION; KINOME; SHAPE	Triple negative breast cancers (TNBCs) have high recurrence and metastasis rates. Acquisition of a mesenchymal morphology and phenotype in addition to driving migration is a consequential process that promotes metastasis. Although some kinases are known to regulate a mesenchymal phenotype, the role for a substantial portion of the human kinome remains uncharacterized. Here we evaluated the Published Kinase Inhibitor Set (PKIS) and screened a panel of TNBC cell lines to evaluate the compounds' effects on a mesenchymal phenotype. Our screen identified 36 hits representative of twelve kinase inhibitor chemotypes based on reversal of the mesenchymal cell morphology, which was then prioritized to twelve compounds based on gene expression and migratory behavior analyses. We selected the most active compound and confirmed mesenchymal reversal on transcript and protein levels with qRT-PCR and Western Blot. Finally, we utilized a kinase array to identify candidate kinases responsible for the EMT reversal. This investigation shows the novel application to identify previously unrecognized kinase pathways and targets in acquisition of a mesenchymal TNBC phenotype that warrant further investigation. Future studies will examine specific roles of the kinases in mechanisms responsible for acquisition of the mesenchymal and/or migratory phenotype.	[Matossian, Margarite D.; Elliott, Steven; Hoang, Van T.; Burks, Hope E.; Collins-Burow, Bridgette; Burow, Matthew E.] Tulane Univ, Dept Med, Sect Hematol & Oncol, New Orleans, LA 70118 USA; [Phamduy, Theresa B.; Chrisey, Douglas B.] Tulane Univ, Dept Phys, New Orleans, LA 70118 USA; [Zuercher, William J.; Drewry, David H.; Wells, Carrow] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Chapel Hill, NC USA	Tulane University; Tulane University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Burow, ME (corresponding author), Tulane Univ, Dept Med, Sect Hematol & Oncol, New Orleans, LA 70118 USA.	mburow@tulane.edu			National Institutes of Health [1R15CA176496-01A1, R01-CA174785-A1, R01-CA125806-05]; AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA); Janssen, Merck Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; Sao Paulo Research Foundation-FAPESP; Takeda; Wellcome Trust; Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE [R01CA174785] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AbbVie(AbbVie); Bayer Pharma AG; Boehringer Ingelheim(Boehringer Ingelheim); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Eshelman Institute for Innovation; Genome Canada(Genome Canada); Innovative Medicines Initiative (EU/EFPIA); Janssen, Merck Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer(Pfizer); Sao Paulo Research Foundation-FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Takeda(Takeda Pharmaceutical Company Ltd); Wellcome Trust(Wellcome TrustEuropean Commission); Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded with the following grants awarded by National Institutes of Health: 1R15CA176496-01A1 (MEB), R01-CA174785-A1 (BC-B) and R01-CA125806-05 (MEB). The funders both had important roles in study design, data collection and analysis and decision to publish. MEB had an important role in preparation of the manuscript.; We would like to thank GlaxoSmithKline for the generous donation of PKIS and PKIS2 compounds for these studies. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA), Janssen, Merck & Co., Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and Wellcome Trust. We would like to thank our collaborators at the Eshelman School of Pharmacy at the University of North Carolina for their invaluable contribution, discussion and revisions to the manuscript. Furthermore, this work has been supported in part by the Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium. We would also like to acknowledge Matthew Ducot of Tulane University Department of Physics for his assistance developing a method to quantify aspects of cellular morphology. Finally, the results in S4 Fig are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov.	Al-Ali H, 2015, ACS CHEM BIOL, V10, P1939, DOI 10.1021/acschembio.5b00289; Alderton GK, 2013, NAT REV CANCER, V13, P3, DOI 10.1038/nrc3428; American Cancer Society, 2016, CANC FACTS FIGURES 2; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Bae YK, 2015, J BREAST CANCER, V18, P256, DOI 10.4048/jbc.2015.18.3.256; Ball SG, 2012, STEM CELLS, V30, P548, DOI 10.1002/stem.1015; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chua KN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033183; Collins I, 2006, NAT CHEM BIOL, V2, P689, DOI 10.1038/nchembio840; D'Amato NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045684; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Elkins JM, 2016, NAT BIOTECHNOL, V34, P95, DOI 10.1038/nbt.3374; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fedorov O, 2010, NAT CHEM BIOL, V6, P166, DOI 10.1038/nchembio.297; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; He YP, 2015, MOL BIOL CELL, V26, P3229, DOI 10.1091/mbc.E15-03-0142; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Kim HJ, 2015, J BREAST CANCER, V18, P371, DOI 10.4048/jbc.2015.18.4.371; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee WC, 2014, P NATL ACAD SCI USA, V111, pE4409, DOI 10.1073/pnas.1402306111; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Midland AA, 2012, CELL RES, V22, P620, DOI 10.1038/cr.2012.25; Nero TL, 2014, NAT REV CANCER, V14, P248, DOI 10.1038/nrc3690; Ocana A, 2013, CANCER TREAT REV, V39, P68, DOI 10.1016/j.ctrv.2012.05.004; Paul Manash K, 2004, Int J Med Sci, V1, P101; Poage GM, 2013, CANCER RES, V73, P557; Poh AR, 2015, ONCOTARGET, V6, P15752, DOI 10.18632/oncotarget.4199; Rakha EA, 2011, CLIN ONCOL-UK, V23, P587, DOI 10.1016/j.clon.2011.03.013; Rhodes LV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-295; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Sakurai K, 2014, CELL STEM CELL, V14, P523, DOI 10.1016/j.stem.2014.03.001; Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tevaarwerk AJ, 2013, CANCER-AM CANCER SOC, V119, P1140, DOI 10.1002/cncr.27819; Thiery JP, 2010, B CANCER, V97, P1285, DOI 10.1684/bdc.2010.1206; Wang J, 2016, GENES DIS, V3, P3, DOI 10.1016/j.gendis.2016.01.002; Wong IY, 2014, NAT MATER, V13, P1063, DOI [10.1038/NMAT4062, 10.1038/nmat4062]; Yu HY, 2013, ADV HEALTHC MATER, V2, P1188, DOI 10.1002/adhm.201300053	41	8	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2017	12	8							e0177802	10.1371/journal.pone.0177802	http://dx.doi.org/10.1371/journal.pone.0177802			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC5AR	28771473	Green Submitted, gold, Green Published			2023-01-03	WOS:000406853600002
J	Anastasiou, CA; Yannakoulia, M; Kosmidis, MH; Dardiotis, E; Hadjigeorgiou, GM; Sakka, P; Arampatzi, X; Bougea, A; Labropoulos, I; Scarmeas, N				Anastasiou, Costas A.; Yannakoulia, Mary; Kosmidis, Mary H.; Dardiotis, Efthimios; Hadjigeorgiou, Giorgos M.; Sakka, Paraskevi; Arampatzi, Xanthi; Bougea, Anastasia; Labropoulos, Ioannis; Scarmeas, Nikolaos			Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; CARDIOVASCULAR-DISEASE; DEPRESSION SCALE; NORMATIVE DATA; LEWY BODIES; AGED 65; DEMENTIA; RISK; ADHERENCE; DECLINE	Background The Mediterranean dietary pattern has been associated with a decreased risk of many degenerative diseases and cognitive function in particular; however, relevant information from Mediterranean regions, where the prototype Mediterranean diet is typically adhered to, have been very limited. Additionally, predefined Mediterranean diet (MeDi) scores with use of a priori cut-offs have been used very rarely, limiting comparisons between different populations and thus external validity of the associations. Finally, associations between individual components of MeDi (i.e., food groups, macronutrients) and particular aspects of cognitive performance have rarely been explored. We evaluated the association of adherence to an a priori defined Mediterranean dietary pattern and its components with dementia and specific aspects of cognitive function in a representative population cohort in Greece. Methods Participants from the Hellenic Longitudinal Investigation of Ageing and Diet (HELIAD), an on-going population-based study, exploring potential associations between diet and cognitive performance in a representative sample from Greek regions, were included in this analysis. Diagnosis of dementia was made by a full clinical and neuropsychological evaluation, while cognitive performance was assessed according to five cognitive domains (memory, language, attention-speed, executive functioning, visuospatial perception) and a composite cognitive score. Adherence to MeDi was evaluated by an a priori score (range 0-55), derived from a detailed food frequency questionnaire. Results Among 1,865 individuals (mean age 73 +/- 6 years, 41% male), 90 were diagnosed with dementia and 223 with mild cognitive impairment. Each unit increase in the Mediterranean dietary score (MedDietScore) was associated with a 10% decrease in the odds for dementia. Adherence to the MeDi was also associated with better performance in memory, language, visuospatial perception and the composite cognitive score; the associations were strongest for memory. Fish consumption was negatively associated with dementia and cognitive performance positively associated with non-refined cereal consumption. Conclusions Our results suggest that adherence to the MeDi is associated with better cognitive performance and lower dementia rates in Greek elders. Thus, the MeDi in its a priori constructed prototype form may have cognitive benefits in traditional Mediterranean populations.	[Anastasiou, Costas A.; Yannakoulia, Mary] Harokopio Univ, Dept Nutr & Dietet, Athens, Greece; [Anastasiou, Costas A.; Scarmeas, Nikolaos] Univ Athens, Dept Social Med Psychiat & Neurol, Neurol Clin 1, Eginit Hosp, Athens, Greece; [Kosmidis, Mary H.; Arampatzi, Xanthi] Aristotle Univ Thessaloniki, Sch Psychol, Lab Cognit Neurosci, Thessaloniki, Greece; [Dardiotis, Efthimios; Hadjigeorgiou, Giorgos M.] Univ Thessaly, Sch Med, Larisa, Greece; [Sakka, Paraskevi] Athens Assoc Alzheimers Dis & Related Disorders, Maroussi, Greece; [Bougea, Anastasia] Eginit Hosp, Neurol Clin 1, Athens, Greece; [Labropoulos, Ioannis] Biomed Diagnost Lab, Athens, Greece; [Scarmeas, Nikolaos] Columbia Univ, Dept Neurol, Taub Inst Res Alzheimers Dis & Aging Brain, Gertrude H Sergievsky Ctr, New York, NY USA	Harokopio University Athens; National & Kapodistrian University of Athens; Aristotle University of Thessaloniki; University of Thessaly; Columbia University	Scarmeas, N (corresponding author), Univ Athens, Dept Social Med Psychiat & Neurol, Neurol Clin 1, Eginit Hosp, Athens, Greece.; Scarmeas, N (corresponding author), Columbia Univ, Dept Neurol, Taub Inst Res Alzheimers Dis & Aging Brain, Gertrude H Sergievsky Ctr, New York, NY USA.	ns257@columbia.edu	BOUGEA, ANASTASIA/P-8197-2017; Scarmeas, Nikolaos/AAD-2517-2020; Scarmeas, Nikolaos/AAD-2512-2020; Stefanadis, Christodoulos/ABH-2232-2020; Kosmidis, Mary H/AAN-2104-2021	Scarmeas, Nikolaos/0000-0001-6453-8908; Scarmeas, Nikolaos/0000-0001-6453-8908; Stefanadis, Christodoulos/0000-0001-5974-6454; Yannakoulia, Mary/0000-0003-2171-7337; Anastasiou, Costas/0000-0002-3536-3034; Kosmidis, Mary/0000-0001-8790-1220; Dardiotis, Efthimios/0000-0003-2957-641X	Alzheimers Association [IIRG-09-133014]; ESPA-EU program Excellence Grant (ARISTEIA) [189 10276/8/9/2011]; European Social Fund; Greek National resources; Ministry for Health and Social Solidarity (Greece) [DY2b/oik.51657/14.4.2009]; Greek State Scholarships Foundation [MIS: 5001552]	Alzheimers Association(Alzheimer's Association); ESPA-EU program Excellence Grant (ARISTEIA); European Social Fund(European Social Fund (ESF)); Greek National resources(Greek Ministry of Development-GSRT); Ministry for Health and Social Solidarity (Greece); Greek State Scholarships Foundation(Greek Ministry of Development-GSRT)	This study was supported by the following grants: IIRG-09-133014 from the Alzheimers Association; 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA), which is co-funded by the European Social Fund and Greek National resources, and DY2b/oik.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece). Costas A. Anastasiou has received financial support from the Greek State Scholarships Foundation (MIS: 5001552).	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Benton AL, 1994, CONTRIBUTIONS TO NEU; Berr C, 2009, DEMENT GERIATR COGN, V28, P357, DOI 10.1159/000253483; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Bountziouka V, 2012, NUTR METAB CARDIOVAS, V22, P659, DOI 10.1016/j.numecd.2010.10.015; Bozikas VP, 2008, J CLIN EXP NEUROPSYC, V30, P199, DOI 10.1080/13803390701346113; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Cherbuin N, 2012, AM J GERIAT PSYCHIAT, V20, P635, DOI 10.1097/JGP.0b013e31823032a9; Christensen K, 2013, LANCET, V382, P1507, DOI 10.1016/S0140-6736(13)60777-1; Corley J, 2013, INT PSYCHOGERIATR, V25, P1393, DOI 10.1017/S1041610213000793; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; Dardiotis E, 2014, NEUROEPIDEMIOLOGY, V43, P9, DOI 10.1159/000362723; DEVANAND DP, 1992, ARCH NEUROL-CHICAGO, V49, P371, DOI 10.1001/archneur.1992.00530280051022; Dewey ME, 2001, INT J GERIATR PSYCH, V16, P751, DOI 10.1002/gps.397.abs; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Feart C, 2013, P NUTR SOC, V72, P140, DOI 10.1017/S0029665112002959; Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Fountoulakis KN, 1999, AGING-CLIN EXP RES, V11, P367, DOI 10.1007/BF03339814; Gardener H, 2015, AM J CARDIOL, V115, P510, DOI 10.1016/j.amjcard.2014.11.038; Gardener H, 2012, ARCH NEUROL-CHICAGO, V69, P251, DOI 10.1001/archneurol.2011.548; Gardener S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.91; Gardener SL, 2015, MOL PSYCHIATR, V20, P860, DOI 10.1038/mp.2014.79; Giaglis G, 2010, JOURNAL OF THE INTER, V15; Gosche KM, 2002, NEUROLOGY, V58, P1476, DOI 10.1212/WNL.58.10.1476; Gu Y, 2011, CURR ALZHEIMER RES, V8, P510, DOI 10.2174/156720511796391836; Gu Y, 2015, NEUROLOGY, V85, P1744, DOI 10.1212/WNL.0000000000002121; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Jacka FN, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0461-x; Kesse-Guyot E, 2013, AM J CLIN NUTR, V97, P369, DOI 10.3945/ajcn.112.047993; Knight A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090579; Kosmidis MH, 2010, BEHAV NEUROL, V23, P245, DOI [10.1155/2010/956709, 10.3233/BEN-2010-0306]; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Koyama A, 2015, J GERONTOL A-BIOL, V70, P352, DOI 10.1093/gerona/glu097; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Martinez-Lapiscina EH, 2013, J NUTR HEALTH AGING, V17, P544, DOI 10.1007/s12603-013-0027-6; Matthews Dawn C, 2014, Adv J Mol Imaging, V4, P43; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Michopoulos Ioannis, 2008, Ann Gen Psychiatry, V7, P4, DOI 10.1186/1744-859X-7-4; Ministry of Health and Welfare. Scientific Supreme Health Council, 1999, ARCH HELL MED, V16, P516; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Panagiotakos DB, 2006, NUTR METAB CARDIOVAS, V16, P559, DOI 10.1016/j.numecd.2005.08.006; Pitsavos C, 2005, AM J CLIN NUTR, V82, P694, DOI 10.1093/ajcn/82.3.694; Psaltopoulou T, 2008, PUBLIC HEALTH NUTR, V11, P1054, DOI 10.1017/S1368980007001607; Psaltopoulou T, 2013, ANN NEUROL, V74, P580, DOI 10.1002/ana.23944; Roberts RO, 2010, DEMENT GERIATR COGN, V29, P413, DOI 10.1159/000305099; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; Salas-Salvado J, 2008, EUR J CLIN NUTR, V62, P651, DOI 10.1038/sj.ejcn.1602762; Samieri C, 2013, EPIDEMIOLOGY, V24, P490, DOI 10.1097/EDE.0b013e318294a065; Samieri C, 2013, J NUTR, V143, P493, DOI 10.3945/jn.112.169896; Sastre M, 2006, INT J DEV NEUROSCI, V24, P167, DOI 10.1016/j.ijdevneu.2005.11.014; Satizabal CL, 2016, NEW ENGL J MED, V374, P523, DOI 10.1056/NEJMoa1504327; Scarmeas N, 2011, ANN NEUROL, V69, P257, DOI 10.1002/ana.22317; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P216, DOI 10.1001/archneurol.2008.536; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; Singh B, 2014, J ALZHEIMERS DIS, V39, P271, DOI 10.3233/JAD-130830; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Solfrizzi V, 1999, NEUROLOGY, V52, P1563, DOI 10.1212/WNL.52.8.1563; Stakias N, 2006, J GERONTOL A-BIOL, V61, P1228, DOI 10.1093/gerona/61.12.1228; Tangney CC, 2011, AM J CLIN NUTR, V93, P601, DOI 10.3945/ajcn.110.007369; Titova OE, 2013, EXP GERONTOL, V48, P1443, DOI 10.1016/j.exger.2013.10.002; Toole JF, 1996, AM J EPIDEMIOL, V144, P849; Tsapkini K, 2009, BEHAV NEUROL, V22, P111, DOI [10.3233/BEN-2009-0256, 10.3233/ben-2009-0256]; Tsivgoulis G, 2013, NEUROLOGY, V80, P1684, DOI 10.1212/WNL.0b013e3182904f69; Valls-Pedret C, 2015, JAMA INTERN MED, V175, P1094, DOI 10.1001/jamainternmed.2015.1668; Vercambre MN, 2012, J ACAD NUTR DIET, V112, P816, DOI 10.1016/j.jand.2012.02.023; Vlahou CH., 2002, PSYCHOL J HELL PSYCH, V9, P336; Vlahou CH, 2013, ARCH CLIN NEUROPSYCH, V28, P52, DOI 10.1093/arclin/acs099; Walker MP, 2000, BRIT J PSYCHIAT, V177, P252, DOI 10.1192/bjp.177.3.252; Wengreen H, 2013, AM J CLIN NUTR, V98, P1263, DOI 10.3945/ajcn.112.051276; World Health Organisation, 2012, DEMENTIA A PUBLIC HE; World Health Organization (WHO), 2015, WORLD REPORT ON AGEI; Yannakoulia M, 2015, AGEING RES REV, V20, P74, DOI 10.1016/j.arr.2014.10.003; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	84	122	125	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0182048	10.1371/journal.pone.0182048	http://dx.doi.org/10.1371/journal.pone.0182048			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC3VC	28763509	Green Submitted, Green Published, gold			2023-01-03	WOS:000406766500037
J	Li, GH; Zhao, B; Dong, ST; Zhang, JW; Liu, P; Vyn, TJ				Li, Guanghao; Zhao, Bin; Dong, Shuting; Zhang, Jiwang; Liu, Peng; Vyn, Tony J.			Impact of controlled release urea on maize yield and nitrogen use efficiency under different water conditions	PLOS ONE			English	Article							DRY-MATTER; CHINA; GRAIN	Controlled release urea (CRU) has been widely adopted to increase nitrogen (N) use efficiency and maize production, but the impacts can range widely depending on water availability in the soil. In an experiment using Zhengdan 958 (a popular summer maize hybrid), three levels of water treatments (adequate water condition [W3], which maintained soil moisture at about 75% +/- 5% of the soil's field capacity; mild water stress [W2], which maintained moisture content at 55% +/- 5% of field capacity; and severe water stress [W1], which had a moisture content of 35% +/- 5% of field capacity) and four levels of controlled release urea fertilizer (N0, N1, N2 and N3 were 0, 105, 210 and 315 kg N ha(-1), respectively) were compared in a rainout shelter system with soil. The results revealed that CRU had significant effects on maize yields and N use efficiencies under different water conditions. The mean yields increased with increasing water levels and showed significant differences. Under W1, the accumulation of dry matter and N were limited, and N internal efficiency (NIE) and the apparent recovery efficiency of applied N (REN) decreased with N increases; yields of N1, N2, and N3 were similar. Under W2, the dry matter and N accumulation, as well as the yield, showed an increasing trend with an increase in N application, and the NIE and REN of N3 showed no difference from N2. Under W3, yields of N2 and N3 were similar and they were significantly higher than that of N1, but the agronomic N use efficiency (ANUE), REN, and the physiological NUE (PNUE) of N2 were 54.2, 34.9, and 14.4% higher, respectively, than those of N3. N application beyond the optimal N rate did not consistently increase maize yield, and caused a decrease in N use efficiencies. Highest overall dry matter, N accumulation, and yields were observed with N3 under W2, and those showed no differences with N2 and N3 under W3. Under this experimental condition, the CRU of 210 kg ha(-1) was optimized when soil moisture content was 75% +/- 5% of field capacity, but an N rate of 315 kg ha(-1) was superior when soil moisture content during the entire growing season was maintained at 55% +/- 5% of field capacity.	[Li, Guanghao; Zhao, Bin; Dong, Shuting; Zhang, Jiwang; Liu, Peng] Shandong Agr Univ, State Key Lab Crop Biol, Tai An, Shandong, Peoples R China; [Li, Guanghao; Zhao, Bin; Dong, Shuting; Zhang, Jiwang; Liu, Peng] Shandong Agr Univ, Coll Agron, Tai An, Shandong, Peoples R China; [Vyn, Tony J.] Purdue Univ, Dept Agron, W Lafayette, IN 47907 USA	Shandong Agricultural University; Shandong Agricultural University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Zhao, B; Dong, ST (corresponding author), Shandong Agr Univ, State Key Lab Crop Biol, Tai An, Shandong, Peoples R China.; Zhao, B; Dong, ST (corresponding author), Shandong Agr Univ, Coll Agron, Tai An, Shandong, Peoples R China.	zhaobin@sdau.edu.cn; stdong@sdau.edu.cn		Vyn, Tony/0000-0001-9860-4475	Natural Science Foundation of China [31171497, 31301274]; Funds of Shandong "Double Tops" Program [SYL2017XTTD14]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Funds of Shandong "Double Tops" Program	This research was supported by the Natural Science Foundation of China (No.31171497, No.31301274) and Funds of Shandong "Double Tops" Program (SYL2017XTTD14). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to acknowledge the financial support of the Natural Science Foundation of China (No.31171497, No.31301274) and Funds of Shandong "Double Tops" Program (SYL2017XTTD14). We would also like to thank the reviewers for helping us improve our original manuscript. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: hiip://www.LexLcheck.com/certificate/h3YTkF	ALLISON JCS, 1966, ANN BOT-LONDON, V30, P365, DOI 10.1093/oxfordjournals.aob.a084082; Bhadra Parija, 2013, Journal of Plant Science Research, V29, P177; Chen KR, 2015, FIELD CROP RES, V183, P315, DOI 10.1016/j.fcr.2015.08.013; Chen XP, 2014, NATURE, V514, P486, DOI 10.1038/nature13609; Ciampitti IA, 2013, CROP SCI, V53, P366, DOI 10.2135/cropsci2012.07.0439; Ciampitti IA, 2012, CROP SCI, V52, P2728, DOI 10.2135/cropsci2012.05.0305; Ciampitti IA, 2011, FIELD CROP RES, V121, P2, DOI 10.1016/j.fcr.2010.10.009; Diez JA, 1994, NUTR CYCL AGROECOSYS, V43, P191; Duan YH, 2011, SOIL SCI SOC AM J, V75, P1562, DOI 10.2136/sssaj2010.0315; DUVICK DN, 1992, MAYDICA, V37, P69; EGHBALL B, 1991, COMMUN SOIL SCI PLAN, V22, P1367, DOI 10.1080/00103629109368498; Fang Q, 2008, J ENVIRON QUAL, V37, P2232, DOI 10.2134/jeq2007.0601; FREDERICK JR, 1990, ANN BOT-LONDON, V66, P407, DOI 10.1093/oxfordjournals.aob.a088042; Ge TD, 2012, ACTA PHYSIOL PLANT, V34, P1043, DOI 10.1007/s11738-011-0901-y; Geng J, 2016, AGRON J, V108, P1; Gheysari M, 2009, AGR WATER MANAGE, V96, P809, DOI 10.1016/j.agwat.2008.11.003; Gheysari M, 2009, AGR WATER MANAGE, V96, P946, DOI 10.1016/j.agwat.2009.01.005; Guo LW, 2016, EUR J AGRON, V75, P118, DOI 10.1016/j.eja.2016.01.010; Hu HY, 2013, FIELD CROP RES, V142, P85, DOI 10.1016/j.fcr.2012.12.001; Huang P, 2014, BIOL FERT SOILS, V51, P1; HUGGINS DR, 1993, AGRON J, V85, P898, DOI 10.2134/agronj1993.00021962008500040022x; Jia XC, 2014, AGR WATER MANAGE, V137, P92, DOI 10.1016/j.agwat.2014.02.010; Jiang PeiFu, 2006, Transactions of the Chinese Society of Agricultural Engineering, V22, P1; Lal R, 2013, J PLANT NUTR SOIL SC, V176, P479, DOI 10.1002/jpln.201300189; Li GuangHao, 2015, Acta Agronomica Sinica, V41, P1406; Li YJ, 2013, AGR OUTLOOK, V07, P47; Lu RK, 2000, SOIL AGR CHEM ANAL M; Miao WenFang, 2011, Zhongguo Shengtai Nongye Xuebao / Chinese Journal of Eco-Agriculture, V19, P293, DOI 10.3724/SP.J.1011.2011.00293; MOLL RH, 1982, AGRON J, V74, P562, DOI 10.2134/agronj1982.00021962007400030037x; Mueller SM, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00053; Nannen DU, 2011, NUTR CYCL AGROECOSYS, V68, P3; Paponov IA, 2005, J PLANT NUTR SOIL SC, V168, P447, DOI 10.1002/jpln.200520505; Peng Yu, 2014, Acta Agronomica Sinica, V40, P859; Shao GQ, 2013, J PLANT NUTR SOIL SC, V176, P595, DOI 10.1002/jpln.201100185; Shaviv A, 2001, ADV AGRON, V71, P1, DOI 10.1016/S0065-2113(01)71011-5; Teixeira AI, 2014, FIELD CROP RES, V168, P109, DOI 10.1016/j.fcr.2014.08.002; Tollenaar M, 2002, FIELD CROP RES, V75, P161, DOI 10.1016/S0378-4290(02)00024-2; [卫丽 Wei Li], 2010, [植物营养与肥料学报, Plant Nutrition and Fertitizer Science], V16, P773; Wu Z-J, 2001, REV CHINA AGR SCI TE, V3, P73; Zhang M., 2001, J CHEM FERTILIZER IN, V28, P27; Zhang SL, 2014, FIELD CROP RES, V163, P55, DOI 10.1016/j.fcr.2014.04.003; Zhang WF, 2016, NATURE, V537, P671, DOI 10.1038/nature19368; Zhao B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070569; Zhao Bin, 2010, Acta Agronomica Sinica, V36, P1760; [赵荣芳 Zhao Rongfang], 2009, [土壤学报, Acta Pedologica Sinica], V46, P684	45	22	22	4	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2017	12	7							e0181774	10.1371/journal.pone.0181774	http://dx.doi.org/10.1371/journal.pone.0181774			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8BB	28738065	Green Published, Green Submitted, gold			2023-01-03	WOS:000406362700069
J	Leventer-Roberts, M; Hammerman, A; Brufman, I; Hoshen, M; Braun, M; Ashur, Y; Lieberman, N; Balicer, R				Leventer-Roberts, Maya; Hammerman, Ariel; Brufman, Ilan; Hoshen, Moshe; Braun, Marius; Ashur, Yaffa; Lieberman, Nicky; Balicer, Ran			Effectiveness of dasabuvir/ombitasvir/ paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study	PLOS ONE			English	Article							GENOTYPE 1; HCV; RIBAVIRIN; INFECTION; DASABUVIR; REGIMENS; ABT-450/R-OMBITASVIR; CIRRHOSIS; THERAPY; ISRAEL	Background Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials. Aim To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response. Methods Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to- November 31, 2015. Results There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 ( 74.8%) had follow- up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested. Conclusions Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.	[Leventer-Roberts, Maya; Brufman, Ilan; Hoshen, Moshe; Balicer, Ran] Clalit Res Inst, Tel Aviv, Israel; [Leventer-Roberts, Maya] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Hammerman, Ariel; Braun, Marius; Balicer, Ran] Clalit Hlth Serv, Chief Phys Off, Tel Aviv, Israel; [Braun, Marius] Beilinson Med Ctr, Liver Unit, Petah Tiqwa, Israel; [Braun, Marius] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Ashur, Yaffa] Clalit Hlth Serv, Hepatol, Tel Aviv, Israel; [Lieberman, Nicky] Clalit Hlth Serv, Community Med Div, Tel Aviv, Israel; [Balicer, Ran] Ben Gurion Univ Negev, Dept Epidemiol, Fac Hlth Sci, Beer Sheva, Israel	Icahn School of Medicine at Mount Sinai; Clalit Health Services; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Clalit Health Services; Clalit Health Services; Ben Gurion University	Leventer-Roberts, M (corresponding author), Clalit Res Inst, Tel Aviv, Israel.; Leventer-Roberts, M (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.	mayale3@clalit.org.il	Hammerman, Ariel/AAG-4399-2020	Hammerman, Ariel/0000-0002-4396-5246	Abbvie; MSD; Jansen; Gilead; Novartis; Roche; BMS	Abbvie(AbbVie); MSD; Jansen; Gilead(Gilead Sciences); Novartis(Novartis); Roche(Roche Holding); BMS(Bristol-Myers Squibb)	Dr. Braun reports receiving consulting fees from Abbvie, MSD, and Jansen; educational travel grants from Gilead and Novartis; and personal fees from Roche and BMS. All other authors have no conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials.	Andreone P, 2014, GASTROENTEROLOGY, V147, P359, DOI 10.1053/j.gastro.2014.04.045; [Anonymous], 2014, J HOPK ACG SYST VERS; Ara A Kardashian, 2015, Gastroenterol Hepatol (N Y), V11, P458; Backus LI, 2016, ALIMENT PHARM THER, V44, P400, DOI 10.1111/apt.13696; Backus LI, 2015, ALIMENT PHARM THER, V42, P559, DOI 10.1111/apt.13300; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Fabrizi F, 2015, EXPERT REV CLIN PHAR, V8, P785, DOI 10.1586/17512433.2015.1086266; Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338; Gutierrez JA, 2015, J VIRAL HEPATITIS, V22, P861, DOI 10.1111/jvh.12422; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Ioannou GN, 2016, GASTROENTEROLOGY; Karpati T, 2014, POPUL HEALTH METR, V12, DOI 10.1186/s12963-014-0032-y; Klibanov OM, 2015, ANN PHARMACOTHER, V49, P566, DOI 10.1177/1060028015570729; Kohli A, 2015, ANN INTERN MED, V163, P899, DOI 10.7326/M15-0642; Maruyama A, 2015, NEPHROL DIAL TRANSPL; Najafzadeh M, 2015, ANN INTERN MED, V162, P407, DOI 10.7326/M14-1152; Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869; Saeed S, 2016, CLIN INFECT DIS, V62, P919, DOI 10.1093/cid/civ1222; Shmueli A, 2007, HEALTH ECON POLICY L, V2, P251, DOI 10.1017/S1744133107004100; Sulkowski MS, 2015, JAMA-J AM MED ASSOC, V313, P1223, DOI 10.1001/jama.2015.1328; Suwanthawornkul T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145953; Walker DR, 2015, ADV THER, V32, P1117, DOI 10.1007/s12325-015-0258-5; Wilder JM, 2015, THER ADV CHRONIC DIS, V6, P314, DOI 10.1177/2040622315603642; Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561	24	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0176858	10.1371/journal.pone.0176858	http://dx.doi.org/10.1371/journal.pone.0176858			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686590	gold, Green Published, Green Submitted			2023-01-03	WOS:000405464100003
J	Bashir, S; Teo, YY; Naeem, S; Ramesh, S; Ramesh, K				Bashir, Shahid; Teo, Yin Yin; Naeem, Sumaira; Ramesh, S.; Ramesh, K.			pH responsive N-succinyl chitosan/Poly (acrylamide-co-acrylic acid) hydrogels and in vitro release of 5-fluorouracil	PLOS ONE			English	Article							DRUG-DELIVERY; INTERPOLYMERIC PH; SENSITIVE HYDROGELS; SWELLING BEHAVIOR; SODIUM ALGINATE; SEMI-IPN; CHITIN; MICROSPHERES; DERIVATIVES; SYSTEM	There has been significant progress in the last few decades in addressing the biomedical applications of polymer hydrogels. Particularly, stimuli responsive hydrogels have been inspected as elegant drug delivery systems capable to deliver at the appropriate site of action within the specific time. The present work describes the synthesis of pH responsive semi-interpenetrating network (semi-IPN) hydrogels of N-succinyl-chitosan (NSC) via Schiff base mechanism using glutaraldehyde as a crosslinking agent and Poly (acrylamide-co-acrylic acid)(Poly (AAm-co-AA)) was embedded within the N-succinyl chitosan network. The physico-chemical interactions were characterized by Fourier transform infrared (FTIR), X-ray diffraction (XRD), thermogravimetric analysis (TGA), and field emission scanning electron microscope (FESEM). The synthesized hydrogels constitute porous structure. The swelling ability was analyzed in physiological mediums of pH 7.4 and pH 1.2 at 37 degrees C. Swelling properties of formulations with various amounts of NSC/Poly (AAm-co-AA) and crosslinking agent at pH 7.4 and pH 1.2 were investigated. Hydrogels showed higher swelling ratios at pH 7.4 while lower at pH 1.2. Swelling kinetics and diffusion parameters were also determined. Drug loading, encapsulation efficiency, and in vitro release of 5-fluorouracil (5FU) from the synthesized hydrogels were observed. In vitro release profile revealed the significant influence of pH, amount of NSC, Poly (AAm-co-AA), and crosslinking agent on the release of 5-FU. Accordingly, rapid and large release of drug was observed at pH 7.4 than at pH 1.2. The maximum encapsulation efficiency and release of 5-FU from SP2 were found to be 72.45% and 85.99%, respectively. Kinetics of drug release suggested controlled release mechanism of 5-FU is according to trend of non-Fickian. From the above results, it can be concluded that the synthesized hydrogels have capability to adapt their potential exploitation as targeted oral drug delivery carriers.	[Bashir, Shahid; Teo, Yin Yin; Naeem, Sumaira] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur, Malaysia; [Ramesh, S.; Ramesh, K.] Univ Malaya, Dept Phys, Ctr Ion, Fac Sci, Kuala Lumpur, Malaysia	Universiti Malaya; Universiti Malaya	Bashir, S (corresponding author), Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur, Malaysia.; Ramesh, S (corresponding author), Univ Malaya, Dept Phys, Ctr Ion, Fac Sci, Kuala Lumpur, Malaysia.	shahidbashirbaig@gmail.com; rameshtsubra@gmail.com	Ramesh, T.Subramaniam/C-2353-2009; Kasi, Ramesh/B-4765-2011; TEO, YIN YIN/B-9948-2010; Bashir, Shahid/AAH-1116-2019; Naeem, Dr. Sumaira/ACV-6371-2022	Ramesh, T.Subramaniam/0000-0002-5505-6429; Kasi, Ramesh/0000-0001-7843-5723; TEO, YIN YIN/0000-0002-2755-5589; Bashir, Shahid/0000-0001-6745-8874; 	Ministry of Education, Malaysia [H21001-F000046];  [RP025A-14 AFR];  [RP017C-14AFR]	Ministry of Education, Malaysia(Ministry of Education, Malaysia); ; 	This work was supported by the High Impact Research Grant (H21001-F000046) from the Ministry of Education, Malaysia, and University of Malaya Research Grants (RP025A-14 AFR and RP017C-14AFR).	Abdelaal MY, 2007, J APPL POLYM SCI, V103, P2864, DOI 10.1002/app.25154; Abreu Fernanda R. de, 2005, Polímeros, V15, P79, DOI 10.1590/S0104-14282005000200004; Alexander-Bryant AA, 2013, ADV CANCER RES, V118, P1, DOI 10.1016/B978-0-12-407173-5.00002-9; Babu VR, 2006, INT J PHARMACEUT, V325, P55, DOI 10.1016/j.ijpharm.2006.06.020; Bashir S, 2016, POLYMER, V92, P36, DOI 10.1016/j.polymer.2016.03.045; Bashir S, 2015, REV CHEM ENG, V31, P563, DOI 10.1515/revce-2015-0016; BRANNONPEPPAS L, 1990, BIOMATERIALS, V11, P635, DOI 10.1016/0142-9612(90)90021-H; Casettari L, 2012, PROG POLYM SCI, V37, P659, DOI 10.1016/j.progpolymsci.2011.10.001; Cheng R, 2013, BIOMATERIALS, V34, P3647, DOI 10.1016/j.biomaterials.2013.01.084; Costa ES, 2009, CARBOHYD POLYM, V76, P472, DOI 10.1016/j.carbpol.2008.11.015; Damaghi M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00370; Dash M, 2012, MATER CHEM PHYS, V135, P1070, DOI 10.1016/j.matchemphys.2012.06.019; El-Sherbiny IM, 2005, EUR POLYM J, V41, P2584, DOI 10.1016/j.eurpolymj.2005.05.035; Feng ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100732; Finetti F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168727; Fournier E, 2003, INT J PHARMACEUT, V268, P31, DOI 10.1016/j.ijpharm.2003.08.014; Ge HC, 2014, CARBOHYD POLYM, V113, P296, DOI 10.1016/j.carbpol.2014.06.078; Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9; Hashim AI, 2011, NMR BIOMED, V24, P582, DOI 10.1002/nbm.1644; Hawary DL, 2011, J RADIOANAL NUCL CH, V290, P557, DOI 10.1007/s10967-011-1310-9; Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/j.addr.2012.09.010; Hu XY, 2014, CARBOHYD POLYM, V105, P135, DOI 10.1016/j.carbpol.2014.01.051; Islam A, 2012, CARBOHYD POLYM, V88, P1055, DOI 10.1016/j.carbpol.2012.01.070; Jagadish RS, 2011, FOOD HYDROCOLLOID, V25, P1572, DOI 10.1016/j.foodhyd.2011.01.009; Kajjari PB, 2013, POLYM BULL, V70, P3387, DOI 10.1007/s00289-013-1029-6; Khor E, 2002, CURR OPIN SOLID ST M, V6, P313, DOI 10.1016/S1359-0286(02)00002-5; Kulkarni RV, 2012, J COLLOID INTERF SCI, V367, P509, DOI 10.1016/j.jcis.2011.10.025; Kurita K, 2001, PROG POLYM SCI, V26, P1921, DOI 10.1016/S0079-6700(01)00007-7; Kurita K, 2006, MAR BIOTECHNOL, V8, P203, DOI 10.1007/s10126-005-0097-5; Lee WF, 2001, J APPL POLYM SCI, V82, P2487, DOI 10.1002/app.2099; Li P, 2007, MACROMOL MATER ENG, V292, P962, DOI 10.1002/mame.200700081; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Liu XH, 2013, ISRN MATH PHYS, V2013, P1, DOI DOI 10.1016/J.MICR0REL.2012.06.140; Malik NS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172727; Mall ID, 2006, COLLOID SURFACE A, V278, P175, DOI 10.1016/j.colsurfa.2005.12.017; Mathur AM, 1996, J MACROMOL SCI R M C, VC36, P405; Mirzaei BE, 2013, INT J POLYM MATER PO, V62, P605, DOI 10.1080/00914037.2013.769165; Mohan YM, 2005, J APPL POLYM SCI, V96, P1153, DOI 10.1002/app.21565; Mourya VK, 2008, REACT FUNCT POLYM, V68, P1013, DOI 10.1016/j.reactfunctpolym.2008.03.002; Mukhopadhyay P, 2014, CARBOHYD POLYM, V112, P627, DOI 10.1016/j.carbpol.2014.06.045; Mukhopadhyay P, 2013, J APPL POLYM SCI, V129, P835, DOI 10.1002/app.38814; Mura C, 2011, CARBOHYD POLYM, V85, P578, DOI 10.1016/j.carbpol.2011.03.017; Nadeem M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158084; Pal K, 2009, DES MONOMERS POLYM, V12, P197, DOI 10.1163/156855509X436030; Patil NS, 1996, BIOMATERIALS, V17, P2343, DOI 10.1016/S0142-9612(96)00089-0; PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y; Rama AR, 2015, INT J MOL SCI, V16, P12601, DOI 10.3390/ijms160612601; Ravichandran P, 1997, INT J PHARM, V154, P89, DOI 10.1016/S0378-5173(97)00131-2; Ray D, 2008, J BIOMAT SCI-POLYM E, V19, P1487, DOI 10.1163/156856208786140382; Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001; RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4; Rizwan M, 2017, POLYMERS-BASEL, V9, DOI 10.3390/polym9040137; ROORDA WE, 1986, PHARM WEEKBLAD, V8, P165, DOI 10.1007/BF01959775; Sagara A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164250; Samanta HS, 2014, CARBOHYD POLYM, V106, P109, DOI 10.1016/j.carbpol.2014.01.097; Samanta HS, 2014, CARBOHYD POLYM, V99, P666, DOI 10.1016/j.carbpol.2013.09.004; Sashiwa H, 2003, MACROMOL BIOSCI, V3, P231, DOI 10.1002/mabi.200390029; Sastre RL, 2007, INT J PHARMACEUT, V338, P180, DOI 10.1016/j.ijpharm.2007.02.001; Shantha KL, 2000, INT J PHARM, V207, P65, DOI 10.1016/S0378-5173(00)00533-0; Shim JW, 2003, J APPL POLYM SCI, V90, P3270, DOI 10.1002/app.12992; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tharanathan RN, 2003, CRIT REV FOOD SCI, V43, P61, DOI 10.1080/10408690390826455; Thurmer MB, 2014, MATER RES-IBERO-AM J, V17, P109, DOI 10.1590/1516-1439.223613; Wang Q, 2005, J APPL POLYM SCI, V96, P808, DOI 10.1002/app.21518; Yan C., 2006, J PHARM SOC JAPAN, V126, P789; Zeitoun AA, 2003, COMP SINGLE DOSE BIO; Zhang JT, 2010, ACTA BIOMATER, V6, P1297, DOI 10.1016/j.actbio.2009.11.005; Zhang XZ, 2002, INT J PHARMACEUT, V235, P43, DOI 10.1016/S0378-5173(01)00976-0; Zhou JQ, 2009, ENZYME MICROB TECH, V45, P299, DOI 10.1016/j.enzmictec.2009.07.007; Zhu AP, 2007, CARBOHYD POLYM, V69, P363, DOI 10.1016/j.carbpol.2006.11.023	70	51	51	1	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0179250	10.1371/journal.pone.0179250	http://dx.doi.org/10.1371/journal.pone.0179250			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678803	gold, Green Published, Green Submitted			2023-01-03	WOS:000405272200010
J	Tu, XJ; Hwang, WJ; Ma, HI; Chang, LH; Hsu, SP				Tu, Xiao-Jing; Hwang, Wen-Juh; Ma, Hui-Ing; Chang, Ling-Hui; Hsu, Shih-Pin			Determinants of generic and specific healthrelated quality of life in patients with Parkinson's disease	PLOS ONE			English	Article							MDS-UPDRS; NONMOTOR SYMPTOMS; CHINESE VERSION; QUESTIONNAIRE PDQ-39; RATING-SCALES; DISORDER; RECOMMENDATIONS; VALIDATION; CRITIQUE; PROGRESSION	Objectives Generic and disease-specific health-related quality of life (HRQoL) instruments may reflect different aspects of lives in patients with Parkinson's disease (PD) and thus be associated with different determinants. We used the same cluster of predictors for the generic and disease- specific HRQoL instruments to examine and compare the determinants of HRQoL. Method HRQoL was measured in 92 patients with PD by the 36-item Short-Form Health Survey (SF-36) and the 39-item Parkinson's Disease Questionnaire (PDQ-39). The predictors included demographic and disease characteristics, and motor and non-motor symptoms. Multiple regression analyses were used to identify HRQoL determinants. Results Depressive symptoms and motor difficulties of daily living were the first two significant determinants for both instruments. The other significant determinant for the SF-36 was fatigue and non-motor difficulties of daily living, and for the PDQ-39 was motor signs of PD. Conclusions The results suggest the importance of the evaluation and intervention focused on depressive symptoms and motor difficulties of daily living in patients with PD. In addition, the SF-36 seems more related to non-motor symptoms, while the PDQ-39 appears more associated with motor symptoms. This information is important for understanding results from these two instruments and for choosing which to use.	[Tu, Xiao-Jing; Ma, Hui-Ing; Chang, Ling-Hui] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan, Taiwan; [Hwang, Wen-Juh] Natl Cheng Kung Univ, Dept Neurol, Coll Med, Tainan, Taiwan; [Ma, Hui-Ing; Chang, Ling-Hui] Natl Cheng Kung Univ, Dept Occupat Therapy, Coll Med, Tainan, Taiwan; [Hsu, Shih-Pin] E Da Hosp, Dept Neurol, Kaohsiung, Taiwan; [Hsu, Shih-Pin] I Shou Univ, Kaohsiung, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; E-Da Hospital; I Shou University	Ma, HI (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan, Taiwan.; Ma, HI (corresponding author), Natl Cheng Kung Univ, Dept Occupat Therapy, Coll Med, Tainan, Taiwan.; Hsu, SP (corresponding author), E Da Hosp, Dept Neurol, Kaohsiung, Taiwan.; Hsu, SP (corresponding author), I Shou Univ, Kaohsiung, Taiwan.	huingma@mail.ncku.edu.tw; a.pin.hsu@gmail.com	Chang, Ling-Hui/AAG-2410-2019	Chang, Ling Hui/0000-0003-4129-6947	E-Da Hospital, Kaohsiung, Taiwan [NCKUEDA 10214]	E-Da Hospital, Kaohsiung, Taiwan	The study was supported by grant NCKUEDA 10214 from E-Da Hospital, Kaohsiung, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bushnell DM, 1999, QUAL LIFE RES, V8, P345, DOI 10.1023/A:1008979705027; Caap-Ahlgren M, 2001, ARCH GERONTOL GERIAT, V32, P23, DOI 10.1016/S0167-4943(00)00087-X; Carod-Artal FJ, 2007, MOVEMENT DISORD, V22, P1408, DOI 10.1002/mds.21408; Chan ACM, 1996, J AGING HEALTH, V8, P238, DOI 10.1177/089826439600800205; Cubo E, 2002, EUR J NEUROL, V9, P589, DOI 10.1046/j.1468-1331.2002.00484.x; Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1528, DOI 10.1002/mds.21567; Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1390, DOI 10.1002/mds.21539; Dowding CH, 2006, DRUG AGING, V23, P693, DOI 10.2165/00002512-200623090-00001; Duncan GW, 2014, MOVEMENT DISORD, V29, P195, DOI 10.1002/mds.25664; Friedman JH, 2010, MOVEMENT DISORD, V25, P805, DOI 10.1002/mds.22989; Fuh JL, 2000, QUAL LIFE RES, V9, P675, DOI 10.1023/A:1008993821633; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Grosset KA, 2005, MOVEMENT DISORD, V20, P616, DOI 10.1002/mds.20393; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hu MH, 2010, J LONG TERM CARE, V14, P267; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jenkinson C, 1999, PHARMACOECONOMICS, V15, P157, DOI 10.2165/00019053-199915020-00004; Lawrence BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102294; Ma HI, 2005, QUAL LIFE RES, V14, P565, DOI 10.1007/s11136-004-0687-0; Maetzler W, 2009, LANCET NEUROL, V8, P1158, DOI 10.1016/S1474-4422(09)70291-1; Martinez-Martin P, 2014, EUR J NEUROL, V21, P519, DOI 10.1111/ene.12349; Martinez-Martin P, 1998, J NEUROL, V245, pS2, DOI 10.1007/PL00007733; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834; Martinez-Martin P, 2011, J NEUROL SCI, V310, P12, DOI 10.1016/j.jns.2011.05.006; Muangpaisan W, 2009, J EPIDEMIOL, V19, P281, DOI 10.2188/jea.JE20081034; Muller B, 2013, PARKINSONISM RELAT D, V19, P1027, DOI 10.1016/j.parkreldis.2013.07.010; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; Post B, 2007, MOVEMENT DISORD, V22, P1839, DOI 10.1002/mds.21537; Qin ZH, 2009, PARKINSONISM RELAT D, V15, P767, DOI 10.1016/j.parkreldis.2009.05.011; Qin ZH, 2009, CLIN NEUROL NEUROSUR, V111, P733, DOI 10.1016/j.clineuro.2009.07.001; Reuther M, 2007, PARKINSONISM RELAT D, V13, P108, DOI 10.1016/j.parkreldis.2006.07.009; Rodriguez-Blazquez C, 2013, PARKINSONISM RELAT D, V19, P889, DOI 10.1016/j.parkreldis.2013.05.017; Schrag A, 2000, J NEUROL NEUROSUR PS, V69, P308, DOI 10.1136/jnnp.69.3.308; Schrag A, 2007, MOVEMENT DISORD, V22, P1077, DOI 10.1002/mds.21333; Simpson J, 2014, DISABIL REHABIL, V36, P1964, DOI 10.3109/09638288.2014.883442; Skorvanek M, 2015, J NEUROL SCI, V353, P87, DOI 10.1016/j.jns.2015.04.013; Skorvanek M, 2013, J GERIATR PSYCH NEUR, V26, P237, DOI 10.1177/0891988713500587; Soh SE, 2011, PARKINSONISM RELAT D, V17, P1, DOI 10.1016/j.parkreldis.2010.08.012; Tariq SH, 2006, AM J GERIAT PSYCHIAT, V14, P900, DOI 10.1097/01.JGP.0000221510.33817.86; Verbaan D, 2011, PARKINSONISM RELAT D, V17, P632, DOI 10.1016/j.parkreldis.2011.05.022; Wang MY, 2016, QUAL LIFE RES, V25, P89, DOI 10.1007/s11136-015-1056-x; Yu RL, 2017, MOV DISORD CLIN PRAC, V4, P68, DOI 10.1002/mdc3.12349	42	19	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2017	12	6							e0178896	10.1371/journal.pone.0178896	http://dx.doi.org/10.1371/journal.pone.0178896			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EZ2KD	28650957	Green Published, gold, Green Submitted			2023-01-03	WOS:000404537300048
J	Borchmann, P; Goergen, H; Kobe, C; Lohri, A; Greil, R; Eichenauer, DA; Zijlstra, JM; Markova, J; Meissner, J; Feuring-Buske, M; Huttmann, A; Dierlamm, J; Soekler, M; Beck, HJ; Willenbacher, W; Ludwig, WD; Pabst, T; Topp, MS; Hitz, F; Bentz, M; Keller, UB; Kuhnhardt, D; Ostermann, H; Schmitz, N; Hertenstein, B; Aulitzky, W; Maschmeyer, G; Vieler, T; Eich, H; Baues, C; Stein, H; Fuchs, M; Kuhnert, G; Diehl, V; Dietlein, M; Engert, A				Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A.; Zijlstra, Josee M.; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Huttmann, Andreas; Dierlamm, Judith; Soekler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S.; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kuhnhardt, Dagmar; Ostermann, Helmut; Schmitz, Norbert; Hertenstein, Bernd; Aulitzky, Walter; Maschmeyer, Georg; Vieler, Tom; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Kuhnert, Georg; Diehl, Volker; Dietlein, Markus; Engert, Andreas			PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group	LANCET			English	Article							POSITRON-EMISSION-TOMOGRAPHY; PROGRESSION-FREE SURVIVAL; RESPONSE-ADAPTED THERAPY; CANCER-RELATED FATIGUE; BRENTUXIMAB VEDOTIN; EARLY INTERIM; PROGNOSTIC SCORE; CHEMOTHERAPY; ABVD; MULTICENTER	Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense of severe toxicities. Individual patients might be cured with less burdensome therapy. We investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it for PET-2-negative patients. Methods In this open-label, randomised, parallel-group phase 3 trial, we recruited patients aged 18-60 years with newly diagnosed, advanced-stage Hodgkin's lymphoma in 301 hospitals and private practices in Germany, Switzerland, Austria, the Netherlands, and the Czech Republic. After central review of PET-2, patients were assigned (1: 1) to one of two parallel treatment groups on the basis of their PET-2 result. Patients with positive PET-2 were randomised to receive six additional cycles of either standard eBEACOPP (8 x eBEACOPP in total) or eBEACOPP with rituximab (8 x R-eBEACOPP). Those with negative PET-2 were randomised between standard treatment with six additional cycles of eBEACOPP (8 x eBEACOPP) or experimental treatment with two additional cycles (4 x eBEACOPP). A protocol amendment in June, 2011, introduced a reduction of standard therapy to 6 x eBEACOPP; after this point, patients with positive PET-2 were no longer randomised and were all assigned to receive 6 x eBEACOPP and patients with negative PET-2 were randomly assigned to 6 x eBEACOPP (standard) or 4 x eBEACOPP (experimental). Randomisation was done centrally using the minimisation method including a random component, stratified according to centre, age (<45 vs >= 45 years), stage (IIB, IIIA vs IIIB, IV), international prognostic score (0-2 vs 3-7), and sex. eBEACOPP was given as previously described; rituximab was given intravenously at a dose of 375 mg/m(2) (maximum total dose 700 mg). The primary objectives were to show superiority of the experimental treatment in the PET-2-positive cohort, and to show non-inferiority of the experimental treatment in the PET-2-negative cohort in terms of the primary endpoint, progression-free survival. We defined non-inferiority as an absolute difference of 6% in the 5-year progression-free survival estimates. Primary analyses in the PET-2-negative cohort were per protocol; all other analyses were by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT00515554. Findings Between May 14, 2008, and July 18, 2014, we recruited 2101 patients, of whom 137 were found ineligible before randomisation and a further 19 were found ineligible after randomisation. Among 434 randomised patients (217 per arm) with positive PET-2, 5-year progression-free survival was 89.7% (95% CI 85.4-94.0) with eBEACOPP and 88.1% (83.5-92.7) with R-eBEACOPP (log-rank p=0.46). Patients with negative PET-2 randomly assigned to either 8 x eBEACOPP or 6 x eBEACOPP (n=504) or 4 x eBEACOPP (n=501) had 5-year progression-free survival of 90.8% (95% CI 87.9-93.7) and 92.2% (89.4-95.0), respectively (difference 1.4%, 95% CI -2.7 to 5.4). 4 x eBEACOPP was associated with fewer severe infections (40 [8%] of 498 vs 75 [15%] of 502) and organ toxicities (38 [8%] of 498 vs 91 [18%] of 502) than were 8 x eBEACOPP or 6 x eBEACOPP in PET-2-negative patients. Ten treatment-related deaths occurred: four in the PET-2-positive cohort (one [<1%] in the 8 x eBEACOPP group, three [1%] in the 8 x R-eBEACOPP group) and six in the PET-2-negative group (six [1%] in the 8 x eBEACOPP or 6 x eBEACOPP group). Interpretation The favourable outcome of patients treated with eBEACOPP could not be improved by adding rituximab after positive PET-2. PET-2 negativity allows reduction to only four cycles of eBEACOPP without loss of tumour control. PET-2-guided eBEACOPP provides outstanding efficacy for all patients and increases overall survival by reducing treatment-related risks for patients with negative PET-2. We recommend this PET-2-guided treatment strategy for patients with advanced-stage Hodgkin's lymphoma.	[Borchmann, Peter] Univ Hosp Cologne, German Hodgkin Study Grp, Dept Internal Med 1, Cologne, Germany; [Eichenauer, Dennis A.; Fuchs, Michael; Diehl, Volker] Univ Hosp Cologne, H Goergen Dipl Math, Cologne, Germany; [Kobe, Carsten; Kuhnert, Georg; Dietlein, Markus] Univ Hosp Cologne, Dept Nucl Med, Cologne, Germany; [Baues, Christian] Univ Hosp Cologne, Dept Radiotherapy, Cologne, Germany; [Lohri, Andreas] Cantonal Hosp Baselland, Liestal, Switzerland; [Lohri, Andreas; Pabst, Thomas; Hitz, Felicitas] Swiss Grp Clin Canc Res, Bern, Switzerland; [Greil, Richard] Paracelcus Med Univ, Med Dept 3, Salzburg, Austria; [Greil, Richard; Willenbacher, Wolfgang] Salzburg Canc Res Inst, Salzburg, Austria; [Greil, Richard; Willenbacher, Wolfgang] AGMT Arbeitsgemeinschaft Medikamentose Tumorthera, Salzburg, Austria; [Zijlstra, Josee M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Markova, Jana] Charles Univ Prague, Fac Med 3, Dept Internal Med Hematol, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Meissner, Julia] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Feuring-Buske, Michaela] Univ Hosp Ulm, Dept Med 3, Ulm, Germany; [Huttmann, Andreas] Univ Duisburg Essen, Dept Haematol, Univ Hosp, Essen, Germany; [Dierlamm, Judith] Univ Hosp Hamburg Eppendorf, Dept Oncol & Haematol, Hamburg, Germany; [Soekler, Martin] Univ Tubingen, Dept Oncol & Haematol, Tubingen, Germany; [Beck, Hans-Joachim] Univ Hosp Mainz, Dept Oncol & Haematol, Mainz, Germany; [Willenbacher, Wolfgang] Med Univ Innsbruck, Internal Med 5, Hematol & Oncol, Innsbruck, Austria; [Willenbacher, Wolfgang] Oncotyrol, Ctr Personalized Canc Med, Innsbruck, Austria; [Ludwig, Wolf-Dieter] HELIOS Med Ctr Berlin Buch, Berlin, Germany; [Pabst, Thomas] Inselspital Bern, Dept Med Oncol, Bern, Switzerland; [Topp, Max S.] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany; [Hitz, Felicitas] Cantonal Hosp St Gallen, St Gallen, Switzerland; [Bentz, Martin] Stadt Klinikum Karlsruhe, Dept Internal Med 3, Karlsruhe, Germany; [Keller, Ulrich Bernd] Klinikum Rechts Der Isar, Dept Internal Med 3, Munich, Germany; [Kuhnhardt, Dagmar] Charite, Dept Hematol & Oncol, Berlin, Germany; [Ostermann, Helmut] Univ Hosp Munich, Dept Hematol Oncol, Munich, Germany; [Schmitz, Norbert] Asklepios Hosp St Georg, Dept Haematol, Hamburg, Germany; [Hertenstein, Bernd] Klinikum Bremen Mitte, Dept Internal Med 1, Bremen, Germany; [Aulitzky, Walter] Robert Bosch Krankenhaus, Dept Haematol & Oncol, Stuttgart, Germany; [Maschmeyer, Georg] Ernst von Bergmann Hosp, Dept Haematol Oncol & Palliat Care, Potsdam, Germany; [Vieler, Tom] Univ Hosp Schleswig Holstein, Karl Lennert Canc Ctr, Kiel, Germany; [Eich, Hans] Univ Hosp Muenster, Dept Radiotherapy, Munster, Germany; [Stein, Harald] Berlin Reference Ctr Lymphoma & Haematopathol, Berlin, Germany	University of Cologne; University of Cologne; University of Cologne; University of Cologne; Kantonsspital Baselland; Swiss Group for Clinical Cancer Research (SAKK); Paracelsus Private Medical University; Vrije Universiteit Amsterdam; Charles University Prague; University Hospital Vinohrady; Ruprecht Karls University Heidelberg; Ulm University; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; University Hospital Mainz; Medical University of Innsbruck; University of Bern; University Hospital of Bern; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; Kantonsspital St. Gallen; Municipal Hospital Karlsruhe; Technical University of Munich; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Asklepios Klinik St. Georg; Klinikum Bremen-Mitte; Bosch; Robert Bosch Krankenhaus; Klinikum Ernst von Bergmann; University of Kiel; Schleswig Holstein University Hospital; University of Munster	Borchmann, P (corresponding author), Univ Hosp Cologne, GHSG, D-50924 Cologne, Germany.	peter.borchmann@uni-koeln.de	Hüttmann, Andreas/W-6106-2019; Huettmann, Andreas/AAH-6483-2019; Feuring-Buske, Michaela/AAJ-6813-2021; Keller, Ulrich/L-1763-2016	Hüttmann, Andreas/0000-0003-2230-3873; Keller, Ulrich/0000-0002-8485-1958	Deutsche Krebshilfe; Swiss State Secretariat for Education and Research; Roche Pharma AG	Deutsche Krebshilfe(Deutsche Krebshilfe); Swiss State Secretariat for Education and Research; Roche Pharma AG(Roche Holding)	Deutsche Krebshilfe, Swiss State Secretariat for Education and Research, and Roche Pharma AG.	Agostinelli C, 2016, LANCET HAEMATOL, V3, pE467, DOI 10.1016/S2352-3026(16)30108-9; Andre M, 2016, HAEMATOLOGICA, V101, P19; Behringer K, 2010, ANN ONCOL, V21, P2052, DOI 10.1093/annonc/mdq066; Behringer K, 2016, J CLIN ONCOL, V34, P4329, DOI 10.1200/JCO.2016.67.7450; Behringer K, 2013, J CLIN ONCOL, V31, P231, DOI 10.1200/JCO.2012.44.3721; Borchmann P, 2017, LANCET ONCOL, V18, P454, DOI 10.1016/S1470-2045(17)30103-1; Borchmann P, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.580.580; Diehl V, 2003, NEW ENGL J MED, V348, P2386, DOI 10.1056/NEJMoa022473; Engert A, 2012, LANCET, V379, P1791, DOI 10.1016/S0140-6736(11)61940-5; Engert A, 2009, J CLIN ONCOL, V27, P4548, DOI 10.1200/JCO.2008.19.8820; Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525; Gallamini A, 2006, HAEMATOLOGICA, V91, P475; Gordon LI, 2013, J CLIN ONCOL, V31, P684, DOI 10.1200/JCO.2012.43.4803; Hasenclever D, 1996, ANN ONCOL, V7, P95; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Hutchings M, 2006, BLOOD, V107, P52, DOI 10.1182/blood-2005-06-2252; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Josting A, 2003, J CLIN ONCOL, V21, P3440, DOI 10.1200/JCO.2003.07.160; Kreissl S, 2016, LANCET ONCOL, V17, P1453, DOI 10.1016/S1470-2045(16)30093-6; Press OW, 2016, J CLIN ONCOL, V34, P2020, DOI 10.1200/JCO.2015.63.1119; Skoetz N, 2013, LANCET ONCOL, V14, P943, DOI 10.1016/S1470-2045(13)70341-3; Turner S, 1996, BRIT J CANCER, V73, P222, DOI 10.1038/bjc.1996.39; Weihrauch MR, 2002, ANN HEMATOL, V81, P20, DOI 10.1007/s00277-001-0390-y; Wongso D, 2013, J CLIN ONCOL, V31, P2819, DOI 10.1200/JCO.2012.47.9774; Younes A, 2016, LANCET ONCOL, V17, P1283, DOI 10.1016/S1470-2045(16)30167-X; Younes A, 2013, LANCET ONCOL, V14, P1348, DOI 10.1016/S1470-2045(13)70501-1; Younes A, 2012, J CLIN ONCOL, V30, P2183, DOI 10.1200/JCO.2011.38.0410; Zinzani PL, 2016, J CLIN ONCOL, V34, P1376, DOI 10.1200/JCO.2015.63.0699	28	185	187	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 23	2017	390	10114					2790	2802		10.1016/S0140-6736(17)32134-7	http://dx.doi.org/10.1016/S0140-6736(17)32134-7			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ9GF	29061295				2023-01-03	WOS:000418669800024
J	Khosrawipour, T; Khosrawipour, V; Giger-Pabst, U				Khosrawipour, Tanja; Khosrawipour, Veria; Giger-Pabst, Urs			Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma	PLOS ONE			English	Article							SURVIVAL; CANCER; GEMCITABINE; PACLITAXEL; PIPAC	Background Patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma were treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC), initial clinical findings are presented. Methods Single institution, tertiary referral center certified for therapy of peritoneal disease. Prospective data collection of PIPAC therapy with doxorubicin 1.5 mg/m(2) and cisplatin 7.5 mg/m(2) of body surface delivered at intervals of six weeks. The outcome criteria were microscopic pathological response, survival and adverse events (v4.0 CTCAE). Results A total of 20 patients (m/f = 3:1) with a mean age of 64.9 (range: 45.0 to 87.0) years underwent 41 PIPAC procedures without intraoperative complications. The mean number of PIPAC cycles was 2.1 (range: one to four). Ten patients with >= 2 PIPAC applications were eligible for histological analysis to assess carcinoma regression. Complete or high grade tumor regression was found in two (10%) and five (25%) patients, respectively. An overall median survival of 36.6 weeks after the first PIPAC application was observed. One patient died postoperatively due to small bowel obstruction. No CTCAE level 3 and 4 complications occurred. Conclusion In about one third of patients, repeated PIPAC therapy did induce histological regression of systemic chemo-resistant PC of pancreatic adenocarcinoma. Prospective randomized trials are needed to further clarify any clinical impact of such observations.	[Khosrawipour, Tanja; Khosrawipour, Veria; Giger-Pabst, Urs] Ruhr Univ Bochum, St Marys Hosp Herne, Dept Gen Surg, Bochum, Germany; [Khosrawipour, Tanja; Khosrawipour, Veria; Giger-Pabst, Urs] Ruhr Univ Bochum, St Marys Hosp Herne, Therapy Ctr Peritoneal Carcinomatosis, Bochum, Germany; [Khosrawipour, Tanja; Khosrawipour, Veria; Giger-Pabst, Urs] Ruhr Univ Bochum, St Marys Hosp Herne, Dept Surg, Basic Res Labs, Bochum, Germany; [Khosrawipour, Veria] Orthoklin Dortmund, Dept Orthoped & Trauma Surg, Dortmund, Germany	Ruhr University Bochum; St. Marien Hospital; Ruhr University Bochum; St. Marien Hospital; Ruhr University Bochum; St. Marien Hospital	Giger-Pabst, U (corresponding author), Ruhr Univ Bochum, St Marys Hosp Herne, Dept Gen Surg, Bochum, Germany.; Giger-Pabst, U (corresponding author), Ruhr Univ Bochum, St Marys Hosp Herne, Therapy Ctr Peritoneal Carcinomatosis, Bochum, Germany.; Giger-Pabst, U (corresponding author), Ruhr Univ Bochum, St Marys Hosp Herne, Dept Surg, Basic Res Labs, Bochum, Germany.	urs.pabst@elisabethgruppe.de	Giger-Pabst, Urs/AAJ-5008-2021; Khosrawipour, Veria/ABH-8841-2020; Khosrawipour, Tanja/AAI-2372-2019	Khosrawipour, Tanja/0000-0003-0233-551X				Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Dedrick RL, 1997, JNCI-J NATL CANCER I, V89, P480, DOI 10.1093/jnci/89.7.480; Demtroder C, 2016, COLORECTAL DIS, V18, P364, DOI 10.1111/codi.13130; Gohler D, 2017, SURG ENDOSC, V31, P1778, DOI 10.1007/s00464-016-5174-5; Grass F, 2017, BRIT J SURG, V104, P669, DOI 10.1002/bjs.10521; Graversen M, 2017, CLIN EXP METASTAS, V34, P309, DOI 10.1007/s10585-017-9849-7; Khosrawipour V, 2016, ANTICANCER RES, V36, P4595, DOI 10.21873/anticanres.11008; Le Scodan R, 2008, AM J CLIN ONCOL-CANC, V31, P545, DOI 10.1097/COC.0b013e318172d5c5; Lu Z, 2010, FUTURE ONCOL, V6, P1625, DOI 10.2217/FON.10.100; Munch M, 2013, Z GASTROENTEROL, p51 ; Nadiradze G, 2016, J GASTROINTEST SURG, V20, P367, DOI 10.1007/s11605-015-2995-9; Prigerson HG, 2015, JAMA ONCOL, V1, P778, DOI 10.1001/jamaoncol.2015.2378; Robella M, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0892-7; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Smeenk HG, 2005, LANGENBECK ARCH SURG, V390, P94, DOI 10.1007/s00423-004-0476-9; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Solass W, 2016, PLEURA PERITONEUM, V1, P99, DOI [10.1515/pp-2016-0011, 10.1515/pap-2016-0011]; Solass W, 2014, ANN SURG ONCOL, V21, P553, DOI 10.1245/s10434-013-3213-1; Solass W, 2013, ANN SURG ONCOL, V20, P3504, DOI 10.1245/s10434-013-3039-x; Solass W, 2012, SURG ENDOSC, V26, P1849, DOI 10.1007/s00464-012-2148-0; Tabernero J, 2015, ONCOLOGIST, V20, P143, DOI 10.1634/theoncologist.2014-0394; Takahara N, 2016, INVEST NEW DRUG, V34, P636, DOI 10.1007/s10637-016-0369-0; Thomassen I, 2013, PANCREAS, V42, P72, DOI 10.1097/MPA.0b013e31825abf8c; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Yamamoto T, 2015, WORLD J GASTROENTERO, V21, P262, DOI 10.3748/wjg.v21.i1.262	26	41	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0186709	10.1371/journal.pone.0186709	http://dx.doi.org/10.1371/journal.pone.0186709			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0UN	29049340	Green Published, gold, Green Submitted			2023-01-03	WOS:000413195900100
J	Feddock, CA				Feddock, Christopher A.			In small skin abscesses, clindamycin or trimethoprim-sulfamethoxazole after incision and drainage increased cures	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Feddock, Christopher A.] Univ Kentucky, Coll Med, Lexington, KY 40506 USA	University of Kentucky	Feddock, CA (corresponding author), Univ Kentucky, Coll Med, Lexington, KY 40506 USA.							Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Talan DA, 2016, NEW ENGL J MED, V374, P823, DOI 10.1056/NEJMoa1507476	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					JC39	JC39		10.7326/ACPJC-2017-167-8-039	http://dx.doi.org/10.7326/ACPJC-2017-167-8-039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ9JM	29049758				2023-01-03	WOS:000413092700004
J	Angamo, MT; Curtain, CM; Chalmers, L; Yilma, D; Bereznicki, L				Angamo, Mulugeta Tarekegn; Curtain, Colin Michael; Chalmers, Leanne; Yilma, Daniel; Bereznicki, Luke			Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study	PLOS ONE			English	Article							RISK-FACTORS; RENAL-FUNCTION; ADMISSIONS; PREVALENCE; DISEASE; EVENTS; FREQUENCY; COMMUNITY; FEATURES; BURDEN	Background Adverse drug reactions (ADRs) are important causes of morbidity and mortality in the healthcare system; however, there are no studies reporting on the magnitude and risk factors associated with ADR-related hospitalisation in Ethiopia. Objectives To characterise the reaction types and the drugs implicated in admission to Jimma University Specialized Hospital, Southwest Ethiopia, and to identify risk factors associated with ADR-related hospitalisation. Methods A prospective cross-sectional study was conducted from May 2015 to August 2016 among consenting patients aged >= 18 years consecutively admitted to medical wards taking at least one medication prior to admission. ADR-related hospitalisations were determined through expert review of medical records, laboratory tests, patient interviews and physical observation. ADR causality was assessed by the Naranjo algorithm followed by consensus review with internal medicine specialist. ADR preventability was assessed using Schumock and Thornton's criteria. Only definite and probable ADRs that provoked hospitalisation were considered. Binary logistic regression was used to identify independent predictors of ADR-related hospitalisation. Results Of 1,001 patients, 103 (10.3%) had ADR-related admissions. Common ADRs responsible for hospitalisation were hepatotoxicity (35, 29.4%) and acute kidney injury (27, 22.7%). The drug classes most frequently implicated were antitubercular agents (45, 25.0%) followed by antivirals (22, 12.2%) and diuretics (19, 10.6%). Independent predictors of ADR-related hospitalisation were body mass index (BMI) <18.5 kg/m(2) (adjusted odd ratio [AOR] = 1.69; 95% confidence interval [CI] = 1.10-2.62; p = 0.047), pre-existing renal disease (AOR = 2.84; 95% CI = 1.38-5.85, p = 0.004), pre-existing liver disease (AOR = 2.61; 95% CI = 1.38-4.96; p = 0.003), number of comorbidities >= 4 (AOR = 2.09; 95% CI = 1.27-3.44; p = 0.004), number of drugs >= 6 (AOR = 2.02; 95% CI = 1.26-3.25; p = 0.004) and history of previous ADRs (AOR = 24.27; 95% CI = 11.29-52.17; p<0.001). Most ADRs (106, 89.1%) were preventable. Conclusions ADRs were a common cause of hospitalisation. The majority of ADRs were preventable, highlighting the need for monitoring and review of patients with lower BMI, ADR history, renal and liver diseases, multiple comorbidities and medications. ADR predictors should be integrated into clinical pathways and pharmacovigilance systems.	[Angamo, Mulugeta Tarekegn; Curtain, Colin Michael; Chalmers, Leanne; Bereznicki, Luke] Univ Tasmania, Div Pharm, Sch Med, Hobart, Tas, Australia; [Yilma, Daniel] Jimma Univ, Dept Internal Med, Sch Med, Fac Med Sci, Jimma, Ethiopia	University of Tasmania; Jimma University	Angamo, MT (corresponding author), Univ Tasmania, Div Pharm, Sch Med, Hobart, Tas, Australia.	Mulugeta.Angamo@utas.edu.au	Yilma, Daniel/AAJ-2072-2021; Angamo, Mulugeta/O-9568-2014	Yilma, Daniel/0000-0001-6058-2696; Angamo, Mulugeta/0000-0002-8604-6258; Chalmers, Leanne/0000-0002-2477-2190				Alexopoulou A, 2008, EUR J INTERN MED, V19, P505, DOI 10.1016/j.ejim.2007.06.030; Alvarez Paulino A, 2013, Int J Risk Saf Med, V25, P185, DOI 10.3233/JRS-130596; Aminkeng F, 2014, PHARMACOGENOMICS J, V14, P160, DOI 10.1038/tpj.2013.13; Angamo MT, 2016, DRUG SAFETY, V39, P847, DOI 10.1007/s40264-016-0444-7; [Anonymous], 2010, TREATM TUB GUID NAT; Aziz Z, 2007, PHARMACOEPIDEM DR S, V16, P223, DOI 10.1002/pds.1313; Belachew T, 2015, ETHIOP J HEALTH SCI, V25, P1; Bushardt RL, 2008, CLIN INTERV AGING, V3, P383, DOI 10.2147/CIA.S2468; Caamano F, 2005, ARCH GERONTOL GERIAT, V40, P45, DOI 10.1016/j.archger.2004.05.005; Chen YC, 2012, INTERN MED J, V42, P651, DOI 10.1111/j.1445-5994.2011.02684.x; Classification Committee of the World Organization of Family Doctors, 1998, ICPC 2 INT CLASS PRI; Corsonello A, 2012, DRUG SAFETY, V35, P47, DOI 10.1007/BF03319102; Dargie B, 2016, BMC NUTR, V2, P7, DOI DOI 10.1186/S40795-016-0046-X; Gebretekle GB, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0101-z; Gedle D., 2015, BMC NUTR, V1, P5, DOI [10.1186/2055-0928-1-5, DOI 10.1186/2055-0928-1-5]; Getahun W, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-390; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Hassen AA, 2013, PLOS ONE, V8; Henry NL, 2012, PAN AFR MED J, V12, P1; HOIGNE R, 1984, SCHWEIZ MED WSCHR, V114, P1854; Hopf Y, 2008, PHARM WORLD SCI, V30, P854, DOI 10.1007/s11096-008-9240-5; Isah AO, 2012, THER ADV DRUG SAF, V3, P25, DOI 10.1177/2042098611425695; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Levey AS, 2012, LANCET, V379, P165, DOI 10.1016/S0140-6736(11)60178-5; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mamo Y, 2007, CLIN MED, V7, P228, DOI 10.7861/clinmedicine.7-3-228; Manley HJ, 2003, AM J KIDNEY DIS, V41, P386, DOI 10.1053/ajkd.2003.50048; Mannesse CK, 2000, AGE AGEING, V29, P35, DOI 10.1093/ageing/29.1.35; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; Mehta U, 2008, BRIT J CLIN PHARMACO, V65, P396, DOI 10.1111/j.1365-2125.2007.03034.x; Misganaw A, 2014, J HEALTH POPUL NUTR, V32, P1; Mouton JP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003437; Nair NP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165757; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Netsanet WW, 2013, UNIVERSAL HLTH COVER, V10; Ogoina D, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/940580; Olivier P, 2009, DRUG AGING, V26, P475, DOI 10.2165/00002512-200926060-00004; Onder G, 2002, J AM GERIATR SOC, V50, P1962, DOI 10.1046/j.1532-5415.2002.50607.x; Oumer Sada, 2017, African Journal of Pharmacy and Pharmacology, V11, P191, DOI 10.5897/AJPP2017.4736; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Patel Hitesh, 2007, BMC Clin Pharmacol, V7, P9, DOI 10.1186/1472-6904-7-9; Patel K J, 2007, BMC Clin Pharmacol, V7, P8, DOI 10.1186/1472-6904-7-8; Pedros C, 2014, EUR J CLIN PHARMACOL, V70, P361, DOI 10.1007/s00228-013-1630-5; Rehan HS, 2002, NATL MED J INDIA, V15, P24; Reuben A, 2004, HEPATOLOGY, V39, P574, DOI 10.1002/hep.20081; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Ruiter R, 2012, DRUG AGING, V29, P225, DOI 10.2165/11599430-000000000-00000; Munoz-Torrero JFS, 2010, EUR J CLIN PHARMACOL, V66, P1257, DOI 10.1007/s00228-010-0866-6; Schumock G T, 1992, Hosp Pharm, V27, P538; Sekhar MS, 2011, SAUDI PHARM J, V19, P273, DOI 10.1016/j.jsps.2011.04.004; Sharif-Askari FS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095991; Subbaraman R, 2007, CLIN INFECT DIS, V45, P1093, DOI 10.1086/521150; Tegegne GT, 2015, GLOBAL J MED RES, V15, P20; Tipping B, 2006, SAMJ S AFR MED J, V96, P1255; van der Hooft CS, 2008, PHARMACOEPIDEM DR S, V17, P365, DOI 10.1002/pds.1565; van Olmen J, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/349312; Varallo FR, 2011, LAT AM J PHARM, V30, P347; Verbeeck RK, 2008, EUR J CLIN PHARMACOL, V64, P1147, DOI 10.1007/s00228-008-0553-z; Wang HD, 2016, LANCET HIV, V3, pE361, DOI 10.1016/S2352-3018(16)30087-X; Wawruch M, 2009, ARCH GERONTOL GERIAT, V48, P186, DOI 10.1016/j.archger.2008.01.004; World Health Organisation, TUB PROGR ETH; World Health Organization, 2014, NONC DIS NCD COUNTR; World Health Organization, 2002, SAF MED GUID DET REP; Yimer G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027810; Zeeh J, 2002, GERONTOLOGY, V48, P121, DOI 10.1159/000052829; Zhang M, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2752; Zopf Y, 2008, EUR J CLIN PHARMACOL, V64, P999, DOI 10.1007/s00228-008-0494-6; Zopf Y, 2008, DRUG SAFETY, V31, P789, DOI 10.2165/00002018-200831090-00007; [No title captured]	69	24	24	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2017	12	10							e018663	10.1371/journal.pone.0186631	http://dx.doi.org/10.1371/journal.pone.0186631			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ8YP	29036230	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000413054800052
J	Van Boeckel, TP; Glennon, EE; Chen, D; Gilbert, M; Robinson, TP; Grenfell, BT; Levin, SA; Bonhoeffer, S; Laxminarayan, R				Van Boeckel, Thomas P.; Glennon, Emma E.; Chen, Dora; Gilbert, Marius; Robinson, Timothy P.; Grenfell, Bryan T.; Levin, Simon A.; Bonhoeffer, Sebastian; Laxminarayan, Ramanan			Reducing antimicrobial use in food animals Consider user fees and regulatory caps on veterinary use	SCIENCE			English	Editorial Material							ANTIBIOTICS; RESISTANCE; TRENDS		[Van Boeckel, Thomas P.; Bonhoeffer, Sebastian] Swiss Fed Inst Technol, Inst Integrat Biol, CH-8006 Zurich, Switzerland; [Glennon, Emma E.; Chen, Dora; Laxminarayan, Ramanan] Ctr Dis Dynam Econ Policy, Washington, DC 20005 USA; [Glennon, Emma E.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England; [Chen, Dora; Grenfell, Bryan T.; Levin, Simon A.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Gilbert, Marius] Univ Libre Bruxelles, B-1050 Brussels, Belgium; [Gilbert, Marius] Fonds Natl Rech Sci, B-1050 Brussels, Belgium; [Robinson, Timothy P.] Int Livestock Res Inst, Nairobi 00100, Kenya; [Robinson, Timothy P.] Food & Agr Org United Nat, I-00153 Rome, Italy; [Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA; [Levin, Simon A.; Laxminarayan, Ramanan] Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cambridge; Princeton University; Universite Libre de Bruxelles; Fonds de la Recherche Scientifique - FNRS; CGIAR; International Livestock Research Institute (ILRI); Food & Agriculture Organization of the United Nations (FAO); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Princeton University	Laxminarayan, R (corresponding author), Ctr Dis Dynam Econ Policy, Washington, DC 20005 USA.; Laxminarayan, R (corresponding author), Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA.	ramanan@cddep.org	Laxminarayan, Ramanan/ABD-5050-2021; Glennon, Emma/J-3135-2019; Bonhoeffer, Sebastian/A-2735-2008; Levin, Simon A/J-1218-2014	Glennon, Emma/0000-0001-9540-1998; Bonhoeffer, Sebastian/0000-0001-8052-3925; Levin, Simon A/0000-0002-8216-5639	ETH postdoctoral fellowship; ETH Zurich; European Research Council [PBDR 268540]; Science and Technology Directorate, Department of Homeland Security contract [HSHQDC-12-C-00058]; Bill &Melinda Gates Foundation [OP1091919]; Fulbright program of U.S. Department of State; Biotechnology and Biological Sciences Research Council [BB/L019019/1]; Medical Research Council [G1100783] Funding Source: researchfish; BBSRC [BB/L019019/1] Funding Source: UKRI; MRC [G1100783] Funding Source: UKRI	ETH postdoctoral fellowship; ETH Zurich(ETH Zurich); European Research Council(European Research Council (ERC)European Commission); Science and Technology Directorate, Department of Homeland Security contract(United States Department of Homeland Security (DHS)); Bill &Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Fulbright program of U.S. Department of State; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Veterinarians Without Borders for price estimates of veterinary antimicrobials. The authors thank A. Champetier de Ribes and B. Aragosta for discussions on user fees. T.P.V.B. is supported by an ETH postdoctoral fellowship and the program for Adaptation to a Changing Environment from ETH Zurich. S.B. is supported by the European Research Council (PBDR 268540). B.T.G. and S.A.L. were supported by the Science and Technology Directorate, Department of Homeland Security contract (HSHQDC-12-C-00058). B.T.G. and R.L. were supported by the Bill &Melinda Gates Foundation (OP1091919). E.E.G. was supported by the Fulbright program of the U.S. Department of State. T.R. was supported by the Biotechnology and Biological Sciences Research Council (BB/L019019/1). This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.	Aarestrup FM, 2000, MICROB DRUG RESIST, V6, P63, DOI 10.1089/mdr.2000.6.63; Aarestrup FM, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0085; Bowman M, 2016, AM J AGR ECON, V98, P622, DOI 10.1093/ajae/aaw008; Carrique-Mas JJ, 2015, ZOONOSES PUBLIC HLTH, V62, P70, DOI 10.1111/zph.12165; Center for Veterinary Medicine (CVM), 2013, CVM UPD FDA ANN SUMM; Engberg J, 2001, EMERG INFECT DIS, V7, P24, DOI 10.3201/eid0701.010104; Hollis A, 2013, NEW ENGL J MED, V369, P2474, DOI 10.1056/NEJMp1311479; Laxminarayan R, 2014, SCIENCE, V345, P1299, DOI 10.1126/science.1254163; Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7; Lowder SK, 2016, WORLD DEV, V87, P16, DOI 10.1016/j.worlddev.2015.10.041; ONeill J., 2015, REV ANTIMICROBIAL RE; ONeill J., 2016, TACKLING DRUG RESIST; Outterson K, 2011, 186668 SSRN; Teillant, 2015, OECD FOOD AGR FISHER; Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112; van Bunnik BAD, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.161067; Walpole SC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-439; Wang SS, 2016, J ZHEJIANG UNIV-SC B, V17, P649, DOI 10.1631/jzus.B1600341; World Bank, 2016, DRUG RESISTANT INFEC; You YQ, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00284	20	261	265	19	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	2017	357	6358					1350	1352		10.1126/science.aao1495	http://dx.doi.org/10.1126/science.aao1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI3QH	28963240	Green Published			2023-01-03	WOS:000411880800027
J	Peri, E; Ambrosini, E; Colombo, VM; van de Ruit, M; Grey, MJ; Monticone, M; Ferriero, G; Pedrocchi, A; Ferrigno, G; Ferrante, S				Peri, Elisabetta; Ambrosini, Emilia; Colombo, Vera Maria; van de Ruit, Mark; Grey, Michael J.; Monticone, Marco; Ferriero, Giorgio; Pedrocchi, Alessandra; Ferrigno, Giancarlo; Ferrante, Simona			Intra and inter-session reliability of rapid Transcranial Magnetic Stimulation stimulus-response curves of tibialis anterior muscle in healthy older adults	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; NONINVASIVE BRAIN-STIMULATION; INPUT-OUTPUT PROPERTIES; ELECTRICAL-STIMULATION; CORTICOSPINAL PATHWAY; CORTICAL EXCITABILITY; CHRONIC STROKE; PLASTICITY; TMS; NEUROPLASTICITY	Objective The clinical use of Transcranial Magnetic Stimulation (TMS) as a technique to assess corticospinal excitability is limited by the time for data acquisition and the measurement variability. This study aimed at evaluating the reliability of Stimulus-Response (SR) curves acquired with a recently proposed rapid protocol on tibialis anterior muscle of healthy older adults. Methods Twenty-four neurologically-intact adults (age: 55-75 years) were recruited for this test-retest study. During each session, six SR curves, 3 at rest and 3 during isometric muscle contractions at 5% of maximum voluntary contraction (MVC), were acquired. Motor Evoked Potentials (MEPs) were normalized to the maximum peripherally evoked response; the coil position and orientation were monitored with an optical tracking system. Intra-and inter-session reliability of motor threshold (MT), area under the curve (AURC), MEPmax, stimulation intensity at which the MEP is mid-way between MEPmax and MEPmin (I50), slope in I50, MEP latency, and silent period (SP) were assessed in terms of Standard Error of Measurement (SEM), relative SEM, Minimum Detectable Change (MDC), and Intraclass Correlation Coefficient (ICC). Results The relative SEM was <= 10% for MT, I50, latency and SP both at rest and 5% MVC, while it ranged between 11% and 37% for AURC, MEPmax, and slope. MDC values were overall quite large; e.g., MT required a change of 12% MSO at rest and 10% MSO at 5% MVC to be considered a real change. Inter-sessions ICC were >0.6 for all measures but slope at rest and MEPmax and latency at 5% MVC. Conclusions Measures derived from SR curves acquired in <4 minutes are affected by similar measurement errors to those found with long-lasting protocols, suggesting that the rapid method is at least as reliable as the traditional methods. As specifically designed to include older adults, this study provides normative data for future studies involving older neurological patients (e.g. stroke survivors).	[Peri, Elisabetta; Ambrosini, Emilia; Colombo, Vera Maria; Pedrocchi, Alessandra; Ferrigno, Giancarlo; Ferrante, Simona] Politecn Milan, Dept Elect Informat & Bioengn, NearLab, Milan, Italy; [Ambrosini, Emilia; Monticone, Marco; Ferriero, Giorgio] Ist Clin Sci Maugeri, Sci Inst Lissone IRCCS, Dept Phys & Rehabilitat Med, Lissone, MB, Italy; [van de Ruit, Mark] Delft Univ Technol, Dept Biomech Engn, Fac Mech Maritime & Mat Engn, Delft, Netherlands; [Grey, Michael J.] Univ East Anglia, Sch Hlth Sci, Acquired Brain Injury Rehabil Alliance, Norwich, Norfolk, England; [Monticone, Marco] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy	Polytechnic University of Milan; Istituti Clinici Scientifici Maugeri IRCCS; Delft University of Technology; University of East Anglia; University of Cagliari	Peri, E (corresponding author), Politecn Milan, Dept Elect Informat & Bioengn, NearLab, Milan, Italy.	elisabetta.peri@polimi.it	Monticone, Marco/AAC-4494-2022; van de Ruit, Mark/X-4872-2019; Ferriero, Giorgio/K-4217-2018; Pedrocchi, Alessandra/AAF-2655-2019; Colombo, Vera/R-3715-2019; , Giorgio/AAA-3522-2021; Ambrosini, Emilia/R-1371-2016	van de Ruit, Mark/0000-0003-3806-2031; Ferriero, Giorgio/0000-0002-7873-6777; Pedrocchi, Alessandra/0000-0001-9957-2786; Colombo, Vera/0000-0001-6648-1917; , Giorgio/0000-0002-7873-6777; Ambrosini, Emilia/0000-0002-6527-0779	Italian Ministry of Healthy [GR-2010-2312228]	Italian Ministry of Healthy(Ministry of Health, Italy)	This work was supported by the Italian Ministry of Healthy (grant no.: GR-2010-2312228, project title "Fall prevention and locomotion recovery in post-stroke patients: a multimodal training towards a more autonomous daily life" (http://www.salute.gov.it/imos/C_17_pagineAree_4517_listaFile_itemName_7_file.pdt). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrian ED, 1939, J PHYSIOL-LONDON, V97, P153, DOI 10.1113/jphysiol.1939.sp003798; Ambrosini E, 2015, 7 IEEE EMBS C NEUR E; [Anonymous], 2015, NEUROSCI, V9, P335; Beaulieu LD, 2017, BRAIN STIMUL, V10, P196, DOI 10.1016/j.brs.2016.12.008; BREUSCH TS, 1979, ECONOMETRICA, V47, P1287, DOI 10.2307/1911963; Cacchio A, 2011, J NEUROL SCI, V303, P90, DOI 10.1016/j.jns.2011.01.004; Cacchio A, 2009, CLIN NEUROPHYSIOL, V120, P414, DOI 10.1016/j.clinph.2008.11.019; Carroll TJ, 2001, J NEUROSCI METH, V112, P193, DOI 10.1016/S0165-0270(01)00468-X; Carson RG, 2013, BRAIN STIMUL, V6, P760, DOI 10.1016/j.brs.2013.01.016; CHAPMAN JP, 1987, NEUROPSYCHOLOGIA, V25, P579, DOI 10.1016/0028-3932(87)90082-0; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cortes M, 2012, NEUROMODULATION, V15, P316, DOI 10.1111/j.1525-1403.2012.00459.x; DAY BL, 1987, BRAIN, V110, P1191, DOI 10.1093/brain/110.5.1191; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; Di Lazzaro V, 2012, BRAIN STIMUL, V5, P512, DOI 10.1016/j.brs.2011.07.008; Everaert DG, 2010, NEUROREHAB NEURAL RE, V24, P168, DOI 10.1177/1545968309349939; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Jung NH, 2010, BRAIN STIMUL, V3, P87, DOI 10.1016/j.brs.2009.10.003; Kamke MR, 2012, J NEUROSCI, V32, P7001, DOI 10.1523/JNEUROSCI.1028-12.2012; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Liu H, 2014, J NEUROL SCI, V341, P105, DOI 10.1016/j.jns.2014.04.012; Mathias JP, 2014, BRAIN STIMUL, V7, P59, DOI 10.1016/j.brs.2013.08.003; Meaney A, 2015, J CLIN NEUROSCI, V22, P1434, DOI 10.1016/j.jocn.2015.02.034; Peri E, 2016, IFMBE PROC, V57, P1069, DOI 10.1007/978-3-319-32703-7_211; Pitcher JB, 2003, J PHYSIOL-LONDON, V546, P605, DOI 10.1113/jphysiol.2002.029454; Portney LG., 2000, FDN CLIN RES APPL PR, V2, DOI DOI 10.1016/S0039-6257(02)00362-4; Ridding MC, 2010, J PHYSIOL-LONDON, V588, P2291, DOI 10.1113/jphysiol.2010.190314; Ridding MC, 1997, ELECTROMYOGR MOTOR C, V105, P340, DOI 10.1016/S0924-980X(97)00041-6; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Rossini PM, 2013, CURR PHARM DESIGN, V19, P6426, DOI 10.2174/1381612811319360004; Rothwell J., 2005, MAGNETIC STIMULATION, V2nd ed., P43, DOI [10.1016/B978-0-7506-7373-0.50007-9, DOI 10.1016/B978-0-7506-7373-0.50007-9]; Sale MV, 2008, J NEUROSCI, V28, P8285, DOI 10.1523/JNEUROSCI.1963-08.2008; Schmidt S, 2015, HUM BRAIN MAPP, V36, P40, DOI 10.1002/hbm.22611; Smith AE, 2011, J APPL PHYSIOL, V110, P206, DOI 10.1152/japplphysiol.00403.2010; Swayne OBC, 2008, CEREB CORTEX, V18, P1909, DOI 10.1093/cercor/bhm218; Takechi U, 2014, CLIN NEUROPHYSIOL, V125, P2055, DOI 10.1016/j.clinph.2014.01.034; Tallent J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035930; Troni W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155268; van de Ruit M, 26 ANN M SOC NEUR CO; van Hedel HJA, 2007, J NEUROL, V254, P1089, DOI 10.1007/s00415-006-0493-4; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.3.CO;2-5; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Xu Y, 2015, NEURAL REGEN RES, V10, P2072, DOI 10.4103/1673-5374.172329	49	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184828	10.1371/journal.pone.0184828	http://dx.doi.org/10.1371/journal.pone.0184828			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0VR	28910370	Green Published, gold, Green Accepted			2023-01-03	WOS:000410859200100
J	Aihara, T; Ogawa, T; Shimokawa, T; Yamashita, O				Aihara, Takatsugu; Ogawa, Takeshi; Shimokawa, Takeaki; Yamashita, Okito			Anodal transcranial direct current stimulation of the right anterior temporal lobe did not significantly affect verbal insight	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; PREFRONTAL CORTEX; RIGHT-HEMISPHERE; PERFORMANCE; ACTIVATION; TASK; TDCS	Humans often utilize past experience to solve difficult problems. However, if past experience is insufficient to solve a problem, solvers may reach an impasse. Insight can be valuable for breaking an impasse, enabling the reinterpretation or re-representation of a problem. Previous studies using between-subjects designs have revealed a causal relationship between the anterior temporal lobes (ATLs) and non-verbal insight, by enhancing the right ATL while inhibiting the left ATL using transcranial direct current stimulation (tDCS). In addition, neuro-imaging studies have reported a correlation between right ATL activity and verbal insight. Based on these findings, we hypothesized that the right ATL is causally related to both nonverbal and verbal insight. To test this hypothesis, we conducted an experiment with 66 subjects using a within-subjects design, which typically has greater statistical power than a between-subjects design. Subjects participated in tDCS experiments across 2 days, in which they solved both non-verbal and verbal insight problems under active or sham stimulation conditions. To dissociate the effects of right ATL stimulation from those of left ATL stimulation, we used two montage types; anodal tDCS of the right ATL together with cathodal tDCS of the left ATL (stimulating both ATLs) and anodal tDCS of the right ATL with cathodal tDCS of the left cheek (stimulating only the right ATL). The montage used was counterbalanced across subjects. Statistical analyses revealed that, regardless of the montage type, there were no significant differences between the active and sham conditions for either verbal or non-verbal insight, although the finding for non-verbal insight was inconclusive because of a lack of statistical power. These results failed to support previous findings suggesting that the right ATL is the central locus of insight.	[Aihara, Takatsugu; Shimokawa, Takeaki; Yamashita, Okito] Adv Telecommun Res Inst Int ATR, Neural Informat Anal Labs, Kyoto, Japan; [Ogawa, Takeshi] Adv Telecommun Res Inst Int ATR, Cognit Mech Labs, Kyoto, Japan	Advanced Telecommunications Research Institute International; Advanced Telecommunications Research Institute International	Aihara, T (corresponding author), Adv Telecommun Res Inst Int ATR, Neural Informat Anal Labs, Kyoto, Japan.	aihara@atr.jp	Yamashita, Okito/ABW-9839-2022	Yamashita, Okito/0000-0002-6039-3657	ImPACT Program of Council for Science, Technology and Innovation (Cabinet Office, Government of Japan); KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology, Japan [24700617]	ImPACT Program of Council for Science, Technology and Innovation (Cabinet Office, Government of Japan); KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This research was funded by ImPACT Program of Council for Science, Technology and Innovation (Cabinet Office, Government of Japan). Takatsugu Aihara was supported by KAKENHI (24700617) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, JAPANESE J PSYCHOL; Arsalidou M, 2011, NEUROIMAGE, V54, P2382, DOI 10.1016/j.neuroimage.2010.10.009; Bowden EM, 1998, PSYCHOL SCI, V9, P435, DOI 10.1111/1467-9280.00082; Bowden EM, 2005, TRENDS COGN SCI, V9, P322, DOI 10.1016/j.tics.2005.05.012; Bowden EM, 2003, BEHAV RES METH INS C, V35, P634, DOI 10.3758/BF03195543; Bowden EM, 2003, PSYCHON B REV, V10, P730, DOI 10.3758/BF03196539; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Cerruti C, 2009, J COGNITIVE NEUROSCI, V21, P1980, DOI 10.1162/jocn.2008.21143; Chi RP, 2012, NEUROSCI LETT, V515, P121, DOI 10.1016/j.neulet.2012.03.012; Chi RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016655; Chu Y, 2011, J PROBL SOLVING, V3, P119, DOI 10.7771/1932-6246.1094; Gobel SM, 2006, CORTEX, V42, P774, DOI 10.1016/S0010-9452(08)70416-7; Goel V, 2015, J PROBL SOLVING, V8, P23, DOI 10.7771/1932-6246.1172; GRAFMAN J, 1982, CORTEX, V18, P37, DOI 10.1016/S0010-9452(82)80017-8; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jones Kevin T, 2012, Front Psychiatry, V3, P81, DOI 10.3389/fpsyt.2012.00081; Jung YJ, 2013, BIOMED ENG LETT, V3, P39, DOI 10.1007/s13534-013-0087-x; Jung-Beeman M, 2004, PLOS BIOL, V4; Kasahara K, 2013, NEUROSCI LETT, V545, P86, DOI 10.1016/j.neulet.2013.04.022; Kawahito J., 2011, HIROSHIMA PSYCHOL RE, P225, DOI [DOI 10.15027/32396, 10.15027/32396, DOI 10.15027/32396(INJAPANESEWITHENGLISHABSTRACT)]; Kim JH, 2014, NEUROSCI LETT, V564, P6, DOI 10.1016/j.neulet.2014.01.054; Knoblich G, 1999, J EXP PSYCHOL LEARN, V25, P1534, DOI 10.1037/0278-7393.25.6.1534; Kounios J, 2008, NEUROPSYCHOLOGIA, V46, P281, DOI 10.1016/j.neuropsychologia.2007.07.013; Kounios J, 2014, ANNU REV PSYCHOL, V65, P71, DOI 10.1146/annurev-psych-010213-115154; Li LM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00181; Mayer E, 1999, BRAIN, V122, P1107, DOI 10.1093/brain/122.6.1107; Metuki N, 2012, BRAIN STIMUL, V5, P110, DOI 10.1016/j.brs.2012.03.002; Miniussi C., 2012, TRANSCRANIAL BRAIN S; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ollinger M, 2008, EXP PSYCHOL, V55, P269, DOI 10.1027/1618-3169.55.4.269; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Subramaniam K, 2009, J COGNITIVE NEUROSCI, V21, P415, DOI 10.1162/jocn.2009.21057; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zmigrod S, 2015, CREATIVITY RES J, V27, P353, DOI 10.1080/10400419.2015.1087280	37	10	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2017	12	9							e0184749	10.1371/journal.pone.0184749	http://dx.doi.org/10.1371/journal.pone.0184749			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG8GZ	28902872	gold, Green Published, Green Submitted			2023-01-03	WOS:000410669200061
J	Huber, D; Henriksson, R; Jakobsson, S; Mooe, T				Huber, Daniel; Henriksson, Robin; Jakobsson, Stina; Mooe, Thomas			Nurse-led telephone-based follow-up of secondary prevention after acute coronary syndrome: One-year results from the randomized controlled NAILED-ACS trial	PLOS ONE			English	Article							HEART-DISEASE; THERAPEUTIC INERTIA; RISK; IMPLEMENTATION; INTERVENTION; ADHERENCE; PEOPLE	Background Secondary prevention after acute coronary syndrome (ACS) could reduce morbidity and mortality, but guideline targets are seldom reached. We hypothesized that nurse-led telephone- based intervention would increase adherence. Methods The NAILED ACS trial is a prospective, controlled, randomized trial. Patients admitted for ACS at Ostersund hospital, Sweden, were randomized to usual follow-up by a general practitioner or a nurse-led intervention. The intervention comprised telephone follow-up after 1 month and then yearly with lifestyle counselling and titration of medications until reaching target values for LDL-C (< 2.5 mmol/L) and blood pressure (BP; < 140/90 mmHg) or set targets were deemed unachievable. This is a 12-month exploratory analysis of the intervention. Results A total of 768 patients (396 intervention, 372 control) completed the 12-month follow-up. After titration at the 1-month follow-up, mean LDL-C was 0.38 mmol/L (95% CI 0.28 to 0.48, p< 0.05), mean systolic BP 7 mmHg (95% CI 4.5 to 9.2, p< 0.05), and mean diastolic BP 4 mmHg (95% CI 2.4 to 4.1, p< 0.05) lower in the intervention group. Target values for LDL-C and systolic BP were met by 94.1% and 91.9% of intervention patients and 68.4% and 65.6% of controls (p< 0.05). At 12 months, mean LDL was 0.3 mmol/L (95% CI 0.1 to 0.4, p < 0.05), systolic BP 1.5 mmHg (95% CI -1.0 to 4.1, p = 0.24), and mean diastolic BP 2.1 mmHg (95% CI 0.6 to 3.6, p < 0.05) lower in the intervention group. Target values for LDL-C and systolic BP were met in 77.7% and 68.9% of intervention patients and 63.2% and 63.7% of controls (p< 0.05 and p = 0.125). Conclusion Nurse-led telephone-based secondary prevention was significantly more efficient at improving LDL-C and diastolic BP levels than usual care. The effect of the intervention declined between 1 and 12 months. Further evaluation of the persistence to the intervention is needed.	[Huber, Daniel; Henriksson, Robin; Jakobsson, Stina; Mooe, Thomas] Umea Univ, Dept Publ Hlth & Clin Med, Unit Res Educ & Dev Ostersund, Umea, Sweden	Umea University	Huber, D (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, Unit Res Educ & Dev Ostersund, Umea, Sweden.	daniel.huber@regionjh.se		Huber, Daniel/0000-0002-9817-5436; Huber, Daniel/0000-0002-4938-3191; Henriksson, Robin/0000-0001-9571-5946	Unit of Research, Education and Development, Ostersund Hospital, Region Jamtland Harjedalen	Unit of Research, Education and Development, Ostersund Hospital, Region Jamtland Harjedalen	The study and all authors were funded by the Unit of Research, Education and Development, Ostersund Hospital, Region Jamtland Harjedalen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjorck L, 2009, EUR HEART J, V30, P1046, DOI 10.1093/eurheartj/ehn554; Chen HY, 2015, HEART LUNG, V44, P299, DOI 10.1016/j.hrtlng.2015.02.004; Huber D, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1203-x; Jakobsson S, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0252-0; Jorstad HT, 2013, HEART, V99, P1421, DOI 10.1136/heartjnl-2013-303989; Kotb A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096581; Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Mooe T, 2014, JMIR RES PROTOC, V3, DOI 10.2196/resprot.3466; Neubeck L, 2009, EUR J CARDIOV PREV R, V16, P281, DOI 10.1097/HJR.0b013e32832a4e7a; Nieuwlaat R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub4; Okonofua EC, 2006, HYPERTENSION, V47, P345, DOI 10.1161/01.HYP.0000200702.76436.4b; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Perk J, 2015, EUROINTERVENTION, V10, DOI 10.4244/EIJV10I11A223; Piepoli MF, 2016, ATHEROSCLEROSIS, V252, P207, DOI [10.1016/j.atherosclerosis.2016.05.037, 10.1177/2047487316653709]; Redon J, 2010, J HYPERTENS, V28, P1770, DOI 10.1097/HJH.0b013e32833b4953; Smith SC, 2012, EUR HEART J, V33, P2910, DOI 10.1093/eurheartj/ehs313; Snaterse M, 2016, HEART, V102, P50, DOI 10.1136/heartjnl-2015-308050; SPRINT Research Group, 2015, N Engl J Med, V373, P2103, DOI 10.1056/NEJMoa1511939; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397	21	14	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0183963	10.1371/journal.pone.0183963	http://dx.doi.org/10.1371/journal.pone.0183963			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG2YO	28886083	Green Published, gold, Green Submitted			2023-01-03	WOS:000410001100048
J	Haanen, JBAG				Haanen, John B. A. G.			Converting Cold into Hot Tumors by Combining Immunotherapies	CELL			English	Editorial Material								In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1 treatment resulted in a 62% response rate in patients with metastatic melanoma, accompanied by enhanced T cell infiltration in virus-injected lesions.	[Haanen, John B. A. G.] Netherlands Canc Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Haanen, JBAG (corresponding author), Netherlands Canc Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.haanen@nki.nl	Haanen, John/AAD-8534-2022; Haanen, John/AAD-8578-2022	Haanen, John/0000-0001-5884-7704; 				Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954	8	143	147	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 7	2017	170	6					1055	1056		10.1016/j.cell.2017.08.031	http://dx.doi.org/10.1016/j.cell.2017.08.031			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FG1ED	28886376	Bronze			2023-01-03	WOS:000409536000003
J	Peklar, J; Kos, M; O'Dwyer, M; McCarron, M; McCallion, P; Kenny, RA; Henman, MC				Peklar, Jure; Kos, Mitja; O'Dwyer, Maire; McCarron, Mary; McCallion, Philip; Kenny, Rose Anne; Henman, Martin C.			Medication and supplement use in older people with and without intellectual disability: An observational, cross-sectional study	PLOS ONE			English	Article							POPULATION AGED 50; DIETARY-SUPPLEMENTS; ADULTS; MULTIMORBIDITY; PRESCRIPTION; COMPLEXITY; MEDICINES; BURDEN; DRUGS; RISK	Introduction Understanding the medication and supplement use of aging people is critical to ensuring that health service providers in primary care can optimise use of these agents. An increasing number of people with different levels of intellectual disability (ID) are living in the community and becoming for the first time substantial users of primary health care services. This, however, brings new challenges that need to be addressed at the primary health care level. We quantified the use of medicines and food supplements and described the associated patterns of morbidity in the two comparable cohorts of aging population with and without intellectual disability. Method This research aligned participants of 50 years and over who lived in the community from two nationally representative cohorts of older people; those with ID from the Intellectual Disability Supplement (n = 238) and those without ID (n = 8,081) from the Irish Longitudinal Study on Ageing. Results Data showed that both medication and supplement use in the two groups was prevalent but that those with ID received more of both medications and supplements (e.g. polypharmacy was 39.0% in ID vs. 18.1% in non-ID cohort). Moreover, based on an analysis of the therapeutic groups and medications used that treatment was more intense in the ID cohort (95.8 vs. 7.0 International Non-proprietary Names per 100 participants). Supplement use was almost twice as prevalent in the ID group but substantially less diverse with only 10 types of supplements reported. Morbidity was higher in the ID group and showed a higher prevalence of neurological and mental health disorders. Conclusion The results highlight that the burden of therapy management and the potential risks in those ageing with ID differs substantially from those ageing without ID. Understanding the medication and supplement use of people aging with intellectual disability (ID) is critical to ensuring that health service providers in primary/ambulatory care can optimise use of these agents.	[Peklar, Jure; Kos, Mitja] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia; [O'Dwyer, Maire; Henman, Martin C.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland; [O'Dwyer, Maire; McCarron, Mary] Trinity Coll Dublin, Sch Nursing & Midwifery, IDS, TILDA, Dublin, Ireland; [McCarron, Mary] Trinity Coll Dublin, Fac Hlth Sci, Dublin, Ireland; [McCallion, Philip] Temple Univ, Sch Social Work, Philadelphia, PA 19122 USA; [Kenny, Rose Anne] Trinity Coll Dublin, Irish Longitudinal Study Ageing TILDA, Dublin, Ireland; [Kenny, Rose Anne] Trinity Coll Dublin, TCIN, Dublin, Ireland	University of Ljubljana; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Trinity College Dublin; Trinity College Dublin	Peklar, J (corresponding author), Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia.	jure.peklar@gmail.com	Kos, Mitja/C-7440-2019; henman, martin c/D-7606-2013; MCCALLION, PHILIP/Q-6672-2019; O'Dwyer, Maire/AAA-4353-2022	Kos, Mitja/0000-0002-6801-6450; henman, martin c/0000-0002-7922-7691; Kenny, Rose Anne/0000-0002-9336-8124; McCallion, Philip/0000-0001-5129-6399	Irish Life; Department for Health and Children; Atlantic Philanthropies; Health Research Board; Department of Health; IDS-TILDA Scientific Advisory Committee; Intellectual Disability Consultative Groups	Irish Life; Department for Health and Children; Atlantic Philanthropies; Health Research Board; Department of Health; IDS-TILDA Scientific Advisory Committee; Intellectual Disability Consultative Groups	The TILDA study is supported by Irish Life; the Department for Health and Children; and by The Atlantic Philanthropies. The IDS-TILDA study is funded by the Health Research Board and the Department of Health. The sponsors had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review and approval of the manuscript.; The TILDA study is supported by Irish Life; the Department for Health and Children; and by The Atlantic Philanthropies. The IDS-TILDA study is funded by the Health Research Board and the Department of Health. The sponsors had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review and approval of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.; The authors would like to thank the people with ID who participated in this study, their families, the services involved, the IDS-TILDA Scientific Advisory Committee, and the Intellectual Disability Consultative Groups for their support.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Coppus AMW, 2013, DEV DISABIL RES REV, V18, P6, DOI 10.1002/ddrr.1123; Flood B, 2011, INT J PHARMACEUT, V27, P41; Flood B, 2015, BRIT J LEARN DISABIL, V43, P234, DOI 10.1111/bld.12121; Gnjidic D, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-115; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Haveman M, 2010, J POLICY PRACT INTEL, V7, P59, DOI 10.1111/j.1741-1130.2010.00248.x; Health Information Quality Authority, 2015, MED MAN GUID; Health Service Executive, 2011, REP WORK GROUP CONGR; Henman MC, 2012, MEDICATIONS USE REV; Hilmer SN, 2009, CLIN PHARMACOL THER, V85, P86, DOI 10.1038/clpt.2008.224; Kearney PM, 2011, INT J EPIDEMIOL, V40, P877, DOI 10.1093/ije/dyr116; Kelly CS, 2010, ANN REPORT NATL INTE; Mallet L, 2007, LANCET, V370, P185, DOI 10.1016/S0140-6736(07)61092-7; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Matson JL, 2013, RES AUTISM SPECT DIS, V7, P1318, DOI 10.1016/j.rasd.2013.07.018; McCarron M., 2011, GROWING OLDER INTELL; McCarron M, 2015, J APPL RES INTELLECT, V28, P406, DOI 10.1111/jar.12194; McCarron M, 2013, RES DEV DISABIL, V34, P521, DOI 10.1016/j.ridd.2012.07.029; Nahin RL, 2009, J AM GERIATR SOC, V57, P1197, DOI 10.1111/j.1532-5415.2009.02329.x; O'Dwyer M, 2016, BRIT J PSYCHIAT, V209, P504, DOI 10.1192/bjp.bp.115.173971; O'Dwyer M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010505; ODwyer M., 2017, J INTELL DISABIL RES; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Peklar J, 2015, J AM MED DIR ASSOC, V16, P282, DOI 10.1016/j.jamda.2014.10.010; Peklar J, 2014, DRUG AGING, V31, P527, DOI 10.1007/s40266-014-0180-6; Peklar J, 2013, COMPLEMENT THER MED, V21, P333, DOI 10.1016/j.ctim.2013.06.004; Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reeve E, 2015, BRIT J CLIN PHARMACO, V80, P1254, DOI 10.1111/bcp.12732; Shah SM, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X641447; Sinai A, 2012, CURR OPIN PSYCHIATR, V25, P359, DOI 10.1097/YCO.0b013e328355ab26; Straetmans JMJAA, 2007, BRIT J GEN PRACT, V57, P64; Tsai KT, 2012, AM J GERIATR PHARMAC, V10, P61, DOI 10.1016/j.amjopharm.2011.11.005; Uijen Annemarie A, 2008, Eur J Gen Pract, V14 Suppl 1, P28, DOI 10.1080/13814780802436093; van Schrojenstein L antman-de Valk HM, 2008, BMJ-BRIT MED J, P337; World Health Organization, 2011, AN THER CLASS STRUCT	38	20	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184390	10.1371/journal.pone.0184390	http://dx.doi.org/10.1371/journal.pone.0184390			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG0EG	28877256	Green Published, Green Submitted, gold			2023-01-03	WOS:000409391200096
J	Chung, YS; Kim, YJ; Lee, I; Lee, JY; Nam, EJ; Kim, S; Kim, SW; Kim, YT				Chung, Young Shin; Kim, Yun-Ji; Lee, Inha; Lee, Jung-Yun; Nam, Eun Ji; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae			Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer	PLOS ONE			English	Article							PRIMARY SURGERY; PHASE-III; DEBULKING SURGERY; PLATINUM; OUTCOMES; NUMBER	Background There is currently no consensus regarding the optimal number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced ovarian cancer. This study aimed to evaluate the impact of the number of neoadjuvant chemotherapy (NAC) and postoperative adjuvant chemotherapy (POAC) cycles on the survival of patients with advanced ovarian cancer undergoing NAC/IDS/POAC. Methods We retrospectively reviewed data from 203 patients who underwent NAC/IDS/POAC at Yonsei Cancer Hospital between 2006 and 2016. All patients underwent taxane plus carboplatin chemotherapy for NAC and POAC. The patient outcomes were analyzed according to the number of NAC, POAC, and total chemotherapy (NAC+POAC) cycles. Results Patients who received fewer than 6 cycles of total chemotherapy (n = 8) had poorer progression-free survival (PFS) and overall survival (OS) than those completing at least 6 cycles (p = 0.005 and p<0.001, respectively). Among patients who completed at least 6 cycles of total chemotherapy (n = 189), Kaplan-Meier analysis revealed no significant difference in either PFS or OS according to the number of NAC cycles (1-3 vs. >= 4; p = 0.136 and p = 0.267, respectively). Among patients who experienced complete remission after 3 cycles of POAC (n = 98), the addition of further POAC cycles did not improve the PFS or OS (3 vs. >= 4; p = 0.641 and p = 0.104, respectively). Conclusion IDS after 4 cycles of NAC may be a safe and effective option when completing 6 cycles of total chemotherapy. Furthermore, the addition of more than 3 cycles of POAC does not appear to influence the survival of patients achieving completion remission after 3 cycles of POAC.	[Chung, Young Shin; Kim, Yun-Ji; Lee, Inha; Lee, Jung-Yun; Nam, Eun Ji; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae] Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Seoul, South Korea	Yonsei University; Yonsei University Health System	Lee, JY (corresponding author), Yonsei Univ, Coll Med, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Seoul, South Korea.	jungyunlee@yuhs.ac		Nam, Eun Ji/0000-0003-0189-3560; Lee, Inha/0000-0003-4869-6281; Lee, Jung-Yun/0000-0001-7948-1350; kim, sunghoon/0000-0002-1570-3230	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2016R1D1A1B03931916]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2016R1D1A1B03931916).	Akladios C, 2016, ONCOLOGY-BASEL, V91, P331, DOI 10.1159/000449203; Bookman MA, 2013, J GYNECOL ONCOL, V24, P105, DOI 10.3802/jgo.2013.24.2.105; Bristow RE, 2007, GYNECOL ONCOL, V104, P480, DOI 10.1016/j.ygyno.2006.11.002; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chi DS, 2009, GYNECOL ONCOL, V114, P26, DOI 10.1016/j.ygyno.2009.03.018; Colombo PE, 2014, GYNECOL ONCOL, V135, P223, DOI 10.1016/j.ygyno.2014.09.002; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Eisenhauer EL, 2006, GYNECOL ONCOL, V103, P1083, DOI 10.1016/j.ygyno.2006.06.028; Fagotti A, 2016, EUR J CANCER, V59, P22, DOI 10.1016/j.ejca.2016.01.017; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Lee JY, 2015, EJSO-EUR J SURG ONC, V41, P585, DOI 10.1016/j.ejso.2015.01.006; Lee JY, 2014, J GYNECOL ONCOL, V25, P174, DOI 10.3802/jgo.2014.25.3.174; Lee SJ, 2006, INT J GYNECOL CANCER, V16, P95, DOI 10.1111/j.1525-1438.2006.00282.x; Lim MC, 2013, J GYNECOL ONCOL, V24, P298, DOI 10.3802/jgo.2013.24.4.298; Mei L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007414.pub3; Miranda VD, 2014, GYNECOL ONCOL, V132, P287, DOI 10.1016/j.ygyno.2013.12.002; NCCN, 2017, CLIN PRACT GUID ONC; Onda T, 2016, EUR J CANCER, V64, P22, DOI 10.1016/j.ejca.2016.05.017; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Rauh-Hain JA, 2013, GYNECOL ONCOL, V129, P63, DOI 10.1016/j.ygyno.2013.01.009; Schwartz PE, 1999, GYNECOL ONCOL, V72, P93, DOI 10.1006/gyno.1998.5236; Shibata K, 2003, INT J GYNECOL CANCER, V13, P587, DOI 10.1046/j.1525-1438.2003.13388.x; Stoeckle E, 2014, ANN SURG ONCOL, V21, P629, DOI 10.1245/s10434-013-3278-x; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; Wimberger P, 2007, GYNECOL ONCOL, V106, P69, DOI 10.1016/j.ygyno.2007.02.026; Xu X, 2017, ARCH GYNECOL OBSTET, V295, P451, DOI 10.1007/s00404-016-4256-x	26	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2017	12	9							e0183754	10.1371/journal.pone.0183754	http://dx.doi.org/10.1371/journal.pone.0183754			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF8QL	28873393	Green Submitted, Green Published, gold			2023-01-03	WOS:000409282800026
J	Sotillo, WS; Villagomez, R; Smiljanic, S; Huang, XL; Malakpour, A; Kempengren, S; Rodrigo, G; Almanza, G; Sterner, O; Oredsson, S				Sotillo, Wendy Soria; Villagomez, Rodrigo; Smiljanic, Sandra; Huang, Xiaoli; Malakpour, Atena; Kempengren, Sebastian; Rodrigo, Gloria; Almanza, Giovanna; Sterner, Olov; Oredsson, Stina			Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative	PLOS ONE			English	Article							NF-KAPPA-B; BREAST-CANCER	New regimens are constantly being pursued in cancer treatment, especially in the context of treatment-resistant cancer stem cells (CSCs) that are assumed to be involved in cancer recurrence. Here, we investigated the anti-cancer activity of sesquiterpene lactones (SLs) isolated from Ambrosia arborescens and of synthetic derivatives in breast cancer cell lines, with a specific focus on activity against CSCs. The breast cancer cell lines MCF-7, JIMT-1, and HCC1937 and the normal-like breast epithelial cell line MCF-10A were treated with the SLs damsin and coronopilin, isolated from A. arborescens, and with ambrosin and dindol-01, synthesized using damsin. Inhibitory concentration 50 (IC50) values were obtained from dose-response curves. Based on IC50 values, doses in the mu M range were used for investigating effects on cell proliferation, cell cycle phase distribution, cell death, micronuclei formation, and cell migration. Western blot analysis was used to investigate proteins involved in cell cycle regulation as well as in the NF-.B pathway since SLs have been shown to inhibit this transcription factor. Specific CSC effects were investigated using three CSC assays. All compounds inhibited cell proliferation; however, damsin and ambrosin were toxic at singledigit micromolar ranges, while higher concentrations were required for coronopilin and din-dol-01. Of the four cell lines, the compounds had the least effect on the normal-like MCF-10A cells. The inhibition of cell proliferation can partly be explained by downregulation of cyclin-dependent kinase 2. All compounds inhibited tumour necrosis factor-a-induced translocation of NF-B from the cytoplasm to the nucleus. Damsin and ambrosin treatment increased the number of micronuclei; moreover, another sign of DNA damage was the increased level of p53. Treatment with damsin and ambrosin decreased the CSC subpopulation and inhibited cell migration. Our results suggest that these compounds should be further investigated to find efficient CSC-inhibiting compounds.	[Sotillo, Wendy Soria; Smiljanic, Sandra; Huang, Xiaoli; Malakpour, Atena; Kempengren, Sebastian; Oredsson, Stina] Lund Univ, Dept Biol, Lund, Sweden; [Sotillo, Wendy Soria; Rodrigo, Gloria] Univ Major San Andres, Mol Biol & Biotechnol Inst, La Paz, Bolivia; [Villagomez, Rodrigo; Sterner, Olov] Lund Univ, Dept Chem, Ctr Anal & Synth, Lund, Sweden; [Almanza, Giovanna] Univ Major San Andres, Chem Res Inst, La Paz, Bolivia	Lund University; Universidad Mayor de San Andres; Lund University; Universidad Mayor de San Andres	Oredsson, S (corresponding author), Lund Univ, Dept Biol, Lund, Sweden.	stina.oredsson@biol.lu.se		Almanza, Giovanna Rocio/0000-0002-5362-252X; Oredsson, Stina/0000-0003-2529-7106	Swedish International Development Agency (SIDA)	Swedish International Development Agency (SIDA)	The authors are grateful to the Swedish International Development Agency (SIDA) for the support of this study, which is part of the project "Biomolecules" developed between the University of San Andres (UMSA La Paz-Bolivia) and Lund University (Sweden). We also wish to thank Carolina LePrince with the "Kalenderflickorna" and associated sponsors. We thank Ewa Dahlberg for expert technical help.; This work was financially supported by the Swedish International Development Cooperation Agency (SIDA) and by Carolina LePrince with the "Kalenderflickorna" and associated sponsors. The funders had no role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; [Anonymous], 1988, ASSAY GUID MAN, V50, P1; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Cavallo F, 2011, CANCER IMMUNOL IMMUN, V60, P319, DOI 10.1007/s00262-010-0968-0; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gasch C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0601-3; Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016/j.drudis.2010.06.002; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Hale JS, 2012, CELL ADHES MIGR, V6, P346, DOI 10.4161/cam.21294; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HEJCHMAN E, 1995, J MED CHEM, V38, P3407, DOI 10.1021/jm00017a025; Huang XL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2142-3; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jordan CT, 2004, CURR OPIN CELL BIOL, V16, P708, DOI 10.1016/j.ceb.2004.09.002; Lohberger B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066300; Myhre L, 2008, ANTI-CANCER DRUG, V19, P359, DOI 10.1097/CAD.0b013e3282f7f518; Nguyen NP, 2010, CANCER TREAT REV, V36, P485, DOI 10.1016/j.ctrv.2010.02.016; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Saeed M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00267; SEAMAN FC, 1982, BOT REV, V48, P121, DOI 10.1007/BF02919190; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Tanner M, 2004, MOL CANCER THER, V3, P1585; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vazquez-Santillan K, 2015, CELL ONCOL, V38, P327, DOI 10.1007/s13402-015-0236-6; Villagomez R, 2015, CHEM NAT COMPD+, V51, P675, DOI 10.1007/s10600-015-1382-9; Villagomez R, 2014, NATURAL SEMISYNTHETI, P833; Villagomez R, 2014, ANTICANCER RES, V34, P503; Villagomez R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115819; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	33	21	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2017	12	9							e0184304	10.1371/journal.pone.0184304	http://dx.doi.org/10.1371/journal.pone.0184304			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF3ON	28863191	Green Published, gold, Green Submitted			2023-01-03	WOS:000408816900048
J	Helde-Frankling, M; Hoijer, J; Bergqvist, J; Bjorkhem-Bergman, L				Helde-Frankling, Maria; Hoijer, Jonas; Bergqvist, Jenny; Bjorkhem-Bergman, Linda			Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study	PLOS ONE			English	Article							QUALITY-OF-LIFE; 25-HYDROXYVITAMIN D LEVEL; D DEFICIENCY; ASSOCIATION; FATIGUE; BASE; RISK; CARE	Background We previously showed an association between low vitamin D levels and high opioid doses to alleviate pain in palliative cancer patients. The aim of this case-controlled study was to investigate if vitamin D supplementation could improve pain management, quality of life (QoL) and decrease infections in palliative cancer patients. Methods Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched "control"-patients from a previous study at the same ward. Opioid doses, antibiotic consumption and QoL-scores measured with the Edmonton Symptom Assessment Scale (ESAS) were monitored. The primary endpoint was the change from baseline after 1 and 3 months compared between the groups using linear regression with adjustment for a potential cofounding factor. Results After 1 month the vitamin D treated group had a significantly decreased fentanyl dose compared to the untreated group with a difference of 46 mu g/h; 95% CI 24-78, which increased further at 3 months to 91 mu g/h; 95% CI 56-140 mu g/h. The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21). The vitamin D-treated group had significantly lower consumption of antibiotics after 3 months compared to the untreated group, the difference was -26%; 95% CI -0.41%-(-0.12%). Vitamin D was well tolerated by all patients and no adverse events were reported. Conclusion Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment. Decreased infections are noted 3 months after vitamin D treatment. The results from this pilot-study have been used for the power-calculation of a future randomized, placebo-controlled, double-blind study called "Palliative-D" that will start in Nov 2017 and will include 254 palliative cancer patients.	[Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] ASIH Stockholm Sodra, Palliat Home Care & Hosp Ward, Langbro Pk, Alvsjo, Sweden; [Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden; [Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] Karolinska Univ Hosp, Stockholm, Sweden; [Hoijer, Jonas] Karolinska Inst, Inst Environm Med, Unit Biostat, Stockholm, Sweden; [Bergqvist, Jenny] Capio St Gorans Hosp, Dept Surg, Breast Ctr, Stockholm, Sweden; [Bergqvist, Jenny] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Saint Goran's Hospital; Karolinska Institutet	Bjorkhem-Bergman, L (corresponding author), ASIH Stockholm Sodra, Palliat Home Care & Hosp Ward, Langbro Pk, Alvsjo, Sweden.; Bjorkhem-Bergman, L (corresponding author), Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden.; Bjorkhem-Bergman, L (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.	linda.bjorkhem-bergman@ki.se		Bergqvist, Jenny/0000-0002-9875-7946; Bjorkhem-Bergman, Linda/0000-0003-3505-9283	Regional agreement on training and clinical research (ALF); Swedish Cancer Society and Karolinska Institutet.	Regional agreement on training and clinical research (ALF); Swedish Cancer Society and Karolinska Institutet.	Financial support was provided through the Regional agreement on training and clinical research (ALF) between Karolinska Institutet and Stockholm County Council, The Swedish Cancer Society and Karolinska Institutet.	Amir E, 2010, CANCER-AM CANCER SOC, V116, P284, DOI 10.1002/cncr.24749; Anand S, 2011, NEPHROL DIAL TRANSPL, V26, P3683, DOI 10.1093/ndt/gfr098; Aoun SM, 2014, J PAIN SYMPTOM MANAG, V48, P1222, DOI 10.1016/j.jpainsymman.2014.01.007; Bergman Peter, 2015, BMC Res Notes, V8, P498, DOI 10.1186/s13104-015-1504-2; Bergman P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128223; Bergman P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065835; Bjorkhem-Bergman L, 2016, BMJ SUPPORT PALLIAT, V6, P287, DOI 10.1136/bmjspcare-2015-000921; Carlberg C, 2009, ANTICANCER RES, V29, P3485; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CASTRO Francisca DIAS DE, 2015, Arq. Gastroenterol., V52, P260, DOI 10.1590/S0004-28032015000400003; Dev R, 2011, ONCOLOGIST, V16, P1637, DOI 10.1634/theoncologist.2011-0151; Gagnon B, 2015, J PAIN SYMPTOM MANAG, V49, P36, DOI 10.1016/j.jpainsymman.2014.05.015; Gendelman O, 2015, LUPUS, V24, P483, DOI 10.1177/0961203314558676; Gifondorwa DJ, 2016, MUSCLE NERVE, V54, P1120, DOI 10.1002/mus.25146; Heaney RP, 2012, NEW ENGL J MED, V367, P77, DOI 10.1056/NEJMe1206858; Helde-Frankling M, 2016, CANCERS, V8, DOI 10.3390/cancers8090084; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollis BW, 2008, AM J CLIN NUTR, V88, p507S, DOI 10.1093/ajcn/88.2.507S; Juzeniene A, 2012, DERM-ENDOCRINOL, V4, P109, DOI 10.4161/derm.20013; Kabbani TCA, 2016, AM J GASTROENTEROL, V111, P712, DOI 10.1038/ajg.2016.53; Kuru P, 2015, RHEUMATOL INT, V35, P315, DOI 10.1007/s00296-014-3099-7; Martinez-Alonso M, 2016, PALLIATIVE MED, V30, P89, DOI 10.1177/0269216315601954; Maser RE, 2015, ENDOCR PRACT, V21, P174, DOI 10.4158/EP14332.OR; Ohta H, 2014, CLIN THER, V36, P225, DOI 10.1016/j.clinthera.2013.12.007; Ovesjo E ML, 2015, BASIC CLIN PHARM TOX; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sabetta JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011088; Sampaio-Barros MM, 2016, REV BRAS REUMATOL, V56, P337, DOI [10.1016/j.rbre.2016.05.006, 10.1016/j.rbr.2016.03.004]; Science M, 2013, CLIN INFECT DIS, V57, P392, DOI 10.1093/cid/cit289; Sepehrmanesh Z, 2016, J NUTR, V146, P243, DOI 10.3945/jn.115.218883; Shi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086467; Shipton EE, 2015, PAIN THER, V4, P67, DOI 10.1007/s40122-015-0036-8; Straube S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007771.pub3; Straube S, 2009, PAIN, V141, P10, DOI 10.1016/j.pain.2008.11.010; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Watanabe SM, 2012, PSYCHO-ONCOLOGY, V21, P977, DOI 10.1002/pon.1996; Wepner F, 2014, PAIN, V155, P261, DOI 10.1016/j.pain.2013.10.002; Whitehurst JL, 2014, PALLIATIVE MED, V28, P87, DOI 10.1177/0269216313511142; Wu ZQ, 2016, PAIN PHYSICIAN, V19, P415	40	20	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0184208	10.1371/journal.pone.0184208	http://dx.doi.org/10.1371/journal.pone.0184208			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF2PY	28859173	gold, Green Submitted, Green Published			2023-01-03	WOS:000408740500074
J	Steca, P; Monzani, D; Greco, A; Franzelli, C; Magrin, ME; Miglioretti, M; Sarini, M; Scrignaro, M; Vecchio, L; Fattirolli, F; D'Addario, M				Steca, Patrizia; Monzani, Dario; Greco, Andrea; Franzelli, Cristina; Magrin, Maria Elena; Miglioretti, Massimo; Sarini, Marcello; Scrignaro, Marta; Vecchio, Luca; Fattirolli, Francesco; D'Addario, Marco			Stability and change of lifestyle profiles in cardiovascular patients after their first acute coronary event	PLOS ONE			English	Article							CARDIAC REHABILITATION; MYOCARDIAL-INFARCTION; RISK-FACTORS; SECONDARY PREVENTION; PHYSICAL-ACTIVITY; DEPRESSION SCALE; HOSPITAL ANXIETY; PATIENTS BELIEFS; HEART-DISEASE; ASSOCIATION	Background Acute coronary syndrome (ACS) is a major cause of morbidity and mortality. Lifestyle and health behavior changes play an important role in the primary and secondary prevention of ACS recurrence. Changes in unhealthy lifestyles after an acute coronary event have been analyzed by considering separate behaviors individually, even though research on the healthy population has demonstrated that unhealthy behaviors tend to co-occur. Purpose The aim of this study was to identify lifestyle profiles of ACS patients and to explore their pathways of change for one year after their first coronary event by adopting a typological approach. Methods Two hundred and twenty-three patients (84% male; mean age = 57.14) completed self-report measures of health-related behaviors at the beginning of cardiac rehabilitation, and six months and twelve months after. At each wave depression, anxiety and heart rate were also evaluated. Cluster analysis was performed to identify lifestyle profiles and to analyze their change over time. Differences in psychological factors and heart rate among clusters were assessed. Results Patients' diet, physical activity, and smoking behavior greatly improved six months after their first coronary event. No further improvements were detected after one year. At each wave specific lifestyle profiles were identified, ranging from more maladaptive to healthier clusters. Patients with multiple unhealthy behaviors experience greater difficulties in maintaining a healthier lifestyle over time. Moreover, the results demonstrated the association between lifestyle profiles at twelve months after the acute coronary event and depression measured six months earlier. Finally, the most maladaptive lifestyle profile had many members with elevated heart rate at twelve months after the cardiac rehabilitation. Conclusions Current findings may have a strong practical impact in the development and implementation of personalized secondary prevention programs targeting lifestyles of ACS patients.	[Steca, Patrizia; Monzani, Dario; Greco, Andrea; Magrin, Maria Elena; Miglioretti, Massimo; Sarini, Marcello; Scrignaro, Marta; Vecchio, Luca; D'Addario, Marco] Univ Milano Bicocca, Dept Psychol, Milan, Italy; [Franzelli, Cristina] Ist Clin Perfezionamento Hosp, Cardiac Rehabil Ctr, Milan, Italy; [Fattirolli, Francesco] Univ Florence, Dept Med & Surg Crit Care, Cardiac Rehabil Unit, Florence, Italy; [Fattirolli, Francesco] Azienda Osped Univ Careggi, Florence, Italy	University of Milano-Bicocca; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi	Monzani, D (corresponding author), Univ Milano Bicocca, Dept Psychol, Milan, Italy.	dario.monzani@unimib.it	Vecchio, Luca/C-1670-2013; D'Addario, Marco/AAY-6426-2021; Monzani, Dario/AAR-2609-2021; Monzani, Dario/AAP-4501-2020; Greco, Andrea/I-7266-2016	Vecchio, Luca/0000-0001-6784-2817; Greco, Andrea/0000-0002-8086-2801; D'ADDARIO, MARCO/0000-0002-7659-885X	Italian Ministry of Instruction, University and Research - FIRB "Futuro in ricerca" [RBFR08YVUL]	Italian Ministry of Instruction, University and Research - FIRB "Futuro in ricerca"	This work was supported by the Italian Ministry of Instruction, University and Research - FIRB "Futuro in ricerca" [grant number RBFR08YVUL]; Principal Investigator: PS, http://futuroinricerca.miur.it/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Abood D, 1994, HEALTH VALUES, V18, P51; Beckie TM, 2010, J CARDIOPULM REHABIL, V30, P147, DOI 10.1097/HCR.0b013e3181d0c2ce; Bergman L., 2002, SLEIPNER A STATISTIC; Bergman L.R., 2003, STUDYING INDIVIDUAL; Bergman LR, 2012, INT J BEHAV DEV, V36, P237, DOI 10.1177/0165025412440947; Berlin I, 2006, ADDICTION, V101, P1814, DOI 10.1111/j.1360-0443.2006.01616.x; Burke V, 1997, PREV MED, V26, P724, DOI 10.1006/pmed.1997.0198; Cooper AF, 2007, HEART, V93, P53, DOI 10.1136/hrt.2005.081299; Cooper AF, 2005, CLIN REHABIL, V19, P87, DOI 10.1191/0269215505cr818oa; Costantini M, 1999, SUPPORT CARE CANCER, V7, P121, DOI 10.1007/s005200050241; Cuenca-Garcia M, 2013, J NUTR EDUC BEHAV, V45, P549, DOI 10.1016/j.jneb.2013.02.006; de Vries H, 2008, PREV MED, V46, P203, DOI 10.1016/j.ypmed.2007.08.005; Doyle B, 2012, J CLIN NURS, V21, P32, DOI 10.1111/j.1365-2702.2010.03636.x; Facila L, 2012, WORLD J CARDIOL, V4, P15, DOI 10.4330/wjc.v4.i1.15; Farley Robyn L, 2003, Eur J Cardiovasc Nurs, V2, P205; Fine LJ, 2004, AM J PREV MED, V27, P18, DOI 10.1016/j.amepre.2004.04.017; Garcia-Lopez M, 2014, EUR J PREV CARDIOL, V21, P521, DOI 10.1177/2047487312467871; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Grace SL, 2002, GEN HOSP PSYCHIAT, V24, P127, DOI 10.1016/S0163-8343(02)00179-2; Hayes SN, 2009, WOMENS HEALTH, V5, P709, DOI 10.2217/WHE.09.56; Hu MX, 2016, PREV MED, V94, P12; Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401; Lampropoulos K, 2016, KARDIOL POL, V74, P1154, DOI 10.5603/KP.a2016.0059; Mahoney JL, 2001, INT J BEHAV DEV, V25, P509, DOI 10.1080/01650250042000456; Mayou RA, 2000, PSYCHOSOM MED, V62, P212, DOI 10.1097/00006842-200003000-00011; Morris LJ, 2016, PREV MED, V84, P1, DOI 10.1016/j.ypmed.2015.12.009; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Niaura R, 2001, PSYCHOL ADDICT BEHAV, V15, P13, DOI 10.1037/0893-164X.15.1.13; Palaniappan U, 2001, J NUTR, V131, P1952, DOI 10.1093/jn/131.7.1952; Panagiotakos DB, 2015, MATURITAS, V80, P205, DOI 10.1016/j.maturitas.2014.11.011; Piepoli MF, 2010, EUR J CARDIOV PREV R, V17, P1, DOI 10.1097/HJR.0b013e3283313592; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Prochaska JJ, 2011, AM J LIFESTYLE MED, V5, P208, DOI 10.1177/1559827610391883; Schlecht NF, 1999, AM J EPIDEMIOL, V150, P1129, DOI 10.1093/oxfordjournals.aje.a009938; Schuit AJ, 2002, PREV MED, V35, P219, DOI 10.1006/pmed.2002.1064; SIMOES EJ, 1995, AM J PUBLIC HEALTH, V85, P240, DOI 10.2105/AJPH.85.2.240; Slattery ML, 2002, MED SCI SPORT EXER, V34, P913, DOI 10.1097/00005768-200206000-00002; Sofi F, 2011, ACTA CARDIOL, V66, P791, DOI 10.1080/AC.66.6.2136965; Steca P, 2015, APPL PSYCHOL HEALTH; Topolski T. D., 2006, CTR DIS CONTROL PREV, V3, P1; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Vervueren PL, 2012, ARCH CARDIOVASC DIS, V105, P478, DOI 10.1016/j.acvd.2012.05.008; Vickers KS, 2006, AM J HEALTH BEHAV, V30, P353, DOI 10.5993/AJHB.30.4.2; WHO, 2011, GLOBAL STATUS REPORT; WOODWARD M, 1994, PREV MED, V23, P354, DOI 10.1006/pmed.1994.1049; Yehle KS, 2012, J CARDIOPULM REHABIL, V32, P203, DOI 10.1097/HCR.0b013e31825b4e6a; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmermann-Viehoff F, 2010, EUR J CARDIOV PREV R, V17, P509, DOI 10.1097/HJR.0b013e328337b57b	49	22	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2017	12	8							e0183905	10.1371/journal.pone.0183905	http://dx.doi.org/10.1371/journal.pone.0183905			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE9SU	28850579	Green Submitted, Green Published, gold			2023-01-03	WOS:000408544200040
J	Frazier, W; Cochran, G; Lo-Ciganic, WH; Gellad, WF; Gordon, AJ; Chang, CCH; Donohue, JM				Frazier, Winfred; Cochran, Gerald; Lo-Ciganic, Wei-Hsuan; Gellad, Walid F.; Gordon, Adam J.; Chang, Chung-Chou H.; Donohue, Julie M.			Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Frazier, Winfred; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall,A635, Pittsburgh, PA 15261 USA; [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA; [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Gordon, Adam J.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Arizona; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall,A635, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu	Gordon, Adam Joseph/AAX-9001-2020	Gordon, Adam Joseph/0000-0002-2453-8871	Centers for Disease Control and Prevention (CDC) [U01CE002496]; Pennsylvania Department of Human Services (PADHS); University of Pittsburgh; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL [U01CE002496] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Pennsylvania Department of Human Services (PADHS); University of Pittsburgh(University of Pittsburgh); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by grant U01CE002496 from the Centers for Disease Control and Prevention (CDC) and an intergovernmental agreement between the Pennsylvania Department of Human Services (PADHS) and the University of Pittsburgh.	D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038; Naeger S, 2016, J SUBST ABUSE TREAT, V69, P64, DOI 10.1016/j.jsat.2016.07.004; Seymour RB, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0352-x; Sharp MJ, 2015, MMWR-MORBID MORTAL W, V64, P377	6	40	41	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 22	2017	318	8					750	752		10.1001/jama.2017.7818	http://dx.doi.org/10.1001/jama.2017.7818			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE3DE	28829862	Green Published			2023-01-03	WOS:000408095800029
J	McCartney, M				McCartney, Margaret			NO HOLDS BARRED Margaret McCartney: The cult of CPR	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Sokol DK, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i26	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	2017	358								j3831	10.1136/bmj.j3831	http://dx.doi.org/10.1136/bmj.j3831			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE5BX	28811291	Green Published, Bronze			2023-01-03	WOS:000408228100002
J	Schmidt, C				Schmidt, Charles			DRUG DEVELOPMENT Children with cancer get more access to experimental drugs	SCIENCE			English	News Item																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2017	357	6351					540	540		10.1126/science.357.6351.540	http://dx.doi.org/10.1126/science.357.6351.540			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD1VM	28798112				2023-01-03	WOS:000407324800019
J	Han, ZL; Chen, Z; Lan, RF; Di, WC; Li, XH; Yu, HS; Ji, WQ; Zhang, XL; Xu, BA; Xu, W				Han, Zhonglin; Chen, Zheng; Lan, Rongfang; Di, Wencheng; Li, Xiaohong; Yu, Hongsong; Ji, Wenqing; Zhang, Xinlin; Xu, Biao; Xu, Wei			Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy	PLOS ONE			English	Article							LONG-TERM SURVIVAL; GENDER-RELATED DIFFERENCES; VENTRICULAR LEAD POSITION; DOPPLER CROSS-CORRELATION; ATRIAL-FIBRILLATION; DEFIBRILLATOR IMPLANTATION; CARDIOVERTER-DEFIBRILLATOR; MECHANICAL DYSSYNCHRONY; CONDUCTION DELAY; ADVERSE EVENTS	Background Recent studies have reported prognosis differences between male and female heart failure patients following cardiac resynchronization therapy (CRT). However, the potential clinical factors that underpin these differences remain to be elucidated. Methods A meta-analysis was performed to investigate the factors that characterize sex-specific differences following CRT. This analysis involved searching the Medline (Pubmed source) and Embase databases in the period from January 1980 to September 2016. Results Fifty-eight studies involving 33445 patients (23.08% of whom were women) were analyzed as part of this study. Only patients receiving CRT with follow-up greater than six months were included in our analysis. Compared with males, females exhibited a reduction of 33% (hazard ratio, 0.67; 95% confidence interval, 0.62-0.73; P < 0.0001) and 42% (hazard ratio, 0.58; 95% confidence interval, 0.46-0.74; P = 0.003) in all-cause mortality and heart failure hospitalization or heart failure, respectively. Following a stratified analysis of all-cause mortality, we observed that ischemic causes (p = 0.03) were likely to account for most of the sex-specific differences in relation to CRT. Conclusion These data suggest that women have a reduced risk of all-cause mortality and heart failure hospitalization or heart failure following CRT. Based on the results from the stratified analysis, we observed more optimal outcomes for females with ischemic heart disease. Thus, ischemia are likely to play a role in sex-related differences associated with CRT in heart failure patients. Further studies are required to determine other indications and the potential mechanisms that might be associated with sex-specific CRT outcomes.	[Han, Zhonglin; Chen, Zheng; Lan, Rongfang; Di, Wencheng; Li, Xiaohong; Yu, Hongsong; Ji, Wenqing; Zhang, Xinlin; Xu, Biao; Xu, Wei] Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Cardiol, Nanjing, Jiangsu, Peoples R China	Nanjing University	Xu, W (corresponding author), Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.	xuwei2003@medmail.com.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022		National Natural Science Foundation of China [81600267]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (No.81600267) to Zhonglin Han. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Alaeddini J, 2008, PACE, V31, P468, DOI 10.1111/j.1540-8159.2008.01016.x; Arshad A, 2011, J AM COLL CARDIOL, V57, P814, DOI 10.1016/j.jacc.2010.06.061; Auricchio A, 2007, AM J CARDIOL, V99, P232, DOI 10.1016/j.amjcard.2006.07.087; Bai R, 2008, J CARDIOVASC ELECTR, V19, P1259, DOI 10.1111/j.1540-8167.2008.01234.x; Bogale N, 2012, EUR J HEART FAIL, V14, P61, DOI 10.1093/eurjhf/hfr158; Cheng YJ, 2014, CIRC-ARRHYTHMIA ELEC, V7, P807, DOI 10.1161/CIRCEP.113.001786; Cipriani M, 2016, EUR J HEART FAIL, V18, P1060, DOI 10.1002/ejhf.569; Cipriani M, 2016, J CARDIOVASC MED, V17, P291, DOI 10.2459/JCM.0000000000000187; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Dagres N, 2007, J AM COLL CARDIOL, V49, P572, DOI 10.1016/j.jacc.2006.10.047; Delgado V, 2011, CIRCULATION, V123, P70, DOI 10.1161/CIRCULATIONAHA.110.945345; Di Biase L, 2008, EUR HEART J, V29, P2497, DOI 10.1093/eurheartj/ehn221; Eitel C, 2012, EUROPACE, V14, P358, DOI 10.1093/europace/eur298; El-Saed Aiman, 2009, Clin Cardiol, V32, pE33, DOI 10.1002/clc.20490; Fantoni C, 2008, EUR J HEART FAIL, V10, P298, DOI 10.1016/j.ejheart.2008.01.006; Ferreira AM, 2008, EUROPACE, V10, P809, DOI 10.1093/europace/eun135; Foley PWX, 2011, EUR J HEART FAIL, V13, P43, DOI 10.1093/eurjhf/hfq182; Frigerio M, 2014, INT J CARDIOL, V172, P64, DOI 10.1016/j.ijcard.2013.12.005; Gasparini M, 2015, EUR J HEART FAIL, V17, P717, DOI 10.1002/ejhf.269; Gasparini M, 2014, AM HEART J, V167, P203, DOI 10.1016/j.ahj.2013.10.017; Gold MR, 2015, HEART RHYTHM, V12, P524, DOI 10.1016/j.hrthm.2014.11.014; Herz ND, 2015, J WOMENS HEALTH, V24, P261, DOI 10.1089/jwh.2014.4980; Hoke U, 2014, CIRC-CARDIOVASC QUAL, V7, P437, DOI 10.1161/CIRCOUTCOMES.113.000821; Iler MA, 2008, AM J CARDIOL, V101, P359, DOI 10.1016/j.amjcard.2007.08.043; Jacobsson J, 2016, AM J CARDIOL, V118, P389, DOI 10.1016/j.amjcard.2016.05.017; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kappert K, 2012, CIRCULATION, V126, P934, DOI 10.1161/CIRCULATIONAHA.111.086660; Khatib M, 2014, EUR J HEART FAIL, V16, P802, DOI 10.1002/ejhf.102; Kotecha D, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1855; Kreuz J, 2012, EUROPACE, V14, P1596, DOI 10.1093/europace/eus152; Kronborg MB, 2008, EUR J HEART FAIL, V10, P796, DOI 10.1016/j.ejheart.2008.06.013; Leyva F, 2011, PACE, V34, P82, DOI 10.1111/j.1540-8159.2010.02909.x; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lilli A, 2007, PACE, V30, P1349, DOI 10.1111/j.1540-8159.2007.00870.x; Lin G, 2011, EUR HEART J, V32, P184, DOI 10.1093/eurheartj/ehq403; Looi KL, 2014, HEART, V100, P794, DOI 10.1136/heartjnl-2014-305537; Lumens J, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.115.003744; Miller AL, 2011, PACE, V34, P490, DOI 10.1111/j.1540-8159.2010.03014.x; Mitoff PR, 2011, HEART, V97, P382, DOI 10.1136/hrt.2010.199760; Mooyaart EAQ, 2011, AM J CARDIOL, V108, P63, DOI 10.1016/j.amjcard.2011.02.345; Morani G, 2013, EUROPACE, V15, P1273, DOI 10.1093/europace/eut032; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Munir MB, 2016, J CARDIOVASC ELECTR, V27, P730, DOI 10.1111/jce.12951; Nagy VK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143907; Pedram A, 2010, MOL ENDOCRINOL, V24, P2152, DOI 10.1210/me.2010-0154; Perini AP, 2014, EUROPACE, V16, P71, DOI 10.1093/europace/eut190; Pfau G, 2010, J CARDIOTHOR VASC AN, V24, P30, DOI 10.1053/j.jvca.2009.07.009; Poli D, 2015, INT J WOMENS HEALTH, V7, P605, DOI 10.2147/IJWH.S45925; Prochnau D, 2011, CAN J CARDIOL, V27, P363, DOI 10.1016/j.cjca.2010.12.066; Reitan C, 2014, EUROPACE, V16, P1603, DOI 10.1093/europace/euu058; Rickard J, 2015, AM J CARDIOL, V115, P82, DOI 10.1016/j.amjcard.2014.09.052; Rickard J, 2011, AM HEART J, V162, P646, DOI 10.1016/j.ahj.2011.07.008; Risum N, 2013, EUR HEART J, V34, P48, DOI 10.1093/eurheartj/ehs035; Rostom A, 2004, Evid Rep Technol Assess (Summ), P1; Roubicek T, 2015, CIRC-ARRHYTHMIA ELEC, V8, P1113, DOI 10.1161/CIRCEP.115.003004; Sandberg K, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-7; Saxon LA, 2006, CIRCULATION, V114, P2766, DOI 10.1161/CIRCULATIONAHA.106.642892; Schuchert A, 2013, CLIN CARDIOL, V36, P683, DOI 10.1002/clc.22203; Shalaby A, 2008, AM J CARDIOL, V101, P238, DOI 10.1016/j.amjcard.2007.07.064; Sharma AK, 2015, AM J CARDIOL, V115, P1249, DOI 10.1016/j.amjcard.2015.01.559; Shekelle PG, 2003, J AM COLL CARDIOL, V41, P1529, DOI 10.1016/S0735-1097(03)00262-6; Shen XD, 2011, INT J CARDIOL, V152, P13, DOI 10.1016/j.ijcard.2010.06.016; Smit MD, 2011, EUR J HEART FAIL, V13, P543, DOI 10.1093/eurjhf/hfr006; Stabile G, 2015, HEART RHYTHM, V12, P2221, DOI 10.1016/j.hrthm.2015.05.020; Stabile G, 2009, PACE, V32, pS141, DOI 10.1111/j.1540-8159.2008.02271.x; Sutton MGS, 2006, CIRCULATION, V113, P266, DOI 10.1161/CIRCULATIONAHA.104.520817; Taneja T, 2001, PACE, V24, P16, DOI 10.1046/j.1460-9592.2001.00016.x; Tayal B, 2015, J AM SOC ECHOCARDIOG, V28, P1474, DOI 10.1016/j.echo.2015.07.021; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Van Bommel RJ, 2011, J AM COLL CARDIOL, V57, P549, DOI 10.1016/j.jacc.2010.06.060; Wilcox JE, 2014, CIRC-HEART FAIL, V7, P146, DOI 10.1161/CIRCHEARTFAILURE.113.000789; Xu YZ, 2012, J CARDIOVASC ELECTR, V23, P172, DOI 10.1111/j.1540-8167.2011.02168.x; Yanagisawa S, 2015, J INTERV CARD ELECTR, V43, P269, DOI 10.1007/s10840-015-0015-3; Yancy CW, 2009, AM HEART J, V157, P754, DOI 10.1016/j.ahj.2008.12.016; Yu CM, 2005, CIRCULATION, V112, P1580, DOI 10.1161/CIRCULATIONAHA.105.538272; Zabarovskaja S, 2012, EUROPACE, V14, P1148, DOI 10.1093/europace/eus039; Zardkoohi O, 2007, PACE, V30, P1344, DOI 10.1111/j.1540-8159.2007.00869.x; Zhang Q, 2009, CLIN SCI, V117, P397, DOI 10.1042/CS20080580; Zusterzeel R, 2016, J CARDIOVASC TRANSL, V9, P12, DOI 10.1007/s12265-015-9663-z; Zusterzeel R, 2014, JAMA INTERN MED, V174, P1340, DOI 10.1001/jamainternmed.2014.2717	81	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2017	12	7							e0180513	10.1371/journal.pone.0180513	http://dx.doi.org/10.1371/journal.pone.0180513			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA3HX	28683134	Green Published, Green Submitted, gold			2023-01-03	WOS:000405335200045
J	Holmes, HM; Sachs, GA				Holmes, Holly M.; Sachs, Greg A.			Meaningful Deprescribing in the Nursing Home	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Holmes, Holly M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA; Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Sachs, Greg A.] Regenstrief Inst Hlth Care, Indianapolis, IN USA; [Holmes, Holly M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Geriatr & Palliat Med, 6431 Fannin,MSB 5-111, Houston, TX 77030 USA; [Sachs, Greg A.] Indiana Univ, Dept Med F2 624, 5-3 Fac Off Bldg,720 Eskenazi Ave, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University-Purdue University Indianapolis	Holmes, HM (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Geriatr & Palliat Med, 6431 Fannin,MSB 5-111, Houston, TX 77030 USA.	Holly.m.holmes@uth.tmc.edu						Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Halvorsen KH, 2017, PHARMACOEPIDEM DR S, V26, P192, DOI 10.1002/pds.4142; Khodyakov D, 2017, J AM GERIATR SOC, V65, P586, DOI 10.1111/jgs.14689; Lavan AH, 2017, AGE AGEING, V46, P600, DOI 10.1093/ageing/afx005; Maclagan LC, 2017, J AM GERIATR SOC, V65, P2205, DOI 10.1111/jgs.15016; Tjia J, 2010, J AM GERIATR SOC, V58, P880, DOI 10.1111/j.1532-5415.2010.02819.x; Wouters H, 2017, ANN INTERN MED, V167, P609, DOI 10.7326/M16-2729	7	5	5	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2017	167	9					671	+		10.7326/M17-2268	http://dx.doi.org/10.7326/M17-2268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM1DV	29052715				2023-01-03	WOS:000414714700010
J	Kingston, A; Wohland, P; Wittenberg, R; Robinson, L; Brayne, C; Matthews, FE; Jagger, C				Kingston, Andrew; Wohland, Pia; Wittenberg, Raphael; Robinson, Louise; Brayne, Carol; Matthews, Fiona E.; Jagger, Carol		Cognitive Function Ageing Studies	Is late-life dependency increasing or not? A comparison of the Cognitive Function and Ageing Studies (CFAS)	LANCET			English	Article							ENGLAND; EXPECTANCY; HEALTH; OLDER	Background Little is known about how the proportions of dependency states have changed between generational cohorts of older people. We aimed to estimate years lived in different dependency states at age 65 years in 1991 and 2011, and new projections of future demand for care. Methods In this population-based study, we compared two Cognitive Function and Ageing Studies (CFAS I and CFAS II) of older people (aged >= 65 years) who were permanently registered with a general practice in three defined geographical areas (Cambridgeshire, Newcastle, and Nottingham; UK). These studies were done two decades apart (1991 and 2011). General practices provided lists of individuals to be contacted and were asked to exclude those who had died or might die over the next month. Baseline interviews were done in the community and care homes. Participants were stratified by age, and interviews occurred only after written informed consent was obtained. Information collected included basic sociodemographics, cognitive status, urinary incontinence, and self-reported ability to do activities of daily living. CFAS I was assigned as the 1991 cohort and CFAS II as the 2011 cohort, and both studies provided prevalence estimates of dependency in four states: high dependency (24-h care), medium dependency (daily care), low dependency (less than daily), and independent. Years in each dependency state were calculated by Sullivan's method. To project future demands for social care, the proportions in each dependency state (by age group and sex) were applied to the 2014 England population projections. Findings Between 1991 and 2011, there were significant increases in years lived from age 65 years with low dependency (1.7 years [95% CI 1.0-2.4] for men and 2.4 years [1.8-3.1] for women) and increases with high dependency (0.9 years [0.2-1.7] for men and 1.3 years [0.5-2.1] for women). The majority of men's extra years of life were spent independent (36.3%) or with low dependency (36.3%) whereas for women the majority were spent with low dependency (58.0%), and only 4.8% were independent. There were substantial reductions in the proportions with medium and high dependency who lived in care homes, although, if these dependency and care home proportions remain constant in the future, further population ageing will require an extra 71 215 care home places by 2025. Interpretation On average older men now spend 2.4 years and women 3.0 years with substantial care needs, and most will live in the community. These findings have considerable implications for families of older people who provide the majority of unpaid care, but the findings also provide valuable new information for governments and care providers planning the resources and funding required for the care of their future ageing populations. Funding Medical Research Council (G9901400) and (G06010220), with support from the National Institute for Health Research Comprehensive Local research networks in West Anglia and Trent, UK, and Neurodegenerative Disease Research Network in Newcastle, UK. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under CC BY 4.0 license.	[Kingston, Andrew; Robinson, Louise; Matthews, Fiona E.; Jagger, Carol] Newcastle Univ, Fac Med, Inst Hlth & Soc, Newcastle NE4 5PL, England; [Kingston, Andrew; Robinson, Louise; Matthews, Fiona E.; Jagger, Carol] Newcastle Univ, Fac Med, Inst Ageing, Newcastle, England; [Wohland, Pia] Univ Hull, Hull York Med Sch, Kingston Upon Hull, N Humberside, England; [Wittenberg, Raphael] London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London, England; [Brayne, Carol] Univ Cambridge, Cambridge Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England; [Matthews, Fiona E.] Univ Cambridge, Cambridge Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	Newcastle University - UK; Newcastle University - UK; University of Hull; University of York - UK; University of London; London School Economics & Political Science; University of Cambridge; MRC Biostatistics Unit; University of Cambridge	Jagger, C (corresponding author), Newcastle Univ, Fac Med, Inst Hlth & Soc, Newcastle NE4 5PL, England.	carol.jagger@newcastle.ac.uk	Comas-Herrera, Adelina/A-2325-2011; Matthews, Fiona/O-6932-2015; Wohland, Pia/AAV-8877-2020; Comas-Herrera, Adelina/Q-7107-2019; Brayne, Carol/AAA-4285-2020; Wohland, Pia/H-3096-2016; Dening, Tom/E-1335-2013	Comas-Herrera, Adelina/0000-0002-9860-9062; Matthews, Fiona/0000-0002-1728-2388; Comas-Herrera, Adelina/0000-0002-9860-9062; Brayne, Carol/0000-0001-5307-663X; Pickett, James/0000-0002-2657-0795; Jagger, Carol/0000-0002-6377-9926; Kingston, Andrew/0000-0003-4211-7007; Wohland, Pia/0000-0002-6893-5852; Wharton, Stephen B/0000-0003-2785-333X; Dening, Tom/0000-0003-3387-4241; McKeith, Ian/0000-0002-9250-0568	Medical Research Council [G9901400, G06010220]; National Institute for Health Research Comprehensive Local research network in West Anglia; National Institute for Health Research Comprehensive Local research network in Trent, UK; Neurodegenerative Disease Research Network in Newcastle, UK; Economic and Social Research Council [ES/I017399/1] Funding Source: researchfish; Medical Research Council [MC_UU_00002/12, G0601022, MC_U105292687] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10084, NIHR-RP-011-043] Funding Source: researchfish; ESRC [ES/I017399/1] Funding Source: UKRI; MRC [G0601022, G9901400, MC_U105292687, MC_UU_00002/12] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Comprehensive Local research network in West Anglia; National Institute for Health Research Comprehensive Local research network in Trent, UK; Neurodegenerative Disease Research Network in Newcastle, UK; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Medical Research Council (G9901400) and (G06010220), with support from the National Institute for Health Research Comprehensive Local research networks in West Anglia and Trent, UK, and Neurodegenerative Disease Research Network in Newcastle, UK.	Appleby J, 2015, Q MONITORING REPORT; Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140-6736(15)00516-4; Brayne C, 1999, BMJ; Christensen K, 2008, P NATL ACAD SCI USA, V105, P13274, DOI 10.1073/pnas.0804931105; Collerton J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4904; De Brauwer I, 2014, ARCH GERONTOL GERIAT, V59, P175, DOI 10.1016/j.archger.2014.03.005; Ellis G, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6553; Fernandez J-L, 2010, AGEING SOC CHALLENGE; Folstein M, 1975, J PSYCHIAT RES; Freedman VA, 2016, AM J PUBLIC HEALTH, V106, P1079, DOI 10.2105/AJPH.2016.303089; Gerada C, 2012, PREPARING FUTURE GP; Hashimoto S, 2010, J EPIDEMIOL, V20, P308, DOI 10.2188/jea.JE20090190; ISAACS B, 1976, BRIT J PREV SOC MED, V30, P79; Jagger C, CAPABILITY DEPENDENC; Jagger C., HLTH EXPECTANCY CALC; Jagger C, 2016, LANCET, V387, P779, DOI 10.1016/S0140-6736(15)00947-2; Jagger C, 2011, INT HANDB POPUL, V2, P551, DOI 10.1007/978-90-481-9996-9_26; Kingston A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031665; Koopmans RTCM, 2013, J AM MED DIR ASSOC, V14, P781, DOI 10.1016/j.jamda.2013.08.004; Kreft D, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0093-1; Langa KM, 2017, JAMA INTERN MED, V177, P51, DOI 10.1001/jamainternmed.2016.6807; Malley Juliette, 2011, Health Stat Q, P33, DOI 10.1057/hsq.2011.17; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Mathers CD, CAUSES INT INCREASES; Matthews FE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161705; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; McGee MA, 1998, AGE AGEING, V27, P605, DOI 10.1093/ageing/27.5.605; Mortimer J, 2015, HLTH CARE OLDER PEOP; Nadash P, 2017, GERONTOLOGIST, DOI [10.1093/geront/, DOI 10.1093/geront/]; Robinson L., 2015, PRESENT FUTURE CONFI; Seko R, 2012, J EPIDEMIOL, V22, P238, DOI 10.2188/jea.JE20110069; Stineman MG, 2014, PM&R, V6, P976, DOI 10.1016/j.pmrj.2014.05.001; SULLIVAN DF, 1971, HEALTH SERV REP, V86, P347, DOI 10.2307/4594169; UN Department of Economic and Social Affairs, 2009, WORLD POP AG 2009	34	81	81	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 7	2017	390	10103					1676	1684		10.1016/S0140-6736(17)31575-1	http://dx.doi.org/10.1016/S0140-6736(17)31575-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FI9TS	28821408	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000412352800027
J	Bjorkum, AA; Oveland, E; Stuhr, L; Havnes, MB; Berven, F; Gronning, M; Hope, A				Bjorkum, Alvhild Alette; Oveland, Eystein; Stuhr, Linda; Havnes, Marianne Bjordal; Berven, Frode; Gronning, Marit; Hope, Arvid			Fast hyperbaric decompression after heliox saturation altered the brain proteome in rats	PLOS ONE			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; CYCLIN-DEPENDENT KINASE-5; S100B PROTEIN; WHITE-MATTER; SPINAL-CORD; SICKNESS; DIVERS; MRI; INJURY; CDK5	Better understanding of the physiological mechanisms and neurological symptoms involved in the development of decompression sickness could contribute to improvements of diving procedures. The main objective of the present study was to determine effects on the brain proteome of fast decompression (1 bar/20 s) compared to controls (1 bar/10 min) after heliox saturation diving, using rats in a model system. The protein S100B, considered a biomarker for brain injury, was not significantly different in serum samples from one week before, immediately after, and one week after the dive. Alterations in the rat brain proteome due to fast decompression were investigated using both iontrap and orbitrap LC-MS, and 967 and 1062 proteins were quantified, respectively. Based on the significantly regulated proteins in the iontrap (56) and orbitrap (128) datasets, the networks "synaptic vesicle fusion and recycling in nerve terminals" and "translation initiation" were significantly enriched in a system biological database analysis (Metacore). Ribosomal proteins (RLA2, RS10) and the proteins hippocalcin-like protein 4 and proteasome subunit beta type-7 were significantly upregulated in both datasets. The heat shock protein 105 kDa, Rho-associated protein kinase 2 and Dynamin-1 were significantly downregulated in both datasets. Another main effect of hyperbaric fast decompression in our experiment is inhibition of endocytosis and stimulation of exocytosis of vesicles in the presynaptic nerve terminal. In addition, fast decompression affected several proteins taking parts in these two main mechanisms of synaptic strength, especially alteration in CDK5/calcineurin are associated with a broad range of neurological disorders. In summary, fast decompression after heliox saturation affected the brain proteome in a rat model for diving, potentially disturbing protein homeostasis, e.g. in synaptic vesicles, and destabilizing cytoskeletal components. Data are available via ProteomeXchange with identifier PXD006349	[Bjorkum, Alvhild Alette] Western Norway Univ Appl Sci, Dept Biomed Lab Sci & Chem Engn, Bergen, Norway; [Oveland, Eystein; Berven, Frode] Univ Bergen, Fac Med & Dent, Dept Biomed, Prote Unit, Bergen, Norway; [Oveland, Eystein; Gronning, Marit] Univ Bergen, Fac Med & Dent, Dept Clin Med, Bergen, Norway; [Stuhr, Linda] Univ Bergen, Fac Med & Dent, Dept Biomed, Bergen, Norway; [Havnes, Marianne Bjordal] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Circulat & Med Imaging, Trondheim, Norway; [Gronning, Marit] Haukeland Hosp, Dept Occupat Med, Bergen, Norway; [Hope, Arvid] NUI AS, Bergen, Norway	Western Norway University of Applied Sciences; University of Bergen; University of Bergen; University of Bergen; Norwegian University of Science & Technology (NTNU); University of Bergen; Haukeland University Hospital	Bjorkum, AA (corresponding author), Western Norway Univ Appl Sci, Dept Biomed Lab Sci & Chem Engn, Bergen, Norway.	Alvhild.Bjorkum@hvl.no	Oveland, Eystein/X-6006-2019	Oveland, Eystein/0000-0003-2206-1480	Norwegian Research Council [220546]; NUI AS	Norwegian Research Council(Research Council of NorwayEuropean Commission); NUI AS	The project was supported by grants from the Norwegian Research Council (project number 220546). NUI AS did provide support in the form of salary for Arvid Hope, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balestra C, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00696; Berle M, 2010, FLUIDS BARRIERS CNS, V7, DOI 10.1186/1743-8454-7-8; Berle M, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-19; Calcagnile O, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0723-z; Cheung ZH, 2012, TRENDS CELL BIOL, V22, P169, DOI 10.1016/j.tcb.2011.11.003; Connolly DM, 2015, AEROSP MED HUM PERF, V86, P928, DOI 10.3357/AMHP.4392.2015; Cox J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S16-S12; Dadas A, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0045-y; Dutka AJ, 2003, PHYSL MED DIVING; Eftedal I, 2013, PHYSIOL GENOMICS, V45, P965, DOI 10.1152/physiolgenomics.00164.2012; Fassio Anna, 2016, Front Synaptic Neurosci, V8, P10, DOI 10.3389/fnsyn.2016.00010; Ferrazzano PA, 2008, MAGNETIC RESONANCE I; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Forestier A, 2015, HEMOGLOBIN, V39, P438, DOI 10.3109/03630269.2015.1065882; Gempp E, 2014, DIVING HYPERB MED, V44, P26; Gronning M, 2005, UNDERSEA HYPERBAR M, V32, P397; Gronning M, 2011, J NEUROL SCI, V304, P17, DOI 10.1016/j.jns.2011.01.021; Haslene-Hox H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019217; Havnes MB, 2013, EUR J APPL PHYSIOL, V113, P1405, DOI 10.1007/s00421-012-2565-8; Hemelryck W, 2014, SCAND J MED SCI SPOR, V24, P928, DOI 10.1111/sms.12100; Hennedige T, 2012, J MED IMAG RADIAT ON, V56, P282, DOI 10.1111/j.1754-9485.2012.02386.x; Hope A, 2006, 1993 CONS C REV; Hope A, 2015, UNDERSEA HYPERBAR M, V42, P57; Jallul S, 2007, SPINAL CORD, V45, P116, DOI 10.1038/sj.sc.3101923; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; Kei PL, 2007, J NEUROIMAGING, V17, P378, DOI 10.1111/j.1552-6569.2007.00122.x; Lee SY, 2004, P NATL ACAD SCI USA, V101, P546, DOI 10.1073/pnas.0307813100; McLinden Kristina A, 2012, Brain Disord Ther, V2012, P001; Moen G, 2010, ACTA RADIOL, V51, P1050, DOI 10.3109/02841851.2010.515245; Roberts AJ, 2013, NAT REV MOL CELL BIO, V14, P713, DOI 10.1038/nrm3667; Roy PK, 2015, COMPUT MED IMAG GRAP, V45, P102, DOI 10.1016/j.compmedimag.2015.08.005; Skogland S, 2002, J APPL PHYSIOL, V92, P2633, DOI 10.1152/japplphysiol.00795.2001; Su SC, 2011, ANNU REV CELL DEV BI, V27, P465, DOI 10.1146/annurev-cellbio-092910-154023; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Thompson WH, 2016, NEUROIMAGE-CLIN, V12, P1004, DOI 10.1016/j.nicl.2016.05.005; TODNEM K, 1991, BRIT J IND MED, V48, P258; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Vaudel M, 2015, NAT BIOTECHNOL, V33, P22, DOI 10.1038/nbt.3109; Vaudel M, 2011, PROTEOMICS, V11, P996, DOI 10.1002/pmic.201000595; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Yardan T, 2011, J PAK MED ASSOC, V61, P276	43	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2017	12	10							e0185765	10.1371/journal.pone.0185765	http://dx.doi.org/10.1371/journal.pone.0185765			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI7FU	28977037	Green Published, Green Submitted, gold			2023-01-03	WOS:000412163100043
J	Bortfeld, TR; Loeffler, JS				Bortfeld, Thomas R.; Loeffler, Jay S.			Three ways to make proton therapy affordable	NATURE			English	Editorial Material									[Bortfeld, Thomas R.; Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Bortfeld, Thomas R.; Loeffler, Jay S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Bortfeld, TR (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.; Bortfeld, TR (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	tbortfeld@mgh.harvard.edu	Bortfeld, Thomas/AAT-5666-2021					Baumann M, 2016, NAT REV CANCER, V16, P234, DOI 10.1038/nrc.2016.18; Bekelman JE, 2014, J CLIN ONCOL, V32, P1540, DOI 10.1200/JCO.2014.55.6613; Durante M, 2017, NAT REV CLIN ONCOL, V14, P483, DOI 10.1038/nrclinonc.2017.30; Glimelius B, 2005, ACTA ONCOL, V44, P836, DOI 10.1080/02841860500361049; Moteabbed M, 2014, PHYS MED BIOL, V59, P2883, DOI 10.1088/0031-9155/59/12/2883; Polf JC, 2015, PHYS TODAY, V68, P28, DOI 10.1063/PT.3.2945; Schippers JM, 2011, ACTA ONCOL, V50, P838, DOI 10.3109/0284186X.2011.582513; Shah A, 2016, LANCET ONCOL, V17, P559, DOI 10.1016/S1470-2045(16)00171-6; Verma V, 2016, CANCER-AM CANCER SOC, V122, P1483, DOI 10.1002/cncr.29882; Yan SS, 2016, INT J RADIAT ONCOL, V95, P224, DOI 10.1016/j.ijrobp.2015.09.033	10	61	63	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	2017	549	7673					451	453		10.1038/549451a	http://dx.doi.org/10.1038/549451a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI4GT	28959981	Bronze			2023-01-03	WOS:000411930000028
J	Sumankuuro, J; Crockett, J; Wang, SY				Sumankuuro, Joshua; Crockett, Judith; Wang, Shaoyu			The use of antenatal care in two rural districts of Upper West Region, Ghana	PLOS ONE			English	Article							HEALTH; PREGNANCY; DELIVERY; SERVICES; BARRIERS; BIRTH; LABOR	Background Despite decades of implementation of maternity healthcare programmes, including a focus on increasing the use of antenatal care (ANC) and concomitant birth preparedness and complication readiness (BPCR), the uptake of ANC continues to be below expectations in many developing countries. This has attendant implications for maternal and infant morbidity and mortality rates. Known barriers to ANC use include cost, distance to health care services and forces of various socio-cultural beliefs and practices. As part of a larger study on BPCR in rural Ghana, this paper reflects on the use of ANC in the study areas from rights-based and maternal engagement theoretical perspectives, with a focus on the barriers to ANC use. Methods Mixed methods approach was adopted to collect data from 8 study communities from individual in-depth interviews with 80 expectant mothers and 13 health care professionals, and 24 focus groups comprising 240 community members. The qualitative data followed a thematic analytical method, while the quantitative data was analysed using descriptive statistics. Results The average number of ANC visits were 3.34 +/- 1.292, and the majority of expectant mothers (71.3%) enrolled for ANC at the 8(th) week or later, with the longest delay recorded at the 6 th month of gestation. Traditional norms significantly influenced this delay. Likewise, overall use of ANC during pregnancy was shaped by cultural factors related to perceptions of pregnancy, gender-based roles and responsibilities and concerns that ANC would result in an overweighed baby and culturally inappropriate delivery at a health care facility. Conclusion Greater understanding of the sociocultural barriers to ANC is essential if proposed changes in community-specific health education programs are to facilitate early commencement and increased use of ANC.	[Sumankuuro, Joshua; Crockett, Judith; Wang, Shaoyu] Charles Sturt Univ, Sch Community Hlth, Fac Sci, Orange, NSW, Australia	Charles Sturt University	Sumankuuro, J (corresponding author), Charles Sturt Univ, Sch Community Hlth, Fac Sci, Orange, NSW, Australia.	jsumankuuro@csu.edu.au	Sumankuuro, Joshua/AAD-9951-2019; Wang, Shaoyu/M-5948-2015	Sumankuuro, Joshua/0000-0002-8967-1091; Crockett, Judith/0000-0003-2039-4345; Wang, Shaoyu/0000-0001-8674-8965	Ghana Education Trust Fund (GETFUND) Doctorate Studentship	Ghana Education Trust Fund (GETFUND) Doctorate Studentship	This research was funded by Ghana Education Trust Fund (GETFUND) Doctorate Studentship to JS, http://www.getfund.gov.gh/. However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aborigo RA, 2014, AFR J REPROD HEALTH, V18, P78; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Amzat J, 2015, J BIOETHIC INQ, V12, P283, DOI 10.1007/s11673-015-9607-y; Andrew EVW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093025; Atekyereza PR, 2014, TANZANIA J HLTH RES, V16; Atuoye KN, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1005-y; Audet CM, 2016, QUAL HEALTH RES, V26, P1721, DOI 10.1177/1049732315580302; Bayu H, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.28082; Bazzano AN, 2008, INT J GYNECOL OBSTET, V102, P91, DOI 10.1016/j.ijgo.2008.02.004; Bohren MA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001847; Caputi Mary, 2013, FEMINISM POWER NEED; Cofie LE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0604-2; D'Ambruoso L, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-140; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Ganle JK, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0590-4; Ganle JK, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0425-8; Government L, 2014, PROF NAODW DISTR ASS; GSS, 2014, 2010 POP HOUS CENS N; GSS (Ghana Statistical Services), 2014, 2010 POP HOUS CENS D; [Issa Bussie Daffiama], 2015, COMP BUDG DAFF BUSS, P55; Jack SM, 2005, J ADV NURS, V49, P182, DOI 10.1111/j.1365-2648.2004.03278.x; KRUEGER RA, 2000, FOCUS GROUPS; Lincetto O, 2006, ANTENATAL CARE OPPOR; Mrisho M, 2007, TROP MED INT HEALTH, V12, P862, DOI 10.1111/j.1365-3156.2007.01855.x; Ochako R, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-1; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Sumankuuro J, 2016, INT J COMMUNITY MED, V3, P3297, DOI DOI 10.18203/2394-6040.IJCMPH20164251; Sumankuuro J, 2017, PLOS ONE, V12; Sumankuuro J, 2016, INT J INNOVATION APP, V18, P341; Witter S, 2007, INT J HEALTH PLAN M, V22, P133, DOI 10.1002/hpm.867; World Health Organization, 2017, MAT MORT FACT SHEET; World Health Organization (WHO), 2006, BIRTH EM PREP ANT CA	33	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185537	10.1371/journal.pone.0185537	http://dx.doi.org/10.1371/journal.pone.0185537			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957422	Green Published, Green Submitted, gold			2023-01-03	WOS:000411985200079
J	Leiva, A; Contreras-Duarte, S; Amigo, L; Sepulveda, E; Boric, M; Quinones, V; Busso, D; Rigotti, A				Leiva, Andrea; Contreras-Duarte, Susana; Amigo, Ludwig; Sepulveda, Esteban; Boric, Mauricio; Quinones, Veronica; Busso, Dolores; Rigotti, Attilio			Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice	PLOS ONE			English	Article							HIGH-DENSITY-LIPOPROTEIN; RECEPTOR SR-BI; FARNESOID-X-RECEPTOR; E-DEFICIENT MICE; SCAVENGER RECEPTOR; APOLIPOPROTEIN-E; MYOCARDIAL-INFARCTION; CARDIAC DYSFUNCTION; HDL METABOLISM; CHOLESTEROL	For proper cholesterol metabolism, normal expression and function of scavenger receptor class B type I (SR-BI), a high-density lipoprotein (HDL) receptor, is required. Among the factors that regulate overall cholesterol homeostasis and HDL metabolism, the nuclear farnesoid X receptor plays an important role. Guggulsterone, a bioactive compound present in the natural product gugulipid, is an antagonist of this receptor. This natural product is widely used globally as a natural lipid-lowering agent, although its anti-atherogenic cardiovascular benefit in animal models or humans is unknown. The aim of this study was to determine the effects of gugulipid on cholesterol homeostasis and development of mild and severe atherosclerosis in male mice. For this purpose, we evaluated the impact of gugulipid treatment on liver histology, plasma lipoprotein cholesterol, endothelial function, and development of atherosclerosis and/or ischemic heart disease in wild-type mice; apolipoprotein E knockout mice, a model of atherosclerosis without ischemic complications; and SR-B1 knockout and atherogenic-diet-fed apolipoprotein E hypomorphic (SR-BI KO/ApoER61 h/h) mice, a model of lethal ischemic heart disease due to severe atherosclerosis. Gugulipid administration was associated with histological abnormalities in liver, increased alanine aminotransferase levels, lower hepatic SR-BI content, hypercholesterolemia due to increased HDL cholesterol levels, endothelial dysfunction, enhanced atherosclerosis, and accelerated death in animals with severe ischemic heart disease. In conclusion, our data show important adverse effects of gugulipid intake on HDL metabolism and atherosclerosis in male mice, suggesting potential and unknown deleterious effects on cardiovascular health in humans. In addition, these findings reemphasize the need for rigorous preclinical and clinical studies to provide guidance on the consumption of natural products and regulation of their use in the general population.	[Leiva, Andrea; Contreras-Duarte, Susana] Pontificia Univ Catolica Chile, Sch Med, Div Obstet & Gynaecol, CMPL, Santiago, Chile; [Amigo, Ludwig] Pontificia Univ Catolica Chile, Sch Med, Dept Gastroenterol, Santiago, Chile; [Sepulveda, Esteban; Boric, Mauricio] Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile; [Quinones, Veronica; Busso, Dolores; Rigotti, Attilio] Pontificia Univ Catolica Chile, Dept Nutr Diabet & Metab, Santiago, Chile; [Rigotti, Attilio] Pontificia Univ Catolica Chile, Sch Med, Ctr Mol Nutr & Chron Dis, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Leiva, A (corresponding author), Pontificia Univ Catolica Chile, Sch Med, Div Obstet & Gynaecol, CMPL, Santiago, Chile.; Rigotti, A (corresponding author), Pontificia Univ Catolica Chile, Dept Nutr Diabet & Metab, Santiago, Chile.; Rigotti, A (corresponding author), Pontificia Univ Catolica Chile, Sch Med, Ctr Mol Nutr & Chron Dis, Santiago, Chile.	aaleiva@uc.cl; arigotti@med.puc.cl	Busso, Dolores/K-7375-2012; Boric, Mauricio P/G-1574-2013; Busso, Dolores/AAF-2568-2020	Busso, Dolores/0000-0003-2113-1926; Boric, Mauricio P/0000-0001-6735-6675; Contreras Duarte, Susana/0000-0002-4198-7011	Chilean National Research and Technology Commission (Comision Nacional de Investigacion Cientifica y Tecnologica, CONICYT); Fondo Nacional de Desarrollo Cientifico y Tecnologico [1070634, 1150399, 1150344]; CONICYT Ph.D. fellowships	Chilean National Research and Technology Commission (Comision Nacional de Investigacion Cientifica y Tecnologica, CONICYT); Fondo Nacional de Desarrollo Cientifico y Tecnologico(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); CONICYT Ph.D. fellowships	This work was funded by the Chilean National Research and Technology Commission (Comision Nacional de Investigacion Cientifica y Tecnologica, CONICYT), Fondo Nacional de Desarrollo Cientifico y Tecnologico grant #1070634 (A. Rigotti), #1150399 (A. Rigotti), # 1150344 (A. Leiva) and CONICYT Ph.D. fellowships (A. Leiva, E. Sepulveda). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Amigo L, 2000, GASTROENTEROLOGY, V118, P772, DOI 10.1016/S0016-5085(00)70147-8; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Braun A, 2008, CURR DRUG TARGETS, V9, P217; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Buckley ML, 2015, BBA-MOL BASIS DIS, V1852, P1498, DOI 10.1016/j.bbadis.2015.04.011; Chander Ramesh, 2003, Indian J Clin Biochem, V18, P71, DOI 10.1007/BF02867370; Claudel T, 2005, ARTERIOSCL THROM VAS, V25, P2020, DOI 10.1161/01.ATV.0000178994.21828.a7; Das Gupta R, 1990, J Indian Med Assoc, V88, P346; Morales MG, 2010, LIVER INT, V30, P887, DOI 10.1111/j.1478-3231.2010.02230.x; Ghorai M, 2000, PHYTOTHER RES, V14, P200, DOI 10.1002/(SICI)1099-1573(200005)14:3&lt;200::AID-PTR548&gt;3.0.CO;2-T; Goldstein JL, 2015, CELL, V161, P161, DOI 10.1016/j.cell.2015.01.036; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Grieco A, 2009, J HEPATOL, V50, P1273, DOI 10.1016/j.jhep.2009.02.021; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; Hag AMF, 2008, BIOCHEM BIOPH RES CO, V377, P689, DOI 10.1016/j.bbrc.2008.10.037; Hasani-Ranjbar S, 2010, CURR PHARM DESIGN, V16, P2935, DOI 10.2174/138161210793176464; Jain S, 2014, WORLD J PHARM RES, V3, P1616; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lata S, 1991, J Postgrad Med, V37, P132; Leiva A, 2011, ATHEROSCLEROSIS, V217, P299, DOI 10.1016/j.atherosclerosis.2011.05.036; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mardones P, 2001, J LIPID RES, V42, P170; Masten SA, 2005, GUM GUGGUL SOME STER, V2, P1; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Moon DO, 2011, BIOCHEM PHARMACOL, V82, P1641, DOI 10.1016/j.bcp.2011.08.019; Nityanand S, 1989, J Assoc Physicians India, V37, P323; Nohr LA, 2009, COMPLEMENT THER MED, V17, P16, DOI 10.1016/j.ctim.2008.07.001; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Russell A, 2000, J PHARMACOL EXP THER, V294, P598; Sairkar PK, 2017, J PHARM BIOALLIED SC, V9, P1, DOI 10.4103/0975-7406.206225; Sane RT, 1990, INDIAN DRUGS, V28, P86; Sarup P, 2015, SCIENTIFICA, V2015, DOI 10.1155/2015/138039; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; Shah R, 2012, PHYTOTHER RES, V26, P1594, DOI 10.1002/ptr.4647; SINGH RB, 1994, CARDIOVASC DRUG THER, V8, P659, DOI 10.1007/BF00877420; SINGH V, 1990, PHARMACOL RES, V22, P37, DOI 10.1016/1043-6618(90)90741-U; Szapary PO, 2003, JAMA-J AM MED ASSOC, V290, P765, DOI 10.1001/jama.290.6.765; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Ulbricht C, 2005, COMPLEMENT THER MED, V13, P279, DOI 10.1016/j.ctim.2005.08.003; Urizar NL, 2003, ANNU REV NUTR, V23, P303, DOI 10.1146/annurev.nutr.23.011702.073102; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Xu WX, 2017, FEBS J, V284, P114, DOI 10.1111/febs.13956; Xu WX, 2017, TOXICOL APPL PHARM, V315, P23, DOI 10.1016/j.taap.2016.12.001; Yang DF, 2012, J LIPID RES, V53, P529, DOI 10.1194/jlr.M014688; Yesilaltay A, 2006, ENDOCRINOLOGY, V147, P1577, DOI 10.1210/en.2005-1286; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang SW, 2005, CIRCULATION, V111, P3457, DOI 10.1161/CIRCULATIONAHA.104.523563	55	4	6	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184280	10.1371/journal.pone.0184280	http://dx.doi.org/10.1371/journal.pone.0184280			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0VR	28910310	Green Published, gold, Green Submitted			2023-01-03	WOS:000410859200036
J	Patel, SJ; Sanjana, NE; Kishton, RJ; Eidizadeh, A; Vodnala, SK; Cam, M; Gartner, JJ; Jia, L; Steinberg, SM; Yamamoto, TN; Merchant, AS; Mehta, GU; Chichura, A; Shalem, O; Tran, E; Eil, R; Sukumar, M; Guijarro, EP; Day, CP; Robbins, P; Feldman, S; Merlino, G; Zhang, F; Restifo, NP				Patel, Shashank J.; Sanjana, Neville E.; Kishton, Rigel J.; Eidizadeh, Arash; Vodnala, Suman K.; Cam, Maggie; Gartner, Jared J.; Jia, Li; Steinberg, Seth M.; Yamamoto, Tori N.; Merchant, Anand S.; Mehta, Gautam U.; Chichura, Anna; Shalem, Ophir; Tran, Eric; Eil, Robert; Sukumar, Madhusudhanan; Guijarro, Eva Perez; Day, Chi-Ping; Robbins, Paul; Feldman, Steve; Merlino, Glenn; Zhang, Feng; Restifo, Nicholas P.			Identification of essential genes for cancer immunotherapy	NATURE			English	Article							CELL LUNG-CANCER; METASTATIC MELANOMA; DIFFERENTIAL GENE; ENDOTHELIAL-CELLS; CTLA-4 BLOCKADE; PD-1 BLOCKADE; T-CELLS; GENOME; RECEPTOR; LYMPHOCYTES	Somatic gene mutations can alter the vulnerability of cancer cells to T-cell-based immunotherapies. Here we perturbed genes in human melanoma cells to mimic loss-of-function mutations involved in resistance to these therapies, by using a genome-scale CRISPR-Cas9 library that consisted of around 123,000 single-guide RNAs, and profiled genes whose loss in tumour cells impaired the effector function of CD8(+) T cells. The genes that were most enriched in the screen have key roles in antigen presentation and interferon-gamma signalling, and correlate with cytolytic activity in patient tumours from The Cancer Genome Atlas. Among the genes validated using different cancer cell lines and antigens, we identified multiple loss-of-function mutations in APLNR, encoding the apelin receptor, in patient tumours that were refractory to immunotherapy. We show that APLNR interacts with JAK1, modulating interferon-gamma responses in tumours, and that its functional loss reduces the efficacy of adoptive cell transfer and checkpoint blockade immunotherapies in mouse models. Our results link the loss of essential genes for the effector function of CD8(+) T cells with the resistance or non-responsiveness of cancer to immunotherapies.	[Patel, Shashank J.; Kishton, Rigel J.; Eidizadeh, Arash; Vodnala, Suman K.; Cam, Maggie; Gartner, Jared J.; Jia, Li; Steinberg, Seth M.; Yamamoto, Tori N.; Merchant, Anand S.; Mehta, Gautam U.; Chichura, Anna; Tran, Eric; Eil, Robert; Sukumar, Madhusudhanan; Guijarro, Eva Perez; Day, Chi-Ping; Robbins, Paul; Feldman, Steve; Merlino, Glenn; Restifo, Nicholas P.] NCI, NIH, Bethesda, MD 20892 USA; [Patel, Shashank J.] Georgetown Univ, Sch Med, NIH Georgetown Univ Grad Partnership Program, Washington, DC 20057 USA; [Sanjana, Neville E.] New York Genome Ctr, New York, NY 10013 USA; [Sanjana, Neville E.] NYU, Dept Biol, 550 1St Ave, New York, NY 10012 USA; [Yamamoto, Tori N.] Univ Penn, Immunol Grad Grp, Philadelphia, PA 19104 USA; [Shalem, Ophir] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Shalem, Ophir] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; [Zhang, Feng] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Zhang, Feng] MIT, McGovern Inst Brain Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Restifo, Nicholas P.] NIH, Ctr Cell Based Therapy, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; New York University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Patel, SJ; Restifo, NP (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.; Patel, SJ (corresponding author), Georgetown Univ, Sch Med, NIH Georgetown Univ Grad Partnership Program, Washington, DC 20057 USA.; Sanjana, NE (corresponding author), New York Genome Ctr, New York, NY 10013 USA.; Sanjana, NE (corresponding author), NYU, Dept Biol, 550 1St Ave, New York, NY 10012 USA.; Restifo, NP (corresponding author), NIH, Ctr Cell Based Therapy, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.	patelsj@mail.nih.gov; nsanjana@nygenome.org; restifon@mail.nih.gov	Feldman, Steven R./AAH-6971-2021; Mehta, Gautam/AAP-6600-2020; Restifo, Nicholas Phillip/M-6549-2019; wang, edwin/G-5372-2010; Restifo, Nicholas Phillip/Z-1614-2019; Macrae, Rhiannon/AAX-1536-2020	Feldman, Steven R./0000-0002-0090-6289; Mehta, Gautam/0000-0002-8009-6430; Patel, Shashank/0000-0001-6973-6997; Restifo, Nicholas P./0000-0003-4229-4580; Shalem, Ophir/0000-0002-2267-0801	Intramural Research Program of the NCI; Cancer Moonshot program for the Center for Cell-based Therapy at the NCI, NIH; Milstein Family Foundation; NIH through NHGRI [R00-HG008171]; Sidney Kimmel Scholar Award; NATIONAL CANCER INSTITUTE [ZIABC011167] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R00HG008171] Funding Source: NIH RePORTER	Intramural Research Program of the NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Moonshot program for the Center for Cell-based Therapy at the NCI, NIH; Milstein Family Foundation; NIH through NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Sidney Kimmel Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	The research was supported by the Intramural Research Program of the NCI, and by the Cancer Moonshot program for the Center for Cell-based Therapy at the NCI, NIH. The work was also supported by the Milstein Family Foundation. We thank S.A. Rosenberg, K. Hanada, A. Wellstein, C. Hurley and L. M. Weiner for their valuable discussions and intellectual input, M. Kruhlak, Z. Yu, C. Subramaniam, C. Kariya, A. J. Leonardi, N. Ha, H. Xu, M. A. Black and H. Chinnasamy for technical assistance in this project. This work used the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). The results here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This study was done in partial fulfilment of a PhD in Tumor Biology to S.J.P. N.E.S. is supported by the NIH through NHGRI (R00-HG008171) and a Sidney Kimmel Scholar Award.	Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan TA, 2015, NEW ENGL J MED, V373, P1984, DOI 10.1056/NEJMc1508163; Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Indraccolo S, 2007, J IMMUNOL, V178, P1122, DOI 10.4049/jimmunol.178.2.1122; Johnson LA, 2006, J IMMUNOL, V177, P6548, DOI 10.4049/jimmunol.177.9.6548; Kammertoens T, 2017, NATURE, V545, P98, DOI 10.1038/nature22311; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kidoya H, 2012, ONCOGENE, V31, P3254, DOI 10.1038/onc.2011.489; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le D. T., 2017, SCI AAN, V6733; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Nathanson T, 2017, CANCER IMMUNOL RES, V5, P84, DOI 10.1158/2326-6066.CIR-16-0019; Noonan FP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1893; O'Carroll AM, 2013, J ENDOCRINOL, V219, pR13, DOI 10.1530/JOE-13-0227; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2008, J IMMUNOL, V180, P6116, DOI 10.4049/jimmunol.180.9.6116; Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Roh W., 2017, SCI TRANSL MED, V9; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Sanda C, 2006, J INTERF CYTOK RES, V26, P462, DOI 10.1089/jir.2006.26.462; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Viemann D, 2006, J LEUKOCYTE BIOL, V80, P174, DOI 10.1189/jlb.0905530; Wan YW, 2016, BIOINFORMATICS, V32, P952, DOI 10.1093/bioinformatics/btv677; Wang LX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062924; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	49	463	481	4	253	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 31	2017	548	7669					537	+		10.1038/nature23477	http://dx.doi.org/10.1038/nature23477			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF2BO	28783722	Green Published, Green Accepted			2023-01-03	WOS:000408703100028
J	Punia, R; Raina, K; Agarwal, R; Singh, RP				Punia, Reenu; Raina, Komal; Agarwal, Rajesh; Singh, Rana P.			Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells	PLOS ONE			English	Article							CANCER CELLS; IN-VITRO; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CYCLE ARREST; COMBINATION; EXPRESSION; APOPTOSIS; GROWTH; VIVO	Background Anthracyclines are efficient and potent agents to treat broad range of cancers but cytotoxicity induced by them limits their use in therapeutics. Use of plant-derived agents help to prevent or delay the process of cancer progression and their combination increases the anticancer potential of mainstream compound. However, multidrug resistance is major cause of treatment failure in cancer patients. Purpose In this study, combination treatments of fisetin or acacetin with doxorubicin were explored for their potential synergistic effect on non-small-cell lung carcinoma (NSCLC) cells. Study design During this study, NSCLC model cell lines A549 and H1299 were used to determine the combinatorial effect of phytochemicals namly acacetin and fisetin with doxorubicin. Methods The effects of individual compounds and their combination on cell viability, clonogenic potential and cell cycle progression were studied. Efflux of doxorubicin was measured by spectrofluorophotometer, whereas accumulation inside the cells was analyzed by flow cytometry and confocal microscopy. Expression of MDR1 was checked by semi-quantitative PCR. Results The results showed that the cell viability of A549 and H1299 cells were significantly decreased in time-and dose-dependent manner, although A549 cells showed more sensitivity toward doxorubicin than H1299 cells. Mostly, combination of doxorubicin showed good synergy with acacetin in both the cell lines whereas, fisetin exerted synergistic effect only at 72 h of treatment in H1299 cells. Acacetin with doxorubicin caused G2/M arrest by downregulating CDK-cyclin complex in A549 cells. Acacetin-doxorubicin combination decreased the clonogenic potential of A549 and H1299 cells upto 82% and 59%, respectively, as compared to control. Acacetin also decreased efflux of doxorubicin by 59% after 30 mins of exposure to A549 cells and further increased accumulation of doxorubicin inside the cells upto 55% in 2 h. The modulatory effect of acacetin-doxorubicin combination on doxorubicin influx and efflux was mediated through downregulation of MDR1 treansporter in NSCLC cells. Conclusion These findings suggested that acacetin augments the cytotoxicity of doxorubicin at lower concentrations in lung cancer cells. Their combination leads to more retention of doxorubicin in the cells by modulating drug trasporter and thus enhances its therapeutic potential.	[Punia, Reenu; Singh, Rana P.] Cent Univ Gujarat, Sch Life Sci, Gandhinagar, Gujarat, India; [Punia, Reenu; Singh, Rana P.] Jawaharlal Nehru Univ, Sch Life Sci, Canc Biol Lab, New Delhi, India; [Raina, Komal; Agarwal, Rajesh] Univ Colorado Denver, Sch Pharm, Dept Pharmaceut Sci, Aurora, CO USA; [Raina, Komal; Agarwal, Rajesh] Univ Colorado, Ctr Canc, Aurora, CO USA	Central University of Gujarat; Jawaharlal Nehru University, New Delhi; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Singh, RP (corresponding author), Cent Univ Gujarat, Sch Life Sci, Gandhinagar, Gujarat, India.; Singh, RP (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Canc Biol Lab, New Delhi, India.	ranaps@hotmail.com		Singh, Rana Pratap/0000-0003-4261-7044; Raina, Komal/0000-0003-0371-1070	Central University of Gujarat, India; DST-PURSE, India; UPE-II, India; UGCRN, India; JNU, India; NCI Cancer Center Support Grant [P30CA046934]; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	Central University of Gujarat, India; DST-PURSE, India; UPE-II, India; UGCRN, India; JNU, India; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The funding support by Central University of Gujarat, India; DST-PURSE, UPE-II and UGC-RN, JNU, India are gratefully acknowledged. FAGS analysis core facility of University of Colorado Cancer Center through funding from NCI Cancer Center Support Grant (P30CA046934) is acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bai XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149370; Bhat TA, 2013, CANCER PREV RES, V6, P1128, DOI 10.1158/1940-6207.CAPR-13-0209; Bhat TA, 2012, CARCINOGENESIS, V33, P385, DOI 10.1093/carcin/bgr282; Bidet M, 2012, MOL CANCER RES, V10, P1496, DOI 10.1158/1541-7786.MCR-11-0578; Hemaiswarya S, 2013, PHYTOMEDICINE, V20, P151, DOI 10.1016/j.phymed.2012.10.009; Hershman DL, 2009, ONCOLOGY-NY, V23, P227; Hu J, 2015, ONCOTARGET, V6, P44643, DOI 10.18632/oncotarget.5989; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Kim HR, INT J MOL MED; Kim KY, 2015, MOL MED REP, V12, P1898, DOI 10.3892/mmr.2015.3633; Klimaszewska-Wisniewska A, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0288-3; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Mateen S, 2010, MOL CARCINOGEN, V49, P247, DOI 10.1002/mc.20595; Meng GM, 2015, INT J ONCOL, V46, P1007, DOI 10.3892/ijo.2015.2814; Mi J, 2008, MOL THER, V16, P66, DOI 10.1038/sj.mt.6300320; Mittal A, 2014, PHYTOMEDICINE, V21, P340, DOI 10.1016/j.phymed.2013.09.002; Pal HC, 2016, MINI-REV MED CHEM, V16, P953, DOI 10.2174/1389557516666160211120157; Sadava D, 2013, CANCER LETT, V339, P102, DOI 10.1016/j.canlet.2013.07.017; Shanker M, 2010, LUNG CANCER-TARGETS, V1, P23; Shin H, 2012, ONCOL REP, V27, P1111, DOI 10.3892/or.2011.1585; Singh N, 2013, NUTR CANCER, V65, P36, DOI 10.1080/01635581.2013.785007; Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; TAYLOR CW, 1991, BRIT J CANCER, V63, P923, DOI 10.1038/bjc.1991.202; Vatsyayan R, 2009, INT J ONCOL, V34, P1505, DOI 10.3892/ijo_00000279; Vinod BS, 2013, ANTIOXID REDOX SIGN, V18, P1307, DOI 10.1089/ars.2012.4573; Vundru SS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-280; Williams GH, 2012, J PATHOL, V226, P352, DOI 10.1002/path.3022; Xu GD, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-174; Zhou Z, 2016, SCI PROGRAM, V2016, P1, DOI DOI 10.1016/J.T0XLET.2016.07.710	31	42	42	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0182870	10.1371/journal.pone.0182870	http://dx.doi.org/10.1371/journal.pone.0182870			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF2PY	28859099	Green Published, gold, Green Submitted			2023-01-03	WOS:000408740500007
J	Torkamani, A; Andersen, KG; Steinhubl, SR; Topol, EJ				Torkamani, Ali; Andersen, Kristian G.; Steinhubl, Steven R.; Topol, Eric J.			High-Definition Medicine	CELL			English	Review							PLURIPOTENT STEM-CELLS; RANDOMIZED CLINICAL-TRIAL; GENOME-WIDE ASSOCIATION; USUAL BLOOD-PRESSURE; FAMILY-HISTORY; MEDICATION ADHERENCE; GENETIC RISK; DISEASE; CANCER; HEALTH	The foundation for a new era of data-driven medicine has been set by recent technological advances that enable the assessment and management of human health at an unprecedented level of resolution-what we refer to as high-definition medicine. Our ability to assess human health in high definition is enabled, in part, by advances in DNA sequencing, physiological and environmental monitoring, advanced imaging, and behavioral tracking. Our ability to understand and act upon these observations at equally high precision is driven by advances in genome editing, cellular reprogramming, tissue engineering, and information technologies, especially artificial intelligence. In this review, we will examine the core disciplines that enable high-definition medicine and project how these technologies will alter the future of medicine.	[Torkamani, Ali; Andersen, Kristian G.; Steinhubl, Steven R.; Topol, Eric J.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA; [Torkamani, Ali] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Steinhubl, Steven R.; Topol, Eric J.] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Torkamani, A (corresponding author), Scripps Translat Sci Inst, La Jolla, CA 92037 USA.; Torkamani, A (corresponding author), Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.	atorkama@scripps.edu		Torkamani, Ali/0000-0003-0232-8053	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM114833] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR025774] Funding Source: Medline; NHGRI NIH HHS [U01 HG006476] Funding Source: Medline; NIGMS NIH HHS [U54 GM114833] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SMI, 2016, HOTMOBILE'16: PROCEEDINGS OF THE 17TH INTERNATIONAL WORKSHOP ON MOBILE COMPUTING SYSTEMS AND APPLICATIONS, P21, DOI 10.1145/2873587.2873590; Ampofo WK, 2015, VACCINE, V33, P4368, DOI 10.1016/j.vaccine.2015.06.090; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Bartlett MS, 2014, CURR BIOL, V24, P738, DOI 10.1016/j.cub.2014.02.009; Berg AO, 2009, ANN INTERN MED, V151, P872, DOI [10.7326/0000605-200912150-00165, 10.7326/0003-4819-151-12-200912150-00165]; Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424; Blaser MJ, 2014, J CLIN INVEST, V124, P4162, DOI 10.1172/JCI78366; Brinkmann F, 2015, SCI REP-UK, V5, DOI 10.1038/srep15342; Burbelo PD, 2014, CURR OPIN RHEUMATOL, V26, P717, DOI 10.1097/BOR.0000000000000107; Bush WS, 2016, NAT REV GENET, V17, P129, DOI 10.1038/nrg.2015.36; Campbell IM, 2015, TRENDS GENET, V31, P382, DOI 10.1016/j.tig.2015.03.013; Castellani B, 2016, COMPLEXITY, V21, P160, DOI 10.1002/cplx.21728; Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438; Chan AHY, 2013, J ALLER CL IMM-PRACT, V1, P446, DOI 10.1016/j.jaip.2013.06.015; Chan FKL, 2002, LANCET, V359, P9, DOI 10.1016/S0140-6736(02)07272-0; Chatterjee N, 2013, NAT GENET, V45, P400, DOI 10.1038/ng.2579; Checchi KD, 2014, JAMA-J AM MED ASSOC, V312, P1237, DOI 10.1001/jama.2014.10059; Chen R, 2016, NAT BIOTECHNOL, V34, P531, DOI 10.1038/nbt.3514; Cheng Q, 2016, TELEMED E-HEALTH, V22, P132, DOI 10.1089/tmj.2015.0040; Chong JX, 2015, AM J HUM GENET, V97, P199, DOI 10.1016/j.ajhg.2015.06.009; Choudhry NK, 2017, JAMA INTERN MED, V177, P624, DOI 10.1001/jamainternmed.2016.9627; de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339; De Vlaminck I, 2015, P NATL ACAD SCI USA, V112, P13336, DOI 10.1073/pnas.1517494112; Delaney SK, 2016, EXPERT REV MOL DIAGN, V16, P521, DOI 10.1586/14737159.2016.1146593; Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096; Eggington JM, 2014, CLIN GENET, V86, P229, DOI 10.1111/cge.12315; Engelbart D. C., 1992, HIGH PERFORMANCE ORG; Erikson GA, 2016, CELL, V165, P1002, DOI 10.1016/j.cell.2016.03.022; Esteki MZ, 2015, AM J HUM GENET, V96, P894, DOI 10.1016/j.ajhg.2015.04.011; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Faurholt-Jepsen M, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.123; Flannick J, 2014, NAT GENET, V46, P357, DOI 10.1038/ng.2915; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Forsberg LA, 2017, NAT REV GENET, V18, P128, DOI 10.1038/nrg.2016.145; Fourati S, 2015, VIRUSES-BASEL, V7, P6346, DOI 10.3390/v7122941; Gao W, 2016, NATURE, V529, P509, DOI 10.1038/nature16521; Gieger C, 2011, NATURE, V480, P201, DOI 10.1038/nature10659; Grieves M., 2017, TRANSDISCIPLINARY PE, P85, DOI [DOI 10.1007/978-3-319-38756-7_4, 10.1007/978-3-319-38756-7_4]; Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216; Haggstrom M., 2014, WIKIJOURNAL MED, V1; Harrington J, 2013, SLEEP BREATH, V17, P1071, DOI 10.1007/s11325-013-0804-9; Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hockemeyer D, 2016, CELL STEM CELL, V18, P573, DOI 10.1016/j.stem.2016.04.013; Holmes EC, 2016, NATURE, V538, P193, DOI 10.1038/nature19790; Honkoop PJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013935; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Hughes D, 2015, NAT REV GENET, V16, P459, DOI 10.1038/nrg3922; Hughes V., 2015, BUZZFEED NEWS; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Jakicic JM, 2016, JAMA-J AM MED ASSOC, V316, P1161, DOI 10.1001/jama.2016.12858; Jiang J, 2013, NATURE, V500, P296, DOI 10.1038/nature12394; Johannesson B, 2015, EMBO J, V34, P841, DOI 10.15252/embj.201490685; Vaquero JJ, 2015, ANNU REV BIOMED ENG, V17, P385, DOI 10.1146/annurev-bioeng-071114-040723; June CH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3643; Koser CU, 2014, TRENDS GENET, V30, P401, DOI 10.1016/j.tig.2014.07.003; Koh W, 2014, P NATL ACAD SCI USA, V111, P7361, DOI 10.1073/pnas.1405528111; Kramer ADI, 2014, P NATL ACAD SCI USA, V111, P8788, DOI 10.1073/pnas.1320040111; Lefterova MI, 2015, J MOL DIAGN, V17, P623, DOI 10.1016/j.jmoldx.2015.07.004; Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113; Lelieveld J, 2015, NATURE, V525, P367, DOI 10.1038/nature15371; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lind M, 2014, NEW ENGL J MED, V371, P1972, DOI 10.1056/NEJMoa1408214; Lo Sardo V, 2017, NAT BIOTECHNOL, V35, P69, DOI 10.1038/nbt.3749; Loscalzo J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100163; Lu KH, 2014, J CLIN ONCOL, V32, P833, DOI 10.1200/JCO.2013.50.9257; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Malone FD, 2005, NEW ENGL J MED, V353, P2001, DOI 10.1056/NEJMoa043693; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Maor E., 2016, CIRCULATION, V134; Marioni RE, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0584-6; Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036; Maxson T, 2016, TETRAHEDRON, V72, P3609, DOI 10.1016/j.tet.2015.09.069; McKinsey Global Institute, 2011, ANALYTICS; Mega JL, 2015, LANCET, V385, P2264, DOI 10.1016/S0140-6736(14)61730-X; Mendell JR, 2016, CELL RES, V26, P513, DOI 10.1038/cr.2016.28; Mone G, 2015, COMMUN ACM, V58, P15, DOI 10.1145/2800498; Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Myers A, 2015, IEEE I CONF COMP VIS, P1233, DOI 10.1109/ICCV.2015.146; Nakhleh MK, 2017, ACS NANO, V11, P112, DOI 10.1021/acsnano.6b04930; Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818; Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052; Odden MC, 2012, ARCH INTERN MED, V172, P1162, DOI 10.1001/archinternmed.2012.2555; Philips EJ, 2010, PHARMACOGENOMICS, V11, P973, DOI 10.2217/PGS.10.77; Pilz S, 2016, NAT REV CARDIOL, V13, P404, DOI 10.1038/nrcardio.2016.73; Piwek L, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001953; Plenge RM, 2013, NAT REV DRUG DISCOV, V12, P581, DOI 10.1038/nrd4051; Quinn JF, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27495; Rana JS, 2016, J AM COLL CARDIOL, V67, P2118, DOI 10.1016/j.jacc.2016.02.055; Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603; Rodbard D, 2016, DIABETES TECHNOL THE, V18, P3, DOI 10.1089/dia.2015.0417; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Sands TT, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0694-x; Scalbert A, 2014, AM J CLIN NUTR, V99, P1286, DOI 10.3945/ajcn.113.076133; Scheuner MT, 1997, AM J MED GENET, V71, P315, DOI 10.1002/(SICI)1096-8628(19970822)71:3<315::AID-AJMG12>3.0.CO;2-N; Sciences N. A. o. and Medicine N. A. o, 2017, HUM GEN ED SCI ETH G; Seibert T. M., 2016, BIORXIV; Sharp P., 2016, CONVERGENCE FUTURE H; Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI 10.1146/annurev-bioeng-071516-044442; Sheridan C, 2017, NAT BIOTECHNOL, V35, P101, DOI 10.1038/nbt0217-101; Shulman LM, 2008, MOVEMENT DISORD, V23, P790, DOI 10.1002/mds.21879; Snyder MW, 2016, CELL, V164, P57, DOI 10.1016/j.cell.2015.11.050; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Subar AF, 2015, J NUTR, V145, P2639, DOI 10.3945/jn.115.219634; Sund-Levander M, 2002, SCAND J CARING SCI, V16, P122, DOI 10.1046/j.1471-6712.2002.00069.x; Svennberg E, 2015, CIRCULATION, V131, P2176, DOI 10.1161/CIRCULATIONAHA.114.014343; Swan M, 2012, J SENS ACTUAR NETW, V1, P217, DOI 10.3390/jsan1030217; Taylor-Phillips S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010002; Tebas P, 2014, NEW ENGL J MED, V370, P901, DOI 10.1056/NEJMoa1300662; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Topol EJ, 2014, CELL, V157, P241, DOI 10.1016/j.cell.2014.02.012; Trounson A, 2016, NAT REV MOL CELL BIO, V17, P194, DOI 10.1038/nrm.2016.10; Wainwright CE, 2015, NEW ENGL J MED, V373, P1783, DOI 10.1056/NEJMc1510466; Walsh JA, 2014, CIRCULATION, V130, P573, DOI 10.1161/CIRCULATIONAHA.114.009024; Woodsworth DJ, 2013, GENOME MED, V5, DOI 10.1186/gm502; Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864; Wu J, 2017, CELL, V168, P473, DOI 10.1016/j.cell.2016.12.036; Xu GB, 2014, SENSORS-BASEL, V14, P16932, DOI 10.3390/s140916932; Yang LH, 2015, SCIENCE, V350, P1101, DOI 10.1126/science.aad1191; Yong E, 2014, NATURE, V511, P524, DOI 10.1038/511524a; Yoon PW, 2002, GENET MED, V4, P304, DOI 10.1097/00125817-200207000-00009; Zhou KX, 2013, ANNU REV PHARMACOL, V53, P299, DOI 10.1146/annurev-pharmtox-011112-140237; Zmora N, 2016, CELL HOST MICROBE, V19, P12, DOI 10.1016/j.chom.2015.12.016; Zola SM, 2013, AM J ALZHEIMERS DIS, V28, P179, DOI 10.1177/1533317512470484; Zuo J., 2016, SENSORS, V16, pE1692	130	111	119	1	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 24	2017	170	5					828	843		10.1016/j.cell.2017.08.007	http://dx.doi.org/10.1016/j.cell.2017.08.007			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FE7FG	28841416	Green Accepted, Bronze			2023-01-03	WOS:000408372400005
J	Mitsides, N; Cornelis, T; Broers, NJH; Diederen, NMP; Brenchley, P; van der Sande, FM; Schalkwijk, CG; Kooman, JP; Mitra, S				Mitsides, Nicos; Cornelis, Tom; Broers, Natascha J. H.; Diederen, Nanda M. P.; Brenchley, Paul; van der Sande, Frank M.; Schalkwijk, Casper G.; Kooman, Jeroen P.; Mitra, Sandip			Extracellular overhydration linked with endothelial dysfunction in the context of inflammation in haemodialysis dependent chronic kidney disease	PLOS ONE			English	Article							PULSE-WAVE VELOCITY; PERITONEAL-DIALYSIS PATIENTS; CARDIOVASCULAR RISK; MATRIX METALLOPROTEINASES; ARTERIAL STIFFNESS; BLOOD-PRESSURE; SURFACE-LAYER; VOLUME STATUS; P-CRESOL; ASSOCIATION	Background Haemodialysis (HD) patients are predisposed to dysregulated fluid balance leading to extracellular water (ECW) expansion. Fluid overload has been closely linked with outcome in these patients. This has mainly been attributed to cardiac volume overload, but the relation between abnormalities in fluid status with micro-and macrovascular dysfunction has not been studied in detail. We studied the interaction of macro-and microvascular factors in states of normal and over-hydration in HD-dependent CKD. Methods Fluid compartments [total body water (TBW) and ECW] and overhydration index (OH) were measured with Multifrequency bio-impedance (BCM). Overhydration was defined as OH/ECW>7%. Overhydration was also assessed using the ECW/TBW ratio. Macrocirculation was assessed by pulse-wave velocity (PWV) and mean arterial pressure (MAP) measurements while microcirculation through sublingual capillaroscopy assessment of the Perfused Boundary Region of the endothelial glycocalyx (PBR 5-25mcg). A panel of pro-inflammatory and vascular serum biomarkers and growth factors was analysed. Results Of 72 HD participants, 30 were in normohydration (N) range and 42 overhydrated according to the OH/ECW ratio. Average ECW/TBW was 0.48 +/- 0.03. Overhydrated patients had higher MAP (122.9 +/- 22.5 v 111.7 +/- 22.2mmHg, p = 0.04) and comorbidities (median Davies score 1.5 v 1.0, p = 0.03). PWV (p = 0.25) and PBR 5-25mcg (p = 0.97) did not differ between the 2 groups. However, Vascular Adhesion Molecule (VCAM)-1, Interleukin-6 and Thrombomodulin, and reduced Leptin were observed in the overhydrated group. Elevation in VCAM-1 levels (OR 1.03; 95% CI 1.01-1.06; p = 0.02) showed a strong independent association with OH/ECW>7% in an adjusted logistic regression analysis and exhibited a strong linear relationship with ECW/TBW (Bata = 0.210, p = 0.03) in an also adjusted model. Conclusion Extracellular fluid overload is significantly linked to microinflammation and markers of endothelial dysfunction. The study provides novel insight in the cardiovascular risk profile associated with overhydration in uraemia.	[Mitsides, Nicos; Brenchley, Paul; Mitra, Sandip] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cardiovasc Sci,Sch Med Sci, Manchester, Lancs, England; [Mitsides, Nicos; Brenchley, Paul; Mitra, Sandip] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Nephrol Dept, Manchester, Lancs, England; [Mitsides, Nicos; Mitra, Sandip] Royal Hallamshire Hosp, NIHR Devices Dign Healthcare Technol Cooperat, Sheffield, S Yorkshire, England; [Cornelis, Tom] Jessa Hosp, Hasselt, Belgium; [Broers, Natascha J. H.; Diederen, Nanda M. P.; van der Sande, Frank M.; Schalkwijk, Casper G.; Kooman, Jeroen P.] Maastricht Univ, Med Ctr, Div Nephrol, Dept Internal Med, Maastricht, Netherlands; [Broers, Natascha J. H.; Kooman, Jeroen P.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Schalkwijk, Casper G.] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands	University of Manchester; University of Manchester; University of Sheffield; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University	Mitsides, N (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cardiovasc Sci,Sch Med Sci, Manchester, Lancs, England.; Mitsides, N (corresponding author), Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Nephrol Dept, Manchester, Lancs, England.; Mitsides, N (corresponding author), Royal Hallamshire Hosp, NIHR Devices Dign Healthcare Technol Cooperat, Sheffield, S Yorkshire, England.	nicos.mitsides@cmft.nhs.uk	Mitsides, Nicos/ABB-9868-2021	Schalkwijk, Casper G/0000-0003-0190-2690; Mitsides, Nicos/0000-0003-4588-4738	Dutch Kidney Foundation [SB 166]; Baxter International [110ECHHDEU1004]; Clinical Evidence Council of High Dose Hemodialysis; National Institute for Health Research (NIHR) Devices for Dignity Healthcare Technology Co-operative; NIHR Clinical Research Network (CRN) (NIHR UK CRN) [17528]; Manchester Renal Research; Transplant Laboratory	Dutch Kidney Foundation; Baxter International; Clinical Evidence Council of High Dose Hemodialysis; National Institute for Health Research (NIHR) Devices for Dignity Healthcare Technology Co-operative(National Institute for Health Research (NIHR)); NIHR Clinical Research Network (CRN) (NIHR UK CRN); Manchester Renal Research; Transplant Laboratory	Funding for the INTHEMO study was secured through grants from the Dutch Kidney Foundation grant (SB 166; Grant recipient: Dr T Cornelis) and the Clinical Evidence Council of High Dose Hemodialysis, Baxter International (110ECHHDEU1004; Grant recipient: Dr T Cornelis). The research reported in this publication was supported by the National Institute for Health Research (NIHR) Devices for Dignity Healthcare Technology Co-operative and was supported by the NIHR Clinical Research Network (CRN) (NIHR UK CRN ID: 17528). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The above funding and supporting institutions had no role in the study design data collection and analysis, decision to publish or preparation of the manuscript.; We would also like to thank the clinical and technical staff at the participating units and the Manchester Renal Research and Transplant Laboratory for their help and support. The research reported in this publication was supported by the National Institute for Health Research (NIHR) Devices for Dignity Healthcare Technology Co-operative and was supported by the NIHR Clinical Research Network (CRN) (NIHR UK CRN ID: 17528). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Ahbap E, 2015, CLIN NEPHROL, V83, P154, DOI 10.5414/CN108450; Akdam H, 2014, RENAL FAILURE, V36, P28, DOI 10.3109/0886022X.2013.830224; Bao YS, 2014, BIOMARKERS, V19, P275, DOI 10.3109/1354750X.2014.904000; Beberashvili I, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-68; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bemelmans RHH, 2009, NEPHROL DIAL TRANSPL, V24, P3487, DOI 10.1093/ndt/gfp267; Bernardo AP, 2015, THER APHER DIAL, V19, P144, DOI 10.1111/1744-9987.12239; Bia D, 2015, INT J NEPHROL, V2015, DOI 10.1155/2015/628654; Bijuklic K, 2007, AM J PHYSL CELL PHYS, V293; Caballo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043374; Calton MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094549; Chamney PW, 2007, AM J CLIN NUTR, V85, P80, DOI 10.1093/ajcn/85.1.80; Chen YC, 2009, NEPHRON CLIN PRACT, V113, pC112, DOI 10.1159/000228543; Cornelis T, 2014, BLOOD PURIFICAT, V38, P203, DOI 10.1159/000369055; D'Apolito M, 2015, ATHEROSCLEROSIS, V239, P393, DOI 10.1016/j.atherosclerosis.2015.01.034; Dane MJC, 2014, CLIN J AM SOC NEPHRO, V9, P698, DOI 10.2215/CJN.08160813; Davies SJ, 2014, KIDNEY INT, V86, P489, DOI 10.1038/ki.2014.207; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; Death AK, 2003, ATHEROSCLEROSIS, V168, P263, DOI 10.1016/S0021-9150(03)00140-0; Dekker MJE, 2017, KIDNEY INT, V91, P1214, DOI 10.1016/j.kint.2016.12.008; Di Iorio B, 2010, NEPHROL DIAL TRANSPL, V25, P1579, DOI 10.1093/ndt/gfp662; Distasi MR, OPENING FLOOD GATES; Donati A, 2013, MICROVASC RES, V90, P86, DOI 10.1016/j.mvr.2013.08.007; Friese RS, 2009, CLIN EXP HYPERTENS, V31, P521, DOI 10.3109/10641960802668730; Gu YM, 2015, HYPERTENSION, V65, P993, DOI 10.1161/HYPERTENSIONAHA.114.05119; Hung SC, 2014, KIDNEY INT, V85, P703, DOI 10.1038/ki.2013.336; Ioannou K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138461; Jiang B, 2008, ULTRASOUND MED BIOL, V34, P509, DOI 10.1016/j.ultrasmedbio.2007.09.008; Edul VSK, 2012, CRIT CARE MED, V40, P1443, DOI 10.1097/CCM.0b013e31823dae59; Katzarski KS, 1999, NEPHROL DIAL TRANSPL, V14, P369, DOI 10.1093/ndt/14.2.369; Kim ED, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0131-4; Kougias P, 2005, J SURG RES, V126, P121, DOI 10.1016/j.jss.2004.12.023; Koutroumbas G, 2015, NEPHROL DIAL TRANSPL, V30, P2046, DOI 10.1093/ndt/gfv090; Lee BT, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0068-7; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Lin YP, 2002, KIDNEY INT, V62, P1828, DOI 10.1046/j.1523-1755.2002.00610.x; Lindley EJ, 2015, KIDNEY INT, V87, P240, DOI 10.1038/ki.2014.310; Machnik A, 2010, HYPERTENSION, V55, P755, DOI 10.1161/HYPERTENSIONAHA.109.143339; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Mitra S, 2014, KIDNEY INT, V85, P510, DOI 10.1038/ki.2013.481; Mitsides Nicos, 2015, Journal of Medical Engineering & Technology, V39, P424, DOI 10.3109/03091902.2015.1088089; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nongnuch A, 2014, KIDNEY INT, V87, P1; Nugent WH, 2016, REPROD SCI, V23, P542, DOI 10.1177/1933719115607998; Oberleithner H, 2014, NEPHROL DIAL TRANSPL, V29, P240, DOI 10.1093/ndt/gft461; Patel TV, 2008, NEPHRON CLIN PRACT, V110, pC244, DOI 10.1159/000167872; Rodrigues SF, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.978720; Spoto B, 2015, CLIN J AM SOC NEPHRO, V10, P232, DOI 10.2215/CJN.07000714; Takahashi W, 2013, CRIT CARE, V17, DOI 10.1186/cc12839; Tsai YC, 2015, CLIN J AM SOC NEPHRO, V10, P39, DOI 10.2215/CJN.03610414; de Voorde J, 2013, METABOLISM, V62, P1513, DOI 10.1016/j.metabol.2013.06.004; van Sloten TT, 2015, AM J HYPERTENS, V28, P868, DOI 10.1093/ajh/hpu246; van Wetering S, 2003, AM J PHYSIOL-CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003; VanTeeffelen JW, 2007, TRENDS CARDIOVAS MED, V17, P101, DOI 10.1016/j.tcm.2007.02.002; VanTeeffelen JWGE, 2008, CRIT CARE, V12, DOI 10.1186/cc6939; Vlahu CA, 2012, J AM SOC NEPHROL, V23, P1900, DOI 10.1681/ASN.2011121181; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Zahran Manal, 2015, Electron Physician, V7, P1270, DOI 10.14661/1270	60	43	45	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2017	12	8							e0183281	10.1371/journal.pone.0183281	http://dx.doi.org/10.1371/journal.pone.0183281			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2ZB	28829810	Green Published, Green Submitted, gold			2023-01-03	WOS:000408085100035
J	Kim, ED; Lee, YI; Park, HJ				Kim, Eung Don; Lee, Young In; Park, Hue Jung			Comparison of efficacy of continuous epidural block and pulsed radiofrequency to the dorsal root ganglion for management of pain persisting beyond the acute phase of herpes zoster	PLOS ONE			English	Article							INTRATHECAL METHYLPREDNISOLONE ACETATE; POSTHERPETIC NEURALGIA; LOCAL-ANESTHETICS; PREGABALIN THERAPY; NEUROPATHIC PAIN; NERVE; PREVENTION; STIMULATION; GABAPENTIN; LIDOCAINE	Background There is little evidence regarding the effectiveness of intervention methods in the treatment of zoster-related pain (ZAP) after the acute phase of zoster. Generally, if ZAP remains after more than 180 days from its onset, the likelihood of pain reduction is very low; this condition is considered as a "well established" post-herpetic neuralgia (PHN). Although the clinical efficacy of intrathecal steroid injection and spinal cord stimulation (SCS) for ZAP management has been reported, these interventions are not widely used due to inherent disadvantages. Continuous epidural block is widely used in clinical practice, and the effectiveness of pulsed radiofrequency (PRF) to the dorsal root ganglion (DRG) in the treatment of ZAP already has been reported. Objectives The purpose of this study was to compare the clinical efficacy of continuous epidural block and DRG PRF beyond acute phase of zoster, bur before PHN was well established (from 30 days to 180 days after zoster onset). Study design Retrospective comparative study. Methods A total of 42 medical records were analyzed. Patients were divided into two groups according to the type of procedure utilized: continuous epidural block (continuous epidural group) and DRG PRF (PRF group). The clinical efficacy of the procedure was evaluated using a numeric rating scale (NRS) and the medication dose before and 1 to 6 months after the procedure. Results There was a significant decrease in the NRS value with time in both groups. However, this decrease was more significant in the PRF group than in the continuous epidural group. The medication doses decreased significantly in the PRF group over time, but not in the continuous epidural group. The rate of clinically meaningful PHN (NRS >= 3) was also lower in the PRF group than in the continuous epidural group. Conclusions This study revealed that DRG PRF was more effective than a continuous epidural block in treating ZAP after the acute phase of zoster. A neuromodulation method such as DRG PRF may be a useful option for reducing the progression of neuropathic changes caused by the persistent transmission of a pain signal after the acute phase of zoster.	[Kim, Eung Don; Lee, Young In] Catholic Univ Korea, Daejeon St Marys Hosp, Sch Med, Dept Anesthesiol & Pain Med, Daejeon, South Korea; [Park, Hue Jung] Catholic Univ Korea, Seoul St Marys Hosp, Sch Med, Dept Anesthesiol & Pain Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital	Park, HJ (corresponding author), Catholic Univ Korea, Seoul St Marys Hosp, Sch Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.	huejung@catholic.ac.kr	Park, Hue Jung/GLR-6513-2022	Park, Hue Jung/0000-0002-3775-1794				Abejon D, 2003, NEUROMODULATION, V6, P1, DOI 10.1046/j.1525-1403.2003.03009.x; Agarwal-Kozlowski K, 2011, ANAESTHESIA, V66, P699, DOI 10.1111/j.1365-2044.2011.06765.x; Bockbrader HN, 2013, AM J THER, V20, P32, DOI 10.1097/MJT.0b013e318250f80e; Cahana A, 2003, J PAIN, V4, P197, DOI 10.1016/S1526-5900(03)00554-6; CHABAL C, 1989, PAIN, V38, P333, DOI 10.1016/0304-3959(89)90220-0; Coplan PM, 2004, J PAIN, V5, P344, DOI 10.1016/j.jpain.2004.06.001; Cosman ER, 2005, PAIN MED, V6, P405, DOI 10.1111/j.1526-4637.2005.00076.x; DEVOR M, 1992, PAIN, V48, P261, DOI 10.1016/0304-3959(92)90067-L; Dworkin RH, 2008, J PAIN, V9, pS37, DOI 10.1016/j.jpain.2007.10.008; Dworkin RH, 2013, PAIN, V154, P2249, DOI 10.1016/j.pain.2013.06.004; Fishman, 2010, BONICAS MANAGEMENT P; Forbes HJ, 2016, PAIN, V157, P30, DOI 10.1097/j.pain.0000000000000307; Hamann W, 2006, EUR J PAIN, V10, P171, DOI 10.1016/j.ejpain.2005.03.001; Higuchi Y, 2002, NEUROSURGERY, V50, P850, DOI 10.1097/00006123-200204000-00030; Jeon YH, 2015, KOREAN J PAIN, V28, P177, DOI 10.3344/kjp.2015.28.3.177; Ji GL, 2009, ANESTH ANALG, V109, P1651, DOI 10.1213/ANE.0b013e3181b79075; Kim E, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/5461989; Kim K, 2017, PAIN PHYSICIAN, V20, pE411; Kim YH, 2008, ACTA ANAESTH SCAND, V52, P1140, DOI 10.1111/j.1399-6576.2008.01752.x; Kinchington PR, 2011, J NEUROVIROL, V17, P590, DOI 10.1007/s13365-011-0069-7; Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102; Luo F, 2014, PAIN PRACT, V14, P16, DOI 10.1111/papr.12041; Lydick E, 1995, NEUROLOGY, V45, pS52, DOI 10.1212/WNL.45.12_Suppl_8.S52; Ma K, 2013, PAIN PHYSICIAN, V16, P15; Makharita MY, 2015, PAIN PRACT, V15, P229, DOI 10.1111/papr.12179; Manabe H, 2004, CLIN J PAIN, V20, P302, DOI 10.1097/00002508-200409000-00004; Nagda JV, 2011, PAIN PHYSICIAN, V14, P371; Naja ZM, 2006, BRIT J ANAESTH, V96, P381, DOI 10.1093/bja/ael007; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pasqualucci A, 2000, ACTA ANAESTH SCAND, V44, P910, DOI 10.1034/j.1399-6576.2000.440803.x; Rijsdijk M, 2013, EUR J PAIN, V17, P714, DOI 10.1002/j.1532-2149.2012.00233.x; Rijsdijk M, 2012, ANESTHESIOLOGY, V116, P170, DOI 10.1097/ALN.0b013e31823cf035; Sluijter ME, 1998, PAIN CLINIC, V11, P109; Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119; Toth C, 2010, PAIN MED, V11, P456, DOI 10.1111/j.1526-4637.2009.00796.x; van Wijck AJM, 2006, LANCET, V367, P219, DOI 10.1016/S0140-6736(06)68032-X; van Wijck AJM, 2011, PAIN PRACT, V11, P88, DOI 10.1111/j.1533-2500.2010.00428.x; Van Zundert J, 2005, ANESTHESIOLOGY, V102, P125, DOI 10.1097/00000542-200501000-00021; Van Zundert J, 2003, NEUROMODULATION, V6, P6, DOI 10.1046/j.1525-1403.2003.03001.x; Wu YT, 2014, ANESTH ANALG, V119, P686, DOI 10.1213/ANE.0000000000000354; Yanamoto F, 2012, NEUROMODULATION, V15, P151, DOI 10.1111/j.1525-1403.2012.00438.x	41	31	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2017	12	8							e0183559	10.1371/journal.pone.0183559	http://dx.doi.org/10.1371/journal.pone.0183559			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2TT	28827823	gold, Green Submitted, Green Published			2023-01-03	WOS:000408069300028
J	Sawano, M; Kohsaka, S; Abe, T; Inohara, T; Maekawa, Y; Ueda, I; Sueyoshi, K; Suzuki, M; Noma, S; Numasawa, Y; Miyata, H; Fukuda, K; Smolderen, KG; Spertus, JA				Sawano, Mitsuaki; Kohsaka, Shun; Abe, Takayuki; Inohara, Taku; Maekawa, Yuichiro; Ueda, Ikuko; Sueyoshi, Koichiro; Suzuki, Masahiro; Noma, Shigetaka; Numasawa, Yohei; Miyata, Hiroaki; Fukuda, Keiichi; Smolderen, Kim G.; Spertus, John A.			Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry	PLOS ONE			English	Article							2013 AMERICAN-COLLEGE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; LOWERING THERAPY; 000 PARTICIPANTS; REDUCING LIPIDS; KIDNEY-DISEASE; TASK-FORCE; CHOLESTEROL; ASSOCIATION	Statin therapy is regarded as an effective medication to reduce cardiovascular events in patients at higher risk for future incidence of coronary artery disease. However, very few studies have been conducted to examine its implementation in non-Western real-world practice. In this study, we sought to describe statin prescription patterns in relation to patient characteristics in a Japanese multicenter percutaneous coronary intervention (PCI) registry as a foundation for quality improvement. We studied 15,024 patients that were prospectively enrolled in the Japan Cardiovascular Database-Keio interhospital Cardiovascular Study Registry from January 2009 to August 2014. The overall discharge statin non-prescription rate was 15.2%, without significant interhospital (MOR = 1.01) or annual differences (MOR = 1.13) observed. Hierarchical multivariable logistic regression analysis accounting for regional differences revealed that the presence of chronic kidney disease was associated with higher rates of statin non-prescription (OR 1.87, 95% confidence interval, 1.69-2.08, p value <0.001), and higher age (per 1-year increase) showed a trend for prescription of low-intensity statin (OR 1.00, 95% confidence interval, 1.00-1.01, p value = 0.045) within the subset of PCI patients (N = 4,853) enrolled after the year 2011. Our study indicates that patients with chronic kidney disease and elderlies may be the primary targets for maximizing the beneficial effect of statin therapy in post PCI patients.	[Sawano, Mitsuaki; Kohsaka, Shun; Inohara, Taku; Maekawa, Yuichiro; Ueda, Ikuko; Fukuda, Keiichi] Keio Univ, Dept Cardiol, Sch Med, Tokyo, Japan; [Abe, Takayuki] Keio Univ, Sch Med, Ctr Clin Res, Tokyo, Japan; [Sueyoshi, Koichiro] Kawasaki Municipal Kawasaki Hosp, Dept Cardiol, Kawasaki, Kanagawa, Japan; [Suzuki, Masahiro] Saitama Natl Hosp, Natl Hosp Org, Dept Cardiol, Saitama, Japan; [Noma, Shigetaka] Saiseikai Utsunomiya Hosp, Utsunomiya, Tochigi, Japan; [Numasawa, Yohei] Ashikaga Red Cross Hosp, Dept Cardiol, Ashikaga City, Tochigi, Japan; [Miyata, Hiroaki] Keio Univ, Sch Med, Dept Hlth Policy & Management, Tokyo, Japan; [Smolderen, Kim G.; Spertus, John A.] Univ Missouri, Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA	Keio University; Keio University; Keio University; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	Kohsaka, S (corresponding author), Keio Univ, Dept Cardiol, Sch Med, Tokyo, Japan.	sk@keio.jp	Numasawa, Yohei/AAC-9604-2020; Spertus, John/ABD-3075-2021	Numasawa, Yohei/0000-0002-1739-2800; Kohsaka, Shun/0000-0003-3779-2972; Smolderen, Kim/0000-0001-6104-6254	Japan Society for the Promotion of Science(KAKENHI) [25460630, 25460777]	Japan Society for the Promotion of Science(KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The present study was funded by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI; No. 25460630 and 25460777, https://kaken.nii.ac.jp/ja/index/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya T, 2016, AM J CARDIOL, V117, P647, DOI 10.1016/j.amjcard.2015.11.031; Adhyaru BB, 2016, ENDOCRIN METAB CLIN, V45, P17, DOI 10.1016/j.ecl.2015.09.002; Amsterdam, 2014, CIRCULATION, V130, pE433, DOI [10.1161/CIR.0000000000000151, 10.1161/CIR.0000000000000134]; Austin PC, 2003, AM HEART J, V145, P27, DOI 10.1067/mhj.2003.23; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V316, P1997, DOI 10.1001/jama.2016.15450; Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Catapano AL, 2016, ATHEROSCLEROSIS, V253, P281, DOI 10.1016/j.atherosclerosis.2016.08.018; Dasari TW, 2014, AM J CARDIOL, V113, P621, DOI 10.1016/j.amjcard.2013.11.006; DeLong E, 2003, AM HEART J, V145, P16, DOI 10.1067/mhj.2003.27; DrozdaJr JP, 2015, J AM COLL CARDIOLOGY; Fulcher J, 2015, LANCET, V385, P1397, DOI 10.1016/S0140-6736(14)61368-4; Gansevoort RT, 2013, LANCET, V382, P339, DOI 10.1016/S0140-6736(13)60595-4; Grundy SM, 2014, ATHEROSCLEROSIS, V232, P410, DOI 10.1016/j.atherosclerosis.2013.11.031; Javed U, 2011, AM HEART J, V161, P418, DOI 10.1016/j.ahj.2010.12.014; Javed U, 2010, AM HEART J, V160, P1130, DOI 10.1016/j.ahj.2010.08.041; Kaneko H, 2014, HEART VESSELS, V29, P21, DOI 10.1007/s00380-013-0325-2; Kaneko H, 2013, INT HEART J, V54, P335, DOI 10.1536/ihj.54.335; Kohsaka S, 2015, AM HEART J, V170, P1077, DOI 10.1016/j.ahj.2015.09.017; Kuang YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34268; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liao JK, 2007, AM J CARDIOL, V99, P410, DOI 10.1016/j.amjcard.2006.08.051; Mancini GBJ, 2013, CAN J CARDIOL, V29, P1553, DOI 10.1016/j.cjca.2013.09.023; Natsuaki M, 2012, AM J CARDIOL, V110, P1568, DOI 10.1016/j.amjcard.2012.07.021; Natsuaki M, 2012, CIRC J, V76, P1369, DOI 10.1253/circj.CJ-11-1356; O'Gara PT, 2013, J AM COLL CARDIOL, V61, P485, DOI [10.1016/j.jacc.2012.11.018, 10.1161/CIR.0b013e3182742c84]; Ohira T, 2013, CIRC J, V77, P1646, DOI 10.1253/circj.CJ-13-0702; Okamura T, 2007, ATHEROSCLEROSIS, V190, P216, DOI 10.1016/j.atherosclerosis.2006.01.024; Pokharel Y, 2017, JAMA CARDIOL, V2, P361, DOI 10.1001/jamacardio.2016.5922; Reiner Z, 2016, ATHEROSCLEROSIS, V246, P243, DOI 10.1016/j.atherosclerosis.2016.01.018; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Rodriguez F, 2016, JAMA CARDIOLOGY; Rodriguez F, 2017, JAMA CARDIOL, V2, P47, DOI 10.1001/jamacardio.2016.4052; Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Sugiyama D, 2015, J ATHEROSCLER THROMB, V22, P95, DOI 10.5551/jat.25908; Teramoto T, 2013, J ATHEROSCLER THROMB, V20, P517, DOI 10.5551/jat.15792; Ueshima H, 2008, CIRCULATION, V118, P2702, DOI 10.1161/CIRCULATIONAHA.108.790048; Wilmot KA, 2015, CLIN CARDIOL, V38, P56, DOI 10.1002/clc.22338; Wong ND, 2016, J CLIN LIPIDOL, V10, P1109, DOI 10.1016/j.jacl.2016.06.011	42	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2017	12	8							e0182687	10.1371/journal.pone.0182687	http://dx.doi.org/10.1371/journal.pone.0182687			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD9QG	28817616	Green Published, gold, Green Submitted			2023-01-03	WOS:000407856600034
J	Choi, S; Oh, DS; Jerng, UM				Choi, Songie; Oh, Dal-Seok; Jerng, Ui Min			A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin	PLOS ONE			English	Review							KOREAN RED GINSENG; ST-JOHNS-WORT; CONTROLLED-TRIALS; CRANBERRY JUICE; GINKGO; GINGER; DRUGS; INTERVENTIONS; ANTIPLATELET; ECHINACEA	Objectives The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin. Methods Three electronic databases were searched to identify relevant trials. Two reviewers independently performed the study selection and data extraction. The risk of bias and reporting quality were also assessed independently by two reviewers using the Cochrane risk of bias tool and the consolidated standards of reporting trials (CONSORT). Outcomes were measured for all reported PK-PD parameters and adverse events. Results Nine randomized controlled trials met our inclusion criteria. Most of the included studies were unclear regarding the risk of bias and had a low quality of methodology. Using CONSORT, the reporting percentages for the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%. St John's wort and echinacea affected the PK parameters of warfarin. Ginseng, ginger, garlic, and cranberry had no significant effect on the PK parameters. American ginseng altered the PD parameters of warfarin. St John's wort, ginseng, Korea red ginseng, ginkgo, ginger, garlic, aged garlic, and echincea did not significantly alter the PD parameters. Studies of ginkgo and cranberry showed conflicting results on the PK parameters and PD parameters, respectively. The incidence of adverse events in all trials was low and no major adverse events were reported. Conclusions It was difficult to determine whether ten herbal medicines had significant effects on the PK-PD parameters of warfarin. Low quality of evidence, different compounds within and different compositions of the herbs, and methodological limitations of the crossover study, which is a clinical study in which subjects receive a sequence of different interventions, made it difficult to form conclusions. Additional studies that remedy these vulnerabilities are necessary to verify these results.	[Choi, Songie; Oh, Dal-Seok] Korea Inst Oriental Med, Herb Res Ctr K, Daejeon, South Korea; [Jerng, Ui Min] Korea Inst Oriental Med, Clin Res Div, Daejeon, South Korea	Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental Medicine (KIOM)	Jerng, UM (corresponding author), Korea Inst Oriental Med, Clin Res Div, Daejeon, South Korea.	breeze@kiom.re.kr			Research and development of concomitant administration on combinatory effect of herbal and Western medicine [K17252]; Korea Institute of Oriental Medicine [K17124]	Research and development of concomitant administration on combinatory effect of herbal and Western medicine; Korea Institute of Oriental Medicine	This study was funded by the Research and development of concomitant administration on combinatory effect of herbal and Western medicine (No. K17252, grant recipient DSO) and development of Korean Medicine contents for clinical practice (No.K17124, grant recipient UMJ) of the Korea Institute of Oriental Medicine. The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.	Abdul MIM, 2008, BRIT J PHARMACOL, V154, P1691, DOI 10.1038/bjp.2008.210; Abdul MIM, 2010, BRIT J CLIN PHARMACO, V69, P508, DOI 10.1111/j.1365-2125.2010.03620.x; Barnes J, 2001, J PHARM PHARMACOL, V53, P583, DOI 10.1211/0022357011775910; Dhariwal K, 2003, BIOPHARM DRUG DISPOS, V24, P219, DOI 10.1002/bdd.359; Fasinu PS, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00069; Ferrer P, 2014, NEUROEPIDEMIOLOGY, V42, P107, DOI 10.1159/000356807; Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013; Gagnier JJ, 2006, J CLIN EPIDEMIOL, V59, P1134, DOI 10.1016/j.jclinepi.2005.12.020; Ge BK, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/957362; Gorski JC, 2004, CLIN PHARMACOL THER, V75, P89, DOI 10.1016/j.clpt.2003.09.013; Hirsh J, 2003, THROMB RES, V109, pS1, DOI 10.1016/S0049-3848(03)00250-0; Hussain MS, 2011, AFR J TRADIT COMPLEM, V8, P152, DOI 10.4314/ajtcam.v8i5S.8; Izzo AA, 2005, INT J CARDIOL, V98, P1, DOI 10.1016/j.ijcard.2003.06.039; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Jiang XM, 2005, BRIT J CLIN PHARMACO, V59, P425, DOI 10.1111/j.1365-2125.2005.02322.x; Jiang XM, 2004, BRIT J CLIN PHARMACO, V57, P592, DOI 10.1111/j.1365-2125.2003.02051.x; Jiang XM, 2006, J CLIN PHARMACOL, V46, P1370, DOI 10.1177/0091270006292124; Koch E, 2005, PHYTOMEDICINE, V12, P10, DOI 10.1016/j.phymed.2004.02.002; Krishna S. S., 2015, Journal of Chemical and Pharmaceutical Research, V7, P71; Lau AJ, 2009, J ETHNOPHARMACOL, V125, P380, DOI 10.1016/j.jep.2009.07.038; Lee SM, 2013, PHYTOCHEM LETT, V6, P620, DOI 10.1016/j.phytol.2013.08.002; Lee YH, 2010, INT J CARDIOL, V145, P275, DOI 10.1016/j.ijcard.2009.09.553; Li TX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122461; Li ZP, 2006, J AM DIET ASSOC, V106, P2057, DOI 10.1016/j.jada.2006.09.012; Macan H, 2006, J NUTR, V136, p793S, DOI 10.1093/jn/136.3.793S; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Nicoll R, 2009, INT J CARDIOL, V131, P408, DOI 10.1016/j.ijcard.2007.07.107; Nutescu E.A., 2005, CLEV CLIN J MED, V72, P2, DOI DOI 10.3949/CCJM.72.SUPP11.S2; Nutescu EA, 2006, EXPERT OPIN DRUG SAF, V5, P433, DOI 10.1517/14740338.5.3.433; Paeng CH, 2007, CLIN THER, V29, P1730, DOI 10.1016/j.clinthera.2007.08.018; Pham DQ, 2007, AM J HEALTH-SYST PH, V64, P490, DOI 10.2146/ajhp060370; Ramsay NA, 2005, BRIT J HAEMATOL, V130, P777, DOI 10.1111/j.1365-2141.2005.05689.x; Rodriguez M, 2007, ATHEROSCLEROSIS, V192, P438, DOI 10.1016/j.atherosclerosis.2007.02.021; Roskos LK, 2011, BIOANALYSIS, V3, P659, DOI [10.4155/BIO.11.28, 10.4155/bio.11.28]; Rui TQ, 2016, J PHARM SCI-US, V105, P242, DOI 10.1016/j.xphs.2015.10.002; Sollier CBD, 2003, CLIN LAB HAEMATOL, V25, P251, DOI 10.1046/j.1365-2257.2003.00527.x; Sylvan L, 2005, AM FAM PHYSICIAN, V72, P1000; Tsai HH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064255, 10.1371/journal.pone.0083572]; Umegaki K, 2002, JPN J PHARMACOL, V90, P345, DOI 10.1254/jjp.90.345; Vaes LPJ, 2000, ANN PHARMACOTHER, V34, P1478, DOI 10.1345/aph.10031; Yang Y, 2014, FITOTERAPIA, V92, P133, DOI 10.1016/j.fitote.2013.10.010; Yeh GY, 2006, AM J CARDIOL, V98, P673, DOI 10.1016/j.amjcard.2006.03.051; Yuan CS, 2010, J GINSENG RES, V34, P160, DOI 10.5142/jgr.2010.34.3.160; Yuan CS, 2004, ANN INTERN MED, V141, P23, DOI 10.7326/0003-4819-141-1-200407060-00011; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; Yun YP, 2001, J ETHNOPHARMACOL, V77, P259, DOI 10.1016/S0378-8741(01)00303-8; Zhou Yulu, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2290; Zikria J, 2010, AM J MED, V123, P384, DOI 10.1016/j.amjmed.2009.08.019	49	21	22	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0182794	10.1371/journal.pone.0182794	http://dx.doi.org/10.1371/journal.pone.0182794			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28797065	gold, Green Published, Green Submitted			2023-01-03	WOS:000407396200097
J	Bieleninik, L; Geretsegger, M; Mossler, K; Assmus, J; Thompson, G; Gattino, G; Elefant, C; Gottfried, T; Igliozzi, R; Muratori, F; Suvini, F; Kim, J; Crawford, MJ; Odell-Miller, H; Oldfield, A; Casey, O; Finnemann, J; Carpente, J; Park, AL; Grossi, E; Gold, C				Bieleninik, Lucja; Geretsegger, Monika; Mossler, Karin; Assmus, Jorg; Thompson, Grace; Gattino, Gustavo; Elefant, Cochavit; Gottfried, Tali; Igliozzi, Roberta; Muratori, Filippo; Suvini, Ferdinando; Kim, Jinah; Crawford, Mike J.; Odell-Miller, Helen; Oldfield, Amelia; Casey, Orla; Finnemann, Johanna; Carpente, John; Park, A-La; Grossi, Enzo; Gold, Christian		TIME-A Study Team	Effects of Improvisational Music Therapy vs Enhanced Standard Care on Symptom Severity Among Children With Autism Spectrum Disorder The TIME-A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTION	IMPORTANCE Music therapymay facilitate skills in areas affected by autism spectrum disorder (ASD), such as social interaction and communication. OBJECTIVE To evaluate effects of improvisational music therapy on generalized social communication skills of children with ASD. DESIGN, SETTING, AND PARTICIPANTS Assessor-blinded, randomized clinical trial, conducted in 9 countries and enrolling children aged 4 to 7 years with ASD. Childrenwere recruited from November 2011 to November 2015, with follow-up between January 2012 and November 2016. INTERVENTIONS Enhanced standard care (n=182) vs enhanced standard care plus improvisational music therapy (n=182), allocated in a 1: 1 ratio. Enhanced standard care consisted of usual care as locally available plus parent counseling to discuss parents' concerns and provide information about ASD. In improvisational music therapy, trained music therapists sang or played music with each child, attuned and adapted to the child's focus of attention, to help children develop affect sharing and joint attention. MAIN OUTCOMES AND MEASURES The primary outcome was symptom severity over 5 months, based on the Autism Diagnostic Observation Schedule (ADOS), social affect domain (range, 0-27; higher scores indicate greater severity; minimal clinically important difference, 1). Prespecified secondary outcomes included parent-rated social responsiveness. All outcomes were also assessed at 2 and 12 months. RESULTS Among 364 participants randomized (mean age, 5.4 years; 83% boys), 314 (86%) completed the primary end point and 290 (80%) completed the last end point. Over 5 months, participants assigned to music therapy received a median of 19 music therapy, 3 parent counseling, and 36 other therapy sessions, compared with 3 parent counseling and 45 other therapy sessions for those assigned to enhanced standard care. From baseline to 5 months, mean ADOS social affect scores estimated by linear mixed-effects models decreased from 14.08 to 13.23 in the music therapy group and from 13.49 to 12.58 in the standard care group (mean difference, 0.06 [95% CI, - 0.70 to 0.81]; P = .88), with no significant difference in improvement. Of 20 exploratory secondary outcomes, 17 showed no significant difference. CONCLUSIONS AND RELEVANCE Among children with autism spectrum disorder, improvisational music therapy, compared with enhanced standard care, resulted in no significant difference in symptom severity based on the ADOS social affect domain over 5 months. These findings do not support the use of improvisational music therapy for symptom reduction in children with autism spectrum disorder.	[Bieleninik, Lucja; Geretsegger, Monika; Mossler, Karin; Assmus, Jorg; Gold, Christian] Uni Res, GAMUT Grieg Acad Mus Therapy Res Ctr, Uni Res Hlth, POB 7805, N-5020 Bergen, Norway; [Thompson, Grace] Univ Melbourne, Melbourne Conservatorium Mus, Melbourne, Vic, Australia; [Gattino, Gustavo] Aalborg Univ, Dept Commun & Psychol, Aalborg, Denmark; [Gattino, Gustavo] Rio Grande do Sul Fed Univ, Postgrad Program Child & Adolescent Hlth, Fac Med, Porto Alegre, RS, Brazil; [Elefant, Cochavit] Univ Haifa, Sch Creat Arts Therapies, Haifa, Israel; [Gottfried, Tali] David Yelin Coll, Mus Therapy Program, Jerusalem, Israel; [Igliozzi, Roberta; Muratori, Filippo; Suvini, Ferdinando] IRCCS Stella Maris Fdn, Pisa, Italy; [Muratori, Filippo] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy; [Kim, Jinah] Jeonju Univ, Jeonju, South Korea; [Crawford, Mike J.] Imperial Coll London, Ctr Psychiat, London, England; [Odell-Miller, Helen; Oldfield, Amelia; Casey, Orla; Finnemann, Johanna] Anglia Ruskin Univ, Cambridge, England; [Finnemann, Johanna] Univ Cambridge, Dept Psychiat, Cambridge, England; [Carpente, John] Rockville Ctr, Rebecca Ctr Mus Therapy, Molloy Coll, New York, NY USA; [Park, A-La] London Sch Econ & Polit Sci, Personal Social Serv Res Unit, LSE Hlth & Social Care, London, England; [Grossi, Enzo] Villa Santa Maria Inst, Tavernerio, Italy	University of Melbourne; Aalborg University; Universidade Federal do Rio Grande do Sul; University of Haifa; IRCCS Fondazione Stella Maris; University of Pisa; Jeonju University; Imperial College London; Anglia Ruskin University; University of Cambridge; University of London; London School Economics & Political Science	Gold, C (corresponding author), Uni Res, GAMUT Grieg Acad Mus Therapy Res Ctr, Uni Res Hlth, POB 7805, N-5020 Bergen, Norway.	christian.gold@uni.no	Gold, Christian/K-1774-2015; Grossi, Enzo/AAF-7765-2020; Park, A-La/W-2101-2018; Bargagna, Stefania/AAB-7603-2019; Gattino, Gustavo/AAB-3824-2019; Bieleninik, Łucja/I-7804-2019; Igliozzi, Roberta/AAA-4568-2021; Muratori, Filippo/K-3187-2018	Park, A-La/0000-0002-4704-4874; Bargagna, Stefania/0000-0001-6430-9494; Gattino, Gustavo/0000-0002-3048-6246; Bieleninik, Łucja/0000-0001-9685-2934; Igliozzi, Roberta/0000-0002-1245-972X; Muratori, Filippo/0000-0001-9598-0096; Finnemann, Johanna/0000-0002-1049-2155; Kim, Jinah/0000-0002-9528-3773; Crawford, Mike/0000-0003-3137-5772; Thompson, Grace/0000-0002-7501-5325	Research Council of Norway [213844]; POLYFON Knowledge Cluster for Music Therapy, The Grieg Academy Department of Music, University of Bergen; Australia: Melbourne Conservatorium of Music, The University of Melbourne; Austria: Danish Council for Independent Research/Humanities (FKK); Austria: Aalborg University; Austria: Faculty of Psychology, University of Vienna; Brazil: Research Incentive Fund (FIPE) of the Hospital de Clinicas de Porto Alegre (HCPA); Italy: IRCCS Stella Maris Foundation, Pisa; Italy: University of Pisa; Korea: Research Institute of Health and Science, Jeonju University; Norway: Health Authority of Western Norway [911800]; Norway: Bergen municipality (Bergen Culture School); Norway: Fjell municipality (Fjell Culture School); United Kingdom: National Institute for Health Research [12/167/95]; United Kingdom: Cambridge and Peterborough Foundation National Health Service Trust; United Kingdom: Evelyn Trust; United Kingdom: Cambridgeshire Music; United Kingdom: Anglia Ruskin University; United States: Molloy College Faculty research scholarship; United States: Mid-Atlantic Region of the American Music Therapy Association; National Institute for Health Research [12/167/95] Funding Source: researchfish	Research Council of Norway(Research Council of Norway); POLYFON Knowledge Cluster for Music Therapy, The Grieg Academy Department of Music, University of Bergen; Australia: Melbourne Conservatorium of Music, The University of Melbourne; Austria: Danish Council for Independent Research/Humanities (FKK); Austria: Aalborg University; Austria: Faculty of Psychology, University of Vienna; Brazil: Research Incentive Fund (FIPE) of the Hospital de Clinicas de Porto Alegre (HCPA); Italy: IRCCS Stella Maris Foundation, Pisa; Italy: University of Pisa; Korea: Research Institute of Health and Science, Jeonju University; Norway: Health Authority of Western Norway; Norway: Bergen municipality (Bergen Culture School); Norway: Fjell municipality (Fjell Culture School); United Kingdom: National Institute for Health Research(National Institute for Health Research (NIHR)); United Kingdom: Cambridge and Peterborough Foundation National Health Service Trust; United Kingdom: Evelyn Trust; United Kingdom: Cambridgeshire Music; United Kingdom: Anglia Ruskin University; United States: Molloy College Faculty research scholarship; United States: Mid-Atlantic Region of the American Music Therapy Association; National Institute for Health Research(National Institute for Health Research (NIHR))	This trial was funded by the Research Council of Norway (grant 213844, the Clinical Research and Mental Health Programmes). Additional funding was provided by the POLYFON Knowledge Cluster for Music Therapy, The Grieg Academy Department of Music, University of Bergen. Funding for the individual countries came from the following sources: Australia: Melbourne Conservatorium of Music, The University of Melbourne; Austria: Danish Council for Independent Research/Humanities (FKK), Aalborg University, and Faculty of Psychology, University of Vienna; Brazil: Research Incentive Fund (FIPE) of the Hospital de Clinicas de Porto Alegre (HCPA); Italy: IRCCS Stella Maris Foundation, Pisa, and University of Pisa; Korea: Research Institute of Health and Science, Jeonju University; Norway: Health Authority of Western Norway (Helse Vest grant 911800), Bergen municipality (Bergen Culture School), Fjell municipality (Fjell Culture School); United Kingdom: National Institute for Health Research (Health Technology Assessment Programme, National Institute for Health Research grant 12/167/95), Cambridge and Peterborough Foundation National Health Service Trust, The Evelyn Trust, Cambridgeshire Music, Anglia Ruskin University; United States: Molloy College Faculty research scholarship and a collaborative research grant from the Mid-Atlantic Region of the American Music Therapy Association.	Aldred C, 2004, J CHILD PSYCHOL PSYC, V45, P1420, DOI 10.1111/j.1469-7610.2004.00338.x; Alvin J., 1978, MUSIC THERAPY AUTIST; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 1992, INT STAT CLASS DIS R; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Blauth LK, 2017, HEALTH PSYCHOL REP, V5, P138, DOI 10.5114/hpr.2017.63558; Buescher AVS, 2014, JAMA PEDIATR, V168, P721, DOI 10.1001/jamapediatrics.2014.210; Constantino J. N., 2005, SOCIAL RESPONSIVENES; Dawson Geraldine, 2010, Pediatrics, V125, pe17, DOI 10.1542/peds.2009-0958; Geretsegger M, 2016, J MUSIC THER, V53, P93, DOI 10.1093/jmt/thv038; Geretsegger M, 2015, J MUSIC THER, V52, P258, DOI 10.1093/jmt/thv005; Geretsegger M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004381.pub3; Geretsegger M, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-2; Gold C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004381.pub2; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; Gottfried T, 2016, NORD J MUSIC THER, V25, P89, DOI 10.1080/08098131.2016.1180085; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Howlin P, 2007, J CHILD PSYCHOL PSYC, V48, P473, DOI 10.1111/j.1469-7610.2006.01707.x; KANNER L, 1968, ACTA PAEDOPSYCHIATR, V35, P100; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Malloch S., 2008, COMMUNICATIVE MUSICA; McGlothlin AE, 2014, JAMA-J AM MED ASSOC, V312, P1342, DOI 10.1001/jama.2014.13128; Mossler K, 2016, NORD J MUSIC THER, V25, P51, DOI 10.1080/08098131.2016.1179960; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Reichow B, 2012, J AUTISM DEV DISORD, V42, P512, DOI 10.1007/s10803-011-1218-9; Silberman S., 2015, NEUROTRIBES LEGACY A; Solomon R, 2014, J DEV BEHAV PEDIATR, V35, P475, DOI 10.1097/DBP.0000000000000096; Stern D. N., 2010, FORMS VITALITY EXPLO; Weitlauf AS, 2014, THERAPIES CHILDREN W; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z	30	67	67	7	85	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 8	2017	318	6					525	535		10.1001/jama.2017.9478	http://dx.doi.org/10.1001/jama.2017.9478			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	FC9KM	28787504	Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000407160100015
J	Xue, YH; Martelotto, L; Baslan, T; Vides, A; Solomon, M; Mai, TT; Chaudhary, N; Riely, GJ; Li, BT; Scott, K; Cechhi, F; Stierner, U; Chadalavada, K; de Stanchina, E; Schwartz, S; Hembrough, T; Nanjangud, G; Berger, MF; Nilsson, J; Lowe, SW; Reis, J; Rosen, N; Lito, P				Xue, Yaohua; Martelotto, Luciano; Baslan, Timour; Vides, Alberto; Solomon, Martha; Trang Thi Mai; Chaudhary, Neelam; Riely, Greg J.; Li, Bob T.; Scott, Kerry; Cechhi, Fabiola; Stierner, Ulrika; Chadalavada, Kalyani; de Stanchina, Elisa; Schwartz, Sarit; Hembrough, Todd; Nanjangud, Gouri; Berger, Michael F.; Nilsson, Jonas; Lowe, Scott W.; Reis-Filho, Jorge S.; Rosen, Neal; Lito, Piro			An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; BRAF-MUTANT; MEK INHIBITION; OPEN-LABEL; MELANOMA; FEEDBACK; MULTICENTER; DABRAFENIB; TRAMETINIB; TARGETS	The principles that govern the evolution of tumors exposed to targeted therapy are poorly understood. Here we modeled the selection and propagation of an amplification in the BRAF oncogene (BRAF(amp)) in patient-derived tumor xenografts (PDXs) that were treated with a direct inhibitor of the kinase ERK, either alone or in combination with other ERK signaling inhibitors. Single-cell sequencing and multiplex fluorescence in situ hybridization analyses mapped the emergence of extra-chromosomal amplification in parallel evolutionary trajectories that arose in the same tumor shortly after treatment. The evolutionary selection of BRAF(amp) was determined by the fitness threshold, the barrier that subclonal populations need to overcome to regain fitness in the presence of therapy. This differed for inhibitors of ERK signaling, suggesting that sequential monotherapy is ineffective and selects for a progressively higher BRAF copy number. Concurrent targeting of the RAF, MEK and ERK kinases, however, imposed a sufficiently high fitness threshold to prevent the propagation of subclones with high-level BRAF(amp). When administered on an intermittent schedule, this treatment inhibited tumor growth in 11/11 PDXs of lung cancer or melanoma without apparent toxicity in mice. Thus, gene amplification can be acquired and expanded through parallel evolution, enabling tumors to adapt while maintaining their intratumoral heterogeneity. Treatments that impose the highest fitness threshold will likely prevent the evolution of resistance-causing alterations and, thus, merit testing in patients.	[Xue, Yaohua; Martelotto, Luciano; Baslan, Timour; Vides, Alberto; Solomon, Martha; Trang Thi Mai] Human Oncol & Pathogenesis Program, Mem Sloan Kettering Canc Ctr MSKCC, New York, NY 96332 USA; [Trang Thi Mai; Riely, Greg J.; Scott, Kerry; Cechhi, Fabiola; Stierner, Ulrika] Weill Cornell Rockefeller Sloan Kettering Tri Ins, New York, NY USA; [Vides, Alberto; Solomon, Martha; Chaudhary, Neelam; Li, Bob T.; Cechhi, Fabiola] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA; [Vides, Alberto; Riely, Greg J.; Scott, Kerry] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY USA; [Trang Thi Mai; Chaudhary, Neelam; Li, Bob T.; Cechhi, Fabiola] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Vides, Alberto; Riely, Greg J.] NantOm, Rockville, MD USA; [Baslan, Timour; Trang Thi Mai; Riely, Greg J.; Scott, Kerry] Univ Gothenburg, Sahlgrenska Translat Melanoma Grp, Sahlgrenska Canc Ctr, Gothenburg, Sweden; [Vides, Alberto; Solomon, Martha; Chaudhary, Neelam; Li, Bob T.] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core Facil, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Gothenburg; Memorial Sloan Kettering Cancer Center	Xue, YH (corresponding author), Human Oncol & Pathogenesis Program, Mem Sloan Kettering Canc Ctr MSKCC, New York, NY 96332 USA.		Rosen, Neal/ABF-2677-2020; Martelotto, Luciano/D-1946-2015	Nilsson, Jonas/0000-0003-0346-6837; Xue, Jenny/0000-0003-1192-1836; Chaudhary, Neelam/0000-0002-0327-2824; Martelotto, Luciano/0000-0002-9625-1183	US National Institutes of Health (NIH) [K08 CA191082-01A1]; Uniting Against Lung Cancer Foundation; Damon Runyon Clinical Investigator Award; Josie Robertson Investigator Program at MSKCC; Druckenmiller Center for Lung Cancer Center at MSKCC; Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH [T32GM007739]; MSKCC Pilot Center tor Precision Disease Modeling program [U54 OD020355]; William C. and Joyce C. O'Neil Charitable Trust; Memorial Sloan Kettering Single-Cell Sequencing Initiative; Knut and Alice Wallenberg Foundation; MSKCC Support Grant-Core Grant program [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748, R35CA210085, K08CA191082, P01CA129243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U54OD020355] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Uniting Against Lung Cancer Foundation; Damon Runyon Clinical Investigator Award; Josie Robertson Investigator Program at MSKCC; Druckenmiller Center for Lung Cancer Center at MSKCC; Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH; MSKCC Pilot Center tor Precision Disease Modeling program; William C. and Joyce C. O'Neil Charitable Trust; Memorial Sloan Kettering Single-Cell Sequencing Initiative; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); MSKCC Support Grant-Core Grant program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank D. Solit, N. Bouvier and the Center for Molecular Oncology at MSKCC for assistance with next-generation sequencing, Z. Yao(MSKCC) for providing the A375 doxycycline-inducible BRAF<SUP>V600E</SUP> cells, as well as C. Sawyers, C. Rodin, J. Poirier and M. Mroczkowski for reviewing the manuscript. This work was supported by the US National Institutes of Health (NIH) (grant K08 CA191082-01A1; P.L.), the Uniting Against Lung Cancer Foundation (P.L.), the Damon Runyon Clinical Investigator Award (P.L.), the Josie Robertson Investigator Program at MSKCC (P.L.), the Druckenmiller Center for Lung Cancer Center at MSKCC (P.L.) and a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH under award number T32GM007739 to the Weill Cornell-Rockefeller-Sloan Kettering Tri-institutional MD-PhD Program (Y.X.). E.d.S. and S.W.L. are supported in part by the MSKCC Pilot Center tor Precision Disease Modeling program (U54 OD020355). T.B. is supported by the William C. and Joyce C. O'Neil Charitable Trust, Memorial Sloan Kettering Single-Cell Sequencing Initiative. J.N. is supported by the Knut and Alice Wallenberg Foundation. The authors also acknowledge the MSKCC Support Grant-Core Grant program (P30 CA008748).	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Baslan T, 2015, GENOME RES, V25, P714, DOI 10.1101/gr.188060.114; Baslan T, 2012, NAT PROTOC, V7, P1024, DOI 10.1038/nprot.2012.039; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Catenacci DVT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100586; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Einarsdottir BO, 2014, ONCOTARGET, V5, P9609, DOI 10.18632/oncotarget.2445; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641; Garvin T, 2015, NAT METHODS, V12, P1058, DOI [10.1038/NMETH.3578, 10.1038/nmeth.3578]; Hembrough T, 2013, J MOL DIAGN, V15, P454, DOI 10.1016/j.jmoldx.2013.03.002; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lipinski KA, 2016, TRENDS CANCER, V2, P49, DOI 10.1016/j.trecan.2015.11.003; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Melchor L, 2014, LEUKEMIA, V28, P1705, DOI 10.1038/leu.2014.13; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nguyen A, 2016, J CLIN INVEST, V126, P681, DOI 10.1172/JCI83587; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Poirier JT, 2015, ONCOGENE, V34, P5869, DOI 10.1038/onc.2015.38; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Wanjala J, 2015, MOL CANCER THER, V14, P278, DOI 10.1158/1535-7163.MCT-14-0542-T; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wong DJL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-194; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001	48	97	101	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2017	23	8					929	+		10.1038/nm.4369	http://dx.doi.org/10.1038/nm.4369			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FC6JY	28714990	Green Accepted			2023-01-03	WOS:000406947600008
J	Fisher, CJ; Niu, C; Foltz, W; Chen, YH; Sidorova-Darmos, E; Eubanks, JH; Lilge, L				Fisher, Carl J.; Niu, Carolyn; Foltz, Warren; Chen, Yonghong; Sidorova-Darmos, Elena; Eubanks, James H.; Lilge, Lothar			ALA-PpIX mediated photodynamic therapy of malignant gliomas augmented by hypothermia	PLOS ONE			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMA; PROTOPORPHYRIN IX FLUORESCENCE; BRAIN-BARRIER DISRUPTION; ACUTE ISCHEMIC-STROKE; 5-AMINOLEVULINIC ACID; MILD HYPOTHERMIA; GABA(B) RECEPTORS; CLINICAL ARTICLE; GUIDED RESECTION; TREATED RATS	Background Malignant gliomas are highly invasive, difficult to treat, and account for 2% of cancer deaths worldwide. Glioblastoma Multiforme (GBM) comprises the most common and aggressive intracranial tumor. The study hypothesis is to investigate the modification of Photodynamic Therapy (PDT) efficacy by mild hypothermia leads to increased glioma cell kill while protecting normal neuronal structures. Methods Photosensitizer accumulation and PDT efficacy in vitro were quantified in various glioma cell lines, primary rat neurons, and astrocytes. In vivo studies were carried out in healthy brain and RG2 glioma of naive Fischer rats. Hypothermia was induced at 1 hour pre-to 2 hours post-PDT, with ALA-PpIX accumulation and PDT treatments effects on tumor and normal brain PDT quantified using optical spectroscopy, histology, immunohistochemistry, MRI, and survival studies, respectively. Findings In vitro studies demonstrated significantly improved post-PDT survival in primary rat neuronal cells. Rat in vivo studies confirmed a neuroprotective effect to hypothermia following PpIX mediated PDT by T-2 mapping at day 10, reflecting edema/inflammation volume reduction. Mild hypothermia increased PpIX fluorescence in tumors five-fold, and the median post-PDT rat survival time (8.5 days normothermia; 14 days hypothermia). Histology and immunohistochemistry show close to complete cellular protection in normal brain structures under hypothermia. Conclusions The benefits of hypothermia on both normal neuronal tissue as well as increased PpIX fluorescence and RG2 induced rat survival strongly suggest a role for hypothermia in photonics-based surgical techniques, and that a hypothermic intervention could lead to considerable patient outcome improvements.	[Fisher, Carl J.; Lilge, Lothar] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Niu, Carolyn; Chen, Yonghong; Lilge, Lothar] Princess Margaret Canc Ctr, Div Mol Imaging, Toronto, ON, Canada; [Foltz, Warren] Univ Hlth Network, Dept Radiat Oncol, Toronto, ON, Canada; [Sidorova-Darmos, Elena; Eubanks, James H.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Eubanks, James H.] Toronto Western Hosp, Krembil Res Inst, Div Genet & Dev, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lilge, L (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.; Lilge, L (corresponding author), Princess Margaret Canc Ctr, Div Mol Imaging, Toronto, ON, Canada.	llilge@uhnresearch.ca		lilge, lothar/0000-0001-5533-0005; Fisher, Carl/0000-0002-7412-8133; Eubanks, James/0000-0001-8595-2024	Institute of Cancer Research of the Canadian Institutes of Health Research [MOP 93567]; UHN Advanced Optical Microscopy Facility; UHN STTARR imaging facility	Institute of Cancer Research of the Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); UHN Advanced Optical Microscopy Facility; UHN STTARR imaging facility	The study was funded by the Institute of Cancer Research of the Canadian Institutes of Health Research under grant #MOP 93567. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The Authors want to express their thanks to the UHN Advanced Optical Microscopy Facility for their support in microscopic studies and the UHN STTARR imaging facility for their support in the in vivo imaging studies.	Akimoto J, 2016, NEUROL MED-CHIR, V56, P151, DOI 10.2176/nmc.ra.2015-0296; Amelio D, 2010, RADIOTHER ONCOL, V97, P361, DOI 10.1016/j.radonc.2010.08.018; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chang CN, 2003, J NEURO-ONCOL, V61, P45, DOI 10.1023/A:1021270201988; Chi OZ, 2001, ANESTHESIOLOGY, V95, P933, DOI 10.1097/00000542-200110000-00023; Crowley R Webster, 2006, Neurosurg Focus, V20, pE17; DERESKI MO, 1995, NEUROSURGERY, V36, P141, DOI 10.1227/00006123-199501000-00018; Eljamel MS, 2008, LASER MED SCI, V23, P361, DOI 10.1007/s10103-007-0494-2; Eljamel S, 2010, PHOTODIAGN PHOTODYN, V7, P76, DOI 10.1016/j.pdpdt.2010.02.002; Ennis SR, 2003, BRAIN RES, V959, P226, DOI 10.1016/S0006-8993(02)03749-6; Fisher CJ, 2013, LASER SURG MED, V45, P460, DOI 10.1002/lsm.22161; Fritzell S, 2013, J NEUROIMMUNOL, V258, P91, DOI 10.1016/j.jneuroim.2013.02.017; Gao DP, 2015, MOL MED REP, V11, P3009, DOI 10.3892/mmr.2014.3111; Gerard CS, 2014, SEMIN ONCOL, V41, P458, DOI 10.1053/j.seminoncol.2014.06.008; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hammer MD, 2003, NEUROLOGIST, V9, P280, DOI 10.1097/01.nrl.0000094628.29312.2b; Hemmen TM, 2009, J NEUROTRAUM, V26, P387, DOI 10.1089/neu.2008.0574; Hess KR, 2004, CANCER, V101, P2293, DOI 10.1002/cncr.20621; Huang Z, 2010, PROTEIN CELL, V1, P638, DOI 10.1007/s13238-010-0078-y; Johansson A, 2013, LASER SURG MED, V45, P225, DOI 10.1002/lsm.22126; Jones OD, 2015, NEUROSCIENCE, V309, P113, DOI 10.1016/j.neuroscience.2015.08.035; Kim A, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3523616; Kim A, 2010, OPT EXPRESS, V18, P5580, DOI 10.1364/OE.18.005580; Kostaras X, 2014, CURR ONCOL, V21, pE493, DOI 10.3747/co.21.1769; Lee KM, 2009, GENES GENOM, V31, P89, DOI 10.1007/BF03191142; Li B, 2016, ONCOL LETT, V11, P2084, DOI 10.3892/ol.2016.4210; Lilge L, 1998, J CLIN LASER MED SUR, V16, P81, DOI 10.1089/clm.1998.16.81; Lilge L, 1997, J PHOTOCH PHOTOBIO B, V39, P229, DOI 10.1016/S1011-1344(97)00010-9; Lun XQ, 2009, CLIN CANCER RES, V15, P2777, DOI 10.1158/1078-0432.CCR-08-2342; Masubuchi T, 2013, PHOTOMED LASER SURG, V31, P428, DOI 10.1089/pho.2012.3469; Mathews MS, 2011, LASER SURG MED, V43, P892, DOI 10.1002/lsm.21135; Mineharu Y, 2012, NEUROTHERAPEUTICS, V9, P827, DOI 10.1007/s13311-012-0144-7; Moan J, 1999, PHOTOCHEM PHOTOBIOL, V70, P669, DOI 10.1562/0031-8655(1999)070<0669:TTDOPI>2.3.CO;2; MULLER PJ, 1987, PHOTOCHEM PHOTOBIOL, V46, P929, DOI 10.1111/j.1751-1097.1987.tb04871.x; Muragaki Y, 2013, J NEUROSURG, V119, P845, DOI 10.3171/2013.7.JNS13415; Niu CJ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.9.098002; Olivo M, 2004, INT J ONCOL, V25, P37; Ostojic ZS, 2013, NEUROSCIENCE, V238, P39, DOI 10.1016/j.neuroscience.2013.01.072; Paez-Martinez N, 2013, EUR J PHARMACOL, V698, P178, DOI 10.1016/j.ejphar.2012.10.004; Schreer A, 2005, ANAL BIOCHEM, V344, P76, DOI 10.1016/j.ab.2005.06.009; Shaw E G, 1993, Oncology (Williston Park), V7, P97; Shaw EG, 1993, ONCOLOGY, V7, p8 ; Shaw EG, 1993, ONCOLOGY, V7, p[7, 8 ]; Stepp H, 2007, J ENVIRON PATHOL TOX, V26, P157, DOI 10.1615/JEnvironPatholToxicolOncol.v26.i2.110; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Stummer W, 2003, ACT NEUR S, V88, P9; Stummer W, 2011, ACTA NEUROCHIR, V153, P1211, DOI 10.1007/s00701-011-1001-x; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Stylli SS, 2006, J CLIN NEUROSCI, V13, P709, DOI 10.1016/j.jocn.2005.11.012; Valdes PA, 2011, J NEUROSURG, V115, P11, DOI 10.3171/2011.2.JNS101451; Voelzke WR, 2008, CURR TREAT OPTION ON, V9, P23, DOI 10.1007/s11864-008-0053-5; Willey A, 2014, DERMATOL SURG, V40, P1094, DOI 10.1097/01.DSS.0000452662.69539.57; Wong MLH, 2007, J CLIN NEUROSCI, V14, P301, DOI 10.1016/j.jocn.2006.11.005; Yemisci M, 2006, NEUROSURGERY, V59, P1296, DOI 10.1227/01.NEU.0000245607.99946.8F; Yordanova YN, 2011, J NEUROSURG, V115, P232, DOI 10.3171/2011.3.JNS101333; Zagorac D, 2008, J CEREBR BLOOD F MET, V28, P1431, DOI 10.1038/jcbfm.2008.31; Zgavc T, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-105; Zhang XF, 2014, LASER SURG MED, V46, P422, DOI 10.1002/lsm.22248	60	19	20	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2017	12	7							e0181654	10.1371/journal.pone.0181654	http://dx.doi.org/10.1371/journal.pone.0181654			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3TH	28759636	Green Submitted, Green Published, gold			2023-01-03	WOS:000406761600021
J	Reindl-Schwaighofer, R; Kainz, A; Kammer, M; Dumfarth, A; Oberbauer, R				Reindl-Schwaighofer, Roman; Kainz, Alexander; Kammer, Michael; Dumfarth, Alexandra; Oberbauer, Rainer			Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5	PLOS ONE			English	Article							PATIENTS STARTING DIALYSIS; RENAL REPLACEMENT THERAPY; QUALITY-OF-LIFE; DISEASE; MANAGEMENT; OUTCOMES; OCTOGENARIANS	Elderly patients represent a growing population among people suffering from ESRD. So far only limited data on actual survival benefits of elderly adults initiating dialysis have been published. Besides the high burden of preexisting comorbidities, dialysis treatment itself may be associated with a further deterioration in functional status in this population. We retrospectively analyzed the Austrian Dialysis and Transplant Registry and identified 8,622 patients who started maintenance hemodialysis after the age of 65 years between 2002 and 2009. We compared this data set to a cohort of 174 patients aged over 65 years with CKD stage 5 who progressed to an eGFR < 10ml/min/and were managed conservatively in the same era. All patients who died of malignant disease were excluded from this analysis. The risk of mortality was analyzed using multivariable Cox proportional hazards models. Furthermore, a parametric model of time to event analysis was used for visualization of changing risk over time and precise calculation of time to equal risk assuming a Weibull distribution. Hemodialysis treatment was associated with a decreased risk for death with a HR of 0.23 (95% CI 0.18 to 0.29; p<0.001) compared to conservative treatment. The time to event analysis however showed, that although survival was initially superior in the hemodialysis group, hazards crossed thereafter. Time to equal risk was 2.9 months and 1.9 months for female and male patient aged 65, respectively, and decreased to one month in the very elderly aged 95. Elderly patients with ERSD did benefit from initiation of hemodialysis, as the conservative group showed a very high initial mortality rate. This survival benefit of dialysis treatment however did not persist beyond the first two months compared to survivors of the conservative group.	[Reindl-Schwaighofer, Roman; Kainz, Alexander; Dumfarth, Alexandra; Oberbauer, Rainer] Krankenhaus Elisabethinen, Dept Nephrol, Linz, Austria; [Reindl-Schwaighofer, Roman; Kainz, Alexander; Kammer, Michael; Oberbauer, Rainer] Med Univ Vienna, Dept Nephrol, Vienna, Austria; [Kammer, Michael] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria	Ordensklinikum Linz Elisabethinen; Medical University of Vienna; Medical University of Vienna	Oberbauer, R (corresponding author), Krankenhaus Elisabethinen, Dept Nephrol, Linz, Austria.; Oberbauer, R (corresponding author), Med Univ Vienna, Dept Nephrol, Vienna, Austria.	rainer.oberbauer@meduniwien.ac.at	Kainz, Alexander/AAM-7296-2021	Kammer, Michael/0000-0003-4821-9928				Berger JR, 2012, CLIN J AM SOC NEPHRO, V7, P1039, DOI 10.2215/CJN.10411011; Burns A, 2010, HEMODIAL INT, V14, pS32, DOI 10.1111/j.1542-4758.2010.00488.x; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Caplin B, 2011, NEPHROL DIAL TRANSPL, V26, P2656, DOI 10.1093/ndt/gfq763; Carson RC, 2009, CLIN J AM SOC NEPHRO, V4, P1611, DOI 10.2215/CJN.00510109; Chandna SM, 2011, NEPHROL DIAL TRANSPL, V26, P1608, DOI 10.1093/ndt/gfq630; Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176; Couchoud C, 2009, NEPHROL DIAL TRANSPL, V24, P1553, DOI 10.1093/ndt/gfn698; Da Silva-Gane M, 2012, CLIN J AM SOC NEPHRO, V7, P2002, DOI 10.2215/CJN.01130112; Hecking M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001750; Hussain JA, 2013, PALLIATIVE MED, V27, P829, DOI 10.1177/0269216313484380; Jassal SV, 2009, NEW ENGL J MED, V361, P1612, DOI 10.1056/NEJMc0905289; Joly D, 2003, J AM SOC NEPHROL, V14, P1012, DOI 10.1097/01.ASN.0000054493.04151.80; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Lee SML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107567; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Morton RL, 2012, AM J KIDNEY DIS, V59, P419, DOI 10.1053/j.ajkd.2011.08.024; Moss AH, 2010, CLIN J AM SOC NEPHRO, V5, P2380, DOI 10.2215/CJN.07170810; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; O'Connor NR, 2012, J PALLIAT MED, V15, P228, DOI 10.1089/jpm.2011.0207; Renal Physicians Association/American Society of Nephrology Working Group, 2000, J AM SOC NEPHROL, V11, P1788; Rettig RA, 2011, NEW ENGL J MED, V364, P596, DOI 10.1056/NEJMp1014193; Shum CK, 2014, J GERONTOL A-BIOL, V69, P308, DOI 10.1093/gerona/glt098; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; United States Renal Data System, 2014, 2014 ANN DAT REP EP; van Walraven C, 2014, AM J KIDNEY DIS, V63, P491, DOI 10.1053/j.ajkd.2013.09.011; Verdalles U, 2010, NEPHRON CLIN PRACT, V115, pE28, DOI 10.1159/000286347	28	26	28	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2017	12	7							e0181345	10.1371/journal.pone.0181345	http://dx.doi.org/10.1371/journal.pone.0181345			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8BB	28742145	Green Published, Green Submitted, gold			2023-01-03	WOS:000406362700037
J	Goebel, J; Sulke, M; Lazik-Palm, A; Goebel, T; Dechene, A; Bellendorf, A; Mueller, S; Umutlu, L; Theysohn, J				Goebel, Juliane; Sulke, Maximilian; Lazik-Palm, Andrea; Goebel, Thomas; Dechene, Alexander; Bellendorf, Alexander; Mueller, Stefan; Umutlu, Lale; Theysohn, Jens			Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma	PLOS ONE			English	Article							PORTAL-VEIN EMBOLIZATION; ART BRACHYTHERAPY TREATMENT; INTERNAL RADIATION-THERAPY; (90)YTTRIUM MICROSPHERES; Y-90 RADIOEMBOLIZATION; VOLUMETRIC CHANGES; MALIGNANCIES; CIRRHOSIS; CANCER; CELLS	Introduction Radioembolization for the treatment of hepatocellular carcinoma (HCC) induces liver volume changes referred to as "atrophy-hypertrophy complex". The aim of this study was to investigate lobar liver volume changes after unilateral radioembolization and to search for factors associated with hypertrophy of the untreated lobe. Materials and methods Seventy-five patients were retrospectively evaluated. Inclusion criteria were: (1) right-lobar radioembolization for unresectable unilateral HCC, (2) available liver computed tomography scans before, 1, 3, and at least 6 months after radioembolization. Baseline patient characteristics included clinical features, laboratory results, spleen volume, and liver computed tomography. Absolute and relative (referred to the whole liver volume) liver lobe volumes (LLV) as well as relative LLV (rLLV) change per month were evaluated and compared. Results Absolute and relative contralateral LLV continuously increased after radioembolization (p<0.001). Mean relative contralateral LLV increased from 36 +/- 11.6% before radioembolization to 50 +/- 15.3% 6 months after radioembolization. Median contralateral rLLV increase/month (within first 6 months) was 2.5%. Contralateral rLLV increase/month was significantly lower in patients with ascites (p = 0.017) or platelet count <100/nl (p = 0.009). An inverse correlation of contralateral rLVV increase/month with spleen volume (p = 0.017), patient age (p = 0.024), Child Pugh score (p = 0.001), and tumor burden (p = 0.001) was found. Conclusions Significant contralateral hypertrophy and ipsilateral atrophy were common after unilateral radioembolization. Small spleen volume, low patient age, low Child Pugh score, absence of ascites, platelet count >= 100/nl, and low tumor burden were associated with increased contralateral hypertrophy, indicating that younger patients with compensated cirrhosis might benefit most from radioembolization in a "bridge-to-resection" setting.	[Goebel, Juliane; Sulke, Maximilian; Lazik-Palm, Andrea; Umutlu, Lale; Theysohn, Jens] Univ Hosp Essen, Dept Diagnost & Intervent Radiol, Essen, Germany; [Goebel, Thomas] Petrus Hosp, Clin Gastroenterol Hepatol & Diabetol, Wuppertal, Germany; [Bellendorf, Alexander] Univ Hosp Essen, Clin Gastroenterol & Hepatol, Essen, Germany; [Bellendorf, Alexander; Mueller, Stefan] Univ Hosp Essen, Clin Nucl Med, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Goebel, J (corresponding author), Univ Hosp Essen, Dept Diagnost & Intervent Radiol, Essen, Germany.	Juliane.Goebel@uk-essen.de						Azoulay D, 2000, ANN SURG, V231, P480, DOI 10.1097/00000658-200004000-00005; Berzigotti A, 2015, HEPATOLOGY, V61, P526, DOI 10.1002/hep.27431; Bunchorntavakul C, 2016, J VIRAL HEPATITIS, V23, P408, DOI 10.1111/jvh.12534; Couinaud C, 1957, FOIE ETUDES ANATOMIQ; Dezarn WA, 2011, MED PHYS, V38, P4824, DOI 10.1118/1.3608909; Edeline J, 2013, ANN SURG ONCOL, V20, P2518, DOI 10.1245/s10434-013-2906-9; Gaba RC, 2009, ANN SURG ONCOL, V16, P1587, DOI 10.1245/s10434-009-0454-0; Gulec SA, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-6; Hoare M, 2010, J HEPATOL, V53, P950, DOI 10.1016/j.jhep.2010.06.009; Jakobs TF, 2008, DIGEST DIS SCI, V53, P2556, DOI 10.1007/s10620-007-0148-z; Kim Robin D, 2008, Semin Intervent Radiol, V25, P92, DOI 10.1055/s-2008-1076679; Kopp JL, 2016, NAT CELL BIOL, V18, P238, DOI 10.1038/ncb3309; Kordes C, 2013, J CLIN INVEST, V123, P1874, DOI 10.1172/JCI66027; Kubota K, 1997, HEPATOLOGY, V26, P1176; Ladurner R, 2009, HPB SURG, V2009; Liu H, 2009, AM J SURG, V197, P686, DOI [10.1016/j.amjsurg.2008.04.006, 10.1016/j.amjsurg.2008.04.022]; Miyajima A, 2014, CELL STEM CELL, V14, P561, DOI 10.1016/j.stem.2014.04.010; Nadalin S, 2014, Z GASTROENTEROL, V52, P35, DOI 10.1055/s-0033-1356364; Pamecha V, 2009, BRIT J CANCER, V100, P617, DOI 10.1038/sj.bjc.6604872; Salem R, 2006, J VASC INTERV RADIOL, V17, P1571, DOI 10.1097/01.RVI.0000236744.34720.73; Salem R, 2006, J VASC INTERV RADIOL, V17, P1425, DOI 10.1097/01.RVI.0000235779.88652.53; Salem R, 2006, J VASC INTERV RADIOL, V17, P1251, DOI 10.1097/01.RVI.0000233785.75257.9A; Sato K, 2006, CARDIOVASC INTER RAD, V29, P522, DOI 10.1007/s00270-005-0171-4; Swiderska-Syn M, 2014, GUT, V63, P1333, DOI 10.1136/gutjnl-2013-305962; Teo JY, 2014, J DIGEST DIS, V15, P444, DOI 10.1111/1751-2980.12162; Theysohn JM, 2014, CLIN RADIOL, V69, P172, DOI 10.1016/j.crad.2013.09.009; Vouche M, 2013, J HEPATOL, V59, P1029, DOI 10.1016/j.jhep.2013.06.015	27	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2017	12	7							e0181488	10.1371/journal.pone.0181488	http://dx.doi.org/10.1371/journal.pone.0181488			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA7TM	28708902	Green Submitted, Green Published, gold			2023-01-03	WOS:000405649800060
J	Mezmur, M; Navaneetham, K; Letamo, G; Bariagaber, H				Mezmur, Markos; Navaneetham, Kannan; Letamo, Gobopamang; Bariagaber, Hadgu			Individual, household and contextual factors associated with skilled delivery care in Ethiopia: Evidence from Ethiopian demographic and health surveys	PLOS ONE			English	Article							SOCIOECONOMIC-STATUS; SERVICES	Despite evidence that social contexts are key determinants of health, research into factors associated with maternal health service utilization in Ethiopia has often focused on individual and household factors. The downside is that this underestimates the importance of taking contextual factors into account when planning appropriate interventions in promoting safe motherhood in the country. The purpose of this study is to fill this knowledge gap drawing attention to the largely unexplored contextual factors affecting the uptake of skilled attendance at delivery in a nationally representative sample. Data for the study comes from two rounds of the Ethiopian Demographic and Health Surveys (EDHS) conducted in the year 2005 and 2011. Analysis was done using a two-level multivariable multilevel logistic regression model with data from 14, 242 women who had a live birth in the five years preceding the surveys clustered within 540 (in the year 2005) and 624 (in the year 2011) communities. The results of the study point to multiple levels of measured and unmeasured factors affecting the uptake of skilled delivery care in the country. At community level, place of residence, community level of female education and fertility significantly predict the uptake of skilled delivery care. At individual and household level, maternal age, birth order, maternal education, household wealth and access to media predict the uptake of such service. Thus, there is a need to consider community contexts in the design of maternal health programs and employ multi-sectorial approach to addressing barriers at different levels. For example, improving access and availability of skilled delivery care should eventually enhance the uptake of such services at community level in Ethiopia. At individual level, efforts to promote the uptake of such services should constitute targeted interventions paying special attention to the needs of the youth, the multiparous, the less educated and women in the poorest households.	[Mezmur, Markos; Navaneetham, Kannan; Letamo, Gobopamang; Bariagaber, Hadgu] Univ Botswana, Dept Populat Studies, Gaborone, Botswana	University of Botswana	Navaneetham, K (corresponding author), Univ Botswana, Dept Populat Studies, Gaborone, Botswana.	Kannan.Navaneetham@mopipi.ub.bw	Letamo, Gobopamang/AAC-9390-2021; Navaneetham, Kannan/K-6390-2014	Letamo, Gobopamang/0000-0001-7256-4700; Navaneetham, Kannan/0000-0002-5847-4669; Satihal, Dayanand/0000-0002-9575-8265				Abeje G, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-22; Achia TNO, 2015, WOMEN HEALTH, V55, P203, DOI 10.1080/03630242.2014.979971; Adjiwanou V, 2014, HEALTH PLACE, V29, P67, DOI 10.1016/j.healthplace.2014.06.001; Ali J., 2012, J HEALTH DEV, V26, P265; Amano A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-105; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Andersen RM, 2008, MED CARE, V46, P647, DOI 10.1097/MLR.0b013e31817f4d48; [Anonymous], 2011, ETHIOPIA DEMOGRAPHIC, P452; Aremu O, 2012, INT J PREVENTIVE MED, V3, P278; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Babalola SO, 2014, REV PANAM SALUD PUBL, V36, P1; Birmeta K, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-256; Fekadu M, 2014, AFR HEALTH SCI, V14, DOI 10.4314/ahs.v14i4.29; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Gage A, 2007, SOC SCI MED, V06; Hox J.J., 2010, MULTILEVEL ANAL TECH, Vsecond, DOI DOI 10.4324/9781315650982; Kruk ME, 2010, HEALTH POLICY, V97, P209, DOI 10.1016/j.healthpol.2010.05.002; Osorio AM, 2014, CAD SAUDE PUBLICA, V30, P1079, DOI 10.1590/0102-311X00073513; McTavish S, 2010, SOC SCI MED, V71, P1958, DOI 10.1016/j.socscimed.2010.09.007; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Ombaka JH., 2015, AM J PUBLIC HLTH RES, V3, P21, DOI DOI 10.12691/AJPHR-3-1-4; Ononokpono D, 2014, PAN AFR MED, P17; Pearson L, 2011, INT J GYNAECOL OBSTE, V115; Prusty R, 2015, INT J POPULATION RES, V2015, P531; Sepehri A, 2008, SOC SCI MED, V67, P1009, DOI 10.1016/j.socscimed.2008.06.005; Singh P, 2013, HLTH POLICY PLAN, V1, P18; Snijers T, 1999, MULTILEVEL ANAL INTR; Stephenson R, 2006, AM J PUBLIC HEALTH, V96, P1, DOI DOI 10.1016/J.HEALTHPLACE.2011.12.006; Tarekegn SM, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-161; WHO, 2014, WORLD HLTH STAT 2014; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	32	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184688	10.1371/journal.pone.0184688	http://dx.doi.org/10.1371/journal.pone.0184688			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FH0VR	28910341	gold, Green Submitted, Green Published			2023-01-03	WOS:000410859200077
J	Nakayama, M; Itami, N; Suzuki, H; Hamada, H; Osaka, N; Yamamoto, R; Tsunoda, K; Nakano, H; Watanabe, K; Zhu, WJ; Maruyama, Y; Terawaki, H; Kabayama, S; Nakazawa, R; Miyazaki, M; Ito, S				Nakayama, Masaaki; Itami, Noritomo; Suzuki, Hodaka; Hamada, Hiromi; Osaka, Naoyuki; Yamamoto, Ryo; Tsunoda, Kazumasa; Nakano, Hirofumi; Watanabe, Kimio; Zhu, Wan-Jun; Maruyama, Yukio; Terawaki, Hiroyuki; Kabayama, Shigeru; Nakazawa, Ryoichi; Miyazaki, Mariko; Ito, Sadayoshi			Possible clinical effects of molecular hydrogen (H-2) delivery during hemodialysis in chronic dialysis patients: Interim analysis in a 12 month observation	PLOS ONE			English	Article							ELECTROLYZED-REDUCED WATER; RENAL-DISEASE PATIENTS; CHRONIC KIDNEY-DISEASE; OXIDATIVE STRESS; UREMIC PRURITUS; CARDIOVASCULAR-DISEASE; CONTROLLED-TRIAL; INFLAMMATION; THERAPY; FATIGUE	Background and aim It is supposed that enhanced oxidative stress and inflammation are involved with the poor clinical outcomes in patients on chronic dialysis treatment. Recent studies have shown that molecular hydrogen (H-2) is biologically active as an anti-inflammatory agent. Thus, we developed a novel hemodialysis (E-HD) system which delivers H-2 (30 to 80 ppb)-enriched dialysis solution, to conduct a prospective observational study (UMIN000004857) in order to compare the long-term outcomes between E-HD and conventional-HD (C-HD) in Japan. The present interim analysis aimed to look at potential clinical effects of E-HD during the first 12 months observation. Subjects and method 262 patients (140, E-HD; 122, C-HD) were subjected for analysis for comprehensive clinical profiles. They were all participating in the above mentioned study, and they had been under the respective HD treatment for 12 consecutive months without hospitalization. Collected data, such as, physical and laboratory examinations, medications, and self-assessment questionnaires on subjective symptoms (i. e., fatigue and pruritus) were compared between the two groups. Results In a 12-month period, no clinical relevant differences were found in dialysis-related parameters between the two groups. However, there were differences in the defined daily dose of anti-hypertensive agents, and subjective symptoms, such as severe fatigue, and pruritus, which were all less in the E-HD group. Multivariate analysis revealed E-HD was an independent significant factor for the reduced use of anti-hypertensive agents as well as the absence of severe fatigue and pruritus at 12 months after adjusting for confounding factors. Conclusion The data indicates E-HD could have substantial clinical benefits beyond conventional HD therapy, and support the rationale to conduct clinical trials of H-2 application to HD treatment.	[Nakayama, Masaaki; Watanabe, Kimio; Zhu, Wan-Jun; Kabayama, Shigeru; Miyazaki, Mariko; Ito, Sadayoshi] Tohoku Univ, United Ctr Adv Res & Translat Med, Ctr Adv & Integrated Renal Sci, Sendai, Miyagi, Japan; [Nakayama, Masaaki; Zhu, Wan-Jun; Miyazaki, Mariko] Tohoku Univ Hosp, Res Div Chron Kidney Dis & Dialysis Treatment, Sendai, Miyagi, Japan; [Nakayama, Masaaki; Terawaki, Hiroyuki] Fukushima Med Univ, Dept Nephrol & Hypertens, Fukushima, Japan; [Itami, Noritomo; Hamada, Hiromi] Nikko Memorial Hosp, Kidney Ctr, Muroran, Hokkaido, Japan; [Itami, Noritomo; Hamada, Hiromi] Higashi Muroran Satellite Clin, Muroran, Hokkaido, Japan; [Suzuki, Hodaka] Horai Higashi Clin, Fukushima, Japan; [Osaka, Naoyuki] Gumyoji Jin Clin, Yokohama, Kanagawa, Japan; [Yamamoto, Ryo] Tateishi Jin Clin, Tokyo, Japan; [Tsunoda, Kazumasa] Noboribetsu Mem Hosp, Noboribetsu, Japan; [Nakano, Hirofumi] Kashima Hosp, Dialysis Ctr, Iwaki, Fukushima, Japan; [Zhu, Wan-Jun; Kabayama, Shigeru] Trim Med Inst Co Ltd, Osaka, Japan; [Maruyama, Yukio] Tokyo Jikei Univ, Sch Med, Dept Nephrol & Hypertens, Tokyo, Japan; [Nakazawa, Ryoichi] Tokatsu Clin Mirai, Matsudo, Chiba, Japan; [Miyazaki, Mariko; Ito, Sadayoshi] Tohoku Univ Hosp, Div Blood Purificat, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Fukushima Medical University; Jikei University; Tohoku University	Nakayama, M (corresponding author), Tohoku Univ, United Ctr Adv Res & Translat Med, Ctr Adv & Integrated Renal Sci, Sendai, Miyagi, Japan.; Nakayama, M (corresponding author), Tohoku Univ Hosp, Res Div Chron Kidney Dis & Dialysis Treatment, Sendai, Miyagi, Japan.; Nakayama, M (corresponding author), Fukushima Med Univ, Dept Nephrol & Hypertens, Fukushima, Japan.	masaaki.nakayama.c1@tohoku.ac.jp		Ito, Sadayoshi/0000-0002-5092-3626	Nihon Trim Co. Ltd.; Generalbincorporated association of Electrolyzed Water-Hemodialysis Study group	Nihon Trim Co. Ltd.; Generalbincorporated association of Electrolyzed Water-Hemodialysis Study group	The study was conducted by funds from Nihon Trim Co. Ltd., (www.hihon-trim.co.jp), and Generalbincorporated association of Electrolyzed Water-Hemodialysis Study group (www.ew-hd.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Artom M, 2014, KIDNEY INT, V86, P497, DOI 10.1038/ki.2014.86; Aslam S, 2006, KIDNEY INT, V70, P2109, DOI 10.1038/sj.ki.5001983; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Bossola M, 2015, J PAIN SYMPTOM MANAG, V49, P578, DOI 10.1016/j.jpainsymman.2014.07.009; Bossola Maurizio, 2009, Blood Purif, V28, P245, DOI 10.1159/000231985; Buchholz BM, 2008, AM J TRANSPLANT, V8, P2015, DOI 10.1111/j.1600-6143.2008.02359.x; Cai JM, 2008, NEUROSCI LETT, V441, P167, DOI 10.1016/j.neulet.2008.05.077; Cardinal JS, 2010, KIDNEY INT, V77, P101, DOI 10.1038/ki.2009.421; Chen H, 2010, BIOCHEM BIOPH RES CO, V393, P308, DOI 10.1016/j.bbrc.2010.02.005; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Huang KC, 2006, KIDNEY INT, V70, P391, DOI 10.1038/sj.ki.5001576; Huang KC, 2003, KIDNEY INT, V64, P704, DOI 10.1046/j.1523-1755.2003.00118.x; Huang KC, 2010, NEPHROL DIAL TRANSPL, V25, P2730, DOI 10.1093/ndt/gfq082; Jhamb M, 2008, AM J KIDNEY DIS, V52, P353, DOI 10.1053/j.ajkd.2008.05.005; Kajiya M, 2009, BIOCHEM BIOPH RES CO, V386, P11, DOI 10.1016/j.bbrc.2009.05.117; Kendrick J, 2008, NAT CLIN PRACT NEPHR, V4, P672, DOI 10.1038/ncpneph0954; Kimmel M, 2006, NEPHROL DIAL TRANSPL, V21, P749, DOI 10.1093/ndt/gfi204; Koyama H, 2010, CLIN J AM SOC NEPHRO, V5, P659, DOI 10.2215/CJN.08151109; Mathur VS, 2010, CLIN J AM SOC NEPHRO, V5, P1410, DOI 10.2215/CJN.00100110; Mettang T, 2002, NEPHROL DIAL TRANSPL, V17, P1558, DOI 10.1093/ndt/17.9.1558; Nagata K, 2009, NEUROPSYCHOPHARMACOL, V34, P501, DOI 10.1038/npp.2008.95; Nakayama M, 2010, NEPHROL DIAL TRANSPL, V25, P3026, DOI 10.1093/ndt/gfq196; Nakayama Masaaki, 2007, Hemodial Int, V11, P322, DOI 10.1111/j.1542-4758.2007.00187.x; Nakayama M, 2009, NEPHRON CLIN PRACT, V112, pC9, DOI 10.1159/000210569; Narita I, 2006, KIDNEY INT, V69, P1626, DOI 10.1038/sj.ki.5000251; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461; Sela S, 2005, J AM SOC NEPHROL, V16, P2431, DOI 10.1681/ASN.2004110929; Shirahata S, 1997, BIOCHEM BIOPH RES CO, V234, P269, DOI 10.1006/bbrc.1997.6622; Tepel M, 2003, CIRCULATION, V107, P992, DOI 10.1161/01.CIR.0000050628.11305.30; Terawaki H, 2014, HEMODIAL INT, V18, P459, DOI 10.1111/hdi.12112; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; Virga G, 2002, NEPHROL DIAL TRANSPL, V17, P2164, DOI 10.1093/ndt/17.12.2164; Weisbord SD, 2005, J AM SOC NEPHROL, V16, P2487, DOI 10.1681/ASN.2005020157; WERTHEIMER A I, 1986, Hospital Pharmacy, V21, P233; Wood KC, 2007, NAT MED, V13, P673, DOI 10.1038/nm0607-673; World Health Organization, 1993, GUID DRINK WAT QUAL, Vsecond, P1; Yngman-Uhlin P, 2011, SCAND J UROL NEPHROL, V45, P206, DOI 10.3109/00365599.2011.557025; Zhu WJ, 2013, MED GAS RES, V3, DOI 10.1186/2045-9912-3-26; Zhu WJ, 2011, NEPHROL DIAL TRANSPL, V26, P2112, DOI 10.1093/ndt/gfq727; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x	42	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2017	12	9							e0184535	10.1371/journal.pone.0184535	http://dx.doi.org/10.1371/journal.pone.0184535			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG8GZ	28902900	Green Published, Green Submitted, gold			2023-01-03	WOS:000410669200045
J	de Jong, MJ; van der Meulen-de Jong, AE; Romberg-Camps, MJ; Becx, MC; Maljaars, JP; Cilissen, M; van Bodegraven, AA; Mahmmod, N; Markus, T; Hameeteman, WM; Dijkstra, G; Masclee, AA; Boonen, A; Winkens, B; van Tubergen, A; Jonkers, DM; Pierik, MJ				de Jong, Marin J.; van der Meulen-de Jong, Andrea E.; Romberg-Camps, Marielle J.; Becx, Marco C.; Maljaars, Jeroen P.; Cilissen, Mia; van Bodegraven, Ad A.; Mahmmod, Nofel; Markus, Tineke; Hameeteman, Wim M.; Dijkstra, Gerard; Masclee, Ad A.; Boonen, Annelies; Winkens, Bjorn; van Tubergen, Astrid; Jonkers, Daisy M.; Pierik, Marie J.			Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; ULCERATIVE-COLITIS; HEALTH-CARE; IMPROVE; METAANALYSIS; PREDICTORS; STRATEGIES; ADHERENCE; COMMUNITY; COHORT	Background Tight and personalised control of inflammatory bowel disease in a traditional setting is challenging because of the disease complexity, high pressure on outpatient clinics, and rising incidence. We compared the effects of self-management with a telemedicine system, which was developed for all subtypes of inflammatory bowel disease, on health-care utilisation and patient-reported quality of care versus standard care. Methods We did this pragmatic, randomised trial in two academic and two non-academic hospitals in the Netherlands. Outpatients aged 18-75 years with inflammatory bowel disease and without an ileoanal or ileorectal pouch anastomosis, who had internet access and Dutch proficiency, were randomly assigned (1: 1) to care via a telemedicine system (myIBDcoach) that monitors and registers disease activity or standard care and followed up for 12 months. Randomisation was done with a computer-generated sequence and used the minimisation method. Participants, health-care providers, and staff who assessed outcome measures were not masked to treatment allocation. Primary outcomes were the number of outpatient visits and patient-reported quality of care (assessed by visual analogue scale score 0-10). Safety endpoints were the numbers of flares, corticosteroid courses, hospital admissions, emergency visits, and surgeries. Analyses were by intention to treat. This trial is registered with ClinicalTrials. gov, number NCT02173002. Findings Between Sept 9, 2014, and May 18, 2015, 909 patients were randomly assigned to telemedicine (n=465) or standard care (n=444). At 12 months, the mean number of outpatient visits to the gastroenterologist or nurse was significantly lower in the telemedicine group (1.55 [SD1.50]) than in the standard care group (2.34 [1.64]; difference -0.79 [95%CI -0.98 to -0.59]; p < 0.0001), as was the mean number of hospital admissions (0.05 [0.28] vs 0.10 [0.43]; difference -0.05 [-0.10 to 0.00]; p=0.046). At 12 months, both groups reported high mean patient-reported quality of care scores (8.16 [1.37] in the telemedicine group vs 8.27 [1.28] in the standard care group; difference 0.10 [-0.13 to 0.32]; p=0.411). The mean numbers of flares, corticosteroid courses, emergency visits, and surgeries did not differ between groups. Interpretation Telemedicine was safe and reduced outpatient visits and hospital admissions compared with standard care. This self-management tool might be useful for reorganising care of inflammatory bowel disease towards personalised and value-based health care.	[de Jong, Marin J.; Cilissen, Mia; Hameeteman, Wim M.; Masclee, Ad A.; Jonkers, Daisy M.; Pierik, Marie J.] Maastricht Univ, Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Maastricht, Netherlands; [de Jong, Marin J.; Masclee, Ad A.; Jonkers, Daisy M.; Pierik, Marie J.] Maastricht Univ, Med Ctr, NUTRIM, Sch Nutr & Translat Res Metab, Maastricht, Netherlands; [Boonen, Annelies; van Tubergen, Astrid] Maastricht Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Maastricht, Netherlands; [Boonen, Annelies; van Tubergen, Astrid] Maastricht Univ, Med Ctr, Care & Publ Hlth Res Inst, Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [van der Meulen-de Jong, Andrea E.; Maljaars, Jeroen P.] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands; [Romberg-Camps, Marielle J.; van Bodegraven, Ad A.] Zuyderland Med Ctr, Dept Gastroenterol Geriatr Internal & Intens Care, Sittard Geleen, Netherlands; [Becx, Marco C.; Mahmmod, Nofel] St Antonius Hosp, Dept Gastroenterol & Hepatol, Nieuwegein, Netherlands; [Markus, Tineke] CCUVN, Woerden, Netherlands; [Dijkstra, Gerard] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands; [Winkens, Bjorn] Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; St. Antonius Hospital Utrecht; University of Groningen; Maastricht University	Pierik, MJ (corresponding author), Maastricht Univ, Dept Gastroenterol & Hepatol, Med Ctr, NL-6202 AZ Maastricht, Netherlands.	m.pierik@mumc.nl	van Tubergen, Astrid/AAY-7065-2020; van der Meulen, Andrea/AAU-9430-2020; van Bodegraven, Ad A/L-3180-2013; van Bodegraven, Ad/ABG-4367-2020	van Tubergen, Astrid/0000-0001-8477-0683; van der Meulen, Andrea/0000-0001-9353-5431; /0000-0003-4563-7462; Winkens, Bjorn/0000-0002-6747-6228; Maljaars, Jeroen/0000-0003-0477-9499	Maastricht University Medical Centre; Ferring	Maastricht University Medical Centre; Ferring(Ferring Pharmaceuticals)	Maastricht University Medical Centre and Ferring.	Aguas M, 2016, INFLAMM BOWEL DIS, V22, pE4, DOI 10.1097/MIB.0000000000000676; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Bradley SM, 2016, JAMA-J AM MED ASSOC, V316, P487, DOI 10.1001/jama.2016.6495; Burisch J, 2015, SCAND J GASTROENTERO, V50, P942, DOI 10.3109/00365521.2015.1014407; Colombel JF, 2017, GASTROENTEROLOGY, V152, P351, DOI 10.1053/j.gastro.2016.09.046; Cross RK, 2012, INFLAMM BOWEL DIS, V18, P1018, DOI 10.1002/ibd.21795; de Jong M, 2015, J CROHNS COLITIS, V9, pS192; de Jong M, 2017, INFLAMM BOWEL DIS, V23, P485, DOI 10.1097/MIB.0000000000001034; Diez ID, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0537-y; Elkjaer M, 2010, GUT, V59, P1652, DOI 10.1136/gut.2010.220160; Feuerstein JD, 2016, CLIN GASTROENTEROL H, V14, P421, DOI 10.1016/j.cgh.2015.09.042; Gomollon F, 2017, J CROHNS COLITIS, V11, P3, DOI 10.1093/ecco-jcc/jjw168; Huang VW, 2014, WORLD J GASTROENTERO, V20, P829, DOI 10.3748/wjg.v20.i3.829; Irvine EJ, 1996, AM J GASTROENTEROL, V91, P1571; Jackson BD, 2016, J CROHNS COLITIS, V10, P1103, DOI 10.1093/ecco-jcc/jjw059; Jeuring SFG, 2017, AM J GASTROENTEROL, V112, P325, DOI 10.1038/ajg.2016.524; Jeuring SFG, 2015, J CROHNS COLITIS, V9, P837, DOI 10.1093/ecco-jcc/jjv129; Jonkman NH, 2016, INT J CHRONIC OBSTR, V11, P2063, DOI 10.2147/COPD.S107884; Keefer L, 2011, INFLAMM BOWEL DIS, V17, P614, DOI 10.1002/ibd.21314; Lakatos PL, 2009, WORLD J GASTROENTERO, V15, P4234, DOI 10.3748/wjg.15.4234; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Magro F, 2017, J CROHNS COLITIS, V11, P649, DOI 10.1093/ecco-jcc/jjx008; Melmed GY, 2013, INFLAMM BOWEL DIS, V19, P662, DOI 10.1097/mib.0b013e31828278a2; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Pedersen N, 2012, ALIMENT PHARM THER, V36, P840, DOI 10.1111/apt.12043; Pedersen N, 2014, INFLAMM BOWEL DIS, V20, P2276, DOI 10.1097/MIB.0000000000000199; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Reigada LC, 2016, INFLAMM BOWEL DIS, V22, P2127, DOI 10.1097/MIB.0000000000000864; Rudin RS, 2016, NEW ENGL J MED, V375, P815, DOI 10.1056/NEJMp1606884; Siegel CA, 2013, CLIN GASTROENTEROL H, V11, P908, DOI 10.1016/j.cgh.2013.05.027; Sulz MC, 2013, EUR J GASTROEN HEPAT, V25, P790, DOI 10.1097/MEG.0b013e32836019b9; van den Heuvel TR, 2015, INT J EPIDEMIOL	32	166	166	2	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	2017	390	10098					959	968		10.1016/S0140-6736(17)31327-2	http://dx.doi.org/10.1016/S0140-6736(17)31327-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF2SE	28716313	Green Published			2023-01-03	WOS:000408746300025
J	Pepin, KM; Davis, AJ; Cunningham, FL; VerCauteren, KC; Eckery, DC				Pepin, Kim M.; Davis, Amy J.; Cunningham, Fred L.; VerCauteren, Kurt C.; Eckery, Doug C.			Potential effects of incorporating fertility control into typical culling regimes in wild pig populations	PLOS ONE			English	Article							PREDATOR-PREY THEORY; BOAR SUS-SCROFA; FERAL PIGS; SOUTHERN TEXAS; NATIONAL-PARK; BRUSHTAIL POSSUMS; DYNAMICS; REPRODUCTION; ERADICATION; HELICOPTER	Effective management of widespread invasive species such as wild pigs (Sus scrofa) is limited by resources available to devote to the effort. Better insight of the effectiveness of different management strategies on population dynamics is important for guiding decisions of resource allocation over space and time. Using a dynamic population model, we quantified effects of culling intensities and time between culling events on population dynamics of wild pigs in the USA using empirical culling patterns and data-based demographic parameters. In simulated populations closed to immigration, substantial population declines (50-100%) occurred within 4 years when 20-60% of the population was culled annually, but when immigration from surrounding areas occurred, there was a maximum of 50% reduction, even with the maximum culling intensity of 60%. Incorporating hypothetical levels of fertility control with realistic culling intensities was most effective in reducing populations when they were closed to immigration and when intrinsic population growth rate was too high (> = 1.78) to be controlled by culling alone. However, substantial benefits from fertility control used in conjunction with culling may only occur over a narrow range of net population growth rates (i.e., where net is the result of intrinsic growth rates and culling) that varies depending on intrinsic population growth rate. The management implications are that the decision to use fertility control in conjunction with culling should rely on concurrent consideration of achievable culling intensity, underlying demographic parameters, and costs of culling and fertility control. The addition of fertility control reduced abundance substantially more than culling alone, however the effects of fertility control were weaker than in populations without immigration. Because these populations were not being reduced substantially by culling alone, fertility control could be an especially helpful enhancement to culling for reducing abundance to target levels in areas where immigration can't be prevented.	[Pepin, Kim M.; Davis, Amy J.; VerCauteren, Kurt C.; Eckery, Doug C.] USDA, APHIS, Wildlife Serv, Natl Wildlife Res Ctr, Ft Collins, CO 80524 USA; [Cunningham, Fred L.] USDA, APHIS, Wildlife Serv, Natl Wildlife Res Ctr, Mississippi State, MS 80720 USA	United States Department of Agriculture (USDA); Mississippi State University; United States Department of Agriculture (USDA)	Pepin, KM (corresponding author), USDA, APHIS, Wildlife Serv, Natl Wildlife Res Ctr, Ft Collins, CO 80524 USA.	kim.m.pepin@aphis.usda.gov	Davis, Amy/ABE-2065-2021					[Anonymous], HCSU004 U HAW HIL; [Anonymous], 1996, MANAGING VERTEBRATE; Artois M, 1997, REPROD FERT DEVELOP, V9, P17, DOI 10.1071/R96090; BABER DW, 1986, J MAMMAL, V67, P512, DOI 10.2307/1381283; Baber DW, 1977, SOCIAL ORG BEHAV FER; Barlow ND, 2000, J APPL ECOL, V37, P897, DOI 10.1046/j.1365-2664.2000.00591.x; Barlow ND, 1997, WILDLIFE RES, P24; Barlow ND, 1994, J APPL ECOL, V31; BARRETT RH, 1978, HILGARDIA, V46, P283, DOI 10.3733/hilg.v46n09p283; Barrett RH, 1971, ECOLOGY FERAL HOG TE; Barrios-Garcia MN, 2012, BIOL INVASIONS, V14, P2283, DOI 10.1007/s10530-012-0229-6; Belden Robert C., 1990, Proceedings of the Annual Conference Southeastern Association of Fish and Wildlife Agencies, V44, P231; Bieber C, 2005, J APPL ECOL, V42, P1203, DOI 10.1111/j.1365-2664.2005.01094.x; Burton JL, 2013, US ARMY CORPS ENG ER, P1; Campbell TA, 2009, FOREST ECOL MANAG, V257, P2319, DOI 10.1016/j.foreco.2009.03.036; CAUGHLEY G, 1992, WILDLIFE RES, V19, P623, DOI 10.1071/WR9920623; CHOQUENOT D, 1993, WILDLIFE RES, V20, P15, DOI 10.1071/WR9930015; Choquenot D, 1999, WILDLIFE RES, V26, P251, DOI 10.1071/WR98006; Courchamp F, 2000, J APPL ECOL, V37, P903, DOI 10.1046/j.1365-2664.2000.00545.x; Cowled BD, 2006, J WILDLIFE MANAGE, V70, P1690, DOI 10.2193/0022-541X(2006)70[1690:MTDAGE]2.0.CO;2; Crouch LC, 1983, MOVEMENTS HABITAT UT; Cruz F, 2005, BIOL CONSERV, V121, P473, DOI 10.1016/j.biocon.2004.05.018; Delgado-Acevedo J, 2013, INT J PEST MANAGE, V59, P122, DOI 10.1080/09670874.2013.776723; Dexter N, 1996, WILDLIFE RES, V23, P435, DOI 10.1071/WR9960435; Dexter N, 2015, ECOL EVOL, V5, P2036, DOI 10.1002/ece3.1489; Diong CH, 1982, KIPAHULA VALLEY; Ditchkoff SS, 2012, J WILDLIFE MANAGE, V76, P1235, DOI 10.1002/jwmg.356; Duncan RW, 1974, REPROD BIOL EUROPEAN; Gabor TM, 1999, J ZOOL, V247, P311, DOI 10.1111/j.1469-7998.1999.tb00994.x; Garcelon DK, 2005, P 6 CAL ISL S 2003 D; Gee RW, 2002, AUST VET J, V80, P96, DOI 10.1111/j.1751-0813.2002.tb12850.x; Gentle M, 2013, WILDLIFE RES, V40, P459, DOI 10.1071/WR13100; Gese EM, 2015, BIOL CONSERV, V192, P11, DOI 10.1016/j.biocon.2015.09.003; Gonyou HW, 2001, SOCIAL BEHAV FARM AN; Gunduz A, 2007, WILD ENVIRON MED, V18, P117, DOI 10.1580/06-WEME-CR-033R1.1; Hanson LB, 2009, WILDLIFE RES, V36, P185, DOI 10.1071/WR08077; Hanson LB, 2006, DEMOGRAPHY FERAL PIG; HENRY VG, 1968, J WILDLIFE MANAGE, V32, P406, DOI 10.2307/3798986; Henry VG, 1978, P ANN C SE ASS FISH, V32, P406; HONE J, 1990, AUST WILDLIFE RES, V17, P123, DOI 10.1071/WR9900123; HONE J, 1992, J APPL ECOL, V29, P695, DOI 10.2307/2404478; Hone J, 2002, BIOL CONSERV, V105, P231, DOI 10.1016/S0006-3207(01)00185-9; Hughes TW, 1985, HOME RANGE HABITAT U; ILSE LM, 1995, J MAMMAL, V76, P993, DOI 10.2307/1382593; Ji WH, 2000, J APPL ECOL, V37, P926, DOI 10.1046/j.1365-2664.2000.00546.x; Johnson K.G., 1982, Proceedings of the Annual Conference Southeastern Association of Fish and Wildlife Agencies, V36, P552; Kaminski G, 2005, CAN J ZOOL, V83, P474, DOI 10.1139/Z05-019; KATAHIRA LK, 1993, WILDLIFE SOC B, V21, P269; Kay SL, 2017, MOV ECOL, V5, DOI 10.1186/s40462-017-0105-1; Keuling O, 2010, EUR J WILDLIFE RES, V56, P159, DOI 10.1007/s10344-009-0296-x; Klinger R., 2011, Occasional Papers of the IUCN Species Survival Commission, V42, P78; Lombardo CA, 2000, P 5 CAL ISL S APR WA; Massei G, 2015, PEST MANAG SCI, V71, P492, DOI 10.1002/ps.3965; Mayer JJ, 2009, ENERGY DO; Mccann BE, 2008, J WILDLIFE MANAGE, V72, P1287, DOI 10.2193/2007-164; McLeod SR, 2014, ECOL MODEL, V273, P1, DOI 10.1016/j.ecolmodel.2013.10.016; McMahon CR, 2010, METHODS ECOL EVOL, V1, P53, DOI 10.1111/j.2041-210X.2009.00002.x; Mellish JM, 2014, SOUTHEAST NAT, V13, P367, DOI 10.1656/058.013.0217; Merrill JA, 2006, J WILDLIFE MANAGE, V70, P268, DOI 10.2193/0022-541X(2006)70[268:MAODPB]2.0.CO;2; Miller LA, 2013, J ZOO WILDLIFE MED, V44, pS84, DOI 10.1638/1042-7260-44.4S.S84; Morrison SA, 2007, FRONT ECOL ENVIRON, V5, P271, DOI 10.1890/1540-9295(2007)5[271:FTDAEE]2.0.CO;2; Otto S.P., 2007, BIOLOGISTS GUIDE MAT; Parkes JP, 2010, BIOL CONSERV, V143, P634, DOI 10.1016/j.biocon.2009.11.028; Peine JD, 1990, WILD HOG MANAGEMENT; Ramsey D, 2005, J APPL ECOL, V42, P348, DOI 10.1111/j.1365-2664.2005.01006.x; Rushton SP, 2006, J WILDLIFE MANAGE, V70, P1102, DOI 10.2193/0022-541X(2006)70[1102:EOCFPA]2.0.CO;2; Salinas RA, 2015, NAT RESOUR MODEL, V28, P18, DOI 10.1111/nrm.12055; SAUNDERS G, 1988, AUST WILDLIFE RES, V15, P73, DOI 10.1071/WR9880073; Sims R, W70001135 PWD RP; Smith TN, 2014, WILDLIFE SOC B, V38, P175, DOI 10.1002/wsb.376; Snow NP, 2017, J APPL ECOL IN PRESS; Sparklin BD, 2009, J WILDLIFE MANAGE, V73, P497, DOI 10.2193/2007-585; Steen D., 2006, P 22 VET PEST C, P361; Taylor RB, 1998, J MAMMAL, V79, P1325, DOI 10.2307/1383024; Timmons J., 2012, FERAL HOG POPULATION; West Ben C., 2009, P1; Williams BL, 2011, J WILDLIFE MANAGE, V75, P432, DOI 10.1002/jwmg.64; Wood GW, 1977, RES MANAGEMENT WILD, P23; Yoak AJ, 2016, ECOL MODEL, V341, P53, DOI 10.1016/j.ecolmodel.2016.09.018	79	21	21	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2017	12	8							e0183441	10.1371/journal.pone.0183441	http://dx.doi.org/10.1371/journal.pone.0183441			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7CK	28837610	Green Submitted, Green Published, gold			2023-01-03	WOS:000408365000067
J	Brunner, D; Abramovitch, A; Etherton, J				Brunner, Devon; Abramovitch, Amitai; Etherton, Joseph			A yoga program for cognitive enhancement	PLOS ONE			English	Article							ATTENTION AWARENESS SCALE; WORKING-MEMORY CAPACITY; EXECUTIVE FUNCTION; FLUID INTELLIGENCE; OLDER-ADULTS; MINDFULNESS; POPULATION; STRESS; SPAN; MAAS	Background Recent studies suggest that yoga practice may improve cognitive functioning. Although preliminary data indicate that yoga improves working memory (WM), high-resolution information about the type of WM subconstructs, namely maintenance and manipulation, is not available. Furthermore, the association between cognitive enhancement and improved mindfulness as a result of yoga practice requires empirical examination. The aim of the present study is to assess the impact of a brief yoga program on WM maintenance, WM manipulation and attentive mindfulness. Methods Measures of WM(Digit Span Forward, Backward, and Sequencing, and Letter-Number Sequencing) were administered prior to and following 6 sessions of yoga (N = 43). Additionally, the Mindfulness Attention Awareness Scale was administered to examine the potential impact of yoga practice on mindfulness, as well as the relationships among changes in WM and mindfulness. Results Analyses revealed significant improvement from pre- to post- training assessment on both maintenance WM (Digit Span Forward) and manipulation WM(Digit Span Backward and Letter-Number Sequencing). No change was found on Digit Span Sequencing. Improvement was also found on mindfulness scores. However, no correlation was observed between mindfulness and WM measures. Conclusions A 6-session yoga program was associated with improvement on manipulation and maintenance WM measures as well as enhanced mindfulness scores. Additional research is needed to understand the extent of yoga-related cognitive enhancement and mechanisms by which yoga may enhance cognition, ideally by utilizing randomized controlled trials and more comprehensive neuropsychological batteries.	[Brunner, Devon; Abramovitch, Amitai; Etherton, Joseph] Texas State Univ, Dept Psychol, San Marcos, TX 78666 USA	Texas State University System; Texas State University San Marcos	Brunner, D (corresponding author), Texas State Univ, Dept Psychol, San Marcos, TX 78666 USA.	brunner.devon@gmail.com	Abramovitch, Amitai/AAJ-9762-2021	Abramovitch, Amitai/0000-0001-9640-0970; Brunner, Devon/0000-0002-9690-7103	Texas State University	Texas State University	This study was supported by a grant that was an internal grant for under graduate students from Texas State University (DB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson J, 2000, LEARNING MEMORY; [Anonymous], [No title captured]; Bhatia T, 2016, ACTA NEUROPSYCH 0812, P1; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; Black DS, 2012, ASSESSMENT, V19, P42, DOI 10.1177/1073191111415365; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Brown RP, 2005, J ALTERN COMPLEM MED, V11, P711, DOI 10.1089/acm.2005.11.711; Carlson LE, 2005, J PSYCHOSOM RES, V58, P29, DOI 10.1016/j.jpsychores.2004.04.366; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Chandra S, 2016, BRAIN INFORM; Conway ARA, 2002, INTELLIGENCE, V30, P163, DOI 10.1016/S0160-2896(01)00096-4; Desai R, 2015, COMPLEMENT THER CLIN, V21, P112, DOI 10.1016/j.ctcp.2015.02.002; Hernandez SE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150757; Estevis E, 2012, CLIN NEUROPSYCHOL, V26, P239, DOI 10.1080/13854046.2012.659219; Evans JST, 2003, TRENDS COGN SCI, V7, P454, DOI 10.1016/j.tics.2003.08.012; Frazier TW, 2004, NEUROPSYCHOLOGY, V18, P543, DOI 10.1037/0894-4105.18.3.543; Gard T, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00137; Geyer Jason, 2015, Alzheimers Dement (Amst), V1, P260, DOI 10.1016/j.dadm.2015.04.002; Gothe NP, 2016, BIOL PSYCHOL, V121, P109, DOI 10.1016/j.biopsycho.2016.10.010; Gothe NP, 2015, PSYCHOSOM MED, V77, P784, DOI 10.1097/PSY.0000000000000218; Gothe NP, 2014, J GERONTOL A-BIOL, V69, P1109, DOI 10.1093/gerona/glu095; Hale JB, 2002, J PSYCHOEDUC ASSESS, V20, P128, DOI 10.1177/073428290202000202; Hardy JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134467; Hariprasad VR, 2013, INDIAN J PSYCHIAT, V55, pS357, DOI 10.4103/0019-5545.116308; IMPETT E. A., 2006, SEX RES SOC POL, V3, P39, DOI [DOI 10.1525/SRSP.2006.3.4.39, 10.1525/srsp.2006.3.4.39]; Iyengar BK, 1996, LIGHT YOGA BIBLE MOD; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Jerath R, 2006, MED HYPOTHESES, V67, P566, DOI 10.1016/j.mehy.2006.02.042; Jermann F, 2009, PSYCHOL ASSESSMENT, V21, P506, DOI 10.1037/a0017032; Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438; Kane MJ, 2004, J EXP PSYCHOL GEN, V133, P189, DOI 10.1037/0096-3445.133.2.189; Khalsa S.B.S., 2007, PRINCIPLES PRACTICE, P449; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Leh SE, 2010, NEUROPSYCHOPHARMACOL, V35, P70, DOI 10.1038/npp.2009.88; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; MacKillop J, 2007, J PSYCHOPATHOL BEHAV, V29, P289, DOI 10.1007/s10862-007-9045-1; McCall Marcy C, 2014, Int J Yoga, V7, P4, DOI 10.4103/0973-6131.123470; Mehling WE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048230; Melby-Lervag M, 2016, PERSPECT PSYCHOL SCI, V11, P512, DOI 10.1177/1745691616635612; Melby-Lervag M, 2013, DEV PSYCHOL, V49, P270, DOI 10.1037/a0028228; Nangia D., 2012, J INDIAN ACAD APPL P, V38, P262; Parker MG, 2007, GERONTOLOGIST, V47, P150, DOI 10.1093/geront/47.2.150; Rocha KKF, 2012, CONSCIOUS COGN, V21, P843, DOI 10.1016/j.concog.2012.01.014; Rodgers WL, 2003, J GERONTOL B-PSYCHOL, V58, pS338, DOI 10.1093/geronb/58.6.S338; Salmon P, 2009, COGN BEHAV PRACT, V16, P59, DOI 10.1016/j.cbpra.2008.07.002; Saoji A, 2016, J RELIG HLTH; Saper HB, 2004, ALTERNATIVE THERAPIE, V10; Shepherd GMG, 2013, NAT REV NEUROSCI, V14, P278, DOI 10.1038/nrn3469; Snyder HR, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00328; Subramanya P, 2009, BIOPSYCHOSOC MED, V3, DOI 10.1186/1751-0759-3-8; Theiling J, 2016, J ATTEN DISORD, V20, P913, DOI 10.1177/1087054713518241; Tran M D, 2001, Prev Cardiol, V4, P165, DOI 10.1111/j.1520-037X.2001.00542.x; Waters AJ, 2009, SUBST ABUS, V30, P328, DOI 10.1080/08897070903252080; Wechsler D, 2008, WAIS 4 WECHSLER ADUL; Wiley J, 2011, J EXP PSYCHOL LEARN, V37, P256, DOI 10.1037/a0021613; Woodyard Catherine, 2011, Int J Yoga, V4, P49, DOI 10.4103/0973-6131.85485; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	57	22	23	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2017	12	8							e0182366	10.1371/journal.pone.0182366	http://dx.doi.org/10.1371/journal.pone.0182366			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC6IS	28783749	gold, Green Published, Green Submitted			2023-01-03	WOS:000406944300034
J	Jana, S; Patel, D; Patel, S; Upadhyay, K; Thadani, J; Mandal, R; Das, S; Devkar, R				Jana, Sarmita; Patel, Dipak; Patel, Shweta; Upadhyay, Kapil; Thadani, Jaymesh; Mandal, Rahul; Das, Santasabuj; Devkar, Ranjitsinh			Anthocyanin rich extract of Brassica oleracea L. alleviates experimentally induced myocardial infarction	PLOS ONE			English	Article							INDUCED CARDIAC-FAILURE; OXIDATIVE STRESS; FREE-RADICALS; IDENTIFICATION; CALCIUM; RATS; ANTIOXIDANTS; VEGETABLES; RECEPTOR; ATPASE	Cardioprotective potential of anthocyanin rich red cabbage extract (ARCE) was assessed in H2O2 treated rat neonatal cardiomyoblasts (H9c2 cells) and isoproterenol (ISO) induced rodent model of myocardial infarction. H2O2 treated H9c2 cells recorded cytotoxicity (48-50%) and apoptosis (57.3%), the same were reduced in presence of ARCE (7-10% & 12.3% respectively). Rats pretreated with ARCE for 30 days followed by ISO treatment recorded favourable heart: body weight ratio as compared to ISO treated group. Also, the mRNA levels of enzymatic antioxidants (sod and catalase) and apoptotic genes (bax and bcl-2) in ARCE+ISO treated group were similar to the control group suggesting that ARCE pretreatment prevents ISO induced depletion of enzymatic antioxidants and apoptosis. Histoarchitecture of ventricular tissue of ISO treated group was marked by infracted areas (10%) and derangement of myocardium whereas, ARCE+ISO treated group (4.5%) recorded results comparable to control (0%). ARCE+ISO treated group accounted for upregulation of caveolin-3 and SERCA2a expression as compared to the ISO treated group implying towards ARCE mediated reduction in membrane damage and calcium imbalance. Molecular docking scores and LigPlot analysis of cyanidin-3-glucoside (-8.7 Kcal/mol) and delphinidin-3-glucoside (-8.5 Kcal/mol) showed stable hydrophobic and electrostatic interactions with beta(1) adrenergic receptor. Overall this study elucidates the mechanism of ARCE mediated prevention of experimentally induced myocardial damage.	[Jana, Sarmita; Patel, Dipak; Patel, Shweta; Upadhyay, Kapil; Thadani, Jaymesh; Devkar, Ranjitsinh] Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Zool, Phytotherapeut & Metab Endocrinol Div, Vadodara, India; [Patel, Dipak] Jai Res Fdn, Ecotoxicol Lab, Vapi, India; [Mandal, Rahul; Das, Santasabuj] Natl Inst Cholera & Enter Dis, Biomed Informat Ctr, Kolkata, India	Maharaja Sayajirao University Baroda; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Devkar, R (corresponding author), Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Zool, Phytotherapeut & Metab Endocrinol Div, Vadodara, India.	rv.devkar-zoo@msubaroda.ac.in	Upadhyay, Kapil/AAU-2192-2020	Upadhyay, Kapil/0000-0002-0000-5085; Devkar, Ranjitsinh/0000-0002-9863-7418	University Grant Commission [41-89/2012/SR]	University Grant Commission(University Grants Commission, India)	The authors are thankful to University Grant Commission for providing financial assistance in form of Major Research Project (F.No. 41-89/2012/SR). We are also thankful to the Co-ordinator, DBTMSUB-ILSPARE, for technical support. Help rendered by Dr. Kishore Rajput for microscopy, Ms. Ramadevi Pulipaka and Ms. Kavita Shirsath is also duly acknowledged.	Afroz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6437641; Bers DM, 2008, ANNU REV PHYSIOL, V70, P23, DOI 10.1146/annurev.physiol.70.113006.100455; BLOOM S, 1972, AM J PATHOL, V69, P459; Cassidy A, 2013, CIRCULATION, V127, P188, DOI 10.1161/CIRCULATIONAHA.112.122408; Charron CS, 2007, J AGR FOOD CHEM, V55, P5354, DOI 10.1021/jf0710736; Christopher JA, 2013, J MED CHEM, V56, P3446, DOI 10.1021/jm400140q; Devkar RV, 2012, FOOD FUNCT, V3, P837, DOI 10.1039/c2fo00001f; Draghici G, 2013, MAGNESIUM, V28, P26; Duchnowicz P, 2012, ENVIRON TOXICOL PHAR, V34, P783, DOI 10.1016/j.etap.2012.09.008; Glinska S, 2011, ECOTOX ENVIRON SAFE, V74, P93, DOI 10.1016/j.ecoenv.2010.06.018; Grishko V, 2003, AM J PHYSIOL-HEART C, V285, pH2364, DOI 10.1152/ajpheart.00408.2003; Guo HH, 2012, FOOD CHEM TOXICOL, V50, P3040, DOI 10.1016/j.fct.2012.06.015; Hidalgo M, 2012, GENES NUTR, V7, P295, DOI 10.1007/s12263-011-0263-5; Igarashi K, 2000, BIOSCI BIOTECH BIOCH, V64, P1600, DOI 10.1271/bbb.64.1600; Jadeja RN, 2010, CARDIOVASC TOXICOL, V10, P174, DOI 10.1007/s12012-010-9076-9; Jennings A, 2012, AM J CLIN NUTR, V96, P781, DOI 10.3945/ajcn.112.042036; Jing L, 2015, HEART LUNG CIRC, V24, P602, DOI 10.1016/j.hlc.2014.11.018; Joseph DR, 1908, J EXP MED, V10, P521, DOI 10.1084/jem.10.4.521; Kataya HAH, 2008, EVID-BASED COMPL ALT, V5, P281, DOI 10.1093/ecam/nem029; Lee Y, 2009, APOPTOSIS, V14, P536, DOI 10.1007/s10495-008-0302-x; Li CL, 2006, BIOCHEM BIOPH RES CO, V344, P1135, DOI 10.1016/j.bbrc.2006.04.024; Li CM, 2011, FOOD CHEM TOXICOL, V49, P2090, DOI 10.1016/j.fct.2011.05.022; Lipskaia L, 2010, EXPERT OPIN BIOL TH, V10, P29, DOI 10.1517/14712590903321462; Lipskaia L, 2009, PFLUG ARCH EUR J PHY, V457, P673, DOI 10.1007/s00424-007-0428-7; Lo Scalzo R, 2008, FOOD CHEM, V107, P136, DOI 10.1016/j.foodchem.2007.07.072; Nimse SB, 2015, RSC ADV, V5, P27986, DOI 10.1039/c4ra13315c; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Padmanabhan M, 2006, TOXICOLOGY, V224, P128, DOI 10.1016/j.tox.2006.04.039; Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814; Roth DM, 2011, PEDIATR CARDIOL, V32, P329, DOI 10.1007/s00246-010-9881-8; Sankhari JM, 2012, J SCI FOOD AGR, V92, P1688, DOI 10.1002/jsfa.5532; Santos CXC, 2011, FREE RADICAL BIO MED, V50, P777, DOI 10.1016/j.freeradbiomed.2011.01.003; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shih PH, 2010, J NUTR BIOCHEM, V21, P598, DOI 10.1016/j.jnutbio.2009.03.008; Shim SH, 2012, J MED FOOD, V15, P818, DOI 10.1089/jmf.2012.2241; SINGAL PK, 1982, CAN J PHYSIOL PHARM, V60, P1390, DOI 10.1139/y82-207; Sun X, 2011, J CELL BIOCHEM, V112, P2019, DOI 10.1002/jcb.23121; Thounaojam MC, 2011, J FOOD SCI, V76, pT35, DOI 10.1111/j.1750-3841.2010.01962.x; Thounaojam MC, 2010, J HEALTH SCI, V56, P92, DOI 10.1248/jhs.56.92; Wagner H, 1996, PLANT DRUG ANAL THIN; Wiczkowski W, 2013, FOOD RES INT, V51, P303, DOI 10.1016/j.foodres.2012.12.015; Wu XL, 2005, J AGR FOOD CHEM, V53, P3101, DOI 10.1021/jf0478861; YEAGER JC, 1982, LIFE SCI, V30, P299, DOI 10.1016/0024-3205(82)90512-4; YEAGER JC, 1981, CIRC SHOCK, V8, P151	45	20	21	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2017	12	8							e0182137	10.1371/journal.pone.0182137	http://dx.doi.org/10.1371/journal.pone.0182137			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC3VC	28763488	Green Submitted, Green Published, gold			2023-01-03	WOS:000406766500045
J	Armstrong, NM; Gitlin, LN; Parisi, JM; Carlson, MC; Rebok, GW; Gross, AL				Armstrong, Nicole M.; Gitlin, Laura N.; Parisi, Jeanine M.; Carlson, Michelle C.; Rebok, George W.; Gross, Alden L.			E pluribus unum: Harmonization of physical functioning across intervention studies of middle-aged and older adults	PLOS ONE			English	Article							ITEM RESPONSE THEORY; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; HOME INTERVENTION; DEMENTIA; HEALTH; SCALE; ADL; INDIVIDUALS; RASCH	Common scales for physical functioning are not directly comparable without harmonization techniques, complicating attempts to pool data across studies. Our aim was to provide a standardized metric for physical functioning in adults based on basic and instrumental activities of daily living scaled to NIH PROMIS norms. We provide an item bank to compare the difficulty of various physical functioning activities. We used item response theory methods to place 232 basic and instrumental activities of daily living questions, administered across eight intervention studies of middle-aged and older adults (N = 2,556), on a common metric. We compared the scale's precision to an average z-score of items and evaluated criterion validity based on objective measures of physical functioning and Fried's frailty criteria. Model-estimated item thresholds were widely distributed across the range of physical functioning. From test information plots, the lowest precision in each dataset was 0.80. Using power calculations, the sample size needed to detect 25% physical functional decline with 80% power based on the physical functioning factor was less than half of what would be needed using an average z-score. The physical functioning factor correlated in expected directions with objective measurements from the Timed Up and Go task, tandem balance, gait speed, chair stands, grip strength, and frailty status. Item-level harmonization enables direct comparison of physical functioning measures across existing and potentially future studies and across levels of function using a nationally representative metric. We identified key thresholds of physical functioning items in an item bank to facilitate clinical and epidemiologic decision-making.	[Armstrong, Nicole M.; Gross, Alden L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Armstrong, Nicole M.; Carlson, Michelle C.; Rebok, George W.; Gross, Alden L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21218 USA; [Gitlin, Laura N.] Johns Hopkins Sch Med, Div Geriatr & Gerontol, Dept Med, Baltimore, MD USA; [Gitlin, Laura N.; Parisi, Jeanine M.] Johns Hopkins Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA; [Parisi, Jeanine M.; Carlson, Michelle C.; Rebok, George W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Armstrong, NM (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.; Armstrong, NM (corresponding author), Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21218 USA.	narmstr2@jhu.edu			Johns Hopkins School of Nursing Center for Innovative Care in Aging; Epidemiology and Biostatistics of Aging Training Program, Johns Hopkins Center on Aging and Health [T32AG000247]; National Institute on Aging [R01AG13687, R01 AG041781-01A, P01 AG027735-03, P30-AG021134, P30-AG02113, R37-AG19905]; National Institute on Aging; National Institute on Nursing Research [R01AG22254, AG13305, AG13289, AG13313, AG20277, AG13265, NR004261]; Alzheimer's Association [NPSASA-10-174265]; National Institute of Mental Health [R01 MH079814, RC1MH090770, R21MH069425]; Pennsylvania Department of Health and Tobacco Funds [41000272]; John A. Hartford Foundation; NATIONAL INSTITUTE ON AGING [P50AG005146, T32AG000247] Funding Source: NIH RePORTER	Johns Hopkins School of Nursing Center for Innovative Care in Aging; Epidemiology and Biostatistics of Aging Training Program, Johns Hopkins Center on Aging and Health; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute on Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); Alzheimer's Association(Alzheimer's Association); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Pennsylvania Department of Health and Tobacco Funds; John A. Hartford Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a Pilot Award from the Johns Hopkins School of Nursing Center for Innovative Care in Aging (PI: Gross) and T32AG000247 (Epidemiology and Biostatistics of Aging Training Program, Johns Hopkins Center on Aging and Health) (Armstrong). ABLE was funded by the National Institute on Aging (Grant Number: R01AG13687, PI, Gitlin). ACT was funded by the National Institute on Aging and the National Institute on Nursing Research (Grant Number: R01AG22254, PI, Gitlin). ALZQOL was funded by Alzheimer's Association (Grant Number: NPSASA-10-174265, PI, Gitlin). Beat the Blues (BTB) was funded by the National Institute of Mental Health (Grant Numbers: R01 MH079814, RC1MH090770, PI, Gitlin). COPE was funded by the Pennsylvania Department of Health and Tobacco Funds (Grant Number: SAP#41000272, PI, Gitlin). REACH II was funded by the National Institute on Aging and the National Institute on Nursing Research (AG13305, AG13289, AG13313, AG20277, AG13265, NR004261, PI, Gitlin). TAP was funded by the National Institute of Mental Health (Grant Number: R21MH069425) and currently by the National Institute on Aging (Grant Number: R01 AG041781-01A). BECT was funded by the National Institute on Aging (P01 AG027735-03 and P30-AG021134), the John A. Hartford Foundation, and the Johns Hopkins Older Americans Independence Center under the National Institute on Aging (P30-AG02113 and R37-AG19905). Role of Sponsors/Funders: The contents do not necessarily represent views of the funding entities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASBERG KH, 1989, SCAND J REHABIL MED, V21, P171; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Bjorner JB, 1998, J CLIN EPIDEMIOL, V51, P1189, DOI 10.1016/S0895-4356(98)00111-5; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BORTZ WM, 1993, J AM GERIATR SOC, V41, P1004; BUJA A, 1992, MULTIVAR BEHAV RES, V27, P509, DOI 10.1207/s15327906mbr2704_2; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Fieo RA, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-42; Fisher W P Jr, 1997, J Outcome Meas, V1, P329; Fried LP, 2013, CONTEMP CLIN TRIALS, V36, P1, DOI 10.1016/j.cct.2013.05.003; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gitlin L., 2005, PHYS FUNCTION OLDER; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2014, AM J GERIAT PSYCHIAT, V22, P587, DOI 10.1016/j.jagp.2012.11.005; Gitlin LN, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-4; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2009, GERONTOLOGIST, V49, P428, DOI 10.1093/geront/gnp087; Gitlin LN, 2009, J AM GERIATR SOC, V57, P476, DOI 10.1111/j.1532-5415.2008.02147.x; Gitlin LN, 2005, J AGING HEALTH, V17, P148, DOI 10.1177/0898264304274184; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Gross AL, 2015, PSYCHOL AGING, V30, P863, DOI 10.1037/pag0000032; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Jenkinson C, 2001, J NEUROL NEUROSUR PS, V71, P220, DOI 10.1136/jnnp.71.2.220; JORESKOG KG, 1975, J AM STAT ASSOC, V70, P631, DOI 10.2307/2285946; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Liu H., 2009, J CLIN EPIDEMIOL, V63, P1169, DOI DOI 10.1016/J.JCLINEPI.2009.11.021]; Lord FM, 1953, EDUC PSYCHOL MEAS, V13, P517, DOI 10.1177/001316445301300401; Mathews CE, 2012, EXERC SPORT SCI REV, V40, P118, DOI 10.1097/JES.0b013e31825b34a0; Muthen L. K., 2010, MPLUS USERS GUIDE, V6th; Raczek AE, 1998, J CLIN EPIDEMIOL, V51, P1203, DOI 10.1016/S0895-4356(98)00112-7; Rose M, 2008, J CLIN EPIDEMIOL, V61, P17, DOI 10.1016/j.jclinepi.2006.06.025; Rose M, 2014, J CLIN EPIDEMIOL, V67, P516, DOI 10.1016/j.jclinepi.2013.10.024; Stewart AL, 1992, MEASURING FUNCTIONIN, P86; TAKANE Y, 1987, PSYCHOMETRIKA, V52, P393, DOI 10.1007/BF02294363; Tonner M Christine, 2004, Home Health Care Serv Q, V22, P65, DOI 10.1300/J027v22n04_04; Tsuji T, 1995, AM J PHYS MED REHAB, V74, P432, DOI 10.1097/00002060-199511000-00007; VANDERHEIDE A, 1993, ANN RHEUM DIS, V52, P497, DOI 10.1136/ard.52.7.497; Woods CM, 2009, APPL PSYCH MEAS, V33, P42, DOI 10.1177/0146621607314044	45	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2017	12	7							e0181746	10.1371/journal.pone.0181746	http://dx.doi.org/10.1371/journal.pone.0181746			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC1ED	28753644	Green Submitted, gold, Green Published			2023-01-03	WOS:000406579300024
J	Clark, WR; Ding, XQ; Qiu, HB; Ni, ZH; Chang, P; Fu, P; Xu, JR; Wang, MM; Yang, L; Wang, J; Ronco, C				Clark, William R.; Ding, Xiaoqiang; Qiu, Haibo; Ni, Zhaohui; Chang, Ping; Fu, Ping; Xu, Jiarui; Wang, MinMin; Yang, Li; Wang, Jing; Ronco, Claudio			Renal replacement therapy practices for patients with acute kidney injury in China	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; RANDOMIZED CLINICAL-TRIAL; INTENSIVE-CARE-UNIT; CONTINUOUS HEMOFILTRATION; SURVIVAL; DIALYSIS; FAILURE; NOMENCLATURE; RECOVERY; SCORE	Recent data indicate AKI is very common among hospitalized Chinese patients and continuous renal replacement therapy (CRRT) is increasingly offered for treatment. However, only anecdotal information regarding CRRT's use in relation to other modalities and the specific manner in which it is prescribed exists currently. This report summarizes the results of a comprehensive physician survey designed to characterize contemporary dialytic management of AKI patients in China, especially with respect to the utilization of CRRT. The survey queried both nephrologists and critical care physicians across a wide spectrum of hospitals about factors influencing initial RRT modality selection, especially patient clinical characteristics and willingness to receive RRT, treatment location, and institutional capabilities. For patients initially treated with CRRT, data related to indication, timing of treatment initiation, dose, anticoagulation technique, and duration of therapy were also collected. Among AKI patients considered RRT candidates, the survey indicated 15.1% (95% CI, 12.3%-17.9%) did not actually receive dialysis at Chinese hospitals. The finding was largely attributed to prohibitively high therapy costs in the view of patients or their families. The survey confirmed the dichotomy in RRT delivery in China, occurring both in the nephrology department (with nephrologists responsible) and the intensive care unit (with critical care physicians responsible). For all patients who were offered and received RRT, the survey participants reported 63.9% (56.4%-71.3%) were treated initially with CRRT and 24.8% (19.2%-30.3%) with intermittent hemodialysis (HD) (P<0.001). The mean percentage of patients considered hemodynamically unstable at RRT initiation was 36.2% (31.3%-41.1%), although this figure was two-fold higher in patients treated initially with CRRT (43.1%; 35.8%-50.4%) in comparison to those initially treated with HD (22.4%; 16.4%-28.4%)(P<0.001). An overwhelming majority of intensive care patients were treated initially with CRRT (86.6%; 79.8-93.4%) while it was the initial modality in only 44.6% (33.5-55.7%) of patients treated in a nephrology department (P<0.001). Approximately 70% of respondents overall reported prescribing a CRRT dose in the range of 20-30 mL/kg/hr while approximately 20% of prescriptions fell above this range. Daily prescribed therapy duration demonstrated a marked divergence from values reported in the literature and standard clinical practice. Overall, the most common average prescribed value (50% of respondents) fell in the 10-20 hr range, with only 18% in the 20-24 hr range. Moreover, 32% of respondents reported an average prescribed value of less than 10 hrs per day. While the percentages for the 10-20 hrs range were essentially the same for nephrology and ICU programs, a daily duration of less than 10 hrs was much more common in nephrology programs (48.0%; 38.3%-57.9%) versus ICU programs (16%; 10.0%-24.6%)(P<0.001). Our analysis demonstrates both similarities and differences between RRT practices for AKI in China and those in the developed world. While some differences are driven by non-medical factors, future studies should explore these issues further as Chinese RRT practices are harmonized with those in the rest of the world.	[Clark, William R.] Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN 47907 USA; [Ding, Xiaoqiang; Xu, Jiarui] Fudan Univ, Zhongshan Hosp, Dept Nephrol, Shanghai, Peoples R China; [Ding, Xiaoqiang; Xu, Jiarui] Shanghai Inst Kidney Dis & Dialysis, Shanghai Qual Control Ctr Dialysis, Shanghai, Peoples R China; [Qiu, Haibo] Southeast Univ, Nanjing Zhongda Hosp, Dept Crit Care Med, Nanjing, Jiangsu, Peoples R China; [Ni, Zhaohui] Shanghai Jiao Tong Univ, Renji Hosp, Dept Nephrol, Sch Med, Shanghai, Peoples R China; [Fu, Ping] Southern Med Univ, Zhujiang Hosp, Dept ICU, Guangzhou, Guangdong, Peoples R China; [Fu, Ping] Sichuan Univ, Div Nephrol, West China Hosp, Chengdu, Peoples R China; [Wang, MinMin; Yang, Li] Baxter Healthcare, Shanghai, Peoples R China; [Wang, Jing] Guanlan Networks CO LTD, Hangzhou, Zhejiang, Peoples R China; [Ronco, Claudio] San Bortolo Hosp, IRRIV, Vicenza, Italy; [Ronco, Claudio] San Bortolo Hosp, Dept Nephrol, Vicenza, Italy	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Fudan University; Southeast University - China; Shanghai Jiao Tong University; Southern Medical University - China; Sichuan University; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Clark, WR (corresponding author), Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN 47907 USA.	clarkw@purdue.edu	Qiu, Haibo/AAS-9047-2021; Wang, Minmin/AAR-3106-2021; xu, jia/GSD-6347-2022	Qiu, Haibo/0000-0001-8589-4717; Wang, Minmin/0000-0002-7556-2601; Ronco, Claudio/0000-0002-6697-4065	Baxter Healthcare	Baxter Healthcare	The study was supported by a grant from Baxter Healthcare to DXY.cn (GUANLAN NETWORKS (HANGZHOU) CO., Ltd., Hangzhou, China). The grantee at Guanlan Networks CO., LTD. was Dr. Jing Wang. Baxter Healthcare and Guanlan Networks CO., Ltd. provided support in the form of salaries for authors MW, YL, and JW. The funders did not have an additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Akhoundi A, 2015, BLOOD PURIFICAT, V39, P333, DOI 10.1159/000380903; [Anonymous], 2015, MEDICAL DEVICES MARK; Bagshaw SM, 2016, NAT REV NEPHROL, V12, P445, DOI 10.1038/nrneph.2016.92; Bell M, 2007, INTENS CARE MED, V33, P773, DOI 10.1007/s00134-007-0590-6; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; Clark WR, 2004, CONTRIB NEPHROL, V144, P264; Del Granado R Claure-, 2016, BMC NEPHROL, V17, P109; Fang Y, 2015, HEMODIAL INT, V19, P2, DOI 10.1111/hdi.12193; Fang Y, 2010, BLOOD PURIFICAT, V30, P120, DOI 10.1159/000319972; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Foland JA, 2004, CRIT CARE MED, V32, P1771, DOI 10.1097/01.CCM.0000132897.52737.49; Garzotto F, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1355-9; HM Oudemans-van Straaten, 2014, CRIT CARE, V18, P661; Hsu RK, 2013, J AM SOC NEPHROL, V24, P37, DOI 10.1681/ASN.2012080800; KDIGO, 2012, KIDNEY INT S, V2; Lombardi R, 2014, NEPHROL DIAL TRANSPL, V29, P1369, DOI 10.1093/ndt/gfu078; Lu RH, 2014, BLOOD PURIFICAT, V38, P140, DOI 10.1159/000366127; Mehta RL, 2001, KIDNEY INT, V60, P1154, DOI 10.1046/j.1523-1755.2001.0600031154.x; National health and family planning commission of the People's Republic of China, 2015, STAT YB CHIN HLTH FA; Neri M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1489-9; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Pickkers P, 2017, INTENSIVE CARE MED; Rewa OG, 2016, INTENSIVE CARE MED; Ronco C, 2007, INT J ARTIF ORGANS, V30, P89, DOI 10.1177/039139880703000202; Ronco C, 2007, CLIN J AM SOC NEPHRO, V2, P597, DOI 10.2215/CJN.00430107; Saudan P, 2006, KIDNEY INT, V70, P1312, DOI 10.1038/sj.ki.5001705; Vaara ST, 2016, KIDNEY INT, V89, P200, DOI [10.1016/j.kint.2015.12.007, 10.1038/ki.2015.269]; Vaara ST, 2014, CLIN J AM SOC NEPHRO, V9, P1577, DOI 10.2215/CJN.12691213; Vaara ST, 2012, CRIT CARE, V16, DOI 10.1186/cc11682; Vanholder R, 2011, CRIT CARE, V15, DOI 10.1186/cc9345; Vesconi S, 2009, CRIT CARE, V13, DOI 10.1186/cc7784; Villa G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1456-5; Wang YM, 2016, CONTRIB NEPHROL, V187, P1, DOI 10.1159/000443008; Yang L, 2015, LANCET, V386, P1465, DOI 10.1016/S0140-6736(15)00344-X; Zaragoza JJ, 2015, BLOOD PURIFICAT, V39, P246, DOI 10.1159/000381009; Zhang P, 2012, NEPHROL DIAL TRANSPL, V27, P967, DOI 10.1093/ndt/gfr486; Zhu H, 2016, CHINESE HLTH SERVICE, V33, P512	39	13	14	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0178509	10.1371/journal.pone.0178509	http://dx.doi.org/10.1371/journal.pone.0178509			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28692694	Green Published, Green Submitted, gold			2023-01-03	WOS:000405544800004
J	Houston, DMJ; Bugert, JJ; Denyer, SP; Heard, CM				Houston, David M. J.; Bugert, Joachim J.; Denyer, Stephen P.; Heard, Charles M.			Potentiated virucidal activity of pomegranate rind extract (PRE) and punicalagin against Herpes simplex virus (HSV) when co-administered with zinc (II) ions, and antiviral activity of PRE against HSV and aciclovir-resistant HSV	PLOS ONE			English	Article							ACID; ELLAGITANNINS; REPLICATION; HUSK	Background There is a clinical need for new therapeutic products against Herpes simplex virus (HSV). The pomegranate, fruit of the tree Punica granatum L, has since ancient times been linked to activity against infection. This work probed the activity of pomegranate rind extract (PRE) and co-administered zinc (II) ions. Materials and methods PRE was used in conjunction with zinc (II) salts to challenge HSV-1 and aciclovir-resistant HSV in terms of virucidal plaque assay reduction and antiviral activities in epithelial Vero host cells. Cytotoxicity was determined by the MTS assay using a commercial kit. Results Zinc sulphate, zinc citrate, zinc stearate and zinc gluconate demonstrated similar potentiated virucidal activity with PRE against HSV-1 by up to 4-fold. A generally parabolic relationship was observed when HSV-1 was challenged with PRE and varying concentrations of ZnSO4, with a maximum potentiation factor of 5.5. Punicalagin had 8-fold greater virucidal activity than an equivalent mass of PRE. However, antiviral data showed that punicalagin had significantly lower antiviral activity compared to the activity of PRE (EC50 = 0.56 mu g mL(-1)) a value comparable to aciclovir (EC50 = 0.18 mu g mL(-1)); however, PRE also demonstrated potency against aciclovir-resistant HSV (EC50 = 0.02 mu mL(-1)), whereas aciclovir showed no activity. Antiviral action of PRE was not influenced by ZnSO4. No cytotoxicity was detected with any test solution. Conclusions The potentiated virucidal activity of PRE by coadministered zinc (II) has potential as a multiaction novel topical therapeutic agent against HSV infections, such as coldsores.	[Houston, David M. J.; Denyer, Stephen P.; Heard, Charles M.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, S Glam, Wales; [Houston, David M. J.; Bugert, Joachim J.] Cardiff Univ, Sch Med, Dept Microbiol & Infect Dis, Cardiff, S Glam, Wales; [Bugert, Joachim J.] Inst Mikrobiol Bundeswehr, Neuherbergstr 11, Munich, Germany; [Denyer, Stephen P.] Univ Brighton, Mithras House,Lewes Rd, Brighton, E Sussex, England	Cardiff University; Cardiff University; University of Brighton	Heard, CM (corresponding author), Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, S Glam, Wales.	heard@cardiff.ac.uk	Bugert, Joachim/AAK-6459-2021; Heard, Charles/O-3362-2014; Bugert, Joachim Jakob/D-1705-2012	Heard, Charles/0000-0001-9703-9777; Bugert, Joachim Jakob/0000-0002-0556-3211	Welsh Assembly Government [RESSA07-03-013]	Welsh Assembly Government	This work was funded by the Welsh Assembly Government RESSA07-03-013.	Aranha-Creado H, 1999, PDA J PHARM SCI TECH, V53, P75; Arens M, 2000, J CLIN MICROBIOL, V38, P1758, DOI 10.1128/JCM.38.5.1758-1762.2000; Braga LKA, 2011, AFR J PHARM PHARMACO, V5, P2145, DOI 10.5897/AJPP11.414; Cam M, 2009, FOOD CHEM, V112, P721, DOI 10.1016/j.foodchem.2008.06.009; Colombo E, 2013, EVIDENCE BASED COMPL; Corao GMD, 2001, THESIS; Ekambaram SP, 2016, PHYTOTHER RES, V30, P1035, DOI 10.1002/ptr.5616; Golstein J, 1996, J ENDOCRINOL INVEST, V19, P119, DOI 10.1007/BF03349847; Greenwood N.N., 1997, CHEM ELEMENTS, Vsecond; Hobden JA, 2011, INVEST OPHTH VIS SCI, V52, P830, DOI 10.1167/iovs.10-5671; Houston DMJ, 2017, EUR J PHARM BIOPHARM, V112, P30, DOI 10.1016/j.ejpb.2016.11.014; Houston DMJ, 2017, EUR J PHARM SCI, V96, P99, DOI 10.1016/j.ejps.2016.08.013; Houston DM, 2011, THESIS; Hulisz Darrell, 2004, J Am Pharm Assoc (2003), V44, P594, DOI 10.1331/1544-3191.44.5.594.Hulisz; Kenney J, 2013, ANTIMICROB AGENTS CH, V57, P4001, DOI 10.1128/AAC.00796-13; KUMEL G, 1990, J GEN VIROL, V71, P2989, DOI 10.1099/0022-1317-71-12-2989; Lin LT, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-187; Lin LT, 2011, J VIROL, V85, P4386, DOI 10.1128/JVI.01492-10; Lopes GKB, 1999, BBA-GEN SUBJECTS, V1472, P142, DOI 10.1016/S0304-4165(99)00117-8; Lu JJ, 2007, J CHROMATOGR B, V857, P175, DOI 10.1016/j.jchromb.2007.06.038; Mahajan B B, 2013, Indian J Sex Transm Dis AIDS, V34, P32, DOI 10.4103/0253-7184.112867; Murthy KNC, 2002, J AGR FOOD CHEM, V50, P4791, DOI 10.1021/jf0255735; Nagai T, 1993, ANTIVIR RES, V21, P289; Negi P.S., 2003, FOOD MICROBIOL SAF, V68, P1136; Neurath AR, 2005, ANN NY ACAD SCI, V1056, P311, DOI 10.1196/annals.1352.015; Patel C, 2008, FOOD CHEM TOXICOL, V46, P2728, DOI 10.1016/j.fct.2008.04.035; Pieren M, 2012, CURR OPIN PHARMACOL, V12, P551, DOI 10.1016/j.coph.2012.07.005; Piret J, 2011, ANTIMICROB AGENTS CH, V55, P459, DOI 10.1128/AAC.00615-10; Qiu M, 2013, ANTIVIR RES, V100, P44, DOI 10.1016/j.antiviral.2013.07.001; Sanchez-Lamar A, 2008, J ETHNOPHARMACOL, V115, P416, DOI 10.1016/j.jep.2007.10.011; Sarisky RT, 2001, CLIN INFECT DIS, V33, P2034, DOI 10.1086/338046; Seeram N, 2005, SEP PURIF TECHNOL, V41, P49, DOI 10.1016/j.seppur.2004.04.003; Seeram NP, 2005, J NUTR BIOCHEM, V16, P360, DOI 10.1016/j.jnutbio.2005.01.006; Seeram NP, 2006, POMEGRANATES ANCIENT, P193; Stewart GSAB, 1998, J APPL MICROBIOL, V84, P777, DOI 10.1046/j.1365-2672.1998.00408.x; Vilhelmova-Ilieva N, 2014, ANTIVIR RES, V110, P104, DOI 10.1016/j.antiviral.2014.07.017; Wei ZY, 2012, VET MICROBIOL, V160, P468, DOI 10.1016/j.vetmic.2012.06.019	37	32	35	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2017	12	6							e0179291	10.1371/journal.pone.0179291	http://dx.doi.org/10.1371/journal.pone.0179291			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3KB	28665969	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000404608700032
J	Jiang, XN; Yu, BH; Wang, WG; Zhou, XY; Li, XQ				Jiang, Xiang-Nan; Yu, Bao-Hua; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu			Anaplastic lymphoma kinase-positive large B-cell lymphoma: Clinico-pathological study of 17 cases with review of literature	PLOS ONE			English	Article							ALK FUSION; COMPLEX KARYOTYPE; NPM-ALK; REARRANGEMENTS; STAT3; IDENTIFICATION; TRANSLOCATION; SEC31A-ALK; SQSTM1-ALK; INHIBITOR	We retrospectively analysed 17 cases of anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+, LBCL) according to the morphological, immunohistochemical, molecular and clinical features, using which we intend to elucidate the clinicopathological characteristics of this rare entity. In this study, all cases de facto share common features that defined them as a single entity, and various characteristics may expand the spectrum. Among 15 cases, 60% followed an aggressive clinical course with advanced stage and high IPI scores; the median survival of these patients was only 8 months. An analysis showed that both the IPI score and the Ann Arbor stage were significant prognostic factors. Most patients received a chemotherapy regimen including CHOP, CHOEP, EPOCH, and CVAD, and some also underwent localized radiotherapy. However, ALK+, LBCL cases display a dismal clinical outcome and can only be cured with conventional chemotherapy protocols at the stage of localized disease. Novel front-line intensive chemotherapy regimens should therefore be evaluated in this group of patients.	[Jiang, Xiang-Nan; Yu, Bao-Hua; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Jiang, Xiang-Nan; Yu, Bao-Hua; Wang, Wei-Ge; Zhou, Xiao-Yan; Li, Xiao-Qiu] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Fudan University; Fudan University	Li, XQ (corresponding author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Li, XQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	leexiaoqiu@hotmail.com			Guide Project of Science and Technology Commission of Shanghai Municipality [134119a5000]	Guide Project of Science and Technology Commission of Shanghai Municipality	This study was supported by a grant from the Guide Project of Science and Technology Commission of Shanghai Municipality (No. 134119a5000). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam P, 2003, AM J SURG PATHOL, V27, P1473, DOI 10.1097/00000478-200311000-00012; [Anonymous], 2013, VYSIS ALK BREAK APAR; Bedwell C, 2011, HAEMATOL-HEMATOL J, V96, P343, DOI 10.3324/haematol.2010.031484; Beltran B, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-11; Cerchietti L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018436; Chen YP, 2013, EUR J HAEMATOL, V90, P261, DOI 10.1111/ejh.12031; Cheng MG, 2012, MOL CANCER THER, V11, P670, DOI 10.1158/1535-7163.MCT-11-0776; d'Amore ESG, 2013, AM J SURG PATHOL, V37, P780, DOI 10.1097/PAS.0b013e318287791f; De Paepe P, 2003, BLOOD, V102, P2638, DOI 10.1182/blood-2003-04-1050; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Gascoyne RD, 2003, BLOOD, V102, P2568, DOI 10.1182/blood-2003-03-0786; Laurent C, 2009, J CLIN ONCOL, V27, P4211, DOI 10.1200/JCO.2008.21.5020; Lee HW, 2008, HEMATOL ONCOL, V26, P108, DOI 10.1002/hon.841; Li K, 2011, INT J CLIN EXP PATHO, V4, P190; Momose S, 2009, HUM PATHOL, V40, P75, DOI 10.1016/j.humpath.2008.06.009; Morgan Elizabeth A, 2012, Adv Hematol, V2012, P529572, DOI 10.1155/2012/529572; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Pan ZG, 2017, AM J SURG PATHOL, V41, P25, DOI 10.1097/PAS.0000000000000753; Rudzki Zbigniew, 2005, Polish Journal of Pathology, V56, P37; Shi M, 2011, HUM PATHOL, V42, P1562, DOI 10.1016/j.humpath.2011.01.012; Stachurski D, 2007, HUM PATHOL, V38, P940, DOI 10.1016/j.humpath.2006.12.019; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Takeuchi K, 2011, HAEMATOL-HEMATOL J, V96, P464, DOI 10.3324/haematol.2010.033514; Valera A, 2013, MODERN PATHOL, V26, P1329, DOI 10.1038/modpathol.2013.73; Van Roosbroeck K, 2010, HAEMATOL-HEMATOL J, V95, P509, DOI 10.3324/haematol.2009.014761; Wang Wei-ya, 2006, Zhonghua Bing Li Xue Za Zhi, V35, P529; Wass M, 2014, EUR J HAEMATOL, V92, P268, DOI 10.1111/ejh.12240; Yu Hong, 2011, Chinese Journal of Pathology, V40, P561, DOI 10.3760/cma.j.issn.0529-5807.2011.08.016	29	7	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2017	12	6							e0178416	10.1371/journal.pone.0178416	http://dx.doi.org/10.1371/journal.pone.0178416			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3KB	28665943	Green Submitted, Green Published, gold			2023-01-03	WOS:000404608700001
J	Tonelli, MR; Shirts, BH				Tonelli, Mark R.; Shirts, Brian H.			Knowledge for Precision Medicine Mechanistic Reasoning and Methodological Pluralism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-PRACTICE; VARIANTS; GENETICS; GENOMICS		[Tonelli, Mark R.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Tonelli, Mark R.] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98195 USA; [Shirts, Brian H.] Univ Washington, Dept Lab Med, NW120,1959 NE Pacific St,POB 357110, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shirts, BH (corresponding author), Univ Washington, Dept Lab Med, NW120,1959 NE Pacific St,POB 357110, Seattle, WA 98195 USA.	shirtsb@uw.edu		Shirts, brian/0000-0002-7188-6764	National Institutes of Health [R21HG008513, 5P30 CA015704-39]; Damon Runyon Cancer Research Foundation [DRR-33-15]; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG008513] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Dr Shirts's research is supported by grants from the National Institutes of Health (R21HG008513, 5P30 CA015704-39) and the Damon Runyon Cancer Research Foundation (DRR-33-15).	Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Feero WG, 2017, JAMA-J AM MED ASSOC, V317, P1842, DOI 10.1001/jama.2016.20625; Nardini C, 2012, J EVAL CLIN PRACT, V18, P1000, DOI 10.1111/j.1365-2753.2012.01907.x; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Shirts BH, 2016, TRENDS MOL MED, V22, P925, DOI 10.1016/j.molmed.2016.09.007; Solomon M., 2015, MAKING MED KNOWLEDGE; Tonelli MR, 2006, J EVAL CLIN PRACT, V12, P248, DOI 10.1111/j.1365-2753.2004.00551.x	7	35	37	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 7	2017	318	17					1649	1650		10.1001/jama.2017.11914	http://dx.doi.org/10.1001/jama.2017.11914			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM0CW	29052713				2023-01-03	WOS:000414627500010
J	Silvers, MA; Deja, S; Singh, N; Egnatchik, RA; Sudderth, J; Luo, XQ; Beg, MS; Burgess, SC; DeBerardinis, RJ; Boothman, DA; Merritt, ME				Silvers, Molly A.; Deja, Stanislaw; Singh, Naveen; Egnatchik, Robert A.; Sudderth, Jessica; Luo, Xiuquan; Beg, Muhammad S.; Burgess, Shawn C.; DeBerardinis, Ralph J.; Boothman, David A.; Merritt, Matthew E.			The NQO1 bioactivatable drug, -lapachone, alters the redox state of NQO1+pancreatic cancer cells, causing perturbation in central carbon metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						anaerobic glycolysis; drug metabolism; energy metabolism; isotopic tracer; nicotinamide adenine dinucleotide (NAD); nuclear magnetic resonance (NMR); oxidation-reduction (redox); oxidative stress; pyruvate; pyruvate dehydrogenase complex (PDC)	OXIDOREDUCTASE(1) DT-DIAPHORASE; BETA-LAPACHONE; PANCREATIC-CANCER; MAGNETIC-RESONANCE; C-13 NMR; EXPRESSION; GROWTH; APOPTOSIS; BIOMARKER; EXCHANGE	Many cancer treatments, such as those for managing recalcitrant tumors like pancreatic ductal adenocarcinoma, cause off-target toxicities in normal, healthy tissue, highlighting the need for more tumor-selective chemotherapies. -Lapachone is bioactivated by NAD(P)H:quinone oxidoreductase 1 (NQO1). This enzyme exhibits elevated expression in most solid cancers and therefore is a potential cancer-specific target. -Lapachone's therapeutic efficacy partially stems from the drug's induction of a futile NQO1-mediated redox cycle that causes high levels of superoxide and then peroxide formation, which damages DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD(+)/ATP depletion. However, the effects of this drug on energy metabolism due to NAD(+) depletion were never described. The futile redox cycle rapidly consumes O-2, rendering standard assays of Krebs cycle turnover unusable. In this study, a multimodal analysis, including metabolic imaging using hyperpolarized pyruvate, points to reduced oxidative flux due to NAD(+) depletion after -lapachone treatment of NQO1+ human pancreatic cancer cells. NAD(+)-sensitive pathways, such as glycolysis, flux through lactate dehydrogenase, and the citric acid cycle (as inferred by flux through pyruvate dehydrogenase), were down-regulated by -lapachone treatment. Changes in flux through these pathways should generate biomarkers useful for in vivo dose responses of -lapachone treatment in humans, avoiding toxic side effects. Targeting the enzymes in these pathways for therapeutic treatment may have the potential to synergize with -lapachone treatment, creating unique NQO1-selective combinatorial therapies for specific cancers. These findings warrant future studies of intermediary metabolism in patients treated with -lapachone.	[Silvers, Molly A.; Singh, Naveen; Luo, Xiuquan; Boothman, David A.] Simmons Comprehens Canc Ctr, Dept Pharmacol, Dallas, TX 75390 USA; [Silvers, Molly A.; Singh, Naveen; Luo, Xiuquan; Boothman, David A.] Simmons Comprehens Canc Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; [Deja, Stanislaw; Burgess, Shawn C.] Simmons Comprehens Canc Ctr, Adv Imaging Res Ctr AIRC, Div Metab Mech Dis, Dallas, TX 75390 USA; [Egnatchik, Robert A.; Sudderth, Jessica; DeBerardinis, Ralph J.] Simmons Comprehens Canc Ctr, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA; [Beg, Muhammad S.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Merritt, Matthew E.] Univ Texas Southwestern Med Ctr Dallas, AIRC, Dallas, TX 75390 USA; [Merritt, Matthew E.] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; State University System of Florida; University of Florida	Boothman, DA (corresponding author), Simmons Comprehens Canc Ctr, Dept Pharmacol, Dallas, TX 75390 USA.; Boothman, DA (corresponding author), Simmons Comprehens Canc Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA.; Merritt, ME (corresponding author), Univ Texas Southwestern Med Ctr Dallas, AIRC, Dallas, TX 75390 USA.; Merritt, ME (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.	David.Boothman@utsouthwestern.edu; matthewmerritt@ufl.edu	Deja, Stanislaw/AAI-7526-2020; Boothman, David/Q-7776-2019	Deja, Stanislaw/0000-0002-7714-2547; Merritt, Matthew/0000-0003-4617-9651; Singh, Naveen/0000-0003-3465-8591	Robert A. Welch Foundation [I-1804]; National Institutes of Health [P41 EB015908, R01DK078184, R01CA157996-06]; AACR/PanCan Rising Tide Grant [14-65-25-BOOT]; NCI, National Institutes of Health [R01CA102792-19, R01CA221158-01]; NATIONAL CANCER INSTITUTE [R01CA157996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK097209, R01DK105346, R01DK087977, R01DK078184] Funding Source: NIH RePORTER	Robert A. Welch Foundation(The Welch Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR/PanCan Rising Tide Grant; NCI, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Robert A. Welch Foundation Grant I-1804 and National Institutes of Health Grant P41 EB015908.; Supported by National Institutes of Health Grant R01DK078184.; Supported by National Institutes of Health Grant R01CA157996-06.; Supported by AACR/PanCan Rising Tide Grant 14-65-25-BOOT and NCI, National Institutes of Health, Grants R01CA102792-19 and R01CA221158-01. To whom correspondence may be addressed. E-mail: David.Boothman@utsouthwestern.edu.	Allison SJ, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.16; Awadallah NS, 2008, APPL IMMUNOHISTO M M, V16, P24, DOI 10.1097/pai.0b013e31802e91d0; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; Bentle MS, 2006, J BIOL CHEM, V281, P33684, DOI 10.1074/jbc.M603678200; Bey E. A., 2016, STRATEGIES ENHANCE T, P225; Bey EA, 2007, P NATL ACAD SCI USA, V104, P11832, DOI 10.1073/pnas.0702176104; Bey EA, 2013, MOL CANCER THER, V12, P2110, DOI 10.1158/1535-7163.MCT-12-0962; Cao LF, 2014, ANTIOXID REDOX SIGN, V21, P237, DOI 10.1089/ars.2013.5462; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarti G, 2015, SCI REP-UK, V5, DOI 10.1038/srep17066; Chakrabarti G, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0137-1; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; Cunningham CH, 2016, CIRC RES, V119, P1177, DOI 10.1161/CIRCRESAHA.116.309769; DAWSON DM, 1964, SCIENCE, V143, P929, DOI 10.1126/science.143.3609.929; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Dong Y, 2010, CANCER RES, V70, P8088, DOI 10.1158/0008-5472.CAN-10-1418; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Harrison C, 2012, NMR BIOMED, V25, P1286, DOI 10.1002/nbm.2801; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hill DK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071996, 10.1371/journal.pone.0074627]; Huang XM, 2016, CANCER CELL, V30, P940, DOI 10.1016/j.ccell.2016.11.006; Huang XM, 2012, CANCER RES, V72, P3038, DOI 10.1158/0008-5472.CAN-11-3135; JOSEPH P, 1994, ONCOL RES, V6, P525; Kern SE, 2011, J PATHOL, V223, P295, DOI 10.1002/path.2813; Keshari KR, 2013, CANCER RES, V73, P529, DOI 10.1158/0008-5472.CAN-12-3461; Kettunen MI, 2010, MAGN RESON MED, V63, P872, DOI 10.1002/mrm.22276; Khemtong C, 2015, MAGN RESON MED, V74, P312, DOI 10.1002/mrm.25419; Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205; Li LS, 2011, CLIN CANCER RES, V17, P275, DOI 10.1158/1078-0432.CCR-10-1983; Logsdon CD, 2003, CANCER RES, V63, P2649; Lumata L, 2015, METHOD ENZYMOL, V561, P73, DOI 10.1016/bs.mie.2015.04.006; Ma XP, 2015, J DRUG TARGET, V23, P672, DOI 10.3109/1061186X.2015.1073296; Ma XP, 2015, J CONTROL RELEASE, V200, P201, DOI 10.1016/j.jconrel.2014.12.027; Madajewski B, 2016, MOL CANCER RES, V14, P14, DOI 10.1158/1541-7786.MCR-15-0207-T; Moore Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.564; Murphy TA, 2013, BIOTECHNOL BIOENG, V110, P1748, DOI 10.1002/bit.24836; Nelson SJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006070; Ough M, 2005, CANCER BIOL THER, V4, P95; Park JM, 2016, NMR BIOMED, V29, P650, DOI 10.1002/nbm.3509; Pink JJ, 2000, J BIOL CHEM, V275, P5416, DOI 10.1074/jbc.275.8.5416; Planchon SM, 2001, EXP CELL RES, V267, P95, DOI 10.1006/excr.2001.5234; Purmal C, 2014, AM J PHYSIOL-HEART C, V307, pH1134, DOI 10.1152/ajpheart.00407.2014; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reinicke KE, 2005, CLIN CANCER RES, V11, P3055, DOI 10.1158/1078-0432.CCR-04-2185; Rodrigues TB, 2014, NAT MED, V20, P93, DOI 10.1038/nm.3416; Ross D, 2004, METHOD ENZYMOL, V382, P115; Salamanca-Cardona L, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0136-2; Serrao EM, 2016, GUT, V65, P465, DOI 10.1136/gutjnl-2015-310114; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sriram R, 2015, NMR BIOMED, V28, P1141, DOI 10.1002/nbm.3354; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; Tagliarino C, 2003, CANCER BIOL THER, V2, P141, DOI 10.4161/cbt.2.2.237; TeSlaa T, 2014, METHOD ENZYMOL, V542, P91, DOI 10.1016/B978-0-12-416618-9.00005-4; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wegner A, 2014, ANAL CHEM, V86, P2221, DOI 10.1021/ac403879d; Wilson DM, 2010, J MAGN RESON, V205, P141, DOI 10.1016/j.jmr.2010.04.012; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yang CD, 2014, J BIOL CHEM, V289, P6212, DOI 10.1074/jbc.M113.543637	60	50	52	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	2017	292	44					18203	18216		10.1074/jbc.M117.813923	http://dx.doi.org/10.1074/jbc.M117.813923			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FL7VE	28916726	Green Published, hybrid			2023-01-03	WOS:000414458200018
J	Scott, A				Scott, Andrew			On the treatment trail for ALS	NATURE			English	Editorial Material																			0	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 19	2017	550	7676					S120	S121		10.1038/550S120a	http://dx.doi.org/10.1038/550S120a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK1NF	29045376	Bronze			2023-01-03	WOS:000413247900013
J	Angermann, S; Baumann, M; Steubl, D; Lorenz, G; Hauser, C; Suttmann, Y; Reichelt, AL; Satanovskij, R; Sonntag, F; Heemann, U; Grimmer, T; Schmaderer, C				Angermann, Susanne; Baumann, Marcus; Steubl, Dominik; Lorenz, Georg; Hauser, Christine; Suttmann, Yana; Reichelt, Anna-Lena; Satanovskij, Robin; Sonntag, Franziska; Heemann, Uwe; Grimmer, Timo; Schmaderer, Christoph			Cognitive impairment in hemodialysis patients: Implementation of cut-off values for the Montreal Cognitive Assessment (MoCA)-testfor feasible screening	PLOS ONE			English	Article							MINI-MENTAL STATE; DEMENTIA; ADULTS	Objective Reliable identification of cognitive impairment in hemodialysis patients is of utmost importance, as it is associated with poor outcomes including dialysis withdrawal and death. High prevalence of cognitive impairment has been demonstrated in several studies using brief screening instruments or neuropsychological test batteries. However, the relevance of cognitive impairment as well as the accuracy of screening procedures have never been studied in this patient population. Methods 151 chronic hemodialysis patients (mean age 65.78 +/- 14.88 years, 73,5% male) underwent cognitive testing under standardized conditions by the Montreal Cognitive Assessment (MoCA) and, in a second step, the Clinical Dementia Rating scale (CDR), an international standard to measure the severity of dementia. For calculating MoCA cut-off values on the basis of the CDR global score, receiver operator characteristics (ROC) analysis and c-statistic were applied. Results 49.0% of patients were categorized as 0.5 in the CDR global with memory being the predominantly affected domain (47.7% of patients scored >= 0.5). Youden's Index led to a threshold of 23.5 points for the MoCA test for optimal differentiation between cognitively normal (CDR global < 0.5) and impaired patients (CDR global >= 0.5) based on a sensitivity of approximately 99% and a specificity of approximately 74%. Conclusion Interference of cognitive impairment with patients' independence and daily life was shown using the CDR for the first time in hemodialysis patients. A MoCA score of 23.5 points turned out as optimal threshold to differentiate between patients with and without functional impairment in the CDR, thereby paving the way for implementation of the MoCA test as a quick and thus highly feasible screening instrument for periodic testing in clinical routine.	[Angermann, Susanne; Steubl, Dominik; Lorenz, Georg; Hauser, Christine; Suttmann, Yana; Reichelt, Anna-Lena; Satanovskij, Robin; Sonntag, Franziska; Heemann, Uwe; Schmaderer, Christoph] Tech Univ Munich, Klinikum Rechts Isar, Dept Nephrol, Munich, Bavaria, Germany; [Baumann, Marcus] Friedrich Alexander Univ Erlangen Nurnberg, Klinikum Ansbach, Dept Nephrol, Erlangen, Bavaria, Germany; [Grimmer, Timo] Tech Univ Munich, Klinikum Rechts Isar, Dept Psychiat & Psychotherapy, Munich, Bavaria, Germany	Technical University of Munich; University of Erlangen Nuremberg; Technical University of Munich; University of Munich	Angermann, S; Schmaderer, C (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Nephrol, Munich, Bavaria, Germany.	Susanne.angermann@mri.tum.de; Christoph.Schmaderer@mri.tum.de	Lorenz, georg/AAK-4185-2021					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Carrasco FR, 2009, TRANSPL P, V41, P2430, DOI 10.1016/j.transproceed.2009.06.166; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kurella M, 2004, J AM GERIATR SOC, V52, P1863, DOI 10.1111/j.1532-5415.2004.52508.x; Kurella M, 2006, NEPHROL DIAL TRANSPL, V21, P2543, DOI 10.1093/ndt/gfl275; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Pereira Arema A, 2007, Hemodial Int, V11, P309, DOI 10.1111/j.1542-4758.2007.00185.x; Rakowski DA, 2006, CLIN J AM SOC NEPHRO, V1, P1000, DOI 10.2215/CJN.00470705; Schmaderer C, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0374-8; Sugarman J, 1998, J AM GERIATR SOC, V46, P517, DOI 10.1111/j.1532-5415.1998.tb02477.x; Tamura MK, 2010, CLIN J AM SOC NEPHRO, V5, P1429, DOI 10.2215/CJN.01090210; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tholen S, 2014, DEMENT GERIATR COGN, V38, P31, DOI 10.1159/000357803; Tiffin-Richards FE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106700; World Health Organization, INT CLASS DIS ICD	17	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2017	12	10							e0184589	10.1371/journal.pone.0184589	http://dx.doi.org/10.1371/journal.pone.0184589			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ3JE	29016605	Green Published, gold, Green Submitted			2023-01-03	WOS:000412627400009
J	Shah, FM; Razaq, M; Ali, A; Han, P; Chen, JL				Shah, Farhan Mahmood; Razaq, Muhammad; Ali, Abid; Han, Peng; Chen, Julian			Comparative role of neem seed extract, moringa leaf extract and imidacloprid in the management of wheat aphids in relation to yield losses in Pakistan	PLOS ONE			English	Article							ESSENTIAL OILS; BOTANICAL INSECTICIDES; CEREAL APHIDS; WINTER-WHEAT; BENEFICIAL ARTHROPODS; CHRYSOPERLA-CARNEA; AZADIRACHTA-INDICA; TRITICUM-AESTIVUM; NATURAL ENEMIES; BEMISIA-TABACI	Wheat being staple food of Pakistan is constantly attacked by major wheat aphid species, Schizaphis graminum (R.), Rhopalosiphum padi (L.) and Sitobion avenae (F.). Due to concern on synthetic chemical use in wheat, it is imperative to search for alternative environment-and human-friendly control measures such as botanical pesticides. In the present study, we evaluated the comparative role of neem seed extract (NSE), moringa leaf extract (MLE) and imidacloprid (I) in the management of the aphid as well as the yield losses parameters in late planted wheat fields. Imidacloprid reduced significantly aphids infestation compared to the other treatments, hence resulting in higher yield, particularly when applied with MLE. The percentages of yield increase in I+MLE treated plots over the control were 19.15-81.89% for grains per spike, 5.33-37.62% for thousand grain weight and 27.59-61.12% for yield kg/ha. NSE was the second most effective control measure in suppressing aphid population, but the yield protected by NSE treatment over the control was comparable to that by imidacloprid. Population densities of coccinellids and syrphids in the plots treated with NSE-2 were higher than those treated with imidacloprid in two out of three experiments during 2013-14. Low predator density in imidacloprid-treated plots was attributed to the lower availability of prey aphids. The efficacy of NSE against aphids varied depending on degree of synchronization among the application timing, the activity of aphids, crop variety and environmental conditions. Despite that, we suggested NSE to be a promising alternative botanical insecticide compared to the most commonly recommended imidiacloprid. Further studies should consider the side effects of biopesticides on non-target organisms in order to provide better management practices in the field.	[Shah, Farhan Mahmood; Razaq, Muhammad] Bahauddin Zakariya Univ, Fac Agr Sci & Technol, Dept Entomol, Multan, Pakistan; [Ali, Abid] Univ Agr Faisalabad, Dept Entomol, Faisalabad, Pakistan; [Han, Peng] Univ Nice Sophia Antipolis, CNRS, French Natl Inst Agr Res, Inst Sophia Agrobiotech,INRA,UMR 1355 7254, Sophia Antipolis, France; [Chen, Julian] Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing, Peoples R China	Bahauddin Zakariya University; University of Agriculture Faisalabad; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Cote d'Azur; Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS	Razaq, M (corresponding author), Bahauddin Zakariya Univ, Fac Agr Sci & Technol, Dept Entomol, Multan, Pakistan.; Chen, JL (corresponding author), Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing, Peoples R China.	muhammadrazaq@bzu.edu.pk; chenjulian@ippcaas.cn	Han, Peng/Y-4457-2019; Razaq, Muhammad/GYQ-5405-2022; Ali, Abid/AAJ-5282-2020; Ali, Abid/S-7218-2019; Chen, Julian/AAB-1846-2022	Ali, Abid/0000-0003-3674-7811; 	948 Project in China "Introduction and Utilization of Biological Control Technology to Plant Disease and Insect Pests Management" [2016-X48]; National Key RD Plan in China [2016YFD0300701, 2017YFD0201701]	948 Project in China "Introduction and Utilization of Biological Control Technology to Plant Disease and Insect Pests Management"; National Key RD Plan in China	This study was funded by 948 Project in China "Introduction and Utilization of Biological Control Technology to Plant Disease and Insect Pests Management" (2016-X48), and National Key R&D Plan in China (2016YFD0300701, 2017YFD0201701).r We thank Muhammad Waseem Shahzad and Muhammad Faheem Khalid (Bahauddin Zakariya University, Multan, Pakistan) for their help in the identification of predators and aphid species. We thank ZhaoXue (Tianjin Normal University, China) for improving the language of manuscript. This study was funded by 948 Project in China "Introduction and Utilization of Biological Control Technology to Plant Disease and Insect Pests Management" (2016-X48), and ational Key R&D Plan in China (2016YFD0300701, 2017YFD0201701).N	Agra-Neto AC, 2014, PARASITOL RES, V113, P175, DOI 10.1007/s00436-013-3640-8; Aheer G, 1993, J AGR RES, V31, P307; Akhtar Y., 2008, Phytochemistry Reviews, V7, P77, DOI 10.1007/s11101-006-9048-7; Ali A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24273; Ali A, 2012, J PEST SCI, V85, P359, DOI 10.1007/s10340-012-0426-1; Ali A, 2014, ENTOMOL GEN, V35, P129, DOI 10.1127/0171-8177/2014/0045; Ali H, 2015, AFR J AGR SCI TECHNO, V3, P310; Alyokhin A, 2007, PEST MANAG SCI, V63, P32, DOI 10.1002/ps.1305; Ambrosino MD, 2007, ENTOMOL EXP APPL, V122, P99, DOI 10.1111/j.1570-7458.2006.00499.x; Amin A. A., 2003, EGYPT J APPL SCI, V18, P34; Anita S., 2012, Recent Research in Science and Technology, V4, P19; [Anonymous], 2014, ENTOMOL GEN, V35, P87; Aslam Muhammad, 2005, Pakistan Entomologist, V27, P79; Aziz MA, 2013, INT J AGRIC BIOL, V15, P279; Bacci L, 2015, ENTOMOL EXP APPL, V156, P66, DOI 10.1111/eea.12317; BARDNER R, 1974, B ENTOMOL RES, V64, P141, DOI 10.1017/S0007485300027061; Basra SMA, 2011, INT J AGRIC BIOL, V13, P1006; BELL CH, 1995, J STORED PROD RES, V31, P199, DOI 10.1016/0022-474X(95)00012-V; Belmain SR, 2001, FOOD CHEM TOXICOL, V39, P287, DOI 10.1016/S0278-6915(00)00134-4; Biondi A, 2015, CHEMOSPHERE, V128, P142, DOI 10.1016/j.chemosphere.2015.01.034; Biondi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076548; Biondi A, 2012, PEST MANAG SCI, V68, P1523, DOI 10.1002/ps.3396; Blackman R.L.Eastop, 2006, APHIDS WORLDS HERBAC, V2, P1439; Boursier CM, 2011, CROP PROT, V30, P318, DOI 10.1016/j.cropro.2010.11.022; Brandt A, 2016, J INSECT PHYSIOL, V86, P40, DOI 10.1016/j.jinsphys.2016.01.001; Brathe A, 2002, BIOORGAN MED CHEM, V10, P1581, DOI 10.1016/S0968-0896(01)00427-8; BUTTERWORTH JH, 1968, CHEM COMMUN, P23, DOI 10.1039/c19680000023; Campolo O, 2014, IND CROP PROD, V61, P361, DOI 10.1016/j.indcrop.2014.07.028; Campolo O, 2014, PHYTOPARASITICA, V42, P223, DOI 10.1007/s12600-013-0355-4; Chander S, 2014, P NATL ACAD SCI IN B, V86, P315, DOI DOI 10.1007/40011-014-0439; Coelho JS, 2009, CHEMOSPHERE, V77, P934, DOI 10.1016/j.chemosphere.2009.08.022; Copping LG, 2000, PEST MANAG SCI, V56, P651, DOI 10.1002/1526-4998(200008)56:8<651::AID-PS201>3.0.CO;2-U; Santos NDD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044840; Desneux N, 2007, ANNU REV ENTOMOL, V52, P81, DOI 10.1146/annurev.ento.52.110405.091440; Dively GP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118748; Douglas MR, 2015, J APPL ECOL, V52, P250, DOI 10.1111/1365-2664.12372; Fekri MS, 2016, ENTOMOL GEN, V35, P229, DOI 10.1127/entomologia/2016/0020; FENG R, 1995, EXPERIENTIA, V51, P831, DOI 10.1007/BF01922438; Foidle N., 2001, MIRACLE TREE MULTIPL, P45; Fossen M., 2006, ENV FATE IMIDIACLOPR; Fuglie L.J., 1999, MIRACLE TREE MORINGA, P172; Gahukar RT, 2000, INT J PEST MANAGE, V46, P149, DOI 10.1080/096708700227516; Gontijo PC, 2014, J PEST SCI, V87, P711, DOI 10.1007/s10340-014-0611-5; GOP, 2016, EC SURV PAK 2015 16, P28; Goulson D, 2013, J APPL ECOL, V50, P977, DOI 10.1111/1365-2664.12111; Gray SM, 1996, CROP PROT, V15, P687, DOI 10.1016/S0261-2194(96)00040-3; Hagvar E.B., 1991, Biocontrol News and Information, V12, P13; Hallmann CA, 2014, NATURE, V511, P341, DOI 10.1038/nature13531; Han P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102980; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146; Isman MB, 1996, RECENT ADV PHYTOCHEM, V30, P155; Kannan H. O., 1999, Sudan Journal of Agricultural Research, V2, P65; Khan MB, 2010, PAK J BOT, V42, P1561; Khattak MK, 2007, PAK J ZOOL, V39, P109; Kindler SD, 2002, J ECON ENTOMOL, V95, P89, DOI 10.1603/0022-0493-95.1.89; Krcmar S, 2016, ENTOMOL GEN, V36, P97, DOI 10.1127/entomologia/2016/0121; Krieger R. I, 2001, HDB PESTICIDE TOXICO, V2, P1123; Liang GM, 2003, CROP PROT, V22, P333, DOI 10.1016/S0261-2194(02)00175-8; LOWERY DT, 1993, J ECON ENTOMOL, V86, P864, DOI 10.1093/jee/86.3.864; LOWERY DT, 1995, PHYTOPARASITICA, V23, P297, DOI 10.1007/BF02981422; Lu YH, 2012, NATURE, V487, P362, DOI 10.1038/nature11153; Melesse T., 2012, International Journal of Agricultural Technology, V8, P125; Mirande L, 2015, J PEST SCI, V88, P155, DOI 10.1007/s10340-014-0597-z; Miresmailli S, 2014, TRENDS PLANT SCI, V19, P29, DOI 10.1016/j.tplants.2013.10.002; MORDUE AJ, 1993, J INSECT PHYSIOL, V39, P903, DOI 10.1016/0022-1910(93)90001-8; Mujahid Manzoor, 2015, Journal of Biopesticides, V8, P120; Myers SW, 2005, J ECON ENTOMOL, V98, P2006, DOI 10.1603/0022-0493-98.6.2006; Nathan SS, 2005, CROP PROT, V24, P760, DOI 10.1016/j.cropro.2005.01.009; Palmeri V, 2007, J APICULT RES, V46, P105, DOI 10.1080/00218839.2007.11101375; Palumbo JC, 2001, CROP PROT, V20, P739, DOI 10.1016/S0261-2194(01)00117-X; Pansa MG, 2015, J PEST SCI, V88, P201, DOI 10.1007/s10340-014-0572-8; PIKE KS, 1985, J ECON ENTOMOL, V78, P676, DOI 10.1093/jee/78.3.676; Pontual EV, 2012, ARCH INSECT BIOCHEM, V79, P135, DOI 10.1002/arch.21012; Prabhaker N, 2011, J ECON ENTOMOL, V104, P773, DOI 10.1603/EC10362; Qu YY, 2015, ECOTOXICOLOGY, V24, P479, DOI 10.1007/s10646-014-1396-2; de Oliveira CFR, 2011, PROCESS BIOCHEM, V46, P498, DOI 10.1016/j.procbio.2010.09.025; Regnault-Roger C, 2012, ANNU REV ENTOMOL, V57, P405, DOI 10.1146/annurev-ento-120710-100554; Roh HS, 2015, J PEST SCI, V88, P621, DOI 10.1007/s10340-014-0631-1; Royer T, 1998, SMALL GRAIN APHIDS O; Royer TA, 2011, CROP PROT, V30, P826, DOI 10.1016/j.cropro.2011.03.002; Saeed NA, 2014, PAK J ZOOL, V46, P1193; Saeed R, 2015, J PEST SCI, V88, P517, DOI 10.1007/s10340-014-0638-7; Saeed R, 2015, PAK J ZOOL, V47, P103; Sallam AA, 2009, J PLANT DIS PROTECT, V116, P283, DOI 10.1007/BF03356325; Saroukolai AT, 2010, J PEST SCI, V83, P3, DOI 10.1007/s10340-009-0261-1; SCHMUTTERER H, 1988, J INSECT PHYSIOL, V34, P713, DOI 10.1016/0022-1910(88)90082-0; Seagraves MP, 2009, BIOL CONTROL, V51, P313, DOI 10.1016/j.biocontrol.2009.05.015; Shaaya E, 1997, J STORED PROD RES, V33, P7, DOI 10.1016/S0022-474X(96)00032-X; Shahzad MW, 2013, PAK J BOT, V45, P2005; Shani E, 2006, CURR OPIN PLANT BIOL, V9, P484, DOI 10.1016/j.pbi.2006.07.008; Sharma-Natu Poonam, 2006, Indian Journal of Plant Physiology, V11, P239; SINGH RP, 1988, PHYTOPARASITICA, V16, P225, DOI 10.1007/BF02979523; Snedecor G. W., 1989, STAT METHODS, P289; Subhan F., 2004, SARHAD J AGR, V20, P51; Tang YQ, 2002, ENVIRON ENTOMOL, V31, P172, DOI 10.1603/0046-225X-31.1.172; Turek C, 2013, COMPR REV FOOD SCI F, V12, P40, DOI 10.1111/1541-4337.12006; Ugarte C, 2007, FIELD CROP RES, V100, P240, DOI 10.1016/j.fcr.2006.07.010; van der Sluijs JP, 2015, ENVIRON SCI POLLUT R, V22, P148, DOI 10.1007/s11356-014-3229-5; Wang SY, 2017, J PEST SCI, V90, P389, DOI 10.1007/s10340-016-0770-7; WEISENBURGER DD, 1993, HUM PATHOL, V24, P571, DOI 10.1016/0046-8177(93)90234-8; Xiao D, 2016, ECOTOXICOLOGY, V25, P1782, DOI 10.1007/s10646-016-1721-z; Yasmeen A, 2013, PLANT GROWTH REGUL, V69, P225, DOI 10.1007/s10725-012-9764-5; Yasmeen A, 2012, CHIL J AGR RES, V72, P92, DOI 10.4067/S0718-58392012000100015; Zhang YX, 2016, INSECT BIOCHEM MOLEC, V79, P50, DOI 10.1016/j.ibmb.2016.10.009	105	24	24	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2017	12	9							e0184639	10.1371/journal.pone.0184639	http://dx.doi.org/10.1371/journal.pone.0184639			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4WR	28953894	Green Published, gold, Green Submitted			2023-01-03	WOS:000411980300018
J	Roffe, C; Nevatte, T; Sim, J; Bishop, J; Ives, N; Ferdinand, P; Gray, R				Roffe, Christine; Nevatte, Tracy; Sim, Julius; Bishop, Jon; Ives, Natalie; Ferdinand, Phillip; Gray, Richard		Stroke Oxygen Study Investigators; Stroke Oxygen Study Collaborative	Effect of Routine Low-Dose Oxygen Supplementation on Death and Disability in Adults With Acute Stroke The Stroke Oxygen Study Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ISCHEMIC-STROKE; TISSUE; INFARCTION; MORTALITY; HYPEROXIA; THERAPY	IMPORTANCE Hypoxia is common in the first few days after acute stroke, is frequently intermittent, and is often undetected. Oxygen supplementation could prevent hypoxia and secondary neurological deterioration and thus has the potential to improve recovery. OBJECTIVE To assess whether routine prophylactic low-dose oxygen therapy was more effective than control oxygen administration in reducing death and disability at 90 days, and if so, whether oxygen given at night only, when hypoxia is most frequent, and oxygen administration is least likely to interfere with rehabilitation, was more effective than continuous supplementation. DESIGN, SETTING, AND PARTICIPANTS In this single-blind randomized clinical trial, 8003 adults with acute stroke were enrolled from 136 participating centers in the United Kingdom within 24 hours of hospital admission if they had no clear indications for or contraindications to oxygen treatment (first patient enrolled April 24, 2008; last follow-up January 27, 2015). INTERVENTIONS Participants were randomized 1: 1: 1 to continuous oxygen for 72 hours (n = 2668), nocturnal oxygen (21: 00 to 07: 00 hours) for 3 nights (n = 2667), or control (oxygen only if clinically indicated; n = 2668). Oxygen was given via nasal tubes at 3 L/min if baseline oxygen saturation was 93% or less and at 2 L/min if oxygen saturation was greater than 93%. MAIN OUTCOMES AND MEASURES The primary outcomewas reported using the modified Rankin Scale score (disability range, 0 [no symptoms] to 6 [death]; minimum clinically important difference, 1 point), assessed at 90 days by postal questionnaire (participant aware, assessor blinded). The modified Rankin Scale score was analyzed by ordinal logistic regression, which yields a common odds ratio (OR) for a change from one disability level to the next better (lower) level; OR greater than 1.00 indicates improvement. RESULTS A total of 8003 patients (4398 (55%) men; mean [SD] age, 72 [13] years; median National Institutes of Health Stroke Scale score, 5; mean baseline oxygen saturation, 96.6%) were enrolled. The primary outcome was available for 7677 (96%) participants. The unadjusted OR for a better outcome (calculated via ordinal logistic regression) was 0.97 (95% CI, 0.89 to 1.05; P =.47) for oxygen vs control, and the OR was 1.03 (95% CI, 0.93 to 1.13; P = .61) for continuous vs nocturnal oxygen. No subgroup could be identified that benefited from oxygen. At least 1 serious adverse event occurred in 348 (13.0%) participants in the continuous oxygen group, 294 (11.0%) in the nocturnal group, and 322 (12.1%) in the control group. No significant harms were identified. CONCLUSIONS AND RELEVANCE Among nonhypoxic patients with acute stroke, the prophylactic use of low-dose oxygen supplementation did not reduce death or disability at 3 months. These findings do not support low-dose oxygen in this setting.	[Roffe, Christine; Ferdinand, Phillip] Univ Hosp North Midlands NHSTrust, Stoke On Trent, Staffs, England; [Roffe, Christine; Nevatte, Tracy; Sim, Julius] Keele Univ, Fac Med & Hlth Sci, Stoke On Trent, Staffs, England; [Nevatte, Tracy] Keele Univ, Directorate Engagement & Partnerships, Stoke On Trent, Staffs, England; [Bishop, Jon; Ives, Natalie; Gray, Richard] Univ Birmingham, Birmingham Clin Trials Unit, Birmingham, W Midlands, England; [Gray, Richard] Univ Oxford, MRC Populat Hlth Res Unit, Oxford, England	Keele University; Keele University; University of Birmingham; University of Oxford	Roffe, C (corresponding author), Keele Univ, Inst Sci & Technol Med, Guy Hilton Res Ctr, Thornburrow Dr, Stoke On Trent ST4 7QB, Staffs, England.	christine.roffe@uhnm.nhs.uk	Roffe, Christine/AAT-5611-2020	Roffe, Christine/0000-0002-5259-6649; Ives, Natalie/0000-0002-1664-7541; Bishop, Jonathan/0000-0003-1789-5886	NIHR Health Technology Assessment Programme [09/104/21]; Research for Patient Benefit Programme; National Institute for Health Research [09/104/21] Funding Source: researchfish	NIHR Health Technology Assessment Programme(National Institute for Health Research (NIHR)); Research for Patient Benefit Programme; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the NIHR Health Technology Assessment Programme (project number 09/104/21) and the Research for Patient Benefit Programme.	Alawneh JA, 2011, BRAIN, V134, P1765, DOI 10.1093/brain/awr100; Ali M, 2010, INT J STROKE, V5, P10, DOI 10.1111/j.1747-4949.2009.00393.x; Bravata DM, 2010, ARCH INTERN MED, V170, P804, DOI 10.1001/archinternmed.2010.92; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Ciccone A, 2013, COCHRANE DB SYST REV, V5; Collin C, 1988, Int Disabil Stud, V10, P61; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Dennis M, 2005, LANCET, V365, P2005, DOI 10.1016/S0140-6736(05)66691-3; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870; Heiss WD, 2012, ANN NY ACAD SCI, V1268, P26, DOI 10.1111/j.1749-6632.2012.06668.x; Lopez-Cancio E, 2015, STROKE, V46, P3405, DOI 10.1161/STROKEAHA.115.010909; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Padma MV, 2010, ANN INDIAN ACAD NEUR, V13, P284, DOI 10.4103/0972-2327.74203; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Rocco A, 2007, STROKE, V38, P1225, DOI 10.1161/01.STR.0000259659.91505.40; Roffe C, 2003, STROKE, V34, P2641, DOI 10.1161/01.STR.0000095188.65567.4F; Roffe C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-99; Roffe C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019113; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rowat AM, 2006, CEREBROVASC DIS, V21, P166, DOI 10.1159/000090528; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Sim J, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-229; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, NORMOBARIC OXYGEN TH; Smith CJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001307; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	33	106	110	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 26	2017	318	12					1125	1135		10.1001/jama.2017.11463	http://dx.doi.org/10.1001/jama.2017.11463			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FI2LE	28973619	Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000411769300019
J	Nugent, SM; Morasco, BJ; O'Neil, ME; Freeman, M; Low, A; Kondo, K; Elven, C; Zakher, B; Motu'apuaka, M; Paynter, R; Kansagara, D				Nugent, Shannon M.; Morasco, Benjamin J.; O'Neil, Maya E.; Freeman, Michele; Low, Allison; Kondo, Karli; Elven, Camille; Zakher, Bernadette; Motu'apuaka, Makalapua; Paynter, Robin; Kansagara, Devan			The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							CENTRAL NEUROPATHIC PAIN; MARIJUANA USE; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; PULMONARY ASPERGILLOSIS; HYPEREMESIS SYNDROME; MEDICINAL EXTRACTS; MEDICAL CANNABIS; SUBSTANCE USE; VAPORIZED CANNABIS	Background: Cannabis is increasingly available for the treatment of chronic pain, yet its efficacy remains uncertain. Purpose: To review the benefits of plant-based cannabis preparations for treating chronic pain in adults and the harms of cannabis use in chronic pain and general adult populations. Data Sources: MEDLINE, Cochrane Database of Systematic Reviews, and several other sources from database inception to March 2017. Study Selection: Intervention trials and observational studies, published in English, involving adults using plant-based cannabis preparations that reported pain, quality of life, or adverse effect outcomes. Data Extraction: Two investigators independently abstracted study characteristics and assessed study quality, and the investigator group graded the overall strength of evidence using standard criteria. Data Synthesis: From 27 chronic pain trials, there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations. According to 11 systematic reviews and 32 primary studies, harms in general population studies include increased risk for motor vehicle accidents, psychotic symptoms, and short-term cognitive impairment. Although adverse pulmonary effects were not seen in younger populations, evidence on most other long-term physical harms, in heavy or long-term cannabis users, or in older populations is insufficient. Limitation: Few methodologically rigorous trials; the cannabis formulations studied may not reflect commercially available products; and limited applicability to older, chronically ill populations and patients who use cannabis heavily. Conclusion: Limited evidence suggests that cannabis may alleviate neuropathic pain in some patients, but insufficient evidence exists for other types of chronic pain. Among general populations, limited evidence suggests that cannabis is associated with an increased risk for adverse mental health effects.	[Nugent, Shannon M.; O'Neil, Maya E.] VA Portland Hlth Care Syst, Mail Code R&D66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Morasco, Benjamin J.] VA Portland Hlth Care Syst, Mail Code R&D99,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Freeman, Michele; Low, Allison; Kondo, Karli; Motu'apuaka, Makalapua; Paynter, Robin; Kansagara, Devan] VA Portland Hlth Care Syst, Mail Code R&D71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Elven, Camille] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA; [Zakher, Bernadette] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University	Nugent, SM (corresponding author), VA Portland Hlth Care Syst, Mail Code R&D66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Shannon.Nugent@va.gov; kansagar@ohsu.edu	Kondo, Karli/R-3994-2019	Kondo, Karli/0000-0002-4635-5056; Paynter, Robin/0000-0002-6969-4261	U.S. Department of Veterans Affairs [PROSPERO: CRD42016033623]	U.S. Department of Veterans Affairs(US Department of Veterans Affairs)	U.S. Department of Veterans Affairs. (PROSPERO: CRD42016033623)	Abrams DI, 2007, NEUROLOGY, V68, P515, DOI 10.1212/01.wnl.0000253187.66183.9c; Abrams DI, 2011, CLIN PHARMACOL THER, V90, P844, DOI 10.1038/clpt.2011.188; Adler JN, 2013, NEW ENGL J MED, V368, pE30, DOI 10.1056/NEJMclde1305159; Ashrafioun L, 2015, ADDICT BEHAV, V42, P185, DOI 10.1016/j.addbeh.2014.11.024; Atkins D, 2013, AHRQ PUBLICATION; Berkman ND, 2013, METHODS GUIDE EFFECT; Berman JS, 2004, PAIN, V112, P299, DOI 10.1016/j.pain.2004.09.013; Blake DR, 2006, RHEUMATOLOGY, V45, P50, DOI 10.1093/rheumatology/kei183; Blanco C, 2016, JAMA PSYCHIAT, V73, P388, DOI 10.1001/jamapsychiatry.2015.3229; Bonn-Miller MO, 2014, AM J DRUG ALCOHOL AB, V40, P23, DOI 10.3109/00952990.2013.821477; Borges G, 2016, J AFFECT DISORDERS, V195, P63, DOI 10.1016/j.jad.2016.02.007; Butler M, MED CANNABIS NONCANC; Callaghan RC, 2013, CANCER CAUSE CONTROL, V24, P1811, DOI 10.1007/s10552-013-0259-0; Carabellese F, 2013, RIV PSICHIATR, V48, P43, DOI 10.1708/1228.13614; Cescon DW, 2008, J CLIN ONCOL, V26, P2214, DOI 10.1200/JCO.2007.15.2777; Chacko JA, 2006, UROLOGY, V67, P100, DOI 10.1016/j.urology.2005.07.005; CHUSID MJ, 1975, ANN INTERN MED, V82, P682, DOI 10.7326/0003-4819-82-5-682; Collin C, 2010, NEUROL RES, V32, P451, DOI 10.1179/016164109X12590518685660; Corey-Bloom J, 2012, CAN MED ASSOC J, V184, P1143, DOI 10.1503/cmaj.110837; de Carvalho MFF, 2015, ARCH ORAL BIOL, V60, P1750, DOI 10.1016/j.archoralbio.2015.09.009; de Vries M, 2016, CLIN GASTROENTEROL H, DOI [10.1016/j.cgh.2016.09, DOI 10.1016/J.CGH.2016.09]; Degenhardt L, 2015, DRUG ALCOHOL DEPEN, V147, P144, DOI 10.1016/j.drugalcdep.2014.11.031; DeGeorge M, 2017, P 2013 ANN M AM AC P; Di Forti M, 2009, BRIT J PSYCHIAT, V195, P488, DOI 10.1192/bjp.bp.109.064220; Dominguez MDG, 2010, AM J PSYCHIAT, V167, P1075, DOI 10.1176/appi.ajp.2010.09060883; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Ellis RJ, 2009, NEUROPSYCHOPHARMACOL, V34, P672, DOI 10.1038/npp.2008.120; Englund A, 2013, J PSYCHOPHARMACOL, V27, P19, DOI 10.1177/0269881112460109; Fiz J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018440; Fleming MF, 2007, J PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Frost L, 2013, AM HEART J, V165, P170, DOI 10.1016/j.ahj.2012.11.007; Ganzer F, 2016, NEUROPSYCHOL REV, V26, P186, DOI 10.1007/s11065-016-9316-2; Gibbs M, 2015, J AFFECT DISORDERS, V171, P39, DOI 10.1016/j.jad.2014.09.016; Gurney J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1905-6; Hancox RJ, 2010, EUR RESPIR J, V35, P42, DOI 10.1183/09031936.00065009; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Haroutounian S, 2016, CLIN J PAIN, V32, P1036, DOI 10.1097/AJP.0000000000000364; Hefner K, 2015, AM J ADDICTION, V24, P538, DOI 10.1111/ajad.12260; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ilgen MA, 2013, DRUG ALCOHOL DEPEN, V132, P654, DOI 10.1016/j.drugalcdep.2013.04.019; Institute of Medicine Committee on Advancing Pain Research Care and Education, 2011, REL PAIN AM BLUEPR T; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Kansagara D, CANNABIS MANAGEMENT; Kansagara D, 2016, BENEFITS HARMS CANNA; Kaufmann RM, 2010, PHARMACOPSYCHIATRY, V43, P24, DOI 10.1055/s-0029-1237397; Kuepper R, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d738; Langford RM, 2013, J NEUROL, V260, P984, DOI 10.1007/s00415-012-6739-4; Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018; Marks WH, 1996, TRANSPLANTATION, V61, P1771, DOI 10.1097/00007890-199606270-00018; Mason O, 2009, PSYCHOL MED, V39, P951, DOI 10.1017/S0033291708004741; Mittleman MA, 2001, CIRCULATION, V103, P2805; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Munckhof WJ, 2003, INT J TUBERC LUNG D, V7, P860; MYERSCOUGH R, 1985, J PERS SOC PSYCHOL, V49, P1541; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C; National Conference of State Legislatures, 2017, MAR OV; Notcutt W, 2004, ANAESTHESIA, V59, P440, DOI 10.1111/j.1365-2044.2004.03674.x; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; Nurmikko TJ, 2007, PAIN, V133, P210, DOI 10.1016/j.pain.2007.08.028; Oeltmann JE, 2006, EMERG INFECT DIS, V12, P1156, DOI 10.3201/eid1207.051436; Pletcher MJ, 2012, JAMA-J AM MED ASSOC, V307, P173, DOI 10.1001/jama.2011.1961; Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003; Ramos S, 2013, PSYCHOTHER PSYCHOSOM, V82, P90; Reisfield GM, 2009, PAIN MED, V10, P1434, DOI 10.1111/j.1526-4637.2009.00726.x; Rossler W, 2012, ADDICTION, V107, P1174, DOI 10.1111/j.1360-0443.2011.03760.x; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Rogeberg O, 2016, ADDICTION, V111, P1348, DOI 10.1111/add.13347; Ryan-Ibarra S, 2015, DRUG ALCOHOL REV, V34, P141, DOI 10.1111/dar.12207; Sadiq M., 2013, J ADDICT MED S, V7, pE3, DOI [10.1097/ADM.0b013e3182a3b16f, DOI 10.1097/ADM.0B013E3182A3B16F]; Schreiner AM, 2012, EXP CLIN PSYCHOPHARM, V20, P420, DOI 10.1037/a0029117; Selvarajah D, 2010, DIABETES CARE, V33, P128, DOI 10.2337/dc09-1029; Serpell M, 2014, EUR J PAIN, V18, P999, DOI 10.1002/j.1532-2149.2013.00445.x; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Sorensen CJ, 2017, J MED TOXICOL, V13, P71, DOI 10.1007/s13181-016-0595-z; Soriano-Co M, 2010, DIGEST DIS SCI, V55, P3113, DOI 10.1007/s10620-010-1131-7; Storr M, 2014, INFLAMM BOWEL DIS, V20, P472, DOI 10.1097/01.MIB.0000440982.79036.d6; Tetrault JM, 2007, ARCH INTERN MED, V167, P221, DOI 10.1001/archinte.167.3.221; van Amerongen G, 2018, CLIN THER, V40, P1467, DOI 10.1016/j.clinthera.2017.01.016; van Nierop M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076690; Vandrey R, 2015, JAMA-J AM MED ASSOC, V313, P2491, DOI 10.1001/jama.2015.6613; Velasco A, 2012, J HOSP MED S2, V7; Viswanathan M, 2012, AHRQ PUBLICATION; Vujasinovic M, 2012, ZDR VESTN, V81, P159; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Wade DT, 2003, CLIN REHABIL, V17, P21, DOI 10.1191/0269215503cr581oa; Wallace MS, 2015, J PAIN, V16, P616, DOI 10.1016/j.jpain.2015.03.008; Ware MA, 2010, CAN MED ASSOC J, V182, pE694, DOI 10.1503/cmaj.091414; Ware MA, 2015, J PAIN, V16, P1233, DOI 10.1016/j.jpain.2015.07.014; Welder JD, 2012, J GEN INTERN MED, V27, pS480; Wells GA, NEWCASTLE OTTAWA SCA; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Wilsey B, 2008, J PAIN, V9, P506, DOI 10.1016/j.jpain.2007.12.010; Wilsey B, 2016, J PAIN, V17, P982, DOI 10.1016/j.jpain.2016.05.010; Wilsey B, 2013, J PAIN, V14, P136, DOI 10.1016/j.jpain.2012.10.009; Woods JA, 2016, AM J THER, V23, pE601, DOI 10.1097/MJT.0000000000000034; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek JP, 2012, J NEUROL NEUROSUR PS, V83, P1125, DOI 10.1136/jnnp-2012-302468; Zhang LR, 2015, INT J CANCER, V136, P894, DOI 10.1002/ijc.29036	99	179	180	2	76	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2017	167	5					319	+		10.7326/M17-0155	http://dx.doi.org/10.7326/M17-0155			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF6LC	28806817				2023-01-03	WOS:000409120400006
J	Hurley, R				Hurley, Richard			HUMANITARIAN AID On a mission to relieve the global epidemic of untreated pain	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												rhurley@bmj.com						International Narcotics Control Board, 2015, AV INT CONTR DRUGS E; Pettus K, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j309	2	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	2017	358								j4022	10.1136/bmj.j4022	http://dx.doi.org/10.1136/bmj.j4022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG0CK	28851682				2023-01-03	WOS:000409386400008
J	Zhang, AL; Wang, DY; Li, JY; Gao, F; Fan, XC				Zhang, Ailian; Wang, Danyang; Li, Jinyao; Gao, Feng; Fan, Xucheng			The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity	PLOS ONE			English	Article							CHINESE HERBAL MEDICINE; IN-VIVO; CTL RESPONSE; POLYSACCHARIDES; INFECTION; IMMUNIZATION; ADULTS; CELLS; MACROPHAGES; MATURATION	Potent adjuvant can improve the effectiveness of vaccines and reduce the antigen doses required for initiating the protective immunity. In this study, we identified that aqueous extract of Artemisia rupestris L. (AEAR) could be employed as an efficient adjuvant for influenza virus vaccine (V) to enhance immune responses and reduce the antigen doses required for initiating immunity, without compromising the immune response. ICR mice were subcutaneously co-administrated with V combined with different concentrations of AEAR demonstrated that 300 mu g AEAR could significantly improve hemagglutination inhibition (HI) and increase IgG antibody titers in serum (P < 0.05) and the population of CD4(+)CD44(+) and CD8(+)CD44(+) (P < 0.05). Next, 300 mu g AEAR combined with different doses of V in vivo markedly increased HI and specific IgG antibody level(P < 0.05). It also significantly increased the amount of CD4(+) and CD8(+) T cells, CD4(+)CD44(+) and CD8(+)CD44(+) T cells (P < 0.05), improved lymphocyte proliferation, the secretion of CD4(+) IL-4, CD4(+) IFN-gamma and CD8(+)IFN-gamma (P < 0.05), and the killing efficacy of cytotoxic T lymphocyte (CTL) (P < 0.05). Furthermore, the combination increased the expression of major histocompatibility complex-II (MHC-II) and co-stimulatory molecules including CD40, CD80, and CD86 on dendritic cells (DCs), and downregulated the expression of CD25(+) Foxp3(+)Treg cells (P < 0.05). No significant difference was observed between high-dose V and low-dose AEAR-V (10-fold lower) vaccination group (P > 0.05), indicating a 10-fold reduction of antigen required for V vaccine administration. In conclusion, this study demonstrated that AEAR, as an adjuvant for influenza vaccine, could stimulate potent humoral and cellular immune responses and reduce the antigen dose required for effective vaccination, which were mediated by promoting DCs activation and repressing Treg expression.	[Zhang, Ailian; Wang, Danyang; Li, Jinyao] Xinjiang Univ, Coll Life Sci & Technol, Xinjiang Key Lab Biol Resources & Genet Engn, Urumqi, Peoples R China; [Gao, Feng; Fan, Xucheng] Urumqi Ctr Dis Control & Prevent, Urumqi, Peoples R China	Xinjiang University	Zhang, AL (corresponding author), Xinjiang Univ, Coll Life Sci & Technol, Xinjiang Key Lab Biol Resources & Genet Engn, Urumqi, Peoples R China.	xjzal@163.com			National Natural Science Foundation of China [31360224, 31660259]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (31360224,31660259). The funders had no role in study design, data collection and analysis, decision to publish, preparation or of the manuscript.	Akira S, 2011, PHILOS T R SOC B, V366, P2748, DOI 10.1098/rstb.2011.0106; Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; Belska NV, 2010, INT IMMUNOPHARMACOL, V10, P933, DOI 10.1016/j.intimp.2010.05.005; Bijker MS, 2007, J IMMUNOL, V179, P5033, DOI 10.4049/jimmunol.179.8.5033; Chen H, 2016, J MED FOOD, V19, P253, DOI 10.1089/jmf.2015.3513; Ciabattini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019346; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Feng HB, 2015, INT J BIOL MACROMOL, V78, P405, DOI 10.1016/j.ijbiomac.2015.04.044; Feng HB, 2015, IMMUNOL INVEST, V44, P288, DOI 10.3109/08820139.2015.1009546; Gritzapis AD, 2006, CANCER RES, V66, P5452, DOI 10.1158/0008-5472.CAN-05-4018; Hasegawa H, 2015, CURR TOP MICROBIOL, V386, P371, DOI 10.1007/82_2014_402; Honda-Okubo Y, 2012, VACCINE, V30, P5373, DOI 10.1016/j.vaccine.2012.06.021; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Hung YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159333; Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497; Jiang MH, 2010, EXPERT OPIN THER TAR, V14, P1367, DOI 10.1517/14728222.2010.531010; Jin ML, 2014, INT J BIOL MACROMOL, V64, P257, DOI 10.1016/j.ijbiomac.2013.12.002; Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336; Lai CY, 2010, VACCINE, V28, P4945, DOI 10.1016/j.vaccine.2010.05.037; Li JY, 2015, J ETHNOPHARMACOL, V171, P184, DOI 10.1016/j.jep.2015.05.050; Liu G, 2011, PLOS ONE, V6, P9408; Loubet P, 2016, EXPERT REV VACCINES, V15, P1507, DOI 10.1080/14760584.2016.1188696; Muranski P, 2009, CURR OPIN IMMUNOL, V21, P200, DOI 10.1016/j.coi.2009.02.004; Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007; Principi N, 2012, HUM VACC IMMUNOTHER, V8, P59, DOI 10.4161/hv.8.1.18011; Raghavan S, 2010, INFECT IMMUN, V78, P4251, DOI 10.1128/IAI.00536-10; Rechtsteiner G, 2005, J IMMUNOL, V174, P2476, DOI 10.4049/jimmunol.174.5.2476; Rupp R, 2015, VACCINE, V33, P6351, DOI 10.1016/j.vaccine.2015.09.008; Shim BS, 2013, J MICROBIOL, V51, P130, DOI 10.1007/s12275-013-2399-z; Tan S, 2011, J INFECTION, V62, P388, DOI 10.1016/j.jinf.2011.03.002; Tsai TF, 2011, YAKUGAKU ZASSHI, V131, P1733, DOI 10.1248/yakushi.131.1733; Ulrich JT, 2000, J IMMUNOL, V164, P5492, DOI 10.4049/jimmunol.164.10.5492; Walker WT, 2010, EXPERT REV VACCINES, V9, P1385, DOI [10.1586/erv.10.141, 10.1586/ERV.10.141]; Wang M, 2016, INT J BIOL MACROMOL, V6, p809 ; Xu ZT, 2011, AM J CHINESE MED, V39, P15, DOI 10.1142/S0192415X11008610; Yoo DG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033678; Yoshida A, 2009, ANTICANCER RES, V29, P4867; Yu HJ, 2013, LANCET, V382, P138, DOI 10.1016/S0140-6736(13)61207-6; Zaragoza B, 2016, NAT MED, V22, P16, DOI 10.1038/nm.4019; Zhang AL, 2017, VACCINE, V35, P1037, DOI 10.1016/j.vaccine.2017.01.002; Zhu FJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00066	41	11	16	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2017	12	8							e0183720	10.1371/journal.pone.0183720	http://dx.doi.org/10.1371/journal.pone.0183720			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7EP	28841693	Green Published, gold, Green Submitted			2023-01-03	WOS:000408370700052
J	Moss, EL; Falconer, SB; Tkachenko, E; Wang, M; Systrom, H; Mahabamunuge, J; Relman, DA; Hohmann, EL; Bhatt, AS				Moss, Eli L.; Falconer, Shannon B.; Tkachenko, Ekaterina; Wang, Mingjie; Systrom, Hannah; Mahabamunuge, Jasmin; Relman, David A.; Hohmann, Elizabeth L.; Bhatt, Ami S.			Long-term taxonomic and functional divergence from donor bacterial strains following fecal microbiota transplantation in immunocompromised patients	PLOS ONE			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; STEM-CELL TRANSPLANT; EPIDEMIOLOGY; DISEASE; GENES	Immunocompromised individuals are at high risk of developing Clostridium difficile-associated disease (CDAD). Fecal microbiota transplantation (FMT) is a highly effective therapy for refractory or recurrent CDAD and, despite safety concerns, has recently been offered to immunocompromised patients. We investigated the genomics of bacterial composition following FMT in immunocompromised patients over a 1-year period. Metagenomic, strain and gene-level bacterial dynamics were characterized in two CDAD-affected hematopoietic stem cell (HCT) recipients following FMT. We found alterations in gene content, including loss of virulence and antibiotic resistance genes. These alterations were accompanied by long-term bacterial divergence at the species and strain levels. Our findings suggest limited durability of the specific bacterial consortium introduced with FMT and indicate that alterations of the functional potential of the microbiome are more complex than can be inferred by taxonomic information alone. Our observation that FMT alone cannot induce long-term donor-like alterations of the microbiota of HCT recipients suggests that FMT cannot indefinitely supersede environmental and/or host factors in shaping bacterial composition.	[Moss, Eli L.; Tkachenko, Ekaterina; Wang, Mingjie; Bhatt, Ami S.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Moss, Eli L.; Falconer, Shannon B.; Tkachenko, Ekaterina; Wang, Mingjie; Relman, David A.; Bhatt, Ami S.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Falconer, Shannon B.; Relman, David A.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Relman, David A.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Systrom, Hannah; Mahabamunuge, Jasmin; Hohmann, Elizabeth L.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Systrom, Hannah; Mahabamunuge, Jasmin; Hohmann, Elizabeth L.] Harvard Med Sch, Boston, MA 02115 USA	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Bhatt, AS (corresponding author), Stanford Univ, Dept Genet, Stanford, CA 94305 USA.; Bhatt, AS (corresponding author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.; Hohmann, EL (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.; Hohmann, EL (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	ehohmann@partners.org; asbhatt@stanford.edu		Relman, David A./0000-0001-8331-1354; Tkachenko, Eugene/0000-0002-8858-5642; Bhatt, Ami/0000-0001-8099-2975	National Science Foundation Graduate Research Fellowship [DGE-114747]; American Society of Hematology Scholar; Amy Strelzer Manasevit (National Marrow Donor Program); National Cancer Institute [K08 CM 84420]; Thomas C. and Joan M. Merigan Endowment at Stanford University; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000044] Funding Source: NIH RePORTER	National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); American Society of Hematology Scholar; Amy Strelzer Manasevit (National Marrow Donor Program); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Thomas C. and Joan M. Merigan Endowment at Stanford University; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	National Science Foundation Graduate Research Fellowship (nsfgrfp.org) DGE-114747 awarded to ELM; American Society of Hematology (hematology.org) Scholar and Amy Strelzer Manasevit (National Marrow Donor Program (bethematch.org)) award to ASB; National Cancer Institute (cancer.gov) K08 CM 84420 to ASB., and the Thomas C. and Joan M. Merigan Endowment at Stanford University to DAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Aroniadis OC, 2016, J CLIN GASTROENTEROL, V50, P398, DOI 10.1097/MCG.0000000000000374; Baker TM, 2016, LEUKEMIA LYMPHOMA, V57, P2245, DOI 10.1080/10428194.2016.1193859; Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; BEALS EW, 1984, ADV ECOL RES, V14, P1, DOI 10.1016/S0065-2504(08)60168-3; Broecker F, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000448; Bruminhent J, 2014, BIOL BLOOD MARROW TR, V20, P1329, DOI 10.1016/j.bbmt.2014.04.026; Chao A, 2005, ECOL LETT, V8, P148, DOI 10.1111/j.1461-0248.2004.00707.x; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Chopra T, 2011, CLIN TRANSPLANT, V25, pE82, DOI 10.1111/j.1399-0012.2010.01331.x; de Castro CG, 2015, BONE MARROW TRANSPL, V50, P145, DOI 10.1038/bmt.2014.212; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1658/1100-9233(2003)014[0927:VAPORF]2.0.CO;2; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Hojsgaard S, 2006, NEWSLETTER R PROJECT, V6, P1; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.2307/1390807]; Jalanka J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0698-z; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kelly CR, 2014, AM J GASTROENTEROL, V109, P1065, DOI 10.1038/ajg.2014.133; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; McArthur AG, 2013, ANTIMICROB AGENTS CH, V57, P3348, DOI 10.1128/AAC.00419-13; Millan B, 2016, CLIN INFECT DIS, V62, P1479, DOI 10.1093/cid/ciw185; Mittal C, 2015, BONE MARROW TRANSPL, V50, P1010, DOI 10.1038/bmt.2015.85; Neemann K, 2012, TRANSPL INFECT DIS, V14, pE161, DOI 10.1111/tid.12017; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Schmieder R, 2011, BIOINFORMATICS; Scholz M, 2016, NAT METHODS, V13, P435, DOI [10.1038/NMETH.3802, 10.1038/nmeth.3802]; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; Shahinas D, 2012, MBIO, V3, DOI 10.1128/mBio.00338-12; Suzek BE, 2007, BIOINFORMATICS, V23, P1282, DOI 10.1093/bioinformatics/btm098; Tenaillon O, 2010, NAT REV MICROBIOL, V8, P207, DOI 10.1038/nrmicro2298; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Webb BJ, 2016, TRANSPL INFECT DIS, V18, P628, DOI 10.1111/tid.12550; Weingarden A, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0070-0; Wickham H, 2012, RESHAPE2 FLEXIBLY RE, P1; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46; Youngster I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0680-9; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875	42	40	41	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2017	12	8							e0182585	10.1371/journal.pone.0182585	http://dx.doi.org/10.1371/journal.pone.0182585			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2TT	28827811	Green Submitted, Green Published, gold			2023-01-03	WOS:000408069300004
J	Skar, MW; Haugland, GT; Powell, MD; Wergeland, HI; Samuelsen, OB				Skar, Malene W.; Haugland, Gyri T.; Powell, Mark D.; Wergeland, Heidrun I.; Samuelsen, Ole B.			Development of anaesthetic protocols for lumpfish (Cyclopterus lumpus L.): Effect of anaesthetic concentrations, sea water temperature and body weight	PLOS ONE			English	Article							DENTAL AFFERENT NEURONS; SALMON SALMO-SALAR; COD GADUS-MORHUA; ATLANTIC COD; TELEOST FISH; ONCORHYNCHUS-MYKISS; LOCAL-ANESTHETICS; TRICAINE MS-222; PLASMA-CORTISOL; XENOPUS OOCYTES	In recent years, use of lumpfish (Cyclopterus lumpus L.) as cleaner-fish to remove sea-lice have been chosen by many salmon farmers in Europe and Canada as an alternative to medical treatment, which has led to large scale production of lumpfish. At present, there is limited knowledge of how lumpfish respond upon anaesthesia, which anaesthetics and concentrations that are efficient and conditions for euthanasia. We have therefore tested and developed protocols for bath immersion for three commonly used anaesthetics metacaine (Finquel, buffered tricaine methanesulfonate, MS-222 and Tricaine Pharmaq), benzocaine (Benzoak vet) and isoeugenol (Aqui-S), determined concentration for normal and fast anaesthesia and evaluated safety margin for each condition. Also, a behavioral matrix has been developed. We have examined the effect of fish size (10-20 g, 200-400 g and 600-1300 g) and sea water temperature (6 degrees C and 12 degrees C). We found that 200 mg L-1 metacaine is an efficient dose for deep narcosis independently for fish size and temperature due to good safety margins with regards to both exposure times and doses. However, for many tasks lighter anaesthesia is sufficient, and then 100 mg L-1 metacaine can be used. Benzocaine is less efficient than metacaine, but can be used as anaesthetic of fish < 400 g. The optimal doses of benzocaine were 100-200 mg L-1 for small fish (10-20 g) and 200 mg L-1 for medium sized fish (200-400 g). For larger fish (> 600 g), benzocaine is not suitable. Isoeugenol cannot be recommended for full anesthesia of lumpfish. The conditions for lethal doses varied with chosen anaesthetic, fish size and temperature. For small fish (10-20 g), exposure to 1600 mgL(-1) of metacaine in 10 minutes it lethal. Guided protocols for non-lethal anaesthesia will contribute to ensure safe treatment of lumpfish according to an ethical standard for good fish welfare.	[Skar, Malene W.; Haugland, Gyri T.; Powell, Mark D.; Wergeland, Heidrun I.; Samuelsen, Ole B.] Univ Bergen, Dept Biol, Bergen, Norway; [Samuelsen, Ole B.] Inst Marine Res, Bergen, Norway	University of Bergen; Institute of Marine Research - Norway	Haugland, GT (corresponding author), Univ Bergen, Dept Biol, Bergen, Norway.	Gyr.Haugland@uib.no		Haugland, Gyri/0000-0001-9494-9214	Research Council of Norway [244148 GTH]	Research Council of Norway(Research Council of Norway)	This work was supported by The Research Council of Norway (grant number 244148 GTH)	Ackerman P., 2005, CCAC GUIDELINES FISH; Aoshima H, 1999, BIOSCI BIOTECH BIOCH, V63, P743, DOI 10.1271/bbb.63.743; Barton BA, 2002, INTEGR COMP BIOL, V42, P517, DOI 10.1093/icb/42.3.517; Bell G., CANADIAN TECHNICAL R, P16; Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591; Bowser P.R., 2001, RECENT ADV VET ANEST; Braithwaite VA, 2004, ANIM WELFARE, V13, pS87; Chandroo KP, 2004, APPL ANIM BEHAV SCI, V86, P225, DOI 10.1016/j.applanim.2004.02.004; Clarke A, 1999, J ANIM ECOL, V68, P893, DOI 10.1046/j.1365-2656.1999.00337.x; Close B, 1997, LAB ANIM-UK, V31, P1, DOI 10.1258/002367797780600297; Dunlop R, 2005, J PAIN, V6, P561, DOI 10.1016/j.jpain.2005.02.010; FRAZIER DT, 1975, EUR J PHARMACOL, V33, P313, DOI 10.1016/0014-2999(75)90175-2; GILDERHUS P A, 1987, North American Journal of Fisheries Management, V7, P288, DOI 10.1577/1548-8659(1987)7&lt;288:CEOACO&gt;2.0.CO;2; Hale ME, 2000, AM ZOOL, V40, P1040; Hara K, 2007, ANESTH ANALG, V104, P1434, DOI 10.1213/01.ane.0000261509.72234.a6; Hedrick MS, 2003, AM J PHYSIOL-REG I, V284, pR405, DOI 10.1152/ajpregu.00418.2002; HIKASA Y, 1986, JPN J VET SCI, V48, P341; Hoskonen P, 2004, J FISH BIOL, V64, P1136, DOI 10.1111/j.1095-8649.2004.00359.x; HOUSTON AH, 1976, COMP BIOCHEM PHYS C, V54, P1, DOI 10.1016/0306-4492(76)90016-2; Imsland AK, 2014, AQUACULTURE, V424, P18, DOI 10.1016/j.aquaculture.2013.12.033; Iversen MH, 2014, SEDASJON BERGGYLTE R, P42; Javahery S, 2012, FISH PHYSIOL BIOCHEM, V38, P1545, DOI 10.1007/s10695-012-9682-5; Kiessling A, 2009, AQUACULTURE, V286, P301, DOI 10.1016/j.aquaculture.2008.09.037; Kristan J, 2014, NEUROENDOCRINOL LETT, V35, P81; Lee MH, 2005, J DENT RES, V84, P848, DOI 10.1177/154405910508400913; MARKING LL, 1985, FISHERIES, V10, P2, DOI 10.1577/1548-8446(1985)010<0002:ABANIF>2.0.CO;2; Neiffer DL, 2009, ILAR J, V50, P343, DOI 10.1093/ilar.50.4.343; NEUMCKE B, 1981, PFLUG ARCH EUR J PHY, V390, P230, DOI 10.1007/BF00658267; OLSEN YA, 1995, AQUACULTURE, V134, P155, DOI 10.1016/0044-8486(95)00008-P; Park CK, 2006, J DENT RES, V85, P900, DOI 10.1177/154405910608501005; Popovic NT, 2012, J APPL ICHTHYOL, V28, P553, DOI 10.1111/j.1439-0426.2012.01950.x; Powell AJ, 2017, ROUTL STUD RELIG, P1; Rose JD, 2002, REV FISH SCI, V10, P1, DOI 10.1080/20026491051668; Ross LG, 2008, ANAESTHETIC AND SEDATIVE TECHNIQUES FOR AQUATIC ANIMALS, 3RD EDITION, P1, DOI 10.1002/9781444302264; SAUNDERS RL, 1963, J FISH RES BOARD CAN, V20, P373, DOI 10.1139/f63-031; Schurmann H, 1997, J FISH BIOL, V50, P1166, DOI 10.1006/jfbi.1997.0387; Sneddon LU, 2003, APPL ANIM BEHAV SCI, V83, P153, DOI 10.1016/S0168-1591(03)00113-8; Sneddon LU, 2003, BRAIN RES, V972, P44, DOI 10.1016/S0006-8993(03)02483-1; Sneddon LU, 2002, NEUROSCI LETT, V319, P167, DOI 10.1016/S0304-3940(01)02584-8; Stehly GR, 1999, AQUAC RES, V30, P365, DOI 10.1046/j.1365-2109.1999.00339.x; SYLVESTER JR, 1982, PROG FISH CULT, V44, P138, DOI 10.1577/1548-8659(1982)44[138:IOTWHA]2.0.CO;2; Tsantilas H, 2006, AQUACULTURE, V253, P64, DOI 10.1016/j.aquaculture.2005.07.034; Ueta K, 2007, REGION ANESTH PAIN M, V32, P462, DOI 10.1016/j.rapm.2007.06.391; Wie MB, 1997, NEUROSCI LETT, V225, P93, DOI 10.1016/S0304-3940(97)00195-X; Zahl IH, 2012, FISH PHYSIOL BIOCHEM, V38, P201, DOI 10.1007/s10695-011-9565-1; Zahl IH, 2011, AQUAC RES, V42, P1235, DOI 10.1111/j.1365-2109.2010.02711.x; Zahl IH, 2010, FISH PHYSIOL BIOCHEM, V36, P719, DOI 10.1007/s10695-009-9346-2; Zahl IH, 2009, AQUACULTURE, V295, P52, DOI 10.1016/j.aquaculture.2009.06.019	48	18	19	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0179344	10.1371/journal.pone.0179344	http://dx.doi.org/10.1371/journal.pone.0179344			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678815	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000405272200013
J	Haun, CT; Roberts, MD; Romero, MA; Osburn, SC; Mobley, CB; Anderson, RG; Goodlett, MD; Pascoe, DD; Martin, JS				Haun, Cody T.; Roberts, Michael D.; Romero, Matthew A.; Osburn, Shelby C.; Mobley, Christopher B.; Anderson, Richard G.; Goodlett, Michael D.; Pascoe, David D.; Martin, Jeffrey S.			Does external pneumatic compression treatment between bouts of overreaching resistance training sessions exert differential effects on molecular signaling and performance-related variables compared to passive recovery? An exploratory study	PLOS ONE			English	Article							UBIQUITIN PROTEASOME SYSTEM; MESSENGER-RNA EXPRESSION; SKELETAL-MUSCLE; DYNAMIC COMPRESSION; CREATINE-KINASE; PAIN THRESHOLD; EXERCISE; SINGLE; SYMPTOMS; PROTEIN	Purpose We sought to compare the effects of external pneumatic compression (EPC) and sham when used concurrently with resistance training on performance-related outcomes and molecular measures related to recovery. Methods Twenty (N = 20) resistance-trained male participants (aged 21.6 +/- 2.4 years) were randomized to balanced sham or EPC intervention groups. The protocol consisted of 3 consecutive days of heavy, voluminous back squat exercise followed by EPC/sham treatment (Days2-4) and 3 consecutive days of recovery (Days5-7) with EPC/sham only on Days5-6. On Day1 (PRE), and Days3-7, venipuncture, flexibility and pressure-to-pain threshold (PPT) measures were performed. Vastsus lateralis muscle tissue was biopsied at PRE, 1-h post-EPC/ sham treatment on Day2 (POST1) and 24-h post-EPC/sham treatment on Day? (POST2). Isokinetic peak torque was assessed at PRE and POST2. Results Peak isokinetic strength did not change from PRE to POST2 in either group. The PPT was significantly lower on Days3-6 with sham, indicating greater muscle soreness, though this was largely abolished in the EPC group. A significant decrease in flexibility with sham was observed on Day3 (+/- 16.2 +/- 4.6% knee joint angle; P<0.01) whereas there was no change with EPC (+2.8 3.8%; P>0.01). Vastus lateralis poly-ubiquitinated proteins significantly increased at the POST2 time point relative to PRE with sham (+66.6 +/- 24.6%; P<0.025) and were significantly greater (P<0.025) than those observed with EPC at the same time point (-18.6 8.5%). 4-hydroxynonenal values were significantly lower at POST2 relative to PRE with EPC (-16.2 +/- 5.6%; P<0.025) and were significantly lower (P<0.025) than those observed with sham at the same time point (+11.8 +/- 5.9%). Conclusion EPC mitigated a reduction in flexibility and PPT that occurred with sham. Moreover, EPC reduced select skeletal muscle oxidative stress and proteolysis markers during recovery from heavy resistance exercise.	[Haun, Cody T.; Roberts, Michael D.; Romero, Matthew A.; Osburn, Shelby C.; Mobley, Christopher B.; Anderson, Richard G.; Pascoe, David D.; Martin, Jeffrey S.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA; [Roberts, Michael D.; Goodlett, Michael D.; Martin, Jeffrey S.] Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn Campus, Auburn, AL 36832 USA; [Goodlett, Michael D.] Auburn Univ, Athlet Dept, Auburn, AL 36849 USA	Auburn University System; Auburn University; Auburn University System; Auburn University	Martin, JS (corresponding author), Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA.; Martin, JS (corresponding author), Edward Via Coll Osteopath Med, Dept Cell Biol & Physiol, Auburn Campus, Auburn, AL 36832 USA.	jmartin@auburn.vcom.edu	Mobley, Christopher/AAC-2123-2020	Mobley, C. Brooks/0000-0002-4045-9962				Attaix D, 1998, REPROD NUTR DEV, V38, P153, DOI 10.1051/rnd:19980202; Augustsson J, 2000, SCAND J MED SCI SPOR, V10, P164, DOI 10.1034/j.1600-0838.2000.010003164.x; Baird MF, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/960363; Baker S J, 1997, Eur J Pain, V1, P229, DOI 10.1016/S1090-3801(97)90108-7; BERRY MJ, 1990, CAN J SPORT SCI, V15, P244; Bilodeau PA, 2016, AM J PHYSIOL-CELL PH, V311, pC392, DOI 10.1152/ajpcell.00125.2016; Cochrane DJ, 2013, INT J SPORTS MED, V34, P969, DOI 10.1055/s-0033-1337944; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Crane JD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002882; Duffield R, 2010, J SCI MED SPORT, V13, P136, DOI 10.1016/j.jsams.2008.10.006; Gill ND, 2006, BRIT J SPORT MED, V40, P260, DOI 10.1136/bjsm.2005.022483; Gulick Dawn T., 1996, Journal of Athletic Training, V31, P145; HAMILL J, 1991, INT J SPORT BIOMECH, V7, P125, DOI 10.1123/ijsb.7.2.125; Hilbert JE, 2003, BRIT J SPORT MED, V37, P72, DOI 10.1136/bjsm.37.1.72; JENSEN R, 1992, PAIN, V48, P197, DOI 10.1016/0304-3959(92)90059-K; Kephart WC, 2016, J INT SOC SPORT NUTR, V13, DOI 10.1186/s12970-016-0142-y; Kephart WC, 2015, EXP PHYSIOL, V100, P852, DOI 10.1113/EP085160; Koch AJ, 2014, J MUSCULOSKEL NEURON, V14, P68; KOSEK E, 1993, SCAND J REHABIL MED, V25, P117; Kraemer WJ, 2001, J ORTHOP SPORT PHYS, V31, P282, DOI 10.2519/jospt.2001.31.6.282; Krivickas LS, 1996, ARCH PHYS MED REHAB, V77, P1139, DOI 10.1016/S0003-9993(96)90137-9; Louis E, 2007, J APPL PHYSIOL, V103, P1744, DOI 10.1152/japplphysiol.00679.2007; MacDonald GZ, 2013, J STRENGTH COND RES, V27, P812, DOI 10.1519/JSC.0b013e31825c2bc1; Martin JS, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13029; Martin JS, 2015, APPL PHYSIOL NUTR ME, V40, P1214, DOI 10.1139/apnm-2015-0247; Martin JS, 2015, EUR J APPL PHYSIOL, V115, P2019, DOI 10.1007/s00421-015-3187-8; Martin JS, 2015, J STRENGTH COND RES, V29, P2900, DOI 10.1519/JSC.0000000000000928; Martin JS, 2016, CLIN PHYSL FUNCT IMA; Mascher H, 2008, AM J PHYSIOL-ENDOC M, V294, pE43, DOI 10.1152/ajpendo.00504.2007; Murton AJ, 2008, BBA-MOL BASIS DIS, V1782, P730, DOI 10.1016/j.bbadis.2008.10.011; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pillon NJ, 2012, ENDOCRINOLOGY, V153, P2099, DOI 10.1210/en.2011-1957; Proske U, 1999, J MUSCLE RES CELL M, V20, P433, DOI 10.1023/A:1005573625675; Raue U, 2007, J GERONTOL A-BIOL, V62, P1407, DOI 10.1093/gerona/62.12.1407; Sands WA, 2015, J STRENGTH COND RES, V29, P1263, DOI 10.1519/JSC.0000000000000412; Sands WA, 2014, J STRENGTH COND RES, V28, P1058, DOI 10.1519/JSC.0000000000000244; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Siu PM, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-58; THOMPSON HS, 1994, BIOCHEM BIOPH RES CO, V204, P1193, DOI 10.1006/bbrc.1994.2589; Van Thienen R, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.286; WORRELL T W, 1991, Journal of Orthopaedic and Sports Physical Therapy, V13, P118; Yang YF, 2006, J APPL PHYSIOL, V101, P1442, DOI 10.1152/japplphysiol.00438.2006; Zarkovic Neven, 2003, Molecular Aspects of Medicine, V24, P281, DOI 10.1016/S0098-2997(03)00023-2	43	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180429	10.1371/journal.pone.0180429	http://dx.doi.org/10.1371/journal.pone.0180429			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662152	gold, Green Published, Green Submitted			2023-01-03	WOS:000404608300154
J	Davies, R				Davies, Rachael			Felicia Marie Knaul: advocate for better pain relief and palliative care	LANCET			English	Biographical-Item														Knaul, Felicia/0000-0002-0512-4788					0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2018	391	10128					1349	1349		10.1016/S0140-6736(17)32663-6	http://dx.doi.org/10.1016/S0140-6736(17)32663-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB8RK	29032992				2023-01-03	WOS:000429342800014
J	Yun, MR; Choi, HM; Kang, HN; Lee, Y; Joo, HS; Kim, DH; Kim, HR; Hong, MH; Yoon, SO; Cho, BC				Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Joo, H-S; Kim, D. H.; Kim, H. R.; Hong, M. H.; Yoon, S. O.; Cho, B. C.			ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma	ONCOGENE			English	Article							I PI3K INHIBITOR; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHASE-I; BUPARLISIB BKM120; LUNG-CANCER; EGFR INHIBITORS; DOSE-ESCALATION; METASTATIC HEAD; COMBINATION	Hyperactivation of phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in head and neck squamous cell carcinoma (HNSCC). However, clinical outcomes of targeting the PI3K pathway have been underwhelming. In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC. Treatment of NVP-BKM120, a pan-PI3K inhibitor, led to upregulation of interleukin-6 (IL-6) and subsequent activation of either extracellular signal-regulated kinase (ERK) or signal transducers and activators of transcription 3 (STAT3), causing modest antitumor effects on the growth of HNSCC cells. Blockade of autocrine IL-6 signaling with siRNA or neutralizing antibody for IL-6 receptor (IL-6R) completely abolished NVP-BKM120-induced activation of ERK and STAT3 as well as expression of c-Myc oncogene, which resulted in enhanced sensitivity to NVP-BKM120. Moreover, when compared with a pharmacologic inhibitor or silencing of STAT3, trametinib, a MEK inhibitor, in combination with NVP-BKM120 yielded more potent anti-proliferative effects by inhibiting S phase transition, arresting cells at G0/G1 phase, and downregulating IL-6 and c-Myc expression. Furthermore, as compared with either agent alone, combination of NVP-BKM120 with trametinib or tocilizumab, a humanized anti-IL-6R antibody, significantly suppressed tumor growth in NVP-BKM120-resistant patient-derived tumor xenograft (PDTX) models, which was also confirmed in PDTX-derived cell lines. Collectively, these results suggested that IL-6/ERK signaling is closely involved in adaptive resistance of NVP-BKM120 in HNSCC cells, providing a rationale for a novel combination therapy to overcome resistance to PI3K inhibitors.	[Yun, M. R.; Kang, H. N.; Joo, H-S; Kim, D. H.; Cho, B. C.] JEUK Co Ltd, JEUK Inst Canc Res, Gumi, Kyungbuk, South Korea; [Yun, M. R.; Choi, H. M.; Kang, H. N.; Lee, Yw; Kim, H. R.; Hong, M. H.; Cho, B. C.] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; [Yoon, S. O.] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, BC (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Canc Ctr,Div Med Oncol, 50 Yonsei Ro, Seoul 120752, South Korea.	cbc1971@yuhs.ac		Kim, Hye Ryun/0000-0002-1842-9070; Hong, Min Hee/0000-0003-3490-2195; Cho, Byoung Chul/0000-0002-5562-270X	National Research Foundation of Korea (NRF) - Korea government [NRF-2014R1A1A1006865, 2015R1A2A1A15055817]	National Research Foundation of Korea (NRF) - Korea government(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea (NRF) funded by the Korea government (NRF-2014R1A1A1006865 to MR Yun and 2015R1A2A1A15055817 to BC Cho).	Awad Mark M, 2014, Clin Adv Hematol Oncol, V12, P429; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bhattacharya N, 2009, J ORAL PATHOL MED, V38, P759, DOI 10.1111/j.1600-0714.2009.00781.x; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Brachmann SM, 2012, MOL CANCER THER, V11, P1747, DOI 10.1158/1535-7163.MCT-11-1021; Du L, 2012, J ONCOL, V2012, DOI 10.1155/2012/450179; Eichten A, 2016, CANCER RES, V76, P2327, DOI 10.1158/0008-5472.CAN-15-1443; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Giudice FS, 2013, J CARCINOG MUTAGEN, V2, P5; Grana B, 2011, J CLIN ONCOL, V29; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Heo TH, 2016, ONCOTARGET, V7, P15460, DOI 10.18632/oncotarget.7102; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Hyman DM, 2015, CANCER CHEMOTH PHARM, V75, P747, DOI 10.1007/s00280-015-2693-z; Jimeno A, 2015, ORAL ONCOL, V51, P383, DOI 10.1016/j.oraloncology.2014.12.013; Kim HS, 2015, CLIN CANCER RES, V21, P544, DOI 10.1158/1078-0432.CCR-14-1756; Kim HR, 2015, CO CLIN TRIALS DEMON; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koul D, 2012, CLIN CANCER RES, V18, P184, DOI 10.1158/1078-0432.CCR-11-1558; Leon X, 2005, CLIN ONCOL-UK, V17, P418, DOI 10.1016/j.clon.2005.02.014; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Ma PF, 2016, THERANOSTICS, V6, P1232, DOI 10.7150/thno.14409; Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Michmerhuizen Nicole L, 2016, Otorhinolaryngol Head Neck Surg, V1, P44; Miller A, 2015, ONCOGENE, V34, P1510, DOI 10.1038/onc.2014.99; Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377; Munster PN, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3018; Nagasaki T, 2014, RECEPTORS CLIN INVES, V1, pe202; Neel DS, 2013, CLIN CANCER RES, V19, P3, DOI 10.1158/1078-0432.CCR-12-3232; Patel JD, 2014, J CLIN ONCOL, V32, P129, DOI 10.1200/JCO.2013.53.7076; Ren H, 2016, ONCOTARGET, V7, P67277, DOI 10.18632/oncotarget.11645; Ren H, 2012, CANCER LETT, V325, P139, DOI 10.1016/j.canlet.2012.06.018; Rodon J, 2014, INVEST NEW DRUG, V32, P670, DOI 10.1007/s10637-014-0082-9; Roper J, 2014, CANCER LETT, V347, P204, DOI 10.1016/j.canlet.2014.02.018; Rosell R, 2013, TRANSL LUNG CANCER R, V2, P152, DOI 10.3978/j.issn.2218-6751.2012.12.08; Scherzad A, 2015, INT J ONCOL, V47, P391, DOI 10.3892/ijo.2015.3009; Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sos ML, 2014, CELL REP, V8, P1037, DOI 10.1016/j.celrep.2014.07.010; Stanam A, 2015, MOL ONCOL, V9, P1371, DOI 10.1016/j.molonc.2015.03.008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sun SY, 2014, CANCER RES, V74, P7546, DOI 10.1158/0008-5472.CAN-14-0826; Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Von Hoff DD, 2010, J CLIN ONCOL, V28, P2541; Vyse S, 2017, J MOL BIOL, V429, P1767, DOI 10.1016/j.jmb.2017.04.018; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang L, 2014, BIOCHEM BIOPH RES CO, V453, P582, DOI 10.1016/j.bbrc.2014.09.129; Zhang H, 2015, ONCOTARGET, V6, P3085, DOI 10.18632/oncotarget.3099	62	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					377	388		10.1038/onc.2017.339	http://dx.doi.org/10.1038/onc.2017.339			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945228				2023-01-03	WOS:000422753900010
J	Chan, JSK; Sng, MK; Teo, ZQ; Chong, HC; Twang, JS; Tan, NS				Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.			Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors	ONCOGENE			English	Article							METASTATIC COLORECTAL-CANCER; RESISTANT PROSTATE-CANCER; PHASE-II TRIAL; RETINOIC ACID; CELL; PROGRESSION; TRANILAST; MICROENVIRONMENT; HYPOXIA; DISEASE	Most anticancer therapies to date focus on druggable features of tumor epithelia. Despite the increasing repertoire of treatment options, patient responses remain varied. Moreover, tumor resistance and relapse remain persistent clinical challenges. These observations imply an incomplete understanding of tumor heterogeneity. The tumor microenvironment is a major determinant of disease progression and therapy outcome. Cancer-associated fibroblasts (CAFs) are the dominant cell type within the reactive stroma of tumors. They orchestrate paracrine pro-tumorigenic signaling with adjacent tumor cells, thus exacerbating the hallmarks of cancer and accelerating tumor malignancy. Although CAF-derived soluble factors have been investigated for tumor stroma-directed therapy, the underlying transcriptional programs that enable the oncogenic functions of CAFs remain poorly understood. Nuclear receptors (NRs), a large family of ligand-responsive transcription factors, are pharmacologically viable targets for the suppression of CAF-facilitated oncogenesis. In this study, we defined the expression profiles of NRs in CAFs from clinical cutaneous squamous cell carcinoma (SCC) biopsies. We further identified a cluster of driver NRs in CAFs as important modifiers of CAF function with profound influence on cancer cell invasiveness, proliferation, drug resistance, energy metabolism and oxidative stress status. Importantly, guided by the NR profile of CAFs, retinoic acid receptor beta and androgen receptor antagonists were identified for concurrent therapy with cisplatin, resulting in the inhibition of chemoresistance in recurred SCC: CAF xenografts. Our work demonstrates that treatments targeting both the tumor epithelia and the surrounding CAFs can extend the efficacy of conventional chemotherapy.	[Chan, J. S. K.; Sng, M. K.; Teo, Z. Q.; Chong, H. C.; Twang, J. S.; Tan, N. S.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Sng, M. K.; Tan, N. S.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Tan, N. S.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Tan, N. S.] KK Womens & Children Hosp, Singapore, Singapore; [Chong, H. C.] DeNova Sci Pte Ltd, 16 Nanyang Dr, Singapore 637722, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Chan, JSK; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	CHAN0693@e.ntu.edu.sg; nstan@ntu.edu.sg	Tan, Nguan Soon/A-2220-2011; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Sng, Ming Keat/0000-0002-5529-4371	Singapore Ministry of Education [MOE2014-T2-1-012]; Singapore Ministry of Education (AcRF Tier 1) [RG134/15]; Nanyang President Graduate Scholarship	Singapore Ministry of Education(Ministry of Education, Singapore); Singapore Ministry of Education (AcRF Tier 1)(Ministry of Education, Singapore); Nanyang President Graduate Scholarship	The work was supported by grants from the Singapore Ministry of Education (MOE2014-T2-1-012 and AcRF Tier 1 RG134/15) to NST. JSKC is a recipient of the Nanyang President Graduate Scholarship.	Bhagwat AS, 2015, TRENDS CANCER, V1, P53, DOI 10.1016/j.trecan.2015.07.001; Bizzarri M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/934038; Byun JS, 2013, AM J PATHOL, V182, P1055, DOI 10.1016/j.ajpath.2013.01.009; Chen YY, 2007, BIOMED CHROMATOGR, V21, P628, DOI 10.1002/bmc.798; Darby IA, 2016, CELL MOL LIFE SCI, V73, P1145, DOI 10.1007/s00018-015-2110-0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Ghandadi M, 2016, CURR PHARM DESIGN, V22, P518, DOI 10.2174/1381612822666151124234417; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Hong K, 2014, IMMUNOL LETT, V162, P34, DOI 10.1016/j.imlet.2014.06.011; Hong LZ, 2013, ONCOL LETT, V6, P1595, DOI 10.3892/ol.2013.1590; Izumi K, 2010, ANTICANCER RES, V30, P3077; Izumi K, 2009, PROSTATE, V69, P1222, DOI 10.1002/pros.20975; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Lam CRI, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.339; Lisanti MP, 2010, CANCER BIOL THER, V10, P537, DOI 10.4161/cbt.10.6.13370; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Ohshio Y, 2014, SCAND J IMMUNOL, V80, P408, DOI 10.1111/sji.12242; Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI [10.2217/fon.14.83, 10.2217/FON.14.83]; Redmond Aisling M, 2009, Genome Biol, V10, P311, DOI 10.1186/gb-2009-10-7-311; Rieger S, 2015, CELL BIOCHEM FUNCT, V33, P1, DOI 10.1002/cbf.3086; Rio D.C., 2010, COLD SPRING HARBOR P, P5439, DOI DOI 10.1101/PDB.PROT5439; Rothaeusler K, 2007, CURR PROTOC CYTOM, V7, P31; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Simkova D, 2016, BIOMED PAP, V160, P467, DOI 10.5507/bp.2016.037; Sladek FM, 2003, EXPERT OPIN THER TAR, V7, P679; Sonnenschein C, 2016, PROG BIOPHYS MOL BIO, V122, P70, DOI 10.1016/j.pbiomolbio.2016.07.004; Spaw M, 2017, MOL CARCINOGEN, V56, P1199, DOI 10.1002/mc.22583; SUZAWA H, 1992, JPN J PHARMACOL, V60, P91, DOI 10.1254/jjp.60.91; Tan NS, 2016, PROG LIPID RES, V64, P98, DOI 10.1016/j.plipres.2016.09.001; Tesei A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062657; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Togo Shinsaku, 2013, Cancers (Basel), V5, P149, DOI 10.3390/cancers5010149; van de Pavert SA, 2009, NAT IMMUNOL, V10, P1193, DOI 10.1038/ni.1789; Vazquez-Villa F, 2015, TUMOR BIOL, V36, P2213, DOI 10.1007/s13277-015-3295-4; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yin K, 2016, CELL MOL LIFE SCI, V73, P3789, DOI 10.1007/s00018-016-2329-4; Zou CH, 2005, J BIOCHEM BIOPH METH, V64, P207, DOI 10.1016/j.jbbm.2005.08.001	50	44	44	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					160	173		10.1038/onc.2017.319	http://dx.doi.org/10.1038/onc.2017.319			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892046	Green Published, hybrid			2023-01-03	WOS:000422631700003
J	Cruz-Acuna, R; Quiros, M; Farkas, AE; Dedhia, PH; Huang, S; Siuda, D; Garcia-Hernandez, V; Miller, AJ; Spence, JR; Nusrat, A; Garcia, AJ				Cruz-Acuna, Ricardo; Quiros, Miguel; Farkas, Attila E.; Dedhia, Priya H.; Huang, Sha; Siuda, Dorothee; Garcia-Hernandez, Vicky; Miller, Alyssa J.; Spence, Jason R.; Nusrat, Asma; Garcia, Andres J.			Synthetic hydrogels for human intestinal organoid generation and colonic wound repair	NATURE CELL BIOLOGY			English	Article							PLURIPOTENT STEM-CELLS; IN-VITRO; ENGRAFTMENT; INDUCTION; PEPTIDES; DISEASE; CULTURE; MARKER; CANCER; TISSUE	In vitro differentiation of human intestinal organoids (HIOs) from pluripotent stem cells is an unparalleled system for creating complex, multicellular three-dimensional structures capable of giving rise to tissue analogous to native human tissue. Current methods for generating HIOs rely on growth in an undefined tumour-derived extracellular matrix (ECM), which severely limits the use of organoid technologies for regenerative and translational medicine. Here, we developed a fully defined, synthetic hydrogel based on a four-armed, maleimide-terminated poly( ethylene glycol) macromer that supports robust and highly reproducible in vitro growth and expansion of HIOs, such that three-dimensional structures are never embedded in tumour-derived ECM. We also demonstrate that the hydrogel serves as an injection vehicle that can be delivered into injured intestinal mucosa resulting in HIO engraftment and improved colonic wound repair. Together, these studies show proof-of-concept that HIOs may be used therapeutically to treat intestinal injury.	[Cruz-Acuna, Ricardo] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Cruz-Acuna, Ricardo; Garcia, Andres J.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; [Quiros, Miguel; Siuda, Dorothee; Garcia-Hernandez, Vicky; Nusrat, Asma] Univ Michigan, Dept Pathol, Ann Arbor, MI 48104 USA; [Farkas, Attila E.] Hungarian Acad Sci, Inst Biophys, Biol Res Ctr, H-6726 Szeged, Hungary; [Dedhia, Priya H.; Huang, Sha; Miller, Alyssa J.; Spence, Jason R.] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48104 USA; [Dedhia, Priya H.; Huang, Sha; Spence, Jason R.] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48104 USA; [Dedhia, Priya H.; Huang, Sha; Spence, Jason R.] Univ Michigan, Sch Med, Ctr Organogenesis, Ann Arbor, MI 48104 USA; [Garcia, Andres J.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Michigan System; University of Michigan; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Georgia; Georgia Institute of Technology	Garcia, AJ (corresponding author), Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.; Nusrat, A (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48104 USA.; Spence, JR (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48104 USA.; Spence, JR (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48104 USA.; Spence, JR (corresponding author), Univ Michigan, Sch Med, Ctr Organogenesis, Ann Arbor, MI 48104 USA.; Garcia, AJ (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	spencejr@umich.edu; anusrat@med.umich.edu; andres.garcia@me.gatech.edu	Farkas, Attila/J-3879-2015	Farkas, Attila/0000-0002-9519-5968; Miller, Alyssa/0000-0002-4069-1550; Garcia, Andres/0000-0001-6602-2518; Quiros, Miguel/0000-0002-0089-3502; Spence, Jason/0000-0001-7869-3992; Cruz-Acuna, Ricardo/0000-0002-1772-6102	National Institute of Health; Regenerative Engineering; Medicine Research Center between Emory University, Georgia Tech; University of Georgia; Intestinal Stem Cell Consortium [U01DK103141]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); NIAID Novel, Alternative Model Systems for Enteric Diseases (NAMSED) consortium [U19AI116482]; PHS from Clinical and Translational Science Award Program [UL1TR000454]; National Science Foundation Graduate Research Fellowship [DGE-1650044]; Alfred P. Sloan Foundation's Minority Ph.D. (MPHD) Program [G-2016-20166039]; Crohn's and Colitis Foundation of America (CCFA) [326912]; Janos Bolyai Research Fellowship [BO/00023/17/8];  [R01 AR062368];  [R01 AR062920];  [DK055679];  [DK059888];  [DK089763]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL115372, R01HL119215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI116482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR062920, R01AR062368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE007057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK089763, R01DK055679, R01DK059888, U01DK103141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Regenerative Engineering; Medicine Research Center between Emory University, Georgia Tech; University of Georgia; Intestinal Stem Cell Consortium; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID Novel, Alternative Model Systems for Enteric Diseases (NAMSED) consortium; PHS from Clinical and Translational Science Award Program; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); Alfred P. Sloan Foundation's Minority Ph.D. (MPHD) Program; Crohn's and Colitis Foundation of America (CCFA); Janos Bolyai Research Fellowship(Hungarian Academy of Sciences); ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by the National Institute of Health (A.J.G. was supported by R01 AR062368 and R01 AR062920; A.N. was supported by DK055679, DK059888 and DK089763) and a seed grant from the Regenerative Engineering and Medicine Research Center between Emory University, Georgia Tech and the University of Georgia. J.R.S. was supported by the Intestinal Stem Cell Consortium (U01DK103141), a collaborative research project funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Allergy and Infectious Diseases (NIAID), by the NIAID Novel, Alternative Model Systems for Enteric Diseases (NAMSED) consortium (U19AI116482) and PHS Grant UL1TR000454 from the Clinical and Translational Science Award Program. R.C.-A. is supported by the National Science Foundation Graduate Research Fellowship (DGE-1650044) and the Alfred P. Sloan Foundation's Minority Ph.D. (MPHD) Program (G-2016-20166039). M.Q. is supported by a fellowship from the Crohn's and Colitis Foundation of America (CCFA 326912). A.E.F. is supported by Janos Bolyai Research Fellowship (BO/00023/17/8). We would like to thank Y.-H. Tsai (University of Michigan, USA) for providing tissue sections for immunohistochemical analysis.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Besson D, 2011, MOL CELL PROTEOMICS, V10, DOI [10.1074/mcp.M111.009712-1, 10.1074/mcp.M111.009712]; Caiazzo M, 2016, NAT MATER, V15, P344, DOI [10.1038/nmat4536, 10.1038/NMAT4536]; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Dekkers JF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8278; Dekkers JF, 2013, NAT MED, V19, P939, DOI 10.1038/nm.3201; Dye BR, 2016, ELIFE, V5, DOI 10.7554/eLife.19732; Dye BR, 2015, ELIFE, V4, DOI 10.7554/eLife.05098; Emsley J, 2004, J MOL BIOL, V335, P1019, DOI 10.1016/j.jmb.2003.11.030; Enemchukwu NO, 2016, J CELL BIOL, V212, P113, DOI 10.1083/jcb.201506055; Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312; Finkbeiner SR, 2015, BIOL OPEN, V4, P1462, DOI 10.1242/bio.013235; Finkbeiner SR, 2015, STEM CELL REP, V4, P1140, DOI 10.1016/j.stemcr.2015.04.010; Fox IJ, 2014, SCIENCE, V345, P889, DOI 10.1126/science.1247391; Gerbe F, 2009, GASTROENTEROLOGY, V137, P2179, DOI 10.1053/j.gastro.2009.06.072; Glorevski N, 2016, NATURE, V539, P560, DOI 10.1038/nature20168; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Hughes CS, 2010, PROTEOMICS, V10, P1886, DOI 10.1002/pmic.200900758; Jang BG, 2016, HISTOPATHOLOGY, V68, P567, DOI 10.1111/his.12787; Kikkawa Y, 2013, CELL ADHES MIGR, V7, P150, DOI 10.4161/cam.22827; Kita-Matsuo H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005046; Leoni G, 2015, J CLIN INVEST, V125, P1215, DOI 10.1172/JCI76693; Leslie JL, 2015, INFECT IMMUN, V83, P138, DOI 10.1128/IAI.02561-14; McCracken KW, 2011, NAT PROTOC, V6, P1920, DOI 10.1038/nprot.2011.410; Phelps EA, 2013, BIOMATERIALS, V34, P4602, DOI 10.1016/j.biomaterials.2013.03.012; Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574; Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761; Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2015, DEVELOPMENT, V142, P3274, DOI 10.1242/dev.114249; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; Wells JM, 2014, DEVELOPMENT, V141, P752, DOI 10.1242/dev.097386; Wickstrom SA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005116; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695	38	276	282	26	230	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2017	19	11					1326	+		10.1038/ncb3632	http://dx.doi.org/10.1038/ncb3632			19	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FM5JG	29058719	Green Accepted			2023-01-03	WOS:000415069100008
J	Lee, JE; Lim, JH; Jang, HM; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Kwon, E; Kim, HJ; Park, JM; Jung, HY; Choi, JY; Park, SH; Kim, CD; Cho, JH; Kim, YL				Lee, Ji-Eun; Lim, Jeong-Hoon; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Kwon, Eugene; Kim, Hyun-Ji; Park, Jeung-Min; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Cho, Jang-Hee; Kim, Yong-Lim		Clinical Res Center End Stage	Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: A prospective multicenter cohort study	PLOS ONE			English	Article							MINERAL METABOLISM; HEMODIALYSIS-PATIENTS; KIDNEY-DISEASE; HYPOPHOSPHATEMIA; CALCIUM; CONSEQUENCES; PHOSPHORUS; OUTCOMES; DEATH; CKD	Background The role of mineral metabolism in mortality among dialysis patients has received increased attention, but some aspects remain unclear. The aim of the present study was to investigate the prognostic value of serum calcium and phosphate levels for all-cause mortality and cause-specific mortality in dialysis patients. Methods Patients on hemodialysis and peritoneal dialysis were enrolled from a multicenter prospective cohort study in Korea (NCT00931970). The patients were divided into low, normal, and high groups according to their baseline serum calcium or phosphate levels. Cox proportional analysis and a proportional hazards model for the subdistribution of a competing risk were used to calculate hazard ratios (HRs) for the association of serum calcium and phosphate levels with all-cause and cause-specific mortality. Time- dependent values of calcium and phosphate were also evaluated to assess the effect of longitudinal change in mineral metabolism parameters on mortality types. Results A total of 3,226 dialysis patients were followed up for a mean of 19.8 +/- 8.2 months. Infection was the most common cause of death. Low serum phosphate was significantly associated with all-cause and infection-related death using time-dependent values (HR, 1.43 [95% confidence interval (CI), 1.06-1.93], P = 0.02, and HR, 1.66 [95% CI, 1.02-2.70], P = 0.04, respectively). Low serum phosphate was associated with significantly higher infectionrelated mortality, especially in patients older than 65 years or on dialysis more than one year or with serum albumin lower than 3.9 g/dL (HR, 2.06 [95% CI, 1.13-3.75], P = 0.02, HR, 2.19 [95% CI, 1.20-4.01], P = 0.01, and HR, 1.77 [95% CI, 1.00-3.13], P = 0.05, respectively). Multinomial logistic regression analysis results suggested that low serum albumin, creatinine, and body mass index correlated with low serum phosphate. Conclusions Low serum phosphate in dialysis patients was an independent risk factor for infectionrelated death, especially in elderly patients. Persistently low serum phosphate might be a nutritional biomarker to predict increased susceptibility to infection and in turn worse outcomes in dialysis patients.	[Lee, Ji-Eun; Lim, Jeong-Hoon; Kwon, Eugene; Kim, Hyun-Ji; Park, Jeung-Min; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Cho, Jang-Hee; Kim, Yong-Lim] Kyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South Korea; [Lee, Ji-Eun; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Kwon, Eugene; Kim, Hyun-Ji; Park, Jeung-Min; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Cho, Jang-Hee; Kim, Yong-Lim] Clin Res Ctr End Stage Renal Dis, Daegu, South Korea; [Jang, Hye Min] Kyungpook Natl Univ, Dept Stat, Daegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Med Sch, Dept Internal Med, Gwangju, South Korea	Kyungpook National University; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University	Cho, JH; Kim, YL (corresponding author), Kyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South Korea.; Cho, JH; Kim, YL (corresponding author), Clin Res Ctr End Stage Renal Dis, Daegu, South Korea.	jh-cho@knu.ac.kr; ylkim@knu.ac.kr	Cho, Jang-hee/ABD-3534-2020; Lim, Jeong-Hoon/ABE-6003-2020; Park, Sun/GSD-9620-2022	Cho, Jang-hee/0000-0002-7031-5214; Lim, Jeong-Hoon/0000-0001-5517-9886; Jung, Hee-Yeon/0000-0003-0232-7202	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C0001, HC15C1129]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant numbers: HI15C0001 and HC15C1129, URL: https://www.khidi.or.kr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amanzadeh J, 2006, NAT CLIN PRACT NEPHR, V2, P136, DOI 10.1038/ncpneph0124; [Anonymous], 2003, AM J KIDNEY DIS S, V42, pS1, DOI DOI 10.1016/S0272-6386(03)00905-3; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Choi JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084257; Chung S, 2012, OPEN J INT MED, V2, P89, DOI [DOI 10.4236/OJIM.2012.22018, 10.4236/ojim.2012.2201]; Collins AJ, 2009, AM J KIDNEY DIS, V55, pS1; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Haglin L, 2001, POSTGRAD MED J, V77, P305, DOI 10.1136/pmj.77.907.305; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Koch M, 2000, NEPHRON, V86, P552, DOI 10.1159/000045869; Liamis G, 2010, QJM-INT J MED, V103, P449, DOI 10.1093/qjmed/hcq039; Lin Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/430185; Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P563, DOI 10.1093/ndt/17.4.563; London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48; Mazzaferro S, 2014, SEMIN NEPHROL, V34, P598, DOI 10.1016/j.semnephrol.2014.09.006; McDonald S, 2012, ANZDATA REGISTRY REP; Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542; Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98; Movilli E, 2005, NEPHRON CLIN PRACT, V101, pC161, DOI 10.1159/000087391; Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013; Noordzij M, 2008, BLOOD PURIFICAT, V26, P231, DOI 10.1159/000118847; OECD Publishing, 2014, OECD OB UPD 2014; Panichi V, 2008, NEPHROL DIAL TRANSPL, V23, P2337, DOI 10.1093/ndt/gfm951; Reffelmann T, 2011, ATHEROSCLEROSIS, V219, P280, DOI 10.1016/j.atherosclerosis.2011.05.038; Rivara MB, 2015, J AM SOC NEPHROL, V26, P1671, DOI 10.1681/ASN.2014050472; Saleh FN, 2003, EUR HEART J, V24, P2054, DOI 10.1016/j.ehj.2003.09.010; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1111/j.1523-1755.2000.00337.x; Shinaberger CS, 2008, AM J CLIN NUTR, V88, P1511, DOI 10.3945/ajcn.2008.26665; Stenvinkel P, 2005, KIDNEY INT, V67, P1216, DOI 10.1111/j.1523-1755.2005.00200.x; Tangri N, 2011, AM J KIDNEY DIS, V57, P415, DOI 10.1053/j.ajkd.2010.08.037; US Renal Data System, 2013, USRDS 2013 ANN DAT R; Wald R, 2008, AM J KIDNEY DIS, V52, P531, DOI 10.1053/j.ajkd.2008.05.020; Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523-1755.2005.00185.x	33	10	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2017	12	10							e0185853	10.1371/journal.pone.0185853	http://dx.doi.org/10.1371/journal.pone.0185853			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI6UJ	28973026	gold, Green Submitted, Green Published			2023-01-03	WOS:000412131900062
J	Sacks, HS				Sacks, Henry S.			Review: In older patients with chronic disease, transitional care reduces mortality and readmissions	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Sacks, Henry S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sacks, HS (corresponding author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.							Bryant-Lukosius D, 2015, J EVAL CLIN PRACT, V21, P763, DOI 10.1111/jep.12401; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Van Spall Harriette G C, 2017, Eur J Heart Fail, V19, P1427, DOI 10.1002/ejhf.765	3	2	2	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 19	2017	167	6					JC32	JC32		10.7326/ACPJC-2017-167-6-032	http://dx.doi.org/10.7326/ACPJC-2017-167-6-032			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH2YU	28975322				2023-01-03	WOS:000411009900009
J	Hoogeveen, EK; Rothman, KJ; Voskamp, PWM; de Mutsert, R; Halbesma, N; Dekker, FW				Hoogeveen, Ellen K.; Rothman, Kenneth J.; Voskamp, Pauline W. M.; de mutsert, Renee; Halbesma, Nynke; Dekker, Friedo W.		PREPARE-2 Study Grp	Obesity and risk of death or dialysis in younger and older patients on specialized pre-dialysis care	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; BODY-MASS INDEX; RENAL REPLACEMENT THERAPY; SURVIVAL ANALYSIS; MORTALITY; ASSOCIATION; BMI	Background Obesity is associated with increased mortality and accelerated decline in kidney function in the general population. Little is known about the effect of obesity in younger and older predialysis patients. The aim of this study was to assess the extent to which obesity is a risk factor for death or progression to dialysis in younger and older patients on specialized pre-dialysis care. Method In a multicenter Dutch cohort study, 492 incident pre-dialysis patients (> 18y) were included between 2004-2011 and followed until start of dialysis, death or October 2016. We grouped patients into four categories of baseline body mass index (BMI): < 20, 20-24 (reference), 25-29, and-30 (obesity) kg/m(2) and stratified patients into two age categories (<65y or >= 65y). Results The study population comprised 212 patients younger than 65 years and 280 patients 65 years and older; crude cumulative risk of dialysis and mortality at the end of follow-up were 66% and 4% for patients < 65y and 64% and 14%, respectively, for patients >= 65y. Among the < 65y patients, the age-sex standardized combined outcome rate was 2.3 times higher in obese than those with normal BMI, corresponding to an excess rate of 35 events/ 100 patient-years. After multivariable adjustment the hazard ratios (HR) (95% CI) for the combined endpoint by category of increasing BMI were, for patients < 65y, 0.92 (0.41-2.09), 1 (reference), 1.76 (1.16-2.68), and 1.81 (1.17-2.81). For patients >= 65y the BMI-specific HRs were 1.73 (0.97-3.08), 1 (reference), 1.25 (0.91-1.71) and 1.30 (0.79-1.90). In the competing risk analysis, taking dialysis as the event of interest and death as a competing event, the BMI-specific multivariable adjusted subdistribution HRs (95% CI) were, for patients <65y, 0.90 (0.38-2.12), 1 (reference), 1.47 (0.96-2.24) and 1.72 (1.15-2.59). For patients-65y the BMI-specific SHRs (95% CI) were 1.68 (0.93-3.02), 1 (reference), 1.50 (1.05-2.14) and 1.80 (1.23-2.65). Conclusion We found that obesity in younger pre-dialysis patients and being underweight in older pre-dialysis patients are risk factors for starting dialysis and for death, compared with those with a normal BMI.	[Hoogeveen, Ellen K.; Voskamp, Pauline W. M.; de mutsert, Renee; Halbesma, Nynke; Dekker, Friedo W.] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands; [Hoogeveen, Ellen K.] Jeroen Bosch Hosp, Dept Nephrol, Den Bosch, Netherlands; [Rothman, Kenneth J.] RTI Int, RTI Hlth Solut, Res Triangle Pk, NC USA; [Halbesma, Nynke] Univ Edinburgh, Usher Inst Populat Hlth Sci & Med Informat, Edinburgh, Midlothian, Scotland	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Jeroen Bosch Ziekenhuis; Research Triangle Institute; University of Edinburgh	Hoogeveen, EK (corresponding author), Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands.; Hoogeveen, EK (corresponding author), Jeroen Bosch Hosp, Dept Nephrol, Den Bosch, Netherlands.	ellen.hoogeveen@planet.nl	Hoogeveen, Ellen K./I-2947-2019; Dekker, Friedo/B-6452-2011	Hoogeveen, Ellen K./0000-0002-5482-2013; Dekker, Friedo/0000-0002-2433-2494	Dutch Kidney Foundation [SB 110]; Amgen; Baxter	Dutch Kidney Foundation; Amgen(Amgen); Baxter	This study was supported by a grant from the Dutch Kidney Foundation (SB 110) and previously by unrestricted grants from Amgen and Baxter. The funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials.	Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; [Anonymous], 2009, ANN REP 2009; [Anonymous], 2011, KINDN DIS IMPR GLOB; Brown RNKL, 2012, NEPHROL DIAL TRANSPL, V27, P2776, DOI 10.1093/ndt/gfr757; Collins AJ, 2015, KIDNEY INT SUPPL, V5, P2, DOI 10.1038/kisup.2015.2; de Goeij MCM, 2012, E COMMUNICATION; de Goeij MCM, 2015, NEPHRON EXTRA, V5, P19, DOI 10.1159/000371410; de Goeij MCM, 2014, NEPHROL DIAL TRANSPL, V29, P1391, DOI 10.1093/ndt/gft533; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; de Mutsert R, 2009, KIDNEY INT, V75, P677, DOI 10.1038/ki.2008.645; Dekker FW, 2008, KIDNEY INT, V74, P994, DOI 10.1038/ki.2008.328; Dutch Federation of Nephrology, 2011, MULT GUID PRED; Ejerblad E, 2006, J AM SOC NEPHROL, V17, P1695, DOI 10.1681/ASN.2005060638; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Garofalo C, 2017, KIDNEY INT, V91, P1224, DOI 10.1016/j.kint.2016.12.013; Hoogeveen EK, 2012, CLIN J AM SOC NEPHRO, V7, P280, DOI 10.2215/CJN.05700611; Hoogeveen EK, 2011, TRANSPLANTATION, V91, P869, DOI 10.1097/TP.0b013e3182100f3a; Hsu CY, 2009, ARCH INTERN MED, V169, P342, DOI 10.1001/archinternmed.2008.605; Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248; Iseki K, 2004, KIDNEY INT, V65, P1870, DOI 10.1111/j.1523-1755.2004.00582.x; Jager KJ, 2010, NEPHROL DIAL TRANSPL, V25, P3836, DOI 10.1093/ndt/gfq540; Jin DC, 2015, KIDNEY INT SUPPL, V5, P8, DOI 10.1038/kisup.2015.3; Kleinbaum DG, 1997, SURVIVAL ANAL SELF L, P133; Lu JL, 2015, LANCET DIABETES ENDO, V3, P704, DOI 10.1016/S2213-8587(15)00128-X; Lu JL, 2014, J AM SOC NEPHROL, V25, P2088, DOI 10.1681/ASN.2013070754; Mallamaci F, 2011, J AM SOC NEPHROL, V22, P1122, DOI 10.1681/ASN.2010090969; Noordzij M, 2013, NEPHROL DIAL TRANSPL, V28, P2670, DOI 10.1093/ndt/gft355; O'Hare AM, 2006, J AM SOC NEPHROL, V17, P846, DOI 10.1681/ASN.2005090986; Pippias M, 2015, CLIN KIDNEY J, V8, P248, DOI 10.1093/ckj/sfv014; Praga M, 2002, NEPHROL DIAL TRANSPL, V17, P1157, DOI 10.1093/ndt/17.7.1157; Rosansky SJ, 2013, J AM SOC NEPHROL, V24, P1367, DOI 10.1681/ASN.2013050458; Rothman KJ, 2008, INT J OBESITY, V32, pS56, DOI 10.1038/ijo.2008.87; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, Vsecond, P329; ROTHMAN KJ, 1974, AM J EPIDEMIOL, V99, P385, DOI 10.1093/oxfordjournals.aje.a121626; ROTHMAN KJ, 1980, AM J EPIDEMIOL, V112, P467, DOI 10.1093/oxfordjournals.aje.a113015; Rothman KJ, 2012, EPIDEMIOLOGY INTRO, V2nd, P198; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; van Dis I, 2009, EUR J CARDIOV PREV R, V16, P729, DOI 10.1097/HJR.0b013e328331dfc0; World Health Organization, 2000, WHO TECH REP SER, V894, P39	40	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2017	12	9							e0184007	10.1371/journal.pone.0184007	http://dx.doi.org/10.1371/journal.pone.0184007			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF8QL	28873467	gold, Green Published, Green Submitted			2023-01-03	WOS:000409282800041
J	Cardea, E; Nordhjem, B; Marcusson-Clavertz, D; Holmqvist, K				Cardea, Etzel; Nordhjem, Barbara; Marcusson-Clavertz, David; Holmqvist, Kenneth			The "hypnotic state" and eye movements: Less there than meets the eye?	PLOS ONE			English	Article							HYPNOSIS; SUSCEPTIBILITY; HYPOTHESIS	Responsiveness to hypnotic procedures has been related to unusual eye behaviors for centuries. Kallio and collaborators claimed recently that they had found a reliable index for "the hypnotic state" through eye-tracking methods. Whether or not hypnotic responding involves a special state of consciousness has been part of a contentious debate in the field, so the potential validity of their claim would constitute a landmark. However, their conclusion was based on 1 highly hypnotizable individual compared with 14 controls who were not measured on hypnotizability. We sought to replicate their results with a sample screened for High (n = 16) or Low (n = 13) hypnotizability. We used a factorial 2 (high vs. low hypnotizability) x 2 (hypnosis vs. resting conditions) counterbalanced order design with these eye-tracking tasks: Fixation, Saccade, Optokinetic nystagmus (OKN), Smooth pursuit, and Antisaccade (the first three tasks has been used in Kallio et al.'s experiment). Highs reported being more deeply in hypnosis than Lows but only in the hypnotic condition, as expected. There were no significant main or interaction effects for the Fixation, OKN, or Smooth pursuit tasks. For the Saccade task both Highs and Lows had smaller saccades during hypnosis, and in the Antisaccade task both groups had slower Antisaccades during hypnosis. Although a couple of results suggest that a hypnotic condition may produce reduced eye motility, the lack of significant interactions (e.g., showing only Highs expressing a particular eye behavior during hypnosis) does not support the claim that eye behaviors (at least as measured with the techniques used) are an indicator of a "hypnotic state." Our results do not preclude the possibility that in a more spontaneous or different setting the experience of being hypnotized might relate to specific eye behaviors.	[Cardea, Etzel; Marcusson-Clavertz, David] Lund Univ, Dept Psychol, Ctr Res Consciousness & Anomalous Psychol CERCAP, Lund, Sweden; [Nordhjem, Barbara] Univ Groningen, Univ Med Ctr Groningen, Sch Behav & Cognit Neurosci, Lab Expt Ophthalmol, Groningen, Netherlands; [Marcusson-Clavertz, David] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA; [Holmqvist, Kenneth] Lund Univ, Humanities Lab, Eye Tracking Grp, Lund, Sweden; [Holmqvist, Kenneth] UPSET, NWU Vaal, Vanderbijlpark, South Africa	Lund University; University of Groningen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Lund University	Cardea, E (corresponding author), Lund Univ, Dept Psychol, Ctr Res Consciousness & Anomalous Psychol CERCAP, Lund, Sweden.	etzel.cardena@psy.lu.se		Cardena, Etzel/0000-0001-6775-8017; Nordhjem, Barbara/0000-0001-7725-4437	Bial [227-10]; European Union's Horizon 2020 Research and Innovation Programme [641805]	Bial(Bial Group); European Union's Horizon 2020 Research and Innovation Programme	The first author's contribution was partly supported by Bial grant # 227-10. The authors also gratefully acknowledge the Lund University Humanities Lab. The second author (BN) received funding from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no. 641805. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r The first author's contribution was partly supported by Bial grant # 227-10. The authors also gratefully acknowledge the Lund University Humanities Lab. The second author (BN) received funding from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 641805. We thank Sakari Kallio, Ph. D., for sending us his three eye tracking programs, on which we modeled our corresponding ones. The ms. also includes our responses to his review (as per PLOS ONE policy). We are also grateful to two anonymous reviewers who provided very useful suggestions to improve the paper.	Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Braffman W, 1999, J PERS SOC PSYCHOL, V77, P578, DOI 10.1037/0022-3514.77.3.578; Cardena E., 2016, PSYCHOL CONSCIOUS, V3, P61, DOI [10.1037/cns0000080, DOI 10.1037/CNS0000080]; Cardena E, 2013, CORTEX, V49, P375, DOI 10.1016/j.cortex.2012.04.001; Carlson EB, ASSESSMENT; Charcot JM, 1972, DEMONIAQUES ART; Cornelissen FW, 2002, BEHAV RES METH INS C, V34, P613, DOI 10.3758/BF03195489; Council Jr, 1999, DISSOCIAT TRAUM MEM, P119; Crawford HJ, 2000, NEUROIMAGE, P11; Deuter CE, 2013, PSYCHOPHYSIOLOGY, V50, P1056, DOI 10.1111/psyp.12083; Di Gruttola F, 2014, EXP BRAIN RES, V232, P3763, DOI 10.1007/s00221-014-4073-z; DUNWOODY RC, 1974, AM J CLIN HYPN, V16, P270; Eckstein MK, 2016, DEV COGN NEUROSCI; Ellenberger H., 1970, DISCOV UNCONSCIOUS; EVANS FJ, 1966, INT J CLIN EXP HYP, V14, P333, DOI 10.1080/00207146608412976; Hutton SB, 2008, BRAIN COGNITION, V68, P327, DOI 10.1016/j.bandc.2008.08.021; Irwin HJ, 1999, PERCEPT MOTOR SKILL, V89, P1230; Kallio S, 2016, INT J CLIN EXP HYP, V64, P261, DOI 10.1080/00207144.2016.1171088; Kallio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026374; Kihlstrom J.F., 2008, OXFORD HDB HYPNOSIS, P21, DOI [https://doi.org/10.1093/oxfordhb/9780198570097.013.0002, DOI 10.1093/OXFORDHB/9780198570097.013.0002]; KIRSCH I, 1995, AM PSYCHOL, V50, P846, DOI 10.1037/0003-066X.50.10.846; KIRSCH I, 1990, INT J CLIN EXP HYP, V38, P112, DOI 10.1080/00207149008414506; Laeng B, 2012, PERSPECT PSYCHOL SCI, V7, P18, DOI 10.1177/1745691611427305; LAURENCE JR, 1986, INT J CLIN EXP HYP, V34, P215, DOI 10.1080/00207148608406987; Levy Deborah L, 2004, World Psychiatry, V3, P32; Lichtenberg P, 2008, INT J CLIN EXP HYP, V56, P243, DOI 10.1080/00207140802039474; LINDSAY S, 1993, INT J CLIN EXP HYP, V41, P92, DOI 10.1080/00207149308414540; Liversedge SP, 2000, TRENDS COGN SCI, V4, P6, DOI 10.1016/S1364-6613(99)01418-7; McGeown WJ, 2009, CONSCIOUS COGN, V18, P848, DOI 10.1016/j.concog.2009.09.001; O'Driscoll GA, 2008, BRAIN COGNITION, V68, P359, DOI 10.1016/j.bandc.2008.08.023; REGISTER PA, 1986, INT J CLIN EXP HYP, V34, P84, DOI 10.1080/00207148608406974; Sargant W, 1973, MIND POSSESSED PHYSL; Sargant W., 1957, BATTLE FOR THE MIND; SHEEHAN DV, 1979, INT J CLIN EXP HYP, V27, P103, DOI 10.1080/00207147908407550; Shor RE, 1962, HARVARD GROUP SCALE; Smilek D, 2010, PSYCHOL SCI, V21, P786, DOI 10.1177/0956797610368063; Spiegel H., 1978, TRANCE TREATMENT CLI; TEBECIS AK, 1975, BIOL PSYCHOL, V3, P31, DOI 10.1016/0301-0511(75)90004-6; Weitzenhoffer A., 1969, AM J CLIN HYPN, p11 221; WEITZENHOFFER A M, 1971, American Journal of Clinical Hypnosis, V14, P102; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; WEITZENHOFFER AM, 1969, PERCEPT MOTOR SKILL, V28, P671, DOI 10.2466/pms.1969.28.2.671; Woody Erik Z., 1994, P52; Yeates LB, 2013, THESIS	44	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2017	12	8							e0182546	10.1371/journal.pone.0182546	http://dx.doi.org/10.1371/journal.pone.0182546			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE8EO	28846696	Green Published, Green Submitted, gold			2023-01-03	WOS:000408438600012
J	Olusanya, BO; Slusher, TM; Imosemi, DO; Emokpae, AA				Olusanya, Bolajoko O.; Slusher, Tina M.; Imosemi, Donald O.; Emokpae, Abieyuwa A.			Maternal detection of neonatal jaundice during birth hospitalization using a novel twocolor icterometer	PLOS ONE			English	Article							NEWBORN; HYPERBILIRUBINEMIA; COUNTRIES; DISCHARGE; KERNICTERUS; READMISSION; BILIRUBIN; VIETNAM; INFANTS; MOTHERS	Background Mothers are frequently the first to observe the onset of jaundice in their newborn infants before the decision to seek treatment. However, simple-to-use tools that could facilitate early detection of jaundice and assist mothers to seek professional care, especially after hospital discharge, are rare. This study therefore, set out to evaluate the performance of a -two-color icterometer (Bilistrip T) as a possible screening tool for detecting significant jaundice by mothers or care-givers in the first week of life. Methods Prior to discharge, mothers in a maternity hospital were trained to use the Bilistrip T on the blanched skin of their baby's nose to ascertain absence (Light Yellow) or presence (Dark Yellow) of significant jaundice. Their babies had transcutaneous bilirubin (TcB) measurements independently, along with total serum bilirubin (TSB) if indicated. The reliability of Bilistrip T as a screening test for significant jaundice was determined at different TcB and TSB thresholds. The predictive performance of Bilistrip T was also evaluated with multivariable logistic regression. Results Some 2492 mother-infant pairs were enrolled over 15 months, of which 347 (13.9%) chose Dark Yellow. The mean TcB for Dark Yellow (10mg/ dL) was significantly higher (p < 0.001) than for Light Yellow (6.1mg/ dL). Bilistrip T showed increasing sensitivity (47.0% -92.6%) and negative predictive value (NPV) (91.4% -99.9%) for selected TcB thresholds (>= 10mg/ dL, >= 12mg/ dL, >= 15mg/ dL, and >= 17mg/ dL). Among neonates with TSB measurements (n = 124), Bilistrip T was associated also with increasing sensitivity (86.8% -100%) and NPV (62.5% -100%). The sensitivity and NPV for detecting neonates requiring phototherapy were 95.8% respectively. Only one of the 24 neonates who required phototherapy was missed by the Bilistrip (TM) Conclusions Bilistrip T is a potential decision-making tool for empowering mothers to detect neonates with clinically significant jaundice that may require close monitoring or treatment, and neonates not requiring treatment for jaundice in the first week of life.	[Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Lagos, Nigeria; [Slusher, Tina M.] Univ Minnesota, Dept Pediat, Div Global Hlth, Minneapolis, MN 55455 USA; [Slusher, Tina M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Imosemi, Donald O.] Lagos Isl Matern Hosp, Lagos, Nigeria; [Emokpae, Abieyuwa A.] Massey St Childrens Hosp, Lagos, Nigeria	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center	Olusanya, BO (corresponding author), Ctr Hlth Start Initiat, Lagos, Nigeria.	bolajoko.olusanya@uclmail.net	Olusanya, Bolajoko O./F-4504-2012	Olusanya, Bolajoko O./0000-0002-3826-0583	Advanced Instruments Norwood, MA	Advanced Instruments Norwood, MA	Draeger Medical Telford, PA loaned the JM103 (R) transcutaneous bilirubinometer; Advanced Instruments Norwood, MA provided BR2 kits at a subsidized cost for our Advanced Bilirubin Stat-Analyzer. Bilimetrix and sponsors had no role in conceptualizing, analyzing, interpreting, writing, or the decision to submit this paper for publication. The authors have indicated they have no other financial relationships relevant to this article to disclose.	American Academy of Pediatrics Subcommittee on Hyperbilirrubinemia, 2004, PEDIATRICS, V114, P297, DOI DOI 10.1542/PEDS.114.1.297; Austin PC, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-82; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Boo N Y, 2011, Med J Malaysia, V66, P239; Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1148/radiol.2015151516, 10.1373/clinchem.2015.246280]; Burke BL, 2009, PEDIATRICS, V123, P524, DOI 10.1542/peds.2007-2915; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; CHAIBVA NTR, 1974, S AFR MED J, V48, P1533; Ezeaka CV, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-192; GOSSET IH, 1960, LANCET, V1, P87; Goulet L, 2007, BIRTH-ISS PERINAT C, V34, P131, DOI 10.1111/j.1523-536X.2007.00159.x; GUPTA P C, 1991, Indian Pediatrics, V28, P473; HAMEL BCJ, 1982, TROP DOCT, V12, P213, DOI 10.1177/004947558201200429; Hannon PR, 2001, ARCH PEDIAT ADOL MED, V155, P1357, DOI 10.1001/archpedi.155.12.1357; Hansen TWR, 2011, DEV MED CHILD NEUROL, V53, P24, DOI 10.1111/j.1469-8749.2011.04059.x; Herbert HK, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001183; Lain SJ, 2015, PEDIATRICS, V135, P314, DOI 10.1542/peds.2014-2388; Le LT, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-264; Luu MN, 2014, J PAEDIATR CHILD H, V50, P674, DOI 10.1111/jpc.12611; Madlon-Kay DJ, 2002, J FAM PRACTICE, V51, P445; MadlonKay DJ, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.3.e3; Maisels MJ, 2016, ACTA PAEDIATR, V105, pE567, DOI 10.1111/apa.13599; Moawad EMI, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004804; NICE. UK National Institute for Health and Clinical Excellence, 2010, CLIN GUID NEON JAUND; Obuchowski N A, 1998, Stat Methods Med Res, V7, P371, DOI 10.1191/096228098678080061; Olusanya BO, 2016, NIGER J CLIN PRACT, V19, P1, DOI 10.4103/1119-3077.173703; Olusanya BO, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0907; Olusanya BO, 2015, WORLD J PEDIATR, V11, P293, DOI 10.1007/s12519-015-0037-z; Olusanya BO, 2014, ARCH DIS CHILD, V99, P1117, DOI 10.1136/archdischild-2013-305506; SCHUMACHER RE, 1985, PEDIATRICS, V76, P10; Slusher TM, 2015, NEW ENGL J MED, V373, P1115, DOI 10.1056/NEJMoa1501074; Xue GC, 2016, ACTA PAEDIATR, V105, pE561, DOI 10.1111/apa.13542; Zhang L, 2015, MED SCI MONITOR, V21, P1668	33	13	15	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2017	12	8							e0183882	10.1371/journal.pone.0183882	http://dx.doi.org/10.1371/journal.pone.0183882			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7CK	28837635	Green Published, gold, Green Submitted			2023-01-03	WOS:000408365000133
J	Sellami, M; Dhahbi, W; Hayes, LD; Padulo, J; Rhibi, F; Djemail, H; Chaouachi, A				Sellami, Maha; Dhahbi, Wissem; Hayes, Lawrence D.; Padulo, Johnny; Rhibi, Fatma; Djemail, Hanen; Chaouachi, Anis			Combined sprint and resistance training abrogates age differences in somatotropic hormones	PLOS ONE			English	Article							GROWTH-FACTOR-I; FACTOR-BINDING-PROTEIN; HUMAN SKELETAL-MUSCLE; CATECHOLAMINE RESPONSES; SUPRAMAXIMAL EXERCISE; GLUCOREGULATORY HORMONES; PLASMA-GLUCOSE; AGING MEN; 30 S; INTERVAL	The aim of this investigation was to compare serum growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) in response to a combined sprint and resistance training (CSRT) program in young and middle-aged men. Thirty-eight healthy, moderately trained men participated in this study. Young and middle-aged men were randomly assigned to, a young training group (YT = 10, 21.4 +/- 1.2yrs) ora young control group (YC = 9, 21.6 +/- 1.8 yrs), a middle-aged training group (MAT = 10, 40.4 +/- 2.1 yrs) or a middle-aged control group (MAC = 9, 40.5 +/- 1.8 yrs). Participants performed the Wingate Anaerobic Test (WAnT) before and after a 13-week CSRT program (three sessions per week). Blood samples were collected at rest, after warm-up, immediately post-WAnT, and 10 min post-WAnT. CSRT induced increases in GH at rest and in response to the WAnT in YT and MAT (P<0.05). CSRT-induced increases were observed for IGF-1 and IGFBP-3 at rest in MAT only (P<0.05). Pre-training, GH, IGF-1 and IGFBP-3 were significantly higher at rest and in response to the WAnT in young participants as compared to their middle-aged counterparts (P<0.05). Post-training, YT and MAT had comparable basal GH (P>0.05). In response to the WAnT, amelioration of the age-effect was observed between YT and MAT for IGF-1 and IGF-1/IGFBP-3 ratio following CSRT (P>0.05). These data suggest that CSRT increases the activity of the GH/IGF-1 axis at rest and in response to the WAnT in young and middle-aged men. In addition, CSRT reduces the normal age-related decline of somatotropic hormones in middle-age men.	[Sellami, Maha; Dhahbi, Wissem; Padulo, Johnny; Chaouachi, Anis] Natl Ctr Med & Sci Sports, Tunisian Res Lab Sport Performance Optimizat, Tunis, Tunisia; [Hayes, Lawrence D.] Univ Cumbria, Dept Med & Sport Sci, Act Ageing Res Grp, Bowerham Rd, Lancaster, England; [Padulo, Johnny] Univ eCampus, Novedrate, Italy; [Padulo, Johnny] Univ Split, Fac Kinesiol, Split, Croatia; [Rhibi, Fatma] Univ Rennes 2, Movement Sport Hlth & Sci Lab M2S, Rennes, France; [Djemail, Hanen] Mil Hosp Instruct Tunis, Dept Endocrinol, Tunis, Tunisia	Centre National de la Medecine Sciences des Sports; University of Cumbria; Universita Ecampus; University of Split; Universite Rennes 2	Padulo, J (corresponding author), Natl Ctr Med & Sci Sports, Tunisian Res Lab Sport Performance Optimizat, Tunis, Tunisia.; Padulo, J (corresponding author), Univ eCampus, Novedrate, Italy.; Padulo, J (corresponding author), Univ Split, Fac Kinesiol, Split, Croatia.	sportcinetic@gmail.com	Dhahbi, Wissem/A-1445-2019; Hayes, Lawrence D/I-9694-2019; RHIBI, Fatma/H-1353-2019; Hayes, Lawrence/AAI-1315-2020; Padulo, Johnny/AAK-2207-2020	Dhahbi, Wissem/0000-0001-6221-546X; Hayes, Lawrence D/0000-0002-6654-0072; Padulo, Johnny/0000-0002-4254-3105; Sellami, Maha/0000-0003-1832-409X; Rhibi, Fatma/0000-0003-4017-7663				Adams K., 1992, J STRENGTH COND RES, V6, P36, DOI DOI 10.1519/00124278-199202000-00006; Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; Arnarson A, 2015, J NUTR HEALTH AGING, V19, P856, DOI 10.1007/s12603-015-0547-3; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; Ayalon A, 1974, BIOMECHANICS, P572; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Birzniece V, 2011, TRENDS ENDOCRIN MET, V22, P171, DOI 10.1016/j.tem.2011.02.005; Blackman MB, 2002, JAMA-J AM MED ASSOC, V288, P2282, DOI 10.1001/jama.288.18.2282; Borst SE, 2001, MED SCI SPORT EXER, V33, P648; Botcazou M, 2007, PEDIATR EXERC SCI, V19, P132, DOI 10.1123/pes.19.2.132; Brandt T., 2003, NEUROLOGICAL DISORDE; Burgomaster KA, 2005, J APPL PHYSIOL, V98, P1985, DOI 10.1152/japplphysiol.01095.2004; Burgomaster KA, 2006, J APPL PHYSIOL, V100, P2041, DOI 10.1152/japplphysiol.01220.2005; CAPPON J, 1994, J APPL PHYSIOL, V76, P2490, DOI 10.1152/jappl.1994.76.6.2490; Chikani V, 2016, CLIN ENDOCRINOLOGY; Codner E, 1999, REV MED CHILE, V127, P807; Cooper CS, 1998, EUR J ENDOCRINOL, V138, P517, DOI 10.1530/eje.0.1380517; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; De Palo EF, 2008, CLIN CHIM ACTA, V387, P71, DOI 10.1016/j.cca.2007.09.005; de Salles BF, 2009, SPORTS MED, V39, P765, DOI 10.2165/11315230-000000000-00000; Derbre F, 2010, INT J SPORTS MED, V31, P291, DOI 10.1055/s-0030-1248243; DOTAN R, 1983, EUR J APPL PHYSIOL O, V51, P409, DOI 10.1007/BF00429077; DOTAN R, 1980, EUR J APPL PHYSIOL, V44, P237, DOI 10.1007/BF00421623; Driss T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/589361; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Eliakim A, 1996, J CLIN ENDOCR METAB, V81, P3986, DOI 10.1210/jc.81.11.3986; Eliakim A, 2005, ENCYCL SPORTS MED, P165; Fekedulegn DB, 2007, PSYCHOSOM MED, V69, P651, DOI 10.1097/PSY.0b013e31814c405c; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; FRONTERA WR, 1991, J APPL PHYSIOL, V71, P644, DOI 10.1152/jappl.1991.71.2.644; Frystyk J, 2010, MED SCI SPORT EXER, V42, P58, DOI 10.1249/MSS.0b013e3181b07d2d; Gent DN, 2013, J SPORT SCI, V31, P97, DOI 10.1080/02640414.2012.721561; Gibala MJ, 2006, J PHYSIOL-LONDON, V575, P901, DOI 10.1113/jphysiol.2006.112094; Giovannini S, 2010, J NUTR HEALTH AGING, V14, P457; Godfrey RJ, 2003, SPORTS MED, V33, P599, DOI 10.2165/00007256-200333080-00005; Gonzalez A, 2015, LECT NOTES COMPUT SC, V9117, P3, DOI 10.1007/978-3-319-19390-8_1; Harvey S., 1994, GROWTH HORMONE; Hayes LD, 2015, AGING MALE, V18, P195, DOI 10.3109/13685538.2015.1046123; HELLENIUS MLB, 1995, J INTERN MED, V238, P121, DOI 10.1111/j.1365-2796.1995.tb00909.x; Hermann M, 2001, EXP GERONTOL, V36, P1075, DOI 10.1016/S0531-5565(01)00113-9; HO KKY, 1993, HORM RES, V40, P80, DOI 10.1159/000183771; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; INBAR O, 1986, MED SCI SPORT EXER, V18, P264, DOI 10.1249/00005768-198606000-00002; Jaafar H, 2016, INT J SPORT PHYSIOL, V11, P48, DOI 10.1123/ijspp.2015-0063; Jacob C, 2004, EUR J APPL PHYSIOL, V91, P35, DOI 10.1007/s00421-003-1002-4; Jurimae J, 2015, CLIN PHYSL FUNCTIONA; Kim T, 2015, INT J SOFTW INNOV, V3, P1, DOI 10.4018/ijsi.2015010101; Knowles AM, 2015, AGE, V37, DOI 10.1007/s11357-015-9763-3; Korhonen MT, 2003, MED SCI SPORT EXER, V35, P1419, DOI 10.1249/01.MSS.0000079080.15333.CA; Kotzamanidis C, 2005, J STRENGTH COND RES, V19, P369; Kucera R, 2015, CLIN CHIM ACTA, V444, P271, DOI 10.1016/j.cca.2015.02.036; Maharam LG, 1999, SPORTS MED, V28, P273, DOI 10.2165/00007256-199928040-00005; Manetta J, 2002, AM J PHYSIOL-ENDOC M, V283, pE929, DOI 10.1152/ajpendo.00539.2001; Mazziotti G, 2013, NAT REV ENDOCRINOL, V9, P265, DOI 10.1038/nrendo.2013.5; McCall GE, 1999, CAN J APPL PHYSIOL, V24, P96, DOI 10.1139/h99-009; Meinhardt UJ, 2006, CLIN ENDOCRINOL, V65, P413, DOI 10.1111/j.1365-2265.2006.02676.x; Moussa E, 2003, J SPORT MED PHYS FIT, V43, P546; Naspi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098641; Nevill ME, 1996, EUR J APPL PHYSIOL, V72, P460, DOI 10.1007/BF00242276; Olivecrona H, 1999, J CLIN ENDOCR METAB, V84, P553, DOI 10.1210/jc.84.2.553; Ozaki H, 2013, EUR REV AGING PHYS A, V10, P107, DOI 10.1007/s11556-013-0120-1; Padulo J, 2015, J SPORT MED PHYS FIT, V55, P604; Padulo J, 2012, INT J SPORTS MED, V33, P376, DOI 10.1055/s-0031-1299702; Padulo J, 2013, J HUM KINET, V37, P5, DOI 10.2478/hukin-2013-0019; PATTON JF, 1985, INT J SPORTS MED, V6, P82, DOI 10.1055/s-2008-1025818; POEHLMAN ET, 1994, METABOLISM, V43, P1401, DOI 10.1016/0026-0495(94)90035-3; Reaburn P, 1997, J STRENGTH COND RES, V11, P256; RUTANEN EM, 1988, J CLIN ENDOCR METAB, V66, P173, DOI 10.1210/jcem-66-1-173; Salvadori A, 2010, CLIN ENDOCRINOL, V73, P491, DOI 10.1111/j.1365-2265.2010.03837.x; Sculthorpe N, 2015, J AM GERIATR SOC, V63, P2412, DOI 10.1111/jgs.13863; Sellami M, 2019, ETHNIC HEALTH, V24, P182, DOI 10.1080/13557858.2017.1315375; Sellami M, 2017, EXP BIOL MED, V242, P113, DOI 10.1177/1535370216662711; Sellami M, 2014, EUR J APPL PHYSIOL, V114, P969, DOI 10.1007/s00421-014-2828-7; Sipila S, 2013, BIOGERONTOLOGY, V14, P231, DOI 10.1007/s10522-013-9425-8; Sloth M, 2013, SCAND J MED SCI SPOR, V23, pE341, DOI 10.1111/sms.12092; Stokes KA, 2004, EUR J APPL PHYSIOL, V92, P26, DOI 10.1007/s00421-003-1038-5; Stokes KA, 2002, J SPORT SCI, V20, P487, DOI 10.1080/02640410252925152; SWAIN DP, 1994, MED SCI SPORT EXER, V26, P112; Tsai C-L, 2015, FRONTIERS BEHAV NEUR, V9; VANDEWALLE H, 1985, EUR J APPL PHYSIOL, V54, P222, DOI 10.1007/BF02335934; Velloso CP, 2008, BRIT J PHARMACOL, V154, P557, DOI 10.1038/bjp.2008.153; Vitiello MV, 1997, J GERONTOL A-BIOL, V52, pM149, DOI 10.1093/gerona/52A.3.M149; Wideman L, 2002, SPORTS MED, V32, P987, DOI 10.2165/00007256-200232150-00003; Wieczorek-Baranowska A, 2011, J SPORT MED PHYS FIT, V51, P525; Winter E.M., 2006, SPORT EXERCISE PHYSL, VI; Zouhal H, 1998, SCI SPORT, V13, P112, DOI 10.1016/S0765-1597(98)80046-4; Zouhal H, 1999, INT J SPORTS MED, V20, P343, DOI 10.1055/s-2007-971142; Zouhal H, 2001, J SPORT MED PHYS FIT, V41, P330; Zouhal H, 2008, SPORTS MED, V38, P401, DOI 10.2165/00007256-200838050-00004; Zouhal H, 2009, J SCI MED SPORT, V12, P652, DOI 10.1016/j.jsams.2008.03.003	92	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2017	12	8							e0183184	10.1371/journal.pone.0183184	http://dx.doi.org/10.1371/journal.pone.0183184			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD3KL	28800636	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000407431800062
J	Stone, RM; Mandrekar, SJ; Sanford, BL; Laumann, K; Geyer, S; Bloomfield, CD; Thiede, C; Prior, TW; Dohner, K; Marcucci, G; Lo-Coco, F; Klisovic, RB; Wei, A; Sierra, J; Sanz, MA; Brandwein, JM; de Witte, T; Niederwieser, D; Appelbaum, FR; Medeiros, BC; Tallman, MS; Krauter, J; Schlenk, RF; Ganser, A; Serve, H; Ehninger, G; Amadori, S; Larson, RA; Dohner, H				Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S.; Bloomfield, C. D.; Thiede, C.; Prior, T. W.; Doehner, K.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R. A.; Doehner, H.			Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; PHASE-I; FAVORABLE PROGNOSIS; WILD-TYPE; SORAFENIB; YOUNGER; TRIAL; DISTINCT	BACKGROUND Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in this population. METHODS We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 mutations. Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either midostaurin or placebo; those who were in remission after consolidation therapy entered a maintenance phase in which they received either midostaurin or placebo. Randomization was stratified according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal tandem duplication (ITD) mutation with either a high ratio (> 0.7) or a low ratio (0.05 to 0.7) of mutant to wild-type alleles (ITD [high] and ITD [low], respectively). Allogeneic transplantation was allowed. The primary end point was overall survival. RESULTS A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 357 to the placebo group. The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, and TKD in 162 patients. The treatment groups were well balanced with respect to age, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin group vs. 59.4% in the placebo group were women, P = 0.04). Overall survival was significantly longer in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002). In both the primary analysis and an analysis in which data for patients who underwent transplantation were censored, the benefit of midostaurin was consistent across all FLT3 subtypes. The rate of severe adverse events was similar in the two groups. CONCLUSIONS The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261.)	[Stone, R. M.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,D-2053, Boston, MA 02115 USA; [Mandrekar, S. J.; Laumann, K.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Mandrekar, S. J.; Laumann, K.; Geyer, S.] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA; [Sanford, B. L.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA; [Geyer, S.; Bloomfield, C. D.; Prior, T. W.; Marcucci, G.; Klisovic, R. B.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Thiede, C.; Ehninger, G.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany; [Doehner, K.; Schlenk, R. F.; Doehner, H.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany; [Niederwieser, D.] Univ Leipzig, Hematol & Oncol, Leipzig, Germany; [Krauter, J.; Ganser, A.] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [Serve, H.] Goethe Univ Hosp Frankfurt, Dept Med 2, Hematol Oncol, Frankfurt, Germany; [Lo-Coco, F.; Amadori, S.] Univ Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Wei, A.] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia; [Wei, A.] Monash Univ, Melbourne, Vic, Australia; [Sierra, J.] Autonomous Univ Barcelona, Dept Hematol, Hosp Santa Creu & St Pau, Barcelona, Spain; [Sanz, M. A.] Univ Valencia, Dept Med, Dept Hematol, Hosp Univ Fe, Valencia, Spain; [Brandwein, J. M.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada; [de Witte, T.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Studies, Nijmegen, Netherlands; [Appelbaum, F. R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Medeiros, B. C.] Stanford Univ, Stanford Comprehens Canc Ctr, Div Hematol Oncol, Stanford, CA 94305 USA; [Tallman, M. S.] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA; [Tallman, M. S.] Weill Cornell Med Coll, New York, NY USA; [Larson, R. A.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; Mayo Clinic; Duke University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Ulm University; Leipzig University; Hannover Medical School; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Rome Tor Vergata; Florey Institute of Neuroscience & Mental Health; Monash University; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; University of Valencia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Radboud University Nijmegen; Fred Hutchinson Cancer Center; Stanford University; Memorial Sloan Kettering Cancer Center; Cornell University; University of Chicago	Stone, RM (corresponding author), Dana Farber Canc Inst, 450 Brookline Ave,D-2053, Boston, MA 02115 USA.	richard_stone@dfci.harvard.edu	Schlenk, Richard/AAG-3218-2019; Döhner, Hartmut/C-8933-2016; de Witte, T.J.M./L-4762-2015; Sanz, Miguel A./F-7485-2018	Döhner, Hartmut/0000-0003-2116-5536; Sanz, Miguel A./0000-0003-1489-1177; Medeiros, Bruno/0000-0001-6972-8137; Thiede, Christian/0000-0003-1241-2048; Wei, Andrew/0000-0002-7514-3298	National Cancer Institute; Novartis; NATIONAL CANCER INSTITUTE [U10CA180836, U10CA032291, U10CA180867, P30CA016058, U10CA180821, U10CA077658, U10CA033601, U10CA180791, U10CA180882, U10CA180850, U10CA077651, U10CA031946, U10CA180820, U10CA180888, U10CA041287, U10CA180861] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Novartis(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261.	Chen YB, 2014, BIOL BLOOD MARROW TR, V20, P2042, DOI 10.1016/j.bbmt.2014.09.007; Cortes JE, 2013, J CLIN ONCOL, V31, P3681, DOI 10.1200/JCO.2013.48.8783; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Fischer T, 2010, J CLIN ONCOL, V28, P4339, DOI 10.1200/JCO.2010.28.9678; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kindler T, 2010, BLOOD, V116, P5089, DOI 10.1182/blood-2010-04-261867; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Mead AJ, 2007, BLOOD, V110, P1262, DOI 10.1182/blood-2006-04-015826; Metzelder S, 2009, BLOOD, V113, P6567, DOI 10.1182/blood-2009-03-208298; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Perl AE, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1069.1069; Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485; Rollig C, 2015, LANCET ONCOL, V16, P1691, DOI 10.1016/S1470-2045(15)00362-9; Schlenk R, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.322.322; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Stone RM, 2012, LEUKEMIA, V26, P2061, DOI 10.1038/leu.2012.115; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Thol F, 2015, BLOOD, V126, P319, DOI 10.1182/blood-2014-10-551911; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Whitman SP, 2001, CANCER RES, V61, P7233; Whitman SP, 2008, BLOOD, V111, P1552, DOI 10.1182/blood-2007-08-107946	30	1134	1155	9	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 3	2017	377	5					454	464		10.1056/NEJMoa1614359	http://dx.doi.org/10.1056/NEJMoa1614359			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC3NW	28644114	Green Accepted, Bronze			2023-01-03	WOS:000406747100007
J	Schneider, A; Rosenberger, S; Bobardt, J; Bungartz-Catak, J; Atmann, O; Haller, B; Kennedy, A; Enck, P				Schneider, Antonius; Rosenberger, Stefanie; Bobardt, Johanna; Bungartz-Catak, Jessica; Atmann, Oxana; Haller, Bernhard; Kennedy, Anne; Enck, Paul			Self-help guidebook improved quality of life for patients with irritable bowel syndrome	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; COPING STRATEGIES; CENTERED CARE; SYNDROME IBS; DISORDERS; INTERVENTIONS; VALIDITY; COSTS	Background The primary aim of our study was to evaluate the impact of a comprehensive self-help guidebook on the disease related quality of life for patients with irritable bowel syndrome (IBS). The secondary aim was to evaluate whether the guidebook is less effective in IBS patients with depression, somatization disorder or panic disorder as a psychiatric comorbidity. Methods Prospective observational study. At baseline (t1), patients filled in the A Functional Digestive Disorders Quality of Life A (FDDQL) questionnaire and received the IBS guidebook together with an explanation of its content and use. Depression, anxiety and somatization were evaluated with the Patient Health Questionnaire (PHQ). Three (t2) and six months (t3) later, the questionnaire was sent by mail to the patients for follow-up evaluation. Data were analyzed with repeated measures ANOVA. Results 71 patients participated (74.6% female). 53 (74.6%) completed the final assessment at t3 after 6 months. The global FDDQL score increased from 49.3 (SD 12.7) at t1 to 64.3 (SD 16.0) at t3 (p < 0.001). There was a significant between-subjects effect on the global FDDQL score related to depression (p = 0.001), anxiety (p = 0.001) and somatization (p = 0.011). Thus, the quality of life of patients with psychosomatic comorbidity was lower at baseline, but showed a similar increase within the following six months. Conclusion The self-help guidebook significantly improved measured quality of life for IBS patients. The use of screening questionnaires like PHQ might be valuable to identify patients with more complex problems. This might be helpful for them to intensify and adapt therapy. Further research has to evaluate if patients with psychological comorbidity are treated more effectively when they receive psychotherapy or specific medication in addition to the self-management guidebook.	[Schneider, Antonius; Rosenberger, Stefanie; Bobardt, Johanna; Bungartz-Catak, Jessica; Atmann, Oxana] Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Inst Gen Practice, Munich, Germany; [Haller, Bernhard] Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Inst Med Stat & Epidemiol, Munich, Germany; [Kennedy, Anne] Univ Southampton, Fac Hlth Sci, NIHR Collaborat Leadership Appl Hlth Res CLAHRC W, Highfield Campus, Southampton, Hants, England; [Enck, Paul] Univ Hosp, Dept Internal Med Psychosomat Med & Psychotherapy, Tubingen, Germany	Technical University of Munich; University of Munich; Technical University of Munich; University of Munich; University of Southampton; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schneider, A (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Inst Gen Practice, Munich, Germany.	antonius.schneider@mri.tum.de	Haller, Bernhard/I-1943-2019	Haller, Bernhard/0000-0002-9723-393X; Schneider, Antonius/0000-0002-2847-8626				Ahl A, 2013, J PSYCHOSOM RES, V75, P113, DOI 10.1016/j.jpsychores.2013.04.008; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Boger E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130990; Canavan C, 2016, PHARMACOECONOMICS, V34, P181, DOI 10.1007/s40273-015-0339-y; Chassany O, 1999, GUT, V44, P527, DOI 10.1136/gut.44.4.527; Donnachie E, 2017, GUT; Dorn SD, 2015, NEUROGASTROENT MOTIL, V27, P128, DOI 10.1111/nmo.12487; Dorn SD, 2010, ALIMENT PHARM THER, V32, P513, DOI 10.1111/j.1365-2036.2010.04374.x; Elsenbruch S, 2010, GASTROENTEROLOGY, V139, P1310, DOI 10.1053/j.gastro.2010.06.054; Elwyn G, 2014, ANN FAM MED, V12, P270, DOI 10.1370/afm.1615; Enck P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.14; Flik CE, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0398-8; Grodzinsky E, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0225-x; Gwee KA, 1999, GUT, V44, P400, DOI 10.1136/gut.44.3.400; Hauser G, 2014, WORLD J GASTROENTERO, V20, P6744, DOI 10.3748/wjg.v20.i22.6744; Jones MC, 2011, J NURS HEALTHC CHOIN, V3, P174, DOI [DOI 10.1111/J.1752-9824.2011.01096.X, 10.1111/j.1752-9824.2011]; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kennedy A, 2003, PATIENT EDUC COUNS, V50, P303, DOI 10.1016/S0738-3991(03)00054-5; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Layer P, 2011, Z GASTROENTEROL, V49, P237, DOI 10.1055/s-0029-1245976; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; Lowe B, 2004, J AFFECT DISORDERS, V78, P131, DOI 10.1016/S0165-0327(02)00237-9; Muller-Lissner SA, 2002, EUR J GASTROEN HEPAT, V14, P1325; Rathert C, 2013, MED CARE RES REV, V70, P351, DOI 10.1177/1077558712465774; Robinson A, 2006, GUT, V55, P643, DOI 10.1136/gut.2004.062901; Rogers A, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-6; Schwille-Kiuntke J, 2015, Aliment Pharmacol Ther, V41, P1029, DOI 10.1111/apt.13199; Stanculete MF, 2015, J GASTROINTEST LIVER, V24, P159, DOI 10.15403/jgld.2014.1121.242.strt; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2	31	10	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2017	12	7							e0181764	10.1371/journal.pone.0181764	http://dx.doi.org/10.1371/journal.pone.0181764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB8DV	28742808	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000406370000053
J	Dharmarajan, K; Wang, YF; Lin, ZQ; Normand, SLT; Ross, JS; Horwitz, LI; Desai, NR; Suter, LG; Drye, EE; Bernheim, SM; Krumholz, HM				Dharmarajan, Kumar; Wang, Yongfei; Lin, Zhenqiu; Normand, Sharon-Lise T.; Ross, Joseph S.; Horwitz, Leora I.; Desai, Nihar R.; Suter, Lisa G.; Drye, Elizabeth E.; Bernheim, Susannah M.; Krumholz, Harlan M.			Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; REDUCTION PROGRAM; UNINTENDED CONSEQUENCES; MEDICARE BENEFICIARIES; 30-DAY READMISSION; NATIONAL TRENDS; PERFORMANCE; CARE; INTERVENTION	IMPORTANCE The Affordable Care Act has led to US national reductions in hospital 30-day readmission rates for heart failure (HF), acute myocardial infarction (AMI), and pneumonia. Whether readmission reductions have had the unintended consequence of increasing mortality after hospitalization is unknown. OBJECTIVE To examine the correlation of paired trends in hospital 30-day readmission rates and hospital 30-day mortality rates after discharge. DESIGN, SETTING, AND PARTICIPANTS Retrospective study of Medicare fee-for-service beneficiaries aged 65 years or older hospitalized with HF, AMI, or pneumonia from January 1, 2008, through December 31, 2014. EXPOSURE Thirty-day risk-adjusted readmission rate (RARR). MAIN OUTCOMES AND MEASURES Thirty-day RARRs and 30-day risk-adjusted mortality rates (RAMRs) after discharge were calculated for each condition in each month at each hospital in 2008 through 2014. Monthly trends in each hospital's 30-day RARRs and 30-day RAMRs after discharge were examined for each condition. The weighted Pearson correlation coefficient was calculated for hospitals' paired monthly trends in 30-day RARRs and 30-day RAMRs after discharge for each condition. RESULTS In 2008 through 2014, 2 962 554 hospitalizations for HF, 1 229 939 for AMI, and 2 544 530 for pneumonia were identified at 5016, 4772, and 5057 hospitals, respectively. In January 2008, mean hospital 30-day RARRs and 30-day RAMRs after discharge were 24.6% and 8.4% for HF, 19.3% and 7.6% for AMI, and 18.3% and 8.5% for pneumonia. Hospital 30-day RARRs declined in the aggregate across hospitals from 2008 through 2014; monthly changes in RARRs were -0.053%(95% CI, -0.055% to -0.051%) for HF, -0.044% (95% CI, -0.047% to -0.041%) for AMI, and -0.033%(95% CI, -0.035% to -0.031%) for pneumonia. In contrast, monthly aggregate changes across hospitals in hospital 30-day RAMRs after discharge varied by condition: HF, 0.008%(95% CI, 0.007% to 0.010%); AMI, -0.003%(95% CI, -0.005% to -0.001%); and pneumonia, 0.001%(95% CI, -0.001% to 0.003%). However, correlation coefficients in hospitals' paired monthly changes in 30-day RARRs and 30-day RAMRs after discharge were weakly positive: HF, 0.066 (95% CI, 0.036 to 0.096); AMI, 0.067 (95% CI, 0.027 to 0.106); and pneumonia, 0.108 (95% CI, 0.079 to 0.137). Findings were similar in secondary analyses, including with alternate definitions of hospital mortality. CONCLUSIONS AND RELEVANCE Among Medicare fee-for-service beneficiaries hospitalized for heart failure, acute myocardial infarction, or pneumonia, reductions in hospital 30-day readmission rates were weakly but significantly correlated with reductions in hospital 30-day mortality rates after discharge. These findings do not support increasing postdischarge mortality related to reducing hospital readmissions.	[Dharmarajan, Kumar; Wang, Yongfei; Lin, Zhenqiu; Ross, Joseph S.; Desai, Nihar R.; Suter, Lisa G.; Drye, Elizabeth E.; Bernheim, Susannah M.; Krumholz, Harlan M.] Yale New Haven Hlth, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Dharmarajan, Kumar; Wang, Yongfei; Desai, Nihar R.; Krumholz, Harlan M.] Yale Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT USA; [Dharmarajan, Kumar] Clover Hlth, Jersey City, NJ 07302 USA; [Normand, Sharon-Lise T.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Normand, Sharon-Lise T.] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Ross, Joseph S.; Bernheim, Susannah M.] Yale Sch Med, Gen Internal Med Sect, Dept Internal Med, New Haven, CT USA; [Ross, Joseph S.; Bernheim, Susannah M.; Krumholz, Harlan M.] Yale Sch Med, Clin Scholars Program, Robert Wood Johnson Fdn, Dept Internal Med, New Haven, CT USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Horwitz, Leora I.] NYU Langone Med Ctr, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY USA; [Suter, Lisa G.] Yale Sch Med, Rheumatol Sect, Dept Internal Med, New Haven, CT USA; [Drye, Elizabeth E.] Yale Sch Med, Sect Gen Pediat, Dept Pediat, New Haven, CT USA	Yale University; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Yale University; Robert Wood Johnson Foundation (RWJF); Yale University; Yale University; NYU Langone Medical Center; New York University; New York University; Yale University; Yale University	Dharmarajan, K (corresponding author), Clover Hlth, Harborside Financial Ctr, 3 Second St,Plaza 10,Ste 803, Jersey City, NJ 07302 USA.	kumar.dharmarajan@cloverhealth.com	, Harlan/AAI-2875-2020; Horwitz, Leora/ABD-1292-2020	Ross, Joseph/0000-0002-9218-3320	National Institute on Aging [K23AG048331]; American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; Yale Claude D. Pepper Older Americans Independence Center [P30AG021342]; Agency for Healthcare Research and Quality [R01HS022882, K12HS023000]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS022882] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863, KL2TR001862] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG048331, P30AG021342] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research through the Paul B. Beeson Career Development Award Program; Yale Claude D. Pepper Older Americans Independence Center; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Dharmarajan is supported by grant K23AG048331 from the National Institute on Aging and the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program, and by grant P30AG021342 from the Yale Claude D. Pepper Older Americans Independence Center. Drs Ross and Horwitz are supported by grant R01HS022882 from the Agency for Healthcare Research and Quality. Dr Desai is supported by grant K12HS023000 from the Agency for Healthcare Research and Quality.	American Hospital Association, 2014, AV LENGTH STAY COMM; Bhalla R, 2010, ANN INTERN MED, V152, P114, DOI 10.7326/0003-4819-152-2-201001190-00185; Bradley EH, 2015, J GEN INTERN MED, V30, P605, DOI 10.1007/s11606-014-3105-5; Bradley EH, 2013, CIRC-CARDIOVASC QUAL, V6, P444, DOI 10.1161/CIRCOUTCOMES.111.000101; Brewster AL, 2016, MED CARE, V54, P600, DOI 10.1097/MLR.0000000000000530; Brotman DJ, 2016, J HOSP MED, V11, P650, DOI 10.1002/jhm.2604; Carey K, 2016, HEALTH AFFAIR, V35, P1918, DOI 10.1377/hlthaff.2016.0537; Carlson Joe, 2013, MODERN HEALTHCARE; Chen J, 2013, J AM COLL CARDIOL, V61, P1078, DOI 10.1016/j.jacc.2012.11.057; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Desai NR, 2016, JAMA-J AM MED ASSOC, V316, P2647, DOI 10.1001/jama.2016.18533; Drye EE, 2012, ANN INTERN MED, V156, P19, DOI 10.7326/0003-4819-156-1-201201030-00004; Figueroa JF, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2214; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Himmelstein D., 2015, HLTH AFFAIRS BLOG; Horwitz LI, 2015, J HOSP MED, V10, P670, DOI 10.1002/jhm.2416; Joynt KE, 2016, AM J MANAG CARE, V22, pE287; Joynt KE, 2016, ANN INTERN MED, V165, P153, DOI 10.7326/M15-1462; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kociol RD, 2012, CIRC-HEART FAIL, V5, P680, DOI 10.1161/CIRCHEARTFAILURE.112.967406; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; Nallamothu BK, 2015, LANCET, V385, P1114, DOI 10.1016/S0140-6736(14)61932-2; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor MD, 2012, HEALTH AFFAIR, V31, P1623, DOI 10.1377/hlthaff.2012.0110; Ouslander JG, 2014, J AM MED DIR ASSOC, V15, P162, DOI 10.1016/j.jamda.2013.12.005; Sacks NC, 2015, EPIDEMIOLOGY, V26, pE46, DOI 10.1097/EDE.0000000000000298; Werner RM, 2010, HEALTH AFFAIR, V29, P1319, DOI 10.1377/hlthaff.2008.0770; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	40	138	140	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 18	2017	318	3					270	278		10.1001/jama.2017.8444	http://dx.doi.org/10.1001/jama.2017.8444			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA9OJ	28719692	Green Published			2023-01-03	WOS:000405775000013
J	Charych, D; Khalili, S; Dixit, V; Kirk, P; Chang, T; Langowski, J; Rubas, W; Doberstein, SK; Eldon, M; Hoch, U; Zalevsky, J				Charych, Deborah; Khalili, Samira; Dixit, Vidula; Kirk, Peter; Chang, Thomas; Langowski, John; Rubas, Werner; Doberstein, Stephen K.; Eldon, Michael; Hoch, Ute; Zalevsky, Jonathan			Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy	PLOS ONE			English	Article							RENAL-CELL CARCINOMA; REGULATORY T-CELLS; HIGH-DOSE INTERLEUKIN-2; LONG-TERM SAFETY; MODULATION THERAPIES; ALPHA-RECEPTOR; LIGAND-BINDING; IL-2; COMPLEXES; CYTOKINE	Cytokines are potent immune modulating agents but are not ideal medicines in their natural form due to their short half-life and pleiotropic systemic effects. NKTR-214 is a clinical-stage biologic that comprises interleukin-2 (IL2) protein bound by multiple releasable polyethylene glycol (PEG) chains. In this highly PEG-bound form, the IL2 is inactive; therefore, NKTR214 is a biologic prodrug. When administered in vivo, the PEG chains slowly release, creating a cascade of increasingly active IL2 protein conjugates bound by fewer PEG chains. The 1-PEG-IL2 and 2-PEG-IL2 species derived from NKTR-214 are the most active conjugatedIL2 species. Free-IL2 protein is undetectable in vivo as it is eliminated faster than formed. The PEG chains on NKTR-214 are located at the region of IL2 that contacts the alpha (a) subunit of the heterotrimeric IL2 receptor complex, IL2Rapy, reducing its ability to bind and activate the heterotrimer. The IL2Rapy complex is constitutively expressed on regulatory T cells (Tregs). Therefore, without the use of mutations, PEGylation reduces the affinity for IL2Rapy to a greater extent than for IL293y, the receptor complex predominant on CD8 T cells. NKTR-214 treatment in vivo favors activation of CD8 T cells over Tregs in the tumor microenvironment to provide anti-tumor efficacy in multiple syngeneic models. Mechanistic modeling based on in vitro and in vivo kinetic data provides insight into the mechanism of NKTR-214 pharmacology. The model reveals that conjugated-IL2 protein derived from NKTR-214 occupy IL-293y to a greater extent compared to free-IL2 protein. The model accurately describes the sustained in vivo signaling observed after a single dose of NKTR214 and explains how the properties of NKTR-214 impart a unique kinetically-controlled immunological mechanism of action.	[Charych, Deborah; Khalili, Samira; Dixit, Vidula; Kirk, Peter; Chang, Thomas; Langowski, John; Rubas, Werner; Doberstein, Stephen K.; Eldon, Michael; Hoch, Ute; Zalevsky, Jonathan] Nektar Therapeut, San Francisco, CA 94158 USA	Nektar Therapeutics	Charych, D (corresponding author), Nektar Therapeut, San Francisco, CA 94158 USA.	DCharych@nektar.com			Nektar Therapeutics, San Francisco, California, United States of America	Nektar Therapeutics, San Francisco, California, United States of America	The study was funded by Nektar Therapeutics, San Francisco, California, United States of America. All authors are salaried employees of Nektar Therapeutics. DC, SK and JZ were involved in the study design, data collection and analysis. DC and JZ were involved in the decision to publish. DC, SK and UH were involved with the writing and preparation of the manuscript. Nektar Therapeutics provided support in the form of salaries for all authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Alexandrescu DT, 2005, J IMMUNOTHER, V28, P144, DOI 10.1097/01.cji.0000154250.82007.4a; Assal A, 2015, IMMUNOTHERAPY-UK, V7, P1169, DOI 10.2217/imt.15.78; Bos GW, 2004, EUR J PHARM SCI, V21, P561, DOI 10.1016/j.ejps.2003.12.007; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Busse D, 2010, P NATL ACAD SCI USA, V107, P3058, DOI 10.1073/pnas.0812851107; Charych DH, 2016, CLIN CANCER RES, V22, P680, DOI 10.1158/1078-0432.CCR-15-1631; Craiu A, 2001, AIDS RES HUM RETROV, V17, P873, DOI 10.1089/088922201750290005; Dutcher J, 2002, ONCOLOGY-NY, V16, P4; Feinerman O, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.90; Fishburn CS, 2008, J PHARM SCI-US, V97, P4167, DOI 10.1002/jps.21278; Garcia-Martinez K, 2012, INT IMMUNOL, V24, P427, DOI 10.1093/intimm/dxr120; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Konigsberg PJ, 1998, BBA-BIOMEMBRANES, V1370, P243, DOI 10.1016/S0005-2736(97)00269-1; Koreth J, 2011, NEW ENGL J MED, V365, P2055, DOI 10.1056/NEJMoa1108188; Le Mercier I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00418; Leon K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00439; Letourneau S, 2010, P NATL ACAD SCI USA, V107, P2171, DOI 10.1073/pnas.0909384107; Levin AM, 2012, NATURE, V484, P529, DOI 10.1038/nature10975; Lipiainen T, 2015, J PHARM SCI-US, V104, P307, DOI 10.1002/jps.24243; Luheshi NM, 2016, ONCOTARGET, V7, P18508, DOI 10.18632/oncotarget.7610; McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421; McDermott DF, 2015, J CLIN ONCOL, V33, P2013, DOI 10.1200/JCO.2014.58.1041; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Payne R, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-13; Penichet Manuel L., 1997, Human Antibodies, V8, P106; Rickert M, 2004, J MOL BIOL, V339, P1115, DOI 10.1016/j.jmb.2004.04.038; Samlowski WE, 2006, J IMMUNOTHER, V29, P524, DOI 10.1097/01.cji.0000211306.05869.25; Schein CH, 2002, CURR PHARM DESIGN, V8, P2113, DOI 10.2174/1381612023393161; Shanafelt AB, 2000, NAT BIOTECHNOL, V18, P1197, DOI 10.1038/81199; Sim GC, 2014, IL 2 CYTOKINE FAMILY; Stauber DJ, 2006, P NATL ACAD SCI USA, V103, P2788, DOI 10.1073/pnas.0511161103; Sznol M, 2015, NEW ENGL J MED, V372, P374, DOI 10.1056/NEJMe1413488; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; Zhang L, 2015, MOL CANC THERAPEUTIC; Zhang L, 2015, MOL CANC THERAPEU S2, V14, pA6	38	92	102	4	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0179431	10.1371/journal.pone.0179431	http://dx.doi.org/10.1371/journal.pone.0179431			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678791	Green Published, Green Submitted, gold			2023-01-03	WOS:000405272200014
J	Daum, RS; Miller, LG; Immergluck, L; Fritz, S; Creech, CB; Young, D; Kumar, N; Downing, M; Pettibone, S; Hoagland, R; Eells, SJ; Boyle, MG; Parker, TC; Chambers, HF				Daum, Robert S.; Miller, Loren G.; Immergluck, Lilly; Fritz, Stephanie; Creech, C. Buddy; Young, David; Kumar, Neha; Downing, Michele; Pettibone, Stephanie; Hoagland, Rebecca; Eells, Samantha J.; Boyle, Mary G.; Parker, Trisha Chan; Chambers, Henry F.		DMID 07-0051 Team	A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS INFECTIONS; SOFT-TISSUE INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE; PRACTICE GUIDELINES; DISEASES SOCIETY; MANAGEMENT; CHILDREN; RISK	BACKGROUND Uncomplicated skin abscesses are common, yet the appropriate management of the condition in the era of community-associated methicillin-resistant Staphylococcus aureus (MRSA) is unclear. METHODS We conducted a multicenter, prospective, double-blind trial involving outpatient adults and children. Patients were stratified according to the presence of a surgically drainable abscess, abscess size, the number of sites of skin infection, and the presence of non-purulent cellulitis. Participants with a skin abscess 5 cm or smaller in diameter were enrolled. After abscess incision and drainage, participants were randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for 10 days. The primary outcome was clinical cure 7 to 10 days after the end of treatment. RESULTS We enrolled 786 participants: 505 (64.2%) were adults and 281 (35.8%) were children. A total of 448 (57.0%) of the participants were male. S. aureus was isolated from 527 participants (67.0%), and MRSA was isolated from 388 (49.4%). Ten days after therapy in the intention-to-treat population, the cure rate among participants in the clindamycin group was similar to that in the TMP-SMX group (221 of 266 participants [83.1%] and 215 of 263 participants [81.7%], respectively; P = 0.73), and the cure rate in each active-treatment group was higher than that in the placebo group (177 of 257 participants [68.9%], P<0.001 for both comparisons). The results in the population of patients who could be evaluated were similar. This beneficial effect was restricted to participants with S. aureus infection. Among the participants who were initially cured, new infections at 1 month of follow-up were less common in the clindamycin group (15 of 221, 6.8%) than in the TMP-SMX group (29 of 215 [13.5%], P = 0.03) or the placebo group (22 of 177 [12.4%], P = 0.06). Adverse events were more frequent with clindamycin (58 of 265 [21.9%]) than with TMP-SMX (29 of 261 [11.1%]) or placebo (32 of 255 [12.5%]); all adverse events resolved without sequelae. One participant who received TMP-SMX had a hypersensitivity reaction. CONCLUSIONS As compared with incision and drainage alone, clindamycin or TMP-SMX in conjunction with incision and drainage improves short-term outcomes in patients who have a simple abscess. This benefit must be weighed against the known side-effect profile of these antimicrobials. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00730028.)	[Daum, Robert S.; Kumar, Neha] Univ Chicago Hosp, Chicago, IL 60637 USA; [Miller, Loren G.; Eells, Samantha J.] Harbor UCLA Med Ctr, Los Angeles, CA USA; [Miller, Loren G.; Eells, Samantha J.] Harbor UCLA Med Ctr, Los Angeles BioMed Res Inst, Los Angeles, CA USA; [Young, David; Downing, Michele; Chambers, Henry F.] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA; [Immergluck, Lilly; Parker, Trisha Chan] Morehouse Sch Med, Atlanta, GA 30310 USA; [Immergluck, Lilly; Parker, Trisha Chan] Emory Univ, Grady Mem Hosp, Atlanta, GA 30322 USA; [Immergluck, Lilly; Parker, Trisha Chan] Childrens Healthcare Atlanta, Atlanta, GA USA; [Fritz, Stephanie; Boyle, Mary G.] Washington Univ, Sch Medicine, Barnes Jewish Hosp, St Louis, MO USA; [Fritz, Stephanie; Boyle, Mary G.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Creech, C. Buddy] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Creech, C. Buddy] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Pettibone, Stephanie] EMMES Corp, Rockville, MD USA; [Hoagland, Rebecca] Cota Enterprises, Meriden, KS USA	University of Chicago; University of Illinois System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Morehouse School of Medicine; Emory University; Children's Healthcare of Atlanta (CHOA); Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Vanderbilt University; Vanderbilt University; Emmes Corporation	Daum, RS (corresponding author), Univ Maryland, Sch Med, Dept Med, 655 W Baltimore St, Baltimore, MD 21201 USA.	rsdaum@gmail.com	Rodriguez, Renee/GYR-1896-2022	Creech, Clarence/0000-0002-8276-9053; Rodriguez, Robert/0000-0003-1354-1773; Self, Wesley/0000-0002-9300-3045	National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200700031C]; National Center for Research Resources [UL1RR033176, UL1TR000124]; Pfizer; Dynavax; Theravance; Merck; Gilead Sciences; Achaogen; Abbott; Cepheid; Tetraphase; GlaxoSmithKline; Genentech; AstraZeneca; Allergan; Cempra; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS024338] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001881, UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR033176] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Pfizer(Pfizer); Dynavax; Theravance; Merck(Merck & Company); Gilead Sciences(Gilead Sciences); Achaogen; Abbott(Abbott Laboratories); Cepheid; Tetraphase; GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); Allergan(AbbVieAllergan); Cempra; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by a contract from the National Institute of Allergy and Infectious Diseases (NIAID) (HHSN272200700031C to Dr. Chambers) and the National Center for Research Resources (UL1RR033176, now at the National Center for Advancing Translational Sciences, UL1TR000124).; Dr. Daum reports receiving fees for serving on an advisory board from Pfizer and Dynavax and grant support from Theravance and Merck; Dr. Miller, receiving grant support from Gilead Sciences, Achaogen, Merck, Abbott, and Cepheid and consulting fees from Tetraphase; Dr. Creech, receiving grant support from Pfizer, grant support and consulting fees from GlaxoSmithKline, and consulting fees from Theravance; and Dr. Chambers, previously holding stock in Merck and receiving grant support and fees for serving on an advisory board from Genentech and fees for serving on an advisory board from AstraZeneca, Pfizer, Cubist (now Merck), Theravance, Allergan, and Cempra. No other potential conflict of interest relevant to this article was reported.	CLSI, 2015, CLSI DOCUMENT M07 A1, V10th; David MZ, 2010, CLIN MICROBIOL REV, V23, P616, DOI 10.1128/CMR.00081-09; Duong M, 2010, ANN EMERG MED, V55, P401, DOI 10.1016/j.annemergmed.2009.03.014; Fitch MT, 2007, NEW ENGL J MED, V357, pE20, DOI 10.1056/NEJMvcm071319; Holmes L, 2016, J PEDIATR-US, V169, P128, DOI 10.1016/j.jpeds.2015.10.044; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Lipsky BA, 2010, INFECT CONT HOSP EP, V31, P828, DOI 10.1086/654007; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Miller LG, 2015, NEW ENGL J MED, V372, P1093, DOI 10.1056/NEJMoa1403789; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Rajendran PM, 2007, ANTIMICROB AGENTS CH, V51, P4044, DOI 10.1128/AAC.00377-07; Schmitz GR, 2010, ANN EMERG MED, V56, P283, DOI 10.1016/j.annemergmed.2010.03.002; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Sitali L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0935-7; Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu296, 10.1093/cid/ciu444]	15	100	104	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2017	376	26					2545	2555		10.1056/NEJMoa1607033	http://dx.doi.org/10.1056/NEJMoa1607033			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY8QE	28657870	Green Accepted, Bronze			2023-01-03	WOS:000404259200008
J	Naziroglu, M; Cig, B; Blum, W; Vizler, C; Buhala, A; Marton, A; Katona, R; Josvay, K; Schwaller, B; Olah, Z; Pecze, L				Naziroglu, Mustafa; Cig, Bilal; Blum, Walter; Vizler, Csaba; Buhala, Andrea; Marton, Annamaria; Katona, Robert; Josvay, Katalin; Schwaller, Beat; Olah, Zoltan; Pecze, Laszlo			Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels	PLOS ONE			English	Article							RECEPTOR POTENTIAL VANILLOID-1; CAPSAICIN RECEPTOR; OXIDATIVE STRESS; ION-CHANNEL; ACTIVATION; APOPTOSIS; EXPRESSION; TOXICITY; RELEASE; NEURONS	There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 mu M) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 mu M) either alone or together with CAPS (10 mu M). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicinevoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 mu M). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.	[Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, Isparta, Turkey; [Naziroglu, Mustafa; Cig, Bilal] Suleyman Demirel Univ, Hlth Sci Inst, Dept Neurosci, Isparta, Turkey; [Blum, Walter; Schwaller, Beat; Pecze, Laszlo] Univ Fribourg, Dept Med, Unit Anat, Fribourg, Switzerland; [Vizler, Csaba; Buhala, Andrea; Marton, Annamaria; Katona, Robert; Josvay, Katalin] Hungarian Acad Sci, Biol Res Ctr, Inst Biochem, Szeged, Hungary; [Olah, Zoltan] Univ Miskolc, Fac Mat Sci & Engn, Inst Chem, Miskolc, Hungary; [Olah, Zoltan] Acheuron Ltd, Szeged, Hungary	Suleyman Demirel University; Suleyman Demirel University; University of Fribourg; Hungarian Academy of Sciences; Hungarian Biological Research Center; University of Miskolc	Pecze, L (corresponding author), Univ Fribourg, Dept Med, Unit Anat, Fribourg, Switzerland.	laszlo.pecze@unifr.ch	ÇİĞ, BILAL/A-1747-2018; Blum, Walter/A-5996-2016	ÇİĞ, BILAL/0000-0001-7832-066X; Schwaller, Beat/0000-0002-8277-7555; Blum, Walter/0000-0003-2219-9180	Swiss National Science Foundation SNSF [130680]; Acheuron Ltd.;  [GINOP-2.3.2-15-2016-00001];  [GINOP-2.3.2-15-201600039]	Swiss National Science Foundation SNSF(Swiss National Science Foundation (SNSF)); Acheuron Ltd.; ; 	This project was supported by GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-201600039 to VC and the Swiss National Science Foundation SNSF grant # 130680 to BS. Acheuron Ltd. provided support in the form of salaries for the author ZO, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of authors are articulated in the 'author contributions' section.	Azimi I, 2014, BRIT J PHARMACOL, V171, P945, DOI 10.1111/bph.12486; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barar J, 2012, BIOIMPACTS, V2, P1, DOI 10.5681/bi.2012.001; Bevan S, 2014, HANDB EXP PHARMACOL, V222, P207, DOI 10.1007/978-3-642-54215-2_9; Bode AM, 2011, CANCER RES, V71, P2809, DOI 10.1158/0008-5472.CAN-10-3756; BRUCE RD, 1985, FUND APPL TOXICOL, V5, P151, DOI 10.1016/0272-0590(85)90059-4; Carnevale V, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030052; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cetin ES, 2017, J RECEPT SIG TRANSD, V37, P84, DOI 10.3109/10799893.2016.1160931; Cig B, 2015, BBA-BIOMEMBRANES, V1848, P2756, DOI 10.1016/j.bbamem.2015.02.013; Czifra G, 2009, J CANCER RES CLIN, V135, P507, DOI 10.1007/s00432-008-0482-3; Ding XZ, 2001, INT J CANCER, V94, P630, DOI 10.1002/ijc.1527.abs; GAO X, 1995, UROLOGY, V46, P227, DOI 10.1016/S0090-4295(99)80198-8; Gerry AB, 2014, ATHEROSCLEROSIS, V233, P537, DOI 10.1016/j.atherosclerosis.2014.01.014; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V206, P495, DOI 10.1113/jphysiol.1970.sp009027; Jankovic Bojana, 2010, Can Urol Assoc J, V4, pE9; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Karai L, 2004, J CLIN INVEST, V113, P1344, DOI 10.1172/JCI200420449; Kaszas K, 2012, J PHARMACOL EXP THER, V340, P152, DOI 10.1124/jpet.111.183053; Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-89; Kosar PA, 2016, J MEMBRANE BIOL, V249, P129, DOI 10.1007/s00232-015-9855-0; Lebovitz EE, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-70; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Lv J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3942; Mori A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087; Natarajan Rama, 1998, Frontiers in Bioscience, V3, pE81; Neelands TR, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-28; Nie D, 1998, CANCER RES, V58, P4047; Olah Z, 2002, J BIOL CHEM, V277, P35752, DOI 10.1074/jbc.M201551200; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Olah Z, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000545; Pecze L, 2016, BBA-MOL CELL RES, V1863, P2905, DOI 10.1016/j.bbamcr.2016.09.013; Pecze L, 2016, BBA-MOL CELL RES, V1863, P2054, DOI 10.1016/j.bbamcr.2016.05.007; Pecze L, 2013, BBA-MOL CELL RES, V1833, P1680, DOI 10.1016/j.bbamcr.2012.08.018; Pecze L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003419; Pecze L, 2009, CAN J NEUROL SCI, V36, P234, DOI 10.1017/S0317167100006600; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Roh EJ, 2008, BIOORGAN MED CHEM, V16, P9349, DOI 10.1016/j.bmc.2008.08.048; Sanchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Spindler SA, 1997, BIOCHEM BIOPH RES CO, V239, P775, DOI 10.1006/bbrc.1997.7471; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; Stampfer MR, 2002, CULTURE EPITHELIAL C, P95; Starowicz K, 2007, PHARMACOL THERAPEUT, V114, P13, DOI 10.1016/j.pharmthera.2007.01.005; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Uguz AC, 2009, J MEMBRANE BIOL, V232, P15, DOI 10.1007/s00232-009-9212-2; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vercelli C, 2014, J BREAST CANCER, V17, P332, DOI 10.4048/jbc.2014.17.4.332; Veronesi B, 1999, NEUROPEPTIDES, V33, P447, DOI 10.1054/npep.1999.0761; Weber LV, 2016, BREAST CANCER-TARGET, V8, P243, DOI 10.2147/BCTT.S121610; Wen HR, 2012, J BIOL CHEM, V287, P13868, DOI 10.1074/jbc.M111.334896; Wu C LY, 2012, CANC RES S, V72; Wu TTL, 2014, CELL CALCIUM, V56, P59, DOI 10.1016/j.ceca.2014.04.006; Xie CQ, 2011, ENDOCRINOLOGY, V152, P3811, DOI 10.1210/en.2011-0141; Zhou YiMing, 2013, Nature Communications, V4, P2408; Zygmunt PM, 2000, EUR J PHARMACOL, V396, P39, DOI 10.1016/S0014-2999(00)00207-7	59	22	24	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2017	12	6							e0179950	10.1371/journal.pone.0179950	http://dx.doi.org/10.1371/journal.pone.0179950			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY6ZV	28640864	gold, Green Published, Green Submitted			2023-01-03	WOS:000404135800085
J	Armstrong, S				Armstrong, Stephen			Data, data everywhere: the challenges of personalised medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												stephen.armstrong@me.com						Swainston J., 1989, Rephiberary, P1; [Anonymous], 2017, QUARTZ MEDIA     AUG; [Anonymous], 2017, CNBC; [Anonymous], 2016, NEW SCI, P359; [Anonymous], 2017, LIFE SCI IND STRATEG; [Anonymous], 2017, WIRED; [Anonymous], 2017, DAILY TELEGRAPH; [Anonymous], 2015, NATL INFORM BOARD NA; Clinical Digital Maturity Index, 2017, CLIN DIGITAL MATURIT; Denham E, 2017, 4 LESSONS NHS TRUSTS; NHS pulls the plug on its &POUND;11bn IT system, 2011, INDEPENDENT; Reuters, 2017, DOCT VIEW TECHN LARG; Shanafelt TD, 2015, CHANGES BURNOUT SATI; Taunton and Somerset NHS Foundation Trust, 2017, BBC NEWS 0703; The Wirecutter, 2017, WHAT IS AL WHAT IS A	15	8	8	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2017	359								j4546	10.1136/bmj.j4546	http://dx.doi.org/10.1136/bmj.j4546			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK1TH	29021195				2023-01-03	WOS:000413265400003
J	Merten, H; van Galen, LS; Wagner, C				Merten, Hanneke; van Galen, Louise S.; Wagner, Cordula			Safe handover	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							OF-THE-LITERATURE; HEALTH-CARE; COMMUNICATION; IMPLEMENTATION; INTERVENTIONS; CHECKLISTS		[Merten, Hanneke; Wagner, Cordula] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [van Galen, Louise S.] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands; [Wagner, Cordula] NIVEL, Otterstr 118-124, NL-3513 CR Utrecht, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Netherlands Institute for Health Services Research	Merten, H (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	h.merten@vumc.nl						Abraham J, 2014, J AM MED INFORM ASSN, V21, P154, DOI 10.1136/amiajnl-2012-001351; Australian Commission on Safety and Quality in Health Care, 2012, IMPL TOOLK CLIN HAND; Australian Medical Association, 2006, SAF HAND SAF PAT GUI; Borchard A, 2012, ANN SURG, V256, P925, DOI 10.1097/SLA.0b013e3182682f27; British Medical Association, 2004, SAF HAND SAF PAT GUI; Buurman BM, 2016, INT J QUAL HEALTH C, V28, P384, DOI 10.1093/intqhc/mzw046; Flink M, 2012, BMJ QUAL SAF, V21, P89, DOI 10.1136/bmjqs-2012-001171; Foronda C, 2016, NURSE EDUC PRACT, V19, P36, DOI 10.1016/j.nepr.2016.04.005; Gordon M, 2011, MED EDUC, V45, P1081, DOI 10.1111/j.1365-2923.2011.04049.x; Haig KM, 2006, JT COMM J QUAL PATIE, V32, P167, DOI 10.1016/S1553-7250(06)32022-3; Joint Commission International, 2010, ACCR STAND HOSP; Manias E, 2014, INT J NURS STUD, V51, P1539, DOI 10.1016/j.ijnurstu.2014.08.004; Mardis T, 2016, J NURS CARE QUAL, V31, P54, DOI 10.1097/NCQ.0000000000000142; Nagpal K, 2010, ANN SURG, V252, P225, DOI 10.1097/SLA.0b013e3181e495c2; Robertson ER, 2014, BMJ QUAL SAF, V23, P600, DOI 10.1136/bmjqs-2013-002309; Starmer AJ, 2014, NEW ENGL J MED, V371, P1803, DOI 10.1056/NEJMsa1405556; The Joint Commission, 2012, HOT TOP HLTH CAR 201; The Joint Commission, 2016, SENT EV DAT ROOT CAU; Urbach DR, 2014, NEW ENGL J MED, V370, P1029, DOI 10.1056/NEJMsa1308261; Vermeir P, 2015, INT J CLIN PRACT, V69, P1257, DOI 10.1111/ijcp.12686; Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103; WHO Collaborating Centre for Patient Safety Solutions, 2007, COMM PAT HAND OV	22	41	41	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2017	359								j4328	10.1136/bmj.j4328	http://dx.doi.org/10.1136/bmj.j4328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK1SK	28993308	Bronze			2023-01-03	WOS:000413262800001
J	da Silva, CMG; Franz-Montan, M; Limia, CEG; Ribeiro, LND; Braga, MA; Guilherme, VA; da Silva, CB; Casadei, BR; Cereda, CMS; de Paula, E				Goncalves da Silva, Camila Morais; Franz-Montan, Michelle; Gomez Limia, Cintia Elisabeth; de Morais Ribeiro, Ligia Nunes; Braga, Mario Antonio; Guilherme, Viviane Aparecida; da Silva, Camila Batista; Casadei, Bruna Renata; Saia Cereda, Cintia Maria; de Paula, Eneida			Encapsulation of ropivacaine in a combined (donor-acceptor, ionic-gradient) liposomal system promotes extended anesthesia time	PLOS ONE			English	Article							LOCAL-ANESTHETICS; BUPIVACAINE; DELIVERY; FORMULATION; ANALGESIA; PRILOCAINE; TOXICITY; RELEASE	Ropivacaine is a local anesthetic with similar potency but lower systemic toxicity than bupivacaine, the most commonly used spinal anesthetic. The present study concerns the development of a combined drug delivery system for ropivacaine, comprised of two types of liposomes: donor multivesicular vesicles containing 250 mM (NH4)(2)SO4 plus the anesthetic, and acceptor large unilamellar vesicles with internal pH of 5.5. Both kinds of liposomes were composed of hydrogenated soy-phosphatidylcholine: cholesterol (2: 1 mol%) and were prepared at pH 7.4. Dynamic light scattering, transmission electron microscopy and electron paramagnetic resonance techniques were used to characterize the average particle size, polydispersity, zeta potential, morphology and fluidity of the liposomes. In vitro dialysis experiments showed that the combined liposomal system provided significantly longer (72 h) release of ropivacaine, compared to conventional liposomes (similar to 45 h), or plain ropivacaine (similar to 4 h) (p<0.05). The pre-formulations tested were significantly less toxic to 3T3 cells, with toxicity increasing in the order: combined system < ropivacaine in donor or acceptor liposomes < ropivacaine in conventional liposomes < plain ropivacaine. The combined formulation, containing 2% ropivacaine, increased the anesthesia duration up to 9 h after subcutaneous infiltration in mice. In conclusion, a promising drug delivery system for ropivacaine was described, which can be loaded with large amounts of the anesthetic (2%), with reduced in vitro cytotoxicity and extended anesthesia time.	[Goncalves da Silva, Camila Morais; Gomez Limia, Cintia Elisabeth; de Morais Ribeiro, Ligia Nunes; Braga, Mario Antonio; Guilherme, Viviane Aparecida; Casadei, Bruna Renata; Saia Cereda, Cintia Maria; de Paula, Eneida] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, UNICAMP, Campinas, SP, Brazil; [Franz-Montan, Michelle; da Silva, Camila Batista] Univ Estadual Campinas, UNICAMP, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, SP, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual de Campinas	de Paula, E (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, UNICAMP, Campinas, SP, Brazil.	depaula@unicamp.br	Franz-Montan, Michelle/E-2865-2010; de Paula, Eneida/C-3031-2013; Ribeiro, Lígia/AAJ-2820-2020; Franz-Montan, Michelle/V-3301-2019; Franz-Montan, Michelle/AAN-1071-2021; Casadei, Bruna R/D-5658-2015; da Silva de Araujo Candido, Camila Batista/C-5918-2014; Guilherme, Viviane Ap./Q-4155-2017; Cereda, Cintia/E-4182-2013	de Paula, Eneida/0000-0003-4504-5723; Ribeiro, Lígia/0000-0001-6097-5449; Franz-Montan, Michelle/0000-0003-0760-1389; Franz-Montan, Michelle/0000-0003-0760-1389; Casadei, Bruna R/0000-0002-4103-0084; da Silva de Araujo Candido, Camila Batista/0000-0003-1897-3567; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [14/14457-5, 2011/21735-3]; Conselho Nacional de Ciencia e Tecnologia (CNPq) [464708/2014-1]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Ciencia e Tecnologia (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, grant # 14/14457-5 and fellowship to CMGS # 2011/21735-3) and Conselho Nacional de Ciencia e Tecnologia (CNPq, # 464708/2014-1).	ADADE AB, 1984, J BIOENERG BIOMEMBR, V16, P353, DOI 10.1007/BF00743231; Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Barenholz Y, Method of amphiphatic drug loading in liposomes by pH gradient. US Patent, Patent No. 51993192549; Barenholz Y, 2007, A liposomal combination and uses thereof. Patent, Patent No. 2007/; BROCKWAY MS, 1991, BRIT J ANAESTH, V66, P31, DOI 10.1093/bja/66.1.31; Cereda CMS, 2004, J PHARM PHARM SCI, V7, P235; Christie LE, 2014, BJA ED, P136; Cohen R, 2012, J CONTROL RELEASE, V160, P346, DOI 10.1016/j.jconrel.2011.12.030; Crepaldi Domingues C, 2009, J MEMBRANE BIOL, V227, P39, DOI 10.1007/s00232-008-9142-4; de Araujo DR, 2008, J PHARM PHARMACOL, V60, P1449, DOI 10.1211/jpp/60.11.0005; DE PAULA E, 1995, BBA-BIOMEMBRANES, V1240, P25, DOI 10.1016/0005-2736(95)00155-6; de Paula E, 2012, EXPERT OPIN DRUG DEL, V9, P1505, DOI 10.1517/17425247.2012.738664; de Paula Eneida, 2010, Recent Pat Drug Deliv Formul, V4, P23; Epstein-Barash H, 2009, P NATL ACAD SCI USA, V106, P7125, DOI 10.1073/pnas.0900598106; Fraceto LF, 2005, BIOPHYS CHEM, V115, P11, DOI 10.1016/j.bpc.2004.12.003; Franz-Montan M, 2013, J LIPOSOME RES, V23, P54, DOI 10.3109/08982104.2012.742536; Ginosar Y, 2016, ANESTH ANALG, V122, P1673, DOI 10.1213/ANE.0000000000001217; da Silva CMG, 2016, J LIPOSOME RES, V26, P1, DOI 10.3109/08982104.2015.1022555; Grant GJ, 2004, ANESTHESIOLOGY, V101, P133, DOI 10.1097/00000542-200407000-00021; Grant GJ, 1997, ACTA ANAESTH SCAND, V41, P204, DOI 10.1111/j.1399-6576.1997.tb04666.x; Grant Stuart A, 2002, Best Pract Res Clin Anaesthesiol, V16, P345, DOI 10.1053/bean.2002.0242; Gubernator J, 2011, EXPERT OPIN DRUG DEL, V8, P565, DOI 10.1517/17425247.2011.566552; Howell BA, 2009, ANESTH ANALG, V109, P678, DOI 10.1213/ane.0b013e3181a8da61; Malheiros SVP, 2004, BIOPHYS CHEM, V110, P213, DOI 10.1016/j.bpc.2004.01.013; Martinov T, 2013, JOVE-J VIS EXP, DOI 10.3791/51212; Mendyk A, 2007, EXPERT SYST APPL, V32, P1124, DOI 10.1016/j.eswa.2006.02.019; Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mowat JJ, 1996, ANESTHESIOLOGY, V85, P635, DOI 10.1097/00000542-199609000-00024; Papadopoulou V, 2006, INT J PHARMACEUT, V309, P44, DOI 10.1016/j.ijpharm.2005.10.044; PLANAS ME, 1992, ANESTH ANALG, V75, P615; Ribeiro LNM, 2016, EUR J PHARM SCI, V93, P192, DOI 10.1016/j.ejps.2016.08.030; Cereda CMS, 2013, J LIPOSOME RES, V23, P228, DOI 10.3109/08982104.2013.796975; SCHREIER S, 1978, BIOCHIM BIOPHYS ACTA, V515, P375; Shen Y, 2011, DRUG DELIV, V18, P361, DOI 10.3109/10717544.2011.557788; Tu S, 2010, J PHARM SCI-US, V99, P2672, DOI 10.1002/jps.22017; Wei YM, 2014, INT J NANOMED, V9, P3623, DOI 10.2147/IJN.S66312; Weiniger CF, 2010, EXPERT OPIN DRUG DEL, V7, P737, DOI 10.1517/17425241003767383; Wiles MD, 2010, ANAESTHESIA, V65, P22, DOI 10.1111/j.1365-2044.2009.06201.x; Zhang XK, 2009, J DRUG TARGET, V17, P399, DOI 10.1080/10611860902795407; Zucker D, 2009, J CONTROL RELEASE, V139, P73, DOI 10.1016/j.jconrel.2009.05.036	41	15	15	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2017	12	10							e0185828	10.1371/journal.pone.0185828	http://dx.doi.org/10.1371/journal.pone.0185828			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI9WM	28982145	gold, Green Published, Green Submitted			2023-01-03	WOS:000412360300072
J	Wang, HH; Hung, SY; Chang, MY; Lee, YC; Lin, HF; Lin, TM; Yang, SP; Lin, HH; Yang, SC; Wang, JL				Wang, Hsi-Hao; Hung, Shih-Yuan; Chang, Min-Yu; Lee, Yi-Che; Lin, Hsiu-Fang; Lin, Tsun-Mei; Yang, Su-Pen; Lin, Hsi-Hsun; Yang, Su-Ching; Wang, Jiun-Ling			Bacterial colonization patterns in daily chlorhexidine care at the exit site in peritoneal dialysis patients-A prospective, randomized controlled trial	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; CATHETER-RELATED INFECTIONS; GRAM-NEGATIVE BACTERIA; METHICILLIN-RESISTANT; NASAL CARRIAGE; MUPIROCIN OINTMENT; LOCAL APPLICATION; PREVENTION; STRATEGIES; BIOCIDES	Bacterial colonization patterns in daily chlorhexidine care at the exit site in peritoneal dialysis (PD) patients were not known. We performed a prospective, randomized controlled trial enrolling 89 PD patients. After stratification by initial Staphylococcus aureus (SA) carrier status, patients were randomly assigned to receive daily 4% chlorhexidine care (intervention group) or normal saline (control group) at the exit site. Monthly, we cultured bacteria from the exit site and nasal swabs for 1 year. The SA colonization rates at exit site at 6 and 12 months were significantly lower in the intervention group than the control group (5.0% vs. 22.9%, p = 0.023 and 8.6% vs. 28.1%, p = 0.037 for 6 and 12 months, respectively). The Methicillin-resistant SA (MRSA) colonization rate at exit site at 6 months was similar (5.7% vs. 2.5%, p = 0.596) in control and intervention group, but significantly lower in the intervention group than the control group at exit site at 12months (0% vs. 12.5%, p = 0.047). The gram-negative bacilli (GNB) colonization rates were similar between the intervention and control groups at 6 and 12 months. Genotyping of all MRSA isolates showed ST (sequence type) 59 was the most predominant clone. In conclusion, chlorhexidine care at the exit site in PD patients may be a good strategy for SA and MRSA decolonization.	[Wang, Hsi-Hao; Hung, Shih-Yuan; Chang, Min-Yu; Lee, Yi-Che; Yang, Su-Pen; Lin, Hsi-Hsun] E DA Hosp, Internal Med Dept, Kaohsiung, Taiwan; [Wang, Hsi-Hao; Hung, Shih-Yuan; Chang, Min-Yu; Lee, Yi-Che; Yang, Su-Pen; Lin, Hsi-Hsun] I Shou Univ, Sch Med, Kaohsiung, Taiwan; [Lin, Hsiu-Fang; Lin, Tsun-Mei] I Shou Univ, E DA Hosp, Dept Lab Med, Kaohsiung, Taiwan; [Yang, Su-Ching] Natl Tainan Inst Nursing, Dept Nursing, Tainan, Taiwan; [Wang, Jiun-Ling] Natl Cheng Kung Univ, Dept Internal Med, Tainan, Taiwan; [Wang, Jiun-Ling] Natl Cheng Kung Univ, Dept Med, Tainan, Taiwan	E-Da Hospital; I Shou University; E-Da Hospital; I Shou University; National Cheng Kung University; National Cheng Kung University	Wang, JL (corresponding author), Natl Cheng Kung Univ, Dept Internal Med, Tainan, Taiwan.; Wang, JL (corresponding author), Natl Cheng Kung Univ, Dept Med, Tainan, Taiwan.	jiunlingwang@gmail.com	Wang, 竣令王 Jiun-Ling/L-9627-2015	Wang, 竣令王 Jiun-Ling/0000-0002-9465-8692	E-DA Hospital [EDAHP99020]; Taiwan National Science Council [100-2314-B-214-005]	E-DA Hospital; Taiwan National Science Council(Ministry of Science and Technology, Taiwan)	This study was supported by a grant from the E-DA Hospital (No. EDAHP99020) and Taiwan National Science Council (No. 100-2314-B-214-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study was supported by a grant from the E-DA Hospital (No. EDAHP99020) and Taiwan National Science Council (No. 100-2314-B-214-005). The authors declare that there are no conflicts of interest in this study. Some content of this study has been presented in the 7th International Congress. of the Asia Pacific Society of Infection Control.	Akoh Jacob A, 2012, World J Nephrol, V1, P106, DOI 10.5527/wjn.v1.i4.106; Al-Hwiesh AK, 2013, INT J ARTIF ORGANS, V36, P473, DOI 10.5301/ijao.5000207; Bernardini J, 1996, AM J KIDNEY DIS, V27, P695, DOI 10.1016/S0272-6386(96)90105-5; Bernardini J, 2005, J AM SOC NEPHROL, V16, P539, DOI 10.1681/ASN.2004090773; Campbell D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004679.pub3; Chu KH, 2008, PERITON DIALYSIS INT, V28, P505; Crawford S, 2014, REN SOC AUSTRALAS J, V10, P116; DAVIES SJ, 1989, PERITON DIALYSIS INT, V9, P61; Derde LPG, 2012, INTENS CARE MED, V38, P931, DOI 10.1007/s00134-012-2542-z; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008, DOI 10.1128/JCM.38.3.1008-1015.2000; FUCHS J, 1990, DIALYSIS TRANSPLANT, V19, P81; Higgins CS, 2001, CLIN MICROBIOL INFEC, V7, P308, DOI 10.1046/j.1198-743x.2001.00253.x; Kang YC, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-284; Lee SM, 2014, KIDNEY RES CLIN PRAC, V33, P144, DOI 10.1016/j.krcp.2014.05.030; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; McCormack K, 2007, HEALTH TECHNOL ASSES, V11, P1; McQuillan RF, 2012, CLIN J AM SOC NEPHRO, V7, P297, DOI 10.2215/CJN.07970811; Milstone AM, 2008, CLIN INFECT DIS, V46, P274, DOI 10.1086/524736; Mullany LC, 2008, PEDIATR INFECT DIS J, V27, P505, DOI 10.1097/INF.0b013e31816791a2; Mullany LC, 2012, PEDIATR INFECT DIS J, V31, P444, DOI 10.1097/INF.0b013e3182468ff0; Piraino B, 2005, PERITON DIALYSIS INT, V25, P107; Piraino B, 2000, ASAIO J, V46, pS13, DOI 10.1097/00002480-200011000-00031; Piraino B, 2011, PERITON DIALYSIS INT, V31, P614, DOI 10.3747/pdi.2011.00057; Ques AAM, 2013, JBI DATABASE SYSTEMA, V11, P133; Ritzau J, 2001, PERITON DIALYSIS INT, V21, P471; Rosenblum A, 2014, AM J KIDNEY DIS, V63, P259, DOI 10.1053/j.ajkd.2013.08.019; Safdar N, 2014, CRIT CARE MED, V42, P1703, DOI 10.1097/CCM.0000000000000319; Sandri AM, 2006, INFECT CONT HOSP EP, V27, P185, DOI 10.1086/500625; Schaefer F, 1999, J AM SOC NEPHROL, V10, P136; Smith K, 2008, J MED MICROBIOL, V57, P966, DOI 10.1099/jmm.0.47668-0; STICKLER DJ, 1987, J HOSP INFECT, V10, P28, DOI 10.1016/0195-6701(87)90029-6; Stickler DJ, 2002, J APPL MICROBIOL, V92, p163S, DOI 10.1046/j.1365-2672.92.5s1.6.x; Szeto CC, 2007, CLIN J AM SOC NEPHRO, V2, P245, DOI 10.2215/CJN.03180906; Thodis E, 1998, PERITON DIALYSIS INT, V18, P261; Thomas L, 2000, J HOSP INFECT, V46, P297, DOI 10.1053/jhin.2000.0851; Uttley L, 2004, J NEPHROL, V17, P242; Vychytil A, 1998, J AM SOC NEPHROL, V9, P669; Wang JL, 2008, CLIN INFECT DIS, V46, P799, DOI 10.1086/527389; Wanten GJA, 1996, PERITON DIALYSIS INT, V16, P352; WONG FS-Y, 2002, HONG KONG J NEPHROL, V4, p54 ~ 9	40	5	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2017	12	10							e0184859	10.1371/journal.pone.0184859	http://dx.doi.org/10.1371/journal.pone.0184859			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI9WM	28981543	Green Published, Green Submitted, gold			2023-01-03	WOS:000412360300021
J	Cappuccio, G; Pinelli, M; Alagia, M; Donti, T; Day-Salvatore, DL; Veggiotti, P; De Giorgis, V; Lunghi, S; Vari, MS; Striano, P; Brunetti-Pierri, N; Kennedy, AD; Elsea, SH				Cappuccio, Gerarda; Pinelli, Michele; Alagia, Marianna; Donti, Taraka; Day-Salvatore, Debra-Lynn; Veggiotti, Pierangelo; De Giorgis, Valentina; Lunghi, Simona; Vari, Maria Stella; Striano, Pasquale; Brunetti-Pierri, Nicola; Kennedy, Adam D.; Elsea, Sarah H.			Biochemical phenotyping unravels novel metabolic abnormalities and potential biomarkers associated with treatment of GLUT1 deficiency with ketogenic diet	PLOS ONE			English	Article							MUTATIONS; CARNITINE; EPILEPSY; CHILDREN; REVEALS	Global metabolomic profiling offers novel opportunities for the discovery of biomarkers and for the elucidation of pathogenic mechanisms that might lead to the development of novel therapies. GLUT1 deficiency syndrome (GLUT1-DS) is an inborn error of metabolism due to reduced function of glucose transporter type 1. Clinical presentation of GLUT1-DS is heterogeneous and the disorder mirrors patients with epilepsy, movement disorders, or any paroxysmal events or unexplained neurological manifestation triggered by exercise or fasting. The diagnostic biochemical hallmark of the disease is a reduced cerebrospinal fluid (CSF)/blood glucose ratio and the only available treatment is ketogenic diet. This study aimed at advancing our understanding of the biochemical perturbations in GLUT1-DS pathogenesis through biochemical phenotyping and the treatment of GLUT1-DS with a ketogenic diet. Metabolomic analysis of three CSF samples from GLUT1-DS patients not on ketogenic diet was feasible inasmuch as CSF sampling was used for diagnosis before to start with ketogenic diet. The analysis of plasma and urine samples obtained from GLUT1-DS patients treated with a ketogenic diet showed alterations in lipid and amino acid profiles. While subtle, these were consistent findings across the patients with GLUT1-DS on ketogenic diet, suggesting impacts on mitochondrial physiology. Moreover, low levels of free carnitine were present suggesting its consumption in GLUT1-DS on ketogenic diet. 3-hydroxybutyrate, 3-hydroxybutyrylcarnitine, 3-methyladipate, and N-acetylglycine were identified as potential biomarkers of GLUT1-DS on ketogenic diet. This is the first study to identify CSF, plasma, and urine metabolites associated with GLUT1-DS, as well as biochemical changes impacted by a ketogenic diet. Potential biomarkers and metabolic insights deserve further investigation.	[Cappuccio, Gerarda; Pinelli, Michele; Alagia, Marianna; Brunetti-Pierri, Nicola] Univ Naples Federico II, Sect Pediat, Dept Translat Med, Naples, Italy; [Cappuccio, Gerarda; Pinelli, Michele; Alagia, Marianna; Brunetti-Pierri, Nicola] Telethon Inst Genet & Med, Naples, Italy; [Cappuccio, Gerarda; Donti, Taraka; Elsea, Sarah H.] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza, Houston, TX 77030 USA; [Donti, Taraka] Greenwood Genet Ctr, Greenwood, SC 29646 USA; [Day-Salvatore, Debra-Lynn] St Peters Univ Hosp, Dept Med Genet & Genom Med, New Brunswick, NJ USA; [Veggiotti, Pierangelo; De Giorgis, Valentina; Lunghi, Simona] Fdn IRCCS C, Dept Brain & Behav Sci, Mondino, Italy; [Vari, Maria Stella; Striano, Pasquale] Univ Genoa, Gaslini Inst, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, G Gaslini Inst,Pediat Neurol & Muscular Dis Unit, Genoa, Italy; [Kennedy, Adam D.] Metabolon, Morrisville, NC USA	University of Naples Federico II; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Baylor College of Medicine; Greenwood Genetic Center; Saint Peter's University Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; Metabolon	Elsea, SH (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza, Houston, TX 77030 USA.	Sarah.Elsea@bcm.edu	De Giorgis, Valentina/AAB-7643-2019; De Giorgis, Valentina/K-4730-2018; Vari, Maria Stella/AAJ-9154-2020; Striano, Pasquale/F-9117-2014; Cappuccio, Gerarda/W-3576-2018; Pinelli, Michele/A-1584-2010; Donti, Taraka/K-5648-2013; Brunetti-Pierri, Nicola/K-8465-2016	De Giorgis, Valentina/0000-0002-5828-7070; De Giorgis, Valentina/0000-0002-5828-7070; Striano, Pasquale/0000-0002-6065-1476; Cappuccio, Gerarda/0000-0003-3934-2342; Pinelli, Michele/0000-0002-5927-1185; Elsea, Sarah/0000-0002-1400-8519; Donti, Taraka/0000-0002-3830-155X; Brunetti-Pierri, Nicola/0000-0002-6895-8819				Amaral AI, 2013, J INHERIT METAB DIS, V36, P621, DOI 10.1007/s10545-012-9553-3; Atwal PS, 2015, MOL GENET METAB, V115, P91, DOI 10.1016/j.ymgme.2015.04.008; Berry-Kravis T, 2001, EPILEPSIA, V42, P1445; Bertoli S, 2015, NUTRITION, V31, P981, DOI 10.1016/j.nut.2015.02.017; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Burrage LC, 2016, J PEDIATR-US, V169, P208, DOI 10.1016/j.jpeds.2015.10.045; Dahlin M, 2007, EPILEPSY RES, V73, P199, DOI 10.1016/j.eplepsyres.2006.10.005; Dashti Hussein M, 2004, Exp Clin Cardiol, V9, P200; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Donti TR, 2016, MOL GENET METAB REP, V8, P61, DOI 10.1016/j.ymgmr.2016.07.007; Evans AM, 2014, METABOLOMICS, V4, P1; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Guay C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077097; Haces ML, 2010, NEUROSCIENCE, V165, P28, DOI 10.1016/j.neuroscience.2009.10.003; Isaev NK, 2007, BIOCHEMISTRY-MOSCOW+, V72, P471, DOI 10.1134/S0006297907050021; Kennedy AD, 2016, GENET TEST MOL BIOMA, V20, P485, DOI 10.1089/gtmb.2015.0291; Klepper J, 2004, PROSTAG LEUKOTR ESS, V70, P321, DOI 10.1016/j.plefa.2003.07.004; Larsen J, 2015, EPILEPSIA, V56, pE203, DOI 10.1111/epi.13222; Leen WG, 2013, JAMA NEUROL, V70, P1440, DOI 10.1001/jamaneurol.2013.3090; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Makowski L, 2009, FASEB J, V23, P586, DOI 10.1096/fj.08-119420; Marin-Valencia I, 2012, NEUROBIOL DIS, V48, P92, DOI 10.1016/j.nbd.2012.04.011; Mescka CP, 2015, METAB BRAIN DIS, V30, P1167, DOI 10.1007/s11011-015-9686-9; Miller M, 2015, J INHERIT METAB DIS, P1; Miller MJ, 2016, J INHERIT METAB DIS, V39, P757, DOI 10.1007/s10545-016-9944-y; Mochel F, 2015, TRIHEPTANOIN DRAMATI, pS479; Mugabo Y, 2016, P NATL ACAD SCI USA, V113, pE430, DOI 10.1073/pnas.1514375113; Neal EG, 2012, EPILEPSY RES, V100, P267, DOI 10.1016/j.eplepsyres.2012.04.021; Nguyen NHT, 2003, J NEUROCHEM, V85, P831, DOI 10.1046/j.1471-4159.2003.01762.x; Roe CR, 2006, J INHERIT METAB DIS, V29, P332, DOI 10.1007/s10545-006-0290-3; Ruskin DN, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00033; Sato T, 2016, METABOLISM, V65, P1646, DOI 10.1016/j.metabol.2016.08.005; Soeters MR, 2012, METABOLISM, V61, P966, DOI 10.1016/j.metabol.2011.11.009; Striano P, 2012, NEUROLOGY, V78, P557, DOI 10.1212/WNL.0b013e318247ff54; Szczepanik E, 2014, DEV PERIOD MED, V19, P454; Veggiotti P, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0291-8; Verbeek MM, 2016, J CEREBR BLOOD F MET, V36, P899, DOI 10.1177/0271678X16637612; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038; Yazdani A, 2016, OMICS, V20, P480, DOI 10.1089/omi.2016.0071; Yubero D, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0284-5	40	18	18	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2017	12	9							e0184022	10.1371/journal.pone.0184022	http://dx.doi.org/10.1371/journal.pone.0184022			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI5MG	28961260	Green Published, Green Submitted, gold			2023-01-03	WOS:000412027700003
J	Turino, C; Bertran, S; Gavalda, R; Teixido, I; Woehrle, H; Rue, M; Solsona, F; Escarrabill, J; Colls, C; Garcia-Altes, A; de Batlle, J; de-la-Torre, MS; Barbe, F				Turino, Cecilia; Bertran, Sandra; Gavalda, Ricard; Teixido, Ivan; Woehrle, Holger; Rue, Montserrat; Solsona, Francesc; Escarrabill, Joan; Colls, Cristina; Garcia-Altes, Anna; de Batlle, Jordi; Sanchez de-la-Torre, Manuel; Barbe, Ferran			Characterization of the CPAP-treated patient population in Catalonia	PLOS ONE			English	Article							OBSTRUCTIVE SLEEP-APNEA; POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; ASSOCIATION; HYPERTENSION; ACCIDENTS; DISEASE; HEALTH; ASTHMA	There are different phenotypes of obstructive sleep apnoea (OSA), many of which have not been characterised. Identification of these different phenotypes is important in defining prognosis and guiding the therapeutic strategy. The aim of this study was to characterise the entire population of continuous positive airway pressure (CPAP)-treated patients in Catalonia and identify specific patient profiles using cluster analysis. A total of 72,217 CPAP-treated patients who contacted the Catalan-Health System (Cat-Salut) during the years 2012 and 2013 were included. Six clusters were identified, classified as "Neoplastic patients" (Cluster 1, 10.4%), "Metabolic syndrome patients" (Cluster 2, 27.7%), "Asthmatic patients" (Cluster 3, 5.8%), "Musculoskeletal and joint disorder patients" (Cluster 4, 10.3%), "Patients with few comorbidities" (Cluster 5, 35.6%) and "Oldest and cardiac disease patients" (Cluster 6, 10.2%). Healthcare facility use and mortality were highest in patients from Cluster 1 and 6. Conversely, patients in Clusters 2 and 4 had low morbidity, mortality and healthcare resource use. Our findings highlight the heterogeneity of CPAP-treated patients, and suggest that OSA is associated with a different prognosis in the clusters identified. These results suggest the need for a comprehensive and individualised approach to CPAP treatment of OSA.	[Turino, Cecilia; Bertran, Sandra; de Batlle, Jordi; Sanchez de-la-Torre, Manuel; Barbe, Ferran] Hosp Univ Arnau Vilanova & Santa Maria, Grp Translat Res Resp Med, IRBLleida, Lleida, Spain; [Turino, Cecilia; Bertran, Sandra; de Batlle, Jordi; Sanchez de-la-Torre, Manuel; Barbe, Ferran] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain; [Gavalda, Ricard] UPC BarcelonaTech, Dept Comp Sci, Barcelona, Spain; [Teixido, Ivan; Solsona, Francesc] Univ Lleida, Dept Comp Sci, Lleida, Spain; [Teixido, Ivan; Solsona, Francesc] Univ Lleida, INSPIRES, Lleida, Spain; [Woehrle, Holger] Resp Ctr Ulm, Sleep & Ventilat Ctr Blaubeuren, Ulm, Germany; [Rue, Montserrat] IRBLleida, Unit Bioestat & Epidemiol, Lleida, Spain; [Escarrabill, Joan] Hosp Clin Barcelona, Chron Care Program, Barcelona, Spain; [Escarrabill, Joan] Minist Hlth, Master Plan Resp Dis, Barcelona, Spain; [Escarrabill, Joan] REDISSEC, Barcelona, Spain; [Colls, Cristina; Garcia-Altes, Anna] Govt Catalonia, Publ Hlth Dept, Barcelona, Spain	University Hospital Arnau de Vilanova; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Universitat Politecnica de Catalunya; Universitat de Lleida; Universitat de Lleida; University of Barcelona; Hospital Clinic de Barcelona	Barbe, F (corresponding author), Hosp Univ Arnau Vilanova & Santa Maria, Grp Translat Res Resp Med, IRBLleida, Lleida, Spain.; Barbe, F (corresponding author), Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain.	febarbe.lleida.ics@gencat.cat	Rue, Montserrat/B-5663-2009; de la Torre, Manuel Sanchez/B-5578-2009; Sánchez-de-la-Torre, Manuel/AAC-9514-2022; Sanchez-de-la-Torre, Manuel/AAP-2663-2020; Barbé, Ferran/A-5988-2010; de Batlle, Jordi/G-6724-2016; Solsona, Francesc/AAR-4195-2020	Rue, Montserrat/0000-0002-7862-9365; de la Torre, Manuel Sanchez/0000-0002-5695-348X; Sanchez-de-la-Torre, Manuel/0000-0002-5695-348X; Barbé, Ferran/0000-0002-2340-8928; de Batlle, Jordi/0000-0003-3500-6608; Gavalda, Ricard/0000-0003-4736-7179	Spanish Respiratory Society (SEPAR); Associacio Lleidatana de Respiratori (ALLER); ResMed	Spanish Respiratory Society (SEPAR); Associacio Lleidatana de Respiratori (ALLER); ResMed	This study was supported by the Spanish Respiratory Society (SEPAR), Associacio Lleidatana de Respiratori (ALLER) and ResMed, a company that provides diagnostic services and treatment for sleep apnoea. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. ResMed paid the salaries of the author HW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailly S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157318; Barbe F, 1998, AM J RESP CRIT CARE, V158, P18, DOI 10.1164/ajrccm.158.1.9709135; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Campos-Rodriguez F, 2013, AM J RESP CRIT CARE, V187, P99, DOI 10.1164/rccm.201209-1671OC; Catala R, 2016, ARCH BRONCONEUMOL, V52, P461, DOI 10.1016/j.arbres.2016.02.005; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Gozal D, 2016, SLEEP, V39, P1493, DOI 10.5665/sleep.6004; Greenberg-Dotan S, 2007, SLEEP, V30, P1173, DOI 10.1093/sleep/30.9.1173; Howell S, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-96; Jennum P, 2017, SLEEP MED, V36, P62, DOI 10.1016/j.sleep.2017.04.018; Kent BD, 2015, J THORAC DIS, V7, P1343, DOI 10.3978/j.issn.2072-1439.2015.08.11; Lacedonia D, 2016, J SLEEP RES, V25, P724, DOI 10.1111/jsr.12429; Madama D, 2016, REV PORT PNEUMOL, V22, P6, DOI 10.1016/j.rppnen.2015.08.005; Martinez-Garcia MA, 2009, SLEEP MED, V10, P104, DOI 10.1016/j.sleep.2007.11.009; Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Pamidi Sushmita, 2012, Front Neurol, V3, P126; Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342; Sanchez-de-la-Torre M, 2013, LANCET RESP MED, V1, P61, DOI 10.1016/S2213-2600(12)70051-6; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Teodorescu M, 2015, JAMA-J AM MED ASSOC, V313, P156, DOI 10.1001/jama.2014.17822; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Trzepizur W, 2013, CHEST, V143, P1584, DOI 10.1378/chest.12-1652; Ye LC, 2014, EUR RESPIR J, V44, P1600, DOI 10.1183/09031936.00032314	24	13	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0185191	10.1371/journal.pone.0185191	http://dx.doi.org/10.1371/journal.pone.0185191			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH7CN	28934303	Green Submitted, gold, Green Published			2023-01-03	WOS:000411339900117
J	Abe, M; Hamano, T; Wada, A; Nakai, S; Masakane, I				Abe, Masanori; Hamano, Takayuki; Wada, Atsushi; Nakai, Shigeru; Masakane, Ikuto		Renal Data Registry Comm; Japanese Soc Dialysis Therapy	Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry	PLOS ONE			English	Article							SERUM BETA(2)-MICROGLOBULIN LEVEL; THERAPY CLINICAL GUIDELINE; PREDICT MORTALITY; ASSOCIATION; SOCIETY; BETA-2-MICROGLOBULIN; INFLAMMATION; MORBIDITY; QUALITY; SYSTEM	Background Little information is available regarding which type of dialyzer membrane results in good prognosis in patients on chronic hemodialysis. Therefore, we conducted a cohort study from a nationwide registry of hemodialysis patients in Japan to establish the association between different dialyzer membranes and mortality rates. Methods We followed 142,412 patients on maintenance hemodialysis (female, 39.1%; mean age, 64.8 +/- 12.3 years; median dialysis duration, 7[4-12] years) for a year from 2008 to 2009. We included patients treated with seven types of high-flux dialyzer membranes at baseline, including cellulose triacetate (CTA), ethylene vinyl alcohol (EVAL), polyacrylonitrile (PAN), polyester polymer alloy (PEPA), polyethersulfone (PES), polymethylmethacrylate (PMMA), and polysulfone (PS). Cox regression was used to estimate the association between baseline dialyzers and all-cause mortality as hazard ratios (HRs) and 95% confidence intervals for 1-year mortality adjusting for potential confounders, and propensity score matching analysis was performed. Results The distribution of patients treated with each membrane was as follows: PS (56.0%), CTA (17.3%), PES (12.0%), PEPA (7.5%), PMMA (4.9%), PAN (1.2%), and EVAL (1.1%). When data were adjusted using basic factors, with PS as a reference group, the mortality rate was significantly higher in all groups except for the PES group. When data were further adjusted groups. When the data were further adjusted for nutrition-and inflammation-related factors, HRs were significantly lower for the PMMA and PES groups compared with the PS group. After propensity score matching, HRs were significantly lower for the PMMA group than for the PS group. Conclusion The results suggest that the use of different membrane types may affect mortality in hemodialysis patients. However, further long-term prospective studies are needed to clarify these findings, including whether the use of the PMMA membrane can improve prognosis.	[Abe, Masanori] Nihon Univ, Sch Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan; [Hamano, Takayuki] Osaka Univ, Grad Sch Med, Dept Comprehens Kidney Dis Res, Osaka, Japan; [Wada, Atsushi] Kitasaito Hosp, Dept Nephrol, Asahikawa, Hokkaido, Japan; [Nakai, Shigeru] Fujita Hlth Univ, Dept Clin Engn, Toyoake, Aichi, Japan; [Masakane, Ikuto] Yabuki Hosp, Yamagata, Japan; [Abe, Masanori] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan	Nihon University; Osaka University; Fujita Health University; Nihon University	Abe, M (corresponding author), Nihon Univ, Sch Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan.; Abe, M (corresponding author), Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo, Japan.	abe.masanori@nihon-u.ac.jp	Hamano, TAKAYUKI/AAZ-4837-2021	Hamano, TAKAYUKI/0000-0002-2100-9106				Aucella F, 2007, NEPHROL DIAL TRANSPL, V22, P8, DOI 10.1093/ndt/gfm293; Aucella F, 2013, BLOOD PURIFICAT, V35, P42, DOI 10.1159/000350847; Cheung AK, 2008, CLIN J AM SOC NEPHRO, V3, P69, DOI 10.2215/CJN.02340607; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; Higuchi T, 2015, SLEEP MED, V16, P941, DOI 10.1016/j.sleep.2015.03.025; Iseki K, 2011, NEPHROL DIAL TRANSPL, V26, P963, DOI 10.1093/ndt/gfq507; Koda Y, 1997, KIDNEY INT, V52, P1096, DOI 10.1038/ki.1997.434; Kopple JD, 1999, KIDNEY INT, V56, P1136, DOI 10.1046/j.1523-1755.1999.00615.x; Kreusser W, 2010, CLIN KIDNEY J, V3, pI12, DOI 10.1093/ndtplus/sfq032; Lin YC, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0380-7; Lin YK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/234245; Liu CT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00080-4; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; MacLeod A.M., 2005, COCHRANE DB SYST REV, V3, P1, DOI DOI 10.1002/14651858.CD003234.PUB2; Masakane I, 2015, THER APHER DIAL, V19, P540, DOI 10.1111/1744-9987.12378; Masakane I, 2010, CLIN KIDNEY J, V3, pI28, DOI 10.1093/ndtplus/sfq034; Masakane I, 2009, BLOOD PURIFICAT, V27, P11, DOI 10.1159/000213491; Nakai S, 2001, AM J KIDNEY DIS, V38, pS212, DOI 10.1053/ajkd.2001.27449; Nakai S, 2012, THER APHER DIAL, V16, P483, DOI 10.1111/j.1744-9987.2012.01143.x; Nakai S, 2012, THER APHER DIAL, V16, P11, DOI 10.1111/j.1744-9987.2011.01050.x; Nakai S, 2010, THER APHER DIAL, V14, P505, DOI 10.1111/j.1744-9987.2010.00893.x; National Kidney Foundation, 2006, AM J KIDNEY DIS, V48, ps12; Okuno S, 2009, NEPHROL DIAL TRANSPL, V24, P571, DOI 10.1093/ndt/gfn521; Saito A, 2011, CONTRIB NEPHROL, V173, P1, DOI 10.1159/000328938; Sakai Y, 2011, CONTRIB NEPHROL, V173, P137, DOI 10.1159/000329052; Santoro A, 2013, BLOOD PURIFICAT, V35, P5, DOI 10.1159/000350837; Schiffl H, 2001, NEPHROL DIAL TRANSPL, V17, P1814; SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980; Shinzato T, 1997, NEPHROL DIAL TRANSPL, V12, P884, DOI 10.1093/ndt/12.5.884; Shinzato T, 1997, ARTIF ORGANS, V21, P864; Shoji T, 2011, CLIN J AM SOC NEPHRO, V6, P1112, DOI 10.2215/CJN.09961110; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Tattersall J, 2007, NEPHROL DIAL TRANSPL, V22, P5, DOI 10.1093/ndt/gfm022; Traut M, 2007, BLOOD PURIFICAT, V25, P432, DOI 10.1159/000110069; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; Watanabe Y, 2015, THER APHER DIAL, V19, P93, DOI 10.1111/1744-9987.12293; Yamashita AC, 2011, CONTRIB NEPHROL, V173, P95, DOI 10.1159/000328946	41	31	33	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184424	10.1371/journal.pone.0184424	http://dx.doi.org/10.1371/journal.pone.0184424			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0VR	28910324	gold, Green Published, Green Submitted			2023-01-03	WOS:000410859200046
J	Hajjar, R; Bassatne, A; Cheaito, MA; El Dine, RN; Traboulsy, S; Haddadin, F; Honein-AbouHaidar, G; Aki, EA				Hajjar, Rima; Bassatne, Aya; Cheaito, Mohamad Ali; El Dine, Rabie Naser; Traboulsy, Sarah; Haddadin, Fadi; Honein-AbouHaidar, Gladys; Aki, Elie A.			Characterizing the interaction between physicians, pharmacists and pharmaceutical representatives in a middle-income country: A qualitative study	PLOS ONE			English	Article							DRUG PROMOTION; PAYMENTS; HEALTH; SALES	Background Studies around the world have shown that interactions between pharmaceutical companies, pharmacists and physicians have a great influence on prescribing and drug dispensing practices. In middle-income countries, the nature and extent of these interactions have not been well researched. Our objectives were to qualitatively explore the nature of the interactions between pharmaceutical companies, physicians and pharmacists, their impact on drug prescription and dispensing practices in Lebanon. Methods and findings We used grounded theory approach as well as the known sponsor, purposive, and snowballing sampling strategies to identify interviewees from the three respective groups: physicians, pharmacists, and pharmaceutical representatives. We conducted semi-structured and analyzed transcripts thematically. This study encompassed 6 pharmaceutical representatives, 13 physicians and 13 pharmacists. The following themes emerged: purpose and driver for the interactions, nature of the interactions, incentives, impact on prescription practices, ethical considerations, and suggestions for managing the interactions. The main purposes for the interaction were educational, promotional, and monitoring prescription practices and dispensing, while the main drivers for these interactions were market potential and neighborhood socio-economic status. Physicians, pharmacists and pharmaceutical representatives who engage in these interactions benefit from a variety of incentives, some of which were characterized as unethical. It appears that pharmaceutical companies give prominence to selected physicians within their communities. Although members of the three interviewed groups refer to some of the interactions as being problematic, they described a culture of acceptance of gift giving. We developed a framework that depicts the prevailing politico-cultural environment, the interactions between the three professional groups, and their impact on drug prescription. Underreporting is the main limitation of this study. Conclusion Interactions between physicians, pharmacists and pharmaceutical representatives are frequent. Although these interactions can be beneficial, they still have a substantial effect on drug prescription and dispensing practices. Hence, the need for new policies that regulate these interactions and penalize any misconduct.	[Hajjar, Rima; Bassatne, Aya; Cheaito, Mohamad Ali; El Dine, Rabie Naser; Traboulsy, Sarah; Haddadin, Fadi; Aki, Elie A.] Amer Univ Beirut, Fac Med, Beirut, Lebanon; [Honein-AbouHaidar, Gladys] Amer Univ Beirut, Hariri Sch Med, Beirut, Lebanon	American University of Beirut; American University of Beirut	Aki, EA (corresponding author), Amer Univ Beirut, Fac Med, Beirut, Lebanon.	ea32@aub.edu.lb	Akl, Elie/K-5269-2019; Honein-AbouHaidar, Gladys N./M-4308-2013; Akl, Elie A./R-2079-2016	Honein-AbouHaidar, Gladys N./0000-0001-6208-7859; Cheaito, Mohamad Ali/0000-0001-6653-8848; Traboulsy, Sarah/0000-0001-6876-1066; Akl, Elie A./0000-0002-3444-8618				Agrawal S, 2016, NEW ENGL J MED, V374, P906, DOI 10.1056/NEJMp1509103; Alssageer MA, 2013, PAN AFR MED J, V14, DOI 10.11604/pamj.2013.14.132.2598; Blominvest Bank, 2016, PHARM HEALTHC LEB NU; Brax H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175493; Buchman S, 2012, CAN FAM PHYSICIAN, V58, P229; Corbin J., 1998, BASICS QUALITATIVE R; DeAngelis CD, 2014, MILBANK Q, V92, P195, DOI 10.1111/1468-0009.12052; El-Jardali F, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0556-1; Francer J, 2014, PHILOS ETHICS HUM ME, V9, DOI 10.1186/1747-5341-9-7; Fugh-Berman A, 2008, J GEN INTERN MED, V23, P1277, DOI 10.1007/s11606-008-0630-0; Ghaith A., 2013, EUR J SOCIAL SCI, V36, P528; Goodley S., 2014, GUARDIAN; Grouse L, 2014, J THORAC DIS, V6, P558, DOI 10.3978/j.issn.2072-1439.2014.01.25; Kamal S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140457; Lai Taavi, 2013, HLTH SYSTEMS TRANSIT, V15; Lakoff A, 2004, SOC STUD SCI, V34, P247, DOI 10.1177/0306312704042624; Lotfi T, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1299-4; Mello MM, 2011, NEW ENGL J MED, V365, P1248, DOI 10.1056/NEJMhle1107678; Mikhael E., 2014, PHARM PHARMACOL-RUSS, V5, P705, DOI [10.4236/pp.2014.57080, DOI 10.4236/PP.2014.57080]; Ministry of Public Health, 2016, COD ETH MED PROD PRO; Oldani MJ, 2004, MED ANTHROPOL Q, V18, P325, DOI 10.1525/maq.2004.18.3.325; Pham-Kanter G, 2017, J GEN INTERN MED, V32, P767, DOI 10.1007/s11606-017-4012-3; Publishing O, 2013, HLTH GLANC 2013; Rothman DJ, 2014, MILBANK Q, V92, P471, DOI 10.1111/1468-0009.12074; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Zaki NM, 2014, SAUDI PHARM J, V22, P528, DOI 10.1016/j.jsps.2014.02.008	26	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2017	12	9							e0184662	10.1371/journal.pone.0184662	http://dx.doi.org/10.1371/journal.pone.0184662			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG6AR	28898296	Green Published, Green Submitted, gold			2023-01-03	WOS:000410449500041
J	Agodi, A; Barchitta, M; Quattrocchi, A; Spera, E; Gallo, G; Auxilia, F; Brusaferro, S; D'Errico, MM; Montagna, MT; Pasquarella, C; Tardivo, S; Mura, I				Agodi, Antonella; Barchitta, Martina; Quattrocchi, Annalisa; Spera, Emiliano; Gallo, Giovanni; Auxilia, Francesco; Brusaferro, Silvio; D'Errico, Marcello Mario; Montagna, Maria Teresa; Pasquarella, Cesira; Tardivo, Stefano; Mura, Ida		GISIO-Siti Working Grp	Preventable proportion of intubation-associated pneumonia: Role of adherence to a care bundle	PLOS ONE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; UNIT-ACQUIRED INFECTIONS; PARAMETRIC-G-FORMULA; NETWORK SPIN-UTI; ACINETOBACTER-BAUMANNII; NOSOCOMIAL INFECTIONS; PATIENT; MORTALITY; SURVEILLANCE; HOSPITALS	Objective The aim of the present study was to estimate the preventable proportion of Intubation-Associated Pneumonia (IAP) in the Intensive Care Units (ICUs) participating in the Italian Nosocomial Infections Surveillance in ICUs (SPIN-UTI) network, taking into account differences in intrinsic patients' risk factors, and additionally considering the compliance with the European bundle for IAP prevention. Methods A prospective patient-based survey was conducted and all patients staying in ICU for more than 2 days were enrolled in the surveillance. Compliance with the bundle was assessed using a questionnaire for each intubated patient. A twofold analysis by the parametric g-formula was used to compute the number of infections to be expected if the infection incidence in all ICUs could be reduced to that one of the top-tenth-percentile-ranked ICUs and to that one of the ICU with the highest compliance to all five bundle components. Results A total of 1,840 patients and of 17 ICUs were included in the first analysis showing a preventable proportion of 44% of IAP. In a second analysis on a subset of data, considering compliance with the European bundle, a preventable proportion of 40% of IAP was shown. A significant negative trend of IAP incidences was observed with increasing number of bundle components performed (p<0.001) and a strong negative correlation between these two factors was shown (r = -0.882; p = 0.048). Conclusions The g-formula controlled for time-varying factors is a valuable approach for estimating the preventable proportion of IAP and the impact of interventions, based entirely on an observed population in a real-world setting. However, both the study design that cannot definitively prove a causative relationship between bundle compliance and IAP risk, and the small number of patients included in the care bundle compliance analysis, may represent limits of the study and further and larger studies should be conducted.	[Agodi, Antonella; Barchitta, Martina; Quattrocchi, Annalisa] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy; [Spera, Emiliano; Gallo, Giovanni] Univ Catania, Dept Math & Informat, Catania, Italy; [Auxilia, Francesco] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Brusaferro, Silvio] Univ Udine, Dept Med, Udine, Italy; [D'Errico, Marcello Mario] Polytech Univ Marche, Dept Biomed Sci & Publ Hlth, Ancona, Italy; [Montagna, Maria Teresa] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy; [Pasquarella, Cesira] Univ Parma, Dept Med & Surg, Parma, Italy; [Tardivo, Stefano] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy; [Mura, Ida] Univ Sassari, Dept Biomed Sci, Sassari, Italy; [GISIO-Siti Working Grp] Italian Study Grp Hosp Hyg, GISIO SItI Working Grp, Italian Soc Hyg Prevent Med & Publ Hlth, Udine, Italy	University of Catania; University of Catania; University of Milan; University of Udine; Marche Polytechnic University; Universita degli Studi di Bari Aldo Moro; University of Parma; University of Verona; University of Sassari	Agodi, A (corresponding author), Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy.	agodia@unict.it	Quattrocchi, Annalisa/S-8119-2019; Agodi, Antonella/B-3501-2011; Quattrocchi, Annalisa/AAU-5458-2020; Pasquarella, Cesira/S-8637-2019; Agodi, Antonella/AIF-3938-2022; Barchitta, Martina/A-1362-2015	Quattrocchi, Annalisa/0000-0002-5764-6721; Agodi, Antonella/0000-0002-4405-8162; Agodi, Antonella/0000-0002-4405-8162; Barchitta, Martina/0000-0002-0905-5003; Gallo, Giovanni/0000-0002-6701-0620	Italian Ministry of Health [CCM 2012]	Italian Ministry of Health(Ministry of Health, Italy)	Project realized with partial financial support by the Italian Ministry of Health, CCM 2012.	Agodi A, 2014, J HOSP INFECT, V86, P260, DOI 10.1016/j.jhin.2014.02.001; Agodi A, 2013, J HOSP INFECT, V84, P52, DOI 10.1016/j.jhin.2013.02.012; Agodi A, 2010, J HOSP INFECT, V74, P258, DOI 10.1016/j.jhin.2009.08.015; Agodi A, 2015, HOSP HEALTHCARE EURO, P146; Agodi Antonella, 2014, Epidemiol Prev, V38, P153; Agodi Antonella, 2014, Epidemiol Prev, V38, P51; Al-Thaqafy MS, 2014, ANN THORAC MED, V9, P221, DOI 10.4103/1817-1737.140132; Barchitta M, 2009, INT J HYG ENVIR HEAL, V212, P330, DOI 10.1016/j.ijheh.2008.07.001; Bekaert M, 2011, AM J RESP CRIT CARE, V184, P1133, DOI 10.1164/rccm.201105-0867OC; Centers for Disease Control and Prevention, 2017, SURV VENT ASS EV; D'Alessandro D, 2014, NURS EDUC TODAY, V34, P191, DOI 10.1016/j.nedt.2013.05.005; European Centre for Disease Prevention and Control, 2010, EUR SURV HEALTHC ASS; European Centre for Disease Prevention and Control (ECDC), 2015, ANN EP REP 2014 ANT; Flodgren G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006559.pub2; Grundmann H, 2005, CRIT CARE MED, V33, P946, DOI 10.1097/01.CCM.0000163223.26234.56; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990; Hamishehkar H, 2014, J RES PHARM PRACT, V3, P51, DOI 10.4103/2279-042X.137070; Harbarth S, 2003, J HOSP INFECT, V54, P258, DOI 10.1016/S0195-6701(03)00150-6; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; Keil AP, 2014, EPIDEMIOLOGY, V25, P889, DOI 10.1097/EDE.0000000000000160; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Klompas M, 2007, JAMA-J AM MED ASSOC, V297, P1583, DOI 10.1001/jama.297.14.1583; Klompas M, 2016, JAMA INTERN MED, V176, P1277, DOI 10.1001/jamainternmed.2016.2427; Klompas M, 2010, AM J INFECT CONTROL, V38, P237, DOI 10.1016/j.ajic.2009.10.003; Lambert ML, 2014, INFECT CONT HOSP EP, V35, P494, DOI 10.1086/675824; Lisboa T, 2013, CRIT CARE, V17, DOI 10.1186/cc12590; Masia MD, 2010, J HOSP INFECT, V76, P139, DOI 10.1016/j.jhin.2010.05.013; Mitharwal SM, 2016, AM J INFECT CONTROL, V44, pE113, DOI 10.1016/j.ajic.2016.01.021; Mizgerd JP, 2008, NEW ENGL J MED, V358, P716, DOI 10.1056/NEJMra074111; Morrow LE, 2010, CRIT CARE MED, V38, pS352, DOI 10.1097/CCM.0b013e3181e6cc98; Neophytou AM, 2016, EPIDEMIOLOGY, V27, P21, DOI 10.1097/EDE.0000000000000389; Rahmqvist M, 2016, AM J INFECT CONTROL, V44, P500, DOI 10.1016/j.ajic.2016.01.035; Rello J, 2013, CLIN MICROBIOL INFEC, V19, P363, DOI 10.1111/j.1469-0691.2012.03808.x; Rello J, 2010, INTENS CARE MED, V36, P773, DOI 10.1007/s00134-010-1841-5; Roquilly A, 2015, CLIN INFECT DIS, V60, P64, DOI 10.1093/cid/ciu740; Umscheid CA, 2011, INFECT CONT HOSP EP, V32, P101, DOI 10.1086/657912	37	10	10	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0181170	10.1371/journal.pone.0181170	http://dx.doi.org/10.1371/journal.pone.0181170			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877171	Green Published, Green Submitted, gold			2023-01-03	WOS:000409391200007
J	Li, ZH; Li, DC; Choi, EY; Lapidus, R; Zhang, L; Huang, SM; Shapiro, P; Wang, HB				Li, Zhihui; Li, Daochuan; Choi, Eun Yong; Lapidus, Rena; Zhang, Lei; Huang, Shiew-Mei; Shapiro, Paul; Wang, Hongbing			Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-CITRATE LYASE; GENOMIC ORGANIZATION; FUNCTIONAL FEATURES; INSULIN-RESISTANCE; HEPATIC STEATOSIS; MAMMALIAN-CELLS; TRANSPORTER; METABOLISM; RECEPTOR; NACT	The solute carrier family 13 member 5 (SLC13A5), a sodium-coupled citrate transporter, plays a key role in importing citrate from the circulation into liver cells. Recent evidence has revealed that SLC13A5 deletion protects mice from high-fat diet-induced hepatic steatosis and that mutation of the SLC13A5 orthologues in Drosophila melanogaster and Caenorhabditis elegans promotes longevity. However, despite the emerging importance of SLC13A5 in energy homeostasis, whether perturbation of SLC13A5 affects the metabolism and malignancy of hepatocellular carcinoma is unknown. Here, we sought to determine whether SLC13A5 regulates hepatic energy homeostasis and proliferation of hepatoma cells. RNAi-mediated silencing of SLC13A5 expression in two human hepatoma cell lines, HepG2 and Huh7, profoundly suppressed cell proliferation and colony formation, and induced cell cycle arrest accompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expression of cyclin B1. Furthermore, such suppressive effects were also observed on the growth of HepG2 cell-derived xenografts expressing SLC13A5-shRNA in nude mice. Metabolically, knockdown of SLC13A5 in HepG2 and Huh7 cells was associated with a decrease in intracellular levels of citrate, the ratio of ATP/ADP, phospholipid content, and ATP citrate lyase expression. Moreover, both in vitro and in vivo assays demonstrated that SLC13A5 depletion promotes activation of the AMP-activated protein kinase, which was accompanied by deactivation of oncogenic mechanistic target of rapamycin signaling. Together, our findings expand the role of SLC13A5 from facilitating hepatic energy homeostasis to influencing hepatoma cell proliferation and suggest a potential role of SLC13A5 in the progression of human hepatocellular carcinoma.	[Li, Zhihui; Shapiro, Paul; Wang, Hongbing] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA; [Choi, Eun Yong; Lapidus, Rena; Shapiro, Paul; Wang, Hongbing] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, 20 Penn St, Baltimore, MD 21201 USA; [Zhang, Lei; Huang, Shiew-Mei] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Off Translat Sci, Silver Spring, MD 20993 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Food & Drug Administration (FDA)	Wang, HB (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	hongbing.wang@rx.umaryland.edu			National Institutes of Health [GM107058]; Research Participation Program at the Center for Drug Evaluation and Research	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Participation Program at the Center for Drug Evaluation and Research	The study was partially supported by National Institutes of Health Grant GM107058 (to H.W.). This work was also supported in part by the Research Participation Program at the Center for Drug Evaluation and Research, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U. S. Department of Energy and FDA (to Z. L.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the FDA.	Barbato DL, 2014, BBA-REV CANCER, V1845, P317, DOI 10.1016/j.bbcan.2014.02.003; Bhalla K, 2012, CANCER PREV RES, V5, P544, DOI 10.1158/1940-6207.CAPR-11-0228; Birkenfeld AL, 2011, CELL METAB, V14, P184, DOI 10.1016/j.cmet.2011.06.009; Brito AF, 2012, CHEMOTHERAPY, V58, P381, DOI 10.1159/000343656; CARLSON CA, 1973, J BIOL CHEM, V248, P378; Catalina-Rodriguez O, 2012, ONCOTARGET, V3, P1220; Chypre M, 2012, BIOCHEM BIOPH RES CO, V422, P1, DOI 10.1016/j.bbrc.2012.04.144; Coloff JL, 2016, CELL METAB, V23, P867, DOI 10.1016/j.cmet.2016.03.016; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Fei YJ, 2004, BIOCHEM J, V379, P191, DOI 10.1042/BJ20031807; Gopal E, 2007, AM J PHYSIOL-GASTR L, V292, pG402, DOI 10.1152/ajpgi.00371.2006; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Iacobazzi V, 2014, BIOL CHEM, V395, P387, DOI 10.1515/hsz-2013-0271; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Infantino V, 2011, BIOCHEM J, V438, P433, DOI 10.1042/BJ20111275; Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261; Inoue K, 2002, BIOCHEM BIOPH RES CO, V299, P465, DOI 10.1016/S0006-291X(02)02669-4; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; Lee JH, 2015, FEBS J, V282, P361, DOI 10.1111/febs.13139; Li LH, 2015, MOL PHARMACOL, V87, P674, DOI 10.1124/mol.114.097287; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Migita T, 2014, INT J CANCER, V135, P37, DOI 10.1002/ijc.28652; Mycielska ME, 2009, BIOESSAYS, V31, P10, DOI 10.1002/bies.080137; Neretti N, 2009, P NATL ACAD SCI USA, V106, P2277, DOI 10.1073/pnas.0812484106; Neuschafer-Rube F, 2015, TOXICOLOGY, V337, P1, DOI 10.1016/j.tox.2015.08.007; O'Neill Luke A J, 2011, Biochem J, V438, pe5, DOI 10.1042/BJ20111386; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Pajor AM, 2014, PFLUG ARCH EUR J PHY, V466, P119, DOI 10.1007/s00424-013-1369-y; Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pesta DH, 2015, AGING-US, V7, P1086, DOI 10.18632/aging.100854; Rodriguez-Enriquez S, 2009, MOL NUTR FOOD RES, V53, P29, DOI 10.1002/mnfr.200700470; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sanli T, 2014, CANCER BIOL THER, V15, P156, DOI 10.4161/cbt.26726; von Loeffelholz C, 2017, HEPATOLOGY, V66, P616, DOI 10.1002/hep.29089; Yang H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130953; Zaidi N, 2012, MOL CANCER THER, V11, P1925, DOI 10.1158/1535-7163.MCT-12-0095; Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112; Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928; Zulato E, 2014, BRIT J CANCER, V111, P25, DOI 10.1038/bjc.2014.274	47	18	18	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2017	292	33					13890	13901		10.1074/jbc.M117.783860	http://dx.doi.org/10.1074/jbc.M117.783860			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE0XG	28655760	Green Published, hybrid			2023-01-03	WOS:000407942400014
J	Johansen, MY; MacDonald, CS; Hansen, KB; Karstoft, K; Christensen, R; Pedersen, M; Hansen, LS; Zacho, M; Wedell-Neergaard, AS; Nielsen, ST; Iepsen, UW; Langberg, H; Vaag, AA; Pedersen, BK; Ried-Larsen, M				Johansen, Mette Yun; MacDonald, Christopher Scott; Hansen, Katrine Bagge; Karstoft, Kristian; Christensen, Robin; Pedersen, Maria; Hansen, Louise Seier; Zacho, Morten; Wedell-Neergaard, Anne-Sophie; Nielsen, Signe Tellerup; Iepsen, Ulrik Wining; Langberg, Henning; Vaag, Allan Arthur; Pedersen, Bente Klarlund; Ried-Larsen, Mathias			Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPEN-LABEL; PHYSICAL-ACTIVITY; INSULIN GLARGINE; RISK-FACTORS; EXERCISE; NONINFERIORITY; ASSOCIATION; PHASE-3; COST	IMPORTANCE It is unclear whether a lifestyle intervention can maintain glycemic control in patients with type 2 diabetes. OBJECTIVE To test whether an intensive lifestyle intervention results in equivalent glycemic control compared with standard care and, secondarily, leads to a reduction in glucose-lowering medication in participants with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS Randomized, assessor-blinded, single-center study within Region Zealand and the Capital Region of Denmark (April 2015-August 2016). Ninety-eight adult participants with non-insulin-dependent type 2 diabetes who were diagnosed for less than 10 years were included. Participants were randomly assigned (2: 1; stratified by sex) to the lifestyle group (n = 64) or the standard care group (n = 34). INTERVENTIONS All participants received standard care with individual counseling and standardized, blinded, target-driven medical therapy. Additionally, the lifestyle intervention included 5 to 6 weekly aerobic training sessions (duration 30-60 minutes), of which 2 to 3 sessions were combined with resistance training. The lifestyle participants received dietary plans aiming for a body mass index of 25 or less. Participants were followed up for 12 months. MAIN OUTCOMES AND MEASURES Primary outcome was change in hemoglobin A(1c) (HbA(1c)) from baseline to 12-month follow-up, and equivalence was prespecified by a CI margin of +/- 0.4% based on the intention-to-treat population. Superiority analysis was performed on the secondary outcome reductions in glucose-lowering medication. RESULTS Among 98 randomized participants (mean age, 54.6 years [SD, 8.9]; women, 47 [48%]; mean baseline HbA(1c), 6.7%), 93 participants completed the trial. From baseline to 12-month follow-up, the mean HbA(1c) level changed from 6.65% to 6.34% in the lifestyle group and from 6.74% to 6.66% in the standard care group (mean between-group difference in change of -0.26%[95% CI, -0.52% to -0.01%]), not meeting the criteria for equivalence (P = .15). Reduction in glucose-lowering medications occurred in 47 participants (73.5%) in the lifestyle group and 9 participants (26.4%) in the standard care group (difference, 47.1 percentage points [95% CI, 28.6-65.3]). There were 32 adverse events (most commonly musculoskeletal pain or discomfort and mild hypoglycemia) in the lifestyle group and 5 in the standard care group. CONCLUSIONS AND RELEVANCE Among adults with type 2 diabetes diagnosed for less than 10 years, a lifestyle intervention compared with standard care resulted in a change in glycemic control that did not reach the criterion for equivalence, but was in a direction consistent with benefit. Further research is needed to assess superiority, as well as generalizability and durability of findings.	[Johansen, Mette Yun; MacDonald, Christopher Scott; Hansen, Katrine Bagge; Karstoft, Kristian; Pedersen, Maria; Hansen, Louise Seier; Zacho, Morten; Wedell-Neergaard, Anne-Sophie; Nielsen, Signe Tellerup; Iepsen, Ulrik Wining; Langberg, Henning; Vaag, Allan Arthur; Pedersen, Bente Klarlund; Ried-Larsen, Mathias] Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, Copenhagen, Denmark; [Johansen, Mette Yun; MacDonald, Christopher Scott; Hansen, Katrine Bagge; Karstoft, Kristian; Pedersen, Maria; Hansen, Louise Seier; Zacho, Morten; Wedell-Neergaard, Anne-Sophie; Nielsen, Signe Tellerup; Iepsen, Ulrik Wining; Langberg, Henning; Vaag, Allan Arthur; Pedersen, Bente Klarlund; Ried-Larsen, Mathias] Univ Copenhagen, Rigshosp, Ctr Phys Act Res, Copenhagen, Denmark; [MacDonald, Christopher Scott; Langberg, Henning] Univ Copenhagen, CopenRehab, Copenhagen, Denmark; [Christensen, Robin] Parker Inst, Musculoskeletal Stat Unit, Copenhagen, Denmark; [Christensen, Robin] Frederiksberg Univ Hosp, Copenhagen, Denmark; [Pedersen, Maria] Herlev Hosp, Dept Clin Physiol & Nucl Med, Herlev, Denmark; [Vaag, Allan Arthur] AstraZeneca, Translat Res & Early Clin Dev, Cardiovasc & Metab Res, Molndal, Sweden; [Ried-Larsen, Mathias] Odense Univ Hosp, Danish Diabet Acad, Odense, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; AstraZeneca; University of Southern Denmark; Odense University Hospital	Ried-Larsen, M (corresponding author), Rigshosp 7641, Ctr Inflammat & Metab, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.; Ried-Larsen, M (corresponding author), Rigshosp 7641, Ctr Phys Act Res, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	mathias.ried-larsen@regionh.dk	Ried-Larsen, Mathias/GPX-7640-2022; Pedersen, Bente Klarlund/AGR-3217-2022; Iepsen, Ulrik Winning/AGZ-2144-2022; Johansen, Mette Yun/AAD-9067-2021	Ried-Larsen, Mathias/0000-0002-8388-5291; Pedersen, Bente Klarlund/0000-0001-6508-6288; Iepsen, Ulrik Winning/0000-0002-8140-2583; Yun Johansen, Mette/0000-0001-5517-1454; Vaag, Allan Arthur/0000-0002-3690-2191; Christensen, Robin/0000-0002-6600-0631; Hansen, Katrine Bagge/0000-0002-2587-5589; Karstoft, Kristian/0000-0002-6596-4199	TrygFonden; Danish Council for Strategic Research [09-067009, 09-075724]; Danish Diabetes Academy; Novo Nordisk Foundation	TrygFonden; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Diabetes Academy; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	This project was funded by TrygFonden. The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. Centre for Inflammation and Metabolism/CFAS is a member of the Danish Center for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grants 09-067009 and 09-075724). The Contour Next glucose monitors were provided by Bayer A/S, Copenhagen, Denmark. This work was also supported by a grant from the Danish Diabetes Academy, which is supported by the Novo Nordisk Foundation (Dr Ried-Larsen).	Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS47, DOI 10.2337/dc16-S009; Andrews RC, 2011, LANCET, V378, P129, DOI 10.1016/S0140-6736(11)60442-X; Balducci S, 2010, ARCH INTERN MED, V170, P1794, DOI 10.1001/archinternmed.2010.380; Bland JM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3985; Blonde L, 2015, LANCET, V385, P2057, DOI 10.1016/S0140-6736(15)60936-9; Boule NG, 2003, DIABETOLOGIA, V46, P1071, DOI 10.1007/s00125-003-1160-2; Brancati F, 2003, CONTROL CLIN TRIALS, V24, P610, DOI 10.1016/S0197-2456(03)00064-3; Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710; Coppell KJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3337; Delahanty LM, 2015, OBESITY, V23, P1792, DOI 10.1002/oby.21172; Espeland M, 2007, DIABETES CARE, V30, P1374; Espeland MA, 2014, DIABETES CARE, V37, P2548, DOI 10.2337/dc14-0093; Gorter KJ, DIABETES GLYCAEMIC C; Gregg EW, 2012, JAMA-J AM MED ASSOC, V308, P2489, DOI 10.1001/jama.2012.67929; Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Huang ES, 2007, DIABETES CARE, V30, P2478, DOI 10.2337/dc07-0499; Inagaki N, 2015, LANCET DIABETES ENDO, V3, P191, DOI 10.1016/S2213-8587(14)70251-7; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI 10.2337/dc12-0413; Kaul S, 2006, ANN INTERN MED, V145, P62, DOI 10.7326/0003-4819-145-1-200607040-00011; KOSKINEN PJ, 1993, DIABETES CARE, V16, P1049, DOI 10.2337/diacare.16.7.1049b; Lewis JA, 1999, STAT MED, V18, P1903, DOI 10.1002/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Prasad-Reddy Lalita, 2015, Drugs Context, V4, P212283, DOI 10.7573/dic.212283; Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8; Redmon JB, 2010, DIABETES CARE, V33, P1153, DOI 10.2337/dc09-2090; Ried-Larsen M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009764; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Sigal RJ, 2010, DIABETES CARE, V33, P147, DOI DOI 10.2337/DC10-9990; Trabulsi J, 2001, AM J PHYSIOL-ENDOC M, V281, pE891, DOI 10.1152/ajpendo.2001.281.5.E891; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Umpierre D, 2013, DIABETOLOGIA, V56, P242, DOI 10.1007/s00125-012-2774-z; Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576; US Department of Health and Human Services FaDA Center for Drug Evaluation and Research, GUID IND DIAB MELL D; Walker E, 2011, J GEN INTERN MED, V26, P192, DOI 10.1007/s11606-010-1513-8; Zinman B, 2013, LANCET DIABETES ENDO, V1, P123, DOI 10.1016/S2213-8587(13)70013-5	35	93	100	2	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 15	2017	318	7					637	646		10.1001/jama.2017.10169	http://dx.doi.org/10.1001/jama.2017.10169			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD6CH	28810024	Green Published			2023-01-03	WOS:000407616000018
J	Gomez, JL; Bonaventura, J; Lesniak, W; Mathews, WB; Sysa-Shah, P; Rodriguez, LA; Ellis, RJ; Richie, CT; Harvey, BK; Dannals, RF; Pomper, MG; Bonci, A; Michaelides, M				Gomez, Juan L.; Bonaventura, Jordi; Lesniak, Wojciech; Mathews, William B.; Sysa-Shah, Polina; Rodriguez, Lionel A.; Ellis, Randall J.; Richie, Christopher T.; Harvey, Brandon K.; Dannals, Robert F.; Pomper, Martin G.; Bonci, Antonello; Michaelides, Michael			Chemogenetics revealed: DREADD occupancy and activation via converted clozapine	SCIENCE			English	Article							BLOOD-BRAIN-BARRIER; N-OXIDE; IN-VIVO; METABOLISM; DRUGS; MICE; RAT	The chemogenetic technology DREADD (designer receptors exclusively activated by designer drugs) is widely used for remote manipulation of neuronal activity in freely moving animals. DREADD technology posits the use of "designer receptors," which are exclusively activated by the "designer drug" clozapine N-oxide (CNO). Nevertheless, the in vivo mechanism of action of CNO at DREADDs has never been confirmed. CNO does not enter the brain after systemic drug injections and shows low affinity for DREADDs. Clozapine, to which CNO rapidly converts in vivo, shows high DREADD affinity and potency. Upon systemic CNO injections, converted clozapine readily enters the brain and occupies central nervous system-expressed DREADDs, whereas systemic subthreshold clozapine injections induce preferential DREADD-mediated behaviors.	[Gomez, Juan L.; Bonaventura, Jordi; Rodriguez, Lionel A.; Ellis, Randall J.; Michaelides, Michael] NIDA, Biobehav Imaging & Mol Neuropsychopharmacol, Intramural Res Program, Baltimore, MD 21224 USA; [Lesniak, Wojciech; Mathews, William B.; Sysa-Shah, Polina; Dannals, Robert F.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Richie, Christopher T.; Harvey, Brandon K.] NIDA, Intramural Res Program, Optogenet & Transgen Technol Core, Baltimore, MD 21224 USA; [Bonci, Antonello] NIDA, Synapt Plast Sect, Intramural Res Program, Baltimore, MD 21224 USA; [Michaelides, Michael] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins Medicine	Michaelides, M (corresponding author), NIDA, Biobehav Imaging & Mol Neuropsychopharmacol, Intramural Res Program, Baltimore, MD 21224 USA.; Michaelides, M (corresponding author), Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.	mike.michaelides@nih.gov	Michaelides, Mike/V-5199-2019; Harvey, Brandon Keith/AAY-4080-2021; Harvey, Brandon K/A-5559-2010; Bonaventura, Jordi/A-5229-2019; Gomez, Juan/O-7541-2017; Michaelides, Michael/K-4736-2013	Harvey, Brandon Keith/0000-0002-4036-1383; Bonaventura, Jordi/0000-0002-4745-0151; Gomez, Juan/0000-0003-3170-9904; Dannals, Robert/0000-0002-5483-5914; Michaelides, Michael/0000-0003-0398-4917; Ellis, Randall/0000-0003-3862-0881; Michaelides, Michel/0000-0002-1552-7046; Mathews, William/0000-0001-8001-416X	NIDA [ZIA000069, ZIA000526]; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000526, ZIADA000069] Funding Source: NIH RePORTER	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the NIDA Intramural Research Program (ZIA000069 and ZIA000526). We thank M. Higuchi, B. Ji, and T. Minamimoto for providing access to WT and hM4Di transgenic mouse tissue. We thank M. Sanchez-Soto and D. Howard for assisting with in vitro studies. Last, we thank G. Smith, H. Davis, N. Ator, D. Jacob, J. Engles, B. Liu, and M. Morales for research and administrative support and Y. Shaham, A. Newman, and C. Bradberry for their comments on the manuscript. M.M. is a cofounder and owns stock in Metis Laboratories. All other authors declare no conflicts of interest. All data are stored in our laboratory and freely available upon request. J.L.G., J.B., and M.M. designed experiments, performed experiments, and wrote the manuscript. W.L., P.S.-S., C.T.R., W.B.M., L.A.R., and R.J.E. performed experiments. B.K.H., R.F.D., M.G.P., and A.B. provided access to administrative/research support, reagents, and/or equipment. All coauthors reviewed the manuscript and provided comments.	Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; BENDER D, 1994, NUCL MED BIOL, V21, P921, DOI 10.1016/0969-8051(94)90080-9; Chang WH, 1998, PROG NEURO-PSYCHOPH, V22, P723, DOI 10.1016/S0278-5846(98)00035-9; Eldridge MAG, 2016, NAT NEUROSCI, V19, P37, DOI 10.1038/nn.4192; English JG, 2015, JAMA NEUROL, V72, P1361, DOI 10.1001/jamaneurol.2015.1921; Fang J, 2000, EUR J DRUG METAB PH, V25, P109, DOI 10.1007/BF03190076; Guettier JM, 2009, P NATL ACAD SCI USA, V106, P19197, DOI 10.1073/pnas.0906593106; JANN MW, 1994, ARCH INT PHARMACOD T, V328, P243; Ji B, 2016, J NEUROSCI, V36, P11544, DOI 10.1523/JNEUROSCI.1279-16.2016; Lin G, 1996, J PHARMACEUT BIOMED, V14, P1561, DOI 10.1016/0731-7085(96)01738-4; MacLaren D. A., 2016, ENEURO, DOI [10.1126/science.aan2475, DOI 10.1523/ENEUR0.0219-16.2016]; Mahler SV, 2014, NAT NEUROSCI, V17, P577, DOI 10.1038/nn.3664; Michaelides M, 2013, J CLIN INVEST, V123, P5342, DOI 10.1172/JCI72117; Pardridge WM, 2016, EXPERT OPIN DRUG DEL, V13, P963, DOI 10.1517/17425247.2016.1171315; Raper J, 2017, ACS CHEM NEUROSCI, V8, P1570, DOI 10.1021/acschemneuro.7b00079; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schotte A, 1996, PSYCHOPHARMACOLOGY, V124, P57, DOI 10.1007/BF02245606; Urban DJ, 2015, ANNU REV PHARMACOL, V55, P399, DOI 10.1146/annurev-pharmtox-010814-124803	18	523	526	12	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2017	357	6350					503	+		10.1126/science.aan2475	http://dx.doi.org/10.1126/science.aan2475			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC4VW	28774929	Green Accepted			2023-01-03	WOS:000406840100038
J	Goswami, S; Sharma, P				Goswami, Sangeeta; Sharma, Padmanee			Genetic biomarker for cancer immunotherapy	SCIENCE			English	Editorial Material							CTLA-4 BLOCKADE; COLORECTAL-CANCER; PD-1 BLOCKADE; LANDSCAPE; MELANOMA		[Goswami, Sangeeta; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	padsharma@mdanderson.org		Goswami, Sangeeta/0000-0001-9201-4503				ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X	14	6	8	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	2017	357	6349					358	358		10.1126/science.aao1894	http://dx.doi.org/10.1126/science.aao1894			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB8AX	28751597				2023-01-03	WOS:000406362300026
J	Goodman, JE; Loftus, CT; Liu, XB; Zu, K				Goodman, Julie E.; Loftus, Christine T.; Liu, Xiaobin; Zu, Ke			Impact of respiratory infections, outdoor pollen, and socioeconomic status on associations between air pollutants and pediatric asthma hospital admissions	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT VISITS; CASE-CROSSOVER ANALYSIS; NEW-YORK-CITY; TIME-SERIES; ENVIRONMENTAL EPIDEMIOLOGY; PARTICULATE MATTER; MEASUREMENT ERROR; NEW-JERSEY; CHILDREN; POLLUTION	Background Epidemiology studies have shown that ambient concentrations of ozone and fine particulate matter (PM2.5) are associated with increased emergency department (ED) visits and hospital admissions (HAs) for asthma. Objective Evaluate the impact of outdoor pollen, respiratory infections, and socioeconomic status (SES) on the associations between ambient ozone and PM2.5 and asthma HAs in New York City. Methods Daily ozone, PM2.5, meteorological factors, pollen, and hospitalization records during 1999 to 2009 were obtained for New York City residents. Daily counts of HAs for asthma and respiratory infections were calculated for all-age and specific age groups, and for high-and low-SES communities. Generalized additive models were used to examine ambient concentrations of ozone and PM2.5 and asthma HAs, potential confounding effects of outdoor pollen and HAs for respiratory infections, and potential effect modification by neighborhood SES. Results Both ozone and PM2.5 were statistically significantly associated with increased asthma HAs in children aged 6-18 years (per 10 ppb increase in ozone: RR = 1.0203, 95% CI: 1.0028-1.0382; per 10 mu g/m(3) increase in PM2.5: RR = 1.0218, 95% CI: 1.0007-1.0434), but not with total asthma HAs, or asthma HAs in other age groups. These associations were stronger for children living in the high-SES areas. Adjustment for respiratory infection HAs at various lags did not result in changes greater than 10% in the risk estimates for either ozone or PM2.5. In contrast, adjustment for outdoor pollen generally attenuated the estimated RRs for both ozone and PM2.5. Conclusions Ambient ozone and PM2.5 are associated with asthma HAs in school-age children, and these associations are not modified by SES. HAs for respiratory infections do not appear to be a confounder for observed ozone- and PM2.5-asthma HAs associations, but pollen may be a weak confounder.	[Goodman, Julie E.; Liu, Xiaobin; Zu, Ke] Gradient, Cambridge, MA 02138 USA; [Loftus, Christine T.] Gradient, Seattle, WA USA; [Loftus, Christine T.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Goodman, JE (corresponding author), Gradient, Cambridge, MA 02138 USA.	jgoodman@gradientcorp.com			Exxonmobil Biomedical Sciences, Inc.	Exxonmobil Biomedical Sciences, Inc.	The work reported in this paper was conducted by the authors during the normal course of their employment, with funding provided by the Exxonmobil Biomedical Sciences, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell ML, 2004, ANNU REV PUBL HEALTH, V25, P247, DOI 10.1146/annurev.publhealth.25.102802.124329; Bhaskaran K, 2013, INT J EPIDEMIOL, V42, P1187, DOI 10.1093/ije/dyt092; Canova C, 2013, EUR RESPIR J, V42, P935, DOI 10.1183/09031936.00097412; Dales RE, 2008, INT ARCH ALLERGY IMM, V146, P241, DOI 10.1159/000116360; Darrow LA, 2012, J ALLERGY CLIN IMMUN, V130, P630, DOI 10.1016/j.jaci.2012.06.020; DellaValle CT, 2012, EPIDEMIOLOGY, V23, P55, DOI 10.1097/EDE.0b013e31823b66b8; Dvorin DJ, 2001, ANN ALLERG ASTHMA IM, V87, P394, DOI 10.1016/S1081-1206(10)62921-3; Eggleston PA, 2009, PEDIATRICS, V123, pS160, DOI 10.1542/peds.2008-2233F; Eggo RM, 2016, P NATL ACAD SCI USA, V113, P2194, DOI 10.1073/pnas.1518677113; Evans KA, 2014, ENVIRON RES, V129, P11, DOI 10.1016/j.envres.2013.12.001; Forno E, 2012, AM J RESP CRIT CARE, V185, P1033, DOI 10.1164/rccm.201202-0350ED; Gleason JA, 2014, ENVIRON RES, V132, P421, DOI 10.1016/j.envres.2014.03.035; Goldman GT, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-61; Ito K, 2007, J EXPO SCI ENV EPID, V17, pS45, DOI 10.1038/sj.jes.7500627; Ito K, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0057-0; Jalaludin B, 2008, INT ARCH OCC ENV HEA, V81, P967, DOI 10.1007/s00420-007-0290-0; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Kloepfer KM, 2010, IMMUNOL ALLERGY CLIN, V30, P553, DOI 10.1016/j.iac.2010.08.002; Lim Hyungryul, 2016, J Prev Med Public Health, V49, P205, DOI 10.3961/jpmph.16.037; Lumley T, 2000, ENVIRONMETRICS, V11, P705, DOI 10.1002/1099-095X(200011/12)11:6<705::AID-ENV444>3.0.CO;2-H; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; O'Lenick CR, 2016, J EPIDEMIOL COMMUNIT; Rabinovitch N, 2004, J ALLERGY CLIN IMMUN, V114, P1131, DOI 10.1016/j.jaci.2004.08.026; Rhomberg LR, 2011, CRIT REV TOXICOL, V41, P651, DOI 10.3109/10408444.2011.563420; Sheffield PE, 2011, ISRN ALLERGY, V2011; Sheffield PE, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0010-2; Strickland MJ, 2014, EPIDEMIOLOGY, V25, P843, DOI 10.1097/EDE.0000000000000170; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; U.S. Environmental Protection Agency (U.S. EPA), 2013, EPA600R10076F US EPA; US EPA, 2009, EPA600R08139F2 US EP; van der Zee SC, 2000, EUR RESPIR J, V15, P700, DOI 10.1034/j.1399-3003.2000.15d13.x; Villeneuve PJ, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-40; Wilhelm M, 2009, HEALTH PLACE, V15, P25, DOI 10.1016/j.healthplace.2008.02.002; Yap PS, 2013, AM J PUBLIC HEALTH, V103, P695, DOI 10.2105/AJPH.2012.300945; Zheng XQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117773	37	16	18	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2017	12	7							e0180522	10.1371/journal.pone.0180522	http://dx.doi.org/10.1371/journal.pone.0180522			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB3RW	28719626	Green Published, Green Submitted, gold			2023-01-03	WOS:000406061400014
J	Sahin, U; Derhovanessian, E; Miller, M; Kloke, BP; Simon, P; Lower, M; Bukur, V; Tadmor, AD; Luxemburger, U; Schrors, B; Omokoko, T; Vormehr, M; Albrecht, C; Paruzynski, A; Kuhn, AN; Buck, J; Heesch, S; Katharina, H; Muller, F; Ortseifer, I; Vogler, I; Godehardt, E; Attig, S; Rae, R; Breitkreuz, A; Tolliver, C; Suchan, M; Martic, G; Hohberger, A; Sorn, P; Diekmann, J; Ciesla, J; Waksmann, O; Burck, AK; Witt, M; Zillgen, M; Rothermel, A; Kasemann, B; Langer, D; Bolte, S; Diken, M; Kreiter, S; Nemecek, R; Gebhardt, C; Grabbe, S; Holler, C; Utikal, J; Huber, C; Loquai, C; Tureci, O				Sahin, Ugur; Derhovanessian, Evelyna; Miller, Matthias; Kloke, Bjoern-Philipp; Simon, Petra; Loewer, Martin; Bukur, Valesca; Tadmor, Arbel D.; Luxemburger, Ulrich; Schroers, Barbara; Omokoko, Tana; Vormehr, Mathias; Albrecht, Christian; Paruzynski, Anna; Kuhn, Andreas N.; Buck, Janina; Heesch, Sandra; Katharina, H.; Mueller, Felicitas; Ortseifer, Inga; Vogler, Isabel; Godehardt, Eva; Attig, Sebastian; Rae, Richard; Breitkreuz, Andrea; Tolliver, Claudia; Suchan, Martin; Martic, Goran; Hohberger, Alexander; Sorn, Patrick; Diekmann, Jan; Ciesla, Janko; Waksmann, Olga; Burck, Alexandra-Kemmer; Witt, Meike; Zillgen, Martina; Rothermel, Andree; Kasemann, Barbara; Langer, David; Bolte, Stefanie; Diken, Mustafa; Kreiter, Sebastian; Nemecek, Romina; Gebhardt, Christoffer; Grabbe, Stephan; Holler, Christoph; Utikal, Jochen; Huber, Christoph; Loquai, Carmen; Tuereci, Oezlem			Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer	NATURE			English	Article							PD-1 BLOCKADE; MASS-SPECTROMETRY; CTLA-4 BLOCKADE; T-CELLS; MUTATIONS; ALIGNMENT; REVEALS; SENSITIVITY; EFFICIENCY; STABILITY	T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous immune recognition of mutations is inefficient. We recently introduced the concept of individualized mutanome vaccines and implemented an RNA-based poly-neoepitope approach to mobilize immunity against a spectrum of cancer mutations(1,2). Here we report the first-in-human application of this concept in melanoma. We set up a process comprising comprehensive identification of individual mutations, computational prediction of neo-epitopes, and design and manufacturing of a vaccine unique for each patient. All patients developed T cell responses against multiple vaccine neo-epitopes at up to high single-digit percentages. Vaccine-induced T cell infiltration and neo-epitope-specific killing of autologous tumour cells were shown in post-vaccination resected metastases from two patients. The cumulative rate of metastatic events was highly significantly reduced after the start of vaccination, resulting in a sustained progression-free survival. Two of the five patients with metastatic disease experienced vaccine-related objective responses. One of these patients had a late relapse owing to outgrowth of beta 2-microglobulin-deficient melanoma cells as an acquired resistance mechanism. A third patient developed a complete response to vaccination in combination with PD-1 blockade therapy. Our study demonstrates that individual mutations can be exploited, thereby opening a path to personalized immunotherapy for patients with cancer.	[Sahin, Ugur; Derhovanessian, Evelyna; Miller, Matthias; Kloke, Bjoern-Philipp; Simon, Petra; Bukur, Valesca; Luxemburger, Ulrich; Omokoko, Tana; Vormehr, Mathias; Paruzynski, Anna; Kuhn, Andreas N.; Buck, Janina; Heesch, Sandra; Katharina, H.; Mueller, Felicitas; Ortseifer, Inga; Vogler, Isabel; Godehardt, Eva; Breitkreuz, Andrea; Tolliver, Claudia; Diekmann, Jan; Burck, Alexandra-Kemmer; Witt, Meike; Zillgen, Martina; Langer, David; Bolte, Stefanie; Diken, Mustafa; Kreiter, Sebastian; Huber, Christoph] Biopharmaceut New Technol BioNTech Corp, Goldgrube 12, D-55131 Mainz, Germany; [Sahin, Ugur; Loewer, Martin; Bukur, Valesca; Tadmor, Arbel D.; Schroers, Barbara; Albrecht, Christian; Attig, Sebastian; Rae, Richard; Suchan, Martin; Martic, Goran; Sorn, Patrick; Rothermel, Andree; Kasemann, Barbara; Diken, Mustafa; Kreiter, Sebastian; Huber, Christoph] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Freiligrathstr 12, D-55131 Mainz, Germany; [Sahin, Ugur; Vormehr, Mathias; Attig, Sebastian; Hohberger, Alexander; Grabbe, Stephan; Huber, Christoph; Loquai, Carmen] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany; [Ciesla, Janko; Waksmann, Olga] EUFETS GmbH, Vollmersbachstr 66, D-55743 Idar Oberstein, Germany; [Nemecek, Romina; Holler, Christoph] Med Univ Vienna, Spitalgasse 23, A-1090 Vienna, Austria; [Gebhardt, Christoffer; Utikal, Jochen] German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [Gebhardt, Christoffer; Utikal, Jochen] Heidelberg Univ, Univ Med Ctr Mannheim, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany; [Tuereci, Oezlem] CI3 Cluster Individualized Immunointervent eV, Holderlinstr 8, D-55131 Mainz, Germany	BioNTech SE; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Medical University of Vienna; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Sahin, U (corresponding author), Biopharmaceut New Technol BioNTech Corp, Goldgrube 12, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Freiligrathstr 12, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	sahin@uni-mainz.de	Vormehr, Mathias/AAJ-7808-2021; Loquai, Carmen/AAW-9241-2020; Sahin, Ugur/L-4818-2017; Grabe, Stephan/AAJ-4578-2021	Vormehr, Mathias/0000-0001-7788-3380; Sahin, Ugur/0000-0003-0363-1564; Grabe, Stephan/0000-0002-6863-8719; Schrors, Barbara/0000-0001-9758-250X; Gebhardt, Christoffer/0000-0001-7090-9584; Utikal, Jochen/0000-0001-5316-0241; Suchan, Martin/0000-0001-6625-6162; Oehm, Petra/0000-0002-1086-2726	CI3 cluster program of the Federal Ministry of Education and Research (BMBF)	CI3 cluster program of the Federal Ministry of Education and Research (BMBF)	We thank J. de Graaf, I. Eichelbronner, L. Leppin, L. Giese and S. Vogler, D. Becker, M. Dorner, J. Grutzner, M. Hossainzadeh, A. Selmi, S. Wessel, C. Ecker, M. Lochschmitt, B. Schmitz, C. Anft, N. Bidmon, H. Schroder, D. Barea Roldan, C. Walter, S. Woll, C. Rohde, O. Renz, F. Bayer, C. Kroner, B. Otte, T. Stricker, M. Drude S. Petri, M. Mechler, L. Hebich, B. Steege, A. Oelbermann, J. Schwarz, C. Britten, J. C. Castle and B. Pless for technical support, project management and advice. We thank A. Tuttenberg for support with a figure. We thank I. Mellman, L. Delamarre and G. Fine for critical reading of the manuscript. We thank K. Sahin for her advice. The study was supported by the CI3 cluster program of the Federal Ministry of Education and Research (BMBF).	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Berensmeier S, 2006, APPL MICROBIOL BIOT, V73, P495, DOI 10.1007/s00253-006-0675-0; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Delamarre L, 2015, SCIENCE, V348, P760, DOI 10.1126/science.aab3465; Dudley ME, 2003, J IMMUNOTHER, V26, P332, DOI 10.1097/00002371-200307000-00005; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Grudzien-Nogalska Ewa, 2013, Methods Mol Biol, V969, P55, DOI 10.1007/978-1-62703-260-5_4; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202. Article published online before March 2002, 10.1101/gr.229202]; Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438; Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091; Kreiter S, 2008, J IMMUNOL, V180, P309, DOI 10.4049/jimmunol.180.1.309; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699; Kuhn AN, 2010, GENE THER, V17, P961, DOI 10.1038/gt.2010.52; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Omokoko TA, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9540975; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Simon P, 2014, CANCER IMMUNOL RES, V2, P1230, DOI 10.1158/2326-6066.CIR-14-0108; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhao Q.-Y., BMC BIOINFORMATI S14, V12, pS2	42	1208	1301	21	422	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 13	2017	547	7662					222	+		10.1038/nature23003	http://dx.doi.org/10.1038/nature23003			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA3AX	28678784				2023-01-03	WOS:000405314500040
J	Dyer, C				Dyer, Clare			Law, ethics, and emotion: the Charlie Gard case	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								The fight over the treatment of terminally ill baby Charlie Gard has been unprecedented, both legally and in its coverage on social media. His parents' last hope, the European Court of Human Rights, turned them down last week, ruling that the baby should be allowed to die. Clare Dyer looks back at this case and considers where it leaves doctors				claredyer4@gmail.com							0	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	2017	358								j3152	10.1136/bmj.j3152	http://dx.doi.org/10.1136/bmj.j3152			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA3DM	28676496				2023-01-03	WOS:000405322100002
J	Shankaran, S; Laptook, AR; Pappas, A; McDonald, SA; Das, A; Tyson, JE; Poindexter, BB; Schibler, K; Bell, EF; Heyne, RJ; Pedroza, C; Bara, R; Van Meurs, KP; Huitema, CMP; Grisby, C; Devaskar, U; Ehrenkranz, RA; Harmon, HM; Chalak, LF; DeMauro, SB; Garg, M; Hartley-McAndrew, ME; Khan, AM; Walsh, MC; Ambalavanan, N; Brumbaugh, JE; Watterberg, KL; Shepherd, EG; Hamrick, SEG; Barks, J; Cotten, CM; Kilbride, HW; Higgins, RD				Shankaran, Seetha; Laptook, Abbot R.; Pappas, Athina; McDonald, Scott. A.; Das, Abhik; Tyson, Jon E.; Poindexter, Brenda B.; Schibler, Kurt; Bell, Edward F.; Heyne, Roy J.; Pedroza, Claudia; Bara, Rebecca; Van Meurs, Krisa P.; Huitema, Carolyn M. Petrie; Grisby, Cathy; Devaskar, Uday; Ehrenkranz, Richard A.; Harmon, Heidi M.; Chalak, Lina F.; DeMauro, Sara B.; Garg, Meena; Hartley-McAndrew, Michelle E.; Khan, Amir M.; Walsh, Michele C.; Ambalavanan, Namasivayam; Brumbaugh, Jane E.; Watterberg, Kristi L.; Shepherd, Edward G.; Hamrick, Shannon E. G.; Barks, John; Cotten, C. Michael; Kilbride, Howard W.; Higgins, Rosemary D.		Eunice Kennedy Shriver Natl Inst	Effect of Depth and Duration of Cooling on Death or Disability at Age 18 Months Among Neonates With Hypoxic-Ischemic Encephalopathy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD OUTCOMES; FETAL SHEEP; HYPOTHERMIA; PROTECTION; ASPHYXIA; INJURY; WHITE	IMPORTANCE Hypothermia for 72 hours at 33.5C for neonatal hypoxic-ischemic encephalopathy reduces death or disability, but rates continue to be high. OBJECTIVE To determine if cooling for 120 hours or to a temperature of 32.0C reduces death or disability at age 18 months in infants with hypoxic-ischemic encephalopathy. DESIGN, SETTING, AND PARTICIPANTS Randomized 2 x 2 factorial clinical trial in neonates (36 weeks' gestation) with hypoxic-ischemic encephalopathy at 18 US centers in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network between October 2010 and January 2016. INTERVENTIONS A total of 364 neonates were randomly assigned to 4 hypothermia groups: 33.5C for 72 hours (n = 95), 32.0C for 72 hours (n = 90), 33.5C for 120 hours (n = 96), or 32.0C for 120 hours (n = 83). MAIN OUTCOMES AND MEASURES The primary outcomewas death or moderate or severe disability at 18 to 22 months of age adjusted for center and level of encephalopathy. Severe disability included any of Bayley Scales of Infant Development III cognitive score less than 70, Gross Motor Function Classification System (GMFCS) level of 3 to 5, or blindness or hearing loss despite amplification. Moderate disability was defined as a cognitive score of 70 to 84 and either GMFCS level 2, active seizures, or hearing with amplification. RESULTS The trial was stopped for safety and futility in November 2013 after 364 of the planned 726 infants were enrolled. Among 347 infants (95%) with primary outcome data (mean age at follow-up, 20.7 [SD, 3.5] months; 42% female), death or disability occurred in 56 of 176 (31.8%) cooled for 72 hours and 54 of 171 (31.6%) cooled for 120 hours (adjusted risk ratio, 0.92 [95% CI, 0.68-1.25]; adjusted absolute risk difference, -1.0% [95% CI, -10.2% to 8.1%]) and in 59 of 185 (31.9%) cooled to 33.5C and 51 of 162 (31.5%) cooled to 32.0C (adjusted risk ratio, 0.92 [95% CI, 0.68-1.26]; adjusted absolute risk difference, -3.1% [95% CI, -12.3% to 6.1%]). A significant interaction between longer and deeper cooling was observed (P =.048), with primary outcome rates of 29.3% at 33.5C for 72 hours, 34.5% at 32.0C for 72 hours, 34.4% at 33.5C for 120 hours, and 28.2% at 32.0C for 120 hours. CONCLUSIONS AND RELEVANCE Among term neonates with moderate or severe hypoxic-ischemic encephalopathy, cooling for longer than 72 hours, cooling to lower than 33.5C, or both did not reduce death or moderate or severe disability at 18 months of age. However, the trial may be underpowered, and an interaction was found between longer and deeper cooling. These results support the current regimen of cooling for 72 hours at 33.5C.	[Shankaran, Seetha; Pappas, Athina; Bara, Rebecca] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [McDonald, Scott. A.] RTI Int, Social Stat & Environm Sci Unit, Res Triangle Pk, NC USA; [Das, Abhik; Huitema, Carolyn M. Petrie] RTI Int, Social Stat & Environm Sci Unit, Rockville, MD USA; [Tyson, Jon E.; Pedroza, Claudia; Khan, Amir M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat, Houston, TX 77030 USA; [Poindexter, Brenda B.; Harmon, Heidi M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Poindexter, Brenda B.; Schibler, Kurt; Grisby, Cathy] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Cincinnati, OH 45229 USA; [Bell, Edward F.; Brumbaugh, Jane E.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Heyne, Roy J.; Chalak, Lina F.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Van Meurs, Krisa P.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA; [Van Meurs, Krisa P.] Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA; [Devaskar, Uday; Garg, Meena] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [DeMauro, Sara B.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Hartley-McAndrew, Michelle E.] SUNY Buffalo, Dept Pediat, Buffalo, NY USA; [Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Ambalavanan, Namasivayam] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA; [Watterberg, Kristi L.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Shepherd, Edward G.] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Hamrick, Shannon E. G.] Emory Univ, Sch Med, Dept Pediat, Childrens Hlthcare Atlanta, Atlanta, GA USA; [Barks, John] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Cotten, C. Michael] Duke Univ, Dept Pediat, Durham, NC 27706 USA; [Kilbride, Howard W.] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA; [Kilbride, Howard W.] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA	Wayne State University; Brown University; Women & Infants Hospital Rhode Island; Research Triangle Institute; Research Triangle Institute; University of Texas System; University of Texas Health Science Center Houston; Indiana University System; Indiana University Bloomington; Cincinnati Children's Hospital Medical Center; University of Iowa; University of Texas System; University of Texas Southwestern Medical Center Dallas; Stanford University; Lucile Packard Children's Hospital (LPCH); University of California System; University of California Los Angeles; Yale University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University of Alabama System; University of Alabama Birmingham; University of New Mexico; University of New Mexico's Health Sciences Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Children's Healthcare of Atlanta (CHOA); Emory University; University of Michigan System; University of Michigan; Duke University; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Shankaran, S (corresponding author), Childrens Hosp Michigan, 3901 Beaubien Blvd, Detroit, MI 48201 USA.	sshankar@med.wayne.edu	Ambalavanan, Namasivayam/AAI-4088-2020; Das, Abhik/AAF-1883-2020; Shah, Birju A./C-4811-2014; Kilbride, Howard/I-2342-2019; Ambalavanan, Namasivayam/AAL-3832-2020; DeMauro, Sara/ABD-6568-2021	Ambalavanan, Namasivayam/0000-0003-0731-9092; Das, Abhik/0000-0003-2722-0479; Shah, Birju A./0000-0002-9051-1183; DeMauro, Sara/0000-0003-1647-4000; Pedroza, Claudia/0000-0003-4235-1282; Shankaran, Seetha/0000-0001-5512-9571; Bell, Edward/0000-0002-5568-0889; Harmon, Heidi/0000-0003-2413-1278; McDonald, Scott/0000-0002-0054-1099; Huitema, Carolyn/0000-0001-8569-2795; Barks, John/0000-0003-1320-905X	National Institutes of Health; NICHD; National Center for Advancing Translational Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [UG1HD027880, U10HD021385, UG1HD027904, UG1HD040689, U10HD021373, UG1HD053109, UG1HD053089, UG1HD087229, U10HD068244] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371, UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS102617] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The National Institutes of Health, the NICHD, and the National Center for Advancing Translational Sciences provided grant support for the Neonatal Research Network through cooperative agreements.	Alonso-Alconada D, 2015, STROKE, V46, P275, DOI 10.1161/STROKEAHA.114.007330; Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Bayley N, 2006, MANUAL BAYLEY SCALES; Bennet L, 2007, J PHYSIOL-LONDON, V578, P491, DOI 10.1113/jphysiol.2006.119602; Davidson JO, 2016, SCI REP-UK, V6, DOI 10.1038/srep25178; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Pedroza C, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1480-4; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Thoresen M, 1996, ARCH DIS CHILD-FETAL, V74, pF3, DOI 10.1136/fn.74.1.F3; Wood T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23430	13	131	136	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2017	318	1					57	67		10.1001/jama.2017.7218	http://dx.doi.org/10.1001/jama.2017.7218			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ4YF	28672318	Green Published, Green Accepted			2023-01-03	WOS:000404717700015
J	Ross-Degnan, D; Chalker, J; Liana, J; Kajoka, MD; Valimba, R; Kimatta, S; Dillip, A; Vialle-Valentin, C; Embrey, M; Lieber, R; Johnson, K				Ross-Degnan, Dennis; Chalker, John; Liana, Jafary; Kajoka, Mwikemo Deborah; Valimba, Richard; Kimatta, Suleiman; Dillip, Angel; Vialle-Valentin, Catherine; Embrey, Martha; Lieber, Rachel; Johnson, Keith			A group randomized trial using an appointment system to improve adherence to ART at reproductive and child health clinics implementing Option B plus in Tanzania	PLOS ONE			English	Article							TIME-SERIES ANALYSES; ANTIRETROVIRAL THERAPY; RETENTION; WOMEN; PROGRAM; CARE; CHALLENGES; DESIGN; COHORT	Introduction In October 2013, Tanzania adopted Option B+ under which HIV-positive pregnant women are initiated on antiretroviral therapy in reproductive and child health clinics at diagnosis. Studies have shown that adherence and retention to antiretroviral treatment can be problematic. Methods We implemented a group randomized controlled trial in 24 reproductive and child health clinics in eight districts in Mbeya region. The trial tested the impact of implementing paper-based appointment tracking and community outreach systems on the rate of missed appointments and number of days covered by dispensed antiretroviral medications among women previously established on antiretroviral therapy. We used interrupted time series analysis to assess study outcomes. Clinic staff and patients in intervention clinics were aware of the intervention because of change in clinic procedures; data collectors knew the study group assignment. Results Three months pre-intervention, we identified 1924 and 1226 patients established on antiretroviral therapy for six months or more in intervention and control clinics, respectively, of whom 83.4% and 86.9% had one or more post-intervention visits. The unadjusted rate of missed visits declined from 36.5% to 34.4% in intervention clinics and increased from 38.9% to 45.5% in control clinics following the intervention. Interrupted time series analyses demonstrated a net decrease of 13.7% (95% CI [-15.4,-12.1]) for missed visits at six months post-intervention. Similar differential changes were observed for visits missed by 3, 7, 15, or 60 days. Conclusion Appointment-tracking and community outreach significantly improved appointment-keeping for women on antiretroviral therapy. The facility staff controlled their workload better, identified missing patients rapidly, and worked with existing community organizations. There is now enough evidence to scale up this approach to all antiretroviral therapy and Option B+ reproductive and child health clinics in Tanzania as well as to evaluate the intervention in medical clinics that treat other chronic health conditions.	[Ross-Degnan, Dennis; Vialle-Valentin, Catherine] Harvard Med Sch, Boston, MA USA; [Ross-Degnan, Dennis; Vialle-Valentin, Catherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Chalker, John; Embrey, Martha; Lieber, Rachel; Johnson, Keith] Management Sci Hlth, Pharmaceut & Hlth Technol Grp, Arlington, VA 22203 USA; [Liana, Jafary] Apotheker Consultancy Ltd, Dar Es Salaam, Tanzania; [Kajoka, Mwikemo Deborah] Minist Hlth Community Dev Gender Elderly & Childr, Dar Es Salaam, Tanzania; [Valimba, Richard; Kimatta, Suleiman] Management Sci Hlth, Dar Es Salaam, Tanzania; [Dillip, Angel] Ifakara Hlth Inst, Dar Es Salaam, Tanzania	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Ifakara Health Institute	Chalker, J (corresponding author), Management Sci Hlth, Pharmaceut & Hlth Technol Grp, Arlington, VA 22203 USA.	John.chalker@ymail.com			International Initiative for Impact Evaluation (3ie); Apotheker Consultancy (T) Limited	International Initiative for Impact Evaluation (3ie); Apotheker Consultancy (T) Limited	The study was funded by the International Initiative for Impact Evaluation (3ie). The funder provided support in the form of salaries for authors [DRD, JC, JL, RV, SK, AD, CW, ME, RL and KJ]. The funders commented on the study design but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. Author JL is employed by Apotheker Consultancy (T) Limited. Apotheker Consultancy (T) Limited provided support in the form of salary for author JL, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the Author Contributions section.	Atanga PN, 2017, TROP MED INT HEALTH, V22, P161, DOI 10.1111/tmi.12816; Boruett P, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-242; Chalker JC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-43; Elwell K, 2016, AIDS CARE, V28, P971, DOI 10.1080/09540121.2016.1153586; Fayorsey RN, 2016, JAIDS-J ACQ IMM DEF, V72, pS137, DOI 10.1097/QAI.0000000000001060; Geldsetzer P, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20679; Haas AD, 2016, CLIN INFECT DIS, V63, P1227, DOI 10.1093/cid/ciw500; Haas AD, 2016, LANCET HIV, V3, pE175, DOI 10.1016/S2352-3018(16)00008-4; Helova A, 2017, HEALTH POLICY PLANN, V32, P283, DOI 10.1093/heapol/czw122; Kim MH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149527; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kruk ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160764; Linden A, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-119; Llenas-Garcia J, 2016, TROP MED INT HEALTH, V21, P1003, DOI 10.1111/tmi.12728; Mitiku I, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20662; Mwatawala S, 2012, INT J PERS CTR MED, V2, P825; Napua M, 2016, JAIDS-J ACQ IMM DEF, V72, pS181, DOI 10.1097/QAI.0000000000001061; Ross-Degnan D, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-42; StataCorp, 2015, STAT STAT SOFTW REL; Woelk GB, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20837; World Health Organization, 2010, NEW GUID PREV MOTH T; Zhang F, 2011, J CLIN EPIDEMIOL, V64, P1252, DOI 10.1016/j.jclinepi.2011.02.007; Zhang F, 2009, J CLIN EPIDEMIOL, V62, P143, DOI 10.1016/j.jclinepi.2008.08.007	23	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0184591	10.1371/journal.pone.0184591	http://dx.doi.org/10.1371/journal.pone.0184591			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957381	Green Published, gold, Green Submitted			2023-01-03	WOS:000411985200015
J	Ayyagari, VN; Diaz-Sylvester, PL; Hsieh, THJ; Brard, L				Ayyagari, Vijayalakshmi N.; Diaz-Sylvester, Paula L.; Hsieh, Tsung-han Jeff; Brard, Laurent			Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines	PLOS ONE			English	Article							IN-VITRO; APOPTOSIS; CISPLATIN; EXPRESSION; AUTOTAXIN; P53; DOXORUBICIN; SENSITIVITY; GENERATION; RESISTANCE	Previously, Bithionol (BT) was shown to enhance the chemosensitivity of ovarian cancer cell lines to cisplatin treatment. In the present study, we focused on the anti-tumor potential of the BT-paclitaxel combination when added to a panel of ovarian cancer cell lines. This in vitro study aimed to 1) determine the optimum schedule for combination of BT and paclitaxel and 2) assess the nature and mechanism(s) underlying BT-paclitaxel interactions. The cytotoxic effects of both drugs either alone or in combination were assessed by presto-blue cell viability assay using six human ovarian cancer cell lines. Inhibitory concentrations to achieve 50% cell death (IC50) were determined for BT and paclitaxel in each cell line. Changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27 were determined via immunoblot. Luminescent and colorimetric assays were used to determine caspases 3/7 and autotaxin (ATX) activity. Cellular reactive oxygen species (ROS) were measured by flow cytometry. Our results show that the efficacy of the BT-paclitaxel combination depends upon the concentrations and sequence of addition of paclitaxel and BT. Pretreatment with BT followed by paclitaxel resulted in antagonistic interactions whereas synergistic interactions were observed when both drugs were added simultaneously or when cells were pretreated with paclitaxel followed by BT. Synergistic interactions between BT and paclitaxel were attributed to increased ROS generation and enhanced apoptosis. Decreased expression of pro-survival factors (XIAP, bcl-2, bcl-xL) and increased expression of pro-apoptotic factors (caspases 3/7, PARP cleavage) was observed. Additionally, increased expression of key cell cycle regulators p21 and p27 was observed. These results show that BT and paclitaxel interacted synergistically at most drug ratios which, however, was highly dependent on the sequence of the addition of drugs. Our results suggest that BT-paclitaxel combination therapy may be effective in sensitizing ovarian cancer cells to paclitaxel treatment, thus mitigating some of the toxic effects associated with high doses of paclitaxel.	[Ayyagari, Vijayalakshmi N.; Diaz-Sylvester, Paula L.; Hsieh, Tsung-han Jeff; Brard, Laurent] Southern Illinois Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Springfield, IL 62794 USA; [Diaz-Sylvester, Paula L.] Southern Illinois Univ, Sch Med, Ctr Clin Res, Springfield, IL USA; [Brard, Laurent] Southern Illinois Univ, Sch Med, Simmons Canc Inst SIU, Springfield, IL 62702 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University	Brard, L (corresponding author), Southern Illinois Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Springfield, IL 62794 USA.; Brard, L (corresponding author), Southern Illinois Univ, Sch Med, Simmons Canc Inst SIU, Springfield, IL 62702 USA.	lbrard@siumed.edu		Ayyagari, Vijayalakshmi/0000-0003-1001-7044; Diaz-Sylvester, Paula/0000-0002-1531-1958	National Cancer Institute (NCI) of the National Institutes of Health (NIH) [P20CA192987]	National Cancer Institute (NCI) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this manuscript was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number P20CA192987 (LB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Alexandre J, 2007, CANCER RES, V67, P3512, DOI 10.1158/0008-5472.CAN-06-3914; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Ayyagari VN, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3034-2; Ayyagari VN, 2016, ANTI-CANCER DRUG, V27, P547, DOI 10.1097/CAD.0000000000000364; Ayyagari VN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-61; BACQ Y, 1991, HEPATOLOGY, V14, P1066, DOI 10.1002/hep.1840140620; Band Horwitz S., TRENDS PHARM SCI, V13, P134; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; Braddock D, 2009, Application, Patent No. [WO2009151644 A2, 2009151644]; CHEN HW, 1995, CARCINOGENESIS, V16, P1963, DOI 10.1093/carcin/16.8.1963; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cristea Mihaela, 2010, Ther Adv Med Oncol, V2, P175, DOI 10.1177/1758834010361333; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Hadzic T, 2010, FREE RADICAL BIO MED, V48, P1024, DOI 10.1016/j.freeradbiomed.2010.01.018; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Herod JJO, 1996, CANCER RES, V56, P2178; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Kampan NC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/413076; Kasibhatla S., 2006, CSH PROTOC, V2006; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4; Kikuchi Y, 2001, Hum Cell, V14, P115; Kim JS, 2008, INT J CANCER, V122, P672, DOI 10.1002/ijc.23158; Kim KK, 2011, GYNECOL ONCOL, V122, P183, DOI 10.1016/j.ygyno.2011.03.035; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; Lambert HE, 2004, INT J GYNECOL CANCER, V14, P772, DOI 10.1111/j.1048-891X.2004.014507.x; Leitao MM, 2003, GYNECOL ONCOL, V91, P123, DOI 10.1016/S0090-8258(03)00464-5; LIPTON RB, 1989, NEUROLOGY, V39, P368, DOI 10.1212/WNL.39.3.368; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Marx D, 2000, METH MOLEC MED, V39, P687; Meshkini A, 2012, EXP TOXICOL PATHOL, V64, P357, DOI 10.1016/j.etp.2010.09.010; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Naumann RW, 2011, DRUGS, V71, P1397, DOI 10.2165/11591720-000000000-00000; Ott I, 2007, ARCH PHARM, V340, P117, DOI 10.1002/ardp.200600151; Pace A, 1997, ITAL J NEUROL SCI, V18, P73, DOI 10.1007/BF01999566; Park YD, 2016, MBIO, V7, DOI 10.1128/mBio.01073-16; Piccart MJ, 2000, J CLIN ONCOL, V18, P1193, DOI 10.1200/JCO.2000.18.6.1193; Pinato DJ, 2013, CANCER TREAT REV, V39, P153, DOI 10.1016/j.ctrv.2012.04.004; Rakovitch E, 1999, INT J RADIAT ONCOL, V44, P1119, DOI 10.1016/S0360-3016(99)00109-1; Rosenberg P, 2002, ACTA ONCOL, V41, P418, DOI 10.1080/028418602320404998; Rowinsky E K, 1993, J Natl Cancer Inst Monogr, P107; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Saunders LP, 2008, MOL CANCER THER, V7, P3352, DOI 10.1158/1535-7163.MCT-08-0463; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Sevko A, 2012, J IMMUNOTOXICOL, V9, P275, DOI 10.3109/1547691X.2012.655343; Sherman-Baust CA, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-21; Sui MH, 2006, CANCER BIOL THER, V5, P1015, DOI 10.4161/cbt.5.8.2909; Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tsai-Turton M, 2007, TOXICOL SCI, V98, P216, DOI 10.1093/toxsci/kfm087; Witham J, 2007, CLIN CANCER RES, V13, P7191, DOI 10.1158/1078-0432.CCR-07-0362; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zeng S, 2000, CLIN CANCER RES, V6, P3766; Zhang DS, 2014, DRUG DES DEV THER, V8, P279, DOI 10.2147/DDDT.S56801	60	6	6	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0185111	10.1371/journal.pone.0185111	http://dx.doi.org/10.1371/journal.pone.0185111			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931042	Green Submitted, Green Published, gold			2023-01-03	WOS:000411314700071
J	Duggan, CP; Jaksic, T				Duggan, Christopher P.; Jaksic, Tom			Pediatric Intestinal Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHORT-BOWEL SYNDROME; SERIAL TRANSVERSE ENTEROPLASTY; PARENTERAL-NUTRITION; IMPROVED SURVIVAL; LIVER-DISEASE; CHILDREN; OUTCOMES; INFANTS; RISK; ADAPTATION		[Duggan, Christopher P.; Jaksic, Tom] Boston Childrens Hosp, Ctr Adv Intestinal Rehabil, Boston, MA USA; [Duggan, Christopher P.] Boston Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Boston, MA USA; [Jaksic, Tom] Boston Childrens Hosp, Dept Surg, Boston, MA USA; Harvard Med Sch, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Duggan, CP (corresponding author), Boston Childrens Hosp, Ctr Nutr, Div Gastroenterol Hepatol & Nutr, 333 Longwood Ave, Boston, MA 02115 USA.	duggan@childrens.harvard.edu			Shire Pharmaceuticals; MedShape	Shire Pharmaceuticals; MedShape	Dr. Duggan reports receiving grant support from Shire Pharmaceuticals; and Dr. Jaksic, receiving grant support from MedShape and holding a pending patent for "Extraluminal enterogenesis device" (no. 14/881,150). No other potential conflict of interest relevant to this article was reported.	Andorsky DJ, 2001, J PEDIATR-US, V139, P27, DOI 10.1067/mpd.2001.114481; Ardura MI, 2015, JAMA PEDIATR, V169, P324, DOI 10.1001/jamapediatrics.2014.3291; AYNSLEYGREEN A, 1982, ACTA PAEDIATR SCAND, V71, P379, DOI 10.1111/j.1651-2227.1982.tb09438.x; BIANCHI A, 1980, J PEDIATR SURG, V15, P145, DOI 10.1016/S0022-3468(80)80005-4; Bines J, 1998, J PEDIATR GASTR NUTR, V26, P123, DOI 10.1097/00005176-199802000-00001; Canani RB, 2006, PEDIATRICS, V117, pE817, DOI 10.1542/peds.2005-1655; Carter BA, 2017, J PEDIATR-US, V181, P102, DOI 10.1016/j.jpeds.2016.10.027; Chang RW, 2006, ANN SURG, V243, P223, DOI 10.1097/01.sla.0000197704.76166.07; Chen GQ, 2013, DIGEST DIS SCI, V58, P2478, DOI 10.1007/s10620-013-2680-3; Cober MP, 2012, J PEDIATR-US, V160, P421, DOI 10.1016/j.jpeds.2011.08.047; Cole CR, 2008, PEDIATRICS, V122, pE573, DOI 10.1542/peds.2007-3449; Collier S, 2012, CLINICAL MANAGEMENT OF INTESTINAL FAILURE, P117; CORTOT A, 1979, NEW ENGL J MED, V300, P79, DOI 10.1056/NEJM197901113000207; D'Antiga L, 1999, J PEDIATR GASTR NUTR, V29, P588, DOI 10.1097/00005176-199911000-00021; De Groote MA, 2005, PEDIATR INFECT DIS J, V24, P278, DOI 10.1097/01.inf.0000154588.79356.e6; DeLegge M, 2010, NUTR CLIN PRACT, V25, P76, DOI 10.1177/0884533609354901; Diamond IR, 2016, JPEN J PARENTER ENTE; Duro D, 2008, J PEDIATR GASTR NUTR, V46, P461, DOI 10.1097/MPG.0b013e3181373b91; El Kasmi KC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006898; Fisher JG, 2015, J PEDIATR SURG, V50, P938, DOI 10.1016/j.jpedsurg.2015.03.013; Fitzgibbons SC, 2009, J PEDIATR SURG, V44, P1072, DOI 10.1016/j.jpedsurg.2009.02.013; Frongia G, 2013, J PEDIATR SURG, V48, P1794, DOI 10.1016/j.jpedsurg.2013.05.018; Gosselin KB, 2014, J PEDIATR-US, V165, P1085, DOI 10.1016/j.jpeds.2014.08.012; Goulet O, 2004, J PEDIATR GASTR NUTR, V38, P250, DOI 10.1097/00005176-200403000-00006; Grant CN, 2015, AM J PHYSIOL-GASTR L, V308, pG664, DOI 10.1152/ajpgi.00111.2014; Groen H, 2017, AM J CLIN NUTR, V105, P417, DOI 10.3945/ajcn.116.135160; Gutierrez IM, 2012, J PEDIATR SURG, V47, P1150, DOI 10.1016/j.jpedsurg.2012.03.019; Hess RA, 2011, J SURG RES, V170, P27, DOI 10.1016/j.jss.2011.03.037; Hong SN, 2016, STEM CELL TRANSL MED; Jeppesen PB, 2011, GUT, V60, P902, DOI 10.1136/gut.2010.218271; Jeppesen PB, 2005, GUT, V54, P1224, DOI 10.1136/gut.2004.061440; Jeppesen PB, 2003, J NUTR, V133, P3721, DOI 10.1093/jn/133.11.3721; Joly F, 2009, GASTROENTEROLOGY, V136, P824, DOI 10.1053/j.gastro.2008.10.084; Jones AM, 2016, MMWR-MORBID MORTAL W, V65, P23, DOI 10.15585/mmwr.mm6502a2; Jones BA, 2013, J AM COLL SURGEONS, V216, P438, DOI 10.1016/j.jamcollsurg.2012.12.018; Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x; Kelly DG, 2014, JPEN-PARENTER ENTER, V38, P427, DOI 10.1177/0148607113512678; Khan FA, 2015, J PEDIAT, V167; Kim HB, 2003, J PEDIATR SURG, V38, P425, DOI 10.1053/jpsu.2003.50073; Kulkarni S, 2013, J PEDIATR GASTR NUTR, V57, P383, DOI 10.1097/MPG.0b013e31829b68f3; Kunz AN, 2004, J PEDIATR GASTR NUTR, V38, P457, DOI 10.1097/00005176-200404000-00017; Lau ECT, 2016, J PEDIATR SURG, V51, P1914, DOI 10.1016/j.jpedsurg.2016.09.010; Lee WS, 2015, J PEDIATR-US, V167, P519, DOI 10.1016/j.jpeds.2015.05.048; McSweeney Maireade E, 2016, Gastrointest Endosc Clin N Am, V26, P169, DOI 10.1016/j.giec.2015.09.001; Mercer DF, 2014, J PEDIATR-US, V164, P93, DOI 10.1016/j.jpeds.2013.08.039; Miller M, 2013, J PEDIATR SURG, V48, P1099, DOI 10.1016/j.jpedsurg.2013.01.023; Modi BP, 2008, J PEDIATR SURG, V43, P20, DOI 10.1016/j.jpedsurg.2007.09.014; Modi BP, 2012, SURG CLIN N AM, V92, P729, DOI 10.1016/j.suc.2012.03.012; Nandivada P, 2017, JPEN-PARENTER ENTER, V41, P930, DOI 10.1177/0148607116633796; Nandivada P, 2016, AM J CLIN NUTR, V103, p629S, DOI 10.3945/ajcn.114.103986; NEHME AE, 1980, JAMA-J AM MED ASSOC, V243, P1906, DOI 10.1001/jama.243.19.1906; Neu J, 2011, NEW ENGL J MED, V364, P255, DOI 10.1056/NEJMra1005408; Huynh N, 2016, J PEDIATR SURG, V51, P1983, DOI 10.1016/j.jpedsurg.2016.09.024; NORDGAARD I, 1994, LANCET, V343, P373, DOI 10.1016/S0140-6736(94)91220-3; O'Keefe SJD, 2013, CLIN GASTROENTEROL H, V11, P815, DOI 10.1016/j.cgh.2012.12.029; Oliveira C, 2012, PEDIATRICS, V129, P318, DOI 10.1542/peds.2011-1602; PARKER P, 1981, J PEDIATR-US, V99, P360, DOI 10.1016/S0022-3476(81)80318-6; Pereira-Fantini PM, 2008, JPEN-PARENTER ENTER, V32, P266, DOI 10.1177/0148607108316197; Puder M, 2009, ANN SURG, V250, P395, DOI 10.1097/SLA.0b013e3181b36657; Rangel SJ, 2012, J PEDIATR SURG, V47, P225, DOI 10.1016/j.jpedsurg.2011.10.007; RICKHAM P P, 1967, Annals of the Royal College of Surgeons of England, V41, P480; Rollins MD, 2013, J PEDIATR SURG, V48, P1348, DOI 10.1016/j.jpedsurg.2013.03.040; ROYALL D, 1992, AM J GASTROENTEROL, V87, P751; Rubin DC, 2016, BEST PRACT RES CL GA, V30, P237, DOI 10.1016/j.bpg.2016.03.007; Section on Breastfeeding, 2012, Pediatrics, V129, pe827, DOI 10.1542/peds.2011-3552; Sentongo TA, 2008, J PEDIATR GASTR NUTR, V46, P41, DOI 10.1097/01.mpg.0000304452.92175.f5; Shores DR, 2015, J PERINATOL, V35, P941, DOI 10.1038/jp.2015.105; Smith JM, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14127; So S, 2016, EARLY HUM DEV, V101, P11, DOI 10.1016/j.earlhumdev.2016.05.012; Sondheimer JM, 1998, J PEDIATR-US, V132, P80, DOI 10.1016/S0022-3476(98)70489-5; Squires RH, 2014, J PEDIATR GASTR NUTR, V59, P537, DOI 10.1097/MPG.0000000000000456; Squires RH, 2012, J PEDIATR-US, V161, P723, DOI 10.1016/j.jpeds.2012.03.062; Stanger JD, 2013, J PEDIATR SURG, V48, P983, DOI 10.1016/j.jpedsurg.2013.02.070; Sudan D, 2014, AM J TRANSPLANT, V14, P1976, DOI 10.1111/ajt.12812; Sueyoshi R, 2014, TISSUE ENG PT A, V20, P830, DOI 10.1089/ten.TEA.2013.0383; Ubesie AC, 2013, J PEDIATR GASTR NUTR, V57, P372, DOI 10.1097/MPG.0b013e31829c10eb; VANDERHOOF JA, 1984, JPEN-PARENTER ENTER, V8, P685, DOI 10.1177/0148607184008006685; Wales PW, 2014, JPEN-PARENTER ENTER, V38, P538, DOI 10.1177/0148607114527772; Wales PW, 2004, J PEDIATR SURG, V39, P690, DOI 10.1016/j.jpedsurg.2004.01.036; Wester T, 2014, BRIT J SURG, V101, P1329, DOI 10.1002/bjs.9583; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1444, DOI 10.1056/NEJM197806292982604; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1393, DOI 10.1056/NEJM197806222982505; WILMORE DW, 1972, J PEDIATR-US, V80, P88, DOI 10.1016/S0022-3476(72)80459-1; Winkler MF, 2016, JPEN-PARENTER ENTER, V40, P1140, DOI 10.1177/0148607115586575; Yang CF, 2011, J PEDIAT, V159	85	127	130	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 17	2017	377	7					666	675		10.1056/NEJMra1602650	http://dx.doi.org/10.1056/NEJMra1602650			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD7FG	28813225				2023-01-03	WOS:000407691400009
J	Timmermans, MJC; van Vught, AJAH; Peters, YAS; Meermans, G; Peute, JGM; Postma, CT; Smit, PC; Verdaasdonk, E; Reilingh, TSD; Wensing, M; Laurant, MGH				Timmermans, Marijke J. C.; van Vught, Anneke J. A. H.; Peters, Yvonne A. S.; Meermans, Geert; Peute, Joseph G. M.; Postma, Cornelis. T.; Smit, P. Casper; Verdaasdonk, Emiel; Reilingh, Tammo S. de Vries; Wensing, Michel; Laurant, Miranda G. H.			The impact of the implementation of physician assistants in inpatient care: A multicenter matched-controlled study	PLOS ONE			English	Article							ACADEMIC-MEDICAL-CENTER; NURSE-PRACTITIONERS; HOSPITALIST MODEL; PATIENT OUTCOMES; WARD CARE; NETHERLANDS; CONTINUITY; PROTOCOL; SERVICE; IMPROVE	Background Medical care for admitted patients in hospitals is increasingly reallocated to physician assistants (PAs). There is limited evidence about the consequences for the quality and safety of care. This study aimed to determine the effects of substitution of inpatient care from medical doctors (MDs) to PAs on patients' length of stay (LOS), quality and safety of care, and patient experiences with the provided care. Methods In a multicenter matched-controlled study, the traditional model in which only MDs are employed for inpatient care (MD model) was compared with a mixed model in which besides MDs also PAs are employed (PA/MD model). Thirty-four wards were recruited across the Netherlands. Patients were followed from admission till one month after discharge. Primary outcome measure was patients' LOS. Secondary outcomes concerned eleven indicators for quality and safety of inpatient care and patients' experiences with the provided care. Results Data on 2,307 patients from 34 hospital wards was available. The involvement of PAs was not significantly associated with LOS (beta 1.20, 95% CI 0.99-1.40, p = .062). None of the indicators for quality and safety of care were different between study arms. However, the involvement of PAs was associated with better experiences of patients (beta 0.49, 95% CI 0.22-0.76, p = .001). Conclusions This study did not find differences regarding LOS and quality of care between wards on which PAs, in collaboration with MDs, provided medical care for the admitted patients, and wards on which only MDs provided medical care. Employing PAs seems to be safe and seems to lead to better patient experiences.	[Timmermans, Marijke J. C.; Peters, Yvonne A. S.; Wensing, Michel; Laurant, Miranda G. H.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Sci Ctr Qual Healthcare,IQ Healthcare, Nijmegen, Netherlands; [Timmermans, Marijke J. C.; van Vught, Anneke J. A. H.; Laurant, Miranda G. H.] HAN Univ Appl Sci, Fac Hlth & Social Studies, Nijmegen, Netherlands; [Meermans, Geert] Bravis Hosp, Dept Orthopaed, Bergen Op Zoom, Netherlands; [Meermans, Geert] Bravis Hosp, Dept Orthopaed, Roosendaal, Netherlands; [Peute, Joseph G. M.] VieCuri Med Ctr Noord Limburg, Dept Cardiol, Venlo, Netherlands; [Postma, Cornelis. T.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands; [Smit, P. Casper] Reinier Haga Grp, Dept Surg, Delft, Netherlands; [Verdaasdonk, Emiel] Jeroen Bosch Hosp, Dept Surg, Shertogenbosch, Netherlands; [Reilingh, Tammo S. de Vries] Elkerliek Hosp, Dept Surg, Helmond, Netherlands; [Wensing, Michel] Heidelberg Univ Hosp, Dept Gen Practice & Hlth Serv Res, Heidelberg, Germany	Radboud University Nijmegen; VieCuri Medical Center; Radboud University Nijmegen; Jeroen Bosch Ziekenhuis; Ruprecht Karls University Heidelberg	Timmermans, MJC (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Sci Ctr Qual Healthcare,IQ Healthcare, Nijmegen, Netherlands.; Timmermans, MJC (corresponding author), HAN Univ Appl Sci, Fac Hlth & Social Studies, Nijmegen, Netherlands.	Marijke.Timmermans@radboudumc.nl	Laurant, Miranda/H-6488-2015; van Vught, Anneke/ABA-4289-2021; Meermans, Geert/AAI-6464-2020; Peters, Yvonne AS/F-3096-2016; Wensing, Michel/H-8113-2014; Postma, C.T./L-4585-2015	Laurant, Miranda/0000-0002-8826-3352; van Vught, Anneke/0000-0002-4266-744X; Wensing, Michel/0000-0001-6569-8137; 	etherlands Organization for Health Research and Development (ZonMw) [171202006]	etherlands Organization for Health Research and Development (ZonMw)	This study was funded by a research grant from the Netherlands Organization for Health Research and Development (ZonMw) (project number 171202006), http://www.zonmw.nl/en/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], LENGTH HOSP STAY IND; Borghans I, 2012, HEALTH POLICY, V104, P222, DOI 10.1016/j.healthpol.2011.12.010; Bos WJ, 2011, ZIEKENHUISLANDSCHAP; Cabana MD, 2004, J FAM PRACTICE, V53, P974; Clarke A, 2001, EUR J PUBLIC HEALTH, V11, P166, DOI 10.1093/eurpub/11.2.166; De Bruijn-Geraets DP, 2014, J ADV NURS, V70, P2673, DOI 10.1111/jan.12396; Dhuper S, 2009, AM J MED QUAL, V24, P132, DOI 10.1177/1062860608329646; Ford WT, 2010, J HOSP MED, V5, P99, DOI 10.1002/jhm.556; Gezondheidszorg IVD, 2012, BAS KWAL ZIEK 2013; Hartsell Zachary, 2007, JAAPA, V20, P10; Hooker Roderick S, 2011, J Physician Assist Educ, V22, P53; Kleinpell RM, 2008, CRIT CARE MED, V36, P2888, DOI 10.1097/CCM.0b013e318186ba8c; Laurant M, 2009, MED CARE RES REV, V66, p36S, DOI 10.1177/1077558709346277; Makoul G, 2007, PATIENT EDUC COUNS, V67, P333, DOI 10.1016/j.pec.2007.05.005; Merkle F, 2011, HEART LUNG VESSEL, V3, P255; Miller W, 1998, J TRAUMA, V44, P372, DOI 10.1097/00005373-199802000-00025; Mittman DE, 2002, BMJ-BRIT MED J, V325, P485, DOI 10.1136/bmj.325.7362.485; Nishimura RA, 2004, ACAD MED, V79, P426, DOI 10.1097/00001888-200405000-00011; Roy CL, 2008, J HOSP MED, V3, P361, DOI 10.1002/jhm.352; Singh S, 2011, J HOSP MED, V6, P122, DOI 10.1002/jhm.826; Spenkelink-Schut G., 2008, J PHYS ASSIST ED, V19, P46; Timmermans MJC, 2016, J EVAL CLIN PRACT, V22, P395, DOI 10.1111/jep.12499; Timmermans MJC, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1330-9; Timmermans MJC, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-43; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; Wensing M., 1998, EUR J GEN PRACT, V4, P150	26	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2017	12	8							e0178212	10.1371/journal.pone.0178212	http://dx.doi.org/10.1371/journal.pone.0178212			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC9YJ	28793317	gold, Green Published, Green Submitted			2023-01-03	WOS:000407196700001
J	Knafl, D; Thalhammer, F; Vossen, MG				Knafl, Daniela; Thalhammer, Florian; Vossen, Matthias G.			In-vitro release pharmacokinetics of amikacin, teicoplanin and polyhexanide in a platelet rich fibrin D layer (PRF) D a laboratory evaluation of a modern, autologous wound treatment	PLOS ONE			English	Article							CHRONIC LEG ULCERS; HUMAN BETA-DEFENSIN-2	Objectives Platelet rich fibrin (PRF) is an autologous fibrin glue, produced from patients' blood, which, besides intraoperative use, has applications in the treatment of infected wounds. The combination with antimicrobial agents results in a prolonged antibacterial effect allowing for wound dressing change intervals of seven days even in infected wounds. The aim of this study was to evaluate release kinetics of amikacin, teicoplanin or polyhexanide from a PRF- layer. Methods PRF mixed with teicoplanin, amikacin or polyhexanide was sprayed on a silicon gauze patch and put on a colombia agar with bacteria with known minimal inhibitory concentration (MIC) and incubated for 24 hours and afterwards transferred to another agar with the same bacterial strain. Inhibition zones were measured every 24 hours. This was repeated on 7 consecutive days. Antibiotic concentrations were calculated by interpolation. Results More than 1000 mg/L teicoplanin were released within the first 24 hours and 28.22 mg/L after 168 hours. Amikacin release was above 10,000 mg/L within the first 24 hours and still 120.8 mg/L after 120 hours. A release of polyhexanide could be verified for the first 24 hours only. Consequently teicoplanin and amikacin released from PRF showed antimicrobial invitro effects for almost a week, whereas an antimicrobial effect of polyhexanide could only be verified for the first 24 hours. Conclusions Our Results show that a weekly dressing regimen may be justified in wounds treated with PRF plus amikacin or teicoplanin, since bacteria will be eradicated over a considerable period of time after a single application of PRF.	[Knafl, Daniela; Thalhammer, Florian; Vossen, Matthias G.] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, Vienna, Austria	Medical University of Vienna	Vossen, MG (corresponding author), Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, Vienna, Austria.	matthias.vossen@meduniwien.ac.at	Vossen, Matthias Gerhard/H-8761-2019		Vivostat A/S	Vivostat A/S	F.T. and M.G.V. received an unrestricted research grant from Vivostat A/S. D.K. did not receive any grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. http://www.vivostat.com/.	[Anonymous], 2008, WOUND REPAIR REGENER, V16, P356; Bayer A, 2016, EXP DERMATOL, V25, P460, DOI 10.1111/exd.12966; Carter Marissa J, 2011, Eplasty, V11, pe38; EUCAST, 2020, EUR COMM ANT SUSC TE; Giamarellos-Bourboulis EJ, 2005, DIAGN MICR INFEC DIS, V51, P113, DOI 10.1016/j.diagmicrobio.2004.09.004; Hurd T, 2008, INT WOUND J, V5, P296, DOI 10.1111/j.1742-481X.2008.00484.x; Jockenhofer F, 2014, J DTSCH DERMATOL GES, V12, P1121, DOI 10.1111/ddg.12540; Korber A, 2011, J DTSCH DERMATOL GES, V9, P116, DOI 10.1111/j.1610-0387.2010.07535.x; O'Meara S, 2000, Health Technol Assess, V4, P1; Ruttermann M, 2013, DTSCH ARZTEBL INT, V110, P25, DOI 10.3238/arztebl.2013.0025; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Steenvoorde P, 2008, J Wound Care, V17, P60; Tohidnezhad M, 2011, HISTOCHEM CELL BIOL, V135, P453, DOI 10.1007/s00418-011-0808-0; Tohidnezhad M, 2012, PLATELETS, V23, P217, DOI 10.3109/09537104.2011.610908; Tohidnezhad M, 2011, INJURY, V42, P682, DOI 10.1016/j.injury.2010.12.010	16	5	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0181090	10.1371/journal.pone.0181090	http://dx.doi.org/10.1371/journal.pone.0181090			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686663	Green Submitted, gold, Green Published			2023-01-03	WOS:000405464100131
J	Magnes, T; Melchardt, T; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Gampenrieder, S; Moser, G; Gaggl, A; Greil, R; Egle, A				Magnes, Teresa; Melchardt, Thomas; Weiss, Lukas; Mittermair, Christof; Neureiter, Daniel; Klieser, Eckhard; Gampenrieder, Simon; Moser, Gerhard; Gaggl, Alexander; Greil, Richard; Egle, Alexander			Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; C-REACTIVE PROTEIN; OPEN-LABEL; HUMAN-PAPILLOMAVIRUS; LYMPHOCYTE RATIO; PLUS CETUXIMAB; CISPLATIN; FLUOROURACIL; MULTICENTER; DOCETAXEL	Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and clinical parameters may help improve the prognostication in this patient group. This retrospective monocenter analysis includes 128 patients with recurrent or metastatic SCCHN treated with cetuximab alone or in combination with polychemotherapy as first line therapy. Factors with independent prognostic power in the multivariate analysis were used to build up a score separating patient groups with different survival. Patients had a median age of 61 years and 103 patients were treated with polychemotherapy plus cetuximab. An ECOG score above 1, high CRP and leukocyte levels, less intensive treatment and a time below 12 months from primary diagnosis to relapse remained as independent negative prognostic factors in multivariate analysis. Patients with 0 to 1 risk factors had a median OS of 13.6 months compared to a median OS of less than one month for patients 4 to 5 risk factors (p< 0.001). This study identifies 5 clinical and serum values that influence survival of patients with recurrent or metastatic SCCHN treated with cetuximab. By combining these factors to create a score for OS, it is possible to distinguish a group of patients with significantly improved survival and define those most likely to have no benefit from cetuximab treatment.	[Magnes, Teresa; Melchardt, Thomas; Weiss, Lukas; Mittermair, Christof; Gampenrieder, Simon; Greil, Richard; Egle, Alexander] Paracelsus Med Univ, Med Dept 3, Salzburg, Austria; [Magnes, Teresa; Melchardt, Thomas; Weiss, Lukas; Mittermair, Christof; Gampenrieder, Simon; Greil, Richard; Egle, Alexander] Salzburg Canc Res Inst, Salzburg, Austria; [Magnes, Teresa; Melchardt, Thomas; Weiss, Lukas; Mittermair, Christof; Gampenrieder, Simon; Greil, Richard; Egle, Alexander] Canc Cluster Salzburg, Salzburg, Austria; [Neureiter, Daniel; Klieser, Eckhard] Paracelsus Med Univ, Inst Pathol, Salzburg, Austria; [Moser, Gerhard] Paracelsus Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Salzburg, Austria; [Gaggl, Alexander] Paracelsus Med Univ, Dept Oral & Maxillofacial Surg, Salzburg, Austria	Paracelsus Private Medical University; Paracelsus Private Medical University; Paracelsus Private Medical University; Paracelsus Private Medical University	Egle, A (corresponding author), Paracelsus Med Univ, Med Dept 3, Salzburg, Austria.; Egle, A (corresponding author), Salzburg Canc Res Inst, Salzburg, Austria.; Egle, A (corresponding author), Canc Cluster Salzburg, Salzburg, Austria.	a.egle@salk.at	Gampenrieder, Simon Peter/AFM-7798-2022; Egle, Alexander/AAC-3787-2020; Moser, Gerhard/N-7402-2013	Egle, Alexander/0000-0003-0648-4416; Weiss, Lukas/0000-0002-2174-5613; Moser, Gerhard/0000-0003-4916-5490	PMU Research Fund- PMU FFF [R-16/02/081-MAM]; province of Salzburg; company Merck	PMU Research Fund- PMU FFF; province of Salzburg; company Merck	This work was supported by the PMU Research Fund- PMU FFF [grant number: R-16/02/081-MAM] and the province of Salzburg. The author Thomas Melchardt received an unrestricted grant from the company Merck. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argiris A, 2004, CANCER, V101, P2222, DOI 10.1002/cncr.20640; Argiris A, 2014, ANN ONCOL, V25, P1410, DOI 10.1093/annonc/mdu167; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bektas-Kayhan K, 2012, ORAL DIS, V18, P55, DOI 10.1111/j.1601-0825.2011.01843.x; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; de Mello RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086697; Fang HY, 2013, LARYNGOSCOPE, V123, P2690, DOI 10.1002/lary.24105; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Guo Y, 2015, HEAD NECK-J SCI SPEC, V37, P1081, DOI 10.1002/hed.23707; Jalali MM, 2011, ASIAN PAC J CANCER P, V12, P1731; Keil F, 2013, EUR J CANCER, V49, P352, DOI 10.1016/j.ejca.2012.08.004; Khandavilli SD, 2009, ORAL ONCOL, V45, P912, DOI 10.1016/j.oraloncology.2009.03.015; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Lynggaard CD, 2015, ACTA ONCOL, V54, P1071, DOI 10.3109/0284186X.2014.964308; Melchardt T, 2015, J NATL COMPR CANC NE, V13, P1501, DOI 10.6004/jnccn.2015.0178; Millrud CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051120; Misiukiewicz K, 2014, ANN ONCOL, V25, P1667, DOI 10.1093/annonc/mdu194; Nakayama M, 2015, HEAD NECK-J SCI SPEC, V37, P1745, DOI 10.1002/hed.23823; Perisanidis C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0334-5; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Purdue MP, 2013, BLOOD, V122, P951, DOI 10.1182/blood-2013-01-481077; Ramsey S, 2006, BRIT J CANCER, V95, P1076, DOI 10.1038/sj.bjc.6603387; Rischin D, 2010, J CLIN ONCOL, V28, P4142, DOI 10.1200/JCO.2010.29.2904; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Selzer E, 2015, STRAHLENTHER ONKOL, V191, P486, DOI 10.1007/s00066-014-0803-1; Stotz M, 2013, BRIT J CANCER, V109, P416, DOI 10.1038/bjc.2013.332; Troppan KT, 2014, BRIT J CANCER, V111, P55, DOI 10.1038/bjc.2014.277; Ueda M, 2010, AURIS NASUS LARYNX, V37, P488, DOI 10.1016/j.anl.2009.11.012; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Vermorken JB, 2013, LANCET ONCOL, V14, P697, DOI 10.1016/S1470-2045(13)70181-5	32	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180995	10.1371/journal.pone.0180995	http://dx.doi.org/10.1371/journal.pone.0180995			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686697	Green Submitted, Green Published, gold			2023-01-03	WOS:000405464100130
J	Ho, SY; Liu, PH; Hsu, CY; Hsia, CY; Lee, YH; Lee, RC; Huang, YH; Lee, FY; Hou, MC; Tsai, YJ; Huo, TI				Ho, Shu-Yein; Liu, Po-Hong; Hsu, Chia-Yang; Hsia, Cheng-Yuan; Lee, Yun-Hsuan; Lee, Rheun-Chuan; Huang, Yi-Hsiang; Lee, Fa-Yauh; Hou, Ming-Chih; Tsai, Ya-Ju; Huo, Teh-Ia			Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization	PLOS ONE			English	Article							HEPATITIS-B; RENAL-FAILURE; CIRRHOSIS; SCORE; FIBROSIS; DISEASE; RISK; DETERMINANTS; VALIDATION; PREDICTION	Background Various noninvasive liver reserve markers were proposed to indicate the severity of liver damage. However, the role and feasibility of these markers to predict the prognosis of patients with hepatocellular carcinoma (HCC) are unknown. We aimed to identify the prognostic role of the 8 currently used hepatic reserve markers in patients with HCC undergoing transarterial chemoembolization (TACE). Methods Between 2002 and 2013, a total of 881 patients with HCC undergoing TACE were prospectively identified and retrospectively analyzed. The baseline characteristics, tumor status and noninvasive markers were collected. Homogeneity and corrected Akaike information criteria (AICc) were compared between these markers. The Cox proportional hazards model was used to identify independent predictors of survival. Results Significant differences in survival distribution were found for albumin-bilirubin (ALBI) grade, Child-Turcotte-Pugh (CTP) class, Lok index, fibrosis index based on 4 factors (FIB-4), Go E teborg University cirrhosis index (GUCI), cirrhosis discriminant index (CDI) and model for endstage liver disease (MELD) score (all p values <0.05). Among these markers, the ALBI grade showed the highest homogeneity and lowest AICc value, indicating a better prognostic performance. Cox multivariate analysis confirmed that ALBI grade 2, ascites, serum alkaline phosphatase and alpha-fetoprotein level, tumor diameter, vascular invasion and performance status were significant independent prognostic predictors. The distribution of the ALBI score well correlated with baseline CTP and MLED scores. Conclusions Our data suggest that among the currently used liver reserve markers, ALBI grade may serve as an objective and feasible surrogate to predict the prognosis of HCC patients undergoing TACE.	[Ho, Shu-Yein; Liu, Po-Hong; Lee, Yun-Hsuan; Huang, Yi-Hsiang; Lee, Fa-Yauh; Hou, Ming-Chih; Huo, Teh-Ia] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan; [Ho, Shu-Yein; Liu, Po-Hong; Hsu, Chia-Yang; Hsia, Cheng-Yuan; Lee, Yun-Hsuan; Lee, Rheun-Chuan; Huang, Yi-Hsiang; Lee, Fa-Yauh; Hou, Ming-Chih; Huo, Teh-Ia] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan; [Liu, Po-Hong] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Hsu, Chia-Yang] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA; [Hsia, Cheng-Yuan] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; [Lee, Rheun-Chuan] Taipei Vet Gen Hosp, Dept Radiol, Taipei, Taiwan; [Huang, Yi-Hsiang] Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei, Taiwan; [Tsai, Ya-Ju] Renown Reg Med Ctr, Reno, NV USA; [Huo, Teh-Ia] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Harvard University; Harvard T.H. Chan School of Public Health; Nevada System of Higher Education (NSHE); University of Nevada Reno; Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Huo, TI (corresponding author), Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan.; Huo, TI (corresponding author), Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan.; Huo, TI (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei, Taiwan.	tihuo@vghtpe.gov.tw	Liu, Po-Hong/HGB-9015-2022; Liu, Po-Hong/G-8459-2015	Liu, Po-Hong/0000-0001-6205-3704; Huang, Yi-Hsiang/0000-0001-5241-5425	Center of Excellence for Cancer Research at Taipei Veterans General Hospital Taiwan [MOHW104-TDUB -211-124-001]; Taipei Veterans Genera lHospital Taiwan [V105C-009, V105A-011, VN1061 1]	Center of Excellence for Cancer Research at Taipei Veterans General Hospital Taiwan; Taipei Veterans Genera lHospital Taiwan(Taipei Veterans General Hospital)	This study was supported by grants from the Center of Excellence for Cancer Research at Taipei Veterans General Hospital (MOHW104-TDUB -211-124-001), Taiwan, from Taipei Veterans Genera lHospital (V105C-009,V105A-011,VN1061 1), Taiwan.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Bonacini M, 1997, AM J GASTROENTEROL, V92, P1302; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Castera L, 2012, GASTROENTEROLOGY, V142, P1293, DOI 10.1053/j.gastro.2012.02.017; Chan AWH, 2016, J GASTROEN HEPATOL, V31, P1300, DOI 10.1111/jgh.13291; Choi WM, 2015, LIVER INT, V35, P1992, DOI 10.1111/liv.12776; Durand F, 2008, SEMIN LIVER DIS, V28, P110, DOI 10.1055/s-2008-1040325; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Hiraoka A, 2016, J GASTROEN HEPATOL, V31, P1031, DOI 10.1111/jgh.13250; Hsu CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118825; Hsu CY, 2013, HEPATOLOGY, V57, P112, DOI 10.1002/hep.25950; Hsu CY, 2010, LIVER INT, V30, P77, DOI 10.1111/j.1478-3231.2009.02128.x; Huang YH, 2005, ALIMENT PHARM THER, V21, P687, DOI 10.1111/j.1365-2036.2005.02404.x; Huo TI, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-146; Huo TI, 2006, J CLIN GASTROENTEROL, V40, P543, DOI 10.1097/00004836-200607000-00014; Huo TI, 2004, ALIMENT PHARM THER, V19, P999, DOI 10.1111/j.1365-2036.2004.01936.x; Ibrahim JG, 2012, J CLIN ONCOL, V30, P3297, DOI 10.1200/JCO.2011.38.7589; Johnson PJ, 2015, J CLIN ONCOL, V33, P550, DOI 10.1200/JCO.2014.57.9151; Kao WY, 2011, WORLD J SURG, V35, P858, DOI 10.1007/s00268-010-0928-z; Lee IC, 2012, HEPATOL INT, V6, P753, DOI 10.1007/s12072-011-9322-7; Lee MH, 2013, HEPATOLOGY, V58, P546, DOI 10.1002/hep.26385; Lee YH, 2014, J CLIN GASTROENTEROL, V48, P734, DOI 10.1097/MCG.0b013e3182a8a254; Liu P. H., 2016, J GASTROENTEROL HEPA; Liu PH, 2016, EUR J CANCER, V63, P25, DOI 10.1016/j.ejca.2016.04.023; Liu PH, 2016, J HEPATOL, V64, P601, DOI 10.1016/j.jhep.2015.10.029; Liu PH, 2015, J SURG ONCOL, V111, P404, DOI 10.1002/jso.23854; Lok ASF, 2005, HEPATOLOGY, V42, P282, DOI 10.1002/hep.20772; Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrick JL, 2016, J CLIN ONCOL, V34, P1787, DOI 10.1200/JCO.2015.64.7412; Regev A, 2002, AM J GASTROENTEROL, V97, P2614, DOI 10.1111/j.1572-0241.2002.06038.x; Schutte K, 2009, DIGEST DIS, V27, P80, DOI 10.1159/000218339; Su YW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174333; Tournoux-Facon C, 2011, J HEPATOL, V54, P108, DOI 10.1016/j.jhep.2010.06.015; Udell JA, 2012, JAMA-J AM MED ASSOC, V307, P832, DOI 10.1001/jama.2012.186; Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Waked I, 2017, BRIT J CANCER, V116, P448, DOI 10.1038/bjc.2016.423	39	24	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2017	12	7							e0180408	10.1371/journal.pone.0180408	http://dx.doi.org/10.1371/journal.pone.0180408			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2JX	28672011	gold, Green Submitted, Green Published			2023-01-03	WOS:000405268500051
J	Chang, SH; Chou, IJ; Yeh, YH; Chiou, MJ; Wen, MS; Kuo, CT; See, LC; Kuo, CF				Chang, Shang-Hung; Chou, I-Jun; Yeh, Yung-Hsin; Chiou, Meng-Jiun; Wen, Ming-Shien; Kuo, Chi-Tai; See, Lai-Chu; Kuo, Chang-Fu			Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRACEREBRAL HEMORRHAGE; DABIGATRAN ETEXILATE; PROPENSITY SCORE; MORTALITY RISKS; ARISTOTLE TRIAL; STATIN THERAPY; WARFARIN; METAANALYSIS; RIVAROXABAN; STROKE	IMPORTANCE Non-vitamin (oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. OBJECTIVE To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016. EXPOSURES NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin. MAIN OUTCOMES AND MEASURES Major bleeding, defined as hospitalization or emergency department visit with a primary diagnosis of intracranial hemorrhage or gastrointestinal, urogenital, or other bleeding. Adjusted incidence rate differences between person-quarters (exposure time for each person during each quarter of the calendar year) of NOAC with or without concurrent medications were estimated using Poisson regression and inverse probability of treatment weighting using the propensity score. RESULTS Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54006 patients; and apixaban, 12 886 patients), 4770 major bleeding events occurred during 447 037 person-quarters with NOAC prescriptions. The most common medications co-prescribed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%). Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant increase in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% Cl, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% Cl, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% Cl, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin (difference, 52.31 [99% Cl, 32.18-72.44]; P < .01 for all comparisons). Compared with NOAC use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone. CONCLUSIONS AND RELEVANCE Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the use of NOACs alone, was associated with increased risk of major bleeding. Physicians prescribing NOAC medications should consider the potential risks associated with concomitant use of other drugs.	[Chang, Shang-Hung; Yeh, Yung-Hsin; Wen, Ming-Shien; Kuo, Chi-Tai] Chang Gung Mem Hosp, Cardiovasc Dept, Taoyuan, Taiwan; [Chang, Shang-Hung; Chiou, Meng-Jiun; Kuo, Chang-Fu] Chang Gung Mem Hosp, Ctr Big Data Analyt & Stat, Taoyuan, Taiwan; [Chang, Shang-Hung; Chou, I-Jun; Yeh, Yung-Hsin; Wen, Ming-Shien; Kuo, Chi-Tai; Kuo, Chang-Fu] Chang Gung Univ, Sch Med, Taoyuan, Taiwan; [Chou, I-Jun] Chang Gung Mem Hosp, Div Pediat Neurol, Taoyuan, Taiwan; [See, Lai-Chu] Chang Gung Univ, Coll Med, Dept Publ Hlth, Taoyuan, Taiwan; [See, Lai-Chu] Chang Gung Univ, Mol Med Res Ctr, Biostat Core Lab, Taoyuan, Taiwan; [See, Lai-Chu; Kuo, Chang-Fu] Chang Gung Mem Hosp, Div Rheumatol Allergy & Immunol, Taoyuan, Taiwan; [Kuo, Chang-Fu] Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham, England	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; University of Nottingham	Kuo, CF (corresponding author), Nottingham City Hosp, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.; Kuo, CF (corresponding author), 5 Fuxing St, Taoyuan 333, Taiwan.	zandis@gmail.com	Wen, Chen Jing/F-9676-2010; Yeh, Yung-Hsin/ABD-9351-2021	Chang, Shang-hung/0000-0003-0462-2344; See, Lai-Chu/0000-0002-1379-8969	Chang Gung Memorial Hospital [CORPG3E0142, CMRPG3F0851]; Taiwan Ministry of Science and Technology [103-2314-B-182-043-MY2]; Maintenance project of the Center for Big Data Analytics and Statistics [CLRPG3D0043]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Taiwan Ministry of Science and Technology; Maintenance project of the Center for Big Data Analytics and Statistics	This study was financially supported by grants CORPG3E0142 and CMRPG3F0851 from Chang Gung Memorial Hospital and 103-2314-B-182-043-MY2 from the Taiwan Ministry of Science and Technology. This study is based in part on National Health Insurance Research Database data provided by the Applied Health Research Data Integration Service from National Health Insurance Administration. Chang Gung Memorial Hospital provided statistical assistance and support from the Maintenance project of the Center for Big Data Analytics and Statistics (grant CLRPG3D0043).	Atar S, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2006.02.013; Chan YH, 2016, J AM COLL CARDIOL, V68, P2272, DOI 10.1016/j.jacc.2016.08.063; Chan YH, 2016, J AM COLL CARDIOL, V68, P1389, DOI 10.1016/j.jacc.2016.06.062; Chan YH, 2016, STROKE, V47, P441, DOI 10.1161/STROKEAHA.115.011476; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Deedwania P, 2017, J AM COLL CARDIOL, V69, P786, DOI 10.1016/j.jacc.2016.11.062; Delavenne X, 2013, BRIT J CLIN PHARMACO, V76, P107, DOI 10.1111/bcp.12055; Flaker G, 2014, J AM COLL CARDIOL, V64, P1541, DOI 10.1016/j.jacc.2014.07.967; Focks JJ, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2868; Fralick M, CMAJ, V188, P669; Gerhard-Herman MD, 2017, J AM COLL CARDIOL, V69, pE71, DOI 10.1016/j.jacc.2016.11.007; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Green B, 2016, J ORAL PATHOL MED, V45, P551, DOI 10.1111/jop.12441; Grobbee DE, 1997, BRIT MED J, V315, P1151; Heidbuchel H, 2017, EUR HEART J, V38, P2137, DOI 10.1093/eurheartj/ehw058; Heidbuchel H, 2013, EUR HEART J, V34, P2094, DOI 10.1093/eurheartj/eht134; Jia WH, 2013, J CLIN NEUROL, V9, P139, DOI 10.3988/jcn.2013.9.3.139; Kishimoto W, 2014, DRUG METAB DISPOS, V42, P257, DOI 10.1124/dmd.113.053769; Li BZ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4052; Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x; Lip GYH, 2016, CIRCULATION, V133, P1498, DOI 10.1161/CIRCULATIONAHA.115.016713; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; McKinney JS, 2012, STROKE, V43, P2149, DOI 10.1161/STROKEAHA.112.655894; Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075; Olesen JB, 2015, EUROPACE, V17, P187, DOI 10.1093/europace/euu225; Pandit AK, 2016, ACTA NEUROL SCAND, V134, P22, DOI 10.1111/ane.12540; Parasrampuria DA, 2016, BRIT J CLIN PHARMACO, V82, P1591, DOI 10.1111/bcp.13092; Piccini JP, 2016, CIRCULATION, V133, P352, DOI 10.1161/CIRCULATIONAHA.115.018544; Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134; Romley JA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6223; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Ruff CT, 2016, CIRCULATION, V134, P248, DOI 10.1161/CIRCULATIONAHA.116.021831; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Stangier J, 2012, J CLIN PHARMACOL, V52, P243, DOI 10.1177/0091270010393342; Stangier J, 2009, AM J CARDIOVASC DRUG, V9, P59, DOI 10.2165/00129784-200909010-00006; Tamayo SG, 2016, J AM COLL CARDIOL, V68, P1144, DOI 10.1016/j.jacc.2016.06.028; Wang Yishen, 2016, Pharmacy Pract (Granada), V14, DOI 10.18549/PharmPract.2016.02.706; Wannhoff A, 2014, TRANSPLANTATION, V98, pE12, DOI 10.1097/TP.0000000000000223; Wiggins BS, 2016, PHARMACOTHERAPY, V36, pE5, DOI 10.1002/phar.1698	42	217	227	5	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 3	2017	318	13					1250	1259		10.1001/jama.2017.13883	http://dx.doi.org/10.1001/jama.2017.13883			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FI8CW	28973247	Green Published, Green Accepted			2023-01-03	WOS:000412229600017
J	Soria, I; Quattrocchi, V; Langellotti, C; Gammella, M; Digiacomo, S; de la Torre, BG; Andreu, D; Montoya, M; Sobrino, F; Blanco, E; Zamorano, P				Soria, Ivana; Quattrocchi, Valeria; Langellotti, Cecilia; Gammella, Mariela; Digiacomo, Sebastian; Garcia de la Torre, Beatriz; Andreu, David; Montoya, Maria; Sobrino, Francisco; Blanco, Esther; Zamorano, Patricia			Dendrimeric peptides can confer protection against foot-and-mouth disease virus in cattle	PLOS ONE			English	Article							B-CELL; RESPIRATORY-TRACT; SOLID PROTECTION; IMMUNE-RESPONSE; ANTIBODIES; VACCINE; EPITOPE; TRANSMISSION; CHALLENGE; VP1	Foot-and-mouth disease virus (FMDV) causes a highly contagious disease in cloven-hoofed animals. A synthetic vaccine candidate consisting of dendrimeric peptides harbouring two copies of a B-epitope [VP1(136-154)] linked to a T-cell epitope [3A(21-35)] of FMDV confers protection to type O FMDV challenge in pigs. Herein we show in cattle that novel dendrimeric peptides bearing a T-cell epitope [VP1(21-40] and two or four copies of a B-cell epitope [VP1(135-160)] from type O1 Campos FMDV (termed B2T and B4T, respectively) elicited FMDV specific immune responses to similar levels to a commercial vaccine. Animals were challenged with FMDV and 100% of vaccinated cattle with B2T or B4T were protected to podal generalization. Moreover, bovines immunized with B4T were completely protected (with no clinical signs) against FMDV challenge after three vaccine doses, which was associated with titers of viral neutralizing antibodies in serum higher than those of B2T group (p< 0.05) and levels of opsonic antibodies similar to those of animals immunized with one dose of FMDV commercial vaccine. Bovines vaccinated with both dendrimeric peptides presented high levels of IgG1 anti FMDV in sera and in mucosa. When IgA in nasal secretions was measured, 20% or 40% of the animals in B2T or B4T groups respectively, showed antiFMDV IgA titers. In addition, B2T and B4T peptides evoked similar consistent T cell responses, being recognized in vitro by lymphocytes from most of the immunized cattle in the proliferation assay, and from all animals in the IFN-. production assay. Taken together, these results support the potential of dendrimers B2T or B4T in cattle as a highly valuable, cost-effective FMDV candidate vaccine with DIVA potential.	[Soria, Ivana; Quattrocchi, Valeria; Langellotti, Cecilia; Gammella, Mariela; Digiacomo, Sebastian; Zamorano, Patricia] Inst Nacl Tecnol Agr INTA Castelar, Inst Virol, Ctr Invest Ciencias Vet, Buenos Aires, DF, Argentina; [Soria, Ivana; Langellotti, Cecilia; Zamorano, Patricia] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Garcia de la Torre, Beatriz; Andreu, David] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Montoya, Maria] Pirbright Inst, Ash Rd, Woking, Surrey, England; [Sobrino, Francisco] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid, Spain; [Blanco, Esther] Ctr Invest Sanidad Anim CISA INIA, Madrid, Spain	Instituto Nacional de Tecnologia Agropecuaria (INTA); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Pompeu Fabra University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Soria, I; Zamorano, P (corresponding author), Inst Nacl Tecnol Agr INTA Castelar, Inst Virol, Ctr Invest Ciencias Vet, Buenos Aires, DF, Argentina.; Soria, I; Zamorano, P (corresponding author), Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.; Sobrino, F (corresponding author), Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid, Spain.	soria.ivana@inta.gob.ar; fsobrino@cbm.csic.es; zamorano.patricia@inta.gob.ar	de la Torre, Beatriz G./N-6995-2019; Montoya, Maria/G-3430-2015; Blanco, Esther/C-1245-2013; de la Torre, Beatriz G/AAF-1419-2020	de la Torre, Beatriz G./0000-0001-8521-9172; Montoya, Maria/0000-0002-5703-7360; Blanco, Esther/0000-0001-8413-4222; Sobrino, Francisco/0000-0003-4968-8291	National Institute of Agricultural Technology [PNSA 1115052]; INTA-INIA (Argentina-Spain) [SA 20938]; MINECO, Spain [AGL2014-52395-C2]	National Institute of Agricultural Technology; INTA-INIA (Argentina-Spain); MINECO, Spain	Work at INTA was supported by the National Institute of Agricultural Technology (grant number PNSA 1115052) and cooperation agreement INTA-INIA (Argentina-Spain SA 20938). Evaluation of vaccine immunogenicity and protection in cattle. Work at Universitat Pompeu Fabra and CBMSO was supported by MINECO, Spain (grant number AGL2014-52395-C2). Dendrimeric peptides synthesis and article submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Romera SA, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-8; Alexandersen S, 2005, CURR TOP MICROBIOL, V288, P9; Lavoria MA, 2012, VACCINE, V30, P6845, DOI 10.1016/j.vaccine.2012.09.011; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Barteling SJ, 2004, DEV BIOLOGICALS, V119, P449; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; Blanco E, 2016, ANTIVIR RES, V129, P74, DOI 10.1016/j.antiviral.2016.03.005; Blanco E, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/475960; Bouvet JP, 2002, TRENDS IMMUNOL, V23, P209, DOI 10.1016/S1471-4906(02)02186-5; Brocchi E, 2006, VACCINE, V24, P6966, DOI 10.1016/j.vaccine.2006.04.050; Capozzo AVE, 1997, VACCINE, V15, P624, DOI 10.1016/S0264-410X(96)00284-8; COLLEN T, 1991, J IMMUNOL, V146, P749; Cubillos C, 2008, J VIROL, V82, P7223, DOI 10.1128/JVI.00401-08; Diaz-San Segundo F, 2016, VET MICROBIOL; DIMARCHI R, 1986, SCIENCE, V232, P639, DOI 10.1126/science.3008333; GLASS EJ, 1991, IMMUNOLOGY, V74, P594; Goddeeris B, 1998, HANDBOOK OF INVERTEBRATE IMMUNOLOGY, P439; Heegaard PMH, 2010, BIOCONJUGATE CHEM, V21, P405, DOI 10.1021/bc900290d; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Law M, 2008, CURR OPIN IMMUNOL, V20, P486, DOI 10.1016/j.coi.2008.06.005; Maradei E, 2008, VACCINE, V26, P6577, DOI 10.1016/j.vaccine.2008.09.033; MCCULLOUGH KC, 1992, J VIROL, V66, P1835, DOI 10.1128/JVI.66.4.1835-1840.1992; MCCULLOUGH KC, 1988, IMMUNOLOGY, V65, P187; Monso M, 2013, BIOCONJUGATE CHEM, V24, P578, DOI 10.1021/bc300515t; Moraes MP, 2002, VACCINE, V20, P1631, DOI 10.1016/S0264-410X(01)00483-2; OIE, 2017, MANUAL DIAGNOSTIC TE; Orsel K, 2007, VACCINE, V25, P6381, DOI 10.1016/j.vaccine.2007.06.010; Orsel K, 2005, VACCINE, V23, P4887, DOI 10.1016/j.vaccine.2005.05.014; Orsel K, 2009, CAN VET J, V50, P1059; Pega J, 2015, J VIROL, V89, P9581, DOI 10.1128/JVI.01082-15; Pega J, 2013, J VIROL, V87, P2489, DOI 10.1128/JVI.02879-12; Porta C, 2013, J VIROL METHODS, V187, P406, DOI 10.1016/j.jviromet.2012.11.011; Quattrocchi V, 2014, VACCINE, V32, P2167, DOI 10.1016/j.vaccine.2014.02.061; Quattrocchi V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00037; Rodriguez LL, 2003, VACCINE, V21, P3751, DOI 10.1016/S0264-410X(03)00364-5; Sadler Kristen, 2002, J Biotechnol, V90, P195; SELLERS RF, 1971, LANCET, V1, P1238; STABEL JR, 1995, VET IMMUNOL IMMUNOP, V45, P211, DOI 10.1016/0165-2427(94)05348-V; Taboga O, 1997, J VIROL, V71, P2606, DOI 10.1128/JVI.71.4.2606-2614.1997; Tekleghiorghis T, 2014, CLIN VACCINE IMMUNOL, V21, P674, DOI 10.1128/CVI.00034-14; ZAMORANO P, 1994, VIROLOGY, V201, P383, DOI 10.1006/viro.1994.1305; Zamorano PI, 1998, VACCINE, V16, P558, DOI 10.1016/S0264-410X(97)00244-2; Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045	43	16	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2017	12	9							e0185184	10.1371/journal.pone.0185184	http://dx.doi.org/10.1371/journal.pone.0185184			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI1DL	28949998	Green Submitted, Green Published, gold			2023-01-03	WOS:000411671000029
J	Yacoub, R; Nugent, M; Cai, WJ; Nadkarni, GN; Chaves, LD; Abyad, S; Honan, AM; Thomas, SA; Zheng, W; Valiyaparambil, SA; Bryniarski, MA; Sun, YJ; Buck, M; Genco, RJ; Quigg, RJ; He, JC; Uribarri, J				Yacoub, Rabi; Nugent, Melinda; Cai, Weijin; Nadkarni, Girish N.; Chaves, Lee D.; Abyad, Sham; Honan, Amanda M.; Thomas, Shruthi A.; Zheng, Wei; Valiyaparambil, Sujith A.; Bryniarski, Mark A.; Sun, Yijun; Buck, Michael; Genco, Robert J.; Quigg, Richard J.; He, John C.; Uribarri, Jaime			Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial	PLOS ONE			English	Article							INTESTINAL MICROBIOTA; RENAL-FAILURE; GLYCOTOXINS; GLYCOXIDATION; ACCUMULATION; ENDPRODUCTS; OBESITY; INFLAMMATION; DIVERSITY; PRECEDES	The modern Western diet is rich in advanced glycation end products (AGEs). We have previously shown an association between dietary AGEs and markers of inflammation and oxidative stress in a population of end stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD). In the current pilot study we explored the effects of dietary AGEs on the gut bacterial microbiota composition in similar patients. AGEs play an important role in the development and progression of cardiovascular (CVD) disease. Plasma concentrations of different bacterial products have been shown to predict the risk of incident major adverse CVD events independently of traditional CVD risk factors, and experimental animal models indicates a possible role AGEs might have on the gut microbiota population. In this pilot randomized open label controlled trial, twenty PD patients habitually consuming a high AGE diet were recruited and randomized into either continuing the same diet (HAGE, n = 10) or a one-month dietary AGE restriction (LAGE, n = 10). Blood and stool samples were collected at baseline and after intervention. Variable regions V3-V4 of 16s rDNA were sequenced and taxa was identified on the phyla, genus, and species levels. Dietary AGE restriction resulted in a significant decrease in serum N-epsilon-(carboxymethyl) lysine (CML) and methylglyoxal-derivatives (MG). At baseline, our total cohort exhibited a lower relative abundance of Bacteroides and Alistipes genus and a higher abundance of Prevotella genus when compared to the published data of healthy population. Dietary AGE restriction altered the bacterial gut microbiota with a significant reduction in Prevotella copri and Bifidobacterium animalis relative abundance and increased Alistipes indistinctus, Clostridium citroniae, Clostridium hathewayi, and Ruminococcus gauvreauii relative abundance. We show in this pilot study significant microbiota differences in peritoneal dialysis patients' population, as well as the effects of dietary AGEs on gut microbiota, which might play a role in the increased cardiovascular events in this population and warrants further studies.	[Yacoub, Rabi; Chaves, Lee D.; Abyad, Sham; Honan, Amanda M.; Thomas, Shruthi A.; Quigg, Richard J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Internal Med, Buffalo, NY 14260 USA; [Nugent, Melinda; Cai, Weijin; Nadkarni, Girish N.; He, John C.; Uribarri, Jaime] Icahn Sch Med Mt Sinai, Dept Internal Med, New York, NY 10029 USA; [Zheng, Wei] SUNY Buffalo, Dept Comp Sci & Engn, Buffalo, NY USA; [Valiyaparambil, Sujith A.; Buck, Michael] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY USA; [Bryniarski, Mark A.] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Phamaceut Sci, Buffalo, NY USA; [Sun, Yijun] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY USA; [Genco, Robert J.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Oral Biol, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yacoub, R (corresponding author), SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Internal Med, Buffalo, NY 14260 USA.	rabiyaco@buffalo.edu			National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001412]; NIH; University at Buffalo Genome, Environment and Microbiome (GEM); department fund; Innovative Micro-Programs Accelerating Collaboration in Themes (IMPACT); National Institute of Diabetes and Digestive and Kidney Diseases [K23DK107908-01A1]; NIH [R01A1125982, R01DE024523];  [101BX000345];  [R01DK078897]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI125982] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University at Buffalo Genome, Environment and Microbiome (GEM); department fund; Innovative Micro-Programs Accelerating Collaboration in Themes (IMPACT); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo and by the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This was also supported by University at Buffalo Genome, Environment and Microbiome (GEM), and department fund for RY and LC. Innovative Micro-Programs Accelerating Collaboration in Themes (IMPACT) for RY. GNK is supported by National Institute of Diabetes and Digestive and Kidney Diseases, K23DK107908-01A1. YS is supported by NIH R01A1125982, R01DE024523. JCH is supported by 101BX000345, R01DK078897.	Ahmad S, 2014, GLYCOBIOLOGY, V24, P979, DOI 10.1093/glycob/cwu057; Aikawa E, 2016, STEM CELLS DEV, V25, P1721, DOI 10.1089/scd.2016.0067; Ames JM, 1999, BRIT J NUTR, V82, P489, DOI 10.1017/S0007114599001749; Baig MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06067-5; Baothman OA, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0278-4; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; Bohlender JM, 2005, AM J PHYSIOL-RENAL, V289, pF645, DOI 10.1152/ajprenal.00398.2004; Borrelli RC, 2005, MOL NUTR FOOD RES, V49, P673, DOI 10.1002/mnfr.200500011; Boulange CL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0303-2; Busch M, 2010, EUR J CLIN INVEST, V40, P742, DOI 10.1111/j.1365-2362.2010.02317.x; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chen YP, 2016, J ETHNOPHARMACOL, V194, P850, DOI 10.1016/j.jep.2016.10.079; Cho Y, 2013, NEPHROL DIAL TRANSPL, V28, P1899, DOI 10.1093/ndt/gft050; Coyte KZ, 2015, SCIENCE, V350, P663, DOI 10.1126/science.aad2602; Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222; Ding T, 2014, NATURE, V509, P357, DOI 10.1038/nature13178; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Eid HM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00387; Flint HJ, 2008, NAT REV MICROBIOL, V6, P121, DOI 10.1038/nrmicro1817; Ghazalpour A, 2016, CURR OPIN LIPIDOL, V27, P141, DOI 10.1097/MOL.0000000000000278; Gkogkolou P, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22028; Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214; Hartog JWL, 2005, ANN NY ACAD SCI, V1043, P299, DOI 10.1196/annals.1333.037; He CJ, 1999, DIABETES, V48, P1308, DOI 10.2337/diabetes.48.6.1308; Hegab Z, 2012, WORLD J CARDIOL, V4, P90, DOI 10.4330/wjc.v4.i4.90; Henle T, 2003, KIDNEY INT, V63, pS145, DOI 10.1046/j.1523-1755.63.s84.16.x; Kellow NJ, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472-6823-14-55; Kim D, 2016, ARTHRITIS RHEUMATOL, V68, P2565, DOI 10.1002/art.39807; Knip M, 2016, NAT REV ENDOCRINOL, V12, P154, DOI 10.1038/nrendo.2015.218; KORBET SM, 1993, AM J KIDNEY DIS, V22, P588, DOI 10.1016/S0272-6386(12)80933-4; Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474; Lan PG, 2014, CLIN J AM SOC NEPHRO, V9, P1091, DOI 10.2215/CJN.09730913; Louis P, 2009, FEMS MICROBIOL LETT, V294, P1, DOI 10.1111/j.1574-6968.2009.01514.x; Luevano-Contreras C, 2010, NUTRIENTS, V2, P1247, DOI 10.3390/nu2121247; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; McNally L, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2015.16, 10.1038/NMICROBIOL.2015.16]; Meerwaldt R, 2005, DIABETOLOGIA, V48, P1637, DOI 10.1007/s00125-005-1828-x; Moschen AR, 2016, CELL HOST MICROBE, V19, P455, DOI 10.1016/j.chom.2016.03.007; Musso G, 2010, DIABETES CARE, V33, P2277, DOI 10.2337/dc10-0556; Nara N, 2013, CLIN IMMUNOL, V146, P112, DOI 10.1016/j.clim.2012.12.001; Noordzij MJ, 2008, J REN CARE, V34, P207, DOI 10.1111/j.1755-6686.2008.00038.x; OBRIEN J, 1989, CRIT REV FOOD SCI, V28, P211, DOI 10.1080/10408398909527499; Ottum MS, 2015, J CLIN BIOCHEM NUTR, V57, P1, DOI 10.3164/jcbn.15-3; Peppa M, 2008, CURR DIABETES REV, V4, P92, DOI 10.2174/157339908784220732; Prasad A, 2012, CARDIOL REV, V20, P177, DOI 10.1097/CRD.0b013e318244e57c; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rosenbaum JT, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0614-8; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sanders ME, 2006, J CLIN GASTROENTEROL, V40, P776, DOI 10.1097/01.mcg.0000225576.73385.f0; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074; Shekhtman A., 2016, EXPERT REV PROTEOMIC, P1; Singh VP, 2014, KOREAN J PHYSIOL PHA, V18, P1, DOI 10.4196/kjpp.2014.18.1.1; Stirban A, 2014, MOL METAB, V3, P94, DOI 10.1016/j.molmet.2013.11.006; Tilg H, 2011, J CLIN INVEST, V121, P2126, DOI 10.1172/JCI58109; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Turroni F, 2009, APPL ENVIRON MICROB, V75, P1534, DOI 10.1128/AEM.02216-08; Uribarri J, 2003, J AM SOC NEPHROL, V14, P728, DOI 10.1097/01.ASN.0000051593.41395.B9; Uribarri J, 2007, J GERONTOL A-BIOL, V62, P427, DOI 10.1093/gerona/62.4.427; Uribarri J, 2010, J AM DIET ASSOC, V110, P911, DOI 10.1016/j.jada.2010.03.018; Vaziri ND, 2013, KIDNEY INT, V83, P308, DOI 10.1038/ki.2012.345; Vlassara H, 2004, REV ENDOCR METAB DIS, V5, P181, DOI 10.1023/B:REMD.0000032406.84813.f6; Woting A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040202; Yu T, 2017, EXP MOL PATHOL, V102, P7, DOI 10.1016/j.yexmp.2016.12.002; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593	68	70	71	4	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0184789	10.1371/journal.pone.0184789	http://dx.doi.org/10.1371/journal.pone.0184789			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931089	Green Published, gold, Green Submitted			2023-01-03	WOS:000411314700036
J	Cebolla, A; Demarzo, M; Martins, P; Soler, J; Garcia-Campayo, J				Cebolla, Ausias; Demarzo, Marcelo; Martins, Patricia; Soler, Joaquim; Garcia-Campayo, Javier			Unwanted effects: Is there a negative side of meditation? A multicentre survey	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIALS; PSYCHOLOGICAL TREATMENTS; BODY AWARENESS; MINDFULNESS; PSYCHOTHERAPY; METAANALYSIS; INTERVENTIONS; PERSPECTIVE; MECHANISMS; THERAPY	Objectives Despite the long-term use and evidence-based efficacy of meditation and mindfulness-based interventions, there is still a lack of data about the possible unwanted effects (UEs) of these practices. The aim of this study was to evaluate the occurrence of UEs among meditation practitioners, considering moderating factors such as the type, frequency, and lifetime duration of the meditation practices. Methods An online survey was developed and disseminated through several websites, such as Spanish-, English- and Portuguese-language scientific research portals related to mindfulness and meditation. After excluding people who did not answer the survey correctly or completely and those who had less than two months of meditation experience, a total of 342 people participated in the study. However, only 87 reported information about UEs. Results The majority of the practitioners were women from Spain who were married and had a University education level. Practices were more frequently informal, performed on a daily basis, and followed by focused attention (FA). Among the participants, 25.4% reported UEs, showing that severity varies considerably. The information requested indicated that most of the UEs were transitory and did not lead to discontinuing meditation practice or the need for medical assistance. They were more frequently reported in relation to individual practice, during focused attention meditation, and when practising for more than 20 minutes and alone. The practice of body awareness was associated with UEs to a lesser extent, whereas focused attention was associated more with UEs. Conclusions This is the first large-scale, multi-cultural study on the UEs of meditation. Despite its limitations, this study suggests that UEs are prevalent and transitory and should be further studied. We recommend the use of standardized questionnaires to assess the UEs of meditation practices.	[Cebolla, Ausias] Univ Valencia, Valencia, Spain; [Cebolla, Ausias] Inst Salud Carlos III, CIBER Fisiopatol Obesidad Nutr CIBEROBN, Madrid, Spain; [Demarzo, Marcelo; Martins, Patricia] Univ Fed Sao Paulo, Mente Aberta Brazilian Ctr Mindfulness & Hlth Pro, Sao Paulo, Brazil; [Demarzo, Marcelo] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Soler, Joaquim] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Soler, Joaquim] Inst Invest Biomed Sant Pau IIB SantPau, Barcelona, Spain; [Soler, Joaquim] Univ Autonoma Barcelona, Psychiat & Legal Med Dept, Barcelona, Spain; [Soler, Joaquim] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain; [Garcia-Campayo, Javier] Hosp Univ Miguel Servet, Zaragoza, Spain; [Garcia-Campayo, Javier] Inst Aragones Ciencias Salud, Zaragoza, Spain; [Garcia-Campayo, Javier] Red Invest Actividades Prevenc Promoc Salud REDIA, Zaragoza, Spain	University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert Einstein; Hospital of Santa Creu i Sant Pau; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III; Miguel Servet University Hospital	Cebolla, A (corresponding author), Univ Valencia, Valencia, Spain.; Cebolla, A (corresponding author), Inst Salud Carlos III, CIBER Fisiopatol Obesidad Nutr CIBEROBN, Madrid, Spain.	ausias.cebolla@uv.es	Marti, Ausias Cebolla/E-8410-2012; Demarzo, Marcelo/A-7021-2010	Marti, Ausias Cebolla/0000-0002-3456-9743; Demarzo, Marcelo/0000-0002-7447-1839; Soler, Joaquim/0000-0001-8077-3641; Garcia-Campayo, Javier/0000-0002-3797-4218	Network for Prevention and Health Promotion in primary Care - Institute de Salud Carlos III of the Ministry of Economy and Competitiveness (Spain) [RD12/0005/0006]; European Union ERDF funds (FEDER "Una manera de hacer Europa"); Red de Excelencia PROMOSAM [13512014-56303-REDT]; Ministry of Economy and Competitiveness (Spain) (Plan Nacional I+D+I) [13512013-41783-R]	Network for Prevention and Health Promotion in primary Care - Institute de Salud Carlos III of the Ministry of Economy and Competitiveness (Spain); European Union ERDF funds (FEDER "Una manera de hacer Europa"); Red de Excelencia PROMOSAM; Ministry of Economy and Competitiveness (Spain) (Plan Nacional I+D+I)	The project has received funding from the Network for Prevention and Health Promotion in primary Care (RD12/0005/0006) grant from the Institute de Salud Carlos III of the Ministry of Economy and Competitiveness (Spain), co financed with European Union ERDF funds (FEDER "Una manera de hacer Europa"). The funding source did not have any influence on the design of the study, data collection and analysis or writing of the manuscript.; CIBEROBN is an initiative of the ISCIII. Ministry of Economy and Competitiveness (Spain) (Plan Nacional I+D+I. 13512013-41783-R). We thank the Red de Excelencia PROMOSAM (13512014-56303-REDT) for its support in the development of this study.	Banks K, 2015, J CLIN PSYCHOL, V71, P935, DOI 10.1002/jclp.22200; Barlow DH, 2010, AM PSYCHOL, V65, P13, DOI 10.1037/a0015643; Berk M, 2009, AUST NZ J PSYCHIAT, V43, P787, DOI 10.1080/00048670903107559; Boettcher J., 2014, INTERNET INTERVENTIO, V1, P3, DOI [10.1016/j.invent.2014.02.002, DOI 10.1016/J.INVENT.2014.02.002]; Bohlmeijer E, 2010, J PSYCHOSOM RES, V68, P539, DOI 10.1016/j.jpsychores.2009.10.005; Buddhaghosa B., 1999, VISSUDHIMAGGA PATH P; Bystedt S, 2014, COGN BEHAV THERAPY, V43, P319, DOI 10.1080/16506073.2014.939593; Cebolla A, 2016, MINDFULNESS, V7, P1297, DOI 10.1007/s12671-016-0569-x; Cramer H, 2015, AM J EPIDEMIOL, V182, P281, DOI 10.1093/aje/kwv071; Dahl CJ, 2015, TRENDS COGN SCI, V19, P515, DOI 10.1016/j.tics.2015.07.001; Dalai Lama HH, 2001, STAGES OF MEDITATION; Dimidjian S, 2010, AM PSYCHOL, V65, P21, DOI 10.1037/a0017299; Dobkin PL, 2012, MINDFULNESS, V3, P44, DOI 10.1007/s12671-011-0079-9; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; FRENCH AP, 1975, J NERV MENT DIS, V161, P55, DOI 10.1097/00005053-197507000-00007; Grabovac A, 2015, MINDFULNESS, V6, P589, DOI 10.1007/s12671-014-0294-2; Guimaraes LP, 2012, REV BRASILEIRA FARMA, V3, P15; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Jaseja H, 2006, MED HYPOTHESES, V66, P925, DOI 10.1016/j.mehy.2005.11.043; Jonsson U, 2014, CONTEMP CLIN TRIALS, V38, P1, DOI 10.1016/j.cct.2014.02.005; Josipovic Z, 2015, FRONT PSYCHOL, P6; Keng SL, 2011, CLIN PSYCHOL REV, V31, P1041, DOI 10.1016/j.cpr.2011.04.006; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Kuijpers HJH, 2007, PSYCHOPATHOLOGY, V40, P461, DOI 10.1159/000108125; Kuyken W, 2015, LANCET, V386, P63, DOI 10.1016/S0140-6736(14)62222-4; Lindahl JR, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00973; Linden M, 2014, WORLD PSYCHIATRY, V13, P306, DOI 10.1002/wps.20153; Linden M, 2013, CLIN PSYCHOL PSYCHOT, V20, P286, DOI 10.1002/cpp.1765; LINGJAERDE O, 1987, ACTA PSYCHIAT SCAND, V76, P7; Lustyk M Kathleen B, 2009, Adv Mind Body Med, V24, P20; Nakaya M., 2010, GER J PSYCHIAT, V13, P161; Otis L. S., 1984, MEDITATION CLASSIC C, P201; Petry NM, 2008, J CONSULT CLIN PSYCH, V76, P1076, DOI 10.1037/a0013679; Quezada-Berumen LD, 2014, ACTAS ESP PSIQUIATRI, V42, P57; Shapiro D H Jr, 1992, Int J Psychosom, V39, P62; Shonin E, 2014, BRIT J GEN PRACT, V64, P368, DOI 10.3399/bjgp14X680725; Siff J., 2005, INSIGHT J, V24, P24; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; Tran US, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110192; WALSH R, 1979, AM J PSYCHIAT, V136, P1085; Yorston G.A., 2001, MENTAL HLTH RELIG CU, V4, P209, DOI DOI 10.1080/713685624	41	75	75	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2017	12	9							e0183137	10.1371/journal.pone.0183137	http://dx.doi.org/10.1371/journal.pone.0183137			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FF8QL	28873417	Green Published, Green Submitted, gold			2023-01-03	WOS:000409282800011
J	Zhang, JQ; Yu, JD; Bao, Y; Xie, Q; Xu, Y; Zhang, JM; Wang, P				Zhang, Jiaqi; Yu, Jiadan; Bao, Yong; Xie, Qing; Xu, Yang; Zhang, Junmei; Wang, Pu			Constraint-induced aphasia therapy in post-stroke aphasia rehabilitation: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							INDUCED MOVEMENT THERAPY; INDUCED LANGUAGE THERAPY; QUALITY-OF-LIFE; CLINICAL-TRIAL; MIRROR THERAPY; STROKE; RECOVERY; PILOT; REORGANIZATION; INDIVIDUALS	Background Constraint-induced aphasia therapy (CIAT) has been widely used in post-stroke aphasia rehabilitation. An increasing number of clinical controlled trials have investigated the efficacy of the CIAT for the post-stroke aphasia. Purpose To systematically review the randomized controlled trials (RCTs) concerning the effect of the CIAT in post-stroke patients with aphasia, and to identify the useful components of CIAT in post-stroke aphasia rehabilitation. Methods A computerized database search was performed through five databases (Pubmed, EMbase, Medline, ScienceDirect and Cochrane library). Cochrane handbook domains were used to evaluate the methodological quality of the included RCTs. Results Eight RCTs qualified in the inclusion criteria. Inconsistent results were found in comparing the CIAT with conventional therapies without any component from the CIAT based on the results of three RCTs. Five RCTs showed that the CIAT performed equally well as other intensive aphasia therapies, in terms of improving language performance. One RCT showed that therapies embedded with social interaction were likely to enhance the efficacy of the CIAT. Conclusion CIAT may be useful for improving chronic post-stroke aphasia, however, limited evidence to support its superiority to other aphasia therapies. Massed practice is likely to be a useful component of CIAT, while the role of constraint is needed to be further explored. CIAT embedded with social interaction may gain more benefits.	[Zhang, Jiaqi] Chinese Univ Hong Kong, Fac Med, Master Sci Neurol Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jiadan; Xu, Yang] Sichuan Univ, West China Sch Med, Sch Rehabil Sci, Chengdu, Sichuan, Peoples R China; [Bao, Yong] Shanghai Jiao Tong Univ, Ruijin Rehabil Hosp, Shanghai, Peoples R China; [Xie, Qing; Wang, Pu] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Rehabil Med, Shanghai, Peoples R China; [Zhang, Junmei] Wuhan Univ Technol, Dept Phys Educ, Wuhan, Peoples R China	Chinese University of Hong Kong; Sichuan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Wuhan University of Technology	Wang, P (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Rehabil Med, Shanghai, Peoples R China.	wangpu_03@126.com		/0000-0001-5783-3693; Yu, Jiadan/0000-0002-9660-8736; ZHANG, Jack Jiaqi/0000-0002-4656-1909				Balardin Joana Bisol, 2009, Dement. neuropsychol., V3, P275, DOI 10.1590/S1980-57642009DN30400003; Bang DH, 2015, NEUROREHABILITATION, V37, P131, DOI 10.3233/NRE-151245; Berthier ML, 2011, NEUROPSYCHOL REV, V21, P302, DOI 10.1007/s11065-011-9177-7; Boehme AK, 2016, NEUROLOGY, V87, P2348, DOI 10.1212/WNL.0000000000003297; Brady MC, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000425.pub3, 10.1002/14651858.CD000425.pub4]; Breier JI, 2009, ARCH PHYS MED REHAB, V90, P2026, DOI 10.1016/j.apmr.2009.08.144; Chen WL, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01665; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); Ciccone N, 2016, APHASIOLOGY, V30, P566, DOI 10.1080/02687038.2015.1071480; Difrancesco S, 2012, APHASIOLOGY, V26, P1317, DOI 10.1080/02687038.2012.705815; Dignam J, 2015, STROKE, V46, P2206, DOI 10.1161/STROKEAHA.115.009522; Dignam JK, 2016, PM&R, V8, P254, DOI 10.1016/j.pmrj.2015.06.010; Fama ME, 2016, TOP STROKE REHABIL, V23, P276, DOI 10.1080/10749357.2016.1155277; Fang YN, 2003, CLIN REHABIL, V17, P608, DOI 10.1191/0269215503cr655oa; Hamilton RH, 2011, BRAIN LANG, V118, P40, DOI 10.1016/j.bandl.2011.02.005; Hung GKN, 2015, HONG KONG J OCCUP TH, V26, P51, DOI 10.1016/j.hkjot.2015.12.003; Johnson ML, 2014, AM J SPEECH-LANG PAT, V23, P60, DOI 10.1044/1058-0360(2013/12-0168); Kavian S, 2014, INT J PREVENTIVE MED, V5, P782; Koleck M, 2017, QUAL LIFE RES, V26, P45, DOI 10.1007/s11136-016-1361-z; Kristensen LF, 2015, APHASIOLOGY, V29, P1152, DOI 10.1080/02687038.2015.1028328; Kurland J, 2016, AM J SPEECH-LANG PAT, V25, pS798, DOI 10.1044/2016_AJSLP-15-0135; Kurland J, 2012, AM J SPEECH-LANG PAT, V21, pS65, DOI 10.1044/1058-0360(2012/11-0113); Lee H, 2015, YONSEI MED J, V56, P1694, DOI 10.3349/ymj.2015.56.6.1694; Leung DPK, 2009, HUM MOVEMENT SCI, V28, P798, DOI 10.1016/j.humov.2009.04.006; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maher LM, 2006, J INT NEUROPSYCH SOC, V12, P843, DOI 10.1017/S1355617706061029; Meinzer M, 2005, STROKE, V36, P1462, DOI 10.1161/01.STR.0000169941.29831.2a; Meinzer M, 2007, J INT NEUROPSYCH SOC, V13, P846, DOI 10.1017/S1355617707071111; Meinzer M, 2007, NEUROREHABILITATION, V22, P311; Meinzer M, 2012, ARCH PHYS MED REHAB, V93, pS35, DOI 10.1016/j.apmr.2011.06.040; Mohr B, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00919; Mohr B, 2016, NEUROPSYCHOLOGIA, V93, P413, DOI 10.1016/j.neuropsychologia.2016.04.006; Morris DM, 1997, NEUROREHABILITATION, V9, P29, DOI 10.3233/NRE-1997-9104; Mozeiko J, 2016, APHASIOLOGY, V30, P339, DOI 10.1080/02687038.2015.1070949; Nickels L, 2016, NEUROREHABILITATION, V39, P97, DOI 10.3233/NRE-161341; Norise C, 2017, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00675; Pulvermuller F, 2005, NEUROIMAGE, V28, P481, DOI 10.1016/j.neuroimage.2005.06.038; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Rosbergen ICM, 2017, CLIN REHABIL, V31, P1516, DOI 10.1177/0269215517705181; Rose ML, 2013, AM J SPEECH-LANG PAT, V22, pS227, DOI 10.1044/1058-0360(2012/12-0091); Sickert A, 2014, J NEUROL NEUROSUR PS, V85, P51, DOI 10.1136/jnnp-2012-304297; Stahl B, 2016, CORTEX, V85, P90, DOI 10.1016/j.cortex.2016.09.021; Szaflarski JP, 2008, MED SCI MONITOR, V14, pCR243; Szaflarski JP, 2015, MED SCI MONITOR, V21, P2861, DOI 10.12659/MSM.894291; Thrane G, 2014, J REHABIL MED, V46, P833, DOI 10.2340/16501977-1859; Toh SFM, 2012, HONG KONG J OCCUP TH, V22, P84, DOI 10.1016/j.hkjot.2012.12.009; van de Sandt-Koenderman ME, 2012, ARCH PHYS MED REHAB, V93, pS1, DOI 10.1016/j.apmr.2011.08.037; Wilssens I, 2015, AM J SPEECH-LANG PAT, V24, P281, DOI 10.1044/2015_AJSLP-14-0018; Woldag H, 2017, NEUROREHAB NEURAL RE, V31, P72, DOI 10.1177/1545968316662707; Yu KW, 2014, J NEUROL SCI, V347, P275, DOI 10.1016/j.jns.2014.10.022	50	24	25	2	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2017	12	8							e0183349	10.1371/journal.pone.0183349	http://dx.doi.org/10.1371/journal.pone.0183349			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE8EO	28846724	Green Published, gold, Green Submitted			2023-01-03	WOS:000408438600026
J	Dienstmann, R; Tabernero, J				Dienstmann, Rodrigo; Tabernero, Josep			CANCER A precision approach to tumour treatment	NATURE			English	Editorial Material							COLORECTAL-CANCER; MEDICINE; MODELS		[Dienstmann, Rodrigo] Vall dHebron Inst Oncol, Barcelona 08035, Spain; [Dienstmann, Rodrigo] Sage Bionetworks, Seattle, WA 98109 USA; [Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Dienstmann, R (corresponding author), Vall dHebron Inst Oncol, Barcelona 08035, Spain.; Dienstmann, R (corresponding author), Sage Bionetworks, Seattle, WA 98109 USA.	rdienstmann@vhio.net; jtabernero@vhio.net	He, Liye/C-8843-2015; Tabernero, Josep/AAG-5026-2019	He, Liye/0000-0002-6632-2112; Tabernero, Josep/0000-0002-2495-8139				Crespo M, 2017, NAT MED, V23, P878, DOI 10.1038/nm.4355; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Pauli C, 2017, CANCER DISCOV, V7, P462, DOI 10.1158/2159-8290.CD-16-1154; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053	6	20	22	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 3	2017	548	7665					40	41		10.1038/nature23101	http://dx.doi.org/10.1038/nature23101			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC4SU	28723897				2023-01-03	WOS:000406831700032
J	Li, Q; Zhang, ZH; Xie, B; Ji, XW; Lu, JH; Jiang, RL; Lei, S; Mao, SH; Ying, LJ; Lu, D; Si, XS; Ji, MX; He, JX; Chen, MY; Zheng, WJ; Wang, J; Huang, J; Wang, JF; Ji, YL; Chen, GD; Zhu, JH; Shao, YD; Lin, RH; Zhang, C; Zhang, WW; Luo, J; Lou, TZ; He, XW; Chen, K; Peng, W; Sun, RH				Li, Qian; Zhang, Zhongheng; Xie, Bo; Ji, Xiaowei; Lu, Jiahong; Jiang, Ronglin; Lei, Shu; Mao, Shihao; Ying, Lijun; Lu, Di; Si, Xiaoshui; Ji, Mingxia; He, Jianxing; Chen, Mengyan; Zheng, Wenjuan; Wang, Jiao; Huang, Jing; Wang, Junfeng; Ji, Yaling; Chen, Guodong; Zhu, Jianhua; Shao, Yadi; Lin, Ronghai; Zhang, Chao; Zhang, Weiwen; Luo, Jian; Lou, Tianzheng; He, Xuwei; Chen, Kun; Peng, Wei; Sun, Renhua			Effectiveness of enteral feeding protocol on clinical outcomes in critically ill patients: A before and after study	PLOS ONE			English	Article							BIG DATA; PARENTERAL-NUTRITION; MULTICENTER; METAANALYSIS; VOLUME; ROUTE; RISK	Background and objective Enteral nutrition (EN) feeding protocol was proposed to have positive impact on critically ill patients. However, current studies showed conflicting results. The present study aimed to investigate whether enteral feeding protocol was able to improve clinical outcomes in critically ill patients. Methods A before (stage 1) and after (stage 2) interventional study was performed in 10 tertiary care hospitals. All patients expected to stay in the intensive care unit (ICU) for over three days were potentially eligible. Clinical outcomes such as 28-day mortality, ICU length of stay, duration of mechanical ventilation (MV), and nosocomial infection were compared between the two stages. Main results A total of 410 patients were enrolled during the study period, including 236 in stage 1 and 174 in stage 2. EN feeding protocol was able to increase the proportion of EN in day 2 (41.8 +/- 22.3 vs. 50.0 +/- 28.3%; p = 0.006) and day 6 (70.3 +/- 25.2 vs. 77.6 +/- 25.8%; p = 0.006). EN percentages tended to be higher in stage 1 than that in stage 2 on other days, but statistical significance was not reached. There was no difference in 28-day mortality between stage 1 and 2 (0.14 vs. 0.14; p = 0.984). Implementation of EN feeding protocol marginally reduced ICU length of stay (19.44 +/- 18.48 vs. 16.29 +/- 16.19 days; p = 0.077). There was no difference in the duration of MV between stage a and stage 2 (14.24 +/- 14.49 vs. 14.51 +/- 17.55 days; p = 0.877). Conclusions The study found that the EN feeding protocol was able to increase the proportion of EN feeding, but failed to reduce 28-day mortality, incidence of nosocomial infection or duration of MV.	[Li, Qian; Sun, Renhua] Zhejiang Prov Peoples Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China; [Zhang, Zhongheng] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Emergency Med, Hangzhou, Zhejiang, Peoples R China; [Xie, Bo; Ji, Xiaowei; Lu, Jiahong] Huzhou Cent Hosp, Dept Crit Care Med, Huzhou, Zhejiang, Peoples R China; [Jiang, Ronglin; Lei, Shu; Mao, Shihao] Zhejiang Prov Hosp TCM, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China; [Ying, Lijun; Lu, Di] Shaoxing Peoples Hosp, Dept Crit Care Med, Shaoxing, Zhejiang, Peoples R China; [Si, Xiaoshui; Ji, Mingxia; He, Jianxing; Chen, Mengyan; Zheng, Wenjuan; Wang, Jiao; Huang, Jing; Wang, Junfeng; Ji, Yaling] YiWu Cent Hosp, Dept Crit Care Med, Jinhua, Zhejiang, Peoples R China; [Chen, Guodong; Zhu, Jianhua; Shao, Yadi] NingBo First Hosp, Dept Crit Care Med, Ningbo, Zhejiang, Peoples R China; [Lin, Ronghai; Zhang, Chao] TaiZhou Hosp, Dept Crit Care Med, Taizhou, Zhejiang, Peoples R China; [Zhang, Weiwen; Luo, Jian] QuZhou Peoples Hosp, Dept Crit Care Med, Quzhou, Zhejiang, Peoples R China; [Lou, Tianzheng; He, Xuwei] LiShui Peoples Hosp, Dept Crit Care Med, Lishui, Zhejiang, Peoples R China; [Chen, Kun; Peng, Wei] Zhejiang Univ, Jinhua Hosp, Jinhua Municipal Cent Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China	Zhejiang Provincial People's Hospital; Zhejiang University; Huzhou University; Zhejiang Chinese Medical University; Zhejiang University	Sun, RH (corresponding author), Zhejiang Prov Peoples Hosp, Dept Crit Care Med, Hangzhou, Zhejiang, Peoples R China.	zjpphicu@126.com	zhang, zh/GWV-4677-2022; Zhang, Zhongheng/E-1282-2011	Zhang, Zhongheng/0000-0002-2336-5323; Li, Qian/0000-0001-7311-105X				Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1539-3; Arabi YM, 2011, AM J CLIN NUTR, V93, P569, DOI 10.3945/ajcn.110.005074; Compton F, 2014, AM J CRIT CARE, V23, P396, DOI 10.4037/ajcc2014140; Ventura AMC, 2015, NUTR CLIN PRACT, V30, P351, DOI 10.1177/0884533614547765; Cunningham CA, 2017, JPEN J PARENTER ENTE, V170; Declercq B, 2016, ANAESTH INTENS CARE, V44, P93, DOI 10.1177/0310057X1604400114; Desachy A, 2008, INTENS CARE MED, V34, P1054, DOI 10.1007/s00134-007-0983-6; Elke G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1298-1; Franzosi OS, 2017, NUTR HOSP, V34, P19, DOI [10.20960/nh.971, 10.20960/nh.443]; Gavri C, 2016, CLIN NUTR ESPEN, V12, pE14, DOI 10.1016/j.clnesp.2016.01.002; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; Haskins IN, 2015, JPEN J PARENTER ENTE, V42; Havens JM, 2016, JPEN J PARENTER ENTE, V43; Heyland DK, 2015, CLIN NUTR, V34, P659, DOI 10.1016/j.clnu.2014.07.008; Heyland DK, 2010, CRIT CARE, V14, DOI 10.1186/cc8991; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Hofman Z, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0220-y; Kim SH, 2017, ASIA PAC J CLIN NUTR, V26, P27, DOI 10.6133/apjcn.122015.01; Kuppinger DD, 2013, NUTRITION, V29, P1075, DOI 10.1016/j.nut.2013.01.025; Kuslapuu M, 2015, INTENS CRIT CARE NUR, V31, P309, DOI 10.1016/j.iccn.2015.03.001; Lew CCH, 2016, JPEN J PARENTER ENTE, V5; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; McClave SA, 2015, JPEN-PARENTER ENTER, V39, P707, DOI 10.1177/0148607114540004; Mehta NM, 2012, CRIT CARE MED, V40, P2204, DOI 10.1097/CCM.0b013e31824e18a8; Ming-Chao F, 2016, CHIN MED SCI J, V31, P213; Padar Martin, 2017, World J Crit Care Med, V6, P56, DOI 10.5492/wjccm.v6.i1.56; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Stewart ML, 2014, WORLDV EVID-BASED NU, V11, P194, DOI 10.1111/wvn.12036; Su YY, 2016, ASIA PAC J CLIN NUTR, V25, P521, DOI 10.6133/apjcn.092015.20; Wang D, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0094-0; Wilson Sara, 2016, World J Crit Care Med, V5, P180, DOI 10.5492/wjccm.v5.i3.180; Zhang Z., 2017, J EMERGENCY CRITICAL, V1; Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.07.15; Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.02.15; Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.3978/j.issn.2305-5839.2015.12.38; Zhang ZH, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.12.11; Zhang ZH, 2015, J THORAC DIS, V7, P238, DOI 10.3978/j.issn.2072-1439.2015.02.14; Zhang ZH, 2014, J THORAC DIS, V6, P1659, DOI 10.3978/j.issn.2072-1439.2014.12.12; Zhang ZH, 2014, QUANT IMAGING MED SU, V4, P426, DOI 10.3978/j.issn.2223-4292.2014.09.03; Zhang ZH, 2014, J CRIT CARE, V29, P865, DOI 10.1016/j.jcrc.2014.06.015; Zhang ZH, 2014, J THORAC DIS, V6, P995, DOI 10.3978/j.issn.2072-1439.2014.07.01	41	11	16	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2017	12	8							e0182393	10.1371/journal.pone.0182393	http://dx.doi.org/10.1371/journal.pone.0182393			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC5AR	28771622	Green Published, gold, Green Submitted			2023-01-03	WOS:000406853600100
J	Lin, B; Sun, XG; Su, SL; Lv, CX; Zhang, XF; Lin, L; Wang, R; Fu, JH; Kang, DM				Lin, Bin; Sun, Xiaoguang; Su, Shengli; Lv, Cuixia; Zhang, Xiaofei; Lin, Lin; Wang, Rui; Fu, Jihua; Kang, Dianmin			HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China	PLOS ONE			English	Article							TRANSCRIPTASE INHIBITOR RESISTANCE; IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTYPE DIVERSITY; MUTATIONS; SUSCEPTIBILITY; INFECTION; PATTERNS; THERAPY; ADHERENCE; IMPACT	The efficacy of antiretroviral drugs is limited by the development of drug resistance. Therefore, it is important to examine HIV drug resistance following the nationwide implementation of drug resistance testing in China since 2009. We conducted drug resistance testing in patients who were already on or new to HIV antiretroviral therapy (ART) in Shandong Province, China, from 2011 to 2013, and grouped them based on the presence or absence of drug resistance to determine the effects of age, gender, ethnicity, marital status, educational level, route of transmission and treatment status on drug resistance. We then examined levels of drug resistance the following year. The drug resistance rates of HIV patients on ART in Shandong from 2011 to 2013 were 3.45% (21/608), 3.38% (31/916), and 4.29% (54/1259), per year, respectively. M184V was the most frequently found point mutation, conferring resistance to the nucleoside reverse transcriptase inhibitor, while Y181C, G190A, K103N and V179D/E/F were the most frequent point mutations conferring resistance to the non-nucleoside reverse transcriptase inhibitor. In addition, the protease inhibitor drug resistance mutations I54V and V82A were identified for the first time in Shandong Province. Primary resistance accounts for 20% of the impact factors for drug resistance. Furthermore, it was found that educational level and treatment regimen were high-risk factors for drug resistance in 2011 (P < 0.05), while treatment regimen was a high risk factor for drug resistance in 2012 and 2013 (P < 0.05). Among the 106 drug-resistant patients, 77 received immediate adjustment of treatment regimen following testing, and 69 (89.6%) showed a reduction in drug resistance the following year. HIV drug resistance has a low prevalence in Shandong Province. However, patients on second line ART regimens and those with low educational level need continuous monitoring. Active drug resistance testing can effectively prevent the development of drug resistance.	[Lin, Bin; Sun, Xiaoguang; Su, Shengli; Lv, Cuixia; Zhang, Xiaofei; Lin, Lin; Fu, Jihua; Kang, Dianmin] Shandong Ctr Dis Control & Prevent, Shandong Ctr AIDS Control & Prevent, Jinan, Shandong, Peoples R China; [Wang, Rui] Shandong Univ, Qilu Hosp, Jinan, Shandong, Peoples R China	Shandong University	Fu, JH; Kang, DM (corresponding author), Shandong Ctr Dis Control & Prevent, Shandong Ctr AIDS Control & Prevent, Jinan, Shandong, Peoples R China.	fujihua1958@163.com; dmkang1962@163.com	zhang, xiaofei/HJA-9117-2022		National Science and Technology Key Projects on Major Infectious Diseases [2014ZX10001002-001-003]	National Science and Technology Key Projects on Major Infectious Diseases	The payment of publishing this research paper was supported by National Science and Technology Key Projects on Major Infectious Diseases (2014ZX10001002-001-003).	[Anonymous], ADV MAT SCI ENG, DOI DOI 10.1016/J.SURFC0AT.2015.10.001; Avila-Rios S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164156; Cabello M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106045; Dunne AL, 2001, AIDS, V15, P1471, DOI 10.1097/00002030-200108170-00003; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Eron JJ, 2007, JAIDS-J ACQ IMM DEF, V45, P249, DOI 10.1097/QAI.0b013e318050d61f; Frost SDW, 2000, J VIROL, V74, P6262, DOI 10.1128/JVI.74.14.6262-6268.2000; FuJie Z., 2016, CHINAS NATL FREE ANT, P27; Geretti Anna Maria, 2006, J HIV Ther, V11, P72; Haaland RE, 2013, PUBLIC HEALTH GENOM, V16, P31, DOI 10.1159/000345935; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Hassan AS, 2014, AIDS RES THER, V11, DOI 10.1186/1742-6405-11-9; Hatano H, 2007, BRIT MED J, V334, P1124, DOI 10.1136/bmj.39205.386609.80; He X., 2012, INT J ANTENN PROPAG, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0047289; Jiao Y, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0689-7; Keulen W, 1996, ANTIVIR RES, V31, P45, DOI 10.1016/0166-3542(96)00944-8; Kiertiburanakul S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147945; Kulkarni R, 2012, JAIDS-J ACQ IMM DEF, V59, P47, DOI 10.1097/QAI.0b013e31823aca74; Li JY, 2010, CHIN J AIDS STD, V16, P195; Liao LJ, 2010, JAIDS-J ACQ IMM DEF, V53, pS10, DOI 10.1097/QAI.0b013e3181c7d363; Lin B., 2010, PREV MED TRIB, V16, P207; Melikian GL, 2012, ANTIMICROB AGENTS CH, V56, P2305, DOI 10.1128/AAC.05487-11; Mendoza Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154317; Menendez-Arias L, 2002, PROG NUCLEIC ACID RE, V71, P91, DOI 10.1016/S0079-6603(02)71042-8; Meresse M, 2014, HIV MED, V15, P478, DOI 10.1111/hiv.12140; Pai NP, 2012, JAIDS-J ACQ IMM DEF, V59, P382, DOI 10.1097/QAI.0b013e31824a0628; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Qin BY, 2012, PRACTICAL PREVENTIVE, V19, P964; Reuman EC, 2010, J ANTIMICROB CHEMOTH, V65, P1477, DOI 10.1093/jac/dkq140; Ross L, 2004, AIDS, V18, P1691, DOI 10.1097/01.aids.0000131355.44834.e4; Rusconi Stefano, 2006, J HIV Ther, V11, P81; Rusine J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064345; Santoro Maria Mercedes, 2013, ISRN Microbiol, V2013, P481314, DOI 10.1155/2013/481314; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Shao Y., 2010, MONITORING STRATEGIE, P53; Sui HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091803; Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737; Tong Y, 2016, CLIN RES PRACT, V1, P100; van Westen GJP, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002899; Wainberg MA, 2010, VIRUSES-BASEL, V2, P2493, DOI 10.3390/v2112493; Wang Ning, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P1205; Wang Y, 2012, EURASIP J ADV SIG PR, P1, DOI 10.1186/1687-6180-2012-40; WHO, 2012, WHO GLOB STRAT SURV; Wu H, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-2; Yu A, 2016, CHINESE J AIDS STD, V22, P864; [袁源 Yuan Yuan], 2016, [中国病原生物学杂志, Journal of Pathogen Biology], V11, P329; Zang X, 2015, CHINESE J PUBLIC HLT, V14, P574; Zheng J, 2011, CHINESE J AIDS STD, V17, P529	48	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							e0181997	10.1371/journal.pone.0181997	http://dx.doi.org/10.1371/journal.pone.0181997			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1CT	28750025	Green Submitted, gold, Green Published			2023-01-03	WOS:000406575700111
J	Chiu, WT; Hong, CT; Chi, NF; Hu, CJ; Hu, HH; Chan, L				Chiu, Wei Ting; Hong, Chien Tai; Chi, Nai Fang; Hu, Chaur Jong; Hu, Han Hwa; Chan, Lung			The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; PLASMINOGEN-ACTIVATOR; CONTROLLED-TRIAL; EARLY MANAGEMENT; ECASS II; THERAPY; RUPTURE; TRANSFORMATION; ASSOCIATION; PREVALENCE	Background The presence of an intracranial aneurysm is contraindicated to recombinant tissue plasminogen activator (r-tPA) treatment for acute ischemic stroke. However, it is difficult to exclude asymptomatic intracranial aneurysms by using conventional, noncontrast head computed tomography (CT), which is the only neuroimaging suggested before r-tPA. Recent case reports and series have shown that administering r-tPA to patients with a pre-existing aneurysm does not increase the bleeding risk. However, Asians are known to have a relatively higher bleeding risk, and little evidence is available regarding the risk of using r-tPA on Asian patients with intracranial aneurysms. Methods Medical records from the Shuang Ho hospital stroke registration between July 2010 and December 2014 were retrospectively reviewed, and 144 patients received r-tPA. Unruptured intracranial aneurysms were detected using CT, or magnetic resonance or conventional angiography after r-tPA. The primary and secondary outcomes were the difference in overall intracranial hemorrhage (ICH) and symptomatic ICH after r-tPA. The differences were analyzed using Fisher's exact or Mann Whitney U tests, and p < 0.05 was defined as the statistical significance. Results A total of 144 patients were reviewed, and incidental unruptured intracranial aneurysms were found in 11 of them (7.6%). No significant difference was observed in baseline demographic data between the aneurysm and nonaneurysm groups. Among patients with an unruptured aneurysm, two had giant aneurysms (7.7 and 7.4 mm, respectively). The bleeding risk was not significant different between aneurysm group (2 out of 11, 18%) with nonaneurysm group (7 out of 133, 5.3%) (p = 0.14). None of the patients with an unruptured aneurysm had symptomatic ICH, whereas one patient without an aneurysm exhibited symptomatic ICH. Conclusions The presence of an unruptured intracranial aneurysm did not significantly increase the risk of overall and symptomatic ICH in Taiwanese patients after they received r-tPA.	[Chiu, Wei Ting; Hong, Chien Tai; Chi, Nai Fang; Hu, Chaur Jong; Hu, Han Hwa; Chan, Lung] Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, New Taipei, Taiwan; [Chiu, Wei Ting; Hong, Chien Tai; Chi, Nai Fang; Hu, Chaur Jong; Hu, Han Hwa; Chan, Lung] Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan; [Chiu, Wei Ting; Hong, Chien Tai; Chi, Nai Fang; Hu, Chaur Jong; Hu, Han Hwa; Chan, Lung] Taipei Med Univ, Shuang Ho Hosp, Stroke Ctr, New Taipei, Taiwan	Taipei Medical University; Shuang Ho Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Chan, L (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Neurol, New Taipei, Taiwan.; Chan, L (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Neurol, Taipei, Taiwan.; Chan, L (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Stroke Ctr, New Taipei, Taiwan.	cjustinmd@gmail.com	Chi, Nai-Fang/G-3561-2016; Chan, Lung/AAM-3231-2021; Chan, Lung/AAI-6349-2020; Chi, Nai-Fang/E-2851-2017	Chi, Nai-Fang/0000-0002-2204-4923; Chan, Lung/0000-0001-5795-4460; Chi, Nai-Fang/0000-0002-2204-4923				Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; Almeida A, 2014, CASE REPORTS NEUROLO, V2014; Chao AC, 2010, STROKE, V41, P885, DOI 10.1161/STROKEAHA.109.575605; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; del Zoppo GJ, 1998, J NEUROL NEUROSUR PS, V65, P1, DOI 10.1136/jnnp.65.1.1; Derex L, 2008, J NEUROL NEUROSUR PS, V79, P1093, DOI 10.1136/jnnp.2007.133371; Dharmasaroja PA, 2013, J STROKE CEREBROVASC, V22, P227, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.001; Ding JY, 2016, AM J EMERG MED, V34, P636, DOI 10.1016/j.ajem.2015.12.025; Edwards NJ, 2012, STROKE, V43, P412, DOI 10.1161/STROKEAHA.111.634147; Ganesalingam J, 2013, JRSM CARDIOVASC DIS, V2, DOI 10.1177/2048004013478808; Garibaldi AA, 2006, J ENDOVASC THER, V13, P111, DOI 10.1583/05-1551.1; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Haji F, 2014, CAN J NEUROL SCI, V41, P95, DOI 10.1017/S0317167100016358; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kim JE, 2012, J BREAST CANCER, V15, P197, DOI 10.4048/jbc.2012.15.2.197; Lansberg MG, 2007, CEREBROVASC DIS, V24, P1, DOI 10.1159/000103110; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; Mehta RH, 2014, STROKE, V45, P2263, DOI 10.1161/STROKEAHA.114.005019; Mowla A, 2015, INT J STROKE, V10, P113, DOI 10.1111/ijs.12616; Rammos SK, 2012, NEUROSURGERY, V70, pE1603, DOI 10.1227/NEU.0b013e31822e1097; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Saver JL, 2007, STROKE, V38, P2279, DOI 10.1161/STROKEAHA.107.487009; Sheth KN, 2012, NEUROCRIT CARE, V17, P199, DOI 10.1007/s12028-012-9734-9; Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0; Wang Hsin-Fan, 2013, Acta Neurol Taiwan, V22, P43; Xu M, 2014, CNS NEUROSCI THER, V20, P473, DOI 10.1111/cns.12254; Yoneda Y, 2009, CASE REP NEUROL, V1, P20, DOI 10.1159/000224714; Zaldivar-Jolissaint JF, 2015, J STROKE CEREBROVASC, V24, pE63, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.004	28	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180021	10.1371/journal.pone.0180021	http://dx.doi.org/10.1371/journal.pone.0180021			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662192	Green Published, Green Submitted, gold			2023-01-03	WOS:000404608300087
J	Anderson, CS; Arima, H; Lavados, P; Billot, L; Hackett, ML; Olavarria, VV; Venturelli, PM; Brunser, A; Peng, B; Cui, L; Song, L; Rogers, K; Middleton, S; Lim, JY; Forshaw, D; Lightbody, CE; Woodward, M; Pontes-Neto, O; De Silva, HA; Lin, RT; Lee, TH; Pandian, JD; Mead, GE; Robinson, T; Watkins, C				Anderson, C. S.; Arima, H.; Lavados, P.; Billot, L.; Hackett, M. L.; Olavarria, V. V.; Munoz Venturelli, P.; Brunser, A.; Peng, B.; Cui, L.; Song, L.; Rogers, K.; Middleton, S.; Lim, J. Y.; Forshaw, D.; Lightbody, C. E.; Woodward, M.; Pontes-Neto, O.; De Silva, H. A.; Lin, R. -T.; Lee, T. -H.; Pandian, J. D.; Mead, G. E.; Robinson, T.; Watkins, C.		HeadPoST Investigators Coordinator	Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE ISCHEMIC-STROKE; BLOOD-FLOW-VELOCITY; CEREBRAL OXYGENATION; GUIDELINES; TELEPHONE; SCALE; CARE	BACKGROUND The role of supine positioning after acute stroke in improving cerebral blood flow and the countervailing risk of aspiration pneumonia have led to variation in head positioning in clinical practice. We wanted to determine whether outcomes in patients with acute ischemic stroke could be improved by positioning the patient to be lying flat (i.e., fully supine with the back horizontal and the face upwards) during treatment to increase cerebral perfusion. METHODS In a pragmatic, cluster-randomized, crossover trial conducted in nine countries, we assigned 11,093 patients with acute stroke (85% of the strokes were ischemic) to receive care in either a lying-flat position or a sitting-up position with the head elevated to at least 30 degrees, according to the randomization assignment of the hospital to which they were admitted; the designated position was initiated soon after hospital admission and was maintained for 24 hours. The primary outcome was degree of disability at 90 days, as assessed with the use of the modified Rankin scale (scores range from 0 to 6, with higher scores indicating greater disability and a score of 6 indicating death). RESULTS The median interval between the onset of stroke symptoms and the initiation of the assigned position was 14 hours (interquartile range, 5 to 35). Patients in the lying-flat group were less likely than patients in the sitting-up group to maintain the position for 24 hours (87% vs. 95%, P<0.001). In a proportional-odds model, there was no significant shift in the distribution of 90-day disability outcomes on the global modified Rankin scale between patients in the lying-flat group and patients in the sitting-up group (unadjusted odds ratio for a difference in the distribution of scores on the modified Rankin scale in the lying-flat group, 1.01; 95% confidence interval, 0.92 to 1.10; P = 0.84). Mortality within 90 days was 7.3% among the patients in the lying-flat group and 7.4% among the patients in the sitting-up group (P = 0.83). There were no significant between-group differences in the rates of serious adverse events, including pneumonia. CONCLUSIONS Disability outcomes after acute stroke did not differ significantly between patients assigned to a lying-flat position for 24 hours and patients assigned to a sitting-up position with the head elevated to at least 30 degrees for 24 hours. (Funded by the National Health and Medical Research Council of Australia; HeadPoST ClinicalTrials.gov number, NCT02162017.)	[Anderson, C. S.; Arima, H.; Billot, L.; Hackett, M. L.; Munoz Venturelli, P.; Rogers, K.; Lim, J. Y.; Woodward, M.] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Anderson, C. S.; Billot, L.; Hackett, M. L.; Song, L.; Rogers, K.; Lim, J. Y.; Woodward, M.] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Anderson, C. S.] Sydney Hlth Partners, Royal Prince Alfred Hosp, Neurol Dept, Sydney, NSW, Australia; [Middleton, S.] St Vincents Hlth, Nursing Res Inst, Sydney, NSW, Australia; [Middleton, S.; Watkins, C.] Australian Catholic Univ, Sydney, NSW, Australia; [Anderson, C. S.; Song, L.] Peking Univ, Hlth Sci Ctr, George Inst China, Beijing, Peoples R China; [Peng, B.; Cui, L.] Beijing Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China; [Song, L.] 85 Hosp Peoples Liberat Army, Dept Neurol, Shanghai, Peoples R China; [Arima, H.] Fukuoka Univ, Fac Med, Dept Prevent Med & Publ Hlth, Fukuoka, Japan; [Lavados, P.; Olavarria, V. V.; Munoz Venturelli, P.; Brunser, A.] Clin Alemana De Santiago, Dept Neurol & Psychiat, Santiago, Chile; [Lavados, P.] Clin Alemana Univ Desarrollo, Fac Med, Santiago, Chile; [Lavados, P.] Univ Chile, Fac Med, Dept Ciencias Neurol, Santiago, Chile; [Hackett, M. L.; Forshaw, D.; Lightbody, C. E.; Watkins, C.] Univ Cent Lancashire, Coll Hlth & Wellbeing, Preston, Lancs, England; [Woodward, M.] Univ Oxford, George Inst Global Hlth, Edinburgh, Midlothian, Scotland; [Mead, G. E.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Robinson, T.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Robinson, T.] Univ Leicester, NIHR Biomed Res Unit, Leicester, Leics, England; [Woodward, M.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; [Pontes-Neto, O.] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurosci & Behav, Stroke Serv Neurol Div, Sao Paulo, Brazil; [De Silva, H. A.] Univ Kelaniya, Fac Med, Dept Pharmacol, Clin Trials Unit, Kelaniya, Sri Lanka; [Pandian, J. D.] Christian Med Coll & Hosp, Dept Neurol, Ludhiana, Punjab, India; [Lin, R. -T.] Kaohsiung Med Univ & Hosp, Dept Neurol, Kaohsiung, Taiwan; [Lee, T. -H.] Chang Gung Univ, Linkou Chang Gung Mem Hosp & Coll Med, Stroke Ctr, Taoyuan, Taiwan; [Lee, T. -H.] Chang Gung Univ, Linkou Chang Gung Mem Hosp & Coll Med, Dept Neurol, Taoyuan, Taiwan	George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of New South Wales Sydney; University of Sydney; Australian Catholic University; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Fukuoka University; Clinica Alemana; Universidad del Desarrollo; Universidad de Chile; University of Central Lancashire; University of Oxford; University of Edinburgh; University of Leicester; University of Leicester; Johns Hopkins University; Universidade de Sao Paulo; University Kelaniya; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Chang Gung University; Chang Gung University	Anderson, CS (corresponding author), Peking Univ, Hlth Sci Ctr, George Inst Global Hlth China, Ste 1801,Tower B,Horizon Tower,6 Zhichun Rd, Beijing 100088, Peoples R China.	canderson@georgeinstitute.org.cn	Luvizutto, Gustavo/F-3709-2019; Song, Lili/AGY-5209-2022; Lindley, Richard/B-8148-2013; Chen, Christopher/E-7023-2013; Demchuk, Andrew M/E-1103-2012; Woodward, Mark/L-6817-2017; Middleton, Sandy/J-5526-2015; Carbonera, Leonardo Augusto A/Q-5674-2018; Pandian, Jeyaraj Durai/AAV-5591-2020; Billot, Laurent/Y-1241-2019; Pontes-Neto, Octavio Marques/G-4294-2012; Hackett, Maree L/O-8752-2016; Edwards, Taiza GS/F-9214-2012; Shafras, Mohamed/O-3516-2018; Munoz Venturelli, Paula/O-6701-2018; Watkins, Caroline/E-6898-2013	Luvizutto, Gustavo/0000-0002-6914-7225; Song, Lili/0000-0002-6105-1720; Lindley, Richard/0000-0002-0104-5679; Chen, Christopher/0000-0002-1047-9225; Demchuk, Andrew M/0000-0002-4930-7789; Middleton, Sandy/0000-0002-7201-4394; Carbonera, Leonardo Augusto A/0000-0002-9313-7967; Billot, Laurent/0000-0002-4975-9793; Pontes-Neto, Octavio Marques/0000-0003-0317-843X; Hackett, Maree L/0000-0003-1211-9087; Edwards, Taiza GS/0000-0003-3033-2981; Forshaw, Denise/0000-0001-5725-3736; Shafras, Mohamed/0000-0002-4827-0275; Jan, Stephen/0000-0003-2839-1405; Anderson, Craig/0000-0002-7248-4863; Pandian, Jeyaraj/0000-0003-0028-1968; Woodward, Mark/0000-0001-9800-5296; Munoz Venturelli, Paula/0000-0003-1869-2255; Blacker, David/0000-0003-0046-9776; Robinson, Thompson/0000-0003-2144-2468; Lightbody, Elizabeth/0000-0001-5016-3471; Lim, Joyce Y/0000-0003-0659-1078; Emsley, Hedley/0000-0003-0129-4488; Watkins, Caroline/0000-0002-9403-3772; Richardson, Carla/0000-0002-1774-7261; SEAK, CHEN-JUNE/0000-0003-0984-8385; Liu, Kuan-Ting/0000-0002-1355-5019	National Health and Medical Research Council of Australia; National Institute for Health Research [NF-SI-0515-10116] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institute for Health Research(National Institute for Health Research (NIHR))	Funded by the National Health and Medical Research Council of Australia; HeadPoST ClinicalTrials.gov number, NCT02162017.	Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Billot L, 2017, INT J STROKE; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273; Cumbler E, 2014, STROKE, V45, P231, DOI 10.1161/STROKEAHA.113.003617; Dennis M, 2012, STROKE, V43, P851, DOI 10.1161/STROKEAHA.111.639708; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Hargroves D, 2008, AGE AGEING, V37, P581, DOI 10.1093/ageing/afn143; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Katzan IL, 2015, STROKE, V46, P1153, DOI 10.1161/STROKEAHA.115.009084; Mehagnoul-Schipper DJ, 2000, STROKE, V31, P1615, DOI 10.1161/01.STR.31.7.1615; Menon BK, 2016, STROKE, V47, P1972, DOI 10.1161/STROKEAHA.116.013829; Morgan KE, 2017, STAT MED, V36, P318, DOI 10.1002/sim.7137; Venturelli PM, 2015, J STROKE CEREBROVASC, V24, P1564, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.023; Munoz-Venturelli P, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0767-1; Olavarria VV, 2014, CEREBROVASC DIS, V37, P401, DOI 10.1159/000362533; Palazzo P, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.425; Quinn TJ, 2009, INT J STROKE, V4, P200, DOI 10.1111/j.1747-4949.2009.00271.x; Quinn TJ, 2009, STROKE, V40, P3393, DOI [10.1161/STROKEAHA.109.557256, 10.1161/STROKEAHA.108.522516]; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Sackett DL, 2000, CAN MED ASSOC J, V162, P1311; Schwarz S, 2002, STROKE, V33, P497, DOI 10.1161/hs0202.102376; Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8; Sutton CJ, 2013, INT J STROKE, V8, P566, DOI 10.1111/j.1747-4949.2012.00915.x; Turner RM, 2007, STAT MED, V26, P274, DOI 10.1002/sim.2537; Tyson SF, 2004, CLIN REHABIL, V18, P801, DOI 10.1191/0269215504cr744oa; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Wang YJ, 2011, INT J STROKE, V6, P355, DOI 10.1111/j.1747-4949.2011.00584.x; Wojner-Alexander AW, 2005, NEUROLOGY, V64, P1354, DOI 10.1212/01.WNL.0000158284.41705.A5	30	95	104	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 22	2017	376	25					2437	2447		10.1056/NEJMoa1615715	http://dx.doi.org/10.1056/NEJMoa1615715			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY2BW	28636854	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000403774400007
J	Bellmunt, J				Bellmunt, Joaquim			Antiangiogenesis to curb urothelial cancer	LANCET			English	Editorial Material							OPEN-LABEL; PHASE-II; CARCINOMA; RAMUCIRUMAB; THERAPY; TRIAL		[Bellmunt, Joaquim] Dana Farber Canc Inst, Boston, MA 02215 USA; [Bellmunt, Joaquim] IMIM PSMAR Med Res Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute	Bellmunt, J (corresponding author), Dana Farber Canc Inst, Boston, MA 02215 USA.; Bellmunt, J (corresponding author), IMIM PSMAR Med Res Inst, Boston, MA 02215 USA.	joaquim_bellmunt@dfci.harvard.edu	Bellmunt, Joaquim/B-8151-2019	Bellmunt, Joaquim/0000-0003-2328-3421	Roche/Genentech; Pfizer; Merck; AstraZeneca; Bristol-Myers Squibb; Pierre Fabre	Roche/Genentech(Roche HoldingGenentech); Pfizer(Pfizer); Merck(Merck & Company); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Pierre Fabre	I have received lecture and advisory board fees from Roche/Genentech, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre.	Agarwal N, 2014, CLIN GENITOURIN CANC, V12, P130, DOI 10.1016/j.clgc.2013.09.002; Bellmunt J, 2011, ANN ONCOL, V22, P2646, DOI 10.1093/annonc/mdr023; Bellmunt J, 2017, NEW ENGL J MED, V376, P2304, DOI 10.1056/NEJMc1704612; Bellmunt J, 2010, J CLIN ONCOL, V28, P1850, DOI 10.1200/JCO.2009.25.4599; Choueiri TK, 2012, J CLIN ONCOL; Grivas P, 2012, P AM SOC CLIN ONCOL, V30; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Necchi A, 2012, LANCET ONCOL, V13, P810, DOI 10.1016/S1470-2045(12)70294-2; Petrylak D. P., 2017, LANCET; Petrylak DP, 2016, J CLIN ONCOL, V34, P1500, DOI 10.1200/JCO.2015.65.0218; Shariat SF, 2010, J UROLOGY, V183, P1744, DOI 10.1016/j.juro.2010.01.018; Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537	12	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 18	2017	390	10109					2220	2221		10.1016/S0140-6736(17)32388-7	http://dx.doi.org/10.1016/S0140-6736(17)32388-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN0DH	28916369				2023-01-03	WOS:000415645700006
J	Andrade, HB; Shinotsuka, CR; da Silva, IRF; Donini, CS; Li, HY; de Carvalho, FB; do Brasil, PEAA; Bozza, FA; Japiassu, AM				Andrade, Hugo Boechat; Shinotsuka, Cassia Righy; Ferreira da Silva, Ivan Rocha; Donini, Camila Sunaitis; Li, Ho Yeh; de Carvalho, Frederico Bruzzi; Alvarenga Americano do Brasil, Pedro Emmanuel; Bozza, Fernando Augusto; Japiassu, Andre Miguel			Highly active antiretroviral therapy for critically ill HIV patients: A systematic review and meta-analysis	PLOS ONE			English	Review							AIDS-DEFINING ILLNESSES; VIRUS-INFECTED PATIENTS; INTENSIVE-CARE; SEVERE SEPSIS; SURVIVAL; ERA; EPIDEMIOLOGY; MORTALITY; SPECTRUM; OUTCOMES	Introduction It is unclear whether the treatment of an HIV infection with highly active antiretroviral therapy (HAART) affects intensive care unit (ICU) outcomes. In this paper, we report the results of a systematic review and meta-analysis performed to summarize the effects of HAART on the prognosis of critically ill HIV positive patients. Materials and methods A bibliographic search was performed in 3 databases (PubMed, Web of Science and Scopus) to identify articles that investigated the use of HAART during ICU admissions for shortand long-term mortality or survival. Eligible articles were selected in a staged process and were independently assessed by two investigators. The methodological quality of the selected articles was evaluated using the Methodological Index for Non-Randomized Studies (MINORS) tool. Results Twelve articles met the systematic review inclusion criteria and examined short-term mortality. Six of them also examined long-term mortality (>= 90 days) after ICU discharge. The short-term mortality meta-analysis showed a significant beneficial effect of initiating or maintaining HAART during the ICU stay (random effects odds ratio 0.53, p = 0.02). The data analysis of long-term outcomes also suggested a reduced mortality when HAART was used, but the effect of HAART on long-term mortality of HIV positive critically ill patients remains uncertain. Conclusions This meta-analysis suggests improved survival rates for HIV positive patients who were treated with HAART during their ICU admission.	[Andrade, Hugo Boechat; Shinotsuka, Cassia Righy; Ferreira da Silva, Ivan Rocha; Alvarenga Americano do Brasil, Pedro Emmanuel; Bozza, Fernando Augusto; Japiassu, Andre Miguel] Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Intens Care Unit, Rio De Janeiro, RJ, Brazil; [Donini, Camila Sunaitis; Li, Ho Yeh] Univ Sao Paulo, Faculdade Medicina, Hosp Clin, Infect Dis Intens Care Unit, Sao Paulo, SP, Brazil; [de Carvalho, Frederico Bruzzi] Fundacao Hosp Estado Minas Gerais, Hosp Eduardo, Intens Care Unit, Belo Horizonte, MG, Brazil	Fundacao Oswaldo Cruz; Universidade de Sao Paulo	Japiassu, AM (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Intens Care Unit, Rio De Janeiro, RJ, Brazil.	andrejapi@gmail.com	Brasil, Pedro E A A/B-4357-2008; Carvalho, Frederico B/J-4879-2012; Ho, Yeh Li/A-7197-2013; de Carvalho, Frederico Bruzzi/ABB-3911-2020; Shinotsuka, Cássia Righy/H-9181-2013; Bozza, Fernando A/A-2618-2013; BOECHAT ANDRADE, HUGO/M-6631-2013	Brasil, Pedro E A A/0000-0002-6700-2268; Carvalho, Frederico B/0000-0002-9752-5625; Ho, Yeh Li/0000-0001-8719-2508; de Carvalho, Frederico Bruzzi/0000-0002-9752-5625; Shinotsuka, Cássia Righy/0000-0002-9206-9552; Bozza, Fernando A/0000-0003-4878-0256; rocha ferreira da silva, ivan/0000-0001-8572-9631; BOECHAT ANDRADE, HUGO/0000-0001-6781-6125				Adlakha A, 2011, INT J STD AIDS, V22, P498, DOI 10.1258/ijsa.2011.010496; Altman DG, 1984, SCI REV RES; Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389; Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4; Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x; Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7; Chiang H-H, 2006, CRIT CARE, P15; Cribbs SK, 2015, CRIT CARE MED, V43, P1638, DOI 10.1097/CCM.0000000000001003; Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7; Easterbrook P, 2001, J ROY SOC MED, V94, P442, DOI 10.1177/014107680109400907; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030; Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; Ives NJ, 2001, J INFECTION, V42, P134, DOI 10.1053/jinf.2001.0810; Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334; Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27; Michaels SH, 1999, CLIN INFECT DIS, V29, P468, DOI 10.1086/520251; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Morquin D, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-25; Morris A, 2003, AIDS, V17, P73, DOI 10.1097/00002030-200301030-00010; Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Ramos GV, 2014, J CLIN PHARM THER; Schwarcz SK, 2014, AIDS PATIENT CARE ST, V28, P517, DOI 10.1089/apc.2014.0079; Sedgwick P, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1342; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; van Lelyveld SFL, 2011, EUR J CLIN MICROBIOL, V30, P1085, DOI 10.1007/s10096-011-1196-z; Vargas-Infante YA, 2007, ARCH MED RES, V38, P827, DOI 10.1016/j.arcmed.2007.05.007; Wit FWNM, 2002, J INFECT DIS, V186, P23, DOI 10.1086/341084; Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575	36	26	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2017	12	10							e0186968	10.1371/journal.pone.0186968	http://dx.doi.org/10.1371/journal.pone.0186968			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK5VD	29065165	Green Published, Green Submitted, gold			2023-01-03	WOS:000413568900057
J	Mason, DJ				Mason, Diana J.			Long-term Care: Investing in Models That Work	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Mason, Diana J.] CUNY Hunter Coll, Ctr Hlth Media & Policy, New York, NY 10021 USA; [Mason, Diana J.] George Washington Univ, Sch Nursing, Washington, DC 20052 USA; [Mason, Diana J.] Amer Acad Nursing, Washington, DC 20005 USA	City University of New York (CUNY) System; Hunter College (CUNY); George Washington University	Mason, DJ (corresponding author), CUNY Hunter Coll, Ctr Hlth Media & Policy, New York, NY 10021 USA.; Mason, DJ (corresponding author), George Washington Univ, Sch Nursing, Washington, DC 20052 USA.; Mason, DJ (corresponding author), Amer Acad Nursing, Washington, DC 20005 USA.	djmasonrn@gmail.com							0	1	1	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2017	318	16					1529	1530		10.1001/jama.2017.15230	http://dx.doi.org/10.1001/jama.2017.15230			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK6EX	29067411				2023-01-03	WOS:000413597200002
J	Kawaguchi, I; Kobayashi, A; Higashide, T; Takeji, Y; Sakurai, K; Kawaguchi, C; Sugiyama, K				Kawaguchi, Ichiro; Kobayashi, Akira; Higashide, Tomomi; Takeji, Yasuhiro; Sakurai, Kazushi; Kawaguchi, Chiaki; Sugiyama, Kazuhisa			Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits	PLOS ONE			English	Article							BENZALKONIUM CHLORIDE; SODIUM HYALURONATE; GOBLET CELLS; INCREASES; CORNEAL; CONJUNCTIVA; EXPRESSION; OPC-12759; DRUG	Purpose This study aimed to determine if rebamipide eyedrops can improve ocular surface damage caused by the use of glaucoma eyedrops. Methods Female Kbl:Dutch rabbits were used to evaluate glaucoma eyedrop-induced ocular surface damage; one eye of each rabbit was untreated and the other was administered glaucoma eyedrops for 30 days. To evaluate the effects of rebamipide on ocular surface damage, one eye of each rabbit was administered vehicle-treated glaucoma eyedrops and the other was administered rebamipide-treated glaucoma eyedrops for 30 days. Corneal and conjunctival epithelial damage was evaluated using fluorescein and rose bengal staining, respectively. Conjunctival inflammation was observed by light microscopy with hematoxylin-eosin staining. Dark cells (in which the corneal microvilli were damaged) were analyzed by scanning electron microscopy. Results There were no significant differences in fluorescein staining between the untreated and glaucoma eyedrop-treated groups; however, rose bengal staining and the number of inflammatory cells in the conjunctiva significantly increased after glaucoma eyedrop treatment. There was a four-fold increase in the number of dark cells in the glaucoma eyedrop-treated group compared to untreated. In contrast, in the conjunctiva of the rebamipide-treated glaucoma eyedrop group, rose bengal staining scores, the number of inflammatory cells, and the number of dark cells were decreased compared to the vehicle-treated glaucoma eyedrop group. Conclusions Results from our in vivo rabbit study demonstrated that short-term use of glaucoma eyedrops induces corneal epithelium disorders at the cellular level, but that simultaneous use of rebamipide has the potential to protect and repair the ocular surface.	[Kawaguchi, Ichiro; Kobayashi, Akira; Higashide, Tomomi; Kawaguchi, Chiaki; Sugiyama, Kazuhisa] Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa, Japan; [Takeji, Yasuhiro; Sakurai, Kazushi] Otsuka Pharmaceut Co Ltd, Ako Res Inst, Ako, Hyogo, Japan	Kanazawa University; Otsuka Pharmaceutical	Kobayashi, A (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol, Kanazawa, Ishikawa, Japan.	eyekoba@gmail.com			Otsuka pharmaceutical Co. Ltd.	Otsuka pharmaceutical Co. Ltd.(Otsuka Pharmaceutical)	The funder (Otsuka pharmaceutical Co. Ltd.) provided support in the form of salaries for authors [YT, KS]. Authors [IK, AK, TH, CK, KS] received no specific funding for this work.	Baudouin C, 2004, OPHTHALMOLOGY, V111, P2186, DOI 10.1016/j.ophtha.2004.06.023; Baudouin C, 2012, EUR J OPHTHALMOL; Baudouin C, 2008, ACTA OPHTHALMOL, V86, P716, DOI 10.1111/j.1755-3768.2008.01250.x; Baudouin C, 2007, INVEST OPHTH VIS SCI, V48, P4123, DOI 10.1167/iovs.07-0266; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P2525; Dogan AL, 2004, CLIN EXP OPHTHALMOL, V32, P62, DOI 10.1046/j.1442-9071.2003.00760.x; Fukuchi T, 2010, CLIN OPHTHALMOL, V4, P203; Gipson IK, 2016, PROG RETIN EYE RES, V54, P49, DOI 10.1016/j.preteyeres.2016.04.005; Govindarajan B, 2010, EXP EYE RES, V90, P655, DOI 10.1016/j.exer.2010.02.014; HERRERAS JM, 1992, OPHTHALMOLOGY, V99, P1082; Iijima K, 2009, DIGEST DIS SCI, V54, P1500, DOI 10.1007/s10620-008-0507-4; Kahook MY, 2008, ADV THER, V25, P743, DOI 10.1007/s12325-008-0078-y; KERN TJ, 1988, VET PATHOL, V25, P468, DOI 10.1177/030098588802500610; Kinoshita S, 2013, OPHTHALMOLOGY, V120, P1158, DOI 10.1016/j.ophtha.2012.12.022; Leung EW, 2008, J GLAUCOMA, V17, P350, DOI 10.1097/IJG.0b013e31815c5f4f; Naito Y, 2010, EXPERT REV GASTROENT, V4, P261, DOI [10.1586/egh.10.25, 10.1586/EGH.10.25]; Noecker RJ, 2004, CORNEA, V23, P490, DOI 10.1097/01.ico.0000116526.57227.82; Ohguchi T, 2013, INVEST OPHTH VIS SCI, V54, P7793, DOI 10.1167/iovs.13-13128; Tanaka H, 2013, BRIT J OPHTHALMOL, V97, P912, DOI 10.1136/bjophthalmol-2012-302868; Terai N, 2011, CLIN OPHTHALMOL, V5, P517, DOI 10.2147/OPTH.S18849; TODA I, 1993, CORNEA, V12, P366, DOI 10.1097/00003226-199307000-00015; Tokuda N, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/689076; TSENG SCG, 1994, INT OPHTHALMOL CLIN, V34, P57, DOI 10.1097/00004397-199403410-00007; Urashima H, 2004, CORNEA, V23, P613, DOI 10.1097/01.ico.0000126436.25751.fb; Urashima H, 2012, J OCUL PHARMACOL TH, V28, P264, DOI 10.1089/jop.2011.0147; YAMASAKI K, 1987, EUR J PHARMACOL, V142, P23; Yu FF, 2013, INVEST OPHTH VIS SCI, V54, P3385, DOI 10.1167/iovs.12-11181	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0186714	10.1371/journal.pone.0186714	http://dx.doi.org/10.1371/journal.pone.0186714			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0UN	29049370	gold, Green Published, Green Submitted			2023-01-03	WOS:000413195900102
J	Backhausen, MG; Tabor, A; Albert, H; Rosthoj, S; Damm, P; Hegaard, HK				Backhausen, Mette G.; Tabor, Ann; Albert, Hanne; Rosthoj, Susanne; Damm, Peter; Hegaard, Hanne K.			The effects of an unsupervised water exercise program on low back pain and sick leave among healthy pregnant women - A randomised controlled trial	PLOS ONE			English	Article							PELVIC GIRDLE PAIN; LUMBOPELVIC PAIN; STABILIZING EXERCISES; PREVALENCE; QUESTIONNAIRE; GUIDELINES	Background Low back pain is highly prevalent among pregnant women, but evidence of an effective treatment are still lacking. Supervised exercise-either land or water based-has shown benefits for low back pain, but no trial has investigated the evidence of an unsupervised water exercise program on low back pain. We aimed to assess the effect of an unsupervised water exercise program on low back pain intensity and days spent on sick leave among healthy pregnant women. Methods In this randomised, controlled, parallel-group trial, 516 healthy pregnant women were randomly assigned to either unsupervised water exercise twice a week for a period of 12 weeks or standard prenatal care. Healthy pregnant women aged 18 years or older, with a single fetus and between 16-17 gestational weeks were eligible. The primary outcome was low back pain intensity measured by the Low Back Pain Rating scale at 32 weeks. The secondary outcomes were self-reported days spent on sick leave, disability due to low back pain (Roland Morris Disability Questionnaire) and self-rated general health (EQ-5D and EQ-VAS). Results Low back pain intensity was significantly lower in the water exercise group, with a score of 2.01 (95% CI 1.75-2.26) vs. 2.38 in the control group (95% CI 2.12-2.64) (mean difference = 0.38, 95% CI 0.02-0.74 p = 0.04). No difference was found in the number of days spent on sick leave (median 4 vs. 4, p = 0.83), disability due to low back pain nor self-rated general health. There was a trend towards more women in the water exercise group reporting no low back pain at 32 weeks (21% vs. 14%, p = 0.07). Conclusions Unsupervised water exercise results in a statistically significant lower intensity of low back pain in healthy pregnant women, but the result was most likely not clinically significant. It did not affect the number of days on sick leave, disability due to low back pain nor self-rated health.	[Backhausen, Mette G.; Tabor, Ann; Damm, Peter; Hegaard, Hanne K.] Copenhagen Univ Hosp, Rigshosp, Dept Obstet, Copenhagen, Denmark; [Backhausen, Mette G.] Zealand Univ Hosp, Dept Gynecol & Obstet, Roskilde, Denmark; [Backhausen, Mette G.; Hegaard, Hanne K.] Copenhagen Univ Hosp, Rigshosp, Juliane Marie Ctr, Res Unit Womens & Childrens Hlth, Copenhagen, Denmark; [Tabor, Ann; Damm, Peter; Hegaard, Hanne K.] Univ Copenhagen, Fac Hlth & Med Sci, Inst Clin Med, Copenhagen, Denmark; [Albert, Hanne] Modic Clin, Odense, Denmark; [Rosthoj, Susanne] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen	Backhausen, MG (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Obstet, Copenhagen, Denmark.; Backhausen, MG (corresponding author), Zealand Univ Hosp, Dept Gynecol & Obstet, Roskilde, Denmark.; Backhausen, MG (corresponding author), Copenhagen Univ Hosp, Rigshosp, Juliane Marie Ctr, Res Unit Womens & Childrens Hlth, Copenhagen, Denmark.	mette.backhausen@regionh.dk	albert, hanne/L-7201-2019	Damm, Peter/0000-0002-2067-5246; Backhausen, Mette/0000-0002-8312-5567; Rosthoj, Susanne/0000-0002-3619-413X; Hegaard, Hanne Kristine/0000-0002-7093-0719; Tabor, Ann/0000-0001-7450-1543	Danish Rheumatism Association [R101-A2033]; Danish Association of Midwives; Lundbeck Foundation; Augustinus Foundation [12-0615]; TrygFonden [7-12-1088]	Danish Rheumatism Association; Danish Association of Midwives; Lundbeck Foundation(Lundbeckfonden); Augustinus Foundation; TrygFonden	This work was supported by TrygFonden (7-12-1088), www.trygfonden.dk (HKH); The Danish Rheumatism Association (R101-A2033), www.gigtforeningen.dk (HKH); The Danish Association of Midwives, www.jordemoderforeningen.dk (HKH); Lundbeck Foundation, www.lundbeckfonden.com (HKH); and The Augustinus Foundation (12-0615), www.augustinusfonden.dk (HKH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert HB, 2002, SPINE, V27, P2831, DOI 10.1097/00007632-200212150-00020; Andersen L K, 2015, SEXUAL REPROD HEALTH; Backhausen MG, 2014, SEX REPROD HEALTHC, V5, P176, DOI 10.1016/j.srhc.2014.09.005; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Broberg L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0756-0; Comm Obstet Practice, 2015, OBSTET GYNECOL, V126, pe135, DOI 10.1097/AOG.0000000000001214; Comm Obstetric Practice, 2002, INT J GYNECOL OBSTET, V77, P79; Eggen MH, 2012, PHYS THER, V92, P781, DOI 10.2522/ptj.20110119; Elden H, 2005, BMJ-BRIT MED J, V330, P761, DOI 10.1136/bmj.38397.507014.E0; George JW, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.869; Gjestland K, 2013, BRIT J SPORT MED, V47, P515, DOI 10.1136/bjsports-2012-091344; Granath AB, 2006, JOGNN-J OBST GYN NEO, V35, P465, DOI 10.1111/J.1552-6909.2006.00066.x; Haakstad LAH, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-66; Hegaard HK, 2011, MATERN CHILD HLTH J, V15, P806, DOI 10.1007/s10995-010-0647-y; Juhl M., 2009, PHYS EXERCISE PREGNA; Juhl M, 2010, EPIDEMIOLOGY, V21, P253, DOI 10.1097/EDE.0b013e3181cb6267; Katz VL, 2003, CLIN OBSTET GYNECOL, V46, P432, DOI 10.1097/00003081-200306000-00022; Kihlstrand M, 1999, ACTA OBSTET GYN SCAN, V78, P180, DOI 10.1034/j.1600-0412.1999.780302.x; Kluge J, 2011, INT J GYNECOL OBSTET, V113, P187, DOI 10.1016/j.ijgo.2010.10.030; Kordi R, 2013, J BACK MUSCULOSKELET, V26, P133, DOI 10.3233/BMR-2012-00357; Kovacs FM, 2012, SPINE, V37, P1516, DOI 10.1097/BRS.0b013e31824dcb74; Kristiansson P, 1996, SPINE, V21, P702, DOI 10.1097/00007632-199603150-00008; Liddle SD, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001139.pub4; MANNICHE C, 1994, PAIN, V57, P317, DOI 10.1016/0304-3959(94)90007-8; Mens JMA, 2009, OBSTET GYNECOL SURV, V64, P200, DOI 10.1097/OGX.0b013e3181950f1b; Miquelutti MA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-154; Mogren IM, 2005, SPINE, V30, P983, DOI 10.1097/01.brs.0000158957.42198.8e; Mogren I, 2006, ACTA OBSTET GYN SCAN, V85, P647, DOI 10.1080/00016340600607297; Morkved S, 2007, ACTA OBSTET GYN SCAN, V86, P276, DOI 10.1080/00016340601089651; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; OSTGAARD HC, 1991, SPINE, V16, P549, DOI 10.1097/00007632-199105000-00011; Owe KM, 2009, SCAND J MED SCI SPOR, V19, P637, DOI 10.1111/j.1600-0838.2008.00840.x; Pedersen BK, FYSISK AKTIVITET HAN, V2011; Pool-Goudzwaard A. L., 1998, Man Ther, V3, P12, DOI 10.1054/math.1998.0311; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Stafne SN, 2012, ACTA OBSTET GYN SCAN, V91, P552, DOI 10.1111/j.1600-0412.2012.01382.x; Stuge B, 2004, SPINE, V29, P351, DOI 10.1097/01.BRS.0000090827.16926.1D; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; van Buuren S., 2012, FLEXIBLE IMPUTATION; Vleeming A, 2008, EUR SPINE J, V17, P794, DOI 10.1007/s00586-008-0602-4; Wang SM, 2004, OBSTET GYNECOL, V104, P65, DOI 10.1097/01.AOG.0000129403.54061.0e	41	9	11	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0182114	10.1371/journal.pone.0182114	http://dx.doi.org/10.1371/journal.pone.0182114			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877165	Green Submitted, Green Published, gold			2023-01-03	WOS:000409391200011
J	Holloway, KA; Batmanabane, G; Puri, M; Tisocki, K				Holloway, Kathleen Anne; Batmanabane, Gitanjali; Puri, Monika; Tisocki, Klara			Antibiotic use in South East Asia and policies to promote appropriate use: reports from country situational analyses	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIMICROBIAL RESISTANCE; NEW-DELHI; MEDICINES		[Holloway, Kathleen Anne] Int Inst Hlth Management Res, Jaipur, Rajasthan, India; [Holloway, Kathleen Anne] Univ Sussex, Inst Dev Studies, Brighton, E Sussex, England; [Holloway, Kathleen Anne] Univ Delhi, Vallabhbhai Patel Chest Inst, New Delhi, India; [Batmanabane, Gitanjali] All India Inst Med Sci, Bhubaneswar, Orissa, India; [Puri, Monika; Tisocki, Klara] WHO Reg Off South East Asia, New Delhi, India	University of Sussex; University of Delhi; All India Institute of Medical Sciences (AIIMS) Bhubaneswar	Holloway, KA (corresponding author), Int Inst Hlth Management Res, Jaipur, Rajasthan, India.; Holloway, KA (corresponding author), Univ Sussex, Inst Dev Studies, Brighton, E Sussex, England.; Holloway, KA (corresponding author), Univ Delhi, Vallabhbhai Patel Chest Inst, New Delhi, India.	kaholloway54@gmail.com	Kotwani, Anita/ABF-6201-2021	Kotwani, Anita/0000-0003-3182-5155	WHO/SEARO	WHO/SEARO(World Health Organization)	We have read and understood BMJ policy on declaration of interests, and declare that all five authors were recruited by WHO to facilitate one or more country situational analyses and one or more of the meetings described in the manuscript. KAH is a former regional adviser in essential drugs and other medicines at WHO/SEARO. WHO/SEARO funded all the situational analyses.	[Anonymous], 2006, WHOTCM20062; Bigdeli M, 2014, MED HLTH SYSTEMS ADV, P18; Harbarth S, 2005, EMERG INFECT DIS, V11, P794, DOI 10.3201/eid1106.050167; Holloway K, 2011, WORLD MED SITUATION; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Holloway K. A., 2011, Regional Health Forum, V15, P122; Holloway KA, 2003, CLIN INFECT DIS   S1, V36, pS11; Holloway KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152020; Holloway KA, 2015, PAEDIATR INT CHILD H, V35, P5, DOI 10.1179/2046905514Y.0000000115; Holloway KA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001724; Holloway Kathleen Anne, 2011, Expert Rev Clin Pharmacol, V4, P335, DOI 10.1586/ecp.11.14; Kotwani A, 2014, TROP MED INT HEALTH, V19, P761, DOI 10.1111/tmi.12327; Kotwani A, 2012, VALUE HEALTH, V15, pS116, DOI 10.1016/j.jval.2011.11.008; Radyowijati A, 2003, SOC SCI MED, V57, P733, DOI 10.1016/S0277-9536(02)00422-7; Sumpradit N, 2017, BMJ-BRIT MED J, V358, P20, DOI 10.1136/bmj.j2423; Sumpradit N, 2012, B WORLD HEALTH ORGAN, V90, P905, DOI 10.2471/BLT.12.105445; WHO, 2001, WHO GLOB STRAT CONT; World Health Organisation, 2009, MED US PRIM HLTH CAR; World Health Organization, 2015, A6820 WHO; World Health Organization, 2007, WHO OP PACK ASS MON; World Health Organization, 2010, WHOEMPMPC20101; World Health Organization Regional Office for South-East Asia, 2011, INT M NEW DELH IND 1; World Health Organization Regional Office for South-East Asia, 2013, EFF MAN MED REP S E	23	51	51	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	2017	358						9	13	j2291	10.1136/bmj.j2291	http://dx.doi.org/10.1136/bmj.j2291			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG7ED	28874360	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000410575100001
J	Kang, HJ; Kim, SW; Son, SH				Kang, Hye Jin; Kim, Shin-Wook; Son, Seok Hyun			The feasibility of a heart block with an electron compensation as an alternative whole breast radiotherapy technique in patients with underlying cardiac or pulmonary disease	PLOS ONE			English	Article							MODULATED RADIATION-THERAPY; CONFORMAL RADIOTHERAPY; EARLY-STAGE; LOCAL RECURRENCE; CANCER; RISK; PNEUMONITIS; IRRADIATION; MASTECTOMY; IMRT	Purpose We aimed to evaluate the feasibility of the heart block with electron compensation (HBE) technique, based on three-dimensional conformal radiotherapy (3D-CRT) in left-sided breast cancer patients with underlying cardiac or pulmonary disease. Methods Twenty patients with left-sided breast cancer who were treated with whole breast radiotherapy (WBRT) were included in this study. Intensity-modulated radiotherapy (IMRT), 3D-CRT, and HBE treatment plans were generated for each patient. Based on the 3D-CRT plan, the HBE plan included a heart block from the medial tangential field to shield the heart and added an electron beam to compensate for the loss in target volume coverage. The dosimetric parameters for the heart and lung and the target volume between the three treatment types were compared. Results Of the three plans, the HBE plan yielded the most significant reduction in the doses received by the heart and lung (heart Dmean: 5.1 Gy vs. 12.9 Gy vs. 4.0 Gy and lung Dmean: 11.4 Gy vs. 13.2 Gy vs. 10.5 Gy, for 3D-CRT, IMRT, and HBE, respectively). Target coverage with all three techniques was within the acceptable range (Dmean 51.0 Gy vs. 51.2 Gy vs. 50.6 Gy, for 3D-CRT, IMRT, and HBE, respectively). Conclusions The HBE plan effectively reduced the amount of radiation exposure to the heart and lung. It could be beneficial for patients who are vulnerable to radiation-related cardiac or pulmonary toxicities.	[Kang, Hye Jin; Kim, Shin-Wook; Son, Seok Hyun] Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Dept Radiat Oncol, Seoul, South Korea	Catholic University of Korea	Son, SH (corresponding author), Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Dept Radiat Oncol, Seoul, South Korea.	sonshyun@catholic.ac.kr		Son, Seok Hyun/0000-0002-2577-1915				Abe O, 2005, LANCET, V366, P2087; Ahmed RS, 2008, MED DOSIM, V33, P71, DOI 10.1016/j.meddos.2007.10.001; Allen AM, 2006, INT J RADIAT ONCOL, V65, P640, DOI 10.1016/j.ijrobp.2006.03.012; Ares C, 2010, INT J RADIAT ONCOL, V76, P685, DOI 10.1016/j.ijrobp.2009.02.062; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Darby SC, 2010, INT J RADIAT ONCOL, V76, P656, DOI 10.1016/j.ijrobp.2009.09.064; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Formenti SC, 2007, J CLIN ONCOL, V25, P2236, DOI 10.1200/JCO.2006.09.1041; Gagliardi G, 1996, BRIT J RADIOL, V69, P839, DOI 10.1259/0007-1285-69-825-839; Gagliardi G, 2010, INT J RADIAT ONCOL, V76, pS77, DOI 10.1016/j.ijrobp.2009.04.093; Gerardina S, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160039; Gielda BT, 2011, AM J CLIN ONCOL-CANC, V34, P223, DOI 10.1097/COC.0b013e3181dbb9c1; Gokula K, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-268; Goldman UB, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-99; Hardenbergh PH, 2001, INT J RADIAT ONCOL, V49, P1023, DOI 10.1016/S0360-3016(00)01531-5; Hu Y, 2013, ONCOL LETT, V5, P714, DOI 10.3892/ol.2012.1053; JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402; Jaen J, 2006, INT J RADIAT ONCOL, V65, P1381, DOI 10.1016/j.ijrobp.2006.03.008; Jagsi R, 2010, J CLIN ONCOL, V28, P2396, DOI 10.1200/JCO.2009.26.8433; Kahan Z, 2007, INT J RADIAT ONCOL, V68, P673, DOI 10.1016/j.ijrobp.2006.12.016; Kong FM, 2015, SEMIN RADIAT ONCOL, V25, P100, DOI 10.1016/j.semradonc.2014.12.003; Lee TF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131736; Lin LL, 2015, ACTA ONCOL, V54, P1032, DOI 10.3109/0284186X.2015.1011756; Lind PA, 2006, INT J RADIAT ONCOL, V64, P765, DOI 10.1016/j.ijrobp.2005.08.011; Lind PARM, 2001, BREAST CANCER RES TR, V68, P199, DOI 10.1023/A:1012292019599; Lohr F, 2009, INT J RADIAT ONCOL, V74, P73, DOI 10.1016/j.ijrobp.2008.07.018; Ma CM, 2003, PHYS MED BIOL, V48, P909, DOI 10.1088/0031-9155/48/7/308; Marks LB, 1997, INT J RADIAT ONCOL, V38, P399, DOI 10.1016/S0360-3016(97)00013-8; Michalski A, 2014, MED DOSIM, V39, P163, DOI 10.1016/j.meddos.2013.12.003; Mulliez T, 2015, RADIOTHER ONCOL, V114, P79, DOI 10.1016/j.radonc.2014.11.038; Offersen BV, 2015, RADIOTHER ONCOL, V114, P3, DOI 10.1016/j.radonc.2014.11.030; Ozawa Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140437; Poggi MM, 2003, CANCER, V98, P697, DOI 10.1002/cncr.11580; Raj KA, 2006, CANCER J, V12, P309, DOI 10.1097/00130404-200607000-00010; Rudat V, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-26; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; Sanuki N, 2012, J RADIAT RES, V53, P110, DOI 10.1269/jrr.110142; Schubert LK, 2011, RADIOTHER ONCOL, V100, P241, DOI 10.1016/j.radonc.2011.01.004; Senkus-Konefka E, 2007, CANCER TREAT REV, V33, P578, DOI 10.1016/j.ctrv.2007.07.011; Swanson T, 2013, AM J CLIN ONCOL-CANC, V36, P24, DOI 10.1097/COC.0b013e31823fe481; Taylor CW, 2009, INT J RADIAT ONCOL, V73, P1061, DOI 10.1016/j.ijrobp.2008.05.066; van Nimwegen FA, 2016, J CLIN ONCOL, V34, P235, DOI 10.1200/JCO.2015.63.4444; Wang SL, 2006, INT J RADIAT ONCOL, V66, P1399, DOI 10.1016/j.ijrobp.2006.07.1337; Wollschlager D, 2016, RADIOTHER ONCOL, V119, P65, DOI 10.1016/j.radonc.2016.01.020	45	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2017	12	9							e0184137	10.1371/journal.pone.0184137	http://dx.doi.org/10.1371/journal.pone.0184137			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF3ON	28863179	Green Submitted, gold, Green Published			2023-01-03	WOS:000408816900030
J	Kaushik, J; Tandon, S; Gupta, V; Nayyar, J; Singla, SK; Tandon, C				Kaushik, Jyoti; Tandon, Simran; Gupta, Varun; Nayyar, Jasamrit; Singla, Surinder Kumar; Tandon, Chanderdeep			Response surface methodology based extraction of Tribulus terrestris leads to an upsurge of antilithiatic potential by inhibition of calcium oxalate crystallization processes	PLOS ONE			English	Article							DIHYDRATE CRYSTALS; CELLS; MONOHYDRATE; OPTIMIZATION; PROTEIN	Tribulus terrestris has significant antilithiatic efficacy established via both in vitro as well as in vivo studies and is used in numerous anti-urolithiatic herbal formulations viz. Cystone, Uri-flow, Uritone and Neeri. However, to fully utilize its antilithiatic potential, the influence of different extraction parameters on antilithiatic ability of T. terrestris aqueous extract needs elucidation. Thus, the current study was undertaken using statistically optimized extraction conditions for aqueous extract preparation. Response surface methodology was employed to observe the influence of three variables i.e. temperature (degrees C), time (h) and solid: liquid ratio (S: L) on the extraction yield (%) and protein content (mg/g) of T. terrestris aqueous extract. RSM results revealed that the high S: L ratio, low temperature and reduced incubation time were optimal conditions for aqueous extraction. Under such extraction conditions the protein content reached the value of 26.6 +/- 1.22 mg/g and the obtained extraction yield was 27.32 +/- 1.62%. The assessment of antilithiatic activity of 4 selected extracts (AE1-4), revealed enhanced nucleation and aggregation inhibition of calcium oxalate crystals with AE1 and AE2, which in addition significantly altered the size and morphology of calcium oxalate monohydrate (COM) crystals compared to AE3 and AE4. In vitro cell culture based studies on renal epithelial cells (MDCK, NRK-52E and PK 15) proved that the AE1 showed higher cytoprotective potency by increasing cell viability as compared to the oxalate treated group. The free radical scavenging activity of aqueous extract lowered the reactive oxygen specie's induced damage and potentially reduced the signals of programmed cell death due to oxalate injury. In addition, modulation of the COM crystal morphology was enhanced by AE1 as compared to AE2. The FTIR and GC-MS analysis of AE1, showed the presence of biomolecules which could aid in the attenuation of lithiatic process. In the light of these results the utility of the RSM approach to fully optimize the antilithiatic potential of T. terrestris cannot be undermined.	[Kaushik, Jyoti; Tandon, Chanderdeep] Amity Univ, Amity Inst Biotechnol, Noida, India; [Tandon, Simran] Amity Univ, Amity Inst Mol Med & Stem Cell Res, Noida, India; [Gupta, Varun] Jaypee Univ Informat Technol, Dept Biotechnol & Bioinformat, Solan, Himachal Prades, India; [Nayyar, Jasamrit] SD Coll, Dept Chem, Chandigarh, India; [Singla, Surinder Kumar] Panjab Univ, Dept Biochem, Chandigarh, India	Amity University Noida; Amity University Noida; Jaypee University of Information Technology; Goswami Ganesh Dutta S. D. College; Panjab University	Tandon, C (corresponding author), Amity Univ, Amity Inst Biotechnol, Noida, India.	ctandon@amity.edu	Tandon, Chanderdeep/AAF-1124-2020; TANDON, simran/AAF-1158-2020; Kaur, Jasamrit/AAI-1966-2020; Kumar, Varun/AAC-9780-2020	Tandon, Chanderdeep/0000-0003-3720-0455; Kaur, Jasamrit/0000-0002-6068-1245; Tandon, Simran/0000-0002-6937-0216	Department of Biotechnology (DBT) [BT/PR7290/PBD/17/853/2013]; Ministry of Science and Technology, Govt. of India	Department of Biotechnology (DBT)(Department of Biotechnology (DBT) India); Ministry of Science and Technology, Govt. of India	This work was funded by Department of Biotechnology (DBT), Project No. BT/PR7290/PBD/17/853/2013, Ministry of Science and Technology, Govt. of India.; This work was financially supported by the Department of Biotechnology (DBT), Project No. BT/PR7290/PBD/17/853/2013, Ministry of Science and Technology, Govt. of India and carried out at Amity University, Noida, India.	Aggarwal A, 2014, INDIAN J EXP BIOL, V52, P103; Aggarwal A, 2012, PROTEIN PEPTIDE LETT, V19, P812, DOI 10.2174/092986612801619552; Aparna V, 2012, CHEM BIOL DRUG DES, V80, P434, DOI 10.1111/j.1747-0285.2012.01418.x; Barros ME, 2003, UROL RES, V30, P374, DOI 10.1007/s00240-002-0285-y; Bashir S, 2009, J ETHNOPHARMACOL, V122, P106, DOI 10.1016/j.jep.2008.12.004; Basvaraj DR, 2007, EUR ASS UROL, V5, P126; Bele A.A., 2011, IRJP, V2, P56; BOX GEP, 1951, J R STAT SOC B, V13, P1, DOI 10.1111/j.2517-6161.1951.tb00067.x; Box GEP, 2005, STAT EXPT, V2nd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Citalingam K, 2015, MOLECULES, V20, P3406, DOI 10.3390/molecules20023406; Coe FL, 2005, J CLIN INVEST, V115, P2598, DOI 10.1172/JCI26662; Conrad J, 2004, FITOTERAPIA, V75, P117, DOI 10.1016/j.fitote.2003.09.001; Indu S., 2014, EUR J BIOT BIOS, V2, P38; Jambrak AR, 2011, J FOOD PROCESSING TE, V2, P2, DOI [10.4172/2157-7110.1000102e, DOI 10.4172/2157-7110.1000102E]; Joshi VS, 2005, J CRYST GROWTH, V275, pE1403, DOI 10.1016/j.jcrysgro.2004.11.240; Khan S., 2000, EFFECTS EXTRACT HERN, P621; Khan Saeed R, 2004, Clin Exp Nephrol, V8, P75; Khan SR, 2014, TRANSL ANDROL UROL, V3, P256, DOI 10.3978/j.issn.2223-4683.2014.06.04; Kim JH, 2014, PHARMACOGN MAG, V10, P606, DOI 10.4103/0973-1296.139798; Koganti B, 2008, EVALUATION SESBANIA, P300; Kumari V, 2016, 3 BIOTECH, V6, DOI 10.1007/s13205-016-0460-4; Lieske JC, 1996, CALCIFIED TISSUE INT, V58, P195, DOI 10.1007/BF02526887; Lieske JC, 1998, KIDNEY INT, V54, P796, DOI 10.1046/j.1523-1755.1998.00058.x; Liyana-Pathirana CM, 2005, J AGR FOOD CHEM, V53, P2433, DOI 10.1021/jf049320i; Mitra N., 2012, International Journal of Modern Botany, V2, P35, DOI 10.5923/j.ijmb.20120203.01; Mittal A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162600; Nessa F, 2015, EUROPEAN J MED PLANT, V9, P1; Pachana K, 2010, SCIENCEASIA, V36, P165, DOI 10.2306/scienceasia1513-1874.2010.36.165; Prasad K., 2007, PHCOG REV, V1, P175; Price R., 1985, PHYSL PLANT PATHOL, V27, P255, DOI DOI 10.1016/0048-4059(85)90073-6; Raja M., 2011, Der Pharmacia Sinica, V2, P136; Schepers MSJ, 2003, KIDNEY INT, V64, P493, DOI 10.1046/j.1523-1755.2003.00107.x; Sharma D, 2016, EGYPT J BASIC APPL S, P1; Shi H, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-83; Sun XY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.359; Usman H., 2007, RES J BIOSCI, V2, P244; Wang TT, 2010, BJU INT, V106, P1768, DOI 10.1111/j.1464-410X.2010.09258.x; WHO, 2002, ANC REM NEW DIS; Wiessner JH, 2001, KIDNEY INT, V59, P637, DOI 10.1046/j.1523-1755.2001.059002637.x; World Health Organisation (WHO), 2002, MON SEL MED PLANTS; Wu TS, 1999, PHYTOCHEMISTRY, V50, P1411, DOI 10.1016/S0031-9422(97)01086-8; Zhang CY, 2012, MAR DRUGS, V10, P119, DOI 10.3390/md10010119	43	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2017	12	8							e0183218	10.1371/journal.pone.0183218	http://dx.doi.org/10.1371/journal.pone.0183218			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE8EO	28846699	gold, Green Submitted, Green Published			2023-01-03	WOS:000408438600023
J	Hendlin, YH; Elias, J; Ling, PM				Hendlin, Yogi Hale; Elias, Jesse; Ling, Pamela M.			The Pharmaceuticalization of the Tobacco Industry	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hendlin, Yogi Hale; Elias, Jesse; Ling, Pamela M.] Univ Calif San Francisco, 530 Parnassus Ave,Suite 366, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Ling, PM (corresponding author), Univ Calif San Francisco, 530 Parnassus Ave,Suite 366, San Francisco, CA 94143 USA.	pamela.ling@ucsf.edu	Hendlin, Yogi/Q-9777-2019	Hendlin, Yogi/0000-0002-1714-6132; Ling, Pamela/0000-0001-6166-9347	National Cancer Institute at the National Institutes of Health [R01-CA141661, R01-87472]; NATIONAL CANCER INSTITUTE [R01CA087472, R01CA141661] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	By the National Cancer Institute at the National Institutes of Health (grants R01-CA141661 and R01-87472).	Crowley RA, 2015, ANN INTERN MED, V162, P583, DOI 10.7326/M14-2481; Euromonitor International, 2016, GLOB TOB KEY FIND PA; Food and Drug Administration HHS, 2017, FINAL RULE PUBMED FE, V82, P2193; Medicines and Healthcare products Regulatory Agency, 2017, LIC PROC EL CIG OTH; Philip Morris International, 2016, ASS RISK RED; Reynolds R.J., 2008, RJRT STRATEGIC REV; Syqe Medical, 2016, THE SYQ INH; WHO, 2008, GUID IMPL ART 5 3 WH; Williams SJ, 2011, SOCIOL HEALTH ILL, V33, P710, DOI 10.1111/j.1467-9566.2011.01320.x	9	19	19	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	2017	167	4					278	+		10.7326/M17-0759	http://dx.doi.org/10.7326/M17-0759			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD8TR	28715843	Green Accepted, Green Submitted			2023-01-03	WOS:000407797500017
J	Chee, CG; Kim, YH; Lee, KH; Lee, YJ; Park, JH; Lee, HS; Ahn, S; Kim, B				Chee, Choong Guen; Kim, Young Hoon; Lee, Kyoung Ho; Lee, Yoon Jin; Park, Ji Hoon; Lee, Hye Seung; Ahn, Soyeon; Kim, Bohyoung			CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis	PLOS ONE			English	Article							TUMOR HETEROGENEITY; RADIATION-THERAPY; PREOPERATIVE CHEMORADIOTHERAPY; PREDICTS SURVIVAL; UTERINE CERVIX; HYPOXIA; CARCINOMA; CHEMORADIATION; CHEMOTHERAPY; ASSOCIATION	Purpose To evaluate the association of computed tomography (CT) texture features of locally advanced rectal cancer with neoadjuvant chemoradiotherapy (CRT) response and disease-free survival (DFS). Methods and findings The institutional review board approved this retrospective study. 95 patients who received neoadjuvant CRT, followed by surgery, for locally advanced rectal cancer were included. Texture features (entropy, uniformity, kurtosis, skewness, and standard deviation) were assessed in pretreatment CT images and obtained without filtration and with Laplacian of Gaussian spatial filter of various filter values (1.0, 1.5, 2.0, and 2.5). Dworak pathologic grading was used for treatment response assessment. Independent t-test was used to compare each texture feature between the treatment responder and non-responder groups. DFS was assessed with Kaplan-Meier method, and differences were compared with log-rank test. Cox proportional hazards models were constructed to predict prognosis based on stage, age, and each texture feature. Treatment responders (n = 32) showed significantly lower entropy, higher uniformity, and lower standard deviation in no filtration, fine (1.0), and medium (1.5) filter values. Entropy, uniformity, and standard deviation without filtration showed significant difference in DFS in Kaplan-Meier analysis (P = 0.015, 0.025, and 0.038). Homogeneous texture features (<= 6.7 for entropy, > 0.0118 for uniformity, and <= 28.06 for standard deviation) were associated with higher DFS. Entropy, uniformity, and standard deviation were independent texture features in predicting DFS (P = 0.017, 0.03, and 0.036) Conclusions Homogeneous texture features are associated with better neoadjuvant CRT response and higher DFS in patients with locally advanced rectal cancer.	[Chee, Choong Guen; Kim, Young Hoon; Lee, Kyoung Ho; Lee, Yoon Jin; Park, Ji Hoon] Seoul Natl Univ, Bundang Hosp, Dept Radiol, Coll Med,Inst Radiat Med,Med Res Ctr, Seongnamsi, South Korea; [Lee, Hye Seung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Pathol, Seongnam Si, South Korea; [Ahn, Soyeon] Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Seongnam Si, South Korea; [Kim, Bohyoung] Hankuk Univ Foreign Studies, Div Biomed Engn, Yongin, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Hankuk University Foreign Studies	Kim, YH (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Radiol, Coll Med,Inst Radiat Med,Med Res Ctr, Seongnamsi, South Korea.	yhkrad@gmail.com	Lee, Hye Seung/G-6419-2011	Lee, Hye Seung/0000-0002-1667-7986; Lee, Kyoung Ho/0000-0001-6045-765X	SNUBH Research fund [02-2016-031]	SNUBH Research fund	This work was supported by SNUBH Research fund (https://rnsri.snubh.org/index.do), Grant number: 02-2016-031.	Bezy-Wendling J, 2001, IEEE T BIO-MED ENG, V48, P120, DOI 10.1109/10.900272; Chan I, 2006, J CLIN ONCOL, V24, P668, DOI 10.1200/JCO.2005.04.4875; Davnall F, 2012, INSIGHTS IMAGING, V3, P573, DOI 10.1007/s13244-012-0196-6; DeVries AF, 2014, INT J RADIAT ONCOL, V90, P1161, DOI 10.1016/j.ijrobp.2014.07.042; Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Ganeshan B, 2012, CLIN RADIOL, V67, P157, DOI 10.1016/j.crad.2011.08.012; Ganeshan B, 2012, EUR RADIOL, V22, P796, DOI 10.1007/s00330-011-2319-8; Goh V, 2011, RADIOLOGY, V261, P165, DOI 10.1148/radiol.11110264; Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; Hockel M, 1996, CANCER RES, V56, P4509; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Kim SH, 2009, RADIOLOGY, V253, P116, DOI 10.1148/radiol.2532090027; Lubner MG, 2015, ABDOM IMAGING, V40, P2331, DOI 10.1007/s00261-015-0438-4; Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI 10.1200/JCO.2011.37.7176; Martin ST, 2012, BRIT J SURG, V99, P918, DOI 10.1002/bjs.8702; Miles KA, 2009, RADIOLOGY, V250, P444, DOI 10.1148/radiol.2502071879; Movsas B, 2000, CANCER, V89, P2018, DOI 10.1002/1097-0142(20001101)89:9<2018::AID-CNCR19>3.3.CO;2-P; National cancer information center, CANC FACTS FIG 2012; National Comprehensive Cancer Network, 2015, RECT CANC VERS 2 201; Ng F, 2013, EUR J RADIOL, V82, P342, DOI 10.1016/j.ejrad.2012.10.023; Ng F, 2013, RADIOLOGY, V266, P177, DOI 10.1148/radiol.12120254; Park IJ, 2012, J CLIN ONCOL, V30, P1770, DOI 10.1200/JCO.2011.39.7901; Pucciarelli S, 2013, DIS COLON RECTUM, V56, P1349, DOI 10.1097/DCR.0b013e3182a2303e; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Taylor FGM, 2011, ANN SURG, V253, P711, DOI 10.1097/SLA.0b013e31820b8d52; TEICHER BA, 1995, HEMATOL ONCOL CLIN N, V9, P475; Yang ZH, 2011, AM J SURG PATHOL, V35, P853, DOI 10.1097/PAS.0b013e31821a0696; Yip C, 2014, RADIOLOGY, V270, P141, DOI 10.1148/radiol.13122869; Zhang HW, 2013, RADIOLOGY, V269, P801, DOI 10.1148/radiol.13130110	33	54	59	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0182883	10.1371/journal.pone.0182883	http://dx.doi.org/10.1371/journal.pone.0182883			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28797063	Green Submitted, Green Published, gold			2023-01-03	WOS:000407396200112
J	Choi, YR; Kim, JH; Park, SJ; Hur, BY; Han, JK				Choi, Ye Ra; Kim, Jung Hoon; Park, Sang Joon; Hur, Bo Yun; Han, Joon Koo			Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images	PLOS ONE			English	Article							3-DIMENSIONAL ULTRASOUND; VOLUMETRIC MEASUREMENTS; LIVER-TRANSPLANTATION; VERSION 1.1; RELIABILITY; ULTRASONOGRAPHY; VALIDITY; RECIST; CRITERIA; NODULES	Background & aims To evaluate accuracy and reliability of three-dimensional ultrasound (3D US) for response evaluation of hepatic metastasis from colorectal cancer (CRC) using a personalized 3D-printed tumor model. Methods Twenty patients with liver metastasis from CRC who underwent baseline and after chemotherapy CT, were retrospectively included. Personalized 3D-printed tumor models using CT were fabricated. Two radiologists measured volume of each 3D printing model using 3D US. With CT as a reference, we compared difference between CT and US tumor volume. The response evaluation was based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results 3D US tumor volume showed no significant difference from CT volume (7.18 +/- 5.44 mL, 8.31 +/- 6.32 mL vs 7.42 +/- 5.76 mL in CT, p>0.05). 3D US provided a high correlation coefficient with CT (r = 0.953, r = 0.97) as well as a high inter-observer intraclass correlation (0.978; 0.958-0.988). Regarding response, 3D US was in agreement with CT in 17 and 18 out of 20 patients for observer 1 and 2 with excellent agreement (k = 0.961). Conclusions 3D US tumor volume using a personalized 3D-printed model is an accurate and reliable method for the response evaluation in comparison with CT tumor volume.	[Choi, Ye Ra] Boramae Med Ctr, Dept Radiol, Seoul, South Korea; [Kim, Jung Hoon; Han, Joon Koo] Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea; [Kim, Jung Hoon; Han, Joon Koo] Seoul Natl Univ, Coll Med, Inst Radiat Med, Seoul, South Korea; [Park, Sang Joon] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Hur, Bo Yun] Natl Canc Ctr, Dept Radiol, Gyeonggi Do, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC)	Kim, JH (corresponding author), Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea.; Kim, JH (corresponding author), Seoul Natl Univ, Coll Med, Inst Radiat Med, Seoul, South Korea.	jhkim2008@gmail.com			National Research Foundation of Korea (NRF) - Ministry of Education [2013 R1 A1 A2058033]	National Research Foundation of Korea (NRF) - Ministry of Education	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2013 R1 A1 A2058033).; This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2013 R1 A1 A2058033). We thank Bonnie Hami, M.A. (USA) for her editorial assistance in the preparation of this manuscript.	Baimakhanov Z, 2015, LIVER TRANSPLANT, V21, P266, DOI 10.1002/lt.24019; Benacerraf BR, 2006, J ULTRAS MED, V25, P165, DOI 10.7863/jum.2006.25.2.165; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boito SME, 2002, RADIOLOGY, V223, P661, DOI 10.1148/radiol.2233010656; Burfeindt MJ, 2012, IEEE ANTENN WIREL PR, V11, P1610, DOI 10.1109/LAWP.2012.2236293; Chang FM, 1997, ULTRASOUND MED BIOL, V23, P381, DOI 10.1016/S0301-5629(96)00218-9; Chung WS, 2012, AM J ROENTGENOL, V199, P809, DOI 10.2214/AJR.11.7910; Downey DB, 2000, RADIOGRAPHICS, V20, P559, DOI 10.1148/radiographics.20.2.g00mc19559; Ehler ED, 2014, PHYS MED BIOL, V59, P5763, DOI 10.1088/0031-9155/59/19/5763; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fang WJ, 2013, ASIAN PAC J CANCER P, V14, P4151, DOI 10.7314/APJCP.2013.14.7.4151; Farrell T, 2001, BRIT J OBSTET GYNAEC, V108, P573, DOI 10.1016/S0306-5456(00)00148-0; Frauenfelder T, 2011, EUR RESPIR J, V38, P162, DOI 10.1183/09031936.00146110; Galizia MS, 2011, ACAD RADIOL, V18, P1555, DOI 10.1016/j.acra.2011.08.011; Igami T, 2014, WORLD J SURG, V38, P3163, DOI 10.1007/s00268-014-2740-7; Kim HC, 2002, ACTA RADIOL, V43, P571, DOI 10.1034/j.1600-0455.2002.430606.x; Landry A, 2004, STROKE, V35, P864, DOI 10.1161/01.STR.0000121161.61324.ab; Lyshchik A, 2004, J ULTRAS MED, V23, P247, DOI 10.7863/jum.2004.23.2.247; Martins WP, 2007, ULTRASOUND OBST GYN, V29, P210, DOI 10.1002/uog.3916; Matsumoto JS, 2015, RADIOGRAPHICS, V35, P1990, DOI 10.1148/rg.2015140260; Mitsouras D, 2015, RADIOGRAPHICS, V35, P1966, DOI 10.1148/rg.2015140320; Pang BSF, 2006, ULTRASOUND MED BIOL, V32, P1193, DOI 10.1016/j.ultrasmedbio.2006.04.012; Park SH, 2004, ULTRASOUND MED BIOL, V30, P27, DOI 10.1016/j.ultrasmedbio.2003.09.010; Pauletzki J, 1996, J CLIN ULTRASOUND, V24, P277, DOI 10.1002/(SICI)1097-0096(199607/08)24:6<277::AID-JCU1>3.0.CO;2-F; Prasad SR, 2002, RADIOLOGY, V225, P416, DOI 10.1148/radiol.2252011604; Raine-Fenning NJ, 2003, ULTRASOUND OBST GYN, V21, P283, DOI 10.1002/uog.61; Sohaib SA, 2000, BRIT J RADIOL, V73, P1178, DOI 10.1259/bjr.73.875.11144795; Souzaki R, 2015, PEDIATR SURG INT, V31, P593, DOI 10.1007/s00383-015-3709-9; Tong SD, 1998, ULTRASOUND MED BIOL, V24, P673, DOI 10.1016/S0301-5629(98)00039-8; Tran LN, 2004, ACAD RADIOL, V11, P1355, DOI 10.1016/j.acra.2004.09.004; Vogl TJ, 2008, RADIOLOGY, V249, P865, DOI 10.1148/radiol.2491072079; Winer-Muram HT, 2003, RADIOLOGY, V229, P184, DOI 10.1148/radiol.2291020859; Xu HX, 2003, ULTRASOUND MED BIOL, V29, P839, DOI 10.1016/S0301-5629(02)00775-5; Yankelevitz DF, 2000, RADIOLOGY, V217, P251, DOI 10.1148/radiology.217.1.r00oc33251	34	9	11	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0182596	10.1371/journal.pone.0182596	http://dx.doi.org/10.1371/journal.pone.0182596			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28797089	Green Submitted, gold, Green Published			2023-01-03	WOS:000407396200067
J	Agar, M; Luckett, T; Luscombe, G; Phillips, J; Beattie, E; Pond, D; Mitchell, G; Davidson, PM; Cook, J; Brooks, D; Houltram, J; Goodall, S; Chenoweth, L				Agar, Meera; Luckett, Tim; Luscombe, Georgina; Phillips, Jane; Beattie, Elizabeth; Pond, Dimity; Mitchell, Geoffrey; Davidson, Patricia M.; Cook, Janet; Brooks, Deborah; Houltram, Jennifer; Goodall, Stephen; Chenoweth, Lynnette			Effects of facilitated family case conferencing for advanced dementia: A cluster randomised clinical trial	PLOS ONE			English	Article							OF-LIFE CARE; NURSING-HOME RESIDENTS; PALLIATIVE CARE; OLDER-PEOPLE; END; OUTCOMES; SCALES; CHALLENGES; DECISIONS; ATTITUDES	Background Palliative care planning for nursing home residents with advanced dementia is often suboptimal. This study compared effects of facilitated case conferencing (FCC) with usual care (UC) on end-of-life care. Methods A two arm parallel cluster randomised controlled trial was conducted. The sample included people with advanced dementia from 20 Australian nursing homes and their families and professional caregivers. In each intervention nursing home (n = 10), Palliative Care Planning Coordinators (PCPCs) facilitated family case conferences and trained staff in person-centred palliative care for 16 hours per week over 18 months. The primary outcome was familyrated quality of end-of-life care (End-of-Life Dementia [EOLD] Scales). Secondary outcomes included nurse-rated EOLD scales, resident quality of life (Quality of Life in Latestage Dementia [QUALID]) and quality of care over the last month of life (pharmacological/non-pharmacological palliative strategies, hospitalization or inappropriate interventions). Results Two-hundred-eighty-six people with advanced dementia took part but only 131 died (64 in UC and 67 in FCC which was fewer than anticipated), rendering the primary analysis under- powered with no group effect seen in EOLD scales. Significant differences in pharmacological (P < 0.01) and non-pharmacological (P < 0.05) palliative management in last month of life were seen. Intercurrent illness was associated with lower family-rated EOLD Satisfaction with Care (coefficient 2.97, P < 0.05) and lower staff-rated EOLD Comfort Assessment with Dying (coefficient 4.37, P < 0.01). Per protocol analyses showed positive relationships between EOLD and staff hours to bed ratios, proportion of residents with dementia and staff attitudes. Conclusion FCC facilitates a palliative approach to care. Future trials of case conferencing should consider outcomes and processes regarding decision making and planning for anticipated events and acute illness.	[Agar, Meera; Luckett, Tim; Phillips, Jane; Davidson, Patricia M.; Cook, Janet] Univ Technol Sydney, Fac Hlth, Ultimo, NSW, Australia; [Agar, Meera] Univ New South Wales, South Western Sydney Clin Sch, Liverpool, NSW, Australia; [Agar, Meera] Ingham Inst Appl Med Res, Liverpool, NSW, Australia; [Agar, Meera] Improving Palliat Care Clin Trials ImPaCCT, Sydney, NSW, Australia; [Luscombe, Georgina] Univ Sydney, Sydney Med Sch, Ultimo, NSW, Australia; [Beattie, Elizabeth; Brooks, Deborah] Queensland Univ Technol, Sch Nursing, Herston, Qld, Australia; [Pond, Dimity] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Mitchell, Geoffrey] Univ Queensland, Fac Med, St Lucia, Qld, Australia; [Davidson, Patricia M.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; [Houltram, Jennifer; Goodall, Stephen] UTS, Fac Business, Ctr Hlth Res & Evaluat CHERE, Haymarket, NSW, Australia; [Chenoweth, Lynnette] Univ New South Wales, Ctr Hlth Brain Ageing, Randwick, NSW, Australia	University of Technology Sydney; University of New South Wales Sydney; Ingham Institute for Applied Medical Research; University of Sydney; Queensland University of Technology (QUT); University of Newcastle; University of Queensland; Johns Hopkins University; University of Technology Sydney; University of New South Wales Sydney	Luckett, T (corresponding author), Univ Technol Sydney, Fac Hlth, Ultimo, NSW, Australia.	tim.luckett@uts.edu.au	Phillips, Jane/A-7780-2015; Pond, Constance Dimity/I-1390-2019; Agar, Meera/AAI-4002-2021; Luscombe, Georgina/L-4460-2019	Phillips, Jane/0000-0002-3691-8230; Pond, Constance Dimity/0000-0001-6520-4213; Agar, Meera/0000-0002-6756-6119; Luscombe, Georgina/0000-0002-4767-5131; Brooks, Deborah/0000-0003-4902-0654; Davidson, Patricia M./0000-0003-2050-1534; Luckett, Tim/0000-0001-6121-5409	Australian Department of Health	Australian Department of Health(Australian GovernmentDepartment of Health & Ageing)	This work was supported by the Australian Department of Health (previously Department of Health and Ageing) (http://www.health.gov.au/).	Abbey J, 2008, DEV TRIAL EVALUATE M; Abernethy Amy P, 2005, BMC Palliat Care, V4, P7; Abernethy AP, 2013, J PAIN SYMPTOM MANAG, V45, P488, DOI 10.1016/j.jpainsymman.2012.02.024; Abernethy AP, 2006, CONTEMP CLIN TRIALS, V27, P83, DOI 10.1016/j.cct.2005.09.006; Abernethy AP, 2007, 8 AUSTR PALL CAR C S; Agar M, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0061-8; Bayer A, 2006, AGE AGEING, V35, P101, DOI 10.1093/ageing/afj033; Birch D, 2008, J CLIN NURS, V17, P1144, DOI 10.1111/j.1365-2702.2007.02220.x; Bosek Marcia Sue DeWolf, 2003, JONAS Healthc Law Ethics Regul, V5, P34, DOI 10.1097/00128488-200306000-00006; Chang E, 2009, INT J NURS PRACT, V15, P41, DOI 10.1111/j.1440-172X.2008.01723.x; Clay-Williams R, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-369; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Di Giulio P, 2008, J PALLIAT MED, V11, P1023, DOI 10.1089/jpm.2008.0020; Engel SE, 2006, J AM GERIATR SOC, V54, P1567, DOI 10.1111/j.1532-5415.2006.00900.x; ERSEK M, 2006, J HOSP PALLIAT NURS, V8, P42; Givens JL, 2010, ARCH INTERN MED, V170, P1102, DOI 10.1001/archinternmed.2010.181; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Hertogh CMPM, 2006, AGE AGEING, V35, P553, DOI 10.1093/ageing/afl103; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; Kiely DK, 2006, ALZ DIS ASSOC DIS, V20, P176, DOI 10.1097/00002093-200607000-00009; Kiely DK, 2012, ALZ DIS ASSOC DIS, V26, P358, DOI 10.1097/WAD.0b013e318247c41b; Kiely DK, 2012, SCALES EVALUATION EN; Long CO, 2012, AM J ALZHEIMERS DIS, V27, P537, DOI 10.1177/1533317512459793; Lurie JD, 2013, J COMP EFFECT RES, V2, P53, DOI [10.2217/CER.12.74, 10.2217/cer.12.74]; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; McAuliffe L, 2009, J ADV NURS, V65, P2, DOI 10.1111/j.1365-2648.2008.04861.x; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Mitchell GK, 2008, PALLIATIVE MED, V22, P904, DOI 10.1177/0269216308096721; Mitchell Geoffrey, 2005, Aust Fam Physician, V34, P389; Mitchell GK, 2002, MED J AUSTRALIA, V177, P95, DOI 10.5694/j.1326-5377.2002.tb04680.x; Mitchell SL, 2004, ARCH INTERN MED, V164, P321, DOI 10.1001/archinte.164.3.321; Mitchell SL, 2007, J AM GERIATR SOC, V55, P432, DOI 10.1111/j.1532-5415.2007.01086.x; Mitchell SL, 2015, NEW ENGL J MED, V372, P2533, DOI [10.1056/NEJMcp1412652, 10.1056/NEJMc1509349]; Mitchell SL, 2010, J PAIN SYMPTOM MANAG, V40, P639, DOI 10.1016/j.jpainsymman.2010.02.014; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Phillips JL, 2013, INT J NURS STUD, V50, P1122, DOI 10.1016/j.ijnurstu.2012.11.001; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Reuther S, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-319; Reuther S, 2012, INT PSYCHOGERIATR, V24, P1891, DOI 10.1017/S1041610212001342; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Rurup ML, 2006, PATIENT EDUC COUNS, V61, P372, DOI 10.1016/j.pec.2005.04.016; Sampson EL, 2006, AGE AGEING, V35, P187, DOI 10.1093/ageing/afj025; Sorrell JM, 2010, J PSYCHOSOC NURS MEN, V48, P15, DOI 10.3928/02793695-20100331-02; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Teno Joan M, 2003, J Palliat Med, V6, P293, DOI 10.1089/109662103764978614; van der Steen JT, 2014, ALZ DIS ASSOC DIS, V28, P88, DOI 10.1097/WAD.0b013e318293b380; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; van der Steen JT, 2012, J PALLIAT MED, V15, P1292, DOI 10.1089/jpm.2012.0136; van der Steen JT, 2009, INT PSYCHOGERIATR, V21, P321, DOI 10.1017/S1041610208008399; van Soest-Poortvliet MC, 2015, PALLIATIVE MED, V29, P538, DOI 10.1177/0269216315570409; van Soest-Poortvliet MC, 2012, QUAL LIFE RES, V21, P671, DOI 10.1007/s11136-011-9978-4; Volicer L, 2001, ALZ DIS ASSOC DIS, V15, P194, DOI 10.1097/00002093-200110000-00005; Weiner M F, 2000, J Am Med Dir Assoc, V1, P114; Zimmerman S, 2015, J PAIN SYMPTOM MANAG, V49, P666, DOI 10.1016/j.jpainsymman.2014.08.009	55	40	40	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2017	12	8							e0181020	10.1371/journal.pone.0181020	http://dx.doi.org/10.1371/journal.pone.0181020			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC7CP	28786995	Green Submitted, Green Published, gold			2023-01-03	WOS:000406998800004
J	Staveteig, S				Staveteig, Sarah			Fear, opposition, ambivalence, and omission: Results from a follow-up study on unmet need for family planning in Ghana	PLOS ONE			English	Article							FERTILITY PREFERENCES; QUALITATIVE METHODS; CONTRACEPTIVE USE; TIME DYNAMICS; WOMEN	Introduction Despite a relatively strong family planning program and regionally modest levels of fertility, Ghana recorded one of the highest levels of unmet need for family planning on the African continent in 2008. Unmet need for family planning is a composite measure based on apparent contradictions between women's reproductive preferences and practices. Women who want to space or limit births but are not using contraception are considered to have an unmet need for family planning. The study sought to understand the reasons behind high levels of unmet need for family planning in Ghana. Methods A mixed methods follow-up study was embedded within the stratified, two-stage cluster sample of the 2014 Ghana Demographic and Health Survey (GDHS). Women in 13 survey clusters who were identified as having unmet need, along with a reference group of current family planning users, were approached to be reinterviewed within an average of three weeks from their GDHS interview. Follow-up respondents were asked a combination of closed- and open-ended questions about fertility preferences and contraceptive use. Closed-ended responses were compared against the original survey; transcripts were thematically coded and analyzed using qualitative analysis software. Results Among fecund women identified by the 2014 GDHS as having unmet need, follow-up interviews revealed substantial underreporting of method use, particularly traditional methods. Complete postpartum abstinence was sometimes the intended method of family planning but was overlooked during questions about method use. Other respondents classified as having unmet need had ambivalent fertility preferences. In several cases, respondents expressed revised fertility preferences upon follow-up that would have made them ineligible for inclusion in the unmet need category. The reference group of family planning users also expressed unstable fertility preferences. Aversion to modern method use was generally more substantial than reported in the GDHS, particularly the risk of menstrual side effects, personal or partner opposition to family planning, and religious opposition to contraception.	[Staveteig, Sarah] Avenir Hlth, Glastonbury, CT 06033 USA; [Staveteig, Sarah] Demog & Hlth Surveys DHS Program, Rockville, MD 20850 USA		Staveteig, S (corresponding author), Avenir Hlth, Glastonbury, CT 06033 USA.; Staveteig, S (corresponding author), Demog & Hlth Surveys DHS Program, Rockville, MD 20850 USA.	sstaveteig@avenirhealth.org		Staveteig Ford, Sarah/0000-0003-4330-2917	United States Agency for International Development (USAID) through The Demographic and Health Surveys (DHS) Program [AIDOAA-C-13-00095]	United States Agency for International Development (USAID) through The Demographic and Health Surveys (DHS) Program(United States Agency for International Development (USAID))	This study was funded by the United States Agency for International Development (USAID) through The Demographic and Health Surveys (DHS) Program (#AIDOAA-C-13-00095). The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript.	Adanu R M, 2012, Ghana Med J, V46, P58; Agadjanian V, 2005, POPUL RES POLICY REV, V24, P617, DOI 10.1007/s11113-005-5096-8; Andro A, 2001, POPULATION, V56, P721, DOI 10.2307/1534884; [Anonymous], 2015, UPTAKE DISCONTINUATI; Arnold, 1994, EVALUATION PAKISTAN; Aryeetey R, 2010, AFRICAN J REPROD HLT, V14; Bankole A, 1999, POPUL RES POLICY REV, V18, P579, DOI 10.1023/A:1006373106870; Becker S, 1999, INT FAM PLAN PERSPEC, V25, P172, DOI 10.2307/2991881; Bignami- Van Assche S, 2003, INDIVIDUAL CONSISTEN, pS1; Blanc AK, 2002, J BIOSOC SCI, V34, P475, DOI 10.1017/S0021932002004753; Bradley SEK, 2014, STUD FAMILY PLANN, V45, P123, DOI 10.1111/j.1728-4465.2014.00381.x; Bradley SarahE.K., 2012, DHS ANAL STUDIES; Brown W, 2014, STUD FAMILY PLANN, V45, P73, DOI 10.1111/j.1728-4465.2014.00377.x; Carr B, 2012, LANCET, V380, P80, DOI 10.1016/S0140-6736(12)60905-2; Casterline JB, 2003, INT FAM PLAN PERSPEC, V29, P158, DOI 10.2307/3181044; Casterline JB, 2000, POPUL DEV REV, V26, P691, DOI 10.1111/j.1728-4457.2000.00691.x; Cleland J, 2014, STUD FAMILY PLANN, V45, P105, DOI 10.1111/j.1728-4465.2014.00380.x; Crissman HP, 2012, STUD FAMILY PLANN, V43, P201, DOI 10.1111/j.1728-4465.2012.00318.x; DIXONMUELLER R, 1992, STUD FAMILY PLANN, V23, P330, DOI 10.2307/1966531; Eliason S, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-65; Finlay Jocelyn E, 2013, Int J Gynaecol Obstet, V123 Suppl 1, pe24, DOI 10.1016/j.ijgo.2013.07.008; Freedman R., 1974, CROSS CULTURAL COMP; Ghana Statistical Service Ghana Health Service and ICF International, 2015, GHAN DEM HLTH SURV 2; Ghana Statistical Service Ghana Health Service Macro International, 2009, GHAN MAT HLTH SURV 2; Ghana Statistical Service Research, 2008, GHAN DEM HLTH SURV 2; Hindin MJ, 2014, J FAM PLAN REPROD H, V40, P30, DOI 10.1136/jfprhc-2012-100464; Irwin S., 2010, HDB EMERGENT METHODS, P427; Johnson R.B., 2004, EDUC RESEARCHER, V33, P14, DOI [10.3102/0013189X033007014, DOI 10.3102/0013189X033007014]; Johnson-Hanks J, 2002, POPUL DEV REV, V28, P229, DOI 10.1111/j.1728-4457.2002.00229.x; Johnson- Hanks J., 2005, CURRENT ANTHR; Knodel J, 1997, POPUL DEV REV, V23, P847, DOI 10.2307/2137386; Kodzi IA, 2010, DEMOGR RES, V22, P965, DOI 10.4054/DemRes.2010.22.30; Kodzi IA, 2010, STUD FAMILY PLANN, V41, P45, DOI 10.1111/j.1728-4465.2010.00223.x; Machiyama K, 2014, STUD FAMILY PLANN, V45, P203, DOI 10.1111/j.1728-4465.2014.00385.x; Obermeyer CM, 1997, POPUL DEV REV, V23, P813, DOI 10.2307/2137381; Osei I, 2005, Afr J Reprod Health, V9, P76; Page HJ., 1981, CHILD SPACING TROPIC; Robey B, 1996, Popul Rep J, P1; Rossier C, 2014, STUD FAMILY PLANN, V45, P171, DOI 10.1111/j.1728-4465.2014.00383.x; SCHATZ E, 2003, DEMOGRAPHIC RES S, V0001; Schatz E, 2012, CULT HEALTH SEX, V14, P811, DOI 10.1080/13691058.2012.698309; Schatz E, 2012, POP STUD-J DEMOG, V66, P183, DOI 10.1080/00324728.2012.658851; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Sedgh G, 2014, STUD FAMILY PLANN, V45, P151, DOI 10.1111/j.1728-4465.2014.00382.x; Sennott C, 2012, INT PERSPECT SEX R H, V38, P34, DOI 10.1363/3803412; Singh S, 2012, ADDING IT COSTS BENE; Speizer IS, 2013, CONTRACEPTION, V88, P553, DOI 10.1016/j.contraception.2013.04.006; Stash S, 1999, STUD FAMILY PLANN, V30, P267, DOI 10.1111/j.1728-4465.1999..x; STAVETEIG S, 2017, GLOBAL HLTH ACTION, V10; TAN PC, 1994, STUD FAMILY PLANN, V25, P222, DOI 10.2307/2137905; Westoff C. F., 1988, International Family Planning Perspectives, V14, P45, DOI 10.2307/2947679; Westoff CF, 1998, INT FAM PLAN PERSPEC, V24, P12, DOI 10.2307/2991914; Westoff CF, 1991, UNMET NEED DEMAND FA	53	23	23	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2017	12	7							e0182076	10.1371/journal.pone.0182076	http://dx.doi.org/10.1371/journal.pone.0182076			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC3TH	28759624	Green Published, Green Submitted, gold			2023-01-03	WOS:000406761600049
J	Babel, P; Bajcar, EA; Adamczyk, W; Kicman, P; Lisinska, N; Swider, K; Colloca, L				Babel, Przemyslaw; Bajcar, Elzbieta A.; Adamczyk, Waclaw; Kicman, Pawel; Lisinska, Natalia; Swider, Karolina; Colloca, Luana			Classical conditioning without verbal suggestions elicits placebo analgesia and nocebo hyperalgesia	PLOS ONE			English	Article							RESPONSE EXPECTANCY; PAIN; EXPERIENCE; ANXIETY; MODELS	The aim of this study was to examine the relationships among classical conditioning, expectancy, and fear in placebo analgesia and nocebo hyperalgesia. A total of 42 healthy volunteers were randomly assigned to three groups: placebo, nocebo, and control. They received 96 electrical stimuli, preceded by either orange or blue lights. A hidden conditioning procedure, in which participants were not informed about the meaning of coloured lights, was performed in the placebo and nocebo groups. Light of one colour was paired with pain stimuli of moderate intensity (control stimuli), and light of the other colour was paired with either non-painful stimuli (in the placebo group) or painful stimuli of high intensity (in the nocebo group). In the control group, both colour lights were followed by control stimuli of moderate intensity without any conditioning procedure. Participants rated pain intensity, expectancy of pain intensity, and fear. In the testing phase, when both of the coloured lights were followed by identical moderate pain stimuli, we found a significant analgesic effect in the placebo group, and a significant hyperalgesic effect in the nocebo group. Neither expectancy nor fear ratings predicted placebo analgesia or nocebo hyperalgesia. It appears that a hidden conditioning procedure, without any explicit verbal suggestions, elicits placebo and nocebo effects, however we found no evidence that these effects are predicted by either expectancy or fear. These results suggest that classical conditioning may be a distinct mechanism for placebo and nocebo effects.	[Babel, Przemyslaw; Bajcar, Elzbieta A.; Adamczyk, Waclaw; Kicman, Pawel; Lisinska, Natalia; Swider, Karolina] Jagiellonian Univ, Inst Psychol, Pain Res Grp, Krakow, Poland; [Adamczyk, Waclaw] Jerzy Kukuczka Acad Phys Educ, Dept Kinesiotherapy & Special Methods Physiothera, Katowice, Poland; [Swider, Karolina] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behaviour, Nijmegen, Netherlands; [Colloca, Luana] Univ Maryland, Sch Nursing, Dept Pain & Translat Symptom Sci, Baltimore, MD 21201 USA; [Colloca, Luana] Univ Maryland, Sch Nursing, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Jagiellonian University; Akademia Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach; Radboud University Nijmegen; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Babel, P (corresponding author), Jagiellonian Univ, Inst Psychol, Pain Res Grp, Krakow, Poland.	przemyslaw.babel@uj.edu.pl	Colloca, Luana/S-1389-2018; Adamczyk, Waclaw M./X-5590-2018	Colloca, Luana/0000-0002-6503-4709; Adamczyk, Waclaw M./0000-0001-8941-8355	National Science Centre in Poland [2014/14/E/HS6/00415]	National Science Centre in Poland(National Science Centre, Poland)	The study was funded by the National Science Centre in Poland under the grant no. 2014/14/E/HS6/00415.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; [Anonymous], 2008, STUD PSYCHOL, V46, P13; [Anonymous], 2016, PLOS ONE, V11; Barlow DH, 2000, AM PSYCHOL, V55, P1247, DOI 10.1037/0003-066X.55.11.1247; Benedetti F, 2003, J NEUROSCI, V23, P4315; Carlino E, 2015, EUR J PAIN, V19, P546, DOI 10.1002/ejp.579; Colagiuri B, 2015, J PAIN, V16, P995, DOI 10.1016/j.jpain.2015.06.012; Colloca L, 2008, PAIN, V136, P211, DOI 10.1016/j.pain.2008.02.006; Colloca L, 2008, PAIN, V139, P306, DOI 10.1016/j.pain.2008.04.021; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; Colloca Luana, 2014, Handb Exp Pharmacol, V225, P17, DOI 10.1007/978-3-662-44519-8_2; Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398; Colloca L, 2011, CURR OPIN PSYCHIATR, V24, P149, DOI 10.1097/YCO.0b013e328343803b; Colloca L, 2010, PAIN, V151, P430, DOI 10.1016/j.pain.2010.08.007; Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033; De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7; deJong PJ, 1996, INT J BEHAV MED, V3, P14, DOI 10.1207/s15327558ijbm0301_2; Ehman O A, 2008, HDB EMOTIONS, P709; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Grillon C, 2008, PSYCHOPHARMACOLOGY, V199, P421, DOI 10.1007/s00213-007-1019-1; Hunter T, 2014, EUR J PAIN, V18, P914, DOI 10.1002/j.1532-2149.2013.00436.x; Jensen K, 2015, P NATL ACAD SCI USA, V112, P7863, DOI 10.1073/pnas.1504567112; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Kirsch I, 2004, J CLIN PSYCHOL, V60, P369, DOI 10.1002/jclp.10251; Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5; KIRSCH I, 1985, AM PSYCHOL, V40, P1189, DOI 10.1037/0003-066X.40.11.1189; Kirsch I., 1997, PLACEBO EFFECT INTER, P166; Kirsch Irving, 2014, Psychol Conscious (Wash D C), V1, P51; Klinger R, 2007, PAIN, V128, P31, DOI 10.1016/j.pain.2006.08.025; Miller FG, 2010, PERSPECT BIOL MED, V53, P509, DOI 10.1353/pbm.2010.0004; Montgomery GH, 1997, PAIN, V72, P107, DOI 10.1016/S0304-3959(97)00016-X; Ploghaus A, 2003, TRENDS COGN SCI, V7, P197, DOI 10.1016/S1364-6613(03)00061-5; Portney L, 2009, FDN CLIN RES APPL PR, P557; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Racine M, 2012, PAIN, V153, P602, DOI 10.1016/j.pain.2011.11.025; Reicherts P, 2016, J PAIN, V17, P203, DOI 10.1016/j.jpain.2015.10.010; Schafer SM, 2015, J PAIN, V16, P412, DOI 10.1016/j.jpain.2014.12.008; Vogtle E, 2013, PAIN, V154, P1427, DOI 10.1016/j.pain.2013.04.041; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; VOUDOURIS NJ, 1985, J PERS SOC PSYCHOL, V48, P47, DOI 10.1037/0022-3514.48.1.47; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976; Yeung STA, 2014, PAIN, V155, P1110, DOI 10.1016/j.pain.2014.02.022	45	44	44	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							e0181856	10.1371/journal.pone.0181856	http://dx.doi.org/10.1371/journal.pone.0181856			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC1CT	28750001	gold, Green Published			2023-01-03	WOS:000406575700091
J	Sharma, P; Finley, R; Weese, S; Glass-Kaastra, S; McIsaac, W				Sharma, Prateek; Finley, Rita; Weese, Scott; Glass-Kaastra, Shiona; McIsaac, Warren			Antibiotic prescriptions for outpatient acute rhinosinusitis in Canada, 2007-2013	PLOS ONE			English	Article							NATIONAL TRENDS; VISIT RATES; CHILDREN; GUIDELINES; PROGRAM; DISEASE; ADULTS	Introduction Acute rhinosinusitis (ARS) is a respiratory disease commonly caused by viral infections. Physicians regularly prescribe antibiotics despite bacterial etiologies being uncommon. This is of concern, as this use adds to the selection pressure for resistance. Here we present the descriptive epidemiology of acute rhinosinusitis and corresponding antibiotic prescribing practices by Canadian outpatient physicians from 2007-2013. Materials/Methods Diagnosis and antibiotic prescription data for ARS were extracted from the Canadian Disease and Therapeutic Index for 2007 to 2013, and population data were acquired from Statistics Canada. ARS diagnosis and antibiotic prescription rates and frequencies of antibiotic classes were calculated. Results Eighty-eight percent of patients diagnosed with ARS in 2013 were adults, with a greater rate of antibiotic prescriptions observed among the adults relative to the pediatric patients (1632.9 and 468.6 antibiotic prescriptions per 10,000 inhabitants). Between 2007 and 2013, the ARS diagnosis rate decreased from 596 to 464 diagnoses per 10,000 inhabitants, while the percentage of diagnoses with antibiotic prescriptions at the national level remained stable (87% to 84%). From 2007 to 2013, prescription rates for macrolides decreased from 203.5 to 105.4 prescriptions per 10,000 inhabitants. In 2013, penicillins with extended spectrum were more commonly prescribed compared to macrolides among adult patients (153.5 and 105.4 prescriptions per 10,000 inhabitants, respectively). Conclusion This study is the first to describe physician antibiotic prescribing practices for treatment of ARS in Canada. Results show that antibiotic treatment for ARS represents an area for implementing antimicrobial stewardship, and through it, managing antibiotic resistance. Further work is required to better understand diagnosing practices and treatment criteria for ARS, and use this information to further assist physicians to limit unnecessary antibiotic prescribing practices.	[Sharma, Prateek; Weese, Scott] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON, Canada; [Finley, Rita; Glass-Kaastra, Shiona] Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada; [McIsaac, Warren] Mt Sinai Hosp, Ray D Wolfe Dept Family Med, Granovsky Gluskin Family Med Ctr, Toronto, ON, Canada; [McIsaac, Warren] Univ Toronto, Dept Community & Family Med, Toronto, ON, Canada	University of Guelph; Public Health Agency of Canada; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto	Finley, R (corresponding author), Publ Hlth Agcy Canada, Ctr Food Borne Environm & Zoonot Infect Dis, Guelph, ON, Canada.	rita.finley@phac-aspc.gc.ca						Ahovuo-Saloranta A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000243.pub3; [Anonymous], 1997, Ear Nose Throat J, V76, P1; [Anonymous], 2012, GUIDELINES ATC CLASS; [Anonymous], 2012, ANTIINFECTIVE REV PA; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Blondel-Hill E., 2012, BUGS DRUGS 2012; Bulloch AGM, 2012, CAN J PSYCHIAT, V57, P263, DOI 10.1177/070674371205700410; Chow AW, 2012, CLIN INFECT DIS, V54, pE72, DOI [10.1093/cid/cis370, 10.1093/cid/cir1043]; Desrosiers M, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-2; Fairlie T, 2012, ARCH INTERN MED, V172, P1513, DOI 10.1001/archinternmed.2012.4089; Finley R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076398; Fuertes EI, 2010, CAN J PUBLIC HEALTH, V101, P304, DOI 10.1007/BF03405291; Kellner JD, 2011, PAED CHILD HEALT-CAN, V16, P233, DOI 10.1093/pch/16.4.233; Mckay RM, 2011, CAN J INFECT DIS MED, V22, P19, DOI 10.1155/2011/745090; Meeker D, 2014, JAMA INTERN MED, V174, P425, DOI 10.1001/jamainternmed.2013.14191; Mol PGM, 2005, J ANTIMICROB CHEMOTH, V55, P550, DOI 10.1093/jac/dki037; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Morris A, 2012, ANTIMICROBIAL STEWAR; Parkins MD, 2009, CANADIAN J INFECT DI, V20, P81; Public Health Agency of Canada, 2014, 20122013 PUBL HLT AG; Public Health Agency of Canada, 2016, CAPT SYST BIAS US CO, P1; Public Health Agency of Canada, 2015, HUM ANT US REP 2014; R Core Team, 2021, R LANG ENV STAT COMP; Shapiro DJ, 2011, PEDIATRICS, V127, P28, DOI 10.1542/peds.2010-1340; Smith SS, 2013, OTOLARYNG HEAD NECK, V148, P852, DOI 10.1177/0194599813479768; Statistics Canada, 2011, DEM DIV DEM EST SECT; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8; Worrall G, 2011, CAN FAM PHYSICIAN, V57, P565	28	7	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2017	12	7							e0181957	10.1371/journal.pone.0181957	http://dx.doi.org/10.1371/journal.pone.0181957			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1CT	28750020	gold, Green Published, Green Submitted			2023-01-03	WOS:000406575700106
J	Kolek, V; Grygarkova, I; Koubkova, L; Skrickova, J; Svecova, J; Sixtova, D; Bartos, J; Tichopad, A				Kolek, Vitezslav; Grygarkova, Ivona; Koubkova, Leona; Skrickova, Jana; Svecova, Jirina; Sixtova, Dimka; Bartos, Jiri; Tichopad, Ales			Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up	PLOS ONE			English	Article							RANDOMIZED CLINICAL-TRIALS; ADJUVANT CHEMOTHERAPY; PLUS CISPLATIN; PHASE-II; METAANALYSIS; IMPACT; NSCLC	Objectives Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions. Material and methods A prospective, single-arm, multicenter, non-interventional study evaluated the tolerability, dose intensity and survival resulting from adjuvant use of intravenous carboplatin (AUC 5 on day 1) with vinorelbine administered both intravenously (25 mg/m(2) on day 1) and orally (60 mg/m(2) on day 8) within four cycles of 21 days each. A total of 74 patients with a median age of 64 years were observed. Results The mean number of accomplished cycles was 3.78, and 62 patients (83.7%) completed all four planned cycles. Relative dose intensity for carboplatin was 88.9%, for intravenous vinorelbine 93.1%, and for oral vinorelbine 83.2%. Median follow-up was 4.73 years. Median disease-specific survival (DSS) was 7.63 years, median overall survival (OS) was 5.90 years, median disease-free survival (DFS0) was 4.43 years, and five-year survival was 56.2%. TNM stage of disease significantly affected DSS and OS. Favorable survival was observed in females, nonsmokers, patients aged over 65 years, patient with prior lobectomy, patients with tumor of squamous histology, and those who finished the planned therapy, but the differences were non-significant. Conclusion Adjuvant carboplatin with vinorelbine switched from intravenous to oral administration was shown to be a favorable regimen with regard to tolerability and safety. Compliance to therapy was high, and survival parameters were promising, showing that applied regimen can be another potential option for adjuvant chemotherapy in patients with NSCLC.	[Kolek, Vitezslav; Grygarkova, Ivona] Univ Hosp, Dept Resp Med, Olomouc, Czech Republic; [Koubkova, Leona] Univ Hosp, Dept Pneumol, Prague, Czech Republic; [Skrickova, Jana] Univ Hosp Brno, Dept Resp Dis & TB, Brno, Czech Republic; [Svecova, Jirina] Hosp Tabor, Dept Oncol, Tabor, Czech Republic; [Sixtova, Dimka] Mem Thomayer Hosp, Dept Resp Dis, Prague, Czech Republic; [Bartos, Jiri] Reg Hosp Liberec, Dept Oncol, Liberec, Czech Republic; [Tichopad, Ales] Kantar Hlth Sro, Prague, Czech Republic	University Hospital Olomouc; General University Hospital Prague; University Hospital Brno; Thomayer Hospital	Tichopad, A (corresponding author), Kantar Hlth Sro, Prague, Czech Republic.	tichopada@gmail.com			Ministry of Health of the Czech Republic [NV16-32318A, NT 13569]	Ministry of Health of the Czech Republic(Ministry of Health, Czech Republic)	The study was funded by a grant provided by the Ministry of Health of the Czech Republic, reference number: NV16-32318A, NT 13569 to Professor Kolek from Palacky University of Olomouc. Kantar Health had no role in study design, data collection and analysis or decision to publish the manuscript. Kantar Health has just contributed to preparation of the manuscript and provided financial support in the form of author's salary [AT]. The Ministry of Health of the Czech Republic did not intervene in the study design or its conduct, except for assessment of its compliance and registration. The specific roles of all authors are articulated in the 'author contributions' section.	Ardizzoni A, 2007, J NATL CANCER I, V99, P847, DOI 10.1093/jnci/djk196; Arriagada R, 2010, J CLIN ONCOL, V28, P35, DOI 10.1200/JCO.2009.23.2272; Cortes AA, 2015, TRANSL LUNG CANCER R, V4, P191, DOI 10.3978/j.issn.2218-6751.2014.06.01; Bria E, 2009, LUNG CANCER, V63, P50, DOI 10.1016/j.lungcan.2008.05.002; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Catania C, 2005, BREAST CANCER RES TR, V92, P265, DOI 10.1007/s10549-005-3376-y; Coello Michael C, 2004, Clin Lung Cancer, V5, P214; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Gu F, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.7014; Hotta K, 2004, J CLIN ONCOL, V22, P3852, DOI 10.1200/JCO.2004.02.109; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; Jassem J, 2001, ANN ONCOL, V12, P1375, DOI 10.1023/A:1012539225493; Jensen LH, 2008, LUNG CANCER, V62, P85, DOI 10.1016/j.lungcan.2008.02.009; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Non-Small Cell Lung Cancer Collaborative Group, 1995, BMJ-BRIT MED J, V311, P899, DOI DOI 10.1136/BMJ.311.7010.899; O'Brien MER, 2004, ANN ONCOL, V15, P921, DOI 10.1093/annonc/mdh233; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Sedrakyan A, 2004, J THORAC CARDIOV SUR, V128, P414, DOI 10.1016/j.jtcvs.2004.04.027; Shepherd FA, 2015, J CLIN ONCOL, V33; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sorensen SF, 2015, LUNG CANCER, V88, P167, DOI 10.1016/j.lungcan.2015.02.010; Speicher PJ, 2015, J NATL COMPR CANC NE, V13, P755, DOI 10.6004/jnccn.2015.0090; Stinchcombe TE, 2008, J THORAC ONCOL, V3, P145, DOI 10.1097/JTO.0b013e318160c5f1; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Sun H, 2009, CHIN J LUNG CANC, V12, P975; Wakelee HA, 2011, J THORAC ONCOL, V6, pS464; Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041; Williams CD, 2014, CANCER-AM CANCER SOC, V120, P1939, DOI 10.1002/cncr.28679; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Wisnivesky JP, 2011, BMJ-BRIT MED J, V343, P247; Younis T, 2008, J THORAC ONCOL, V3, P1272, DOI 10.1097/JTO.0b013e318189f562	33	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2017	12	7							e0181803	10.1371/journal.pone.0181803	http://dx.doi.org/10.1371/journal.pone.0181803			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC2BU	28732018	gold, Green Published, Green Submitted			2023-01-03	WOS:000406643100063
J	Jamei, M; Nisnevich, A; Wetchler, E; Sudat, S; Liu, E				Jamei, Mehdi; Nisnevich, Aleksandr; Wetchler, Everett; Sudat, Sylvia; Liu, Eric			Predicting all-cause risk of 30-day hospital readmission using artificial neural networks	PLOS ONE			English	Article							HEART-FAILURE; MODELS	Avoidable hospital readmissions not only contribute to the high costs of healthcare in the US, but also have an impact on the quality of care for patients. Large scale adoption of Electronic Health Records (EHR) has created the opportunity to proactively identify patients with high risk of hospital readmission, and apply effective interventions to mitigate that risk. To that end, in the past, numerous machine-learning models have been employed to predict the risk of 30-day hospital readmission. However, the need for an accurate and real-time predictive model, suitable for hospital setting applications still exists. Here, using data from more than 300,000 hospital stays in California from Sutter Health's EHR system, we built and tested an artificial neural network (NN) model based on Google's TensorFlow library. Through comparison with other traditional and non-traditional models, we demonstrated that neural networks are great candidates to capture the complexity and interdependency of various data fields in EHRs. LACE, the current industry standard, showed a precision (PPV) of 0.20 in identifying high-risk patients in our database. In contrast, our NN model yielded a PPV of 0.24, which is a 20% improvement over LACE. Additionally, we discussed the predictive power of Social Determinants of Health (SDoH) data, and presented a simple cost analysis to assist hospitalists in implementing helpful and cost-effective post-discharge interventions.	[Jamei, Mehdi; Nisnevich, Aleksandr; Wetchler, Everett; Liu, Eric] Bayes Impact, Technol 501 c3 Nonprofit, San Francisco, CA 94103 USA; [Sudat, Sylvia] Sutter Hlth, Res Dev & Disseminat, Walnut Creek, CA USA		Jamei, M (corresponding author), Bayes Impact, Technol 501 c3 Nonprofit, San Francisco, CA 94103 USA.	mehdi@bayesimpact.org; keuters@sutterhealth.org		Jamei, Mehdi/0000-0003-0658-9621; Upadhyaya, Kirtan/0000-0002-0708-0141	Robert Wood Johnson Foundation;  [33676]	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); 	Robert Wood Johnson Foundation (www.rwjf.org) funded this study through a grant. Eric Liu was awarded grant #33676. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abadi M., 2016, P 12 USENIX S OPERAT, DOI DOI 10.48550/ARXIV.1603.04467; Amarasingham R, 2010, MED CARE, V48, P981, DOI 10.1097/MLR.0b013e3181ef60d9; [Anonymous], 2015, SOCIAL EXPLORER TABL; Bayati M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109264; Chollet F., 2015, KERAS DEEP LEARNING; Commission MPA, 2007, REP C PROM GREAT EFF; Futoma J, 2015, J BIOMED INFORM, V56, P229, DOI 10.1016/j.jbi.2015.05.016; Gerhardt G, 2012, MED MED RES REV, V2013, P3; Goodman D, 2013, REVOLVING DOOR REPOR; Hao SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140271; He DN, 2014, J AM MED INFORM ASSN, V21, P272, DOI 10.1136/amiajnl-2013-002151; Ho TK, 1995, P 3 INT C DOC AN REC; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kingma D. P., 2015, P INT C LEARN REPR, P1; McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270; McKinney W., 2010, P 9 PYTH SCI C, DOI DOI 10.25080/MAJORA-92BF1922-00A; Meyer PA, 2013, MMWR-MORBID MORTAL W, V62, P3; Navathe A., 2016, AC HLTH ANN RES M BO; QGIS A., 2015, FREE OP SOURC GEOGR; Rockville M., 2015, HOSP GUIDE REDUCING; Shams I, 2015, HEALTH CARE MANAG SC, V18, P19, DOI 10.1007/s10729-014-9278-y; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117	22	61	62	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2017	12	7							e0181173	10.1371/journal.pone.0181173	http://dx.doi.org/10.1371/journal.pone.0181173			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA7TM	28708848	Green Submitted, gold, Green Published			2023-01-03	WOS:000405649800045
J	Chandra, A; Garthwaite, C				Chandra, Amitabh; Garthwaite, Craig			The Economics of Indication-Based Drug Pricing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chandra, Amitabh] Harvard Kennedy Sch, Cambridge, MA 02138 USA; [Garthwaite, Craig] Northwestern Univ, Kellogg Sch Management, Evanston, IL USA	Harvard University; Northwestern University	Chandra, A (corresponding author), Harvard Kennedy Sch, Cambridge, MA 02138 USA.							Bach PB, 2014, JAMA-J AM MED ASSOC, V312, P1629, DOI 10.1001/jama.2014.13235; Dickson Virgil, 2015, MODERN HEALTHCARE; Pearson S, 2016, INDICATION SPECIFIC; Rockoff Jonathan D., 2015, WALL STREET J; Stern AD, 2017, SCIENCE, V355, P1131, DOI 10.1126/science.aai8707	5	40	40	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2017	377	2					103	106		10.1056/NEJMp1705035	http://dx.doi.org/10.1056/NEJMp1705035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA2PC	28700848				2023-01-03	WOS:000405282300002
J	Zhalyalov, AS; Panteleev, MA; Gracheva, MA; Ataullakhanov, FI; Shibeko, AM				Zhalyalov, Ansar S.; Panteleev, Mikhail A.; Gracheva, Marina A.; Ataullakhanov, Fazoil I.; Shibeko, Alexey M.			Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts	PLOS ONE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; MASSIVE PULMONARY-EMBOLISM; FACTOR-VII ACTIVATION; RANDOMIZED-TRIAL; MODELING FIBRINOLYSIS; THROMBOLYTIC THERAPY; CONFOCAL MICROSCOPY; ENDOTHELIAL-CELLS; POSITIVE FEEDBACK	Fibrinolysis is a cascade of proteolytic reactions occurring in blood and soft tissues, which functions to disintegrate fibrin clots when they are no more needed. In order to elucidate its regulation in space and time, fibrinolysis was investigated using an in vitro reaction-diffusion experimental model of blood clot formation and dissolution. Clotting was activated by a surface with immobilized tissue factor in a thin layer of recalcified blood plasma supplemented with tissue plasminogen activator (TPA), urokinase plasminogen activator or streptokinase. Formation and dissolution of fibrin clot was monitored by videomicroscopy. Computer systems biology model of clot formation and lysis was developed for data analysis and experimental planning. Fibrin clot front propagated in space from tissue factor, followed by a front of clot dissolution propagating from the same source. Velocity of lysis front propagation linearly depended on the velocity clotting front propagation (correlation r(2) = 0.91). Computer model revealed that fibrin formation was indeed the rate-limiting step in the fibrinolysis front propagation. The phenomenon of two fronts which switched the state of blood plasma from liquid to solid and then back to liquid did not depend on the fibrinolysis activator. Interestingly, TPA at high concentrations began to increase lysis onset time and to decrease lysis propagation velocity, presumably due to plasminogen depletion. Spatially non-uniform lysis occurred simultaneously with clot formation and detached the clot from the procoagulant surface. These patterns of spatial fibrinolysis provide insights into its regulation and might explain clinical phenomena associated with thrombolytic therapy.	[Zhalyalov, Ansar S.; Panteleev, Mikhail A.; Ataullakhanov, Fazoil I.; Shibeko, Alexey M.] Ctr Theoret Problems Physicochem Pharmacol RAS, Moscow, Russia; [Panteleev, Mikhail A.; Gracheva, Marina A.; Ataullakhanov, Fazoil I.] Natl Sci & Pract Ctr Pediat Hematol, Oncol & Immunol, Moscow, Russia; [Panteleev, Mikhail A.; Ataullakhanov, Fazoil I.] Moscow MV Lomonosov State Univ, Dept Phys, Moscow, Russia; [Panteleev, Mikhail A.; Ataullakhanov, Fazoil I.] Moscow Inst Phys & Technol, Fac Biol & Med Phys, Dolgoprudnyi, Russia	Russian Academy of Sciences; Lomonosov Moscow State University; Moscow Institute of Physics & Technology	Shibeko, AM (corresponding author), Ctr Theoret Problems Physicochem Pharmacol RAS, Moscow, Russia.	alshibeko@gmail.com	Ataullakhanov, Fazoil/J-8076-2012; Panteleev, Mikhail A/H-5491-2012; Ataullakhanov, Fazoil/O-3458-2019; Gracheva, Marina/A-8559-2014; Shibeko, Alexey/A-9447-2014	Panteleev, Mikhail A/0000-0002-8128-7757; Shibeko, Alexey/0000-0003-1494-3125; Gracheva, Marina/0000-0002-7522-168X	Russian Foundation for Basic Research [15-51-15008, 17-04-01309]; Russian Academy of Sciences; President of Russian Federation Grant [MK-9245.2016.4, MD-229.2017.4]; Russian Science Foundation [16-14-00-224]; Russian Science Foundation [16-14-00224] Funding Source: Russian Science Foundation	Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR)); Russian Academy of Sciences(Russian Academy of Sciences); President of Russian Federation Grant; Russian Science Foundation(Russian Science Foundation (RSF)); Russian Science Foundation(Russian Science Foundation (RSF))	The project was supported by Russian Foundation for Basic Research grants 15-51-15008 and 17-04-01309 to MAP; by Russian Academy of Sciences grants to FIA (Molecular and Cellular Biology, Basic Research for Development of Biomedical Technologies, Molecular Mechanisms of Physiologic Functions) and to MAP (Basic Science for Medicine); by Grant of President of Russian Federation MK-9245.2016.4 to AMS and MD-229.2017.4 to MAP. Theoretical modelling was supported by grant from Russian Science Foundation 16-14-00-224 to FIA (sections Computational model of fibrin clot growth and lysis and Computer simulation of spatial clot growth and lysis; Figures 6 and 7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1970, JAMA-J AM MED ASSOC, V214, p2163/2172; Balandina AN, 2011, BIOPHYS J, V101, P1816, DOI 10.1016/j.bpj.2011.08.034; Bannish BE, 2014, MATH MED BIOL, V31, P17, DOI 10.1093/imammb/dqs029; Bannish BE, 2014, MATH MED BIOL, V31, P45, DOI 10.1093/imammb/dqs030; Bizjak N, 2014, THROMB RES, V133, P908, DOI 10.1016/j.thromres.2014.02.008; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Bucay I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116350; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; Campbell RA, 2008, ARTERIOSCL THROM VAS, V28, P2247, DOI 10.1161/ATVBAHA.108.176008; Campbell RA, 2010, THROMB HAEMOSTASIS, V104, P1281, DOI 10.1160/TH10-07-0442; Campbell RA, 2009, BLOOD, V114, P4886, DOI 10.1182/blood-2009-06-228940; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; Chernysh IN, 2015, J THROMB HAEMOST, V13, P601, DOI 10.1111/jth.12857; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; Collet JP, 2003, J BIOL CHEM, V278, P21331, DOI 10.1074/jbc.M212734200; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Danforth CM, 2009, MATH MED BIOL, V26, P323, DOI 10.1093/imammb/dqp011; Dashkevich NM, 2012, BIOPHYS J, V103, P2233, DOI 10.1016/j.bpj.2012.10.011; DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6; Fadeeva OA, 2010, BIOCHEMISTRY-MOSCOW+, V75, P734, DOI 10.1134/S0006297910060088; GEMMILL JD, 1991, BRIT J CLIN PHARMACO, V31, P143, DOI 10.1111/j.1365-2125.1991.tb05502.x; KRUITHOF EKO, 1987, BLOOD, V70, P1645; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; Lindahl TL, 2015, THROMB RES, V135, P544, DOI 10.1016/j.thromres.2014.12.019; Lipets E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087692; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; Longstaff C, 2015, J THROMB HAEMOST, V13, pS98, DOI 10.1111/jth.12935; Longstaff C, 2011, BLOOD, V117, P661, DOI 10.1182/blood-2010-06-290338; Luan D, 2007, PLOS COMPUT BIOL, V3, P1347, DOI 10.1371/journal.pcbi.0030142; Meneveau N, 1997, EUR HEART J, V18, P1141; MEYER G, 1992, J AM COLL CARDIOL, V19, P239, DOI 10.1016/0735-1097(92)90472-Y; Meyerovitz MF, 1995, J VASC INTERV RADIOL, V6, P775, DOI 10.1016/S1051-0443(95)71184-8; Michels HR, 1999, J THROMB THROMBOLYS, V8, P213, DOI 10.1023/A:1008914321384; Mutch NJ, 2007, J THROMB HAEMOST, V5, P812, DOI 10.1111/j.1538-7836.2007.02430.x; Ovanesov MV, 2005, J THROMB HAEMOST, V3, P321, DOI 10.1111/j.1538-7836.2005.01128.x; Ovanesov MV, 2003, THROMB HAEMOSTASIS, V89, P235; Ovanesov MV, 2002, BBA-GEN SUBJECTS, V1572, P45, DOI 10.1016/S0304-4165(02)00278-7; Panteleev MA, 2006, BIOPHYS J, V90, P1489, DOI 10.1529/biophysj.105.069062; Panteleev MA, 2004, BIOCHEM J, V381, P779, DOI 10.1042/BJ20031748; Panteleev MA, 2015, THROMB RES, V136, P699, DOI 10.1016/j.thromres.2015.07.025; Panteleev MA, 2010, BIOPHYS J, V98, P1751, DOI 10.1016/j.bpj.2010.01.027; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; ROSSI E, 1988, THROMB RES, V52, P453, DOI 10.1016/0049-3848(88)90029-1; Ruiz-Bailen M, 2002, MED SCI MONITOR, V8, pI85; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SEIFRIED E, 1989, THROMB HAEMOSTASIS, V61, P497; Sharifi M, 2013, CARDIOVASC INTER RAD, V36, P1586, DOI 10.1007/s00270-013-0569-3; Shibeko AM, 2016, BRIEF BIOINFORM, V17, P429, DOI 10.1093/bib/bbv040; Shibeko AM, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-5; Soshitova NP, 2012, BLOOD COAGUL FIBRIN, V23, P498, DOI 10.1097/MBC.0b013e328352e90e; Takahashi K, 1998, AM J PHYSIOL-LUNG C, V275, pL47, DOI 10.1152/ajplung.1998.275.1.L47; TANSWELL P, 1992, J AM COLL CARDIOL, V19, P1071, DOI 10.1016/0735-1097(92)90297-Z; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; TORR SR, 1992, J AM COLL CARDIOL, V19, P1085, DOI 10.1016/0735-1097(92)90300-C; Varju I, 2011, J THROMB HAEMOST, V9, P979, DOI 10.1111/j.1538-7836.2011.04203.x; Welsh JD, 2014, BLOOD, V124, P1808, DOI 10.1182/blood-2014-01-550335; WIMAN B, 1978, EUR J BIOCHEM, V87, P143, DOI 10.1111/j.1432-1033.1978.tb12360.x; Wootton DM, 2002, BIOTECHNOL BIOENG, V77, P405, DOI 10.1002/bit.10127	59	10	10	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180668	10.1371/journal.pone.0180668	http://dx.doi.org/10.1371/journal.pone.0180668			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686711	Green Published, Green Submitted, gold			2023-01-03	WOS:000405464100089
J	Li, B; Guo, WR; Zhang, F; Liu, MY; Wang, S; Liu, ZH; Xiang, SL; Zeng, YL				Li, Bo; Guo, Wanrong; Zhang, Fan; Liu, Meiyan; Wang, Shang; Liu, Zhonghua; Xiang, Shuanglin; Zeng, Youlin			Synthesis and evaluation of L-arabinose-based cationic glycolipids as effective vectors for pDNA and siRNA in vitro	PLOS ONE			English	Article							MEDIATED DNA-TRANSFECTION; GENE DELIVERY; VIRAL VECTORS; LIPIDS; EFFICIENCY; THERAPY; VIVO; CELLS; MECHANISMS; COMPLEXES	Glycolipids might become a new type of promising non-viral gene delivery systems because of their low cytotoxicity, structural diversity, controllable aqua-and lipo-solubility, appropriate density and distribution of positive charges, high transfer efficiency and potential targeting function. In this study, four kinds of L-arabinose-based cationic glycolipids (Ara-DiC12MA, Ara-DiC14MA, Ara-DiC16MA and Ara-DiC18MA) containing quaternary ammonium as hydrophilic headgroup and two alkane chains as hydrophobic domain were synthesized and characterized. They were observed to have strong affinities for plasmid DNA (pDNA) and siRNA, the pDNA can be completely condensed at N/P ratio less than 2, and the siRNA can be completely retarded at N/P ratio less than 3. The dynamic light scattering (DLS) experiment and atomic force microscopy (AFM) experiment demonstrated that cationic lipids and their lipoplexes possessed suitable particle sizes with near-spherical shape and proper.-potentials for cell transfection. The Ara-DiC16MA liposome was found to have good transfection efficacy in HEK293, PC-3 and Mat cells compared with other three kinds of liposomes, and also maintain low cytotoxicity and better uptake capability in vitro. Furthermore, the gene silencing assay showed that Ara-DiC14MA and Ara-DiC16MA liposomes have demonstrated effective delivery and higher gene knockdown activity (>80%) in the above mentioned cells than Lipofectamine 2000. These results indicated Ara-DiC16MA can be developed for efficient and low toxic gene delivery.	[Li, Bo; Guo, Wanrong; Zhang, Fan; Liu, Meiyan; Zeng, Youlin] Hunan Normal Univ, Coll Chem & Chem Engn, Natl & Local Joint Engn Lab New Petrochem Mat & F, Changsha, Hunan, Peoples R China; [Wang, Shang; Xiang, Shuanglin] Hunan Normal Univ, Coll Life Sci, State Educ Minist China, Key Lab Prot Chem & Dev Biol, Changsha, Hunan, Peoples R China; [Liu, Zhonghua] Hunan Normal Univ, Coll Life Sci, Natl & Local Joint Engn Lab Anim Peptide Drug Dev, Changsha, Hunan, Peoples R China	Hunan Normal University; Hunan Normal University; Hunan Normal University	Zeng, YL (corresponding author), Hunan Normal Univ, Coll Chem & Chem Engn, Natl & Local Joint Engn Lab New Petrochem Mat & F, Changsha, Hunan, Peoples R China.	youlinzengcn@gmail.com	Zeng, Youlin/HCI-6949-2022	zeng, youlin/0000-0002-1110-4759	Nation Nature Sciences Foundation of China [21272064]; Science & Technology Department of Changsha City [K1205221-31]	Nation Nature Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Science & Technology Department of Changsha City	Tis research was financially supported by the Nation Nature Sciences Foundation of China (Gene ral Program: 21272064) and Science & Technology Department of Changsha City (K1205221-31)	Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bae YU, 2012, MOL PHARMACEUT, V9, P3579, DOI 10.1021/mp300458h; Bovolenta C, 2013, CURR PHARM BIOTECHNO, V14, P488, DOI 10.2174/138920101405131111104009; Byk G, 1998, J MED CHEM, V41, P224, DOI 10.1021/jm9704964; CAPLEN NJ, 1995, GENE THER, V2, P603; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Chan CL, 2012, BIOMATERIALS, V33, P4928, DOI 10.1016/j.biomaterials.2012.03.038; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; Duan Y, 2009, EXPERT OPIN DRUG DEL, V6, P1351, DOI 10.1517/17425240903287153; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Gopal V, 2006, BIOCONJUGATE CHEM, V17, P1530, DOI 10.1021/bc0601020; Gopal V, 2011, BIOCONJUGATE CHEM, V22, P2244, DOI 10.1021/bc2002874; Gu L, 2014, J CONTROL RELEASE, V184, P28, DOI 10.1016/j.jconrel.2014.04.005; Guillot-Nieckowski M, 2007, NEW J CHEM, V31, P1111, DOI 10.1039/b614877h; Guo QF, 2011, INT J NANOMED, V6, P1641, DOI 10.2147/IJN.S21141; Guo QF, 2009, INT J PHARMACEUT, V379, P82, DOI 10.1016/j.ijpharm.2009.06.010; He CX, 2016, ORG BIOMOL CHEM, V14, P1611, DOI 10.1039/c5ob02107c; Herrera-Carrillo E, 2015, EXPERT OPIN THER TAR, V19, P245, DOI 10.1517/14728222.2014.980236; Jiang TY, 2012, BIOMATERIALS, V33, P9246, DOI 10.1016/j.biomaterials.2012.09.027; JOLLY D, 1994, CANCER GENE THER, V1, P51; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Kedika B, 2012, MOL PHARMACEUT, V9, P1146, DOI 10.1021/mp200435y; Kim HS, 2004, BIOCONJUGATE CHEM, V15, P1095, DOI 10.1021/bc049934t; Koynova R, 2009, MOL PHARMACEUT, V6, P951, DOI 10.1021/mp8002573; Lee SJ, 2016, ADV DRUG DELIVER REV, V104, P2, DOI 10.1016/j.addr.2016.05.010; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Liu JL, 2011, EUR J MED CHEM, V46, P4133, DOI 10.1016/j.ejmech.2011.06.015; Medina-Kauwe LK, 2006, GENE THER GENE THERA, V12, P1734; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Miller AD, 1998, ANGEW CHEM INT EDIT, V37, P1769; Mrsny RJ, 1999, J DRUG TARGET, V7, P1; Mun JY, 2016, BIOMATERIALS, V101, P310, DOI 10.1016/j.biomaterials.2016.05.057; Ojeda E, 2015, ORG BIOMOL CHEM, V13, P1068, DOI 10.1039/c4ob02087a; Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775; Pathak Atul, 2009, Biotechnology Journal, V4, P1559, DOI 10.1002/biot.200900161; Peel AL, 2000, J NEUROSCI METH, V98, P95, DOI 10.1016/S0165-0270(00)00183-7; Qiao WH, 2014, J SURFACTANTS DETERG, V17, P261, DOI 10.1007/s11743-013-1474-0; Rajesh M, 2007, J AM CHEM SOC, V129, P11408, DOI 10.1021/ja0704683; Raper SE, 2002, HUM GENE THER, V13, P163, DOI 10.1089/10430340152712719; Raviv L, 2015, MOL PHARMACEUT, V12, P453, DOI 10.1021/mp5005492; Risbo J., 2010, APPL ENVIRON MICROB, V76, P7925; Santos JL, 2011, CURRENT GENE THERAPY, V11, P35; Sapru MK, 2002, J NEUROSCI METH, V114, P99, DOI 10.1016/S0165-0270(01)00518-0; Sheng RL, 2014, COLLOID SURFACE B, V116, P32, DOI 10.1016/j.colsurfb.2013.12.039; Shi QS, 2014, J BIOMED NANOTECHNOL, V10, P436, DOI 10.1166/jbn.2014.1728; Shi S, 2014, BIOMATERIALS, V35, P4536, DOI 10.1016/j.biomaterials.2014.02.010; Sobajima S, 2004, GENE THER, V11, P390, DOI 10.1038/sj.gt.3302200; Teo PY, 2016, ADV DRUG DELIVER REV, V98, P41, DOI 10.1016/j.addr.2015.10.014; Terada T, 2006, J CONTROL RELEASE, V111, P333, DOI 10.1016/j.jconrel.2005.12.023; Thapa B, 2015, BIOMACROMOLECULES, V16, P3008, DOI 10.1021/acs.biomac.5b00906; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Vora L, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2781-8; Wang F, 2014, ACTA MATER, V80, P77, DOI 10.1016/j.actamat.2014.07.048; Wang N, 2014, EUR J PHARM BIOPHARM, V88, P194, DOI 10.1016/j.ejpb.2014.04.007; Xia YQ, 2016, BIOMATERIALS, V79, P56, DOI 10.1016/j.biomaterials.2015.11.056; YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568; Zhang M, 2003, BIOCONJUGATE CHEM, V14, P709, DOI 10.1021/bc034038n; Zhi DF, 2013, BIOCONJUGATE CHEM, V24, P487, DOI 10.1021/bc300381s; Zhi DF, 2010, BIOCONJUGATE CHEM, V21, P563, DOI 10.1021/bc900393r	62	3	3	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2017	12	7							e0180276	10.1371/journal.pone.0180276	http://dx.doi.org/10.1371/journal.pone.0180276			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2JX	28672000	gold, Green Published, Green Submitted			2023-01-03	WOS:000405268500037
J	Galvin, M; Ryan, P; Maguire, S; Heverin, M; Madden, C; Vajda, A; Normand, C; Hardiman, O				Galvin, Miriam; Ryan, Padhraig; Maguire, Sinead; Heverin, Mark; Madden, Caoifa; Vajda, Alice; Normand, Charles; Hardiman, Orla			The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population-based study of consultations, interventions and costs	PLOS ONE			English	Article							ALS; MANAGEMENT; TIMELINES; SURVIVAL; SYSTEM	Background Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological condition that requires coordinated, multidisciplinary clinical management. ALS is prone to misdiagnosis as its signs and symptoms may be non-specific, which may prolong patients' journey to multidisciplinary ALS care. Methods Using chart review and national register data, we have detailed the journey of a national cohort of ALS patients (n = 155) from the time of first symptom to presentation at a multidisciplinary clinic (MDC). Key milestones were analysed, including frequency of consultations, clinical interventions, and associated economic cost. Results A majority of patients was male (60%), 65 years of age and over (54%), and had spinal onset ALS (72%). Time from onset of first symptoms to ALS diagnosis was a mean of 15.1 months (median, 11). There was a mean interval of 17.4 months (median 12.5) from first symptoms to arrival at the MDC, and a mean of 4.09 (median, 4) consultations with health care professionals. Electromyography and nerve conduction studies were among the most common interventions. Direct referral by a general practitioner (GP) to a neurologist was associated with reduced cost, but not reduced diagnostic delay. Bulbar ALS was associated with shorter time from symptom onset to diagnosis. Neurologist consultation in the first three consultations was associated with lower costs prior to the ALS clinic attendance but not a shorter time from first symptom to final diagnosis. Mean cost prior to attending the MDC was (sic)3,486 per patient. Conclusions Expedited referral to the multidisciplinary ALS clinic would have reduced costs by an estimated (sic)2,072 per patient. Development of a standardised pathway with early referral to neurology of patients with suspected symptoms of ALS could limit unnecessary interventions and reduce cost of care.	[Galvin, Miriam; Heverin, Mark; Madden, Caoifa; Vajda, Alice; Hardiman, Orla] Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin, Ireland; [Ryan, Padhraig; Normand, Charles] Trinity Coll Dublin, Dept Hlth Policy & Management, Dublin, Ireland; [Maguire, Sinead; Hardiman, Orla] Beaumont Hosp, Natl ALS Clin, Dept Neurol, Natl Neurosci Ctr, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin	Galvin, M (corresponding author), Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin, Ireland.	GALVINMI@tcd.ie	Hardiman, Orla/Y-3441-2019	Hardiman, Orla/0000-0003-2610-1291; Galvin, Miriam/0000-0002-8232-8020; Vajda, Alice/0000-0001-9105-6680; Ryan, Padhraig/0000-0001-7852-5606; Normand, Charles/0000-0002-0885-5754	Irish Health Research Board Dublin, as part of the HRB Interdisciplinary Capacity Enhancement Awards [ICE/2012/]	Irish Health Research Board Dublin, as part of the HRB Interdisciplinary Capacity Enhancement Awards	This research was supported by funding from the Irish Health Research Board Dublin (http://www.hrb.ie), as part of the HRB Interdisciplinary Capacity Enhancement Awards (ICE/2012/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Cellura E, 2012, CLIN NEUROL NEUROSUR, V114, P550, DOI 10.1016/j.clineuro.2011.11.026; Chio A, 2006, NEUROLOGY, V67, P902, DOI 10.1212/01.wnl.0000233840.41688.df; Cristini Jacqueline, 2006, JAAPA, V19, P29; Department of Health Ireland, 2016, DHA39 PRINC PROC AG; Elamin M, 2013, NEUROLOGY, V80, P1590, DOI 10.1212/WNL.0b013e31828f18ac; Galvin M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1229-x; Hardiman O, 2011, NAT REV NEUROL, V7, P639, DOI 10.1038/nrneurol.2011.153; Hobson E, 2015, CLIN REV MOTOR NEURO; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Mitchell JD, 2010, AMYOTROPH LATERAL SC, V11, P537, DOI 10.3109/17482968.2010.495158; Motor Neurone Disease Association and Royal College of General Practitioners, 2014, PROGR WEAKN COULD BE; O'Brien MR, 2011, AMYOTROPH LATERAL SC, V12, P97, DOI 10.3109/17482968.2010.546414; Paganoni S, 2015, NEUROREHABILITATION, V37, P53, DOI 10.3233/NRE-151240; Paganoni S, 2014, AMYOTROPH LAT SCL FR, V15, P453, DOI 10.3109/21678421.2014.903974; Roche JC, 2012, BRAIN, V135, P847, DOI 10.1093/brain/awr351; Rooney J, 2015, J NEUROL NEUROSUR PS, V86, P496, DOI 10.1136/jnnp-2014-309601; Rooney J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074733; Srinivasan J, 2006, MUSCLE NERVE, V34, P359, DOI 10.1002/mus.20555; Stephens HE, 2015, AMYOTROPH LAT SCL FR, V16, P196, DOI 10.3109/21678421.2014.994530; Tramacere I, 2015, J NEUROL NEUROSUR PS, V86, P1180, DOI 10.1136/jnnp-2014-310176; Van Der Steen I, 2009, AMYOTROPH LATERAL SC, V10, P27, DOI 10.1080/17482960802103131	22	29	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2017	12	6							e0179796	10.1371/journal.pone.0179796	http://dx.doi.org/10.1371/journal.pone.0179796			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY6ZV	28640860	Green Published, Green Submitted, gold			2023-01-03	WOS:000404135800067
J	Huffaker, TB; Lee, SH; Tang, WW; Wallace, JA; Alexander, M; Runtsch, MC; Larsen, DK; Thompson, J; Ramstead, AG; Voth, WP; Hu, RZ; Round, JL; Williams, MA; O'Connell, RM				Huffaker, Thomas B.; Lee, Soh-Hyun; Tang, William W.; Wallace, Jared A.; Alexander, Margaret; Runtsch, Marah C.; Larsen, Dane K.; Thompson, Jacob; Ramstead, Andrew G.; Voth, Warren P.; Hu, Ruozhen; Round, June L.; Williams, Matthew A.; O'Connell, Ryan M.			Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						cellular immune response; leukocyte; microRNA (miRNA); tumor immunology; tumor microenvironment; T cell; miR-155	TUMOR-ASSOCIATED MACROPHAGES; UNTREATED MELANOMA; SUPPRESSOR-CELLS; MIR-155; CANCER; IPILIMUMAB; EXPRESSION; NIVOLUMAB; MICRORNAS; THERAPY	MicroRNA-155 (miR-155) regulates antitumor immune responses. However, its specific functions within distinct immune cell types have not been delineated in conditional KO mouse models. In this study, we investigated the role of miR-155 specifically within T cells during the immune response to syngeneic tumors. We found that miR-155 expression within T cells is required to limit syngeneic tumor growth and promote IFN production by T cells within the tumor microenvironment. Consequently, we found that miR-155 expression by T cells is necessary for proper tumor-associated macrophage expression of IFN-inducible genes. We also found that immune checkpoint-blocking (ICB) antibodies against programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) restored antitumor immunity in miR-155 T cell-conditional KO mice. We noted that these ICB antibodies rescued the levels of IFN-expressing T cells, expression of multiple activation and effector genes expressed by tumor-infiltrating CD8(+) and CD4(+) T cells, and tumor-associated macrophage activation. Moreover, the ICB approach partially restored expression of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8(+) T cells, suggesting that miR-155 and ICB regulate overlapping pathways to promote antitumor immunity. Taken together, our findings highlight the multifaceted role of miR-155 in T cells, in which it promotes antitumor immunity. These results suggest that the augmentation of miR-155 expression could be used to improve anticancer immunotherapies.	[Huffaker, Thomas B.; Lee, Soh-Hyun; Tang, William W.; Wallace, Jared A.; Alexander, Margaret; Runtsch, Marah C.; Larsen, Dane K.; Thompson, Jacob; Ramstead, Andrew G.; Voth, Warren P.; Hu, Ruozhen; Round, June L.; Williams, Matthew A.; O'Connell, Ryan M.] Univ Utah, Sch Med, Dept Pathol, Div Microbiol & Immunol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	O'Connell, RM (corresponding author), Univ Utah, Sch Med, Dept Pathol, 15 N Med Dr E,JMRB4280, Salt Lake City, UT 84112 USA.	ryan.oconnell@path.utah.edu		Thompson, Jacob/0000-0002-0952-5765; Williams, Matthew/0000-0002-4721-4482; Alexander, Margaret/0000-0003-2972-7521; Larsen, Dane/0000-0002-9841-1443; Tang, William/0000-0001-7036-6460	American Cancer Society scholar award; NIA, National Institutes of Health Grant [RO1AG047956]; NCI, National Institutes of Health Grant [F30CA189731]; NATIONAL CANCER INSTITUTE [F30CA189731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK091317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG047956] Funding Source: NIH RePORTER	American Cancer Society scholar award(American Cancer Society); NIA, National Institutes of Health Grant; NCI, National Institutes of Health Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding for this research was provided by an American Cancer Society scholar award (to R. M. O.); NIA, National Institutes of Health Grant RO1AG047956 (to R. M. O.); and NCI, National Institutes of Health Grant F30CA189731 (to T. B. H.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Bell JJ, 2008, NATURE, V452, P764, DOI 10.1038/nature06840; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Carrette F, 2012, SEMIN IMMUNOL, V24, P209, DOI 10.1016/j.smim.2012.04.010; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Chen SQ, 2015, CANCER RES, V75, P519, DOI 10.1158/0008-5472.CAN-14-2331; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Gottwein E, 2007, NATURE, V450, P1096, DOI 10.1038/nature05992; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu RZ, 2014, IMMUNITY, V41, P605, DOI 10.1016/j.immuni.2014.09.015; Hu RZ, 2013, J IMMUNOL, V190, P5972, DOI 10.4049/jimmunol.1300351; Huffaker TB, 2012, CELL REP, V2, P1697, DOI 10.1016/j.celrep.2012.10.025; Ji Y, 2015, P NATL ACAD SCI USA, V112, P476, DOI 10.1073/pnas.1422916112; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023; Mehta A, 2016, NAT REV IMMUNOL, V16, P279, DOI 10.1038/nri.2016.40; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; O'Connell RM, 2008, J EXP MED, V205, P585, DOI 10.1084/jem.20072108; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Shiao SL, 2011, GENE DEV, V25, P2559, DOI 10.1101/gad.169029.111; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trotta R, 2012, BLOOD, V119, P3478, DOI 10.1182/blood-2011-12-398099; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wang JF, 2015, INT J CANCER, V136, pE602, DOI 10.1002/ijc.29151; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Yu F, 2013, MOL CANCER RES, V11, P923, DOI 10.1158/1541-7786.MCR-12-0686; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	40	52	56	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2017	292	45					18530	18541		10.1074/jbc.M117.808121	http://dx.doi.org/10.1074/jbc.M117.808121			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM4CG	28912267	hybrid, Green Published			2023-01-03	WOS:000414958100012
J	Minguillon, J; Lopez-Gordo, MA; Renedo-Criado, DA; Sanchez-Carrion, MJ; Pelayo, F				Minguillon, Jesus; Angel Lopez-Gordo, Miguel; Renedo-Criado, Diego A.; Jose Sanchez-Carrion, Maria; Pelayo, Francisco			Blue lighting accelerates post-stress relaxation: Results of a preliminary study	PLOS ONE			English	Article							HEART-RATE; DIFFERENT COLORS; MENTAL STRESS; HUMAN BRAIN; EEG; WAVELENGTH; STIMULATION; SENSITIVITY; ADAPTATION; MELATONIN	Several authors have studied the influence of light on both human physiology and emotions. Blue light has been proved to reduce sleepiness by suppression of melatonin secretion and it is also present in many emotion-related studies. Most of these have a common lack of objective methodology since results and conclusions are based on subjective perception of emotions. The aim of this work was the objective assessment of the effect of blue lighting in post-stress relaxation, in comparison with white lighting, by means of bio-signals and standardized procedures. We conducted a study in which twelve healthy volunteers were stressed and then performed a relaxation session within a chromotherapy room with blue (test group) or white (control group) lighting. We conclude that the blue lighting accelerates the relaxation process after stress in comparison with conventional white lighting. The relaxation time decreased by approximately three-fold (1.1 vs. 3.5 minutes). We also observed a convergence time (3.5-5 minutes) after which the advantage of blue lighting disappeared. This supports the relationship between color of light and stress, and the observations reported in previous works. These findings could be useful in clinical and educational environments, as well as in daily-life context and emerging technologies such as neuromarketing. However, our study must be extended to draw reliable conclusions and solid scientific evidence.	[Minguillon, Jesus; Pelayo, Francisco] Univ Granada, Dept Comp Architecture & Technol, Granada, Spain; [Minguillon, Jesus; Pelayo, Francisco] Univ Granada, Res Ctr Informat & Commun Technol CITIC, Granada, Spain; [Angel Lopez-Gordo, Miguel; Renedo-Criado, Diego A.] Univ Granada, Dept Signal Theory Telemat & Commun, Granada, Spain; [Angel Lopez-Gordo, Miguel] Nicolo Assoc, Churriana De La Vega, Spain; [Jose Sanchez-Carrion, Maria] Sch Special Educ San Rafael, Granada, Spain	University of Granada; University of Granada; University of Granada	Minguillon, J (corresponding author), Univ Granada, Dept Comp Architecture & Technol, Granada, Spain.; Minguillon, J (corresponding author), Univ Granada, Res Ctr Informat & Commun Technol CITIC, Granada, Spain.	minguillon@ugr.es	Minguillon, Jesus/C-9013-2015; LOPEZ, MIGUEL A/A-6629-2013	Minguillon, Jesus/0000-0003-4682-6898; LOPEZ, MIGUEL A/0000-0002-5470-1764	Nicolo Association for the R+D in Neurotechnologies for disability; Ministry of Economy and Competitiveness [DPI2015-69098-REDT]; Junta of Andalucia (Spain) [P11-TIC-7983]; Spanish National Grant [TIN2015-67020]; European Regional Development Fund (ERDF); School for Special Education San Rafael of Granada	Nicolo Association for the R+D in Neurotechnologies for disability; Ministry of Economy and Competitiveness; Junta of Andalucia (Spain)(Junta de Andalucia); Spanish National Grant(Spanish Government); European Regional Development Fund (ERDF)(European Commission); School for Special Education San Rafael of Granada	This work was supported by Nicolo Association for the R+D in Neurotechnologies for disability, the Ministry of Economy and Competitiveness DPI2015-69098-REDT, the research project P11-TIC-7983 of Junta of Andalucia (Spain) and the Spanish National Grant TIN2015-67020, co-financed by the European Regional Development Fund (ERDF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank all the people who participated in the study, including participants and students that collaborated. The authors would also like to thank the School for Special Education San Rafael of Granada for their support and the provided facilities.	Al-Ayash A, 2015, COLOR RES APPL; ALI MR, 1972, ELECTROEN CLIN NEURO, V33, P332, DOI 10.1016/0013-4694(72)90162-9; Azeemi STY, 2005, EVID-BASED COMPL ALT, V2, P481, DOI 10.1093/ecam/neh137; Bali A, 2015, REV NEUROSCIENCE, V26, P555, DOI 10.1515/revneuro-2015-0004; Bellia L, 2016, COLOUR COLORIMETRY B, VXII, P129; Besenecker U, 2016, COLOUR COLORIMETRY B, VXII, P109; Brouwer A.-M, 2011, J CYBERTHER REHABIL, V4, P21; Cajochen C, 2005, J CLIN ENDOCR METAB, V90, P1311, DOI 10.1210/jc.2004-0957; Casciani D, 2016, COLOUR COLORIMETRY B, VXII, P81; Chandiramani S, 2007, PACE, V30, P976, DOI 10.1111/j.1540-8159.2007.00795.x; Dagher A, 2009, BRAIN RES, V1293, P40, DOI 10.1016/j.brainres.2009.07.048; Dedovic K, 2005, J PSYCHIATR NEUROSCI, V30, P319; Dedovic K, 2009, BRAIN RES, V1293, P49, DOI 10.1016/j.brainres.2009.06.044; Deguchi Takatsugu, 1992, Annals of Physiological Anthropology, V11, P37; Dimitriev D A, 2015, Ross Fiziol Zh Im I M Sechenova, V101, P98; Ebbesen F, 2003, ARCH DIS CHILD-FETAL, V88, pF430, DOI 10.1136/fn.88.5.F430; Figueiro MG, 2007, ACTA NEUROBIOL EXP, V67, P171; Hi LS, 2009, J HUMAN ENV SYST, V12, P27; Jenke R, 2014, IEEE T AFFECT COMPUT, V5, P327, DOI 10.1109/TAFFC.2014.2339834; Kuijsters A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132732; Kuller R., 1993, Lighting Research and Technology, V25, P71; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Minguillon J, 2016, FRONT COMPUT NEUROSC, V10, DOI 10.3389/fncom.2016.00101; Moridis CN, 2010, P IEEE EMBS REG 8 IN, P3; Munch M, 2014, NEUROIMAGE, V101, P547, DOI 10.1016/j.neuroimage.2014.06.071; Munch M, 2006, AM J PHYSIOL-REG I, V290, pR1421, DOI 10.1152/ajpregu.00478.2005; Nagano-Saito A, 2013, SYNAPSE, V67, P821, DOI 10.1002/syn.21700; Nardelli M, 2015, IEEE T AFFECT COMPUT, V6, P385, DOI 10.1109/TAFFC.2015.2432810; Papousek I, 2014, BIOL PSYCHOL, V103, P184, DOI 10.1016/j.biopsycho.2014.09.001; Picard RW, 2010, IEEE T AFFECT COMPUT, V1, P11, DOI 10.1109/T-AFFC.2010.10; Rahman SA, 2014, SLEEP, V37, P271, DOI 10.5665/sleep.3396; Regula M, 2014, PROCEEDINGS OF THE 2014 16TH INTERNATIONAL CONFERENCE ON MECHATRONICS (MECHATRONIKA 2014), P639, DOI 10.1109/MECHATRONIKA.2014.7018334; Reinhardt T, 2012, PSYCHIAT RES, V198, P106, DOI 10.1016/j.psychres.2011.12.009; Remor E, 2006, SPAN J PSYCHOL, V9, P86, DOI 10.1017/S1138741600006004; Sanchez-Carrion MJ, 2013, PARTICIP ED REV CONS, V2, P105; SCHAUSS AG, 1979, J ORTHOMOL MED, V8, P218; Semmlow JL, 2014, BIOSIGNAL AND MEDICA; Sroykham W, 2015, BMEICON 2014 7 BIOM; Ssang-Hee Seo, 2010, Convergence and Hybrid Information Technologies, P413; Steinhubl SR, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00145; Tanida M, 2007, BRAIN RES, V1184, P210, DOI 10.1016/j.brainres.2007.09.058; VALDEZ P, 1994, J EXP PSYCHOL GEN, V123, P394, DOI 10.1037/0096-3445.123.4.394; Vandewalle G, 2006, CURR BIOL, V16, P1616, DOI 10.1016/j.cub.2006.06.031; Wark B, 2007, CURR OPIN NEUROBIOL, V17, P423, DOI 10.1016/j.conb.2007.07.001; Wright HR, 2001, CHRONOBIOL INT, V18, P801, DOI 10.1081/CBI-100107515; Yoto Ai, 2007, Journal of Physiological Anthropology, V26, P373, DOI 10.2114/jpa2.26.373; Zschucke E, 2015, PSYCHONEUROENDOCRINO, V51, P414, DOI 10.1016/j.psyneuen.2014.10.019	47	18	18	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0186399	10.1371/journal.pone.0186399	http://dx.doi.org/10.1371/journal.pone.0186399			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK0UN	29049332	gold, Green Published, Green Submitted			2023-01-03	WOS:000413195900062
J	Mantovani, A; Rigolon, R; Pichiri, I; Bonapace, S; Morani, G; Zoppini, G; Bonora, E; Targher, G				Mantovani, Alessandro; Rigolon, Riccardo; Pichiri, Isabella; Bonapace, Stefano; Morani, Giovanni; Zoppini, Giacomo; Bonora, Enzo; Targher, Giovanni			Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus	PLOS ONE			English	Article							PROLONGED PR INTERVAL; CARDIOVASCULAR-DISEASE; PREVALENCE; DYSFUNCTION; OUTCOMES	Recent studies suggested that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiac tachyarrhythmias (mainly atrial fibrillation) in patients with and without type 2 diabetes mellitus. The aim of this study was to examine whether an association also exists between NAFLD and heart block. We have retrospectively evaluated a hospital-based cohort of 751 patients with type 2 diabetes discharged from our Division of Diabetes and Endocrinology during years 2007-2014. Standard electrocardiograms were performed on all patients. Diagnosis of NAFLD was based on ultrasonography, whereas the severity of advanced hepatic fibrosis was based on the fibrosis (FIB)-4 score and other non-invasive fibrosis markers. Overall, 524 (69.8%) patients had NAFLD and 202 (26.9%) had heart block (defined as at least one block among first-degree atrio-ventricular block, second-degree block, third-degree block, left bundle branch block, right bundle branch block, left anterior hemi-block or left posterior hemi-block) on electrocardiograms. Patients with NAFLD had a remarkably higher prevalence of any persistent heart block than those without NAFLD (31.3% vs. 16.7%, p<0.001); this prevalence was particularly increased among those with higher FIB-4 score. NAFLD was associated with a threefold increased risk of prevalent heart block (adjusted-odds ratio 3.04, 95% CI 1.81-5.10), independently of age, sex, hypertension, prior ischemic heart disease, hemoglobin A1c, microvascular complication status, use of medications and other potentially confounding factors. In conclusion, this is the largest cross-sectional study to show that NAFLD and its severity are independently associated with an increased risk of prevalent heart block in hospitalized patients with type 2 diabetes.	[Mantovani, Alessandro; Rigolon, Riccardo; Pichiri, Isabella; Zoppini, Giacomo; Bonora, Enzo; Targher, Giovanni] Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy; [Mantovani, Alessandro; Rigolon, Riccardo; Pichiri, Isabella; Zoppini, Giacomo; Bonora, Enzo; Targher, Giovanni] Azienda Osped Univ Integrata Verona, Verona, Italy; [Bonapace, Stefano] Sacro Cuore Hosp, Div Cardiol, Verona, Italy; [Morani, Giovanni] Univ Verona, Dept Med, Sect Cardiol, Verona, Italy; [Morani, Giovanni] Azienda Osped Univ Integrata Verona, Verona, Italy	University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; IRCCS Sacro Cuore Don Calabria; University of Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Targher, G (corresponding author), Univ Verona, Dept Med, Sect Endocrinol Diabet & Metab, Verona, Italy.; Targher, G (corresponding author), Azienda Osped Univ Integrata Verona, Verona, Italy.	giovanni.targher@univr.it	Mantovani, Alessandro/AAB-9015-2019; zoppini, giacomo/AAA-9000-2022; Morani, Giovanni/AAX-7857-2020; Targher, Giovanni/AAB-9008-2019; Bonora, Enzo/AAA-5300-2022	Mantovani, Alessandro/0000-0002-7271-6329; zoppini, giacomo/0000-0003-1085-554X; Targher, Giovanni/0000-0002-4325-3900; Bonapace, Stefano/0000-0001-9122-2642				Adams LA, 2017, GUT, V66, P1138, DOI 10.1136/gutjnl-2017-313884; Bonapace S, 2012, DIABETES CARE, V35, P389, DOI 10.2337/dc11-1820; Bussink BE, 2013, EUR HEART J, V34, P138, DOI 10.1093/eurheartj/ehs291; Byrne CD, 2016, GASTROENTEROLOGY, V150, P7, DOI 10.1053/j.gastro.2015.11.016; Castera L, 2013, NAT REV GASTRO HEPAT, V10, P666, DOI 10.1038/nrgastro.2013.175; Cheng S, 2009, JAMA-J AM MED ASSOC, V301, P2571, DOI 10.1001/jama.2009.888; Coumbe AG, 2013, HEART, V99, P334, DOI 10.1136/heartjnl-2012-302770; Hallsworth K, 2013, J HEPATOL, V58, P757, DOI 10.1016/j.jhep.2012.11.015; Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452; Hung CS, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001820; Karajamaki AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142937; Kuehl M, 2012, NAT REV ENDOCRINOL, V8, P405, DOI 10.1038/nrendo.2012.21; Kwok CS, 2016, HEART, V102, P672, DOI 10.1136/heartjnl-2015-308956; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liu YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061803; Lonardo A, 2016, METABOLISM, V65, P1136, DOI 10.1016/j.metabol.2015.09.017; Lonardo A, 2015, DIGEST LIVER DIS, V47, P997, DOI 10.1016/j.dld.2015.08.004; Mangi MA, 2017, CUREUS, V9, DOI 10.7759/cureus.1107; Mantovani A, 2016, DIABETES CARE, V39, P1416, DOI 10.2337/dc16-0091; Mantovani A, 2016, DIGEST DIS SCI, V61, P1246, DOI 10.1007/s10620-016-4040-6; Mantovani A, 2015, METABOLISM, V64, P879, DOI 10.1016/j.metabol.2015.04.003; Marchesini G, 2016, J HEPATOL, V64, P1388, DOI 10.1016/j.jhep.2015.11.004; McPherson S, 2017, AM J GASTROENTEROL, V112, P740, DOI 10.1038/ajg.2016.453; Park CC, 2017, GASTROENTEROLOGY, V152, P598, DOI 10.1053/j.gastro.2016.10.026; Pokorney SD, 2016, AM HEART J, V171, P25, DOI 10.1016/j.ahj.2015.09.004; Prineas RJ, 2010, MINNESOTA CODE MANUA; Targher G, 2016, J HEPATOL, V65, P589, DOI 10.1016/j.jhep.2016.05.013; Targher G, 2014, NUTR METAB CARDIOVAS, V24, P663, DOI 10.1016/j.numecd.2014.01.005; Targher G, 2013, CLIN SCI, V125, P301, DOI 10.1042/CS20130036; Targher G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057183; Targher G, 2012, DIABETES CARE, V35, P2347, DOI 10.2337/dc12-0259; Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063; VanWagner LB, 2015, HEPATOLOGY, V62, P773, DOI 10.1002/hep.27869; Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431	34	29	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2017	12	10							e0185459	10.1371/journal.pone.0185459	http://dx.doi.org/10.1371/journal.pone.0185459			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI9WM	28981521	Green Published, Green Submitted, gold			2023-01-03	WOS:000412360300040
J	Xu, RZ; Lin, LB; Li, Y; Li, Y				Xu, Rongzhong; Lin, Liubing; Li, Yong; Li, Yan			ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis	PLOS ONE			English	Article							CHINESE MEDICINAL HERBS	Objective This study aims to investigate cellular immunity and clinical efficacy of ShenQi FuZheng Injection (SFI) in the associated chemotherapy of colorectal cancer (CRC). Methods PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Full-text Database (VIP), WanFang Database and Chinese Biomedical Literature Database (CBM) searches were undertaken to identify randomized controlled trials of SFI plus chemotherapy versus chemotherapy alone in CRC patients. The quality of each trial was assessed according to the Jadad's scale, and Review Manager 5 was used to statisitically analyze the outcomes. Results Eight studies involving 722 patients were included in this review. The meta-analyses suggested there was a significantly higher overall response rate (OR 1.89; CI: 1.10-3.24; p = 0.02), grades of KPS (OR 2.35; CI: 1.55-3.56; p<0.01), CD3+cells (MD 10.29; CI: 8.46-12.12; p<0.01), CD4+cells (MD 7.06; CI: 5.33-8.794; p<0.01), CD4/CD8+ cells (MD 0.32; CI: 0.25-0.40; p<0.01), NK+ (MD 7.20; CI: 2.02-12.37, p = 0.006), WBC (MD 1.24; CI: 0.59-1.89; p<0.01), HB (MD 14.55; CI: 7.47-21.63; p<0.01), and PLT (MD 19.05; CI: 4.29-33.81; p = 0.01), but lower severe toxicity for leukocytopenia (OR 0.37; CI: 0.17-0.80; p = 0.01), thrombocytopenia (OR 0.32; CI: 0.14-0.74; p = 0.008), gastrointestinal toxicity (OR 0.48; CI: 0.24-0.96; p = 0.04), when chemotherapy combined with SFI was compared with chemotherapy alone. There were similarities between two groups in liver dysfunction (OR 0.44; CI: 0.18-1.08; p = 0.07) and CD8+ (MD 0.54; CI: -1.89-2.96; p = 0.66). Also, there was presence of heterogeneity in the CD8 results; after the sensitivity analysis, the result of CD8+ was reversed (MD 1.57; CI: 0.32-2.81; p = 0.01). There was no significant publication bias across studies according to the Egger's (P = 0.19) and Begg's test (P = 0.23). Conclusion SFI enhances chemotherapy efficiency as they are combined and used in the treatment of colorectal cancer patients. At the same time, SFI also improves patients' immunity function.	[Xu, Rongzhong; Li, Yan] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, Shanghai, Peoples R China; [Lin, Liubing; Li, Yong] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Digest Dept, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine	Li, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, Shanghai, Peoples R China.	18916767226@163.com			National Natural Science Foundation of China [81473627]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by National Natural Science Foundation of China (grant 81473627).	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; [Anonymous], 2003, Altern Med Rev, V8, P72; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Dai Zhen, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P598; Dedong C, 2016, PLOS ONE, V11; Dekker JWT, 2014, EJSO-EUR J SURG ONC, V40, P1481, DOI 10.1016/j.ejso.2014.05.010; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fan Xiao-hua, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P307; Goi T, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0704-5; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Li J, 2015, CHIN J INTEGR MED, V21, P71, DOI 10.1007/s11655-014-1768-8; Liang Qi-Lian, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P439; Liu DW, 2009, ANTI-CANCER AGENT ME, V9, P392, DOI 10.2174/1871520610909040392; Liu G Z, 1988, J Tradit Chin Med, V8, P41; Luo HX, 2007, J FOOD PROTECT, V70, P1440, DOI 10.4315/0362-028X-70.6.1440; Shan BE, 1999, INT J IMMUNOPHARMACO, V21, P149, DOI 10.1016/S0192-0561(98)00074-5; Song M, 2015, GUIDING J TRADITIONA, V21, P46, DOI DOI 10.13862/J.CNKI.CN43-1446/R.2015.02.017; Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6; Wang CB, 2010, ZHEJIANG J TRADITION, V45, P801; Wang JX, 2014, J ETHNOPHARMACOL, V155, P405, DOI 10.1016/j.jep.2014.05.038; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Xu C, 2012, INT J BIOL MACROMOL, V50, P891, DOI 10.1016/j.ijbiomac.2012.01.013; [燕飞 Yan Fei], 2014, [中国现代医学杂志, China Journal of Modern Medicine], V24, P72; Yoshida Y, 1997, INT J IMMUNOPHARMACO, V19, P359, DOI 10.1016/S0192-0561(97)00076-3; Zhang W., 2015, MOD PRACT MED, V27, P358; Zhang X. H., 2009, CHINA PRACTICAL MED, V4, P129; Zhang Yan, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P280; [邹劲林 Zou Jinlin], 2012, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V29, P755	30	18	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2017	12	9							e0185254	10.1371/journal.pone.0185254	http://dx.doi.org/10.1371/journal.pone.0185254			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4WR	28953950	gold, Green Published, Green Submitted			2023-01-03	WOS:000411980300050
J	Kim, SW; Shin, HJ; Hwang, JH; Shin, JS; Park, SK; Kim, JY; Kim, KJ; Kay, CS; Kang, YN				Kim, Shin-Wook; Shin, Hun-Joo; Hwang, Jin-Ho; Shin, Jin-Sol; Park, Sung-Kwang; Kim, Jin-Young; Kim, Ki-Jun; Kay, Chul-Seung; Kang, Young-Nam			Image similarity evaluation of the bulk-density-assigned synthetic CT derived from MRI of intracranial regions for radiation treatment	PLOS ONE			English	Article							RADIOTHERAPY; SIMULATION	Objective Various methods for radiation-dose calculation have been investigated over previous decades, focusing on the use of magnetic resonance imaging (MRI) only. The bulk-densityassignment method based on manual segmentation has exhibited promising results compared to dose-calculation with computed tomography (CT). However, this method cannot be easily implemented in clinical practice due to its time-consuming nature. Therefore, we investigated an automatic anatomy segmentation method with the intention of providing the proper methodology to evaluate synthetic CT images for a radiation-dose calculation based on MR images. Methods CT images of 20 brain cancer patients were selected, and their MR images including T1-weighted, T2-weighted, and PETRA were retrospectively collected. Eight anatomies of the patients, such as the body, air, eyeball, lens, cavity, ventricle, brainstem, and bone, were segmented for bulk-density-assigned CT image (BCT) generation. In addition, water-equivalent CT images (WCT) with only two anatomies D body and air D were generated for a comparison with BCT. Histogram comparison and gamma analysis were performed by comparison with the original CT images, after the evaluation of automatic segmentation performance with the dice similarity coefficient (DSC), false negative dice (FND) coefficient, and false positive dice (FPD) coefficient. Results The highest DSC value was 99.34 for air segmentation, and the lowest DSC value was 73.50 for bone segmentation. For lens segmentation, relatively high FND and FPD values were measured. The cavity and bone were measured as over-segmented anatomies having higher FPD values than FND. The measured histogram comparison results of BCT were better than those of WCT in all cases. In gamma analysis, the averaged improvement of BCT compared to WCT was measured. All the measured results of BCT were better than those of WCT. Therefore, the results of this study show that the introduced methods, such as histogram comparison and gamma analysis, are valid for the evaluation of the synthetic CT generation from MR images. Conclusions The image similarity results showed that BCT has superior results compared to WCT for all measurements performed in this study. Consequently, more accurate radiation treatment for the intracranial regions can be expected when the proper image similarity evaluation introduced in this study is performed.	[Kim, Shin-Wook; Shin, Hun-Joo; Kay, Chul-Seung] Catholic Univ Korea, Incheon St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Hwang, Jin-Ho; Shin, Jin-Sol] Catholic Univ Korea, Dept Biomed Engn, Coll Med, Seoul, South Korea; [Park, Sung-Kwang] Inje Univ, Busan Paik Hosp, Dept Radiat Oncol, Busan, South Korea; [Kim, Jin-Young] Inje Univ, Haeundae Paik Hosp, Dept Radiat Oncol, Busan, South Korea; [Kim, Ki-Jun] Catholic Univ Korea, Incheon St Marys Hosp, Dept Radiol, Coll Med, Seoul, South Korea; [Kang, Young-Nam] Catholic Univ Korea, Seoul St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Inje University; Inje University; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital	Kang, YN (corresponding author), Catholic Univ Korea, Seoul St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea.	ynkang33@gmail.com						[Anonymous], 2011, R OPENCV 2 COMPUTER; Chen L, 2004, PHYS MED BIOL, V49, P5157, DOI 10.1088/0031-9155/49/22/010; Dean CJ, 2012, BRIT J RADIOL, V85, P61, DOI 10.1259/bjr/11855927; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Dowling JA, 2012, INT J RADIAT ONCOL, V83, pE5, DOI 10.1016/j.ijrobp.2011.11.056; Eilertsen K, 2008, ACTA ONCOL, V47, P1294, DOI 10.1080/02841860802256426; Evans PM, 2008, PHYS MED BIOL, V53, pR151, DOI 10.1088/0031-9155/53/12/R01; Johansson A, 2012, MED PHYS, V39, P3283, DOI 10.1118/1.4711807; Johansson A, 2011, MED PHYS, V38, P2708, DOI 10.1118/1.3578928; Jonsson JH, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-62; Kapanen M, 2013, MAGN RESON MED, V70, P127, DOI 10.1002/mrm.24459; Karlsson M, 2009, INT J RADIAT ONCOL, V74, P644, DOI 10.1016/j.ijrobp.2009.01.065; Korhonen J, 2014, MED PHYS, V41, DOI 10.1118/1.4842575; Korsholm ME, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-16; Lambert J, 2011, RADIOTHER ONCOL, V98, P330, DOI 10.1016/j.radonc.2011.01.012; Lee YK, 2003, RADIOTHER ONCOL, V66, P203, DOI 10.1016/S0167-8140(02)00440-1; Low DA, 1998, MED PHYS, V25, P656, DOI 10.1118/1.598248; Njeh CF, 2008, J MED PHYS, V33, P136, DOI 10.4103/0971-6203.44472; Nyholm T, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-54; Paulson ES, 2015, MED PHYS, V42, P28, DOI 10.1118/1.4896096; Pereira GC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/231090; Roberson PL, 2005, MED PHYS, V32, P473, DOI 10.1118/1.1851920; Saito AI, 2009, J APPL CLIN MED PHYS, V10, P92, DOI 10.1120/jacmp.v10i2.2847; Schmidt MA, 2015, PHYS MED BIOL, V60, pR323, DOI 10.1088/0031-9155/60/22/R323; Stanescu T, 2008, PHYS MED BIOL, V53, P3579, DOI 10.1088/0031-9155/53/13/013; Uha J, 2014, MED PHYS, V41, DOI 10.1118/1.4873315; ZIJDENBOS AP, 1994, IEEE T MED IMAGING, V13, P716, DOI 10.1109/42.363096	27	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2017	12	9							e0185082	10.1371/journal.pone.0185082	http://dx.doi.org/10.1371/journal.pone.0185082			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH4XT	28926610	Green Submitted, Green Published, gold			2023-01-03	WOS:000411166600067
J	Liu, MY; Pan, YS; Zhou, LC; Wang, YJ				Liu, Mingyong; Pan, Yuesong; Zhou, Lichun; Wang, Yongjun			Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; INTRACEREBRAL HEMORRHAGE; INTRAVENOUS THROMBOLYSIS; ALTEPLASE 3; RISK; THERAPY; AGE; IMPLEMENTATION; OUTCOMES; SCALE	Background and purpose Predictors of symptomatic intracranial hemorrhage (sICH) in Chinese patients with acute ischemic stroke treated with recombinant tissue plasminogen activator remain unclear. Methods Data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) study were assessed to explore risk factors for symptomatic intracranial hemorrhage after intravenous thrombolysis. Three candidate sICH definitions were analyzed. Results Among 1128 patients with acute ischemic stroke treated with intravenous rtPA within 4.5 hours of symptom onset, 23 (2.0%), 44(3.9%) and 61 (5.4%) experienced modified mSITS-MOST, ECASS II, and NINDS defined sICH, respectively. Multivariate logistic regression revealed independent risk factors for sICH were age. 70 years-old(sICH per NINDS, adjusted OR = 1.73[95% CI1.02-2.95], p = 0.04), diabetes(sICH per SITS-MOST, adjusted OR = 3.50 [95% CI1.34-9.16], p = 0.01), serum glucose on admission >9.0mmol/L(sICH per ECASS II, adjusted OR = 2.84[95% CI1.48-5.46], p = 0.002), NIHSS on admission>20(sICH per SITS-MOST, adjusted OR = 5.06[95% CI1.68-15.20], p = 0.004 or sICH per NINDS, adjusted OR 2.81[95% CI1.42-5.57], p = 0.003) and cardioembolism(sICH per SITS-MOST, adjusted OR = 7.09[95% CI2.41-20.87], p<0.001 or sICH per ECASS II, adjusted OR = 4.99 [95% CI2.53-9.84], p<0.001) or sICH per NINDS, adjusted OR = 2.47[95% CI1.39-4.39], p = 0.002). Conclusion Cardioembolism, NIHSS on admission higher than 20, serum glucose on admission higher than 9.0 mmol/L and age >= 70 years were independent risk factors for symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke treated with recombinant tissue plasminogen activator.	[Liu, Mingyong; Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Ctr Stroke, Beijing, Peoples R China; [Liu, Mingyong; Wang, Yongjun] Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; [Liu, Mingyong; Wang, Yongjun] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China; [Liu, Mingyong; Wang, Yongjun] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China; [Liu, Mingyong; Zhou, Lichun] Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing, Peoples R China; [Pan, Yuesong] Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China; [Pan, Yuesong] Beijing Municipal Key Lab Clin Epidemiol, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University	Wang, YJ (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Ctr Stroke, Beijing, Peoples R China.; Wang, YJ (corresponding author), Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Wang, YJ (corresponding author), Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.; Wang, YJ (corresponding author), Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China.; Zhou, LC (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing, Peoples R China.	13701279076@163.com; yongjunwang1962@gmail.com	Pan, Yuesong/AAI-6303-2020; Mingyong, Liu/D-1500-2014	Pan, Yuesong/0000-0003-3082-6789; Mingyong, Liu/0000-0001-6187-8587	National Science and Technology Major Project of China [2011BA108602]; State Key Development Program of Basic Research of China [2009CB521905]	National Science and Technology Major Project of China; State Key Development Program of Basic Research of China(State Key Development Program for Basic Research of China)	This study was funded by the National Science and Technology Major Project of China (2011BA108602) and the State Key Development Program of Basic Research of China (2009CB521905) to YW.	Al-Khaled M, 2014, J STROKE CEREBROVASC, V23, P7, DOI 10.1016/j.jstrokecerebrovasdis.2012.04.004; Anderson CS, 2016, NEW ENGL J MED, V374, P2313, DOI 10.1056/NEJMoa1515510; Brown DL, 2005, ANN EMERG MED, V46, P56, DOI 10.1016/j.annemergmed.2004.12.025; Costello CA, 2012, J CLIN NEUROSCI, V19, P360, DOI 10.1016/j.jocn.2011.08.014; Cronin CA, 2012, STROKE, V43, P1684, DOI 10.1161/STROKEAHA.112.656587; Cucchiara Brett, 2008, J Stroke Cerebrovasc Dis, V17, P331, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.012; Dharmasaroja PA, 2013, J STROKE CEREBROVASC, V22, P227, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.001; Dharmasaroja PA, 2012, J CLIN NEUROSCI, V19, P799, DOI 10.1016/j.jocn.2011.08.035; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Ginsberg MD, 2015, INT J STROKE, V10, P494, DOI 10.1111/ijs.12476; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; Kono S, 2013, J STROKE CEREBROVASC, V22, P190, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.016; Lee HJ, 2017, J STROKE, V19, P229, DOI 10.5853/jos.2016.01109; Liao XL, 2013, CNS NEUROSCI THER, V19, P43, DOI 10.1111/cns.12031; Liao XL, 2014, STROKE, V45, P2354, DOI 10.1161/STROKEAHA.114.005989; Lin QQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153486; Lindley RI, 2015, STROKE, V46, P746, DOI 10.1161/STROKEAHA.114.006573; Lou M, 2008, NEUROLOGY, V71, P1417, DOI 10.1212/01.wnl.0000330297.58334.dd; Matsuo R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110444; Matute MC, 2012, CEREBROVASC DIS, V33, P231, DOI 10.1159/000334662; Mazya M, 2012, STROKE, V43, P1524, DOI 10.1161/STROKEAHA.111.644815; Menon BK, 2012, STROKE, V43, P2293, DOI 10.1161/STROKEAHA.112.660415; Mosimann PJ, 2013, STROKE, V44, P806, DOI 10.1161/STROKEAHA.112.675678; Muengtaweepongsa S, 2015, ANN INDIAN ACAD NEUR, V18, P181, DOI 10.4103/0972-2327.150592; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581; Orlando A, 2016, J STROKE CEREBROVASC, V25, P969, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.003; Saposnik G, 2013, NEUROLOGY, V80, P21, DOI 10.1212/WNL.0b013e31827b1ace; Seet RCS, 2012, CEREBROVASC DIS, V34, P106, DOI 10.1159/000339675; Strbian D, 2011, Neurology, V77, P341, DOI 10.1212/WNL.0b013e3182267b8c; Strbian D, 2014, STROKE, V45, P752, DOI 10.1161/STROKEAHA.113.003806; Strbian D, 2012, ANN NEUROL, V71, P634, DOI 10.1002/ana.23546; Sung SF, 2013, STROKE, V44, P1561, DOI 10.1161/STROKEAHA.111.000651; Tong X, 2014, INT J STROKE, V9, P728, DOI 10.1111/ijs.12155; Ueshima S, 2002, THROMB HAEMOSTASIS, V87, P544, DOI 10.1055/s-0037-1613042; Urra X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059420; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Xian Y, 2012, JAMA-J AM MED ASSOC, V307, P2600, DOI 10.1001/jama.2012.6756	37	19	22	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2017	12	9							e0184646	10.1371/journal.pone.0184646	http://dx.doi.org/10.1371/journal.pone.0184646			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH3OQ	28922363	Green Submitted, gold, Green Published			2023-01-03	WOS:000411059300020
J	Zhang, LW; Zeng, YB; Fang, Y				Zhang, Liangwen; Zeng, Yanbing; Fang, Ya			The effect of health status and living arrangements on long term care models among older Chinese: A cross-sectional study	PLOS ONE			English	Article							TRENDS; ADULTS; PEOPLE	Background Currently, there are many studies focusing on the influencing factors of the elderly people's living arrangements or health status, but little is known about the relationship between living arrangements or health status and long-term care models for the old-age, especially the joint effects. Objective We aimed to assess the effects of health status and living arrangements on long-term care models (LTCM) among the elderly of Xiamen, China, especially their cumulative joint effects. Methods A total of 14,373 participants aged >= 60 years by multistage sampling in Xiamen of China were enrolled. Multinomial logistic regression was used to estimate the Odds ratios (ORs) regressing LTCM on health status and living arrangements using the Anderson model as theoretical framework. Results Totally, 14,292 valid questionnaires were obtained, of which 86.37% selected home care. With the increase of disability degree, older people are more likely to choose institutional care, compared to living alone (ORs = 1.75, 2.06, 4.00, 4.01 for the "relatively independent', "mild disability', "moderate disability', and "total disability', respectively, in comparison with "completely independent'). The elderly living with children and other family members preferred to choose home care. (ORs = 0.50, 0.39, 0.40, and 0.43 for the "living with children', "living with spouse', "living with children and spouse', and "living with others', respectively, in comparison with "alone'). Additionally, residence, number of children, education level, and feelings of loneliness were the determinants of the choice of social pension. Conclusion A multitude of older people are trended to choose home care in Xiamen of China. There was an interaction and joint effect between the degree of disability and the living arrangements on LTCM. Therefore, policymakers should pay close attention to care for those living alone, childless, and disabled elders to meet their care needs, especially in home care. In addition, the social construction of facilities for elders in rural areas should be strengthened.	[Zhang, Liangwen; Zeng, Yanbing; Fang, Ya] Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Fujian, Peoples R China; [Zhang, Liangwen; Zeng, Yanbing; Fang, Ya] Xiamen Univ, Sch Publ Hlth, Key Lab Hlth Technol Assessment, Fujian Prov Univ, Xiamen, Fujian, Peoples R China	Xiamen University; Fuzhou University; Xiamen University	Fang, Y (corresponding author), Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Fujian, Peoples R China.; Fang, Y (corresponding author), Xiamen Univ, Sch Publ Hlth, Key Lab Hlth Technol Assessment, Fujian Prov Univ, Xiamen, Fujian, Peoples R China.	Fangya@xmu.edu.cn			Center for Health Economics and Policy at the School of Public Health, Xiamen University; Youth Project of National Natural Science Fund [71403229]; project of National Natural Science Fund [81573257]; project of Natural Science Fund of Fujian Province [2017J01133]	Center for Health Economics and Policy at the School of Public Health, Xiamen University; Youth Project of National Natural Science Fund; project of National Natural Science Fund; project of Natural Science Fund of Fujian Province	This study was supported by The Center for Health Economics and Policy at the School of Public Health, Xiamen University, the Youth Project of National Natural Science Fund (No. 71403229), the project of National Natural Science Fund (No. 81573257), and the project of Natural Science Fund of Fujian Province (No. 2017J01133). All funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An Y, 2007, LTCM, V25, P86; [Anonymous], 2000, J POPULAT, V3, P30; Bei Z, 2012, RES PROGR LONG TERM; Chen SY, 2009, AGEING INT, V34, P172, DOI 10.1007/s12126-009-9043-6; Chen W, 2015, ASSESSMENT DISABILIT; China NBoSoPsRo, 2015, NAT EC SOC DEV STAT; Chou YC, 2015, EUR J AGEING, V12, P95, DOI 10.1007/s10433-014-0322-z; ChuWHD Song G, 2008, CHINESE HLTH ENTERPR, V23, P836; Arias-Merino ED, 2012, ARCH GERONTOL GERIAT, V54, pE271, DOI 10.1016/j.archger.2012.02.010; Feng W., 2007, POPULATION CHINA BEG, P177; Gaymu J, 2008, EUR J AGEING, V5, P5, DOI 10.1007/s10433-008-0072-x; Gaymu J, 2006, EUR J POPUL, V22, P241, DOI 10.1007/s10680-006-9004-7; Jing Wang MW, 2008, CHINESE GEN PRACTICE; Kim HJ, 2015, J DEV PHYS DISABIL, V27, P307, DOI 10.1007/s10882-014-9418-9; Kuo T T-GFM, 2001, RES AGING; Lefevre T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115064; Li LW, 2009, SOC SCI MED, V68, P220, DOI 10.1016/j.socscimed.2008.10.013; Long S FX, 2007, NANJING SOCIAL SCI, P98; Lu L ZG, 2014, HLTH RELATED QUALITY; Ouellette-Kuntz H, 2015, INT REV RES DEV DISA, V48, P151, DOI 10.1016/bs.irrdd.2015.03.004; Peng X SS, 2010, PLOS ONE, V5, P121; Sereny M, 2011, RES AGING, V33, P172, DOI 10.1177/0164027510392387; [苏丽惠 SU Li-hui], 2010, [广东医学, Guangdong Medical Journal], V31, P633; Wang H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053879, 10.1371/journal.pone.0057030, 10.1371/journal.pone.0062841, 10.1371/journal.pone.0067140]; Woo J, 2002, INT J EPIDEMIOL, V31, P772, DOI 10.1093/ije/31.4.772; Yang M., 2012, CHINESE NURSING RES, V26, P37; Zhang WP, 2009, INT C POWER ELECT DR, P159; Zhao P, 2010, JPN J CLIN ONCOL, V40, P281, DOI 10.1093/jjco/hyp187; Zheng H CSL, 2011, SHANGHAI ARCH PSYCHI, V23, P79	29	23	25	2	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2017	12	9							e0182219	10.1371/journal.pone.0182219	http://dx.doi.org/10.1371/journal.pone.0182219			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG0PY	28880887	Green Published, gold, Green Submitted			2023-01-03	WOS:000409467200006
J	Koek, MBG; Hopmans, TEM; Soetens, LC; Wille, JC; Geerlings, SE; Vos, MC; van Benthem, BHB; de Greeff, SC				Koek, Mayke B. G.; Hopmans, Titia E. M.; Soetens, Loes C.; Wille, Jan C.; Geerlings, Suzanne E.; Vos, Margreet C.; van Benthem, Birgit H. B.; de Greeff, Sabine C.			Adhering to a national surgical care bundle reduces the risk of surgical site infections	PLOS ONE			English	Article							COLORECTAL SURGERY; IMPROVEMENT PROJECT; PREVENTION; PROGRAM; IMPLEMENTATION; GUIDELINES; EXPERIENCE; REDUCTION; CHECKLIST; OUTCOMES	Background In 2008, a bundle of care to prevent Surgical Site Infections (SSIs) was introduced in the Netherlands. The bundle consisted of four elements: antibiotic prophylaxis according to local guidelines, no hair removal, normothermia and 'hygiene discipline' in the operating room (i.e. number of door movements). Dutch hospitals were advised to implement the bundle and to measure the outcome. This study's goal was to assess how effective the bundle was in reducing SSI risk. Methods Hospitals assessed whether their staff complied with each of the bundle elements and voluntary reported compliance data to the national SSI surveillance network (PREZIES). From PREZIES data, we selected data from 2009 to 2014 relating to 13 types of surgical procedures. We excluded surgeries with missing (non) compliance data, and calculated for each remaining surgery with reported (non) compliance data the level of compliance with the bundle (that is, being compliant with 0, 1, 2, 3, or 4 of the elements). Subsequently, we used this level of compliance to assess the effect of bundle compliance on the SSI risk, using multi-level logistic regression techniques. Results 217 489 surgeries were included, of which 62 486 surgeries (29%) had complete bundle reporting. Within this group, the SSI risk was significantly lower for surgeries with complete bundle compliance compared to surgeries with lower compliance levels. Odds ratios ranged from 0.63 to 0.86 (risk reduction of 14% to 37%), while a 13% risk reduction was demonstrated for each point increase in compliance-level. Sensitivity analysis indicated that due to analysing reported bundles only, we probably underestimated the total effect of implementing the bundle. Conclusions This study demonstrated that adhering to a surgical care bundle significantly reduced the risk of SSIs. Reporting of and compliance with the bundle compliance can, however, still be improved. Therefore an even greater effect might be achieved.	[Koek, Mayke B. G.; Hopmans, Titia E. M.; Soetens, Loes C.; Wille, Jan C.; van Benthem, Birgit H. B.; de Greeff, Sabine C.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control CIb, Dept Epidemiol & Surveillance, Bilthoven, Netherlands; [Soetens, Loes C.] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; [Geerlings, Suzanne E.] Acad Med Ctr, Dept Infect Dis, Amsterdam, Netherlands; [Vos, Margreet C.] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands	Netherlands National Institute for Public Health & the Environment; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC	Koek, MBG (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control CIb, Dept Epidemiol & Surveillance, Bilthoven, Netherlands.	mayke.koek@rivm.nl						Anthony T, 2011, ARCH SURG-CHICAGO, V146, P263, DOI 10.1001/archsurg.2010.249; Berenguer CM, 2010, J AM COLL SURGEONS, V210, P737, DOI 10.1016/j.jamcollsurg.2010.01.029; Berrios-Torres SI, 2017, JAMA SURG; Bull A, 2011, J HOSP INFECT, V78, P297, DOI 10.1016/j.jhin.2011.03.029; Cima R, 2013, J AM COLL SURGEONS, V216, P23, DOI 10.1016/j.jamcollsurg.2012.09.009; Crolla RMPH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044599; de Bruijne MC, 2007, PATIENT SAFETY DUTCH; de Lissovoy G, 2009, AM J INFECT CONTROL, V37, P387, DOI 10.1016/j.ajic.2008.12.010; Gagliardi AR, 2009, AM J INFECT CONTROL, V37, P398, DOI 10.1016/j.ajic.2008.10.027; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Haraden C., IMPROVEMENT STORIES; Hawn MT, 2011, ANN SURG, V254, P494, DOI 10.1097/SLA.0b013e31822c6929; Hedrick TL, 2007, J AM COLL SURGEONS, V205, P432, DOI 10.1016/j.jamcollsurg.2007.04.042; Horan TC., 2004, HOSP EPIDEMIOL INFEC, P1659; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Itani KMF, 2015, JAMA-J AM MED ASSOC, V314, P289, DOI 10.1001/jama.2015.4473; Keenan JE, 2014, JAMA SURG, V149, P1045, DOI 10.1001/jamasurg.2014.346; Koek MB, 2015, EURO SURVEILL, V20; Kurmann A, 2011, BRIT J SURG, V98, P1021, DOI 10.1002/bjs.7496; Larochelle M, 2011, DIS COLON RECTUM, V54, P394, DOI 10.1007/DCR.0b013e318206165b; Leaper DJ, 2015, INT WOUND J, V12, P357, DOI 10.1111/iwj.12243; Liau KH, 2010, SURG INFECT, V11, P151, DOI 10.1089/sur.2008.081; Lutfiyya Waleed, 2012, Perm J, V16, P10; Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X; Meeks DW, 2011, AM J SURG, V201, P76, DOI 10.1016/j.amjsurg.2009.07.050; Pastor C, 2010, DIS COLON RECTUM, V53, P24, DOI 10.1007/DCR.0b013e3181ba782a; Prakken Frederik J, 2011, Ned Tijdschr Geneeskd, V155, pA3269; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Sainani KL, 2014, PM&R, V6, P841, DOI 10.1016/j.pmrj.2014.08.941; SWAB (Stichting Werkgroep Antibioticabeleid), NAT BOOK ANT SURG PR; Tanner J, 2015, SURGERY, V158, P66, DOI 10.1016/j.surg.2015.03.009; Tillman M, 2013, J SURG RES, V184, P150, DOI 10.1016/j.jss.2013.03.048; van Daalen FV, 2016, EUR J CLIN MICROBIOL, V35, P545, DOI 10.1007/s10096-015-2569-5; van der Slegt J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071566; van Kasteren M E, 2000, Ned Tijdschr Geneeskd, V144, P2049; VMS Safety Program, DUTCH HOSP PAT SAF P; Waits SA, 2014, SURGERY, V155, P602, DOI 10.1016/j.surg.2013.12.004; Wick EC, 2008, DIS COLON RECTUM, V51, P1004, DOI 10.1007/s10350-007-9142-y; Wick EC, 2012, J AM COLL SURGEONS, V215, P193, DOI 10.1016/j.jamcollsurg.2012.03.017; Workinggroup Infection Prevention (WIP), 2011, GUID PREV SURG SIT I; World Health Organization, 2016, GLOB GUID PREV SURG; Young B, 2011, ANTIMICROB AGENTS CH, V55, P4659, DOI 10.1128/AAC.00562-11	42	30	32	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184200	10.1371/journal.pone.0184200	http://dx.doi.org/10.1371/journal.pone.0184200			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877223	Green Published, gold, Green Submitted			2023-01-03	WOS:000409391200071
J	Agusti, A; Celli, B; Faner, R				Agusti, Alvar; Celli, Bartolome; Faner, Rosa			What does endotyping mean for treatment in chronic obstructive pulmonary disease?	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; AIR-FLOW OBSTRUCTION; SHORT-TERM RESPONSE; SYSTEMS BIOLOGY; ALPHA1-ANTITRYPSIN DEFICIENCY; PERSONALIZED MEDICINE; SPUTUM-EOSINOPHILIA; NETWORK MEDICINE; RESPIRATORY SYMPTOMS	Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease, both at the clinical and biological level. However, COPD is still diagnosed and treated according to simple clinical measures (level of airflow limitation, symptoms, and frequency of previous exacerbations). To address this clinical and biological complexity and to move towards precision medicine in COPD, we need to integrate (bioinformatics) and interpret (clinical science) the vast amount of high-throughput information that existing technology provides (systems biology and network medicine) so diagnosis, stratification, and treatment of patients with COPD can occur on the basis of their pathobiological mechanism (ie, endotypes). Therefore, this Series paper discusses a possible new taxonomy of COPD, the role of endotypes and associated biomarkers and phenotypes, the gaps (and opportunities) in existing knowledge of COPD pathobiology, how systems biology and network medicine can improve understanding of the disease and help to identify relevant endotypes and their specific biomarkers, and how endotypes and their biomarkers can improve the precision, effectiveness, and safety of the treatment of patients with COPD.	[Agusti, Alvar] Univ Barcelona, Resp Inst, Hosp Clin, Barcelona, Spain; [Agusti, Alvar; Faner, Rosa] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Agusti, Alvar; Faner, Rosa] CIBER Enfermedades Resp, Madrid, Spain; [Celli, Bartolome] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Agusti, A (corresponding author), Hosp Clin Barcelona, Resp Inst, Barcelona 08036, Spain.	AAGUSTI@clinic.cat		Faner, Rosa/0000-0002-8159-0115	Instituto de Salud Carlos III (ISCiii) FEDER FIS [PI15/00799, CP16/00096]; Instituto de Salud Carlos III (ISCiii) FEDER FIS (COPD research programme of CIBERES); SEPAR [PI065/2013, PI068/2015]; AstraZeneca	Instituto de Salud Carlos III (ISCiii) FEDER FIS; Instituto de Salud Carlos III (ISCiii) FEDER FIS (COPD research programme of CIBERES); SEPAR; AstraZeneca(AstraZeneca)	We acknowledge the comments and criticisms of the three anonymous reviewers of this paper who greatly contributed to its improvement. This paper is supported, in part, by Instituto de Salud Carlos III (ISCiii) FEDER FIS (PI15/00799; CP16/00096 and the COPD research programme of CIBERES), SEPAR (PI065/2013 & PI068/2015), and AstraZeneca (2016 COPD young researcher award to RF). RF also has a Miguel Servet research contract from ISCiii, Spain.	Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI 10.1183/09031936.03.00405703; Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Agusti A, 2016, RESPIROLOGY, V21, P24, DOI 10.1111/resp.12585; Agusti A, 2015, AM J RESP CRIT CARE, V191, P391, DOI 10.1164/rccm.201410-1935PP; Agusti A, 2014, THORAX, V69, P857, DOI 10.1136/thoraxjnl-2014-205507; Agusti A, 2013, THORAX, V68, P687, DOI 10.1136/thoraxjnl-2012-202772; Agusti A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037483; Agusti A, 2011, AM J RESP CRIT CARE, V183, P1129, DOI 10.1164/rccm.201009-1414PP; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Barabasi AL, 2007, NEW ENGL J MED, V357, P404, DOI 10.1056/NEJMe078114; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Beghe B, 2013, EUR RESPIR J, V41, P993, DOI 10.1183/09031936.00180812; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Bush A, 2016, ANN AM THORAC SOC, V13, pS438, DOI 10.1513/AnnalsATS.201602-112AW; Cesario A, 2014, CURR PHARM DESIGN, V20, P5945, DOI 10.2174/1381612820666140314130449; Chapman KR, 2015, LANCET, V386, P360, DOI 10.1016/S0140-6736(15)60860-1; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Diez D, 2014, AM J RESP CRIT CARE, V190, P981, DOI 10.1164/rccm.201403-0421PP; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Fabbri LM, 2016, NEW ENGL J MED, V374, P1885, DOI 10.1056/NEJMe1515508; Faner R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02086-2016; Faner R, 2016, ANN AM THORAC SOC, V13, pS466, DOI 10.1513/AnnalsATS.201605-372AW; Faner R, 2016, AM J RESP CRIT CARE, V193, P1242, DOI 10.1164/rccm.201507-1311OC; Faner R, 2015, EUR RESPIR J, V46, P1001, DOI 10.1183/13993003.00763-2015; Faner R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097491; Faner R, 2013, EXPERT REV CLIN IMMU, V9, P821, DOI 10.1586/1744666X.2013.828875; Feghali-Bostwick CA, 2008, AM J RESP CRIT CARE, V177, P156, DOI 10.1164/rccm.200701-014OC; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GANROT PO, 1967, SCAND J CLIN LAB INV, V19, P205, DOI 10.3109/00365516709090627; Ghiassian SD, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004120; Ghosh S, 2011, NAT REV GENET, V12, P821, DOI 10.1038/nrg3096; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Gomez-Cabrero D, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1291-3; Grosdidier S, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0111-4; Gustafsson M, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0082-6; Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402-0207OC; Hidalgo CA, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000353; Hofmann-Apitius M, 2015, NAT REV DRUG DISCOV, V14, P75, DOI 10.1038/nrd4537; Holgate S, 2015, NAT REV DRUG DISCOV, V14, P367, DOI 10.1038/nrd4645; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Jameson JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMsb1503104; Jensen AB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5022; Jobe AH, 2016, FETAL NEONATAL LUNG; Jones PW, 2006, EUR RESPIR J, V27, P822, DOI 10.1183/09031936.06.00145104; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254; Kitano H, 2001, FDN SYSTEMS BIOL; Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC; Kohl P, 2010, CLIN PHARMACOL THER, V88, P25, DOI 10.1038/clpt.2010.92; Kola I, 2011, NAT REV DRUG DISCOV, V10, P641, DOI 10.1038/nrd3534; Kusko RL, 2016, AM J RESP CRIT CARE, V194, P948, DOI 10.1164/rccm.201510-2026OC; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; LAURELL CB, 1971, SCAND J CLIN LAB INV, V28, P1, DOI 10.3109/00365517109090655; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Longo DL, 2016, NEW ENGL J MED, V374, P276, DOI 10.1056/NEJMe1516564; Loscalzo J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100163; Loscalzo J, 2011, WIRES SYST BIOL MED, V3, P619, DOI 10.1002/wsbm.144; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Mannino DM, 2008, EUR RESPIR J, V32, P962, DOI 10.1183/09031936.00012408; Martinez FD, 2016, NEW ENGL J MED, V375, P871, DOI 10.1056/NEJMra1603287; McDonald VM, 2013, THORAX; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Menche J, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S2-S8; Morrow JD, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-014-0072-y; Obeidat M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0558-1; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2017, LANCET IN PRESS; Polverino F, 2015, AM J RESP CRIT CARE, V192, P695, DOI 10.1164/rccm.201501-0107OC; Rodriguez-Roisin R, 2017, AM J RESP CRIT CARE, V195, P17, DOI 10.1164/rccm.201607-1376PP; Rosenbaum L, 2017, NEW ENGL J MED, V376, P2201, DOI 10.1056/NEJMp1704482; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; SCADDING JG, 1988, J MED ETHICS, V14, P118, DOI 10.1136/jme.14.3.118; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Sharma A, 2015, HUM MOL GENET, V24, P3005, DOI 10.1093/hmg/ddv001; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Tuder Rubin M, 2006, Proc Am Thorac Soc, V3, P673, DOI 10.1513/pats.200605-124SF; TURINO GM, 1969, SCIENCE, V165, P709, DOI 10.1126/science.165.3894.709; Vanfleteren LEGW, 2014, THORAX, V69, P72, DOI 10.1136/thoraxjnl-2013-203602; Vogelmeier C, 2017, GLOBAL STRATEGY DIAG; Vrijheid M, 2014, THORAX, V69, P876, DOI 10.1136/thoraxjnl-2013-204949; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Woodruff PG, 2015, LANCET, V385, P1789, DOI 10.1016/S0140-6736(15)60693-6; Woodruff PG, 2014, EUR RESPIR J, V43, P295, DOI 10.1183/09031936.00140613	92	59	60	1	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 2	2017	390	10098					980	987		10.1016/S0140-6736(17)32136-0	http://dx.doi.org/10.1016/S0140-6736(17)32136-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF2SE	28872030				2023-01-03	WOS:000408746300027
J	Hui, D; Frisbee-Hume, S; Wilson, A; Dibaj, SS; Nguyen, T; De La Cruz, M; Walker, P; Zhukovsky, DS; Delgado-Guay, M; Vidal, M; Epner, D; Reddy, A; Tanco, K; Williams, J; Hall, S; Liu, D; Hess, K; Amin, S; Breitbart, W; Bruera, E				Hui, David; Frisbee-Hume, Susan; Wilson, Annie; Dibaj, Seyedeh S.; Thuc Nguyen; De La Cruz, Maxine; Walker, Paul; Zhukovsky, Donna S.; Delgado-Guay, Marvin; Vidal, Marieberta; Epner, Daniel; Reddy, Akhila; Tanco, Kimerson; Williams, Janet; Hall, Stacy; Liu, Diane; Hess, Kenneth; Amin, Sapna; Breitbart, William; Bruera, Eduardo			Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSESSMENT SCALE; SEDATION SCALE; UNIT PATIENTS; ICU PATIENTS; MANAGEMENT; DEXMEDETOMIDINE; CHLORPROMAZINE; NEUROLEPTICS; RELIABILITY; DISTRESS	IMPORTANCE The use of benzodiazepines to control agitation in delirium in the last days of life is controversial. OBJECTIVE To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer. DESIGN, SETTING, AND PARTICIPANTS Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016. INTERVENTIONS Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode. MAIN OUTCOMES AND MEASURES The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range, -5 [unarousable] to 4 [very agitated or combative]) from baseline to 8 hours after treatment administration. Secondary end points were rescue neuroleptic use, delirium recall, comfort (perceived by caregivers and nurses), communication capacity, delirium severity, adverse effects, discharge outcomes, and overall survival. RESULTS Among 90 randomized patients (mean age, 62 years; women, 42 [47%]), 58 (64%) received the study medication and 52 (90%) completed the trial. Lorazepam + haloperidol resulted in a significantly greater reduction of RASS score at 8 hours (-4.1 points) than placebo + haloperidol (-2.3 points) (mean difference, -1.9 points [95% CI, -2.8 to -0.9]; P<.001). The lorazepam + haloperidol group required less median rescue neuroleptics (2.0 mg) than the placebo + haloperidol group (4.0 mg) (median difference, -1.0 mg [95% CI, -2.0 to 0]; P=.009) and was perceived to be more comfortable by both blinded caregivers and nurses (caregivers: 84% for the lorazepam + haloperidol group vs 37% for the placebo + haloperidol group; mean difference, 47%[95% CI, 14% to 73%], P=.007; nurses: 77% for the lorazepam + haloperidol group vs 30% for the placebo + haloperidol group; mean difference, 47%[95% CI, 17% to 71%], P=.005). No significant between-group differences were found in delirium-related distress and survival. The most common adverse effect was hypokinesia (3 patients in the lorazepam + haloperidol group [19%] and 4 patients in the placebo + haloperidol group [27%]). CONCLUSIONS AND RELEVANCE In this preliminary trial of hospitalized patients with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperidol compared with haloperidol alone resulted in a significantly greater reduction in agitation at 8 hours. Further research is needed to assess generalizability and adverse effects.	[Hui, David; Frisbee-Hume, Susan; Wilson, Annie; Thuc Nguyen; De La Cruz, Maxine; Walker, Paul; Zhukovsky, Donna S.; Delgado-Guay, Marvin; Vidal, Marieberta; Epner, Daniel; Reddy, Akhila; Tanco, Kimerson; Williams, Janet; Hall, Stacy; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA; [Dibaj, Seyedeh S.; Liu, Diane; Hess, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA; [Breitbart, William] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1275 York Ave, New York, NY 10021 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center	Hui, D (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.	dhui@mdanderson.org	Bruera, Eduardo/AAA-1550-2022; Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	National Cancer Institute [R21CA186000-01A1]; American Cancer Society [MRSG-14-1418-01-CCE]; Andrew Sabin Family Foundation; National Institutes of Health Cancer Center [P30CA016672]; National Institutes of Health [R01CA200867]; NATIONAL CANCER INSTITUTE [R01CA200867, P30CA016672, R21CA186000, P30CA008748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Andrew Sabin Family Foundation; National Institutes of Health Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grant R21CA186000-01A1 from the National Cancer Institute (Drs Hui, Bruera, Hess, and Breitbart); a Mentored Research Scholar Grant in Applied and Clinical Research (MRSG-14-1418-01-CCE) from the American Cancer Society (Dr Hui) and the Andrew Sabin Family Fellowship Award (Dr Hui) from the Andrew Sabin Family Foundation; grant P30CA016672 from the National Institutes of Health Cancer Center (Drs Diba and Hess and Ms Liu); and grant R01CA200867 from the National Institutes of Health (Dr Delgado-Guay).	Agar MR, 2017, JAMA INTERN MED, V177, P34, DOI 10.1001/jamainternmed.2016.7491; Aggarwal R, 2011, CURR PSYCHIAT, V10, P4; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Breitbart W, 2002, PSYCHOSOMATICS, V43, P183, DOI 10.1176/appi.psy.43.3.183; Breitbart W, 2008, JAMA-J AM MED ASSOC, V300, P2898, DOI 10.1001/jama.2008.885; Bruera E, 1991, J Palliat Care, V7, P6; Bruera E, 2009, CANCER, V115, P2004, DOI 10.1002/cncr.24215; de Wit M, 2006, INT J CLIN PHARM TH, V44, P466; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Fadul N, 2007, SUPPORT CARE CANCER, V15, P1271, DOI 10.1007/s00520-007-0247-6; GREENBLATT DJ, 1989, J PHARMACOL EXP THER, V250, P134; Hosie A, 2013, PALLIATIVE MED, V27, P486, DOI 10.1177/0269216312457214; Hui D, 2017, JAMA INTERN MED, V177, P1052, DOI 10.1001/jamainternmed.2017.1783; Hui D, 2017, J PAIN SYMPTOM MANAG, V53, P630, DOI 10.1016/j.jpainsymman.2016.10.370; Hui D, 2016, CURR OPIN SUPPORT PA, V10, P316, DOI 10.1097/SPC.0000000000000236; Hui D, 2015, J PAIN SYMPTOM MANAG, V50, P488, DOI 10.1016/j.jpainsymman.2014.09.003; Hui D, 2014, J PALLIAT CARE, V30, P259, DOI 10.1177/082585971403000403; Hui D, 2011, J PALLIAT CARE, V27, P141, DOI 10.1177/082585971102700210; Hui D, 2010, J PAIN SYMPTOM MANAG, V39, P186, DOI 10.1016/j.jpainsymman.2009.07.009; Hui D, 2010, JAMA-J AM MED ASSOC, V303, P1054, DOI 10.1001/jama.2010.258; Kehl Karen A, 2004, J Pain Palliat Care Pharmacother, V18, P5; Levy MH, NCCN CLIN PRACTICE G; Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; Lonergan E, 2009, COCHRANE DATABASE SY; Maeda I, 2016, LANCET ONCOL, V17, P115, DOI 10.1016/S1470-2045(15)00401-5; Maltoni M, 2009, ANN ONCOL, V20, P1163, DOI 10.1093/annonc/mdp048; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MENZA MA, 1988, HEART LUNG, V17, P238; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Reade MC, 2016, JAMA-J AM MED ASSOC, V315, P1460, DOI 10.1001/jama.2016.2707; Rijcken CAW, 2003, J CLIN PSYCHOPHARM, V23, P657, DOI 10.1097/01.jcp.0000096247.29231.3a; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shin SH, 2015, CANCER RES TREAT, V47, P399, DOI 10.4143/crt.2013.229; Zaal IJ, 2015, INTENS CARE MED, V41, P2130, DOI 10.1007/s00134-015-4063-z	36	107	110	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP	2017	318	11					1047	1056		10.1001/jama.2017.11468	http://dx.doi.org/10.1001/jama.2017.11468			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH7DP	28975307	Green Accepted			2023-01-03	WOS:000411343400017
J	van Vugt, VA; van der Horst, HE; Payne, RA; Maarsingh, OR				van Vugt, Vincent A.; van der Horst, Henriette E.; Payne, Rupert A.; Maarsingh, Otto R.			CHANGE Chronic vertigo: treat with exercise, not drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PATIENT		[van Vugt, Vincent A.; van der Horst, Henriette E.; Maarsingh, Otto R.] Vrije Univ Amsterdam Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Gen Practice & Elderly Care Med, NL-1081 BT Amsterdam, Netherlands; [Payne, Rupert A.] Univ Bristol, Ctr Acad Primary Care, Bristol, Avon, England	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Bristol	van Vugt, VA (corresponding author), Vrije Univ Amsterdam Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Gen Practice & Elderly Care Med, NL-1081 BT Amsterdam, Netherlands.	v.vanvugt@vumc.nl	Maarsingh, Otto/AAD-1553-2022	Maarsingh, Otto/0000-0002-3747-9217				Adrion C, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6816; Agus S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00048; Bhattacharyya N, 2017, OTOLARYNG HEAD NECK, V156, pS1, DOI 10.1177/0194599816689667; Brandt T, 2010, RESTOR NEUROL NEUROS, V28, P69, DOI 10.3233/RNN-2010-0504; Bronstein AM, 2010, RESTOR NEUROL NEUROS, V28, P83, DOI 10.3233/RNN-2010-0530; Eguale T, 2012, ARCH INTERN MED, V172, P781, DOI 10.1001/archinternmed.2012.340; Fishman JM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008607.pub2; Geraghty AWA, 2017, ANN FAM MED, V15, P209, DOI 10.1370/afm.2070; Gijsen R, 2009, PHARMACOEPIDEM DR S, V18, P84, DOI 10.1002/pds.1689; Goebel JA, 2000, OTOLARYNG CLIN N AM, V33, P483, DOI 10.1016/S0030-6665(05)70222-X; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; Harcourt J, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i46; Hilton MP, 2014, COCHRANE DB SYST REV, V358; James AL., 2001, COCHRANE DB SYST REV, V2001, pCD001873, DOI [10.1002/14651858.CD001873, DOI 10.1002/14651858.CD001873, 10.1002/14651858.cd001873]; Jayarajan V, 2003, J LARYNGOL OTOL, V117, P599, DOI 10.1258/002221503768199915; Jeck-Thole S, 2006, DRUG SAFETY, V29, P1049, DOI 10.2165/00002018-200629110-00004; Kaski D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5809; Lacour M, 2016, J NEUROL, V263, pS54, DOI 10.1007/s00415-015-7903-4; Lempert T, 2013, SEMIN NEUROL, V33, P212, DOI 10.1055/s-0033-1354596; Little P, 2004, BMJ-BRIT MED J, V328, P444, DOI 10.1136/bmj.38013.644086.7C; Ludman H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g283; Fernandez MM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010600.pub2; McDonnell MN, 2015, COCHRANE DB SYST REV, V358; Murdin L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010696.pub2; National Institute for Health and Care Excellence, 2011, CLIN KNOWL SUMM VES; Neuhauser HK, 2009, SEMIN NEUROL, V29, P473, DOI 10.1055/s-0029-1241043; Obermann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00257; Phillips JS, 2008, BRIT J CLIN PHARMACO, V65, P470, DOI 10.1111/j.1365-2125.2007.03079.x; Reinink H, 2014, OTOLARYNG HEAD NECK, V151, P399, DOI 10.1177/0194599814536530; Sloane PD, 2001, ANN INTERN MED, V134, P823, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00005; Strupp M, 2015, ANN NY ACAD SCI, V1343, P27, DOI 10.1111/nyas.12774; Vugt VA, 2017, SCAND J PRIM HEALTH, V35, P19, DOI 10.1080/02813432.2017.1288683; van Vugt VA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015479; Yardley L, 1998, CLIN OTOLARYNGOL, V23, P442, DOI 10.1046/j.1365-2273.1998.00179.x; Yardley L, 2004, ANN INTERN MED, V141, P598, DOI 10.7326/0003-4819-141-8-200410190-00007; Yardley L, 2006, PSYCHOSOM MED, V68, P762, DOI 10.1097/01.psy.0000232269.17906.92; Yardley Lucy, 2012, BMJ, V344, pe2237, DOI 10.1136/bmj.e2237	37	14	14	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2017	358								j3727	10.1136/bmj.j3727	http://dx.doi.org/10.1136/bmj.j3727			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF1SR	28835412	Green Published			2023-01-03	WOS:000408679700001
J	Gupta, N; Vashist, P; Tandon, R; Gupta, SK; Kalaivani, M; Dwivedi, SN				Gupta, Noopur; Vashist, Praveen; Tandon, Radhika; Gupta, Sanjeev K.; Kalaivani, Mani; Dwivedi, S. N.			Use of traditional eye medicine and self-medication in rural India: A population-based study	PLOS ONE			English	Article							CORNEAL DISEASE; ANDHRA-PRADESH; SOUTH-INDIA; SERVICES; PATTERNS; NIGERIA; MALAWI	Objective To determine the type and nature of traditional eye medicine (TEM), their sources and use and practices related to self-medication for ophthalmic diseases in a rural Indian population. Methods A population-based, cross-sectional study was conducted in 25 randomly selected clusters of Rural Gurgaon, Haryana, India as part of CORE (Cornea Opacity Rural Epidemiological) study. In addition to comprehensive ophthalmic examination, health-seeking behavior and use of self-medication and TEM was assessed in the adult population using a semi-structured questionnaire. Physical verification of available ophthalmic medications in the enumerated households was conducted by the study team. Descriptive statistics were computed along with multivariable logistic regression analysis to determine associated factors for use of self-medication and TEM. Results Of the 2160 participants interviewed, 396 (18.2%) reported using ophthalmic medications without consulting an ophthalmologist, mainly for symptoms like watering (37.1%), redness (27.7%), itching (19.2%) and infection (13.6%). On physical verification of available eye drops that were being used without prescription, 26.4% participants were practicing self-medication. Steroid, expired/unlabeled and indigenous eye drops were being used by 151 (26.5%), 120(21.1%) and 75 (13.2%) participants respectively. Additionally, 25.7% (529) participants resorted to home remedies like 'kajal'(61.4%), honey (31.4%), ghee (11.7%) and rose water (9.1%). Conclusion Use of TEM is prevalent in this population. The rampant use of steroid eye drops without prescription along with use of expired or unlabelled eye drops warrants greater emphasis on safe eye care practices in this population. Public awareness and regulatory legislations must be implemented to decrease harmful effects arising due to such practices.	[Gupta, Noopur; Vashist, Praveen; Tandon, Radhika] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India; [Gupta, Sanjeev K.] All India Inst Med Sci, Ctr Community Med, New Delhi, India; [Kalaivani, Mani; Dwivedi, S. N.] All India Inst Med Sci, Dept Biostat, New Delhi, India	All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra Prasad Centre for Ophthalmic Sciences; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Vashist, P (corresponding author), All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India.	praveenvashist@yahoo.com	GUPTA, NOOPUR/AAX-5043-2021	GUPTA, NOOPUR/0000-0001-8022-6656; Gupta, Sanjeev/0000-0002-2014-5333				Abasaeed A, 2009, J INFECT DEV COUNTR, V3, P491, DOI 10.3855/jidc.466; Adegbehingbe B O, 2008, Tanzan J Health Res, V10, P240; Bharathi Jayahar M., 2007, Indian Journal of Ophthalmology, V55, P37; Bisika T, 2009, AFR J TRADIT COMPLEM, V6, P23; Carvalho RS, 2009, CLINICS, V64, P735, DOI 10.1590/S1807-59322009000800005; COURTRIGHT P, 1994, BRIT J OPHTHALMOL, V78, P810, DOI 10.1136/bjo.78.11.810; Courtright P, 1996, BRIT J OPHTHALMOL, V80, P694, DOI 10.1136/bjo.80.8.694; Dandona R, 2000, BRIT J OPHTHALMOL, V84, P22, DOI 10.1136/bjo.84.1.22; Editorial, 2001, REV ASSOC MED BRAS, V47, P269; Eze BI, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-40; Fletcher AE, 1999, ARCH OPHTHALMOL-CHIC, V117, P1393, DOI 10.1001/archopht.117.10.1393; Fraunfelder FW, 2004, AM J OPHTHALMOL, V138, P639, DOI 10.1016/j.ajo.2004.04.072; Albarran KF, 2008, PHARM WORLD SCI, V30, P863, DOI 10.1007/s11096-008-9241-4; Gupta N, 2015, BRIT J OPHTHALMOL, V99, P147, DOI 10.1136/bjophthalmol-2014-305945; Gupta Noopur, 2013, Indian J Community Med, V38, P198, DOI 10.4103/0970-0218.120153; Jaya Y, 2014, Cent Afr J Med, V60, P36; Kadri R, 2011, INT J BIOL MED RES, V2, P528; Kara-Jose N, 1985, ARQ BRAS OFTALMOL, V48, P160; Kovai Vilas, 2007, Indian Journal of Ophthalmology, V55, P365; LEWALLEN S, 1995, BRIT J OPHTHALMOL, V79, P343, DOI 10.1136/bjo.79.4.343; Marquez GE, 2012, OPHTHAL EPIDEMIOL, V19, P236, DOI 10.3109/09286586.2012.689076; Marquez GE, 2014, J CLIN EXP OPHTHALMO, V5, P330; Nwosu SNN, 2011, NIGER J CLIN PRACT, V14, P405, DOI 10.4103/1119-3077.91744; Osahon AI., 1995, NIGER J OPHTHALMOL, V3, P51; PRAJNA VN, 1999, INDIAN J OPHTHALMOL, V47, P15; Stanifer JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122638; Ukponmwan CU, 2010, MIDDLE EAST AFR J OP, V17, P315, DOI 10.4103/0974-9233.71596	27	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2017	12	8							e0183461	10.1371/journal.pone.0183461	http://dx.doi.org/10.1371/journal.pone.0183461			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2ZB	28829812	gold, Green Submitted, Green Published			2023-01-03	WOS:000408085100046
J	Booiman, T; Wit, FW; Girigorie, AF; Maurer, I; De Francesco, D; Sabin, CA; Harskamp, AM; Prins, M; Franceschi, C; Deeks, SG; Winston, A; Reiss, P; Kootstra, NA				Booiman, Thijs; Wit, Ferdinand W.; Girigorie, Arginell F.; Maurer, Irma; De Francesco, Davide; Sabin, Caroline A.; Harskamp, Agnes M.; Prins, Maria; Franceschi, Claudio; Deeks, Steven G.; Winston, Alan; Reiss, Peter; Kootstra, Neeltje A.		Behalf Co-MorBidity Relation	Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls	PLOS ONE			English	Article							IMMUNOGLOBULIN-G ANTIBODY; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; REPLICATIVE SENESCENCE; CIGARETTE-SMOKING; CYTOMEGALOVIRUS; INFLAMMATION; CD4(+); DISEASE; AGE	HIV-1-positive individuals on successful antiretroviral therapy (ART) are reported to have higher rates of age-associated non-communicable comorbidities (AANCCs). HIV-associated immune dysfunction has been suggested to contribute to increased AANCC risk. Here we performed a cross-sectional immune phenotype analysis of T cells in ART-treated HIV-1-positive individuals with undetectable vireamia (HIV-positives) and HIV-1-negative individuals (HIV-negatives) over 45 years of age. In addition, two control groups were studied: HIV-negative adults selected based on lifestyle and demographic factors (Co-morBidity in Relation to AIDS, or COBRA) and unselected age-matched donors from a blood bank. Despite long-term ART (median of 12.2 years), HIV-infected adults had lower CD4(+) T-cell counts and higher CD8+ T-cell counts compared to well-matched HIV-negative COBRA participants. The proportion of CD38(+)HLA-DR+ and PD-1(+)CD4(+) T-cells was higher in HIV-positive cohort compared to the two HIV-negative cohorts. The proportion CD57(+) and CD27(-)CD28(-)cells of both CD4(+) and CD8(+) T-cells in HIV-positives was higher compared to unselected adults (blood bank) as reported before but this difference was not apparent in comparison with well-matched HIV-negative COBRA participants. Multiple regression analysis showed that the presence of an increased proportion of terminally differentiated T cells was strongly associated with CMV infection. Compared to appropriately selected HIV-negative controls, HIV-positive individuals on ART with long-term suppressed viraemia exhibited incomplete immune recovery and increased immune activation/exhaustion. CMV infection rather than treated HIV-infection appears to have more consistent effects on measures of terminal differentiation of T cells.	[Booiman, Thijs; Girigorie, Arginell F.; Maurer, Irma; Harskamp, Agnes M.; Kootstra, Neeltje A.] Univ Amsterdam, Acad Med Ctr, Amsterdam Infect & Immun Inst, Dept Expt Immunol, Amsterdam, Netherlands; [Booiman, Thijs; Wit, Ferdinand W.; Girigorie, Arginell F.; Reiss, Peter] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands; [Wit, Ferdinand W.; Reiss, Peter] Univ Amsterdam, Dept Global Hlth, Amsterdam, Netherlands; [Wit, Ferdinand W.; Reiss, Peter] Univ Amsterdam, Div Infect Dis, Acad Med Ctr, Amsterdam, Netherlands; [Wit, Ferdinand W.; Reiss, Peter] HIV Monitoring Fdn, Amsterdam, Netherlands; [De Francesco, Davide; Sabin, Caroline A.] UCL, Dept Infect & Populat Hlth, London, England; [Prins, Maria] Publ Hlth Serv, Amsterdam, Netherlands; [Franceschi, Claudio] Alma Mater Studiorum Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Winston, Alan] Imperial Coll Sci Technol & Med, London, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of London; University College London; Public Health Service Amsterdam; University of Bologna; University of California System; University of California San Francisco; Imperial College London	Kootstra, NA (corresponding author), Univ Amsterdam, Acad Med Ctr, Amsterdam Infect & Immun Inst, Dept Expt Immunol, Amsterdam, Netherlands.	n.a.kootstra@amc.uva.nl	Winston, Alan/AGZ-3015-2022; Sabin, Caroline/C-2464-2008; Pasternak, Alexander/P-2067-2017; Wit, Ferdinand/AAC-3803-2019	Winston, Alan/0000-0002-5847-8416; Sabin, Caroline/0000-0001-5173-2760; Pasternak, Alexander/0000-0002-4097-4251; Deeks, Steven/0000-0001-6371-747X; Kootstra, Neeltje A./0000-0001-9429-7754; De Francesco, Davide/0000-0002-6185-0514	European Union's Seventh Framework Programme for research, technological development and demonstration [305522]	European Union's Seventh Framework Programme for research, technological development and demonstration	The COBRA project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305522. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2011, AIDS, V25, P1813, DOI 10.1097/QAD.0b013e32834640e6; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Breton G, 2013, J IMMUNOL, V191, P2194, DOI 10.4049/jimmunol.1200646; Brunt SJ, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/947432; Chevalier MF, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003453; Cockerham LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110731; de Heens GLT, 2009, CYTOKINE, V47, P157, DOI 10.1016/j.cyto.2009.05.006; Deeks SG, 2013, IMMUNITY, V39, P633, DOI 10.1016/j.immuni.2013.10.001; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Deeks Steven G, 2009, Top HIV Med, V17, P118; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; Dock JN, 2011, AGING DIS, V2, P382; Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150; Franceschi C, 2000, VACCINE, V18, P1717, DOI 10.1016/S0264-410X(99)00513-7; Franceschi C, 1996, NEPHROL DIAL TRANSPL, V11, P18; Freeman ML, 2016, CLIN INFECT DIS, V62, P392, DOI 10.1093/cid/civ840; Gianella S, 2014, J VIROL, V88, P7818, DOI 10.1128/JVI.00831-14; Gkrania-Klotsas E, 2012, J INFECT DIS, V206, P1897, DOI 10.1093/infdis/jis620; Grady BPX, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0065-0; Guaraldi G, 2011, CLIN INFECT DIS, V53, P1120, DOI 10.1093/cid/cir627; Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626; HOLT PG, 1987, THORAX, V42, P241, DOI 10.1136/thx.42.4.241; Hunt PW, 2011, J INFECT DIS, V203, P1474, DOI 10.1093/infdis/jir060; Jimenez V Cobos, 2016, J INFECT DIS; Kalayjian RC, 2003, J INFECT DIS, V187, P1924, DOI 10.1086/375372; Karim R, 2014, JAIDS-J ACQ IMM DEF, V67, P349, DOI 10.1097/QAI.0000000000000311; Klenerman P, 2016, NAT REV IMMUNOL, V16, P367, DOI 10.1038/nri.2016.38; Kooij KW, 2016, J INFECT DIS, V214, P1817, DOI 10.1093/infdis/jiw459; Le Priol Y, 2006, J IMMUNOL, V177, P5145, DOI 10.4049/jimmunol.177.8.5145; Lee SA, 2014, J INFECT DIS, V210, P374, DOI 10.1093/infdis/jiu109; Lee SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089444; Lichtner M, 2015, J INFECT DIS, V211, P178, DOI 10.1093/infdis/jiu417; Lim A, 2007, AIDS, V21, P1525, DOI 10.1097/QAD.0b013e32825eab8b; McComsey GA, 2014, JAIDS-J ACQ IMM DEF, V65, P167, DOI 10.1097/01.qai.0000437171.00504.41; Naeger DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008886; Parrinello CM, 2012, J INFECT DIS, V205, P1788, DOI 10.1093/infdis/jis276; Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168; Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce; Roberts ET, 2010, AM J EPIDEMIOL, V172, P363, DOI 10.1093/aje/kwq177; Said EA, 2010, NAT MED, V16, P452, DOI 10.1038/nm.2106; Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701; Skiest DJ, 1996, AM J MED, V101, P605, DOI 10.1016/S0002-9343(96)00329-4; Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530; Tassiopoulos K, 2012, J INFECT DIS, V205, P1730, DOI 10.1093/infdis/jis260; Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254; Valiathan R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097698; Wada N, 2013, AM J EPIDEMIOL, V177, P116, DOI 10.1093/aje/kws321; Weber R, 2013, HIV MED, V14, P195, DOI 10.1111/j.1468-1293.2012.01051.x; Weiss L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011659; Wittkop L, 2013, J INFECT DIS, V207, P622, DOI 10.1093/infdis/jis732; Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179	52	32	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2017	12	8							e0183357	10.1371/journal.pone.0183357	http://dx.doi.org/10.1371/journal.pone.0183357			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD5CP	28806406	Green Published, gold, Green Submitted			2023-01-03	WOS:000407548800069
J	Nicholl, D				Nicholl, David			Why I've changed my views on assisted dying	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nicholl, David] City Hosp, Birmingham, W Midlands, England	University of Birmingham	Nicholl, D (corresponding author), City Hosp, Birmingham, W Midlands, England.	david.nicholl@nhs.net							0	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	2017	358								j3566	10.1136/bmj.j3566	http://dx.doi.org/10.1136/bmj.j3566			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD0CI	28775164				2023-01-03	WOS:000407207000004
J	Persoon, S; Chinapaw, MJM; Buffart, LM; Liu, RDK; Wijermans, P; Koene, HR; Minnema, MC; Lugtenburg, PJ; Marijt, EWA; Brug, J; Nollet, F; Kersten, MJ				Persoon, Saskia; ChinAPaw, Mai J. M.; Buffart, Laurien M.; Liu, Roberto D. K.; Wijermans, Pierre; Koene, Harry R.; Minnema, Monique C.; Lugtenburg, Pieternella J.; Marijt, Erik W. A.; Brug, Johannes; Nollet, Frans; Kersten, Marie Jose			Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study	PLOS ONE			English	Article							QUALITY-OF-LIFE; CANCER SURVIVORS; PHYSICAL-EXERCISE; HOSPITAL ANXIETY; RESISTANCE; STRENGTH; FATIGUE; FITNESS; INTERVENTION; DETERMINANTS	Background This single blind, multicenter randomized controlled trial aimed to evaluate the effectiveness of a supervised high intensity exercise program on physical fitness and fatigue in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. Methods 109 patients were randomly assigned to the 18-week exercise intervention or the usual care control group. The primary outcomes included physical fitness (VO2-peak andWpeak determined using a cardiopulmonary exercise test; grip strength and the 30s chair stand test) and fatigue (Multidimensional Fatigue Inventory) and were assessed prior to randomization and after completion of the intervention or at similar time points for the control group. Multivariable multilevel linear regression analyses were performed to assess intervention effects. Results Patients in the intervention group attended 86% of the prescribed exercise sessions. Of the patients in the control group, 47% reported >= 10 physiotherapy sessions, which most likely included supervised exercise, suggesting a high rate of contamination. Median improvements in physical fitness ranged between 16 and 25% in the intervention group and between 12 and 19% in the control group. Fatigue decreased in both groups. There were no significant differences between the intervention and control group. Conclusion We found no significant beneficial effects of the supervised high intensity exercise program on physical fitness and fatigue when compared to usual care. We hypothesized that the lack of significant intervention effects may relate to suboptimal timing of intervention delivery, contamination in the control group and/or suboptimal compliance to the prescribed exercise intervention.	[Persoon, Saskia; Nollet, Frans] Univ Amsterdam, Acad Med Ctr, Dept Rehabil, Amsterdam, Netherlands; [ChinAPaw, Mai J. M.] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [ChinAPaw, Mai J. M.; Buffart, Laurien M.; Brug, Johannes] EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Buffart, Laurien M.; Brug, Johannes] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Liu, Roberto D. K.; Kersten, Marie Jose] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands; [Wijermans, Pierre] Haga Teaching Hosp, Dept Hematol, The Hague, Netherlands; [Koene, Harry R.] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands; [Minnema, Monique C.] UMC Utrecht, Dept Hematol, Utrecht, Netherlands; [Lugtenburg, Pieternella J.] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands; [Marijt, Erik W. A.] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Haga Hospital; St. Antonius Hospital Utrecht; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kersten, MJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands.	m.j.kersten@amc.uva.nl	Buffart, Laurien/ABA-8889-2020; Paw, Mai Chin A/N-1665-2019; Brug, Johannes/A-8242-2018	Buffart, Laurien/0000-0002-8095-436X; Paw, Mai Chin A/0000-0001-6259-2441; Brug, Johannes/0000-0002-1904-7349	Alpe d'HuZes/KWF Fund; Dutch Cancer Society [ALPE 2009-4620]	Alpe d'HuZes/KWF Fund; Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by the Alpe d'HuZes/KWF Fund. The research grant was provided by the Dutch Cancer Society (Grant number: ALPE 2009-4620), http://www.kwf.nl. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; [Anonymous], 2009, ACSMS GUIDELINES EXE; Braamse AMJ, 2014, BONE MARROW TRANSPL, V49, P292, DOI 10.1038/bmt.2013.155; Campbell KL, 2012, BRIT J SPORT MED, V46, P909, DOI [10.1136/bjsports-2010-082719, 10.1136/bjsm.2010.082719]; Chinapaw MJM, 2012, INT J BEHAV MED, V19, P143, DOI 10.1007/s12529-011-9158-5; Choi L, 2011, MED SCI SPORT EXER, V43, P357, DOI 10.1249/MSS.0b013e3181ed61a3; Cocks K, 2007, EUR J CANCER, V43, P1670, DOI 10.1016/j.ejca.2007.04.022; Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638; Cramp F, 2012, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD006145.PUB3; De Backer IC, 2008, BRIT J CANCER, V99, P30, DOI 10.1038/sj.bjc.6604433; De Backer IC, 2007, ACTA ONCOL, V46, P1143, DOI 10.1080/02841860701418838; De Backer IC, 2007, ARCH PHYS MED REHAB, V88, P610, DOI 10.1016/j.apmr.2007.02.013; Fess EE, 1992, CLIN ASSESSMENT RECO, V2nd; Hacker ED, 2017, BIOL BLOOD MARROW TR, V23, P659, DOI 10.1016/j.bbmt.2016.12.637; Hacker ED, 2014, EUR J ONCOL NURS, V18, P175, DOI 10.1016/j.ejon.2013.10.013; Hacker ED, 2011, CANCER NURS, V34, P238, DOI 10.1097/NCC.0b013e3181fb3686; Hayes SC, 2004, BRIT J SPORT MED, V38, P304, DOI 10.1136/bjsm.2002.003632; Hayward V, 2014, ADV FITNESS ASSESSME; Hulscher MEJL, 2003, QUAL SAF HEALTH CARE, V12, P40, DOI 10.1136/qhc.12.1.40; Jones LW, 2011, ONCOLOGIST, V16, P112, DOI 10.1634/theoncologist.2010-0197; Kampshoff CS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0513-2; Knols RH, 2011, BONE MARROW TRANSPL, V46, P1245, DOI 10.1038/bmt.2010.288; Kuehl R, 2016, SUPPORT CARE CANCER, V24, P4327, DOI 10.1007/s00520-016-3271-6; Mosher CE, 2009, PSYCHO-ONCOLOGY, V18, P113, DOI 10.1002/pon.1399; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Padilha CS, 2017, J CANCER SURVIV, V11, P339, DOI 10.1007/s11764-016-0592-x; Persoon S, 2013, CANCER TREAT REV, V39, P682, DOI 10.1016/j.ctrv.2013.01.001; Persoon S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-671; Pidala J, 2010, BRIT J HAEMATOL, V148, P373, DOI 10.1111/j.1365-2141.2009.07992.x; POSNER JD, 1995, ARCH PHYS MED REHAB, V76, P373, DOI 10.1016/S0003-9993(95)80664-4; Rikli RE, 1999, J AGING PHYS ACTIV, V7, P129, DOI 10.1123/japa.7.2.129; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Strasser B, 2013, MED SCI SPORT EXER, V45, P2080, DOI 10.1249/MSS.0b013e31829a3b63; Twisk J, 2006, APPL MULTILEVEL ANAL, DOI [10.1017/CBO9780511610806, DOI 10.1017/CBO9780511610806]; van Haren IEPM, 2013, PHYS THER, V93, P514, DOI 10.2522/ptj.20120181; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Winters-Stone KM, 2014, BRIT J SPORT MED, V48, P987, DOI 10.1136/bjsports-2012-091732; Wolin KY, 2010, LEUKEMIA, V24, P1113, DOI 10.1038/leu.2010.54; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	41	47	47	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2017	12	7							e0181313	10.1371/journal.pone.0181313	http://dx.doi.org/10.1371/journal.pone.0181313			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC1YQ	28727771	Green Published, Green Submitted, gold			2023-01-03	WOS:000406634500055
J	von der Beck, D; Seeger, W; Herold, S; Gunther, A; Loh, B				von der Beck, Daniel; Seeger, Werner; Herold, Susanne; Guenther, Andreas; Loeh, Benjamin			Characteristics and outcomes of a cohort hospitalized for pandemic and seasonal influenza in Germany based on nationwide inpatient data	PLOS ONE			English	Article							A H1N1 VIRUS; INFECTION; A(H1N1); PREGNANCY; ILLNESS; DEATH; 1ST	Rationale From June of 2009 to August of 2010 the influenza subtype H1N1pdm09 caused a worldwide pandemic. The impact on populations and health care systems around the globe evolved differently. Substantial data come from the German national surveillance network in an outpatient and private practice setting, while information on hospitalized patients in Germany is rather limited. Methods Data from the Federal Statistics Office comprising health insurance claims of the entire nationwide inpatient sample from 2005 to 2012 were used to identify patients who were hospitalized for laboratory-confirmed influenza and to analyse demographical aspects, comorbidities, hospitalization duration, outcomes and ventilator use during the pandemic and seasonal waves of influenza. Measurements and main results A number of 34,493 admissions for laboratory-confirmed influenza occurred during waves between 2005 and 2012. During the pandemic seasonal waves, the number of hospitalizations vastly surpassed the level that was seen in any of the seasonal waves. A major demographic shift was seen with respect to patient age, as younger patients (< 60 years old) were more frequently hospitalized. Mean length of stay was shorter (149 vs. 193 hours), mean time on ventilation tended to be shorter (261 vs. 305 hours) in young children (< 4 years old) and longer (393 vs. 339 hours) in the elderly (> 60 years old). Time to ventilation was shorter in non-fatal cases (328 vs. 349 hours) and longer in fatal cases (419 vs. 358 hours). Logistic regression was used to show the impact of comorbidities and co-diagnoses on mortality and the need for ventilation, as well as differences between pandemic and seasonal influenza. Conclusions Inpatient data suggest differences in patient populations during pandemic and seasonal influenza. Younger patients were more frequently hospitalized. Differences with respect to the presence of certain comorbidities and co-diagnoses, length of stay, time to ventilation and ventilation time could be identified.	[von der Beck, Daniel; Seeger, Werner; Herold, Susanne; Guenther, Andreas; Loeh, Benjamin] Univ Giessen, Giessen, Germany; [von der Beck, Daniel; Seeger, Werner; Herold, Susanne; Guenther, Andreas; Loeh, Benjamin] German Ctr Lung Res DZL, Marburg Lung Ctr UGMLC, Giessen, Germany; [Guenther, Andreas; Loeh, Benjamin] Agaples Lung Clin Waldhof Elgershausen, Greifensstein, Germany	Justus Liebig University Giessen	von der Beck, D (corresponding author), Univ Giessen, Giessen, Germany.; von der Beck, D (corresponding author), German Ctr Lung Res DZL, Marburg Lung Ctr UGMLC, Giessen, Germany.	daniel.vdbeck@outlook.de		Herold, Susanne/0000-0001-6343-0911; Seeger, Werner/0000-0003-1946-0894				Adlhoch C, 2012, INFLUENZA OTHER RESP, V6, pe162, DOI 10.1111/j.1750-2659.2012.00404.x; Balanzat AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033670; Becker A, 2007, MDK AUTWANDSPAUSCHAL, V76, P508; Buda S, 2010, BUNDESGESUNDHEITSBLA, V53, P1223, DOI 10.1007/s00103-010-1158-0; Buda S, 2010, BERICHT EPIDEMIOLOGI; Chen CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024440; Chowell G, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/914196; Chowell G, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000436; CULLEN G, 2009, EURO SURVEILL, V14; Denholm JT, 2010, MED J AUSTRALIA, V192, P84, DOI 10.5694/j.1326-5377.2010.tb03424.x; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; Hansen C, 2012, J INFECT DIS, V206, P1260, DOI 10.1093/infdis/jis488; Helferty M, 2010, CAN MED ASSOC J, V182, P1981, DOI 10.1503/cmaj.100746; Hewagama S, 2010, CLIN INFECT DIS, V50, P686, DOI 10.1086/650460; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Lemaitre M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-162; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Louie JK, 2010, NEW ENGL J MED, V65, P227, DOI DOI 10.1097/01.0GX.0000371713.49382.2F; Pebody RG, 2010, EUROSURVEILLANCE, V15; Poggensee G, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-155; Reed C, 2014, CLIN INFECT DIS, V59, P166, DOI 10.1093/cid/ciu285; Santa-Olalla Peralta P, 2010, EUROSURVEILLANCE, V15; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; VAILLANT L, 2009, EURO SURVEILL, V14; van Kerkhove MD, 2013, INFLUENZA OTHER RESP, V7, P872, DOI DOI 10.1111/IRV.12074; Widgren K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013939; Wilson N, 2009, EUROSURVEILLANCE, V14; World Health Organization, 2015, MAN EST DIS BURD ASS; World Health Organization, 2009, WHO GUID DOC; Yang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125447; Yu HJ, 2011, CLIN INFECT DIS, V52, P457, DOI 10.1093/cid/ciq144; Zarychanski R, 2010, CAN MED ASSOC J, V182, P257, DOI 10.1503/cmaj.091884	34	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2017	12	7							e0180920	10.1371/journal.pone.0180920	http://dx.doi.org/10.1371/journal.pone.0180920			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA7TM	28708896	Green Published, Green Submitted, gold			2023-01-03	WOS:000405649800029
J	Knaul, FM; Farmer, PE; Krakauer, EL; De Lima, L; Bhadelia, A; Kwete, XJ; Arreola-Ornelas, H; Gomez-Dantes, O; Rodriguez, NM; Alleyne, GAO; Connor, SR; Hunter, DJ; Lohman, D; Rodbruch, L; Madrigal, MDS; Atun, R; Foley, KM; Freuk, J; Jamison, DT; Rajagopal, MR				Knaul, Felicia Marie; Farmer, Paul E.; Krakauer, Eric L.; De Lima, Liliana; Bhadelia, Afsan; Kwete, Xiaoxiao Jiang; Arreola-Ornelas, Hector; Gomez-Dantes, Octavio; Rodriguez, Natalia M.; Alleyne, George A. O.; Connor, Stephen R.; Hunter, Davie J.; Lohman, Diederik; Rodbruch, Lukas; Madrigal, Maria del Rocio Saenz; Atun, Rifat; Foley, Kathleen M.; Freuk, Julio; Jamison, Dean T.; Rajagopal, M. R.		Lancet Commission Palliative Care	Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report	LANCET			English	Review							OF-LIFE CARE; TERMINALLY-ILL PATIENTS; CHRONIC NONCANCER PAIN; TERM OPIOID THERAPY; SUB-SAHARAN AFRICA; ESSENTIAL MEDICINES; COST-EFFECTIVENESS; ADVANCED CANCER; ECONOMIC-IMPACT; PUBLIC-HEALTH		[Knaul, Felicia Marie; Farmer, Paul E.] Univ Miami, Sch Med, Dept Publ Hlth Sci, Coral Gables, FL USA; [Knaul, Felicia Marie; De Lima, Liliana; Bhadelia, Afsan; Kwete, Xiaoxiao Jiang; Rodriguez, Natalia M.] Univ Miami, Inst Adv Study Amer, Coral Gables, FL USA; [Knaul, Felicia Marie] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL USA; [Freuk, Julio] Univ Miami, Sch Business Adm, Coral Gables, FL USA; [Knaul, Felicia Marie] Tomatelo Pecho AC, Mexico City, DF, Mexico; [Knaul, Felicia Marie; Arreola-Ornelas, Hector] Fdn Mexicana Salud AC, Mexico City, DF, Mexico; [Farmer, Paul E.; Krakauer, Eric L.; Atun, Rifat] Harvard Med Sch, Boston, MA USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Krakauer, Eric L.] WHO, Geneva, Switzerland; [De Lima, Liliana; Rodbruch, Lukas] Int Assoc Hospice & Palliat Care, Houston, TX USA; [Bhadelia, Afsan; Kwete, Xiaoxiao Jiang; Atun, Rifat] HarvardTH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA; [Atun, Rifat] HarvardTH Chan Sch Publ Hlth, Detp Hlth Policy & Management, Boston, MA USA; [Hunter, Davie J.] HarvardTH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Hunter, Davie J.] HarvardTH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Alleyne, George A. O.] Natl Inst Publ Hlth, Morelos, Mexico; [Alleyne, George A. O.] Pan Amer Hlth Org, Reg Off WHO, Washington, DC USA; [Connor, Stephen R.] Worldwide Hospice Palliat Care Alliance, London, England; [Hunter, Davie J.] Univ Oxford, Nuffield Dept Populat, Oxford, England; [Lohman, Diederik] Human Rights Watch, Bonn Germany, Maplewood, NJ USA; [Rodbruch, Lukas] Univ Hosp, Dept Palliat Med, Bonn, Germany; [Rodbruch, Lukas] Malteser Hosp, Bonn, Germany; [Madrigal, Maria del Rocio Saenz] Costa Rican Social Secur Fund, San Jose, Costa Rica; [Foley, Kathleen M.] Weill Cornell Med Coll, New York, NY USA; [Jamison, Dean T.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Rajagopal, M. R.] Trivandrum Inst Palliat Sci, WHO Collaborating Ctr Training & Policy Access Pa, Trivandrum, Kerala, India	University of Miami; University of Miami; University of Miami; University of Miami; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; World Health Organization; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Instituto Nacional de Salud Publica; Pan American Health Organization; University of Oxford; University of Bonn; Cornell University; University of California System; University of California San Francisco	Knaul, FM (corresponding author), Univ Miami, Inst Adv Study Amer, Miami, FL 33146 USA.	fknaul@miami.edu	Harding, Richard/G-9729-2012; Atun, Rifat/AAH-5537-2021; Arreola Ornelas, Héctor/HCG-9350-2022; Rodriguez, Natalia/AAP-8861-2021; Connor, Stephen R/B-3353-2009; Perez-Cruz, Pedro/AAV-1968-2020; Gillespie, James/P-4007-2019; Higginson, Irene Julie/C-7309-2012	Arreola Ornelas, Héctor/0000-0002-7615-6218; Rodriguez, Natalia/0000-0002-2633-4397; Connor, Stephen R/0000-0003-0332-2067; Perez-Cruz, Pedro/0000-0001-6265-6919; Gillespie, James/0000-0002-0355-4178; Reddy, K Srinath/0000-0003-3416-3548; Bhadelia, Nahid/0000-0003-4512-2741; Allende-Perez, Silvia/0000-0002-6136-6968; Downing, Julia/0000-0002-3450-785X; Higginson, Irene Julie/0000-0002-3687-1313; Fan, Victoria Y./0000-0001-7755-9425; De Lima, Liliana/0000-0002-0435-1620; Knaul, Felicia/0000-0002-0512-4788; Atun, Rifat/0000-0002-1531-5983; Zimmermann, Camilla/0000-0003-4889-0244	University of Miami Institute for Advanced Study of the Americas; Harvard Global Equity Initiative; Office of the President and Provost at Harvard University; American Cancer Society; CRDF Global; JM Foundation; Mayday Fund; National Cancer Institute (USA); Pan American Health Organization; Susan G Komen; Harvard T.H. Chan School of Public Health; Roche through the University of Miami	University of Miami Institute for Advanced Study of the Americas; Harvard Global Equity Initiative; Office of the President and Provost at Harvard University; American Cancer Society(American Cancer Society); CRDF Global; JM Foundation; Mayday Fund; National Cancer Institute (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pan American Health Organization; Susan G Komen(Susan G. Komen Breast Cancer Foundation); Harvard T.H. Chan School of Public Health; Roche through the University of Miami	This Commission was financially supported by the University of Miami Institute for Advanced Study of the Americas, the Harvard Global Equity Initiative, and the Office of the President and Provost at Harvard University. It also received grant support from the American Cancer Society, CRDF Global, JM Foundation, Mayday Fund, National Cancer Institute (USA), Pan American Health Organization, Susan G Komen, and unrestricted gift support from Pfizer to the University of Miami and the Harvard T.H. Chan School of Public Health. The funding covered three meetings of the Commission, working group meetings, research assistance, core analysis, and writing. Dissemination will partially be supported by Roche through the University of Miami. Funds were also provided to Fundacitan Mexicana para la Salud, A.C. for HA-O and OM-C by an anonymous source. Additionally, institutional support was provided by Fundacitan Mexicana para la Salud, A.C., Tematelo a Pecho, A.C., and Harvard T.H. Chan School of Public Health.	African Palliative Care Association, 2013, GUID ENS PAT ACC SAF; Aguilera X, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001676; Al-Samarrai NR, 2007, J AM MED DIR ASSOC, V8, P253, DOI 10.1016/j.jamda.2006.10.001; Albanese TH, 2013, J PALLIAT MED, V16, P289, DOI 10.1089/jpm.2012.0243; Aldridge MD, 2016, PALLIATIVE MED, V30, P224, DOI 10.1177/0269216315606645; Amblas J, 2017, BUILDING INTEGRATED; Anderson ED, 2010, BREAKING CYCLE PREVE; [Anonymous], 2017, LANCET, V389, P763, DOI 10.1016/S0140-6736(17)30578-0; [Anonymous], 1993, Commun Dis Rep CDR Wkly, V3, P137; [Anonymous], 2016, MENSTRUAL CUP REV; [Anonymous], 2009, EUR J PALLIAT CARE; [Anonymous], INT CONV PROT HUM RI; [Anonymous], 2017, ECONOMIST; [Anonymous], 2014, INT DRUG PRIC IND GU; [Anonymous], 2012, DELICIOUS DAY   0402; [Anonymous], 2011, MD MAGAZINE     0822; [Anonymous], [No title captured]; [Anonymous], 2017, NY TIMES; Aramis Da Costa Foster G, 2016, M WORK GROUP EFF MOD; Arreola-Ornelas H, 2016, M WORK GROUP EFF MOD; Atun R, 2014, DIRECTIVE CHANGE SOC; Atun R, 2015, LANCET ONCOL, V16, P1153, DOI 10.1016/S1470-2045(15)00222-3; Atun R, 2015, LANCET, V385, P1230, DOI 10.1016/S0140-6736(14)61646-9; Authier EL, 2007, DISABIL REHABIL, V29, P963, DOI 10.1080/09638280701240714; Bah EI, 2015, NEW ENGL J MED, V372, P40, DOI 10.1056/NEJMoa1411249; Barnes E, 2014, J INT AIDS SOC, V17, P104, DOI 10.7448/IAS.17.4.19651; Basu R.R., 2013, J MANAG GLOB SUSTAIN, V1, P63, DOI [10.13185/JM2013.01204, DOI 10.13185/JM2013.01204]; Bausewein C, 2016, PALLIATIVE MED, V30, P6, DOI 10.1177/0269216315589898; Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Bhadelia A, 2017, THESIS; Bhalla K, 2016, CASE STUDIES MULTISE, V2; Bhutta ZA, 2010, LANCET, V375, P1137, DOI 10.1016/S0140-6736(10)60450-3; Blanchet N, 2014, GLOBAL COLLECTIVE AC; Bobadilla J. L., 1995, J INT DEV, V7, P543; BOBADILLA JL, 1994, B WORLD HEALTH ORGAN, V72, P653; Bobadilla JL, 1994, ESSENTIAL PACKAGE HL; Bonica JJ VV, 1979, INT S PAIN ADV CANC; Bosnjak S, 2011, SUPPORT CARE CANCER, V19, P1239, DOI 10.1007/s00520-011-1200-2; Brett-Major DM, 2015, AM J TROP MED HYG, V92, P233, DOI 10.4269/ajtmh.14-0746; Brinda EM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-207; Callaway M, 2007, J PAIN SYMPTOM MANAG, V33, P509, DOI 10.1016/j.jpainsymman.2007.02.003; Calo E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024; Canadian Medical Association, 2015, HARMS ASS OP OTH PSY; Carrillo JE, 2011, J HEALTH CARE POOR U, V22, P562, DOI 10.1353/hpu.2011.0037; Carroll I, 2012, ANESTH ANALG, V115, P694, DOI 10.1213/ANE.0b013e31825c049f; Casarett D, 2015, OXFORD TXB PALLIATIV; Casarett DJ, 2003, J PAIN SYMPTOM MANAG, V25, pS3, DOI 10.1016/S0885-3924(03)00058-7; Centeno C, 2016, BMJ SUPPORT PALLIAT, V6, P128, DOI 10.1136/bmjspcare-2014-000646; Centers for Disease Control and Prevention, 2017, PROV COUNTS DRUG OV; Chalkidou K, 2014, LANCET ONCOL, V15, pE119, DOI 10.1016/S1470-2045(13)70547-3; Clark D., 2016, COMFORT ALWAYS HIST; Clark David A., 2010, OCEANS 2010 IEEE - Sydney, DOI 10.1109/OCEANSSYD.2010.5603523; Cleary J, 2006, DIS CONTROL PRIORITI; COFEPRIS, 2015, SIST REC EL MED FRAC; COFEPRIS, 2015, SIST EL TRAM SAN; Coleman-Lochner L, 2016, ADULT DIAPER MARKET; Collahan D., 2002, ETHICAL DIMENSIONS H, P395; Comision Federal para la Proteccion contra Riesgos Sanitarios, 2015, EST PSIC SUST QUIM; Coneval, 2014, MED POBR EST UN MEX; Connor SR., 2013, ASSESSMENT NEED PALL; Connor SR, 2014, GLOBAL ATLAS PALLIAT; Connor SR, 2017, J PAIN SYMPTOM MANAG, V53, P171, DOI 10.1016/j.jpainsymman.2016.08.020; Consejo General de Salubridad, 2015, LANZ REC LIBR EL; Consejo Nacional de Evaluacion de la Politica de Desarrollo Social, 2014, MED POBR EST UN MED; Covarrubias-Gomez A, 2008, REV MEXICANA ANESTES, V31, P66; Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-6736(16)00619-X; Danis M, 2015, AM J BIOETHICS, V15, P70, DOI 10.1080/15265161.2015.1011000; Das P, 2017, LANCET, V389, P337, DOI 10.1016/S0140-6736(16)31907-9; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; Davis MP, 2015, ANN PALLIAT MED, V4, P99, DOI 10.3978/j.issn.2224-5820.2015.04.04; de Cerqueira AC, 2015, COMPR PSYCHIAT, V63, P10, DOI 10.1016/j.comppsych.2015.08.001; De Lima L, 2007, J PAIN SYMPTOM MANAG, V33, P521, DOI 10.1016/j.jpainsymman.2007.02.006; De Lima L, 2016, J PALLIAT MED, V19, P964, DOI 10.1089/jpm.2016.0091; De Lima L, 2014, J PAIN SYMPTOM MANAG, V48, P649, DOI 10.1016/j.jpainsymman.2013.12.237; De Lima Liliana, 2012, J Pain Palliat Care Pharmacother, V26, P118, DOI 10.3109/15360288.2012.680010; Delgado-Guay MO, 2011, J PAIN SYMPTOM MANAG, V41, P986, DOI 10.1016/j.jpainsymman.2010.09.017; DesRosiers T, 2014, J PAIN SYMPTOM MANAG, V47, P786, DOI 10.1016/j.jpainsymman.2013.05.021; Dhillon Paul, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211384; Directorate General of Health Services Ministry of Health & Family Welfare, 2012, PROP STRAT PALL CAR; Donabedian A, 2002, INTRO QUALITY ASSURA; Dos Santos CS, 2017, PALLIAT SUPPORT CARE, V15, P425, DOI 10.1017/S1478951516000869; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Dussel V, 2011, J CLIN ONCOL, V29, P1007, DOI 10.1200/JCO.2009.27.8960; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; Dy Sydney M, 2012, Evid Rep Technol Assess (Full Rep), P1; Economist Intelligence Unit, 2015, 2015 QUAL DEATH IND; Elsner F, 2012, FUTURE ONCOL, V8, P1183, DOI [10.2217/fon.12.97, 10.2217/FON.12.97]; Elsner M, 2016, LIT REV BEREAVEMENT; Emanuel N, 2010, J PALLIAT MED, V13, P941, DOI 10.1089/jpm.2010.0055; Emanuel RH, 2008, J PALLIAT MED, V11, P746, DOI 10.1089/jpm.2007.0220; Esquibel AY, 2014, PAIN, V155, P2575, DOI 10.1016/j.pain.2014.09.018; Eyssallenne AP, 2012, NEW ENGL J MED, V367, P8, DOI 10.1056/NEJMp1201108; Fader M, 2008, HEALTH TECHNOL ASSES, V12, P1; Farage MA, 2007, CONTACT DERMATITIS, V57, P211, DOI 10.1111/j.1600-0536.2007.01199.x; Farmer P., 2015, LONDON REV BOOKS, P25; Field D, 2001, RES PALLIATIVE CARE; Foley KM, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P981; Foster L, 2013, J POVERTY SOC JUSTIC, V21, P77, DOI 10.1332/175982712X657145; Fowler RA, 2014, AM J RESP CRIT CARE, V190, P733, DOI 10.1164/rccm.201408-1514CP; Franke MF, 2013, CLIN INFECT DIS, V56, P1319, DOI 10.1093/cid/cis1193; Frenk J, 2004, GLOBAL FORUM UPDATE, P48; Frenk J, 2006, LANCET, V368, P954, DOI 10.1016/S0140-6736(06)69376-8; Frenk J, 2015, LANCET, V385, P1352, DOI 10.1016/S0140-6736(14)61467-7; Frenk J, 2013, NEW ENGL J MED, V368, P936, DOI 10.1056/NEJMra1109339; Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5; Frost LJ, 2008, ACCESS GOOD HLTH TEC; Gamondi C., 2013, EUROPEAN J PALLIATIV, V20, P86; Gamondi C., 2013, EUR J PALLIAT CARE, V20, P140; Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC; Gardiner C, 2014, PALLIATIVE MED, V28, P375, DOI 10.1177/0269216313510588; Gawande A, 2014, BEING MORTAL MED WHA; Gawande AA, 2017, ANN SURG, V265, P693, DOI 10.1097/SLA.0000000000002133; Gelband H, 2016, LANCET, V387, P2133, DOI 10.1016/S0140-6736(15)00755-2; Glassman A, 2015, LATIN AM CASH TRANSF; Global Commission on Drug Policy, 2015, NEG IMP DRUG CONTR P; Dantes OG, 2011, SALUD PUBLICA MEXICO, V53, pS220; Gomez-Batiste X, 2017, PALLIATIVE MED, V31, P754, DOI 10.1177/0269216316676647; Gotti D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094768; Grassi L, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0550-8; Gudex C, 1988, THE QALY TOOLKIT; Gwyther L, 2013, EHOSPICE        0627; Gwyther L, 2009, J PAIN SYMPTOM MANAG, V38, P767, DOI 10.1016/j.jpainsymman.2009.03.003; Hauser W, 2016, PAIN MANAG, V6, P249, DOI 10.2217/pmt.16.5; Hanson LC, 2008, J PAIN SYMPTOM MANAG, V35, P340, DOI 10.1016/j.jpainsymman.2007.06.008; Harding R, 2016, CHRONIC PAIN HIV PRA, P150; Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Herce ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110457; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Hongoro C, 2011, J PAIN SYMPTOM MANAG, V41, P1015, DOI 10.1016/j.jpainsymman.2010.08.014; Horton R, 2017, LANCET, V390, P346, DOI 10.1016/S0140-6736(17)31919-0; Howitt P, 2012, LANCET, V380, P507, DOI 10.1016/S0140-6736(12)61127-1; Hughes D, 2007, HEALTH AFFAIR, V26, P999, DOI 10.1377/hlthaff.26.4.999; Hui D, 2016, NAT REV CLIN ONCOL, V13, P159, DOI 10.1038/nrclinonc.2015.201; Human Rights Watch, 2009, PLEAS NOT MAK US SUF; Human Rights Watch, 2016, PAIN TEARS ME AP; Human Rights Watch, 2014, W AFR RES RIGHTS EB; Humphreys K, 2017, LANCET, V390, P437, DOI 10.1016/S0140-6736(17)31918-9; Institute for Health Metrics and Evaluation (IHME), 2016, GBD COMP DAT VIS; Institute of Medicine, 2015, DYING AM IMPR QUAL H; International Children's Palliative Care Network, HER AR SOM FREQ ASK; International Federation of Red Cross And Red Crescent Societies, 2014, PSYCH SUPP OUTBR EB; International Narcotic Control Board, 2017, NARC DRUGS TECHN REP; International Narcotics Control Board, 2007, REP INT NARC CONTR B; International Narcotics Control Board, 2010, REP INT NARC CONT BO; Jack BA, 2012, PALLIATIVE MED, V26, P753, DOI 10.1177/0269216311413628; Jackson K, 2004, COCHRANE DB SYST REV, V2; Jackson K, 2016, EHOSPICE        0523; Jagwe J, 2007, J PAIN SYMPTOM MANAG, V33, P547, DOI 10.1016/j.jpainsymman.2007.02.014; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Jamison DT, 1998, LANCET, V351, P514, DOI 10.1016/S0140-6736(97)11451-9; Jamison DT, 2015, LANCET; Jamison RN, 2016, PAIN MED, V17, P99, DOI 10.1111/pme.12871; Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234; Jefferds Alexandra N, 2010, Phys Med Rehabil Clin N Am, V21, P221, DOI 10.1016/j.pmr.2009.07.011; Jha P, 1996, MEASURING BURDEN DIS; Jubb AM, 2002, J MED ETHICS, V28, P342, DOI 10.1136/jme.28.6.342; Jung HM, 2012, SUPPORT CARE CANCER, V20, P29, DOI 10.1007/s00520-010-1047-y; Kaundal V, 2013, C ADV COMM CONTR SYS, P277; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Kelley AS, 2013, HEALTH AFFAIR, V32, P552, DOI 10.1377/hlthaff.2012.0851; Kersting A, 2011, J AFFECT DISORDERS, V131, P339, DOI 10.1016/j.jad.2010.11.032; Khosla D, 2012, INDIAN J PALLIAT CAR, V18, P149, DOI 10.4103/0973-1075.105683; Knaul F, 2012, CLOSING CANC DIVIDE; Knaul FM, 2015, LANCET, V386, P722, DOI 10.1016/S0140-6736(15)60289-6; Knaul FM, 2015, HEALTH AFFAIR, V34, P1514, DOI 10.1377/hlthaff.2015.0514; Knaul FM, 2012, CLOSE CANC DIVIDE EQ; Krakauer EL, 2017, DIS CONTROL PRIORITI; Krakauer EL, 2007, ETHNOG STUD SUBJ, V7, P381; Krakauer EL, 2008, J PAIN SYMPTOM MANAG, V36, P505, DOI 10.1016/j.jpainsymman.2007.11.015; Krakauer EL, 2007, J PAIN SYMPTOM MANAG, V33, P578, DOI 10.1016/j.jpainsymman.2007.02.004; Krakauer EL, 2010, J PAIN SYMPTOM MANAG, V40, P27, DOI 10.1016/j.jpainsymman.2010.04.009; Krug E, 2016, PLANNING IMPLEMENTIN; Kumar SK, 2007, J PAIN SYMPTOM MANAG, V33, P623, DOI 10.1016/j.jpainsymman.2007.02.005; Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827; Lamontagne F, 2014, NEW ENGL J MED, V371, P1565, DOI 10.1056/NEJMp1411310; Lampl C, 2012, J HEADACHE PAIN, V13, P67, DOI 10.1007/s10194-011-0398-1; Langer A, 2015, LANCET, V386, P1165, DOI 10.1016/S0140-6736(15)60497-4; Laursen L, 2016, NATURE, V535, pS16, DOI 10.1038/535S16a; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; Logie DE, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-82; Lohman D, 2017, BUILDING INTEGRATED; Lohman D, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-8; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lutz ST, 2014, J CLIN ONCOL, V32, P2913, DOI 10.1200/JCO.2014.55.1143; Ly KL, 2002, PALLIATIVE MED, V16, P279, DOI 10.1191/0269216302pm570oa; Lynch T, 2013, J PAIN SYMPTOM MANAG, V45, P1094, DOI 10.1016/j.jpainsymman.2012.05.011; Lynn J, 2003, LIVING WELL END LIFE; Malhotra C, 2015, PALLIATIVE MED, V29, P842, DOI 10.1177/0269216315578803; Knaul FM, 2012, LANCET, V380, P1259, DOI 10.1016/S0140-6736(12)61068-X; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; Maru D, 2012, HEALTH HUM RIGHTS, V14, P1; Matzo M, 2009, BIOSECUR BIOTERROR, V7, P199, DOI 10.1089/bsp.2009.0017; Maurer MA, 2017, J PAIN PALLIAT CARE, V31, P45, DOI 10.1080/15360288.2017.1279504; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; McIntyre, 2014, FISCAL SPACE DOMESTI; McIntyre T, 2011, WORLD J SURG, V35, P745, DOI 10.1007/s00268-011-0961-6; McMahon SA, 2016, HEALTH POLICY PLANN, V31, P1232, DOI 10.1093/heapol/czw055; McManus R., 2014, MORTALITY, V19, P379, DOI [10.1080/13576275.2014.948413, DOI 10.1080/13576275.2014.948413, https://doi.org/10.1080/13576275.2014.948413]; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; Merriman Anne, 2010, Philos Ethics Humanit Med, V5, P10, DOI 10.1186/1747-5341-5-10; Miner TJ, 2005, AM J CLIN ONCOL-CANC, V28, P411, DOI 10.1097/01.coc.0000158489.82482.2b; Ministerio de Salud de Chile, 2009, NORM GEN TECN NO 32; Miranda P, 2016, EL UNIVERSAL; Morgan S, 2012, J HOLIST NURS, V30, P6, DOI 10.1177/0898010111412189; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Morrison RS, 2011, HEALTH AFFAIR, V30, P454, DOI 10.1377/hlthaff.2010.0929; Mosoiu D, 2014, J PAIN SYMPTOM MANAG, V48, P719, DOI 10.1016/j.jpainsymman.2013.11.017; Mount B, 1997, HOSPICE CARE INT SCE; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Murray SA, 2012, INT PERSPECT PUBLIC, V30, P2017; Naik Gautam, 2004, Wall St J (East Ed), pA12; Nardelli S, 2013, METAB BRAIN DIS, V28, P239, DOI 10.1007/s11011-012-9364-0; National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S; Nishtar S, 2017, LANCET; Nolte Ellen., 2004, DOES HLTH CARE SAVE; Ntizimira CR, 2016, CURR OBSTET GYNECOL, V5, P273, DOI 10.1007/s13669-016-0186-7; O'Brien M, 2013, LANCET ONCOL, V14, pE176, DOI 10.1016/S1470-2045(12)70343-1; Odonkor CA, 2017, PAIN MED, V18, P363, DOI 10.1093/pm/pnw143; Pahuja M, 2015, OXFORD TXB PALLIATIV; Pan American Health Organization WHO, 2013, LIST PROD THER CLASS; Pastrana T, 2014, PALLIATIVE MED, V28, P1231, DOI 10.1177/0269216314538893; Paudel BD, 2015, J PAIN SYMPTOM MANAG, V49, P111, DOI 10.1016/j.jpainsymman.2014.02.011; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2012, MMWR-MORBID MORTAL W, V63, P563; Pearlman J, 2008, IEEE ENG MED BIOL, V27, P12, DOI 10.1109/EMB.2007.907372; Pearlman J, 2009, DISABIL REHABIL-ASSI, V4, P42, DOI 10.1080/17483100802338440; Pellecchia U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143036; Perkins P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006271.pub2; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Piot P, 2015, LANCET, V386, P171, DOI 10.1016/S0140-6736(15)60658-4; Pogorelc D, 2012, DIAPER SENSOR DATA I; Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024; Postier A, 2014, J PALLIAT MED, V17, P183, DOI 10.1089/jpm.2013.0287; Powell RA, 2017, LANCET, V389, P1498, DOI 10.1016/S0140-6736(17)30978-9; Powell RA, 2014, J PAIN SYMPTOM MANAG, V47, P315, DOI 10.1016/j.jpainsymman.2013.03.022; Prommer E, 2012, AM J HOSP PALLIAT ME, V29, P295, DOI 10.1177/1049909111423094; Quinones S., 2015, DREAMLAND TRUE TALE; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Rabow MW, 2012, EVIDENCED BASED PRAC; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Radbruch L, 2011, ENSURING BALANCE NAT; Radbruch L, 2014, J PALLIAT MED, V17, P262, DOI 10.1089/jpm.2014.9445; Radcliffe Institute For Advanced Study Harvard University, 2014, CLOS PAIN DIV; Rajagopal MR, 2007, J PAIN SYMPTOM MANAG, V33, P615, DOI 10.1016/j.jpainsymman.2007.02.028; Rajagopal M.R., 2015, CURRENT STATUS PALLI; Rajagopal MR, 2001, LANCET, V358, P139, DOI 10.1016/S0140-6736(01)05322-3; Ramsey SD, 2016, J CLIN ONCOL, V34, P980, DOI 10.1200/JCO.2015.64.6620; Rhee JY, 2017, LANCET ONCOL, V18, pE522, DOI [10.1016/S1470-2045(17)30420-5, 10.1016/s1470-2045(17)30420-5]; Riedel DJ, 2013, AIDS, V27, P1109, DOI 10.1097/QAD.0b013e32835dc068; Riedel O, 2010, J NEUROL, V257, P1073, DOI 10.1007/s00415-010-5465-z; Roeland EJ, 2017, J CLIN ONCOL, V35, P813, DOI 10.1200/JCO.2016.71.2174; Rolles, 2016, ALTERNATIVE WORLD DR; Romero B, 2009, P IEEE AFRICON NAIR, P1; Rosoff PM, 2015, AM J BIOETHICS, V15, P26, DOI 10.1080/15265161.2015.1010995; Ruhe N, 2015, MEDCITY NEWS    0602; Sagui E, 2015, CLIN INFECT DIS, V61, P1627, DOI 10.1093/cid/civ606; Sallnow L, 2013, PROGR PALLIAT CARE, V18, P14; Saunders, 1964, PRESCRIBERS J, V4, P68; Schulz R, 2008, AM J NURS, V108, P23, DOI 10.1097/01.NAJ.0000336406.45248.4c; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Sepulveda J, 2006, LANCET, V368, P2017, DOI 10.1016/S0140-6736(06)69569-X; Shakarishvili G, CONVERGING HLTH SYST; Sharkey L, 2018, PALLIATIVE MED, V32, P106, DOI 10.1177/0269216317716060; Shaw RP, 2015, HEALTH SYST REFORM, V1, P72, DOI 10.1080/23288604.2014.996413; Shear MK, 2016, JAMA PSYCHIAT, V73, P685, DOI 10.1001/jamapsychiatry.2016.0892; Shore SL, 2008, MED SCI MONITOR, V14, pPH71; Shulman LN, 2016, J CLIN ONCOL, V34, P69, DOI 10.1200/JCO.2015.61.8736; Shultz JM, 2011, PREHOSP DISASTER MED, V26, P353, DOI 10.1017/S1049023X11006716; Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367; Sixty-ninth World Health Assembly, 2016, STRENGTH INT PEOPL; Slama S, 2017, LANCET, V389, P326, DOI 10.1016/S0140-6736(16)31404-0; Sleeman KE, 2012, LANCET, V379, P519, DOI 10.1016/S0140-6736(12)60230-X; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Smith TJ, 2009, J PAIN SYMPTOM MANAG, V38, P32, DOI 10.1016/j.jpainsymman.2009.05.001; Sorbye LW, 2009, SCAND J CARING SCI, V23, P33, DOI 10.1111/j.1471-6712.2007.00588.x; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Syed ST, 2013, J COMMUN HEALTH, V38, P976, DOI 10.1007/s10900-013-9681-1; Szlezak NA, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000183; Tamir O, 2007, PALLIATIVE MED, V21, P537, DOI 10.1177/0269216307080822; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The World Bank, 2014, MOD MEX WORLD; The Worldwide Hospice Palliative Care Alliance, 2016, CIV SOC REP UPD IMPL; Trowbridge MM, 2017, SKIN RES TECHNOL, V23, P202, DOI 10.1111/srt.12320; Ughasoro MD, 2014, NIGER J CLIN PRACT, V17, P506, DOI 10.4103/1119-3077.134054; UICC, 2014, EC CANC PREV CONTR D; UN, PROGR GOAL 3 2017; UN Programme on HIV/AIDS (UNAIDS), 2017, END AIDS PROGR 90 90; UN Programme on HIV/AIDS (UNAIDS), 2017, AIDSINFO; UNDP, 2012, UN CORP BRING AFF HY; UNGASS, 2016, SPEC SESS UN GEN ASS; United Nations, 2017, TRINET MESSAGE; United Nations Office on Drugs and Crime, PROM AD AV INT CONTR; United Nations Office on Drugs and Crime, 1961, SINGL CONV NARC DRUG; Van Bortel T, 2016, B WORLD HEALTH ORGAN, V94, P210, DOI 10.2471/BLT.15.158543; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Verguet S, 2015, HEALTH ECON, V24, P318, DOI 10.1002/hec.3019; Verguet S, 2013, VACCINE, V31, P4902, DOI 10.1016/j.vaccine.2013.07.014; Vincent HK, 2015, PM&R, V7, P978, DOI 10.1016/j.pmrj.2015.03.007; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Voon P, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0120-7; Vreeman RC, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18466; Walsh D, 2017, SUPPORT CARE CANCER, V25, P333, DOI 10.1007/s00520-016-3371-3; Wamala S, 2014, HDB GLOBAL HLTH POLI, P425; Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0; Watkins D, 2017, DCP3 WORKING PAPER S, V20; Watkins DA, 2017, DIS CONTROL PRIORITI, V3rd; WHO, 2016, PROGR REP REP SECR; WHO, WHAT IS UN COV; who, WHO DEF PALL CAR; WHO, 2017, GLOBAL ATLAS MEDICAL; WHO, 2017, GLOB STRAT ACT PLAN; WHO Unit Name MND, 2017, EV 6 WHO PALL CAR DE; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Bank, 2014, POV HEADC RAT 1 90 D; World Bank, 2015, POP TOT; World Health Organisation, 2016, EB SIT REP 30 MARCH; World Health Organization,, 1986, CANC PAIN REL; World Health Organization, 2015, TRACK UN HLTH COV 1; World Health Organization, 2015, WORLD POP AG 2015; World Health Organization, 1990, CANC PAIN REL PALL C; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2014, WHA6719 WHO; World Health Organization, 2017, ESSE MED LIST; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2017, WHO MOD LISTS ESS ME; World Health Organization, 2007, WHO GUID EFF PROGR M; Yang J, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1416-3; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zeschky M, 2011, RES TECHNOL MANAGE, V54, P38, DOI 10.5437/08956308X5404007; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2; Zipfel E, 2007, DISABIL REHABIL, V29, P949, DOI 10.1080/09638280701240672; Zollfrank AA, 2015, J PALLIAT MED, V18, P408, DOI 10.1089/jpm.2014.0306	337	469	484	18	128	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2018	391	10128					1391	1454		10.1016/S0140-6736(17)32513-8	http://dx.doi.org/10.1016/S0140-6736(17)32513-8			64	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB8RK	29032993				2023-01-03	WOS:000429342800027
J	Hector, AJ; McGlory, C; Damas, F; Mazara, N; Baker, SK; Phillips, SM				Hector, Amy J.; McGlory, Chris; Damas, Felipe; Mazara, Nicole; Baker, Steven K.; Phillips, Stuart M.			Pronounced energy restriction with elevated protein intake results in no change in proteolysis and reductions in skeletal muscle protein synthesis that are mitigated by resistance exercise	FASEB JOURNAL			English	Article						muscle protein turnover; weight loss; dietary protein	FAT-FREE MASS; WEIGHT-LOSS; IN-VIVO; DIETARY-PROTEIN; AMINO-ACIDS; OLDER MEN; DEFICIT; HUMANS; MYOFIBRILLAR; INGESTION	Preservation of lean body mass (LBM) may be important during dietary energy restriction (ER) and requires equal rates of muscle protein synthesis(MPS) and muscle protein breakdown(MPB). Currently, the relative contribution of MPS and MPB to the loss of LBM during ER in humans is unknown. We aimed to determine the impact of dietary protein intake and resistance exercise on MPS and MPB during a controlled short-term energy deficit. Adult men (body mass index, 28.66 +/- 0.6 kg/m(2); age 22 +/- 1 yr) underwent 10 d of 40%-reduced energy intake while performing unilateral resistance exercise and consuming lower protein (1.2 g/kg/d, n = 12) or higher protein (2.4 g/kg/d, n = 12). Pre- and postintervention testing included dual-energy X-ray absorptiometry, primed constant infusion of ring-[C-13(6)] phenylalanine, and (15)[N] phenylalanine to measure acute postabsorptive MPS and MPB; D2O to measure integrated MPS; and gene and protein expression. There was a decrease in acute MPS after ER (higher protein, 0.059 +/- 0.006 to 0.051 +/- 0.009%/h; lower protein, 0.061 +/- 0.005 to 0.045 +/- 0.006%/h; P < 0.05) that was attenuated with resistance exercise (higher protein, 0.067 +/- 0.01%/h; lower protein, 0.061 +/- 0.006%/hr), and integrated MPS followed a similar pattern. There was no change in MPB (energy balance, 0.080 +/- 0.01%/hr; ER rested legs, 0.078 +/- 0.008%/hr; ER exercised legs, 0.079 +/- 0.006%/hr). We conclude that a reduction in MPS is the main mechanism that underpins LBM loss early in ER in adult men.	[Hector, Amy J.; McGlory, Chris; Mazara, Nicole; Phillips, Stuart M.] McMaster Univ, Dept Kinesiol, 1280 Main St West, Hamilton, ON L8S 4K1, Canada; [Baker, Steven K.] McMaster Univ, Div Phys Med & Rehabil, Dept Med, Hamilton, ON, Canada; [Damas, Felipe] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil	McMaster University; McMaster University; Universidade de Sao Paulo	Phillips, SM (corresponding author), McMaster Univ, Dept Kinesiol, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.	phillis@mcmaster.ca	Damas, Felipe/S-7122-2019; Damas, Felipe/F-1143-2013; Phillips, Stuart/B-2343-2009	Damas, Felipe/0000-0001-9049-3598; Damas, Felipe/0000-0001-9049-3598; Phillips, Stuart/0000-0002-1956-4098; McGlory, Chris/0000-0003-4853-4960	National Science and Engineering Research Council of Canada; Canada Research Chairs Program	National Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Research Chairs Program(Canada Research Chairs)	This work was supported by a grant from the National Science and Engineering Research Council of Canada (to S.M.P.). S.M.P. was supported by the Canada Research Chairs Program and greatly acknowledges that funding. The authors thank Todd Prior (McMaster University) for technical assistance during laboratory analyses. The authors declare no conflicts of interest.	Areta JL, 2014, AM J PHYSIOL-ENDOC M, V306, pE989, DOI 10.1152/ajpendo.00590.2013; Bellamy LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109739; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE75, DOI 10.1152/ajpendo.1995.268.1.E75; Brook MS, 2016, J PHYSIOL-LONDON, V594, P7399, DOI 10.1113/JP272857; Burd NA, 2012, J APPL PHYSIOL, V113, P896, DOI 10.1152/japplphysiol.00513.2012; Burd NA, 2009, J APPL PHYSIOL, V106, P1692, DOI 10.1152/japplphysiol.91351.2008; Burke LM, 2011, J SPORT SCI, V29, pS17, DOI 10.1080/02640414.2011.585473; Canadian Institutes of Health Research Natural Sciences and Engineering Research Council of Canada and Social Sciences and Humanities Research Council of Canada, 2014, TRIC POL STAT ETH CO; Carbone JW, 2014, APPL PHYSIOL NUTR ME, V39, P960, DOI 10.1139/apnm-2013-0433; Carbone JW, 2013, FASEB J, V27, P5104, DOI 10.1096/fj.13-239228; Greenhaff PL, 2008, AM J PHYSIOL-ENDOC M, V295, pE595, DOI 10.1152/ajpendo.90411.2008; Hammond KM, 2016, MED SCI SPORT EXER, V48, P2108, DOI 10.1249/MSS.0000000000001009; Hector AJ, 2015, J NUTR, V145, P246, DOI 10.3945/jn.114.200832; Henry CJK, 2005, PUBLIC HEALTH NUTR, V8, P1133, DOI 10.1079/PHN2005801; Heymsfield SB, 2011, OBES REV, V12, pe348, DOI 10.1111/j.1467-789X.2010.00767.x; Jamart C, 2012, EUR J APPL PHYSIOL, V112, P3173, DOI 10.1007/s00421-011-2287-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longland TM, 2016, AM J CLIN NUTR, V103, P738, DOI 10.3945/ajcn.115.119339; Margolis LM, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00445; Mathis AD, 2017, MOL CELL PROTEOMICS, V16, P243, DOI 10.1074/mcp.M116.063255; Moore DR, 2009, J PHYSIOL-LONDON, V587, P897, DOI 10.1113/jphysiol.2008.164087; Murphy C. J., 2016, THESIS; Murphy CH, 2016, AM J CLIN NUTR, V104, P1594, DOI 10.3945/ajcn.116.136424; Murphy CH, 2015, EUR J SPORT SCI, V15, P21, DOI 10.1080/17461391.2014.936325; Pasiakos SM, 2015, FASEB J, V29, P1136, DOI 10.1096/fj.14-266890; Pasiakos SM, 2013, FASEB J, V27, P3837, DOI 10.1096/fj.13-230227; Pasiakos SM, 2010, J NUTR, V140, P745, DOI 10.3945/jn.109.118372; Paul PK, 2012, MOL CELL BIOL, V32, P1248, DOI 10.1128/MCB.06351-11; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Smiles WJ, 2015, AM J PHYSIOL-REG I, V309, pR603, DOI 10.1152/ajpregu.00413.2014; Stefanetti RJ, 2015, PFLUG ARCH EUR J PHY, V467, P1523, DOI 10.1007/s00424-014-1587-y; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Wilkinson DJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE571, DOI 10.1152/ajpendo.00650.2013; Wolfe RR, 2006, AM J CLIN NUTR, V84, P475, DOI 10.1093/ajcn/84.3.475; Zhang XJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE759, DOI 10.1152/ajpendo.1996.270.5.E759	36	50	50	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2018	32	1					265	275		10.1096/fj.201700158RR	http://dx.doi.org/10.1096/fj.201700158RR			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FR6JU	28899879				2023-01-03	WOS:000419172700025
J	Kshirsagar, AV; Manickam, RN; Mu, Y; Flythe, JE; Chin, AI; Bang, H				Kshirsagar, Abhijit V.; Manickam, Raj N.; Mu, Yi; Flythe, Jennifer E.; Chin, Andrew I.; Bang, Heejung			Area-level poverty, race/ethnicity & dialysis star ratings	PLOS ONE			English	Article							INCIDENT HEMODIALYSIS-PATIENTS; VASCULAR ACCESS; UNITED-STATES; DISPARITIES; ASSOCIATION; SEGREGATION; POPULATION; MORTALITY; VETERANS; OUTCOMES	The Centers for Medicare and Medicaid Services recently released a five star rating system as part of 'Dialysis Facility Compare' to help patients identify and choose high performing clinics in the US. Eight dialysis-related measures determine ratings. Little is known about the association between surrounding community sociodemographic characteristics and star ratings. Using data from the U.S. Census and over 6000 dialysis clinics across the country, we examined the association between dialysis clinic star ratings and characteristics of the local population: 1) proportion of population below the federal poverty level (FPL); 2) proportion of black individuals; and 3) proportion of Hispanic individuals, by correlation and regression analyses. Secondary analyses with Quality Incentive Program (QIP) scores and population characteristics were also performed. We observed a negligible correlation between star ratings and the proportion of local individuals below FPL; Spearman coefficient, R = -0.09 (p<0.0001), and a stronger correlation between star ratings and the proportion of black individuals; R = -0.21 (p<0.0001). Ordered logistic regression analyses yielded adjusted odds ratio of 0.91 (95% confidence interval [0.80-1.30], p =0.12) and 0.55 ([0.48-0.63], p<0.0001) for high vs. low level of proportion below FPL and proportion of black individuals, respectively. In contrast, a near-zero correlation was observed between star ratings and the proportion of Hispanic individuals. Correlations varied substantially by country region, clinic profit status and clinic size. Analyses using clinic QIP scores provided similar results. Sociodemographic characteristics of the surrounding community, factors typically outside of providers' direct control, have varying levels of association with clinic dialysis star ratings.	[Kshirsagar, Abhijit V.; Flythe, Jennifer E.] Univ N Carolina, Div Nephrol & Hypertens, UNC Kidney Ctr, Chapel Hill, NC 27599 USA; [Manickam, Raj N.; Mu, Yi; Bang, Heejung] Univ Calif Davis, Grad Grp Epidemiol, Davis, CA 95616 USA; [Chin, Andrew I.] Univ Calif Sacramento, Davis Sch Med, Div Nephrol, Sacramento, CA USA; [Chin, Andrew I.] VA Northern Calif Hlth Care Syst, Sacramento VA Med Ctr, Div Nephrol, Mather Field, CA USA; [Bang, Heejung] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA; [Bang, Heejung] Univ Calif Sacramento, Ctr Healthcare Policy & Res, Sch Med, Sacramento, CA USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis; California State University System; California State University Sacramento; University of California System; University of California Davis; California State University System; California State University Sacramento	Kshirsagar, AV (corresponding author), Univ N Carolina, Div Nephrol & Hypertens, UNC Kidney Ctr, Chapel Hill, NC 27599 USA.	sagar@med.unc.edu		Flythe, Jennifer/0000-0003-4596-8536	National Institutes of Health through grants [UL1 TR001860]; Dialysis Clinic, Inc.; National Institute of Diabetes and Digestive and Kidney Diseases grant [K23DK109401]; Amgen for Investigator Initiated Research; Renal Research Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK109401] Funding Source: NIH RePORTER	National Institutes of Health through grants; Dialysis Clinic, Inc.; National Institute of Diabetes and Digestive and Kidney Diseases grant; Amgen for Investigator Initiated Research; Renal Research Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	HB was partly supported by the National Institutes of Health through grants UL1 TR001860. HB and YM were additionally supported by Dialysis Clinic, Inc. JEF is supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK109401. AVK has received funding from Amgen for Investigator Initiated Research. JEF has received speaking honoraria from Dialysis Clinic, Inc., Renal Ventures, American Renal Associates, American Society of Nephrology, Baxter and numerous universities and research funding for studies unrelated to the present study from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The interpretation and reporting of the data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.	Agency for Healthcare Quality and Research, NAT QUAL STRAT; Astor BC, 2005, J AM SOC NEPHROL, V16, P1449, DOI 10.1681/ASN.2004090748; Bernheim SM, 2016, HEALTH AFFAIR, V35, P1461, DOI 10.1377/hlthaff.2015.0394; Bower KM, 2014, PREV MED, V58, P33, DOI 10.1016/j.ypmed.2013.10.010; Centers for Medicare and Medicaid Services (CMS), 2012, FED REGISTER, V77, P40952; Centers for Medicare & Medicaid Services ( CMS) HHS, 2010, FED REGISTER, V75, P49030; Chand DH, 2008, NEPHRON CLIN PRACT, V108, pC91, DOI 10.1159/000113525; Chetty R, 2016, JAMA-J AM MED ASSOC, V315, P1750, DOI 10.1001/jama.2016.4226; Cook NL, 2015, CIRCULATION, V132, P1519, DOI 10.1161/CIRCULATIONAHA.115.018953; Daumit GL, 1999, ANN INTERN MED, V130, P173, DOI 10.7326/0003-4819-130-3-199902020-00002; Erickson KF, 2017, CLIN J AM SOC NEPHRO, V12, P536, DOI 10.2215/CJN.06340616; Garrity BH, 2016, HEMODIAL INT, V20, P78, DOI 10.1111/hdi.12325; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Hall YN, 2014, HEALTH SERV RES, V49, P971, DOI 10.1111/1475-6773.12144; Hilmers A, 2012, AM J PUBLIC HEALTH, V102, P1644, DOI 10.2105/AJPH.2012.300865; Iceland J, 2013, DEMOGRAPHY, V50, P97, DOI 10.1007/s13524-012-0136-6; Kovesdy CP, 2015, CIRCULATION, V132, P1538, DOI 10.1161/CIRCULATIONAHA.114.015124; Krumholz HM, 2014, ANN INTERN MED, V161, P833, DOI 10.7326/M14-2308; Manickam RN, 2017, AM J MED, V130, pE153, DOI 10.1016/j.amjmed.2016.08.047; Martsolf GR, 2016, J HLTH CARE ORG PROV, V53, P1, DOI DOI 10.1177/0046958016667596; Moore LV, 2006, AM J PUBLIC HEALTH, V96, P325, DOI 10.2105/AJPH.2004.058040; Nee R, 2015, AM J NEPHROL, V42, P328, DOI 10.1159/000441804; Norton JM, 2016, J AM SOC NEPHROL, V27, P2576, DOI 10.1681/ASN.2016010027; Saha S, 2008, J GEN INTERN MED, V23, P654, DOI 10.1007/s11606-008-0521-4; Walker RE, 2010, HEALTH PLACE, V16, P876, DOI 10.1016/j.healthplace.2010.04.013; World Health Organization, SOCIAL DETERMINANTS	26	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2017	12	10							e0186651	10.1371/journal.pone.0186651	http://dx.doi.org/10.1371/journal.pone.0186651			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK0KA	29040342	Green Published, Green Submitted, gold			2023-01-03	WOS:000413167500067
J	Yang, D; Forsmark, CE				Yang, Dennis; Forsmark, Christopher E.			Review: In adult inpatients with mild or moderate acute pancreatitis, early feeding may reduce length of stay	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Yang, Dennis; Forsmark, Christopher E.] Univ Florida, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Yang, D (corresponding author), Univ Florida, Gainesville, FL 32611 USA.							Bakker OJ, 2014, NEW ENGL J MED, V371, P1983, DOI 10.1056/NEJMoa1404393; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					JC44	JC44		10.7326/ACPJC-2017-167-8-044	http://dx.doi.org/10.7326/ACPJC-2017-167-8-044			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ9JM	29049763				2023-01-03	WOS:000413092700009
J	Tinnermann, A; Geuter, S; Sprenger, C; Finsterbusch, J; Buchel, C				Tinnermann, A.; Geuter, S.; Sprenger, C.; Finsterbusch, J.; Buechel, C.			Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia	SCIENCE			English	Article							PERIAQUEDUCTAL GRAY; PLACEBO ANALGESIA; PAIN PERCEPTION; FUNCTIONAL CONNECTIVITY; RESPONSES; FMRI; REPRESENTATION; EXPECTATION; ACTIVATION; MECHANISMS	Value information about a drug, such as the price tag, can strongly affect its therapeutic effect. We discovered that value information influences adverse treatment outcomes in humans even in the absence of an active substance. Labeling an inert treatment as expensive medication led to stronger nocebo hyperalgesia than labeling it as cheap medication. This effect was mediated by neural interactions between cortex, brainstem, and spinal cord. In particular, activity in the prefrontal cortex mediated the effect of value on nocebo hyperalgesia. Value furthermore modulated coupling between prefrontal areas, brainstem, and spinal cord, which might represent a flexible mechanism through which higher-cognitive representations, such as value, can modulate early pain processing.	[Tinnermann, A.; Geuter, S.; Sprenger, C.; Finsterbusch, J.; Buechel, C.] Univ Med Ctr Hamburg Eppendorf, Inst Syst Neurosci, D-20246 Hamburg, Germany; [Geuter, S.] Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA; [Sprenger, C.] Univ Cambridge, Dept Engn, Computat & Biol Learning Lab, Cambridge CB2 1PZ, England	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Colorado System; University of Colorado Boulder; University of Cambridge	Tinnermann, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Inst Syst Neurosci, D-20246 Hamburg, Germany.	a.tinnermann@uke.de		GEUTER, STEPHAN/0000-0002-4935-5692	German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) [SFB 936]; European Research Council [ERC-2010-AdG_20100407]; DFG Fellowship [GE 2774-1/1]	German Research Foundation (DFG, Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); DFG Fellowship(German Research Foundation (DFG))	A.T., S.G., and C.B. were supported by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft), SFB 936, project A06. C.S. and C.B. were supported by the European Research Council grant ERC-2010-AdG_20100407, and S.G. was supported by the DFG Fellowship (GE 2774-1/1). The authors declare no conflicts of interest. All raw data are archived at the Institute of Systems Neuroscience in the University Medical Center Hamburg-Eppendorf. Results reported in the paper are available in the supplementary materials. We thank M. Menz for helpful methodological discussions and L. Kampermann for assisting with the thermode data. Furthermore, we thank H. Blank, M. Feldhaus, B. Horing, and L. Kampermann for helpful comments on the manuscript. We also thank our radiographers for their contribution in collecting the fMRI data.	Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Benedetti F, 2006, J NEUROSCI, V26, P12014, DOI 10.1523/JNEUROSCI.2947-06.2006; BRANTHWAITE A, 1981, BRIT MED J, V282, P1576, DOI 10.1136/bmj.282.6276.1576; Buchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042; Chib VS, 2009, J NEUROSCI, V29, P12315, DOI 10.1523/JNEUROSCI.2575-09.2009; Coulombe MA, 2016, HUM BRAIN MAPP, V37, P1514, DOI 10.1002/hbm.23117; Eippert F, 2009, SCIENCE, V326, P404, DOI 10.1126/science.1180142; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Finsterbusch J, 2013, NEUROIMAGE, V79, P153, DOI 10.1016/j.neuroimage.2013.04.021; Geuter S, 2013, J NEUROSCI, V33, P13784, DOI 10.1523/JNEUROSCI.2191-13.2013; Geuter S, 2013, NEUROIMAGE, V67, P227, DOI 10.1016/j.neuroimage.2012.11.029; Jensen KB, 2015, CEREB CORTEX, V25, P3903, DOI 10.1093/cercor/bhu275; Keay KA, 1997, J COMP NEUROL, V385, P207, DOI 10.1002/(SICI)1096-9861(19970825)385:2<207::AID-CNE3>3.0.CO;2-5; Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087; Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008; Linnman C, 2012, NEUROIMAGE, V60, P505, DOI 10.1016/j.neuroimage.2011.11.095; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Roy M, 2014, NAT NEUROSCI, V17, P1607, DOI 10.1038/nn.3832; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Sprenger C, 2015, J NEUROSCI, V35, P4248, DOI 10.1523/JNEUROSCI.4897-14.2015; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vahdat S, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002186; Waber RL, 2008, JAMA-J AM MED ASSOC, V299, P1016, DOI 10.1001/jama.299.9.1016; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976; Wiech K, 2016, SCIENCE, V354, P584, DOI 10.1126/science.aaf8934	30	99	101	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	2017	358	6359					105	108		10.1126/science.aan1221	http://dx.doi.org/10.1126/science.aan1221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI9WF	28983051				2023-01-03	WOS:000412359600062
J	Davidov, DM; Davis, SM; Zhu, MT; Afifi, TO; Kimber, M; Goldstein, AL; Pitre, N; Gurka, KK; Stocks, C				Davidov, Danielle M.; Davis, Stephen M.; Zhu, Motao; Afifi, Tracie O.; Kimber, Melissa; Goldstein, Abby L.; Pitre, Nicole; Gurka, Kelly K.; Stocks, Carol			Intimate partner violence-related hospitalizations in Appalachia and the non-Appalachian United States	PLOS ONE			English	Article							PHYSICAL HEALTH CONSEQUENCES; EMERGENCY-DEPARTMENTS; DOMESTIC VIOLENCE; SUBSTANCE-ABUSE; NATIONAL-SURVEY; RISK-FACTORS; OF-LIFE; PREVALENCE; WOMEN; CARE	The highly rural region of Appalachia faces considerable socioeconomic disadvantage and health disparities that are recognized risk factors for intimate partner violence (IPV). The objective of this study was to estimate the rate of IPV-related hospitalizations in Appalachia and the non-Appalachian United States for 2007-2011 and compare hospitalizations in each region by clinical and sociodemographic factors. Data on IPV-related hospitalizations were extracted from the State Inpatient Databases, which are part of the Healthcare Cost and Utilization Project. Hospitalization day, year, in-hospital mortality, length of stay, average and total hospital charges, sex, age, payer, urban-rural location, income, diagnoses and procedures were compared between Appalachian and non-Appalachian counties. Poisson regression models were constructed to test differences in the rate of IPV-related hospitalizations between both regions. From 2007-2011, there were 7,385 hospitalizations related to IPV, with one-third (2,645) occurring in Appalachia. After adjusting for age and rurality, Appalachian counties had a 22% higher hospitalization rate than non-Appalachian counties (ARR = 1.22, 95% CI: 1.14-1.31). Appalachian residents may be at increased risk for IPV and associated conditions. Exploring disparities in healthcare utilization and costs associated with IPV in Appalachia is critical for the development of programs to effectively target the needs of this population.	[Davidov, Danielle M.; Davis, Stephen M.] West Virginia Univ, Dept Emergency Med & Social & Behav Sci, Morgantown, WV 26506 USA; [Davidov, Danielle M.] West Virginia Univ, Dept Social & Behav Sci, Morgantown, WV 26506 USA; [Zhu, Motao; Gurka, Kelly K.] West Virginia Univ, Dept Epidemiol, Morgantown, WV USA; [Afifi, Tracie O.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Afifi, Tracie O.] Univ Manitoba, Dept Psychiat, Winnipeg, MB, Canada; [Kimber, Melissa] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Goldstein, Abby L.] Univ Toronto, Dept Appl Psychol & Human Dev, OISE, Toronto, ON, Canada; [Pitre, Nicole] Univ Alberta, Fac Nursing, Edmonton, AB, Canada; [Stocks, Carol] Agcy Healthcare Res & Qual, Rockville, MD USA; [Zhu, Motao] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA; [Zhu, Motao] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Gurka, Kelly K.] Univ Florida, Dept Epidemiol, Gainesville, FL USA	West Virginia University; West Virginia University; West Virginia University; University of Manitoba; University of Manitoba; McMaster University; University of Toronto; University of Alberta; Agency for Healthcare Research & Quality; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; State University System of Florida; University of Florida	Davidov, DM (corresponding author), West Virginia Univ, Dept Emergency Med & Social & Behav Sci, Morgantown, WV 26506 USA.; Davidov, DM (corresponding author), West Virginia Univ, Dept Social & Behav Sci, Morgantown, WV 26506 USA.	ddavidov@hsc.wvu.edu; carol.stocks@ahrq.hhs.gov	Kimber, Melissa/ABH-5900-2020; Gurka, Kelly K./M-2004-2014	Kimber, Melissa/0000-0002-1255-8947; Gurka, Kelly K./0000-0003-2779-3234; afifi, tracie/0000-0002-3745-9785; zhu, motao/0000-0001-5639-4801; Davidov, Danielle/0000-0002-6754-6724	Canadian Institutes of Health Research Institute of Gender and Health; Institute of Neurosciences Mental Health and Addictions [RDG99326]; National Institute Of General Medical Sciences of the National Institutes of Health [U54GM104942]; National Institute on Minority Health and Health Disparities; Research Manitoba Establishment Award; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	Canadian Institutes of Health Research Institute of Gender and Health(Canadian Institutes of Health Research (CIHR)); Institute of Neurosciences Mental Health and Addictions; National Institute Of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); Research Manitoba Establishment Award; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by the Canadian Institutes of Health Research Institute of Gender and Health and Institute of Neurosciences Mental Health and Addictions to the PreVAiL Preventing Violence Across the Lifespan Research Network) (Centre for Research Development in Gender, Mental Health and Violence across the Lifespan, grant #RDG99326). DD is supported by a grant from the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number U54GM104942 and a Loan Repayment Program Grant from the National Institute on Minority Health and Health Disparities. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. TA is supported by a Research Manitoba Establishment Award and a Canadian Institutes of Health Research New Investigator Award. MK is supported by a Women's Health Scholar Post Doctoral Fellowship Award from the Ontario Ministry of Health and Long-Term Care.	ABBOTT J, 1995, JAMA-J AM MED ASSOC, V273, P1763, DOI 10.1001/jama.273.22.1763; Afifi TO, 2009, J INTERPERS VIOLENCE, V24, P1398, DOI 10.1177/0886260508322192; [Anonymous], 2016, DEF PAT CTR MED HOM; [Anonymous], APP REG DAT OV 2010; [Anonymous], 2017, REP HLTH SYST IMPR; [Anonymous], 2015, HCUP CLIN CLASS SOFT; [Anonymous], 2016, HCUP DAT; Appalachian Regional Commission, AB ARC; Bailey BA, 2010, INT J WOMENS HEALTH, V2, P183, DOI 10.2147/ijwh.s8632; Behringer B., 2006, PREV CHRONIC DIS, V3, P1; Bennett L, 2008, VAWNET, V16, P2009; Bonomi AE, 2006, AM J PREV MED, V30, P458, DOI 10.1016/j.amepre.2006.01.015; Bonomi AE, 2009, HEALTH SERV RES, V44, P1052, DOI 10.1111/j.1475-6773.2009.00955.x; Breiding M., 2015, INTIMATE PARTNER VIO, V2nd; Breiding MJ, 2008, AM J PREV MED, V34, P112, DOI 10.1016/j.amepre.2007.10.001; Breiding MJ, 2009, J RURAL HEALTH, V25, P240, DOI 10.1111/j.1748-0361.2009.00225.x; Btoush R, 2008, J EMERG NURS, V34, P419, DOI 10.1016/j.jen.2007.10.015; Btoush R, 2009, WOMEN HEALTH ISS, V19, P253, DOI 10.1016/j.whi.2009.03.004; Bushy A, 1998, J Am Med Womens Assoc (1972), V53, P53; Campbell J, 2002, ARCH INTERN MED, V162, P1157, DOI 10.1001/archinte.162.10.1157; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Capaldi DM, 2012, PARTN ABUSE, V3, P231, DOI 10.1891/1946-6560.3.2.231; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P527; Coker AL, 2000, ARCH FAM MED, V9, P451, DOI 10.1001/archfami.9.5.451; Coker AL, 2004, PAEDIATR PERINAT EP, V18, P260, DOI 10.1111/j.1365-3016.2004.00569.x; Coker AL, 2000, AM J PUBLIC HEALTH, V90, P553, DOI 10.2105/AJPH.90.4.553; Dunn LL, 2004, JOGNN, V33, P54, DOI 10.1177/0884217503261080; Edwards KM, 2015, TRAUMA VIOLENCE ABUS, V16, P359, DOI 10.1177/1524838014557289; Edwards KM, 2014, AM J COMMUN PSYCHOL, V53, P198, DOI 10.1007/s10464-014-9633-7; El-Bassel N, 2003, WOMEN HEALTH ISS, V13, P16, DOI 10.1016/S1049-3867(02)00142-1; El-Bassel N, 2005, AM J PUBLIC HEALTH, V95, P465, DOI 10.2105/AJPH.2003.023200; Gallup-Black A, 2005, HOMICIDE STUD, V9, P149, DOI 10.1177/1088767904274158; Gold M, 2008, J PUBLIC HEALTH MAN, pS36, DOI 10.1097/01.PHH.0000338385.82436.44; Halverson JA, 2002, ETHNIC DIS, V12, pS3; Halverson JA, 2004, ANAL DISPARITIES HLT; Healthcare Cost and Utilization Project (HCUP), 2016, AGENCY HEALTHCARE RE; Hendryx M, 2008, J RURAL HEALTH, V24, P179, DOI 10.1111/j.1748-0361.2008.00155.x; Hink AB, 2015, J TRAUMA ACUTE CARE, V79, P709, DOI 10.1097/TA.0000000000000856; Kelly U, 2010, WEST J EMERG MED, V11, P247; Kernic MA, 2000, AM J PUBLIC HEALTH, V90, P1416, DOI 10.2105/AJPH.90.9.1416; Koss M P, 1992, Arch Fam Med, V1, P53, DOI 10.1001/archfami.1.1.53; Kothari CL, 2015, ADV EMERG MED, V22; Kothari RU, 2014, J TRAUMA ACUTE CARE, V77, P129, DOI 10.1097/TA.0000000000000269; Kramer A, 2004, WOMEN HEALTH ISS, V14, P19, DOI 10.1016/j.whi.2003.12.002; Lane NM, 2012, HLTH CARE COSTS ACCE; LAST JM, 1963, LANCET, V2, P28; Lipsky S, 2004, MATERN CHILD HLTH J, V8, P55, DOI 10.1023/B:MACI.0000025727.68281.aa; Logan TK, 2003, J FAM VIOLENCE, V18, P83, DOI 10.1023/A:1022837114205; Malcoe LH, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-20; Mixer SJ, 2014, J HOSP PALLIAT NURS, V16, P526, DOI 10.1097/NJH.0000000000000114; Morenoff JD, 1997, SOC FORCES, V76, P31, DOI 10.2307/2580317; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peek-Asa C, 2011, J WOMENS HEALTH, V20, P1743, DOI 10.1089/jwh.2011.2891; Plichta SB, 2007, TRAUMA VIOLENCE ABUS, V8, P226, DOI 10.1177/1524838007301220; Roberts GL, 1996, ANN EMERG MED, V27, P747, DOI 10.1016/S0196-0644(96)70194-4; Rudman WJ, 2000, WOMEN HEALTH, V30, P1, DOI 10.1300/J013v30n04_01; Schafer SD, 2008, PUBLIC HEALTH REP, V123, P628, DOI 10.1177/003335490812300513; Seiling S, 2003, CONSUMER INTERESTS A, V49; Shannon Lisa, 2006, Violence Vict, V21, P167, DOI 10.1891/088667006780644226; Smith SG, 2017, NATL INTIMATE PARTNE; Thomson G.E., 2006, EXAMINING HLTH DISPA; U.S. Census Bureau, 2016, POP HOUS UN EST; Wallis AB, 2010, HEALTH CARE WOMEN IN, V31, P113, DOI 10.1080/07399330903042815; Zhang Z A Infante M Meit N English M Dunn and K H Bowers, 2008, ANAL MENTAL HLTH SUB; Zhu MT, 2013, ANN EPIDEMIOL, V23, P377, DOI 10.1016/j.annepidem.2013.04.001	65	8	8	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0184222	10.1371/journal.pone.0184222	http://dx.doi.org/10.1371/journal.pone.0184222			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG2YO	28886119	gold, Green Published, Green Submitted			2023-01-03	WOS:000410001100084
J	Petersen, A; Held, N; Heide, L				Petersen, Albert; Held, Nadja; Heide, Lutz		Difam-EPN Minilab Survey Grp	Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab	PLOS ONE			English	Article							THIN-LAYER-CHROMATOGRAPHY; SUB-SAHARAN AFRICA; QUALITY; ANTIMALARIAL; MALAWI; DRUGS	Background Substandard and falsified medical products present a serious threat to public health, especially in low-and middle-income countries. Their identification using pharmacopeial analysis is expensive and requires sophisticated equipment and highly trained personnel. Simple, low-cost technologies are required in addition to full pharmacopeial analysis in order to accomplish widespread routine surveillance for poor-quality medicines in low-and middle-income countries. Methods Ten faith-based drug supply organizations in seven countries of Africa and Asia were each equipped with a Minilab of the Global Pharma Health Fund (GPHF, Frankfurt, Germany), suitable for the analysis of about 85 different essential medicines by thin-layer chromatography. Each organization was asked to collect approximately 100 medicine samples from private local medicine outlets, especially from the informal sector. The medicine samples were tested locally according to the Minilab protocols. Medicines which failed Minilab testing were subjected to confirmatory analysis in a WHO-prequalified medicine quality control laboratory in Kenya. Results Out of 869 medicine samples, 21 were confirmed to be substandard or falsified medical products. Twelve did not contain the stated active pharmaceutical ingredient (API), six contained insufficient amounts of the API, and three showed insufficient dissolution of the API. The highest proportion of substandard and falsified medicines was found in Cameroon (7.1%), followed by the Democratic Republic of Congo (2.7%) and Nigeria (1.1%). Antimalarial medicines were most frequently found to be substandard or falsified (9.5% of all antimalarials). Thin-layer chromatography according to the Minilab protocols was found to be specific and reproducible in the identification of medicines which did not contain the stated API. Since only samples which failed Minilab testing were subjected to confirmatory testing using pharmacopeial methods, this study did not assess the sensitivity of the Minilab methodology in the detection of substandard medicines, and may underestimate the prevalence of poor-quality medicines. Conclusions Surveillance for poor-quality medicines can be carried out by local organizations in low-and middle-income countries using a simple, low-cost technology. Such surveillance can identify an important subgroup of the circulating substandard and falsified medical products and can help to prevent them from causing harm in patients. A collaboration of the national drug regulatory authorities with faith-based organizations and other NGOs may therefore represent a promising strategy towards the Sustainable Development Goal of "ensuring access to quality medicines".	[Petersen, Albert] Difam German Inst Med Mission, Tubingen, Germany; [Held, Nadja; Heide, Lutz] Eberhard Karls Univ Tubingen, Inst Pharmaceut, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Petersen, A (corresponding author), Difam German Inst Med Mission, Tubingen, Germany.; Heide, L (corresponding author), Eberhard Karls Univ Tubingen, Inst Pharmaceut, Tubingen, Germany.	petersen.amh@difaem.de; heide@uni-tuebingen.de		Heide, Lutz/0000-0001-7809-7453	Brot fur die Welt, Berlin, Germany (grant title: Starkung kirchlicher Gesundheitssysteme in Afrika und Asien mit einem Schwerpunkt in der Pharmazeutischen Entwicklungszusammenarbeit.); Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen; Deutsche Forschungsgemeinschaft; University of Tubingen	Brot fur die Welt, Berlin, Germany (grant title: Starkung kirchlicher Gesundheitssysteme in Afrika und Asien mit einem Schwerpunkt in der Pharmazeutischen Entwicklungszusammenarbeit.); Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Tubingen	This study was financially supported by Brot fur die Welt, Berlin, Germany (grant title: Starkung kirchlicher Gesundheitssysteme in Afrika und Asien mit einem Schwerpunkt in der Pharmazeutischen Entwicklungszusammenarbeit.) We acknowledge support for open access publication by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of University of Tubingen.	Almuzaini T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002923; ATTARAN A, 2012, BMJ-BRIT MED J, V345, DOI DOI 10.1136/BMJ.E7381; Fernandez FM, 2011, ANALYST, V136, P3073, DOI 10.1039/c0an00627k; Global Pharma Health Fund, SIMPL DRUG QUAL VER; Global Pharma Health Fund, EX COUNT MED; Green MD, 2007, J PHARMACEUT BIOMED, V43, P105, DOI 10.1016/j.jpba.2006.06.047; Hajjou M, 2015, AM J TROP MED HYG, V92, P68, DOI 10.4269/ajtmh.14-0535; Hamburg Margaret, 2015, Am J Trop Med Hyg, V92, P1, DOI 10.4269/ajtmh.15-0046; Jahnke R, 2008, CONCISE QUALITY CONT, V1; Jahnke R., 2008, CONCISE QUALITY CONT, VII; Jahnke RW, 2004, PHARM IND, V66, P1187; Jahnke RWO, CONCISE QUALITY CONT, V2; Kaur H, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1096-x; Kaur H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125577; Kelesidis T, 2015, CLIN MICROBIOL REV, V28, P443, DOI 10.1128/CMR.00072-14; Khuluza F, 2017, AM J TROP MED HYG, V96, P1124, DOI 10.4269/ajtmh.16-1008; Khuluza F, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1259-9; Nayyar GML, 2015, AM J TROP MED HYG, V92, P2, DOI 10.4269/ajtmh.15-0221; Nayyar GML, 2012, LANCET INFECT DIS, V12, P488, DOI 10.1016/S1473-3099(12)70064-6; Newton PN, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000052; Pribluda VS, 2014, PHARM REGUL AFF OPEN, V3, P1; Ravinetto RM, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3618; Renschler JP, 2015, AM J TROP MED HYG, V92, P119, DOI 10.4269/ajtmh.14-0725; Risha PG, 2008, HEALTH POLICY, V87, P217, DOI 10.1016/j.healthpol.2007.12.010; Sarbartova JT, 2011, SURVEY QUALITY SELEC, P1; Tipke M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-95; Tshilumba PM, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.318.7302; United Nations Department of Economic and Social Affairs, 2014, NON TRADITIONAL REF; WHO, 2016, WHO TECH REP SER, V996, P1; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, DRUG AL NO 132 FALS; World Health Organization, ASS MED SYST SUBS AF; World Health Organization, 2017, WHO EXC BOARD 140 SE; World Health Organization (WHO), 2017, ATC DDD IND 2017; World Health Organization (WHO), 2016, LIST PREQ QUAL CONTR; World Health Organization (WHO), 2016, LIST PREQ MED PROD; Yu H, 2016, J PHARMACEUT BIOMED, V125, P85, DOI 10.1016/j.jpba.2016.03.018	37	38	38	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184165	10.1371/journal.pone.0184165	http://dx.doi.org/10.1371/journal.pone.0184165			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877208	Green Published, gold, Green Submitted			2023-01-03	WOS:000409391200068
J	Wilkinson, ST; Sanacora, G				Wilkinson, Samuel T.; Sanacora, Gerard			Considerations on the Off-label Use of Ketamine as a Treatment forMood Disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wilkinson, Samuel T.; Sanacora, Gerard] Yale Sch Med, Dept Psychiat, 100 York St,Ste 2J, New Haven, CT 06511 USA; [Wilkinson, Samuel T.; Sanacora, Gerard] Yale New Haven Hlth, Yale Psychiat Hosp, New Haven, CT USA	Yale University; Yale University	Sanacora, G (corresponding author), Yale Sch Med, Dept Psychiat, 100 York St,Ste 2J, New Haven, CT 06511 USA.	gerard.sanacora@yale.edu	Sanacora, Gerard/AAF-1135-2019; Wilkinson, Samuel/GQP-1952-2022		National Institute of Mental Health [T32MH062994-15]; Brain and Behavior Research Foundation; Robert F. Leet and Clara Guthrie Patterson Trust; State of Connecticut Department of Mental Health and Additive Services; Pfeiffer Research Foundation; Yale New Haven Hospital; National Center for Posttraumatic Stress Disorder; Allergan; Alkermes; AstraZeneca; Avanier Pharmaceuticals; BioHaven Pharmaceuticals; Hoffmann-La Roche; Janssen; Merck; Naurex; Novartis; Noven Pharmaceuticals; Sage Pharmaceuticals; Servier Pharmaceuticals; Taisho Pharmaceuticals; Teva; Valeant; Vistagen Therapeutics; Bristol-Myers Squibb; Eli Lilly; Johnson Johnson; Servier; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH062994] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Brain and Behavior Research Foundation; Robert F. Leet and Clara Guthrie Patterson Trust; State of Connecticut Department of Mental Health and Additive Services; Pfeiffer Research Foundation; Yale New Haven Hospital; National Center for Posttraumatic Stress Disorder; Allergan(AbbVieAllergan); Alkermes; AstraZeneca(AstraZeneca); Avanier Pharmaceuticals; BioHaven Pharmaceuticals; Hoffmann-La Roche(Hoffmann-La Roche); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Naurex; Novartis(Novartis); Noven Pharmaceuticals; Sage Pharmaceuticals; Servier Pharmaceuticals(Servier); Taisho Pharmaceuticals; Teva(Teva Pharmaceutical Industries); Valeant; Vistagen Therapeutics; Bristol-Myers Squibb(Bristol-Myers Squibb); Eli Lilly(Eli Lilly); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Servier(Servier); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Both authors have completed and submitted the ICMJE Formfor Disclosure of Potential Conflicts of Interest. Dr Wilkinson receives research and salary support fromthe National Institute of Mental Health (T32MH062994-15), the Brain and Behavior Research Foundation, and the Robert F. Leet and Clara Guthrie Patterson Trust. Dr Sanacora acknowledges the support of the State of Connecticut Department of Mental Health and Additive Services, the Brain and Behavior Research Foundation, the Pfeiffer Research Foundation, Yale New Haven Hospital, and the National Center for Posttraumatic Stress Disorder. Over the last 36 months, Dr Sanacora has received consulting fees from Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, BioHaven Pharmaceuticals, Hoffmann-La Roche, Janssen, Merck, Naurex, Novartis, Noven Pharmaceuticals, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffmann-La Roche, Merck, Naurex, and Servier over the last 36 months. Contracts with Johnson & Johnson are related to the development of esketamine, a proprietary compound that is an enantiomer of racemic ketamine, as an antidepressant. No-cost medication was provided to Dr Sanacora for a National Institutes of Health-sponsored study by Sanofi-Aventis. In addition, he holds shares in BioHaven Pharmaceuticals Holding Company and is a coinventor on a patent (Glutamate agents in the treatment of mental disorders, No. 8778979).	Fava M, 2017, ANN M AM SOC CLIN PH; Newport DJ, 2015, AM J PSYCHIAT, V172, P950, DOI 10.1176/appi.ajp.2015.15040465; Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080; Singh JB, 2016, AM J PSYCHIAT, V173, P816, DOI 10.1176/appi.ajp.2016.16010037; Su TP, 2017, NEUROPSYCHOPHARMACOL, V42, P2482, DOI 10.1038/npp.2017.94; Vuyk J, 2015, MILLERS ANESTHESIA, V8th, P854; Wilkinson ST, 2017, AM J PSYCHIAT, V174, P695, DOI 10.1176/appi.ajp.2017.17020239	7	21	22	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 5	2017	318	9					793	794		10.1001/jama.2017.10697	http://dx.doi.org/10.1001/jama.2017.10697			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF7GE	28806440	Green Accepted			2023-01-03	WOS:000409183700006
J	Reck, M; Rabe, KF				Reck, Martin; Rabe, Klaus F.			Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; PLATINUM-BASED CHEMOTHERAPY; OPEN-LABEL; EGFR MUTATIONS; 1ST-LINE TREATMENT; DOUBLE-BLIND; 8TH EDITION; PHASE-III; MULTICENTER; CRIZOTINIB		[Reck, Martin; Rabe, Klaus F.] LungenClin Grosshansdorf, Grosshansdorf, Germany; [Reck, Martin; Rabe, Klaus F.] Airway Res Ctr North, Grosshansdorf, Germany; [Reck, Martin; Rabe, Klaus F.] German Ctr Lung Res, Giessen, Germany; [Reck, Martin] Univ Lubeck, Lubeck, Germany; [Rabe, Klaus F.] Christian Albrechts Univ Kiel, Kiel, Germany	Grosshansdorf Hospital; University of Lubeck; University of Kiel	Reck, M (corresponding author), LungenClin Grosshansdorf, Dept Thorac Oncol, Woehrendamm 80, D-22927 Grosshansdorf, Germany.	m.reck@lungenclinic.de	Reck, Martin/ABF-5721-2020; Rabe, Klaus F./AAW-6296-2021	Reck, Martin/0000-0002-5348-4462; Rabe, Klaus F./0000-0002-7020-1401				[Anonymous], 2016, GUID NONS CELL LUNG; [Anonymous], 2013, GLOBOCAN 2012 V1 0 C; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Cortot AB, 2016, J CLIN ONCOL S, V34; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Dagogo-Jack I, 2016, ANN ONCOL, V27, P42, DOI 10.1093/annonc/mdw305; Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205; Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Folch E, 2015, TRANSL LUNG CANCER R, V4, P392, DOI 10.3978/j.issn.2218-6751.2015.08.02; Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Islam S, 2013, CANCER J, V19, P208, DOI 10.1097/PPO.0b013e318295185f; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Janne PA, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.46; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Langer CJ, 2016, J THORAC ONCOL, V11, P2066, DOI 10.1016/j.jtho.2016.08.138; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Lee CK, 2015, J CLIN ONCOL, V33, P1958, DOI 10.1200/JCO.2014.58.1736; Lee KJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091893; Li M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037229; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Navani N, 2015, LANCET RESP MED, V3, P282, DOI 10.1016/S2213-2600(15)00029-6; Nokihara H, 2016, J CLIN ONCOL S, V34; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Paz-Ares L, 2016, ANN ONCOL, V27, P1573, DOI 10.1093/annonc/mdw214; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2; Rimm DL, 2017, JAMA ONCOL; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rivera GA, 2016, ADV EXP MED BIOL, V893, P43, DOI 10.1007/978-3-319-24223-1_3; Sahgal A, 2015, INT J RADIAT ONCOL, V91, P710, DOI 10.1016/j.ijrobp.2014.10.024; Schwartz AG, 2016, ADV EXP MED BIOL, V893, P21, DOI 10.1007/978-3-319-24223-1_2; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Silvestri GA, 2017, CHEST S, V143; Socinski M, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.39; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Soria JC, 2013, ANN ONCOL, V24, P20, DOI 10.1093/annonc/mds590; Soria JC, 2017, LANCET, V389, P917, DOI 10.1016/S0140-6736(17)30123-X; Soria JC, 2015, LANCET ONCOL, V16, P897, DOI 10.1016/S1470-2045(15)00006-6; Suda K, 2010, CANCER METAST REV, V29, P49, DOI 10.1007/s10555-010-9209-4; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Travis W.D, 2015, WHO CLASSIFICATION T, V4; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; van Eijk R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017791; Vilmann P, 2015, ENDOSCOPY, V47, P546, DOI 10.1055/s-0034-1392040; Yang JCH, 2015, LANCET ONCOL, V16, P830, DOI 10.1016/S1470-2045(15)00026-1; Yi CA, 2008, RADIOLOGY, V248, P632, DOI 10.1148/radiol.2482071822; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhou CC, 2015, J CLIN ONCOL, V33, P2197, DOI 10.1200/JCO.2014.59.4424	68	427	446	2	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	2017	377	9					849	861		10.1056/NEJMra1703413	http://dx.doi.org/10.1056/NEJMra1703413			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF0YG	28854088				2023-01-03	WOS:000408626400008
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: In support of acute internal medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												Davidoliver372@googlemail.com						Jones M., 2016, HOSP J, V358, P45; Kar P., 2017, FULL CIRCLE; NHS Improvement, 2017, GOOD PRACT GUID FOC; Oliver David, 2016, Future Hosp J, V3, P49, DOI 10.7861/futurehosp.3-1-49; Oliver D, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1684; Ross Calum N, 2017, Future Healthc J, V4, P151, DOI 10.7861/futurehosp.4-2-151a; Royal College of Physicians, 2016, 2015 16 CENS UK CONS; Royal College of Physicians, 2014, SPEC SPOTTL AC INT M; Royal College of Physicians, 2017, MED CARE	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	2017	358								j3832	10.1136/bmj.j3832	http://dx.doi.org/10.1136/bmj.j3832			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE5BX	28811277	Green Published, Bronze			2023-01-03	WOS:000408228100003
J	Fang, XC; Xie, HY; Duan, HY; Li, P; Yousaf, M; Xu, HY; Yang, YL; Wang, C				Fang, Xiaocui; Xie, Hanyi; Duan, Hongyang; Li, Ping; Yousaf, Maryam; Xu, Haiyan; Yang, Yanlian; Wang, Chen			Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; CHEMOKINE RECEPTOR CXCR4; CANCER METASTASIS; DRUG-DELIVERY; MICELLES; EXPRESSION; TUMORS; THERAPEUTICS; NETWORKS; CELLS	Cancer is the leading cause of death worldwide, and metastasis is the main attribute to cancer death. CXCR4 and its natural ligand CXCL12 have been known to play a critical role in tumorigenesis, angiogenesis and metastasis. Therefore, designing a new CXCR4 antagonist to prevent tumor metastasis will be of great significance. Herein, a novel chemically synthesized peptide (E5) that has an ability to target CXCR4/CXCL12 axis was loaded in micelle glycol-phosphatidylethanolamine (PEG-PE) block copolymer to form micelle-encapsulated E5 (M-E5). We demonstrated that M-E5 exhibited higher affinity for CXCR4-overexpressing MCF-7 and HepG2 tumor cells as compared to free E5, and efficiently inhibited the tumor cells migration. Mechanistic studies implied that PEG-PE micelle can encapsulate E5 and improve E5 targeting efficiency for CXCR4 by accumulating E5 on the tumor cell membrane. Furthermore, through encapsulation of chemotherapeutic drug doxorubicin (Dox) in PEG-PE micelle, we proved that PEG-PE micelle could serve as a co-carrier for both E5 and Dox (M-E5-Dox). M-E5 enhanced the efficiency of Dox by down-regulating the phosphorylation level of Akt, Erk and p38/MAPK proteins. In conclusion, PEG-PE micelle demonstrated a promising delivery system for E5, and M-E5 is expected to be a potential therapeutic agent that will help to improve the clinical benefits in current therapies used for solid tumors.	[Fang, Xiaocui; Duan, Hongyang; Yousaf, Maryam; Yang, Yanlian] Natl Ctr Nanosci & Technol Beijing, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing, Peoples R China; [Xie, Hanyi; Li, Ping; Wang, Chen] Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China; [Xu, Haiyan] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China; [Xu, Haiyan] Peking Union Med Coll, Beijing, Peoples R China	Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Yang, YL (corresponding author), Natl Ctr Nanosci & Technol Beijing, CAS Ctr Excellence Nanosci, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing, Peoples R China.; Wang, C (corresponding author), Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing, Peoples R China.; Xu, HY (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China.; Xu, HY (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	xuhy@pumc.edu.cn; yangyl@nanoctr.cn; wangch@nanoctr.cn	Yousaf, Maryam/AAH-2654-2020		Chinese Academy of Sciences [XDA09030306, XDA09040300]; Chinese Postdoctoral Science Foundation [Y6791Z11GJ]	Chinese Academy of Sciences(Chinese Academy of Sciences); Chinese Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was financially supported by the Strategic Priority Research Program of Chinese Academy of Sciences (Grant No. XDA09030306, recipient:Y.Y., and XDA09040300, recipient:C.W.) and the Chinese Postdoctoral Science Foundation (Y6791Z11GJ, recipient:X.F.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Aryal S, 2010, ACS NANO, V4, P251, DOI 10.1021/nn9014032; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Debnath B, 2013, THERANOSTICS, V3, P47, DOI 10.7150/thno.5376; Gao ZG, 2002, NANO LETT, V2, P979, DOI 10.1021/nl025604a; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kaspar AA, 2013, DRUG DISCOV TODAY, V18, P807, DOI 10.1016/j.drudis.2013.05.011; Kryczek I, 2005, CANCER RES, V65, P465; Li XJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16228; LI XM, 2014, SCI REP UK, V4; Lou CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050956; Markovic SN, 2007, MAYO CLIN PROC, V82, P364; Mendoza M, 2009, INT J BIOCHEM CELL B, V41, P1452, DOI 10.1016/j.biocel.2009.01.015; Monk BJ, 2014, LANCET ONCOL, V15, P799, DOI 10.1016/S1470-2045(14)70244-X; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Pienta KJ, 2013, CLIN CANCER RES, V19, P5849, DOI 10.1158/1078-0432.CCR-13-2158; Pu X, 2017, APOPTOSIS, V22, P357, DOI 10.1007/s10495-016-1323-5; Qin L, 2013, J CONTROL RELEASE, V171, P133, DOI 10.1016/j.jconrel.2013.07.005; Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101; Shim H, 2009, SEMIN CANCER BIOL, V19, P123, DOI 10.1016/j.semcancer.2008.11.004; Tang N, 2007, JNCI-J NATL CANCER I, V99, P1004, DOI 10.1093/jnci/djm027; Tavor S, 2010, SEMIN CANCER BIOL, V20, P178, DOI 10.1016/j.semcancer.2010.07.001; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torchilin Vladimir P., 2005, Current Drug Delivery, V2, P319, DOI 10.2174/156720105774370221; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100; Vaquero J, 2017, J HEPATOL, V66, P424, DOI 10.1016/j.jhep.2016.09.010; Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009; Wang J, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0309; Wang J, 2012, ACS NANO, V6, P5018, DOI 10.1021/nn300571c; Wang J, 2012, J CONTROL RELEASE, V160, P637, DOI 10.1016/j.jconrel.2012.02.021; Wang YG, 2010, PHARM RES-DORDR, V27, P361, DOI 10.1007/s11095-009-0029-6; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wei XL, 2012, PHARM RES-DORDR, V29, P1977, DOI 10.1007/s11095-012-0725-5; Yuan QA, 2010, BIOMACROMOLECULES, V11, P1940, DOI 10.1021/bm100589g; Zhu XL, 2016, INT J ONCOL, V48, P2321, DOI 10.3892/ijo.2016.3485	39	5	6	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2017	12	8							e0182697	10.1371/journal.pone.0182697	http://dx.doi.org/10.1371/journal.pone.0182697			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC9YJ	28793338	gold, Green Published, Green Submitted			2023-01-03	WOS:000407196700060
J	Choi, CY; Park, JS; Yoon, KT; Gil, HW; Lee, EY; Hong, SY				Choi, Chi-Young; Park, Jae Seok; Yoon, Kyu Tae; Gil, Hyo Wook; Lee, Eun Young; Hong, Sae Yong			Intra-dialytic hypertension is associated with high mortality in hemodialysis patients	PLOS ONE			English	Article							BLOOD-PRESSURE; INTRADIALYTIC HYPERTENSION; DIETARY POTASSIUM; DIALYSIS; ERYTHROPOIETIN; PREVALENCE	Background Intra-dialytic hypertension (IDH) is emerging as an important issue in hemodialysis patients. Its risk factors and clinical outcomes are unclear. Methods A total of 73 prevalent hemodialysis patients were enrolled. They included 14 (19.2%) patients with baseline IDH and 59 patients without IDH. Their clinical parameters, laboratory parameters, and mortality were investigated over 78 months. Results The risks factor of IDH included low serum potassium levels, low ultrafiltration, and low arm muscle area. Lower median survival was evident in the IDH group compared to the non-IDH group, but was not significantly different. After adjusting for relevant confounders for age, the IDH group displayed 2.846 times higher mortality rate than the non-IDH Group (adjusted hazard ratio: 2.846; 95% confidence interval: 1.081-7.490; P = 0.034). Conclusion IDH is associated with high mortality in hemodialysis patients. Clinicians should be aware of the risk factors. Future research studies are needed to explore the mechanisms involved in the association between IDH and mortality.	[Choi, Chi-Young; Park, Jae Seok; Yoon, Kyu Tae; Gil, Hyo Wook; Lee, Eun Young; Hong, Sae Yong] Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea	Soonchunhyang University	Lee, EY (corresponding author), Soonchunhyang Univ, Cheonan Hosp, Dept Internal Med, Cheonan, South Korea.	eylee@sch.ac.kr	Lee, Eun Young/Q-6592-2019	Lee, Eun Young/0000-0002-4513-9888; hong, saeyong/0000-0001-7854-3871	National Research Foundation of Korea (NRF) - Ministry of Education [2015R1A6A1A03032522]; Soonchunhyang University	National Research Foundation of Korea (NRF) - Ministry of Education; Soonchunhyang University	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1A6A1A03032522) and Soonchunhyang University Research Fund.; This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1A6A1A03032522) and Soonchunhyang University Research Fund.	ABRAHAM PA, 1991, J AM SOC NEPHROL, V2, P927; Amerling R, 1995, CLIN DIALYSIS, V3, P235; Ando K, 2010, CURR VASC PHARMACOL, V8, P59, DOI 10.2174/157016110790226561; Azadbakht L, 2005, DIABETES CARE, V28, P2823, DOI 10.2337/diacare.28.12.2823; Bazzato G, 1983, CONTRIBUTIONS NEPHRO, V41, P292; BodeBoger SM, 1996, KIDNEY INT, V50, P1255, DOI 10.1038/ki.1996.435; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; Chou KJ, 2006, KIDNEY INT, V69, P1833, DOI 10.1038/sj.ki.5000266; CIRIT M, 1995, NEPHROL DIAL TRANSPL, V10, P1417; Dwyer JT, 2002, J RENAL NUTR, V12, P213, DOI 10.1053/jren.2002.35297; Fellner SK, 1993, SEMINARS DIALYSIS; Foley RN, 1998, J NEPHROL, V11, P239; FUJITA T, 1984, HYPERTENSION, V6, P184, DOI 10.1161/01.HYP.6.2_Pt_1.184; Grekas D, 2000, CLIN NEPHROL, V53, P164; Inrig JK, 2007, KIDNEY INT, V71, P454, DOI 10.1038/sj.ki.5002077; Inrig JK, 2011, CLIN J AM SOC NEPHRO, V6, P2016, DOI 10.2215/CJN.11351210; Inrig JK, 2010, AM J KIDNEY DIS, V55, P580, DOI 10.1053/j.ajkd.2009.08.013; Kopple JD, 2001, AM J KIDNEY DIS, V37, pS66, DOI 10.1053/ajkd.2001.20748; LAWTON WJ, 1990, CIRCULATION, V81, P173, DOI 10.1161/01.CIR.81.1.173; Levin NW, 1993, SEMINARS DIALYSIS; Movilli E, 2013, AM J NEPHROL, V38, P413, DOI 10.1159/000355974; POULTER NR, 1985, CLIN EXP PHARMACOL P, V12, P211, DOI 10.1111/j.1440-1681.1985.tb02633.x; Raj DSC, 2002, KIDNEY INT, V61, P697, DOI 10.1046/j.1523-1755.2002.00150.x; Sarkar SR, 2005, CLIN DIALYSIS, V4, P237; Seok Su Jin, 2010, Korean Journal of Internal Medicine, V25, P188, DOI 10.3904/kjim.2010.25.2.188; Tayyem RF, 2008, J RENAL NUTR, V18, P202, DOI 10.1053/j.jrn.2007.10.001; Van Buren PN, 2012, INT J ARTIF ORGANS, V35, P1031, DOI 10.5301/ijao.5000126	27	2	4	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2017	12	7							e0181060	10.1371/journal.pone.0181060	http://dx.doi.org/10.1371/journal.pone.0181060			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8DV	28742805	Green Published, Green Submitted, gold			2023-01-03	WOS:000406370000021
J	Steinborn, C; Klemd, AM; Sanchez-Campillo, AS; Rieger, S; Scheffen, M; Sauer, B; Garcia-Kaufer, M; Urech, K; Follo, M; Ucker, A; Kienle, GS; Huber, R; Grundemann, C				Steinborn, Carmen; Klemd, Amy Marisa; Sanchez-Campillo, Ann-Sophie; Rieger, Sophie; Scheffen, Marieke; Sauer, Barbara; Garcia-Kaeufer, Manuel; Urech, Konrad; Follo, Marie; Uecker, Annekathrin; Kienle, Gunver Sophia; Huber, Roman; Gruendemann, Carsten			Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN DENDRITIC CELLS; PANCREATIC-CANCER; MISTLETOE; MATURATION; ACTIVATION; THERAPY; LECTINS; STIMULATION; INHIBITION	Tumor cells have the capacity to secrete immunosuppressive substances in order to diminish dendritic cell (DC) activity and thereby escape from immune responses. The impact of mistletoe (Viscum album) extracts (VAE), which are frequently used as an additive anti-cancer therapy to stimulate the immune response, is still unknown. Using a human cellular system, the impact of two different VAE (VAEA + VAEI) on the maturation of human dendritic cells and on T cell function has been investigated using flow cytometry, automated fluorescence microscopy and cytokine bead array assays. Furthermore, we examined whether VAEI was able to counteract tumor-induced immunosuppression within this cellular system using a renal cancer cell model. The role of mistletoe lectin (ML) was analyzed using ML-specific antibodies and ML-depleted VAEI. VAEI and VAEA augmented the maturation of dendritic cells. VAEI abrogated tumor-induced immunosuppression of dendritic cells and both processes were partially mediated by ML since ML-depleted VAEI and ML-specific antibodies almost neutralized the rehabilitative effects of VAEI on DC maturation. Using these settings, co-culture experiments with purified CD4(+) T cells had no influence on T cell proliferation and activation but did have an impact on IFN-Upsilon secretion. The study provides a potential mode-of-action of VAE as an additive cancer therapy based on immunomodulatory effects. However, the impact on the in vivo situation has to be evaluated in further studies.	[Steinborn, Carmen; Klemd, Amy Marisa; Sanchez-Campillo, Ann-Sophie; Rieger, Sophie; Scheffen, Marieke; Sauer, Barbara; Garcia-Kaeufer, Manuel; Uecker, Annekathrin; Kienle, Gunver Sophia; Huber, Roman; Gruendemann, Carsten] Univ Freiburg, Ctr Complementary Med, Inst Infect Prevent & Hosp Epidemiol, Fac Med, Freiburg, Germany; [Urech, Konrad] Verein Krebsforsch, Arlesheim, Switzerland; [Follo, Marie] Univ Freiburg, Lighthouse Core Facil, Dept Med 1, Med Ctr,Fac Med, Freiburg, Germany	University of Freiburg; University of Freiburg	Grundemann, C (corresponding author), Univ Freiburg, Ctr Complementary Med, Inst Infect Prevent & Hosp Epidemiol, Fac Med, Freiburg, Germany.	carsten.gruendemann@uniklinik-freiburg.de	Garcia-Käufer, Manuel/AAF-8340-2020	Follo, Marie/0000-0002-3090-7442	Software AG foundation; DAMUSDONATA e.V.; Iscador AG; ABNOBA GmbH; Verein zur Forderung der Naturheilkunde am Universitatsklinikum Freiburg e.V.	Software AG foundation; DAMUSDONATA e.V.; Iscador AG; ABNOBA GmbH; Verein zur Forderung der Naturheilkunde am Universitatsklinikum Freiburg e.V.	CG and CS have been financed by the Software AG foundation and DAMUSDONATA e.V.. The study was kindly financially supported by the Iscador AG, ABNOBA GmbH and the Verein zur Forderung der Naturheilkunde am Universitatsklinikum Freiburg e.V. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bantel H, 1999, CANCER RES, V59, P2083; Chen X, 2017, ONCOTARGET, P5; Elluru SR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-161; Frantz M, 2000, ARZNEIMITTEL-FORSCH, V50, P471; FRANZ H, 1986, ONCOLOGY, V43, P23, DOI 10.1159/000226417; Fricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Horneber MA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003297.pub2; Huber R, 2005, EUR J MED RES, V10, P411; Huber Roman, 2006, J Soc Integr Oncol, V4, P3; Huber R, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-116; Hubo M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00082; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; JAGGY C, 1995, ARZNEIMITTEL-FORSCH, V45-2, P905; Kelter G, 2007, ANTICANCER RES, V27, P223; Kienle GS, 2010, INTEGR CANCER THER, V9, P142, DOI 10.1177/1534735410369673; Lechmann M, 2002, INT ARCH ALLERGY IMM, V129, P113, DOI 10.1159/000065883; Oosterhoff D, 2012, ONCOIMMUNOLOGY, V1, P649, DOI 10.4161/onci.20365; Podlech O, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/501796; Rostock M, 2005, ANTICANCER RES, V25, P1969; Saha C, 2016, MOLECULES, V21, DOI 10.3390/molecules21070912; Schad F, 2014, INTEGR CANCER THER, V13, P332, DOI 10.1177/1534735413513637; Seifert G, 2008, CANCER LETT, V264, P218, DOI 10.1016/j.canlet.2008.01.036; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Sombroek CC, 2002, J IMMUNOL, V168, P4333, DOI 10.4049/jimmunol.168.9.4333; Stein GM, 2002, ANTICANCER RES, V22, P4215; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Takahashi A, 2004, CANCER IMMUNOL IMMUN, V53, P543, DOI 10.1007/s00262-003-0466-8; Troger W, 2013, EUR J CANCER, V49, P3788, DOI 10.1016/j.ejca.2013.06.043; Troy AJ, 1998, CLIN CANCER RES, V4, P585; Urech K, 2006, ARZNEIMITTEL-FORSCH, V56, P428; Valentiner U, 2002, TOXICOLOGY, V171, P187, DOI 10.1016/S0300-483X(01)00581-9; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Webster R, 2014, NAT REV DRUG DISCOV, V13, P883, DOI 10.1038/nrd4476	35	20	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2017	12	7							e0181553	10.1371/journal.pone.0181553	http://dx.doi.org/10.1371/journal.pone.0181553			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3RW	28719632	gold, Green Published			2023-01-03	WOS:000406061400055
J	Mihoubi, W; Sahli, E; Gargouri, A; Amiel, C				Mihoubi, Wafa; Sahli, Emna; Gargouri, Ali; Amiel, Caroline			FTIR spectroscopy of whole cells for the monitoring of yeast apoptosis mediated by p53 over-expression and its suppression by Nigella sativa extracts	PLOS ONE			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; RADIATION-INDUCED APOPTOSIS; SACCHAROMYCES-CEREVISIAE; IR SPECTROSCOPY; FATTY-ACID; HL60 CELLS; MICROSPECTROSCOPY; DEATH; STRESS; IDENTIFICATION	p53 over expression in yeast results in cell death with typical markers of apoptosis such as DNA fragmentation and phosphatidylserine externalization. We aimed to substitute/ supplement classical fluorescent techniques (TUNEL, Annexin V, ROS detection) usually used to detect biochemical changes occurring during yeast apoptosis mediated by p53 over expression and the effect of anti-apoptotic purified molecules from Nigel (Nigella sativa) extracts on these same yeasts by the label free technique of FTIR spectroscopy. The comparison of the entire IR spectra highlighted clear modifications between apoptotic p53-expressing yeasts and normal ones. More precisely, DNA damage was detected by the decrease of band intensities at 1079 and 1048 cm(-1). While phosphatidylserine exposure was followed by the increase of.sCH(2) and.asCH(2) bands of unsaturated fatty acids that were exhibited at 2855 and 2926 cm(-1), and the appearance of the C = O ester functional group band at 1740 cm(-1). In a second step, this FTIR approach was used to estimate the effect of a purified fraction of the Nigel extract. The modulation of band intensities specific to DNA and membrane status was in agreement with apoptosis supression in presence of the Nigel extracts. FTIR spectroscopy is thus proven to be a very reliable technique to monitor the apoptotic cell death in yeast and to be used as a means of evaluating the biomolecules effect on yeast survival.	[Mihoubi, Wafa; Sahli, Emna; Gargouri, Ali] Ctr Biotechnol Sfax, Lab Biotechnol Mol Eucaryotes, Sfax, Tunisia; [Amiel, Caroline] Univ Caen Normandie, Unite Rech Aliments Bioproc Toxicol Environm, EA 4651, Blvd Marechal Juin, Caen, France	Centre de Biotechnologie de Sfax; Universite de Sfax; Universite de Caen Normandie	Mihoubi, W (corresponding author), Ctr Biotechnol Sfax, Lab Biotechnol Mol Eucaryotes, Sfax, Tunisia.	fafani.mihoubi@yahoo.fr						Abbott GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049070; Amiel C, 2000, LAIT, V80, P445, DOI 10.1051/lait:2000137; Balzan R, 2004, MICROBIOL-SGM, V150, P109, DOI 10.1099/mic.0.26578-0; Bellisola G, 2012, AM J CANCER RES, V2, P1; BENEDETTI E, 1986, APPL SPECTROSC, V40, P39, DOI 10.1366/0003702864815565; BENEDETTI E, 1990, APPL SPECTROSC, V44, P1276, DOI 10.1366/000370290789619621; Cakmak G, 2006, AQUAT TOXICOL, V77, P53, DOI 10.1016/j.aquatox.2005.10.015; Carmona-Gutierrez D, 2010, CELL DEATH DIFFER, V17, P763, DOI 10.1038/cdd.2009.219; Casiano CA, 1998, CELL DEATH DIFFER, V5, P183, DOI 10.1038/sj.cdd.4400336; Cheung HY, 1999, MICROBIOL-SGM, V145, P1043, DOI 10.1099/13500872-145-5-1043; CHOO LP, 1993, BIOCHIM BIOPHYS ACTA, V1182, P333, DOI 10.1016/0925-4439(93)90078-F; Corte L, 2010, ANAL CHIM ACTA, V659, P258, DOI 10.1016/j.aca.2009.11.035; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; Diem M, 1999, APPL SPECTROSC, V53, p148A, DOI 10.1366/0003702991946712; Dixit VM, 1996, ADV EXP MED BIOL, V406, P113; Dogan A, 2007, APPL SPECTROSC, V61, P199, DOI 10.1366/000370207779947459; Erukhimovitch V, 2009, BIOPOLYMERS, V91, P61, DOI 10.1002/bip.21082; Ferreira P, 2014, FEMS YEAST RES, V14, P1006, DOI 10.1111/1567-1364.12189; Gao YF, 2015, MOL MED REP, V11, P2585, DOI 10.3892/mmr.2014.3088; Gasparri F, 2003, BIOCHEM J, V369, P239, DOI 10.1042/BJ20021021; Gaudenzi AS, 2004, CELL APOPTOSIS SPECI, V18, P415; Gault N, 2003, RADIAT RES, V160, P238, DOI 10.1667/RR3020.1; Gautam R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045521; Granot D, 2003, FEMS YEAST RES, V4, P7, DOI 10.1016/S1567-1356(03)00154-5; Griffiths P., 1986, FOURIER TRANSFORM IN; Guibet M, 2006, CARBOHYD RES, V341, P1859, DOI 10.1016/j.carres.2006.04.018; HELM D, 1991, J GEN MICROBIOL, V137, P69, DOI 10.1099/00221287-137-1-69; Jamin N, 2003, BIOPOLYMERS, V72, P366, DOI 10.1002/bip.10435; Jamin N, 1998, P NATL ACAD SCI USA, V95, P4837, DOI 10.1073/pnas.95.9.4837; Kamnev AA, 2005, J TRACE ELEM MED BIO, V19, P91, DOI 10.1016/j.jtemb.2005.03.002; Kendall C, 2009, ANALYST, V134, P1029, DOI 10.1039/b822130h; Lasch P, 2008, BIOMEDICAL VIBRATION, P79; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Liu KZ, 2007, BRIT J HAEMATOL, V136, P713, DOI 10.1111/j.1365-2141.2006.06474.x; Liu KZ, 2005, BLOOD CELL MOL DIS, V35, P404, DOI 10.1016/j.bcmd.2005.06.009; Liu KZ, 2001, J MOL STRUCT, V565, P299, DOI 10.1016/S0022-2860(00)00817-6; Ludovico P, 2001, MICROBIOL-SGM, V147, P2409, DOI 10.1099/00221287-147-9-2409; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mahmood MS, 2003, PHYTOTHER RES, V17, P921, DOI 10.1002/ptr.1251; MANTSCH HH, 1991, CHEM PHYS LIPIDS, V57, P213, DOI 10.1016/0009-3084(91)90077-O; Mantsch HH, 2002, VIB SPECTROSC, V30, P31, DOI 10.1016/S0924-2031(02)00036-X; Mecozzi M, 2007, VIB SPECTROSC, V44, P228, DOI 10.1016/j.vibspec.2006.11.006; Melin AM, 2001, ARCH BIOCHEM BIOPHYS, V394, P265, DOI 10.1006/abbi.2001.2533; Moen B, 2005, APPL ENVIRON MICROB, V71, P2086, DOI 10.1128/AEM.71.4.2086-2094.2005; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; NAUMANN D, 1991, NATURE, V351, P81, DOI 10.1038/351081a0; Perromat A, 2003, BIOPOLYMERS, V72, P207, DOI 10.1002/bip.10381; Portenier I, 2005, J ENDODONT, V31, P380, DOI 10.1097/01.don.0000145421.84121.c8; Pozzi D, 2007, RADIAT RES, V168, P698, DOI 10.1667/RR0991.1; Ryser S, 1999, CURR GENET, V36, P21, DOI 10.1007/s002940050468; Saharan RK, 2011, VIB SPECTROSC, V55, P85, DOI 10.1016/j.vibspec.2010.08.003; Sajbidor J, 1995, FOLIA MICROBIOL, V40, P508, DOI 10.1007/BF02814733; Sambrook J., MOL CLONING LAB MANU; Saulou C, 2010, ANAL BIOANAL CHEM, V396, P1441, DOI 10.1007/s00216-009-3316-5; Schultz CP, 1998, ONCOL RES, V10, P277; Scott CE, 1999, J CELL PHYSIOL, V181, P147, DOI 10.1002/(SICI)1097-4652(199910)181:1<147::AID-JCP15>3.0.CO;2-M; Singh JK, 1996, BBA-LIPID LIPID MET, V1304, P171, DOI 10.1016/S0005-2760(96)00134-8; Stehfest K, 2005, PLANT PHYSIOL BIOCH, V43, P717, DOI 10.1016/j.plaphy.2005.07.001; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Szeghalmi A, 2007, ANAL BIOANAL CHEM, V387, P1779, DOI 10.1007/s00216-006-0850-2; TAILLANDIER E, 1992, METHOD ENZYMOL, V211, P307; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toyran N, 2005, INT J RADIAT BIOL, V81, P911, DOI 10.1080/09553000600571022; van den Driesche S, 2013, SENSOR ACTUAT B-CHEM, V179, P150, DOI 10.1016/j.snb.2012.10.139; Wu B., 2015, DISCRETE DYN NAT SOC, V2015, P1, DOI DOI 10.1186/S12967-015-0468-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yacoubi-Hadj Amor I, 2008, FEMS YEAST RES, V8, P1, DOI DOI 10.1111/J.1567-1364.2008.00445; Yu CX, 2005, BIOPOLYMERS, V77, P368, DOI 10.1002/bip.20247; Zelig U, 2009, BIOPHYS J, V97, P2107, DOI 10.1016/j.bpj.2009.07.026; ZEROUAL W, 1995, PATHOL BIOL, V43, P300; Zhou JB, 2001, BIOTECHNOL APPL BIOC, V33, P127, DOI 10.1042/BA20000074	73	43	44	5	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2017	12	7							e0180680	10.1371/journal.pone.0180680	http://dx.doi.org/10.1371/journal.pone.0180680			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA7TK	28704406	Green Published, Green Submitted, gold			2023-01-03	WOS:000405649600042
J	Zhang, T; Li, J; Yin, F; Lin, B; Wang, Z; Xu, J; Wang, H; Zuo, D; Wang, G; Hua, Y; Cai, Z				Zhang, T.; Li, J.; Yin, F.; Lin, B.; Wang, Z.; Xu, J.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.			Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; BREAST-CANCER; TUMOR-METASTASIS; MALIGNANT-CELLS; EXPRESSION; ANGIOGENESIS; ACTIVATION; PATHWAY; OVEREXPRESSION; SPECIFICITY	Signal transducer and activator of transcription 3(STAT3) is an emerging target for cancer therapy. In this study, we identify Toosendanin (TSN) is an effective inhibitor of STAT3, leading to the impediment of various oncogenic processes in osteosarcoma. TSN selectively inactivates phospho-STAT3 (Tyr-705); subsequent molecular docking and in vitro SPR analysis uncover TSN directly binds to the SH2 domain of STAT3. Consequently, TSN blocks STAT3 dimerization and impairs the complex formation of STAT3 and epidermal growth factor receptor (EGFR). In an animal tumor model study, TSN is well tolerated, inhibits osteosarcoma growth and metastasis. In another osteosarcoma patient-derived xenografts (PDX) model, we find TSN triggers strong inhibitory effects on patient-derived tumors. Further studies show that TSN also displays activity against other solid tumors. Our preclinical work therefore supports that TSN acts as a novel inhibitor of STAT3 that blocks tumorigenesis in ostoesarcoma.	[Zhang, T.; Yin, F.; Wang, Z.; Hua, Y.; Cai, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China; [Zhang, T.; Yin, F.; Lin, B.; Wang, Z.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.] Shanghai Bone Tumor Inst, Shanghai, Peoples R China; [Li, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Inst Translat Med, Shanghai, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, Y; Cai, Z (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthopaed, 100 Haining Rd, Shanghai 200080, Peoples R China.	zhangtaoabc@2008.sina.com; hua_yingqi@163.com; czd856@vip.163.com			NSFC [81502604]; Shanghai Science and Technology Commission [14140904000]; Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine [BXJ201732]; Research Grant from Shanghai Hospital Development Center [SHDC12013107]	NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine; Research Grant from Shanghai Hospital Development Center	This work was supported by NSFC (81502604); Shanghai Science and Technology Commission (14140904000); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine (No. BXJ201732) and Research Grant from Shanghai Hospital Development Center (SHDC12013107).	Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f; Cao L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111928; Chun J, 2015, CANCER LETT, V357, P393, DOI 10.1016/j.canlet.2014.11.049; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fossey SL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-81; Haan S, 1999, J BIOL CHEM, V274, P1342, DOI 10.1074/jbc.274.3.1342; Hao WS, 2008, BIOORG MED CHEM LETT, V18, P4988, DOI 10.1016/j.bmcl.2008.08.032; Hayakawa F, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.63; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Li JJ, 2015, BRIT J PHARMACOL, V172, P3817, DOI 10.1111/bph.13165; Lu XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34225; Malaney P, 2014, CANCER LETT, V344, P1, DOI 10.1016/j.canlet.2013.10.010; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Nair RR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00030; Nakajima M, 1991, Semin Cancer Biol, V2, P115; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang JQ, 2014, BREAST CANCER RES TR, V148, P279, DOI 10.1007/s10549-014-3165-6; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang HY, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3640; ZHANG T, 2016, CELL DEATH DIS, V7; Zhang T, 2014, NEOPLASIA, V16, P665, DOI 10.1016/j.neo.2014.07.009; Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5; Zhang XL, 2013, CANCER RES, V73, P1922, DOI 10.1158/0008-5472.CAN-12-3175; Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001	43	81	84	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6627	6639		10.1038/onc.2017.270	http://dx.doi.org/10.1038/onc.2017.270			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783167	Green Published, hybrid			2023-01-03	WOS:000416049200011
J	Nissim, L; Wu, MR; Pery, E; Binder-Nissim, A; Suzuki, HI; Stupp, D; Wehrspaun, C; Tabach, Y; Sharp, PA; Lu, TK				Nissim, Lior; Wu, Ming-Ru; Pery, Erez; Binder-Nissim, Adina; Suzuki, Hiroshi I.; Stupp, Doron; Wehrspaun, Claudia; Tabach, Yuval; Sharp, Phillip A.; Lu, Timothy K.			Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy	CELL			English	Article							HUMAN TRANSCRIPTION FACTORS; TUMOR-CELLS; EXPRESSION; RECOGNITION; SENSITIVITY; PROFILES; PROMOTER; DATABASE	Despite its success in several clinical trials, cancer immunotherapy remains limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppression, and toxicity triggered by systemic delivery of potent immunomodulators. Here, we present a proof-of-concept immunomodulatory gene circuit platform that enables tumor-specific expression of immunostimulators, which could potentially overcome these limitations. Our design comprised de novo synthetic cancer-specific promoters and, to enhance specificity, an RNA-based AND gate that generates combinatorial immunomodulatory outputs only when both promoters are mutually active. These outputs included an immunogenic cell-surface protein, a cytokine, a chemokine, and a checkpoint inhibitor antibody. The circuits triggered selective T cell-mediated killing of cancer cells, but not of normal cells, in vitro. In in vivo efficacy assays, lentiviral circuit delivery mediated significant tumor reduction and prolonged mouse survival. Our design could be adapted to drive additional immunomodulators, sense other cancers, and potentially treat other diseases that require precise immunological programming.	[Nissim, Lior; Wu, Ming-Ru; Pery, Erez; Binder-Nissim, Adina; Wehrspaun, Claudia; Lu, Timothy K.] MIT, Elect Res Lab, Synthet Biol Grp, Cambridge, MA 02139 USA; [Suzuki, Hiroshi I.; Sharp, Phillip A.; Lu, Timothy K.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Stupp, Doron; Tabach, Yuval] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel; [Stupp, Doron; Tabach, Yuval] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; [Sharp, Phillip A.] MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Biol Engn, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Lu, Timothy K.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA; [Lu, Timothy K.] Harvard Univ, Biophys Program, Boston, MA 02115 USA; [Lu, Timothy K.] MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Hebrew University of Jerusalem; Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT)	Lu, TK (corresponding author), MIT, Elect Res Lab, Synthet Biol Grp, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Dept Biol Engn, Synthet Biol Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.; Lu, TK (corresponding author), Harvard Univ, Biophys Program, Boston, MA 02115 USA.; Lu, TK (corresponding author), MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	timlu@mit.edu	Tabach, Yuval/Q-8488-2019	Stupp, Doron/0000-0002-1556-666X; Suzuki, Hiroshi/0000-0003-4682-5086; Nissim, Lior/0000-0001-6495-4741	National Institutes of Health [1P50GM098792, R01-GM034277, R01-CA133404]; Department of Defense [W81XWH-16-1-0565, W81XWH-16-1-0452]; Defense Advanced Research Projects Agency; Koch Institute Frontier Research Program; Koch Institute from the National Cancer Institute [P30-CA14051]; Uehara Memorial Foundation Research Fellowship; Osamu Hayaishi Memorial Scholarship for Study Abroad; NATIONAL CANCER INSTITUTE [P30CA014051, R01CA133404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM098792, R01GM034277] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Koch Institute Frontier Research Program; Koch Institute from the National Cancer Institute; Uehara Memorial Foundation Research Fellowship(Uehara Memorial Foundation); Osamu Hayaishi Memorial Scholarship for Study Abroad; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	L.N. dedicates this work to Zmira Nissim. L.N. thanks Yaakov Nissim, Aviva Yitzhak, and Ovad Nissim for their invaluable support. We thank Ramez Daniel for discussion. We thank Mark Mimee and Karen Weisinger for editing the manuscript. We thank the staff of the Division of Comparative Medicine at Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology for helping with animal experiments. We thank the Swanson Biotechnology Center at Koch Institute for assisting with animal imaging. This work was supported by the National Institutes of Health (1P50GM098792, R01-GM034277, R01-CA133404), the Department of Defense (W81XWH-16-1-0565, W81XWH-16-1-0452), the Defense Advanced Research Projects Agency, and the Koch Institute Frontier Research Program and in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. H.I.S. is supported by the Uehara Memorial Foundation Research Fellowship and the Osamu Hayaishi Memorial Scholarship for Study Abroad. L.N., M.-R.W., and T.K.L. have filed a patent application on this work. T.K.L. is a member of the scientific advisory board at Senti Biosciences and holds shares in the company.	Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031; Baccarini A, 2011, CURR BIOL, V21, P369, DOI 10.1016/j.cub.2011.01.067; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Covassin L, 2011, CLIN EXP IMMUNOL, V166, P269, DOI 10.1111/j.1365-2249.2011.04462.x; Daily K, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-495; De N, 2013, MOL CELL, V50, P344, DOI 10.1016/j.molcel.2013.04.001; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Greber D, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn443; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Leonard JP, 1997, BLOOD, V90, P2541; Liao KW, 2003, CANCER GENE THER, V10, P779, DOI 10.1038/sj.cgt.7700637; Liao KW, 2000, GENE THER, V7, P339, DOI 10.1038/sj.gt.3301080; Lin Y, 2014, CANCERS, V6, P1098, DOI 10.3390/cancers6021098; Liu YC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6393; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Morel M, 2016, P NATL ACAD SCI USA, V113, P8133, DOI 10.1073/pnas.1604391113; Neri D, 2016, CURR OPIN IMMUNOL, V40, P96, DOI 10.1016/j.coi.2016.03.006; Nissim L, 2014, MOL CELL, V54, P698, DOI 10.1016/j.molcel.2014.04.022; Nissim L, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.99; Pardee K, 2016, CELL, V165, P1255, DOI 10.1016/j.cell.2016.04.059; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Schukur L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4964; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Selvakumaran M, 2001, CANCER RES, V61, P1291; Shukla S, 2016, EXP BIOL MED, V241, P1116, DOI 10.1177/1535370216647123; Suzuki HI, 2015, NAT STRUCT MOL BIOL, V22, P512, DOI 10.1038/nsmb.3050; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Tugues S, 2015, CELL DEATH DIFFER, V22, P237, DOI 10.1038/cdd.2014.134; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; VONNICKISCHROSENEG, 2012, J NANOBIOTECHNOL, V10, DOI DOI 10.1186/1477-3155-10-1; Wingender E, 2013, NUCLEIC ACIDS RES, V41, pD165, DOI 10.1093/nar/gks1123; Xie M, 2016, SCIENCE, V354, P1296, DOI 10.1126/science.aaf4006; Xie Z, 2011, SCIENCE, V333, P1307, DOI 10.1126/science.1205527; Yun HJ, 2008, EXP MOL MED, V40, P345, DOI 10.3858/emm.2008.40.3.345	50	83	93	6	74	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2017	171	5					1138	+		10.1016/j.cell.2017.09.049	http://dx.doi.org/10.1016/j.cell.2017.09.049			28	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM8DY	29056342	Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000415317000016
J	Katsanos, K; Kitrou, P; Spiliopoulos, S; Maroulis, I; Petsas, T; Karnabatidis, D				Katsanos, Konstantinos; Kitrou, Panagiotis; Spiliopoulos, Stavros; Maroulis, Ioannis; Petsas, Theodore; Karnabatidis, Dimitris			Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; PERCUTANEOUS ETHANOL INJECTION; DOXORUBICIN-ELUTING BEADS; DECISION-MAKING; LIPIODOL CHEMOEMBOLIZATION; SYMPTOMATIC TREATMENT; PHASE-III; CONVENTIONAL CHEMOEMBOLIZATION; CLINICAL-PRACTICE; LIVER-TUMORS	Background The optimal transcatheter embolization strategy for patients with unresectable hepatocellular carcinoma (HCC) remains elusive. We conducted a systematic review and network meta-analysis (NMA) of different embolization options for unresectable HCC. Methods Medical databases were searched for randomized controlled trials evaluating bland transarterial embolization (TAE), conventional TACE, drug-eluting bead chemoembolization (DEB-TACE), or transarterial radioembolization (TARE), either alone or combined with adjuvant chemotherapy, or local liver ablation, or external radiotherapy for unresectable HCC up to June 2017. Random effects Bayesian models with a binomial and normal likelihood were fitted (WinBUGS). Primary endpoint was patient survival expressed as hazard ratios (HR) and 95% credible intervals. An exponential model was used to fit patient survival curves. Safety and objective response were calculated as odds ratios (OR) and accompanying 95% credible intervals. Competing treatments were ranked with the SUCRA statistic. Heterogeneity-adjusted effective sample sizes were calculated to evaluate information size for each comparison. Quality of evidence (QoE) was assessed with the GRADE system adapted for NMA reports. All analyses complied with the ISPOR-AMCP-NCP Task Force Report for good practice in NMA. Findings The network of evidence included 55 RCTs (12 direct comparisons) with 5,763 patients with preserved liver function and unresectable HCC (intermediate to advanced stage). All embolization strategies achieved a significant survival gain over control treatment (HR range, 0.42-0.76; very low-to-moderate QoE). However, TACE, DEB-TACE, TARE and adjuvant systemic agents did not confer any survival benefit over bland TAE alone (moderate QoE, except low in case of TARE). There was moderate QoE that TACE combined with external radiation or liver ablation achieved the best patient survival (SUCRA 86% and 96%, respectively). Estimated median survival was 13.9 months in control, 18.1 months in TACE, 20.6 months with DEB-TACE, 20.8 months with bland TAE, 30.1 months in TACE plus external radiotherapy, and 33.3 months in TACE plus liver ablation. TARE was the safest treatment (SUCRA 77%), however, all examined therapies were associated with a significantly higher risk of toxicity over control (OR range, 6.35 to 68.5). TACE, DEB-TACE, TARE and adjuvant systemic agents did not improve objective response over bland embolization alone (OR range, 0.85 to 1.65). There was clinical diversity among included randomized controlled trials, but statistical heterogeneity was low. Conclusions Chemo-and radio-embolization for unresectable hepatocellular carcinoma may improve tumour objective response and patient survival, but are not more effective than bland particle embolization. Chemoembolization combined with external radiotherapy or local liver ablation may significantly improve tumour response and patient survival rates over embolization monotherapies. Quality of evidence remains mostly low to moderate because of clinical diversity.	[Katsanos, Konstantinos; Kitrou, Panagiotis; Petsas, Theodore; Karnabatidis, Dimitris] Patras Univ Hosp, Sch Med, Dept Intervent Radiol, Rion, Greece; [Katsanos, Konstantinos] Guys & St Thomas Hosp, Dept Intervent Radiol, Kings Hlth Partners, NHS Fdn Trust, London, England; [Spiliopoulos, Stavros] Attikon Univ Hosp, Sch Med, Dept Intervent Radiol, Athens, Greece; [Maroulis, Ioannis] Patras Univ Hosp, Sch Med, Dept Liver Surg, Rion, Greece	University of Patras; Guy's & St Thomas' NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; University of London; King's College London; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; University of Patras	Katsanos, K (corresponding author), Patras Univ Hosp, Sch Med, Dept Intervent Radiol, Rion, Greece.; Katsanos, K (corresponding author), Guys & St Thomas Hosp, Dept Intervent Radiol, Kings Hlth Partners, NHS Fdn Trust, London, England.	katsanos@med.upatras.gr	Spiliopoulos, Stavros/I-9280-2019	Spiliopoulos, Stavros/0000-0003-1860-0568				Achana FA, 2013, STAT MED, V32, P752, DOI 10.1002/sim.5539; BARTOLOZZI C, 1995, RADIOLOGY, V197, P812, DOI 10.1148/radiology.197.3.7480761; Becker G, 2005, WORLD J GASTROENTERO, V11, P6104, DOI 10.3748/wjg.v11.i39.6104; Bhardwaj N, 2010, SURG ENDOSC, V24, P254, DOI 10.1007/s00464-009-0590-4; Boily G, 2015, HPB, V17, P52, DOI 10.1111/hpb.12273; Britten CD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-16; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Brown KT, 2016, J CLIN ONCOLOGY OFFI; Brown S, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-110; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041; Cabibbo G, 2010, HEPATOLOGY, V51, P1274, DOI 10.1002/hep.23485; Camma C, 2002, RADIOLOGY, V224, P47, DOI 10.1148/radiol.2241011262; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; CHANG JM, 1994, CANCER, V74, P2449, DOI 10.1002/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4; de Baere T, 2016, CARDIOVASC INTER RAD, V39, P334, DOI 10.1007/s00270-015-1208-y; Delicque J, 2016, CLIN RES HEPATOLOGY; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Dias S, 2013, MED DECIS MAKING, V33, P618, DOI 10.1177/0272989X13485157; Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724; Doffoel M, 2008, EUR J CANCER, V44, P528, DOI 10.1016/j.ejca.2008.01.004; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Facciorusso A, 2016, INT J HYPERTHER, P1; Facciorusso A, 2017, UNITED EUR GASTROENT, V5, P511, DOI 10.1177/2050640616673516; Facciorusso A, 2016, DIGEST LIVER DIS, V48, P571, DOI 10.1016/j.dld.2016.02.005; Forner A, 2012, J HEPATOL, V56, P984, DOI 10.1016/j.jhep.2011.08.017; Fu Y, 2015, INT J CLIN EXP MED, V8, P10388; Gaba RC, 2016, J VASC INTERV RADIOL, V27, P457, DOI 10.1016/j.jvir.2015.12.752; Gao S, 2013, HEPATO-GASTROENTEROL, V60, P813, DOI 10.5754/hge121025; Golfieri R, 2014, BRIT J CANCER, V111, P255, DOI 10.1038/bjc.2014.199; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Han SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102686; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; HIGUCHI T, 1994, CANCER, V73, P2259, DOI 10.1002/1097-0142(19940501)73:9<2259::AID-CNCR2820730905>3.0.CO;2-P; Hirooka T, 2009, METHOD INFORM MED, V48, P104, DOI 10.3414/ME0535; Huang C, 2016, J CANCER RES THER, V12, pC148, DOI 10.4103/0973-1482.200605; Huang KJ, 2014, J GASTROEN HEPATOL, V29, P920, DOI 10.1111/jgh.12439; Huo YR, 2015, JAMA ONCOL, V1, P756, DOI 10.1001/jamaoncol.2015.2189; Inaba Y, 2013, EUR J CANCER, V49, P2832, DOI 10.1016/j.ejca.2013.05.011; Jansen JP, 2014, VALUE HEALTH, V17, P157, DOI 10.1016/j.jval.2014.01.004; Jansen JP, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-159; Jansen MC, 2005, EJSO-EUR J SURG ONC, V31, P331, DOI 10.1016/j.ejso.2004.10.011; Kallini JR, 2016, ADV THER, V33, P699, DOI 10.1007/s12325-016-0324-7; Katsanos K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135692; Katsanos K, 2014, J VASC SURG, V59, P1123, DOI 10.1016/j.jvs.2014.01.041; KAWAI S, 1992, CANCER CHEMOTH PHARM, V31, pS1, DOI 10.1007/BF00687096; Kolligs FT, 2015, LIVER INT, V35, P1715, DOI 10.1111/liv.12750; Kudo M, 2014, HEPATOLOGY, V60, P1697, DOI 10.1002/hep.27290; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Kwan SW, 2012, LIVER TRANSPLANT, V18, P727, DOI 10.1002/lt.23413; Lammer Johannes, 2010, Cardiovasc Intervent Radiol, V33, P41, DOI 10.1007/s00270-009-9711-7; Lan T, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003185; Lencioni R, 2016, HEPATOLOGY, V64, P106, DOI 10.1002/hep.28453; Lencioni R, 2016, J HEPATOL, V64, P1090, DOI 10.1016/j.jhep.2016.01.012; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Leng ZQ, 2000, CHIN J RAD ONCOL, V9, P99, DOI DOI 10.3760/J.ISSN:1004-4221.2000.02.007; Li L, 2016, TUMORI J, V102, P301, DOI 10.5301/tj.5000491; Li MQ, 2009, J GASTROEN HEPATOL, V24, P1437, DOI 10.1111/j.1440-1746.2009.05863.x; [李玉 Li Yu], 2003, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V12, P30; Liao MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068453; [廖小方 Liao Xiaofang], 2010, [实用肿瘤杂志, Journal of Practical Oncology], V25, P681; LIN DY, 1988, GASTROENTEROLOGY, V94, P453, DOI 10.1016/0016-5085(88)90436-2; Liu DX, 2009, J INTERVENT RADIOL, V18, P389; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091124; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.19, 10.1038/nrdp.2016.18]; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Mabed M, 2009, EUR J CANCER CARE, V18, P492, DOI 10.1111/j.1365-2354.2008.00984.x; MADDEN MV, 1993, GUT, V34, P1598, DOI 10.1136/gut.34.11.1598; Malagari K, 2010, CARDIOVASC INTER RAD, V33, P541, DOI 10.1007/s00270-009-9750-0; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; Marrero JA, 2016, J HEPATOL, V65, P1140, DOI 10.1016/j.jhep.2016.07.020; Mathurin P, 1998, ALIMENT PHARM THERAP, V12, P111; Meng MB, 2009, RADIOTHER ONCOL, V92, P184, DOI 10.1016/j.radonc.2008.11.002; Meyer T, 2013, BRIT J CANCER, V108, P1252, DOI 10.1038/bjc.2013.85; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Ni JY, 2014, WORLD J GASTROENTERO, V20, P17206, DOI 10.3748/wjg.v20.i45.17206; Ni JY, 2013, J CANCER RES CLIN, V139, P653, DOI 10.1007/s00432-012-1369-x; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; Oliveri RS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004787.pub2; Park YN, 1998, AM J SURG PATHOL, V22, P656, DOI 10.1097/00000478-199806000-00002; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D; Pelletier G, 1998, J HEPATOL, V29, P129, DOI 10.1016/S0168-8278(98)80187-6; Peng KG, 2000, CHIN J RAD ONCOL, V9, P11, DOI DOI 10.3760/J.ISSN:1004-4221.2000.01.003; Pinter M, 2015, RADIOLOGY, V277, P903, DOI 10.1148/radiol.2015142140; Pitton MB, 2015, CARDIOVASC INTER RAD, V38, P352, DOI 10.1007/s00270-014-1012-0; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Qi XS, 2016, ONCOTARGET, V7, P34703, DOI 10.18632/oncotarget.9157; Rammohan A, 2012, WORLD J RADIOL, V4, P405, DOI 10.4329/wjr.v4.i9.405; RAOUL JL, 1994, J NUCL MED, V35, P1782; Raoul JL, 1997, HEPATOLOGY, V26, P1156; Ray CE, 2015, AM J ROENTGENOL, V204, P440, DOI 10.2214/AJR.14.12844; Sacco R, 2011, J VASC INTERV RADIOL, V22, P1545, DOI 10.1016/j.jvir.2011.07.002; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Salem R, 2016, GASTROENTEROLOGY, V151, P1155, DOI 10.1053/j.gastro.2016.08.029; Salem R, 2013, HEPATOLOGY, V58, P2188, DOI 10.1002/hep.26382; Sansonno D, 2012, ONCOLOGIST, V17, P359, DOI 10.1634/theoncologist.2011-0313; Shang Y, 2007, SHIJIE HUAREN XIAOHU, V15, P3140, DOI DOI 10.3969/J.ISSN.1009-3079.2007.29.016; Thorlund K, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-41; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; US Department of Health and Human Services, 2010, COMM TERM CRIT ADV E; van Malenstein H, 2011, ONKOLOGIE, V34, P368, DOI 10.1159/000329602; Vente MAD, 2009, EUR RADIOL, V19, P951, DOI 10.1007/s00330-008-1211-7; Verslype C, 2012, ANN ONCOL, V23, P41, DOI 10.1093/annonc/mds225; Wang G, 2000, J CLIN ONCOL, V5, P380, DOI [10.1007/PL00012067, DOI 10.1007/PL00012067, 10.1007/PL0001206]; Wang H, 2015, CANCER-AM CANCER SOC, V121, P2917, DOI 10.1002/cncr.29456; Wang XH, 2006, SHAXI YIXUE ZAZHI, V35, P461, DOI DOI 10.3969/J.ISSN.1000-7377.2006.04.030; Wang YB, 2007, QUAL LIFE RES, V16, P389, DOI 10.1007/s11136-006-9133-9; Wen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23269; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Woods BS, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-54; World Health Organization, 1979, WHO HDB REP RES CANC; Wu Peihong, 1998, Zhonghua Zhongliu Zazhi, V20, P391; [肖泽民 XIAO Zemin], 2008, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V35, P18; Xie ZB, 2015, HEPATOL RES, V45, P190, DOI 10.1111/hepr.12450; [许国辉 Xu Guohui], 2002, [临床放射学杂志, Journal of Clinical Radiology], V21, P66; Xue HZ, 1995, CHIN J RAD ONCOL, V4, P84; Yamamoto K, 1997, SEMINARS ONCOLOGY S6, V24; Yang M, 2014, MOL BIOL REP, V41, P6575, DOI 10.1007/s11033-014-3541-7; Yang P, 2008, ADV THER, V25, P787, DOI 10.1007/s12325-008-0079-x; Yu SCH, 2014, RADIOLOGY, V270, P607, DOI 10.1148/radiol.13130498; Zhang LD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100305; [张志良 Zhang Zhiliang], 2012, [介入放射学杂志, Journal of Interventional Radiology], V21, P596; Zhao MH, 2006, ZHONGHUA FANGSHE CHO, V15, P39, DOI DOI 10.3760/J.ISSN:1004-4221.2006.01.010; Zhao Ming, 2011, Zhonghua Yi Xue Za Zhi, V91, P1167; Zou LQ, 2014, WORLD J GASTROENTERO, V20, P17227, DOI 10.3748/wjg.v20.i45.17227	130	62	69	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0184597	10.1371/journal.pone.0184597	http://dx.doi.org/10.1371/journal.pone.0184597			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH7CN	28934265	Green Submitted, gold, Green Published			2023-01-03	WOS:000411339900034
J	Su, SF; Bao, H; Wang, XY; Wang, ZQ; Li, X; Zhang, MQ; Wang, JY; Jiang, H; Wang, WJ; Qu, SY; Liu, MN				Su, Shaofei; Bao, Han; Wang, Xinyu; Wang, Zhiqiang; Li, Xi; Zhang, Meiqi; Wang, Jiaying; Jiang, Hao; Wang, Wenji; Qu, Siyang; Liu, Meina			The quality of invasive breast cancer care for low reimbursement rate patients: A retrospective study	PLOS ONE			English	Article							UNIVERSAL HEALTH-INSURANCE; SOCIOECONOMIC-STATUS; CONSERVING SURGERY; CHINESE WOMEN; MASTECTOMY; RACE/ETHNICITY; PERFORMANCE; DISPARITIES; INDICATORS; THERAPY	Though evidence-based treatments have been recommended for breast cancer, underuse of the treatments was still observed. To certain extent, patients' access to care, which can be enhanced by increasing the coverage of health insurance, could account for the current underuse in recommended care. This study aimed to examine the association between different proportions of reimbursement and quality of recommended breast cancer care, as well as length of hospital stay. In this retrospective study, 3669 patients diagnosed with invasive breast cancer between 1 June, 2011 and 30 June, 2013 were recruited. Seven quality indicators from preoperative diagnosis procedures to adjuvant therapy and one composite indicator were selected as dependent variables. Logistic regression and generalized linear models were used to explore the association between quality of care and length of hospital stay with different reimbursement rates. Compared with UEBMI (urban employment basic medical insurance), which represented high level reimbursement rate, patients with lower rates of reimbursement were less likely to receive core biopsy, HER-2 (human epidermal growth factor receptor-2) testing, BCS (breast conserving surgery), SLNB (sentinel lymph nodes biopsy), adjuvant therapy and hormonal treatment. No significant difference in preoperative length of hospital stay was observed among the three insurance schemes, however URBMI (urban resident basic medical insurance) insured patients stayed longer for total length of hospital stay. Significant disparities in utilization of evidence-based breast cancer care among patients with different proportions of reimbursement were observed. Patients with lower rate of reimbursement were less likely to receive recommended care. Our findings could provide important support for further healthcare reform and quality improvement in breast cancer care.	[Su, Shaofei; Wang, Xinyu; Li, Xi; Zhang, Meiqi; Wang, Jiaying; Jiang, Hao; Wang, Wenji; Qu, Siyang; Liu, Meina] Harbin Med Univ, Dept Biostat, Publ Hlth Coll, Harbin, Heilongjiang, Peoples R China; [Bao, Han] Inner Mongolia Med Univ, Dept Biostat, Publ Hlth Coll, Hohhot, Peoples R China; [Wang, Zhiqiang] Univ Queensland, Sch Med, Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia	Harbin Medical University; Inner Mongolia Medical University; Royal Brisbane & Women's Hospital; University of Queensland	Liu, MN (corresponding author), Harbin Med Univ, Dept Biostat, Publ Hlth Coll, Harbin, Heilongjiang, Peoples R China.	liumeina369@163.com	Wang, Zhiqiang/A-5835-2010	Wang, Zhiqiang/0000-0002-5839-743X; Wang, Xinyu/0000-0001-5377-0816	National Natural Science Foundation of China [81273183]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by National Natural Science Foundation of China (grant number 81273183), http://www.nsfe.gov.cni/.; This study was funded by National Natural Science Foundation of China (grant number 81273183).	[Anonymous], 2013, NATL EC SOCIAL DEV S; Badakhshi H, 2013, CANCER MED-US, V2, P712, DOI 10.1002/cam4.114; Bao H, 2016, J CANCER RES CLIN, V142, P1079, DOI 10.1007/s00432-015-2106-z; Bao H, 2015, INT J QUAL HEALTH C, V27, P291, DOI 10.1093/intqhc/mzv042; Chen Z, 2009, LANCET, V373, P1322, DOI 10.1016/S0140-6736(09)60753-4; Coburn N, 2008, BREAST J, V14, P128, DOI 10.1111/j.1524-4741.2007.00542.x; Eberth JM, 2014, J CLIN ONCOL, V32, P2206, DOI 10.1200/JCO.2013.52.8257; Freedman RA, 2011, CANCER-AM CANCER SOC, V117, P180, DOI 10.1002/cncr.25542; Fung KW, 2001, ANZ J SURG, V71, P202, DOI 10.1046/j.1440-1622.2001.02094.x; Gomez SL, 2004, ETHNIC DIS, V14, P134; Gray JE, 2011, J ONCOL PRACT, V7, P247, DOI 10.1200/JOP.2010.000174; Halpern MT, 2007, CANCER, V110, P403, DOI 10.1002/cncr.22786; Hargraves JL, 2003, HEALTH SERV RES, V38, P809, DOI 10.1111/1475-6773.00148; Hu RW, 2014, J IMMIGR MINOR HEALT, V16, P565, DOI 10.1007/s10903-013-9966-6; Jiong TU, 2014, 18 ISA WORLD C SOC; Jubelirer S J, 2001, W V Med J, V97, P144; Kimmick GG, 2015, J ONCOL PRACT, V11, pE9, DOI 10.1200/JOP.2014.001397; Lam WW, 2005, PSYCHO-ONCOLOGY, V14, P585, DOI 10.1002/pon.877; Lee MC, 2009, BREAST J, V15, P34, DOI 10.1111/j.1524-4741.2008.00668.x; Li C, 2011, SOC SCI MED, V73, P359, DOI 10.1016/j.socscimed.2011.06.002; Malin JL, 2006, J CLIN ONCOL, V24, P626, DOI 10.1200/JCO.2005.03.3365; Malin JL, 2002, J CLIN ONCOL, V20, P4381, DOI 10.1200/JCO.2002.04.020; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Moreland Amber, 2009, Am J Surg, V198, P787, DOI 10.1016/j.amjsurg.2009.05.031; Niu XL, 2013, CANCER MED-US, V2, P403, DOI 10.1002/cam4.84; Pan Y, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0102-4; Richardson LC, 2006, AM J PUBLIC HEALTH, V96, P160, DOI 10.2105/AJPH.2004.053579; Shi RH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1228-7; Stenehjem DD, 2014, BREAST CANCER-TARGET, V6, P169, DOI 10.2147/BCTT.S69416; Temple WJ, 2006, J CLIN ONCOL, V24, P3367, DOI 10.1200/JCO.2005.02.7771; Thompson B, 2008, ANN SURG ONCOL, V15, P443, DOI 10.1245/s10434-007-9584-4; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989; Wu XC, 2012, J CLIN ONCOL, V30, P142, DOI 10.1200/JCO.2011.36.8399; Yu H, 2015, HEALTH POLICY, V119, P1145, DOI 10.1016/j.healthpol.2015.07.008; Zhang L, 2012, PSYCHO-ONCOLOGY, V21, P488, DOI 10.1002/pon.1922	35	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184866	10.1371/journal.pone.0184866	http://dx.doi.org/10.1371/journal.pone.0184866			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FH0VR	28910357	Green Submitted, Green Published, gold			2023-01-03	WOS:000410859200111
J	Hoque, DME; Kumari, V; Hoque, M; Ruseckaite, R; Romero, L; Evans, SM				Hoque, Dewan Md Emdadul; Kumari, Varuni; Hoque, Masuma; Ruseckaite, Rasa; Romero, Lorena; Evans, Sue M.			Impact of clinical registries on quality of patient care and clinical outcomes: A systematic review	PLOS ONE			English	Review							ACUTE MYOCARDIAL-INFARCTION; NATIONAL REGISTRY; HEALTH-CARE; OF-CARE; STROKE REGISTRY; HEART-FAILURE; RHEUMATOID-ARTHRITIS; REPERFUSION THERAPY; DISEASE REGISTRIES; ISCHEMIC-STROKE	Background Clinical quality registries (CQRs) are playing an increasingly important role in improving health outcomes and reducing health care costs. CQRs are established with the purpose of monitoring quality of care, providing feedback, benchmarking performance, describing pattern of treatment, reducing variation and as a tool for conducting research. Objectives To synthesise the impact of clinical quality registries (CQRs) as an 'intervention' on (I) mortality/survival; (II) measures of outcome that reflect a process or outcome of health care; (III) health care utilisation; and (IV) healthcare-related costs. Methods The following electronic databases were searched: MEDLINE, EMBASE, CENTRAL, CINAHL and Google Scholar. In addition, a review of the grey literature and a reference check of citations and reference lists within articles was undertaken to identify relevant studies in English covering the period January 1980 to December 2016. The PRISMA-P methodology, checklist and standard search strategy using pre-defined inclusion and exclusion criteria and structured data extraction tools were used. Data on study design and methods, participant characteristics attributes of included registries and impact of the registry on outcome measures and/or processes of care were extracted. Results We identified 30102 abstracts from which 75 full text articles were assessed and finally 17 articles were selected for synthesis. Out of 17 studies, six focused on diabetes care, two on cardiac diseases, two on lung diseases and others on organ transplantations, rheumatoid arthritis, ulcer healing, surgical complications and kidney disease. The majority of studies were "before after" design (#11) followed by cohort design (#2), randomised controlled trial (#2), experimental non randomised study and one cross sectional comparison. The measures of impact of registries were multifarious and included change in processes of care, quality of care, treatment outcomes, adherence to guidelines and survival. Sixteen of 17 studies demonstrated positive findings in their outcomes after implementation of the registry. Conclusions Despite the large number of published articles using data derived from CQRs, few have rigorously evaluated the impact of the registry as an intervention on improving health outcomes. Those that have evaluated this impact have mostly found a positive impact on healthcare processes and outcomes.	[Hoque, Dewan Md Emdadul; Kumari, Varuni; Hoque, Masuma; Ruseckaite, Rasa; Evans, Sue M.] Monash Univ, Sch Publ Hlth & Prevent Med, Alfred Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Hoque, Dewan Md Emdadul] Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, Bangladesh; [Romero, Lorena] Alfred Ctr, Ian Potter Lib, Melbourne, Vic, Australia	Monash University; International Centre for Diarrhoeal Disease Research (ICDDR)	Hoque, DME (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Alfred Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.; Hoque, DME (corresponding author), Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, Bangladesh.	emdad.hoque@monash.edu	Ruseckaite, Rasa/H-4060-2014; Hoque, Dewan Md. Emdadul/J-1999-2019; Hoque, Dewan/O-3606-2015	Hoque, Dewan Md. Emdadul/0000-0001-8219-9196; Hoque, Dewan/0000-0001-8219-9196; Evans, Sue/0000-0003-2962-8400; Ruseckaite, Rasa/0000-0002-9078-2696	MIPRS; MGS; Monash Partners Academic Health Science Centre; Monash [25762931]	MIPRS; MGS; Monash Partners Academic Health Science Centre; Monash	DEH has received MIPRS for tuition fees and MGS scholarship for living costs and Monash ID: 25762931 for PhD Programme. SE has received funding support from Monash Partners Academic Health Science Centre. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACSQHC, 2016, EC EV CLIN QUAL REG; Armstrong BK, 2007, MED J AUSTRALIA, V187, P485, DOI 10.5694/j.1326-5377.2007.tb01383.x; Asplund K, 2003, CEREBROVASC DIS, V15, P5, DOI 10.1159/000068203; Australian Commission on Safety and Quality in Health Care, 2012, LOG DES AUSTR CLIN Q; Autier P, 2011, LANCET, V377, P99, DOI 10.1016/S0140-6736(10)62347-1; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; Bhatt DL, 2010, JAMA-J AM MED ASSOC, V303, P2188, DOI 10.1001/jama.2010.743; Black N, 2004, BMJ-BRIT MED J, V328, P1478, DOI 10.1136/bmj.328.7454.1478; Bradley EH, 2004, JAMA-J AM MED ASSOC, V292, P1563, DOI 10.1001/jama.292.13.1563; Breckenridge K, 2015, NEPHROL DIAL TRANSPL, V30, P1605, DOI 10.1093/ndt/gfv209; Brown C.A., 2006, BMC MED RES METHODOL, V6, P54, DOI DOI 10.1186/1471-2288-6-54; Bufalino VJ, 2011, CIRCULATION, V123, P2167, DOI 10.1161/CIR.0b013e3182181529; Carlhed R, 2006, AM HEART J, V152, P1175, DOI 10.1016/j.ahj.2006.07.028; CfD Control Prevention, 2011, MMWR-MORBID MORTAL W, V60, P206; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Dall TM, 2009, POPUL HEALTH MANAG, V12, P103, DOI 10.1089/pop.2009.12203; Dokholyan RS, 2009, AM HEART J, V157, P971, DOI 10.1016/j.ahj.2009.03.023; Emilsson L, 2015, J INTERN MED, V277, P94, DOI 10.1111/joim.12303; Evans SM, 2011, MED J AUSTRALIA, V194, P360, DOI 10.5694/j.1326-5377.2011.tb03007.x; Ferguson TB, 2003, JAMA-J AM MED ASSOC, V290, P49, DOI 10.1001/jama.290.1.49; Fonarow GC, 2005, ARCH INTERN MED, V165, P1469, DOI 10.1001/archinte.165.13.1469; Fonarow GC, 2010, CIRCULATION, V122, P585, DOI 10.1161/CIRCULATIONAHA.109.934471; Franklin PD, 2014, J BONE JOINT SURG AM, V96A, P104, DOI 10.2106/JBJS.N.00328; French WJ, 2012, JAMA-J AM MED ASSOC, V308, P771, DOI 10.1001/jama.2012.9500; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; George Mary G., 2009, Morbidity and Mortality Weekly Report, V58, P1; Georgiou A, 2006, Aust Fam Physician, V35, P77; Geubbels ELPE, 2006, INT J QUAL HEALTH C, V18, P127, DOI 10.1093/intqhc/mzi103; Gibson CM, 2008, AM HEART J, V156, P1035, DOI 10.1016/j.ahj.2008.07.029; Gitt AK, 2010, EUROPEAN HEART J; Gliklich RE., 2014, REGISTRIES EVALUATIN; Goldfracht M, 2011, INT J QUAL HEALTH C, V23, P674, DOI 10.1093/intqhc/mzr051; Grau AJ, 2010, STROKE, V41, P1495, DOI 10.1161/STROKEAHA.110.582239; Han W, 2015, J AM MED INFORM ASS; Harris MF, 2002, MED J AUSTRALIA, V177, P250, DOI 10.5694/j.1326-5377.2002.tb04757.x; Harrison JK, 2015, NEPHRON, V129, P209, DOI 10.1159/000371888; Hickey GL, 2013, EUROPEAN J CARDIOTHO; Hills NK, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-20; Hoekstra JW, 2002, ACAD EMERG MED, V9, P1146, DOI 10.1111/j.1553-2712.2002.tb01569.x; Hong Yuling, 2006, Crit Pathw Cardiol, V5, P179, DOI 10.1097/01.hpc.0000243588.00012.79; Hoque DME, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010654; Jakobsen E, 2013, J THORAC ONCOL, V8, P1238, DOI 10.1097/JTO.0b013e3182a4070f; Johnson SC, 2005, NEUROLOGY, V64, P654; Jonsson A, 2010, EUR J HEART FAIL, V12, P25, DOI 10.1093/eurjhf/hfp175; Kapral MK, 2004, STROKE, V35, P1756, DOI 10.1161/01.STR.0000130423.50191.9f; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; Koduri G, 2010, RHEUMATOLOGY, V49, P1483, DOI 10.1093/rheumatology/keq035; LaBresh KA, 2008, ARCH INTERN MED, V168, P411, DOI 10.1001/archinternmed.2007.101; Larsson S, 2012, HEALTH AFFAIR, V31, P220, DOI 10.1377/hlthaff.2011.0762; Lim TO, 2008, NEPHROLOGY, V13, P745, DOI 10.1111/j.1440-1797.2008.01044.x; Lorenzoni L, 2014, LANCET, V384, P83, DOI 10.1016/S0140-6736(14)60571-7; Lundstrom M, 2014, INT J HEALTH CARE Q, V27, P140, DOI 10.1108/IJHCQA-10-2012-0101; Lyu H, 2015, J HEALTHCARE QUAL; Madhok R, 2002, BAYLOR U MED CTR P; Mallinson EKL, 2010, GUT, V59, P1378, DOI 10.1136/gut.2010.212449; McClellan M. B., 2008, EVIDENCE BASED MED C; McNeil JJ, 2010, MED J AUSTRALIA, V192, P244, DOI 10.5694/j.1326-5377.2010.tb03499.x; Mehra S, 2015, THYROID, V25, P157, DOI 10.1089/thy.2014.0270; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Oien R F, 2006, J Wound Care, V15, P259; Oien RF, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003091; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Peterson ED, 2007, RES METHODS SPEED DE; Peterson ED, 2008, AM HEART J, V156, P1045, DOI 10.1016/j.ahj.2008.07.028; Pollard C, 2009, J RURAL HEALTH, V25, P77, DOI 10.1111/j.1748-0361.2009.00202.x; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Registry ASC, 2014, ANN REPORT; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Roski J, 2003, PREV MED, V36, P291, DOI 10.1016/S0091-7435(02)00052-X; Salim A, 2010, J TRAUMA, V69, P451, DOI 10.1097/TA.0b013e3181e7847a; Schechter MS, 2014, BMJ QUAL SAF, V23, P9, DOI 10.1136/bmjqs-2013-002378; Schmittdiel J, 2005, J GEN INTERN MED, V20, P855, DOI 10.1111/j.1525-1497.2005.0171.x; Schwamm LH, 2009, CIRCULATION, V119, P107, DOI 10.1161/CIRCULATIONAHA.108.783688; Scottish Intercollegiate Guidelines Network for RCT, COH CAS CONTR STUD; Shah Nipa R, 2015, J Registry Manag, V42, P3; Sorensen HT, 1996, INT J RISK SAFETY ME, V10, P1; Spertus JA, 2006, AM HEART J, V151, P589, DOI 10.1016/j.ahj.2005.05.026; Sposato LA, 2008, STROKE, V39, P3036, DOI 10.1161/STROKEAHA.108.521062; Stroebel Robert J, 2002, Jt Comm J Qual Improv, V28, P441; Thomas KG, 2007, J GEN INTERN MED, V22, P1740, DOI 10.1007/s11606-007-0431-x; Tottenborg SS, 2013, CLIN RESPIR J, V7, P319, DOI 10.1111/crj.12009; van der Veer SN, 2010, INT J MED INFORM, V79, P305, DOI 10.1016/j.ijmedinf.2010.01.011; Young A, 2007, RHEUMATOLOGY, V46, P350, DOI 10.1093/rheumatology/kel253; Young A, 2010, RHEUMATOLOGY	84	96	97	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0183667	10.1371/journal.pone.0183667	http://dx.doi.org/10.1371/journal.pone.0183667			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG2YO	28886607	gold, Green Published, Green Submitted			2023-01-03	WOS:000410001100032
J	Adane, M; Mengistie, B; Kloos, H; Medhin, G; Mulat, W				Adane, Metadel; Mengistie, Bezatu; Kloos, Helmut; Medhin, Girmay; Mulat, Worku			Sanitation facilities, hygienic conditions, and prevalence of acute diarrhea among under-five children in slums of Addis Ababa, Ethiopia: Baseline survey of a longitudinal study	PLOS ONE			English	Article							SHARED SANITATION; ENVIRONMENTAL-FACTORS; INFORMAL SETTLEMENTS; HEALTH; MORTALITY; LATRINE; WATER; ENTEROPATHY; BANGLADESH; COUNTRIES	Background In developing countries, children under the age of five years who live in slums are highly vulnerable to diarrhea. However, there is a paucity of information on the relationship between sanitation facilities and hygienic conditions to acute diarrhea among under-five children in slum areas of Addis Ababa, Ethiopia. Therefore, this study examines the sanitation facilities and hygienic conditions in the slums of Addis Ababa and identifies the main factors significantly associated with acute diarrhea among children aged 0-50 months in those slums. Methods A community-based cross-sectional household survey was carried out between September and November 2014, that then served as the baseline survey of a longitudinal study. For this survey, 697 children aged 0-50 months were recruited from two slum districts in Addis Ababa. A pre-tested structured questionnaire and an observational checklist were used for data collection. Multivariable logistic regression analysis was used to identify sanitation facilities and hygiene-related factors that were significantly associated with acute diarrhea by controlling potential confounding effects of selected socio-demographic factors. Adjusted odds ratio (AOR) with corresponding 95% confidence interval (CI) was used to quantify the strength of association. Main findings The prevalence of acute diarrhea among children aged 0-50 months in the study area was 11.9% and 94.6% of the sanitation facilities were unimproved. Sharing of a sanitation facility by six or more households (AOR = 4.7; 95% CI: 2.4-9.4), proximity of sanitation facilities within 15 meters of homes (AOR = 6.6; 95% CI: 2.5-17.0), presence of feces (AOR = 3.9; 95% CI: 1.5-10.3) and flies (AOR = 2.5; 95% CI: 1.3-5.0) on the floor of and/or around sanitation facilities, and presence of uncollected garbage inside house compounds (AOR = 3.2; 95% CI: 1.2-8.4) were significantly associated with acute diarrhea. Conclusion This study reveals the slum environment to be high risk for diarrhea due to close proximity of sanitation facilities to homes, sharing of sanitation facilities, and poor hygiene of the sanitation facilities and housing compounds. We recommend the development of a comprehensive diarrheal disease prevention program that focuses on improving the cleanliness of the sanitation facilities and housing compounds. Increasing the number of improved sanitation facilities at an appropriate distance from houses is also essential in order to reduce the number of households that share one latrine.	[Adane, Metadel] Univ Addis Ababa, EIWR, Addis Ababa, Ethiopia; [Mengistie, Bezatu] Haramaya Univ, Coll Hlth & Med Sci, Haramaya, Ethiopia; [Kloos, Helmut] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Medhin, Girmay] Univ Addis Ababa, Aklilu Lemma Inst Pathobiol, Addis Ababa, Ethiopia; [Mulat, Worku] Univ Connecticut, Dept Civil & Environm Engn, Storrs, CT USA	Addis Ababa University; Haramaya University; University of California System; University of California San Francisco; Addis Ababa University; University of Connecticut	Adane, M (corresponding author), Univ Addis Ababa, EIWR, Addis Ababa, Ethiopia.	metadel.adane2@gmail.com	Adane, Metadel/AFQ-9478-2022	Adane, Metadel/0000-0002-7039-4768; Medhin, Girmay/0000-0003-2146-4261	Ethiopian Institute of Water Resources of Addis Ababa University	Ethiopian Institute of Water Resources of Addis Ababa University	Ethiopian Institute of Water Resources of Addis Ababa University funded this research project. The funders had no role in study design, data collection and analysis, decisions to publish, interpretation of the data and preparation of the manuscript for publication.	Adane M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181516; Adane M, 2017, J HEALTH POPUL NUTR, V36, P1, DOI 10.1186/s41043-017-0085-1; Alam MZ, 2013, AM ACAD SCHOLARLY RE, V1, P1; Alemayehu Elias Yitbarek, 2008, THESIS; [Anonymous], 2008, PROGR DRINK WAT SAN; Azage M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144690; Azage M, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0090-z; Baker KK, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002010; Bartlett S, 2003, ENVIRON URBAN, V15, P57, DOI 10.1177/095624780301500220; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Berhe F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-187; Beyene A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1804-4; Boadi K.O., 2005, J HLTH POPULAT DEV C, V7, P15; Borah H, 2014, IND J SCI RES TECH, V2, P16; Carlton EJ, 2014, AM J EPIDEMIOL, V179, P344, DOI 10.1093/aje/kwt279; Central Statistical Agency, 2013, POP PROJ ETH REG WER; Central Statistical Agency,, 2012, ETH DEM HLTH SURV 20; Central Statistical Agency [Ethiopia] ICF, 2016, ETH DEM HLTH SURV 20; Checkley W, 2008, INT J EPIDEMIOL, V37, P816, DOI 10.1093/ije/dyn099; Choyon K., 2012, CURR RES J SOC SCI, V4, P304; Collinet-Adler S, 2015, APPL ENVIRON MICROB, V81, P6053, DOI 10.1128/AEM.01236-15; Corbett JJ, 2015, J METHANE EMISSIONS, P1, DOI DOI 10.1155/2015/; de Melo MCN, 2008, BRAZ J INFECT DIS, V12, P89, DOI 10.1590/S1413-86702008000100019; Escamilla V, 2013, ANN ASSOC AM GEOGR, V103, P299, DOI 10.1080/00045608.2013.756257; Ezeh A, 2017, LANCET, V389, P547, DOI 10.1016/S0140-6736(16)31650-6; Fadel ME, 2014, ENVIRON MONIT ASSESS, V186, P665, DOI DOI 10.1007/S10661-013-3406-X; Federal Democratic Republic of Ethiopia, 2011, WAT SUPPL SAN HYG WA; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, HLTH SECT DEV PROGR; Ferdous F, 2013, AM J TROP MED HYG, V89, P223, DOI 10.4269/ajtmh.12-0743; Fetene N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156438; Fotso JC, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-218; Fotso Jean-Christophe, 2006, Int J Equity Health, V5, P9, DOI 10.1186/1475-9276-5-9; Fuller JA, 2014, AM J TROP MED HYG, V91, P173, DOI 10.4269/ajtmh.13-0503; Garenne M, 2010, ARCH DIS CHILD, V95, P464, DOI 10.1136/adc.2009.172585; Gebru T, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-395; Gilmartin AA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0143; Gould WTS, 1998, HEALTH PLACE, V4, P171, DOI 10.1016/S1353-8292(98)00009-4; Guerrant RL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158772; Heijnen M, 2014, TROP MED INT HEALTH, V19, P1334, DOI 10.1111/tmi.12375; Heijnen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093300; Hosmer JD, 2013, APPL LOGISTIC REGRES; Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8; Irish S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067951; Kalakheti B, 2017, J LUMBINI MED COLL, V4, P94; Kelsey JL., 1996, METHODS OBSERVATIONA; Keusch GT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P371; Kimani-Murage EW, 2007, J URBAN HEALTH, V84, P829, DOI 10.1007/s11524-007-9199-x; Kirkwood B.R., 2003, ESSENTIAL MED STAT, V2; Korpe PS, 2012, TRENDS MOL MED, V18, P328, DOI 10.1016/j.molmed.2012.04.007; Kwiringira J, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3036-7; Leon DA, 2008, INT J EPIDEMIOL, V37, P4, DOI 10.1093/ije/dym271; Lindo S, 2012, WORLD GASTROENTEROLO, P1; McNamee R, 2003, OCCUP ENVIRON MED, V60, P227, DOI 10.1136/oem.60.3.227; Ministry of Urban Development and Housing of Ethiopia, 2015, STRAT SCAL SAF NET R; Mukabutera A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3435-9; Mutisya M, 2010, TROP MED INT HEALTH, V15, P132, DOI 10.1111/j.1365-3156.2009.02419.x; Nakagiri A, 2015, HABITAT INT, V49, P529, DOI 10.1016/j.habitatint.2015.07.005; Nelson KB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103886; Nirgude S, 2014, INDIAN J APPL RES, V4, P11; Owolabi AA, 2012, AFR J MICROBIOL RES, V6, P3465, DOI 10.5897/AJMR11.1535; Riley Lee W, 2007, BMC Int Health Hum Rights, V7, P2, DOI 10.1186/1472-698X-7-2; Sclar ED, 2005, LANCET, V365, P901, DOI 10.1016/S0140-6736(05)71049-7; Semba RD, 2011, AM J TROP MED HYG, V84, P443, DOI 10.4269/ajtmh.2011.10-0244; Simiyu S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-4009-6; Spears D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073784; Strina A, 2003, AM J EPIDEMIOL, V157, P1032, DOI 10.1093/aje/kwg075; Sudipta Basa, 2015, Asian Journal of Biomedical and Pharmaceutical Sciences, V5, P8, DOI 10.15272/ajbps.v5i45.701; Tessema RA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175233; Tumwebaze IK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1260; UN, 2019, IMPROVING SUSTAINABL; UN HABITAT, 2008, ETH ADD AB URB PROF; UN-Habitat , 2010, ETH CAS COND HOUS IN; Unger A, 2013, ARCH DIS CHILD, V98, P799, DOI 10.1136/archdischild-2011-301621; UNICEF, 2012, STAT WORLDS CHILDR 2; United Nations Human Settlements Programme (UN -Habitat), 2003, CHALL SLUMS GLOB REP; United Nations (UN), 2013, MILL DEV GOALS REP 2; Uwizeye D, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-745; Vedachalam S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176272; Vedachalam S, 2015, ENVIRON URBAN, V27, P117, DOI 10.1177/0956247814560978; World Health Organization, 2005, TREATM DIARRH MAN PH; Worldwatch-Institue, 2007, OUR URB FUT, V24th edn ed.	82	49	51	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2017	12	8							e0182783	10.1371/journal.pone.0182783	http://dx.doi.org/10.1371/journal.pone.0182783			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FF1XX	28854200	Green Published, gold, Green Submitted			2023-01-03	WOS:000408693600017
J	Micic, D; Gaetano, JN; Rubin, JN; Cohen, RD; Sakuraba, A; Rubin, DT; Pekow, J				Micic, Dejan; Gaetano, John N.; Rubin, Jonah N.; Cohen, Russell D.; Sakuraba, Atsushi; Rubin, David T.; Pekow, Joel			Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease	PLOS ONE			English	Article							POPULATION-BASED COHORT; CROHNS-DISEASE; UNITED-STATES; RISK-FACTORS; CLOSTRIDIUM-DIFFICILE; ULCERATIVE-COLITIS; HEALTH-INSURANCE; HEART-FAILURE; RATES; CARE	Background Management of inpatients with inflammatory bowel disease (IBD) requires increasing resources. We aimed to identify factors associated with hospital readmissions among individuals with IBD. Materials & methods We collected data from the Healthcare Cost and Utilization Project Nationwide Readmissions Database 2013. We identified individuals with index hospitalizations for IBD. Patient-specific factors, comorbidities and hospitalization characteristics were extracted for the index hospitalization. We performed logistic regression modeling to create adjusted odds ratios (ORs) for 30-day hospital readmission. Subgroup analysis was performed based on disease type and performance of surgery. Results We analyzed a total of 55,942 index hospital discharges; 3037 patients (7.0%) were readmitted to the hospital within 30 days. Increasing patient age (> 65: OR: 0.45; 95% CI 0.39-0.53) was associated with a decreased risk of readmission, while a diagnosis of Crohn's disease (OR: 1.09; 95% CI 1.00-1.18) and male sex (OR: 1.16; 95% CI 1.07-1.25) were associated with an increased risk of readmission. The comorbidities of smoking (OR: 1.09; 95% CI 1.00-1.19), anxiety (OR: 1.17; 95% CI 1.01-1.36) and opioid dependence (OR: 1.40; 95% CI 1.06-1.86) were associated with an increased risk of 30-day readmission. Individual hospitalization characteristics and disease complications were significantly associated with readmission. Performance of a surgery during the index admission was associated with a decreased risk of readmission (OR: 0.57; 95% CI 0.33-0.96). Conclusion Analyzing data from a US publicly available all-payer inpatient healthcare database, we identified patient and hospitalization risk factors associated with 30-day readmission. Identifying patients at high risk for readmission may allow for interventions during or after the index hospitalization to decrease this risk.	[Micic, Dejan; Gaetano, John N.; Cohen, Russell D.; Sakuraba, Atsushi; Rubin, David T.; Pekow, Joel] Univ Chicago, Dept Internal Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA; [Rubin, Jonah N.] Univ Chicago, Dept Internal Med, Sect Hosp Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Micic, D (corresponding author), Univ Chicago, Dept Internal Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA.	dejan.micic@northwestern.edu	Sakuraba, Atsushi/ABD-6796-2020	Sakuraba, Atsushi/0000-0003-2519-6129; Pekow, Joel/0000-0002-4790-8994	National Institutes of Health [T32DK007074, K08DK090152, P30DK42086]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK090152, P30DK042086] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the National Institutes of Health [grant number T32DK007074, K08DK090152 (JP), P30DK42086]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegretti JR, 2015, INFLAMM BOWEL DIS, V21, P2583, DOI 10.1097/MIB.0000000000000537; Ananthakrishnan AN, 2008, GUT, V57, P205, DOI 10.1136/gut.2007.128231; Ananthakrishnan AN, 2008, AM J GASTROENTEROL, V103, P2789, DOI 10.1111/j.1572-0241.2008.02054.x; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Barnes EL, 2017, INFLAMM BOWEL DIS, V23, P875, DOI 10.1097/MIB.0000000000001121; Benbassat J, 2000, ARCH INTERN MED, V160, P1074, DOI 10.1001/archinte.160.8.1074; Bernstein CN, 2006, AM J GASTROENTEROL, V101, P110, DOI 10.1111/j.1572-0241.2006.00330.x; Bewtra M, 2007, CLIN GASTROENTEROL H, V5, P597, DOI 10.1016/j.cgh.2007.01.015; Damle RN, 2016, J SURG RES, V200, P200, DOI 10.1016/j.jss.2015.06.052; Frolkis AD, 2013, GASTROENTEROLOGY, V145, P996, DOI 10.1053/j.gastro.2013.07.041; Hazratjee N, 2013, AM J GASTROENTEROL, V108, P1024, DOI 10.1038/ajg.2012.343; Horton HA, 2014, ANTIMICROB AGENTS CH, V58, P5054, DOI 10.1128/AAC.02606-13; Horwitz L, 2014, J HOSP MED, V9, P743, DOI 10.1002/jhm.2271; Introduction to the HCUP Nationwide Readmissions Database (NRD), 2013, INTR HCUP NAT READM; Jennings JH, 2015, CHEST, V147, P1227, DOI 10.1378/chest.14-1123; Kappelman MD, 2008, GASTROENTEROLOGY, V135, P1907, DOI 10.1053/j.gastro.2008.09.012; Kulaylat AN, 2015, COLORECTAL DIS, V17, P891, DOI 10.1111/codi.12958; Lawrence Kosinski JVB, 2016, PROJECT SONAR REDUCT; Lichtenstein GR, 2005, GASTROENTEROLOGY, V128, P862, DOI 10.1053/j.gastro.2005.01.048; Loop MS, 2016, AM J CARDIOL, V118, P79, DOI 10.1016/j.amjcard.2016.04.015; Nguyen GC, 2008, INFLAMM BOWEL DIS, V14, P1105, DOI 10.1002/ibd.20429; Nguyen GC, 2007, INFLAMM BOWEL DIS, V13, P1408, DOI 10.1002/ibd.20200; Nguyen GC, 2014, CLIN GASTROENTEROL H, V12, P1897, DOI 10.1016/j.cgh.2014.02.042; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; Park KT, 2016, AM J GASTROENTEROL, V111, P15, DOI 10.1038/ajg.2015.207; Poojary P, 2017, INFLAMM BOWEL DIS, V23, P347, DOI 10.1097/MIB.0000000000001041; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P402, DOI 10.1053/j.gastro.2003.11.014; Silverstein MD, 1999, GASTROENTEROLOGY, V117, P49, DOI 10.1016/S0016-5085(99)70549-4; Singh G, 2016, CHEST, V149, P905, DOI 10.1378/chest.15-0449; Tapper EB, 2016, CLIN GASTROENTEROL H, V14, P1181, DOI 10.1016/j.cgh.2016.04.009; Villani A, 2014, J TELEMED TELECARE, V20, P468, DOI 10.1177/1357633X14555644	31	30	30	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2017	12	8							e0182900	10.1371/journal.pone.0182900	http://dx.doi.org/10.1371/journal.pone.0182900			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7CK	28837634	Green Submitted, Green Published, gold			2023-01-03	WOS:000408365000033
J	Peters, JM				Peters, Jeffrey M.			Flipping a citrate switch on liver cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							HEPATOCELLULAR-CARCINOMA; METABOLISM	Energy homeostasis and oncogenic signaling are critical determinants of the growth of human liver cancer cells, providing a strong rationale to elucidate the regulatory mechanisms for these systems. A new study reports that loss of solute carrier family 13 member 5, which transports citrate across cell membranes, halts liver cancer cell growth by altering both energy production and mammalian target of rapamycin signaling in human liver cancer cell lines and in both an in vitro and in vivo model of liver tumors, suggesting a new target for liver cancer chemoprevention and/or chemotherapy.	[Peters, Jeffrey M.] Penn State Univ, Dept Vet & Biomed Sci, 312 Life Sci Bldg, University Pk, PA 16802 USA; [Peters, Jeffrey M.] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, 312 Life Sci Bldg, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Peters, JM (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, 312 Life Sci Bldg, University Pk, PA 16802 USA.; Peters, JM (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, 312 Life Sci Bldg, University Pk, PA 16802 USA.	jmp21@psu.edu		Peters, Jeffrey/0000-0003-2782-2998	National Institutes of Health [R01CA124533, R01CA141029]; NATIONAL CANCER INSTITUTE [R01CA141029, R01CA124533] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health Grants R01CA124533 and R01CA141029. The author declares that he has no conflicts of interest with the contents of this article. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.	Bupathi M, 2015, MOL ONCOL, V9, P1501, DOI 10.1016/j.molonc.2015.06.005; Chypre M, 2012, BIOCHEM BIOPH RES CO, V422, P1, DOI 10.1016/j.bbrc.2012.04.144; Cidon EU, 2017, WORLD J HEPATOL, V9, P797, DOI 10.4254/wjh.v9.i18.797; Icard P, 2012, BBA-REV CANCER, V1825, P111, DOI 10.1016/j.bbcan.2011.10.007; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; Li ZH, 2017, J BIOL CHEM, V292, P13890, DOI 10.1074/jbc.M117.783860; Mycielska ME, 2009, BIOESSAYS, V31, P10, DOI 10.1002/bies.080137; Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	9	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2017	292	33					13902	13903		10.1074/jbc.H117.783860	http://dx.doi.org/10.1074/jbc.H117.783860			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE0XG	28821606	hybrid, Green Published			2023-01-03	WOS:000407942400021
J	Hwang, TJ; Kesselheim, AS; Sarpatwari, A				Hwang, Thomas J.; Kesselheim, Aaron S.; Sarpatwari, Ameet			Value-Based Pricing and State Reform of Prescription Drug Costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hwang, Thomas J.; Kesselheim, Aaron S.; Sarpatwari, Ameet] Brigham & Womens Hosp, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Hwang, Thomas J.; Kesselheim, Aaron S.; Sarpatwari, Ameet] Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sarpatwari, A (corresponding author), Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.; Sarpatwari, A (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@bwh.harvard.edu	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Hwang, Thomas/0000-0003-0717-1497	Engelberg Foundation; Laura and John Arnold Foundation; Harvard Program in Therapeutic Science	Engelberg Foundation; Laura and John Arnold Foundation; Harvard Program in Therapeutic Science	This work is supported by grants from the Engelberg Foundation, Laura and John Arnold Foundation, and Harvard Program in Therapeutic Science (all from both Drs Kesselheim and Sarpatwari).	Sarpatwari A, 2016, NEW ENGL J MED, V374, P2301, DOI 10.1056/NEJMp1605100	1	24	23	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 15	2017	318	7					609	610		10.1001/jama.2017.8255	http://dx.doi.org/10.1001/jama.2017.8255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD6CH	28692713				2023-01-03	WOS:000407616000011
J	Zakrzewska, KE; Samluk, A; Wencel, A; Dudek, K; Pijanowska, DG; Pluta, KD				Zakrzewska, Karolina Ewa; Samluk, Anna; Wencel, Agnieszka; Dudek, Krzysztof; Pijanowska, Dorota Genowefa; Pluta, Krzysztof Dariusz			Liver tissue fragments obtained from males are the most promising source of human hepatocytes for cell-based therapies - Flow cytometric analysis of albumin expression	PLOS ONE			English	Article								Cell-based therapies that could provide an alternative treatment for the end-stage liver disease require an adequate source of functional hepatocytes. There is little scientific evidence for the influence of patient's age, sex, and chemotherapy on the cell isolation efficiency and metabolic activity of the harvested hepatocytes. The purpose of this study was to investigate whether hepatocytes derived from different sources display differential viability and biosynthetic capacity. Liver cells were isolated from 41 different human tissue specimens. Hepatocytes were labeled using specific antibodies and analyzed using flow cytometry. Multiparametric analysis of the acquired data revealed statistically significant differences between some studied groups of patients. Generally, populations of cells isolated from the male specimens had greater percentage of biosynthetically active hepatocytes than those from the female ones regardless of age and previous chemotherapy of the patient. Based on the albumin staining (and partially on the alpha-1-antitrypsin labeling) after donor liver exclusion (6 out of 41 samples), our results indicated that: 1. samples obtained from males gave a greater percentage of active hepatocytes than those from females (p = 0.034), and 2. specimens from the males after chemotherapy greater than those from the treated females (p = 0.032).	[Zakrzewska, Karolina Ewa; Samluk, Anna; Wencel, Agnieszka; Pijanowska, Dorota Genowefa; Pluta, Krzysztof Dariusz] Polish Acad Sci, Dept Hybrid Microbiosyst Engn, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland; [Dudek, Krzysztof] Med Univ Warsaw, Chair & Dept Gen Transplant & Liver Surg, Warsaw, Poland	Polish Academy of Sciences; Nalecz Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Sciences; Medical University of Warsaw	Pluta, KD (corresponding author), Polish Acad Sci, Dept Hybrid Microbiosyst Engn, Nalecz Inst Biocybernet & Biomed Engn, Warsaw, Poland.	kpluta@ibib.waw.pl	Pijanowska, Dorota/AAJ-3586-2021; Pijanowska, Dorota G/W-3182-2018; Wencel, Agnieszka/AAM-2346-2021	Pijanowska, Dorota/0000-0001-8431-8910; Pijanowska, Dorota G/0000-0001-8431-8910; Pluta, Krzysztof/0000-0003-1706-2788; Zakrzewska, Karolina/0000-0002-1346-2445; Wencel, Agnieszka/0000-0003-4582-8250	Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences	Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences	Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences statutory funding.	Alexandre E., 2002, Cell and Tissue Banking, V3, P223; Auguie B., 2017, GRIDEXTRA MISCELLANE; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhogal RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018222; Donato MT, 2008, CELL TRANSPLANT, V17, P1211, DOI 10.3727/096368908787236620; Hughes RD, 2006, LIVER TRANSPLANT, V12, P713, DOI 10.1002/lt.20732; Kadyk LC, 2015, STEM CELL TRANSL MED, V4, P207, DOI 10.5966/sctm.2014-0276; Kleine M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101386; Kochanek KD, 2014, NATL VITAL STAT REPO, V65, P1; Lee SML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107567; Lloyd T. D. R., 2004, Cell and Tissue Banking, V5, P81, DOI 10.1023/B:CATB.0000034079.10985.bd; Mennecozzi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122786; No DY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050723; Parkinson A, 2004, TOXICOL APPL PHARM, V199, P193, DOI 10.1016/j.taap.2004.01.010; Richert L, 2004, LIVER INT, V24, P371, DOI 10.1111/j.1478-3231.2004.0930.x; Samluk A, 2013, ARTIF ORGANS, V37, pE123, DOI 10.1111/aor.12064; Schmucker Douglas L, 2011, Curr Gerontol Geriatr Res, V2011, P526379, DOI 10.1155/2011/526379; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; TUKEY JW, 1949, BIOMETRICS, V5, P99, DOI 10.2307/3001913; Vondran FWR, 2008, ARTIF ORGANS, V32, P205, DOI 10.1111/j.1525-1594.2007.00524.x	20	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2017	12	8							e0182846	10.1371/journal.pone.0182846	http://dx.doi.org/10.1371/journal.pone.0182846			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC9YJ	28793328	Green Submitted, Green Published, gold			2023-01-03	WOS:000407196700071
J	Schuchat, A; Houry, D; Guy, GP				Schuchat, Anne; Houry, Debra; Guy, Gery P., Jr.			New Data on Opioid Use and Prescribing in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							OVERDOSE; PRESCRIPTION; DEPENDENCE; ABUSE		[Schuchat, Anne; Houry, Debra; Guy, Gery P., Jr.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D14, Atlanta, GA 30329 USA	Centers for Disease Control & Prevention - USA	Schuchat, A (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D14, Atlanta, GA 30329 USA.	aschuchat@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Centers for Disease Control and Prevention, 2017, OP OV GUID RES CLIN; Dowell D, 2016, HEALTH AFFAIR, V35, P1876, DOI 10.1377/hlthaff.2016.0448; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625; Guy Jr GP, 2017, MMWR MORB MORTAL WKL, V6; Mercado MC, 2018, PAIN MED, V19, P511, DOI 10.1093/pm/pnx015; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1	8	190	190	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 1	2017	318	5					425	426		10.1001/jama.2017.8913	http://dx.doi.org/10.1001/jama.2017.8913			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC2HZ	28687823	Green Accepted			2023-01-03	WOS:000406659800011
J	Schwartz, M				Schwartz, Michal			Can immunotherapy treat neurodegeneration?	SCIENCE			English	Editorial Material							ALZHEIMERS-DISEASE; CHOROID-PLEXUS; PATHOLOGY; BLOCKADE; MEMORY		[Schwartz, Michal] Weizmann Inst Sci, Dept Neurobiol, IL-7610001 Rehovot, Israel	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-7610001 Rehovot, Israel.	michal.schwartz@weizmann.ac.il			E.U. Seventh Framework Program HEALTH [279017]; Israel Science Foundation-Legacy Heritage Biomedical Science Partnership-research [1354/15]; ERC-ADG [741744]	E.U. Seventh Framework Program HEALTH; Israel Science Foundation-Legacy Heritage Biomedical Science Partnership-research; ERC-ADG	I thank T. Wiesel and S. Schwarzbaum for their input. This work was supported by the E.U. Seventh Framework Program HEALTH-2011 (grant 279017), the Israel Science Foundation-Legacy Heritage Biomedical Science Partnership-research (grant 1354/15), and the ERC-2016-ADG (grant 741744).	Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Breitner J, 2015, ALZHEIMERS DEMENT, V11, P216, DOI 10.1016/j.jalz.2014.03.009; Da Mesquita S, 2015, BRAIN BEHAV IMMUN, V49, P280, DOI 10.1016/j.bbi.2015.06.008; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Marsh SE, 2016, P NATL ACAD SCI USA, V113, pE1316, DOI 10.1073/pnas.1525466113; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Naert G, 2013, J MOL CELL BIOL, V5, P284, DOI 10.1093/jmcb/mjt028; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	15	32	32	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 21	2017	357	6348					254	255		10.1126/science.aai8231	http://dx.doi.org/10.1126/science.aai8231			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB1KF	28729500				2023-01-03	WOS:000405901600024
J	Pannakal, ST; Jager, S; Duranton, A; Tewari, A; Saha, S; Radhakrishnan, A; Roy, N; Kuntz, JF; Fermas, S; James, D; Mellor, J; Misra, N; Breton, L				Pannakal, Steve Thomas; Jager, Sibylle; Duranton, Albert; Tewari, Amit; Saha, Subarna; Radhakrishnan, Aneesha; Roy, Nita; Kuntz, Jean Francois; Fermas, Soraya; James, Darryl; Mellor, Jane; Misra, Namita; Breton, Lionel			Longevity effect of a polysaccharide from Chlorophytum borivilianum on Caenorhabditis elegans and Saccharomyces cerevisiae	PLOS ONE			English	Article							IONIZATION MASS-SPECTROMETRY; CHRONOLOGICAL LIFE-SPAN; HUMAN SKIN; OXIDATIVE STRESS; CD44; AGE; SECRETION; GENETICS	The traditional Indian medicine, Ayurveda, provides insights and practical solutions towards a healthy life style. Rasayana is a branch of Ayurveda known for preserving and promoting health, enhancing the quality of life and delaying the aging process. In the traditional knowledge, the Rasayana herb, Chlorophytum borivilianum (C. borivilanum) is regarded as a general health promoting tonic that delays aging and increases lifespan, cognitive function and physical strength. Aging is a complex and multifactorial physiological phenomenon that manifests itself over a wide range of biological systems, tissues, and functions. Longevity is an obvious marker of physiological aging. Simple model systems such as the single-cell budding yeast Saccharomyces cerevisiae (S. cerevisiae) and the nematode, Caenorhabditis elegans (C. elegans) are widely used to study the aging process and longevity. Here, we show that a polysaccharide fraction obtained from C. borivilianum increases the lifespan of S. cerevisiae and C. elegans, using an automated screening platform (Chronoscreen TM). Chemical analysis of this extract revealed a low molecular weight polysaccharide of 1000 Da, predominantly comprising Glu1 -> 6Glu linkage. This polysaccharide showed significant dose-dependent extension of the median lifespan of S. cerevisiae by up to 41% and of the median lifespan of C. elegans by up to 10%. Taking cue from these results and the traditionally described benefits of Rasayanas on skin rejuvenation, we tested in vitro the polysaccharide for potential skin benefits. In a keratinocyte culture, we observed that this polysaccharide increased cell proliferation significantly, and induced synthesis of hyaluronic acid (HA), a well-known extracellular matrix component. Furthermore, when added to culture medium of human reconstructed epidermis, we observed an enhanced production of epidermal markers, e.g. CD44 and HA that are otherwise diminished in aged skin. Together, these results suggest that in addition to lifespan extension of S. cerevisiae and C. elegans, a polysaccharide from the Rasayana herb, C. borivilianum may have beneficial effects on skin aging parameters.	[Pannakal, Steve Thomas; Tewari, Amit; Saha, Subarna; Roy, Nita; James, Darryl; Misra, Namita] LOreal Res & Innovat, Bangalore, Karnataka, India; [Jager, Sibylle; Duranton, Albert; Kuntz, Jean Francois; Fermas, Soraya; Breton, Lionel] LOreal Res & Innovat, Aulnay Sous Bois, France; [Radhakrishnan, Aneesha] Inst Bioinformat, Int Tech Pk, Bangalore, Karnataka, India; [Mellor, Jane] Univ Oxford, Dept Biochem, Oxford, England; [Mellor, Jane] Sibelius Ltd, Oxford, England	L'Oreal Group; L'Oreal Group; University of Oxford	Pannakal, ST; Misra, N (corresponding author), LOreal Res & Innovat, Bangalore, Karnataka, India.	spannakal@rd.loreal.com; nmisra@rd.loreal.com		Mellor, Jane/0000-0002-5196-3734; Jager, Sibylle/0000-0001-8102-7149; Duranton, Albert/0000-0002-4057-7176				Averbeck M, 2007, J INVEST DERMATOL, V127, P687, DOI 10.1038/sj.jid.5700614; Baaten Bas Jg, 2010, Commun Integr Biol, V3, P508, DOI 10.4161/cib.3.6.13495; Balasubramani SP, 2011, CHIN J INTEGR MED, V17, P88, DOI 10.1007/s11655-011-0659-5; Bhullar KS, 2015, BBA-MOL BASIS DIS, V1852, P1209, DOI 10.1016/j.bbadis.2015.01.012; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bourguignon LYW, 2006, J INVEST DERMATOL, V126, P1356, DOI 10.1038/sj.jid.5700260; Bourguignon LYW, 2014, AM J PATHOL, V184, P1912, DOI 10.1016/j.ajpath.2014.03.010; BRENNER S, 1974, GENETICS, V77, P71; Chetty C, 2012, CELL SIGNAL, V24, P549, DOI 10.1016/j.cellsig.2011.10.008; Daubenmier JJ, 2007, ANN BEHAV MED; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ELIAS PM, 1991, J CONTROL RELEASE, V15, P199, DOI 10.1016/0168-3659(91)90111-P; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; GARROZZO D, 1995, RAPID COMMUN MASS SP, V9, P937, DOI 10.1002/rcm.1290091014; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Guo LQ, 2007, FOOD CHEM, V100, P643, DOI 10.1016/j.foodchem.2005.09.087; Hsu AL, 2009, NEUROBIOL AGING, V30, P1498, DOI 10.1016/j.neurobiolaging.2007.12.007; Hughes SE, 2007, PLOS GENET, V3, P254, DOI 10.1371/journal.pgen.0030025; Ido Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115341; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Khanam Z, 2013, J ETHNOPHARMACOL, V150, P421, DOI 10.1016/j.jep.2013.08.064; Kim MS, 2005, INT J ONCOL, V27, P839; Kumar R, 2013, ANN NEUROSCI, V20, P13, DOI 10.5214/ans.0972.7531.200106; Larsen BS, 1996, J AM SOC MASS SPECTR, V7, P287, DOI 10.1016/1044-0305(95)00706-7; Laurent M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009346; Li WJ, 2012, J AGR FOOD CHEM, V60, P1413, DOI 10.1021/jf204748a; Lorencini M, 2014, AGEING RES REV, V15, P100, DOI 10.1016/j.arr.2014.03.002; Makrantonaki E, 2007, ANN NY ACAD SCI, V1119, P40, DOI 10.1196/annals.1404.027; Mechref Y, 2003, ANAL CHEM, V75, P4895, DOI 10.1021/ac0341968; Murakami S, 2005, NEUROBIOL AGING, V26, P899, DOI 10.1016/j.neurobiolaging.2004.08.007; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Oh JH, 2011, EXP DERMATOL, V20, P455, DOI 10.1111/j.1600-0625.2011.01258.x; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Olshansky SJ, 2007, ANN NY ACAD SCI, V1114, P11, DOI 10.1196/annals.1396.050; Papakonstantinou E, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.21923; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Priess J. R., 1997, C ELEGANS 2; Raja R, 2016, ONCOTARGET, V7, P61229, DOI 10.18632/oncotarget.11310; Rizzarelli P, 2006, RAPID COMMUN MASS SP, V20, P1683, DOI 10.1002/rcm.2483; Robert C, 2003, PATHOL BIOL, V51, P586, DOI 10.1016/j.patbio.2003.09.009; Ronkart SN, 2006, TALANTA, V70, P1006, DOI 10.1016/j.talanta.2006.02.024; Scherfer C, 2013, AGING-US, V5, P276, DOI 10.18632/aging.100549; Singh R, 2008, BIOGERONTOLOGY, V9, P369, DOI 10.1007/s10522-008-9185-z; Subramaniam V, 2007, EXP MOL PATHOL, V83, P341, DOI 10.1016/j.yexmp.2007.08.007; Tatar M, 2009, J GERONTOL A-BIOL, V64, P161, DOI 10.1093/gerona/gln067; THURINGER JM, 1959, J INVEST DERMATOL, V33, P35, DOI 10.1038/jid.1959.119; Udapa MH, 2004, COMPREHENSIVE KAAYAC; VARANI J, 1994, J CLIN INVEST, V94, P1747, DOI 10.1172/JCI117522; Varley H, 1980, PRACTICAL CLIN CHEM, VI, P491; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; Wilson MA, 2006, AGING CELL, V5, P59, DOI 10.1111/j.1474-9726.2006.00192.x; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Yang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023525; Zhang YS, 2015, PHARMACOGN MAG, V11, P449, DOI [10.4103/0973-1296.1604471, 10.4103/0973-1296.160447]; 2006, ULTRAFLEX 3 USER MAN	59	5	6	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2017	12	7							e179813	10.1371/journal.pone.0179813	http://dx.doi.org/10.1371/journal.pone.0179813			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1YQ	28727758	gold, Green Submitted, Green Published			2023-01-03	WOS:000406634500010
J	Sun, Q; Zhu, JJ; Cao, FW; Chen, FJ				Sun, Qi; Zhu, Jiajin; Cao, Feiwei; Chen, Fengjia			Anti-inflammatory properties of extracts from Chimonanthus nitens Oliv. leaf	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; BIOACTIVE COMPOUNDS; PHENOLIC-COMPOUNDS; COMPREHENSIVE CHARACTERIZATION; ANTIOXIDANT ACTIVITY; IMMUNE-RESPONSES; ZEBRAFISH LARVAE; INFLAMMATION; MODEL; IDENTIFICATION	Chimonanthus nitens Oliv. (CN) is a species in the family Calycanthaceae. Its leaf is widely used to make traditional herbal tea in southern China and has a wide range of therapeutic effects. The profile of the ethanol extracts from CN leaves was identified by UPLC-QTOFMS/ MS. Forty seven compounds were determined including organic acids, phenolic acids and derivatives, flavonoids, coumarins, fatty acids and other compounds. The effect of the CN extracts on the inflammatory damage in zebrafish and in RAW 264.7 cells was investigated. The extracts demonstrated a strong ability to inhibit the recruitment of neutrophils in LPS-stimulated zebrafish, but macrophage migration was not significantly affected. Proinflammatory cytokines (i.e., TNF-alpha, IL-6 and IL-1 beta) were also determined by q-PCR. The extracts strongly reduced mRNA expression of TNF-alpha, IL-6 but not IL-1 beta in zebrafish model, while significantly inhibited the production of the factors in the RAW 264.7 cells. Therefore, our results suggest that the ethanol extracts of CN leaves may serve as a source of nutraceutical compounds with anti-inflammatory properties.	[Sun, Qi; Zhu, Jiajin; Cao, Feiwei; Chen, Fengjia] Zhejiang Univ, Zhejiang Key Lab Agrofood Proc, Zhejiang Engn Ctr Food Technol & Equipment, Fuli Inst Food Sci,Coll Biosyst Engn & Food Sci, Hangzhou, Zhejiang, Peoples R China	Zhejiang University	Zhu, JJ (corresponding author), Zhejiang Univ, Zhejiang Key Lab Agrofood Proc, Zhejiang Engn Ctr Food Technol & Equipment, Fuli Inst Food Sci,Coll Biosyst Engn & Food Sci, Hangzhou, Zhejiang, Peoples R China.	jjzhu@zju.edu.cn	朱, 加进/HHS-3257-2022		National High-tech Research and Development Program of China (863 Program) [2011AA100804]; Research Fund of Fuli Institute of Food Science Zhejiang University [KY201403]	National High-tech Research and Development Program of China (863 Program); Research Fund of Fuli Institute of Food Science Zhejiang University	This research was funded by National High-tech Research and Development Program of China (863 Program) (No. 2011AA100804) (http://program.most.gov.cn/) and Research Fund of Fuli Institute of Food Science Zhejiang University (No. KY201403) (http://fifs.zju.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Chen H, 2016, PLOS ONE, V11, P14; Chen L, 2014, MODERN FOOD SCI TECH, V30, P13; Cho SY, 2003, MOL CELL BIOCHEM, V243, P153, DOI 10.1023/A:1021624520740; Chuang CC, 2011, ANNU REV NUTR, V31, P155, DOI 10.1146/annurev-nutr-072610-145149; Chyau CC, 2015, J FUNCT FOODS, V18, P159, DOI 10.1016/j.jff.2015.06.025; [Commission CP. Pharmacopoeia of the People's Republic of China. Health PCoMo], 1977, PHARMACOPOEIA OF THE; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Cruz FF, 2017, COMP BIOCHEM PHYS C, V194, P28, DOI 10.1016/j.cbpc.2017.01.007; Cadiz-Gurrea MD, 2014, INT J MOL SCI, V15, P20382, DOI 10.3390/ijms151120382; Cadiz-Gurrea MD, 2013, FOOD RES INT, V50, P197, DOI 10.1016/j.foodres.2012.09.038; Debnath T, 2013, MOLECULES, V18, P7253, DOI 10.3390/molecules18067253; Ding ZQ, 2008, PHARM BIOL, V46, P854, DOI 10.1080/13880200802367155; DuPont MS, 2000, J AGR FOOD CHEM, V48, P3957, DOI 10.1021/jf0002387; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Farag MA, 2013, PHYTOCHEM ANALYSIS, V24, P277, DOI 10.1002/pca.2408; FINGER A, 1991, PHYTOCHEMISTRY, V30, P2057, DOI 10.1016/0031-9422(91)85066-9; Fylaktakidou KC, 2004, CURR PHARM DESIGN, V10, P3813, DOI 10.2174/1381612043382710; Gut P, 2013, NAT CHEM BIOL, V9, P97, DOI [10.1038/NCHEMBIO.1136, 10.1038/nchembio.1136]; Hall JE, 2011, GUYTON AND HALL TEXT; Hartman J, 2014, CARDIOL REV, V22, P147, DOI 10.1097/CRD.0000000000000021; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Huang J, 2016, IND CROP PROD, V91, P302, DOI 10.1016/j.indcrop.2016.07.033; Iswaldi I, 2013, FOOD RES INT, V50, P77, DOI 10.1016/j.foodres.2012.09.030; Kawabata K, 2015, FOOD FUNCT, V6, P1399, DOI [10.1039/c4fo01178c, 10.1039/C4FO01178C]; Kim HP, 2004, J PHARMACOL SCI, V96, P229, DOI 10.1254/jphs.CRJ04003X; Kim SM, 2012, BIOMED CHROMATOGR, V26, P199, DOI 10.1002/bmc.1646; Kitajima M, 2006, TETRAHEDRON LETT, V47, P3199, DOI 10.1016/j.tetlet.2006.03.047; Kupeli E, 2007, J ETHNOPHARMACOL, V114, P234, DOI 10.1016/j.jep.2007.08.005; Kwon JH, 2011, ARCH PHARM RES, V34, P1459, DOI 10.1007/s12272-011-0907-4; Le Guyader D, 2008, BLOOD, V111, P132, DOI 10.1182/blood-2007-06-095398; Li CQ, 2007, J ETHNOPHARMACOL, V114, P212, DOI 10.1016/j.jep.2007.08.002; Li L, 2012, J BIOL CHEM, V287, P25353, DOI 10.1074/jbc.M112.349126; Li YJ, 2012, J GENET GENOMICS, V39, P521, DOI 10.1016/j.jgg.2012.07.006; Li Z, 2010, J AGR FOOD CHEM, V58, P6503, DOI 10.1021/jf1006962; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lim D, 2015, J DERMATOL SCI, V79, P288, DOI 10.1016/j.jdermsci.2015.06.012; Lima A, 2014, ZEBRAFISH, V11, P434, DOI 10.1089/zeb.2014.1001; Liu ZZ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/789263; Lv HP, 2015, J FUNCT FOODS, V19, P194, DOI 10.1016/j.jff.2015.09.047; Marcon M, 2016, PSYCHOPHARMACOLOGY, V233, P3815, DOI 10.1007/s00213-016-4408-5; Meier SM, 2015, PLOS ONE, V10, P16; Mena P, 2014, IUBMB LIFE, V66, P745, DOI 10.1002/iub.1332; Mullen W, 2004, J CHROMATOGR A, V1058, P163, DOI 10.1016/j.chroma.2004.08.117; Nabavi SF, 2015, FOOD CHEM, V179, P305, DOI 10.1016/j.foodchem.2015.02.006; Ni SM, 2010, J CHROMATOGR B, V878, P2741, DOI 10.1016/j.jchromb.2010.08.014; Olszewski MB, 2007, J IMMUNOL, V178, P5701, DOI 10.4049/jimmunol.178.9.5701; Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498; Patel PS, 2013, J OBES, V2013, DOI 10.1155/2013/616193; Qing LS, 2012, J CHROMATOGR A, V1249, P130, DOI 10.1016/j.chroma.2012.06.013; Riveiro ME, 2010, CURR MED CHEM, V17, P1325, DOI 10.2174/092986710790936284; Ryu HW, 2015, J FUNCT FOODS, V17, P774, DOI 10.1016/j.jff.2015.06.036; Sanz M, 2010, J AGR FOOD CHEM, V58, P9631, DOI 10.1021/jf102718t; Shelembe JS, 2012, INT J FOOD SCI TECH, V47, P648, DOI 10.1111/j.1365-2621.2011.02889.x; Stankovic MS, 2017, IND CROP PROD, V95, P493, DOI 10.1016/j.indcrop.2016.09.070; Sun Y, 2015, J FUNCT FOODS, V18, P300, DOI 10.1016/j.jff.2015.07.009; Uddin MN, 2016, INT J FOOD PROP, V19, P911, DOI 10.1080/10942912.2015.1048355; [王凌云 Wang Lingyun], 2012, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V23, P3103; Wang WX, 2011, PHYTOCHEM LETT, V4, P271, DOI 10.1016/j.phytol.2011.04.012; Wang XJ, 2005, BIOL PHARM BULL, V28, P1106, DOI 10.1248/bpb.28.1106; Xu W, 2016, J ZHEJIANG UNIV-SC B, V17, P425, DOI 10.1631/jzus.B1500213; Yan B, 2014, J IMMUNOL, V192, P5998, DOI 10.4049/jimmunol.1301645; Yang LL, 2014, MOLECULES, V19, P2390, DOI 10.3390/molecules19022390; Yen CT, 2009, CHEM PHARM BULL, V57, P280, DOI 10.1248/cpb.57.280; Zhang CN, 2017, ECOTOX ENVIRON SAFE, V138, P1, DOI 10.1016/j.ecoenv.2016.12.016; Zhao J, 2013, J CHROMATOGR A, V1313, P2, DOI 10.1016/j.chroma.2013.07.039; Zhou L, 2008, J PHARMACEUT BIOMED, V47, P39, DOI 10.1016/j.jpba.2007.12.009; Zhou Y, 2010, J SEP SCI, V33, P3675, DOI 10.1002/jssc.201000452; Zhu ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096576; Zon LI, 1999, GENOME RES, V9, P99	71	27	32	7	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0181094	10.1371/journal.pone.0181094	http://dx.doi.org/10.1371/journal.pone.0181094			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28700722	Green Published, gold, Green Submitted			2023-01-03	WOS:000405544800120
J	Quill, TE; Arnold, RM; Youngner, SJ				Quill, Timothy E.; Arnold, Robert M.; Youngner, Stuart J.			Physician-Assisted Suicide: Finding a Path Forward in a Changing Legal Environment	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EUTHANASIA		[Quill, Timothy E.] Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 687, Rochester, NY 14642 USA; [Arnold, Robert M.] Univ Pittsburgh, Pittsburgh, PA USA; [Youngner, Stuart J.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Arnold, Robert M.] 1232 North Highland Ave, Pittsburgh, PA 15206 USA; [Youngner, Stuart J.] Case Western Reserve Univ, Dept Bioeth, 10900 Euclid Ave, Cleveland, OH 44106 USA	University of Rochester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University; Case Western Reserve University	Quill, TE (corresponding author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 687, Rochester, NY 14642 USA.	timothy_quill@urmc.rochester.edu						Emanuel EJ, 2016, JAMA-J AM MED ASSOC, V316, P79, DOI 10.1001/jama.2016.8499; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Oregon Health Authority, 2017, DEATH DIGN ACT ANN R; Pearlman RA, 2005, J GEN INTERN MED, V20, P234, DOI 10.1111/j.1525-1497.2005.40225.x; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Sulmasy LS, 2017, ANN INTERN MED, V167, P576, DOI 10.7326/M17-0938	7	5	5	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 17	2017	167	8					597	+		10.7326/M17-2160	http://dx.doi.org/10.7326/M17-2160			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ9JM	28975245				2023-01-03	WOS:000413092700026
J	Cavalcanti, AB; Suzumura, EA; Laranjeira, LN; Paisani, DD; Damiani, LP; Guimaraes, HP; Romano, ER; Regenga, MD; Taniguchi, LNT; Teixeira, C; de Oliveira, RP; Machado, FR; Diaz-Quijano, FA; de Alencar, MS; Maia, IS; Caser, EB; de Oliveira, W; Borges, MD; Martins, PD; Matsui, M; Ospina-Tascon, GA; Giancursi, TS; Giraldo-Rarnirez, ND; Vieira, SRR; Assef, MDPD; Hasan, MS; Szczeklik, W; Rios, F; Amato, MBP; Berwanger, O; de Carvalho, CRR				Cavalcanti, Alexandre Biasi; Suzumura, Erica Aranha; Laranjeira, Ligia Nasi; Paisani, Denise de Moraes; Damiani, Lucas Petri; Guimaraes, Helio Penna; Romano, Edson Renato; Regenga, Marisa de Moraes; Taniguchi, Luzia Noriko Takahashi; Teixeira, Cassiano; de Oliveira, Roselaine Pinheiro; Machado, Flavia Ribeiro; Diaz-Quijano, Fredi Alexander; de Alencar Filho, Meton Soares; Maia, Israel Silva; Caser, Eliana Bernardete; de Oliveira Filho, Wilson; Borges, Marcos de Carvalho; Martins, Priscilla de Aquino; Matsui, Mirna; Ospina-Tascon, Gustavo Adolfo; Giancursi, Thiago Simoes; Giraldo-Rarnirez, Nelson Dario; Rios Vieira, Silvia Regina; Pasquotto de Lima Assef, Maria da Graca; Hasan, Mohd Shahnaz; Szczeklik, Wojciech; Rios, Fernando; Amato, Marcelo Britto Passos; Berwanger, Otavio; Ribeiro de Carvalho, Carlos Roberto		Writing Grp Alveolar Recruitment	Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATION STRATEGY; DRIVING PRESSURE; TIDAL VOLUMES; INJURY; ARDS; MANEUVERS; SUBPHENOTYPES; OUTCOMES	IMPORTANCE The effects of recruitment maneuvers and positive end-expiratory pressure (PEEP) titration on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncertain. OBJECTIVE To determine if lung recruitment associated with PEEP titration according to the best respiratory-system compliance decreases 28-day mortality of patients with moderate to severe ARDS compared with a conventional low-PEEP strategy. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized trial conducted at 120 intensive care units (ICUs) from 9 countries from November 17, 2011, through April 25, 2017, enrolling adults with moderate to severe ARDS. INTERVENTIONS An experimental strategy with a lung recruitment maneuver and PEEP titration according to the best respiratory-system compliance (n = 501; experimental group) or a control strategy of low PEEP (n = 509). All patients received volume-assist control mode until weaning. MAIN OUTCOMES AND MEASURES The primary outcomewas all-cause mortality until 28 days. Secondary outcomes were length of ICU and hospital stay; ventilator-free days through day 28; pneumothorax requiring drainage within 7 days; barotrauma within 7 days; and ICU, in-hospital, and 6-month mortality. RESULTS A total of 1010 patients (37.5% female; mean [SD] age, 50.9 [17.4] years) were enrolled and followed up. At 28 days, 277 of 501 patients (55.3%) in the experimental group and 251 of 509 patients (49.3%) in the control group had died (hazard ratio [HR], 1.20; 95% CI, 1.01 to 1.42; P =.041). Compared with the control group, the experimental group strategy increased 6-month mortality (65.3% vs 59.9%; HR, 1.18; 95% CI, 1.01 to 1.38; P =.04), decreased the number of mean ventilator-free days (5.3 vs 6.4; difference, -1.1; 95% CI, -2.1 to -0.1; P =.03), increased the risk of pneumothorax requiring drainage (3.2% vs 1.2%; difference, 2.0%; 95% CI, 0.0% to 4.0%; P =.03), and the risk of barotrauma (5.6% vs 1.6%; difference, 4.0%; 95% CI, 1.5% to 6.5%; P =.001). There were no significant differences in the length of ICU stay, length of hospital stay, ICU mortality, and in-hospital mortality. CONCLUSIONS AND RELEVANCE In patients with moderate to severe ARDS, a strategy with lung recruitment and titrated PEEP compared with low PEEP increased 28-day all-cause mortality. These findings do not support the routine use of lung recruitment maneuver and PEEP titration in these patients. (C) 2017 American Medical Association. All rights reserved.	[Cavalcanti, Alexandre Biasi; Suzumura, Erica Aranha; Laranjeira, Ligia Nasi; Paisani, Denise de Moraes; Damiani, Lucas Petri; Guimaraes, Helio Penna; Romano, Edson Renato; Regenga, Marisa de Moraes; Taniguchi, Luzia Noriko Takahashi; Berwanger, Otavio] HCor Res Inst, Sao Paulo, Brazil; [Amato, Marcelo Britto Passos; Ribeiro de Carvalho, Carlos Roberto] Univ Sao Paulo, Cardiopulmonary Dept, Div Pulm, Heart Inst Incor, Sao Paulo, Brazil; [Teixeira, Cassiano] Hosp Moinhos de Vento, Porto Alegre, RS, Brazil; [de Oliveira, Roselaine Pinheiro] Irmandade Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil; [Machado, Flavia Ribeiro] Fed Univ Sao Paulo UNIFESP, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil; [Diaz-Quijano, Fredi Alexander] Univ Sao Paulo, Dept Epidemiol, Sch Publ Hlth, Sao Paulo, Brazil; [de Alencar Filho, Meton Soares] Hosp Maternidade Sao Vicente Paulo, Barbalha, Brazil; [Maia, Israel Silva] Hosp Nereu Ramos, Florianopolis, SC, Brazil; [Caser, Eliana Bernardete] Hosp Unimed Vitoria, Vitoria, Brazil; [de Oliveira Filho, Wilson] Hosp & Prontosocorro 28 Agosto, Manaus, Amazonas, Brazil; [Borges, Marcos de Carvalho] Univ Sao Paulo, Unidade Emergencia Hosp Clin FMRP, Ribeirao Preto, Brazil; [Martins, Priscilla de Aquino] Hosp Estadual Dr Jayme Santos Neves, Serra, Brazil; [Martins, Priscilla de Aquino] Fundacao Univ Fed Grande Dourados, Univ Hosp, Dourados, Brazil; [Ospina-Tascon, Gustavo Adolfo] Univ ICESI, Fdn Valle Lili, Dept Intens Care Med, Cali, Colombia; [Giancursi, Thiago Simoes] Hosp Univ Oeste Parana, Cascavel, Brazil; [Giraldo-Rarnirez, Nelson Dario] Hosp Pablo Tobon Uribe, Medellin, Colombia; [Rios Vieira, Silvia Regina] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Pasquotto de Lima Assef, Maria da Graca] Hosp Reg Hans Dieter Schmidt, Joinville, Brazil; [Hasan, Mohd Shahnaz] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; [Szczeklik, Wojciech] Jagiellonian Univ, Med Coll, Dept Intens Care & Perioperat Med, Krakow, Poland; [Rios, Fernando] Hosp Nacl Alejandro Posadas, Moron, Argentina	Hospital do Coracao - HCor; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Federal da Grande Dourados; Fundacion Valle del Lili; Universidad ICESI; Universiti Malaya; Jagiellonian University; Collegium Medicum Jagiellonian University	Cavalcanti, AB (corresponding author), Hosp Coracao, HCor Res Inst, Rua Abilio Soares 250,12th Floor, BR-04005000 Sao Paulo, SP, Brazil.	abiasi@hcor.com.br	Romano, Marcelo Luz Pereira/AAN-6490-2020; amato, Marcelo Britto Passo/L-5001-2016; Teixeira, Cassiano/V-8764-2019; Tascón, Gustavo Adolfo Ospina/AAF-5200-2019; Diaz-Quijano, Fredi Alexander/I-3740-2012; Carvalho, Carlos Roberto R/N-9827-2018; Nowak-Kózka, Ilona/AGU-7285-2022; Guimaraes, Helio Penna/AAD-8681-2019; Suzumura, Erica A/C-4197-2013; Hasan, Mohd Shahnaz/B-9124-2010; Ramli, Mohd Afiq Syahmi/ACE-2786-2022; Szczeklik, Wojciech/N-8096-2014; Ribeiro De Santis Santiago, Roberta/AAV-7359-2020; Réa-Neto, Álvaro/AAR-7909-2020; Hasan, Mohd Shahnaz/AAA-7431-2019; Borges, Marcos Carvalho/A-3585-2014; Cortegiani, Andrea/H-4902-2016; Damiani, Lucas/F-8576-2015	Romano, Marcelo Luz Pereira/0000-0001-6773-1666; amato, Marcelo Britto Passo/0000-0003-3525-8282; Diaz-Quijano, Fredi Alexander/0000-0002-1134-1930; Carvalho, Carlos Roberto R/0000-0002-1618-8509; Nowak-Kózka, Ilona/0000-0003-2807-2500; Suzumura, Erica A/0000-0003-1752-6095; Hasan, Mohd Shahnaz/0000-0002-7493-7416; Szczeklik, Wojciech/0000-0002-1349-1123; Ribeiro De Santis Santiago, Roberta/0000-0002-5818-0361; Hasan, Mohd Shahnaz/0000-0002-7493-7416; Borges, Marcos Carvalho/0000-0001-6280-0714; Rea-Neto, Alvaro/0000-0001-5524-0907; Ferrando, Carlos/0000-0002-1907-5323; Cortegiani, Andrea/0000-0003-1416-9993; Abrahao Hajjar, Ludhmila/0000-0001-5645-2055; Sega, Aurelia/0000-0003-3260-7942; Oliveira, Catherine Cely/0000-0003-0376-5204; Damiani, Lucas/0000-0002-5836-3379; Bermudez-Bravo, William F/0000-0003-3544-5635; Paulino, Maria Carolina/0000-0002-5870-9544; Ospina-Tascon, Gustavo Adolfo/0000-0001-9370-3298; PUIG, JAUME/0000-0001-8272-3859; Guimaraes Leal Guadalupe, Erika/0000-0002-6684-7330; Ambrosina de Oliveira Vargas, Mara/0000-0003-4721-4260	Brazilian Ministry of Health; Brazilian Ministry of Health	Brazilian Ministry of Health; Brazilian Ministry of Health	This study was funded by and conducted as part of the Program to Support Institutional Development of Universal System (PROADI) from the Brazilian Ministry of Health. The trial was coordinated by the HCor Research Institute and endorsed by the Brazilian Research in Intensive Care Network (BRICNet).	Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Beitler JR, 2016, INTENS CARE MED, V42, P1427, DOI 10.1007/s00134-016-4423-3; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-976OC; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cavalcanti AB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-153; Chanques G, 2013, CRIT CARE MED, V41, P2177, DOI 10.1097/CCM.0b013e31828c2d7a; Damiani Lucas Petri, 2017, Rev. bras. ter. intensiva, V29, P142, DOI [10.5935/0103-507x.20170024, 10.5935/0103-507X.20170024]; de Matos GFJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10602; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2016, INTENS CARE MED, V42, P663, DOI 10.1007/s00134-015-4200-8; Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7; Goligher EC, 2015, AM J RESP CRIT CARE, V192, P1416, DOI 10.1164/rccm.201410-1832CP; Guerin C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1556-2; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Guerin C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-9; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Hodgson C, 2016, COCHRANE DB SYST REV, V11; Hodgson CL, 2011, CRIT CARE, V15, DOI 10.1186/cc10249; Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Retamal J, 2015, ACTA ANAESTH SCAND, V59, P1161, DOI 10.1111/aas.12563; Suzumura EA, 2014, INTENS CARE MED, V40, P1227, DOI 10.1007/s00134-014-3413-6	30	485	502	3	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 10	2017	318	14					1335	1345		10.1001/jama.2017.14171	http://dx.doi.org/10.1001/jama.2017.14171			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ6BP	28973363	Green Published, Bronze			2023-01-03	WOS:000412838900017
J	Aoun, SM; Rumbold, B; Howting, D; Bolleter, A; Breen, LJ				Aoun, Samar M.; Rumbold, Bruce; Howting, Denise; Bolleter, Amanda; Breen, Lauren J.			Bereavement support for family caregivers: The gap between guidelines and practice in palliative care	PLOS ONE			English	Article							ADVANCE DIRECTIVES; WESTERN-AUSTRALIA; NEEDS-ASSESSMENT; INTERVENTION; PREDICTORS; NETWORK; PEOPLE	Background Standards for bereavement care propose that support should be matched to risk and need. However, studies in many countries demonstrate that palliative care services continue to adopt a generic approach in offering support to bereaved families. Objective To identify patterns of bereavement support in palliative care services based upon the experience of bereaved people from a population based survey and in relation to clinical practice guidelines. Design An anonymous postal survey collected information from clients of six funeral providers in four Australian states (2014-15), 6 to 24 months after the death of their family member or friend, with 1,139 responding. Responses from 506 bereaved relatives of people who had terminal illnesses were analysed. Of these, 298 had used palliative care services and 208 had not. Results More people with cancer (64%) had received palliative care in comparison to other illnesses such as heart disease, dementia and organ failure (4-10%). The support for family caregivers before and after their relative's death was not considered optimal. Only 39.4% of the bereaved reported being specifically asked about their emotional/psychological distress pre-bereavement, and just half of the bereaved perceived they had enough support from palliative care services. Half of the bereaved had a follow up contact from the service at 3-6 weeks, and a quarter had a follow-up at 6 months. Their qualitative feedback underlined the limited helpfulness of the blanket approach to bereavement support, which was often described as "not personal" or "generic", or "just standard practice". Conclusions Timeliness and consistency of relationship is crucial to building rapport and trust in the service's ability to help at post-bereavement as well as a focus on the specific rather than the generic needs of the bereaved. In light of these limitations, palliative care services might do better investing their efforts principally in assessing and supporting family caregivers during the pre-bereavement period and developing community capacity and referral pathways for bereavement care. Our findings suggest that bereavement support in Australian palliative care services has only a tenuous relationship with guidelines and assessment tools, a conclusion also drawn in studies from other countries, emphasizing the international implications of our study.	[Aoun, Samar M.; Howting, Denise] Curtin Univ, Fac Hlth Sci, Sch Nursing Midwifery & Paramed, Perth, WA, Australia; [Rumbold, Bruce] La Trobe Univ, Palliat Care Unit, Dept Publ Hlth, Melbourne, Vic, Australia; [Bolleter, Amanda] Hlth Dept WA, WA Canc & Palliat Care Network, Perth, WA, Australia; [Breen, Lauren J.] Curtin Univ, Sch Psychol & Speech Pathol, Fac Hlth Sci, Perth, WA, Australia	Curtin University; La Trobe University; Curtin University	Aoun, SM (corresponding author), Curtin Univ, Fac Hlth Sci, Sch Nursing Midwifery & Paramed, Perth, WA, Australia.	s.aoun@curtin.edu.au	Rumbold, Bruce/AAJ-5261-2020; Howting, Denise Ann/GWU-5045-2022; Breen, Lauren J/B-8746-2013	Rumbold, Bruce/0000-0001-6733-6201; Howting, Denise Ann/0000-0001-8753-5849; Breen, Lauren J/0000-0002-0463-0363; Aoun, Samar/0000-0002-4073-4805	WA Cancer and Palliative Care Network, Health Department of Western Australia	WA Cancer and Palliative Care Network, Health Department of Western Australia	The authors acknowledge the financial support of the WA Cancer and Palliative Care Network, Health Department of Western Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r The authors acknowledge the financial support of the WA Cancer and Palliative Care Network, Health Department of Western Australia, the cooperation of funeral providers who assisted with the recruitment of participants, and the bereaved families who agreed to complete the survey and contributed to our understanding in this field.	Abbott J, 2008, AUST J CANC NURS, V9, P12; Agnew A, 2010, PALLIATIVE MED, V24, P46, DOI 10.1177/0269216309107013; Aoun S, 2015, PLOS ONE, P10; Aoun S, 2010, J PALLIAT MED, V13, P653, DOI 10.1089/jpm.2009.0318; Aoun SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121101; Aoun SM, 2014, AUST NZ J PUBL HEAL, V38, P473, DOI 10.1111/1753-6405.12177; Aoun SM, 2012, AUST NZ J PUBL HEAL, V36, P14, DOI 10.1111/j.1753-6405.2012.00825.x; Auerbach AD, 2008, J HOSP MED, V3, P437, DOI 10.1002/jhm.369; Australian Bureau of Statistics, 2015, 33030 AUSTR BUR STAT; Australian Institute for Health and Welfare, 2016, PALL CAR OUTC; Bergman EJ, 2009, J PALLIAT MED, V12, P170, DOI 10.1089/jpm.2008.0237; Breen LJ, 2017, AM J HOSP PALLIAT ME, V34, P275, DOI 10.1177/1049909115615568; Breen LJ, 2014, DEATH STUD, V38, P54, DOI 10.1080/07481187.2012.725451; Burns CM, 2013, PALLIATIVE MED, V27, P608, DOI 10.1177/0269216313483664; Calanzani N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146134; Foliart DE, 2001, DEATH STUD, V25, P461, DOI 10.1080/074811801750257545; Ghesquiere A, 2016, AM J HOSP PALLIAT ME, V33, P124, DOI 10.1177/1049909114555155; Grande GE, 2017, BMJ SUPPORT PALLIAT, V7, P326, DOI 10.1136/bmjspcare-2014-000829; Guldin M., 2015, EUR J PALLIAT CARE, V22, P185; Hall C., 2012, BEREAVEMENT SUPPORT; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hudson P., 2010, CLIN PRACTICE GUIDEL; Hunt KJ, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-3; Lewis E, 2016, PALLIATIVE MED, V30, P807, DOI 10.1177/0269216316637239; Mather MA, 2008, MED J AUSTRALIA, V188, P228, DOI 10.5694/j.1326-5377.2008.tb01590.x; McNamara B, 2006, J PAIN SYMPTOM MANAG, V32, P5, DOI 10.1016/j.jpainsymman.2005.12.018; National Hospice and Palliative Care Organization, 2008, GUID BER CAR HOSP; Nielsen MK, 2017, J PAIN SYMPTOM MANAG, V53, P540, DOI 10.1016/j.jpainsymman.2016.09.013; Office for National Statistics (UK), 2012, NAT BER SURV VOICES; Onwuteaka-Philipsen BD, 2012, PALLIATIVE MED, V26, P656; Palliative Care Australia, 2005, STAND PROV QUAL PALL; Pautex S, 2008, PALLIATIVE MED, V22, P835, DOI 10.1177/0269216308094336; Pidgeon TM, 2017, PALLIAT SUPPORT CARE, P1; Rosenwax LK, 2006, PALLIATIVE MED, V20, P439, DOI 10.1191/0269216306pm1146oa; Rumbold B, 2015, BEREAVE CARE, V34, P99, DOI 10.1080/02682621.2015.1115185; Rumbold B, 2014, PROG PALLIAT CARE, V22, P131, DOI 10.1179/1743291X13Y.0000000079; Schut H, 2001, HDB BEREAVEMENT RES, P705, DOI DOI 10.1037/10436-029; Sealey M, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0046-7; Stroebe M, 2015, PALLIATIVE MED, V29, P574, DOI 10.1177/0269216315585952; Toye C, 2016, INT J NURS STUD, V64, P32, DOI 10.1016/j.ijnurstu.2016.09.012; Walter T., 1999, BEREAVEMENT CULTURE; White B, 2014, INTERN MED J, V44, P975, DOI 10.1111/imj.12549; Williams BR, 2008, DEATH STUD, V32, P197, DOI 10.1080/07481180701881297; World Health Organization, 2007, WHO GUID EFF PROGR P	44	66	68	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2017	12	10							e0184750	10.1371/journal.pone.0184750	http://dx.doi.org/10.1371/journal.pone.0184750			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI7FU	28977013	Green Published, gold, Green Submitted			2023-01-03	WOS:000412163100011
J	Sheridan, C				Sheridan, Cormac			Novartis trial validates inflammasome as chronic disease driver	NATURE BIOTECHNOLOGY			English	News Item																		2015, NAT MED, V21, P248	1	5	5	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2017	35	10					893	894		10.1038/nbt1017-893	http://dx.doi.org/10.1038/nbt1017-893			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FJ5CZ	29020007				2023-01-03	WOS:000412764600003
J	Nogrady, B				Nogrady, Bianca			Too much of a good thing	NATURE			English	Editorial Material							RESTRICTIVE TRANSFUSION											Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612	4	0	0	7	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	2017	549	7673					S22	S23		10.1038/549S22a	http://dx.doi.org/10.1038/549S22a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI4GT	28953864	Bronze			2023-01-03	WOS:000411930000005
J	Hart, G; Gaoue, OG; de la Torre, L; Navarrete, H; Muriel, P; Macia, MJ; Balslev, H; Leon-Yanez, S; Jorgensen, P; Duffy, DC				Hart, G.; Gaoue, Orou G.; de la Torre, Lucia; Navarrete, Hugo; Muriel, Priscilla; Macia, Manuel J.; Balslev, Henrik; Leon-Yanez, Susana; Jorgensen, Peter; Duffy, David Cameron			Availability, diversification and versatility explain human selection of introduced plants in Ecuadorian traditional medicine	PLOS ONE			English	Article							ETHNOBOTANICAL SURVEY; PATTERNS; WEEDS	Globally, a majority of people use plants as a primary source of healthcare and introduced plants are increasingly discussed as medicine. Protecting this resource for human health depends upon understanding which plants are used and how use patterns will change over time. The increasing use of introduced plants in local pharmacopoeia has been explained by their greater abundance or accessibility (availability hypothesis), their ability to cure medical conditions that are not treated by native plants (diversification hypothesis), or as a result of the introduced plants' having many different simultaneous roles (versatility hypothesis). In order to describe the role of introduced plants in Ecuador, and to test these three hypotheses, we asked if introduced plants are over-represented in the Ecuadorian pharmacopoeia, and if their use as medicine is best explained by the introduced plants' greater availability, different therapeutic applications, or greater number of use categories. Drawing on 44,585 plant-use entries, and the checklist of >17,000 species found in Ecuador, we used multi-model inference to test if more introduced plants are used as medicines in Ecuador than expected by chance, and examine the support for each of the three hypotheses above. We find nuanced support for all hypotheses. More introduced plants are utilized than would be expected by chance, which can be explained by geographic distribution, their strong association with cultivation, diversification (except with regard to introduced diseases), and therapeutic versatility, but not versatility of use categories. Introduced plants make a disproportionately high contribution to plant medicine in Ecuador. The strong association of cultivation with introduced medicinal plant use highlights the importance of the maintenance of human-mediated environments such as homegardens and agroforests for the provisioning of healthcare services.	[Hart, G.; Gaoue, Orou G.; Duffy, David Cameron] Univ Hawaii Manoa, Dept Bot, Honolulu, HI 96822 USA; [Gaoue, Orou G.] Univ Johannesburg, Dept Geog Environm Management & Energy Studies, APK Campus, Johannesburg, South Africa; [de la Torre, Lucia] Pontificia Univ Catolica Ecuador, Herbario QCA, Quito, Ecuador; [Navarrete, Hugo; Muriel, Priscilla; Leon-Yanez, Susana] Pontificia Univ Catolica Ecuador, Escuela Biol, Quito, Ecuador; [Macia, Manuel J.] Univ Autonoma Madrid, Dept Biol, Area Bot, Madrid, Spain; [Balslev, Henrik] Aarhus Univ, Inst Biosci, Aarhus, Denmark; [Jorgensen, Peter] Missouri Bot Garden, St Louis, MO USA; [Duffy, David Cameron] Univ Hawaii Manoa, Pacific Cooperat Studies Unit, Honolulu, HI 96822 USA; [Gaoue, Orou G.] Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN USA	University of Hawaii System; University of Hawaii Manoa; University of Johannesburg; Pontificia Universidad Catolica del Ecuador; Pontificia Universidad Catolica del Ecuador; Autonomous University of Madrid; Aarhus University; Missouri Botanical Gardens; University of Hawaii System; University of Hawaii Manoa; University of Tennessee System; University of Tennessee Knoxville	Hart, G (corresponding author), Univ Hawaii Manoa, Dept Bot, Honolulu, HI 96822 USA.	gmhart@hawaii.edu	Gaoue, Orou G./B-4932-2011; Balslev, Hendrik/AAE-4071-2020; Muriel, Priscilla/V-2760-2019; Macia, Manuel J/H-4631-2012; Navarrete, Hugo/CAJ-3461-2022	Gaoue, Orou G./0000-0002-0946-2741; Muriel, Priscilla/0000-0002-7874-8057; Macia, Manuel J/0000-0002-4676-612X; Navarrete, Hugo/0000-0002-5262-9754				Alchon S.A., 1991, NATIVE SOC DIS COLON; Alencar NL, 2014, REV BRAS FARMACOGN, V24, P506, DOI 10.1016/j.bjp.2014.09.003; Alencar NL, 2010, ECON BOT, V64, P68, DOI 10.1007/s12231-009-9104-5; [Anonymous], 2000, ECOLOGY INVASIONS AN, DOI DOI 10.1111/j.1469-8137.2011.03775.x; Bennett BC, 2000, ECON BOT, V54, P90, DOI 10.1007/BF02866603; Bennett BC, 2008, J ETHNOPHARMACOL, V116, P422, DOI 10.1016/j.jep.2007.12.006; Bjora CS, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/s13002-015-0060-0; Bletter N, 2010, PLANTS ADOPTION WHY, P1; Bussmann RW, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-47; Bussmann RW, 2015, MED PLANTS ANDES AMA; Cadena-Gonzalez AL, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-23; Cook F. E. M., 1995, Economic botany data collection standard.; Cook Noble David, 1998, BORN DIE DIS NEW WOR; Crawley M.J., 2012, R BOOK; da Silva TC, 2014, ETHNOBIOL CONSERV, V3, DOI 10.15451/ec2014-6-3.4-1-12; de Albuquerque UP, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-30; de Almeida CFCBR, 2005, J ARID ENVIRON, V62, P127, DOI 10.1016/j.jaridenv.2004.09.020; De la Torre L., 2008, ENCICLOPEDIA PLANTAS; de la Torre L, 2012, ECOL SOC, V17, DOI 10.5751/ES-04582-170115; de Medeiros PM, 2013, J ETHNOPHARMACOL, V150, P729, DOI 10.1016/j.jep.2013.09.026; dos Santos LL, 2014, ECON BOT, V68, P283, DOI 10.1007/s12231-014-9281-8; Eyssartier C, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-25; FEENY D, 1990, HUM ECOL, V18, P1, DOI 10.1007/BF00889070; Feeny P., 1976, BIOCHEMICAL INTERACT, V10, P1, DOI [DOI 10.1007/978-1-4684-2646-5_1, 10.1007/978-1-4684-2646-5_1]; Fenn Elizabeth, 2001, POX AM GREAT SMALLPO; Gavin MC, 2009, J APPL ECOL, V46, P1275, DOI 10.1111/j.1365-2664.2009.01713.x; Giovannini P, 2015, J ETHNOPHARMACOL, V164, P78, DOI 10.1016/j.jep.2015.01.038; Gruca M, 2014, J ETHNOPHARMACOL, V155, P1388, DOI 10.1016/j.jep.2014.06.047; Hofmann A., 1979, PLANTS GODS THEIR SA; Jorgensen P., 2018, CATALOGUE VASCULAR P; Jorgensen PM, 2004, CLIM CHANG BIODIVERS, P192; Kirkham WS, 2005, UNDERSTANDING MERREM; Kunwar RM, 2015, J ETHNOPHARMACOL, V163, P210, DOI 10.1016/j.jep.2015.01.035; Kunwar RM, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/792789; Lewu FB, 2009, AFR J BIOTECHNOL, V8, P929; Lukes J, 2007, P NATL ACAD SCI USA, V104, P9375, DOI 10.1073/pnas.0703678104; Macia MJ, 2005, J ETHNOPHARMACOL, V97, P337, DOI 10.1016/j.jep.2004.11.022; McClatchey WC, 2009, PHARMACOL THERAPEUT, V123, P239, DOI 10.1016/j.pharmthera.2009.04.002; MOERMAN DE, 1979, J ETHNOPHARMACOL, V1, P111, DOI 10.1016/0378-8741(79)90002-3; Moerman DE, 1996, J ETHNOPHARMACOL, V52, P1, DOI 10.1016/0378-8741(96)01393-1; Muniz de Medeiros P., 2015, EVOLUTIONARY ETHNOBI, P163; Neill D, 2012, REV AMAZONICA CIENCI, V1, P70; Palmer CT, 2004, ECON BOT, V58, pS280, DOI 10.1663/0013-0001(2004)58[S280:TIORIP]2.0.CO;2; Pfeiffer JM, 2008, ENVIRON CONSERV, V35, P281, DOI 10.1017/S0376892908005146; PRANCE G T, 1987, Conservation Biology, V1, P296, DOI 10.1111/j.1523-1739.1987.tb00050.x; Prance G. T., 1998, Plants for food and medicine. Proceedings of the joint conference of the Society for Economic Botany and the International Society for Ethnopharmacology, London, UK, 1-6 July 1996., P185; Robinson M.M., 2011, WORLD MED SITUATION, P27; Soldati GT, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/648469; Stepp JR, 2004, J ETHNOPHARMACOL, V92, P163, DOI 10.1016/j.jep.2004.03.002; Stepp JR, 2001, J ETHNOPHARMACOL, V75, P19, DOI 10.1016/S0378-8741(00)00385-8; Team R. C, 2018, R LANG ENV STAT COMP; Turner N., 2014, ANCIENT PATHWAYS ANC, V74; Vitousek PM, 1997, NEW ZEAL J ECOL, V21, P1; Voeks RA, 2004, ANN ASSOC AM GEOGR, V94, P868; Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775; Yessoufou K, 2015, MOL ECOL RESOUR, V15, P405, DOI 10.1111/1755-0998.12310; Zimdahl R. L., 1999, FUNDAMENTALS WEED SC	57	26	28	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0184369	10.1371/journal.pone.0184369	http://dx.doi.org/10.1371/journal.pone.0184369			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG2YO	28886104	Green Submitted, Green Published, gold			2023-01-03	WOS:000410001100103
J	O'Neil, ME; Nugent, SM; Morasco, BJ; Freeman, M; Low, A; Kondo, K; Zakher, B; Elven, C; Motu'apuaka, M; Paynter, R; Kansagara, D				O'Neil, Maya E.; Nugent, Shannon M.; Morasco, Benjamin J.; Freeman, Michele; Low, Allison; Kondo, Karli; Zakher, Bernadette; Elven, Camille; Motu'apuaka, Makalapua; Paynter, Robin; Kansagara, Devan			Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							MEDICAL MARIJUANA; SYMPTOM SEVERITY; UNITED-STATES; MENTAL-HEALTH; PTSD; NIGHTMARES; VETERANS; PREVALENCE	Background: Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose: To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based cannabis preparations in treating PTSD in adults. Data Sources: MEDLINE, the Cochrane Library, and other sources from database inception to March 2017. Study Selection: English-language systematic reviews, trials, and observational studies with a control group that reported PTSD symptoms and adverse effects of plant-based cannabis use in adults with PTSD. Data Extraction: Study data extracted by 1 investigator was checked by a second reviewer; 2 reviewers independently assessed study quality, and the investigator group graded the overall strength of evidence by using standard criteria. Data Synthesis: Two systematic reviews, 3 observational studies, and no randomized trials were found. The systematic reviews reported insufficient evidence to draw conclusions about benefits and harms. The observational studies found that compared with nonuse, cannabis did not reduce PTSD symptoms. Studies had medium and high risk of bias, and overall evidence was judged insufficient. Two randomized trials and 6 other studies examining outcomes of cannabis use in patients with PTSD are ongoing and are expected to be completed within 3 years. Limitation: Very scant evidence with medium to high risk of bias. Conclusion: Evidence is insufficient to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD, but several ongoing studies may soon provide important results.	[O'Neil, Maya E.; Nugent, Shannon M.; Morasco, Benjamin J.] Vet Affairs Portland Hlth Care Syst, RD 66,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA; [Freeman, Michele; Low, Allison; Kondo, Karli; Motu'apuaka, Makalapua; Paynter, Robin] VA Portland Hlth Care Syst, RD 71,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA; [Zakher, Bernadette; Elven, Camille] Oregon Hlth & Sci Univ, 3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA; [Kansagara, Devan] VA Portland Hlth Care Syst, P3MED,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	O'Neil, ME (corresponding author), Vet Affairs Portland Hlth Care Syst, RD 66,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.	maya.oneil@va.gov	Kondo, Karli/R-3994-2019	Kondo, Karli/0000-0002-4635-5056; Paynter, Robin/0000-0002-6969-4261	U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative [PROSPERO: CRD42016033623]	U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative(US Department of Veterans Affairs)	U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. (PROSPERO: CRD42016033623)	Adler JN, 2013, NEW ENGL J MED, V368, pE30, DOI 10.1056/NEJMclde1305159; Atkins D, 2011, AHRQ PUBLICATION; Berkman N, 2011, AHRQ PUBLICATION, V11-E006; Boden MT, 2013, AM J ADDICTION, V22, P277, DOI 10.1111/j.1521-0391.2012.12018.x; Bonn-Miller MO, 2015, AM J DRUG ALCOHOL AB, V41, DOI 10.3109/00952990.2015.1043209; Bonn-Miller MO, 2014, DRUG ALCOHOL DEPEN, V136, P162, DOI 10.1016/j.drugalcdep.2013.12.008; Bonn-Miller MO, 2013, PSYCHOL TRAUMA-US, V5, P193, DOI 10.1037/a0026621; Bonn-Miller MO, 2017, MARIJUANA USE PTSD V; Bowles DW, 2012, J PALLIAT MED, V15, P9, DOI 10.1089/jpm.2011.0356; Butler M, 2016, MED CANNABIS NONCANC; Cameron C, 2014, J CLIN PSYCHOPHARM, V34, P559, DOI 10.1097/JCP.0000000000000180; Committee on Treatment of Posttraumatic Stress Disorder, 2014, TREATM POSTTR STRESS; Fraser GA, 2009, CNS NEUROSCI THER, V15, P84, DOI 10.1111/j.1755-5949.2008.00071.x; Greer GR, 2014, J PSYCHOACTIVE DRUGS, V46, P73, DOI 10.1080/02791072.2013.873843; Hasin DS, 2015, JAMA PSYCHIAT, V72, P1235, DOI 10.1001/jamapsychiatry.2015.1858; Jetly R, 2015, PSYCHONEUROENDOCRINO, V51, P585, DOI 10.1016/j.psyneuen.2014.11.002; Johnson MJ, 2016, J AFFECT DISORDERS, V190, P439, DOI 10.1016/j.jad.2015.10.048; Kansagara D, 2016, CANNABIS MANAGEMENT; Kansagara D, 2016, 05225 VA ESP; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; Management of Post-Traumatic Stress Working Group, 2010, VA DOD CLIN PRACT GU; Mashiah M., 2012, PAT OUT TIM C TUCS A; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C; National Conference of State Legislatures, 2017, MAR OV; Nugent SM, 2017, ANN INTERN MED, V167, P319, DOI 10.7326/M17-0155; Reznik I., 2011, INT C INT MED JER IS; Roitman P, 2014, CLIN DRUG INVEST, V34, P587, DOI 10.1007/s40261-014-0212-3; Ruglass LM, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020014; Ryan-Ibarra S, 2015, DRUG ALCOHOL REV, V34, P141, DOI 10.1111/dar.12207; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; U.S. Department of Veterans Affairs; National Center for PTSD, 2017, COOCC COND PTSD; Viswanathan M AM, 2012, METHODS GUIDE EFFECT; Walsh Z, 2017, CLIN PSYCHOL REV, V51, P15, DOI 10.1016/j.cpr.2016.10.002; Wells G, 2014, NEWCASTLE OTTAWA SCA; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Wilkinson ST, 2016, J CLIN PSYCHIAT, V77, P1050, DOI 10.4088/JCP.15r10036; Wilkinson ST, 2015, J CLIN PSYCHIAT, V76, P1174, DOI 10.4088/JCP.14m09475	37	41	41	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2017	167	5					332	+		10.7326/M17-0477	http://dx.doi.org/10.7326/M17-0477			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF6LC	28806794				2023-01-03	WOS:000409120400007
J	Lee, EP; Hsia, SH; Hsiao, HF; Chen, MC; Lin, JJ; Chan, OW; Lin, CY; Yang, MC; Liao, SL; Lai, SH				Lee, En-Pei; Hsia, Shao-Hsuan; Hsiao, Hsiu-Feng; Chen, Min-Chi; Lin, Jainn-Jim; Chan, Oi-Wa; Lin, Chia-Ying; Yang, Mei-Chin; Liao, Sui-Ling; Lai, Shen-Hao			Evaluation of diaphragmatic function in mechanically ventilated children: An ultrasound study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; PEDIATRIC INTENSIVE-CARE; RISK-FACTORS; EXTUBATION; DYSFUNCTION; THICKNESS; ATROPHY; FIBERS	Background The recovery of diaphragmatic function is vital for successful extubation from mechanical ventilation. Recent studies have detected diaphragm atrophy in ventilated adults by using ultrasound, but no similar report has been conducted in children. In the current study, we hypothesized that mechanically ventilated children may also develop diaphragm atrophy and diaphragmatic dysfunction. Materials and methods Children who were admitted to the pediatric intensive care unit and were newly intubated for mechanical ventilation were enrolled into this prospective case-control study. Diaphragm ultrasound assessments were performed daily to evaluate diaphragmatic function in the enrolled children until their discharge from the pediatric intensive care unit. Diaphragm thickness and the diaphragmatic thickening fraction (DTF) were measured through these assessments. Results A total of 31 patients were enrolled, and overall, 1389 ultrasound assessments were performed. Immediately after intubation, the initial diaphragm thickness and DTF were measured to be 1.94 +/- 0.44 mm and 25.85% +/- 3.29%, respectively. In the first 24 hours of mechanical ventilation, diaphragm thickness and the DTF decreased substantially and decreased gradually thereafter. After extubation, the DTF was significantly different between the successful and failed extubation groups (P < 0.001), and a DTF value of <17% was associated with extubation failure. Conclusions Diaphragm ultrasound is a noninvasive method for measuring diaphragmatic function in mechanically ventilated children. In this study, significant diaphragm atrophy and a decreased DTF were observed within 24 hours of mechanical ventilation. The recovery of diaphragm thickness and the DTF may be a potential predictor of successful extubation from mechanical ventilation.	[Lee, En-Pei; Hsia, Shao-Hsuan; Lin, Jainn-Jim; Chan, Oi-Wa; Lin, Chia-Ying] Chang Gung Mem Hosp Linkou, Dept Pediat, Div Pediat Crit Care Med, Taoyuan, Taiwan; [Lee, En-Pei; Hsia, Shao-Hsuan; Lin, Jainn-Jim; Chan, Oi-Wa; Lin, Chia-Ying; Liao, Sui-Ling; Lai, Shen-Hao] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Hsiao, Hsiu-Feng; Yang, Mei-Chin] Chang Gung Mem Hosp Linkou, Dept Resp Therapy, Taoyuan, Taiwan; [Chen, Min-Chi] Chang Gung Mem Hosp, Dept Hematol & Oncol, Chiayi, Taiwan; [Chen, Min-Chi] Chang Gung Univ, Coll Med, Dept Publ Hlth, Taoyuan, Taiwan; [Chen, Min-Chi] Chang Gung Univ, Coll Med, Biostat Consulting Ctr, Taoyuan, Taiwan; [Lin, Jainn-Jim] Chang Gung Mem Hosp Linkou, Dept Pediat, Div Pediat Neurol, Taoyuan, Taiwan; [Liao, Sui-Ling] Chang Gung Mem Hosp Keelung, Dept Pediat, Keelung, Taiwan; [Lai, Shen-Hao] Chang Gung Mem Hosp Linkou, Dept Pediat, Div Pediat Pulmonol, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Lai, SH (corresponding author), Chang Gung Univ, Coll Med, Taoyuan, Taiwan.; Lai, SH (corresponding author), Chang Gung Mem Hosp Linkou, Dept Pediat, Div Pediat Pulmonol, Taoyuan, Taiwan.	kpm104@adm.cgmh.org.tw			Chang Gung Memorial Hospital [CMRPG3E1211, CMRPG3E1212, CMRPG3E1213, CMRPG3E1211-3]; Ministry of Health and Ware, Taiwan [KMRPB3F032]; Ministry of Health and Ware [KMRPB3F032]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Ministry of Health and Ware, Taiwan; Ministry of Health and Ware	This work was supported by Chang Gung Memorial Hospital (CMRPG3E1211, CMRPG3E1212, and CMRPG3E1213) and the Ministry of Health and Ware, Taiwan (KMRPB3F032). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors are grateful to the financial support of the Ministry of Health and Ware (KMRPB3F032) and Chang Gung Memorial Hospital (CMRPG3E1211-3).	Baldwin CE, 2011, RESPIROLOGY, V16, P1136, DOI 10.1111/j.1440-1843.2011.02005.x; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cholette J, 2009, CRIT CARE MED, V37, pA434, DOI 10.1097/CCM.0b013e3181b6e760; Cohn D, 1997, J APPL PHYSIOL, V83, P291, DOI 10.1152/jappl.1997.83.1.291; Demoule A, 2013, AM J RESP CRIT CARE, V188, P213, DOI 10.1164/rccm.201209-1668OC; DiNino E, 2014, THORAX, V69, P423, DOI 10.1136/thoraxjnl-2013-204111; Farias JA, 2004, INTENS CARE MED, V30, P918, DOI 10.1007/s00134-004-2225-5; Ferrari G, 2014, CRIT ULTRASOUND J, V6, DOI 10.1186/2036-7902-6-8; Fontela Patricia S, 2005, Pediatr Crit Care Med, V6, P166, DOI 10.1097/01.PCC.0000154922.65189.48; Goligher EC, 2015, INTENS CARE MED, V41, P642, DOI 10.1007/s00134-015-3687-3; Grosu HB, 2012, CHEST, V142, P1455, DOI 10.1378/chest.11-1638; Khemani RG, 2007, PEDIAT CRIT CARE M S, V8, pA39, DOI [DOI 10.1001/JAMA.293.4.470, 10.1001/jama.293.4.470]; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; Kurachek SC, 2003, CRIT CARE MED, V31, P2657, DOI 10.1097/01.CCM.0000094228.90557.85; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Matamis D, 2013, INTENS CARE MED, V39, P801, DOI 10.1007/s00134-013-2823-1; McCool FD, 1997, AM J RESP CRIT CARE, V155, P1329, DOI 10.1164/ajrccm.155.4.9105075; Newth CJL, 2009, PEDIATR CRIT CARE ME, V10, P1, DOI 10.1097/PCC.0b013e318193724d; Polla B, 2004, THORAX, V59, P808, DOI 10.1136/thx.2003.009894; Powers SK, 2013, AM J PHYSIOL-REG I, V305, pR464, DOI 10.1152/ajpregu.00231.2013; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Umbrello M, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0894-9; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Vivier E, 2012, INTENS CARE MED, V38, P796, DOI 10.1007/s00134-012-2547-7; Zambon M, 2013, ANN UPDATE INTENSIVE, V2013, P427; Zambon M, 2016, CRIT CARE MED, V44, P1347, DOI 10.1097/CCM.0000000000001657; Zambon M, 2013, INTENS CARE MED, V39, P986, DOI 10.1007/s00134-013-2882-3	28	26	29	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2017	12	8							e0183560	10.1371/journal.pone.0183560	http://dx.doi.org/10.1371/journal.pone.0183560			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE2ZB	28829819	Green Submitted, gold, Green Published			2023-01-03	WOS:000408085100057
J	Rodriguez, K; Srivaths, PR; Tal, L; Watson, MN; Riley, AA; Himes, RW; Desai, MS; Braun, MC; Arikan, AA				Rodriguez, Keila; Srivaths, Poyyapakkam R.; Tal, Leyat; Watson, Mary N.; Riley, Alyssa A.; Himes, Ryan W.; Desai, Moreshwar S.; Braun, Michael C.; Arikan, Ayse Akcan			Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure	PLOS ONE			English	Article							CONTINUOUS VENOVENOUS HEMODIALYSIS; HEPARIN ANTICOAGULATION; CRRT; METAANALYSIS; SUPERIOR; SAFETY	Pediatric liver failure patients frequently develop multiple organ failure and require continuous renal replacement therapy (CRRT) as part of supportive therapy in the pediatric intensive care unit. While many centers employ no anticoagulation for fear of bleeding complications, balanced coagulation disturbance predisposes these patients to clotting as well as bleeding, making maintenance of longer circuit life to deliver adequate dialysis clearance challenging. Regional citrate anticoagulation (RCA) is an attractive option as it avoids systemic anticoagulation, but since citrate metabolism is impaired in liver failure, concerns about toxicity has limited its use. Pediatric data on RCA with liver failure is very scarce. We aimed to establish safety and efficacy of RCA in pediatric liver failure patients on CRRT. Retrospective review of pediatric patients with liver failure receiving CRRT over 30 months. Demographic data and CRRT related data were collected by chart review. Citrate accumulation (CA) was defined as total calcium (mg/dl) /ionized calcium (mmol/L) ratio >2.5 for >48 hours. Efficacy was assessed by filter life. Safety was assessed by frequency of adverse events ((AEs) defined as bleeding, hemodynamic instability, arrhythmias). Fifty-one patients (median age 3.5 (IQR 0.75-14.2) years) received 861 CRRT days; 70% experienced at least one episode of CA, only 37% were recorded as such in the medical record. AE rate was 93/1000 CRRT days and did not differ between CA days and others. Median filter life was 66 hours (IQR 29-74); 63% filters lasted longer than 48 hrs. Though common, CA was not associated with increased AEs on in pediatric liver failure patients on CRRT receiving RCA. Filter life was adequate. RCA appears an effective anticoagulation for CRRT in pediatric liver failure. Application of a structured definition would increase recognition of CA to allow timely intervention.	[Rodriguez, Keila] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Srivaths, Poyyapakkam R.; Tal, Leyat; Riley, Alyssa A.; Braun, Michael C.; Arikan, Ayse Akcan] Baylor Coll Med, Dept Pediat, Renal Sect, Houston, TX 77030 USA; [Watson, Mary N.] Texas Childrens Hosp, Houston, TX 77030 USA; [Himes, Ryan W.] Baylor Coll Med, Dept Pediat, Liver Sect, Houston, TX 77030 USA; [Desai, Moreshwar S.; Arikan, Ayse Akcan] Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Arikan, AA (corresponding author), Baylor Coll Med, Dept Pediat, Renal Sect, Houston, TX 77030 USA.; Arikan, AA (corresponding author), Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA.	aysea@bcm.edu		Himes, Ryan/0000-0002-0116-2613; Akcan Arikan, Ayse/0000-0002-5123-6713				Agarwal B, 2009, J HEPATOL, V51, P504, DOI 10.1016/j.jhep.2009.05.028; Ashbrook MJ, 2015, CLIN EXP IMMUNOL; Bagshaw SM, 2005, J CRIT CARE, V20, P155, DOI 10.1016/j.jcrc.2005.01.001; Bai M, 2015, INTENS CARE MED, V41, P2098, DOI 10.1007/s00134-015-4099-0; Betrosian AP, 2007, WORLD J GASTROENTERO, V13, P5552, DOI 10.3748/wjg.v13.i42.5552; Brophy PD, 2005, NEPHROL DIAL TRANSPL, V20, P1416, DOI 10.1093/ndt/gfh817; Chadha V, 2002, PEDIATR NEPHROL, V17, P819, DOI 10.1007/s00467-002-0963-6; Cubattoli L, 2007, INT J ARTIF ORGANS, V30, P244, DOI 10.1177/039139880703000310; De Vico P, 2015, THER APHER DIAL, V19, P272, DOI 10.1111/1744-9987.12280; Deep A, 2016, CRIT CARE MED, V44, P1910, DOI 10.1097/CCM.0000000000001826; Elhanan N, 2004, PEDIATR NEPHROL, V19, P208, DOI 10.1007/s00467-003-1328-5; Gonwa TA, 2012, BLOOD PURIFICAT, V33, P144, DOI 10.1159/000334149; Gutierrez-Bernays D, 2016, THER APHER DIAL, V20, P53, DOI 10.1111/1744-9987.12331; Jacobs R, 2015, BLOOD PURIFICAT, V40, P194, DOI 10.1159/000438820; Jalan R, 2012, J HEPATOL, V57, P1336, DOI 10.1016/j.jhep.2012.06.026; Khadzhynov D, 2014, J CRIT CARE, V29, P265, DOI 10.1016/j.jcrc.2013.10.015; Lexmond WS, 2015, LIVER TRANSPLANT, V21, P369, DOI 10.1002/lt.24037; Liet JM, 2014, PEDIATR NEPHROL, V29, P1647, DOI 10.1007/s00467-014-2881-9; Liet JM, 2014, PEDIATR NEPHROL, V29, P1625, DOI 10.1007/s00467-014-2770-2; MacLaren G, 2009, INTENS CARE MED, V35, P596, DOI 10.1007/s00134-009-1425-4; Mariano F, 2011, INT J NEPHROL, V2011, DOI 10.4061/2011/748320; Meier-Kriesche HU, 2001, CRIT CARE MED, V29, P748, DOI 10.1097/00003246-200104000-00010; Musielak A, 2016, THER APHER DIAL; Fernandez SN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/786301; Oudemans-van Straaten HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11645; Park Joon-Sung, 2011, Korean Journal of Internal Medicine, V26, P68, DOI 10.3904/kjim.2011.26.1.68; Rico MP, 2016, PEDIATR NEPHROL, P1; Schilder L, 2014, CRIT CARE, V18; Schultheiss C, 2012, CRIT CARE, V16, DOI 10.1186/cc11485; SLOWINSKI T, 2015, CRIT CARE, V19; Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115; Symons JM, 2007, CLIN J AM SOC NEPHRO, V2, P732, DOI 10.2215/CJN.03200906; Wu MY, 2012, AM J KIDNEY DIS, V59, P810, DOI 10.1053/j.ajkd.2011.11.030	33	20	21	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2017	12	8							e0182134	10.1371/journal.pone.0182134	http://dx.doi.org/10.1371/journal.pone.0182134			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC9EU	28792509	Green Published, Green Submitted, gold			2023-01-03	WOS:000407144700012
J	Fralick, M; Avorn, J; Kesselheim, AS				Fralick, Michael; Avorn, Jerry; Kesselheim, Aaron S.			The Price of Crossing the Border for Medications	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Fralick, Michael; Avorn, Jerry; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Fralick, Michael; Avorn, Jerry; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA; [Fralick, Michael] Univ Toronto, Clinician Scientist Training Program, Toronto, ON, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Toronto	Fralick, M (corresponding author), Brigham & Womens Hosp, Dept Med, Program Regulat Therapeut & Law, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.; Fralick, M (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Fralick, M (corresponding author), Univ Toronto, Clinician Scientist Training Program, Toronto, ON, Canada.		Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Califf RM, 2017, COMMUNICATION; Health Canada, INSP PROGR ANN INSP; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Sanders B, AFFORDABLE SAFE PRES; Vega Ana D, 2016, Manag Care, V25, P41	5	11	11	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	2017	377	4					311	313		10.1056/NEJMp1704489	http://dx.doi.org/10.1056/NEJMp1704489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BB	28745989				2023-01-03	WOS:000406295000002
J	Haga, F; Maruko, R; Sato, C; Kataoka, K; Ito, Y; Terasaki, H				Haga, Fuminori; Maruko, Ruka; Sato, Chiaki; Kataoka, Keiko; Ito, Yasuki; Terasaki, Hiroko			Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study	PLOS ONE			English	Article							SUBFOVEAL CHOROIDAL THICKNESS; HUMAN EYES; VERTEPORFIN; CORTICOSTEROIDS; RETINOPATHY; RISK	Purpose To evaluate the long-term efficacy and factors involved in the recurrence and persistence of subretinal fluid (SRF) after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Methods In this retrospective observational case series, 79 eyes (73 patients) with chronic CSC were treated with half-dose PDT and followed up for at least 3 years. They were divided into successful (64 eyes) and unsuccessful (15 eyes) groups based on SRF absorption and disease recurrence after one PDT session. Age, best-corrected visual acuity (BCVA), central foveal thickness, neuroretinal thickness, height of SRF, subfoveal choroidal thickness, window defect area detected by fluorescein angiography, and PDT spot area were compared between the groups. Factors associated with PDT success and BCVA at 3 years were investigated. Results LogMAR BCVA improved from 0.21 +/- 0.24 to 0.08 +/- 0.16 (P<0.001) at 3 years after PDT. Compared with the unsuccessful group, the successful group had a significantly younger mean age (50.5 +/- 9.7 vs. 56.5 +/- 9.1 years, P = 0.032) and better baseline BCVA (0.18 +/- 0.23 vs. 0.32 +/- 0.25, P = 0.034). Other parameters were not significantly different. Multivariate analyses showed that unsuccessful PDT was significantly associated with lower baseline BCVA (P = 0.026) and older age (P = 0.029) and that BCVA at 3 years after PDT was positively associated with baseline BCVA (P<0.001). Conclusions Half-dose PDT has a long-term efficacy in chronic CSC. Relatively early PDT may improve anatomic and functional outcomes of chronic CSC.	[Haga, Fuminori; Maruko, Ruka; Sato, Chiaki; Kataoka, Keiko; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi, Japan	Nagoya University	Ito, Y (corresponding author), Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi, Japan.	yasu@med.nagoya-u.ac.jp	Maruko, Ruka/M-4929-2014; Ito, Yasuki/M-4876-2014; Kataoka, Keiko/B-2806-2016	Maruko, Ruka/0000-0003-0208-1011; Ito, Yasuki/0000-0001-9219-9261; Kataoka, Keiko/0000-0002-8795-6536	Japan Society for the Promotion of Science (JSPS, Tokyo, Japan) KAKENHI [16K11265, 15H04994]	Japan Society for the Promotion of Science (JSPS, Tokyo, Japan) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by Japan Society for the Promotion of Science (JSPS, Tokyo, Japan) KAKENHI Grant Number (16K11265 (YI) and 15H04994(HT)). There was no additional external funding received for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENNETT G, 1955, Br J Ophthalmol, V39, P605, DOI 10.1136/bjo.39.10.605; Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X; Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014; Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f; Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453; CHUMBLEY LC, 1974, AM J OPHTHALMOL, V77, P158, DOI 10.1016/0002-9394(74)90667-9; Colucciello M, 2006, RETINA-J RET VIT DIS, V26, P239, DOI 10.1097/00006982-200602000-00027; Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034; Gass JD, 1967, AM J OPHTHALMOL S, V63; GELBER GS, 1987, AM J PSYCHIAT, V144, P46; GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815; Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024; Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017; Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83; Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011; Karakus SH, 2013, EYE, V27, P612, DOI 10.1038/eye.2013.24; KLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247; Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282; Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z; Lim JI, 2014, OPHTHALMOLOGY, V121, P1073, DOI 10.1016/j.ophtha.2013.11.040; Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1; Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023; Moon JW, 2009, GRAEF ARCH CLIN EXP, V247, P1315, DOI 10.1007/s00417-009-1104-8; Ooto S, 2010, OPHTHALMOLOGY, V117, P1800, DOI 10.1016/j.ophtha.2010.01.042; PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5; Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002; Prunte C, 1996, AM J OPHTHALMOL, V121, P26; Pryds A, 2012, ACTA OPHTHALMOL, V90, P738, DOI 10.1111/j.1755-3768.2011.02157.x; Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4; Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043; Thavikulwat AT, 2015, DOC OPHTHALMOL; Tsai DC, 2014, RETINA-J RET VIT DIS, V34, P1867, DOI 10.1097/IAE.0000000000000159; Tseng CC, 2015, BR J OPHTHALMOL; Uetani R, 2012, EYE, V26, P641, DOI 10.1038/eye.2012.66; Wang MSM, 2002, AM J OPHTHALMOL, V133, P787, DOI 10.1016/S0002-9394(02)01438-1; Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048; Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799; Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002	38	30	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2017	12	7							e0181479	10.1371/journal.pone.0181479	http://dx.doi.org/10.1371/journal.pone.0181479			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8BB	28742138	Green Published, gold, Green Submitted			2023-01-03	WOS:000406362700046
J	Anaker, A; von Koch, L; Sjostrand, C; Bernhardt, J; Elf, M				Anaker, Anna; von Koch, Lena; Sjostrand, Christina; Bernhardt, Julie; Elf, Marie			A comparative study of patients' activities and interactions in a stroke unit before and after reconstruction-The significance of the built environment	PLOS ONE			English	Article							ENRICHED ENVIRONMENT; PHYSICAL-ACTIVITY; REHABILITATION; CARE; ROOMS; EMERGENCY	Early mobilization and rehabilitation, multidisciplinary stroke expertise and comprehensive therapies are fundamental in a stroke unit. To achieve effective and safe stroke care, the physical environment in modern stroke units should facilitate the delivery of evidence-based care. Therefore, the purpose of this study was to explore patients' activities and interactions in a stroke unit before the reconstruction of the physical environment, while in a temporary location and after reconstruction. This case study examined a stroke unit as an integrated whole. The data were collected using a behavioral mapping technique at three different time points: in the original unit, in the temporary unit and in the new unit. A total of 59 patients were included. The analysis included field notes from observations of the physical environment and examples from planning and design documents. The findings indicated that in the new unit, the patients spent more time in their rooms, were less active, and had fewer interactions with staff and family than the patients in the original unit. The reconstruction involved a change from a primarily multi-bed room design to single-room accommodations. In the new unit, the patients' lounge was located in a far corner of the unit with a smaller entrance than the patients' lounge in the old unit, which was located at the end of a corridor with a noticeable entrance. Changes in the design of the stroke unit may have influenced the patients' activities and interactions. This study raises the question of how the physical environment should be designed in the future to facilitate the delivery of health care and improve outcomes for stroke patients. This research is based on a case study, and although the results should be interpreted with caution, we strongly recommend that environmental considerations be included in future stroke guidelines.	[Anaker, Anna; von Koch, Lena; Elf, Marie] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Anaker, Anna; Elf, Marie] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden; [von Koch, Lena; Sjostrand, Christina] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden; [Sjostrand, Christina] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Bernhardt, Julie] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Elf, Marie] Chalmers Univ Technol, Sch Architecture, Gothenburg, Sweden	Karolinska Institutet; Dalarna University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Florey Institute of Neuroscience & Mental Health; Chalmers University of Technology	Anaker, A (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden.; Anaker, A (corresponding author), Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden.	anna.anaker@ki.se	von Koch, Lena/P-2310-2018; Bernhardt, Julie/F-9538-2015	von Koch, Lena/0000-0002-8560-3016; Bernhardt, Julie/0000-0002-2787-8484	Swedish Research Council Formas; Swedish Stroke Association; Doctoral School in Health Care Sciences at Karolinska Institutet	Swedish Research Council Formas(Swedish Research CouncilSwedish Research Council Formas); Swedish Stroke Association; Doctoral School in Health Care Sciences at Karolinska Institutet	Financial support was provided through the Swedish Research Council Formas, the Swedish Stroke Association and the Doctoral School in Health Care Sciences at Karolinska Institutet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Financial support was provided through the Swedish Research Council Formas, the Swedish Stroke Association and the Doctoral School in Health Care Sciences at Karolinska Institutet. We would like to thank Christina Nylen and Olivia Ortlund, who both worked as research assistants in the study, and Jan Chamberlain for support with data processing.	Astrand A, 2016, J STROKE CEREBROVASC, V25, P938, DOI 10.1016/j.jstrokecerebrovasdis.2015.12.046; Barlas D, 2001, ANN EMERG MED, V38, P135, DOI 10.1067/mem.2001.115441; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Chaudhury H, 2005, ENVIRON BEHAV, V37, P760, DOI 10.1177/0013916504272658; De Wit L, 2005, STROKE, V36, P1977, DOI 10.1161/01.STR.0000177871.59003.e3; Devlin AS, 2016, HERD-HEALTH ENV RES, V9, P190, DOI 10.1177/1937586715607052; Elf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161942; Elf M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0782-7; Hagerman I, 2005, INT J CARDIOL, V98, P267, DOI 10.1016/j.ijcard.2003.11.006; Hamilton D.K., 2003, HEALTHCARE DESIGN, V3, P18; Hendrich AL, 2004, AM J CRIT CARE, V13, P35, DOI 10.4037/ajcc2004.13.1.35; Hokstad A, 2015, J STROKE CEREBROVASC, V24, P1333, DOI 10.1016/j.jstrokecerebrovasdis.2015.02.009; Janssen H, 2014, DISABIL REHABIL, V36, P255, DOI 10.3109/09638288.2013.788218; Keysor JJ, 2006, ARCH PHYS MED REHAB, V87, P1566, DOI 10.1016/j.apmr.2006.08.347; Kramer SF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/460482; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lincoln N B, 1989, Int Disabil Stud, V11, P149; Maben J, 2015, ONE SIZE FITS ALL MI; Malenbaum S, 2008, PAIN, V134, P241, DOI 10.1016/j.pain.2007.12.002; McDonald S., 2005, QUAL RES, V5, P455, DOI [10.1177/1468794105056923, DOI 10.1177/1468794105056923]; Persson E, 2015, SCAND J CARING SCI, V29, P340, DOI 10.1111/scs.12168; RIKS Stroke, 2014, STROK TIA; Ringelstein EB, 2013, STROKE, V44, P828, DOI 10.1161/STROKEAHA.112.670430; Sadler BL, 2011, HASTINGS CENT REP, V41, P13; Salonen H, 2013, INTELL BUILD INT, V5, P26, DOI 10.1080/17508975.2013.764839; Satink T, 2013, ARCH PHYS MED REHAB, V94, P1171, DOI 10.1016/j.apmr.2013.01.011; Schneidert M, 2003, DISABIL REHABIL, V25, P588, DOI 10.1080/0963828031000137090; Singh I, 2016, GERONTOLOGY GEARIATR, V2; Spradley J.P., 2016, PARTICIPANT OBSERVAT; Steinke C, 2009, HERD, V3, P63; Steinke C, 2015, HERD-HEALTH ENV RES, V8, P31, DOI 10.1177/1937586714565611; SUTC, 2013, COCHRANE DATABASE SY; Teasell R. W., 2015, TOP STROKE REHABIL; Tinson D J, 1989, Int Disabil Stud, V11, P45; Ulrich RS, 2010, HERD-HEALTH ENV RES, V4, P95, DOI 10.1177/193758671000400107; Ulrich RS, 2008, HERD-HEALTH ENV RES, V1, P61, DOI 10.1177/193758670800100306; West T, 2011, STROKE RES TREATMENT; White JH, 2014, DISABIL REHABIL, V36, P1783, DOI 10.3109/09638288.2013.872200; World Health Organization (WHO), 2015, INT CLASS FUNCT DIS, V1st; Yin R.K., 1994, CASE STUDY RES DESIG, V2nd ed., DOI DOI 10.33524/CJAR.V14I1.73	41	27	27	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2017	12	7							e0177477	10.1371/journal.pone.0177477	http://dx.doi.org/10.1371/journal.pone.0177477			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC1YQ	28727727	Green Published, Green Submitted, gold			2023-01-03	WOS:000406634500001
J	Vanobberghen, F; Letang, E; Gamell, A; Mnzava, DK; Faini, D; Luwanda, LB; Mapesi, H; Mwamelo, K; Sikalengo, G; Tanner, M; Hatz, C; Furrer, H; Battegay, M; Glass, TR				Vanobberghen, Fiona; Letang, Emilio; Gamell, Anna; Mnzava, Dorcas K.; Faini, Diana; Luwanda, Lameck B.; Mapesi, Herry; Mwamelo, Kim; Sikalengo, George; Tanner, Marcel; Hatz, Christoph; Furrer, Hansjakob; Battegay, Manuel; Glass, Tracy R.		KIULARCO Study Grp	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort	PLOS ONE			English	Article							RECONSTITUTION INFLAMMATORY SYNDROME; RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL TREATMENT PROGRAMS; SUB-SAHARAN AFRICA; FOLLOW-UP; INFECTED PATIENTS; CASE DEFINITIONS; KAPOSI-SARCOMA; THERAPY; MORTALITY	Objectives Our objectives were to describe trends in enrolment and clinical outcomes in the open, prospective Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) in the Morogoro region of southern Tanzania, and identify strengths and areas for improvement in the care of HIV-positive individuals in rural Tanzania. Methods We included adults (>= 15 years) and children (<15 years) enrolled in the cohort in 2005-014. The cohort underwent significant changes from autumn 2012 to optimise care. We evaluated mortality and loss to follow-up (LTFU) using competing risks methods, ART usage, opportunistic infections (OI), co-infections and laboratory abnormalities. Results Overall, 7010 adults and 680 children were enrolled; enrolment peaked in 2008 but has increased steadily since 2011. Among adults (65% female; median age 37 [interquartile range 31-45] years), the proportion referred from hospital wards quadrupled in 2013-14 versus earlier years. 653 (9%) adults died and 2648 (38%) were LTFU; the five-year cumulative probabilities of death and LTFU were 10.3% and 44.0%, respectively. Among children, 69 (10%) died and 225 (33%) were LTFU. The corresponding five-year probabilities were 12.1% and 39.6%. Adult ART use (regardless of eligibility) increased from 5% in 2005 to 89% in 2014 (similarly among children), with 9% on second-line therapy in 2014 (17% of children). OI diagnoses increased over time; tuberculosis prevalence at enrolment quadrupled from 6% in 2011 to 26% in 2014. The proportion of newly-enrolled participants assessed for laboratory abnormalities peaked at nearly 100% in 2014 (from a minimum of 24%), yet abnormality prevalences remained fairly constant. Conclusions In this cohort, ART usage improved dramatically and is approaching targets of 90%. Improved screening led to increases in detection of OIs and laboratory abnormalities, suggesting that a large number of these co-morbidities previously went undetected and untreated. Further work will address the high LTFU rates and implications for mortality estimates, and the management and outcomes of co-morbidities.	[Vanobberghen, Fiona; Letang, Emilio; Gamell, Anna; Tanner, Marcel; Hatz, Christoph; Glass, Tracy R.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland; [Vanobberghen, Fiona; Letang, Emilio; Gamell, Anna; Tanner, Marcel; Hatz, Christoph; Battegay, Manuel; Glass, Tracy R.] Univ Basel, Basel, Switzerland; [Letang, Emilio; Gamell, Anna; Mnzava, Dorcas K.; Faini, Diana; Luwanda, Lameck B.; Mapesi, Herry; Mwamelo, Kim; Sikalengo, George] Ifakara Hlth Inst, Ifakara, Tanzania; [Letang, Emilio] Univ Barcelona, Hosp Clin, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Furrer, Hansjakob] Bern Univ Hosp, Bern, Switzerland; [Furrer, Hansjakob] Univ Bern, Bern, Switzerland; [Battegay, Manuel] Univ Hosp Basel, Dept Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Ifakara Health Institute; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; University of Bern; University Hospital of Bern; University of Bern; University of Basel	Glass, TR (corresponding author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.; Glass, TR (corresponding author), Univ Basel, Basel, Switzerland.	tracy.glass@unibas.ch	Furrer, Hansjakob/G-6768-2013; Glass, Tracy R/D-5046-2017	Furrer, Hansjakob/0000-0002-1375-3146; Glass, Tracy R/0000-0001-7075-9803; Mapesi, Herry/0000-0001-7753-464X	Swiss Tropical & Public Health Institute and development funds from the Canton of Basel-Stadt, Switzerland; Government of the Canton of Basel, Switzerland; Swiss Tropical & Public Health Institute; Ifakara Health Institute; Government of Tanzania; United States Agency for International Development through TUNAJALI-Deloitte	Swiss Tropical & Public Health Institute and development funds from the Canton of Basel-Stadt, Switzerland; Government of the Canton of Basel, Switzerland; Swiss Tropical & Public Health Institute; Ifakara Health Institute; Government of Tanzania; United States Agency for International Development through TUNAJALI-Deloitte(United States Agency for International Development (USAID))	This work was supported by the Swiss Tropical & Public Health Institute and development funds from the Canton of Basel-Stadt, Switzerland. The Kilombero and Ulanga Antiretroviral Cohort and the Chronic Diseases Clinic Ifakara receive financial support from the Government of the Canton of Basel, Switzerland, the Swiss Tropical & Public Health Institute, the Ifakara Health Institute, the Government of Tanzania, and the United States Agency for International Development through TUNAJALI-Deloitte. Cryptococcal antigen lateral flow assays are donated by IMMY, Norman, Oklahoma. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amerson E, 2016, JAIDS-J ACQ IMM DEF, V71, P295, DOI 10.1097/QAI.0000000000000862; Bekolo Cavin Epie, 2013, BMC Res Notes, V6, P512, DOI 10.1186/1756-0500-6-512; Brinkhof MWG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014149; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Chi BH, 2010, AM J EPIDEMIOL, V171, P924, DOI 10.1093/aje/kwq008; Colebunders R, 2005, AIDS REV, V7, P148; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Delpierre C, 2008, EUR J PUBLIC HEALTH, V18, P345, DOI 10.1093/eurpub/ckm117; Dong BJ, 2012, AIDS, V26, P833, DOI 10.1097/QAD.0b013e328351a521; Faini D, 2016, C RETR OPP INFL; Faini D, 2015, MYCOSES, V58, P70, DOI 10.1111/myc.12390; Franzeck FC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-90; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Gamell A, 2016, JAIDS-J ACQ IMM DEF, V73, pE67, DOI 10.1097/QAI.0000000000001178; Geng EH, 2016, CLIN INFECT DIS, V62, P935, DOI 10.1093/cid/civ1004; Haddow LJ, 2010, LANCET INFECT DIS, V10, P791, DOI 10.1016/S1473-3099(10)70170-5; Haraka F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123275; Jafari A, 2014, EUR J CLIN PHARMACOL, V70, P1029, DOI 10.1007/s00228-014-1712-z; Jamisse L, 2007, JAIDS-J ACQ IMM DEF, V44, P371, DOI 10.1097/QAI.0b013e318032bbee; Lawn SD, 2010, CURR OPIN HIV AIDS, V5, P18, DOI 10.1097/COH.0b013e328333850f; Letang E, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv046; Letang E, 2012, CLIN INFECT DIS, V55, P157, DOI 10.1093/cid/cis308; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1; Ministry of Health and Social Welfare; National AIDS Control Program, 2013, NAT AIDS CONTR PROGR; Montlahuc C, 2013, JAIDS-J ACQ IMM DEF, V64, P197, DOI 10.1097/QAI.0b013e31829cfbfa; Mossdorf E, 2010, TROP MED INT HEALTH, V15, P567, DOI 10.1111/j.1365-3156.2010.02490.x; Mutyaba I, 2015, JAIDS-J ACQ IMM DEF, V69, P481, DOI 10.1097/QAI.0000000000000620; Mwita J, 2012, East Afr J Public Health, V9, P10; Parkes-Ratanshi Rosalind, 2015, J Int Assoc Provid AIDS Care, V14, P455, DOI 10.1177/2325957414557264; Pintilie M, 2006, COMPETING RISKS PRAC; Ramirez-Mena A, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw162; Ruhl CE, 2012, HEPATOLOGY, V55, P447, DOI 10.1002/hep.24725; Shiels MS, 2017, CURR OPIN HIV AIDS, V12, P6, DOI 10.1097/COH.0000000000000327; Tanzania Ministry of Health and Social Welfare National Tuberculosis and Leprosy Programme, 2013, MAN MAN TUB LEPR; Tanzania National AIDS Control Program, 2015, NAT GUID MAN HIV AID; Tanzania National AIDS Control Program, 2012, NAT GUID MAN HIV AID; UNAIDS, 2013, GLOBAL REPORT UNAIDS; UNAIDS, 2014, 90 90 90 AMB TREATM; Wandeler G, 2013, AIDS, V27, P2225, DOI 10.1097/QAD.0b013e328362d887; Wasserman S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1809-3; Waters L, 2011, EXPERT REV ANTI-INFE, V9, P877, DOI [10.1586/eri.11.106, 10.1586/ERI.11.106]; WHO, 2016, CONGUID UANT DRU; WHO, 2013, GLOB UPD HIV TREATM; World Health Organization, 2011, SER FERR CONC ASS IR; Zhou JL, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-5	47	19	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2017	12	7							e0180983	10.1371/journal.pone.0180983	http://dx.doi.org/10.1371/journal.pone.0180983			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3RW	28719610	Green Published, gold, Green Submitted			2023-01-03	WOS:000406061400025
J	Bienholz, A; Walter, B; Pless-Petig, G; Guberina, H; Kribben, A; Witzke, O; Rauen, U				Bienholz, Anja; Walter, Bjoern; Pless-Petig, Gesine; Guberina, Hana; Kribben, Andreas; Witzke, Oliver; Rauen, Ursula			Characterization of injury in isolated rat proximal tubules during cold incubation and rewarming	PLOS ONE			English	Article							LIVER ENDOTHELIAL-CELLS; HYPOTHERMIC MACHINE PERFUSION; DONOR KIDNEY-TRANSPLANTATION; PRESERVATION SOLUTION; ORGAN PRESERVATION; INDUCED APOPTOSIS; MITOCHONDRIAL DYSFUNCTION; CHELATABLE IRON; GRAFT FUNCTION; STORAGE	Organ shortage leads to an increased utilization of marginal organs which are particularly sensitive to storage-associated damage. Cold incubation and rewarming-induced injury is iron-dependent in many cell types. In addition, a chloride-dependent component of injury has been described. This work examines the injury induced by cold incubation and rewarm-ing in isolated rat renal proximal tubules. The tissue storage solution TiProtec (R) and a chloride-poor modification, each with and without iron chelators, were used for cold incubation. Incubation was performed 4 degrees C for up to 168 h, followed by rewarming in an extracellular buffer (3 h at 37 degrees C). After 48, 120 and 168 h of cold incubation LDH release was lower in solutions containing iron chelators. After rewarming, injury increased especially after cold incubation in chelator-free solutions. Without addition of iron chelators LDH release showed a tendency to be higher in chloride-poor solutions. Following rewarming after 48 h of cold incubation lipid peroxidation was significantly decreased and metabolic activity was tendentially better in tubules incubated with iron chelators. Morphological alterations included mitochondrial swelling and fragmentation being partially reversible during rewarming. ATP content was better preserved in chloride-rich solutions. During rewarming, there was a further decline of ATP content in the so far best conditions and minor alterations under the other conditions, while oxygen consumption was not significantly different compared to non-stored control tubules. Results show an iron-dependent component of preservation injury during cold incubation and rewarming in rat proximal renal tubules and reveal a benefit of chloride for the maintenance of tubular energy state during cold incubation.	[Bienholz, Anja; Kribben, Andreas] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany; [Walter, Bjoern; Pless-Petig, Gesine; Rauen, Ursula] Univ Duisburg Essen, Univ Hosp Essen, Inst Physiol Chem, Essen, Germany; [Guberina, Hana; Witzke, Oliver] Univ Duisburg Essen, Univ Hosp Essen, Dept Infect Dis, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Bienholz, A (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany.	anja.bienholz@uk-essen.de	Pless-Petig, Gesine/F-3639-2010	Pless-Petig, Gesine/0000-0001-8843-6607	Dr. Werner Jackstadt-Foundation	Dr. Werner Jackstadt-Foundation	AB and UR received support from the Dr. Werner Jackstadt-Foundation.	Arnau A, 2012, TRANSPL P, V44, P2555, DOI 10.1016/j.transproceed.2012.09.061; Bartels-Stringer M, 2003, CRYOBIOLOGY, V47, P82, DOI 10.1016/S0011-2240(03)00071-3; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; Bienholz A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094584; ERHARD J, 1994, TRANSPLANT INT, V7, P177, DOI 10.1007/BF00327084; Feldkamp T, 2009, NEPHROL DIAL TRANSPL, V24, P43, DOI 10.1093/ndt/gfn436; Fingas CD, 2011, LIVER TRANSPLANT, V17, P650, DOI 10.1002/lt.22275; Fuckert O, 2000, TRANSPLANTATION, V70, P723, DOI 10.1097/00007890-200009150-00003; Gallinat A, 2013, CRYOBIOLOGY, V66, P131, DOI 10.1016/j.cryobiol.2012.12.007; Garbe S, 2011, J VASC SURG, V53, P1063, DOI 10.1016/j.jvs.2010.10.093; Gizewski ER, 1997, BIOCHEM J, V322, P693, DOI 10.1042/bj3220693; Heuer N, 2010, EUR J MED RES, V15, P31, DOI 10.1186/2047-783X-15-1-31; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; Kerkweg U, 2003, TRANSPLANTATION, V76, P501, DOI 10.1097/01.TP.0000069830.78758.1C; Kyllonen LEJ, 2000, TRANSPLANT INT, V13, P122, DOI 10.1111/j.1432-2277.2000.tb01051.x; Lam VWT, 2013, J SURG RES, V180, P176, DOI 10.1016/j.jss.2012.10.055; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Minor T, 2015, TRANSPL INT, V28, P1102, DOI 10.1111/tri.12593; Moers C, 2012, NEW ENGL J MED, V366, P770, DOI 10.1056/NEJMc1111038; NOLL T, 1987, ARCH BIOCHEM BIOPHYS, V252, P284, DOI 10.1016/0003-9861(87)90033-6; Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; Petrat F, 1999, HEPATOLOGY, V29, P1171, DOI 10.1002/hep.510290435; Pless G, 2012, CELL TRANSPLANT, V21, P23, DOI 10.3727/096368911X580509; Pless-Petig G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040444; Quiroga I, 2006, NEPHROL DIAL TRANSPL, V21, P1689, DOI 10.1093/ndt/gfl042; Rauen U, 2007, CELL MOL LIFE SCI, V64, P192, DOI 10.1007/s00018-006-6456-1; Rauen U, 2004, J INVEST MED, V52, P299, DOI 10.1136/jim-52-05-29; Rauen U, 2003, FREE RADICAL BIO MED, V35, P1664, DOI 10.1016/j.freeradbiomed.2003.09.018; Rauen U, 1999, FASEB J, V13, P155, DOI 10.1096/fasebj.13.1.155; Rauen U, 2007, CRYOBIOLOGY, V54, P77, DOI 10.1016/j.cryobiol.2006.11.008; Romanello V, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00422; Salahudeen AK, 2004, AM J PHYSIOL-RENAL, V287, pF181, DOI 10.1152/ajprenal.00098.2004; Salahudeen AK, 2003, AM J TRANSPLANT, V3, P273, DOI 10.1034/j.1600-6143.2003.00042.x; Salahudeen AK, 2000, TRANSPLANTATION, V70, P1424, DOI 10.1097/00007890-200011270-00005; Tomaskova Z, 2010, FEBS LETT, V584, P2085, DOI 10.1016/j.febslet.2010.01.035; Vaziri N, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-15; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; Wille T, 2008, J VASC SURG, V47, P422, DOI 10.1016/j.jvs.2007.09.048; WIRTHENSOHN G, 1990, METHOD ENZYMOL, V191, P325	42	7	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2017	12	7							e0180553	10.1371/journal.pone.0180553	http://dx.doi.org/10.1371/journal.pone.0180553			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2JX	28672023	Green Published, gold, Green Submitted			2023-01-03	WOS:000405268500064
J	Yu, CF; Li, HF; Zhang, QN; He, HY; Chen, XH; Hua, ZY				Yu, Canfeng; Li, Huifan; Zhang, Qiannan; He, Huayun; Chen, Xinhong; Hua, Ziyu			Report about term infants with severe hyperbilirubinemia undergoing exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011	PLOS ONE			English	Article							WEIGHT-LOSS; NEONATAL HYPERBILIRUBINEMIA; EXTREME HYPERBILIRUBINEMIA; BREAST	Objectives This study was intended to explore the etiology and risk factors of severe neonatal hyperbilirubinemia and to analyze the adverse events associated with ECT (Exchange Transfusion), as well as to identify the factors related to the poor prognosis. Methods All of the full-term neonates who had undergone ECT for hyperbilirubinemia at Children's Hospital of Chongqing Medical University from January 2001 to December 2011 were enrolled in this study. General demographic characteristics, comorbidities, pre- and post-exchange TSB(Total Serum Bilirubin) levels, duration and frequency of ECT, and clinical outcomes were recorded and analyzed anonymously. Results Of 614 total infants, 368 patients (59.9%) with ABO incompatibility were identified, of whom 197 (53.5%) developed acute bilirubin encephalopathy (ABE) and 16 (4.3%) suffered a poor prognosis. The etiology was unidentified in 103 patients (16.8%), of whom 62 (60.1%) developed ABE and 9 (8.7%) had a poor prognosis. Identified adverse events secondary to ECT included thrombocytopenia (54.6%), hyperglycemia (42.8%), apnea (3.3%) and necrotizing enterocolitis (NEC) (1.3%). No ECT-related mortality was documented in this study. Conclusions The etiology, peak TSB level before ECT, and time of ECT had a significant impact on the outcome of severe neonatal hyperbilirubinemia. ABO incompatibility was the most common cause of extreme neonatal hyperbilirubinemia. Pathological weight loss could be involved in the development of extreme hyperbilirubinemia with an unidentified cause.	[Yu, Canfeng; Li, Huifan; Zhang, Qiannan; He, Huayun; Chen, Xinhong; Hua, Ziyu] Chongqing Med Univ, Childrens Hosp, Dept Neonatol, Chongqing, Peoples R China; [Yu, Canfeng; Li, Huifan; Zhang, Qiannan; He, Huayun; Chen, Xinhong; Hua, Ziyu] Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China; [Yu, Canfeng] Key Lab Pediat Chongqing, Chongqing, Peoples R China; [Li, Huifan; Hua, Ziyu] Chongqing Int Sci & Technol Cooperat Ctr Child De, Chongqing, Peoples R China	Chongqing Medical University	Hua, ZY (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Neonatol, Chongqing, Peoples R China.; Hua, ZY (corresponding author), Minist Educ, Key Lab Child Dev & Disorders, Chongqing, Peoples R China.; Hua, ZY (corresponding author), Chongqing Int Sci & Technol Cooperat Ctr Child De, Chongqing, Peoples R China.	h_ziyu@126.com		zhang, qiannan/0000-0002-6583-0430	National Key Clinical Specialist Construction Programs of China-Neonatology [2011873]; Chongqing Science and Technology Commission [cstc2013jcyjA10020]	National Key Clinical Specialist Construction Programs of China-Neonatology; Chongqing Science and Technology Commission(Natural Science Foundation Project of CQ CSTC)	This research is supported by the grant from National Key Clinical Specialist Construction Programs of China-Neonatology (GrantNo. 2011873) and Chongqing Science and Technology Commission (Grant No. cstc2013jcyjA10020)	American Academy of Pediatrics Subcommittee on Hyperbilirrubinemia, 2004, PEDIATRICS, V114, P297, DOI DOI 10.1542/PEDS.114.1.297; Babu TA, 2012, INDIAN J PEDIATR, V79, P202, DOI 10.1007/s12098-011-0501-2; Campistol J, 2012, NEUROLOGIA, V27, P202, DOI 10.1016/j.nrl.2010.03.013; Chang RJ, 2012, PEDIATR NEONATOL, V53, P41, DOI 10.1016/j.pedneo.2011.11.008; Chen HN, 2008, PEDIATRICS, V122, pE905, DOI 10.1542/peds.2008-0249; Cheng Shao-Wen, 2012, Chang Gung Med J, V35, P148; Christensen RD, 2013, BLOOD CELL MOL DIS, V50, P105, DOI 10.1016/j.bcmd.2012.10.004; Davutoglu M, 2010, TURKISH J PEDIATR, V52, P163; Ding GF, 2000, CHIN J PEDIAT, V38, P624; Du CS, 2000, CHIN J HEMATOL, V21, P174; Duman N, 2004, ACTA PAEDIATR, V93, P361, DOI 10.1080/08035250310007475; Ebbesen F, 2005, ACTA PAEDIATR, V94, P59, DOI 10.1080/08035250410022170; Flaherman VJ, 2013, ARCH DIS CHILD-FETAL, V98, pF488, DOI 10.1136/archdischild-2012-303076; Johnson L, 2009, J PERINATOL, V29, pS25, DOI 10.1038/jp.2008.211; Katar S, 2008, J CHILD NEUROL, V23, P415, DOI 10.1177/0883073807309780; Lam S T, 2002, SE ASIAN J TROP MED, V34, P73; Li QP, 2006, J APPL CLIN PEDIAT, V21, P958; Macdonald PD, 2003, ARCH DIS CHILD-FETAL, V88, pF472, DOI 10.1136/fn.88.6.F472; PALMER DC, 1983, AUST PAEDIATR J, V19, P86; Sakha SH, 2010, TURKISH J PEDIATR, V52, P367; Saluja S, 2010, INT J PEDIATR OTORHI, V74, P1292, DOI 10.1016/j.ijporl.2010.08.007; Sgro M, 2011, J PERINATOL, V31, P392, DOI 10.1038/jp.2010.137; Subspecialty Group of Neonatology Society of Pediatrics Chinese Medical Association, 2012, Zhonghua Er Ke Za Zhi, V50, P331; Wang X. M., 2016, INT J CHEM ENG, V2016, P1, DOI DOI 10.3852/16-100; Xiao M, 2011, PRACTICAL NEONATOLOG, P296; Zhuang Yan, 2013, Zhongguo Dang Dai Er Ke Za Zhi, V15, P332	26	18	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0179550	10.1371/journal.pone.0179550	http://dx.doi.org/10.1371/journal.pone.0179550			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662083	Green Submitted, Green Published, gold			2023-01-03	WOS:000404608300033
J	Camera, DM; Burniston, JG; Pogson, MA; Smiles, WJ; Hawley, JA				Camera, Donny M.; Burniston, Jatin G.; Pogson, Mark A.; Smiles, William J.; Hawley, John A.			Dynamic proteome profiling of individual proteins in human skeletal muscle after a high-fat diet and resistance exercise	FASEB JOURNAL			English	Article						muscle protein synthesis; abundance; metabolism; adaptation; protein degradation	MYOFIBER HYPERTROPHY; OLDER-ADULTS; PHOSPHORYLATION; MYOFIBRILLAR; METABOLISM; EXPRESSION; YOUNG; RATES; MICE; TIME	It is generally accepted that muscle adaptation to resistance exercise (REX) training is underpinned by contraction-induced, increased rates of protein synthesis and dietary protein availability. By using dynamic proteome profiling (DPP), we investigated the contribution of both synthesis and breakdown to changes in abundance on a protein-by-protein basis inhuman skeletal muscle. Age-matched, overweight males consumed 9 d of a high-fat, low-carbohydrate diet during which time they either undertook 3 sessions of REX or performed no exercise. Precursor enrichment and the rate of incorporation of deuterium oxide into newly synthesized muscle proteins were determined by mass spectrometry. Ninety proteins were included in the DPP, with 28 proteins exhibiting significant responses to REX. The most common pattern of response was an increase in turnover, followed by an increase in abundance with no detectable increase in protein synthesis. Here, we provide novel evidence that demonstrates that the contribution of synthesis and breakdown to changes in protein abundance induced by REX differ on a protein by-protein basis. We also highlight the importance of the degradation of individual muscle proteins after exercise in human skeletal muscle.	[Camera, Donny M.; Smiles, William J.; Hawley, John A.] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Ctr Exercise & Nutr, Fitzroy, Vic, Australia; [Burniston, Jatin G.; Hawley, John A.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool, Merseyside, England; [Pogson, Mark A.] Liverpool John Moores Univ, Dept Appl Math, Liverpool, Merseyside, England	Australian Catholic University; Liverpool John Moores University; Liverpool John Moores University	Hawley, JA (corresponding author), Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Fitzroy, Vic 3165, Australia.	hawley@acu.edu.au	Camera, Donny/J-1571-2018; Burniston, Jatin G/B-7833-2008; Burniston, Jatin/AAB-8831-2020; Hawley, John A/U-3814-2018; Pogson, Mark/D-9558-2016	Camera, Donny/0000-0002-6494-9472; Burniston, Jatin G/0000-0001-7303-9318; Burniston, Jatin/0000-0001-7303-9318; Hawley, John A/0000-0002-0886-9881; Smiles, William/0000-0002-6846-689X; Pogson, Mark/0000-0002-2116-7200	Australian Catholic University Collaborative Research Network [2013000443]	Australian Catholic University Collaborative Research Network	The authors thank the study participants for their efforts and dedication. This work was supported by an Australian Catholic University Collaborative Research Network Grant to J.A.H. (2013000443). The authors declare no conflicts of interest.	Arndt V, 2010, CURR BIOL, V20, P143, DOI 10.1016/j.cub.2009.11.022; Balagopal P, 2001, AM J PHYSIOL-ENDOC M, V280, pE203, DOI 10.1152/ajpendo.2001.280.2.E203; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BIOLO G, 1995, AM J PHYSIOL-ENDOC M, V268, pE514; Bloch RJ, 2003, EXERC SPORT SCI REV, V31, P73, DOI 10.1097/00003677-200304000-00004; Brook MS, 2015, FASEB J, V29, P4485, DOI 10.1096/fj.15-273755; Burniston JG, 2014, PROTEOMICS, V14, P2339, DOI 10.1002/pmic.201400118; Camera DM, 2015, MED SCI SPORT EXER, V47, P82, DOI 10.1249/MSS.0000000000000390; Camera DM, 2012, J APPL PHYSIOL, V113, P206, DOI 10.1152/japplphysiol.00395.2012; Camera DM, 2010, MED SCI SPORT EXER, V42, P1843, DOI 10.1249/MSS.0b013e3181d964e4; CHESLEY A, 1992, J APPL PHYSIOL, V73, P1383, DOI 10.1152/jappl.1992.73.4.1383; COMMERFORD SL, 1983, RADIAT RES, V94, P151, DOI 10.2307/3575870; Hawley J. A., 1985, J APPL PHYSIOL, V110, P834; HAWLEY JA, 1992, EUR J APPL PHYSIOL, V65, P79, DOI 10.1007/BF01466278; Hawley JA, 2014, CELL, V159, P738, DOI 10.1016/j.cell.2014.10.029; Hesketh S, 2016, PROTEOMES, V4, DOI 10.3390/proteomes4010012; Hipkiss AR, 2011, AGEING RES REV, V10, P498, DOI 10.1016/j.arr.2011.05.003; Kasumov T, 2013, ARTERIOSCL THROM VAS, V33, P1994, DOI 10.1161/ATVBAHA.113.301700; Koopman R, 2006, EUR J APPL PHYSIOL, V96, P525, DOI 10.1007/s00421-005-0118-0; Kosek DJ, 2006, J APPL PHYSIOL, V101, P531, DOI 10.1152/japplphysiol.01474.2005; Lam MPY, 2014, J CLIN INVEST, V124, P1734, DOI 10.1172/JCI73787; Leber Y, 2016, HUM MOL GENET, V25, P2776, DOI 10.1093/hmg/ddw135; Lehti M, 2009, J APPL PHYSIOL, V106, P1419, DOI 10.1152/japplphysiol.90660.2008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Macrae K, 2013, J LIPID RES, V54, P2366, DOI 10.1194/jlr.M036996; Malik ZA, 2013, PROTEOMES, V1, DOI 10.3390/proteomes1030290; Mayhew DL, 2009, J APPL PHYSIOL, V107, P1655, DOI 10.1152/japplphysiol.91234.2008; McCabe BJ, 2006, ANAL BIOCHEM, V350, P171, DOI 10.1016/j.ab.2006.01.020; Meplan C, 2016, FASEB J, V30, P2812, DOI 10.1096/fj.201600251R; Mertens I, 2006, INT J OBESITY, V30, P1308, DOI 10.1038/sj.ijo.0803189; Mitchell CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089431; Moore DR, 2009, J PHYSIOL-LONDON, V587, P897, DOI 10.1113/jphysiol.2008.164087; Noh HS, 2016, AUTOPHAGY, V12, P2183, DOI 10.1080/15548627.2016.1219013; Paulsen G, 2012, EUR J APPL PHYSIOL, V112, P1773, DOI 10.1007/s00421-011-2132-8; Paulsen G, 2009, J APPL PHYSIOL, V107, P570, DOI 10.1152/japplphysiol.00209.2009; Phillips SM, 2005, J AM COLL NUTR, V24, p134S, DOI 10.1080/07315724.2005.10719454; Phillips SM, 1997, AM J PHYSIOL-ENDOC M, V273, pE99, DOI 10.1152/ajpendo.1997.273.1.E99; Price JC, 2012, MOL CELL PROTEOMICS, V11, P1801, DOI 10.1074/mcp.M112.021204; R Core Team, 2016, LANG ENV STAT COMP; Sanger JW, 2017, HANDB EXP PHARMACOL, V235, P39, DOI 10.1007/164_2016_53; Shankaran M, 2016, AM J PHYSIOL-ENDOC M, V310, pE405, DOI 10.1152/ajpendo.00257.2015; Shankaran M, 2016, J CLIN INVEST, V126, P288, DOI 10.1172/JCI79639; Sollanek KJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171007; Stefanyk LE, 2010, CURR OPIN CLIN NUTR, V13, P255, DOI 10.1097/MCO.0b013e328338236e; Tachtsis B, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00144; TESCH PA, 1986, EUR J APPL PHYSIOL, V55, P362, DOI 10.1007/BF00422734; Ulbricht A, 2015, AUTOPHAGY, V11, P538, DOI 10.1080/15548627.2015.1017186; Volek JS., 2011, ART SCI LOW CARBOHYD; Wagenmakers AJM, 1999, P NUTR SOC, V58, P987, DOI 10.1017/S0029665199001305; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Wilkinson DJ, 2017, J PHYSIOL-LONDON, V595, P2873, DOI 10.1113/JP272277; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673; Woolstenhulme MT, 2006, J APPL PHYSIOL, V100, P1876, DOI 10.1152/japplphysiol.01592.2005; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yokoyama T, 2007, J CELL BIOL, V177, P781, DOI 10.1083/jcb.200703195	57	29	31	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2017	31	12					5478	5494		10.1096/fj.201700531R	http://dx.doi.org/10.1096/fj.201700531R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FO2EX	28855275	Green Accepted			2023-01-03	WOS:000416588300030
J	Vinner, GK; Vladisavljevic, GT; Clokie, MRJ; Malik, DJ				Vinner, Gurinder K.; Vladisavljevic, Goran T.; Clokie, Martha R. J.; Malik, Danish J.			Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release	PLOS ONE			English	Article							PHAGE THERAPY; IN-VITRO; MEMBRANE EMULSIFICATION; ALGINATE MICROSPHERES; INTESTINAL DELIVERY; DROPLET FORMATION; DRUG-DELIVERY; INFECTION; MICROPARTICLES; ANTIBIOTICS	The prevalence of pathogenic bacteria acquiring multidrug antibiotic resistance is a global health threat to mankind. This has motivated a renewed interest in developing alternatives to conventional antibiotics including bacteriophages (viruses) as therapeutic agents. The bacterium Clostridium difficile causes colon infection and is particularly difficult to treat with existing antibiotics; phage therapy may offer a viable alternative. The punitive environment within the gastrointestinal tract can inactivate orally delivered phages. C. difficile specific bacteriophage, myovirus CDKM9 was encapsulated in a pH responsive polymer (Eudragit((R)) S100 with and without alginate) using a flow focussing glass microcapillary device. Highly monodispersed core-shell microparticles containing phages trapped within the particle core were produced by in situ polymer curing using 4-aminobenzoic acid dissolved in the oil phase. The size of the generated microparticles could be precisely controlled in the range 80 mu m to 160 mu m through design of the microfluidic device geometry and by varying flow rates of the dispersed and continuous phase. In contrast to free 'naked' phages, those encapsulated within the microparticles could withstand a 3 h exposure to simulated gastric fluid at pH 2 and then underwent a subsequent pH triggered burst release at pH 7. The significance of our research is in demonstrating that C. difficile specific phage can be formulated and encapsulated in highly uniform pH responsive microparticles using a microfluidic system. The microparticles were shown to afford significant protection to the encapsulated phage upon prolonged exposure to an acid solution mimicking the human stomach environment. Phage encapsulation and subsequent release kinetics revealed that the microparticles prepared using Eudragit((R)) S100 formulations possess pH responsive characteristics with phage release triggered in an intestinal pH range suitable for therapeutic purposes. The results reported here provide proof-of-concept data supporting the suitability of our approach for colon targeted delivery of phages for therapeutic purposes.	[Vinner, Gurinder K.; Vladisavljevic, Goran T.; Malik, Danish J.] Loughborough Univ, Chem Engn Dept, Loughborough, Leics, England; [Clokie, Martha R. J.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England	Loughborough University; University of Leicester	Vladisavljevic, GT; Malik, DJ (corresponding author), Loughborough Univ, Chem Engn Dept, Loughborough, Leics, England.	g.vladisavljevic@lboro.ac.uk; d.j.malik@lboro.ac.uk	Vladisavljevic, Goran/D-8962-2011	Vladisavljevic, Goran/0000-0002-8894-975X; Clokie, Martha/0000-0002-6069-8936	EPSRC [EP/M027341/1]; Engineering and Physical Sciences Research Council [EP/M027341/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	The authors would like to acknowledge EPSRC support for this work (Grant no. EP/M027341/1) Tackling Antimicrobial Resistance: An Interdisciplinary Approach.	Abdulamir AS, 2014, ANN CLIN MICROB ANTI, V13, P1; Abedon ST, 2015, PHARMACEUTICALS-BASE, V8, P525, DOI 10.3390/ph8030525; Abedon Stephen T, 2011, Bacteriophage, V1, P66; Abedon ST, 2009, FOODBORNE PATHOG DIS, V6, P807, DOI 10.1089/fpd.2008.0242; Alhnan MA, 2010, J PHARM SCI, V99, P4215; Alisky J, 1998, J INFECTION, V36, P5, DOI 10.1016/S0163-4453(98)92874-2; Allen HK, 2014, ANN NY ACAD SCI, V1323, P91, DOI 10.1111/nyas.12468; Barrow P, 1998, CLIN DIAGN LAB IMMUN, V5, P294, DOI 10.1128/CDLI.5.3.294-298.1998; Barrow PA, 1997, TRENDS MICROBIOL, V5, P268, DOI 10.1016/S0966-842X(97)01054-8; Bean JE, 2014, CHEM MATER, V26, P7201, DOI 10.1021/cm503974g; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Bouza E, 2012, CLIN MICROBIOL INFEC, V18, P5, DOI 10.1111/1469-0691.12064; Briers Y, 2008, BIOCHEM BIOPH RES CO, V374, P747, DOI 10.1016/j.bbrc.2008.07.102; Brouzes E, 2009, P NATL ACAD SCI USA, V106, P14195, DOI 10.1073/pnas.0903542106; Bruttin A, 2005, ANTIMICROB AGENTS CH, V49, P2874, DOI 10.1128/AAC.49.7.2874-2878.2005; Burke KE, 2014, GUT LIVER, V8, P1, DOI [10.5009/gn1.2014.8.1.1, 10.5009/gnl.2014.8.1.1]; Cairns BJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000253; Cerveny KE, 2002, INFECT IMMUN, V70, P6251, DOI 10.1128/IAI.70.11.6251-6262.2002; Chen S.-H., 2016, PROC ASIA PACIFIC SI, P1; Chibani-Chennoufi S, 2004, ANTIMICROB AGENTS CH, V48, P2558, DOI 10.1128/AAC.48.7.2558-2569.2004; Choinska-Pulit A, 2015, TRENDS FOOD SCI TECH, V45, P212, DOI 10.1016/j.tifs.2015.07.001; Colom J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41441; Connerton PL, 2011, J APPL MICROBIOL, V111, P255, DOI 10.1111/j.1365-2672.2011.05012.x; Czaplewski L, 2016, LANCET INFECT DIS, V16, P239, DOI 10.1016/S1473-3099(15)00466-1; DAVIES JD, 1969, J HYG-CAMB, V67, P573, DOI 10.1017/S0022172400042030; Dini C, 2012, MACROMOL BIOSCI, V12, P1200, DOI 10.1002/mabi.201200109; Duan HG, 2016, COLLOID SURFACE B, V145, P510, DOI 10.1016/j.colsurfb.2016.05.038; Egidi E, 2008, J MEMBRANE SCI, V323, P414, DOI 10.1016/j.memsci.2008.06.047; Ekanem EE, 2015, ACS APPL MATER INTER, V7, P23132, DOI 10.1021/acsami.5b06943; Erb RM, 2011, SOFT MATTER, V7, P8757, DOI 10.1039/c1sm06231j; Fernandez-Nieves A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.157801; Freire-Moran L, 2011, DRUG RESIST UPDATE, V14, P118, DOI 10.1016/j.drup.2011.02.003; Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039; Galtier M, 2016, ENVIRON MICROBIOL, V18, P2237, DOI 10.1111/1462-2920.13284; George M, 2006, J CONTROL RELEASE, V114, P1, DOI 10.1016/j.jconrel.2006.04.017; Gibson PR, 2006, ALIMENT PHARM THER, V23, P1017, DOI 10.1111/j.1365-2036.2006.02861.x; Goh S, 2005, J MED MICROBIOL, V54, P129, DOI 10.1099/jmm.0.45821-0; Governal RA, 1997, J IND MICROBIOL BIOT, V18, P297, DOI 10.1038/sj.jim.2900388; He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478; Housby JN, 2009, DRUG DISCOV TODAY, V14, P536, DOI 10.1016/j.drudis.2009.03.006; Huang S, 2008, BIOTECHNOL BIOENG, V101, P1014, DOI 10.1002/bit.21995; Huttner A, 2013, ANTIMICROBIAL RESIST, P1; Ibekwe VC, 2008, PHARM RES-DORDR, V25, P1828, DOI 10.1007/s11095-008-9580-9; Jain D, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060116; Jonczyk E, 2011, FOLIA MICROBIOL, V56, P191, DOI 10.1007/s12223-011-0039-8; Kietzmann D, 2010, EUR J PHARM BIOPHARM, V76, P290, DOI 10.1016/j.ejpb.2010.06.013; Kim S, 2015, INT J FOOD SCI TECH, V50, P913, DOI 10.1111/ijfs.12736; Knezevic P, 2011, J APPL MICROBIOL, V111, P245, DOI 10.1111/j.1365-2672.2011.05043.x; Kong TT, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.4738586; Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003; Lee SW, 2004, NANO LETT, V4, P387, DOI 10.1021/nl034911t; LEIBO SP, 1966, BIOPHYS J, V6, P747, DOI 10.1016/S0006-3495(66)86693-6; Leung SSY, 2016, PHARM RES-DORDR, V33, P1486, DOI 10.1007/s11095-016-1892-6; Levin BR, 2004, NAT REV MICROBIOL, V2, P166, DOI 10.1038/nrmicro822; Lu TK, 2011, CURR OPIN MICROBIOL, V14, P524, DOI 10.1016/j.mib.2011.07.028; Ma YS, 2008, APPL ENVIRON MICROB, V74, P4799, DOI 10.1128/AEM.00246-08; Ma YS, 2012, FOOD HYDROCOLLOID, V26, P434, DOI 10.1016/j.foodhyd.2010.11.017; MAHONEY DE, 1985, J CLIN MICROBIOL, V21, P251, DOI 10.1128/JCM.21.2.251-254.1985; Malik DJ, 2017, ADV COLLOID INTERFAC, V249, P100, DOI 10.1016/j.cis.2017.05.014; McConnell EL, 2008, INT J PHARMACEUT, V364, P213, DOI 10.1016/j.ijpharm.2008.05.012; Merabishvili M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068797; Nale JY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01383; Nale JY, 2016, ANTIMICROB AGENTS CH, V60, P968, DOI 10.1128/AAC.01774-15; Navaneethan U, 2009, GUT PATHOG, V1, DOI 10.1186/1757-4749-1-7; Nguyen DA, 2005, AICHE J, V51, P415, DOI 10.1002/aic.10329; Pirnay JP, 2015, PHARM RES-DORDR, V32, P2173, DOI 10.1007/s11095-014-1617-7; Puapermpoonsiri U, 2009, EUR J PHARM BIOPHARM, V72, P26, DOI 10.1016/j.ejpb.2008.12.001; Rashid S, 2016, VIRUSES, V8, P1; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Saglam D, 2011, FOOD HYDROCOLLOID, V25, P1139, DOI 10.1016/j.foodhyd.2010.10.011; Samtlebe M, 2016, LWT-FOOD SCI TECHNOL, V68, P334, DOI 10.1016/j.lwt.2015.12.039; Sarker SA, 2016, EBIOMEDICINE, V4, P124, DOI 10.1016/j.ebiom.2015.12.023; Schmelcher Mathias, 2014, Bacteriophage, V4, pe28137; Seo M, 2007, SOFT MATTER, V3, P986, DOI 10.1039/b700687j; Shi LE, 2016, LWT-FOOD SCI TECHNOL, V65, P840, DOI 10.1016/j.lwt.2015.08.071; SMITH HW, 1987, J GEN MICROBIOL, V133, P1111; Sookkasem A, 2015, J DRUG DELIV SCI TEC, V29, P159, DOI 10.1016/j.jddst.2015.07.005; Stanford K, 2010, J FOOD PROTECT, V73, P1304, DOI 10.4315/0362-028X-73.7.1304; Stillwell MT, 2007, IND ENG CHEM RES, V46, P965, DOI 10.1021/ie0611094; Summers WC, 2001, ANNU REV MICROBIOL, V55, P437, DOI 10.1146/annurev.micro.55.1.437; Surh J, 2007, J AGR FOOD CHEM, V55, P175, DOI 10.1021/jf061637q; Tang ZX, 2015, LWT-FOOD SCI TECHNOL, V60, P263, DOI 10.1016/j.lwt.2014.08.012; Tang ZX, 2013, FOOD RES INT, V52, P460, DOI 10.1016/j.foodres.2012.12.037; Vandenheuvel D, 2013, EUR J PHARM BIOPHARM, V84, P578, DOI 10.1016/j.ejpb.2012.12.022; Vardakas KZ, 2012, INT J ANTIMICROB AG, V40, P1, DOI 10.1016/j.ijantimicag.2012.01.004; Vemula SK, 2015, EUR J DRUG METAB PH, V40, P301, DOI 10.1007/s13318-014-0210-0; Viswanathan VK, 2009, NAT REV MICROBIOL, V7, P110, DOI 10.1038/nrmicro2053; Vladisavljevic GT, 2012, LANGMUIR, V28, P12948, DOI 10.1021/la302092f; Vladisavljevic GT, 2012, MICROFLUID NANOFLUID, V13, P151, DOI 10.1007/s10404-012-0948-0; Wall SK, 2010, APPL ENVIRON MICROB, V76, P48, DOI 10.1128/AEM.00785-09; Wills QF, 2005, ANTIMICROB AGENTS CH, V49, P1220, DOI 10.1128/AAC.49.3.1220-1221.2005; Wittaya-areekul S, 2006, INT J PHARMACEUT, V312, P113, DOI 10.1016/j.ijpharm.2006.01.003; Yen MM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14187; Young R, 2015, SCIENCE, V350, P1163, DOI 10.1126/science.aad6791	94	40	41	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2017	12	10							e0186239	10.1371/journal.pone.0186239	http://dx.doi.org/10.1371/journal.pone.0186239			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ6DU	29023522	Green Submitted, gold, Green Published			2023-01-03	WOS:000412845100088
J	Kidd, T; Carey, N; Mold, F; Westwood, S; Miklaucich, M; Konstantara, E; Sterr, A; Cooke, D				Kidd, Tara; Carey, Nicola; Mold, Freda; Westwood, Sue; Miklaucich, Maria; Konstantara, Emmanouela; Sterr, Annette; Cooke, Debbie			A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; HEALTH-PROMOTION; MS; DISORDERS; EDUCATION; EFFICACY; PROGRAM; DISABILITY	Background Self-management interventions have become increasingly popular in the management of long-term health conditions; however, little is known about their impact on psychological well-being in people with Multiple Sclerosis ( MS). Purpose To examine the effectiveness of self-management interventions on improving depression, anxiety and health related quality of life in people with MS. Method A structured literature search was conducted for the years 2000 to 2016. The review process followed the PRISMA guidelines, and is registered with PROSPERO ( no. CRD42016033925). Results The review identified 10 RCT trials that fulfilled selection criteria and quality appraisal. Self-management interventions improved health-related quality of life in 6 out of 7 studies, with some evidence of improvement in depression and anxiety symptoms. Conclusion Although the results are promising more robust evaluation is required in order to determine the effectiveness of self-management interventions on depression, anxiety and quality of life in people with MS. Evaluation of the data was impeded by a number of methodological issues including incomplete content and delivery information for the intervention and the exclusion of participants representing the disease spectrum. Recommendations are made for service development and research quality improvement.	[Kidd, Tara; Carey, Nicola; Mold, Freda; Westwood, Sue; Miklaucich, Maria; Konstantara, Emmanouela; Cooke, Debbie] Univ Surrey, Sch Hlth Sci, Fac Hlth & Med Sci, Guildford, Surrey, England; [Sterr, Annette] Univ Surrey, Sch Psychol, Guildford, Surrey, England	University of Surrey; University of Surrey	Kidd, T (corresponding author), Univ Surrey, Sch Hlth Sci, Fac Hlth & Med Sci, Guildford, Surrey, England.	tara.kidd@surrey.ac.uk	Mold, Freda/AAO-2734-2020	Cooke, Debbie/0000-0003-1944-7905; Carey, Nicola/0000-0003-2841-1760; Sterr, Annette/0000-0003-4490-985X; Westwood, Sue/0000-0003-3875-9584; Kidd, Tara/0000-0002-8307-5221	MS Society; MRC [G0200128] Funding Source: UKRI; Medical Research Council [G0200128] Funding Source: researchfish	MS Society; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The literature review upon which this systematic analysis is based was funded by the MS Society. However, the authors received no specific funding for this work.	[Anonymous], 2015, BUILD NHS 5 YEAR FOR; Barlow J, 2001, BEST PRACT RES CL RH, V15, P545, DOI 10.1053/berh.2001.0172; Barlow J, 2009, PATIENT EDUC COUNS, V77, P81, DOI 10.1016/j.pec.2009.02.009; Ben-Zacharia A., 2015, J MULT SCLER, V2, P2376; Berger BA, 2005, J AM PHARM ASSOC, V45, P466, DOI 10.1331/1544345054475469; Bombardier CH, 2008, ARCH PHYS MED REHAB, V89, P1849, DOI 10.1016/j.apmr.2008.03.021; Castro-Borrero W, 2012, THER ADV NEUROL DISO, V5, P205, DOI 10.1177/1756285612450936; Chiaravalloti ND, 2012, J NEUROL, V259, P1337, DOI 10.1007/s00415-011-6353-x; Cochran J, 2008, DIABETES EDUCATOR, V34, P815, DOI 10.1177/0145721708323640; Cooper H., 2009, HDB RES SYNTHESIS ME; Corry M, 2009, SCAND J CARING SCI, V23, P569, DOI 10.1111/j.1471-6712.2008.00645.x; Eaton S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h181; Ehde Dawn M, 2005, Phys Med Rehabil Clin N Am, V16, P437, DOI 10.1016/j.pmr.2005.01.010; Ehde DM, 2015, ARCH PHYS MED REHAB, V96, P1945, DOI 10.1016/j.apmr.2015.07.015; Ennis M, 2006, CLIN REHABIL, V20, P783, DOI 10.1177/0269215506070805; Federation. MSI, 2004, MS FOC; Feinstein A, 2002, NEUROLOGY, V59, P674, DOI 10.1212/WNL.59.5.674; Feinstein A, 2011, MULT SCLER J, V17, P1276, DOI 10.1177/1352458511417835; Finlayson M, 2011, MULT SCLER J, V17, P1130, DOI 10.1177/1352458511404272; Foley JF, 2009, NEUROLOGY, V72, pS1, DOI 10.1212/WNL.0b013e3181a99bc2; Gaikwad R, 2009, HEALTH INFORM J, V15, P122, DOI 10.1177/1460458209102973; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Graziano F, 2014, CLIN REHABIL, V28, P264, DOI 10.1177/0269215513501525; Griffiths K. M., 2006, CLIN PSYCHOL, V10, P16, DOI DOI 10.1080/13284200500378696; Hart S, 2005, QUAL LIFE RES, V14, P695, DOI 10.1007/s11136-004-1364-z; Hermann BP, 1996, EPILEPSY RES, V25, P113, DOI 10.1016/0920-1211(96)00024-1; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hind D, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-5; Janssens ACJW, 2003, MULT SCLER J, V9, P397, DOI 10.1191/1352458503ms930oa; Jongen PJ, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-40; Kern S, 2009, MULT SCLER, V15, P752, DOI 10.1177/1352458509103300; Khan F, 2008, J NEUROL NEUROSUR PS, V79, P1230, DOI 10.1136/jnnp.2007.133777; Korostil M, 2007, MULT SCLER, V13, P67, DOI 10.1177/1352458506071161; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kuspinar A, 2012, MULT SCLER J, V18, P1686, DOI 10.1177/1352458512445201; Michie S, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-40; Miller DM, 2011, TELEMED E-HEALTH, V17, P5, DOI 10.1089/tmj.2010.0133; Minden SL, 2014, NEUROLOGY, V82, P174, DOI 10.1212/WNL.0000000000000013; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mohr DC, 2001, J CLIN PSYCHOL, V57, P479, DOI 10.1002/jclp.1042; Mohr DC, 1999, CLIN PSYCHOL-SCI PR, V6, P1, DOI 10.1093/clipsy/6.1.1; Moss-Morris R, 2012, BEHAV RES THER, V50, P415, DOI 10.1016/j.brat.2012.03.001; Nobles J, 2013, SOC SCI MED, V82, P58, DOI 10.1016/j.socscimed.2013.01.021; Noseworthy JH, 2000, NEUROLOGY, V54, P1726, DOI 10.1212/WNL.54.9.1726; O'Hara L, 2002, CLIN REHABIL, V16, P119, DOI 10.1191/0269215502cr478oa; Patten S. B., 2003, Neurology, V61, P1524; Pinnock H, 2014, HLTH SERV DELIV RES, P2, DOI DOI 10.3310/HSDR02530; Pinnock H, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6795; Plow MA, 2011, PM&R, V3, P251, DOI 10.1016/j.pmrj.2010.11.011; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rae-Grant AD, 2011, J REHABIL RES DEV, V48, P1087, DOI 10.1682/JRRD.2010.08.0159; Richter B, 2000, DIABETOLOGIA, V43, P254, DOI 10.1007/s001250050039; Siegert RJ, 2005, J NEUROL NEUROSUR PS, V76, P469, DOI 10.1136/jnnp.2004.054635; Sollom AC, 2007, MULT SCLER J, V13, P632, DOI 10.1177/1352458507072384; Steed L, 2003, PATIENT EDUC COUNS, V51, P5, DOI 10.1016/S0738-3991(02)00213-6; Stuijbergen AK, 2003, ARCH PHYS MED REHAB, V84, P467, DOI 10.1053/apmr.2003.50028; Stuke K, 2009, J NEUROL, V256, P1932, DOI 10.1007/s00415-009-5257-5; Trappenburg J, 2013, PATIENT EDUC COUNS, V92, P134, DOI 10.1016/j.pec.2013.02.009; Ware Jr John E., 1999, SF 36 HLTH SURVEY; Wildevuur SE, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3687; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	62	39	41	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2017	12	10							e0185931	10.1371/journal.pone.0185931	http://dx.doi.org/10.1371/journal.pone.0185931			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ4ZX	29020113	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000412754400052
J	Freedman, S; Nikpay, S; Carroll, A; Simon, K				Freedman, Seth; Nikpay, Sayeh; Carroll, Aaron; Simon, Kosali			Changes in inpatient payer-mix and hospitalizations following Medicaid expansion: Evidence from all-capture hospital discharge data	PLOS ONE			English	Article							COVERAGE	Context The Affordable Care Act resulted in unprecedented reductions in the uninsured population through subsidized private insurance and an expansion of Medicaid. Early estimates from the beginning of 2014 showed that the Medicaid expansion decreased uninsured discharges and increased Medicaid discharges with no change in total discharges. Objective To provide new estimates of the effect of the ACA on discharges for specific conditions. Design, setting, and participants We compared outcomes between states that did and did not expand Medicaid using statelevel all-capture discharge data from 2009-2014 for 42 states from the Healthcare Costs and Utilization Project's FastStats database; for a subset of states we used data through 2015. We stratified the analysis by baseline uninsured rates and used difference-in-differences and synthetic control methods to select comparison states with similar baseline characteristics that did not expand Medicaid. Main outcome Our main outcomes were total and condition-specific hospital discharges per 1,000 population and the share of total discharges by payer. Conditions reported separately in FastStats included maternal, surgical, mental health, injury, and diabetes. Results The share of uninsured discharges fell in Medicaid expansion states with below (-4.39 percentage points (p. p.), -6.04--2.73) or above (-7.66 p. p., -9.07--6.24) median baseline uninsured rates. The share of Medicaid discharges increased in both small (6.42 p. p. 4.22-6.62) and large (10.5 p. p., 8.48-12.5) expansion states. Total and most condition-specific discharges per 1,000 residents did not change in Medicaid expansion states with high or low baseline uninsured rates relative to non-expansion states (0.418, p = 0.225), with one exception: diabetes. Discharges for that condition per 1,000 fell in states with high baseline uninsured rates relative to non-expansion states (-0.038 95% p = 0.027). Conclusions Early changes in payer mix identified in the first two quarters of 2014 continued through the Medicaid expansion's first year and are distributed across all condition types studied. We found no change in total discharges between Medicaid expansion and non-expansion states, however residents of states that should have been most affected by the Medicaid expansion were less likely to be hospitalized for diabetes.	[Freedman, Seth; Simon, Kosali] Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN 47405 USA; [Nikpay, Sayeh] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA; [Carroll, Aaron] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Vanderbilt University; Indiana University System; Indiana University-Purdue University Indianapolis	Simon, K (corresponding author), Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN 47405 USA.	simonkos@indiana.edu						Abadie A, 2010, J AM STAT ASSOC, V105, P493, DOI 10.1198/jasa.2009.ap08746; Agency for Healthcare Research and Quality, 2017, HLTH COST UT PROJ FA, V7; Cameron A.C., 2013, J HUM RESOU IN PRESS, P221; Casagrande SS, 2012, DIABETES CARE, V35, P2243, DOI 10.2337/dc12-0257; Center for Medicare and Medicaid Services, 2016, ACT REP FIN OUTL MED; Fisher R.A., 1935, DESIGN EXPT; Frean M, 2016, PREMIUM SUBSIDIES MA; Ghosh A, 2017, EFFECT STATE MEDICAI; Hempstead K, 2016, NEW ENGL J MED, V374, P196, DOI 10.1056/NEJMc1507366; Hu L., 2016, EFFECT PATIENT PROTE; Kaestner R., 2015, EFFECTS ACA MEDICAID; Kaiser Family Foundation, 2017, STAT STAT ACT MED EX, V1, P1; Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029; Muhlstein D, 2016, 2016 PRIVATE PUBLIC; Myerson R, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0712-z; Nikpay S, 2016, HEALTH AFFAIR, V35, P106, DOI 10.1377/hlthaff.2015.1144; Wherry LR, 2016, ANN INTERN MED, V164, P795, DOI 10.7326/M15-2234	17	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0183616	10.1371/journal.pone.0183616	http://dx.doi.org/10.1371/journal.pone.0183616			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957347	Green Published, gold, Green Submitted			2023-01-03	WOS:000411985200010
J	Poolsup, N; Suksomboon, N; Paw, NJ				Poolsup, Nalinee; Suksomboon, Naeti; Paw, Naw Juna			Effect of dragon fruit on glycemic control in prediabetes and type 2 diabetes: A systematic review and meta-analysis	PLOS ONE			English	Review							ANTIPROLIFERATIVE ACTIVITIES; HYLOCEREUS-POLYRHIZUS; WHITE PITAYAS; RED PITAYA; ANTIOXIDANT	Objective The purpose of this study was to systematically determine the effect of dragon fruit on glycemic control in prediabetes and type 2 diabetes. Methods Electronic databases including MEDLINE, CENTRAL, CINAHL, Scopus, ScienceDirect r, Proquest, Web of Science((R)), LILACS, NAPRALERT, SciFinder, Clinicalkey, Herbmed, NCCIH and Google Scholar were searched from their earliest inception up to March 2017 for relevant randomized controlled trials (RCTs) which compared dragon fruit with placebo or no treatment in prediabetes or type 2 diabetes. Clinicaltrials. gov, clinicaltrialresults. org, and ISRCTN registry were also searched. Personal contact with experts and historical search of related articles was undertaken. Outcome of interest were fasting plasma glucose (FPG) and 2 hours post-prandial glucose (2HPP). Study selection, data extraction and study quality assessment were performed independently by two investigators. Disagreements were resolved by a third reviewer. Treatment effect was estimated with mean difference (MD). Effect estimates were pooled using inverse-variance weighted method. Heterogeneity was assessed with the Q statistic and quantified with the I 2 statistic. DerSimonian and Laird random- effects model was used when the Q-statistic was significant at the level of 0.1, otherwise a fixed-effects model was used. Results Among 401 studies identified from literature search, 4 RCTs involving 36 prediabetes subjects and 109 type 2 diabetes patients were included in the analysis. In prediabetes, FPG reduction was significant with MD of -15.1 mg/dL (95% CI: -23.8 to -6.5 mg/dL, P-value = 0.0006). Meta-analysis in type 2 diabetes showed no effect of dragon fruit on FPG (MD -26.5 mg/dL, 95% CI: -72.6 mg/dL to 19.6 mg/dL) and in 2HPP (MD -30.5 mg/dL, 95% CI: -80.9 mg/dL to 19.9 mg/dL). Conclusion The available evidence in prediabetes is interesting. This will shed some light on diabetes prevention. The effect in T2DM was not significant. However, a trend towards greater blood glucose reduction with higher dose was observed.	[Poolsup, Nalinee] Silpakorn Univ, Fac Pharm, Dept Pharm, Nakhon Pathom, Thailand; [Suksomboon, Naeti; Paw, Naw Juna] Mahidol Univ, Fac Pharm, Dept Pharm, Bangkok, Thailand	Silpakorn University; Mahidol University	Suksomboon, N (corresponding author), Mahidol Univ, Fac Pharm, Dept Pharm, Bangkok, Thailand.	naeti.suk@mahidol.ac.th			Thailand Research Fund (TRF); Faculty of Pharmacy, Mahidol University, Thailand [IRG5780007]	Thailand Research Fund (TRF)(Thailand Research Fund (TRF)); Faculty of Pharmacy, Mahidol University, Thailand	This research was supported by grants from Thailand Research Fund (TRF) and Faculty of Pharmacy, Mahidol University, Thailand (IRG5780007). The funding organisations played no role in the design, conduct, analysis or publication of this research.	Abd Hadi N., 2012, BORNEO SCI J, V31, P113; Akhiruddin MAB, 2013, THESIS; Akhlis M., 2015, THESIS; [Anonymous], 2017, DIABETES CARE, V40, pS1, DOI 10.2337/dc17-S001; Asyari IHN, 2009, THESIS; Budiatmaja AC, 2014, THESIS; Choo WeeSim, 2011, Advances in Applied Science Research, V2, P418; Egger M, 2017, BMJ-BRIT MED J, V315, P629; Firdayati F., 2015, THESIS MOH POLYTECHN; Hapsari AI, 2015, THESIS; Higgins JP, COCHRANE HDB SYSTEMA; Ismaviani ND, 2014, THESIS; Kim H, 2011, J FOOD SCI, V76, pC38, DOI 10.1111/j.1750-3841.2010.01908.x; Le Bellec Fabrice, 2006, Fruits, V61, P237, DOI 10.1051/fruits:2006021; Lim TK, 2012, EDIBLE MEDICINAL AND NON-MEDICINAL PLANTS: VOL 1, FRUITS, P1, DOI 10.1007/978-90-481-8661-7; Marcelia K., 2015, J NUTR COLL, V4, P79, DOI [10.14710/jnc.v4i1.8624, DOI 10.14710/JNC.V4I2.10056, DOI 10.14710/JNC.V4I1.8624]; Nitithan Suree, 2004, Journal of the Medical Association of Thailand, V87, P1444; Omidizadeh A, 2014, RSC ADV, V4, P62978, DOI 10.1039/c4ra10789f; Pablo P.G., 2015, THESIS; Pertiwi WA, 2014, J NUTR COLL, V3, P762; Prabhakar PK, 2008, CURR DIABETES REV, V4, P291, DOI 10.2174/157339908786241124; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Song HZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149670; Song HZ, 2016, J AGR FOOD CHEM, V64, P236, DOI 10.1021/acs.jafc.5b05177; Suh DH, 2014, J AGR FOOD CHEM, V62, P8764, DOI 10.1021/jf5020704; Swarup KRLA, 2010, PHARMACOGN RES, V2, P31, DOI 10.4103/0974-8490.60582; WHO, GLOB REP DIAB; Wiardani NK, 2014, J SKALA HUSADA, V11, P59; Wu LC, 2006, FOOD CHEM, V95, P319, DOI 10.1016/j.foodchem.2005.01.002; Yeh GY, 2003, DIABETES CARE, V26, P1277, DOI 10.2337/diacare.26.4.1277	30	16	17	3	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2017	12	9							e0184577	10.1371/journal.pone.0184577	http://dx.doi.org/10.1371/journal.pone.0184577			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG2YO	28886195	Green Published, gold, Green Submitted			2023-01-03	WOS:000410001100161
J	Romoren, M; Gjelstad, S; Lindbaek, M				Romoren, Maria; Gjelstad, Svein; Lindbaek, Morten			A structured training program for health workers in intravenous treatment with fluids and antibiotics in nursing homes: A modified stepped-wedge cluster-randomised trial to reduce hospital admissions	PLOS ONE			English	Article							MULTIFACETED INTERVENTION; ACQUIRED PNEUMONIA; RESIDENTS; OUTCOMES; GUIDELINES; INFECTION; MORTALITY; HAZARDS	Objectives Hospitalization is potentially detrimental to nursing home patients and resource demanding for the specialist health care. This study assessed if a brief training program in administrating intravenous fluids and antibiotics in nursing homes could reduce hospital transfers and ensure high quality care locally. Design A pragmatic and modified cluster randomized stepped-wedge trial with randomization on nursing home level. Participants 330 cases in 296 nursing home residents from 30 nursing homes were included. Cases were patients provided intravenous antibiotics or intravenous fluids, in nursing home or hospital. Primary outcome was localization of treatment, secondary outcomes were number of days treated, days of hospitalization among admitted patients, type of antibiotics used and 30-day mortality. Intervention The nursing homes sequentially received a one-day educational program for the health workers including theory and practical training in intravenous treatment of dehydration and infection, run by two skilled nurses. After completing the training program, the nursing homes had competence to provide intravenous treatment locally. Results The intervention had a highly significant effect on treatment in nursing homes (OR 8.35, 2.08 to 33.6; P<0.01, or RR 2.23, 1.48 to 2.56). The number treated in nursing homes was stable over time; the number treated in hospital gradually decreased (chi square for trend P< 0.001). Among patients receiving intravenous antibiotics in the nursing homes, 50 (46%) died within 30 days, compared to 30 (36%) treated in the hospital (P = 0.19). Among patients receiving intravenous fluids locally, 21 (19%) died within 30 days, compared to 2 (8%) in the hospital group (P = 0.34). Mortality was associated with reduced consciousness and elevated c-reactive protein. Conclusions A brief educational program delivered to nursing home personnel was feasible and effective in reducing acute hospital admissions from nursing homes for treatment of dehydration and infections.	[Romoren, Maria] Vestfold Hosp Trust, Dept Adm, Tonsberg, Norway; [Romoren, Maria; Gjelstad, Svein; Lindbaek, Morten] Univ Oslo, Dept Gen Practice, Inst Hlth & Soc, Oslo, Norway	University of Oslo	Romoren, M (corresponding author), Vestfold Hosp Trust, Dept Adm, Tonsberg, Norway.; Romoren, M (corresponding author), Univ Oslo, Dept Gen Practice, Inst Hlth & Soc, Oslo, Norway.	maria.romoren@medisin.uio.no			South-Eastern Norway Regional Health Authority; University of Oslo, Norway	South-Eastern Norway Regional Health Authority; University of Oslo, Norway	The 3iV project received funding grants from the South-Eastern Norway Regional Health Authority and the University of Oslo, Norway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agotnes G, 2016, AGEING INT, V41, P3, DOI 10.1007/s12126-015-9232-4; [Anonymous], 2012, TIDSSKR LAEGEFOREN, DOI DOI 10.4045/TIDSSKR.12.0194; Boockvar KS, 2005, J AM GERIATR SOC, V53, P590, DOI 10.1111/j.1532-5415.2005.53205.x; Carpenter I, 2004, AGING CLIN EXP RES, V16, P259; Coque T M, 2008, Euro Surveill, V13; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Friedman SM, 2008, GERONTOLOGIST, V48, P537, DOI 10.1093/geront/48.4.537; Graverholt B, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-36; Hemming K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h391; Hutt E, 2011, J AM MED DIR ASSOC, V12, P499, DOI 10.1016/j.jamda.2010.03.011; Leontjevas R, 2013, LANCET, V381, P2255, DOI 10.1016/S0140-6736(13)60590-5; Loeb M, 2005, BRIT MED J, V331, P669, DOI 10.1136/bmj.38602.586343.55; Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; Medical Research Council, 2006, DEV EVALUATING COMPL; Naughton BJ, 2001, J AM GERIATR SOC, V49, P1020, DOI 10.1046/j.1532-5415.2001.49203.x; Nielsen L, 2015, OPEN J MED MICROBIOL, V5, P28, DOI [10.4236/ojmm.2015.51005, DOI 10.4236/OJMM.2015.51005]; Norway Statistics, POPULATION; Norwegian Board of Health Supervision, 2003, PLEIE OMS KOMM TJEN; Norwegian Institute of Public Health, CAUS OF DEATH; Office of the Auditor General of Norway, 2016, RIKSR HELS ETT INNF; Onder G, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-5; Ouslander JG, 2010, J AM GERIATR SOC, V58, P627, DOI 10.1111/j.1532-5415.2010.02768.x; Selbaek G, 2007, INT J GERIATR PSYCH, V22, P843, DOI 10.1002/gps.1749; Steen Tore Walgaard, 2013, Tidsskr Nor Laegeforen, V133, P1819, DOI 10.4045/tidsskr.12.0935; Stern A, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-83; The Norwegian Directorate of Health, 2016, NAT GUID ANT PRESCR; The Norwegian Directorate of Health, 2013, NAT GUID ANT PRESCR; Thiem U, 2009, AGE AGEING, V38, P693, DOI 10.1093/ageing/afp164; van der Steen JT, 2004, J AM GERIATR SOC, V52, P691, DOI 10.1111/j.1532-5415.2004.52204.x; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	30	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2017	12	9							e0182619	10.1371/journal.pone.0182619	http://dx.doi.org/10.1371/journal.pone.0182619			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG0PY	28880941	Green Published, Green Submitted, gold			2023-01-03	WOS:000409467200008
J	Hung, CY; Wu, WT; Chang, KV; Wang, TG; Han, DS				Hung, Chen-Yu; Wu, Wei-Ting; Chang, Ke-Vin; Wang, Tyng-Guey; Han, Der-Sheng			Predicting the length of hospital stay of post-acute care patients in Taiwan using the Chinese version of the continuity assessment record and evaluation item set	PLOS ONE			English	Article							INDWELLING URINARY CATHETERS; OF-STAY; ACUTE STROKE; DISCHARGE DESTINATION; ISCHEMIC-STROKE; POSTACUTE CARE; REHABILITATION; EXPERIENCE; ADMISSION; DURATION	Background The Chinese version of the Continuity Assessment Record and Evaluation (CARE-C) item set was developed to facilitate the assessment of post-acute care (PAC) patients in Taiwan. Considering that the length of hospital stay (LOS) has a significant effect on the total healthcare cost, determining whether the CARE-C scores could predict the LOS of PAC patients is of great interest to the PAC providers. Methods This prospective trial included PAC patients with stroke or central nervous system injuries. The demographic data and CARE-C scores were collected after admission and before discharge. A multivariable stepwise linear regression model was used to identify the predictors of the LOS using age, sex, tube placement status, CARE-C component scores at admission, and score differences between admission and discharge as independent variables. Results This study included 178 patients (66 women and 112 men), with a mean age of 61.9 +/- 15.6 years. Indwelling urinary catheter placement status at admission (beta = 0.241, p = 0.002) was a positive predictor of the LOS, whereas age (beta = -0.189, p = 0.010), core transfer subscale score at admission (beta = -0.176, p = 0.020), and difference in continence subscale score (beta = -0.203, p = 0.008) were negative predictors of the LOS. The model explained 14% of the total variance. Conclusions Indwelling urinary catheter placement status at admission, age, core transfer subscale score at admission, and difference in the CARE-C continence subscale score were identified as predictors of the LOS. The explanatory power of these predictors might be limited due to the regulations of Taiwan's National Health Insurance.	[Hung, Chen-Yu; Wu, Wei-Ting; Chang, Ke-Vin; Han, Der-Sheng] Natl Taiwan Univ Hosp, BeiHu Branch, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Ke-Vin; Han, Der-Sheng] Natl Taiwan Univ Hosp, BeiHu Branch, Community & Geriatr Med Res Ctr, Taipei, Taiwan; [Chang, Ke-Vin; Wang, Tyng-Guey; Han, Der-Sheng] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Ke-Vin; Wang, Tyng-Guey; Han, Der-Sheng] Natl Taiwan Univ, Coll Med, Dept Phys Med & Rehabil, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Han, DS (corresponding author), Natl Taiwan Univ Hosp, BeiHu Branch, Dept Phys Med & Rehabil, Taipei, Taiwan.; Han, DS (corresponding author), Natl Taiwan Univ Hosp, BeiHu Branch, Community & Geriatr Med Res Ctr, Taipei, Taiwan.; Han, DS (corresponding author), Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Han, DS (corresponding author), Natl Taiwan Univ, Coll Med, Dept Phys Med & Rehabil, Taipei, Taiwan.	dshan1121@yahoo.com.tw		WANG, TYNG-GUEY/0000-0003-3298-4916; HAN, DER-SHENG/0000-0001-7642-8060	Taiwanese Society of Physical Medicine and Rehabilitation; Bureau of National Health Insurance [F1030033722]	Taiwanese Society of Physical Medicine and Rehabilitation; Bureau of National Health Insurance	This study was sponsored by the Taiwanese Society of Physical Medicine and Rehabilitation, and the Bureau of National Health Insurance grant No. F1030033722. The sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atalay A, 2009, INT J REHABIL RES, V32, P48, DOI 10.1097/MRR.0b013e32830d3689; Beckers V, 2012, ACTA NEUROL BELG, V112, P19, DOI 10.1007/s13760-012-0026-0; Bettger JAP, 2007, ARCH PHYS MED REHAB, V88, P1526, DOI 10.1016/j.apmr.2007.06.768; Bogousslavsky J, 1996, ARCH NEUROL-CHICAGO, V53, P265, DOI 10.1001/archneur.1996.00550030077025; Bohannon R W, 1994, J Stroke Cerebrovasc Dis, V4, P235, DOI 10.1016/S1052-3057(10)80097-7; Chang KC, 2002, STROKE, V33, P2670, DOI 10.1161/01.STR.0000034396.68980.39; Chang KV, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001828; Cowey E, 2012, CLIN REHABIL, V26, P470, DOI 10.1177/0269215511426160; DeJong G, 2014, ARCH PHYS MED REHAB, V95, P218, DOI 10.1016/j.apmr.2013.10.014; Deutsch A, 2012, CONTINUITY ASSESSMEN; Elwood D, 2009, PM&R, V1, P147, DOI 10.1016/j.pmrj.2008.10.010; Gage B., 2012, DEV TESTING CONTINUI; GALSKI T, 1993, STROKE, V24, P1794, DOI 10.1161/01.STR.24.12.1794; Holloway RG, 1996, NEUROLOGY, V46, P854; Holroyd-Leduc JM, 2007, J AM GERIATR SOC, V55, P227, DOI 10.1111/j.1532-5415.2007.01064.x; Hsieh CY, 2014, INT J STROKE, V9, pE3, DOI 10.1111/ijs.12232; Huang YC, 2013, J STROKE CEREBROVASC, V22, pE152, DOI 10.1016/j.jstrokecerebrovasdis.2012.10.014; Jorgensen HS, 1997, STROKE, V28, P1138, DOI 10.1161/01.STR.28.6.1138; Lin CL, 2009, J FORMOS MED ASSOC, V108, P653, DOI 10.1016/S0929-6646(09)60386-7; Saint S, 2000, AM J MED, V109, P476, DOI 10.1016/S0002-9343(00)00531-3; SHAH S, 1990, STROKE, V21, P241, DOI 10.1161/01.STR.21.2.241; Shieh G, 2014, BEHAV RES METHODS, V46, P808, DOI 10.3758/s13428-013-0415-1; Taiwo W, 2016, DISABIL REHABIL, P1; Tan WS, 2009, ARCH PHYS MED REHAB, V90, P1202, DOI 10.1016/j.apmr.2009.01.027; Wee JYM, 2005, AM J PHYS MED REHAB, V84, P604, DOI 10.1097/01.phm.0000171005.08744.ab; Wen CP, 2008, ANN INTERN MED, V148, P258, DOI 10.7326/0003-4819-148-4-200802190-00004; Wu CH, 2013, NEUROUROL URODYNAM, V32, P480, DOI 10.1002/nau.22317; Yeh HJ, 2017, ARCH PHYS MED REHAB, V98, P707, DOI 10.1016/j.apmr.2016.08.468	28	6	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2017	12	8							e0183612	10.1371/journal.pone.0183612	http://dx.doi.org/10.1371/journal.pone.0183612			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE6YW	28832680	Green Published, Green Submitted, gold			2023-01-03	WOS:000408355800070
J	Couzin-Frankel, J				Couzin-Frankel, Jennifer			BIOETHICS Call to halt heart trial raises vexing questions	SCIENCE			English	News Item																			0	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	2017	357	6351					538	539		10.1126/science.357.6351.538	http://dx.doi.org/10.1126/science.357.6351.538			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD1VM	28798111				2023-01-03	WOS:000407324800018
J	Foerster, J; Boswell, K; West, J; Cameron, H; Fleming, C; Ibbotson, S; Dawe, R				Foerster, John; Boswell, Kirsty; West, Jonathan; Cameron, Heather; Fleming, Colin; Ibbotson, Sally; Dawe, Robert			Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice	PLOS ONE			English	Article							EFFICACY	Background Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary. AIMS: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. Methods The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis. Results Around 75% of patients both achieved a status of "clear/minimal disease" and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25%) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations. Conclusions NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.	[Foerster, John; Boswell, Kirsty; West, Jonathan; Cameron, Heather; Fleming, Colin; Ibbotson, Sally; Dawe, Robert] Univ Dundee, Med Sch, Dundee, Scotland; [Foerster, John; Cameron, Heather; Fleming, Colin; Ibbotson, Sally; Dawe, Robert] NHS Tayside, Dept Dermatol & Photobiol, Dundee, Scotland	University of Dundee; University of Dundee	Foerster, J (corresponding author), Univ Dundee, Med Sch, Dundee, Scotland.; Foerster, J (corresponding author), NHS Tayside, Dept Dermatol & Photobiol, Dundee, Scotland.	j.foerster@dundee.ac.uk		West, Jonathan/0000-0002-4044-5931				Chen XM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009481.pub2; Editors TPM, 2014, PLOS MED, V11; GREEN C, 1992, BRIT J DERMATOL, V127, P5, DOI 10.1111/j.1365-2133.1992.tb14815.x; GREEN C, 1988, BRIT J DERMATOL, V119, P691, DOI 10.1111/j.1365-2133.1988.tb03489.x; West J, 2016, BRIT J DERMATOL, V174, P1407, DOI 10.1111/bjd.14452	6	15	15	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2017	12	8							e0181813	10.1371/journal.pone.0181813	http://dx.doi.org/10.1371/journal.pone.0181813			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC5AR	28771503	Green Published, gold, Green Submitted			2023-01-03	WOS:000406853600037
J	Kirkegaard, H; Soreide, E; de Haas, I; Pettila, V; Taccone, FS; Arus, U; Storm, C; Hassager, C; Nielsen, JF; Sorensen, CA; Ilkjaer, S; Jeppesen, AN; Grejs, AM; Duez, CHV; Hjort, J; Larsen, A; Toome, V; Tiainen, M; Hastbacka, J; Laitio, T; Skrifvars, MB				Kirkegaard, Hans; Soreide, Eldar; de Haas, Inge; Pettila, Ville; Taccone, Fabio Silvio; Arus, Urmet; Storm, Christian; Hassager, Christian; Nielsen, Jorgen Feldbaek; Sorensen, Christina Ankjaer; Ilkjaer, Susanne; Jeppesen, Anni Norgaard; Grejs, Anders Morten; Duez, Christophe Henri Valdemar; Hjort, Jakob; Larsen, Alflnge; Toome, Valdo; Tiainen, Marjaana; Hastbacka, Johanna; Laitio, Timo; Skrifvars, Markus B.			Targeted Temperature Management for 48 vs 24 Hours and Neurologic Outcome After Out-of-Hospital Cardiac Arrest A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS; MILD HYPOTHERMIA; CARDIOPULMONARY; RESUSCITATION; INDUCTION; ADMISSION; DURATION; PROTOCOL; CARE	IMPORTANCE International resuscitation guidelines recommend targeted temperature management (TTM) at 33 degrees C to 36 degrees C in unconscious patients with out-of-hospital cardiac arrest for at least 24 hours, but the optimal duration of TTM is uncertain. OBJECTIVE To determine whether TTM at 33 degrees C for 48 hours results in better neurologic outcomes compared with currently recommended, standard, 24-hour TTM. DESIGN, SETTING, AND PARTICIPANTS This was an international, investigator-initiated, blinded-outcome-assessor, parallel, pragmatic, multicenter, randomized clinical superiority trial in 10 intensive care units (ICUs) at 10 university hospitals in 6 European countries. Three hundred fifty-five adult, unconscious patients with out-of-hospital cardiac arrest were enrolled from February 16, 2013, to June 1, 2016, with final follow-up on December 27, 2016. INTERVENTIONS Patients were randomized to TTM(33 +/- 1 degrees C) for 48 hours (n = 176) or 24 hours (n = 179), followed by gradual rewarming of 0.5 degrees C per hour until reaching 37 degrees C. MAIN OUTCOMES AND MEASURES The primary outcome was 6-month neurologic outcome, with a Cerebral Performance Categories (CPC) score of 1 or 2 used to define favorable outcome. Secondary outcomes included 6-month mortality, including time to death, the occurrence of adverse events, and intensive care unit resource use. RESULTS In 355 patients who were randomized (mean age, 60 years; 295 [83%] men), 351 (99%) completed the trial. More patients in the 48-hour group had a favorable outcome, but this was not statistically significant. Six-month mortality was not different between the groups. Adverse events were more common in the 48-hour group than in the 24-hour group. There was no significant difference in the time to mortality (hazard ratio, 0.79; 95% CI, 0.54-1.15; P = .22). The median length of ICU stay (151 vs 117 hours; P < .001), but not hospital stay (11 vs 12 days; P = .50), was longer in the 48-hour group than in the 24-hour group. [GRAPHICS] CONCLUSIONS AND RELEVANCE In unconscious survivors from out-of-hospital cardiac arrest admitted to the ICU, targeted temperature management at 33 degrees C for 48 hours did not significantly improve 6-month neurologic outcome compared with targeted temperature management at 33 degrees C for 24 hours. However, the study may have had limited power to detect clinically important differences, and further research may be warranted.	[Kirkegaard, Hans; Jeppesen, Anni Norgaard; Grejs, Anders Morten; Duez, Christophe Henri Valdemar] Aarhus Univ Hosp, Res Ctr Emergency Med, Noerrebrogade 44,Bldg 1B, DK-8000 Aarhus C, Denmark; [Kirkegaard, Hans; Jeppesen, Anni Norgaard; Grejs, Anders Morten; Duez, Christophe Henri Valdemar] Aarhus Univ Hosp, Dept Anesthesiol & Intens Care Med, Aarhus, Denmark; [Kirkegaard, Hans; Jeppesen, Anni Norgaard; Grejs, Anders Morten; Duez, Christophe Henri Valdemar] Aarhus Univ, Aarhus, Denmark; [Soreide, Eldar] Stavanger Univ Hosp, Dept Anesthesiol & Intens Care, Stavanger, Norway; [Soreide, Eldar] Univ Bergen, Dept Clin Med, Bergen, Norway; [de Haas, Inge] Aalborg Univ Hosp, Dept Anesthesiol & Intens Care Med, Aalborg, Denmark; [de Haas, Inge] Aalborg Univ, Inst Clin, Aalborg, Denmark; [Pettila, Ville; Hastbacka, Johanna; Skrifvars, Markus B.] Univ Helsinki, Div Intens Care, Dept Anesthesiol Intens Care & Pain Med, FIN-00014 Helsinki, Finland; [Pettila, Ville; Tiainen, Marjaana; Hastbacka, Johanna; Skrifvars, Markus B.] Helsinki Univ Hosp, Helsinki, Finland; [Pettila, Ville] Univ Bern, Inselspital, Univ Hosp Bern, Bern, Switzerland; [Taccone, Fabio Silvio] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Arus, Urmet] North Estonia Med Ctr, Dept Intens Cardiac Care, Tallinn, Estonia; [Storm, Christian] Charite Univ Med Berlin, Dept Internal Med Nephrol & Intens Care, Berlin, Germany; [Hassager, Christian] Rigshosp, Copenhagen Univ Hosp, Dept Cardiol, Ctr Heart, Copenhagen, Denmark; [Nielsen, Jorgen Feldbaek] Aarhus Univ, Hammel Neurorehabilitat Ctr, DK-8000 Aarhus C, Denmark; [Nielsen, Jorgen Feldbaek] Aarhus Univ, Univ Res Clin, DK-8000 Aarhus C, Denmark; [Sorensen, Christina Ankjaer] Aalborg Univ Hosp, Dept Anesthesiol & Intens Care Med, Aalborg, Denmark; [Ilkjaer, Susanne] Aarhus Univ Hosp, Dept Anesthesiol & Intens Care Med, Aarhus, Denmark; [Hjort, Jakob] Aarhus Univ, Dept Clin Med, DK-8000 Aarhus C, Denmark; [Larsen, Alflnge] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway; [Larsen, Alflnge] Univ Bergen, Dept Clin Sci, N-5020 Bergen, Norway; [Toome, Valdo] North Estonia Med Ctr, Dept Anesthesiol Intens Care & Emergency Med, Tallinn, Estonia; [Tiainen, Marjaana] Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland; [Laitio, Timo] Turku Univ Hosp, Dept Anesthesiol & Intens Care, Turku, Finland; [Laitio, Timo] Univ Turku, SF-20500 Turku, Finland; [Skrifvars, Markus B.] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia	Aarhus University; Aarhus University; Aarhus University; Stavanger University Hospital; University of Bergen; Aalborg University; Aalborg University Hospital; Aalborg University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Bern; University Hospital of Bern; Universite Libre de Bruxelles; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Rigshospitalet; University of Copenhagen; Aarhus University; Aarhus University; Aalborg University; Aalborg University Hospital; Aarhus University; Aarhus University; Stavanger University Hospital; University of Bergen; University of Helsinki; University of Turku; University of Turku; Monash University	Kirkegaard, H (corresponding author), Aarhus Univ Hosp, Res Ctr Emergency Med, Noerrebrogade 44,Bldg 1B, DK-8000 Aarhus C, Denmark.	hanskirkegaard@dadlnet.dk	Nielsen, Jørgen Feldbæk/AAR-6384-2021; Soreide, Eldar/ABD-8141-2021; Laitio, Timo/GQB-4976-2022	Nielsen, Jørgen Feldbæk/0000-0001-5339-171X; Hastbacka, Johanna/0000-0002-3613-7231; Grejs, Anders/0000-0002-8850-2982; Duez, Christophe/0000-0001-7560-9214; Hassager, Christian/0000-0002-1199-0981	Danish Heart Foundation; Laerdal Foundation; Scandinavian Society of Anaesthesiology and Intensive Care Medicine; Danish Society of Anaesthesiology and Intensive Care Medicine; Augustinus Foundation; Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perklens minne	Danish Heart Foundation; Laerdal Foundation; Scandinavian Society of Anaesthesiology and Intensive Care Medicine; Danish Society of Anaesthesiology and Intensive Care Medicine; Augustinus Foundation; Finska Lakaresallskapet; Medicinska Understodsforeningen Liv och Halsa; Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perklens minne	The study was funded by independent research grants from The Danish Heart Foundation, The Laerdal Foundation, The Scandinavian Society of Anaesthesiology and Intensive Care Medicine, The Danish Society of Anaesthesiology and Intensive Care Medicine, The Augustinus Foundation, Finska Lakaresallskapet, and Medicinska Understodsforeningen Liv och Halsa and Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perklens minne.	ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Adrie C, 2006, EUR HEART J, V27, P2840, DOI 10.1093/eurheartj/ehl335; Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Becker LB, 2015, JAMA-J AM MED ASSOC, V314, P223, DOI 10.1001/jama.2015.8454; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bisschops LLA, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0546-5; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Che DF, 2011, CRIT CARE MED, V39, P1423, DOI 10.1097/CCM.0b013e318212020a; Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Grossestreuer AV, 2016, RESUSCITATION, V109, P21, DOI 10.1016/j.resuscitation.2016.09.006; Hifumi T, 2015, CIRC J, V79, P2201, DOI 10.1253/circj.CJ-15-0308; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2010, NEW ENGL J MED, V363, P1256, DOI 10.1056/NEJMct1002402; Kagawa E, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002123; Kim F, 2014, JAMA-J AM MED ASSOC, V311, P45, DOI 10.1001/jama.2013.282173; Kirkegaard H, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0334-0; Kirkegaard H, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1338-9; Legriel S, 2016, NEW ENGL J MED, V375, P2457, DOI 10.1056/NEJMoa1608193; Moler FW, 2015, NEW ENGL J MED, V372, P1898, DOI 10.1056/NEJMoa1411480; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Nagao K, 2010, CIRC J, V74, P77, DOI 10.1253/circj.CJ-09-0502; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Suh GJ, 2014, CRIT CARE MED, V42, pE132, DOI 10.1097/CCM.0b013e3182a668e4; TEASDALE G, 1974, LANCET, V2, P81; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	29	178	196	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 25	2017	318	4					341	350		10.1001/jama.2017.8978	http://dx.doi.org/10.1001/jama.2017.8978			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB7BS	28742911	Green Published			2023-01-03	WOS:000406296700014
J	Huang, CN; Wang, CJ; Lee, YJ; Peng, CH				Huang, Chien-Ning; Wang, Chau-Jong; Lee, Yi-Ju; Peng, Chiung-Huei			Active subfractions of Abelmoschus esculentus substantially prevent free fatty acid-induced beta cell apoptosis via inhibiting dipeptidyl peptidase-4	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; SIGNALING PATHWAY; PROTEIN-KINASE; HIGH GLUCOSE; AMPK; SURVIVAL; PROLIFERATION; LIPOTOXICITY; LIPOGENESIS; ACTIVATION	Lipotoxicity plays an important role in exacerbating type 2 diabetes mellitus (T2DM) and leads to apoptosis of beta cells. Recently dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as a useful tool in the treatment of T2DM. DPP-4 degrades type 1 glucagon-like peptide (GLP-1), and GLP-1 receptor (GLP-1R) signaling has been shown to protect beta cells by modulating AMPK/mTOR, PI3K, and Bax. The anti-hyperglycemic effect of Abelmoschus esculentus (AE) is well known, however its mucilage makes it difficult to further examine this effect. In our recent report, a sequence of extraction steps was used to obtain a series of subfractions from AE, each with its own composition and property. Among them F1 (rich in quercetin glucosides and pentacyclic triterpene ester) and F2 (containing large amounts of carbohydrates and polysaccharides) were found to be especially effective in attenuating DPP-4 signaling, and to have the potential to counter diabetic nephropathy. Hence, the aim of the present study was to investigate whether AE subfractions can prevent the palmitate-induced apoptosis of beta cells, and the putative signals involved. We demonstrated that AE, and especially 1 mu g/mL of F2, decreased palmitate-induced apoptosis analyzed by flow cytometry. The result of western blot revealed that palmitate-induced decrease in GLP-1R and increase in DPP-4 were restored by F1 and F2. The DPP-4 inhibitor linagliptin decreased the expression of caspase 3, suggesting that DPP-4 is critically involved in apoptotic signaling. Analysis of enzyme activity revealed that palmitate increased the activity of DPP4 nearly 2 folds, while F2 especially inhibited the activation. In addition, AMPK/mTOR, PI3K and mitochondrial pathways were regulated by AE, and this attenuated the palmitate-induced signaling cascades. In conclusion, AE is useful to prevent the exacerbation of beta cell apoptosis, and it could potentially be used as adjuvant or nutraceutical therapy for diabetes.	[Huang, Chien-Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Huang, Chien-Ning] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Wang, Chau-Jong] Chung Shan Med Univ, Inst Biochem Microbiol & Immunol, Taichung, Taiwan; [Lee, Yi-Ju] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Peng, Chiung-Huei] Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Hungkuang University	Peng, CH (corresponding author), Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan.	a222907@sunrise.hk.edu.tw		Peng, Chiung-Huei/0000-0003-1833-5522	Ministry of Science and Techonology, Taiwan [MOST 105-2320-B-241 -004 -MY2]	Ministry of Science and Techonology, Taiwan	This work was supported by the grant MOST 105-2320-B-241 -004 -MY2 of Ministry of Science and Techonology, Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chiu N, 1995, ILLUSTRATED MED PLAN, VI.; Choi YJ, 2005, J NUTR, V135, P707, DOI 10.1093/jn/135.4.707; Council NR, 2006, LOST CROPS AFR; Despres JP, 2006, ANN MED, V38, P52, DOI 10.1080/07853890500383895; Fulop N, 2007, CARDIOVASC RES, V73, P288, DOI 10.1016/j.cardiores.2006.07.018; Hocher B, 2012, KIDNEY BLOOD PRESS R, V36, P65, DOI 10.1159/000339028; Hwang HJ, 2014, MOL CELL ENDOCRINOL, V392, P1, DOI 10.1016/j.mce.2014.04.017; Kim WH, 2007, CELL SIGNAL, V19, P791, DOI 10.1016/j.cellsig.2006.10.004; Lin CL, 2008, MOL NUTR FOOD RES, V52, P930, DOI 10.1002/mnfr.200700437; Liu JH, 2012, TOXICOL IN VITRO, V26, P1093, DOI 10.1016/j.tiv.2012.07.004; Miao XY, 2013, PEPTIDES, V39, P71, DOI 10.1016/j.peptides.2012.10.006; Park KG, 2008, HEPATOLOGY, V48, P1477, DOI 10.1002/hep.22496; Peng CH, 2016, FOOD FUNCT, V7, P728, DOI [10.1039/C5FO01214G, 10.1039/c5fo01214g]; Peterszegi G, 2003, BIOMED PHARMACOTHER, V57, P187, DOI 10.1016/S0753-3322(03)00031-3; Puljak L, 2008, EXP CELL RES, V314, P2100, DOI 10.1016/j.yexcr.2008.03.002; Shirakawa J, 2011, J BIOL CHEM, V286, P25467, DOI 10.1074/jbc.M110.217216; Tseng HL, 2012, TOXICOL APPL PHARM, V264, P104, DOI 10.1016/j.taap.2012.07.022; Wang XM, 2015, CELL PHYSIOL BIOCHEM, V37, P1914, DOI 10.1159/000438552; Wang X, 2007, BIOCHEM BIOPH RES CO, V352, P463, DOI 10.1016/j.bbrc.2006.11.032; Wei Q, 2012, PEPTIDES, V37, P18, DOI 10.1016/j.peptides.2012.06.018; Wu YJ, 2015, METABOLISM, V64, P226, DOI 10.1016/j.metabol.2014.08.006; Yang MY, 2010, J AGR FOOD CHEM, V58, P850, DOI 10.1021/jf903209w; Yang TY, 2016, TOXICOL APPL PHARM, V294, P54, DOI 10.1016/j.taap.2016.01.013; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5	24	23	26	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2017	12	7							e0180285	10.1371/journal.pone.0180285	http://dx.doi.org/10.1371/journal.pone.0180285			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS8PU	28715446	gold, Green Published, Green Submitted			2023-01-03	WOS:000443975500005
J	Barnett, ML; Grabowski, DC; Mehrotra, A				Barnett, Michael L.; Grabowski, David C.; Mehrotra, Ateev			Home-to-Home Time - Measuring What Matters to Patients and Payers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Grabowski, David C.; Mehrotra, Ateev] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Barnett, Michael L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Mehrotra, Ateev] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.; Barnett, ML (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.		Barnett, Michael/ABA-4159-2021; Barnett, Michael/AAF-4017-2019; Mehrotra, Ateev/AAO-8454-2021	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; Mehrotra, Ateev/0000-0003-2223-1582; Grabowski, David/0000-0003-2915-5770				Centers for Medicare and Medicaid Services, CMS PROGR STAT MED U; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; Guterman S, 1986, Health Care Financ Rev, V7, P97; MORRISEY MA, 1988, HEALTH AFFAIR, V7, P52, DOI 10.1377/hlthaff.7.5.52	4	37	37	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2017	377	1					4	6		10.1056/NEJMp1703423	http://dx.doi.org/10.1056/NEJMp1703423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EZ5CS	28679095				2023-01-03	WOS:000404730000002
J	Laptook, AR; Shankaran, S; Tyson, JE; Munoz, B; Bell, EF; Goldberg, RN; Parikh, NA; Ambalavanan, N; Pedroza, C; Pappas, A; Das, A; Chaudhary, AS; Ehrenkranz, RA; Hensman, AM; Van Meurs, KP; Chalak, LF; Hamrick, SEG; Sokol, GM; Walsh, MC; Poindexter, BB; Faix, RG; Watterberg, KL; Frantz, ID; Guillet, R; Devaskar, U; Truog, WE; Chock, VY; Wyckoff, MH; McGowan, EC; Carlton, DP; Harmon, HM; Brumbaugh, JE; Cotten, CM; Sanchez, PJ; Hibbs, AM; Higgins, RD				Laptook, Abbot R.; Shankaran, Seetha; Tyson, Jon E.; Munoz, Breda; Bell, Edward F.; Goldberg, Ronald N.; Parikh, Nehal A.; Ambalavanan, Namasivayam; Pedroza, Claudia; Pappas, Athina; Das, Abhik; Chaudhary, Aasma S.; Ehrenkranz, Richard A.; Hensman, Angelita M.; Van Meurs, Krisa P.; Chalak, Lina F.; Hamrick, Shannon E. G.; Sokol, Gregory M.; Walsh, Michele C.; Poindexter, Brenda B.; Faix, Roger G.; Watterberg, Kristi L.; Frantz, Ivan D., III; Guillet, Ronnie; Devaskar, Uday; Truog, William E.; Chock, Valerie Y.; Wyckoff, Myra H.; McGowan, Elisabeth C.; Carlton, David P.; Harmon, Heidi M.; Brumbaugh, Jane E.; Cotten, C. Michael; Sanchez, Pablo J.; Hibbs, Anna Maria; Higgins, Rosemary D.		Eunice Kennedy Shriver Natl Instit; Human Development Neonatal Res Net	Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHOLE-BODY HYPOTHERMIA; SERVICES TASK-FORCE; NEONATAL ENCEPHALOPATHY; SYSTEMIC HYPOTHERMIA; CARDIOVASCULAR-DISEASE; POSTISCHEMIC SEIZURES; MODERATE HYPOTHERMIA; CHILDHOOD OUTCOMES; CEREBRAL-PALSY; FETAL SHEEP	IMPORTANCE Hypothermia initiated at less than 6 hours after birth reduces death or disability for infants with hypoxic-ischemic encephalopathy at 36 weeks' or later gestation. To our knowledge, hypothermia trials have not been performed in infants presenting after 6 hours. OBJECTIVE To estimate the probability that hypothermiainitiated at 6 to 24 hours after birth reduces the risk of death or disability at 18 months among infants with hypoxic-ischemic encephalopathy. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted between April 2008 and June 2016 among infants at 36 weeks' or later gestation with moderate or severe hypoxic-ischemic encephalopathy enrolled at 6 to 24 hours after birth. Twenty-one US Neonatal Research Network centers participated. Bayesian analyses were prespecified given the anticipated limited sample size. INTERVENTIONS Targeted esophageal temperature was used in 168 infants. Eighty-three hypothermic infants were maintained at 33.5 degrees C (acceptable range, 33 degrees C-34 degrees C) for 96 hours and then rewarmed. Eighty-five noncooled infants were maintained at 37.0 degrees C (acceptable range, 36.5 degrees C-37.3 degrees C). MAIN OUTCOMES AND MEASURES The composite of death or disability (moderate or severe) at 18 to 22 months adjusted for level of encephalopathy and age at randomization. RESULTS Hypothermic and noncooled infants were term (mean [SD], 39 [2] and 39 [1] weeks' gestation, respectively), and 47 of 83 (57%) and 55 of 85 (65%) were male, respectively. Both groups were acidemic at birth, predominantly transferred to the treating center with moderate encephalopathy, and were randomized at a mean (SD) of 16 (5) and 15 (5) hours for hypothermic and noncooled groups, respectively. The primary outcome occurred in 19 of 78 hypothermic infants (24.4%) and 22 of 79 noncooled infants (27.9%) (absolute difference, 3.5%; 95% CI, -1% to 17%). Bayesian analysis using a neutral prior indicated a 76% posterior probability of reduced death or disability with hypothermia relative to the noncooled group (adjusted posterior risk ratio, 0.86; 95% credible interval, 0.58-1.29). The probability that death or disability in cooled infants was at least 1%, 2%, or 3% less than noncooled infants was 71%, 64%, and 56%, respectively. CONCLUSIONS AND RELEVANCE Among term infants with hypoxic-ischemic encephalopathy, hypothermia initiated at 6 to 24 hours after birth compared with noncooling resulted in a 76% probability of any reduction in death or disability, and a 64% probability of at least 2% less death or disability at 18 to 22 months. Hypothermia initiated at 6 to 24 hours after birth may have benefit but there is uncertainty in its effectiveness.	[Laptook, Abbot R.; Hensman, Angelita M.; McGowan, Elisabeth C.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [Shankaran, Seetha; Pappas, Athina] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Tyson, Jon E.; Pedroza, Claudia] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat, Houston, TX 77030 USA; [Munoz, Breda] RTI Int, Social Stat & Environm Sci Unit, Res Triangle Pk, NC USA; [Bell, Edward F.; Brumbaugh, Jane E.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Goldberg, Ronald N.; Cotten, C. Michael] Duke Univ, Dept Pediat, Durham, NC 27706 USA; [Parikh, Nehal A.; Poindexter, Brenda B.] Cincinnati Childrens Hosp Med Ctr, Perinatal Inst, Cincinnati, OH 45229 USA; [Ambalavanan, Namasivayam] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA; [Das, Abhik] RTI Int, Social Stat & Environm Sci Unit, Rockville, MD USA; [Chaudhary, Aasma S.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Van Meurs, Krisa P.; Chock, Valerie Y.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA; [Van Meurs, Krisa P.; Chock, Valerie Y.] Lucile Packard Childrens Hosp, Palo Alto, CA USA; [Chalak, Lina F.; Wyckoff, Myra H.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Hamrick, Shannon E. G.; Carlton, David P.] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA USA; [Sokol, Gregory M.; Poindexter, Brenda B.; Harmon, Heidi M.] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Walsh, Michele C.; Hibbs, Anna Maria] Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Faix, Roger G.] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT USA; [Watterberg, Kristi L.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Frantz, Ivan D., III] Floating Hosp Children, Tufts Med Ctr, Dept Pediat, Div Newborn Med, Boston, MA USA; [Guillet, Ronnie] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Devaskar, Uday] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Truog, William E.] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA; [Truog, William E.] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA; [Sanchez, Pablo J.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Higgins, Rosemary D.] NICHHD, Eunice Kennedy Shriver, NIH, Bethesda, MD 20892 USA	Brown University; Women & Infants Hospital Rhode Island; Wayne State University; University of Texas System; University of Texas Health Science Center Houston; Research Triangle Institute; University of Iowa; Duke University; Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Birmingham; Research Triangle Institute; University of Pennsylvania; Yale University; Stanford University; Lucile Packard Children's Hospital (LPCH); University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Healthcare of Atlanta (CHOA); Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Utah System of Higher Education; University of Utah; University of New Mexico; University of New Mexico's Health Sciences Center; Floating Hospital For Children; Tufts Medical Center; University of Rochester; University of California System; University of California Los Angeles; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Laptook, AR (corresponding author), Women & Infants Hosp Rhode Isl, 101 Dudley St, Providence, RI 02905 USA.	alaptook@wihri.org	Ambalavanan, Namasivayam/AAL-3832-2020; Truog, William/R-5576-2019; Parikh, Nehal/AAB-9981-2022; Das, Abhik/AAF-1883-2020; Shah, Birju A./C-4811-2014; Ambalavanan, Namasivayam/AAI-4088-2020	Das, Abhik/0000-0003-2722-0479; Shah, Birju A./0000-0002-9051-1183; Ambalavanan, Namasivayam/0000-0003-0731-9092; Parikh, Nehal/0000-0002-1375-1247; Pedroza, Claudia/0000-0003-4235-1282; Bell, Edward/0000-0002-5568-0889; Harmon, Heidi/0000-0003-2413-1278; Shankaran, Seetha/0000-0001-5512-9571	National Institutes of Health; NICHD; National Center for Research Resources; National Center for Advancing Translational Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [UG1HD053109, UG1HD027851, UG1HD053089, UG1HD087229, UG1HD040689, UG1HD027904, UG1HD027880] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863, UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS102617] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The National Institutes of Health, the NICHD, the National Center for Research Resources, and the National Center for Advancing Translational Sciences provided grant support for the Neonatal Research Network through cooperative agreements.	American College of Obstetricians and Gynecologists American Academy of Pediatrics, 2014, NEON ENC NEUR OUTC; Azzopardi D, 2014, NEW ENGL J MED, V371, P140, DOI 10.1056/NEJMoa1315788; Azzopardi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038504; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bayley N, 2006, BAYLES SCALES INFANT; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V316, P1997, DOI 10.1001/jama.2016.15450; Bracken MB, 2009, J ROY SOC MED, V102, P120, DOI 10.1258/jrsm.2008.08k033; Chou R, 2016, JAMA-J AM MED ASSOC, V316, P2008, DOI 10.1001/jama.2015.15629; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Doyle LW, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004661.pub3; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1999, PEDIATR RES, V46, P274, DOI 10.1203/00006450-199909000-00005; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 2013, ANN NEUROL, V73, P520, DOI 10.1002/ana.23843; Li Tongchuan, 2009, Hosp Pract (1995), V37, P147, DOI 10.3810/hp.2009.12.269; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; Newman JE, 2012, J PEDIATR-US, V161, P1041, DOI 10.1016/j.jpeds.2012.05.048; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Pedroza C, STAT METHODS MED RES; Rouse DJ, 2008, NEW ENGL J MED, V359, P895, DOI 10.1056/NEJMoa0801187; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2017, JAMA-J AM MED ASSOC, V318, P57, DOI 10.1001/jama.2017.7218; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Shankaran S, 2012, PEDIATR CRIT CARE ME, V13, P53, DOI 10.1097/PCC.0b013e31821926bc; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441; Smit E, 2015, ACTA PAEDIATR, V104, P138, DOI 10.1111/apa.12784; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; Volpe JJ, 2008, NEUROLOGY NEWBORN, V5th; Volpe JJ, 2012, ANN NEUROL, V72, P156, DOI 10.1002/ana.23647; Wijeysundera DN, 2009, J CLIN EPIDEMIOL, V62, P13, DOI 10.1016/j.jclinepi.2008.07.006; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	40	141	146	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2017	318	16					1550	1560		10.1001/jama.2017.14972	http://dx.doi.org/10.1001/jama.2017.14972			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK6EX	29067428	Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000413597200020
J	Naito, T; Namiguchi, K; Yoshikawa, K; Miyamoto, K; Mizoue, S; Kawashima, Y; Shiraishi, A; Shiraga, F				Naito, Tomoko; Namiguchi, Koji; Yoshikawa, Keiji; Miyamoto, Kazuhisa; Mizoue, Shiro; Kawashima, Yoichi; Shiraishi, Atushi; Shiraga, Fumio			Factors affecting eye drop instillation in glaucoma patients with visual field defect	PLOS ONE			English	Article							QUALITY-OF-LIFE; MICROBIAL-CONTAMINATION; MEDICATIONS; POPULATION; IMPAIRMENT; CONTAINERS; DISABILITY; VISION	Background To investigate the success rate of eye drop instillation in glaucoma patients with visual field defect as well as non-glaucoma volunteers. Factors that may affect the success rate of eye drop instillation were also evaluated. Design A prospective, observational study. Participants Seventy-eight glaucoma patients and 85 non-glaucoma volunteers were recruited in this study. Methods Open angle glaucoma patients with visual field defect as well as non-glaucoma volunteers were asked to video record their procedures of eye drop instillation using a 5-mL plastic bottle of artificial tear solution. Success of eye drop instillation was judged on video based on the first one drop of solution successfully applied on the cornea, by two investigators. Main outcome measures Success rate of eye drop instillation in glaucoma patients and non-glaucoma volunteers. Factors related to success rate of eye drop instillation, such as visual field defect and clinical characteristics, were also analyzed using multivariable logistic regression. Results No significant deference in mean age was observed between two groups (glaucoma: 64.5 +/- 14.4 years, non-glaucoma: 60.9 +/- 14.1 years, P = 0.1156). Success rate of eye drop instillation was significantly lower (P = 0.0215) in glaucoma patients (30/78; 38.5%) than in non-glaucoma volunteers (48/85; 56.5%). The most frequent reason of instillation failure in glaucoma patients was touching the bulbar conjunctiva, cornea, eyelid or eyelashes with the tip of the bottle (29.5%). Multivariable logistic regression analysis identified lower corrected visual acuity (VA) (<= 1.0; odds ratio [OR] = 0.20, 95% confidence interval [CI] 0.04-0.93, P = 0.0411), lower mean deviation (MD) (< -12 dB; OR = 0.20, 95% CI 0.05-0.86, P = 0.0307) and visual field defect (VFD) in the inferior hemifield (OR = 0.11, 95% CI 0.02-0.34, P < 0.001) to be significantly related to instillation failure in glaucoma patients. Conclusions Success rate of eye drop instillation was significantly lower in glaucoma patients than in non-glaucoma volunteers. Corrected VA <= 1.0, MD < -12 dB and/or VFD in the inferior hemifield may be related to failure of eye drop instillation.	[Naito, Tomoko; Shiraga, Fumio] Okayama Univ, Grad Sch Med, Dept Ophthalmol, Okayama, Japan; [Namiguchi, Koji; Mizoue, Shiro; Shiraishi, Atushi] Ehime Univ, Dept Ophthalmol, Grad Sch Med, Matsuyama, Ehime, Japan; [Yoshikawa, Keiji] Yoshikawa Eye Clin, Tokyo, Japan; [Miyamoto, Kazuhisa] Sumitomo Besshi Hosp, Niihama, Ehime, Japan; [Kawashima, Yoichi] Kyoto Hitomi Care Res, Kyoto, Japan	Okayama University; Ehime University	Naito, T (corresponding author), Okayama Univ, Grad Sch Med, Dept Ophthalmol, Okayama, Japan.	tomokoum@gmail.com						BROWN MM, 1984, CAN J OPHTHALMOL, V19, P2; BURNS E, 1992, AGE AGEING, V21, P168, DOI 10.1093/ageing/21.3.168; Dietlein TS, 2008, ACTA OPHTHALMOL, V86, P856, DOI 10.1111/j.1755-3768.2007.01155.x; Freeman EE, 2008, OPHTHALMOLOGY, V115, P233, DOI 10.1016/j.ophtha.2007.04.050; GEYER O, 1995, BRIT J OPHTHALMOL, V79, P376, DOI 10.1136/bjo.79.4.376; Gupta R, 2012, J GLAUCOMA, V21, P189, DOI 10.1097/IJG.0b013e31820bd2e1; Hennessy AL, 2011, AM J OPHTHALMOL, V152, P982, DOI 10.1016/j.ajo.2011.05.015; Hennessy AL, 2010, OPHTHALMOLOGY, V117, P2345, DOI 10.1016/j.ophtha.2010.03.040; Imaeda T, 2006, J ORTHOP SCI, V11, P248, DOI 10.1007/s00776-006-1013-1; Kholdebarin R, 2008, CAN J OPHTHALMOL, V43, P454, DOI [10.1139/i08-076, 10.3129/i08-076]; Kim MS, 2008, BRIT J OPHTHALMOL, V92, P1518, DOI 10.1136/bjo.2008.144469; Nelson P, 1999, BRIT J OPHTHALMOL, V83, P546, DOI 10.1136/bjo.83.5.546; Nordstrom BL, 2005, AM J OPHTHALMOL, V140, P598, DOI 10.1016/j.ajo.2005.04.051; O'Hare F, 2009, CLIN EXP OPHTHALMOL, V37, P849, DOI 10.1111/j.1442-9071.2009.02184.x; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9; Rossi GCM, 2011, EUR J OPHTHALMOL, V21, P410, DOI 10.5301/EJO.2010.6112; Sawada H, 2014, J GLAUCOMA, V23, P81, DOI 10.1097/IJG.0b013e318265bbdc; SCHEIN OD, 1988, AM J OPHTHALMOL, V105, P361, DOI 10.1016/0002-9394(88)90298-X; Stone JL, 2009, ARCH OPHTHALMOL-CHIC, V127, P732, DOI 10.1001/archophthalmol.2009.96; Takahashi M, 2010, J EYE ATARASHII GANK, V27, P1107; Tatham AJ, 2013, EYE, V27, P1293, DOI 10.1038/eye.2013.187; Van Santvliet L, 2004, SURV OPHTHALMOL, V49, P197, DOI 10.1016/j.survophthal.2003.12.009; Yoshikawa K, 2010, CLIN OPHTHALMOL, V4, P481	24	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2017	12	10							e0185874	10.1371/journal.pone.0185874	http://dx.doi.org/10.1371/journal.pone.0185874			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ6DU	29023521	gold, Green Submitted, Green Published			2023-01-03	WOS:000412845100035
J	Wang, L; Baser, O; Wells, P; Peacock, WF; Coleman, CI; Fermann, GJ; Schein, J; Crivera, C				Wang, Li; Baser, Onur; Wells, Phil; Peacock, W. Frank; Coleman, Craig I.; Fermann, Gregory J.; Schein, Jeff; Crivera, Concetta			Benefit of early discharge among patients with low-risk pulmonary embolism	PLOS ONE			English	Article							HOSPITAL STAY; OUTPATIENT TREATMENT; SEVERITY INDEX; STRATIFICATION; METAANALYSIS; LENGTH; MORTALITY; COMPLICATIONS; THROMBOSIS; STROKE	Clinical guidelines recommend early discharge of patients with low-risk pulmonary embolism (LRPE). This study measured the overall impact of early discharge of LRPE patients on clinical outcomes and costs in the Veterans Health Administration population. Adult patients with >= 1 inpatient diagnosis for pulmonary embolism (PE) (index date) between 10/2011-06/2015, continuous enrollment for >= 12 months pre-and 3 months post-index date were included. PE risk stratification was performed using the simplified Pulmonary Embolism Stratification Index. Propensity score matching (PSM) was used to compare 90-day adverse PE events (APEs) [recurrent venous thromboembolism, major bleed and death], hospital-acquired complications (HACs), healthcare utilization, and costs among short (<= 2 days) versus long length of stay (LOS). Net clinical benefit was defined as 1 minus the combined rate of APE and HAC. Among 6,746 PE patients, 95.4% were men, 22.0% were African American, and 1,918 had LRPE. Among LRPE patients, only 688 had a short LOS. After 1:1 PSM, there were no differences in APE, but short LOS had fewer HAC (1.5% vs 13.3%, 95% CI: 3.77-19.94) and bacterial pneumonias (5.9% vs 11.7%, 95% CI: 1.24-3.23), resulting in better net clinical benefit (86.9% vs 78.3%, 95% CI: 0.84-0.96). Among long LOS patients, HACs (52) exceeded APEs (14 recurrent DVT, 5 bleeds). Short LOS incurred lower inpatient ($2,164 vs $5,100, 95% CI: $646.8-$5225.0) and total costs ($9,056 vs $12,544, 95% CI: $636.6-$6337.7). LRPE patients with short LOS had better net clinical outcomes at lower costs than matched LRPE patients with long LOS.	[Wang, Li; Baser, Onur] STATinMED Res, Plano, TX 75093 USA; [Baser, Onur] Columbia Univ, Ctr Innovat & Outcomes Res, Dept Surg, New York, NY USA; [Baser, Onur] STATinMED Res, New York, NY USA; [Baser, Onur] MEF Univ, Dept Econ, Istanbul, Turkey; [Wells, Phil] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Wells, Phil] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Peacock, W. Frank] Baylor Coll Med, Emergency Med, Houston, TX 77030 USA; [Coleman, Craig I.] Univ Connecticut, Sch Pharm, Hartford, CT 06112 USA; [Fermann, Gregory J.; Schein, Jeff] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA; [Crivera, Concetta] LLC, Janssen Sci Affairs, Titusville, NJ USA	Columbia University; MEF Universitesi; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Baylor College of Medicine; University of Connecticut; University System of Ohio; University of Cincinnati; Johnson & Johnson; Janssen Pharmaceuticals	Wang, L (corresponding author), STATinMED Res, Plano, TX 75093 USA.	lwang@statinmed.com	Library, MEF/O-1457-2019	Coleman, Craig/0000-0003-4868-7158	Janssen Scientific Affairs, LLC	Janssen Scientific Affairs, LLC	This study was funded by Janssen Scientific Affairs, LLC.	Aujesky D, 2008, ARCH INTERN MED, V168, P706, DOI 10.1001/archinte.168.7.706; Aujesky D, 2009, SWISS MED WKLY, V139, P685, DOI smw-12661; Becattini C, 2007, CIRCULATION, V116, P427, DOI 10.1161/CIRCULATIONAHA.106.680421; BefElohlavekJ Dytrych V, 2013, EXP CLIN CARDIOL, V18, P129; Berghaus TM, 2010, ADV THER, V27, P648, DOI 10.1007/s12325-010-0058-x; Coleman CI, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009251; Cunningham A, 2011, PHARMACOEPIDEM DR S, V20, P560, DOI 10.1002/pds.2109; Dentali F, 2013, J THROMB HAEMOST, V11, P2103, DOI 10.1111/jth.12420; Donadini MP, 2017, THROMB RES, V156, P155, DOI 10.1016/j.thromres.2017.06.009; Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznawania i postepowania w ostrej zatorowosci plucnej, 2014, Kardiol Pol, V72, P997, DOI 10.5603/KP.2014.0211; Hellenkamp K, 2015, INT J CARDIOL, V197, P162, DOI 10.1016/j.ijcard.2015.06.065; Ingeman A, 2011, STROKE, V42, P3214, DOI 10.1161/STROKEAHA.110.610881; Jimenez D, 2016, INTERN EMERG MED, V11, P11, DOI 10.1007/s11739-015-1388-0; Jimenez D, 2010, ARCH INTERN MED, V170, P1383, DOI 10.1001/archinternmed.2010.199; Kang DK, 2011, AM J CARDIOL, V108, P133, DOI 10.1016/j.amjcard.2011.03.009; Kearon C, 2003, CAN MED ASSOC J, V168, P183; Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301; LaMori JC, 2015, CLIN THER, V37, P62, DOI 10.1016/j.clinthera.2014.10.024; Masotti L, 2009, VASC HEALTH RISK MAN, V5, P567; Maynard C, 2004, DIABETES CARE, V27, pB22, DOI 10.2337/diacare.27.suppl_2.B22; Miniati M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030891; Ozsu S, 2014, THROMB RES, V133, P1006, DOI 10.1016/j.thromres.2014.02.032; Piran S, 2013, THROMB RES, V132, P515, DOI 10.1016/j.thromres.2013.08.012; Rali P, 2016, CRIT CARE NURS Q, V39, P131, DOI 10.1097/CNQ.0000000000000106; Research user Guide: Fiscal Year, 2009, VHA MED SAS INPATIEN; Sorbello D, 2009, CEREBROVASC DIS, V28, P378, DOI 10.1159/000230712; Squizzato A, 2012, J THROMB HAEMOST, V10, P1276, DOI 10.1111/j.1538-7836.2012.04739.x; Stamm JA, 2014, SOUTH MED J, V107, P72, DOI 10.1097/SMJ.0000000000000053; Tarbox Abigail K, 2013, Int J Crit Illn Inj Sci, V3, P69, DOI 10.4103/2229-5151.109427; Tirschwell D L, 1999, J Stroke Cerebrovasc Dis, V8, P336, DOI 10.1016/S1052-3057(99)80008-1; VA Information Resource Center, 2009, VIREC RES US GUID VH; VA Information Resource Center, VIREC RES GUID VA DA; Veterans Health Administration, VET HLTH ADM; Zondag W, 2013, EUR RESPIR J, V42, P134, DOI 10.1183/09031936.00093712	34	12	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2017	12	10							e0185022	10.1371/journal.pone.0185022	http://dx.doi.org/10.1371/journal.pone.0185022			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ3JE	29016692	Green Published, gold, Green Submitted			2023-01-03	WOS:000412627400012
J	Paskevicius, S; Starkevic, U; Misiunas, A; Vitkauskiene, A; Gleba, Y; Razanskiene, A				Paskevicius, Sarunas; Starkevic, Urte; Misiunas, Audrius; Vitkauskiene, Astra; Gleba, Yuri; Razanskiene, Ausra			Plant-expressed pyocins for control of Pseudomonas aeruginosa	PLOS ONE			English	Article							TRANSPOSON MUTANT LIBRARY; HIGH-YIELD PRODUCTION; COLICIN M; PROTEIN ANTIBIOTICS; VIRAL VECTORS; BACTERIOCINS; EFFICACY; DISEASE	The emergence, persistence and spread of antibiotic-resistant human pathogenic bacteria heralds a growing global health crisis. Drug-resistant strains of gram-negative bacteria, such as Pseudomonas aeruginosa, are especially dangerous and the medical and economic burden they impose underscore the critical need for finding new antimicrobials. Recent studies have demonstrated that plant-expressed bacteriocins of the colicins family can be efficient antibacterials against all major enteropathogenic strains of E. coli. We extended our studies of colicin-like bacteriocins to pyocins, which are produced by strains of P. aeruginosa for ecological advantage against other strains of the same species. Using a plant-based transient expression system, we expressed six different pyocins, namely S5, PaeM, L1, L2, L3 and one new pyocin, PaeM4, and purified them to homogeneity. Among these pyocins, PaeM4 demonstrated the broadest spectrum of activity by controlling 53 of 100 tested clinical isolates of P. aeruginosa. The activity of plant-made pyocins was confirmed in the agar drop, liquid culture susceptibility and biofilm assays, and in the Galleria mellonella animal infection model.	[Paskevicius, Sarunas; Starkevic, Urte; Misiunas, Audrius; Razanskiene, Ausra] Nomads UAB, Gelezinio Vilko 29A, Vilnius, Lithuania; [Paskevicius, Sarunas; Starkevic, Urte] Vilnius Univ, Inst Biotechnol, Sauletekio Al 7, Vilnius, Lithuania; [Vitkauskiene, Astra] Lithuanian Univ Hlth Sci, A Mickeviciaus G 9, Kaunas, Lithuania; [Gleba, Yuri] Nomad Biosci GmbH, Biozentrum Halle, Weinbergweg 22, Halle, Saale, Germany	Vilnius University; Lithuanian University of Health Sciences	Razanskiene, A (corresponding author), Nomads UAB, Gelezinio Vilko 29A, Vilnius, Lithuania.	ausra@nomadsbio.lt	Paškevičius, Šarūnas/GPK-7815-2022	Gleba, Yuri/0000-0003-4675-7474; Razanskiene, Ausra/0000-0002-0839-1224; Paskevicius, Sarunas/0000-0001-6421-5842	LVPA (Lietuvos verslo paramos agentura, a Lithuanian Business Support Agency) [J05-LVPA-K-01-0035]	LVPA (Lietuvos verslo paramos agentura, a Lithuanian Business Support Agency)	LVPA (Lietuvos verslo paramos agentura, a Lithuanian Business Support Agency) provided funding for the study (grant J05-LVPA-K-01-0035, http://lvpa.lt/). Nomads UAB and its parent company Nomad Bioscience GmbH provided support in the form of salaries for authors SP, US, AM, YG, and AR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "Author Contributions" section.	Barreteau H, 2012, J BIOL CHEM, V287, P37395, DOI 10.1074/jbc.M112.406439; Barreteau H, 2010, J BIOL CHEM, V285, P12378, DOI 10.1074/jbc.M109.093583; Barreteau H, 2009, J BACTERIOL, V191, P3657, DOI 10.1128/JB.01824-08; Bassetti M, 2013, ANN CLIN MICROB ANTI, V12, DOI 10.1186/1476-0711-12-22; Bendandi M, 2010, ANN ONCOL, V21, P2420, DOI 10.1093/annonc/mdq256; Brown CL, 2012, BIOCHEM SOC T, V40, P1549, DOI 10.1042/BST20120241; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DIAZ E, 1994, MOL MICROBIOL, V13, P855, DOI 10.1111/j.1365-2958.1994.tb00477.x; Elfarash A, 2014, MICROBIOL-SGM, V160, P261, DOI 10.1099/mic.0.070672-0; Ghequire MGK, 2017, MBIO, V8, DOI 10.1128/mBio.01961-16; Ghequire MGK, 2015, SCI REP-UK, V5, DOI 10.1038/srep17368; Ghequire MGK, 2014, FEMS MICROBIOL REV, V38, P523, DOI 10.1111/1574-6976.12079; Gleba Y, 2007, CURR OPIN BIOTECH, V18, P134, DOI 10.1016/j.copbio.2007.03.002; Gleba YY, 2014, CURR TOP MICROBIOL, V375, P155, DOI 10.1007/82_2013_352; Grinter R, 2013, FEMS MICROBIOL LETT, V338, P1, DOI 10.1111/1574-6968.12011; Grinter R, 2012, J BIOL CHEM, V287, P38876, DOI 10.1074/jbc.M112.400150; Hahn S, 2015, PLANT BIOTECHNOL J, V13, P708, DOI 10.1111/pbi.12299; Held K, 2012, J BACTERIOL, V194, P6387, DOI 10.1128/JB.01479-12; Hoiby N, 2011, INT J ORAL SCI, V3, P55, DOI 10.4248/IJOS11026; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Mah TF, 2003, LETT NAT, V426, P1, DOI DOI 10.1038/; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; Marillonnet S, 2005, NAT BIOTECHNOL, V23, P718, DOI 10.1038/nbt1094; McCaughey LC, 2016, SCI REP-UK, V6, DOI 10.1038/srep30201; Medina C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023055; Michel-Briand Y, 2002, BIOCHIMIE, V84, P499, DOI 10.1016/S0300-9084(02)01422-0; Moskowitz SM, 2004, J CLIN MICROBIOL, V42, P1915, DOI 10.1128/JCM.42.5.1915-1922.2004; Oey M, 2009, P NATL ACAD SCI USA, V106, P6579, DOI 10.1073/pnas.0813146106; Oey M, 2009, PLANT J, V57, P436, DOI 10.1111/j.1365-313X.2008.03702.x; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777; Scholl D, 2008, ANTIMICROB AGENTS CH, V52, P1647, DOI 10.1128/AAC.01479-07; Schulz S, 2015, P NATL ACAD SCI USA, V112, pE5454, DOI 10.1073/pnas.1513311112; Smith K, 2012, ANTIMICROB AGENTS CH, V56, P1599, DOI 10.1128/AAC.05714-11; Starkevic U, 2015, J BIOTECHNOL, V200, P10, DOI 10.1016/j.jbiotec.2015.02.028; Tommasi R, 2015, NAT REV DRUG DISCOV, V14, P529, DOI 10.1038/nrd4572; Tuse D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/648143; Wiens JR, 2014, MBIO, V5, DOI 10.1128/mBio.01010-13	38	28	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2017	12	10							e0185782	10.1371/journal.pone.0185782	http://dx.doi.org/10.1371/journal.pone.0185782			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI6UJ	28973027	Green Submitted, Green Published, gold			2023-01-03	WOS:000412131900049
J	Lambert, A; Jarlier, M; Bourgade, SG; Conroy, T				Lambert, Aurelien; Jarlier, Marta; Bourgade, Sophie Gourgou; Conroy, Thierry			Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial	PLOS ONE			English	Article							GEMCITABINE	Background Hohla et al. suggested that female gender could positively predict response to FOLFIRINOX in patients with advanced pancreatic cancer. In this study, we explored the response to the FOLFIRINOX regimen by gender within the trial PRODIGE4/ACCORD 11. Patients and methods Data were described by gender, both in FOLFIRINOX group and in the intention-to-treat population of the trial. The relative effect of gender (females in comparison to males) on overall survival (OS) and progression-free survival was estimated by using a Cox proportional hazard model and was presented with the Hazard Ratio and their 95% confidence interval. The analysis of prognostic factors of OS included also: age (older than 65 years), ECOG performance status, primary tumor location, synchronous metastases, number of metastatic sites, hepatic metastasis, pulmonary metastases, lymph node metastases, level of Albumin and level of serum carbohydrate antigen 19-9 and three domains from the EORTC Quality of Life QLQC-30 questionnaire. Results The FOLFIRINOX group (N = 171 patients) included 106 women (62%) and 65 men. No significant differences were observed between genders regarding demographic and clinical parameters, excepted for lymph nodes metastasis (17% and 35% in women and men respectively; p = 0.012). Median OS was longer for females as compared to males in FOLFIRINOX group (13.1 versus 10.3 months respectively; HR = 0.73; 95% CI, 0.51-1.06). Similarly, median PFS was superior (7.2 versus 5.9 months; HR = 0.79; 95% CI, 0.57-1.10). Nevertheless, in both cases, the differences were not statistically significant (p = 0.10 et p = 0.169, respectively). Conclusions In this study, the overall survival and progression-free survival rates were not significantly higher for females than for males in FOLFIRINOX group (HR = 0.73; 95% CI, 0.51-1.06 and HR = 0.79; 95% CI, 0.57-1.10 respectively). Even if the percentage of patients with lymph node metastasis is higher for males than for females, the interaction between gender and lymph node metastasis was non-significant. Our exploratory analysis did not permit to definitively conclude about a possible effect of gender on the prognosis of patients under FOLFIRINOX. This subject deserves further evaluation.	[Lambert, Aurelien; Conroy, Thierry] Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France; [Jarlier, Marta; Bourgade, Sophie Gourgou] Inst Reg Canc Montpellier, Biostat Unit, Parc Euromed, Montpellier, France	UNICANCER; Institut de cancerologie de Lorraine (ICL); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Lambert, A (corresponding author), Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France.	a.lambert@nancy.unicancer.fr	Conroy, Thierry/X-8127-2019	Lambert, Aurelien/0000-0001-9990-1201				Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869; Hidalgo M, 2014, ANN ONCOL         S2, V25; Hohla F, 2014, INT J ONCOL, V44, P319, DOI 10.3892/ijo.2013.2176	4	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0183288	10.1371/journal.pone.0183288	http://dx.doi.org/10.1371/journal.pone.0183288			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931010	Green Submitted, gold, Green Published			2023-01-03	WOS:000411314700008
J	Vitiello, A; Zanetti, M				Vitiello, Antonella; Zanetti, Maurizio			Neoantigen prediction and the need for validation	NATURE BIOTECHNOLOGY			English	Letter							T-CELL RESPONSES; MASS-SPECTROMETRY; CTLA-4 BLOCKADE; CANCER; MELANOMA; PEPTIDE; IMMUNODOMINANCE; IDENTIFICATION; REPERTOIRES; LYMPHOCYTES		[Vitiello, Antonella] PersImmune Inc, San Diego, CA 92121 USA; [Zanetti, Maurizio] Univ Calif San Diego, Dept Med, Lab Immunol, La Jolla, CA 92093 USA; [Zanetti, Maurizio] Univ Calif San Diego, Dept Med, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Vitiello, A (corresponding author), PersImmune Inc, San Diego, CA 92121 USA.	avitiello@persimmune.com; mzanetti@ucsd.edu						Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Akram A, 2013, EUR J IMMUNOL, V43, P3254, DOI 10.1002/eji.201343597; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Gfeller D, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1177691; Gnjatic S, 2002, P NATL ACAD SCI USA, V99, P11813, DOI 10.1073/pnas.142417699; Hernandez J, 2002, P NATL ACAD SCI USA, V99, P12275, DOI 10.1073/pnas.182418399; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Schmidt J, 2017, J BIOL CHEM, V292, P11840, DOI 10.1074/jbc.M117.789511; SETTE A, 1994, J IMMUNOL, V153, P5586; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Vitiello A, 1996, J IMMUNOL, V157, P5555; Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188; Willis RA, 2006, P NATL ACAD SCI USA, V103, P12063, DOI 10.1073/pnas.0605130103; Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005; Zanetti M, 2015, J IMMUNOL, V194, P2049, DOI 10.4049/jimmunol.1402669	30	48	55	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2017	35	9					815	817		10.1038/nbt.3932	http://dx.doi.org/10.1038/nbt.3932			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FG5NR	28898209	Bronze			2023-01-03	WOS:000410371600009
J	Hermetet, C; Dubois, F; Gaudy-Graffin, C; Bacq, Y; Royer, B; Gaborit, C; D'Alteroche, L; Desenclos, JC; Roingeard, P; Grammatico-Guillon, L				Hermetet, Coralie; Dubois, Frederic; Gaudy-Graffin, Catherine; Bacq, Yannick; Royer, Bernard; Gaborit, Christophe; D'Alteroche, Louis; Desenclos, Jean Claude; Roingeard, Philippe; Grammatico-Guillon, Leslie			Continuum of hepatitis C care in France: A 20-year cohort study	PLOS ONE			English	Article							VIRUS-INFECTION; RISK-FACTORS; POPULATION; SOFOSBUVIR; RECOMMENDATIONS; EPIDEMIOLOGY; PROGRESSION; LEDIPASVIR; FIBROSIS; TRIAL	Background Hepatitis C virus (HCV)-infected patients require a specific continuum of care (CoC) from HCV screening to treatment. We assessed CoC of HCV-infected patients in a longitudinal study. Methods We established a cohort of subjects undergoing HCV screening (high alanine aminotransferase levels or risk factors) during preventive consultations at a French regional medical center from 1993 to 2013. Patients were considered to be HCV-infected if HCV RNA was detected in their serum. CoC was assessed as described by Viner et al. (Hepatology 2015): Stage 1, HCV screening; Stage 2, HCV RNA testing; Stage 3, continuing care; Stage 4, antiviral treatment. Cox multivariate analysis was performed to identify factors favoring CoC, defined as at least one course of antiviral treatment. Results In total, 12,993 HCV tests were performed and 478 outpatients were found to be HCV-seropositive. We included 417 seropositive patients, after excluding false positives and patients lost to follow-up. The baseline characteristics of the patients were: sex ratio (M/F) 1.4; mean age 38.5 years; intravenous drug use (IDU) in 55%; and 28% in unstable social situations, estimated by the EPICES deprivation score. Antiviral treatment was initiated for 179 (42.9%) of the 379 (90.9%) patients attending specialist consultations. CoC was associated with screening after 1997 (HR 2.0, 95% CI 1.4-2.9), age > 45 years (HR 1.5, 95% CI 1.02-2.3), patient acceptance of care (HR 9.3, 95% CI 5.4 -16.10), specialist motivation for treatment (HR 10.9, 95% CI 7.4-16.0), and absence of cancer (HR 6.7, 95% CI 1.6-27.9). Other comorbid conditions, such as depression and IDU, were not associated with CoC. Conclusions Our 20-year cohort study reveals the real-life continuum of care for HCV-infected patients in France. The number of patients involved in HCV care after positive testing was substantial due to the organization of healthcare in France. An improved CoC along with new direct-acting antivirals should help to decrease chronic HCV infection.	[Hermetet, Coralie; Gaborit, Christophe; Grammatico-Guillon, Leslie] Univ Tours, CHRU Tours, SIMEES, Lab Sante Publ, Tours, France; [Dubois, Frederic; Gaudy-Graffin, Catherine; Roingeard, Philippe; Grammatico-Guillon, Leslie] Univ Tours, INSERM, U966, Tours, France; [Dubois, Frederic; Gaudy-Graffin, Catherine; Roingeard, Philippe; Grammatico-Guillon, Leslie] CHRU Tours, Tours, France; [Dubois, Frederic; Gaudy-Graffin, Catherine] CHRU Tours, Serv Bacteriol Virol Hyg, Tours, France; [Dubois, Frederic; Royer, Bernard] UC IRSA, Dept 37, La Riche, France; [Bacq, Yannick; D'Alteroche, Louis] CHRU Tours, Serv Hepatogastroenterol, Tours, France; [Desenclos, Jean Claude] InVS, Direct Sci, St Maurice, France; [Roingeard, Philippe] CHRU Tours, Lab Biol Cellulaire, Tours, France	CHU Tours; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours; CHU Tours; CHU Tours; Institute of Public Health Surveillance; CHU Tours	Grammatico-Guillon, L (corresponding author), Univ Tours, CHRU Tours, SIMEES, Lab Sante Publ, Tours, France.; Grammatico-Guillon, L (corresponding author), Univ Tours, INSERM, U966, Tours, France.; Grammatico-Guillon, L (corresponding author), CHRU Tours, Tours, France.	leslie.guillon@univ-tours.fr		Grammatico-Guillon, Leslie/0000-0001-7934-8912				Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; Almasio PL, 2011, DIGEST LIVER DIS, V43, P589, DOI 10.1016/j.dld.2010.12.004; Bansal S, 2015, WORLD J HEPATOL, V7, P806, DOI 10.4254/wjh.v7.i5.806; Brody H, 2011, NATURE, V474, pCP17; Brouard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126920; Castera L, 2003, GUT, V52, P1531, DOI 10.1136/gut.52.10.1531; Chavalitdhamrong D, 2006, WORLD J GASTROENTERO, V12, P5532, DOI 10.3748/wjg.v12.i34.5532; Chen Stephen L, 2006, Int J Med Sci, V3, P47; Delarocque-Astagneau E, 2010, J VIRAL HEPATITIS, V17, P435, DOI 10.1111/j.1365-2893.2009.01196.x; Desenclos JC, 1997, GASTROEN CLIN BIOL, V21, pS25; Dubois F, 1997, HEPATOLOGY, V25, P1490, DOI 10.1002/hep.510250630; Edlin BR, 2013, HEPATOLOGY, V57, P1644, DOI 10.1002/hep.26194; Gaudy C, 2005, J CLIN MICROBIOL, V43, P1722, DOI 10.1128/JCM.43.4.1722-1726.2005; Lawitz E, 2014, LANCET, V383, P515, DOI 10.1016/S0140-6736(13)62121-2; Marcellin P, 2002, HEPATOLOGY, V36, pS47, DOI 10.1053/jhep.2002.36993; Marcellin P, 2008, J HEPATOL, V48, P200, DOI 10.1016/j.jhep.2007.09.010; Meffre C, 2010, J MED VIROL, V82, P546, DOI 10.1002/jmv.21734; Mishra P, 2015, HEPATOLOGY, V62, P1298, DOI 10.1002/hep.27880; Mohd Hanafiah K, 2013, HEPATOLOGY, V57, P1333, DOI DOI 10.1002/HEP.26141; Negro F, 2014, DIGEST LIVER DIS, V46, pS158, DOI 10.1016/j.dld.2014.09.023; Noell BC, 2015, DRUG DES DEV THER, V9, P2367, DOI 10.2147/DDDT.S65255; Pol S, 2014, MED MAL INFECT; Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4; Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1; Vermeiren APA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051194; Viner K, 2015, HEPATOLOGY, V61, P783, DOI 10.1002/hep.27584; Zhou K, LANCET INFECT DIS	27	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2017	12	8							e0183232	10.1371/journal.pone.0183232	http://dx.doi.org/10.1371/journal.pone.0183232			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE9SU	28850623	gold, Green Published, Green Submitted			2023-01-03	WOS:000408544200012
J	Fielding, RA; Guralnik, JM; King, AC; Pahor, M; McDermott, MM; Tudor-Locke, C; Manini, TM; Glynn, NW; Marsh, AP; Axtell, RS; Hsu, FC; Rejeski, WJ				Fielding, Roger A.; Guralnik, Jack M.; King, Abby C.; Pahor, Marco; McDermott, Mary M.; Tudor-Locke, Catrine; Manini, Todd M.; Glynn, Nancy W.; Marsh, Anthony P.; Axtell, Robert S.; Hsu, Fang-Chi; Rejeski, W. Jack		LIFE Study Grp	Dose of physical activity, physical functioning and disability risk in mobility-limited older adults: Results from the LIFE study randomized trial	PLOS ONE			English	Article							LOWER-EXTREMITY FUNCTION; STYLE INTERVENTIONS; ACCELEROMETER ASSESSMENT; MEANINGFUL CHANGE; ELDERLY-PEOPLE; GAIT SPEED; PERFORMANCE; EXERCISE; INDEPENDENCE; ASSOCIATION	Understanding the minimal dose of physical activity required to achieve improvement in physical functioning and reductions in disability risk is necessary to inform public health recommendations. To examine the effect of physical activity dose on changes in physical functioning and the onset of major mobility disability in The Lifestyle Interventions and Independence for Elders (LIFE) Study. We conducted a multicenter single masked randomized controlled trial that enrolled participants in 2010 and 2011 and followed them for an average of 2.6 years. 1,635 sedentary men and women aged 70-89 years who had functional limitations were randomized to a structured moderate intensity walking, resistance, and flexibility physical activity program or a health education program. Physical activity dose was assessed by 7-day accelerometry and self-report at baseline and 24 months. Outcomes included the 400 m walk gait speed, the Short Physical Performance Battery (SPPB), assessed at baseline, 6, 12, and 24 months, and onset of major mobility disability (objectively defined by loss of ability to walk 400 m in 15 min). When the physical activity arm or the entire sample were stratified by change in physical activity from baseline to 24 months, there was a dose-dependent increase in the change in gait speed and SPPB from baseline at 6, 12, and 24 months. In addition, the magnitude of change in physical activity over 24 months was related to the reduction in the onset of major mobility disability (overall P < 0.001) (highest versus the lowest quartile of physical activity change HR 0.23 ((95% CI: 0.10-0.52) P = 0.001) in the physical activity arm. We observed a dose-dependent effect of objectively monitored physical activity on physical functioning and onset of major mobility disability. Relatively small increases (> 48 minutes per week) in regular physical activity participation had significant and clinically meaningful effects on these outcomes.	[Fielding, Roger A.] Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Guralnik, Jack M.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 4655 W Baltimore St, Baltimore, MD 21201 USA; [King, Abby C.] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA USA; [King, Abby C.] Stanford Univ, Dept Med, Stanford Prevent Res Ctr, Sch Med, Stanford, CA 94305 USA; [Pahor, Marco; Manini, Todd M.] Univ Florida, Coll Med, Dept Aging & Geriatr Res, Gainesville, FL USA; [McDermott, Mary M.] Northwestern Univ, Dept Med, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA; [Tudor-Locke, Catrine] Univ Massachusetts, Dept Kinesiol, Amherst, MA 01003 USA; [Tudor-Locke, Catrine] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Glynn, Nancy W.; Rejeski, W. Jack] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Ctr Aging & Populat Hlth, Pittsburgh, PA 15260 USA; [Marsh, Anthony P.] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Axtell, Robert S.] Southern Connecticut State Univ, Dept Exercise Sci, New Haven, CT USA; [Hsu, Fang-Chi] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA	Tufts University; United States Department of Agriculture (USDA); University System of Maryland; University of Maryland Baltimore; Stanford University; Stanford University; State University System of Florida; University of Florida; Northwestern University; Feinberg School of Medicine; University of Massachusetts System; University of Massachusetts Amherst; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Connecticut State University System; Southern Connecticut State University; Wake Forest University	Fielding, RA (corresponding author), Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	roger.fielding@tufts.edu	Tudor-Locke, Catrine/AAC-2829-2021; King, Abby/AAD-5257-2021	Manini, Todd/0000-0002-5970-4462; King, Abby/0000-0002-7949-8811; Glynn, Nancy/0000-0003-2265-0162	National Institutes of Health/National Institute on Aging Cooperative Agreement [U01 AG22376]; Intramural Research Program, National Institute on Aging, NIH; Claude D. Pepper Older Americans Independence Centers at the University of Florida [1 P30 AG028740]; Wake Forest University [1 P30 AG21332]; Tufts University [1P30AG031679]; University of Pittsburgh [P30 AG024827]; Yale University [P30AG021342]; NIH/NCRR CTSA at Stanford University [UL1 RR025744]; Boston Rehabilitation Outcomes Center [1R24HD065688-01A1]; U.S. Department of Agriculture [58-1950-4-003]; National Heart, Lung and Blood Institute [3U01AG022376-05A2S]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD065688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG022376, P30AG024827, P30AG031679, P30AG021342, P30AG021332, P30AG028740] Funding Source: NIH RePORTER	National Institutes of Health/National Institute on Aging Cooperative Agreement; Intramural Research Program, National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Claude D. Pepper Older Americans Independence Centers at the University of Florida; Wake Forest University; Tufts University; University of Pittsburgh(University of Pittsburgh); Yale University; NIH/NCRR CTSA at Stanford University; Boston Rehabilitation Outcomes Center; U.S. Department of Agriculture(United States Department of Agriculture (USDA)); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Lifestyle Interventions and Independence for Elders Study is funded by a National Institutes of Health/National Institute on Aging Cooperative Agreement #U01 AG22376 and a supplement from the National Heart, Lung and Blood Institute 3U01AG022376-05A2S, and sponsored in part by the Intramural Research Program, National Institute on Aging, NIH. The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (1 P30 AG028740), Wake Forest University (1 P30 AG21332), Tufts University (1P30AG031679), University of Pittsburgh (P30 AG024827), and Yale University (P30AG021342) and the NIH/NCRR CTSA at Stanford University (UL1 RR025744). Tufts University is also supported by the Boston Rehabilitation Outcomes Center (1R24HD065688-01A1). Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No. 58-1950-4-003. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept. of Agriculture.	Bann D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116058; Brach JS, 2004, J AM GERIATR SOC, V52, P502, DOI 10.1111/j.1532-5415.2004.52154.x; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; Chale-Rush A, 2010, J AM GERIATR SOC, V58, P1918, DOI 10.1111/j.1532-5415.2010.03008.x; Copeland JL, 2009, J AGING PHYS ACTIV, V17, P17, DOI 10.1123/japa.17.1.17; Corcoran MP, 2016, J NUTR HEALTH AGING, V20, P752, DOI 10.1007/s12603-015-0640-7; Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300; Fielding RA, 2007, MED SCI SPORT EXER, V39, P1997, DOI 10.1249/mss.0b013e318145348d; Fielding RA, 2011, J GERONTOL A-BIOL, V66, P1226, DOI 10.1093/gerona/glr123; Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; King AC, 1998, AM J PREV MED, V15, P316, DOI 10.1016/S0749-3797(98)00085-3; Kwon S, 2009, J NUTR HEALTH AGING, V13, P538, DOI 10.1007/s12603-009-0104-z; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; Leveille SG, 1999, AM J EPIDEMIOL, V149, P654; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Marsh AP, 2013, J GERONTOL A-BIOL, V68, P1549, DOI 10.1093/gerona/glt064; Martin HJ, 2008, AGE AGEING, V37, P589, DOI 10.1093/ageing/afn148; Martin KA, 2001, J AGING PHYS ACTIV, V9, P91, DOI 10.1123/japa.9.2.91; Matthews CE, 2005, MED SCI SPORT EXER, V37, pS512, DOI 10.1249/01.mss.0000185659.11982.3d; McDermott MM, 2013, JAMA-J AM MED ASSOC, V310, P57, DOI 10.1001/jama.2013.7231; McDermott MM, 2006, ANN INTERN MED, V144, P10, DOI 10.7326/0003-4819-144-1-200601030-00005; McDermott MM, 2002, J AM GERIATR SOC, V50, P247, DOI 10.1046/j.1532-5415.2002.50055.x; Messier SP, 2000, J AM GERIATR SOC, V48, P131, DOI 10.1111/j.1532-5415.2000.tb03903.x; Morie M, 2010, J AM GERIATR SOC, V58, P1727, DOI 10.1111/j.1532-5415.2010.03012.x; Nelson ME, 2004, J GERONTOL A-BIOL, V59, P154; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; Rejeski WJ, 2013, CLIN INTERV AGING, V8, P1119, DOI 10.2147/CIA.S49737; Rejeski WJ, 2011, ARCH INTERN MED, V171, P880, DOI 10.1001/archinternmed.2010.522; Rejeski WJ, 2015, J GERONTOL A; Ringsberg KAM, 2001, GERONTOLOGY, V47, P15, DOI 10.1159/000052765; RODRIGUEZ BL, 1994, CIRCULATION, V89, P2540, DOI 10.1161/01.CIR.89.6.2540; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Uusi-Rasi K, 2003, BONE, V33, P132, DOI 10.1016/S8756-3282(03)00082-6	47	68	70	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2017	12	8							e0182155	10.1371/journal.pone.0182155	http://dx.doi.org/10.1371/journal.pone.0182155			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FE1XD	28820909	Green Published, gold, Green Submitted			2023-01-03	WOS:000408010000002
J	Hajek, A; Bock, JO; Konig, HH				Hajek, Andre; Bock, Jens-Oliver; Koenig, Hans-Helmut			The role of personality in health care use: Results of a population-based longitudinal study in Germany	PLOS ONE			English	Article							MENTAL-HEALTH; SERVICE UTILIZATION; MEDICAL-CARE; LIFE-COURSE; MEAN-LEVEL; BIG 5; NEUROTICISM; EXTROVERSION; METAANALYSIS; TRAITS	Objective To determine the role of personality in health care use longitudinally. Methods Data were derived from the German Socio-Economic Panel (GSOEP), a nationally representative, longitudinal cohort study of German households starting in 1984. Concentrating on the role of personality, we used data from the years 2005, 2009 and 2013. Personality was measured by using the GSOEP Big Five Inventory (BFI-S). Number of physician visits in the last 3 months and hospital stays in the last year were used as measures of health care use. Results Adjusting for predisposing factors, enabling resources, and need factors, fixed effects regressions revealed that physician visits increased with increasing neuroticism, whereas extraversion, openness to experience, agreeableness and conscientiousness did not affect physician visits in a significant way. The effect of self-rated health on physician visits was significantly moderated by neuroticism. Moreover, fixed effects regressions revealed that the probability of hospitalization in the past year increased with increasing extraversion, whereas the other personality factors did not affect this outcome measure significantly. Conclusion Our findings suggest that changes in neuroticism are associated with changes in physician visits and that changes in extraversion are associated with the probability of hospitalization. Since recent studies have shown that treatments can modify personality traits, developing interventional strategies should take into account personality factors. For example, efforts to intervene in changing neuroticism might have beneficial effects for the healthcare system.	[Hajek, Andre; Bock, Jens-Oliver; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Hajek, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg, Germany.	a.hajek@uke.de	PAN, ZEQIANG/X-6341-2018; König, Hans-Helmut/P-1211-2018	König, Hans-Helmut/0000-0001-5711-6862; Hajek, Andre/0000-0002-6886-2745				ADAY LA, 1981, MED CARE, V19, P4, DOI 10.1097/00005650-198112001-00004; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Babitsch Birgit, 2012, Psychosoc Med, V9, pDoc11, DOI 10.3205/psm000089; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Bogg T, 2004, PSYCHOL BULL, V130, P887, DOI 10.1037/0033-2909.130.6.887; BOLGER N, 1991, J PERS, V59, P355, DOI 10.1111/j.1467-6494.1991.tb00253.x; Boyce CJ, 2015, J APPL PSYCHOL, V100, P991, DOI 10.1037/a0038647; Boyce CJ, 2013, SOC INDIC RES, V111, P287, DOI 10.1007/s11205-012-0006-z; Cameron A.C., 2005, MICROECONOMETRICS US; Chapman BP, 2009, AM J GERIAT PSYCHIAT, V17, P526, DOI 10.1097/JGP.0b013e3181a2fbb1; Costa P. T, 1992, PERS INDIVIDUAL DIFF, V13, P653, DOI DOI 10.1016/0191-8869(92)90236-I; Costa P. T., 1992, PSYCHOL ASSESSMENT R; Costa PT Jr, 1985, AGING 2000 OUR HLTH, P75; Friedman B, 2013, MILBANK Q, V91, P491, DOI 10.1111/1468-0009.12024; Friedman HS, 2000, J PERS, V68, P1089, DOI 10.1111/1467-6494.00127; Fydrich T, MANUAL; Gohl D, 2012, GMS PSYCHOSOCIAL MED, V9; GOLDBERG LR, 1993, AM PSYCHOL, V48, P26, DOI 10.1037/0003-066X.48.1.26; Goodwin RD, 2002, SOC PSYCH PSYCH EPID, V37, P561, DOI 10.1007/s00127-002-0563-6; Greene W.H., 2012, ECONOMETRIC ANAL; Hahn E, 2012, J RES PERS, V46, P355, DOI 10.1016/j.jrp.2012.03.008; Hakulinen C, 2015, ADDICTION, V110, P1844, DOI 10.1111/add.13079; Hakulinen C, 2015, DRUG ALCOHOL DEPEN, V151, P110, DOI 10.1016/j.drugalcdep.2015.03.008; Heider D, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-71; Hopwood CJ, 2008, PERSONAL MENT HEALTH, V2, P207, DOI 10.1002/pmh.51; Issakidis C, 2002, SOC PSYCH PSYCH EPID, V37, P153, DOI 10.1007/s001270200009; Jackson JJ, 2012, PSYCHOL AGING, V27, P286, DOI 10.1037/a0025918; John O, 1991, BIG 5 INVENTORY VERS; JOHNSON RJ, 1993, J HEALTH SOC BEHAV, V34, P105, DOI 10.2307/2137238; Kandler C, 2015, J PERS SOC PSYCHOL, V109, P175, DOI 10.1037/pspp0000028; Kiecolt-Glaser JK, 2002, ANNU REV PSYCHOL, V53, P83, DOI 10.1146/annurev.psych.53.100901.135217; Lajunen T, 2001, PERS INDIV DIFFER, V31, P1365, DOI 10.1016/S0191-8869(00)00230-0; LARSEN RJ, 1991, J PERS SOC PSYCHOL, V61, P132, DOI 10.1037/0022-3514.61.1.132; Lipps O., 2009, ATTRITION HOUSEHOLDS; Marusic A, 2001, NORD J PSYCHIAT, V55, P157; Michie S, 2002, OCCUP ENVIRON MED, V59, P67, DOI 10.1136/oem.59.1.67; Mroczek DK, 2007, PSYCHOL SCI, V18, P371, DOI 10.1111/j.1467-9280.2007.01907.x; Nettle D, 2005, EVOL HUM BEHAV, V26, P363, DOI 10.1016/j.evolhumbehav.2004.12.004; Pandhi N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009738; Parslow RA, 2000, AUST NZ J PSYCHIAT, V34, P997, DOI 10.1080/000486700276; Paunonen SV, 2000, J PERS, V68, P821, DOI 10.1111/1467-6494.00117; Paunonen SV, 2003, EUR J PERSONALITY, V17, P413, DOI 10.1002/per.496; Ricketts TC, 2005, NURS OUTLOOK, V53, P274, DOI 10.1016/j.outlook.2005.06.007; Roberts BW, 2008, CURR DIR PSYCHOL SCI, V17, P31, DOI 10.1111/j.1467-8721.2008.00543.x; Roberts BW, 2005, REV GEN PSYCHOL, V9, P156, DOI 10.1037/1089-2680.9.2.156; Roberts BW, 2006, PSYCHOL BULL, V132, P1, DOI 10.1037/0033-2909.132.1.1; Schoeni RF, 2013, ANN AM ACAD POLIT SS, V645, P60, DOI 10.1177/0002716212456363; Schupp J., 2005, DIW RES NOTES, V4, P2005, DOI DOI 10.1016/J.JSIS.2005.07.003; Seidl H, 2016, J EVALUATION CLIN PR; Specht J, 2011, J PERS SOC PSYCHOL, V101, P862, DOI 10.1037/a0024950; Springer KW, 2011, J HEALTH SOC BEHAV, V52, P212, DOI 10.1177/0022146510393972; ten Have M, 2006, SOC PSYCH PSYCH EPID, V41, P285, DOI 10.1007/s00127-005-0028-9; ten Have M, 2005, SOC PSYCH PSYCH EPID, V40, P425, DOI 10.1007/s00127-005-0916-z; Unesco, 1997, INT STAT CLASS ED; VANHEMERT AM, 1993, INT J PSYCHIAT MED, V23, P295, DOI 10.2190/TC5N-AQ3R-9CFK-EC9G; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Wagner G.G., 2007, J APPL SOCIAL SCI ST, V127, P139, DOI DOI 10.2139/SSRN.1028709; WEISENBERG M, 1977, PSYCHOL BULL, V84, P1008, DOI 10.1037/0033-2909.84.5.1008; Williams PG, 2004, PERS INDIV DIFFER, V37, P83, DOI 10.1016/j.paid.2003.08.001; Wrzus C, 2016, PERS SOC PSYCHOL REV	60	39	41	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2017	12	7							e0181716	10.1371/journal.pone.0181716	http://dx.doi.org/10.1371/journal.pone.0181716			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB8EN	28746388	gold, Green Published, Green Submitted			2023-01-03	WOS:000406371800052
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Charities should respect evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Cao H, 2012, PLOS ONE, V358; Charity Commission for England and Wales, 2013, GUID CHAR PURP; House of Lords Select Committee, 2000, SCI TECHN 6 REP; Kakaes K., 2016, WASHINGTON POST; MacDougall A., 2017, GLOBE MAIL; Marshall M., 2017, GUARDIAN; Roberts M., 2004, BBC NEWS; Theron I., 2017, FINANCIAL TIMES	8	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	2017	358								j3336	10.1136/bmj.j3336	http://dx.doi.org/10.1136/bmj.j3336			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC3UT	28743824	Green Published, Bronze			2023-01-03	WOS:000406765600001
J	Shen, YQ; Huang, GY; McCormick, BP; Song, T; Xu, XF				Shen, Youqing; Huang, Guoyuan; McCormick, Bryan P.; Song, Tao; Xu, Xiangfeng			Effects of high-intensity interval versus mild-intensity endurance training on metabolic phenotype and corticosterone response in rats fed a high-fat or control diet	PLOS ONE			English	Article							PITUITARY-ADRENAL AXIS; ANXIETY-LIKE BEHAVIORS; REDUCES LIVER FAT; INTERMITTENT EXERCISE; SKELETAL-MUSCLE; INDUCED OBESITY; LOW-VOLUME; STRESS; MODEL; HYPERINSULINEMIA	The aim of the present study was to compare the effects of high-intensity interval training (HI) to mild-intensity endurance training (ME), combined with a high-fat diet (HFD) or control diet (CD) on metabolic phenotype and corticosterone levels in rats. Fifty-three rats were randomized to 6 groups according to diet and training regimen as follows: CD and sedentary (CS, n = 11), CD and ME (CME, n = 8), CD and HI (CHI, n = 8), HFD and sedentary (HS, n = 10), HFD and ME (HME, n = 8), and HFD and HI (HHI, n = 8). All exercise groups were trained for 10 weeks and had matched running distances. Dietary intake, body composition, blood metabolites, and corticosterone levels were measured. Histological lipid droplets were observed in the livers. The HFD led to hyperglycemia, hyperlipidemia and higher body fat (all, P < 0.01, eta(2) > 0.06), as well as higher corticosterone levels (P < 0.01, eta(2) = 0.09) compared with the CD groups. Exercise training improved fat weight, glucose, and lipid profiles, and reduced corticosterone levels (P < 0.01, eta(2) = 0.123). Furthermore, body and fat weight, serum glucose and triglycerides, lipid content in the liver, and corticosterone levels (P < 0.05) were lower with HI training compared to ME training. Reductions in HFD-induced body weight gain, blood glucose and lipid profiles, and corticosterone levels, as well as improvements in QUICKI were better with HHI compared to HME. Correlation analyses revealed that corticosterone levels were significantly associated with phenotype variables (P < 0.01). Corticosterone level was inversely correlated with QUICKI (r = -0.38, P < 0.01). Altogether, these results indicate that HFD may elicit an exacerbated basal serum corticosterone level and thus producing a metabolic imbalance. Compared with ME training, HI training contributes to greater improvements in metabolic and corticosterone responses, leading to a greater reduction in susceptibility to HFD-induced disorders.	[Shen, Youqing] Hubei Univ Educ, Sch Phys Educ, Wuhan, Hubei, Peoples R China; [Huang, Guoyuan] Univ Southern Indiana, Pott Coll Sci Engn & Educ, Evansville, IN USA; [Shen, Youqing; McCormick, Bryan P.] Indiana Univ, Sch Publ Hlth, Bloomington, IN USA; [Song, Tao] Jianghan Univ, Sch Phys Educ, Wuhan, Hubei, Peoples R China; [Xu, Xiangfeng] Wuhan Sports Univ, Sch Phys Educ, Wuhan, Hubei, Peoples R China	Hubei University Education; Indiana University System; Indiana University Bloomington; Jianghan University; Wuhan Sports University	Xu, XF (corresponding author), Wuhan Sports Univ, Sch Phys Educ, Wuhan, Hubei, Peoples R China.	future0104@126.com			Department of Scientific Research, Hubei Province [B2016220]; China Scholarship Council [201508420205]; Wuhan Institutes of Biomedical Science and Jianghan University	Department of Scientific Research, Hubei Province; China Scholarship Council(China Scholarship Council); Wuhan Institutes of Biomedical Science and Jianghan University	This project was partly funded by a Grant (#B2016220) from the Department of Scientific Research, Hubei Province. We also thank the China Scholarship Council (201508420205) for funding Youqing Shen's academic scholarship at the Indiana University-Bloomington, which was a requirement for her research program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; These experiments were supported by Wuhan Institutes of Biomedical Science and Jianghan University. The authors thank Dr. Kai Yue and Qiu Pang for assisting with experimental trials. We are also grateful to Accdon for English language assistance during the revision of this manuscript. The authors have no conflicts to declare.	Alvarez C, 2016, INT J SPORTS MED, V37, P723, DOI 10.1055/s-0042-104935; Anagnostis P, 2009, J CLIN ENDOCR METAB, V94, P2692, DOI 10.1210/jc.2009-0370; Auvinen HE, 2011, HORM METAB RES, V43, P899, DOI 10.1055/s-0031-1291305; Ayroldi E, 2014, FASEB J, V28, P5055, DOI 10.1096/fj.14-254755; Beaudry JL, 2015, J APPL PHYSIOL, V118, P1331, DOI 10.1152/japplphysiol.00467.2014; Beaudry JL, 2013, ENDOCRINOLOGY, V154, P3197, DOI 10.1210/en.2012-2114; BEDFORD TG, 1979, J APPL PHYSIOL, V47, P1278, DOI 10.1152/jappl.1979.47.6.1278; Campeau S, 2010, J NEUROENDOCRINOL, V22, P872, DOI 10.1111/j.1365-2826.2010.02007.x; Cassidy S, 2016, DIABETOLOGIA, V59, P56, DOI 10.1007/s00125-015-3741-2; Duggan GE, 2011, J APPL PHYSIOL, V110, P1311, DOI 10.1152/japplphysiol.00701.2010; Dutheil S, 2016, NEUROPSYCHOPHARMACOL, V41, P1874, DOI 10.1038/npp.2015.357; Ebada ME, 2016, BEHAV BRAIN RES, V311, P228, DOI 10.1016/j.bbr.2016.05.051; Field BCT, 2014, BRIT MED BULL, V109, P73, DOI 10.1093/bmb/ldu001; Galitzky J, 2013, CELL METAB, V18, P3, DOI 10.1016/j.cmet.2013.06.008; Gergerlioglu HS, 2016, LIFE SCI, V148, P279, DOI 10.1016/j.lfs.2016.02.011; Gibala MJ, 2012, J PHYSIOL-LONDON, V590, P1077, DOI 10.1113/jphysiol.2011.224725; Glastras SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162131; Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472; Hallsworth K, 2015, CLIN SCI, V129, P1097, DOI 10.1042/CS20150308; Hare BD, 2014, NEUROPSYCHOPHARMACOL, V39, P1262, DOI 10.1038/npp.2013.329; Hicks JA, 2016, BEHAV BRAIN RES, V310, P1, DOI 10.1016/j.bbr.2016.04.051; Higgins JA, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-49; Jacks DE, 2002, J STRENGTH COND RES, V16, P286, DOI 10.1519/00124278-200205000-00018; Jankord R, 2008, APPL PHYSIOL NUTR ME, V33, P461, DOI 10.1139/H08-022; Jones AB, 2016, BEHAV BRAIN RES, V311, P279, DOI 10.1016/j.bbr.2016.05.058; Karatsoreos IN, 2010, ENDOCRINOLOGY, V151, P2117, DOI 10.1210/en.2009-1436; Lakens Daniel, 2013, Front Psychol, V4, P863, DOI 10.3389/fpsyg.2013.00863; Lee SH, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010401; Legendre A, 2006, AM J PHYSIOL-REG I, V291, pR1288, DOI 10.1152/ajpregu.00234.2006; Li CT, 2015, BEHAV BRAIN RES, V288, P39, DOI 10.1016/j.bbr.2015.04.007; Manolopoulos Konstantinos, 2015, Lancet, V385 Suppl 1, pS63, DOI 10.1016/S0140-6736(15)60378-6; Martins C, 2016, INT J SPORT NUTR EXE, V26, P197, DOI 10.1123/ijsnem.2015-0078; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Morris RT, 2008, J APPL PHYSIOL, V104, P708, DOI 10.1152/japplphysiol.01034.2007; Motta VF, 2016, J SPORT MED PHYS FIT, V56, P655; Muniyappa R, 2009, AM J PHYSIOL-ENDOC M, V297, pE1023, DOI 10.1152/ajpendo.00397.2009; Patterson ZR, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00130; Pimenta M, 2015, LIFE SCI, V139, P75, DOI 10.1016/j.lfs.2015.08.004; Rose AJ, 2010, J STEROID BIOCHEM, V122, P10, DOI 10.1016/j.jsbmb.2010.02.010; Sene-Fiorese M, 2008, OBESITY, V16, P2217, DOI 10.1038/oby.2008.339; Shen YQ, 2015, OBESITY, V23, P1000, DOI 10.1002/oby.21056; Shin AC, 2010, INT J OBESITY, V34, P1218, DOI 10.1038/ijo.2010.34; Shpilberg Y, 2012, DIS MODEL MECH, V5, P671, DOI 10.1242/dmm.008912; Sivanathan S, 2015, BEHAV BRAIN RES, V286, P265, DOI 10.1016/j.bbr.2015.02.036; Smith-Ryan AE, 2016, J SPORT SCI, V34, P2038, DOI 10.1080/02640414.2016.1149609; Suzuki M, 2011, INT J SPORT NUTR EXE, V21, P222, DOI 10.1123/ijsnem.21.3.222; Thompson W. R., 2009, ACSMS GUIDELINES EXE; Touati S, 2011, MED SCI SPORT EXER, V43, P398, DOI 10.1249/MSS.0b013e3181eeb12d; Vicennati V, 2009, OBESITY, V17, P1678, DOI 10.1038/oby.2009.76; Wang Deng, 2015, Zhong Yao Cai, V38, P1919	50	11	11	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2017	12	7							e0181684	10.1371/journal.pone.0181684	http://dx.doi.org/10.1371/journal.pone.0181684			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1YQ	28727846	Green Submitted, gold, Green Published			2023-01-03	WOS:000406634500103
J	Beamish, JA; Chen, E; Putnam, AJ				Beamish, Jeffrey A.; Chen, Evan; Putnam, Andrew J.			Engineered extracellular matrices with controlled mechanics modulate renal proximal tubular cell epithelialization	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; POLY(ETHYLENE GLYCOL) HYDROGELS; FOCAL ADHESION; DIACRYLATE HYDROGELS; MC3T3-E1 CELLS; PROLIFERATION; STIFFNESS; RIGIDITY; FIBROSIS; GROWTH	Acute kidney injury (AKI) is common and associated with significant morbidity and mortality. Recovery from many forms of AKI involves the proliferation of renal proximal tubular epithelial cells (RPTECs), but the influence of the microenvironment in which this recovery occurs remains poorly understood. Here we report the development of a poly(ethylene glycol) (PEG) hydrogel platform to study the influence of substrate mechanical properties on the proliferation of human RPTECs as a model for recovery from AKI. PEG diacrylate based hydrogels were generated with orthogonal control of mechanics and cell-substrate interactions. Using this platform, we found that increased substrate stiffness promotes RPTEC spreading and proliferation. RPTECs showed similar degrees of apoptosis and Yes-associated protein (YAP) nuclear localization regardless of stiffness, suggesting these were not key mediators of the effect. However, focal adhesion formation, cytoskeletal organization, focal adhesion kinase (FAK) activation, and extracellular signal-regulated kinase (ERK) activation were all enhanced with increasing substrate stiffness. Inhibition of ERK activation substantially attenuated the effect of stiffness on proliferation. In long-term culture, hydrogel stiffness promoted the formation of more complete epithelial monolayers with tight junctions, cell polarity, and an organized basement membrane. These data suggest that increased stiffness potentially may have beneficial consequences for the renal tubular epithelium during recovery from AKI.	[Beamish, Jeffrey A.] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; [Chen, Evan; Putnam, Andrew J.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beamish, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA.; Putnam, AJ (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.	jebeamish@med.umich.edu; putnam@umich.edu	Putnam, Andrew J./E-8643-2010	Putnam, Andrew J./0000-0002-1262-4377	University of Michigan O'Brien Kidney Center [DK-P30-081943]; NIH/NHLBI [R01-HL085339]; NIH [T32-DK007378]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK081943, T32DK007378] Funding Source: NIH RePORTER	University of Michigan O'Brien Kidney Center; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Support for this work was provided in part by the University of Michigan O'Brien Kidney Center (DK-P30-081943) and the NIH/NHLBI (R01-HL085339 to AJP). JAB was also supported by NIH T32-DK007378. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alderliesten M, 2007, AM J PATHOL, V171, P452, DOI 10.2353/ajpath.2007.060805; Anvari A, 2015, ABDOM IMAGING, V40, P709, DOI 10.1007/s00261-015-0383-2; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Assoian RK, 2008, TRENDS CELL BIOL, V18, P347, DOI 10.1016/j.tcb.2008.05.002; Beamish JA, 2010, J BIOMED MATER RES A, V92A, P441, DOI 10.1002/jbm.a.32353; Berger K, 2014, P NATL ACAD SCI USA, V111, P1533, DOI 10.1073/pnas.1316177111; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Brito PL, 1998, KIDNEY INT, V53, P754, DOI 10.1046/j.1523-1755.1998.00809.x; Burdick JA, 2002, BIOMATERIALS, V23, P4315, DOI 10.1016/S0142-9612(02)00176-X; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chen JC, 2012, KIDNEY INT, V82, P45, DOI 10.1038/ki.2012.43; Chen WC, 2015, AM J PATHOL, V185, P2468, DOI 10.1016/j.ajpath.2015.05.019; Chen WC, 2014, AM J PHYSIOL-RENAL, V307, pF695, DOI 10.1152/ajprenal.00684.2013; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Coca SG, 2010, CURR OPIN NEPHROL HY, V19, P266, DOI 10.1097/MNH.0b013e3283375538; Cuchiara MP, 2010, BIOMATERIALS, V31, P5491, DOI 10.1016/j.biomaterials.2010.03.031; Cummings BS, 2001, MEASUREMENT CELL DEA, DOI [10.1002/0471141755.ph1208s56, DOI 10.1002/0471141755.PH1208S56]; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Franck C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017833; Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517; Ishani A, 2009, J AM SOC NEPHROL, V20, P223, DOI 10.1681/ASN.2007080837; Ishibe S, 2008, CURR OPIN NEPHROL HY, V17, P379, DOI 10.1097/MNH.0b013e3283046507; Janmey PA, 2011, J CELL SCI, V124, P9, DOI 10.1242/jcs.071001; Kerr M, 2014, NEPHROL DIAL TRANSPL, V29, P1362, DOI 10.1093/ndt/gfu016; Khatiwala CB, 2006, AM J PHYSIOL-CELL PH, V290, pC1640, DOI 10.1152/ajpcell.00455.2005; Khatiwala CB, 2007, J CELL PHYSIOL, V211, P661, DOI 10.1002/jcp.20974; Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]; Kim DH, 2010, P NATL ACAD SCI USA, V107, P565, DOI 10.1073/pnas.0906504107; Kim JH, 2011, J CELL SCI, V124, P1280, DOI 10.1242/jcs.078394; Klein EA, 2009, CURR BIOL, V19, P1511, DOI 10.1016/j.cub.2009.07.069; Kohn JC, 2016, J BIOMECH, V49, P1447, DOI 10.1016/j.jbiomech.2016.03.016; Kusaba T, 2014, P NATL ACAD SCI USA, V111, P1527, DOI 10.1073/pnas.1310653110; Leight JL, 2012, MOL BIOL CELL, V23, P781, DOI 10.1091/mbc.E11-06-0537; Lin L, 2014, ACTA BIOMATER, V10, P5106, DOI 10.1016/j.actbio.2014.08.025; Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100; Mih JD, 2012, J CELL SCI, V125, P5974, DOI 10.1242/jcs.108886; Moon JJ, 2009, TISSUE ENG PT A, V15, P579, DOI 10.1089/ten.tea.2008.0196; Morikawa H, 2011, J GASTROENTEROL, V46, P350, DOI 10.1007/s00535-010-0301-x; Orlacchio A, 2014, ULTRASOUND MED BIOL, V40, P2564, DOI 10.1016/j.ultrasmedbio.2014.06.002; Oxburgh L, 2017, J AM SOC NEPHROL, V28, P1370, DOI 10.1681/ASN.2016101077; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Provenzano PP, 2011, J CELL SCI, V124, P1195, DOI 10.1242/jcs.067009; Qin Y, 2011, AM J PATHOL, V179, P2766, DOI 10.1016/j.ajpath.2011.08.025; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Samir AE, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0120-7; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Singh RK, 2013, BIOMATERIALS, V34, P9331, DOI 10.1016/j.biomaterials.2013.08.016; Wang YH, 2007, J BIOL CHEM, V282, P752, DOI 10.1074/jbc.M604801200; Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]; West MB, 2010, ARCH BIOCHEM BIOPHYS, V504, P177, DOI 10.1016/j.abb.2010.08.019; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Zeisberg M, 2010, J AM SOC NEPHROL, V21, P1819, DOI 10.1681/ASN.2010080793; Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044	56	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2017	12	7							e0181085	10.1371/journal.pone.0181085	http://dx.doi.org/10.1371/journal.pone.0181085			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS8PU	28715434	Green Submitted, Green Published, gold			2023-01-03	WOS:000443975500026
J	Korner, M; Luzay, L; Plewnia, A; Becker, S; Rundel, M; Zimmermann, L; Muller, C				Koerner, Mirjam; Luzay, Leonie; Plewnia, Anne; Becker, Sonja; Rundel, Manfred; Zimmermann, Linda; Mueller, Christian			A cluster-randomized controlled study to evaluate a team coaching concept for improving teamwork and patient-centeredness in rehabilitation teams	PLOS ONE			English	Article							SHARED DECISION-MAKING; CARE; SCALE	Purpose Although the relevance of interprofessional teamwork in the delivery of patient-centered care is well known, there is a lack of interventions for improving team interaction in the context of rehabilitation in Germany. The aim of the present study is to evaluate whether a specially developed team coaching concept (TCC) could improve both teamwork and patient-centeredness. Method A multicenter, cluster-randomized controlled intervention study was conducted with both staff and patient questionnaires. Data was collected at ten German rehabilitation clinics (five clusters) of different indication fields before (t1) and after (t2) the intervention. Intervention clinics received the TCC, while control clinics did not receive any treatment. Staff questionnaires were used to measure internal participation and other aspects of teamwork, such as team organization, while patient questionnaires assessed patient-centeredness. A multivariate analysis of variance was applied for data analysis. Results In order to analyze the effect of TCC on internal participation and teamwork, 305 questionnaires were included for t1 and 213 for t2 in the staff survey. In the patient survey, 523 questionnaires were included for t1 and 545 for t2. The TCC improved team organization, willingness to accept responsibility and knowledge integration according to staff, with small effect sizes (univariate:eta(2)=.010-.017), whereas other parameters including internal participation, team leadership and cohesion did not improve due to the intervention. The patient survey did not show any improvements on the assessed dimensions. Conclusion The TCC improved dimensions that were addressed directly by the approach and were linked to the clinics' needs, such as restructured team meetings and better exchange of information. The TCC can be used to improve team organization, willingness to accept responsibility, and knowledge integration in rehabilitation practice, but some further evaluation is needed to understand contextual factors and processes regarding the implementation of the intervention.	[Koerner, Mirjam; Luzay, Leonie; Plewnia, Anne; Becker, Sonja] Albert Ludwigs Univ, Med Fac, Med Psychol & Med Sociol, Freiburg, Germany; [Rundel, Manfred] Celenus Kliniken GmbH, Offenburg, Germany; [Zimmermann, Linda] Moving Concept, Freiburg, Germany; [Mueller, Christian] Saarland Univ Cooperat Educ Hlth Care & Welf, Saarbrucken, Germany	University of Freiburg	Korner, M (corresponding author), Albert Ludwigs Univ, Med Fac, Med Psychol & Med Sociol, Freiburg, Germany.	mirjam.koerner@mps.uni-freiburg.de			Bundesministerium fur Bildung und Forschung; Deutsche RentenversicherungBund [01GX1024]	Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche RentenversicherungBund	This study was supported by Bundesministerium fur Bildung und Forschung, https://www.bmbf.de/; Deutsche RentenversicherungBund, http://www.deutsche-rentenversicherung.de/Bund/de/Navigation/0_Home/home_node.html, grant number: 01GX1024. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antoni CH, 2010, Z EVIDENZ FORTBILD Q, V104, P18, DOI 10.1016/j.zefq.2009.12.027; Becker S, DEV PILOT TEST UNPUB; Bieber C, 2006, Z MED PSYCHOL, V15, P53; Bieber C, 2008, J PSYCHOSOM RES, V64, P13, DOI 10.1016/j.jpsychores.2007.05.009; Bleich C., 2010, PATIENTENORIENTIERUN, P275; Bleses H., 2005, THESIS; Bortz J., 2009, FORSCHUNGSMETHODEN E; Buljac-Samardzic M, 2010, HEALTH POLICY, V94, P183, DOI 10.1016/j.healthpol.2009.09.015; Cott CA, 2006, DISABIL REHABIL, V28, P1387, DOI 10.1080/09638280600638398; Dinius J, 2016, MANUAL PATIENTENORIE; Eppich W, 2011, SIMUL HEALTHC S, V6, P9; Gaba DM, 2010, BRIT J ANAESTH, V105, P3, DOI 10.1093/bja/aeq124; Gillespie Brigid M, 2010, AORN J, V92, P642, DOI 10.1016/j.aorn.2010.02.015; Grant AM., 2006, INT COACH PSYCHOL RE, V1, P14; Gray D, 2016, QUAL HEALTH RES, V26, P1434, DOI 10.1177/1049732315604589; Hackman JR, 2005, ACAD MANAGE REV, V30, P269, DOI [10.2307/20159119, 10.5465/AMR.2005.16387885]; Hair J.F., 2010, MULTIVARIATE DATA AN, DOI 10.1016/j.ijpharm.2011.02.019; Hox J.J., 2010, MULTILEVEL ANAL TECH, Vsecond, DOI DOI 10.4324/9781315650982; Kauffeld S., 2004, FAT FRAGEBOGEN ARBEI; Kibble S, 2014, BMJ QUALITY IMPROVEM, V3; Klein C, 2009, SMALL GROUP RES; Kockert S, 2011, REHABILITATION, V19, P30; Korner M, 2009, REHABILITATION, V48, P160, DOI 10.1055/s-0029-1220748; Korner M, 2016, J INTERPROF CARE, V30, P15, DOI 10.3109/13561820.2015.1051616; Korner M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-374; Korner M, CLIN REHABI IN PRESS; Korner M., 2013, HLTH IRVINE CALIF, V5, P48, DOI [10.4236/HEALTH.2013.56A2008, DOI 10.4236/HEALTH.2013.56A2008]; Leplege A, 2007, DISABIL REHABIL, V29, P1555, DOI 10.1080/09638280701618661; Loh A, 2007, PATIENT EDUC COUNS, V67, P324, DOI 10.1016/j.pec.2007.03.023; Maynard M Travis, 2012, Adv Health Care Manag, V13, P59; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Mickan Sharon M, 2005, J Interprof Care, V19, P358, DOI 10.1080/13561820500165142; Muller C, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0413-3; Muller C, 2014, REHABILITATION, V53, P390, DOI 10.1055/s-0034-1375639; O'Leary KJ, 2012, J HOSP MED, V7, P48, DOI 10.1002/jhm.970; O'Leary M., 2012, MULTITEAM SYSTEMS OR, P141; Ottevanger N, 2013, J EVAL CLIN PRACT, V19, P1035, DOI 10.1111/jep.12022; Papadimitriou C, 2015, DISABIL REHABIL, V37, P1135, DOI 10.3109/09638288.2014.955138; Quaschning K, 2013, PATIENT EDUC COUNS, V91, P167, DOI 10.1016/j.pec.2012.12.007; Reeves S, 2010, J INTERPROF CARE, V24, P230, DOI 10.3109/13561820903163405; Roberts, 2011, HDB ADV MULTILEVEL A, DOI 10.4324/9780203848852; Robinson JH, 2008, J AM ACAD NURSE PRAC, V20, P600, DOI 10.1111/j.1745-7599.2008.00360.x; Scholl I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107828; Steinheider B, 2009, Z ARB ORGAN, V53, P121, DOI 10.1026/0932-4089.53.3.121; Stewart M, 2003, PATIENT CENTERED MED; Sullivan MD, 2010, CLIN J PAIN, V26, P512, DOI 10.1097/AJP.0b013e3181dc7adc; Wiedemann J, 2001, TEAMPULS INTERNETGES; Zwarenstein M., 2009, INTERPROFESSIONAL CO	48	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2017	12	7							e0180171	10.1371/journal.pone.0180171	http://dx.doi.org/10.1371/journal.pone.0180171			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FA7TL	28704377	Green Published, Green Submitted, gold			2023-01-03	WOS:000405649700030
J	Yu, J; Zhou, Z; McEvoy, D; Anderson, CS; Rodgers, A; Perkovic, V; Neal, B				Yu, Jie; Zhou, Zien; McEvoy, Doug; Anderson, Craig S.; Rodgers, Anthony; Perkovic, Vlado; Neal, Bruce			Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; BLOOD-PRESSURE; RESISTANT HYPERTENSION; CPAP THERAPY; HEART; DISEASE; WEIGHT; STROKE; RISK; PREVALENCE	IMPORTANCE Sleep apnea (obstructive and central) is associated with adverse cardiovascular risk factors and increased risks of cardiovascular disease. Positive airway pressure (PAP) provides symptomatic relief, whether delivered continuously (CPAP) or as adaptive servo-ventilation (ASV), but the associations with cardiovascular outcomes and death are unclear. OBJECTIVE To assess the association of PAP vs control with cardiovascular events and death in patients with sleep apnea. DATA SOURCES AND STUDY SELECTION MEDLINE, EMBASE, and the Cochrane Library were systematically searched from inception date to March 2017 for randomized clinical trials that included reporting of major adverse cardiovascular events or deaths. DATA EXTRACTION AND SYNTHESIS Two authors independently extracted data using standardized forms. Summary relative risks (RRs), risk differences (RDs) and 95% CIs were obtained using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES The main outcomes were a composite of acute coronary syndrome (ACS) events, stroke, or vascular death (major adverse cardiovascular events); cause-specific vascular events; and death. RESULTS The analyses included data from 10 trials (9 CPAP; 1 ASV) of patients with sleep apnea (N = 7266; mean age, 60.9 [range, 51.5 to 71.1] years; 5847 [80.5%] men; mean [SD] body mass index, 30.0 [5.2]. Among 356 major adverse cardiovascular events and 613 deaths recorded, there was no significant association of PAP with major adverse cardiovascular events (RR, 0.77 [95% CI, 0.53 to 1.13]; P=.19 and RD, -0.01 [95% CI, -0.03 to 0.01]; P=.23), cardiovascular death (RR, 1.15 [95% CI, 0.88 to 1.50]; P=.30 and RD -0.00 [95% CI, -0.02 to 0.02]; P=.87), or all-cause death (RR, 1.13 [95% CI, 0.99 to 1.29]; P=.08 and RD, 0.00 [95% CI, -0.01 to 0.01]; P=.51). The same was true for ACS, stroke, and heart failure. There was no evidence of different associations for CPAP vs ASV (all P value homogeneity >.24), and meta-regressions identified no associations of PAP with outcomes for different levels of apnea severity, follow-up duration, or adherence to PAP (all P values >.13). CONCLUSIONS AND RELEVANCE The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.	[Yu, Jie] Peking Univ Third Hosp, Key Lab Cardiovasc Mol Biol & Regulatory Pept, Key Lab Mol Cardiovasc Sci, Minist Hlth,Minist Educ,Dept Cardiol, Beijing, Peoples R China; [Yu, Jie; Zhou, Zien; Anderson, Craig S.; Rodgers, Anthony; Perkovic, Vlado; Neal, Bruce] UNSW Sydney, Fac Med, George Inst Global Hlth, Sydney, NSW 2050, Australia; [Zhou, Zien] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Radiol, Shanghai, Peoples R China; [McEvoy, Doug] Flinders Univ S Australia, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia; [Anderson, Craig S.] Peking Univ, Hlth Sci Ctr, George Inst China, Beijing, Peoples R China; [Anderson, Craig S.] Royal Prince Alfred Hosp, Sydney Hlth Partners, Dept Neurol, Sydney, NSW, Australia; [Neal, Bruce] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia; [Neal, Bruce] Imperial Coll London, Div Epidemiol & Biostat, London, England	Peking University; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Shanghai Jiao Tong University; Flinders University South Australia; Peking University; University of Sydney; University of Sydney; Imperial College London	Neal, B (corresponding author), UNSW Sydney, Fac Med, George Inst Global Hlth, Sydney, NSW 2050, Australia.	bneal@georgeinstitute.org.au	McEvoy, Doug/ABB-8052-2020; Demchuk, Andrew M/E-1103-2012; Perkovic, Vlado/AAY-1933-2021	Demchuk, Andrew M/0000-0002-4930-7789; McEvoy, Doug/0000-0002-5759-0094; Neal, Bruce/0000-0002-0490-7465; Yu, Jie/0000-0002-7401-7580; Zhou, Zien/0000-0001-6543-7113; Rodgers, Anthony/0000-0003-1282-1896; Anderson, Craig/0000-0002-7248-4863	National Health and Medical Research Council (NHMRC) of Australia [APP1052555]	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a program grant from the National Health and Medical Research Council (NHMRC) of Australia (APP1052555).	Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Batool-Anwar S, 2016, J SLEEP RES, V25, P731, DOI 10.1111/jsr.12430; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Bradley TD, 2005, NEW ENGL J MED, V353, P2025, DOI 10.1056/NEJMoa051001; Bratton DJ, 2015, JAMA-J AM MED ASSOC, V314, P2280, DOI 10.1001/jama.2015.16303; Brown DL, 2013, J STROKE CEREBROVASC, V22, P1216, DOI 10.1016/j.jstrokecerebrovasdis.2011.06.010; Campos-Rodriguez F, 2016, AM J RESP CRIT CARE, V194, P1286, DOI 10.1164/rccm.201602-0265OC; Chirinos JA, 2014, NEW ENGL J MED, V370, P2265, DOI 10.1056/NEJMoa1306187; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Cowie MR, 2015, NEW ENGL J MED, V373, P1095, DOI 10.1056/NEJMoa1506459; Craig SE, 2012, THORAX, V67, P1090, DOI 10.1136/thoraxjnl-2012-202178; Drager LF, 2015, THORAX, V70, P258, DOI 10.1136/thoraxjnl-2014-205361; Feng Y, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.5; Gottlieb DJ, 2014, NEW ENGL J MED, V370, P2276, DOI 10.1056/NEJMoa1306766; Grundy SM, 2014, J CLIN LIPIDOL, V8, P29, DOI 10.1016/j.jacl.2013.12.005; Guo J, 2016, SLEEP BREATH, V20, P965, DOI 10.1007/s11325-016-1319-y; Heinzer R, 2015, LANCET RESP MED, V3, P310, DOI 10.1016/S2213-2600(15)00043-0; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoyos CM, 2015, AM J HYPERTENS, V28, P1222, DOI 10.1093/ajh/hpv023; Huang ZW, 2015, AM J HYPERTENS, V28, P300, DOI 10.1093/ajh/hpu147; Iftikhar IH, 2015, J CLIN SLEEP MED, V11, P475, DOI 10.5664/jcsm.4610; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kushida CA, 2012, SLEEP, V35, P1593, DOI 10.5665/sleep.2226; Lacasse Y, 2002, THORAX, V57, P483, DOI 10.1136/thorax.57.6.483; Lavie L, 2015, SLEEP MED REV, V20, P27, DOI 10.1016/j.smrv.2014.07.003; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lozano L, 2010, J HYPERTENS, V28, P2161, DOI 10.1097/HJH.0b013e32833b9c63; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Marin JM, 2012, JAMA-J AM MED ASSOC, V307, P2169, DOI 10.1001/jama.2012.3418; Martinez-Ceron E, 2016, AM J RESP CRIT CARE, V194, P476, DOI 10.1164/rccm.201510-1942OC; Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; McMillan A, 2014, LANCET RESP MED, V2, P804, DOI 10.1016/S2213-2600(14)70172-9; Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5; Minnerup J, 2012, STROKE, V43, P1137, DOI 10.1161/STROKEAHA.111.637611; Pack AI, 2009, PROG CARDIOVASC DIS, V51, P434, DOI 10.1016/j.pcad.2009.01.002; Parra O, 2011, EUR RESPIR J, V37, P1128, DOI 10.1183/09031936.00034410; Parra O, 2015, J SLEEP RES, V24, P47, DOI 10.1111/jsr.12181; Pataka A, 2013, CURR CARDIOL REP, V15, DOI 10.1007/s11886-013-0385-z; Peker Y, 2016, AM J RESP CRIT CARE, V194, P613, DOI 10.1164/rccm.201601-0088OC; Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; Peter B, 2011, PRINCIPLES PRACTICE, P1233; Phillips CL, 2012, THORAX, V67, P639, DOI 10.1136/thoraxjnl-2011-200874; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Povitz M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001762; Qaseem A, 2013, ANN INTERN MED, V159, P471, DOI 10.7326/00030003-4819-159-7-201310010-00704; Quan SF, 1997, SLEEP, V20, P1077; Quan SF, 2013, J CLIN SLEEP MED, V9, P989, DOI 10.5664/jcsm.3064; Ryan CM, 2011, STROKE, V42, P1062, DOI 10.1161/STROKEAHA.110.597468; Schwarz EI, 2015, RESPIROLOGY, V20, P889, DOI 10.1111/resp.12573; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Sundstrom J, 2015, ANN INTERN MED, V162, P184, DOI 10.7326/M14-0773; Sundstrom J, 2014, LANCET, V384, P591, DOI 10.1016/S0140-6736(14)61212-5; Woodward M, 2005, EPIDEMIOLOGY STUDY D; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	58	210	221	1	63	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2017	318	2					156	166		10.1001/jama.2017.7967	http://dx.doi.org/10.1001/jama.2017.7967			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA1HS	28697252	Green Published			2023-01-03	WOS:000405190800017
J	Huang, YH; Yeh, CH; Cheng, NM; Lin, CY; Wang, HM; Ko, SF; Toh, CH; Yen, TC; Liao, CT; Ng, SH				Huang, Yu-Han; Yeh, Chih-Hua; Cheng, Nai-Ming; Lin, Chien-Yu; Wang, Hung-Ming; Ko, Sheung-Fat; Toh, Cheng-Hong; Yen, Tzu-Chen; Liao, Chun-Ta; Ng, Shu-Hang			Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: Relationship with human papillomavirus status and failure patterns	PLOS ONE			English	Article							COMPUTED TOMOGRAPHIC DENSITY; CISPLATIN-BASED CHEMOTHERAPY; NECK-CANCER; LYMPH-NODES; HEAD; AREA; EXPRESSION; SURVIVAL; TAIWAN	Objectives We investigated the relationships of cystic nodal metastasis, human papillomavirus (HPV) status, and treatment failure patterns in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiotherapy. Methods We retrospectively reviewed pretreatment MRI and clinical courses of patients with OPSCC whose tumors were tested for HPV-induced p16 expression via immunohistochemistry and who completed chemoradiotherapy. Cervical cystic nodal metastasis and necrotic nodal metastasis were classified on MRI. Results Of 98 patients eligible for analysis, 33 were p16-positive. Cystic nodal metastasis was significantly more prevalent in p16-positive than in p16-negative patients (39.4% versus 18.5%, respectively; p = 0.025). Necrotic nodal metastasis was significantly more prevalent in p16-negative than in p16-positive patients (73.8% versus 51.5%, respectively; p = 0.027). On multivariate analysis, necrotic nodal metastasis (odds ratio [OR] = 7.310, p = 0.011) was an independent predictor of regional failure, while advanced nodal stage (OR = 4.119, p = 0.022) and cystic nodal metastases (OR = 0.087, p = 0.026) were independent positive and negative predictors of distant failure, respectively. Conclusions Cervical cystic and necrotic nodal metastases are associated with HPV-induced p16-positive and p16-negative OPSCC, respectively. Patients with necrotic nodal metastasis at presentation have an increased risk of regional failure. Distant failure is directly and inversely correlated with advanced nodal stage and cystic nodal metastasis, respectively.	[Huang, Yu-Han] Taipei Med Univ, Shuang Ho Hosp, Dept Radiol, Taipei, Taiwan; [Yeh, Chih-Hua; Cheng, Nai-Ming; Toh, Cheng-Hong; Yen, Tzu-Chen; Ng, Shu-Hang] Chang Gung Mem Hosp, Mol Imaging Ctr, Linkou, Taiwan; [Yeh, Chih-Hua; Ko, Sheung-Fat; Toh, Cheng-Hong; Ng, Shu-Hang] Chang Gung Univ, Chang Gung Mem Hosp, Dept Diagnost Radiol, Taoyuan, Taiwan; [Cheng, Nai-Ming; Yen, Tzu-Chen] Chang Gung Univ, Chang Gung Mem Hosp, Dept Nucl Med, Taoyuan, Taiwan; [Lin, Chien-Yu] Chang Gung Univ, Chang Gung Mem Hosp, Dept Radiat Oncol, Taoyuan, Taiwan; [Wang, Hung-Ming] Chang Gung Univ, Chang Gung Mem Hosp, Dept Med Oncol, Taoyuan, Taiwan; [Liao, Chun-Ta] Chang Gung Univ, Chang Gung Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Taoyuan, Taiwan	Taipei Medical University; Shuang Ho Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University	Ng, SH (corresponding author), Chang Gung Mem Hosp, Mol Imaging Ctr, Linkou, Taiwan.; Ng, SH (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Diagnost Radiol, Taoyuan, Taiwan.	shuhangng@gmail.com	Yeh, Chih-Hua/N-5165-2018	Yeh, Chih-Hua/0000-0001-6988-8739; Toh, Cheng Hong/0000-0002-8871-5101; Ng, Shu-Hang/0000-0002-1842-6179	National Science Council-Taiwan [NSC102-2314-B-182A-098-MY2]	National Science Council-Taiwan(Ministry of Science and Technology, Taiwan)	This study was partially supported by a grant from the National Science Council-Taiwan (NSC102-2314-B-182A-098-MY2).	Amin MB, 2017, CANC STAGING MANUAL, V8th; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Cantrell SC, 2013, AM J NEURORADIOL, V34, P2005, DOI 10.3174/ajnr.A3524; Chien CY, 2008, ORAL ONCOL, V44, P174, DOI 10.1016/j.oraloncology.2007.01.018; Corey A, 2013, NEUROIMAG CLIN N AM, V23, P47, DOI 10.1016/j.nic.2012.08.005; El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974; Gillison ML, 2004, SEMIN ONCOL, V31, P744, DOI 10.1053/j.seminoncol.2004.09.011; Goldenberg D, 2008, HEAD NECK-J SCI SPEC, V30, P898, DOI 10.1002/hed.20796; Ho PS, 2002, J ORAL PATHOL MED, V31, P213, DOI 10.1034/j.1600-0714.2002.310404.x; Jaju S, 2014, J CANCER RES THER, V10, P284, DOI 10.4103/0973-1482.136566; JANOT F, 1993, HEAD NECK-J SCI SPEC, V15, P222, DOI 10.1002/hed.2880150309; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Mirghani H, 2014, ORAL ONCOL, V50, P1, DOI 10.1016/j.oraloncology.2013.10.008; Mokhtari S, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-6; Morani AC, 2013, J COMPUT ASSIST TOMO, V37, P343, DOI 10.1097/RCT.0b013e318282d7c3; MUNCK JN, 1991, J NATL CANCER I, V83, P569, DOI 10.1093/jnci/83.8.569; Okami K, 2016, INT J CLIN ONCOLOGY; Regauer S, 1999, BRIT J CANCER, V79, P1437, DOI 10.1038/sj.bjc.6690229; Regauer S, 2000, HUM PATHOL, V31, P1096, DOI 10.1053/hupa.2000.6279; Thompson LDR, 1998, CANCER, V82, P944, DOI 10.1002/(SICI)1097-0142(19980301)82:5<944::AID-CNCR21>3.0.CO;2-#; Vergeer MR, 2006, RADIOTHER ONCOL, V79, P39, DOI 10.1016/j.radonc.2006.03.008; VERMAN K, 1995, ACTA CYTOL, V39, P478; Wang HM, 1996, CANCER, V78, P1972, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1972::AID-CNCR19>3.0.CO;2-V; Wang HM, 2002, CANCER, V94, P2989, DOI 10.1002/cncr.10570; Wilson L, 2014, J OTOLARYNGOL-HEAD N, V43, DOI 10.1186/1916-0216-43-19	26	15	15	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2017	12	7							e0180779	10.1371/journal.pone.0180779	http://dx.doi.org/10.1371/journal.pone.0180779			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA5DZ	28686646	Green Submitted, Green Published, gold			2023-01-03	WOS:000405464100102
J	Brunoni, AR; Moffa, AH; Sampaio, B; Borrione, L; Moreno, ML; Fernandes, RA; Veronezi, BP; Nogueira, BS; Aparicio, LVM; Razza, LB; Chamorro, R; Tort, LC; Fraguas, R; Lotufo, PA; Gattaz, WF; Fregni, F; Bensenor, IM				Brunoni, A. R.; Moffa, A. H.; Sampaio-Junior, B.; Borrione, L.; Moreno, M. L.; Fernandes, R. A.; Veronezi, B. P.; Nogueira, B. S.; Aparicio, L. V. M.; Razza, L. B.; Chamorro, R.; Tort, L. C.; Fraguas, R.; Lotufo, P. A.; Gattaz, W. F.; Fregni, F.; Bensenor, I. M.		ELECT-TDCS Investigators	Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIRECT-CURRENT STIMULATION; NON-INFERIORITY; CLINICAL-TRIAL; METAANALYSIS; TDCS; TOLERABILITY; VALIDATION; FLUOXETINE; EFFICACY; EPISODES	BACKGROUND We compared transcranial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depression. METHODS In a single-center, double-blind, noninferiority trial involving adults with unipolar depression, we randomly assigned patients to receive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS plus oral placebo. The tDCS was administered in 30-minute, 2-mA prefrontal stimulation sessions for 15 consecutive weekdays, followed by 7 weekly treatments. Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. The primary outcome measure was the change in the 17-item Hamilton Depression Rating Scale (HDRS-17) score (range, 0 to 52, with higher scores indicating more depression). Noninferiority of tDCS versus escitalopram was defined by a lower boundary of the confidence interval for the difference in the decreased score that was at least 50% of the difference in the scores with placebo versus escitalopram. RESULTS A total of 245 patients underwent randomization, with 91 being assigned to escitalopram, 94 to tDCS, and 60 to placebo. In the intention-to-treat analysis, the mean (+/- SD) decrease in the score from baseline was 11.3 +/- 6.5 points in the escitalopram group, 9.0 +/- 7.1 points in the tDCS group, and 5.8 +/- 7.9 points in the placebo group. The lower boundary of the confidence interval for the difference in the decrease for tDCS versus escitalopram (difference, -2.3 points; 95% confidence interval [CI], -4.3 to -0.4; P = 0.69) was lower than the noninferiority margin of -2.75 (50% of placebo minus escitalopram), so noninferiority could not be claimed. Escitalopram and tDCS were both superior to placebo (difference vs. placebo, 5.5 points [95% CI, 3.1 to 7.8; P<0.001] and 3.2 points [95% CI, 0.7 to 5.5; P = 0.01], respectively). Patients receiving tDCS had higher rates of skin redness, tinnitus, and nervousness than did those in the other two groups, and new-onset mania developed in 2 patients in the tDCS group. Patients receiving escitalopram had more frequent sleepiness and obstipation than did those in the other two groups. CONCLUSIONS In a single-center trial, tDCS for the treatment of depression did not show noninferiority to escitalopram over a 10-week period and was associated with more adverse events. (Funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo and others; ELECT-TDCS ClinicalTrials.gov number, NCT01894815.)	[Brunoni, A. R.; Sampaio-Junior, B.; Borrione, L.; Aparicio, L. V. M.; Fraguas, R.; Gattaz, W. F.] Univ Sao Paulo, Lab Neurosci LIM 27, Dept & Inst Psychiat, Serv Interdisciplinary Neuromodulat, Sao Paulo, Brazil; [Brunoni, A. R.; Moffa, A. H.; Sampaio-Junior, B.; Borrione, L.; Moreno, M. L.; Fernandes, R. A.; Veronezi, B. P.; Nogueira, B. S.; Aparicio, L. V. M.; Razza, L. B.; Chamorro, R.; Tort, L. C.; Fraguas, R.; Lotufo, P. A.; Bensenor, I. M.] Univ Sao Paulo, Univ Hosp, Interdisciplinary Ctr Appl Neuromodulat, Sao Paulo, Brazil; [Fregni, F.] Harvard Med Sch, Spaulding Rehabil Hosp, Spaulding Neuromodulat Ctr, Boston, MA USA	Universidade de Sao Paulo; Universidade de Sao Paulo; Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital	Brunoni, AR (corresponding author), Univ Sao Paulo, Interdisciplinary Ctr Appl Neuromodulat, LIM 27, Ave Prof Lineu Prestes 2565,3o Andar, BR-05508000 Sao Paulo, Brazil.; Brunoni, AR (corresponding author), Univ Sao Paulo, Serv Interdisciplinary Neuromodulat, LIM 27, Ave Prof Lineu Prestes 2565,3o Andar, BR-05508000 Sao Paulo, Brazil.	brunoni@usp.br	Moreno, Marina/ADX-7717-2022; de Matos Moffa, Adriano Henrique/AAA-8600-2019; Fraguas, Renerio/AAK-7870-2021; Moreno, Marina Lopes/AAT-6138-2020; Borrione, Lucas/ABB-5874-2020; Razza, Lais/AAD-8636-2020; Brunoni, Andre R./H-8394-2012; Fraguas, Renerio/M-7643-2015; Bensenor, Isabela Judith Martins/L-3306-2017	Moreno, Marina Lopes/0000-0002-4416-9145; Brunoni, Andre R./0000-0002-6310-3571; de Matos Moffa, Adriano Henrique/0000-0002-4365-9046; Boralli Razza, Lais/0000-0002-0071-0921; Fregni, Felipe/0000-0001-9359-8643; Fraguas, Renerio/0000-0002-3052-066X	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), an independent public foundation [2012/20911-5]; state of Sao Paulo; NARSAD Young Investigator from the Brain and Behavior Research Foundation [20493]; FAPESP Young Researcher from the Sao Paulo State Foundation [20911-5]; National Council for Scientific and Technological Development (CNPq) [470904, 30167-PQ2]; Associacao Beneficente Alzira Denise Hertzog da Silva; Brazilian Coordination for the Improvement of Higher Education Personnel; FAPESP	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), an independent public foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); state of Sao Paulo; NARSAD Young Investigator from the Brain and Behavior Research Foundation(NARSAD); FAPESP Young Researcher from the Sao Paulo State Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Associacao Beneficente Alzira Denise Hertzog da Silva; Brazilian Coordination for the Improvement of Higher Education Personnel; FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Supported by a grant (2012/20911-5) from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), an independent public foundation, the income of which is provided by the state of Sao Paulo; by grants from the 2013 NARSAD Young Investigator from the Brain and Behavior Research Foundation (20493, to Dr. Brunoni), the 2013 FAPESP Young Researcher from the Sao Paulo State Foundation (20911-5, to Dr. Brunoni), and the National Council for Scientific and Technological Development (CNPq; 470904 and 30167-PQ2, to Dr. Brunoni); by the Associacao Beneficente Alzira Denise Hertzog da Silva (to the LIM27 neuroscience laboratory); and by scholarships from the Brazilian Coordination for the Improvement of Higher Education Personnel (to Drs. Moffa, Moreno, and Nogueira) and from the FAPESP (to Drs. Fernandes and Veronezi).	Amorim Patricia, 2000, Revista Brasileira de Psiquiatria, V22, P106; Amsterdam JD, 2010, J CLIN PSYCHOPHARM, V30, P306, DOI 10.1097/JCP.0b013e3181da5300; [Anonymous], 2010, GUID IND INF CLIN TR; Aparicio LVM, 2016, BRAIN STIMUL, V9, P671, DOI 10.1016/j.brs.2016.05.004; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Brunoni AR, 2017, JAMA PSYCHIAT, V74, P143, DOI 10.1001/jamapsychiatry.2016.3644; Brunoni AR, 2016, BRIT J PSYCHIAT, V208, P522, DOI 10.1192/bjp.bp.115.164715; Brunoni AR, 2013, JAMA PSYCHIAT, V70, P383, DOI 10.1001/2013.jamapsychiatry.32; Brunoni AR, 2015, SAO PAULO MED J, V133, P252, DOI 10.1590/1516-3180.2014.00351712; Brunoni AR, 2011, J NEUROPSYCHOPHARMAC, V14, P1133, DOI DOI 10.1017/S1461145710001690; Castillo-Saavedra L, 2016, J PAIN, V17, P14, DOI 10.1016/j.jpain.2015.09.009; Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Connolly K Ryan, 2012, J Clin Psychiatry, V73, pe567, DOI 10.4088/JCP.11m07413; Fuentes D., 2000, ESCALAS AVALIA O 150, P363; GAUDRY E, 1975, MULTIVAR BEHAV RES, V10, P331, DOI 10.1207/s15327906mbr1003_6; Guarienti F, 2015, NEUROMODULATION, V18, P261, DOI 10.1111/ner.12230; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; LEVINE J, 1986, PSYCHOPHARMACOL BULL, V22, P343; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Masson SC, 2013, J CLIN EPIDEMIOL, V66, P805, DOI 10.1016/j.jclinepi.2013.01.010; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; Meron D, 2015, NEUROSCI BIOBEHAV R, V57, P46, DOI 10.1016/j.neubiorev.2015.07.012; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Murray CJL, 2015, LANCET, V386, P2145, DOI 10.1016/S0140-6736(15)61340-X; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nutt D, 2008, J PSYCHOPHARMACOL, V22, P409, DOI 10.1177/0269881108091068; Pigeot I, 2003, STAT MED, V22, P883, DOI 10.1002/sim.1450; Rosa MA, 2012, NEUROPSYCHOPHARMACOL, V37, P102, DOI 10.1038/npp.2011.225; Seibt O, 2015, BRAIN STIMUL, V8, P590, DOI 10.1016/j.brs.2015.01.401; Valiengo LCL, 2017, J NEUROL NEUROSUR PS, V88, P170, DOI 10.1136/jnnp-2016-314075; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	33	178	191	8	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2017	376	26					2523	2533		10.1056/NEJMoa1612999	http://dx.doi.org/10.1056/NEJMoa1612999			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY8QE	28657871	Bronze, Green Published			2023-01-03	WOS:000404259200006
J	Lee, JC; Chuang, KS; Chen, YW; Hsu, FY; Chou, FI; Yen, SH; Wu, YH				Lee, Jia-Cheng; Chuang, Keh-Shih; Chen, Yi-Wei; Hsu, Fang-Yuh; Chou, Fong-In; Yen, Sang-Hue; Wu, Yuan-Hung			Preliminary dosimetric study on feasibility of multi-beam boron neutron capture therapy in patients with diffuse intrinsic pontine glioma without craniotomy	PLOS ONE			English	Article							BNCT; BEAM; THOR; RADIATION; CHILDREN; TRIAL	Diffuse intrinsic pontine glioma is a very frustrating disease. Since the tumor infiltrates the brain stem, surgical removal is often impossible. For conventional radiotherapy, the dose constraint of the brain stem impedes attempts at further dose escalation. Boron neutron capture therapy (BNCT), a targeted radiotherapy, carries the potential to selectively irradiate tumors with an adequate dose while sparing adjacent normal tissue. In this study, 12 consecutive patients treated with conventional radiotherapy in our institute were reviewed to evaluate the feasibility of BNCT. NCTPIan Ver. 1.1.44 was used for dose calculations. Compared with two and three fields, the average maximal dose to the normal brain may be lowered to 7.35 +/- 0.72 Gy-Eq by four-field irradiation. The mean ratio of minimal dose to clinical target volume and maximal dose to normal tissue was 2.41 +/- 0.26 by four-field irradiation. A therapeutic benefit may be expected with multi-field boron neutron capture therapy to treat diffuse intrinsic pontine glioma without craniotomy, while the maximal dose to the normal brain would be minimized by using the four-field setting.	[Lee, Jia-Cheng; Chen, Yi-Wei; Yen, Sang-Hue; Wu, Yuan-Hung] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan; [Lee, Jia-Cheng; Chuang, Keh-Shih] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Chen, Yi-Wei; Wu, Yuan-Hung] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Hsu, Fang-Yuh; Chou, Fong-In] Natl Tsing Hua Univ, Nucl Sci & Technol Dev Ctr, Hsinchu, Taiwan; [Wu, Yuan-Hung] Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan; [Wu, Yuan-Hung] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan	Taipei Veterans General Hospital; National Tsing Hua University; National Yang Ming Chiao Tung University; National Tsing Hua University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Wu, YH (corresponding author), Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan.; Wu, YH (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Wu, YH (corresponding author), Natl Yang Ming Univ, Inst Publ Hlth, Taipei, Taiwan.; Wu, YH (corresponding author), Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan.	yuanhung@gmail.com	Chen, Yi/HIR-2608-2022	wu, yuanhung/0000-0003-2908-7704	Taipei Veterans General Hospital [V105A-046, V105A-013, V106A-007, V106A-016]	Taipei Veterans General Hospital(Taipei Veterans General Hospital)	This work was supported by the Taipei Veterans General Hospital (www.vghtpe.gov,tw) No: V105A-046(JCL), V105A-013(YHW), V106A-007(YHW), V106A-016 (JCL), Taipei Veterans General Hospital-National Yang Ming University Excellent Physician Scientists Cultivation Program (www.vghtpe.gov.tw) No. 105-V-B-107(YHW). The funders had no role in study design, data collection	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aoyama H, 2006, INT J RADIAT ONCOL, V64, P962, DOI 10.1016/j.ijrobp.2005.11.005; Benedict SH, 2010, MED PHYS, V37, P4078, DOI 10.1118/1.3438081; Gonzalez S, 2003, NCTPLAN NEW PC VERSI; Hsu FY, 2009, APPL RADIAT ISOTOPES, V67, pS130, DOI 10.1016/j.apradiso.2009.03.033; ICRU, 1992, PHOT EL PROT NEUTR I; Kawabata S, 2011, APPL RADIAT ISOTOPES, V69, P1796, DOI 10.1016/j.apradiso.2011.03.014; Kiger W III, 2002, VERIFICATION VALIDAT, P613; Liu YH, 2009, APPL RADIAT ISOTOPES, V67, pS137, DOI 10.1016/j.apradiso.2009.03.088; Marcus KJ, 2003, INT J RADIAT ONCOL, V55, P1182, DOI 10.1016/S0360-3016(02)04391-2; Morgan-Fletcher S.L., 2001, BRIT J RADIOL, V74, P294, DOI [10.1259/bjr.74.879.740294, DOI 10.1259/bjr.74.879.740294, DOI 10.1259/BJR.74.879.740294]; Nakagawa Y, 2009, APPL RADIAT ISOTOPES, V67, pS27, DOI 10.1016/j.apradiso.2009.03.090; Pelowitz D.B., 2011, 0LACP1100438 LOS AL; Rasband W.S., 2018, IMAGEJ; ROGUS RD, 1994, MED PHYS, V21, P1611, DOI 10.1118/1.597267; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semenenko VA, 2008, MED PHYS, V35, P5851, DOI 10.1118/1.3013556; Skold K, 2014, BRIT J RADIOLOGY; Tung CJ, 2004, APPL RADIAT ISOTOPES, V61, P861, DOI 10.1016/j.apradiso.2004.05.066; Wang LW, 2016, INT J RADIAT ONCOL, V95, P396, DOI 10.1016/j.ijrobp.2016.02.028; Wang LW, 2014, APPL RADIAT ISOTOPES, V88, P23, DOI 10.1016/j.apradiso.2013.11.134; Zamenhof R., 2001, NEUTRON CAPTURE THER, P216	22	3	3	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0180461	10.1371/journal.pone.0180461	http://dx.doi.org/10.1371/journal.pone.0180461			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662135	Green Published, Green Submitted, gold			2023-01-03	WOS:000404608300158
J	Ogawa, C; Tsuchiya, K; Tomosugi, N; Kanda, F; Maeda, K; Maeda, T				Ogawa, Chie; Tsuchiya, Ken; Tomosugi, Naohisa; Kanda, Fumiyoshi; Maeda, Kunimi; Maeda, Teiryo			Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study	PLOS ONE			English	Article							IRON-DEFICIENCY ANEMIA; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; HEPCIDIN LEVELS; THERAPY; MANAGEMENT; RISK; ERYTHROPOIETIN; INFLAMMATION; DIALYSIS	Background Optimal iron levels in patients on hemodialysis are currently unknown, and a higher level than that for the healthy population is usually set for such patients considering the use of erythropoiesis-stimulating agents or the occurrence of chronic inflammation. However, excessive iron causes oxidative stress and impairment of its utilization by cells. Therefore we investigated the relationship between hemoglobin (Hb) level and iron status in hemodialysis patients to identify the optimal iron levels for patients undergoing hemodialysis. Methods A total of 208 outpatients on maintenance hemodialysis were followed up between July 2006 and June 2007. Men accounted for 64.9% cases [mean age, 59.3 +/- 13.1 years and median dialysis history, 7.7 (3.6-13.2) years], and diabetic nephropathy accounted for 25.0% cases. Hemoglobin level was measured twice a month and serum ferritin, serum iron, and total iron-binding capacity were measured once a month. The doses of recombinant human erythropoietin and low-dose iron supplement were adjusted to maintain a hemoglobin level of 10-11 g/dL, according to the guidelines of the Japanese Society for Dialysis Therapy. Hepcidin was measured at baseline. Using the mean values for 1-year period, the relationships among hemoglobin, serum ferritin levels, and transferrin saturation levels were investigated based on a receiver operating characteristic curve and a logistic regression model. In addition, the correlations among serum ferritin, transferrin saturation, and hepcidin levels were analyzed by Pearson product-moment correlation coefficient and linear regression model. Results By receiver operating characteristic curve, the cutoff point of serum ferritin and transferrin saturation levels with a hemoglobin >= 10 g/dL showed <90 ng/mL (sensitivity: 69.1%, specificity: 72.1%, p < 0.001) and >= 20% (sensitivity: 77.6%, specificity: 48.8%, p = 0.302). Upon logistic regression model analysis with a hemoglobin >= 10 g/dL as the endpoint, the analysis of odds ratios relative to a group with serum ferritin >= 90 ng/mL and transferrin saturation <20% revealed that the group with serum ferritin <90 ng/mL and transferrin saturation >= 20% had the highest ratio: 46.75 (95% confidence interval: 10.89-200.70, p < 0.001). In Pearson product-moment correlation coefficient, hepcidin showed a strong positive correlation with serum ferritin [r = 0.78 (95% confidence interval: 0.72-0.83, p < 0.001)] and a weak positive correlation with transferrin saturation [r = 0.18 (95% confidence interval: 0.04-0.31, p = 0.010)]. In the multivariable analyses of the linear regression model, a positive relationship was shown between hepcidin and serum ferritin [beta-coefficient of 0.30 (95% confidence interval: 0.27-0.34, p < 0.001)]; however, no relationship was shown with transferrin saturation [beta-coefficient of 0.09 (95% confidence interval: -0.31-0.49, p = 0.660)]. Conclusions In this study, the iron status of serum ferritin <90 ng/mL and transferrin saturation >= 20% was optimal in hemodialysis patients receiving recombinant human erythropoietin for anemia therapy. This result indicates that the threshold values for the optimal iron status may be lower than those currently recommended in iron-level management guideline.	[Ogawa, Chie; Kanda, Fumiyoshi; Maeda, Kunimi; Maeda, Teiryo] Maeda Inst Renal Res, Kawasaki, Kanagawa, Japan; [Ogawa, Chie; Tsuchiya, Ken; Tomosugi, Naohisa; Maeda, Kunimi; Maeda, Teiryo] INC, Biomarker Soc, Kawasaki, Kanagawa, Japan; [Tsuchiya, Ken] Tokyo Womens Med Univ, Dept Blood Purificat, Tokyo, Japan; [Tomosugi, Naohisa] Kanazawa Med Univ, Med Res Inst, Project Res Ctr, Div Syst Biosci Drug Discovery, Uchinada, Ishikawa, Japan	Tokyo Women's Medical University; Kanazawa Medical University	Ogawa, C (corresponding author), Maeda Inst Renal Res, Kawasaki, Kanagawa, Japan.; Ogawa, C (corresponding author), INC, Biomarker Soc, Kawasaki, Kanagawa, Japan.	tato.ogawa@gmail.com						Akizawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3643, DOI 10.1093/ndt/gfn346; ALI MAM, 1978, CAN MED ASSOC J, V118, P945; [Anonymous], 2011, KIDNEY INT S, V4, P292; [Anonymous], 2006, AM J KIDNEY DIS S, V47, pS11; Anraku M, 2008, CLIN BIOCHEM, V41, P1168, DOI 10.1016/j.clinbiochem.2008.07.007; Bregman DB, 2013, AM J HEMATOL, V88, P97, DOI 10.1002/ajh.23354; Brookhart MA, 2013, J AM SOC NEPHROL, V24, P1151, DOI 10.1681/ASN.2012121164; Bross R, 2009, AM J NEPHROL, V29, P571, DOI 10.1159/000191470; Cristol JP, 1997, NEPHROL DIAL TRANSPL, V12, P2312, DOI 10.1093/ndt/12.11.2312; Drueke T, 2002, CIRCULATION, V106, P2212, DOI 10.1161/01.CIR.0000035250.66458.67; ESCHBACH JW, 1977, ANN INTERN MED, V87, P710, DOI 10.7326/0003-4819-87-6-710; Ferrucci L, 2010, BLOOD, V115, P3810, DOI 10.1182/blood-2009-02-201087; FLYNN TP, 1983, J CLIN INVEST, V71, P1215, DOI 10.1172/JCI110870; Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020; Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467; Goodnough LT, 2010, BLOOD, V116, P4754, DOI 10.1182/blood-2010-05-286260; Hamano T, 2015, KIDNEY INT SUPPL, V5, P23, DOI 10.1038/kisup.2015.6; Kato J, 2007, J GASTROENTEROL, V42, P830, DOI 10.1007/s00535-007-2095-z; Kiechl S, 1997, CIRCULATION, V96, P3300; Kliger SA, AM J KIDNEY DIS, V62, P849; Kuragano T, 2010, AM J NEPHROL, V31, P534, DOI 10.1159/000312381; Locatelli F, 2009, NEPHROL DIAL TRANSPL, V24, P348, DOI 10.1093/ndt/gfn653; Maruyama Y, 2007, NEPHROL DIAL TRANSPL, V22, P1407, DOI 10.1093/ndt/gfl789; Nakanishi T, 2012, CLIN EXP NEPHROL, V16, P819, DOI 10.1007/s10157-012-0694-3; Nakanishi T, 2010, AM J NEPHROL, V32, P439, DOI 10.1159/000320733; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Pasricha SRS, 2010, MED J AUSTRALIA, V193, P525, DOI 10.5694/j.1326-5377.2010.tb04038.x; Reis KA, 2005, INT HEART J, V46, P255, DOI 10.1536/ihj.46.255; Rubab Z, 2015, SAUDI J KIDNEY DIS T, V26, P19; Sargent JA, 2004, BLOOD PURIFICAT, V22, P112, DOI 10.1159/000074931; Takasawa K, 2015, NUTRIENTS, V7, P103, DOI 10.3390/nu7010103; Theurl I, 2009, BLOOD, V113, P5277, DOI 10.1182/blood-2008-12-195651; Tomosugi N, 2006, BLOOD, V108, P1381, DOI 10.1182/blood-2005-10-4043; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; Tsukamoto T, 2016, AM J NEPHROL, V43, P32, DOI 10.1159/000444335; Turenne MN, 2015, J AM SOC NEPHROL, V26, P754, DOI 10.1681/ASN.2013111232; Usberti M, 2002, J NEPHROL, V15, P558; Weiss G, 2009, EUR J CLIN INVEST, V39, P883, DOI 10.1111/j.1365-2362.2009.02182.x; Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506	39	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2017	12	6							e0179608	10.1371/journal.pone.0179608	http://dx.doi.org/10.1371/journal.pone.0179608			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JX	28662118	gold, Green Published, Green Submitted			2023-01-03	WOS:000404608300038
J	Golle, A; Janezic, S; Rupnik, M				Golle, Andrej; Janezic, Sandra; Rupnik, Maja			Low overlap between carbapenem resistant Pseudomonas aeruginosa genotypes isolated from hospitalized patients and wastewater treatment plants	PLOS ONE			English	Article							ANTIMICROBIAL-RESISTANCE; GENETIC DIVERSITY; DRINKING-WATER; SPREAD; DISSEMINATION; ANTIBIOTICS; MECHANISMS; BACTERIA; BRAZIL; SPP.	The variability of carbapenem-resistant Pseudomonas aeruginosa strains (CRPA) isolated from urine and respiratory samples in a large microbiological laboratory, serving several health care settings, and from effluents of two wastewater treatment plants (WWTP) from the same region was assessed by PFGE typing and by resistance to 10 antibiotics. During the 12-month period altogether 213 carbapenem-resistant P. aeruginosa isolates were cultured and distributed into 65 pulsotypes and ten resistance profiles. For representatives of all 65 pulsotypes 49 different MLSTs were determined. Variability of clinical and environmental strains was comparable, 130 carbapenem-resistant P. aeruginosa obtained from 109 patients were distributed into 38 pulsotypes, while 83 isolates from WWTPs were classified into 31 pulsotypes. Only 9 pulsotypes were shared between two or more settings (hospital or WWTP). Ten MLST were determined for those prevalent pulsotypes, two of them (ST111 and ST235) are among most successful CRPA types worldwide. Clinical and environmental carbapenem-resistant P. aeruginosa strains differed in antibiotic resistance. The highest proportion of clinical isolates was resistant to piperacillin/tazobactam (52.3%) and ceftazidime (42.3%). The highest proportion of environmental isolates was resistant to ceftazidime (37.1%) and ciprofloxacin (35.5%). The majority of isolates was resistant only to imipenem and/or meropenem. Strains with additional resistances were distributed into nine different patterns. All of them included clinically relevant strains, while environmental strains showed only four additional different patterns.	[Golle, Andrej; Janezic, Sandra; Rupnik, Maja] Natl Lab Hlth Environm & Food, Maribor, Slovenia; [Janezic, Sandra; Rupnik, Maja] Univ Maribor, Fac Med, Maribor, Slovenia	University of Maribor	Rupnik, M (corresponding author), Natl Lab Hlth Environm & Food, Maribor, Slovenia.; Rupnik, M (corresponding author), Univ Maribor, Fac Med, Maribor, Slovenia.	maja.rupnik@nlzoh.si						Aloush V, 2006, ANTIMICROB AGENTS CH, V50, P43, DOI 10.1128/AAC.50.1.43-48.2006; Birosova L, 2014, SCI TOTAL ENVIRON, V490, P440, DOI 10.1016/j.scitotenv.2014.05.030; Bogino PC, 2013, INT J MOL SCI, V14, P15838, DOI 10.3390/ijms140815838; Breidenstein EBM, 2011, TRENDS MICROBIOL, V19, P419, DOI 10.1016/j.tim.2011.04.005; Cabot G, 2012, ANTIMICROB AGENTS CH, V56, P6349, DOI 10.1128/AAC.01388-12; Cholley P, 2011, J CLIN MICROBIOL, V49, P2578, DOI 10.1128/JCM.00102-11; Czekalski N, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00106; ECDC, 2015, ANN REPORT EUROPEAN; Edelstein MV, 2013, LANCET INFECT DIS, V13, P867, DOI 10.1016/S1473-3099(13)70168-3; Flores Ribeiro Angela, 2014, Sci Total Environ, V490, P370, DOI 10.1016/j.scitotenv.2014.05.012; Fuentefria DB, 2008, REV SOC BRAS MED TRO, V41, P470, DOI 10.1590/S0037-86822008000500007; Garcia-Castillo M, 2011, J CLIN MICROBIOL, V49, P2905, DOI 10.1128/JCM.00753-11; Gellatly SL, 2013, PATHOG DIS, V67, P159, DOI 10.1111/2049-632X.12033; Gomila M, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-138; Hong DJ, 2015, INFECT CHEMOTHER, V47, P81, DOI 10.3947/ic.2015.47.2.81; Kidd TJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044199; Kittinger C, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00586; Libisch B, 2008, RES MICROBIOL, V159, P162, DOI 10.1016/j.resmic.2007.12.008; Lutz JK, 2011, INT J ENV RES PUB HE, V8, P554, DOI 10.3390/ijerph8020554; Martins VV, 2014, ENVIRON SCI POLLUT R, V21, P5873, DOI 10.1007/s11356-014-2509-4; Martins VV, 2014, APMIS, V122, P92, DOI 10.1111/apm.12112; Meletis G, 2012, HIPPOKRATIA, V16, P303; Mesaros N, 2007, CLIN MICROBIOL INFEC, V13, P560, DOI 10.1111/j.1469-0691.2007.01681.x; Miranda CC, 2015, J APPL MICROBIOL, V118, P1276, DOI 10.1111/jam.12792; Nemec A, 2010, RES MICROBIOL, V161, P234, DOI 10.1016/j.resmic.2010.02.002; Pappa O, 2016, FEMS MICROBIOL ECOL, V92, DOI 10.1093/femsec/fiw086; Petit SMC, 2013, RES MICROBIOL, V164, P856, DOI 10.1016/j.resmic.2013.06.007; Picao RC, 2009, ANTIMICROB AGENTS CH, V53, P3908, DOI 10.1128/AAC.00453-09; PIRNAY JP, 2009, PLOS ONE, V4; Poole K, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00065; Rizzo L, 2013, SCI TOTAL ENVIRON, V447, P345, DOI 10.1016/j.scitotenv.2013.01.032; Samuelsen O, 2010, ANTIMICROB AGENTS CH, V54, P346, DOI 10.1128/AAC.00824-09; Schwartz T, 2006, FEMS MICROBIOL ECOL, V57, P158, DOI 10.1111/j.1574-6941.2006.00100.x; Schwartz T, 2015, MICROB BIOTECHNOL, V8, P116, DOI 10.1111/1751-7915.12156; Slekovec C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049300; Streeter K, 2016, INFECT EPIDEMIOL MIC, V2, P25, DOI 10.7508/iem.2016.01.008; Vaz-Moreira I, 2012, SCI TOTAL ENVIRON, V426, P366, DOI 10.1016/j.scitotenv.2012.03.046; Wang H, 2012, APPL ENVIRON MICROB, V78, P6285, DOI 10.1128/AEM.01492-12; Zankari E, 2012, J ANTIMICROB CHEMOTH, V67, P2640, DOI 10.1093/jac/dks261; Zavascki AP, 2010, EXPERT REV ANTI-INFE, V8, P71, DOI [10.1586/eri.09.108, 10.1586/ERI.09.108]	40	10	10	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0186736	10.1371/journal.pone.0186736	http://dx.doi.org/10.1371/journal.pone.0186736			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0UN	29049368	Green Published, gold, Green Submitted			2023-01-03	WOS:000413195900104
J	Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, JJ; Cowey, CL; Lao, CD; Wagstaff, J; Schadendorf, D; Ferrucci, PF; Smylie, M; Dummer, R; Hill, A; Hogg, D; Haanen, J; Carlino, MS; Bechter, O; Maio, M; Marquez-Rodas, I; Guidoboni, M; McArthur, G; Lebbe, C; Ascierto, PA; Long, GV; Cebon, J; Sosman, J; Postow, MA; Callahan, MK; Walker, D; Rollin, L; Bhore, R; Hodi, FS; Larkin, J				Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. -J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A.; Hogg, D.; Haanen, J.; Carlino, M. S.; Bechter, O.; Maio, M.; Marquez-Rodas, I.; Guidoboni, M.; McArthur, G.; Lebbe, C.; Ascierto, P. A.; Long, G. V.; Cebon, J.; Sosman, J.; Postow, M. A.; Callahan, M. K.; Walker, D.; Rollin, L.; Bhore, R.; Hodi, F. S.; Larkin, J.			Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC MELANOMA; UNTREATED MELANOMA	BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS We randomly assigned, in a 1: 1: 1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group. RESULTS At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65[P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. CONCLUSIONS Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone.	[Wolchok, J. D.; Postow, M. A.; Callahan, M. K.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Wolchok, J. D.; Postow, M. A.; Callahan, M. K.] Weill Cornell Med Coll, New York, NY USA; [Chiarion-Sileni, V.] IRCCS, Oncol Inst Veneto, Padua, Italy; [Ferrucci, P. F.] European Inst Oncol, Milan, Italy; [Maio, M.] Univ Hosp Siena, Ctr Immunooncol, Ist Toscano Tumori, Siena, Italy; [Guidoboni, M.] IRCCS, Ist Sci Romagnolo Studio Cura Tumori, Immunotherapy & Somat Cell Therapy Unit, Meldola, Italy; [Ascierto, P. A.] Fdn Pascale, Ist Nazl Tumori, Naples, Italy; [Gonzalez, R.] Univ Colorado, Denver, CO 80202 USA; [Rutkowski, P.] Oncol Ctr, Maria Sklodowska Curie Inst, Warsaw, Poland; [Grob, J. -J.] Aix Marseille Univ, Hop Timone, Marseille, France; [Lebbe, C.] Univ Paris Diderot, Hop St Louis, AP HP, Dermatol & Ctr Invest Clin,INSERM Unite 976, Paris, France; [Cowey, C. L.] Baylor Canc Ctr, Texas Oncol, Dallas, TX USA; [Lao, C. D.] Univ Michigan, Ann Arbor, MI 48109 USA; [Wagstaff, J.] Swansea Univ, Coll Med, Swansea, W Glam, Wales; [Larkin, J.] Royal Marsden NHS Fdn Trust, London, England; [Schadendorf, D.] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany; [Schadendorf, D.] German Canc Consortium, Heidelberg, Germany; [Smylie, M.] Cross Canc Inst, Edmonton, AB, Canada; [Hogg, D.] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Dummer, R.] Univ Spital, Zurich, Switzerland; [Hill, A.] Tasman Oncol Res, Southport Gold Coast, Qld, Australia; [Carlino, M. S.] Univ Sydney, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia; [Long, G. V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, G. V.] Royal North Shore & Mater Hosp, Sydney, NSW, Australia; [McArthur, G.] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Cebon, J.] Univ Melbourne, Oliivia Newton John Canc Res Inst, Melbourne, Vic, Australia; [Haanen, J.] Netherlands Canc Inst, Amsterdam, Netherlands; [Bechter, O.] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium; [Marquez-Rodas, I.] Gen Univ Hosp Gregorio Maranon, Madrid, Spain; [Sosman, J.] Northwestern Univ, Chicago, IL 60611 USA; [Walker, D.; Rollin, L.; Bhore, R.] Bristol Myers Squibb, Princeton, NJ USA; [Hodi, F. S.] Dana Farber Canc Inst, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Cornell University; IRCCS Istituto Oncologico Veneto (IOV); IRCCS European Institute of Oncology (IEO); ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Siena; University Hospital of Siena; IRCCS Meldola (IRST); IRCCS Fondazione Pascale; University of Colorado System; University of Colorado Denver; Maria Sklodowska-Curie National Research Institute of Oncology; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Texas Oncology; University of Michigan System; University of Michigan; Swansea University; Royal Marsden NHS Foundation Trust; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Melanoma Institute Australia; University of Sydney; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Netherlands Cancer Institute; KU Leuven; University Hospital Leuven; General University Gregorio Maranon Hospital; Northwestern University; Bristol-Myers Squibb; Harvard University; Dana-Farber Cancer Institute	Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, Parker Inst & Ludwig Ctr, Dept Med, 1275 York Ave,Box 340, New York, NY 10065 USA.	wolchokj@mskcc.org	Schadendorf, Dirk/AAE-8206-2019; sileni, vanna chiarion/B-9042-2018; Marquez-Rodas, Ivan/ABD-5532-2021; Ascierto, Paolo A/J-9106-2016; Long, Georgina V/C-1771-2013; Bechter, Oliver/H-7634-2013; Haanen, John/AAD-8534-2022; Rutkowski, Piotr/B-3907-2013; Ferrucci, Pier Francesco/AAQ-9002-2020; Haanen, John/AAD-8578-2022; Bechter, Oliver/ABB-5359-2021; Carlino, Matteo/GRS-7198-2022	sileni, vanna chiarion/0000-0001-9191-9124; Marquez-Rodas, Ivan/0000-0002-2476-668X; Ascierto, Paolo A/0000-0002-8322-475X; Long, Georgina V/0000-0001-8894-3545; Bechter, Oliver/0000-0003-0667-3284; Haanen, John/0000-0001-5884-7704; Rutkowski, Piotr/0000-0002-8920-5429; Bechter, Oliver/0000-0003-0667-3284; Wagstaff, John/0000-0002-1140-5981; Melucci, Maria Teresa/0000-0002-1677-3345; McArthur, Grant/0000-0001-8908-6071; Guidoboni, Massimo/0000-0001-7703-790X; Ferrucci, Pier Francesco/0000-0001-6255-5851; Larkin, James/0000-0001-5569-9523; Cebon, Jonathan/0000-0002-3898-950X; Carlino, Matteo/0000-0002-7861-4104	Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.	Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Larkin J, 2017, AM ASS CANC RES ANN; Linden A, 2006, J EVAL CLIN PRACT, V12, P132, DOI 10.1111/j.1365-2753.2005.00598.x; Long GV, 2017, ANN ONCOL; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Ribas A, 2017, AM ASS CANC RES ANN; Robert C, 2017, J CLIN ONCOL S, V15, P35, DOI DOI 10.1200/JC0.2017.35.15_; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Sznol M, 2015, SOC MEL RES ANN M SA; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]	15	2088	2149	7	151	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	2017	377	14					1345	1356		10.1056/NEJMoa1709684	http://dx.doi.org/10.1056/NEJMoa1709684			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ0CB	28889792	Green Submitted, Green Published, Green Accepted, Bronze			2023-01-03	WOS:000412375000014
J	Ostermann, JK; Witt, CM; Reinhold, T				Ostermann, Julia K.; Witt, Claudia M.; Reinhold, Thomas			A retrospective cost-analysis of additional homeopathic treatment in Germany: Long-term economic outcomes	PLOS ONE			English	Article							DISORDERS; TRIAL; CARE	Objectives This study aimed to provide a long-term cost comparison of patients using additional homeopathic treatment (homeopathy group) with patients using usual care (control group) over an observation period of 33 months. Methods Health claims data from a large statutory health insurance company were analysed from both the societal perspective (primary outcome) and from the statutory health insurance perspective (secondary outcome). To compare costs between patient groups, homeopathy and control patients were matched in a 1: 1 ratio using propensity scores. Predictor variables for the propensity scores included health care costs and both medical and demographic variables. Health care costs were analysed using an analysis of covariance, adjusted for baseline costs, between groups both across diagnoses and for specific diagnoses over a period of 33 months. Specific diagnoses included depression, migraine, allergic rhinitis, asthma, atopic dermatitis, and headache. Results Data from 21,939 patients in the homeopathy group (67.4% females) and 21,861 patients in the control group (67.2% females) were analysed. Health care costs over the 33 months were 12,414 EUR [95% CI 12,022-12,805] in the homeopathy group and 10,428 EUR [95% CI 10,036-10,820] in the control group (p< 0.0001). The largest cost differences were attributed to productivity losses (homeopathy: EUR 6,289 [6,118-6,460]; control: EUR 5,498 [5,326-5,670], p< 0.0001) and outpatient costs (homeopathy: EUR 1,794 [1,770-1,818]; control: EUR 1,438 [1,414-1,462], p< 0.0001). Although the costs of the two groups converged over time, cost differences remained over the full 33 months. For all diagnoses, homeopathy patients generated higher costs than control patients. Conclusion The analysis showed that even when following-up over 33 months, there were still cost differences between groups, with higher costs in the homeopathy group.	[Ostermann, Julia K.; Witt, Claudia M.; Reinhold, Thomas] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Witt, Claudia M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Maryland; University of Maryland Baltimore	Ostermann, JK (corresponding author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.	julia.ostermann@charite.de	Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805; Reinhold, Thomas/0000-0001-5169-7029; Ostermann, Julia/0000-0002-0180-8752	statutory health insurance company Techniker Krankenkasse	statutory health insurance company Techniker Krankenkasse	This is an investigator initiated study that is co-sponsored by the statutory health insurance company Techniker Krankenkasse. The co-sponsor provided data, but was not involved in the main data analysis, data interpretation, writing, or decision to submit the manuscript. All authors had full access to the data and are responsible for the veracity and completeness of the data reported. All authors had full access to the data in the study and take final responsibility to submit for publication.	Anlauf M, 2015, GMS, P13; Baars EW, 2014, BMJ OPEN, V4, DOI DOI 10.1136/BMJ0PEN-2014-005332; Brien S, 2011, RHEUMATOLOGY, V50, P1070, DOI 10.1093/rheumatology/keq234; DZVh&Auml;, 2012, SEL KLASS HOM BET KR; Friemel S, 2005, PSYCHIAT PRAX, V32, P113, DOI 10.1055/s-2004-834611; House of Commons Science and Technology Committee, 2010, EV CHECK 2 HOM; Insel TR, 2008, AM J PSYCHIAT, V165, P663, DOI 10.1176/appi.ajp.2008.08030366; Jain Asha, 2003, Homeopathy, V92, P71, DOI 10.1016/S1475-4916(03)00004-3; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kliems H, 2011, J ALTERN COMPLEM MED, V17, P265, DOI 10.1089/acm.2010.0158; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; Marian F, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-52; Mathie RT, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-142; OPATHIE Keine Abrechnung zulasten der gesetzlichen Krankenversicherung, 2017, DTSCH ARZTEBL, V114; Ostermann JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134657; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Roll S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054973; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Smith K, 2012, BIOETHICS, V26, P398, DOI 10.1111/j.1467-8519.2010.01876.x; Statistisches Bundesamt, 2014, JAHR ARB; Studer HP, 2011, FORSCH KOMPLEMENTMED, V18, P315, DOI 10.1159/000334797; Thompson EA, 2011, HOMEOPATHY, V100, P122, DOI 10.1016/j.homp.2011.05.001; Viksveen P, 2014, EUR J HEALTH ECON, V15, P157, DOI 10.1007/s10198-013-0462-7; Witt C, 2005, COMPLEMENT THER MED, V13, P79, DOI 10.1016/j.ctim.2005.03.005; Witt CM, 2009, DERMATOLOGY, V219, P329, DOI 10.1159/000248854	27	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2017	12	9							e0182897	10.1371/journal.pone.0182897	http://dx.doi.org/10.1371/journal.pone.0182897			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0WP	28915242	Green Submitted, Green Published, gold			2023-01-03	WOS:000410861600003
J	Le, NK; Riggi, E; Marrone, G; Vu, TV; Izurieta, RO; Nguyen, CKT; Larsson, M; Do, CD				Le, Nicole K.; Riggi, Emilia; Marrone, Gaetano; Tam Van Vu; Izurieta, Ricardo O.; Chuc Kim Thi Nguyen; Larsson, Mattias; Cuong Duy Do			Assessment of WHO criteria for identifying ART treatment failure in Vietnam from 2007 to 2011	PLOS ONE			English	Article							ANTIRETROVIRAL TREATMENT FAILURE; RESOURCE-LIMITED SETTINGS; VIRAL LOAD; VIROLOGICAL FAILURE; HIV; THERAPY; ADULTS; TRANSMISSION; REGIMEN; AFRICA	Objective We evaluated the sensitivity and specificity of the WHO immunological criteria for detecting antiretroviral therapy (ART) treatment failure in a cohort of Vietnamese patients. We conducted a stratified analysis to determine the effects of BMI, peer support, adherence to antiretroviral (ARV) drugs, age, and gender on the sensitivity and specificity of the WHO criteria. Methods We conducted a retrospective cohort study of 605 HIV-infected patients using data previously collected from a cluster randomized control trial study. We compared the sensitivity and specificity of CD4+ counts to the gold standard of virologic testing as a diagnostic test for ART failure at different time points of 12, 18, and 24 months. Results The sensitivity [95% confidence interval (CI)] of the WHO immunological criteria based on a viral load >= 1000 copies/mL was 12% (5%-23%), 14% (2%-43%), and 12.5% (2%-38%) at 12, 18, and 24 months, respectively. In the same order, the specificity was 93% (90%-96%), 98% (96%-99%), and 98% (96%-100%). The positive predictive values (PPV) at 12, 18, and 24 months were 22% (9%-40%), 20% (3%-56%), and 29% (4%-71%); the negative predictive values (NPV) at the same time points were 87% (84%-90%), 97% (95%-98%), and 96% (93%-98%). The stratified analysis revealed similar sensitivities and specificities. Conclusion The sensitivity of the WHO immunological criteria is poor, but the specificity is high. Although testing costs may increase, we recommend that Vietnam and other similar settings adopt viral load testing as the principal method for determining ART failure.	[Le, Nicole K.] Univ S Florida, Morsani Coll Med, Tampa, FL USA; [Riggi, Emilia] Univ Pavia, Med Stat Unit, Dept Brain & Behav Sci, Pavia, Italy; [Marrone, Gaetano; Larsson, Mattias; Cuong Duy Do] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Tam Van Vu] Uong Bi Gen Hosp, Dept Infect Dis, Uong Bi, Quang Ninh, Vietnam; [Izurieta, Ricardo O.] Univ S Florida, Coll Publ Hlth, Dept Global Hlth, Tampa, FL USA; [Chuc Kim Thi Nguyen] Hanoi Med Univ, Hanoi, Vietnam; [Cuong Duy Do] Bach Mai Hosp, Infect Dis Dept, Hanoi, Vietnam	State University System of Florida; University of South Florida; University of Pavia; Karolinska Institutet; State University System of Florida; University of South Florida; Hanoi Medical University	Do, CD (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.; Do, CD (corresponding author), Bach Mai Hosp, Infect Dis Dept, Hanoi, Vietnam.	doduy.cuong@gmail.com	Riggi, Emilia/AAX-2011-2021; Larsson, Mattias/C-6434-2017	Do Duy, Cuong/0000-0002-1565-642X; RIGGI, EMILIA/0000-0001-8878-7060; Larsson, Mattias/0000-0002-0514-7445	CHAIN EU FP7; Global Fund; CDC-Lifegap Project; Health System Research Project of Hanoi Medical University in Vietnam	CHAIN EU FP7; Global Fund; CDC-Lifegap Project; Health System Research Project of Hanoi Medical University in Vietnam	We wish to acknowledge the support and contribution from the board of directors and colleagues at Uong Bi Hospital. We also want to acknowledge the teams' work at the outpatient clinics at the Provincial Hospital in Quang Ninh, Health Centre in Ha Long, and Yen Hung district hospital. In addition, we would like to acknowledge the CHAIN EU FP7, Global Fund, CDC-Lifegap Project, and Health System Research Project of Hanoi Medical University in Vietnam for providing financial and technical support for the original clinical trial. We are grateful to Dr. Nguyen Phuong Hoa, Ms. Nguyen Binh Minh, Dr. Tran Thanh Do, Dr. Nguyen Phuong Thanh, Dr. Hoang Thi Thao, Dr. Nguyen Thi Tuyet Mai, Ms. Pham Thi Tuoi, Mr. Tran Chi Thanh, Prof. Anders Sonnerborg, Prof. Vinod Diwan, all colleagues, health staff, external supporters, and patients in the DOTARV Project. We want to give a special thanks to the study participants as well as to their families for their valuable contribution to the study. Lastly, we would like to thank the Scholarly Concentrations Program at USF Health Morsani College of Medicine for their continued support.	Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Castelnuovo B, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/736938; Dao H, 2007, AM J OBSTET GYNECOL, V197, pS42, DOI 10.1016/j.ajog.2007.03.001; Cuong DD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2017-x; Cuong DD, 2012, FUTURE VIROL, V7, P923, DOI 10.2217/FVL.12.83; Estill J, 2016, LANCET HIV, V3, pE132, DOI 10.1016/S2352-3018(16)00016-3; Estill J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057611; Fhi360 V UNAIDS & PEPFAR, 2015, RES VIETN ART CASC C; Ford N, 2014, AIDS, V28, P2003, DOI 10.1097/QAD.0000000000000406; Gudo ES, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-211; HEPS- Uganda, 2015, VIR LOAD TEST HIV TR; Huong DTM, 2011, INT J STD AIDS, V22, P659, DOI 10.1258/ijsa.2011.010515; Kantor R, 2009, CLIN INFECT DIS, V49, P454, DOI 10.1086/600396; Keiser O, 2009, AIDS, V23, P1867, DOI 10.1097/QAD.0b013e32832e05b2; Laurent C, 2011, LANCET INFECT DIS, V11, P825, DOI 10.1016/S1473-3099(11)70168-2; Lynen L, 2010, CURR OPIN HIV AIDS, V5, P1, DOI 10.1097/COH.0b013e3283333762; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Meya D, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-3; Ministry of Health, 2007, NAT GUID US ANT THER; MOH, 2014, VIETN AIDS RESP PROG; Moore DM, 2008, JAIDS-J ACQ IMM DEF, V49, P477, DOI 10.1097/QAI.0b013e318186eb18; Petersen ML, 2008, AIDS, V22, P2097, DOI 10.1097/QAD.0b013e32830f97e2; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; R-Core-Team, 2016, LANG ENV STAT COMP; Rangarajan S, 2016, J VIRUS ERAD, V2, P94; Rewari BB, 2010, JAIDS-J ACQ IMM DEF, V55, P610, DOI 10.1097/QAI.0b013e3181f43a31; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Roberts T, 2016, CLIN INFECT DIS, V62, P1043, DOI 10.1093/cid/ciw001; Rutherford GW, 2014, AIDS, V28, pS161, DOI 10.1097/QAD.0000000000000236; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Stevenson M., 2016, EPIR TOOLS ANAL EPID; Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745; Trinh TT, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/230953; UNAIDS, 2014, 90 90 90 AMB TREATM; Vietnam Authority of HIV/AIDS Control, 2012, VIETN HIV AIDS EST P; WHO, 2010, ANT THER HIV INF AD; WHO, 2016, CONGUID UANT DRU	38	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0182688	10.1371/journal.pone.0182688	http://dx.doi.org/10.1371/journal.pone.0182688			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877173	gold, Green Published, Green Submitted			2023-01-03	WOS:000409391200016
J	Saito, Y; Yamamoto, H; Nakajima, H; Takahashi, O; Komatsu, Y				Saito, Yuki; Yamamoto, Hiroyuki; Nakajima, Hideki; Takahashi, Osamu; Komatsu, Yasuhiro			Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors	PLOS ONE			English	Article							RENIN-ANGIOTENSIN SYSTEM; DRUGS	Introduction Renin-angiotensin system (RAS) inhibitors have been increasingly prescribed due to their beneficial effects on end-organ protection. Iatrogenic hyperkalemia is a well-known life-threatening complication of RAS inhibitor use in chronic kidney disease (CKD) patients. We hypothesized that CKD patients treated with RAS inhibitors frequently develop hyperkalemia after hospital discharge even if they were normokalemic during their hospitalization because their lifestyles change substantially after discharge. The present study aimed to examine the incidence of newly diagnosed hyperkalemia, the timing of hyperkalemia, and its risk factors in CKD patients treated with RAS inhibitors at the time of hospital discharge. Methods We retrospectively enrolled patients aged 20 years or older with CKD G3-5 (estimated glomerular filtration rate < 60 mL/min/1.73 m(2)) and who were treated with RAS inhibitors and discharged from St. Luke's International Hospital between July 2011 and December 2015. Patients who were under maintenance dialysis or had hyperkalemic events before discharge were excluded. Data regarding the patients' age, sex, CKD stage, diabetes mellitus status, malignancy status, combined use of RAS inhibitors, concurrent medication, and hyperkalemic events after discharge were extracted from the hospital database. Our primary outcome was hyperkalemia, defined as serum potassium >= 5.5 mEq/L. Multiple logistic regression and Kaplan-Meier analyses were performed to identify the risk factors for and the timing of hyperkalemia, respectively. Results Among the 986 patients, 121 (12.3%) developed hyperkalemia after discharge. In the regression analysis, relative to CKD G3a, G3b [odds ratio (OR): 1.88, 95% confidence interval 1.20-2.97] and G4-5 (OR: 3.40, 1.99-5.81) were significantly associated with hyperkalemia. The use of RAS inhibitor combinations (OR: 1.92, 1.19-3.10), malignancy status (OR: 2.10, 1.14-3.86), and baseline serum potassium (OR: 1.91, 1.23-2.97) were also significantly associated with hyperkalemia. The Kaplan-Meier analysis showed that hyperkalemia was most frequent during the early period after discharge, particularly within one month. Conclusion Hyperkalemia was frequent during the early period after discharge among previously normokalemic CKD patients who were treated with RAS inhibitors. Appropriate follow-up after discharge should be required for these patients, particularly those with advanced CKD or malignancy status, such as hematological malignancy or late-stage malignancy, and those who are treated with multiple RAS inhibitors.	[Saito, Yuki; Yamamoto, Hiroyuki; Komatsu, Yasuhiro] St Lukes Int Hosp, Dept Internal Med, Div Nephrol, Tokyo, Japan; [Saito, Yuki] Keio Univ Hosp, Div Internal Med, Tokyo, Japan; [Yamamoto, Hiroyuki] Univ Tokyo, Grad Sch Med, Dept Healthcare Qual Assessment, Tokyo, Japan; [Nakajima, Hideki] St Lukes Int Hosp, Informat Syst Ctr, Tokyo, Japan; [Takahashi, Osamu] St Lukes Int Hosp, Dept Internal Med, Div Gen Internal Med, Tokyo, Japan; [Takahashi, Osamu] St Lukes Int Univ, Grad Sch Publ Hlth, Div Clin Epidemiol, Tokyo, Japan	St. Luke's International Hospital; Keio University; University of Tokyo; St. Luke's International Hospital; St. Luke's International Hospital; St. Luke's International Hospital	Yamamoto, H; Komatsu, Y (corresponding author), St Lukes Int Hosp, Dept Internal Med, Div Nephrol, Tokyo, Japan.; Yamamoto, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Healthcare Qual Assessment, Tokyo, Japan.	yama-h@umin.ac.jp; komayasu@luke.ac.jp	Komatsu, Yasuhiro/AAW-1969-2020	Yamamoto, Hiroyuki/0000-0003-3337-7595; Saito, Yuki/0000-0003-2686-9604				Acker CG, 1998, ARCH INTERN MED, V158, P917, DOI 10.1001/archinte.158.8.917; Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111/j.1365-2141.2004.05094.x; Christiansen CF, 2011, EUR J INTERN MED, V22, P399, DOI 10.1016/j.ejim.2011.05.005; Drewnowski A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006625; Einhorn LM, 2009, ARCH INTERN MED, V169, P1156, DOI 10.1001/archinternmed.2009.132; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Fleet JL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-002011; Hersh AM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000116; Imai E, 2009, CLIN EXP NEPHROL, V13, P621, DOI 10.1007/s10157-009-0199-x; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kuijvenhoven MA, 2013, INT J CLIN PHARM-NET, V35, P1099, DOI 10.1007/s11096-013-9830-8; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; Lafrance JP, 2012, AM J KIDNEY DIS, V60, P82, DOI 10.1053/j.ajkd.2012.02.328; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Palmer BF, 2015, CLIN J AM SOC NEPHRO, V10, P1050, DOI 10.2215/CJN.08580813; Perazella MA, 2000, AM J MED, V109, P307, DOI 10.1016/S0002-9343(00)00496-4; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RIMMER JM, 1987, ARCH INTERN MED, V147, P867, DOI 10.1001/archinte.147.5.867; Sarafidis PA, 2012, CLIN J AM SOC NEPHRO, V7, P1234, DOI 10.2215/CJN.01150112; Sica Domenic A, 2006, J Clin Hypertens (Greenwich), V8, P67, DOI 10.1111/j.1524-6175.2006.05139.x; The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Workgroup, 2004, AM J KIDNEY DIS, V43, P11, DOI [10.1053/j.ajkd.2004.03.003, DOI 10.1053/J.AJKD.2004.03.003]; Toto RD, 2010, CURR OPIN NEPHROL HY, V19, P444, DOI 10.1097/MNH.0b013e32833ce6d5; Vest JR, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-88; Weir MA, 2010, CLIN J AM SOC NEPHRO, V5, P1544, DOI 10.2215/CJN.01970310; Weir MR, 2007, CLIN THER, V29, P1803, DOI 10.1016/j.clinthera.2007.09.019; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zhou BF, 2003, J HUM HYPERTENS, V17, P623, DOI 10.1038/sj.jhh.1001605	29	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184402	10.1371/journal.pone.0184402	http://dx.doi.org/10.1371/journal.pone.0184402			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877239	gold, Green Submitted, Green Published			2023-01-03	WOS:000409391200098
J	Lasser, KE				Lasser, Karen E.			Prescription Opioid Use Among US Adults: Our Brave New World	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEALTH; CARE; DISPARITIES		[Lasser, Karen E.] Boston Med Ctr, 801 Massachusetts Ave,2094, Boston, MA 02118 USA; [Lasser, Karen E.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Lasser, Karen E.] Sch Publ Hlth, Boston, MA USA	Boston Medical Center; Boston University	Lasser, KE (corresponding author), Boston Med Ctr, 801 Massachusetts Ave,2094, Boston, MA 02118 USA.	karen.lasser@bmc.org			National Institute on Drug Abuse of the National Institutes of Health [1R01 DA034252]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA034252] Funding Source: NIH RePORTER	National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Grant Support: Dr. Lasser is supported by grant 1R01 DA034252 from the National Institute on Drug Abuse of the National Institutes of Health.	Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Lasser KE, 2006, AM J PUBLIC HEALTH, V96, P1300, DOI 10.2105/AJPH.2004.059402; Lasser KE, 2018, HEALTH SERV RES, V53, P1727, DOI 10.1111/1475-6773.12710; Lewin ME, 2007, HEALTH AFFAIR, V26, P1490, DOI 10.1377/hlthaff.26.5.1490; Liebschutz J, 2017, JAMA INTERN IN PRESS; McCormick D, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1480; Parsons JK, 2010, CANCER-AM CANCER SOC, V116, P1378, DOI 10.1002/cncr.24856; Schroeder SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMsa073350; Vance J.D., 2016, HILLBILLY ELEGY	9	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2017	167	5					351	352		10.7326/M17-1559	http://dx.doi.org/10.7326/M17-1559			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF6LC	28761948				2023-01-03	WOS:000409120400009
J	[Anonymous]				[Anonymous]			"Found: A One Day Cure for Syphilis" (Reprinted from JAMA, vol 1201, pg 48-49, 1942)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		2017, JAMA, V318, P871	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 5	2017	318	9					871	871		10.1001/jama.2017.10226	http://dx.doi.org/10.1001/jama.2017.10226			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF7GE	28873151				2023-01-03	WOS:000409183700028
J	Tsuda, T; Kaibori, M; Hishikawa, H; Nakatake, R; Okumura, T; Ozeki, E; Hara, I; Morimoto, Y; Yoshii, K; Kon, M				Tsuda, Takumi; Kaibori, Masaki; Hishikawa, Hidehiko; Nakatake, Richi; Okumura, Tadayoshi; Ozeki, Eiichi; Hara, Isao; Morimoto, Yuji; Yoshii, Kengo; Kon, Masanori			Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma	PLOS ONE			English	Article							SPINAL METASTASIS; DELAYS PARALYSIS; CANCER; SORAFENIB; TUMORS	Background Anticancer agents and operating procedures have been developed for hepatocellular carcinoma (HCC) patients, but their prognosis remains poor. It is necessary to develop novel diagnostic and therapeutic strategies for HCC to improve its prognosis. Lactosome is a core-shell-type polymeric micelle, and enclosing labeling or anticancer agents into this micelle enables drug delivery. In this study, we investigated the diagnostic and therapeutic efficacies of indocyanine green (ICG)-loaded lactosome for near-infrared fluorescence (NIF) imaging and photodynamic therapy (PDT) for HCC. Methods The human HCC cell line HuH-7 was treated with ICG or ICG-lactosome, followed by PDT, and the cell viabilities were measured (in vitro PDT efficiency). For NIF imaging, HuH-7 cells were subcutaneously transplanted into BALB/c nude mice, followed by intravenous administration of ICG or ICG-lactosome. The transplanted animals were treated with PDT, and the antineoplastic effects were analyzed (in vivo PDT efficiency). Results PDT had toxic effects on HuH-7 cells treated with ICG-lactosome, but not ICG alone. NIF imaging revealed that the fluorescence of tumor areas in ICG-lactosome-treated animals was higher than that of contralateral regions at 24 h after injection and thereafter. PDT exerted immediate and continuous phototoxic effects in the transplanted mice treated with ICG-lactosome. Conclusions Our results demonstrate that ICG-lactosome accumulated in xenograft tumors, and that PDT had antineoplastic effects on these malignant implants. NIF imaging and PDT with ICG-lactosome could be useful diagnostic and/or therapeutic strategies for HCC.	[Tsuda, Takumi; Kaibori, Masaki; Hishikawa, Hidehiko; Nakatake, Richi; Okumura, Tadayoshi; Kon, Masanori] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan; [Ozeki, Eiichi; Hara, Isao] Shimadzu Co Ltd, Technol Res Lab, Kyoto, Japan; [Morimoto, Yuji] Natl Def Med Coll, Dept Integrat Physiol & Bionano Med, Tokorozawa, Saitama, Japan; [Yoshii, Kengo] Kyoto Prefectural Univ Med, Dept Math & Stat Med Sci, Kyoto, Japan	Kansai Medical University; Shimadzu Corporation; National Defense Medical College - Japan; Kyoto Prefectural University of Medicine	Kaibori, M (corresponding author), Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan.	Kaibori@hirakata.kmu.ac.jp	MORIMOTO, YUJI/F-2912-2019	MORIMOTO, YUJI/0000-0001-6494-413X	Japan Society for the Promotion of Science (KAKENHI) [15K10175]	Japan Society for the Promotion of Science (KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by Japan Society for the Promotion of Science (KAKENHI; grant number 15K10175).; This study was supported by the Japan Society for the Promotion of Science (KAKENHI; grant number 15K10175).	Alter M, 2015, J DTSCH DERMATOL GES, V13, P863, DOI 10.1111/ddg.12798; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; Cancer Registry and Statistics, CANC REG STAT; CHERRICK GR, 1960, J CLIN INVEST, V39, P592, DOI 10.1172/JCI104072; Engel E, 2008, INVEST OPHTH VIS SCI, V49, P1777, DOI 10.1167/iovs.07-0911; Funayama T, 2013, PHOTODIAGN PHOTODYN, V10, P374, DOI 10.1016/j.pdpdt.2013.03.002; Funayama Toru, 2012, Open Biomed Eng J, V6, P80, DOI 10.2174/1874120701206010080; Funayama T, 2012, PHOTOMED LASER SURG, V30, P47, DOI 10.1089/pho.2011.3080; Hara E, 2014, ACS MED CHEM LETT, V5, P873, DOI 10.1021/ml500112u; Harris K, 2017, CHEST, V151, P674, DOI 10.1016/j.chest.2016.05.025; Hirano T, 2007, J JPN SOC LASER SURG, V28, P122, DOI DOI 10.2530/jslsm.28.122; Ishizawa T, 2009, CANCER-AM CANCER SOC, V115, P2491, DOI 10.1002/cncr.24291; Kaibori M, 2016, CANC IMAGING, V6, P16; Kaneko J, 2014, J GASTROENTEROL, V49, P110, DOI 10.1007/s00535-013-0775-4; Lee YH, 2016, PLOS ONE, V11; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Makino A, 2007, CHEM LETT, V36, P1220, DOI 10.1246/cl.2007.1220; Makino A, 2012, J CONTROL RELEASE, V161, P821, DOI 10.1016/j.jconrel.2012.05.006; Makino A, 2009, BIOMATERIALS, V30, P5156, DOI 10.1016/j.biomaterials.2009.05.046; Mao AW, 2016, GASTROINTEST TUMORS, V3, P59, DOI 10.1159/000447512; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Oinuma T, 2015, LASER THER, V25, P87; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Schenkman Emmanuel, 2004, ScientificWorldJournal, V4 Suppl 1, P387; Tsujimoto H, 2015, ANN SURG ONCOL, V22, pS923, DOI 10.1245/s10434-015-4594-0; Tsujimoto H, 2014, CANCER SCI, V105, P1626, DOI 10.1111/cas.12553; Tsukanishi T, 2014, J PHOTOPOLYM SCI TEC, V27, P449, DOI 10.2494/photopolymer.27.449; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429	30	19	19	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0183527	10.1371/journal.pone.0183527	http://dx.doi.org/10.1371/journal.pone.0183527			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF2PY	28859104	Green Submitted, Green Published, gold			2023-01-03	WOS:000408740500020
J	Krem, MM				Krem, Maxwell M.			Man versus Nature - Also Sprach Zarathustra and an End-of-Life House Call	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Krem, Maxwell M.] Univ Louisville, Sch Med, Div Blood & Bone Marrow Transplantat, Louisville, KY 40292 USA	University of Louisville	Krem, MM (corresponding author), Univ Louisville, Sch Med, Div Blood & Bone Marrow Transplantat, Louisville, KY 40292 USA.							Meltzer K., 2013, JUNE 2013 DISTANT WO	1	0	0	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2017	377	8					709	711		10.1056/NEJMp1705492	http://dx.doi.org/10.1056/NEJMp1705492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ9IS	28834470				2023-01-03	WOS:000413090000003
J	Monge, AA; Bergamasco, RD; de Moraes, FF; Medina, A; Peralta, RM				Monge Neto, Andre Alvares; Bergamasco, Rita de Cassia; de Moraes, Flavio Faria; Neto, Antonio Medina; Peralta, Rosane Marina			Development of a technique for psyllium husk mucilage purification with simultaneous microencapsulation of curcumin	PLOS ONE			English	Article							BETA-CYCLODEXTRIN; FT-RAMAN; STABILITY; SPRAY; SOLUBILITY; NANOPARTICLES; ENCAPSULATION; MALTODEXTRIN; BIXIN; GUM	This study focused on evaluating a technique for the psyllium husk mucilage (PHM) purification with simultaneous microencapsulation of curcumin. PHM was extracted with water and purified with ethanol. For the mucilage purification and simultaneous microencapsulation, an ethanolic solution of curcumin was used. After dehydration, the samples were analysed by instrumental techniques and evaluated for thermal stability. The presence of curcumin in the solution did not impair the yield of precipitated polysaccharide. Interactions of the dye and carbohydrates were confirmed by displacement of peaks in FT-IR and FT-Raman spectroscopy. The onset temperature of degradation of microcapsules was superior to that of curcumin. Thermal stability in solution at 90 degrees C also improved. After 300 minutes of heating, the microcapsules had a remnant curcumin content exceeding 70%, while, in standard sample, the remaining curcumin content was 4.46%. Thus, the developed technique was successful on purification of PHM and microencapsulation of curcumin.	[Monge Neto, Andre Alvares; Peralta, Rosane Marina] Univ Estadual Maringa, Postgrad Program Food Sci, Maringa, Parana, Brazil; [Bergamasco, Rita de Cassia] Univ Estadual Maringa, Dept Food Engn, Maringa, Parana, Brazil; [de Moraes, Flavio Faria] Univ Estadual Maringa, Dept Chem Engn, Maringa, Parana, Brazil; [Neto, Antonio Medina] Univ Estadual Maringa, Dept Phys, Maringa, Parana, Brazil; [Peralta, Rosane Marina] Univ Estadual Maringa, Dept Biochem, Maringa, Parana, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa	Monge, AA (corresponding author), Univ Estadual Maringa, Postgrad Program Food Sci, Maringa, Parana, Brazil.	andre.monge@outlook.com	PERALTA, ROSANE MARINA/J-3912-2016; Medina, Antonio N/H-3244-2012	PERALTA, ROSANE MARINA/0000-0001-5749-0723; Medina, Antonio N/0000-0003-2885-457X; Monge Neto, Andre/0000-0003-4166-3751	Brazilian Agency CAPES; Brazilian Agency CNPq; Brazilian Agency FINEP; Brazilian Agency Fundadcao Araucaria	Brazilian Agency CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Brazilian Agency CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian Agency FINEP(Financiadora de Inovacao e Pesquisa (Finep)); Brazilian Agency Fundadcao Araucaria	This study was funded by Brazilian Agencies CAPES, CNPq, FINEP and Fundadcao Araucaria. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017; Ahmadi R, 2012, J FOOD ENG, V109, P745, DOI 10.1016/j.jfoodeng.2011.11.010; Association of Official Analytical Chemists, 1995, OFF METH AN AOAC INT; Barbosa MIMJ, 2005, FOOD RES INT, V38, P989, DOI 10.1016/j.foodres.2005.02.018; Cano-Higuita DM, 2015, J FOOD PROCESS PRES, V39, P2049, DOI 10.1111/jfpp.12448; Craeyveld V. van, 2009, Food Chemistry, V112, P812, DOI 10.1016/j.foodchem.2008.06.035; Lobato KBD, 2015, LWT-FOOD SCI TECHNOL, V60, P8, DOI 10.1016/j.lwt.2014.09.044; Desai KGH, 2005, DRY TECHNOL, V23, P1361, DOI 10.1081/DRT-200063478; Donsi F, 2017, FOOD HYDROCOLLOID, V63, P508, DOI 10.1016/j.foodhyd.2016.09.039; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Favaro-Trindade CS, 2010, FOOD HYDROCOLLOID, V24, P336, DOI 10.1016/j.foodhyd.2009.10.012; Gharibzahedi SMT, 2013, CARBOHYD POLYM, V92, P2002, DOI 10.1016/j.carbpol.2012.11.083; Gharsallaoui A, 2007, FOOD RES INT, V40, P1107, DOI 10.1016/j.foodres.2007.07.004; Guo Q, 2009, FOOD HYDROCOLLOID, V23, P1542, DOI 10.1016/j.foodhyd.2008.10.012; Iqbal MS, 2011, CARBOHYD POLYM, V86, P1775, DOI 10.1016/j.carbpol.2011.07.020; Kaushik P, 2015, J FUNCT FOODS, V19, P868, DOI [10.1016/j.jff.2014.06.029, 10.1016/j.jssas.2014.08.001]; Kolev TM, 2005, INT J QUANTUM CHEM, V102, P1069, DOI 10.1002/qua.20469; Krausz AE, 2015, NANOMED-NANOTECHNOL, V11, P195, DOI 10.1016/j.nano.2014.09.004; Ladjevardi ZS, 2015, CARBOHYD POLYM, V125, P272, DOI 10.1016/j.carbpol.2015.02.051; Laokuldilok N, 2016, FOOD CHEM, V194, P695, DOI 10.1016/j.foodchem.2015.07.150; Laokuldilok T, 2017, J FOOD PROCESS PRES, V41, DOI 10.1111/jfpp.12877; Li JL, 2016, FOOD HYDROCOLLOID, V56, P41, DOI 10.1016/j.foodhyd.2015.11.024; Liu WJ, 2016, J FOOD ENG, V169, P189, DOI 10.1016/j.jfoodeng.2015.08.034; Mangolim CS, 2014, FOOD CHEM, V153, P361, DOI 10.1016/j.foodchem.2013.12.067; Marcolino VA, 2011, J AGR FOOD CHEM, V59, P3348, DOI 10.1021/jf104223k; Medina-Torres L, 2013, LWT-FOOD SCI TECHNOL, V50, P642, DOI 10.1016/j.lwt.2012.07.038; Mishra A, 2002, IRAN POLYM J, V11, P381; Mohan PRK, 2012, VIB SPECTROSC, V62, P77, DOI 10.1016/j.vibspec.2012.05.002; Paramera EI, 2011, FOOD CHEM, V125, P913, DOI 10.1016/j.foodchem.2010.09.071; Philippe S, 2006, J AGR FOOD CHEM, V54, P5113, DOI 10.1021/jf060466m; Poshadri A., 2010, Journal of Research ANGRAU, V38, P86; Rao M. R. P., 2011, International Journal of PharmTech Research, V3, P1191; Ray S, 2016, FOOD BIOSCI, V13, P76, DOI 10.1016/j.fbio.2015.12.009; Saenz C, 2009, FOOD CHEM, V114, P616, DOI 10.1016/j.foodchem.2008.09.095; Sarossy Z, 2013, FOOD HYDROCOLLOID, V30, P206, DOI 10.1016/j.foodhyd.2012.05.022; Serna-Cock L, 2012, VITAE, V19, P168; Singh B, 2007, INT J PHARMACEUT, V334, P1, DOI 10.1016/j.ijpharm.2007.01.028; Sousdaleff M, 2013, J AGR FOOD CHEM, V61, P955, DOI 10.1021/jf304047g; Wang Y, 2009, INT J FOOD MICROBIOL, V136, P71, DOI 10.1016/j.ijfoodmicro.2009.09.001; Yallapu MM, 2010, J COLLOID INTERF SCI, V351, P19, DOI 10.1016/j.jcis.2010.05.022	40	3	4	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2017	12	8							e0182948	10.1371/journal.pone.0182948	http://dx.doi.org/10.1371/journal.pone.0182948			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD9QG	28817614	Green Published, gold, Green Submitted			2023-01-03	WOS:000407856600054
J	Cordovilla-Guardia, S; Fernandez-Mondejar, E; Vilar-Lopez, R; Navas, JF; Portillo-Santamaria, M; Rico-Martin, S; Lardelli-Claret, P				Cordovilla-Guardia, Sergio; Fernandez-Mondejar, Enrique; Vilar-Lopez, Raquel; Navas, Juan F.; Portillo-Santamaria, Monica; Rico-Martin, Sergio; Lardelli-Claret, Pablo			Effect of a brief intervention for alcohol and illicit drug use on trauma recidivism in a cohort of trauma patients	PLOS ONE			English	Article							BRIEF MOTIVATIONAL INTERVENTION; RANDOMIZED CLINICAL-TRIAL; EMERGENCY-DEPARTMENTS; INJURED PATIENTS; RISK; DRINKING; MISUSE; ADOLESCENTS; IMPULSIVITY; PREVALENCE	Objective Estimate the effectiveness of brief interventions in reducing trauma recidivism in hospitalized trauma patients who screened positive for alcohol and/or illicit drug use. Methods Dynamic cohort study based on registry data from 1818 patients included in a screening and brief intervention program for alcohol and illicit drug use for hospitalized trauma patients. Three subcohorts emerged from the data analysis: patients who screened negative, those who screened positive and were offered brief intervention, and those who screened positive and were not offered brief intervention. Follow-up lasted from 10 to 52 months. Trauma-free survival, adjusted hazard rate ratios (aHRR) and adjusted incidence rate ratios (aIRR) were calculated, and complier average causal effect (CACE) analysis was used. Results We found a higher cumulative risk of trauma recidivism in the subcohort who screened positive. In this subcohort, an aHRR of 0.63 (95% CI: 0.41-0.95) was obtained for the group offered brief intervention compared to the group not offered intervention. CACE analysis yielded an estimated 52% reduction in trauma recidivism associated with the brief intervention. Conclusion The brief intervention offered during hospitalization in trauma patients positive for alcohol and/or illicit drug use can halve the incidence of trauma recidivism.	[Cordovilla-Guardia, Sergio; Rico-Martin, Sergio] Univ Extremadura, Nursing & Occupat Therapy Coll, Nursing Dept, Caceres, Spain; [Fernandez-Mondejar, Enrique] Complejo Hosp Univ Granada, Serv Med Intens, Granada, Spain; [Fernandez-Mondejar, Enrique; Lardelli-Claret, Pablo] Inst Invest Biosanitaria IBS, Granada, Spain; [Vilar-Lopez, Raquel] Univ Granada, Dept Personal Evaluat & Psychol Treatment, Granada, Spain; [Vilar-Lopez, Raquel] Spanish Minist, Inst Salud Carlos III, RTA, Addict Disorders Network, Madrid, Spain; [Vilar-Lopez, Raquel; Navas, Juan F.] Univ Granada, Mind Brain & Behav Res Ctr, Granada, Spain; [Navas, Juan F.] Univ Granada, Dept Expt Psychol, Granada, Spain; [Portillo-Santamaria, Monica] Hosp La Ribera, Serv Salud Mental, Valencia, Spain; [Lardelli-Claret, Pablo] Univ Granada, Sch Med, Dept Prevent Med & Publ Hlth, Granada, Spain; [Lardelli-Claret, Pablo] CIBER Epidemiol & Publ Health, Madrid, Spain	Universidad de Extremadura; University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; Instituto de Salud Carlos III; University of Granada; University of Granada; University of Granada; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Cordovilla-Guardia, S (corresponding author), Univ Extremadura, Nursing & Occupat Therapy Coll, Nursing Dept, Caceres, Spain.	cordovilla@unex.es	Navas, Juan/AAD-3302-2019; Vilar-López, Raquel/I-7847-2016; Sergio, Cordovilla-Guardia/I-7268-2019; Martín, Sergio Rico/ABE-4372-2020	Vilar-López, Raquel/0000-0001-9639-0143; Sergio, Cordovilla-Guardia/0000-0001-7651-5017; Martín, Sergio Rico/0000-0003-4932-1940; Navas, Juan. F./0000-0002-9521-6642	Direccion General de Trafico, Spain [0100DGT22389]; Consejeria de Salud, Junta de Andalucia, Spain [PI-0691-2013]; Spanish Ministry of Education, Culture and Sport [FPU13/00669]	Direccion General de Trafico, Spain; Consejeria de Salud, Junta de Andalucia, Spain(Junta de Andalucia); Spanish Ministry of Education, Culture and Sport	This work was supported by the Direccion General de Trafico, Spain [grant number: 0100DGT22389] http://www.dgt.es/ (EFM); and the Consejeria de Salud, Junta de Andalucia, Spain [grant number: PI-0691-2013] http://www.juntadeandalucia.es/salud/sites/csalud/portal/index.jsp (RVL). JFN is funded by an individual research grant from the Spanish Ministry of Education, Culture and Sport (FPU13/00669) http://www.mecd.gob.es/portada-mecd/. The study sponsors had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.	American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; [Anonymous], 2009, AM J PHARM EDUC; Babor Thomas F, 2007, Subst Abus, V28, P7, DOI 10.1300/J465v28n03_03; Bogenschutz MP, 2014, JAMA INTERN MED, V174, P1736, DOI 10.1001/jamainternmed.2014.4052; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Claassen CA, 2007, J EMERG MED, V32, P141, DOI 10.1016/j.jemermed.2006.05.041; Cochran G, 2016, INJURY PREV, V22, P221, DOI 10.1136/injuryprev-2015-041596; Cochran G, 2014, SUBST ABUS, V35, P153, DOI 10.1080/08897077.2013.820679; Coghlan M, 2010, ACCIDENT ANAL PREV, V42, P476, DOI 10.1016/j.aap.2009.09.010; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Guardia SC, 2013, MED INTENSIVA, V37, P6, DOI 10.1016/j.medin.2012.04.010; Cordovilla-Guardia S, 2014, EUR J TRAUMA EMERG S, V40, P693, DOI 10.1007/s00068-014-0384-9; D'Onofrio G, 2012, ANN EMERG MED, V60, P181, DOI 10.1016/j.annemergmed.2012.02.006; Darnell D, 2016, J SUBST ABUSE TREAT, V60, P36, DOI 10.1016/j.jsat.2015.05.010; Dixon SD, 2014, AM J SURG, V207, P427, DOI 10.1016/j.amjsurg.2013.09.019; Dunn C, 2005, J TRAUMA, V59, pS88, DOI 10.1097/01.ta.0000174682.13138.a3; Farley M, 2004, J SUBST ABUSE TREAT, V27, P161, DOI 10.1016/j.jsat.2004.06.006; Field C, 2014, ANN SURG, V259, P873, DOI 10.1097/SLA.0000000000000339; Gentilello LM, 2005, ANN SURG, V241, P541, DOI 10.1097/01.sla.0000157133.80396.1c; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gonzalez-Cocina E, 2007, REV ESPANOLA CARD SC, V7, P37, DOI DOI 10.1016/S1131-3587(07)75248-2; Havard A, 2008, ADDICTION, V103, P368, DOI 10.1111/j.1360-0443.2007.02072.x; Horst S, 2012, DRUID FINAL REPORT W; Imbens GW, 2015, CAUSAL INFERENCE FOR STATISTICS, SOCIAL, AND BIOMEDICAL SCIENCES: AN INTRODUCTION, P1, DOI 10.1017/CBO9781139025751; Jakubczyk A, 2013, ACCIDENT ANAL PREV, V51, P150, DOI 10.1016/j.aap.2012.11.013; Kaner EFS, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004148.pub3, 10.1002/14651858.CD004148.pub4]; Klimas J, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-3; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; Madson MB, 2009, J SUBST ABUSE TREAT, V36, P101, DOI 10.1016/j.jsat.2008.05.005; McCoy AM, 2013, J TRAUMA ACUTE CARE, V75, P116, DOI 10.1097/TA.0b013e31829231b7; McQueen J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005191, 10.1002/14651858.CD005191.pub3]; Miller W.R., 2013, MOTIVATIONAL INTERVI, V12, P482; Miller WR, 2009, BEHAV COGN PSYCHOTH, V37, P129, DOI 10.1017/S1352465809005128; Moan IS, 2013, J STUD ALCOHOL DRUGS, V74, P114, DOI 10.15288/jsad.2013.74.114; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; Nilsen P, 2008, J SUBST ABUSE TREAT, V35, P184, DOI 10.1016/j.jsat.2007.09.008; Nunn J, 2016, INJURY, V47, P551, DOI 10.1016/j.injury.2016.01.008; Paaver M, 2013, ACCIDENT ANAL PREV, V50, P430, DOI 10.1016/j.aap.2012.05.019; Pearson MR, 2013, ACCIDENT ANAL PREV, V53, P142, DOI 10.1016/j.aap.2013.01.009; Ramchand R, 2009, J TRAUMA, V66, P1461, DOI 10.1097/TA.0b013e318184821d; Richer I, 2009, ACCIDENT ANAL PREV, V41, P299, DOI 10.1016/j.aap.2008.12.004; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Saitz R, 2014, JAMA-J AM MED ASSOC, V312, P502, DOI 10.1001/jama.2014.7862; Soderstrom CA, 2007, J TRAUMA, V62, P1102, DOI 10.1097/TA.0b013e31804bdb26; Sommers MS, 2013, ALCOHOL CLIN EXP RES, V37, P1753, DOI 10.1111/acer.12142; Spirito A, 2004, J PEDIATR-US, V145, P396, DOI 10.1016/j.jpeds.2004.04.057; Torres A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00043; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Woodruff SI, 2014, ADDICT SCI CLIN PRAC, V9, DOI 10.1186/1940-0640-9-8; Woolard R, 2013, ADDICT BEHAV, V38, P1732, DOI 10.1016/j.addbeh.2012.09.006; Worrell SS, 2006, J TRAUMA, V60, P379, DOI 10.1097/01.ta.0000203549.15373.7b; Zatzick D, 2014, ADDICTION, V109, P754, DOI 10.1111/add.12492	52	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2017	12	8							e0182441	10.1371/journal.pone.0182441	http://dx.doi.org/10.1371/journal.pone.0182441			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD6XW	28813444	Green Published, Green Submitted, gold			2023-01-03	WOS:000407672200030
J	Chen, HR; Rairat, T; Loh, SH; Wu, YC; Vickroy, TW; Chou, CC				Chen, Hui-Ru; Rairat, Tirawat; Loh, Shih-Hurng; Wu, Yu-Chieh; Vickroy, Thomas W.; Chou, Chi-Chung			Assessment of veterinary drugs in plants using pharmacokinetic approaches: The absorption, distribution and elimination of tetracycline and sulfamethoxazole in ephemeral vegetables	PLOS ONE			English	Article							PEARL RIVER DELTA; ANTIBIOTIC-RESIDUES; SULFADIAZINE UPTAKE; WASTE STREAMS; MANURE; ENVIRONMENT; SOIL; OXYTETRACYCLINE; ACCUMULATION; SULFONAMIDES	The present study was carried out to demonstrate novel use of pharmacokinetic approaches to characterize drug behaviors/movements in the vegetables with implications to food safety. The absorption, distribution, metabolism and most importantly, the elimination of tetracycline (TC) and sulfamethoxazole (SMX) in edible plants Brassica rapa chinensis and Ipomoea aquatica grown hydroponically were demonstrated and studied using non-compartmental pharmacokinetic analysis. The results revealed drug-dependent and vegetable-dependent pharmacokinetic differences and indicated that ephemeral vegetables could have high capacity accumulating antibiotics (up to 160 mu g g(-1) for TC and 38 mu g g(-1) for SMX) within hours. TC concentration in the root (C-max) could reach 11 times higher than that in the cultivation fluid and 3-28 times higher than the petioles/stems. Based on the volume of distribution (Vss), SMX was 3-6 times more extensively distributed than TC. Both antibiotics showed evident, albeit slow elimination phase with elimination half-lives ranging from 22 to 88 hours. For the first time drug elimination through the roots of a plant was demonstrated, and by viewing the root as a central compartment and continuous infusion without a loading dose as drug administration mode, it is possible to pharmacokinetically monitor the movement of antibiotics and their fate in the vegetables with more detailed information not previously available. Phyto-pharmacokinetic could be a new area worth developing new models for the assessment of veterinary drugs in edible plants.	[Chen, Hui-Ru; Rairat, Tirawat; Wu, Yu-Chieh; Chou, Chi-Chung] Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, Taichung, Taiwan; [Loh, Shih-Hurng] Natl Def Med Ctr, Dept & Grad Inst Pharmacol, Taipei, Taiwan; [Vickroy, Thomas W.] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA	National Chung Hsing University; National Defense Medical Center; State University System of Florida; University of Florida	Chou, CC (corresponding author), Natl Chung Hsing Univ, Dept Vet Med, Coll Vet Med, Taichung, Taiwan.	ccchou@nchu.edu.tw	Rairat, Tirawat/AAX-8198-2021; Chou, Chi-Chung/AAR-5086-2021	Rairat, Tirawat/0000-0001-7966-3592; Loh, Shih-hurng/0000-0001-9269-5580; Chou, Chi-Chung/0000-0002-4622-2552	Ministry of Science and Technology, Taiwan [MOST 101-2621-M-005-002, 102-2621-M-005-002, 103-2621-M-005-001]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was funded by Ministry of Science and Technology, Taiwan, grant numbers: MOST 101-2621-M-005-002,102-2621-M-005-002, 103-2621-M-005-001 (URLs: https://www.most.gov.tw).	Agwuh KN, 2006, J ANTIMICROB CHEMOTH, V58, P256, DOI 10.1093/jac/dkl224; Ahmed MBM, 2015, J AGR FOOD CHEM, V63, P398, DOI 10.1021/jf5034637; Arikan OA, 2007, BIORESOURCE TECHNOL, V98, P169, DOI 10.1016/j.biortech.2005.10.041; Bartikova H, 2016, CHEMOSPHERE, V144, P2290, DOI 10.1016/j.chemosphere.2015.10.137; Boonsaner M, 2012, ECOTOX ENVIRON SAFE, V78, P142, DOI 10.1016/j.ecoenv.2011.11.023; Chee-Sanford JC, 2009, J ENVIRON QUAL, V38, P1086, DOI 10.2134/jeq2008.0128; Christian T, 2003, ACTA HYDROCH HYDROB, V31, P36, DOI 10.1002/aheh.200390014; Daghrir R, 2013, ENVIRON CHEM LETT, V11, P209, DOI 10.1007/s10311-013-0404-8; Du LF, 2012, AGRON SUSTAIN DEV, V32, P309, DOI 10.1007/s13593-011-0062-9; Farkas MH, 2009, ANALYST, V134, P1594, DOI 10.1039/b902147g; Gothwal R, 2015, CLEAN-SOIL AIR WATER, V43, P479, DOI 10.1002/clen.201300989; Grote M, 2007, LANDBAUFORSCH VOLK, V57, P25; Herklotz PA, 2010, CHEMOSPHERE, V78, P1416, DOI 10.1016/j.chemosphere.2009.12.048; Hirsch R, 1999, SCI TOTAL ENVIRON, V225, P109, DOI 10.1016/S0048-9697(98)00337-4; Hu XG, 2010, ENVIRON POLLUT, V158, P2992, DOI 10.1016/j.envpol.2010.05.023; Jjemba PK, 2002, AGR ECOSYST ENVIRON, V93, P267, DOI 10.1016/S0167-8809(01)00350-4; Kang DH, 2013, J AGR FOOD CHEM, V61, P9992, DOI 10.1021/jf404045m; Kemper N, 2008, ECOL INDIC, V8, P1, DOI 10.1016/j.ecolind.2007.06.002; Kim KR, 2011, WATER AIR SOIL POLL, V214, P163, DOI 10.1007/s11270-010-0412-2; Koesukwiwat U, 2007, J CHROMATOGR A, V1140, P147, DOI 10.1016/j.chroma.2006.11.099; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Kong WD, 2007, ENVIRON POLLUT, V147, P187, DOI 10.1016/j.envpol.2006.08.016; Lacy CF, DRUG INFORM HDB 2008; Li LL, 2010, PEDOSPHERE, V20, P807, DOI 10.1016/S1002-0160(10)60071-9; Li WH, 2015, ENVIRON SCI-PROC IMP, V17, P1611, DOI 10.1039/c5em00216h; Li YW, 2011, J AGR FOOD CHEM, V59, P7268, DOI 10.1021/jf1047578; Li ZJ, 2011, PEDOSPHERE, V21, P244, DOI 10.1016/S1002-0160(11)60124-0; Lin AYC, 2009, SCI TOTAL ENVIRON, V407, P3793, DOI 10.1016/j.scitotenv.2009.03.009; Lin AYC, 2008, CHEMOSPHERE, V74, P131, DOI 10.1016/j.chemosphere.2008.08.027; Liu L, 2013, ECOL ENG, V53, P138, DOI 10.1016/j.ecoleng.2012.12.033; Mathews S, 2013, ENVIRON SCI POLLUT R, V20, P4327, DOI 10.1007/s11356-013-1693-y; Michael I, 2013, WATER RES, V47, P957, DOI 10.1016/j.watres.2012.11.027; Michelini L, 2013, PLANT PHYSIOL BIOCH, V67, P55, DOI 10.1016/j.plaphy.2013.02.027; Michelini L, 2012, WATER AIR SOIL POLL, V223, P5243, DOI 10.1007/s11270-012-1275-5; Michelini L, 2015, ENVIRON SCI POLLUT R, V22, P13362, DOI 10.1007/s11356-015-4560-1; MIGLIORE L, 1995, AGR ECOSYST ENVIRON, V52, P103, DOI 10.1016/0167-8809(94)00549-T; Migliore L, 1996, AGR ECOSYST ENVIRON, V60, P121, DOI 10.1016/S0167-8809(96)01090-0; Pan M, 2016, ECOTOX ENVIRON SAFE, V126, P228, DOI 10.1016/j.ecoenv.2015.12.027; Pan M, 2014, J AGR FOOD CHEM, V62, P11062, DOI 10.1021/jf503850v; Rang HP, 2012, RANG DALES PHARM, P99; Sarmah AK, 2006, CHEMOSPHERE, V65, P725, DOI 10.1016/j.chemosphere.2006.03.026; Seo Youngho, 2010, [Korean Journal of Soil Science & Fertilizer, 한국토양비료학회지(Korean Journal of Soil Science and Fertilizer)], V43, P466; Singh OV, 2003, APPL MICROBIOL BIOT, V63, P128, DOI 10.1007/s00253-003-1425-1; Thiele-Bruhn S, 2003, J PLANT NUTR SOIL SC, V166, P145, DOI 10.1002/jpln.200390023; Yoshida S., 1976, LAB MANUAL PHYSL STU, P61	45	25	26	6	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0183087	10.1371/journal.pone.0183087	http://dx.doi.org/10.1371/journal.pone.0183087			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28797073	Green Published, gold, Green Submitted			2023-01-03	WOS:000407396200149
J	Boutevillain, L; Dupeyron, A; Rouch, C; Richard, E; Coudeyre, E				Boutevillain, Laura; Dupeyron, Arnaud; Rouch, Caroline; Richard, Emilie; Coudeyre, Emmanuel			Facilitators and barriers to physical activity in people with chronic low back pain: A qualitative study	PLOS ONE			English	Article							HOME EXERCISE; CLINICAL MANAGEMENT; SELF-MANAGEMENT; FOCUS GROUPS; BELIEFS; ADHERENCE; CARE; REHABILITATION; INTERVENTION; EXPERIENCES	Background For medical teams, one of the main objectives of rehabilitation for people with chronic low back pain is adherence to physical activity (PA). Objective The objective of this study was to identify PA barriers and facilitators in this population. Methods This qualitative study included 4 discussion groups and 16 semi-structured interviews conducted among people with non-specific chronic low back pain who were involved in a specific rehabilitation program or seen in primary care settings. Results Three main themes were identified: physical factors, psychological factors and socio-environmental factors. The main barrier to PA practice is pain. Psychological barriers were associated with the difficulty in integrating PA in the person's daily life. Environmental barriers were dominated by lack of time. Facilitators identified associated the supervised nature of the physical activity (supervision by professionals) and group practice, which improved people's adherence. Conclusion The results of this study will allow teams to target relevant educational objectives for these people and develop dedicated self-management programs.	[Boutevillain, Laura; Rouch, Caroline; Richard, Emilie; Coudeyre, Emmanuel] Ctr Hosp Univ, Serv Med Phys & Readaptat, Clermont Ferrand, France; [Boutevillain, Laura; Coudeyre, Emmanuel] Univ Clermont Auvergne, INRA, Clermont Ferrand, France; [Dupeyron, Arnaud] Ctr Hosp Univ Caremeau, Serv Med Phys & Readaptat, Fac Med Montpellier Nimes, Nimes, France; [Dupeyron, Arnaud] Univ Montpellier, Euromov, Montpellier, France	CHU Clermont Ferrand; INRAE; Universite Clermont Auvergne (UCA); Universite de Montpellier; CHU de Nimes; Universite de Montpellier	Dupeyron, A (corresponding author), Ctr Hosp Univ Caremeau, Serv Med Phys & Readaptat, Fac Med Montpellier Nimes, Nimes, France.; Dupeyron, A (corresponding author), Univ Montpellier, Euromov, Montpellier, France.	arnaud.dupeyron@umontpellier.fr		Dupeyron, Arnaud/0000-0001-5085-3739				Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Beinart NA, 2013, SPINE J, V13, P1940, DOI 10.1016/j.spinee.2013.08.027; Bronfort G, 2011, SPINE J, V11, P585, DOI 10.1016/j.spinee.2011.01.036; Bunzli S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008847; Bunzli S, 2013, CLIN J PAIN, V29, P907, DOI 10.1097/AJP.0b013e31827a6dd8; Byerly P N, 1994, J Athl Train, V29, P352; Chaory K, 2004, SPINE, V29, P908, DOI 10.1097/00007632-200404150-00018; Chou R, 2007, ANN INTERN MED, V147, P492, DOI 10.7326/0003-4819-147-7-200710020-00007; Coppack RJ, 2012, CLIN REHABIL, V26, P1032, DOI 10.1177/0269215512436613; Crowe M, 2010, J ADV NURS, V66, P1478, DOI 10.1111/j.1365-2648.2010.05316.x; Damsgard E, 2011, SCAND J CARING SCI, V25, P108, DOI 10.1111/j.1471-6712.2010.00798.x; Darlow B, 2012, EUR J PAIN, V16, P3, DOI 10.1016/j.ejpain.2011.06.006; Dima A, 2013, BRIT J GEN PRACT, V63, pE490, DOI 10.3399/bjgp13X669211; Dupeyron A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P319, DOI 10.1016/j.rehab.2011.06.001; Engers A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004057.pub3; Escolar-Reina P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-60; Figueiredo IT, 2016, ANN PHYS REHABIL MED, V59, P289, DOI 10.1016/j.rehab.2016.03.006; Friedrich M, 2005, SPINE, V30, P995, DOI 10.1097/01.brs.0000160844.71551.af; Glaser BG, 1968, DISCOVERY GROUNDED T; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Hayden JA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000335.pub2; Jordan JL, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005956.pub2; Keefe FJ, 2012, PAIN, V153, P2163, DOI 10.1016/j.pain.2012.05.030; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Liddle SD, 2007, DISABIL REHABIL, V29, P1899, DOI 10.1080/09638280701189895; Maxwell J, 2008, HDB APPL SOCIAL RES; May S, 2010, NAT REV RHEUMATOL, V6, P199, DOI 10.1038/nrrheum.2010.26; Medina-Mirapeix F, 2009, J REHABIL MED, V41, P347, DOI 10.2340/16501977-0338; Miller JS, 2009, PHYSIOTHERAPY, V95, P29, DOI 10.1016/j.physio.2007.07.009; Palazzo C, 2016, ANN PHYS REHABIL MED, V59, P107, DOI 10.1016/j.rehab.2016.01.009; Prochaska J, 1994, THE TRANSTHEORETICAL; Rainville J, 2011, SPINE J, V11, P895, DOI 10.1016/j.spinee.2011.08.006; Sallis R, 2015, PHYSICIAN SPORTSMED, V43, P22, DOI 10.1080/00913847.2015.1001938; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; Schneiders AG, 1998, MAN THER, V3, P147, DOI [10.1016/S1356-689X(98)80005-2, DOI 10.1016/S1356-689X(98)80005-2]; Slade SC, 2014, CLIN J PAIN, V30, P995, DOI 10.1097/AJP.0000000000000044; Slade SC, 2009, AUST J PHYSIOTHER, V55, P115, DOI 10.1016/S0004-9514(09)70041-8; SLUIJS EM, 1993, PHYS THER, V73, P786, DOI 10.1093/ptj/73.11.786; Snelgrove S, 2013, CHRONIC ILLN, V9, P283, DOI 10.1177/1742395313476901; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; Yvanes-Thomas M, 2002, JOINT BONE SPINE, V69, P397, DOI 10.1016/S1297-319X(02)00415-3	44	50	53	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2017	12	7							e0179826	10.1371/journal.pone.0179826	http://dx.doi.org/10.1371/journal.pone.0179826			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8DV	28742820	Green Published, Green Submitted, gold			2023-01-03	WOS:000406370000007
J	Strom, JB; Kramer, DB; Wang, Y; Shen, CY; Wasfy, JH; Landon, BE; Wilker, EH; Yeh, RW				Strom, Jordan B.; Kramer, Daniel B.; Wang, Yun; Shen, Changyu; Wasfy, Jason H.; Landon, Bruce E.; Wilker, Elissa H.; Yeh, Robert W.			Short-term rehospitalization across the spectrum of age and insurance types in the United States	PLOS ONE			English	Article							READMISSIONS REDUCTION PROGRAM; DIAGNOSES	Few studies have examined rates and causes of short-term readmissions among adults across age and insurance types. We compared rates, characteristics, and costs of 30-day readmission after all-cause hospitalizations across insurance types in the US. We retrospectively evaluated alive patients >= 18 years old, discharged for any cause, 1/1/13-11/31/13, 2006 non-federal hospitals in 21 states in the Nationwide Readmissions Database. The primary stratification variable of interest was primary insurance. Comorbid conditions were assessed based on Elixhauser comorbidities, as defined by administrative billing codes. Additional measures included diagnoses for index hospitalizations leading to rehospitalization. Hierarchical multivariable logistic regression models, with hospital site as a random effect, were used to calculate the adjusted odds of 30-day readmissions by age group and insurance categories. Cost and discharge estimates were weighted per NRD procedures to reflect a nationally representative sample. Diagnoses for index hospitalizations leading to rehospitalization were determined. Among 12,533,551 discharges, 1,818,093 (14.5%) resulted in readmission within 30 days. Medicaid insurance was associated with the highest adjusted odds ratio (AOR) for readmission both in those >= 65 years old (AOR 1.12, 95% CI 1.10-1.14; p < 0.001), and 45-64 (AOR 1.67, 95% CI 1.66-1.69; p < 0.001), and Medicare in the 18-44 group (Medicare vs. private insurance: AOR 1.99, 95% CI 1.96-2.01; p < 0.001). Discharges for psychiatric or substance abuse disorders, septicemia, and heart failure accounted for the largest numbers of readmissions, with readmission rates of 24.0%, 17.9%, 22.9% respectively. Total costs for readmissions were 50.7 billion USD, highest for Medicare (29.6 billion USD), with non-Medicare costs exceeding 21 billion USD. While Medicare readmissions account for more than half of the total burden of readmissions, costs of non-Medicare readmissions are nonetheless substantial. Medicaid patients have the highest odds of readmission in individuals older than age 44, commonly due to hospitalizations for psychiatric illness and substance abuse disorders. Medicaid patients represent a population at uniquely high risk for readmission.	[Strom, Jordan B.; Kramer, Daniel B.; Shen, Changyu; Wilker, Elissa H.; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Richard A & Susan F Smith Ctr Cardiovasc Outcomes, Boston, MA 02215 USA; [Wang, Yun] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Wasfy, Jason H.] Massachusetts Gen Hosp, Div Cardiovasc Med, Boston, MA 02114 USA; [Landon, Bruce E.] Harvard Med Sch, Dept Healthcare Policy, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yeh, RW (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Richard A & Susan F Smith Ctr Cardiovasc Outcomes, Boston, MA 02215 USA.	ryeh@bidmc.harvard.edu	Yeh, Robert/AAJ-3463-2020	Strom, Jordan/0000-0002-6592-6141	National Heart, Lung, and Blood Institute [K23HL118138, 5T32HL007374-37]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by K23HL118138 (RWY) National Heart, Lung, and Blood Institute; 5T32HL007374-37 (JBS) National Heart, Lung, and Blood Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Hospital Association, 2015, RETH HOSP READM RED; [Anonymous], 2015, BLUEPR CMS MEAS MAN; [Anonymous], SIGN MED SPEC COND; [Anonymous], 2014, MANAGEMENT STRATEGIE; [Anonymous], 2015, COST CHARG RAT FIL 2; [Anonymous], 2016, FACTS MED SPENDING F; Arbaje AI, 2008, GERONTOLOGIST, V48, P495, DOI 10.1093/geront/48.4.495; Brown D, 2014, CONSIDERATIONS INTEG; Carnahan RM, 2011, MINI SENTINEL SYSTEM, V14; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Centers for Medicare & Medicaid Services, MEAS METH REP; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Glance LG, 2016, ANN SURG, V263, P698, DOI 10.1097/SLA.0000000000001363; HCUP Cost-to-Charge Ratio Files (CCR), HEALTHC COST UT PROJ; HCUP Databases, 2006, HEALTHC COST UT PROJ; HCUP Elixhauser Comorbidity Software, 2017, HCUP EL COM SOFTW; Healthcare Cost and Utilization Project, HCUP QUAL CONTR PROC; Healthcare Cost and Utilization Project (HCUP), AG HEALTHC RES QUAL; Healthcare Cost and Utilization Project (HCUP), 2015, INTR HCUP NAT READM; Hu J, 2014, HLTH AFF, V33, P1; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Joynt KE, 2011, CIRC-CARDIOVASC QUAL, V4, P53, DOI 10.1161/CIRCOUTCOMES.110.950964; Kostick Karen, 2011, J AHIMA, V82, P60; Martsolf GR, 2016, J HLTH CARE ORG PROV, V53, P1, DOI DOI 10.1177/0046958016667596; National Academies of Sciences Engineering and Medicine, 2016, ACC SOC RISK FACT ME; Silow-Carroll S, 2011, SYNTHESIS REPORT, V1473, P1; Trudnak T, 2014, HEALTH AFFAIR, V33, P1337, DOI 10.1377/hlthaff.2013.0632; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	30	34	34	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0180767	10.1371/journal.pone.0180767	http://dx.doi.org/10.1371/journal.pone.0180767			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28700736	Green Submitted, Green Published, gold			2023-01-03	WOS:000405544800073
J	Liu, ZS; Liu, Y; Xu, HF; He, LY; Chen, YL; Fu, LX; Li, N; Lu, YH; Su, TS; Sun, JH; Wang, J; Yue, ZH; Zhang, W; Zhao, JP; Zhou, ZY; Wu, JN; Zhou, KH; Ai, YK; Zhou, J; Pang, R; Wang, Y; Qin, ZS; Yan, SY; Li, HJ; Luo, L; Liu, BY				Liu, Zhishun; Liu, Yan; Xu, Huanfang; He, Liyun; Chen, Yuelai; Fu, Lixin; Li, Ning; Lu, Yonghui; Su, Tongsheng; Sun, Jianhua; Wang, Jie; Yue, Zenghui; Zhang, Wei; Zhao, Jiping; Zhou, Zhongyu; Wu, Jiani; Zhou, Kehua; Ai, Yanke; Zhou, Jing; Pang, Ran; Wang, Yang; Qin, Zongshi; Yan, Shiyan; Li, Hongjiao; Luo, Lin; Liu, Baoyan			Effect of Electroacupuncture on Urinary Leakage Among Women With Stress Urinary Incontinence A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOUR PAD TEST; PELVIC FLOOR; PLACEBO NEEDLE; WEIGHING TEST; ICIQ; STIMULATION; MULTICENTER; MUSCLE; TESTS	IMPORTANCE Electroacupuncture involving the lumbosacral region may be effective for women with stress urinary incontinence (SUI), but evidence is limited. OBJECTIVE To assess the effect of electroacupuncture vs sham electroacupuncture for women with SUI. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized clinical trial conducted at 12 hospitals in China and enrolling 504 women with SUI between October 2013 and May 2015, with data collection completed in December 2015. INTERVENTIONS Participants were randomly assigned (1:1) to receive 18 sessions (over 6 weeks) of electroacupuncture involving the lumbosacral region (n = 252) or sham electroacupuncture (n = 252) with no skin penetration on sham acupoints. MAIN OUTCOMES AND MEASURES The primary outcome was change from baseline to week 6 in the amount of urine leakage, measured by the 1-hour pad test. Secondary outcomes included mean 72-hour urinary incontinence episodes measured by a 72-hour bladder diary (72-hour incontinence episodes). RESULTS Among the 504 randomized participants (mean [SD] age, 55.3 [8.4] years), 482 completed the study. Mean urine leakage at baseline was 18.4 g for the electroacupuncture group and 19.1 g for the sham electroacupuncture group. Mean 72-hour incontinence episodes were 7.9 for the electroacupuncture group and 7.7 for the sham electroacupuncture group. At week 6, the electroacupuncture group had greater decrease in mean urine leakage (-9.9 g) than the sham electroacupuncture group (-2.6 g) with a mean difference of 7.4 g (95% CI, 4.8 to 10.0; P < .001). During some time periods, the change in the mean 72-hour incontinence episodes from baseline was greater with electroacupuncture than sham electroacupuncture with between-group differences of 1.0 episode in weeks 1 to 6 (95% CI, 0.2-1.7; P = .01), 2.0 episodes in weeks 15 to 18 (95% CI, 1.3-2.7; P < .001), and 2.1 episodes in weeks 27 to 30 (95% CI, 1.3-2.8; P < .001). The incidence of treatment-related adverse events was 1.6% in the electroacupuncture group and 2.0% in the sham electroacupuncture group, and all events were classified as mild. CONCLUSIONS AND RELEVANCE Among women with stress urinary incontinence, treatment with electroacupuncture involving the lumbosacral region, compared with sham electroacupuncture, resulted in less urine leakage after 6 weeks. Further research is needed to understand long-term efficacy and the mechanism of action of this intervention.	[Liu, Zhishun; Xu, Huanfang; Wu, Jiani; Zhou, Jing; Pang, Ran; Wang, Yang; Qin, Zongshi; Liu, Baoyan] China Acad Chinese Med Sci, Guangan Men Hosp, Beijing, Peoples R China; [Liu, Yan; He, Liyun; Ai, Yanke; Yan, Shiyan; Li, Hongjiao; Luo, Lin] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China; [Xu, Huanfang] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Chen, Yuelai] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai, Peoples R China; [Fu, Lixin] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China; [Li, Ning] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [Lu, Yonghui] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China; [Su, Tongsheng] Shaanxi Prov Hosp Tradit Chinese Med, Xian, Peoples R China; [Sun, Jianhua] Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China; [Wang, Jie] Shanxi Hosp Integrated Tradit & Western Med, Taiyuan, Peoples R China; [Yue, Zenghui] Hunan Univ Chinese Med, Hengyang Hosp, Hengyang, Peoples R China; [Zhang, Wei] Hunan Univ Chinese Med, Hosp 1, Changsha, Hunan, Peoples R China; [Zhao, Jiping] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China; [Zhou, Zhongyu] Hubei Prov Hosp Tradit Chinese Med, Wuhan, Peoples R China; [Zhou, Kehua] Daemen Coll, Daemen Coll Phys Therapy Wound Care Clin, Amherst, NY USA	China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Shanghai University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Sichuan University; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; Nanjing University of Chinese Medicine; Hunan University of Chinese Medicine; Hunan University of Chinese Medicine; Beijing University of Chinese Medicine	Liu, BY (corresponding author), China Acad Chinese Med Sci, Dept Acupuncture & Moxibust, Guangan Men Hosp, 5 Beixiange St, Beijing 100053, Peoples R China.	baoyanjournal@163.com	Qin, Zongshi/ABE-2821-2021	Qin, Zongshi/0000-0002-8416-3426; Qin, Zongshi/0000-0001-5888-461X; Pang, Ran/0000-0001-7978-7325; Sun, Jianhua/0000-0002-3398-0346	program of "the 12th Five-year" National Science and Technology Pillar Program by Ministry of Science and Technology of the People's Republic of China [2012BAI24B01, 2012BAI24B02]	program of "the 12th Five-year" National Science and Technology Pillar Program by Ministry of Science and Technology of the People's Republic of China	This study was supported and funded by the program of "the 12th Five-year" National Science and Technology Pillar Program (2012BAI24B01; 2012BAI24B02) by the Ministry of Science and Technology of the People's Republic of China.	ABRAMS P, 1988, SCAND J UROL NEPHROL, P5; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Aksac B, 2003, GYNECOL OBSTET INVES, V56, P23, DOI 10.1159/000072327; Costantini E, 2008, UROL INT, V81, P153, DOI 10.1159/000144053; Cottenden A., 2013, INCONTINENCE 5 INT C, P149; Groutz A, 2000, J UROLOGY, V164, P698, DOI 10.1016/S0022-5347(05)67284-9; Huang L, 2008, NEUROUROL URODYNAM, V27, P522, DOI 10.1002/nau.20546; Karantanis E, 2004, INT UROGYNECOL J, V15, P111, DOI 10.1007/s00192-004-1123-2; Kobashi KC, 2017, SURG TREATMENT FEMAL; Krhut J, 2014, NEUROUROL URODYNAM, V33, P507, DOI 10.1002/nau.22436; Liebergall-Wischnitzer M, 2010, UROLOGY, V76, P1364, DOI 10.1016/j.urology.2010.05.048; Liebergall-Wischnitzer M, 2009, J WOMENS HEALTH, V18, P377, DOI 10.1089/jwh.2008.0950; Lin Alex Tong-Long, 2008, BMC Urol, V8, P2, DOI 10.1186/1471-2490-8-2; Liu BY, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000200; Liu ZS, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-315; LOSE G, 1988, UROLOGY, V32, P78, DOI 10.1016/0090-4295(88)90462-1; LOSE G, 1989, ACTA OBSTET GYN SCAN, V68, P211, DOI 10.3109/00016348909020991; Matharu GS, 2004, EUR UROL, V45, P208, DOI 10.1016/j.eururo.2003.09.006; Mo Q, 2013, BEIJING J TRADIT CHI, V32, P434; Nystrom E, 2015, NEUROUROL URODYNAM, V34, P747, DOI 10.1002/nau.22657; Punter J, COMPLIANCE PAD TESTS; Sari D, 2009, J WOUND OSTOMY CONT, V36, P429, DOI 10.1097/WON.0b013e3181aaf539; Simons AM, 2001, BRIT J OBSTET GYNAEC, V108, P315, DOI 10.1016/S0306-5456(00)00069-3; Sinclair AJ, 2011, OBSTET GYNAECOL, V13, P143, DOI 10.1576/toag.13.3.143.27665; Sjostrom M, 2013, BJU INT, V112, P362, DOI 10.1111/j.1464-410X.2012.11713.x; SMITH ARB, 1989, BRIT J OBSTET GYNAEC, V96, P24, DOI 10.1111/j.1471-0528.1989.tb01571.x; Smither Anna R, 2007, BMC Urol, V7, P2, DOI 10.1186/1471-2490-7-2; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Wang SY, 2012, BJU INT, V110, P1338, DOI 10.1111/j.1464-410X.2012.11029.x; Wang Y., 2013, ADV MATH PHYS, V2013, P7; Xu HF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150821; Yalcin I, 2010, NEUROUROL URODYNAM, V29, P344, DOI 10.1002/nau.20744; Yamanishi T, 1997, J UROLOGY, V158, P2127, DOI 10.1016/S0022-5347(01)68176-X; Yoshimura N, 2012, INT J UROL, V19, P524, DOI 10.1111/j.1442-2042.2012.02976.x; Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652	35	169	235	25	162	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2017	317	24					2493	2501		10.1001/jama.2017.7220	http://dx.doi.org/10.1001/jama.2017.7220			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY6PV	28655016	Green Published, Bronze			2023-01-03	WOS:000404106600019
J	Guidet, B; Leblanc, G; Simon, T; Woimant, M; Quenot, JP; Ganansia, O; Maignan, M; Yordanov, Y; Delerme, S; Doumenc, B; Fartoukh, M; Charestan, P; Trognon, P; Galichon, B; Javaud, N; Patzak, A; Garrouste-Orgeas, M; Thomas, C; Azerad, S; Pateron, D; Boumendil, A				Guidet, Bertrand; Leblanc, Guillaume; Simon, Tabassome; Woimant, Maguy; Quenot, Jean-Pierre; Ganansia, Olivier; Maignan, Maxime; Yordanov, Youri; Delerme, Samuel; Doumenc, Benoit; Fartoukh, Muriel; Charestan, Pierre; Trognon, Pauline; Galichon, Bertrand; Javaud, Nicolas; Patzak, Anabela; Garrouste-Orgeas, Maite; Thomas, Caroline; Azerad, Sylvie; Pateron, Dominique; Boumendil, Ariane		ICE-CUB Study Network	Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; MULTICENTER; ADMISSION; OLDER; ICU; ILLNESS; FRAILTY; BENEFIT	IMPORTANCE The high mortality rate in critically ill elderly patients has led to questioning of the beneficial effect of intensive care unit (ICU) admission and to a variable ICU use among this population. OBJECTIVE To determine whether a recommendation for systematic ICU admission in critically ill elderly patients reduces 6-month mortality compared with usual practice. DESIGN, SETTING, AND PARTICIPANTS Multicenter, cluster-randomized clinical trial of 3037 critically ill patients aged 75 years or older, free of cancer, with preserved functional status (Index of Independence in Activities of Daily Living >= 4) and nutritional status (absence of cachexia) who arrived at the emergency department of one of 24 hospitals in France between January 2012 and April 2015 and were followed up until November 2015. INTERVENTIONS Centers were randomly assigned either to use a program to promote systematic ICU admission of patients (n=1519 participants) or to follow standard practice (n=1518 participants). MAIN OUTCOMES AND MEASURES The primary outcomewas death at 6 months. Secondary outcomes included ICU admission rate, in-hospital death, functional status, and quality of life (12-Item Short Form Health Survey, ranging from 0 to 100, with higher score representing better self-reported health) at 6 months. RESULTS One patient withdrew consent, leaving 3036 patients included in the trial (median age, 85 [interquartile range, 81-89] years; 1361 [45%] men). Patients in the systematic strategy group had an increased risk of death at 6 months (45% vs 39%; relative risk [RR], 1.16; 95% CI, 1.07-1.26) despite an increased ICU admission rate (61% vs 34%; RR, 1.80; 95% CI, 1.66-1.95). After adjustments for baseline characteristics, patients in the systematic strategy group were more likely to be admitted to an ICU (RR, 1.68; 95% CI, 1.54-1.82) and had a higher risk of in-hospital death (RR, 1.18; 95% CI, 1.03-1.33) but had no significant increase in risk of death at 6 months (RR, 1.05; 95% CI, 0.96-1.14). Functional status and physical quality of life at 6 months were not significantly different between groups. CONCLUSIONS AND RELEVANCE Among critically ill elderly patients in France, a program to promote systematic ICU admission increased ICU use but did not reduce 6-month mortality. Additional research is needed to understand the decision to admit elderly patients to the ICU.	[Guidet, Bertrand; Leblanc, Guillaume; Boumendil, Ariane] Hop St Antoine, AP HP, Serv Reanimat Med, Paris, France; [Guidet, Bertrand; Simon, Tabassome; Pateron, Dominique] Univ Paris 06, Sorbonne Univ, Paris, France; [Guidet, Bertrand] INSERM, UMR S 1136, Inst Pierre Louis Epidemiol & Sante Publ, Paris, France; [Leblanc, Guillaume] Univ Laval, Dept Anesthesiol & Crit Care, Quebec City, PQ, Canada; [Simon, Tabassome] Hop St Antoine, AP HP, Dept Pharmacol, Paris, France; [Simon, Tabassome] Hop St Antoine, AP HP, Unite Rech Clin Est Parisien, Paris, France; [Woimant, Maguy] Hop Avicenne, AP HP, SAU, Bobigny, France; [Quenot, Jean-Pierre] CHU Dijon, Serv Reanimat Med, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne Franche Comte, INSERM, UMR 866, Equipe LIPNESS, Dijon, France; [Ganansia, Olivier] Hop St Joseph, SAU, Paris, France; [Maignan, Maxime] CHU Grenoble, SAU, Grenoble, France; [Yordanov, Youri; Pateron, Dominique] Hop St Antoine, AP HP, SAU, Paris, France; [Delerme, Samuel] Hop La Pitie Salpetriere, AP HP, SAU, Paris, France; [Doumenc, Benoit] Hop Cochin, AP HP, SAU, Paris, France; [Fartoukh, Muriel] Hop Tenon, AP HP, Serv Reanimat, Paris, France; [Charestan, Pierre] Hop Robert Ballanger, SAU, Aulnay Sous Bois, France; [Trognon, Pauline] Hop Notre Dame de Bon Secours, SAU, Metz, France; [Galichon, Bertrand] Hop Lariboisiere, AP HP, SAU, Paris, France; [Javaud, Nicolas] Hop Jean Verdier, SAU, Bondy, France; [Patzak, Anabela] Hop Europeen Georges Pompidou, AP HP, SAU, Paris, France; [Garrouste-Orgeas, Maite] Hop St Joseph, Serv Reanimat, Paris, France; [Thomas, Caroline] Hop St Antoine, AP HP, Serv Geriatrie Aigue, Paris, France; [Azerad, Sylvie] Hop Ambroise Pare, AP HP, Unite Rech Clin Paris Ile de France Ouest, F-92104 Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Laval University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Guidet, B (corresponding author), St Antoine Hosp, Med Intens Care Unit, 184 Rue Faubourg St Antoine, F-75012 Paris, France.	bertrand.guidet@aphp.fr		Maignan, Maxime/0000-0002-4301-4213; QUENOT, Jean-Pierre/0000-0003-2351-682X; Boumendil, Ariane/0000-0002-2552-0542	Assistance Publique-Hopitaux de Paris; Departement de la Recherche Clinique et du Developpement [K100103/IDRCB 2011-A00758-33]; Programme Hospitalier de Recherche Clinique of the French Ministry of Health [PHRC 2010 AOM10154 K100103]	Assistance Publique-Hopitaux de Paris; Departement de la Recherche Clinique et du Developpement; Programme Hospitalier de Recherche Clinique of the French Ministry of Health	This study was supported by Assistance Publique-Hopitaux de Paris, Departement de la Recherche Clinique et du Developpement (project code K100103/IDRCB 2011-A00758-33). The study was funded by the Programme Hospitalier de Recherche Clinique 2010 of the French Ministry of Health and (grant PHRC 2010 AOM10154 K100103).	Andersen FH, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0053-0; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P2, DOI 10.1016/j.jclinepi.2008.11.004; Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7768; Boumendil A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034387; Boumendil A, 2011, ARCH INTERN MED, V171, P1116, DOI 10.1001/archinternmed.2011.102; Chin-Yee N, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1689-y; Duke GJ, 2014, MED J AUSTRALIA, V200, P323, DOI 10.5694/mja13.10132; Flaatten H, 2017, INTENS CARE MED, V43, P1319, DOI 10.1007/s00134-017-4718-z; Fuchs L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093234; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Heyland D, 2015, CRIT CARE MED, V43, P1352, DOI 10.1097/CCM.0000000000001024; Heyland DK, 2015, INTENS CARE MED, V41, P1911, DOI 10.1007/s00134-015-4028-2; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Le Maguet P, 2014, INTENS CARE MED, V40, P674, DOI 10.1007/s00134-014-3253-4; Leblanc G, 2017, INTENS CARE MED, V43, P217, DOI 10.1007/s00134-016-4477-2; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Ospina-Tascon GA, 2008, CRIT CARE MED, V36, P1311, DOI 10.1097/CCM.0b013e318168ea3e; Packham V, 2015, CLIN MED, V15, P388, DOI 10.7861/clinmedicine.15-4-388; Parker SL, 2012, J NEUROSURG-SPINE, V16, P61, DOI 10.3171/2011.8.SPINE1194; Pavoni V, 2012, ARCH GERONTOL GERIAT, V54, pE193, DOI 10.1016/j.archger.2011.11.013; Sprung CL, 2012, CRIT CARE MED, V40, P132, DOI 10.1097/CCM.0b013e318232d6b0; Valley TS, 2015, JAMA-J AM MED ASSOC, V314, P1272, DOI 10.1001/jama.2015.11068; Nguyen YL, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-29; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649; Zeng A, 2015, J GERONTOL A-BIOL, V70, P1586, DOI 10.1093/gerona/glv084	25	117	119	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 17	2017	318	15					1450	1459		10.1001/jama.2017.13889	http://dx.doi.org/10.1001/jama.2017.13889			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK0RM	28973065	Bronze, Green Published			2023-01-03	WOS:000413187300017
J	Schmeltz, MT; Gamble, JL				Schmeltz, Michael T.; Gamble, Janet L.			Risk characterization of hospitalizations for mental illness and/or behavioral disorders with concurrent heat-related illness	PLOS ONE			English	Article							POISSON REGRESSION APPROACH; CAUSE-SPECIFIC MORTALITY; DRUG-USE; WAVES; ADMISSIONS; CLIMATE; TEMPERATURE; MORBIDITY; HEATWAVES; IMPACTS	Background Many studies have found significant associations between high ambient temperatures and increases in heat-related morbidity and mortality. Several studies have demonstrated that increases in heat-related hospitalizations are elevated among individuals with diagnosed mental illnesses and/or behavioral disorders (MBD). However, there are a limited number of studies regarding risk factors associated with specific mental illnesses that contribute, at least in part, to heat-related illnesses (HRI) in the United States. Objective To identify and characterize individual and environmental risk factors associated with MBD hospitalizations with a concurrent HRI diagnosis. Methods This study uses hospitalization data from the Nationwide Inpatient Sample (2001-2010). Descriptive analyses of primary and secondary diagnoses of MBDs with an HRI were examined. Risk ratios (RR) were calculated from multivariable models to identify risk factors for hospitalizations among patients with mental illnesses and/or behavioral disorders and HRI. Results Nondependent alcohol/drug abuse, dementia, and schizophrenia were among the disorders that were associated with increased frequency of HRI hospitalizations among MBD patients. Increased risk of MBD hospitalizations with HRI was observed for Males (RR, 3.06), African Americans (RR, 1.16), Native Americans (RR, 1.70), uninsured (RR, 1.92), and those 40 years and older, compared to MBD hospitalizations alone. Conclusions Previous studies outside the U.S. have found that dementia and schizophrenia are significant risk factors for HRI hospitalizations. Our results suggest that hospitalizations among substance abusers may also be an important risk factor associated with heat morbidity. Improved understanding of these relative risks could help inform future public health strategies.	[Schmeltz, Michael T.] US EPA, ASPPH EPA Environm Hlth Fellowship Program, Off Res & Dev, Natl Ctr Environm Assessment, Washington, DC 20460 USA; [Gamble, Janet L.] US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Washington, DC 20460 USA	United States Environmental Protection Agency; United States Environmental Protection Agency	Schmeltz, MT (corresponding author), US EPA, ASPPH EPA Environm Hlth Fellowship Program, Off Res & Dev, Natl Ctr Environm Assessment, Washington, DC 20460 USA.	mschmeltz@gradcenter.cuny.edu		Schmeltz, Michael/0000-0003-4764-9723	U.S. Environmental Protection Agency (EPA) [X3-83555301]; Association of Schools and Programs of Public Health (ASPPH)	U.S. Environmental Protection Agency (EPA)(United States Environmental Protection Agency); Association of Schools and Programs of Public Health (ASPPH)	Michael Schmeltz was supported by the Cooperative Agreement Number X3-83555301 from the U.S. Environmental Protection Agency (EPA) and the Association of Schools and Programs of Public Health (ASPPH).	AHRQ (Agency for Healthcare Research and Quality), 2014, MENT HLTH RES FIND; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Anderson BG, 2009, EPIDEMIOLOGY, V20, P205, DOI 10.1097/EDE.0b013e318190ee08; Bark N, 1998, PSYCHIATR SERV, V49, P1088, DOI 10.1176/ps.49.8.1088; Basagana X, 2011, EPIDEMIOLOGY, V22, P765, DOI 10.1097/EDE.0b013e31823031c5; Berry HL, 2010, INT J PUBLIC HEALTH, V55, P123, DOI 10.1007/s00038-009-0112-0; Bohnert ASB, 2010, ADDICTION, V105, P1049, DOI 10.1111/j.1360-0443.2009.02887.x; Bouchama A, 2007, ARCH INTERN MED, V167, P2170, DOI 10.1001/archinte.167.20.ira70009; Chen P, 2012, J ADOLESCENT HEALTH, V50, P154, DOI 10.1016/j.jadohealth.2011.05.013; Climate Institute, 2011, CLIM SUFF REAL COST; Cotto JH, 2010, GENDER MED, V7, P402, DOI 10.1016/j.genm.2010.09.004; Crimmins A, 2016, IMPACTS CLIMATE CHAN; Crowe AV, 2000, QJM-INT J MED, V93, P147, DOI 10.1093/qjmed/93.3.147; Cusack L, 2011, J ADV NURS, V67, P915, DOI 10.1111/j.1365-2648.2010.05551.x; Deddens JA, 2008, OCCUP ENVIRON MED, V65, P501, DOI 10.1136/oem.2007.034777; Doherty TJ, 2011, AM PSYCHOL, V66, P265, DOI 10.1037/a0023141; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fritze Jessica G, 2008, Int J Ment Health Syst, V2, P13, DOI 10.1186/1752-4458-2-13; Gasparrini A, 2012, OCCUP ENVIRON MED, V69, P56, DOI 10.1136/oem.2010.059782; Hansen A, 2008, ENVIRON HEALTH PERSP, V116, P1369, DOI 10.1289/ehp.11339; Hansen AL, 2008, INT J EPIDEMIOL, V37, P1359, DOI 10.1093/ije/dyn165; HCUP (Healthcare Cost and Utilization Project), 2016, OV NAT NAT INP SAMPL; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Hess JJ, 2014, ENVIRON HEALTH PERSP, V122, P1209, DOI 10.1289/ehp.1306796; Kaiser R, 2001, AM J FOREN MED PATH, V22, P303, DOI 10.1097/00000433-200109000-00022; Keim ME, 2008, AM J PREV MED, V35, P508, DOI 10.1016/j.amepre.2008.08.022; Kingsley SL, 2016, ENVIRON HEALTH PERSP, V124, P460, DOI 10.1289/ehp.1408826; Knowlton K, 2009, ENVIRON HEALTH PERSP, V117, P61, DOI 10.1289/ehp.11594; Li B, 2012, CLIMATIC CHANGE, V110, P959, DOI [10.1007/s10584-011-0120-y, 10.1007/s10584-011-0120-v]; Li MM, 2015, INT J ENV RES PUB HE, V12, P5256, DOI 10.3390/ijerph120505256; Martin-Latry K, 2007, EUR PSYCHIAT, V22, P335, DOI 10.1016/j.eurpsy.2007.03.007; McKibben B, 2014, NEW YORK REV BOOKS, V61, P46; NIMH (National Institute of Mental Health), 2014, ANY MENT ILLN AMI US; Nitschke M, 2007, MED J AUSTRALIA, V187, P662, DOI 10.5694/j.1326-5377.2007.tb01466.x; Nordon C, 2009, AM J GERIAT PSYCHIAT, V17, P1059, DOI 10.1097/JGP.0b013e3181b7ef6e; Page LA, 2012, BRIT J PSYCHIAT, V200, P485, DOI 10.1192/bjp.bp.111.100404; Peng RD, 2011, ENVIRON HEALTH PERSP, V119, P701, DOI 10.1289/ehp.1002430; Trang PM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155609; Ramin B, 2009, J URBAN HEALTH, V86, P654, DOI 10.1007/s11524-009-9354-7; Schmeltz M., 2015, RISK FACTORS COSTS I; Schmeltz MT, 2016, CLIMATIC CHANGE, V138, P567, DOI 10.1007/s10584-016-1747-5; Schmeltz MT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118958; Semenza JC, 1999, AM J PREV MED, V16, P269, DOI 10.1016/S0749-3797(99)00025-2; Shiloh R, 2005, EUR PSYCHIAT, V20, P61, DOI 10.1016/j.eurpsy.2004.09.020; Stollberger C, 2009, EUR J NEUROL, V16, P879, DOI 10.1111/j.1468-1331.2009.02581.x; Swim J, 2009, REPORT AM PSYCHOL AS; Wang X, 2014, J AFFECT DISORDERS, V155, P154, DOI 10.1016/j.jad.2013.10.042; Wang XY, 2012, OCCUP ENVIRON MED, V69, P163, DOI 10.1136/oem.2010.062141; Watts N, 2015, LANCET, V386, P1861, DOI 10.1016/S0140-6736(15)60854-6; Westaway K, 2015, J CLIN PHARM THER, V40, P363, DOI 10.1111/jcpt.12294; Wu LT, 2012, ANN EMERG MED, V60, P172, DOI 10.1016/j.annemergmed.2012.02.003; Wu LT, 2011, ARCH GEN PSYCHIAT, V68, P1176, DOI 10.1001/archgenpsychiatry.2011.120; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	54	15	15	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2017	12	10							e0186509	10.1371/journal.pone.0186509	http://dx.doi.org/10.1371/journal.pone.0186509			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ8YP	29036206	Green Published, gold, Green Submitted			2023-01-03	WOS:000413054800044
J	Calabro, RS; Naro, A; Russo, M; Milardi, D; Leo, A; Filoni, S; Trinchera, A; Bramanti, P				Calabro, Rocco Salvatore; Naro, Antonino; Russo, Margherita; Milardi, Demetrio; Leo, Antonino; Filoni, Serena; Trinchera, Antonia; Bramanti, Placido			Is two better than one? Muscle vibration plus robotic rehabilitation to improve upper limb spasticity and function: A pilot randomized controlled trial	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; DEPRESSION RATING-SCALE; MOTOR RECOVERY; CHRONIC STROKE; INTRACORTICAL FACILITATION; POSTSTROKE DEPRESSION; ASHWORTH SCALE; EXCITABILITY; INHIBITION; MOVEMENT	Even though robotic rehabilitation is very useful to improve motor function, there is no conclusive evidence on its role in reducing post-stroke spasticity. Focal muscle vibration (MV) is instead very useful to reduce segmental spasticity, with a consequent positive effect on motor function. Therefore, it could be possible to strengthen the effects of robotic rehabilitation by coupling MV. To this end, we designed a pilot randomized controlled trial (Clinical Trial NCT03110718) that included twenty patients suffering from unilateral post-stroke upper limb spasticity. Patients underwent 40 daily sessions of Armeo-Power training (1 hour/session, 5 sessions/week, for 8 weeks) with or without spastic antagonist MV. They were randomized into two groups of 10 individuals, which received (group-A) or not (groupB) MV. The intensity of MV, represented by the peak acceleration (a-peak), was calculated by the formula (2 pi f) 2A, where f is the frequency of MV and A is the amplitude. Modified Ash-worth Scale (MAS), short intracortical inhibition (SICI), and H-max/M-max ratio (HMR) were the primary outcomes measured before and after (immediately and 4 weeks later) the end of the treatment. In all patients of group-A, we observed a greater reduction of MAS (p = 0.007, d = 0.6) and HMR (p<0.001, d = 0.7), and a more evident increase of SICI (p<0.001, d = 0.7) up to 4 weeks after the end of the treatment, as compared to group-B. Likewise, group-A showed a greater function outcome of upper limb (Functional Independence Measure p = 0.1, d = 0.7; Fugl-Meyer Assessment of the Upper Extremity p = 0.007, d = 0.4) up to 4 weeks after the end of the treatment. A significant correlation was found between the degree of MAS reduction and SICI increase in the agonist spastic muscles (p = 0.004). Our data show that this combined rehabilitative approach could be a promising option in improving upper limb spasticity and motor function. We could hypothesize that the greater rehabilitative outcome improvement may depend on a reshape of corticospinal plasticity induced by a sort of associative plasticity between Armeo-Power and MV.	[Calabro, Rocco Salvatore; Naro, Antonino; Russo, Margherita; Milardi, Demetrio; Leo, Antonino; Trinchera, Antonia; Bramanti, Placido] IRCCS Ctr Neurolesi Bonino Pulejo Messina, Messina, Italy; [Milardi, Demetrio] Univ Messina, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy; [Filoni, Serena] Fdn Ctr Riabilitaz Padre Pio Onlus, San Giovanni Rotondo, Italy	IRCCS Bonino Pulejo; University of Messina	Calabro, RS (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo Messina, Messina, Italy.	salbro77@tiscali.it	Leo, Antonino/ABI-7198-2020; calabro, rocco salvatore/L-9570-2019; Calabrò, Rocco S/K-7520-2016; Bramanti, Placido/K-5117-2016; MILARDI, DEMETRIO/AAD-7793-2019; Milardi, Demetrio/J-6587-2016; Leo, Antonino/K-7529-2016	Leo, Antonino/0000-0003-4163-5830; calabro, rocco salvatore/0000-0002-8566-3166; MILARDI, DEMETRIO/0000-0001-7311-2757; Milardi, Demetrio/0000-0001-7311-2757; Leo, Antonino/0000-0003-4163-5830; Filoni, Serena/0000-0002-6375-2360				Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386; ANGEL RW, 1963, ARCH NEUROL-CHICAGO, V8, P591, DOI 10.1001/archneur.1963.00460060021002; [Anonymous], 2017, ACTA CLIN CROAT, V53, P294; Arpinar-Avsar P, 2013, EXP BRAIN RES, V229, P103, DOI 10.1007/s00221-013-3597-y; Arwert HJ, 1997, J SHOULDER ELB SURG, V6, P360, DOI 10.1016/S1058-2746(97)90004-5; Avanzino L, 2014, CEREB CORTEX, V24, P2807, DOI 10.1093/cercor/bht139; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; Bartoli F, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/862978; Bilge C, 2008, EUR J PHYS REHAB MED, V44, P13; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Bragoni M, 2013, AM J PHYS MED REHABI, V92, P16; Brown SHM, 2010, MUSCLE NERVE, V41, P234, DOI 10.1002/mus.21470; Calabro RS, 2016, PM&R, pS1934; Caliandro P, 2012, ARCH PHYS MED REHAB, V93, P1656, DOI 10.1016/j.apmr.2012.04.002; Casale R, EUR J PHYS REHABIL M; Chang WH, 2013, J STROKE, V15, P174, DOI 10.5853/jos.2013.15.3.174; Cohen J., 2013, STAT POWER ANAL BEHA; Colomer C, 2013, NEUROLOGIA, V28, P261, DOI 10.1016/j.nrl.2012.04.017; Conrad MO, 2011, NEUROREHAB NEURAL RE, V25, P61, DOI 10.1177/1545968310378507; Cordo P, 2013, J NEUROL PHYS THER, V37, P194, DOI 10.1097/NPT.0000000000000023; Di Pino G, 2014, NAT REV NEUROL, V10, P597, DOI 10.1038/nrneurol.2014.162; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Dimitriou M, 2010, CURR BIOL, V20, P1763, DOI 10.1016/j.cub.2010.08.049; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; Donnellan C, 2010, INT J GERIATR PSYCH, V25, P1288, DOI 10.1002/gps.2482; Douven E, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0588-1; Fazekas G, 2007, J REHABIL MED, V39, P580, DOI 10.2340/16501977-0087; Frisoli A, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-36; Fukuda T.Y., 2010, J APPL RES CLIN EXP, V10, P32; Gijbels D, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-5; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Gregson JM, 2000, AGE AGEING, V29, P223, DOI 10.1093/ageing/29.3.223; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hara Yukihiro, 2015, J Nippon Med Sch, V82, P4, DOI 10.1272/jnms.82.4; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Hu XL, 2009, NEUROREHAB NEURAL RE, V23, P837, DOI 10.1177/1545968309338191; Jarrasse N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00947; Karaahmet OZ, 2017, INT J REHABIL RES, V40, P71, DOI 10.1097/MRR.0000000000000210; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Krabben T, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-44; Krebs HI, 2008, NEUROREHABILITATION, V23, P81; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Kumru H, 2012, CLIN NEUROPHYSIOL, V123, P45, DOI 10.1016/j.clinph.2011.06.036; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lewis GN, 2001, BRAIN RES, V900, P282, DOI 10.1016/S0006-8993(01)02369-1; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; Liepert J, 2010, RESTOR NEUROL NEUROS, V28, P729, DOI 10.3233/RNN-2010-0541; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P441, DOI 10.1177/1545968308328719; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P429, DOI 10.1177/1545968308331144; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P160, DOI 10.1177/1545968308320642; Lundgren-Nilsson A, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-55; Marconi B, 2011, NEUROREHAB NEURAL RE, V25, P48, DOI 10.1177/1545968310376757; Matsuzaki S, 2015, J AFFECT DISORDERS, V176, P56, DOI 10.1016/j.jad.2015.01.020; Mazzoleni S, 2014, IEEE T HAPTICS, V7, P175, DOI 10.1109/TOH.2013.73; McNickle E, 2015, J PHYSIOL-LONDON, V593, P1649, DOI 10.1113/jphysiol.2014.280453; Medical Research Council (Great Britain), 1976, AIDS EX PER NERV SYS; Mehrholz Jan, 2012, Cochrane Database Syst Rev, pCD006876, DOI 10.1002/14651858.CD006876.pub3; Merlo A, 2013, NEUROREHABILITATION, V33, P523, DOI 10.3233/NRE-130998; Michaelsen SM, 2001, STROKE, V32, P1875, DOI 10.1161/01.STR.32.8.1875; Murillo N, 2014, EUR J PHYS REHAB MED, V50, P231; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Nielsen JE, 2001, EUR J NEUROL, V8, P335, DOI 10.1046/j.1468-1331.2001.00249.x; Niogi S, 2010, FRONT NEUROANAT, V4, DOI [10.3389/neuro.05.002.2010, 10.3389/fneur.2010.00149]; Noma T, 2012, J REHABIL MED, V44, P325, DOI 10.2340/16501977-0946; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; Orsnes G, 2000, CLIN NEUROPHYSIOL, V111, P1372, DOI 10.1016/S1388-2457(00)00352-7; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Paoloni M, 2014, NEUROREHABILITATION, V35, P405, DOI 10.3233/NRE-141131; Posteraro F, 2010, J REHABIL MED, V42, P279, DOI 10.2340/16501977-0500; Radovanovic S, 2002, EXP BRAIN RES, V143, P276, DOI 10.1007/s00221-001-0994-4; Reaz MBI, 2006, BIOL PROCED ONLINE, V8, P11, DOI [10.1251/bpo115, 10.1251/bpo124]; Jimenez SR, 2015, EUR J APPL PHYSIOL, V115, P1305, DOI 10.1007/s00421-015-3108-x; Rosenkranz K, 2003, J PHYSIOL-LONDON, V551, P649, DOI 10.1113/jphysiol.2003.043752; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Seo HG, 2016, PM&R, V8, P1083, DOI 10.1016/j.pmrj.2016.03.004; Shaw L, 2000, HEALTH TECHNOL ASSES, V14, P1; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009; Sohn YH, 2003, J NEUROPHYSIOL, V90, P2303, DOI 10.1152/jn.00206.2003; Stoykov ME, 2009, NEUROREHAB NEURAL RE, V23, P945, DOI 10.1177/1545968309338190; Takeuchi N, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/128641; Taub E, 2006, Eura Medicophys, V42, P241; Tavernese E, 2013, NEUROREHABILITATION, V32, P591, DOI 10.3233/NRE-130881; Toris GT, 2012, INT MED J EXP CLIN R, V17, pRA53; Trompetto C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/354906; Tropea P, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-103; Tseng CH, 2012, J PROBABILITY STAT, V2012, P1; van Kordelaar J, 2012, EXP BRAIN RES, V221, P251, DOI 10.1007/s00221-012-3169-6; Verhoog MB, 2013, J NEUROSCI, V 33, P17197, DOI 10.1523/JNEUROSCI.3158-13.2013; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Wessel MJ, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00265; Witte JS, 2000, STAT MED, V19, P369, DOI 10.1002/(SICI)1097-0258(20000215)19:3<369::AID-SIM335>3.0.CO;2-N; Yuan HW, 2014, NEUROL SCI, V35, P171, DOI 10.1007/s10072-013-1464-z; Zariffa J, 2011, IEEE INT C REH ROB, V2011; ZARZECKI P, 1978, EXP BRAIN RES, V33, P269; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 1996, EXP BRAIN RES, V109, P127	99	37	41	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2017	12	10							e0185936	10.1371/journal.pone.0185936	http://dx.doi.org/10.1371/journal.pone.0185936			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FI6UJ	28973024	Green Published, gold, Green Submitted			2023-01-03	WOS:000412131900067
J	Kelen, D; Andorka, C; Szabo, M; Alafuzoff, A; Kaila, K; Summanen, M				Kelen, Dorottya; Andorka, Csilla; Szabo, Mikloa; Alafuzoff, Aleksander; Kaila, Kai; Summanen, Milla			Serum copeptin and neuron specific enolase are markers of neonatal distress and long-term neurodevelopmental outcome	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; PLASMA COPEPTIN; HYPOTHERMIA; VASOPRESSIN; BIOMARKERS; INFANTS; S100B; ASPHYXIA	The objective of this study was to evaluate the early changes in serial serum levels of copeptin and neuron-specific enolase (NSE) in neonates diagnosed with birth asphyxia, and to determine whether these biomarkers measured in the first 168 hours after birth are predictive of long-term neurodevelopmental outcome. Copeptin and NSE levels were measured from serum samples collected 6, 12, 24, 48, 72, and 168 hours after birth from 75 term neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) and treated with therapeutic hypothermia for 72 hours. In addition, serum copeptin levels after birth were measured from 10 HIE diagnosed neonates, who were randomized to the normothermic arm of the TOBY cohort. All neonates underwent neurodevelopmental assessment using the Bayley Scales of Infant and Toddler Development-II at two years of age. Copeptin levels were highest at 6 hours after birth and steadily decreased, whereas the highest NSE levels were measured at 24 hours after birth. The biomarker levels correlated with blood-gas parameters (base excess, pH and lactate) at 6 and 12 hours after birth. Copeptin and NSE levels in the early postnatal period were significantly higher in neonates with poor outcome compared to those with favorable outcome at two years of age. Furthermore, in the TOBY cohort, copeptin levels were significantly lower in hypothermic compared to normothermic neonates. To conclude, copeptin and NSE measured in the early postnatal period are potential prognostic biomarkers of long-term neurodevelopmental outcome in term neonates diagnosed with HIE and treated with therapeutic hypothermia.	[Kelen, Dorottya; Andorka, Csilla; Szabo, Mikloa] Semmelweis Univ, Dept Pediat 1, Budapest, Hungary; [Alafuzoff, Aleksander; Kaila, Kai; Summanen, Milla] Univ Helsinki, Dept Biosci, Helsinki, Finland; [Alafuzoff, Aleksander; Kaila, Kai; Summanen, Milla] Univ Helsinki, Neurosci Ctr, Helsinki, Finland	Semmelweis University; University of Helsinki; University of Helsinki	Kaila, K (corresponding author), Univ Helsinki, Dept Biosci, Helsinki, Finland.; Kaila, K (corresponding author), Univ Helsinki, Neurosci Ctr, Helsinki, Finland.	kai.kaila@helsinki.fi	Kaila, Kai K/R-8528-2016	Kaila, Kai K/0000-0003-0668-5955; Summanen, Milla/0000-0003-3843-2741	European Research Council [ERC-2013-AdG 341116]	European Research Council(European Research Council (ERC)European Commission)	Funding of work and materials for serum biomarker analyses was provided by the European Research Council (https://erc.europa.eu/) grant number ERC-2013-AdG 341116 (KK).	Ahearne Caroline E, 2016, World J Clin Pediatr, V5, P67, DOI 10.5409/wjcp.v5.i1.67; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bailey, 1969, MANUAL BAYLEY SCALES; Bennet L, 2010, SEMIN FETAL NEONAT M, V15, P253, DOI 10.1016/j.siny.2010.05.007; Benzing J, 2011, J CLIN ENDOCR METAB, V96, pE982, DOI 10.1210/jc.2010-2858; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Davidson JO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00198; Evers KS, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00075; GIBBS DM, 1985, ENDOCRINOLOGY, V116, P723, DOI 10.1210/endo-116-2-723; Giuseppe D, 2009, CURR NEUROVASC RES, V6, P110, DOI 10.2174/156720209788185614; Katan M, 2010, SWISS MED WKLY, V140, P11, DOI 10.4414/smw.2010.13101; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; L'Abate P, 2013, RESP PHYSIOL NEUROBI, V185, P222, DOI 10.1016/j.resp.2012.10.011; Lagercrantz H., 1998, FETAL NEONATAL PHYSL, P220; Lv HY, 2015, CLIN CHIM ACTA, V450, P282, DOI 10.1016/j.cca.2015.08.021; Maravic-Stojkovic V, 2014, ANGIOLOGY, V65, P122, DOI 10.1177/0003319712473637; Massaro AN, 2014, PEDIATR CRIT CARE ME, V15, P615, DOI 10.1097/PCC.0000000000000155; Merchant N, 2015, DEV MED CHILD NEUROL, V57, P8, DOI 10.1111/dmcn.12726; Miller SP, 2005, J PEDIATR-US, V146, P453, DOI 10.1016/j.jpeds.2004.12.026; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nickel CH, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-7; Pittman QJ, 1998, PROG BRAIN RES, V119, P383; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Roka A, 2007, ACTA PAEDIATR, V96, P1118, DOI 10.1111/j.1651-2227.2007.00361.x; Roka A, 2012, ACTA PAEDIATR, V101, P319, DOI 10.1111/j.1651-2227.2011.02480.x; Schlapbach LJ, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-38; Sharif-Naeini R, 2008, NEURON, V58, P179, DOI 10.1016/j.neuron.2008.02.013; Summanen M, 2017, NEONATOLOGY, V112, P60, DOI 10.1159/000456063; Wellmann S, 2016, OBSTET GYNECOL; Wellmann S, 2010, J CLIN ENDOCR METAB, V95, P5091, DOI 10.1210/jc.2010-1331	31	22	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2017	12	9							e0184593	10.1371/journal.pone.0184593	http://dx.doi.org/10.1371/journal.pone.0184593			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH6UK	28931055	gold, Green Submitted, Green Published			2023-01-03	WOS:000411314700024
J	Tsukamoto, H; Suga, T; Takenaka, S; Takeuchi, T; Tanaka, D; Hamaoka, T; Hashimoto, T; Isaka, T				Tsukamoto, Hayato; Suga, Tadashi; Takenaka, Saki; Takeuchi, Tatsuya; Tanaka, Daichi; Hamaoka, Takafumi; Hashimoto, Takeshi; Isaka, Tadao			An acute bout of localized resistance exercise can rapidly improve inhibitory control	PLOS ONE			English	Article							INTENSITY INTERVAL EXERCISE; MILD COGNITIVE IMPAIRMENT; EXECUTIVE FUNCTION; MUSCLE; STROOP; INTERFERENCE; PERFORMANCE; METABOLISM; ACTIVATION; DECLINE	The positive effect of acute resistance exercise on executive function, such as inhibitory control (IC), is poorly understood. Several previous studies have demonstrated this effect using whole-body resistance exercise. However, it remains unclear whether localized resistance exercise performed using only limited muscle groups could also acutely improve IC. Thus, the present study examined the effect of an acute bout of localized resistance exercise on IC. Twelve healthy men performed a color-word Stroop task (CWST) before and immediately after the experimental conditions, which consisted of 2 resistance exercises and a resting control (CON). Bilateral knee extension was used to create 2 resistance exercise conditions: light-intensity resistance exercise (LRE) and high-intensity resistance exercise (HRE) conditions, which were 40% and 80% of one-repetition maximum, respectively. The resistance exercise session was programmed for 6 sets with 10 repetitions per set. The CWST-measured IC was significantly improved immediately after both LRE and HRE, but it did not improve immediately after CON. However, the improved IC was significantly greater in HRE than in LRE. The present findings showed that IC could be rapidly improved by an acute bout of localized resistance exercise, especially with high-intensity. Therefore, we suggest that in addition to whole-body resistance exercise, localized resistance exercise performed using limited muscle groups may be sufficient for improving IC.	[Tsukamoto, Hayato; Hashimoto, Takeshi; Isaka, Tadao] Ritsumeikan Univ, Res Org Sci & Technol, Kusatsu, Shiga, Japan; [Suga, Tadashi; Takenaka, Saki; Takeuchi, Tatsuya; Tanaka, Daichi; Hashimoto, Takeshi; Isaka, Tadao] Ritsumeikan Univ, Grad Sch Sport & Hlth Sci, Kusatsu, Shiga, Japan; [Hamaoka, Takafumi] Tokyo Med Univ, Sch Med, Tokyo, Japan	Ritsumeikan University; Ritsumeikan University; Tokyo Medical University	Suga, T (corresponding author), Ritsumeikan Univ, Grad Sch Sport & Hlth Sci, Kusatsu, Shiga, Japan.	t-suga@fc.ritsumei.ac.jp	Tsukamoto, Hayato/AAE-9348-2019	Tsukamoto, Hayato/0000-0001-5512-0497	Japanese Ministry of Education, Culture, Sports, Science, and Technology [15J04023, 15K16497, 15K12676, 15H03077]	Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#15J04023 to Hayato Tsukamoto; #15K16497 to Tadashi Suga; #15K12676 to Takeshi Hashimoto; #15H03077 to Tadao Isaka).; The authors appreciate the time and effort expended by the volunteer subjects. This study was supported by Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#15J04023 to HT; #15K16497 to TS; #15K12676 to TakeH; #15H03077 to TI).	Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Bennett DA, 2002, NEUROLOGY, V59, P198, DOI 10.1212/WNL.59.2.198; Berchicci M, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00135; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Byun KH, 2014, NEUROIMAGE, V98, P336, DOI 10.1016/j.neuroimage.2014.04.067; Chang YK, 2012, BRAIN RES, V1453, P87, DOI 10.1016/j.brainres.2012.02.068; Chang YK, 2015, MED SCI SPORT EXER, V47, P159, DOI 10.1249/MSS.0000000000000383; Chang YK, 2009, J SPORT EXERCISE PSY, V31, P640, DOI 10.1123/jsep.31.5.640; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dai TH, 2001, EXP BRAIN RES, V140, P290, DOI 10.1007/s002210100815; Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461; Elmer SJ, 2011, MED SCI SPORT EXER, V43, P1940, DOI 10.1249/MSS.0b013e31821b00c5; Fabiani M, 2014, NEUROIMAGE, V85, P592, DOI 10.1016/j.neuroimage.2013.04.113; Giuliano C, 2017, INT J CARDIOL, V227, P413, DOI 10.1016/j.ijcard.2016.11.023; Hamaoka T, 1996, J APPL PHYSIOL, V81, P1410; Hung WW, 2009, AM J RESP CRIT CARE, V180, P134, DOI 10.1164/rccm.200902-0276OC; Hyodo K, 2012, NEUROBIOL AGING, V33, P2621, DOI 10.1016/j.neurobiolaging.2011.12.022; Ikeda Y, 2010, PERCEPT MOTOR SKILL, V110, P654, DOI 10.2466/PMS.110.2.654-660; Kraemer WJ, 1997, J APPL PHYSIOL, V83, P270, DOI 10.1152/jappl.1997.83.1.270; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Lin TY, 2016, IEEE T NEUR SYS REH, V24, P1, DOI 10.1109/TNSRE.2015.2429655; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Ogoh S, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12163; Ogoh S, 2010, EXP PHYSIOL, V95, P678, DOI 10.1113/expphysiol.2010.052340; Pedersen BK, 2005, BRAIN BEHAV IMMUN, V19, P371, DOI 10.1016/j.bbi.2005.04.008; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Sander M, 2010, J APPL PHYSIOL, V108, P1691, DOI 10.1152/japplphysiol.91539.2008; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; Scherder E, 2014, AM J GERIAT PSYCHIAT, V22, P782, DOI 10.1016/j.jagp.2012.12.026; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suga T, 2009, J APPL PHYSIOL, V106, P1119, DOI 10.1152/japplphysiol.90368.2008; SVEBAK S, 1985, J PERS SOC PSYCHOL, V48, P107, DOI 10.1037/0022-3514.48.1.107; Tsai CL, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00262; Tsukamoto H, 2016, PHYSIOL BEHAV, V160, P26, DOI 10.1016/j.physbeh.2016.03.029; Tsukamoto H, 2016, PHYSIOL BEHAV, V155, P224, DOI 10.1016/j.physbeh.2015.12.021; van Duinen H, 2008, HUM BRAIN MAPP, V29, P281, DOI 10.1002/hbm.20388; Venturelli M, 2012, AM J PHYSIOL-HEART C, V302, pH333, DOI 10.1152/ajpheart.00851.2011; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; Yanagisawa H, 2010, NEUROIMAGE, V50, P1702, DOI 10.1016/j.neuroimage.2009.12.023	41	25	25	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0184075	10.1371/journal.pone.0184075	http://dx.doi.org/10.1371/journal.pone.0184075			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FG0EG	28877232	Green Published, gold, Green Submitted			2023-01-03	WOS:000409391200061
J	Kang, HR; Lee, SN; Cho, YJ; Jeon, JS; Noh, H; Han, DC; Park, S; Kwon, SH				Kang, Hye Ran; Lee, Si Nae; Cho, Yun Ju; Jeon, Jin Seok; Noh, Hyunjin; Han, Dong Cheol; Park, Suyeon; Kwon, Soon Hyo			A decrease in serum creatinine after ICU admission is associated with increased mortality	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; AUGMENTED RENAL CLEARANCE; CRITICALLY-ILL PATIENTS; LONG-TERM SURVIVAL; INTENSIVE-CARE-UNIT; PROSPECTIVE COHORT; PROGNOSIS; OUTCOMES; IMPACT	Background The elevation of serum creatinine (SCr), acute kidney injury (AKI), is associated with an increase of mortality in critically ill patients. However, it is uncertain whether a decrease in SCr in the intensive care unit (ICU) has an effect on outcomes. Methods In a retrospective study, we enrolled 486 patients who had been admitted to an urban tertiary center ICU between Jan 2014 and Dec 2014. The effect of changes in SCr after ICU admission on 90 day mortality was analyzed. Patients were classified into 3 groups based on change in SCr after ICU admission: a stable SCr group (Delta SCr < 0.3mg/dL during ICU stay), a decreased SCr group (Delta SCr >= -0.3 mg/dL during ICU stay) and an increased SCr group with criteria based on the KDIGO AKI criteria. Results In total, 486 patients were identified. SCr decreased in 123 (25.3%) patients after ICU admission. AKI developed in 125 (24.4%) patients. The overall 90-day mortality rate was 29.0%. In a Kaplan-Meyer analysis, the mortality of the AKI group was higher than that of other groups (p<0.0001). Patients with a decrease in SCr had a higher mortality rate than those with stable SCr (p<0.0001). A Cox analysis showed that both a decrease in SCR (HR, 3.56; 95% CI, 1.59-7.97; p = 0.002) and an increase in SCr (AKI stage 1, HR, 9.35; 95% CI, 4.18-20.9; p<0.0001; AKI stage 2, HR, 11.82; 95% CI, 3.85-36.28; p<0.0001; AKI stage 3, HR, 17.41; 95% CI, 5.50-55.04; p<0.0001) were independent risk factors for death compared to stable SCr. Conclusion Not only an increase in SCr, but also a decrease in SCr was associated with mortality in critically ill patients.	[Kang, Hye Ran; Lee, Si Nae; Cho, Yun Ju; Jeon, Jin Seok; Noh, Hyunjin; Han, Dong Cheol; Kwon, Soon Hyo] Soonchunhyang Univ Hosp, Div Nephrol, Seoul, South Korea; [Jeon, Jin Seok; Noh, Hyunjin; Han, Dong Cheol; Kwon, Soon Hyo] Soonchunhyang Univ Hosp, Hyonam Kidney Lab, Seoul, South Korea; [Park, Suyeon] Soonchunhyang Univ Hosp, Dept Biostat, Seoul, South Korea	Soonchunhyang University; Soonchunhyang University Hospital; Soonchunhyang University; Soonchunhyang University Hospital; Soonchunhyang University; Soonchunhyang University Hospital	Kwon, SH (corresponding author), Soonchunhyang Univ Hosp, Div Nephrol, Seoul, South Korea.; Kwon, SH (corresponding author), Soonchunhyang Univ Hosp, Hyonam Kidney Lab, Seoul, South Korea.	ksoonhyo@schmc.ac.kr		Kwon, Soon Hyo/0000-0002-4114-4196	Soonchunhayng University	Soonchunhayng University	SHK received grant from Soonchunhayng University.	Baptista JP, 2012, INT J ANTIMICROB AG, V39, P420, DOI 10.1016/j.ijantimicag.2011.12.011; Baptista JP, 2011, CRIT CARE, V15, DOI 10.1186/cc10262; Claus BOM, 2013, J CRIT CARE, V28, P695, DOI 10.1016/j.jcrc.2013.03.003; Cruz DN, 2007, CRIT CARE, V11, DOI 10.1186/cc5965; Doi K, 2009, J AM SOC NEPHROL, V20, P1217, DOI 10.1681/ASN.2008060617; Group KAKIW, 2012, KDIGO CLIN PRACT GUI, P131; Hasper D, 2009, CRIT CARE, V13, DOI 10.1186/cc8144; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Kwon SH, 2011, J CRIT CARE, V26, P566, DOI 10.1016/j.jcrc.2011.01.004; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Linder A, 2014, AM J RESP CRIT CARE, V189, P1075, DOI 10.1164/rccm.201311-2097OC; Liu KD, 2011, CRIT CARE MED, V39, P2665, DOI 10.1097/CCM.0b013e318228234b; Loef BG, 2005, J AM SOC NEPHROL, V16, P195, DOI 10.1681/ASN.2003100875; Masewu A, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0333-4; Mehta RH, 2010, AM J CARDIOL, V106, P1728, DOI 10.1016/j.amjcard.2010.07.045; Nisula S, 2013, INTENS CARE MED, V39, P420, DOI 10.1007/s00134-012-2796-5; Ou SM, 2016, J CACHEXIA SARCOPENI, V7, P144, DOI 10.1002/jcsm.12053; Prowle JR, 2014, CLIN J AM SOC NEPHRO, V9, P1015, DOI 10.2215/CJN.11141113; Shacham Y, 2015, CLIN CARDIOL, V38, P274, DOI 10.1002/clc.22384; Soliman IW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1416-0; Srisawat N, 2015, AM J NEPHROL, V41, P81, DOI 10.1159/000371748; Tian JM, 2009, AM J KIDNEY DIS, V53, P974, DOI 10.1053/j.ajkd.2009.02.007; Troger U, 2012, INT J ANTIMICROB AG, V40, P370, DOI 10.1016/j.ijantimicag.2012.05.010; Udy AA, 2014, CRIT CARE MED, V42, P520, DOI 10.1097/CCM.0000000000000029; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Yoo J, 2015, KOREAN J INTERN MED, V30, P205, DOI 10.3904/kjim.2015.30.2.205	27	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2017	12	8							e0183156	10.1371/journal.pone.0183156	http://dx.doi.org/10.1371/journal.pone.0183156			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7CK	28837589	Green Published, gold, Green Submitted			2023-01-03	WOS:000408365000048
J	Weissmueller, NT; Marsay, L; Schiffter, HA; Carlisle, RC; Rollier, CS; Prud'homme, RK; Pollard, AJ				Weissmueller, Nikolas T.; Marsay, Leanne; Schiffter, Heiko A.; Carlisle, Robert C.; Rollier, Christine S.; Prud'homme, Robert K.; Pollard, Andrew J.			Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine	PLOS ONE			English	Article							CAPSULAR POLYSACCHARIDE; BALLISTIC DELIVERY; ANTIBODY-RESPONSES; INFLUENZA VACCINE; PARTICLE-SIZE; HUMAN SKIN; IMMUNOGENICITY; IMMUNIZATION; MICROPARTICLES; FORMULATION	Powder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (T-g = 45.2 +/- 0.5 degrees C) microparticles (58.1 mu m) of a MenY-CRM197 glyconjugate vaccine (0.5% wt.) for intradermal needle-free powder injection (NFPI). SFD used ultrasound atomisation of the liquid vaccine-containing excipient feed, followed by lyophilisation above the glass transition temperature (T-g' = -29.9 +/- 0.3 degrees C). This resulted in robust particles (density similar to 0.53 +/-0.09 g/cm(3)) with a narrow volume size distribution (mean diameter 58.1 mu m, and span = 1.2), and an impact parameter (rho vr similar to 11.5 kg/m.s) sufficient to breach the Stratum corneum (sc). The trehalose, manitol, dextran (10 kDa), dextran (150 kDa) formulation, or TMDD (3:3:3:1), protected the MenY-CRM197 glyconjugate during SFD with minimal loss, no detectable chemical degradation or physical aggregation. In a capsular group Y Neisseria meningitidis serum bactericidal assay (SBA) with human serum complement, the needle free vaccine, which contained no alum adjuvant, induced functional protective antibody responses in vivo of similar magnitude to the conventional vaccine injected by hypodermic needle and syringe and containing alum adjuvant. These results demonstrate that needle-free vaccination is both technically and immunologically valid, and could be considered for vaccines in development.	[Weissmueller, Nikolas T.; Marsay, Leanne; Rollier, Christine S.; Pollard, Andrew J.] Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford, Oxfordshire, England; [Weissmueller, Nikolas T.; Marsay, Leanne; Rollier, Christine S.; Pollard, Andrew J.] NIHR Oxford Biomed Res Inst, Oxford, Oxfordshire, England; [Weissmueller, Nikolas T.; Prud'homme, Robert K.] Princeton Univ, Dept Biol & Chem Engn, Princeton, NJ 08544 USA; [Weissmueller, Nikolas T.; Schiffter, Heiko A.; Carlisle, Robert C.] BUBBL, Inst Biomed Engn, Oxford, Oxfordshire, England; [Schiffter, Heiko A.] Univ Appl Sci, Dept Appl Nat Sci, Cologne, North Rhine Wes, Germany	University of Oxford; Princeton University; University of Oxford	Weissmueller, NT (corresponding author), Univ Oxford, Oxford Vaccine Grp, Dept Paediat, Oxford, Oxfordshire, England.; Weissmueller, NT (corresponding author), NIHR Oxford Biomed Res Inst, Oxford, Oxfordshire, England.; Weissmueller, NT (corresponding author), Princeton Univ, Dept Biol & Chem Engn, Princeton, NJ 08544 USA.; Weissmueller, NT (corresponding author), BUBBL, Inst Biomed Engn, Oxford, Oxfordshire, England.	ntw@princeton.edu		Weissmueller, Nikolas/0000-0003-4589-9286; Schiffter-Weinle, Heiko Alexander/0000-0003-0407-3242	Oxford Martin School, University of Oxford	Oxford Martin School, University of Oxford	This work was supported by the Oxford Martin School, University of Oxford. URL: http://www.oxfordmartin.ox.ac.uk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arora A, 2008, INT J PHARMACEUT, V364, P227, DOI 10.1016/j.ijpharm.2008.08.032; Bal SM, 2010, J CONTROL RELEASE, V148, P266, DOI 10.1016/j.jconrel.2010.09.018; Berti F, 2004, BIOPHYS J, V86, P3, DOI 10.1016/S0006-3495(04)74078-3; Blanchard-Rohner G, 2011, EXPERT REV VACCINES, V10, P673, DOI 10.1586/erv.11.14; Borrow R, 2006, VACCINE, V24, P5093, DOI 10.1016/j.vaccine.2006.03.091; Borrow R, 2000, FEMS IMMUNOL MED MIC, V28, P79, DOI 10.1111/j.1574-695X.2000.tb01460.x; Broker M, 2016, HUM VACC IMMUNOTHER, V12, P1808, DOI 10.1080/21645515.2016.1153206; Burkoth TL, 1999, CRIT REV THER DRUG, V16, P331, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i4.10; Chen Dexiang, 2002, Expert Rev Vaccines, V1, P265, DOI 10.1586/14760584.1.3.265; Chen DX, 2004, VIRUS RES, V103, P147, DOI 10.1016/j.virusres.2004.02.027; Chen DX, 2003, VACCINE, V21, P2830, DOI 10.1016/S0264-410X(03)00175-0; Chen DX, 2000, NAT MED, V6, P1187, DOI 10.1038/80538; Chiu SS, 2009, VACCINE, V27, P4834, DOI 10.1016/j.vaccine.2009.05.066; Costantino HR, 2002, J PHARM SCI-US, V91, P388, DOI 10.1002/jps.10059; Costantino HR, 2000, PHARMACEUT RES, V17, P1374, DOI 10.1023/A:1007570030368; De Gregorio E, 2014, NAT REV IMMUNOL, V14, P505, DOI 10.1038/nri3694; Dean HJ, 2004, VACCINE, V23, P681, DOI 10.1016/j.vaccine.2004.06.041; Dean HJ, 2003, COMP IMMUNOL MICROB, V26, P373, DOI 10.1016/S0147-9571(03)00021-3; GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475, DOI 10.1128/JCM.32.6.1475-1482.1994; Granoff DM, 1998, CLIN DIAGN LAB IMMUN, V5, P479, DOI 10.1128/CDLI.5.4.479-485.1998; Hancock BC, 1997, J PHARM SCI, V86, P1, DOI 10.1021/js9601896; Ho MM, 2000, VACCINE, V19, P716, DOI 10.1016/S0264-410X(00)00261-9; Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17; Johnson KA, 1997, ADV DRUG DELIVER REV, V26, P3, DOI 10.1016/S0169-409X(97)00506-1; Karande P, 2004, NAT BIOTECHNOL, V22, P192, DOI 10.1038/nbt928; Kelly DF, 2004, IMMUNOLOGY, V113, P163, DOI 10.1111/j.1365-2567.2004.01971.x; Kendall M, 2004, J BIOMECH, V37, P1733, DOI 10.1016/j.jbiomech.2004.01.032; Kendall M, 2004, J INVEST DERMATOL, V122, P739, DOI 10.1111/j.0022-202X.2004.22320.x; Kendall MAF, 2002, SHOCK WAVES, V12, P23, DOI 10.1007/s001930200126; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; LEVI G, 1995, FOOD RES INT, V28, P145, DOI 10.1016/0963-9969(95)90798-F; Levine MM, 2003, NAT MED, V9, P99, DOI 10.1038/nm0103-99; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; Liu Y, 2007, MED ENG PHYS, V29, P390, DOI 10.1016/j.medengphy.2006.05.015; Maa YF, 2004, J PHARM SCI-US, V93, P1912, DOI 10.1002/jps.20104; Maa YF, 2003, PHARMACEUT RES, V20, P969, DOI 10.1023/A:1024493719236; Maa YF, 1998, J PHARM SCI, V87, P152, DOI 10.1021/js970308x; Maury M, 2005, EUR J PHARM BIOPHARM, V59, P565, DOI 10.1016/j.ejpb.2004.10.002; McIntosh EDG, 2015, VACCINE, V33, P4414, DOI 10.1016/j.vaccine.2015.07.019; Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728; Moginger U, 2016, SCI REP-UK, V6, DOI 10.1038/srep20488; Mvundura M, 2015, VACCINE, V33, P2697, DOI 10.1016/j.vaccine.2015.03.084; Nail Steven L, 2002, Pharm Biotechnol, V14, P281; Ogura M, 2008, ADV DRUG DELIVER REV, V60, P1218, DOI 10.1016/j.addr.2008.03.006; Perrett KP, 2009, PEDIATR INFECT DIS J, V28, P186, DOI 10.1097/INF.0b013e31818e037d; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564; Rochelle C, 2007, J PHARM SCI-US, V96, P2296, DOI 10.1002/jps.20861; Rubinstein LJ, 1998, INFECT IMMUN, V66, P5450, DOI 10.1128/IAI.66.11.5450-5456.1998; Schiffter H., 2007, EUR PHARM REV, V3, P67; Schiffter H, 2010, J R SOC INTERFACE, V7, pS483, DOI 10.1098/rsif.2010.0114.focus; Snape MD, 2008, JAMA-J AM MED ASSOC, V299, P173, DOI 10.1001/jama.2007.29-c; Sonner C, 2002, J PHARM SCI-US, V91, P2122, DOI 10.1002/jps.10204; Tang XL, 2004, PHARM RES-DORDR, V21, P191, DOI 10.1023/B:PHAM.0000016234.73023.75; WAHL M, 1987, SCAND J INFECT DIS, V19, P617, DOI 10.3109/00365548709117195; Wang W, 2005, INT J PHARMACEUT, V289, P1, DOI 10.1016/j.ijpharm.2004.11.014; Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3; Weissmueller NT, 2015, CLIN VACCINE IMMUNOL, V22, P586, DOI 10.1128/CVI.00121-15; Weissmueller NT, 2013, EXPERT REV VACCINES, V12, P687, DOI [10.1586/ERV.13.48, 10.1586/erv.13.48]; Wilburn SQ, 2004, INT J OCCUP ENV HEAL, V10, P451, DOI 10.1179/oeh.2004.10.4.451; World Health Organization, 2004, SAF INJ GLOB FACTS F; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067	62	5	5	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2017	12	8							e0183427	10.1371/journal.pone.0183427	http://dx.doi.org/10.1371/journal.pone.0183427			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE7CK	28837693	Green Published, gold, Green Submitted			2023-01-03	WOS:000408365000065
J	Bifftu, BB; Dachew, BA; Tiruneh, BT; Alemu, WG				Bifftu, Berhanu Boru; Dachew, Berihun Assefa; Tiruneh, Bewket Tadesse; Alemu, Wondale Getinet			First choice of treatment place in the pathways to epileptic care at the outpatient department of University of Gondar Hospital, Northwest Ethiopia: Cross-sectional institutional based study	PLOS ONE			English	Article							PEOPLE; CHILDREN; PROGRAM; STIGMA	Background Epilepsy treatment gap range from 87% to 98%. In spite of this, there is a gross inadequacy of the availability, accessibility and affordability of Anti-Epileptic Drugs. In countries like Ethiopia, where most populations are less aware about mental health problems, most people seek help for their illness from traditional healers. Thus, the main purpose of this study was to assess the pathways to epilepsy care and associated factors. Methods Cross-sectional study design utilized among 409 participants selected by systematic random sampling technique. Pathways to epilepsy care were assessed by using the WHO Pathway Study tool. Multivariable logistic regression was done to identify factors associated with pathways to epileptic care. Results Overall, 162 (39.6%) of participants first contacted with modern treatment. Two hundred and forty seven (60.4%) of participants counted traditional healers and religious healers were the most common (47.2%). Being men, attending higher education, urban residence, short duration of illness, social support and age at the onset of illness were factors associated with first contact with modern treatment. Conclusion Modern treatment was not the first place of choice for the majority of the respondents. Strengthening awareness creation program about epilepsy and its treatment is highly recommended with special emphases to urban dwellers and less educated people.	[Bifftu, Berhanu Boru; Tiruneh, Bewket Tadesse] Univ Gondar, Coll Med & Hlth Sci, Dept Nursing, Gondar, Ethiopia; [Dachew, Berihun Assefa] Univ Gondar, Coll Med & Hlth Sci, Dept Epidemiol, Gondar, Ethiopia; [Alemu, Wondale Getinet] Univ Gondar, Coll Med & Hlth Sci, Dept Psychiat, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Bifftu, BB (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Dept Nursing, Gondar, Ethiopia.	berhanuboru@gmail.com	Alemu, Wondale Getinet/ABA-3127-2020; Dachew, Berihun Assefa/I-3111-2019	Dachew, Berihun Assefa/0000-0002-4041-6129; Bifftu, Berhanu/0000-0002-4229-847X; Tiruneh, Bewket Tadesse/0000-0003-2825-1293	University of Gondar College of Medicine and Health Science; University of Gondar, Research and Community Service Core Process	University of Gondar College of Medicine and Health Science; University of Gondar, Research and Community Service Core Process	The fund of this manuscript was covered by The University of Gondar College of Medicine and Health Science. Funder had no role in study design, data collection, analysis and decision to publish. The corresponding author had full access to all the data in the study and had accountability for the decision to prepare the manuscript and submit for publication.; Authors' gratitude goes to The University of Gondar, Research and Community Service Core Process for the initiation and financial support to conduct this study. Authors' also would like to thank the study subjects and data collectors for their willingness to participate in the study.	Aliasgharpour M, 2013, SEIZURE-EUR J EPILEP, V22, P48, DOI 10.1016/j.seizure.2012.10.005; [Anonymous], 2002, EPILEPSIA, V43, P31; [Anonymous], 2012, AFR HEALTH SCI, V12, P186; Bekele YY, 2009, PSYCHOL MED, V39, P475, DOI 10.1017/S0033291708003929; Bifftu BB, 2015, AFR HEALTH SCI, V15, P1211, DOI 10.4314/ahs.v15i4.21; Bifftu Berhanu Boru D BA, 2015, BMC RES NOTES, V8, P1; Chisholm D, 2005, EPILEPSIA, V46, P751, DOI 10.1111/j.1528-1167.2005.52704.x; Ding D, 2006, LANCET NEUROL, V5, P823, DOI 10.1016/S1474-4422(06)70528-2; Jacoby A, 2005, LANCET NEUROL, V4, P171, DOI 10.1016/S1474-4422(05)01014-8; Jantzen S, 2009, SEIZURE-EUR J EPILEP, V18, P478, DOI 10.1016/j.seizure.2009.04.007; Kebede Deribe Kassaye, 2006, Ethiopian Journal of Health Development, V20, P127; Mbuba CK, 2012, LANCET NEUROL, V11, P688, DOI 10.1016/S1474-4422(12)70155-2; Meyer AC D T, 2012, EPILEPSIA, V53, P1; Meyer AC DT, 1999, LANCET, V353, P888; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; Munthali A, 2013, AFRICAN J DISABILITY, V2, P8; Organization WH, TRAD MED STRAT; Pal DK, 2002, EPILEPSIA, V43, P904, DOI 10.1046/j.1528-1157.2002.47601.x; Radha krishnan K., 2009, NAT REV NEUROL, V5, P323; ROGLER LH, 1993, AM J PSYCHIAT, V150, P554; Shibru Berhanu, 2002, Ethiopian Journal of Health Development, V16, P235; Sinha Abhik, 2012, Indian J Community Med, V37, P25, DOI 10.4103/0970-0218.94018; Subedi s s p, 2013, J UNIVERSAL COLL MED, V1, P1; TekleHaimanot R, 1997, EPILEPSIA, V38, P541, DOI 10.1111/j.1528-1157.1997.tb01138.x; TEKLEHAIMANOT R, 1991, SOC SCI MED, V32, P203, DOI 10.1016/0277-9536(91)90061-G; Thierry Matonda Ma Nzuzi TMMN, 2016, PAN AFRICAN MED J, V23, P229	26	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2017	12	8							e0181310	10.1371/journal.pone.0181310	http://dx.doi.org/10.1371/journal.pone.0181310			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD5DG	28809921	Green Submitted, Green Published, gold			2023-01-03	WOS:000407550500003
J	Lilly, FR; Culpepper, J; Stuart, M; Steinwachs, D				Lilly, Flavius Robert; Culpepper, Joel; Stuart, Mary; Steinwachs, Donald			Stroke survivors with severe mental illness: Are they at-risk for increased non-psychiatric hospitalizations?	PLOS ONE			English	Article							HEALTH-CARE UTILIZATION; ADMINISTRATIVE DATA; MEDICAL-CARE; VETERANS; READMISSION; COMORBIDITY; PREVALENCE; PEOPLE; SCHIZOPHRENIA; MORTALITY	Background This study examined outcomes for two groups of stroke survivors treated in Veteran Health Administration (VHA) hospitals, those with a severe mental illness (SMI) and those without prior psychiatric diagnoses, to examine risk of non-psychiatric medical hospitalizations over five years after initial stroke. Methods This retrospective cohort study included 523 veterans who survived an initial stroke hospitalization in a VHA medical center during fiscal year 2003. The survivors were followed using administrative data documenting inpatient stroke treatment, patient demographics, disease comorbidities, and VHA hospital admissions. Multivariate Poisson regression was used to examine the relationship between patients with and without SMI diagnosis preceding the stroke and their experience with non-psychiatric medical hospitalizations after the stroke. Results The study included 100 patients with SMI and 423 without SMI. Unadjusted means for pre-stroke non-psychiatric hospitalizations were higher (p = 0.0004) among SMI patients (1.47 +/- 0.51) compared to those without SMI (1.00 +/- 1.33), a difference which persisted through the first year post-stroke (SMI: 2.33 +/- 2.46; No SMI: 1.74 +/- 1.86; p = 0.0004). Number of non-psychiatric hospitalizations were not significantly different between the two groups after adjustment for patient sociodemographic, comorbidity, length of stay and inpatient stroke treatment characteristics. Antithrombotic medications significantly lowered risk (OR = 0.61; 95% CI: 0.49-0.73) for stroke-related readmission within 30 days of discharge. Conclusions No significant differences in medical hospitalizations were present after adjusting for comorbid and sociodemographic characteristics between SMI and non-SMI stroke patients in the five-year follow-up. However, unadjusted results continue to draw attention to disparities, with SMI patients experiencing more non-psychiatric hospitalizations both prior to and up to one year after their initial stroke. Additionally, stroke survivors discharged on antithrombotic medications were at lower risk of re-admission within 30 days suggesting the VHA should continue to focus on effective stroke management irrespective of SMI.	[Lilly, Flavius Robert] Univ Maryland, Grad Sch, Baltimore, MD 21201 USA; [Culpepper, Joel] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD USA; [Stuart, Mary] Univ Maryland Baltimore Cty, Dept Sociol Anthropol & Hlth Adm & Policy, Baltimore, MD 21228 USA; [Steinwachs, Donald] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore County; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lilly, FR (corresponding author), Univ Maryland, Grad Sch, Baltimore, MD 21201 USA.	Flilly@umaryland.edu			VHA	VHA	The study is a subsidiary investigation of the VHA-funded study to translate exercise research into direct patient care delivery for stroke survivors. The parent study, "Translational Research for Task-Oriented Exercise in Chronic Stroke is designed to develop descriptive and comparable data to plan community based demonstration projects using Veterans Affairs administrative databases with the broad goal of improving stroke patient outcomes.	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Billings J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003352; Blank MB, 2002, PSYCHIATR SERV, V53, P868, DOI 10.1176/appi.ps.53.7.868; Borckardt Jeffrey J, 2011, Qual Manag Health Care, V20, P98, DOI 10.1097/QMH.0b013e3182134af0; Camberg LC, 1997, MED CARE, V35, P756, DOI 10.1097/00005650-199708000-00002; Culpepper WJ, 2006, J REHABIL RES DEV, V43, P17, DOI 10.1682/JRRD.2004.09.0122; Curkendall SM, 2004, J CLIN PSYCHIAT, V65, P715; Daumit GL, 2010, PSYCHIAT RES, V176, P242, DOI 10.1016/j.psychres.2009.01.006; Daumit GL, 2003, J NERV MENT DIS, V191, P799, DOI 10.1097/01.nmd.0000100923.20188.2d; De Hert M, 2011, WORLD PSYCHIATRY, V10, P52, DOI 10.1002/j.2051-5545.2011.tb00014.x; Dossa A., 2011, BIOMED CENTRAL HLTH, V11, P1; Drake RE, 2001, COMPREHENSIVE CARE S, P243; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Fleishacker W.W., 2008, J CLIN PSYCHIAT 0318, pe1; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Halfon P, 2006, MED CARE, V44, P972, DOI 10.1097/01.mlr.0000228002.43688.c2; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Hendrie HC, 2013, AM J GERIAT PSYCHIAT, V21, P1267, DOI 10.1016/j.jagp.2013.01.056; Himelhoch S, 2004, AM J PSYCHIAT, V161, P2317, DOI 10.1176/appi.ajp.161.12.2317; Jha A. K., 2009, NEW ENGL J MED, V348, P2218; Jia HG, 2007, STROKE, V38, P355, DOI 10.1161/01.STR.0000254457.38901.fb; Joint Commission, 2008, DIS SPEC CAR CERT PR; Kashner TM, 1998, MED CARE, V36, P1324, DOI 10.1097/00005650-199809000-00005; Kennedy BS, 2005, J NATL MED ASSOC, V97, P699; Kilbourne AM, 2009, PSYCHIAT SERV, V60, P589, DOI 10.1176/appi.ps.60.5.589; Koepsell TD, 2009, PREV MED, V48, P267, DOI 10.1016/j.ypmed.2009.01.008; Lester HE, 2005, BMJ-BRIT MED J, V330, P1122, DOI 10.1136/bmj.38440.418426.8F; Lichtman JH, 2010, STROKE, V41, P2525, DOI 10.1161/STROKEAHA.110.599159; Lichtman JH, 2009, STROKE, V40, P3574, DOI 10.1161/STROKEAHA.109.561472; Lin HC, 2008, SCHIZOPHR RES, V101, P234, DOI 10.1016/j.schres.2007.12.485; Lin HJ, 2011, NEUROLOGY, V76, P438, DOI 10.1212/WNL.0b013e31820a0cd8; Martin MY, 2006, J AGING PHYS ACTIV, V14, P392, DOI 10.1123/japa.14.4.392; Miller DR, 2004, DIABETES CARE, V27, pB10, DOI 10.2337/diacare.27.suppl_2.B10; Montgomery AE, 2013, AM J PUBLIC HEALTH, V103, pS210, DOI 10.2105/AJPH.2013.301398; O'Day B, 2005, PSYCHIATR REHABIL J, V28, P339, DOI 10.2975/28.2005.339.345; Parks J., 2006, MORBIDITY MORTALITY; Peabody JW, 2004, MED CARE, V42, P1066, DOI 10.1097/00005650-200411000-00005; Petersen LA, 2003, HEALTH SERV RES, V38, P41, DOI 10.1111/1475-6773.00104; Phelan M, 2001, BRIT MED J, V322, P443, DOI 10.1136/bmj.322.7284.443; Post EP, 2010, FAM SYST HEALTH, V28, P83, DOI 10.1037/a0020130; QUERI, QUAL ENH RES IN STRO; Saha S, 2007, ARCH GEN PSYCHIAT, V64, P1123, DOI 10.1001/archpsyc.64.10.1123; Saravay SM, 1996, AM J PSYCHIAT, V153, P397; SAS Institute Inc, 2011, BAS SAS 9 3 PROC GUI; Schneider KM, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-82; Stahl S., 2008, STAHLS ESSENTIAL PSY; Sun Y., 2009, VALUE HEALTH, P12; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575; Viron MJ, 2010, PSYCHOSOMATICS, V51, P458, DOI 10.1176/appi.psy.51.6.458; Zeiss AM, 2008, J CLIN PSYCHOL MED S, V15, P73, DOI 10.1007/s10880-008-9100-4	52	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2017	12	8							e0182330	10.1371/journal.pone.0182330	http://dx.doi.org/10.1371/journal.pone.0182330			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD3KL	28800605	gold, Green Published, Green Submitted			2023-01-03	WOS:000407431800013
J	Fang, WF; Chen, YM; Lin, CY; Huang, KT; Kao, HC; Fang, YT; Huang, CH; Chang, YT; Wang, YH; Wang, CC; Lin, MC				Fang, Wen-Feng; Chen, Yu-Mu; Lin, Chiung-Yu; Huang, Kuo-Tung; Kao, Hsu-Ching; Fang, Ying-Tang; Huang, Chi-Han; Chang, Ya-Ting; Wang, Yi-His; Wang, Chin-Chou; Lin, Meng-Chih			Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units	PLOS ONE			English	Article							C-REACTIVE PROTEIN; LUNG-CANCER; FEBRILE NEUTROPENIA; LEVELS CORRELATE; DR EXPRESSION; HLA-DR; PLACE; DEATH; IMMUNOTHERAPY; INTERLEUKIN-6	Background Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed deathligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti- inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU. Methods A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016. Results Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p< 0.001), hypertension (p< 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke ( p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)- 10 levels ( p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) ( p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals). Conclusions Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer.	[Fang, Wen-Feng; Chen, Yu-Mu; Lin, Chiung-Yu; Huang, Kuo-Tung; Kao, Hsu-Ching; Fang, Ying-Tang; Huang, Chi-Han; Chang, Ya-Ting; Wang, Yi-His; Wang, Chin-Chou; Lin, Meng-Chih] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Internal Med,Div Pulm & Critical Care Med, Kaohsiung, Taiwan; [Fang, Wen-Feng; Wang, Yi-His; Wang, Chin-Chou; Lin, Meng-Chih] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Resp Therapy, Kaohsiung, Taiwan; [Fang, Wen-Feng; Wang, Chin-Chou] Chang Gung Univ Sci & Technol, Dept Resp Care, Chiayi, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University of Science & Technology	Fang, WF; Lin, MC (corresponding author), Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Internal Med,Div Pulm & Critical Care Med, Kaohsiung, Taiwan.; Fang, WF; Lin, MC (corresponding author), Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Resp Therapy, Kaohsiung, Taiwan.; Fang, WF (corresponding author), Chang Gung Univ Sci & Technol, Dept Resp Care, Chiayi, Taiwan.	wenfeng@cgmh.org.tw; mengchih@adm.cgmh.org.tw	Fang, Wen-Feng/AAT-6296-2021	Fang, Wen-Feng/0000-0003-0350-9059; Huang, Chi-Han/0000-0002-3393-1587	Chang Gung Memorial Hospital Grant [CMRPG8B1061, CMRPG8B1062, CMRPG8B1063, CMRPG8C0551, CMRPG8C0052, CMRPG8B1071, CMRPG8B1081]; Taiwan Ministry of Science and Technology [MOST 104-2314-B-182A-123-]	Chang Gung Memorial Hospital Grant(Chang Gung Memorial Hospital); Taiwan Ministry of Science and Technology	The work is supported in part by grants from the Chang Gung Memorial Hospital Grant (CMRPG8B1061, CMRPG8B1062, CMRPG8B1063, CMRPG8C0551, and CMRPG8C0052 to WF Fang; CMRPG8B1071 to 73 to YH Wang; CMRPG8B1081 to 83 to CCWang) and a grant from Taiwan Ministry of Science and Technology (MOST 104-2314-B-182A-123-) to WF Fang.	Albano JD, 2007, JNCI-J NATL CANCER I, V99, P1384, DOI 10.1093/jnci/djm127; Allareddy Veerasathpurush, 2015, J Mass Dent Soc, V64, P38; Arens C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1233-5; Bird GT, 2012, BRIT J ANAESTH, V108, P452, DOI 10.1093/bja/aer449; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; Cohen J, 2015, BRIT J CANCER, V113, P1397, DOI 10.1038/bjc.2015.312; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Hawari FI, 2016, CRIT CARE MED, V44, P548, DOI 10.1097/CCM.0000000000001429; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; Jarosek SL, 2016, J AM GERIATR SOC, V64, P1815, DOI 10.1111/jgs.14269; Katki HA, 2016, JAMA-J AM MED ASSOC, V315, P2300, DOI 10.1001/jama.2016.6255; Kumar S, 2010, INDIAN J PATHOL MICR, V53, P494, DOI 10.4103/0377-4929.68290; Landy R, 2016, BR J CANC; Lee LC, 2014, AM J HOSP PALLIAT ME, V31, P300, DOI 10.1177/1049909113487427; Levy MM, 2001, INTENS CARE MED, V29, P530, DOI DOI 10.1007/S00134-003-1662-X; Lim GH, 2012, SINGAP MED J, V53, P3; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Mhaskar R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003039.pub2; Monneret G, 2008, MOL MED, V14, P64, DOI 10.2119/2007-00102.Monneret; Monneret G, 2014, CRIT CARE, V18, DOI 10.1186/cc13179; Murphy CC, 2016, CLIN GASTROENTEROL H; O'Dowd EL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161399; Obeng-Nkrumah Noah, 2015, BMC Res Notes, V8, P742, DOI 10.1186/s13104-015-1701-z; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Pine SR, 2011, JNCI-J NATL CANCER I, V103, P1112, DOI 10.1093/jnci/djr216; Reilly JP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1398-y; Samuels S, 2016, INT J GYNECOL CANCER, V26, P1503, DOI 10.1097/IGC.0000000000000783; Santegoets SJAM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030029; Schaper F, 2015, CYTOKINE GROWTH F R, V26, P475, DOI 10.1016/j.cytogfr.2015.07.004; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e; Sundar KM, 2013, INDIAN J CRIT CARE M, V17, P162, DOI 10.4103/0972-5229.117054; Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713; Tammemagi MC, 2013, NEW ENGL J MED, V368, P728, DOI 10.1056/NEJMoa1211776; Urbonas V, 2012, CYTOKINE, V57, P313, DOI 10.1016/j.cyto.2011.11.012; VandenBerk JMM, 1997, TRANSPLANTATION, V63, P1846, DOI 10.1097/00007890-199706270-00026; Vanska M, 2012, CYTOKINE, V60, P787, DOI 10.1016/j.cyto.2012.07.023; Wittayachamnankul B, 2016, J CRIT CARE, V36, P223, DOI 10.1016/j.jcrc.2016.08.002; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604; Xiao LH, 2016, ASIAN J ANDROL; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Young KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157164	49	18	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2017	12	7							e0179749	10.1371/journal.pone.0179749	http://dx.doi.org/10.1371/journal.pone.0179749			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA6HV	28692671	gold, Green Submitted, Green Published			2023-01-03	WOS:000405544800015
J	Nabi, R; Moldoveanu, Z; Wei, Q; Golub, ET; Durkin, HG; Greenblatt, RM; Herold, BC; Nowicki, MJ; Kassaye, S; Cho, MW; Pinter, A; Landay, AL; Mestecky, J; Kozlowski, PA				Nabi, Rafiq; Moldoveanu, Zina; Wei, Qing; Golub, Elizabeth T.; Durkin, Helen G.; Greenblatt, Ruth M.; Herold, Betsy C.; Nowicki, Marek J.; Kassaye, Seble; Cho, Michael W.; Pinter, Abraham; Landay, Alan L.; Mestecky, Jiri; Kozlowski, Pamela A.			Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT CELLULAR CYTOTOXICITY; CD4(+) T-CELLS; VAGINAL SHIV CHALLENGE; HELPER TYPE 17; IMMUNE-RESPONSES; NONNEUTRALIZING ANTIBODIES; 1-INFECTED INDIVIDUALS; NEUTRALIZING ANTIBODY; INFECTED INDIVIDUALS	Mechanisms responsible for natural control of human immunodeficiency type 1 (HIV) replication in elite controllers (EC) remain incompletely defined. To determine if EC generate high quality HIV-specific IgA responses, we used Western blotting to compare the specificities and frequencies of IgA to HIV antigens in serum of gender-, age-and race-matched EC and aviremic controllers (HC) and viremic noncontrollers (HN) on highly active antiretroviral therapy (HAART). Concentrations and avidity of IgA to HIV antigens were measured using ELISA or multiplex assays. Measurements for IgG were performed in parallel. EC were found to have stronger p24-and V1V2-specific IgG responses than HN, but there were no IgG differences for EC and HC. In contrast, IgA in EC serum bound more frequently to gp160 and gag proteins than IgA in HC or HN. The avidity of anti-gp41 IgA was also greater in EC, and these subjects had stronger IgA responses to the gp41 heptad repeat region 1 (HR1), a reported target of anti-bacterial RNA polymerase antibodies that cross react with gp41. However, EC did not demonstrate greater IgA responses to E. coli RNA polymerase or to peptides containing the shared LRAI sequence, suggesting that most of their HR1-specific IgA antibodies were not induced by intestinal microbiota. In both EC and HAART recipients, the concentrations of HIV-specific IgG were greater than HIV-specific IgA, but their avidities were comparable, implying that they could compete for antigen. Exceptions were C1 peptides and V1V2 loops. IgG and IgA responses to these antigens were discordant, with IgG reacting to V1V2, and IgA reacting to C1, especially in EC. Interestingly, EC with IgG hypergammaglobulinemia had greater HIV-specific IgA and IgG responses than EC with normal total IgG levels. Heterogeneity in EC antibody responses may therefore be due to a more focused HIV-specific B cell response in some of these individuals. Overall, these data suggest that development of HIV-specific IgA responses and affinity maturation of antigp41 IgA antibodies occurs to a greater extent in EC than in subjects on HAART. Future studies will be required to determine if IgA antibodies in EC may contribute in control of viral replication.	[Nabi, Rafiq; Kozlowski, Pamela A.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70803 USA; [Moldoveanu, Zina; Wei, Qing; Mestecky, Jiri] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL USA; [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Durkin, Helen G.] SUNY Downstate, Dept Pathol, Brooklyn, NY USA; [Durkin, Helen G.] SUNY Downstate, Dept Med, Brooklyn, NY USA; [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Epidemiol Biostastist, San Francisco, CA USA; [Herold, Betsy C.] Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA; [Nowicki, Marek J.] Univ Southern Calif, Dept Pediat, Los Angeles, CA USA; [Kassaye, Seble] Georgetown Univ, Dept Med, Washington, DC USA; [Cho, Michael W.] Iowa State Univ, Dept Biomed Sci, Ames, IA USA; [Pinter, Abraham] Rutgers New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA; [Landay, Alan L.] Rush Univ, Med Ctr, Dept Immun & Emerging Pathogens, Chicago, IL 60612 USA; [Mestecky, Jiri] Charles Univ Prague, Inst Immunol & Microbiol, Fac Med 1, Prague, Czech Republic; [Nowicki, Marek J.] Mendez Natl Inst Transplantat Fdn, Los Angeles, CA USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine; University of Southern California; Georgetown University; Iowa State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rush University; Charles University Prague	Kozlowski, PA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70803 USA.	pkozlo@lsuhsc.edu		Herold, Betsy/0000-0001-9974-0786; Cho, Michael/0000-0003-0522-345X	National Institutes of Health [PO1 AI074286, U19 AI091031, AI102718]; Louisiana Vaccine Center - Louisiana Board of Regents; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000004, KL2TR001432, UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034989, U01AI034993, U01AI031834, U01AI035004, U01AI034994, P30AI027763, U01AI042590, R01AI046283] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Vaccine Center - Louisiana Board of Regents; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by National Institutes of Health grants PO1 AI074286 (MWC), U19 AI091031 (MWC) and AI102718 (AP) and by the Louisiana Vaccine Center funded by the Louisiana Board of Regents (PAK).	Ackerman ME, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005315; Adnan S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006104; Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Black KP, 1996, CLIN IMMUNOL IMMUNOP, V81, P182, DOI 10.1006/clin.1996.0175; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Broadbent AJ, 2015, MUCOSAL IMMUNOLOGY, p1129 ~70; Brombin C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058768; BROWN TA, 1985, J CLIN MICROBIOL, V22, P259, DOI 10.1128/JCM.22.2.259-264.1985; BURNETT PR, 1994, J IMMUNOL, V152, P4642; Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108; Cao AT, 2015, MUCOSAL IMMUNOL, V8, P1072, DOI 10.1038/mi.2014.134; Chamcha V, 2016, OPEN FORUM IN PRESS; Christensen D, 2016, MUCOSAL IMMUNOL; Ciccone EJ, 2011, J VIROL, V85, P5880, DOI 10.1128/JVI.02643-10; Collins AM, 2013, VACCINE, V31, P3469, DOI 10.1016/j.vaccine.2013.04.062; COOGAN MM, 1994, INFECT IMMUN, V62, P892, DOI 10.1128/IAI.62.3.892-896.1994; Doria-Rose NA, 2010, J VIROL, V84, P1631, DOI 10.1128/JVI.01482-09; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632; Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10; Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10; Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709; Fink E, 2016, AIDS RES HUM RETROV, V32, P1187, DOI 10.1089/aid.2016.0182; Gaardbo JC, 2014, JAIDS-J ACQ IMM DEF, V65, P10, DOI 10.1097/QAI.0b013e3182a7c932; Gosselin A, 2010, J IMMUNOL, V184, P1604, DOI 10.4049/jimmunol.0903058; Granados-Gonzalez V, 2008, AIDS RES HUM RETROV, V24, P289, DOI 10.1089/aid.2007.0187; Guillot-Delost M, 2012, J IMMUNOL, V188, P981, DOI 10.4049/jimmunol.1101592; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hel Z, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006087; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Holl V, 2006, J VIROL, V80, P6177, DOI 10.1128/JVI.02625-05; Iyer SS, 2016, J VIROL, V90, P8842, DOI 10.1128/JVI.01163-16; Jaffar Z, 2009, EUR J IMMUNOL, V39, P3307, DOI 10.1002/eji.200939498; Kasturi SP, 2017, J VIROL, V91, DOI 10.1128/JVI.01844-16; Kato LM, 2014, IMMUNOL CELL BIOL, V92, P49, DOI 10.1038/icb.2013.54; Kaushik K, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-179; Kovacs A, 2001, LANCET, V358, P1593, DOI 10.1016/S0140-6736(01)06653-3; KOZLOWSKI PA, 1992, AIDS RES HUM RETROV, V8, P1773, DOI 10.1089/aid.1992.8.1773; KOZLOWSKI PA, 1994, AIDS RES HUM RETROV, V10, P813, DOI 10.1089/aid.1994.10.813; Kozlowski PA, 2000, J ACQ IMMUN DEF SYND, V24, P297; Lai JI, 2014, J VIROL, V88, P2799, DOI 10.1128/JVI.03130-13; Lai L, 2007, VIROLOGY, V369, P153, DOI 10.1016/j.virol.2007.07.017; Lai LL, 2012, VACCINE, V30, P1737, DOI 10.1016/j.vaccine.2011.12.026; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Li D, 2011, CLIN EXP IMMUNOL, V165, P363, DOI 10.1111/j.1365-2249.2011.04435.x; Liao HX, 2011, J EXP MED, V208, P2237, DOI 10.1084/jem.20110363; Marthas ML, 2011, VACCINE, V29, P3124, DOI 10.1016/j.vaccine.2011.02.051; Masson L, 2015, IMMUNOLOGY, V146, P557, DOI 10.1111/imm.12527; McKinnon LR, 2015, JAIDS-J ACQ IMM DEF, V68, P6, DOI 10.1097/QAI.0000000000000389; Mestecky J, 2004, AIDS RES HUM RETROV, V20, P972, DOI 10.1089/aid.2004.20.972; Mestecky J, 2011, AIDS RES HUM RETROV, V27, P469, DOI 10.1089/aid.2010.0169; Montefiori D. C., 2005, CURR PROTOC IMMUNOL; Moog C, 2014, MUCOSAL IMMUNOL, V7, P46, DOI 10.1038/mi.2013.23; Murphy BR, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P799, DOI 10.1016/B978-012491543-5/50047-4; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e; Ostrowski SR, 2008, SCAND J IMMUNOL, V68, P652, DOI 10.1111/j.1365-3083.2008.02184.x; Pastori C, 2000, J BIOL REG HOMEOS AG, V14, P15; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pinter A, 1998, VACCINE, V16, P1803, DOI 10.1016/S0264-410X(98)00182-0; Regidor DL, 2011, AIDS, V25, P303, DOI 10.1097/QAD.0b013e32834273ad; REZZA G, 1992, J BIOL REG HOMEOS AG, V6, P15; Ruiz MJ, 2016, J VIROL, V90, P670, DOI 10.1128/JVI.02363-15; Santra S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005042; Schafer F, 2002, GUT, V50, P608, DOI 10.1136/gut.50.5.608; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; Theze J, 2011, CLIN IMMUNOL, V141, P15, DOI 10.1016/j.clim.2011.07.007; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Trama AM, 2014, CELL HOST MICROBE, V16, P215, DOI 10.1016/j.chom.2014.07.003; TYLER DS, 1990, J IMMUNOL, V145, P3276; Velu V, 2016, J IMMUNOL, V197, P1832, DOI 10.4049/jimmunol.1600143; Vingert B, 2012, J VIROL, V86, P10661, DOI 10.1128/JVI.00056-12; Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478; Wang JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024498; Wei Qing, 2012, Open AIDS J, V6, P293, DOI 10.2174/1874613601206010293; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Wright PF, 2002, AIDS RES HUM RETROV, V18, P1291, DOI 10.1089/088922202320886334; Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753; Yamada T, 2004, J IMMUNOL, V172, P2401, DOI 10.4049/jimmunol.172.4.2401; Yates NL, 2013, MUCOSAL IMMUNOL, V6, P692, DOI 10.1038/mi.2012.107; Yu XY, 2013, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2013-52; Zolla-Pazner S, 2004, NAT REV IMMUNOL, V4, P199, DOI 10.1038/nri1307; Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572; Zolla-Pazner S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053629	90	12	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2017	12	7							e0180245	10.1371/journal.pone.0180245	http://dx.doi.org/10.1371/journal.pone.0180245			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2JX	28671952	Green Submitted, Green Published, gold			2023-01-03	WOS:000405268500033
J	Kodaira, S; Li, HK; Konishi, T; Kitamura, H; Kurano, M; Hasegawa, S				Kodaira, Satoshi; Li, Huizi Keiko; Konishi, Teruaki; Kitamura, Hisashi; Kurano, Mieko; Hasegawa, Sumitaka			Validating alpha-particle emission from (211) At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors	PLOS ONE			English	Article							CHARGED-PARTICLES; DISTRIBUTIONS; COMBINATION; MICROSCOPE; RESOLUTION; DOSIMETRY; SURFACE	Recently, (211) At has received increasing attention as a potential radionuclide for cancer radioimmunotherapy. It is a alpha-particle emitter, which is extremely effective against malignant cells. We demonstrate a method to verify the efficiency of (211) At-labeled trastuzumab antibodies ((211) At-trastuzumab) against HER2 antigens, which has not been determined for radioimmunotherapy. A CR-39 plastic nuclear detector is used for measuring the position and the linear energy transfer (LET) of individual (211) At alpha-particle tracks. The tracks and (211) At-trastuzumab-binding cells were co-visualized by using the geometric information recorded on the CR-39. HER2-positive human gastric cancer cells (NCI-N87), labelled with (211) At-trastuzumab, were dropped on the centre of the CR-39 plate. Microscope images of the cells and the corresponding alpha-tracks acquired by position matching were obtained. In addition, 3.5 cm x 3.5 cm macroscopic images of the whole plate were acquired. The distribution of number of a-particles emitted from single cells suggests that 80% of the (211) At-trastuzumab-binding cells emitted alpha-particles. It also indicates that the alpha-particles may strike the cells several times along their path. The track-averaged LET of the alpha-particles is evaluated to be 131 keV/mu m. These results will enable quantitative evaluation of delivered doses to target cells, and will be useful for the in vitro assessment of (211) At-based radioimmunotherapeutic agents.	[Kodaira, Satoshi; Kitamura, Hisashi; Kurano, Mieko] Natl Inst Quantum & Radiol Sci & Technol, Radiat Measurement Res Team, Natl Inst Radiol Sci, Chiba, Japan; [Li, Huizi Keiko; Hasegawa, Sumitaka] Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Radiat & Canc Biol Team, Chiba, Japan; [Li, Huizi Keiko] Chiba Univ, Grad Sch Med & Pharmaceut Sci, Chiba, Japan; [Konishi, Teruaki] Natl Inst Quantum & Radiol Sci & Technol, Regenerat Therapy Res Team, Natl Inst Radiol Sci, Chiba, Japan	National Institutes for Quantum Science & Technology; National Institutes for Quantum Science & Technology; Chiba University; National Institutes for Quantum Science & Technology	Kodaira, S (corresponding author), Natl Inst Quantum & Radiol Sci & Technol, Radiat Measurement Res Team, Natl Inst Radiol Sci, Chiba, Japan.	kodaira.satoshi@qst.go.jp	Konishi, Teruaki/B-9638-2008; Kitamura, Hisashi/AAH-5031-2020; Kodaira, Satoshi/J-3399-2019	Konishi, Teruaki/0000-0002-2485-9659; Kodaira, Satoshi/0000-0003-4216-6984; Kitamura, Hisashi/0000-0002-3449-7364	National Institute of Radiological Sciences	National Institute of Radiological Sciences	This work was supported by the President's grant from National Institute of Radiological Sciences to SH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amemiya K, 2005, RADIAT MEAS, V40, P283, DOI 10.1016/j.radmeas.2005.01.010; Andersson H, 2009, J NUCL MED, V50, P1153, DOI 10.2967/jnumed.109.062604; Benton ER, 2010, RADIAT MEAS, V45, P957, DOI 10.1016/j.radmeas.2010.05.008; BENTON EV, 1969, NUCL INSTRUM METHODS, V67, P343, DOI 10.1016/0029-554X(69)90471-6; Berger M.J., 1993, PENETRATION PROTON B; Claesson K, 2011, INT J RADIAT BIOL, V87, P372, DOI 10.3109/09553002.2011.538127; DOKE T, 1995, RADIAT MEAS, V24, P75, DOI 10.1016/1350-4487(94)00084-E; Fleischer R.L., 1975, NUCL TRACKS SOLIDS; Green DJ, 2015, BLOOD, V125, P2111, DOI 10.1182/blood-2014-11-612770; HILL A, 2004, RADIAT RES, V162, P667; ICRP, 1975, REP TASK GROUP REF M; ICRU, 1970, 16 ICRU, DOI [10.1093/jicru/os9.1.Report16, DOI 10.1093/JICRU/OS9.1.REPORT16]; ISHIGURE N, 1985, Radioisotopes, V34, P101; Kodaira S, 2007, NUCL INSTRUM METH A, V574, P163, DOI 10.1016/j.nima.2007.01.086; Kodaira S, 2016, NUCL INSTRUM METH B, V383, P129, DOI 10.1016/j.nimb.2016.07.002; Kodaira S, 2013, RADIAT MEAS, V50, P232, DOI 10.1016/j.radmeas.2012.10.001; Konishi T, 2007, J RADIAT RES, V48, P255, DOI 10.1269/jrr.06078; Larson SM, 2015, NAT REV CANCER, V15, P347, DOI 10.1038/nrc3925; Li HK, 2015, CANCER BIOTHER RADIO, V30, P349, DOI 10.1089/cbr.2015.1882; Lindegren S, 2008, J NUCL MED, V49, P1537, DOI 10.2967/jnumed.107.049833; Nagatsu K, 2014, APPL RADIAT ISOTOPES, V94, P363, DOI 10.1016/j.apradiso.2014.09.012; Newman HC, 1997, INT J RADIAT BIOL, V71, P347, DOI 10.1080/095530097143978; Ogura K, 2001, NUCL INSTRUM METH B, V185, P222, DOI 10.1016/S0168-583X(01)00816-3; OGURA K, RAD MEAS, V34, P555; Ota S, 2008, RADIAT MEAS, V43, pS195, DOI 10.1016/j.radmeas.2008.04.058; Ota S, 2011, NUCL INSTRUM METH B, V269, P1382, DOI 10.1016/j.nimb.2011.03.018; Ota S, 2011, ASTROPHYS SPACE SCI, V7, P495; Palm S, 2007, INT J RADIAT ONCOL, V69, P572, DOI 10.1016/j.ijrobp.2007.06.023; RAJU MR, 1991, RADIAT RES, V128, P204, DOI 10.2307/3578139; Robinson MK, 2008, CLIN CANCER RES, V14, P875, DOI 10.1158/1078-0432.CCR-07-1250; Skvarc J, 2001, RADIAT MEAS, V34, P113, DOI 10.1016/S1350-4487(01)00134-2; SOMOGYI G, 1973, NUCL INSTRUM METHODS, V109, P211, DOI 10.1016/0029-554X(73)90265-6; Tanaka H, 2014, J RADIAT RES, V55, P373, DOI 10.1093/jrr/rrt110; Tawara H, 2008, JPN J APPL PHYS, V47, P1726, DOI 10.1143/JJAP.47.1726; Vaidyanathan G, 2011, CURR RADIOPHARM, V4, P283, DOI 10.2174/1874471011104040283; Yasuda N, 2005, RADIAT MEAS, V40, P311, DOI 10.1016/j.radmeas.2005.02.013	36	16	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2017	12	6							e0178472	10.1371/journal.pone.0178472	http://dx.doi.org/10.1371/journal.pone.0178472			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ3JT	28658304	gold, Green Submitted, Green Published			2023-01-03	WOS:000404607900005
J	Humphreys, K; Malenka, RC; Knutson, B; MacCoun, RJ				Humphreys, Keith; Malenka, Robert C.; Knutson, Brian; MacCoun, Robert J.			Brains, environments, and policy responses to addiction	SCIENCE			English	Editorial Material							ADOLESCENTS		[Humphreys, Keith] Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA; [Malenka, Robert C.; Knutson, Brian; MacCoun, Robert J.] Stanford Univ, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University	Humphreys, K (corresponding author), Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA.	knh@stanford.edu	MacCoun, Robert/N-1765-2019	MacCoun, Robert/0000-0003-0929-4423; Knutson, Brian/0000-0002-7669-426X	Stanford Neurosciences Institute; Senior Research Career Scientist Award from the Veterans Affairs Health Services Research and Development Service	Stanford Neurosciences Institute; Senior Research Career Scientist Award from the Veterans Affairs Health Services Research and Development Service	The authors are participants in the Neurochoice Initiative funded by the Stanford Neurosciences Institute. K.H. was supported by the Senior Research Career Scientist Award from the Veterans Affairs Health Services Research and Development Service. Some of these ideas were presented by K.H. at the 2016 World Economic Forum and by R.J.M. at the 2016 Neurochoice Symposium. None of the opinions in this article necessarily represent the policy views of any governmental organization for which the authors have worked or have advised.	Babor T. F., 2010, ALCHOL NO ORDINARY C, DOI DOI 10.1093/ACPROF:OSO/9780199551149.003.002; Buchel C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14140; Chan M., 2017, COMMUNICATION   0313; Englund A, 2017, LANCET PSYCHIAT, V4, P643, DOI 10.1016/S2215-0366(17)30075-5; Jensen F. E., 2015, THE TEENAGE BRAIN; Kalant H, 2010, ADDICTION, V105, P780, DOI 10.1111/j.1360-0443.2009.02739.x; Kristjansson AL, 2016, ADDICTION, V111, P645, DOI 10.1111/add.13248; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; MacCoun R, 2008, REV LAW ECON, V4, P695, DOI 10.2202/1555-5879.1226; MacCoun RJ, 2015, NEW ENGL J MED, V372, P989, DOI 10.1056/NEJMp1416014; Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798; PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607; Plassmann H, 2012, J CONSUM PSYCHOL, V22, P18, DOI 10.1016/j.jcps.2011.11.010; Proctor RN, 2011, GOLDEN HOLOCAUST: ORIGINS OF THE CIGARETTE CATASTROPHE AND THE CASE FOR ABOLITION, P1; U.S. Department of Health and Human Services Office of the Surgeon General, 2016, OFF SURG GEN FAC ADD	15	7	7	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	2017	356	6344					1237	1238		10.1126/science.aan0655	http://dx.doi.org/10.1126/science.aan0655			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EY3OM	28642399				2023-01-03	WOS:000403881700022
J	Coffin, PO; Santos, GM; Matheson, T; Behar, E; Rowe, C; Rubin, T; Silvis, J; Vittinghoff, E				Coffin, Phillip Oliver; Santos, Glenn-Milo; Matheson, Tim; Behar, Emily; Rowe, Chris; Rubin, Talia; Silvis, Janelle; Vittinghoff, Eric			Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial	PLOS ONE			English	Article							INJECTION-DRUG USERS; NONFATAL HEROIN OVERDOSE; HIV PREVENTION INTERVENTION; NEW-YORK-CITY; NALOXONE DISTRIBUTION; CLINICAL-TRIAL; SAN-FRANCISCO; PROGRAM; DEATHS; VIRUS	Objective The United States is amidst an opioid epidemic, including synthetic opioids that may result in rapid death, leaving minimal opportunity for bystander rescue. We pilot tested a behavioral intervention to reduce the occurrence of opioid overdose among opioid dependent persons at high-risk for subsequent overdose. Materials and methods We conducted a single-blinded randomized-controlled trial of a repeated dose motivational interviewing intervention (REBOOT) to reduce overdose versus treatment as usual, defined as information and referrals, over 16 months at the San Francisco Department of Public Health from 2014-2016. Participants were 18-65 years of age, had opioid use disorder by Structured Clinical Interview, active opioid use, opioid overdose within 5 years, and prior receipt of naloxone kits. The intervention was administered at months 0, 4, 8, and 12, preceded by the assessment which was also administered at month 16. Dual primary outcomes were any overdose event and number of events, collected by computer-assisted personal interview, as well as any fatal overdose events per vital records. Results A total of 78 persons were screened and 63 enrolled. Mean age was 43 years, 67% were born male, 65% White, 17% African-American, and 14% Latino. Ninety-two percent of visits and 93% of counseling sessions were completed. At baseline, 33.3% of participants had experienced an overdose in the past four months, with a similar mean number of overdoses in both arms (p = 0.95); 29% overdosed during follow-up. By intention-to-treat, participants assigned to REBOOT were less likely to experience any overdose (incidence rate ratio [IRR] 0.62 [95% CI 0.41-0.92, p = 0.019) and experienced fewer overdose events (IRR 0.46, 95% CI 0.24-0.90, p = 0.023), findings that were robust to sensitivity analyses. There were no differences between arms in days of opioid use, substance use treatment, or naloxone carriage. Conclusions REBOOT reduced the occurrence of any opioid overdose and the number of overdoses.	[Coffin, Phillip Oliver; Santos, Glenn-Milo; Matheson, Tim; Behar, Emily; Rowe, Chris; Rubin, Talia; Silvis, Janelle] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; [Coffin, Phillip Oliver; Santos, Glenn-Milo; Behar, Emily; Vittinghoff, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco Department of Public Health; University of California System; University of California San Francisco	Coffin, PO (corresponding author), San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.; Coffin, PO (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	phillip.coffin@ucsf.edu	Coffin, Phillip O/G-3286-2012	Coffin, Phillip O/0000-0002-3891-6570; Santos, Glenn-Milo/0000-0003-1009-5317	National Institute on Drug Abuse [R34DA037194]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R25HD045810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R25DA028567, R34DA037194] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The study was funded by the National Institute on Drug Abuse, grant # R34DA037194. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2000, AIDS PREVENT MENT H; Banta-Green CJ, 2012, COUNC PROBL DRUG DEP; Bennett AS, 2011, J URBAN HEALTH, V88, P1020, DOI 10.1007/s11524-011-9600-7; Bird SM, 2016, ADDICTION, V111, P883, DOI 10.1111/add.13265; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2005, WEB BAINJ STAT QUE; Cherpitel CJ, 2010, ALCOHOL CLIN EXP RES, V34, P1922, DOI 10.1111/j.1530-0277.2010.01281.x; Church D., 2011, Morbidity and Mortality Weekly Report, V60, P1457; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI [10.1197/j.aem.2007.04.005, 10.1111/j.1553-2712.2007.tb01846.x]; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Coffin PO, 2013, ANN INTERN MED, V158, P1, DOI 10.7326/0003-4819-158-1-201301010-00003; Coffin PO, 2003, ADDICTION, V98, P739, DOI 10.1046/j.1360-0443.2003.00376.x; Darke S, 2005, DRUG ALCOHOL REV, V24, P425, DOI 10.1080/09595230500286005; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Darke S, 2011, DRUG ALCOHOL DEPEN, V115, P190, DOI 10.1016/j.drugalcdep.2010.10.021; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Des Jarlais DC, 2007, AIDS, V21, P231, DOI 10.1097/QAD.0b013e3280114a15; Dickson-Gomez J, 2006, SUBST USE MISUSE, V41, P669, DOI 10.1080/10826080500411403; Evans JL, 2012, AM J EPIDEMIOL, V175, P302, DOI 10.1093/aje/kwr318; FISHER JD, 1992, PSYCHOL BULL, V111, P455, DOI 10.1037/0033-2909.111.3.455; Garfein RS, 2007, AIDS, V21, P1923, DOI 10.1097/QAD.0b013e32823f9066; Gossop M DS, 1995, SEVERITY DEPENDENCE, V90, P607; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Havens JR, 2012, COUNC PROBL DRUG DEP; Inocencio TJ, 2013, PAIN MED, V14, P1534, DOI 10.1111/pme.12183; Jenkins LM, 2011, J URBAN HEALTH, V88, P118, DOI 10.1007/s11524-010-9525-6; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Lankenau SE, 2013, J COMMUN HEALTH, V38, P133, DOI 10.1007/s10900-012-9591-7; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Latkin CA, 2003, HEALTH PSYCHOL, V22, P332, DOI 10.1037/0278-6133.22.4.332; Mack KA, 2013, MMWR-MORBID MORTAL W, V62, P537; Mackenzie S, 2012, SUBST USE MISUSE, V47, P522, DOI 10.3109/10826084.2012.644122; Mackesy-Amiti ME, 2011, ADDICTION, V106, P601, DOI 10.1111/j.1360-0443.2010.03251.x; Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11; McAuley A, 2012, DRUG-EDUC PREV POLIC, V19, P309, DOI 10.3109/09687637.2012.682232; Metcalf CA, 2005, SEX TRANSM DIS, V32, P123, DOI 10.1097/01.olq.0000151420.92624.c0; Metsch LR, 2016, JAMA-J AM MED ASSOC, V316, P156, DOI 10.1001/jama.2016.8914; Metsch LR, 2013, JAMA-J AM MED ASSOC, V310, P1701, DOI 10.1001/jama.2013.280034; Nielsen K, 2011, RESUSCITATION, V82, P1410, DOI 10.1016/j.resuscitation.2011.05.027; NYC Department of Health and Mental Hygiene, 2010, NYC VITAL SIGNS, V9, P1; O'Brien CP, 2011, AM J ADDICTION, V20, P106, DOI 10.1111/j.1521-0391.2010.00107.x; Ochoa KC, 2005, DRUG ALCOHOL DEPEN, V80, P297, DOI 10.1016/j.drugalcdep.2005.04.012; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peavy KM, 2012, J PSYCHOACTIVE DRUGS, V44, P259, DOI 10.1080/02791072.2012.704591; Pierce M, 2016, ADDICTION, V111, P298, DOI 10.1111/add.13193; Piper TM, 2008, SUBST USE MISUSE, V43, P858, DOI 10.1080/10826080701801261; Pollini RA, 2006, DRUG ALCOHOL DEPEN, V83, P104, DOI 10.1016/j.drugalcdep.2005.10.015; Rudd RA, 2016, MMWR-MORBID MORTAL W, P65; Sherman SG, 2009, SOC SCI MED, V68, P69, DOI 10.1016/j.socscimed.2008.09.061; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; Stoove MA, 2009, DRUG ALCOHOL REV, V28, P347, DOI 10.1111/j.1465-3362.2009.00057.x; Strassels SA, 2009, J MANAGE CARE PHARM, V15, P556, DOI 10.18553/jmcp.2009.15.7.556; Tobin KE, 2011, ADDICTION, V106, P366, DOI 10.1111/j.1360-0443.2010.03146.x; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Warner-Smith M, 2002, ADDICTION, V97, P963, DOI 10.1046/j.1360-0443.2002.00132.x; Wheeler E, 2012, DATA DRUG OVERDOSE P; White Alan G, 2005, J Manag Care Pharm, V11, P469; Wines JD, 2007, DRUG ALCOHOL DEPEN, V89, P161, DOI 10.1016/j.drugalcdep.2006.12.019; Xu J, 2015, NCHS DATA BRIEF, V2016, P1, DOI DOI 10.1056/NEJM184002260220306; Young AM, 2012, ADDICTION, V107, P587, DOI 10.1111/j.1360-0443.2011.03635.x; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	63	24	24	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							e0183354	10.1371/journal.pone.0183354	http://dx.doi.org/10.1371/journal.pone.0183354			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK0UN	29049282	Green Published, Green Submitted, gold			2023-01-03	WOS:000413195900001
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Promising miracle diet fixes isn't fair on anyone	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MANAGEMENT					margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457; Castaneda-Gonzalez LM, 2011, NUTR HOSP, V26, P1270, DOI [10.1590/S0212-16112011000600013, 10.3305/nh.2011.26.6.5387]; Chatterjee R, 2015, 11 WAYS START REVERS; Eenfeldt A, 2016, TYPE 2 DIABETES REVE; Leslie WS, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0406-2; Lim EL, 2011, DIABETOLOGIA, V54, P2506, DOI 10.1007/s00125-011-2204-7; Murdoch C, 2017, PULSE, P358; Noakes TD, 2013, SAMJ S AFR MED J, V103, P826, DOI [10.7196/samj.7302, 10.7196/SAMJ.7302]; Snorgaard O, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000354; Tay J, 2015, AM J CLIN NUTR, V102, P780, DOI 10.3945/ajcn.115.112581; Tobias DK, 2015, LANCET DIABETES ENDO, V3, P968, DOI 10.1016/S2213-8587(15)00367-8	11	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	2017	358								j4226	10.1136/bmj.j4226	http://dx.doi.org/10.1136/bmj.j4226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FI7DM	28947570	Green Published, Bronze			2023-01-03	WOS:000412156400003
J	Krumholz, HM; Wang, K; Lin, ZQ; Dharmarajan, K; Horwitz, LI; Ross, JS; Drye, EE; Bernheim, SM; Normand, SLT				Krumholz, Harlan M.; Wang, Kun; Lin, Zhenqiu; Dharmarajan, Kumar; Horwitz, Leora I.; Ross, Joseph S.; Drye, Elizabeth E.; Bernheim, Susannah M.; Normand, Sharon-Lise T.			Hospital- Readmission Risk - Isolating Hospital Effects from Patient Effects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADMINISTRATIVE CLAIMS MEASURE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; SOCIOECONOMIC-STATUS; REDUCTION PROGRAM; RATES; PERFORMANCE; OUTCOMES; CARE; QUALITY	BACKGROUND To isolate hospital effects on risk-standardized hospital-readmission rates, we examined readmission outcomes among patients who had multiple admissions for a similar diagnosis at more than one hospital within a given year. METHODS We divided the Centers for Medicare and Medicaid Services hospital-wide readmission measure cohort from July 2014 through June 2015 into two random samples. All the patients in the cohort were Medicare recipients who were at least 65 years of age. We used the first sample to calculate the risk-standardized readmission rate within 30 days for each hospital, and we classified hospitals into performance quartiles, with a lower readmission rate indicating better performance (performance-classification sample). The study sample (identified from the second sample) included patients who had two admissions for similar diagnoses at different hospitals that occurred more than 1 month and less than 1 year apart, and we compared the observed readmission rates among patients who had been admitted to hospitals in different performance quartiles. RESULTS In the performance-classification sample, the median risk-standardized readmission rate was 15.5% (interquartile range, 15.3 to 15.8). The study sample included 37,508 patients who had two admissions for similar diagnoses at a total of 4272 different hospitals. The observed readmission rate was consistently higher among patients admitted to hospitals in a worse-performing quartile than among those admitted to hospitals in a better-performing quartile, but the only significant difference was observed when the patients were admitted to hospitals in which one was in the best-performing quartile and the other was in the worst-performing quartile (absolute difference in readmission rate, 2.0 percentage points; 95% confidence interval, 0.4 to 3.5; P = 0.001). CONCLUSIONS When the same patients were admitted with similar diagnoses to hospitals in the best-performing quartile as compared with the worst-performing quartile of hospital readmission performance, there was a significant difference in rates of readmission within 30 days. The findings suggest that hospital quality contributes in part to readmission rates independent of factors involving patients.	[Krumholz, Harlan M.; Wang, Kun; Dharmarajan, Kumar] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA; [Ross, Joseph S.; Bernheim, Susannah M.] Yale Sch Med, Gen Internal Med Sect, New Haven, CT USA; [Ross, Joseph S.; Bernheim, Susannah M.] Yale Sch Med, Natl Clinician Scholars Program, New Haven, CT USA; [Drye, Elizabeth E.] Yale Sch Med, Dept Internal Med, New Haven, CT USA; [Drye, Elizabeth E.] Yale Sch Med, Dept Pediat, New Haven, CT USA; [Krumholz, Harlan M.; Wang, Kun; Lin, Zhenqiu; Dharmarajan, Kumar; Ross, Joseph S.; Drye, Elizabeth E.; Bernheim, Susannah M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Krumholz, Harlan M.; Ross, Joseph S.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Dharmarajan, Kumar] Clover Hlth, Jersey City, NJ USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA; [Horwitz, Leora I.] NYU, Sch Med, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY USA; [Horwitz, Leora I.] NYU Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA; [Normand, Sharon-Lise T.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Normand, Sharon-Lise T.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; New York University; New York University; NYU Langone Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Krumholz, HM (corresponding author), 1 Church St,Suite 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	Horwitz, Leora/ABD-1292-2020; , Harlan/AAI-2875-2020	Ross, Joseph/0000-0002-9218-3320	Yale-New Haven Hospital Center for Outcomes Research and Evaluation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS022882] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Yale-New Haven Hospital Center for Outcomes Research and Evaluation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Funded by Yale-New Haven Hospital Center for Outcomes Research and Evaluation and others.	Bernheim SM, 2016, HEALTH AFFAIR, V35, P1461, DOI 10.1377/hlthaff.2015.0394; Bernheim SM, 2010, CIRC-CARDIOVASC QUAL, V3, P459, DOI 10.1161/CIRCOUTCOMES.110.957613; Blum AB, 2014, CIRC-CARDIOVASC QUAL, V7, P391, DOI 10.1161/CIRCOUTCOMES.113.000520; Bonito AJ, 2008, AHRQ PUBLICATION, P38; Census Bureau, 2010, 2010 CENS SUMM FIL 1, P619; Conover M., 2012, HOSP WIDE ALL CAUSE; Desai NR, 2016, JAMA-J AM MED ASSOC, V316, P2647, DOI 10.1001/jama.2016.18533; Gerhardt G, 2013, MED MED RES REV, V3; Glance LG, 2016, ANN SURG, V263, P698, DOI 10.1097/SLA.0000000000001363; Horwitz LI, 2015, J HOSP MED, V10, P670, DOI 10.1002/jhm.2416; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Joynt KE, 2017, NEW ENGL J MED, V376, P510, DOI 10.1056/NEJMp1616278; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Konstam MA, 2016, JACC-HEART FAIL, V4, P21, DOI 10.1016/j.jchf.2015.10.002; Krumholz HM, 2016, JACC-HEART FAIL, V4, P12, DOI 10.1016/j.jchf.2015.07.017; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Lipstein SH, 2014, ANN INTERN MED, V161, P594, DOI 10.7326/M14-1601; Rahimi AR, 2007, JAMA-J AM MED ASSOC, V297, P1063, DOI 10.1001/jama.297.10.1063; Rathore SS, 2003, JAMA-J AM MED ASSOC, V289, P2517, DOI 10.1001/jama.289.19.2517; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Yale New Haven Health Services Corporation Center for Outcomes Research and Evaluation, 2016, 2016 MEAS UPD SPEC R; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	25	73	73	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	2017	377	11					1055	1064		10.1056/NEJMsa1702321	http://dx.doi.org/10.1056/NEJMsa1702321			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG6YC	28902587	Green Accepted, Bronze			2023-01-03	WOS:000410545200008
J	Ribas, A; Dummer, R; Puzanov, I; VanderWalde, A; Andtbacka, RHI; Michielin, O; Olszanski, AJ; Malvehy, J; Cebon, J; Fernandez, E; Kirkwood, JM; Gajewski, TF; Chen, L; Gorski, KS; Anderson, AA; Diede, SJ; Lassman, ME; Gansert, J; Hodi, FS; Long, GV				Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert H. I.; Michielin, Olivier; Olszanski, Anthony J.; Malvehy, Josep; Cebon, Jonathan; Fernandez, Eugenio; Kirkwood, John M.; Gajewski, Thomas F.; Chen, Lisa; Gorski, Kevin S.; Anderson, Abraham A.; Diede, Scott J.; Lassman, Michael E.; Gansert, Jennifer; Hodi, F. Stephen; Long, Georgina V.			Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy	CELL			English	Article							TALIMOGENE LAHERPAREPVEC; PEMBROLIZUMAB; IPILIMUMAB; ANTIBODY; RESISTANCE; BLOCKADE	Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8(+) T cells, elevated PD-L1 protein expression, as well as IFN-gamma gene expression on several cell subsets in tumors after talimogene laherparepvec treatment. Response to combination therapy did not appear to be associated with baseline CD8(+) T cell infiltration or baseline IFN-gamma signature. These findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment.	[Ribas, Antoni] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Dummer, Reinhard] Univ Hosp Zurich, Zurich, Switzerland; [Puzanov, Igor] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [VanderWalde, Ari] West Clin, Memphis, TN USA; [Andtbacka, Robert H. I.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Michielin, Olivier] CHU Vaudois, Lausanne, Switzerland; [Olszanski, Anthony J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Malvehy, Josep] Hosp Clin Barcelona, Barcelona, Spain; [Cebon, Jonathan] La Trobe Univ, Olivia Newton John Canc Res Inst, Austin Hlth, Sch Canc Med, Heidelberg, Vic, Australia; [Fernandez, Eugenio] Hop Univ Geneve, Geneva, Switzerland; [Kirkwood, John M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Kirkwood, John M.] Univ Pittsburgh, Hillman UPMC Canc Ctr, Pittsburgh, PA USA; [Gajewski, Thomas F.] Univ Chicago, Sch Med, Chicago, IL 60637 USA; [Chen, Lisa; Anderson, Abraham A.; Gansert, Jennifer] Amgen Inc, Thousand Oaks, CA 91320 USA; [Gorski, Kevin S.] Amgen Inc, San Francisco, CA USA; [Diede, Scott J.; Lassman, Michael E.] Merck & Co Inc, Kenilworth, NJ USA; [Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, Georgina V.] Royal North Shore Hosp, Sydney, NSW, Australia; [Long, Georgina V.] Mater Hosp, Sydney, NSW, Australia	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of Zurich; University Zurich Hospital; Roswell Park Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Fox Chase Cancer Center; University of Barcelona; Hospital Clinic de Barcelona; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; University of Geneva; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Chicago; Amgen; Amgen; Merck & Company; Harvard University; Dana-Farber Cancer Institute; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital	Ribas, A (corresponding author), Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.	aribas@mednet.ucla.edu	Olszanski, Anthony/AAF-8560-2019; Michielin, Olivier/ABE-7924-2020; Long, Georgina V/C-1771-2013; PUZANOV, IGOR/AAP-2966-2020; Chen, Lisa/GXN-0315-2022; Diede, Scott/G-2288-2012	Long, Georgina V/0000-0001-8894-3545; PUZANOV, IGOR/0000-0002-9803-3497; Olszanski, Anthony/0000-0001-5276-5898; Cebon, Jonathan/0000-0002-3898-950X; Diede, Scott/0000-0001-5422-549X	NIH [R35 CA197633, P20CA016056]; Australian NHMRC [APP1119059]; Medical Foundation, University of Sydney [K8625]; Amgen Inc.; Merck; Bristol-Myers Squibb; Astra-Zeneca; Takara; Provectus; Takeda; Kyowa; Immunocore; EMD Serono; Incyte; Eli Lilly; Advaxis; Mirati; Ignyta; Novartis; Pfizer; Kura; G1 therapeutics; Kyowa Hakko Kirin; Almirall; Roche; GlaxoSmithKline; Pierre Fabre; Leo Pharma; CSL; Amgen, Inc.; Prometheus; Green Peptide; Solaran RX; Checkmate Pharmaceuticals; Roche/Genentech; Ono; Seattle Genetics; Celldex; Genentech; Array; Merck Sharp Dohme	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Medical Foundation, University of Sydney(University of Sydney); Amgen Inc.(Amgen); Merck(Merck & Company); Bristol-Myers Squibb(Bristol-Myers Squibb); Astra-Zeneca(AstraZeneca); Takara; Provectus; Takeda(Takeda Pharmaceutical Company Ltd); Kyowa; Immunocore; EMD Serono; Incyte; Eli Lilly(Eli Lilly); Advaxis; Mirati; Ignyta; Novartis(Novartis); Pfizer(Pfizer); Kura; G1 therapeutics; Kyowa Hakko Kirin(Kyowa Kirin Ltd); Almirall(Almirall); Roche(Roche Holding); GlaxoSmithKline(GlaxoSmithKline); Pierre Fabre; Leo Pharma(LEO Pharma); CSL; Amgen, Inc.(Amgen); Prometheus; Green Peptide; Solaran RX; Checkmate Pharmaceuticals; Roche/Genentech(Roche HoldingGenentech); Ono; Seattle Genetics; Celldex; Genentech(Roche HoldingGenentech); Array; Merck Sharp Dohme(Merck & Company)	The authors thank the following individuals: Richard Scolyer, Robyn Saw, Andrew Spillane, Kenneth Lee, and Omgo Neiwig of the Melanoma Institute Australia for tumor excision biopsies to maximize tissue acquisition; Hajime Hiraragi (Amgen Inc.) for peer review of tumor biopsy analyses, Jessica Stern (Amgen Inc.) for flow cytometry peer review and organization of IHC image galleries for preparation of figures, David Kaufman and Christine Gause from Merck & Co for many hours of designing the study and the statistical plan for both the phase 1b and 3 portions, and with special acknowledgment to Jeffrey Chou, MD, PhD, for his medical and scientific contributions to the design and execution of this study during his tenure as the Amgen medical monitor. A.R. is supported by the NIH grant R35 CA197633. I.P. is supported by NIH grant P20CA016056 to Roswell Park Cancer Institute. G.V.L. is supported by an Australian NHMRC fellowship (APP1119059) and the Medical Foundation K8625, University of Sydney. Lastly, we wish to thank Meghan Johnson, PhD (Complete Healthcare Communications, LLC, West Chester, PA), whose work was funded by Amgen Inc., Emily Plummer, PhD (Amgen Inc.), and Mee Rhan Kim, PhD (Amgen Inc.) for assistance in the preparation of this manuscript. The study was funded by Amgen Inc.; A.R. has received consulting fees from Amgen Inc. and Merck. R.D. has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Amgen Inc., Takeda, and Pierre Fabre outside the submitted work. I.P. has received consulting fees and honoraria from Amgen Inc. A.VW. has received research grants from Amgen Inc. and consulting fees from Bristol-Myers Squibb, Astra-Zeneca, and Amgen Inc. R.H.I. A. has received consulting fees from Amgen Inc., Merck, Takara, and Provectus. O.M. has previously served on advisory boards for Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, and Amgen Inc. and has received travel assistance from Bristol-Myers Squibb, Merck Sharp & Dohme, and Amgen Inc. A.J.O. has received research grants from Takeda, Bristol-Myers Squibb, Kyowa, Immunocore, EMD Serono, Amgen Inc., Incyte, Eli Lilly, Advaxis, Mirati, Ignyta, Novartis, Pfizer, and Kura and has received consulting fees from Merck, Takeda, Bristol-Myers Squibb, G1 therapeutics, and Kyowa Hakko Kirin. J.M. has received research grants from Almirall, Amgen Inc., Roche, GlaxoSmithKline, and Bristol-Myers Squibb; has received consulting fees from Almirall, Amgen Inc., Pierre Fabre, and Leo Pharma; and has served on speakers' bureaus for Amgen Inc., Almirall, Novartis, and Isdin. J.C. has received honoraria from GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Merck Sharp & Dohme, and Amgen Inc.; has served in a non-remunerative position of influence for Austin Health Oncology Information System project Control Group, Olivia Newton-John Cancer & Wellness Centre Executive Committee, and Olivia Newton-John Cancer and Wellness Centre MRI Advisory Committee; has served as a consultant/advisor for Amgen Inc., Bionomics, Bristol-Meyers Squibb, Merck Sharp & Dohme, and Novartis; has received research funding to his institution from GlaxoSmithKline and CSL; has patents/intellectual property at GlaxoSmithKline, Bristol-Meyers Squibb, and Novartis; and is an employee of the Olivia Newton-John Cancer Research Institute. E.F. has received consulting fees from Amgen, Inc. J.M.K. has received research grants from Merck and Prometheus and has received consulting fees from Bristol-Myers Squibb, Green Peptide, Roche, Solaran RX, Checkmate Pharmaceuticals, and Novartis. T.F.G. has received research funding from Amgen Inc., Bristol-Myers Squibb, Merck, Roche/Genentech, Ono, Incyte, and Seattle Genetics; has served on advisory board or as a consultant for Merck, Roche/Genentech, Bayer, Abbvie, Aduro, and Jounce; and owns stock in Jounce. L.C., K.S.G., A.A.A., and J.G. are employees of, and own stock in, Amgen Inc. S.J.D. and M.L. are employees of, and own stock in, Merck. F.S.H. has received research funding from Bristol-Myers Squibb; has received consulting fees from Amgen Inc., Merck, Bristol-Myers Squibb, Novartis, EMD Serono, Celldex, and Genentech; and has received royalties to his institution (per institutional policy) from MICA; related disorders patent pending. G.V.L. has received consulting fees from Amgen Inc., Array, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, and Pierre Fabre.	Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Andtbacka RHI, 2016, ANN SURG ONCOL, V23, P4169, DOI 10.1245/s10434-016-5286-0; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chesney J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw379.4; Chesney JA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9509; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Gerdes MJ, 2013, P NATL ACAD SCI USA, V110, P11982, DOI 10.1073/pnas.1300136110; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hoffner B, 2016, ONCOL NURS FORUM, V43, P219, DOI 10.1188/16.ONF.219-226; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Moesta A. K., 2017, CLIN CANC RES; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529; RIBAS A, 2015, J CLIN ONCOL S, V33; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	25	815	851	14	213	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 7	2017	170	6					1109	1119		10.1016/j.cell.2017.08.027	http://dx.doi.org/10.1016/j.cell.2017.08.027			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FG1ED	28886381	Green Accepted, Bronze			2023-01-03	WOS:000409536000009
J	Stolwijk, LJ; Weeke, LC; de Vries, LS; van Herwaarden, MYA; van der Zee, DC; van der Werff, DBM; Benders, MJNL; Toet, M; Lemmers, PMA				Stolwijk, Lisanne J.; Weeke, Lauren C.; de Vries, Linda S.; van Herwaarden, Maud Y. A.; van der Zee, David C.; van der Werff, Desiree B. M.; Benders, Manon J. N. L.; Toet, Mona; Lemmers, Petra M. A.			Effect of general anesthesia on neonatal aEEG - A cohort study of patients with non-cardiac congenital anomalies	PLOS ONE			English	Article							AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; CHILDREN; SEVOFLURANE; INFANTS; EEG; AGE; SURGERY; CHILDHOOD; INDUCTION; EMERGENCE	Introduction The aim of the current study was to determine the effect of general anesthesia on neonatal brain activity using amplitude-integrated EEG (aEEG). Methods A prospective cohort study of neonates (January 2013-December 2015), who underwent major neonatal surgery for non-cardiac congenital anomalies. Anesthesia was administered at the discretion of the anesthetist. aEEG monitoring was started six hours preoperatively until 24 hours after surgery. Analysis of classes of aEEG background patterns, ranging from continuous normal voltage to flat trace in six classes, and quantitative EEG-measures, using spontaneous activity transients (SATs) and interSATintervals (ISI), was performed. Results In total, 111 neonates were included (36 preterm/75 full-term), age at time of surgery was (median (range) 2 (0-32) days. During anesthesia depression of brain activity was seen, with background patterns ranging from flat trace to discontinuous normal voltage. In most patients brain activity was two background pattern classes lower during anesthesia. After cessation of anesthesia, recovery to preoperative brain activity occurred within 24 hours in 86% of the preterm and 96% of the term infants. Gestational age and the dose of sevoflurane were significantly associated with SAT-rate (F(2,68) = 9.288, p < 0.001) and ISI-durations during surgery (F(3,71) = 12.96, p < 0.001). Background pattern and quantitative EEG-values were not associated with brain lesions (chi(2)(4) = 2.086, ns). Conclusion aEEG shows a variable reduction of brain activity in response to anesthesia in neonates with noncardiac congenital anomalies, with fast recovery after cessation of anesthesia. This reduction is related to gestational age and the dose of sevoflurane. The aEEG offers the opportunity to monitor the depth of anesthesia in the neonate.	[Stolwijk, Lisanne J.; Weeke, Lauren C.; de Vries, Linda S.; Toet, Mona; Lemmers, Petra M. A.] Univ Med Ctr Utrecht, Dept Neonatol, Utrecht, Netherlands; [Stolwijk, Lisanne J.; Weeke, Lauren C.; de Vries, Linda S.; Benders, Manon J. N. L.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Stolwijk, Lisanne J.; van Herwaarden, Maud Y. A.; van der Zee, David C.] Univ Med Ctr Utrecht, Dept Pediat Surg, Utrecht, Netherlands; [van der Werff, Desiree B. M.] Univ Med Ctr Utrecht, Dept Anesthesiol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Lemmers, PMA (corresponding author), Univ Med Ctr Utrecht, Dept Neonatol, Utrecht, Netherlands.	p.lemmers@umcutrecht.nl	de Vries, Linda S/AAB-6454-2021					Akeju O, 2015, BRIT J ANAESTH, V115, P66, DOI 10.1093/bja/aev114; Backeljauw B, 2015, PEDIATRICS, V136, pE1, DOI 10.1542/peds.2014-3526; Benders MJ, 2015, CEREB CORTEX, V25, P3014, DOI 10.1093/cercor/bhu097; Brinkman EN, 2016, EUR J ANAESTHESIOL; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Cornelissen L, 2015, ELIFE, V4, DOI 10.7554/eLife.06513; Davidson AJ, 2006, PEDIATR ANESTH, V16, P374, DOI 10.1111/j.1460-9592.2006.01877.x; Davidson AJ, 2015, LANCET; Davidson AJ, 2008, PEDIATR ANESTH, V18, P60, DOI 10.1111/j.1460-9592.2007.02359.x; Davidson AJ, 2007, CURR OPIN ANESTHESIO, V20, P236, DOI 10.1097/ACO.0b013e3280c60c66; de Vries LS, 2005, ARCH DIS CHILD-FETAL, V90, P201, DOI 10.1136/adc.2004.062745; Ganesh Arjunan, 2004, Curr Opin Anaesthesiol, V17, P229, DOI 10.1097/00001503-200406000-00006; Gischler SJ, 2009, J PEDIATR SURG, V44, P1382, DOI 10.1016/j.jpedsurg.2008.12.034; Gorra AS, 2012, J PEDIATR SURG, V47, P125, DOI 10.1016/j.jpedsurg.2011.10.028; Gunn JK, 2012, INTENS CARE MED, V38, P1539, DOI 10.1007/s00134-012-2608-y; Hayashi K, 2012, NEUROSCI LETT, V517, P87, DOI 10.1016/j.neulet.2012.04.028; Hellstrom-Westas L., 2008, ATLAS AMPLITUDE INTE, V2nd; Istaphanous GK, 2010, BEST PRACT RES-CLIN, V24, P433, DOI 10.1016/j.bpa.2010.02.013; Kim HS, 2005, BRIT J ANAESTH, V95, P362, DOI 10.1093/bja/aei196; Kreuzer I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089191; Kuizenga K, 2001, BRIT J ANAESTH, V86, P354, DOI 10.1093/bja/86.3.354; Laing SR, 2011, J PAEDIATR CHILD H, V47, P140, DOI 10.1111/j.1440-1754.2010.01902.x; LERMAN J, 1994, ANESTHESIOLOGY, V80, P814, DOI 10.1097/00000542-199404000-00014; Lo SS, 2009, PEDIATR ANESTH, V19, P1157, DOI 10.1111/j.1460-9592.2009.03128.x; McKeever S, 2014, PEDIATR ANESTH, V24, P766, DOI 10.1111/pan.12366; Mehta B, 2016, J CHILD NEUROL, V31, P1276, DOI 10.1177/0883073816653781; Osredkar D, 2005, PEDIATRICS, V115, P327, DOI 10.1542/peds.2004-0863; Stolwijk LJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1728; Sun LS, 2016, JAMA-J AM MED ASSOC, V315, P2312, DOI 10.1001/jama.2016.6967; Sury MRJ, 2014, BRIT J ANAESTH, V112, P686, DOI 10.1093/bja/aet409; Toet MC, 2008, CLIN PERINATOL, V35, P665, DOI 10.1016/j.clp.2008.07.017; Vakkuri A, 2001, ACTA ANAESTH SCAND, V45, P805, DOI 10.1034/j.1399-6576.2001.045007805.x; Vanhatalo S, 2006, SEMIN FETAL NEONAT M, V11, P471, DOI 10.1016/j.siny.2006.07.008	33	13	13	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0183581	10.1371/journal.pone.0183581	http://dx.doi.org/10.1371/journal.pone.0183581			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF2PY	28859124	Green Submitted, Green Published, gold			2023-01-03	WOS:000408740500023
J	Sumankuuro, J; Crockett, J; Wang, SY				Sumankuuro, Joshua; Crockett, Judith; Wang, Shaoyu			Maternal health care initiatives: Causes of morbidities and mortalities in two rural districts of Upper West Region, Ghana	PLOS ONE			English	Article							STILLBIRTHS	Background Maternal and neonatal morbidities and mortalities have received much attention over the years in sub-Saharan Africa; yet addressing them remains a profound challenge, no more so than in the nation of Ghana. This study focuses on finding explanations to the conditions which lead to maternal and neonatal morbidities and mortalities in rural Ghana, particularly the Upper West Region. Method Mixed methods approach was adopted to investigate the medical and non-medical causes of maternal and neonatal morbidities and mortalities in two rural districts of the Upper West Region of Ghana. Survey questionnaires, in-depth interviews and focus group discussions were employed to collect data from: a) 80 expectant mothers (who were in their second and third trimesters, excluding those in their ninth month), b) 240 community residents and c) 13 healthcare providers (2 district directors of health services, 8 heads of health facilities and 3 nurses). Result Morbidity and mortality during pregnancy is attributed to direct causes such urinary tract infection (48%), hypertensive disorders (4%), mental health conditions (7%), nausea (4%) and indirect related sicknesses such as anaemia (11%), malaria, HIV/AIDS, oedema and hepatitis B (26%). Socioeconomic and cultural factors are identified as significant underlying causes of these complications and to morbidity and mortality during labour and the postnatal period. Birth asphyxia and traditional beliefs and practices were major causes of neonatal deaths. Conclusion These findings provide focused targets and open a window of opportunity for the community-based health services run by Ghana Health Service to intensify health education and promotion programmes directed at reducing risky economic activities and other cultural beliefs and practices affecting maternal and neonatal morbidity and mortality.	[Sumankuuro, Joshua; Crockett, Judith; Wang, Shaoyu] Charles Sturt Univ, Fac Sci, Sch Community Hlth, Orange, NSW, Australia	Charles Sturt University	Sumankuuro, J (corresponding author), Charles Sturt Univ, Fac Sci, Sch Community Hlth, Orange, NSW, Australia.	jsumankuuro@csu.edu.au	Dangal, Ganesh/O-1989-2017; Sumankuuro, Joshua/AAD-9951-2019; Wang, Shaoyu/M-5948-2015	Dangal, Ganesh/0000-0002-5834-5525; Sumankuuro, Joshua/0000-0002-8967-1091; Wang, Shaoyu/0000-0001-8674-8965; Crockett, Judith/0000-0003-2039-4345	Ghana Education Trust Fund (GETFUND) Doctorate Studentship	Ghana Education Trust Fund (GETFUND) Doctorate Studentship	This research was funded by Ghana Education Trust Fund (GETFUND) Doctorate Studentship to JS, http://www.getfund.gov.gh/. However, the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aborigo RA, 2014, AFR J REPROD HEALTH, V18, P78; Aboulghar M, 2016, HUM REPROD, V31, P1631, DOI 10.1093/humrep/dew154; Acosta DF, 2012, REV ESC ENFERM USP, V46, P1328; Alabi AA, 2015, AFR J PRIM HEALTH CA, V7, DOI 10.4102/phcfm.v7i1.881; Anyait A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-132; Asamoah BO, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-159; Bayu H, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.28082; Cofie LE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0604-2; [Daffiama/ Bussie/ Issa Service LG], 2014, DAFF BUSS ISS DISTR; Der E M, 2013, Ghana Med J, V47, P158; Ekabua J., 2011, ISRN OBSTET GYNECOL, V2011, P1, DOI [10. 5402/ 2011/ 560641, DOI 10.5402/2011/560641]; Engmann C, 2012, TROP MED INT HEALTH, V17, P272, DOI 10.1111/j.1365-3156.2011.02931.x; Flenady V, 2016, LANCET, V387, P691, DOI 10.1016/S0140-6736(15)01020-X; Galaa SZ, 2016, GHANA J DEV STUDIES, V13, P80, DOI [10. 4314/gjds. v13i1. 5, DOI 10.4314/GJDS.V13I1.5]; Illah Evance, 2013, Afr J Reprod Health, V17, P119; Masuy-Stroobant G., 2002, DETERMINANTS INFANT, P15; MoH/ GHS, 2010, HLTH SECT MED TERM D; Mosley WH, 1984, POPUL DEV REV, V10, P25, DOI 10.2307/2807954; [NDA Government L], 2014, PROF NAODWL DISTR AS; Otolorin E, 2015, INT J GYNECOL OBSTET, V130, pS46, DOI 10.1016/j.ijgo.2015.03.007; Rahman A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001442; Rishworth A, 2016, SOC SCI MED, V148, P8, DOI 10.1016/j.socscimed.2015.11.018; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Storm F, 2014, LANCET GLOB HEALTH, V2, pE566, DOI 10.1016/S2214-109X(14)70297-9; Sychareun V, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1031-8; Udofia Emilia A, 2013, Afr J Reprod Health, V17, P27; UNDP/ NDPC, 2012, 2010 MILL DEV GOALS; [UNFPA United Nations Population Fund G], 2014, FACTS SHEET, P2; WHO, 2019, MAT MORT; WHO. UNICEF UNFPA World Bank Group Division atUNP, 2015, TRENDS MAT MORT 1990; Witter S, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-16	31	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2017	12	8							e0183644	10.1371/journal.pone.0183644	http://dx.doi.org/10.1371/journal.pone.0183644			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF1XX	28854248	Green Submitted, gold, Green Published			2023-01-03	WOS:000408693600052
J	Kwak, YK; Lee, SW; Kay, CS; Park, HH				Kwak, Yoo-Kang; Lee, Sea-Won; Kay, Chul Seung; Park, Hee Hyun			Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose	PLOS ONE			English	Article							CERVICAL-CANCER; CLINICAL-OUTCOMES; CONCURRENT CHEMOTHERAPY; RADICAL SURGERY; CARCINOMA; WOMEN; IRRADIATION; IMPACT; CISPLATIN; UTERUS	This retrospective study was performed to evaluate and compare gastrointestinal (GI) toxicities caused by conventional radiotherapy (cRT) and intensity modulated radiotherapy (IMRT) in 136 cancer patients treated with pelvic radiotherapy (RT) with moderate radiation dose in a single institution. A matched-pair analysis of the two groups was performed; each group included 68 patients. Conventional RT was delivered using the four-field box technique and IMRT was delivered with helical tomotherapy. The median daily dose was 1.8 Gy and the median total dose was 50.4 Gy (range 25.2-56 Gy). Primary end point was GI toxicity during and after RT. Secondary end point was factors that affect toxicity. Patients treated with IMRT had lower incidence of grade >= 2 acute GI toxicity compared to the patients treated with cRT (p = 0.003). The difference remained significant in multivariate analysis (p = 0.01). The incidence of chronic GI toxicity was not statistically different between the two groups, but the cRT group had higher incidence of grade 3 chronic GI toxicity. Based on our results, IMRT can reduce GI toxicity compared to cRT in the treatment of pelvic radiotherapy even with moderate radiation dose and this will enhance patients' quality of life and treatment compliance.	[Kwak, Yoo-Kang; Lee, Sea-Won] Catholic Univ Korea, Seoul St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Kay, Chul Seung; Park, Hee Hyun] Catholic Univ Korea, Incheon St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea	Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea	Kay, CS (corresponding author), Catholic Univ Korea, Incheon St Marys Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea.	k41645@chol.com		Kwak, Yoo-Kang/0000-0002-7615-7819				Barker CL, 2009, BRIT J CANCER, V100, P1558, DOI 10.1038/sj.bjc.6605050; Barraclough LH, 2012, RADIOTHER ONCOL, V103, P327, DOI 10.1016/j.radonc.2012.04.018; Brixey CJ, 2002, INT J RADIAT ONCOL, V54, P1388, DOI 10.1016/S0360-3016(02)03801-4; Buchali A, 1999, RADIOTHER ONCOL, V52, P29, DOI 10.1016/S0167-8140(99)00068-7; Chan P, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-13; Chen MF, 2007, INT J RADIAT ONCOL, V67, P1438, DOI 10.1016/j.ijrobp.2006.11.005; Denham JW, 1999, RADIOTHER ONCOL, V51, P43, DOI 10.1016/S0167-8140(99)00027-4; Du XL, 2012, GYNECOL ONCOL, V125, P151, DOI 10.1016/j.ygyno.2011.12.432; Eifel PJ, 2004, J CLIN ONCOL, V22, P872, DOI 10.1200/JCO.2004.07.197; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; Gandhi AK, 2013, INT J RADIAT ONCOL, V87, P542, DOI 10.1016/j.ijrobp.2013.06.2059; Gilbert A, 2015, INT J RADIAT ONCOL, V92, P555, DOI 10.1016/j.ijrobp.2015.02.021; Huh SJ, 2004, RADIOTHER ONCOL, V71, P73, DOI 10.1016/j.radonc.2004.01.005; Kidd EA, 2010, INT J RADIAT ONCOL, V77, P1085, DOI 10.1016/j.ijrobp.2009.06.041; Krol R, 2014, INT J COLORECTAL DIS, V29, P273, DOI 10.1007/s00384-013-1784-8; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Lengele B, 2009, RADIOTHER ONCOL, V92, P22, DOI 10.1016/j.radonc.2008.11.007; Lukka H, 2002, CLIN ONCOL-UK, V14, P203, DOI 10.1053/clon.2002.0076; Mell LK, 2008, INT J RADIAT ONCOL, V71, P1504, DOI 10.1016/j.ijrobp.2008.04.046; Mundt AJ, 2002, INT J RADIAT ONCOL, V52, P1330, DOI 10.1016/S0360-3016(01)02785-7; Mundt AJ, 2001, GYNECOL ONCOL, V82, P456, DOI 10.1006/gyno.2001.6250; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Ray A, 2013, ASIA-PAC J CLIN ONCO, V9, P280, DOI 10.1111/ajco.12049; Roeske JC, 2003, RADIOTHER ONCOL, V69, P201, DOI 10.1016/j.radonc.2003.05.001; Roeske JC, 2000, INT J RADIAT ONCOL, V48, P1613, DOI 10.1016/S0360-3016(00)00771-9; Taylor A, 2007, CLIN ONCOL-UK, V19, P542, DOI 10.1016/j.clon.2007.05.002; van de Bunt L, 2008, RADIOTHER ONCOL, V88, P233, DOI 10.1016/j.radonc.2007.12.017; YEOH E, 1993, AM J MED, V95, P397, DOI 10.1016/0002-9343(93)90309-D; Yeoh EEK, 2004, AM J GASTROENTEROL, V99, P361, DOI 10.1111/j.1572-0241.2004.04037.x; Yeoh EEK, 2000, INT J RADIAT ONCOL, V47, P915, DOI 10.1016/S0360-3016(00)00487-9; Yeoh EK, 2012, INT J RADIAT ONCOL, V84, pE593, DOI 10.1016/j.ijrobp.2012.06.032	31	16	20	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2017	12	8							e0183339	10.1371/journal.pone.0183339	http://dx.doi.org/10.1371/journal.pone.0183339			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE8EO	28846718	Green Published, Green Submitted, gold			2023-01-03	WOS:000408438600025
J	Harlow, CR; Wu, X; van Deemter, M; Gardiner, F; Poland, C; Green, R; Sarvi, S; Brown, P; Kadler, KE; Lu, YH; Mason, JI; Critchley, HOD; Hillier, SG				Harlow, Christopher R.; Wu, Xuan; van Deemter, Marielle; Gardiner, Fiona; Poland, Craig; Green, Rebecca; Sarvi, Sana; Brown, Pamela; Kadler, Karl E.; Lu, Yinhui; Mason, J. Ian; Critchley, Hilary O. D.; Hillier, Stephen G.			Targeting lysyl oxidase reduces peritoneal fibrosis	PLOS ONE			English	Article							SURFACE EPITHELIAL-CELLS; TO-MESENCHYMAL TRANSITION; ADHESION FORMATION; CARBON NANOTUBES; INJURED PERITONEUM; MESOTHELIAL CELLS; FOLLICULAR-FLUID; ABDOMINAL-CAVITY; MICE; PROGESTERONE	Background Abdominal surgery and disease cause persistent abdominal adhesions, pelvic pain, infertility and occasionally, bowel obstruction. Current treatments are ineffective and the aetiology is unclear, although excessive collagen deposition is a consistent feature. Lysyl oxidase (Lox) is a key enzyme required for crosslinking and deposition of insoluble collagen, so we investigated whether targeting Lox might be an approach to reduce abdominal adhesions. Methods Female C57Bl/6 mice were treated intraperitoneally with multiwalled carbon nanotubes (NT) to induce fibrosis, together with chemical (beta-aminoproprionitrile-BAPN) or miRNA Lox inhibitors, progesterone or dexamethasone. Fibrotic lesions on the diaphragm, and expression of fibrosis-related genes in abdominal wall peritoneal mesothelial cells (PMC) were measured. Effects of BAPN and dexamethasone on collagen fibre alignment were observed by TEM. Isolated PMC were cultured with interleukin-1 alpha (IL-1 alpha) and progesterone to determine effects on Lox mRNA in vitro. Results NT-induced fibrosis and collagen deposition on the diaphragm was ameliorated by BAPN, Lox miRNA, or steroids. BAPN and dexamethasone disrupted collagen fibres. NT increased PMC Lox, Col1a1, Col3a1 and Bmp1 mRNA, which was inhibited by steroids. Progesterone significantly inhibited IL-1 alpha induced Lox expression by PMC in vitro. Conclusion Our results provide proof-of-concept that targeting peritoneal Lox could be an effective approach in ameliorating fibrosis and adhesion development.	[Harlow, Christopher R.; Wu, Xuan; van Deemter, Marielle; Gardiner, Fiona; Green, Rebecca; Sarvi, Sana; Brown, Pamela; Mason, J. Ian; Critchley, Hilary O. D.; Hillier, Stephen G.] Univ Edinburgh, MRC, Ctr Reprod Hlth, Edinburgh Med Sch,Queens Med Res Inst, 47 Little France Crescent, Edinburgh, Midlothian, Scotland; [Poland, Craig] Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh Med Sch,Queens Med Res Inst, 47 Little France Crescent, Edinburgh, Midlothian, Scotland; [Kadler, Karl E.; Lu, Yinhui] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Michael Smith Bldg, Manchester, Lancs, England	University of Edinburgh; University of Edinburgh; University of Manchester	Harlow, CR (corresponding author), Univ Edinburgh, MRC, Ctr Reprod Hlth, Edinburgh Med Sch,Queens Med Res Inst, 47 Little France Crescent, Edinburgh, Midlothian, Scotland.	c.harlow@ed.ac.uk	CRITCHLEY, HILARY OD/C-7575-2013; KADLER, KARL/ABI-2403-2020; Poland, Craig/AAM-8237-2020	KADLER, KARL/0000-0003-4977-4683; Poland, Craig/0000-0002-5345-1249; CRITCHLEY, HILARY/0000-0003-1913-4044; hillier, stephen/0000-0001-7378-5855	Medical Research Council [G0900550]; Wellcome Trust [091840/Z/10/Z]; Medical Research Council [G0701127] Funding Source: researchfish; MRC [G0701127, G0900550] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was support by Medical Research Council Project Grant G0900550 (to SGH, JIM, HODC, CRH) and a Wellcome Trust Grant 091840/Z/10/Z (to KEK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Prof Ken Donaldson for access to his intra-peritoneal NT-induced fibrosis model, and for his advice throughout the study. We gratefully acknowledge Dr Pamela Brown for advising use of miRNA to knock-down gene expression, and her expertise in generation of the DNA constructs and subsequent lentivirus production (http://surf.ed.ac.uk/viral-vectors/). We also thank Prof John Iredale for his helpful comments and advice during the study. This study was support by Medical Research Council Project Grant G0900550 (to SGH, JIM, HODC & CRH) and a Wellcome Trust Grant 091840/Z/10/Z (to KEK).	ABUHIJLEH MF, 1995, J ANAT, V186, P453; Ahmad G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001298.pub4; Atta HM, 2011, WORLD J GASTROENTERO, V17, P5049, DOI 10.3748/wjg.v17.i46.5049; Binda MM, 2007, SURG ENDOSC, V21, P1826, DOI 10.1007/s00464-007-9296-7; Braun N, 2011, PERITON DIALYSIS INT, V31, P291, DOI 10.3747/pdi.2010.00118; Burnett SH, 2004, J LEUKOCYTE BIOL, V75, P612, DOI 10.1189/jlb.0903442; Calabro ML, 2009, BLOOD, V113, P4525, DOI 10.1182/blood-2008-09-180307; Cicinelli E, 2009, FERTIL STERIL, V92, P306, DOI 10.1016/j.fertnstert.2008.05.044; Colwell AS, 2006, PLAST RECONSTR SURG, V118, P1125, DOI 10.1097/01.prs.0000221056.27536.db; Corona R, 2011, FERTIL STERIL, V95, P1224, DOI 10.1016/j.fertnstert.2011.01.004; diZeregal GS, 2001, HUM REPROD UPDATE, V7, P547, DOI 10.1093/humupd/7.6.547; Donaldson K, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-5; Evans J, 2009, FASEB J, V23, P2165, DOI 10.1096/fj.08-124495; FAYEZ JA, 1987, AM J OBSTET GYNECOL, V157, P1184, DOI 10.1016/S0002-9378(87)80291-0; Fegan KS, 2008, J ENDOCRINOL, V196, P369, DOI 10.1677/JOE-07-0419; FUJII T, 1983, J REPROD FERTIL, V69, P307, DOI 10.1530/jrf.0.0690307; Haney AF, 2000, FERTIL STERIL, V73, P988, DOI 10.1016/S0015-0282(00)00490-8; Harlow CR, 2003, ENDOCRINOLOGY, V144, P154, DOI 10.1210/en.2002-220652; Harlow CR, 1997, FERTIL STERIL, V68, P48, DOI 10.1016/S0015-0282(97)81474-4; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; HOCKEL M, 1987, ANN CHIR GYNAECOL FE, V76, P306; HOFFMAN DL, 1983, EXP MOL PATHOL, V39, P154, DOI 10.1016/0014-4800(83)90048-5; Hoshino A, 2007, J IMMUNOL, V178, P5296, DOI 10.4049/jimmunol.178.8.5296; Jansen R P, 1990, Prog Clin Biol Res, V358, P177; Kamel RM, 2010, EUR J OBSTET GYN R B, V150, P111, DOI 10.1016/j.ejogrb.2010.02.003; Kucukozkan T, 2004, ANZ J SURG, V74, P1111, DOI 10.1111/j.1445-1433.2004.03261.x; Li YC, 2013, P NATL ACAD SCI USA, V110, P2324, DOI 10.1073/pnas.1214136110; Maki JM, 2005, AM J PATHOL, V167, P927, DOI 10.1016/S0002-9440(10)61183-2; Margetts PJ, 2013, NEPHROL DIAL TRANSPL, V28, P2015, DOI 10.1093/ndt/gfs289; MAURER JH, 1983, FERTIL STERIL, V39, P485; McCloskey C, 2014, EMBO MOL MED, V6, P1161, DOI 10.15252/emmm.201403944; Murphy FA, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-8; Olaso E, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-5; OZASA H, 1981, ENDOCRINOLOGY, V109, P618, DOI 10.1210/endo-109-2-618; Pados G, 2010, REPROD BIOMED ONLINE, V21, P290, DOI 10.1016/j.rbmo.2010.04.021; Papacleovoulou G, 2011, J ENDOCRINOL, V211, P273, DOI 10.1530/JOE-11-0081; Perfumo F, 1996, NEPHROL DIAL TRANSPL, V11, P1803; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Qu C, 2012, GENE, V493, P9, DOI 10.1016/j.gene.2011.11.046; Rae MT, 2004, J ENDOCRINOL, V183, P19, DOI 10.1677/joe.1.05754; Rae MT, 2004, J CLIN ENDOCR METAB, V89, P4538, DOI 10.1210/jc.2003-032225; Ruiz LA, 2015, REPROD SCI, V22, P1496, DOI 10.1177/1933719115585144; SIITERI PK, 1977, ANN NY ACAD SCI, V286, P384, DOI 10.1111/j.1749-6632.1977.tb29431.x; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Starborg T, 2013, NAT PROTOC, V8, P1433, DOI 10.1038/nprot.2013.086; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; Sulaiman H, 2002, BIOCHEM SOC T, V30, P126, DOI 10.1042/BST0300126; Trackman PC, 2005, J CELL BIOCHEM, V96, P927, DOI 10.1002/jcb.20605; Vercellini P, 2014, NAT REV ENDOCRINOL, V10, P261, DOI 10.1038/nrendo.2013.255; Wang L, 2014, J BIOL CHEM, V289, P921, DOI 10.1074/jbc.M113.496364; Watson A, 2000, COCHRANE DB SYST REV; Yamaguchi A, 2012, J TOXICOL SCI, V37, P177, DOI 10.2131/jts.37.177; Yaron Y, 1999, J REPROD MED, V44, P253; Yokoi H, 2013, PERITON DIALYSIS INT, V33, P143, DOI 10.3747/pdi.2011.00033	54	26	26	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2017	12	8							e0183013	10.1371/journal.pone.0183013	http://dx.doi.org/10.1371/journal.pone.0183013			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD3KL	28800626	Green Submitted, Green Published, gold			2023-01-03	WOS:000407431800044
J	Tsilimingras, D; Ghosh, S; Duke, A; Zhang, LY; Carretta, H; Schnipper, J				Tsilimingras, Dennis; Ghosh, Samiran; Duke, Ashley; Zhang, Liying; Carretta, Henry; Schnipper, Jeffrey			The association of post-discharge adverse events with timely follow-up visits after hospital discharge	PLOS ONE			English	Article							PATIENTS AFTER-DISCHARGE; PHARMACIST INTERVENTION; CARE	Objective There has been little research to examine the association of post-discharge adverse events (AEs) with timely follow-up visits after hospital discharge. We aimed to examine whether having a timely follow-up outpatient visit would reduce the risk for post-discharge AEs. Methods This was a methods study of patients at risk for post-discharge AEs from December 2011 through October 2012. Five hundred and forty-five patients who were under the care of hospitalist physicians and were discharged home from a community hospital, spoke English, and could be contacted after discharge were evaluated. The aim of the study was to examine the association of post-discharge AEs with timely follow-up visits after hospital discharge based on structured telephone interviews, health record review, and adjudication by two blinded, trained physicians using a previously established methodology. Results We observed a higher incidence of AEs with patients that had their first follow-up visit within 7 days after hospital discharge (33.5% vs. 23.0%, p = 0.007). This effect was attenuated somewhat but remained significant when adjusted for several patient factors (adjusted OR 1.33, 95% confidence interval 1.16-2.71). Conclusion This observational study paradoxically showed an increase in post-discharge AEs with early follow-up, likely a result of confounding by indication and/or information bias that could not be completely adjusted for. This study illustrates the potential hazards with conducting observational studies to determine the efficacy of various transitional care interventions, such as early follow-up, where risk for confounding by indication is high.	[Tsilimingras, Dennis; Ghosh, Samiran; Zhang, Liying] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA; [Duke, Ashley] Tallahassee Mem Hosp, Tallahassee, FL USA; [Carretta, Henry] Florida State Univ, Coll Med, Dept Behav Sci & Social Med, Tallahassee, FL 32306 USA; [Schnipper, Jeffrey] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Schnipper, Jeffrey] Harvard Med Sch, Boston, MA USA	Wayne State University; State University System of Florida; Florida State University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tsilimingras, D (corresponding author), Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA.	dtsilimi@med.wayne.edu		Carretta, Henry/0000-0002-1876-352X	Agency for Healthcare Research and Quality [R01HS018694]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work is supported by an R01 award from the Agency for Healthcare Research and Quality (grant R01HS018694 to Dr. Tsilimingras). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Field TS, 2015, J GEN INTERN MED, V30, P565, DOI 10.1007/s11606-014-3106-4; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Jackson C, 2015, ANN FAM MED, V13, P115, DOI 10.1370/afm.1753; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kashiwagi DT, 2012, AM J MED QUAL, V27, P11, DOI 10.1177/1062860611409197; Kripalani S, 2012, ANN INTERN MED, V157, P1, DOI 10.7326/0003-4819-157-1-201207030-00003; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Misky GJ, 2010, J HOSP MED, V5, P392, DOI 10.1002/jhm.666; Parry C, 2008, MED CARE, V46, P317, DOI 10.1097/MLR.0b013e3181589bdc; Schnipper JL, 2010, CIRC-CARDIOVASC QUAL, V3, P212, DOI 10.1161/CIRCOUTCOMES.109.921833; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Tsilimingras D, 2015, J GEN INTERN MED, V30, P1164, DOI 10.1007/s11606-015-3260-3; Tsilimingras D, 2008, JT COMM J QUAL PATIE, V34, P85, DOI 10.1016/S1553-7250(08)34011-2	15	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2017	12	8							e0182669	10.1371/journal.pone.0182669	http://dx.doi.org/10.1371/journal.pone.0182669			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD2WT	28796810	Green Submitted, Green Published, gold			2023-01-03	WOS:000407396200076
J	Niihata, K; Fukuma, S; Akizawa, T; Fukuhara, S				Niihata, Kakuya; Fukuma, Shingo; Akizawa, Tadao; Fukuhara, Shunichi			Association of coping strategies with mortality and health-related quality of life in hemodialysis patients: The Japan Dialysis Outcomes and Practice Patterns Study	PLOS ONE			English	Article							SHORT-FORM; SURVIVAL; STRESS; CANCER; DOPPS; HOSPITALIZATION; INDIVIDUALS; DEPRESSION; MANAGEMENT; PREDICTOR	Background Hemodialysis patients are exposed to disease-and treatment-related stresses, and use various coping strategies to deal with these stresses. Although some studies have reported the association of coping strategies with mortality or health-related quality of life (QOL) in some populations, the effect of coping strategies on clinical outcomes in hemodialysis patients remains unclear. We investigated the association in a longitudinal design among Japanese hemodialysis patients. Methods We examined Japanese hemodialysis patients who participated in the Dialysis Outcomes and Practice Patterns Study (DOPPS) IV, which was conducted between 2009 and 2012. The exposure variable was stress coping strategy, as assessed using subscales in Coping Strategies Inventory Short Form: problem-focused engagement, problem-focused disengagement, emotion-focused engagement, and emotion-focused disengagement. Hazard ratios were estimated using Cox proportional hazard model for all-cause mortality and mean differences for change in health-related QOL in 1 year were estimated using a regression model. Results Among 1,354 patients, only problem-focused engagement was significantly associated with longer survival; other subscales were not associated with all-cause mortality after adjustment for potential confounding factors. In terms of health-related QOL, the subscale of problem-focused engagement was also associated with improvement in physical functioning and mental health among 1,045 patients. Emotion-focused disengagement was associated with deterioration in mental health, but not with change in physical functioning. The other subscales were not associated with change in physical functioning or mental health. Conclusions Among hemodialysis patients, "problem-focused engagement" coping strategies were associated with longer survival and also with improvement in physical functioning and mental health. To achieve greater longevity and improve QOL in hemodialysis patients under ongoing stresses, problem-focused engagement should be encouraged.	[Niihata, Kakuya] Fukushima Med Univ, Div Clin Epidemiol, Fukushima, Japan; [Niihata, Kakuya; Fukuma, Shingo; Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence CIR, Fukushima, Japan; [Fukuma, Shingo; Fukuhara, Shunichi] Kyoto Univ Med, Sch Publ Hlth, Dept Healthcare & Epidemiol, Kyoto, Japan; [Fukuma, Shingo] Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Kyoto, Japan; [Akizawa, Tadao] Showa Univ, Div Nephrol, Dept Med, Sch Med, Tokyo, Japan	Fukushima Medical University; Fukushima Medical University; Kyoto University; Showa University	Fukuma, S (corresponding author), Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence CIR, Fukushima, Japan.; Fukuma, S (corresponding author), Kyoto Univ Med, Sch Publ Hlth, Dept Healthcare & Epidemiol, Kyoto, Japan.; Fukuma, S (corresponding author), Inst Hlth Outcomes & Proc Evaluat Res iHope Int, Kyoto, Japan.	fukumashingo.3m@kyoto-u.ac.jp		Fukuma, Shingo/0000-0002-8379-8761	Kyowa Hakko Kirin	Kyowa Hakko Kirin(Kyowa Kirin Ltd)	This study was supported by Kyowa Hakko Kirin. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addison Clifton C, 2007, Int J Environ Res Public Health, V4, P289, DOI 10.3390/ijerph200704040004; ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; BOLGER N, 1990, J PERS SOC PSYCHOL, V59, P525, DOI 10.1037/0022-3514.59.3.525; CHRISTENSEN AJ, 1995, J CONSULT CLIN PSYCH, V63, P454, DOI 10.1037//0022-006X.63.3.454; Cukor D, 2014, J AM SOC NEPHROL, V25, P196, DOI 10.1681/ASN.2012111134; Dehkordi Leila Mardanian, 2013, Iran J Nurs Midwifery Res, V18, P42; Gillanders S, 2008, AM J KIDNEY DIS, V51, P651, DOI 10.1053/j.ajkd.2007.12.023; Graven LJ, 2013, HEART LUNG, V42, P183, DOI 10.1016/j.hrtlng.2012.12.002; GREER S, 1991, PSYCHOL MED, V21, P43, DOI 10.1017/S003329170001463X; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Iioka Y, 2015, JPN J NURS SCI, V12, P1, DOI 10.1111/jjns.12036; Ko B, 2007, NEPHROL DIAL TRANSPL, V22, P2985, DOI 10.1093/ndt/gfm341; Krageloh CU, 2011, RELIGIONS, V2, P216, DOI 10.3390/rel2030216; Krageloh CU, 2012, J RELIG HEALTH, V51, P1137, DOI 10.1007/s10943-010-9416-x; Kvillemo P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112733; MacDonald DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117701; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; Messerli-Burgy N, 2015, BRIT J PSYCHIAT, V207, P256, DOI 10.1192/bjp.bp.114.154419; Monti PM, 1997, ADDICTION, V92, P1717, DOI 10.1111/j.1360-0443.1997.tb02892.x; Petticrew M, 2002, BRIT MED J, V325, P1066, DOI 10.1136/bmj.325.7372.1066; Pisoni RL, 2004, AM J KIDNEY DIS, V44, pS7, DOI 10.1053/j.ajkd.2004.08.005; Reynolds P, 2000, AM J EPIDEMIOL, V152, P940, DOI 10.1093/aje/152.10.940; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wolf EJ, 2009, HEALTH PSYCHOL, V28, P330, DOI 10.1037/a0013583; Yalcin BM, 2014, J AM BOARD FAM MED, V27, P645, DOI 10.3122/jabfm.2014.05.140083; Yeh SCJ, 2007, PSYCHOSOM MED, V69, P182, DOI 10.1097/PSY.0b013e318031cdcc; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x	29	16	17	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2017	12	7							e0180498	10.1371/journal.pone.0180498	http://dx.doi.org/10.1371/journal.pone.0180498			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FB8DV	28742807	Green Published, Green Submitted, gold			2023-01-03	WOS:000406370000013
J	Yu, MY; Lee, SW; Baek, SH; Na, KY; Chae, DW; Chin, HJ; Kim, S				Yu, Mi-yeon; Lee, Sung Woo; Baek, Seon Ha; Na, Ki Young; Chae, Dong-Wan; Chin, Ho Jun; Kim, Sejoong			Hypoalbuminemia at admission predicts the development of acute kidney injury in hospitalized patients: A retrospective cohort study	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; NITRIC-OXIDE; SERUM-ALBUMIN; RISK-FACTOR; SURVIVAL; RESUSCITATION; METAANALYSIS; OUTCOMES; SURGERY	Background Development of acute kidney injury (AKI) is common and is associated with poor outcomes. We aimed to determine whether hypoalbuminemia (HA) at admission could be a risk factor for the development of AKI and mortality in hospitalized patients. Methods We enrolled patients who were admitted to Seoul National University Bundang Hospital from January 2013 to December 2013. HA at admission was defined as a serum albumin level < 3.4 mg/dL measured within two days after admission. AKI was defined as an increase in the serum creatinine level by >= 0.3 mg/dL or >= 1.5 times of the baseline value during the hospital stay. Results A total of 19,472 patients were enrolled and divided into HA and normoalbuminemia (NA) groups at admission. The incidence of AKI was 10.7% (340/3179) in the HA group and 4.1% (662/16293) in the NA group (adjusted odds ratio [OR], 1.243; 95% confidence interval [CI], 1.069 +/- 1.445; P = 0.005). The hazard ratios for the 30-day, 90-day, and 1-year mortality were 1.873 (95% CI, 1.383 +/- 2.537; P < 0.001), 1.710 (95% CI, 1.410 +/- 2.072; P < 0.001), and 1.372 (95% CI, 1.214 +/- 1.551; P < 0.001), compared to the NA group. In patients with AKI, albumin replacement improved renal recovery (OR, 2.605; 95% CI, 1.450 +/- 4.681; P = 0.001). The mortality rate was not different according to albumin replacement. Conclusions HA is associated with the development of AKI and high mortality in hospitalized patients. Replacement of albumin after the development of AKI may contribute to renal recovery. Further clinical trials are warranted.	[Yu, Mi-yeon] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Lee, Sung Woo] Eulji Gen Hosp, Dept Internal Med, Seoul, South Korea; [Baek, Seon Ha] Hallym Univ, Dept Internal Med, Dongtan Sacred Heart Hosp, Gyeonggi Do, South Korea; [Na, Ki Young; Chae, Dong-Wan; Chin, Ho Jun; Kim, Sejoong] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea	Seoul National University (SNU); Seoul National University Hospital; Eulji University; Hallym University; Seoul National University (SNU)	Kim, S (corresponding author), Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea.	sejoong2@snu.ac.kr	Yu, Mi-Yeon/ABB-7937-2021; Kim, Sejoong/J-5356-2015	Kim, Sejoong/0000-0002-7238-9962	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C2221]; National Research Foundation of Korea [2017R1A2B4005251]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; National Research Foundation of Korea(National Research Foundation of Korea)	This research was supported by the a grand of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C2221), and a grant No. 2017R1A2B4005251 from the National Research Foundation of Korea.	Asher V, 2012, MED ONCOL, V29, P2005, DOI 10.1007/s12032-011-0019-5; Baek SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156444; Berbel MN, 2011, REV ASSOC MED BRAS, V57, P600, DOI 10.1590/S0104-42302011000500022; Brown JR, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4278579; BURLESON RL, 1978, ARCH SURG-CHICAGO, V113, P688; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Chawla LS, 2005, KIDNEY INT, V68, P2274, DOI 10.1111/j.1523-1755.2005.00686.x; Coca SG, 2009, AM J KIDNEY DIS, V53, P961, DOI 10.1053/j.ajkd.2008.11.034; CONTRERAS AM, 1994, REV INVEST CLIN, V46, P37; DOWEIKO JP, 1991, JPEN-PARENTER ENTER, V15, P207, DOI 10.1177/0148607191015002207; Duly EB, 2003, J CLIN PATHOL, V56, P780, DOI 10.1136/jcp.56.10.780; Frenette AJ, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0602-1; GERKENS JF, 1990, EUR J PHARMACOL, V177, P119, DOI 10.1016/0014-2999(90)90261-4; Hollenberg SM, 1997, AM J PHYSIOL-REG I, V272, pR969, DOI 10.1152/ajpregu.1997.272.3.R969; Hsu RK, 2013, J AM SOC NEPHROL, V24, P37, DOI 10.1681/ASN.2012080800; Igleslas J, 1999, AM J PHYSIOL-RENAL, V277, pF711, DOI 10.1152/ajprenal.1999.277.5.F711; Jellinge ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105983; Kellum JA, 2017, AM J RESP CRIT CARE, V195, P784, DOI 10.1164/rccm.201604-0799OC; Kellum JA, 2016, AM J RESP CRIT CARE, V193, P281, DOI 10.1164/rccm.201505-0995OC; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Lee EH, 2016, ANESTHESIOLOGY, V124, P1001, DOI 10.1097/ALN.0000000000001051; Lee EH, 2012, INTENS CARE MED, V38, P1478, DOI 10.1007/s00134-012-2599-8; Lee SW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162990; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Liangos O, 2006, CLIN J AM SOC NEPHRO, V1, P43, DOI 10.2215/CJN.00220605; Liu M, 2012, EUR J HEART FAIL, V14, P39, DOI 10.1093/eurjhf/hfr154; Lopes JA, 2013, CLIN KIDNEY J, V6, P8, DOI 10.1093/ckj/sfs160; Lyons O, 2010, EUR J INTERN MED, V21, P17, DOI 10.1016/j.ejim.2009.10.010; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; POCKAJ BA, 1994, J IMMUNOTHER, V15, P22, DOI 10.1097/00002371-199401000-00003; Pulimood TB, 2000, CRIT CARE, V4, P151, DOI 10.1186/cc688; ROTHMAN KJ, 1974, AM J EPIDEMIOL, V99, P385, DOI 10.1093/oxfordjournals.aje.a121626; Sang BH, 2015, CRIT CARE MED, V43, P2552, DOI 10.1097/CCM.0000000000001279; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Sung J, 2004, AM SURGEON, V70, P1099; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Thomas ME, 2015, KIDNEY INT, V87, P62, DOI 10.1038/ki.2014.328; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Tsai HS, 2014, ACTA CARDIOL SIN, V30, P93; Wiedermann CJ, 2010, INTENS CARE MED, V36, P1657, DOI 10.1007/s00134-010-1928-z; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Zamlauski-Tucker M, 1988, Ren Physiol, V10, P352	42	30	31	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2017	12	7							e0180750	10.1371/journal.pone.0180750	http://dx.doi.org/10.1371/journal.pone.0180750			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB3UH	28723973	gold, Green Submitted, Green Published			2023-01-03	WOS:000406067800022
J	Sevrin, T; Alexandre-Gouabau, MC; Darmaun, D; Palvadeau, A; Andre, A; Nguyen, P; Ouguerram, K; Boquien, CY				Sevrin, Thomas; Alexandre-Gouabau, Marie-Cecile; Darmaun, Dominique; Palvadeau, Antoine; Andre, Agnes; Nguyen, Patrick; Ouguerram, Khadija; Boquien, Clair-Yves			Use of water turnover method to measure mother's milk flow in a rat model: Application to dams receiving a low protein diet during gestation and lactation	PLOS ONE			English	Article							TOTAL-BODY WATER; DEUTERIUM-OXIDE; RESTRICTION; GROWTH; METABOLISM; INSULIN; YIELD; O-18; LIFE; H-2	Assessment of milk production is of utmost relevance for pediatricians and scientists interested in early life nutrition. The weight-suckle-weight (WSW) method, which consists of weighing babies before and after they suckle their mother, uses the difference in body weight as an estimate of milk intake. However, this is prone to many sources of error. In the current study, we used for the first time the water turnover method and compartmental analysis with deuterated water (D2O) as a non-toxic tracer to quantify in vivo milk production in a rat model. We assessed the effect of a nutritional intervention presumed to affect milk production, a maternal dietary protein restriction during gestation and lactation, which results in the birth of pups with intrauterine growth restriction. The specific aim of this study was to determine milk production with the body water turnover method in rat dams receiving during gestation and lactation, either a control diet (NP) or an iso-caloric low-protein diet (LP). In NP dams, mass of dam's total body water, output flow constant from dam to litter (K21) and median milk flow, calculated between days 11 to 14 after pup birth, were 282.1 g, 0.0122 h(-1) and 3.30 g/h for NP dams, respectively. Maternal dietary protein restriction (-59%) during perinatal period led to a 34% reduction in milk flow (NP versus LP). With the WSW method, milk flow varied from 1.96 g/h to 2.37 g/h between days 11 to 14 for NP dams. The main advantage of the D(2)0 method compared to the WSW method stems from its higher precision, as attested by the narrowest range of measured values of milk flow ([2.90; 3.75] and [0.98; 6.85] g/h, respectively) for NP group. This method could be suitable for testing the effectiveness of candidate galactologue molecules presumed to enhance milk production in the lactating rat model.	[Sevrin, Thomas; Alexandre-Gouabau, Marie-Cecile; Darmaun, Dominique; Palvadeau, Antoine; Ouguerram, Khadija; Boquien, Clair-Yves] Univ Nantes, UMR PhAN, INRA, CRNH Ouest, Nantes, France; [Darmaun, Dominique] CHU Hotel Dieu, Nantes Hosp, CRNH Ouest, IMAD,DHU2020, Nantes, France; [Andre, Agnes; Nguyen, Patrick] Nantes Atlantic Natl Coll Vet Med, ONIRIS, UNE, Nantes, France	INRAE; Nantes Universite; Nantes Universite; CHU de Nantes; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique	Boquien, CY (corresponding author), Univ Nantes, UMR PhAN, INRA, CRNH Ouest, Nantes, France.	clair-yves.boquien@univ-nantes.fr	Darmaun, Dominique/X-8453-2018; Boquien, Clair-Yves/AAP-5275-2020	Darmaun, Dominique/0000-0002-0366-3227; Boquien, Clair-Yves/0000-0001-6944-5372; Alexandre-Gouabau, Marie-Cecile/0000-0002-9966-9593; Sevrin, Thomas/0000-0003-2596-6998	AlimH Department of INRA (AlimH - ANSSD 2015); AlimH Department of INRA (AlimH-ANSSD 2015)	AlimH Department of INRA (AlimH - ANSSD 2015); AlimH Department of INRA (AlimH-ANSSD 2015)	The study was supported, in part, by a grant from the AlimH Department of INRA (AlimH - ANSSD 2015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was supported, in part, by a grant from the AlimH Department of INRA (AlimH-ANSSD 2015). The authors would like to thank specifically Guillaume POUPEAU and Thomas MOYON (PhAN, INRA, Nantes, France) for animal care and for statistical analysis supervision, respectively. The authors also acknowledge Prof. Jean-Francois HUNEAU (Agro-ParisTech) for his invaluable advice in setting up the deuterated water dilution method.	Agnoux AM, 2015, J NUTR BIOCHEM, V26, P784, DOI 10.1016/j.jnutbio.2015.02.012; Agnoux AM, 2014, AM J PHYSIOL-REG I, V307, pR184, DOI 10.1152/ajpregu.00015.2014; Bautista CJ, 2008, PEDIATR RES, V63, P358, DOI 10.1203/01.pdr.0000304938.78998.21; Berman ESF, 2015, EUR J CLIN NUTR, V69, P1091, DOI 10.1038/ejcn.2015.10; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; Coupe B, 2009, AM J PHYSIOL-REG I, V297, pR813, DOI 10.1152/ajpregu.00201.2009; Fanca-Berthon P, 2009, PEDIATR RES, V66, P47, DOI 10.1203/PDR.0b013e3181a2047e; Ferrier L, 2002, J NUTR, V132, p1725S, DOI 10.1093/jn/132.6.1725S; FOY JM, 1960, J PHYSIOL-LONDON, V154, P169, DOI 10.1113/jphysiol.1960.sp006571; Haisma H, 2003, BREAST MILK ENERGY I; Hauck YL, 2011, MATERN CHILD HLTH J, V15, P260, DOI 10.1007/s10995-009-0554-2; Houdebine L- M, 2007, BIOL LACTATION; KANTO U, 1980, J NUTR, V110, P1840, DOI 10.1093/jn/110.9.1840; KLAVER J, 1981, J ANIM SCI, V52, P1091, DOI 10.2527/jas1981.5251091x; Maugeais C, 1998, CLIN CHEM LAB MED, V36, P739, DOI 10.1515/CCLM.1998.131; Morag M, 1975, Lab Anim, V9, P43, DOI 10.1258/002367775780994844; Moretto VL, 2011, ISRN OBSTET GYNECOL, V2011, DOI [10.5402/2011/876502, DOI 10.5402/2011/876502]; Salanave B., 2014, Bulletin Epidemiologique Hebdomadaire, P450; SAMPSON DA, 1984, J PEDIATR GASTR NUTR, V3, P613, DOI 10.1097/00005176-198409000-00023; Savenije OEM, 2006, ARCH DIS CHILD-FETAL, V91, P330, DOI 10.1136/adc.2005.091876; SCHOELLER DA, 1980, AM J CLIN NUTR, V33, P2686, DOI 10.1093/ajcn/33.12.2686; Siret V, 2008, ARCH PEDIATRIE, V15, P1167, DOI 10.1016/j.arcped.2008.04.014; Theil PK, 2002, ACTA AGR SCAND A-AN, V52, P221, DOI 10.1080/090647002762381104; Thulier D, 2009, JOGNN-J OBST GYN NEO, V38, P259, DOI 10.1111/j.1552-6909.2009.01021.x; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Zardooz H, 2010, PHYSIOL RES, V59, P973, DOI 10.33549/physiolres.931896	26	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2017	12	7							e0180550	10.1371/journal.pone.0180550	http://dx.doi.org/10.1371/journal.pone.0180550			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS8PU	28715436	Green Published, gold, Green Submitted			2023-01-03	WOS:000443975500011
J	Deng, JL; Wang, LZ; Zhang, YF; Chang, XY; Ma, XJ				Deng, Jiali; Wang, Lizhong; Zhang, Yinfa; Chang, Xiangyang; Ma, Xingjie			Insertion of an intrathecal catheter in parturients reduces the risk of post-dural puncture headache: A retrospective study and meta-analysis	PLOS ONE			English	Article							ACCIDENTAL DURAL PUNCTURE; OBSTETRIC PATIENTS; EPIDURAL ANALGESIA; MANAGEMENT; LABOR; COMPLICATIONS; EXPERIENCE; BIAS	This study aimed to determine whether insertion of an intrathecal catheter following accidental dural puncture (ADP) in obstetric patients can reduce the incidence of post-dural puncture headache (PDPH) and the requirement of a therapeutic epidural blood patch (TEBP). This was also compared with relocating the epidural catheter at a different vertebral interspace. A retrospective study was performed, as well as a meta-analysis of the literature to further validate our findings. We reviewed the records of 86 obstetric patients who suffered from ADP during epidural anesthesia or combined spinal-epidural anesthesia from October 2015 to November 2016 at our institution. Although, there was no significant decrease in the incidence of PDPH (P = 0.08), the requirement for a TEBP (P = 0.025) was significantly reduced in the intrathecal catheter group compared with the relocated group. In the metaanalysis, 13 eligible studies including 1044 obstetric patients were finally identified. To estimate the pooled risk ratios (RRs), fixed or random effect models were used depending on the heterogeneity. We initially found that an intrathecal catheter significantly reduced the incidence of PDPH (pooled RR = 0.823; 95% CI = 0.700-0.967; P = 0.018) and the requirement of a TEBP (pooled RR = 0.616; 95% CI = 0.443-0.855; P = 0.004). Our study shows that insertion of an intrathecal catheter following ADP might be an effective and dependable method for reducing the risk of a PDPH and requirement for a TEBP in obstetric patients.	[Deng, Jiali; Wang, Lizhong; Zhang, Yinfa; Chang, Xiangyang] Jiaxing Univ, Sch Med, Jiaxing Matern & Child Hlth Hosp, Dept Anesthesia, Jiaxing, Zhejiang, Peoples R China; [Ma, Xingjie] Jiaxing Univ, Sch Med, Hosp Jiaxing 1, Dept Cardiothorac Surg, Jiaxing, Zhejiang, Peoples R China	Jiaxing University; Jiaxing University	Ma, XJ (corresponding author), Jiaxing Univ, Sch Med, Hosp Jiaxing 1, Dept Cardiothorac Surg, Jiaxing, Zhejiang, Peoples R China.	dr_maixngjie@163.com			Jiaxing Science and Technology Bureau in Zhengjiang Province, China [2013AY21050-2]	Jiaxing Science and Technology Bureau in Zhengjiang Province, China	This study was supported by the grant from Jiaxing Science and Technology Bureau in Zhengjiang Province, China (no. 2013AY21050-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes MV, 2016, ACTA MEDICA PORT, V29, P268, DOI 10.20344/amp.6815; Apfel CC, 2010, BRIT J ANAESTH, V105, P255, DOI 10.1093/bja/aeq191; Ayad S, 2003, REGION ANESTH PAIN M, V28, P512, DOI 10.1016/S1098-7339(03)00393-6; Baraz R, 2005, ANAESTHESIA, V60, P673, DOI 10.1111/j.1365-2044.2005.04222.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bolden N, 2016, REGION ANESTH PAIN M, V41, P169, DOI 10.1097/AAP.0000000000000339; COHEN S, 1994, ACTA ANAESTH SCAND, V38, P716, DOI 10.1111/j.1399-6576.1994.tb03983.x; de Velde MV, 2008, INT J OBSTET ANESTH, V17, P329, DOI 10.1016/j.ijoa.2007.04.009; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Heesen M, 2013, INT J OBSTET ANESTH, V22, P26, DOI 10.1016/j.ijoa.2012.10.004; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jagannathan DK, 2016, INT J OBSTET ANESTH, V25, P23, DOI 10.1016/j.ijoa.2015.09.002; Kaddoum R, 2014, J ANESTH, V28, P628, DOI 10.1007/s00540-013-1761-y; NORRIS MC, 1990, REGION ANESTH, V15, P285; Paech M, 2001, INT J OBSTET ANESTH, V10, P162, DOI 10.1054/ijoa.2000.0825; Russell IF, 2012, INT J OBSTET ANESTH, V21, P7, DOI 10.1016/j.ijoa.2011.10.005; Rutter SV, 2001, INT J OBSTET ANESTH, V10, P177, DOI 10.1054/ijoa.2001.0854; Tien M, 2016, CURR MED RES OPIN, V32, P841, DOI 10.1185/03007995.2016.1146665; Verstraete S, 2014, ACTA ANAESTH SCAND, V58, P1233, DOI 10.1111/aas.12394	20	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0180504	10.1371/journal.pone.0180504	http://dx.doi.org/10.1371/journal.pone.0180504			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678882	Green Published, gold, Green Submitted			2023-01-03	WOS:000405272200068
J	Shevelev, OB; Illarionova, NB; Petrovski, DV; Sarapultsev, AP; Chupakhin, ON; Moshkin, MP				Shevelev, O. B.; Illarionova, N. B.; Petrovski, D. V.; Sarapultsev, A. P.; Chupakhin, O. N.; Moshkin, M. P.			Effects of a compound from the group of substituted thiadiazines with hypothermia inducing properties on brain metabolism in rats, a study in vivo and in vitro	PLOS ONE			English	Article							MAGNETIC-RESONANCE; 1,3,4-THIADIAZINE DERIVATIVES; MODERATE HYPOTHERMIA; SPECTROSCOPY; MECHANISMS; PROTECTION; RECEPTORS; MARKER; INJURY	The aim of the present study was to examine how administration of a compound of 1,3,4-thiadiazine class 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine, hydrobromide (L-17) with hypothermia inducing properties affects the brain metabolism. The mechanism by which L-17 induces hypothermia is unknown; it may involve hypothalamic central thermoregulation as well as act via inhibition of energy metabolism. We tested the hypothesis that L-17 may induce hypothermia by directly inhibiting energy metabolism. The study in vivo was carried out on Sprague-Dawley adult rats. Two doses of L-17 were administered (190 mg/kg and 760 mg/kg). Brain metabolites were analyzed in control and treated groups using magnetic resonance spectroscopy, along with blood flow rate measurements in carotid arteries and body temperature measurements. Further in vitro studies on primary cultures from rat hippocampus were carried out to perform a mitochondria function test of L-17 preincubation (100 mu M, 30 min). Analysis of brain metabolites showed no significant changes in 190 mg/kg treated group along with a significant reduction in body temperature by 1.5 degrees C. However, administration of L-17 in higher dose 760 mg/kg provoked changes in brain metabolites indicative of neurotoxicity as well as reduction in carotid arteries flow rate. In addition, a balance change of excitatory and inhibitory neurotransmitters was observed. The L-17 pre-incubation with cell primary cultures from rat brain showed no significant changes in mitochondrial function. The results obtained in the study indicate that acute administration of L-17 190 mg/kg in rats induces mild hypothermia with no adverse effects onto brain metabolism.	[Shevelev, O. B.; Illarionova, N. B.; Petrovski, D. V.; Moshkin, M. P.] Russian Acad Sci, Fed Res Ctr, Inst Cytol & Genet, Siberian Branch, Novosibirsk, Russia; [Sarapultsev, A. P.] Russian Acad Sci, Inst Immunol & Physiol, Ural Branch, Ekaterinburg, Russia; [Sarapultsev, A. P.; Chupakhin, O. N.] Ural Fed Univ, Fed State Autonomous Educ Inst Higher Profess Edu, Ekaterinburg, Russia; [Chupakhin, O. N.] Russian Acad Sci, Inst Organ Synth, Ural Div, Ekaterinburg, Russia; [Moshkin, M. P.] Tomsk State Univ, Dept Vertebrate Zool, Tomsk, Russia	Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Institute of Immunology & Physiology UB RAS; Russian Academy of Sciences; Ural Federal University; Russian Academy of Sciences; Postovsky Institute of Organic Synthesis, Ural Branch of Russian Academy of Sciences; Tomsk State University	Shevelev, OB (corresponding author), Russian Acad Sci, Fed Res Ctr, Inst Cytol & Genet, Siberian Branch, Novosibirsk, Russia.	shevelev.oleg.nsk@gmail.com	Sarapultsev, Alexey P./K-7220-2012; Chupakhin, Oleg/M-7633-2019; Shevelev, Oleg B/U-9436-2017; Illarionova, Nina/AAO-3434-2020; Moshkin, Mikhail P./N-7620-2014	Sarapultsev, Alexey P./0000-0003-3101-9655; Chupakhin, Oleg/0000-0002-1672-2476; Shevelev, Oleg B/0000-0003-3200-958X; 	Russian Science Foundation [14-14-00221]	Russian Science Foundation(Russian Science Foundation (RSF))	The study was supported by the Russian Science Foundation (grant No 14-14-00221) http://www.rscf.ru/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alisultanova N, 2014, IZV SAMAR NAUCHNOG 4, V16, P1205; Allen GI, 2013, STAT ANAL DATA MIN, V6, P302, DOI 10.1002/sam.11169; Arranz ME, 1999, BIOORGAN MED CHEM, V7, P2811, DOI 10.1016/S0968-0896(99)00221-7; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; Blier P, 2002, NEUROPSYCHOPHARMACOL, V27, P301, DOI 10.1016/S0893-133X(02)00318-4; Carlin JL, 2016, J PHARMACOL EXP THER, V356, P474, DOI 10.1124/jpet.115.229872; Chaperon F, 2003, NEUROPHARMACOLOGY, V44, P1047, DOI 10.1016/S0028-3908(03)00113-8; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; FREINKEL N, 1972, NEW ENGL J MED, V287, P841, DOI 10.1056/NEJM197210262871702; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Gordon CJ, 2008, TOXICOLOGY, V244, P87, DOI 10.1016/j.tox.2007.10.030; Lewerenz J, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00469; Logvinova Y. S., 2010, Eksperimental'naya i Klinicheskaya Farmakologiya, V73, P21; Moshkin MP, 2014, NMR BIOMED, V27, P399, DOI 10.1002/nbm.3074; Novikova A.P., 1991, CHEM HETEROCYC COMPO, V27, P1159, DOI [10.1007/BF00471738, DOI 10.1007/BF00471738]; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rantsev MA, 2013, MED ALMANAC, V5, P92; Rawls Scott M, 2011, Front Biosci (Schol Ed), V3, P822; Rawls SM, 2002, J PHARMACOL EXP THER, V301, P963, DOI 10.1124/jpet.301.3.963; Romanovsky AA, 1996, AM J PHYSIOL-REG I, V270, pR693, DOI 10.1152/ajpregu.1996.270.4.R693; Sahu JK, 2014, J ADV PHARM TECHNOL, V5, P90, DOI 10.4103/2231-4040.133434; Sarapultsev AP, 2014, CURR PHARM DESIGN, V20, P1980, DOI 10.2174/13816128113199990492; Sarapultsev AP, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9020027; Sarapultsev P, 2012, INT J EXP PATHOL, V93, P18, DOI 10.1111/j.1365-2613.2011.00794.x; Tuskova R, 2015, BEHAV BRAIN RES, V284, P257, DOI 10.1016/j.bbr.2015.02.016; Vasil'eva T. M., 2009, Eksperimental'naya i Klinicheskaya Farmakologiya, V72, P27; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Willie CK, 2014, J PHYSIOL-LONDON, V592, P841, DOI 10.1113/jphysiol.2013.268953; Yang YJ, 2011, CHEM PHARM BULL, V59, P1016, DOI 10.1248/cpb.59.1016; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yuan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107447	35	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 5	2017	12	7							e0180739	10.1371/journal.pone.0180739	http://dx.doi.org/10.1371/journal.pone.0180739			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA2LF	28678857	gold, Green Published			2023-01-03	WOS:000405272200089
J	Davies, R				Davies, Rachael			Fiona Loud: the kidney patients' champion	LANCET			English	Biographical-Item																			0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2017	390	10089					21	21		10.1016/S0140-6736(17)31673-2	http://dx.doi.org/10.1016/S0140-6736(17)31673-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EZ0LK	28677551				2023-01-03	WOS:000404396300015
J	Uematsu, H; Yamashita, K; Kunisawa, S; Fushimi, K; Imanaka, Y				Uematsu, Hironori; Yamashita, Kazuto; Kunisawa, Susumu; Fushimi, Kiyohide; Imanaka, Yuichi			Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: Retrospective database study of Japanese hospitals	PLOS ONE			English	Article							INFECTION; HEALTH; IMPACT; CARE; OUTCOMES; QUALITY; COSTS	Objectives The nationwide impact of antimicrobial-resistant infections on healthcare facilities throughout Japan has yet to be examined. This study aimed to estimate the disease burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Japanese hospitals. Design Retrospective analysis of inpatients comparing outcomes between subjects with and without MRSA infection. Data source A nationwide administrative claims database. Setting 1133 acute care hospitals throughout Japan. Participants All surgical and non-surgical inpatients who were discharged between April 1, 2014 and March 31, 2015. Main outcome measures Disease burden was assessed using hospitalization costs, length of stay, and in-hospital mortality. Using a unique method of infection identification, we categorized patients into an anti-MRSA drug group and a control group based on anti-MRSA drug utilization. To estimate the burden of MRSA infections, we calculated the differences in outcome measures between these two groups. The estimates were extrapolated to all 1584 acute care hospitals in Japan that have adopted a prospective payment system. Results We categorized 93 838 patients into the anti-MRSA drug group and 2 181 827 patients into the control group. The mean hospitalization costs, length of stay, and in-hospital mortality of the anti-MRSA drug group were US$ 33 548, 75.7 days, and 22.9%, respectively; these values were 3.43, 2.95, and 3.66 times that of the control group, respectively. When extrapolated to the 1584 hospitals, the total incremental burden of MRSA was estimated to be US $ 2 billion (3.41% of total hospitalization costs), 4.34 million days (3.02% of total length of stay), and 14.3 thousand deaths (3.62% of total mortality). Conclusions This study quantified the approximate disease burden of MRSA infections in Japan. These findings can inform policymakers on the burden of antimicrobial-resistant infections and support the application of infection prevention programs.	[Uematsu, Hironori; Yamashita, Kazuto; Kunisawa, Susumu; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Kyoto, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hlth Policy & Informat, Bunkyo Ku, Tokyo, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU)	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Kyoto, Japan.	imanaka-y@umin.net	KUNISAWA, Susumu/HCH-1094-2022; Yuichi, Imanaka/GYR-2098-2022	Yuichi, Imanaka/0000-0003-4613-2159	Ministry of Health, Labour and Welfare of Japan [H27-shinkogyosei-shitei-005, H27-seisaku-shitei-009]; Japan Society for the Promotion of Science [[A]25253033]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported in part by Health Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (H27-shinkogyosei-shitei-005, H27-seisaku-shitei-009; http://www.mhlw.go.jp/), and a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. ([A]25253033; https://www.jsps.go.jp/index.html) to YI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aikawa N, 2013, J INFECT CHEMOTHER, V19, P447, DOI 10.1007/s10156-012-0501-9; Anderson Gerard F, 2010, Issue Brief (Commonw Fund), V90, P1; [Anonymous], 2015, DISCHARGE SURVEY 201; [Anonymous], 2016, JAP NOS INF SURV 201; [Anonymous], 2014, REV ANTIMICROBIAL RE; Bozic KJ, 2005, J BONE JOINT SURG AM, V87A, P1746, DOI 10.2106/JBJS.D.02937; Centres for Disease Control and Prevention (US), 2013, ANT RES THREATS US; COELLO R, 1993, J HOSP INFECT, V25, P239, DOI 10.1016/0195-6701(93)90110-L; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; Filice GA, 2010, INFECT CONT HOSP EP, V31, P365, DOI 10.1086/651094; Guidos RJ, 2011, CLIN INFECT DIS, V52, pS397, DOI 10.1093/cid/cir153; Hamada H, 2012, HEALTH POLICY, V107, P194, DOI 10.1016/j.healthpol.2012.01.002; Lee J, 2011, J HOSP INFECT, V77, P316, DOI 10.1016/j.jhin.2010.11.013; Mauldin PD, 2010, ANTIMICROB AGENTS CH, V54, P109, DOI 10.1128/AAC.01041-09; Park S, 2013, HEALTH POLICY, V111, P264, DOI 10.1016/j.healthpol.2013.05.015; PPP. OECD, 2016, PURCH POW PART PPP I, DOI 10.1787/1290ee5a-en; Reed SD, 2001, NEUROLOGY, V57, P305, DOI 10.1212/WNL.57.2.305; Roberts RR, 2009, CLIN INFECT DIS, V49, P1175, DOI 10.1086/605630; Sasaki T, 2015, NEUROL MED-CHIR, V55, P267, DOI 10.2176/nmc.ra.2014-0317; Sekimoto M, 2010, VOX SANG, V98, P538, DOI 10.1111/j.1423-0410.2009.01290.x; Shih T, 2014, ANONYMOUS SUCCESS AC, P153; Uematsu H, 2016, RESPIROLOGY; Uematsu H, 2016, AM J INFECT CONTROL; Uematsu H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125284; Uematsu H, 2014, INT J QUAL HEALTH C, V26, P100, DOI 10.1093/intqhc/mzt078; World Health Organization, 2014, ANTIMICROBIAL RESIST	26	23	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2017	12	6							e0179767	10.1371/journal.pone.0179767	http://dx.doi.org/10.1371/journal.pone.0179767			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ2LT	28654675	Green Published, gold, Green Submitted			2023-01-03	WOS:000404541500032
J	Koppel, N; Rekdal, VM; Balskus, EP				Koppel, Nitzan; Rekdal, Vayu Maini; Balskus, Emily P.			Chemical transformation of xenobiotics by the human gut microbiota	SCIENCE			English	Review							GLYCYL RADICAL ENZYME; CHOLINE TRIMETHYLAMINE-LYASE; HUMAN INTESTINAL MICROBIOTA; CANCER DRUG TOXICITY; BETA-GLUCURONIDASE; CELIAC-DISEASE; DIETARY FIBER; HUMAN HEALTH; AZO DYES; N-OXIDE	The human gut microbiota makes key contributions to the metabolism of ingested compounds (xenobiotics), transforming hundreds of dietary components, industrial chemicals, and pharmaceuticals into metabolites with altered activities, toxicities, and lifetimes within the body. The chemistry of gut microbial xenobiotic metabolism is often distinct from that of host enzymes. Despite their important consequences for human biology, the gut microbes, genes, and enzymes involved in xenobiotic metabolism are poorly understood. Linking these microbial transformations to enzymes and elucidating their biological effects is undoubtedly challenging. However, recent studies demonstrate that integrating traditional and emerging technologies can enable progress toward this goal. Ultimately, a molecular understanding of gut microbial xenobiotic metabolism will guide personalized medicine and nutrition, inform toxicology risk assessment, and improve drug discovery and development.	[Koppel, Nitzan; Rekdal, Vayu Maini; Balskus, Emily P.] Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA; [Balskus, Emily P.] Broad Inst, Cambridge, MA 02139 USA	Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Balskus, EP (corresponding author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.; Balskus, EP (corresponding author), Broad Inst, Cambridge, MA 02139 USA.	balskus@chemistry.harvard.edu			Smith Family Award for Biomedical Research; Damon Runyon-Rachleff Innovation Award; George W. Merck Fellowship; David and Lucille Packard Foundation; Howard Hughes Medical Institute-Gates Faculty Scholar Award [OPP1158186]; Massachusetts Institute of Technology Center for Microbiome Informatics and Therapeutics; Sloan Research Fellowship; Blavatnik Biomedical Accelerator Award; Takeda; Defense Advanced Research Projects Agency [HR0011-16-2-0013]; NIH [CA208834, 5T32GM007598]; NSF [MCB-1650086, DGE1144152]	Smith Family Award for Biomedical Research; Damon Runyon-Rachleff Innovation Award; George W. Merck Fellowship; David and Lucille Packard Foundation(The David & Lucile Packard Foundation); Howard Hughes Medical Institute-Gates Faculty Scholar Award; Massachusetts Institute of Technology Center for Microbiome Informatics and Therapeutics; Sloan Research Fellowship(Alfred P. Sloan Foundation); Blavatnik Biomedical Accelerator Award; Takeda(Takeda Pharmaceutical Company Ltd); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF))	Human gut microbiota research in the Balskus laboratory has been supported by the Smith Family Award for Biomedical Research, the Damon Runyon-Rachleff Innovation Award, a George W. Merck Fellowship, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Howard Hughes Medical Institute-Gates Faculty Scholar Award (OPP1158186), the Massachusetts Institute of Technology Center for Microbiome Informatics and Therapeutics, a Sloan Research Fellowship, a Blavatnik Biomedical Accelerator Award, Takeda, the Defense Advanced Research Projects Agency (HR0011-16-2-0013), the NIH (CA208834), and the NSF (MCB-1650086). N.K. acknowledges a Graduate Research Fellowship from the NSF (DGE1144152). V.M.R. is funded by an NIH training grant (5T32GM007598). E.P.B. has received honoraria from Procter & Gamble, Cubist (now Merck), Boehringer Ingelheim, New England Biolabs, Eli Lilly, Pfizer, Novartis, and Merck. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.	Aron-Wisnewsky J, 2012, NAT REV GASTRO HEPAT, V9, P590, DOI 10.1038/nrgastro.2012.161; Atkinson C, 2005, EXP BIOL MED, V230, P155, DOI 10.1177/153537020523000302; BERGMARK J, 1972, N-S ARCH PHARMAKOL, V272, P437, DOI 10.1007/BF00501249; Berry D, 2013, P NATL ACAD SCI USA, V110, P4720, DOI 10.1073/pnas.1219247110; Blachier F, 2007, AMINO ACIDS, V33, P547, DOI 10.1007/s00726-006-0477-9; Bodea S, 2016, CELL CHEM BIOL, V23, P1206, DOI 10.1016/j.chembiol.2016.07.020; BOPP BA, 1986, CRC CR REV TOXICOL, V16, P213, DOI 10.3109/10408448609037465; BORZELLECA JF, 1990, FOOD CHEM TOXICOL, V28, P221, DOI 10.1016/0278-6915(90)90034-K; BOS RP, 1986, TOXICOLOGY, V40, P207, DOI 10.1016/0300-483X(86)90080-6; Buckel W, 2006, ANNU REV MICROBIOL, V60, P27, DOI 10.1146/annurev.micro.60.080805.142216; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; CALNE DB, 1971, BRIT MED J, V3, P729, DOI 10.1136/bmj.3.5777.729; Caminero A, 2016, GASTROENTEROLOGY, V151, P670, DOI 10.1053/j.gastro.2016.06.041; Caminero A, 2015, BRIT J NUTR, V114, P1157, DOI 10.1017/S0007114515002767; Escola-Gil JC, 2011, ARTERIOSCL THROM VAS, V31, P2493, DOI 10.1161/ATVBAHA.111.236075; CARTER JH, 1980, BIOCHEM PHARMACOL, V29, P301, DOI 10.1016/0006-2952(80)90504-3; Cho CE, 2017, TRENDS ENDOCRIN MET, V28, P121, DOI 10.1016/j.tem.2016.10.005; Claus SP, 2016, NPJ BIOFILMS MICROBI, V2, DOI 10.1038/npjbiofilms.2016.3; Clavel T, 2006, FEMS MICROBIOL ECOL, V55, P471, DOI 10.1111/j.1574-6941.2005.00057.x; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Cooper AJL, 2011, AMINO ACIDS, V41, P7, DOI 10.1007/s00726-010-0552-0; Craciun S, 2014, ACS CHEM BIOL, V9, P1408, DOI 10.1021/cb500113p; Craciun S, 2012, P NATL ACAD SCI USA, V109, P21307, DOI 10.1073/pnas.1215689109; Cross AJ, 2010, CANCER RES, V70, P2406, DOI 10.1158/0008-5472.CAN-09-3929; DANIELSSON H, 1959, ARCH BIOCHEM BIOPHYS, V83, P482, DOI 10.1016/0003-9861(59)90056-6; Das A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163099; Delomenie C, 2001, J BACTERIOL, V183, P3417, DOI 10.1128/JB.183.11.3417-3427.2001; Devlin AS, 2016, CELL HOST MICROBE, V20, P709, DOI 10.1016/j.chom.2016.10.021; Diaz-Bone RA, 2009, ENVIRON SCI TECHNOL, V43, P5249, DOI 10.1021/es900544c; DOBKIN JF, 1983, SCIENCE, V220, P325; Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018; Dujovne CA, 2002, AM J CARDIOL, V90, P1092, DOI 10.1016/S0002-9149(02)02798-4; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Ellrott K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000798; Feng R, 2015, SCI REP-UK, V5, DOI 10.1038/srep12155; Fennema D, 2016, DRUG METAB DISPOS, V44, P1839, DOI 10.1124/dmd.116.070615; Flint HJ, 2008, NAT REV MICROBIOL, V6, P121, DOI 10.1038/nrmicro1817; Garcia-Villalba R, 2013, J AGR FOOD CHEM, V61, P8797, DOI 10.1021/jf402498b; Gerard P, 2004, FEMS MICROBIOL ECOL, V47, P337, DOI 10.1016/S0168-6496(03)00285-X; Gerlt JA, 2015, BBA-PROTEINS PROTEOM, V1854, P1019, DOI 10.1016/j.bbapap.2015.04.015; GOLDIN BR, 1973, J PHARMACOL EXP THER, V186, P160; Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872; He X, 2013, J AGR FOOD CHEM, V61, P9559, DOI 10.1021/jf4029046; Humblot C, 2007, CARCINOGENESIS, V28, P2419, DOI 10.1093/carcin/bgm170; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Ingelfinger JR, 2008, NEW ENGL J MED, V359, P2745, DOI 10.1056/NEJMp0808410; Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017; Kallemeijn WW, 2014, ADV CARBOHYD CHEM BI, V71, P297, DOI 10.1016/B978-0-12-800128-8.00004-2; Karigar C. S., 2011, Enzyme Research, V2011, P805187, DOI 10.4061/2011/805187; Kassie F, 2001, CARCINOGENESIS, V22, P1721, DOI 10.1093/carcin/22.10.1721; Kim KS, 2014, CHEMOSPHERE, V94, P151, DOI 10.1016/j.chemosphere.2013.09.066; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Kolmeder CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029913; Konstantinidis KT, 2005, P NATL ACAD SCI USA, V102, P2567, DOI 10.1073/pnas.0409727102; Koropatkin NM, 2012, NAT REV MICROBIOL, V10, P323, DOI 10.1038/nrmicro2746; KRISHNAN R, 1980, AUST J EXP BIOL MED, V58, P639, DOI 10.1038/icb.1980.66; Kumano T, 2016, P NATL ACAD SCI USA, V113, P9087, DOI 10.1073/pnas.1605050113; Kurokawa K, 2007, DNA RES, V14, P169, DOI 10.1093/dnares/dsm018; Lasken RS, 2012, NAT REV MICROBIOL, V10, P631, DOI 10.1038/nrmicro2857; Laue H, 2001, J BACTERIOL, V183, P1727, DOI 10.1128/JB.183.5.1727-1733.2001; LAVRIJSEN K, 1995, DRUG METAB DISPOS, V23, P354; LEE SC, 1995, BIOCHEM PHARMACOL, V49, P1567, DOI 10.1016/0006-2952(95)00093-F; Lehouritis P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14554; Levin BJ, 2017, SCIENCE, V355, DOI 10.1126/science.aai8386; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; Liebert CA, 1997, APPL ENVIRON MICROB, V63, P1066, DOI 10.1128/AEM.63.3.1066-1076.1997; LINDENBAUM J, 1981, NEW ENGL J MED, V305, P789, DOI 10.1056/NEJM198110013051403; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; Liu Y, 2006, TOXICOL SCI, V91, P356, DOI 10.1093/toxsci/kfj164; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; MACDONALD IA, 1983, J LIPID RES, V24, P675; Martinez-del Campo A, 2015, MBIO, V6, DOI 10.1128/mBio.00042-15; Moeller AH, 2016, SCIENCE, V353, P380, DOI 10.1126/science.aaf3951; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; Nelson KE, 2010, SCIENCE, V328, P994, DOI 10.1126/science.1183605; NIIMURA T, 1974, J BIOCHEM-TOKYO, V75, P407, DOI 10.1093/oxfordjournals.jbchem.a130407; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; Okuda H, 1997, DRUG METAB DISPOS, V25, P270; PEPPERCORN MA, 1972, J PHARMACOL EXP THER, V181, P555; Rafii F, 1995, ENVIRON HEALTH PERSP, V103, P17, DOI 10.2307/3432471; RAFII F, 1990, APPL ENVIRON MICROB, V56, P2146, DOI 10.1128/AEM.56.7.2146-2151.1990; Rafii F, 1997, FOOD CHEM TOXICOL, V35, P897, DOI 10.1016/S0278-6915(97)00060-4; RELMAN AS, 1982, NEW ENGL J MED, V306, P236, DOI 10.1056/NEJM198201283060410; Ren DW, 1996, STEROIDS, V61, P33, DOI 10.1016/0039-128X(95)00173-N; Renwick AG, 2008, FOOD CHEM TOXICOL, V46, pS70, DOI 10.1016/j.fct.2008.05.008; RENWICK AG, 1986, XENOBIOTICA, V16, P1057, DOI 10.3109/00498258609038983; Romano KA, 2015, MBIO, V6, DOI 10.1128/mBio.02481-14; ROSSOL I, 1992, J BACTERIOL, V174, P2968, DOI 10.1128/JB.174.9.2968-2977.1992; Rothenberg SE, 2016, TOXICOL LETT, V242, P60, DOI 10.1016/j.toxlet.2015.11.022; Rowland I R, 1980, Dev Toxicol Environ Sci, V8, P79; ROWLAND IR, 1978, XENOBIOTICA, V8, P37, DOI 10.3109/00498257809060381; Ryan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098551; Saitta KS, 2014, XENOBIOTICA, V44, P28, DOI 10.3109/00498254.2013.811314; Selmer T, 2001, EUR J BIOCHEM, V268, P1363, DOI 10.1046/j.1432-1327.2001.02001.x; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sharon G, 2016, CELL, V167, P915, DOI 10.1016/j.cell.2016.10.027; Sharon G, 2014, CELL METAB, V20, P719, DOI 10.1016/j.cmet.2014.10.016; Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839; Singh Z, 2016, J OCCUP MED TOXICOL, V11, DOI 10.1186/s12995-016-0128-3; Sousa T, 2008, INT J PHARMACEUT, V363, P1, DOI 10.1016/j.ijpharm.2008.07.009; Spanogiannopoulos P, 2016, NAT REV MICROBIOL, V14, P273, DOI 10.1038/nrmicro.2016.17; STRONG HA, 1987, XENOBIOTICA, V17, P685, DOI 10.3109/00498258709043976; STRUGALA GJ, 1986, BIOCHEM PHARMACOL, V35, P2123, DOI 10.1016/0006-2952(86)90580-0; Sutton D, 1997, J PHARMACOL EXP THER, V282, P294; TAKENO S, 1993, TOXICOL APPL PHARM, V121, P233, DOI 10.1006/taap.1993.1150; Tang J, 2015, BRIT J NUTR, V114, P673, DOI 10.1017/S0007114515002329; Tasse L, 2010, GENOME RES, V20, P1605, DOI 10.1101/gr.108332.110; Ticak T, 2014, P NATL ACAD SCI USA, V111, pE4668, DOI 10.1073/pnas.1409642111; Tozaki H, 1997, J PHARM PHARMACOL, V49, P164, DOI 10.1111/j.2042-7158.1997.tb06773.x; Ulmer JE, 2014, J BIOL CHEM, V289, P24289, DOI 10.1074/jbc.M114.573303; Valdes L, 2015, FOOD FUNCT, V6, P2424, DOI [10.1039/c5fo00322a, 10.1039/C5FO00322A]; VANHOGEZAND RA, 1992, EUR J CLIN PHARMACOL, V43, P189, DOI 10.1007/BF01740669; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wallace BD, 2015, CHEM BIOL, V22, P1238, DOI 10.1016/j.chembiol.2015.08.005; Wallace BD, 2010, SCIENCE, V330, P831, DOI 10.1126/science.1191175; Wang B, 2016, DRUG DELIVERY PRINCI; Wang H, 2014, APPL MICROBIOL BIOT, V98, P3287, DOI 10.1007/s00253-013-5363-2; Wang J, 2015, EUR J PHARM SCI, V78, P31, DOI 10.1016/j.ejps.2015.06.018; Wang ZN, 2015, CELL, V163, P1585, DOI 10.1016/j.cell.2015.11.055; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Williams BB, 2014, CELL HOST MICROBE, V16, P495, DOI 10.1016/j.chom.2014.09.001; Withering W., 1785, ACCOUNT FOXGLOVE; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zhang K, 2014, PROTEIN EXPRES PURIF, V94, P33, DOI 10.1016/j.pep.2013.10.018; Zheng XJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005114	127	425	440	36	275	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	2017	356	6344							eaag2770	10.1126/science.aag2770	http://dx.doi.org/10.1126/science.aag2770			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY3OM	28642381	Green Accepted, Green Published			2023-01-03	WOS:000403881700029
J	Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandala, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM				Long, G. V.; Hauschild, A.; Santinami, M.; Atkinson, V.; Mandala, M.; Chiarion-Sileni, V.; Larkin, J.; Nyakas, M.; Dutriaux, C.; Haydon, A.; Robert, C.; Mortier, L.; Schachter, J.; Schadendorf, D.; Lesimple, T.; Plummer, R.; Ji, R.; Zhang, P.; Mookerjee, B.; Legos, J.; Kefford, R.; Dummer, R.; Kirkwood, J. M.			Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-RISK MELANOMA; PHASE-III; MEK INHIBITION; DOUBLE-BLIND; SURVIVAL; IPILIMUMAB; THERAPY; INTERFERON-ALPHA-2B; PLACEBO; HAZARD	BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months. The primary end point was relapse-free survival. Secondary end points included overall survival, distant metastasis-free survival, freedom from relapse, and safety. RESULTS At a median follow-up of 2.8 years, the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group (hazard ratio for relapse or death, 0.47; 95% confidence interval [CI], 0.39 to 0.58; P<0.001). The 3-year overall survival rate was 86% in the combination-therapy group and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42 to 0.79; P = 0.0006), but this level of improvement did not cross the prespecified interim analysis boundary of P=0.000019. Rates of distant metastasis-free survival and freedom from relapse were also higher in the combination-therapy group than in the placebo group. The safety profile of dabrafenib plus trametinib was consistent with that observed with the combination in patients with metastatic melanoma. CONCLUSIONS Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvant use of placebo and was not associated with new toxic effects.	[Long, G. V.] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia; [Kefford, R.] Univ Sydney, Macquarie Univ, Melanoma Inst Australia, Sydney, NSW, Australia; [Kefford, R.] Westmead Hosp, Sydney, NSW, Australia; [Atkinson, V.] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld, Australia; [Haydon, A.] Alfred Hosp, Melbourne, Vic, Australia; [Hauschild, A.] Univ Hosp Schleswig Holstein, Kiel, Germany; [Schadendorf, D.] Univ Hosp Essen, Essen, Germany; [Schadendorf, D.] German Canc Consortium, Heidelberg, Germany; [Santinami, M.] Fdn Ist Nazl Tumori, Milan, Italy; [Mandala, M.] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy; [Chiarion-Sileni, V.] Veneto Oncol Inst, Melanoma Oncol Unit, Padua, Italy; [Nyakas, M.] Radiumhosp, Rikshosp, Oslo, Norway; [Dutriaux, C.] Hop St Andre, Ctr Hosp Univ Bordeaux, Bordeaux, France; [Robert, C.] Inst Gustave Roussy, Paris, France; [Mortier, L.] Univ Lille, Ctr Hosp Reg Univ Lille, INSERM, Unite 1189, Lille, France; [Lesimple, T.] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France; [Schachter, J.] Sheba Med Ctr, Ella Inst Melanoma, Tel Hashomer, Israel; [Larkin, J.] Royal Marsden NHS Fdn Trust, London, England; [Plummer, R.] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Ji, R.; Zhang, P.; Mookerjee, B.; Legos, J.] Novartis Pharmaceut, E Hanover, NJ USA; [Dummer, R.] Univ Hosp Zurich Skin Canc Ctr, Zurich, Switzerland; [Kirkwood, J. M.] Univ Pittsburgh, Hillman UPMC Canc Ctr, Melanoma Program, Pittsburgh, PA USA	Melanoma Institute Australia; Royal North Shore Hospital; University of Sydney; Macquarie University; Melanoma Institute Australia; University of Sydney; University of Sydney; University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Kiel; Schleswig Holstein University Hospital; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Fondazione IRCCS Istituto Nazionale Tumori Milan; ASST Papa Giovanni XXIII; IRCCS Istituto Oncologico Veneto (IOV); University of Oslo; National Hospital Norway; CHU Bordeaux; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; UNICANCER; Centre Eugene Marquis; Chaim Sheba Medical Center; Royal Marsden NHS Foundation Trust; Newcastle Freeman Hospital; Newcastle University - UK; Novartis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Long, GV (corresponding author), Univ Sydney, Melanoma Inst Australia, 40 Rocklands Rd, Sydney, NSW 2060, Australia.	georgina.long@sydney.edu.au	mandala, mario/AAB-8637-2022; Long, Georgina V/C-1771-2013; Atkinson, Victoria G/G-2507-2015; Mandala', Mario/AAA-4258-2019; Robert, Caroline/G-6157-2018; Schadendorf, Dirk/AAE-8206-2019; Santinami, Mario/I-3795-2017; sileni, vanna chiarion/B-9042-2018	Long, Georgina V/0000-0001-8894-3545; Robert, Caroline/0000-0002-9493-0238; Santinami, Mario/0000-0001-8436-4757; sileni, vanna chiarion/0000-0001-9191-9124; Kefford, Richard/0000-0001-9251-9229; MORTIER, Laurent/0000-0002-2644-1790; Larkin, James/0000-0001-5569-9523	GlaxoSmithKline; Novartis; National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Australian National Health and Medical Research Council fellowship; University of Sydney Medical Foundation; Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Sharp Dohme; Pierre Fabre; Roche; Merck; Provectus; Merck Serono; Philogen; Regeneron; OncoSec; Pfizer; Eisai; Kymab; Roche/Genentech; Secarna; EUSA Pharma; Sysmex; Boehringer Ingelheim; Novartis/GlaxoSmithKline; Teva; Takeda; Prometheus; Genentech; EMD Serono	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Australian National Health and Medical Research Council fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney Medical Foundation(University of Sydney); Amgen(Amgen); Array BioPharma(Pfizer); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck Sharp Dohme(Merck & Company); Pierre Fabre; Roche(Roche Holding); Merck(Merck & Company); Provectus; Merck Serono(Merck & Company); Philogen; Regeneron(Regeneron); OncoSec; Pfizer(Pfizer); Eisai(Eisai Co Ltd); Kymab; Roche/Genentech(Roche HoldingGenentech); Secarna; EUSA Pharma; Sysmex; Boehringer Ingelheim(Boehringer Ingelheim); Novartis/GlaxoSmithKline; Teva(Teva Pharmaceutical Industries); Takeda(Takeda Pharmaceutical Company Ltd); Prometheus; Genentech(Roche HoldingGenentech); EMD Serono	Supported by GlaxoSmithKline and Novartis. Dr. Larkin is supported by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. Dr. Long is supported by an Australian National Health and Medical Research Council fellowship and the University of Sydney Medical Foundation.; Dr. Long reports receiving consulting fees from Amgen, Array BioPharma, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche; Dr. Hauschild, receiving grant support, lecture fees, and consulting fees from Amgen, Bristol-Myers Squibb, Merck, Pierre Fabre, Provectus, and Roche, grant support and consulting fees from Merck Serono, Philogen, and Regeneron, and consulting fees from OncoSec; Dr. Atkinson, receiving travel support, advisory board fees, and lecture fees from Merck Sharp & Dohme, Bristol-Myers Squibb, and Novartis, lecture fees from Roche, and advisory board fees from Pierre Fabre; Dr. Mandala, receiving grant support, advisory board fees, and lecture fees from Roche and advisory board fees and lecture fees from Novartis, Merck Sharp & Dohme, and Bristol-Myers Squibb; Dr. Chiarion-Sileni, receiving advisory board fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, and Merck Serono; Dr. Larkin, receiving grant support, paid to his institution, and consulting fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and Novartis and consulting fees from Eisai, GlaxoSmithKline, Kymab, Roche/Genentech, Secarna, Pierre Fabre, and EUSA Pharma; Dr. Mortier, receiving fees for serving on a medical board from Roche; Dr. Schadendorf, receiving grant support, consulting fees, lecture fees, and fees for serving on speakers bureaus from Novartis and Bristol-Myers Squibb, consulting fees, lecture fees, and fees for serving on speakers bureaus from Merck, Amgen, and GlaxoSmithKline, and consulting fees from Sysmex and Boehringer Ingelheim; Dr. Lesimple, receiving advisory board fees from Novartis, advisory board fees, travel support, and drugs from Roche, and advisory board fees and travel support from Merck Sharp & Dohme; Dr. Plummer, receiving clinical trial support, paid to her institution, and consulting fees from Novartis/GlaxoSmithKline; Dr. Ji, being employed by Novartis; Dr. Zhang, being employed by Novartis; Dr. Mookerjee, being employed by and having stock options in Novartis and GlaxoSmithKline; Dr. Legos, being employed by and being a shareholder in Novartis; Dr. Kefford, receiving advisory board fees and fees for conference reporting, paid to his institution, from Bristol-Myers Squibb, and advisory board fees, paid to his institution, from Merck, Amgen, and Teva; Dr. Dummer, receiving consulting fees from Novartis, Merck Sharp & Dohme, Roche, Takeda, and Pierre Fabre and grant support and consulting fees from Bristol-Myers Squibb and Amgen; and Dr. Kirkwood, receiving grant support, paid to his institution, from Merck and Prometheus and advisory board fees from Bristol-Myers Squibb, Novartis, Roche, Genentech, EMD Serono, and Array BioPharma. No other potential conflict of interest relevant to this article was reported.	Amin MB, 2016, AJCC CANC STAGING MA; Balch CM, 2010, J CLIN ONCOL, V28, P2452, DOI 10.1200/JCO.2009.27.1627; BERNSTEIN L, 1981, BIOMETRICS, V37, P513, DOI 10.2307/2530564; BERRY G, 1991, STAT MED, V10, P749, DOI 10.1002/sim.4780100510; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2008, LANCET, V372, P117, DOI 10.1016/S0140-6736(08)61033-8; Eggermont AMM, 2015, LANCET ONCOL, V16, P522, DOI 10.1016/S1470-2045(15)70122-1; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gershenwald JE, CA CANC J C IN PRESS; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Long GV, 2017, ANN ONCOL; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Mocellin S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008955.pub2; Mocellin S, 2010, JNCI-J NATL CANCER I, V102, P493, DOI 10.1093/jnci/djq009; National Comprehensive Cancer Network, 2017, CLIN PRACT GUID ONC; Robert C, 2015, EUR J CANCER, V51, pS663, DOI 10.1016/S0959-8049(16)31820-2; Robert C, 2016, ANN ONCOL, V6, P27, DOI DOI 10.1093/ANNONC/MDW335.03; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tarhini AA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9500; Weber J, 2015, J IMMUNOTHER CANCER, V2, P3	26	807	818	3	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2017	377	19					1813	1823		10.1056/NEJMoa1708539	http://dx.doi.org/10.1056/NEJMoa1708539			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM2QW	28891408	Green Accepted, Green Published			2023-01-03	WOS:000414845700006
J	Sun, EC; Jena, AB				Sun, Eric C.; Jena, Anupam B.			Distribution of Prescription Opioid Use Among Privately Insured Adults Without Cancer: United States, 2001 to 2013	ANNALS OF INTERNAL MEDICINE			English	Letter									[Sun, Eric C.] Stanford Univ, Stanford, CA 94305 USA; [Jena, Anupam B.] Harvard Med Sch, Boston, MA USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Stanford University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Sun, EC (corresponding author), Stanford Univ, Stanford, CA 94305 USA.		Sun, Eric/K-3900-2019		K08 award; National Institute on Drug Abuse [K08DA042314-01]; National Institutes of Health Early Independence Award; Office of the Director, National Institutes of Health [1DP5OD017897-01]; NATIONAL INSTITUTE ON DRUG ABUSE [K08DA042314] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP5OD017897] Funding Source: NIH RePORTER	K08 award; National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institutes of Health Early Independence Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr. Sun is supported by a K08 award and grant K08DA042314-01 from the National Institute on Drug Abuse. Dr. Jena is supported by the National Institutes of Health Early Independence Award and grant 1DP5OD017897-01 from the Office of the Director, National Institutes of Health.	Aizcorbe Ana, 2012, Stat J IAOS, V28, P43, DOI 10.3233/SJI-2012-0743; American Pain Society, 2008, PRINC AN US TREATM A; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Lipari R.N., 2016, PRESCRIPTION DRUG US; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433	5	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2017	167	9					684	686		10.7326/M17-1408	http://dx.doi.org/10.7326/M17-1408			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM1DV	28892817	Green Accepted			2023-01-03	WOS:000414714700015
J	Cho, JH; Lim, JY; Cho, JY				Cho, Jang Ho; Lim, Jae Yun; Cho, Jae Yong			Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy	PLOS ONE			English	Article							SURGERY; PATTERNS	Aim To compare capecitabine and oxaliplatin (XELOX) with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. Methods Clinical data from 206 patients who received XELOX or S-1 regimens as adjuvant chemotherapy in stage III gastric cancer were collected. Patients were divided into 2 groups according to regimen; the groups were XELOX (n = 114) and S-1 monotherapy (n = 92). Results 3-year disease-free survival (DFS) was higher in the S-1 group than in the XELOX group (66.6% vs 59.1%; p = 0.636).3-year overall survival (OS) was 75.6% in the S-1 group and 69.6% in the XELOX group (p = 0.495). But, the difference was not statistically significant. Especially, for patients with stage IIIC disease, 3-year overall survival was 55.2% in the XELOX group and 39.0% in the S-1 group (hazard ratio, HR 0.50, 95% confidence interval, CI 0.23-1.10; p = 0.075). In multivariate analysis, N stage (HR, 5.639; 95% CI, 1.297- 24.522; p = 0.021) and cycle completion as planned (HR, 5.734; 95% CI, 3.007-10.936; p<0.001) were independent predictors of overall survival. Conclusion Adjuvant XELOX and S-1 regimen did not prove anything superior for stage III gastric cancer in this study. But, XELOX had a tendency to be superior to S-1 in stage IIIC gastric cancer after D2 gastrectomy although the difference was not statistically significant. N stage and cycle completion as planned were prognostic factors.	[Cho, Jang Ho; Lim, Jae Yun; Cho, Jae Yong] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Div Med Oncol,Dept Internal Med, Seoul, South Korea	Yonsei University; Yonsei University Health System	Cho, JY (corresponding author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Div Med Oncol,Dept Internal Med, Seoul, South Korea.	chojy@yuhs.ac		Cho, Jae Yong/0000-0002-0926-1819				Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Deng JY, 2011, SURG TODAY, V41, P210, DOI 10.1007/s00595-009-4251-y; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gallo A, 2006, WORLD J GASTROENTERO, V12, P3237, DOI 10.3748/wjg.v12.i20.3237; Gunderson LL, 2002, SEMIN RADIAT ONCOL, V12, P150, DOI 10.1053/srao.2002.30817; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P113, DOI 10.1007/s10120-011-0042-4; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; NCCN, 2016, GASTRIC CANC; Oh CM, 2016, CANCER RES TREAT, V48, P436, DOI 10.4143/crt.2016.089; Ohtsu A, 2006, J CLIN ONCOL, V24, P2188, DOI 10.1200/JCO.2006.05.9758; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Park Joong-Min, 2006, Cancer Res Treat, V38, P13, DOI 10.4143/crt.2006.38.1.13; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Songun I, 2010, LANCET ONCOL, V11, P439, DOI 10.1016/S1470-2045(10)70070-X; Waddell T, 2013, ANN ONCOL, V24, P57, DOI 10.1093/annonc/mdt344	18	9	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2017	12	10							e186362	10.1371/journal.pone.0186362	http://dx.doi.org/10.1371/journal.pone.0186362			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0KA	29040299	gold, Green Submitted, Green Published			2023-01-03	WOS:000413167500039
J	Marris, E				Marris, Emma			BLUETOPIA	NATURE			English	News Item																		DeNuccio Kyle, 2015, WIRED; Harkinson Josh., 2012, MOTHER JONES; Madrigal Alexis, 2008, WIRED	3	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	2017	550	7674					22	24		10.1038/550022a	http://dx.doi.org/10.1038/550022a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY4NY	28980648	Bronze			2023-01-03	WOS:000426803000001
J	Belkaid, M; Cuperlier, N; Gaussier, P				Belkaid, Marwen; Cuperlier, Nicolas; Gaussier, Philippe			Emotional metacontrol of attention: Top-down modulation of sensorimotor processes in a robotic visual search task	PLOS ONE			English	Article							NOVELTY; SYSTEMS; BRAIN; MODEL	Emotions play a significant role in internal regulatory processes. In this paper, we advocate four key ideas. First, novelty detection can be grounded in the sensorimotor experience and allow higher order appraisal. Second, cognitive processes, such as those involved in self-assessment, influence emotional states by eliciting affects like boredom and frustration. Third, emotional processes such as those triggered by self-assessment influence attentional processes. Last, close emotion-cognition interactions implement an efficient feedback loop for the purpose of top-down behavior regulation. The latter is what we call 'Emotional Metacontrol'. We introduce a model based on artificial neural networks. This architecture is used to control a robotic system in a visual search task. The emotional metacontrol intervenes to bias the robot visual attention during active object recognition. Through a behavioral and statistical analysis, we show that this mechanism increases the robot performance and fosters the exploratory behavior to avoid deadlocks.	[Belkaid, Marwen; Cuperlier, Nicolas; Gaussier, Philippe] Univ Cergy Pontoise, ENSEA, CNRS, Univ Paris Seine,ETIS UMR 8051, Cergy Pontoise, France	Centre National de la Recherche Scientifique (CNRS); CY Cergy Paris Universite	Belkaid, M (corresponding author), Univ Cergy Pontoise, ENSEA, CNRS, Univ Paris Seine,ETIS UMR 8051, Cergy Pontoise, France.	marwen.belkaid@ensea.fr	Cuperlier, Nicolas/AAS-2637-2020; Belkaid, Marwen/AAF-7835-2021	Cuperlier, Nicolas/0000-0001-7610-3143; Belkaid, Marwen/0000-0003-2358-2560	MENESR (Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche); Centre National de la Recherche Scientifique (CNRS); ANR DIRAC [ANR-13-ASTR-0018]; Ecole Doctorale "Science et Ingenierie" of the Universite de Cergy Pontoise	MENESR (Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); ANR DIRAC(French National Research Agency (ANR)); Ecole Doctorale "Science et Ingenierie" of the Universite de Cergy Pontoise	This research was supported by the MENESR (Ministere de l'Education Nationale, de l'Enseignement Superieur et de la Recherche), the Centre National de la Recherche Scientifique (CNRS) and the ANR DIRAC ANR-13-ASTR-0018. MB was supported by The Ecole Doctorale "Science et Ingenierie" of the Universite de Cergy Pontoise. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank the reviewers for their comments, A. Jauffret for his contribution in previous works on the emotional metacontrol, R. Braud, A. Karaouzene and G. Mostafaoui for their advice regarding the visual processing system, and Nils and Orianne for providing the stuffed animals used in the experiment. This work was supported by ANR DIRAC ANR-13-ASTR-0018.	Arbib MA, 2004, TRENDS COGN SCI, V8, P554, DOI 10.1016/j.tics.2004.10.004; Arnold M.B., 1960, EMOTION PERSONALITY, V2; Balcetis E, 2009, PSYCHOL SCI; Belkaid M, P IEEE INT C INT ROB; Breazeal C, 2001, IEEE T SYST MAN CY A, V31, P443, DOI 10.1109/3468.952718; Brooks R. A., 1986, IEEE J ROBOTICS AUTO, V2; Canamero L., 2005, EMOTIONAL DEV; Coello Y, 2012, COGN PROCESS, V13, pS131, DOI 10.1007/s10339-012-0470-z; Csikszentmihalyi M., 1991, FLOW PSYCHOL OPTIMAL; Ethofer T, 2009, J COGNITIVE NEUROSCI, V21, P1255, DOI 10.1162/jocn.2009.21099; Fellous J.M., 2004, HUMAN EMOTIONS ROBOT, P39; Frings C, 2010, Q J EXP PSYCHOL, V63, P42, DOI 10.1080/17470210903156594; Gaussier P, 2004, LECT NOTES ARTIF INT, V3139, P243; Grandjean D, 2011, COGN TECHNOL, P441, DOI 10.1007/978-3-642-15184-2_23; Gray JR, 2002, P NATL ACAD SCI USA, V99, P4115, DOI 10.1073/pnas.062381899; Hasson C., 2011, J BEHAV ROBOTICS, V2, P111, DOI DOI 10.2478/S13230-012-0005-4; Izard CE, 2010, EMOT REV, V2, P363, DOI 10.1177/1754073910374661; Jauffret A, 2013 IEEE 3 JOINT IN; Jauffret A, 2015, FRONT NEUROROBOTICS, V9, DOI 10.3389/fnbot.2015.00001; Jauffret A, 2013, FRONT NEUROROBOTICS, V7, DOI 10.3389/fnbot.2013.00016; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Krichmar JL, 2013, FRONT NEUROROBOTICS, V7, DOI 10.3389/fnbot.2013.00001; LeDoux J, 2012, NEURON, V73, P653, DOI 10.1016/j.neuron.2012.02.004; Lewis MD, 2005, BEHAV BRAIN SCI, V28, P169, DOI 10.1017/S0140525X0500004X; Lisman JE, 2001, HIPPOCAMPUS, V11, P551; Lones J, 2014 IEEE 4 JOINT IN; Lowe R, ROLE EMOTION ADAPTIV; Lowe R, 2007, LECT NOTES ARTIF INT, V4840, P1; Marsland S., 2003, NEURAL COMPUTING SUR, V3, P157; McGaugh JL, 2015, ANNU REV PSYCHOL, V66, P1, DOI 10.1146/annurev-psych-010814-014954; Morgado L, FLAIRS C, P245; Morgado L, 2007, LECT NOTES ARTIF INT, V4840, P59; Ognibene D, 2015, IEEE T AUTON MENT DE, V7, P3, DOI 10.1109/TAMD.2014.2341351; Ohman A, 2001, J EXP PSYCHOL GEN, V130, P466, DOI 10.1037/0096-3445.130.3.466; Ortony A., 1988, COGNITIVE STRUCTURE; Oudeyer PY, 2007, IEEE T EVOLUT COMPUT, V11, P265, DOI 10.1109/TEVC.2006.890271; Pessoa Luiz, 2010, Dialogues Clin Neurosci, V12, P433; Sargolini F, 2006, SCIENCE, V312, P758, DOI 10.1126/science.1125572; Scherer K.R., 2001, APPRAISAL PROCESSES, P92; SCHMIDHUBER J, 1991, IEEE IJCNN, P1458, DOI 10.1109/IJCNN.1991.170605; Tajadura-Jimenez A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026083; Valdes-Conroy B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049162; Wendt J, 2011, BIOL PSYCHOL, V86, P203, DOI 10.1016/j.biopsycho.2010.11.009; Widrow B, 1960, IRE WESCON, DOI DOI 10.21236/AD0241531; Williams JMG, 1996, PSYCHOL BULL, V120, P3, DOI 10.1037/0033-2909.120.1.3	45	5	5	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2017	12	9							e0184960	10.1371/journal.pone.0184960	http://dx.doi.org/10.1371/journal.pone.0184960			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FH7CN	28934291	Green Submitted, Green Published, gold			2023-01-03	WOS:000411339900066
J	Han, B; Compton, WM; Blanco, C; Crane, E; Lee, J; Jones, CM				Han, B.; Compton, W. M.; Blanco, C.; Crane, E.; Lee, J.; Jones, C. M.			Prescription Opioid Use, Misuse, and Use Disorders in US Adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	3	3	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 5	2017	167	5					I24	I24		10.7326/P17-9042	http://dx.doi.org/10.7326/P17-9042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF6LC	28761947				2023-01-03	WOS:000409120400001
J	Truog, RD				Truog, Robert D.			The United Kingdom Sets Limits on Experimental Treatments The Case of Charlie Gard	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Truog, Robert D.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Truog, RD (corresponding author), Harvard Med Sch, Ctr Bioeth, 641 Huntington Ave, Boston, MA 02115 USA.	robert_truog@hms.harvard.edu						[Anonymous], 2017, BBC NEWS; [Anonymous], 2017, NY TIMES; El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6	3	21	21	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP	2017	318	11					1001	1002		10.1001/jama.2017.10410	http://dx.doi.org/10.1001/jama.2017.10410			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH7DP	28727879				2023-01-03	WOS:000411343400007
J	Williams, H; McOwan, PW				Williams, Howard; McOwan, Peter W.			The magic words: Using computers to uncover mental associations for use in magic trick design	PLOS ONE			English	Article								The use of computational systems to aid in the design of magic tricks has been previously explored. Here further steps are taken in this direction, introducing the use of computer technology as a natural language data sourcing and processing tool for magic trick design purposes. Crowd sourcing of psychological concepts is investigated; further, the role of human associative memory and its exploitation in magical effects is explored. A new trick is developed and evaluated: a physical card trick partially designed by a computational system configured to search for and explore conceptual spaces readily understood by spectators.	[Williams, Howard; McOwan, Peter W.] Queen Mary Univ London, Sch Elect Engn & Comp Sci, London, England	University of London; Queen Mary University London	Williams, H (corresponding author), Queen Mary Univ London, Sch Elect Engn & Comp Sci, London, England.	h.williams@eecs.qmul.ac.uk		Williams, Howard/0000-0002-6418-2785	EPSRC [EP/J50029X/1]; Engineering and Physical Sciences Research Council [1086704, EP/J019860/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by EPSRC grant number EP/J50029X/1.	Annemann T, 2008, PRACTICAL MENTAL MAG; Banachek, 1998, PSYCHOL SUBTLETIES; Boden MA, 1998, ARTIF INTELL, V103, P347, DOI 10.1016/S0004-3702(98)00055-1; Corinda T, 1996, 13 STEPS MENTALISM; Diaconis  P., 2012, MAGICAL MATH; Earle L, 2003, MIND MENTALISM NEW D; Erdnase SW. Artifice, 1902, ARTIFICE RUSE SUBTER; Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464; Hartley David, 1834, OBSERVATIONS MAN HIS; Hugard Jean, 1974, EXPERT CARD TECHNIQU; MacTier AF, 2000, CARD CONCEPTS ANTHOL; Mikolov T., 2013, CURRAN ASS INC, P3111; Mikolov T., 2013, WORD2VEC; Mill J., 1822, ANAL PHENOMENA HUMAN; MILLER GA, 1995, COMMUN ACM, V38, P39, DOI 10.1145/219717.219748; Resnik P., 1995, CMPLG9511007 ARXIV; ROBERTSON SE, 1990, J DOC, V46, P359, DOI 10.1108/eb026866; Russell S, 2009, ARTIFICIAL INTELLIGE; Shettleworth S.J., 2009, COGNITION EVOLUTION; Von Eckardt B., 1995, WHAT IS COGNITIVE SC; Williams H, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01283	21	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2017	12	8							e0181877	10.1371/journal.pone.0181877	http://dx.doi.org/10.1371/journal.pone.0181877			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC9YJ	28792941	Green Published, gold, Green Submitted			2023-01-03	WOS:000407196700023
J	Albayrak, T; Sencan, I; Akca, O; Koc, EM; Aksoy, H; Unsal, S; Bulbul, I; Bahadir, A; Kasim, I; Kahveci, R; Ozkara, A				Albayrak, Turgay; Sencan, Irfan; Akca, Omer; Koc, Esra Meltem; Aksoy, Hilal; Unsal, Selim; Bulbul, Iskender; Bahadir, Adem; Kasim, Ismail; Kahveci, Rabia; Ozkara, Ademo			The ideas about advanced life support and affecting factors at the end-stage of life in a hospital in Turkey	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; PATIENT SATISFACTION; DEATH ANXIETY; WITHDRAWAL; ADULTS	Background The participation of the people in health decisions may be structured in various levels. One of these is participation in decisions for the treatment. "Advanced directives" is one of the examples for the participation in decisions for the treatment. Aim We wanted to determine the decisions on advanced life support at the end-stage of life in case of a life-threatening illness for the people themselves and their first degree relatives and the factors effecting these decisions. Design and setting The cross-sectional study was conducted with volunteers among patients and patient relatives who applied to all polyclinics of the Ankara Numune Training and Research Hospital except the emergency, oncology and psychiatry polyclinics between 15.12.2012 and 15.03.2013. Method A questionnaire, the Hospital Anxiety Depression (HAD) scale, and Templer's Death Anxiety Scale (TDA) were applied to all individuals. SPSS for Win. Ver. 17.0 and MS-Excel 2010 Starter software bundles were used for all statistical analysis and calculations. Results The participants want both themselves and their first degree relatives included in end-stage decision-making process. Therefore, the patients and their families should be informed adequately during decision making process and quality communication must be provided. Conclusion Participants who have given their end-stage decisions previously want to be treated according to these decisions. This desire can just be possible by advanced directives. When moral and material loads of end-stage process are taken into consideration, countries, in which advanced directives are practiced, should be examined well and participants' desire should be evaluated in terms of practicability.	[Albayrak, Turgay] Yenimahalle Cigdemtepe Family Hlth Ctr, Ankara, Turkey; [Sencan, Irfan; Kasim, Ismail; Kahveci, Rabia] Ankara Numune Training & Res Hosp, Dept Family Med, Ankara, Turkey; [Akca, Omer] Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey; [Koc, Esra Meltem] Izmir Katip Celebi Univ, Dept Family Med, Fac Med, Izmir, Turkey; [Aksoy, Hilal] Pamukkale Pelitlibag Family Hlth Ctr, Denizli, Turkey; [Unsal, Selim] Sefkat 2 Family Hlth Ctr, Ankara, Turkey; [Bulbul, Iskender] Guzelyurt State Hosp, Aksaray, Turkey; [Bahadir, Adem] Kalkandere 1 Family Hlth Ctr, Rize, Turkey; [Ozkara, Ademo] Corum Hitit Univ, Dept Family Med, Fac Med, Corum, Turkey	Ankara Numune Training & Research Hospital; Kayseri Training & Research Hospital; Izmir Katip Celebi University; Hitit University	Koc, EM (corresponding author), Izmir Katip Celebi Univ, Dept Family Med, Fac Med, Izmir, Turkey.	meltemnuzumlali@yahoo.com	Akça, Ömer Faruk/H-9626-2019; Koç, Esra Meltem/AAB-7724-2021; Şencan, İrfan/AAG-5653-2019	Şencan, İrfan/0000-0003-2008-8700; Kasim, Ismail/0000-0003-0762-5823				Abdel-Khalek AM, 2005, DEATH STUD, V29, P157, DOI 10.1080/07481180590906174; Aday RH, 1985, J DEATH DYING, V15, P67; Akca FK, 2008, CLIN PSYCHIATR, P11; [Anonymous], 1992, NEWSLETTER, V11, P4; Aydemir O., 1997, TURK PSIKIYATRI DERG, V8, P280; Buckley TA, 2004, CRIT CARE MED, V32, P415, DOI 10.1097/01.CCM.0000110675.34569.A9; Carr D, 2013, J GERONTOL B-PSYCHOL, V68, P586, DOI 10.1093/geronb/gbt034; CARRHILL RA, 1992, J PUBLIC HEALTH MED, V14, P236; CONTE HR, 1982, J PERS SOC PSYCHOL, V43, P775, DOI 10.1037/0022-3514.43.4.775; Curtis JR, 2010, LANCET, V376, P1347, DOI 10.1016/S0140-6736(10)60143-2; Ellentuck AB, 1992, NATIONS BUS, V80, P79; Erdogdu M, 2007, J INONU U MEDICAL FA, V14, P171; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Kahveci R., 2007, TURKIYE KLIN J MED E, V15, P90; Kalaoglu Z, 2010, THESIS; Karan MA, 2012, KLIN GELISIM DERGISI; Kastenbaum R., 2007, DEATH ANXIETY; Kastenbaum R., 2007, ENCY STRESS, VSecond, P717; KELLER JW, 1984, J PSYCHOL, V116, P137, DOI 10.1080/00223980.1984.9923628; Mani RK, 2009, INTENS CARE MED, V35, P1713, DOI 10.1007/s00134-009-1561-x; Mc Whinney IR, 2012, CLIN METHOD, P140; Ortin G Diestre, 2013, REV ESP GERIATR GERO, p[48, 228]; Ozer A., 2007, J MED RES, V5, P140; PARK DC, 1994, SOUTH MED J, V87, P971, DOI 10.1097/00007611-199410000-00002; POLLAK JM, 1979, OMEGA-J DEATH DYING, V10, P97, DOI 10.2190/4KG5-HBH0-NNME-DM58; Senol C., 1989, THESIS; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Stewart M, 1995, PATIENT CTR MED TRAN; Sypher B, 2002, AM FAM PHYSICIAN, V65, P2443; TURKEY Guven T., 2008, COUNTRY REPORTS ADV; WILLIAMS B, 1994, SOC SCI MED, V38, P509, DOI 10.1016/0277-9536(94)90247-X; Yazigi A, 2005, INTENS CARE MED, V31, P562, DOI 10.1007/s00134-005-2578-4; YILDIZ M., 1998, THESIS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2017	12	7							e0181456	10.1371/journal.pone.0181456	http://dx.doi.org/10.1371/journal.pone.0181456			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC2BU	28732071	Green Published, gold, Green Submitted			2023-01-03	WOS:000406643100036
J	Perrin, G; Korb-Savoldelli, V; Karras, A; Danchin, N; Durieux, P; Sabatier, B				Perrin, Germain; Korb-Savoldelli, Virginie; Karras, Alexandre; Danchin, Nicolas; Durieux, Pierre; Sabatier, Brigitte			Cardiovascular risk associated with high sodium-containing drugs: A systematic review	PLOS ONE			English	Review							BLOOD-PRESSURE; SALT SENSITIVITY; DOUBLE-BLIND; HYPERTENSION; EFFERVESCENT; REDUCTION; COCHRANE; TRIAL	Background Excess dietary sodium is associated with increased blood pressure (BP). Some drugs are associated with high sodium intake (in particular effervescent tablets), but the cardiovascular risk associated with such high sodium-containing drugs (HSCD) is largely underevaluated. Objectives To summarize the evidence for a potential cardiovascular risk associated with exposure to HSCD, and to highlight possible risk factors associated with this iatrogenic issue; in general and/or specific populations. Methods We conducted a systematic review, by searching electronic databases including MEDLINE, EMBASE, Web of Science, CENTRAL and grey literature between 1960 and 2015. We included studies that reported modification of cardiovascular parameters or incidence/prevalence of cardiovascular outcomes, between a group of subjects exposed to HSCD relative to a non-exposed group. The threshold used to identify HSCD was 391 mg/day. We did not consider studies evaluating exposure to sodium as an active ingredient or those focusing on dialysis solutions or enteral/parenteral nutrition. Study quality was assessed using the EPHPP tool. Results A total of eight studies met our inclusion criteria. Four reported results for short-term exposure to HSCD (<= 7 days) on BP fluctuations. One study reported an elevation of BP (associated sodium intake: 1,656 mg/day). Four studies evaluated a long- term exposure (<= 2 years or discontinuation of a chronic treatment). Two studies reported iatrogenic risk. For these studies, drug associated sodium intake was high (> 1,500 mg/day) in patients with comorbidities (in particular, diabetes mellitus and hypertension). Conclusion Despite numerous study limitations, this systematic review suggests three potential synergistic risk factors for cardiovascular complications after exposure to HSCD: a high sodium intake (>= 1,500 mg/day), a long duration of exposure, and the presence of comorbidities. Further studies are required to characterize this iatrogenic risk.	[Perrin, Germain; Korb-Savoldelli, Virginie; Sabatier, Brigitte] Georges Pompidou European Hosp, Dept Pharm, Paris, France; [Perrin, Germain; Durieux, Pierre; Sabatier, Brigitte] Paris Descartes Univ, Team Informat Sci Support Personalized Med 22, INSERM, UMR 1138, Paris, France; [Korb-Savoldelli, Virginie] Paris Saclay Univ, Clin Pharm Dept, Fac Pharm, Chatenay Malabry, France; [Karras, Alexandre] Georges Pompidou European Hosp, Dept Nephrol, Paris, France; [Karras, Alexandre; Danchin, Nicolas] Paris Descartes Univ, Paris, France; [Danchin, Nicolas] Georges Pompidou European Hosp, Dept Cardiol, Paris, France; [Durieux, Pierre] Georges Pompidou European Hosp, Dept Biomed Informat & Publ Hlth, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Perrin, G (corresponding author), Georges Pompidou European Hosp, Dept Pharm, Paris, France.; Perrin, G (corresponding author), Paris Descartes Univ, Team Informat Sci Support Personalized Med 22, INSERM, UMR 1138, Paris, France.	germain.perrin@aphp.fr	Korb-Savoldelli, Virginie/AAW-7011-2021; Danchin, Nicolas/AAN-8291-2020; Perrin, Germain/AAK-6550-2021; Korb-Savoldelli, Virginie/D-2134-2012	Korb-Savoldelli, Virginie/0000-0003-3496-6244; Sabatier, Brigitte/0000-0003-1643-2070; Perrin, Germain/0000-0002-5330-1777	University of Paris Descartes	University of Paris Descartes	The authors would like to acknowledge Sophie Guiquerro from the University of Paris Descartes for her support developing the literature search strategy.	Basile C, 2016, NEPHROL DIAL TRANSPL, V31, P548, DOI 10.1093/ndt/gfv084; Benitez-Camps M, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0161-7; Bruehl S, 2005, CLIN J PAIN, V21, P147, DOI 10.1097/00002508-200503000-00006; Burnier M, 2007, SODIUM HLTH DIS; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Dawson J, 2013, J HYPERTENS, V31, P1485, DOI 10.1097/HJH.0b013e328360f6f8; de Brito-Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205; Eckel R. H., 2014, Circulation, V129, pS76, DOI [10.1016/j.jacc.2013.11.003, 10.1161/01.cir.0000437740.48606.d1]; Elijovich F, 2016, HYPERTENSION, V68, pE7, DOI 10.1161/HYP.0000000000000047; European Medicines Agency, 2015, REV GUID EXC LAB PAC; George J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6954; Goodacre S, 2015, EMERG MED J, V32, P507, DOI 10.1136/emermed-2015-204761; Granberry MC, 1995, ANN PHARMACOTHER, V29, P1232, DOI 10.1177/106002809502901208; Graudal N, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0522-0; Graudal NA, 2012, AM J HYPERTENS, V25, P1, DOI 10.1038/ajh.2011.210; Grossman A, 2015, EUR J PHARMACOL, V763, P15, DOI 10.1016/j.ejphar.2015.06.027; Hall JE, 2016, CIRCULATION, V133, P894, DOI 10.1161/CIRCULATIONAHA.115.018526; He F. J., 2013, BMJ, V346; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; HUSTED FC, 1975, J CLIN INVEST, V56, P414, DOI 10.1172/JCI108107; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Mahajan A, 2010, KIDNEY INT, V78, P303, DOI 10.1038/ki.2010.129; MARK NH, 1993, CRIT CARE MED, V21, P659, DOI 10.1097/00003246-199305000-00007; Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127; Passfall J, 1997, CLIN NEPHROL, V47, P92; RADACK KL, 1987, ANN INTERN MED, V107, P628, DOI 10.7326/0003-4819-107-5-628; Schmidlin O, 2007, HYPERTENSION, V50, P1085, DOI 10.1161/HYPERTENSIONAHA.107.091694; SHARMA AM, 1992, HYPERTENSION, V19, P541, DOI 10.1161/01.HYP.19.6.541; SHORE AC, 1988, J HYPERTENS, V6, P613, DOI 10.1097/00004872-198808000-00003; Sudano I, 2010, CIRCULATION, V122, P1789, DOI 10.1161/CIRCULATIONAHA.110.956490; Adler Alma J, 2014, Cochrane Database Syst Rev, pCD009217, DOI [10.1002/14651858.CD009217, 10.1002/14651858.CD009217.pub3]; Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x; Thomas E, 2014, ALIMENT PHARM THER, V39, P595, DOI 10.1111/apt.12640; TURNBERG L A, 1970, Journal of Clinical Investigation, V49, P557, DOI 10.1172/JCI106266; Ubeda A, 2009, PHARMACOEPIDEM DR S, V18, P417, DOI 10.1002/pds.1701; Union Re A gionale des Caisses d'Assurance Maladie, 2005, PRESCR MED SOD CHEZ; Uzoigwe OF, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1404; Weinberger MH, 1996, HYPERTENSION, V27, P481, DOI 10.1161/01.HYP.27.3.481; WHO, 2012, GUID SOD INT AD CHIL	40	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2017	12	7							e0180634	10.1371/journal.pone.0180634	http://dx.doi.org/10.1371/journal.pone.0180634			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA3HX	28683120	Green Published, Green Submitted, gold			2023-01-03	WOS:000405335200056
J	Gunasekera, D				Gunasekera, Don			Fight fake reagents with digital tools	NATURE			English	Letter									[Gunasekera, Don] Deakin Univ, Melbourne, Vic, Australia	Deakin University	Gunasekera, D (corresponding author), Deakin Univ, Melbourne, Vic, Australia.	don.gunasekera@deakin.edu.au						Chapron G, 2017, NATURE, V545, P403, DOI 10.1038/545403a; Mackey TK, 2017, EXPERT OPIN DRUG SAF, V16, P587, DOI 10.1080/14740338.2017.1313227; 2017, NATURE, V545, P148	3	2	2	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2017	546	7659					474	474		10.1038/546474c	http://dx.doi.org/10.1038/546474c			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY2QK	28640264	Green Submitted, Bronze			2023-01-03	WOS:000403814100020
J	Bian, X; Gao, J; Luo, F; Rui, C; Zheng, T; Wang, D; Wang, Y; Roberts, TM; Liu, P; Zhao, JJ; Cheng, H				Bian, X.; Gao, J.; Luo, F.; Rui, C.; Zheng, T.; Wang, D.; Wang, Y.; Roberts, T. M.; Liu, P.; Zhao, J. J.; Cheng, H.			PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION REPAIR; OVARIAN-CANCER; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; PROSTATE-CANCER; PI3K INHIBITOR; NUCLEAR PTEN; MUTANT-CELLS; OLAPARIB	Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair. However, as HR-deficient tumors represent only a small fraction of endometrial cancers, the therapeutic utility of PARP inhibitors is limited in this disease. Somatic loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that counteracts phosphoinositide 3-kinase (PI3K) activity, is one of the most common genetic aberrations in endometrioid endometrial cancer. While previous works have identified the role of PTEN in DNA double-strand break repair, vulnerabilities of PTEN-deficient endometrioid endometrial cancers to PARP inhibition remain controversial. Here we find that PTENdeficient endometrioid endometrial cancer cells are not responsive to PARP inhibitor Olaparib alone, but instead show superior sensitivity to compound inhibition with PI3K inhibitor BKM120, as evidenced by reduced clonogenic cell growth and threedimensional (3D) spheroid disintegration. Mechanistically, PI3K blockade by BKM120 attenuated HR competency with.H2AX accumulation and reduced RAD51 and BRCA1 expression in Ishikawa, AN3CA and Nou-1 cells, but the same combination treatment led to enhanced phosphorylation of DNA-PK, a non-homologous end joining repair protein, in Hec-108 cells. Furthermore, we show that CRISPR/Cas9-mediated PTEN depletion rendered PTEN wild-type Hec-1A endometrioid endometrial cancer cells responsive to combined inhibition of PARP/PI3K, with concomitantly induced DNA damage accumulation and repair defects. The combination of BKM120 and Olaparib cooperated to inhibit tumor growth in a genetic mouse model of Pten-deficient endometrioid endometrial cancer. Together, these results suggest PI3K inhibition may be a plausible approach to expand the utility of PARP inhibitors to endometrioid endometrial cancers in a PTEN-deficient setting.	[Bian, X.; Gao, J.; Rui, C.; Wang, D.; Liu, P.; Cheng, H.] Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Canc Inst, Dalian, Peoples R China; [Luo, F.] Dalian Med Univ, Hosp 2, Dept Acute Abdomen Surg, Dalian, Peoples R China; [Zheng, T.] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China; [Wang, Y.] Dalian Med Univ, Dept Obstet & Gynecol, Hosp 2, Dalian, Peoples R China; [Roberts, T. M.; Zhao, J. J.] Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA; [Liu, P.] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Harvard University; Dana-Farber Cancer Institute; Dalian Medical University	Zhao, JJ (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave Smith 936, Boston, MA 02215 USA.; Cheng, H (corresponding author), Dalian Med Univ, Inst Canc, Hosp 2, Dalian 116023, Peoples R China.; Liu, P (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Peoples R China.	pixu_liu@dmu.edu.cn; jean_zhao@dfci.harvard.edu; hailingcheng_dmu@163.com			National Natural Science Foundation of China [81472447, 81672575, 81372853, 81572586, 81602274]; Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning [2014023002]; National Institutes of Health/National Cancer Institute (NIH/NCI) [P50 CA168504, CA187918, P50 CA165962, CA210057-01, CA172461-04]; Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE [R35CA210057, R01CA172461, R01CA187918, P50CA165962, P50CA168504] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Provincial Climbing Scholars Supporting Program of China; Liaoning Provincial Science and Technology Program for Oversea Talents; Provincial Natural Science Foundation of Liaoning; National Institutes of Health/National Cancer Institute (NIH/NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; DFCI SSCWC Program Project Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Natural Science Foundation of China (No. 81472447 and No. 81672575 to H Cheng; No. 81372853 and No. 81572586 to P Liu; No. 81602274 to J Gao), Liaoning Provincial Climbing Scholars Supporting Program of China (H Cheng, P Liu), Liaoning Provincial Science and Technology Program for Oversea Talents (H Cheng), Provincial Natural Science Foundation of Liaoning (No. 2014023002 to P Liu), National Institutes of Health/National Cancer Institute (NIH/NCI) (P50 CA168504, CA187918, P50 CA165962, CA210057-01 and CA172461-04 to JJZ), and Breast Cancer Research Foundation and DFCI SSCWC Program Project Grant.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Bassi C, 2013, SCIENCE, V341, P395, DOI 10.1126/science.1236188; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Cardillo TM, 2017, CLIN CANCER RES, V23, P3405, DOI 10.1158/1078-0432.CCR-16-2401; Cardnell RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152584; Chan SL, 2010, LANCET, V376, P211, DOI 10.1016/S0140-6736(10)61119-1; Cheng HL, 2014, CANCER RES, V74, P15, DOI 10.1158/0008-5472.CAN-13-0544; Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Forster MD, 2011, NAT REV CLIN ONCOL, V8, P302, DOI 10.1038/nrclinonc.2011.42; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Billalabeitia E, 2014, CANCER DISCOV, V4, P896, DOI 10.1158/2159-8290.CD-13-0230; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Janzen DM, 2013, MOL CANCER THER, V12, P2917, DOI 10.1158/1535-7163.MCT-13-0572; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Li L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12235; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Martins FC, 2012, CANCER DISCOV, V2, P503, DOI 10.1158/2159-8290.CD-11-0325; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Miyasaka A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-179; Mo W, 2016, CLIN CANCER RES, V22, P1699, DOI 10.1158/1078-0432.CCR-15-1772; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Okkenhaug K, 2016, CANCER DISCOV, V6, P1090, DOI 10.1158/2159-8290.CD-16-0716; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang D, 2016, GYNECOL ONCOL, V142, P548, DOI 10.1016/j.ygyno.2016.07.092; Wang D, 2016, ONCOTARGET, V7, P13153, DOI 10.18632/oncotarget.7549; Weigelt B, 2013, CLIN CANCER RES, V19, P3533, DOI 10.1158/1078-0432.CCR-12-3815	47	70	72	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					341	351		10.1038/onc.2017.326	http://dx.doi.org/10.1038/onc.2017.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945226	Green Published, hybrid			2023-01-03	WOS:000422753900007
J	Dowell, D; Noonan, RK; Houry, D				Dowell, Deborah; Noonan, Rita K.; Houry, Debra			Underlying Factors in Drug Overdose Deaths	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INCREASES; HEROIN; STATES; TRIAL		[Dowell, Deborah; Noonan, Rita K.; Houry, Debra] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Dowell, D (corresponding author), US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA.	ddowell@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Cicero TJ, 2017, ADDICT BEHAV, V74, P63, DOI 10.1016/j.addbeh.2017.05.030; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gordon MS, 2014, DRUG ALCOHOL DEPEN, V142, P33, DOI 10.1016/j.drugalcdep.2014.05.011; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; US Centers for Disease Control and Prevention, PROV COUNTS DRUG OV	7	95	96	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2017	318	23					2295	2296		10.1001/jama.2017.15971	http://dx.doi.org/10.1001/jama.2017.15971			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ3RJ	29049472	Green Accepted			2023-01-03	WOS:000418274000013
J	Assaf-Balut, C; de la Torre, NG; Duran, A; Fuentes, M; Bordiu, E; del Valle, L; Familiar, C; Ortola, A; Jimenez, I; Herraiz, MA; Izquierdo, N; Perez, N; Torrejon, MJ; Ortega, MI; Illana, FJ; Runkle, I; de Miguel, MP; Montanez, C; Barabash, A; Cuesta, M; Rubio, MA; Calle-Pascual, AL				Assaf-Balut, Carla; Garcia de la Torre, Nuria; Duran, Alejandra; Fuentes, Manuel; Bordiu, Elena; del Valle, Laura; Familiar, Cristina; Ortola, Ana; Jimenez, Ines; Herraiz, Miguel A.; Izquierdo, Nuria; Perez, Noelia; Torrejon, Maria J.; Ortega, Maria I.; Illana, Francisco J.; Runkle, Isabelle; de Miguel, Maria P.; Montanez, Carmen; Barabash, Ana; Cuesta, Martin; Rubio, Miguel A.; Calle-Pascual, Alfonso L.			A Mediterranean diet with additional extra virgin olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): A randomized controlled trial: The St. Carlos GDM prevention study	PLOS ONE			English	Article							LIFE-STYLE INTERVENTION; EARLY-PREGNANCY; RISK; NUTRITION; WOMEN; INFLAMMATION; METAANALYSIS; MULTICENTER; RESISTANCE; ADHERENCE	Background Gestational diabetes mellitus (GDM) prevalence is increasing and becoming a major public health concern. Whether a Mediterranean diet can help prevent GDM in unselected pregnant women has yet to be studied. Methods We conducted a prospective, randomized controlled trial to evaluate the incidence of GDM with two different dietary models. All consecutive normoglycemic (<92 mg/dL) pregnant women at 8-12 gestational weeks (GW) were assigned to Intervention Group (IG, n = 500): MedDiet supplemented with extra virgin olive oil (EVOO) and pistachios; or Control Group (CG, n = 500): standard diet with limited fat intake. Primary outcome was to assess the effect of the intervention on GDM incidence at 24-28 GW. Gestational weight gain (GWG), pregnancy-induced hypertension, caesarean section (CS), preterm delivery, perineal trauma, small and large for gestational age (SGA and LGA) and admissions to neonatal intensive care unit were also assessed. Analysis was by intention-to-treat. Results A total of 874 women completed the study (440/434, CG/IG). According to nutritional questionnaires and biomarker analysis, women in the IG had a good adherence to the intervention. 177/874 women were diagnosed with GDM, 103/440 (23.4%) in CG and 74/ 434(17.1%) in IG, p = 0.012. The crude relative risk (RR) for GDM was 0.73 (95% CI: 0.56-0.95; p = 0.020) IG vs CG and persisted after adjusted multivariable analysis, 0.75(95% CI: 0.57-0.98; p = 0.039). IG had also significantly reduced rates of insulin-treated GDM, prematurity, GWG at 24-28 and 36-38 GW, emergency CS, perineal trauma, and SGA and LGA newborns (all p<0.05). Conclusions An early nutritional intervention with a supplemented MedDiet reduces the incidence of GDM and improves several maternal and neonatal outcomes.	[Assaf-Balut, Carla; Garcia de la Torre, Nuria; Duran, Alejandra; Bordiu, Elena; del Valle, Laura; Familiar, Cristina; Ortola, Ana; Jimenez, Ines; Runkle, Isabelle; de Miguel, Maria P.; Montanez, Carmen; Barabash, Ana; Cuesta, Martin; Rubio, Miguel A.; Calle-Pascual, Alfonso L.] Hosp Clin Univ San Carlos, Endocrinol & Nutr Dept, Madrid, Spain; [Assaf-Balut, Carla; Garcia de la Torre, Nuria; Duran, Alejandra; Fuentes, Manuel; Bordiu, Elena; del Valle, Laura; Familiar, Cristina; Ortola, Ana; Jimenez, Ines; Herraiz, Miguel A.; Izquierdo, Nuria; Perez, Noelia; Torrejon, Maria J.; Ortega, Maria I.; Illana, Francisco J.; Runkle, Isabelle; de Miguel, Maria P.; Montanez, Carmen; Barabash, Ana; Cuesta, Martin; Rubio, Miguel A.; Calle-Pascual, Alfonso L.] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain; [Assaf-Balut, Carla; Duran, Alejandra; Bordiu, Elena; Herraiz, Miguel A.; Izquierdo, Nuria; Runkle, Isabelle; de Miguel, Maria P.; Rubio, Miguel A.; Calle-Pascual, Alfonso L.] Univ Complutense Madrid, Fac Med, Madrid, Spain; [Garcia de la Torre, Nuria; Barabash, Ana; Cuesta, Martin; Calle-Pascual, Alfonso L.] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain; [Fuentes, Manuel] Hosp Clin Univ San Carlos, Prevent Med Dept, Madrid, Spain; [Herraiz, Miguel A.; Izquierdo, Nuria; Perez, Noelia] Hosp Clin Univ San Carlos, Gynecol & Obstet Dept, Madrid, Spain; [Torrejon, Maria J.; Ortega, Maria I.; Illana, Francisco J.] Hosp Clin Univ San Carlos, Clin Lab Dept, Madrid, Spain	Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM	Calle-Pascual, AL (corresponding author), Hosp Clin Univ San Carlos, Endocrinol & Nutr Dept, Madrid, Spain.; Calle-Pascual, AL (corresponding author), Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain.; Calle-Pascual, AL (corresponding author), Univ Complutense Madrid, Fac Med, Madrid, Spain.; Calle-Pascual, AL (corresponding author), Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.	acallepascual@hotmail.com	Barabash, Ana M/B-1612-2012; Rubio, Miguel Angel/GRJ-0134-2022; Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/L-1086-2017; Barabash, Ana/AAD-2141-2020; Calle-Pascual, Alfonso L./D-4531-2017	Barabash, Ana M/0000-0003-2383-1563; Rubio, Miguel Angel/0000-0002-0495-6240; Ferrer, Manuel Enrique Fuentes Ferrer ME Fuentes/0000-0002-5177-1441; Barabash, Ana/0000-0003-2383-1563; Montanez, Carmen/0000-0002-3485-3808; Torrejon, Maria Jose/0000-0002-1963-1027; Calle-Pascual, Alfonso L./0000-0002-3628-9323; Assaf-Balut, Carla/0000-0002-6217-3770	Fundacion para Estudios Endocrinometabolicos; IdISSC Hospital Clinico San Carlos, Madrid; Institute de Salud Carlos III (ISCIII) of Spain [PI14/01563]; Fondo Europeo de Desarrollo Regional (FEDER)	Fundacion para Estudios Endocrinometabolicos; IdISSC Hospital Clinico San Carlos, Madrid; Institute de Salud Carlos III (ISCIII) of Spain(Instituto de Salud Carlos III); Fondo Europeo de Desarrollo Regional (FEDER)(European Commission)	This work was supported by the Fundacion para Estudios Endocrinometabolicos, and IdISSC Hospital Clinico San Carlos, Madrid, and the Institute de Salud Carlos III (ISCIII) of Spain (PI14/01563) and Fondo Europeo de Desarrollo Regional (FEDER). The funders had no role in the design and conduct of the study, collection and management, analysis, and interpretation of the data. The preparation, review, and approval of the manuscript and decision to submit the manuscript for publication are the responsibilities of the authors alone and independent of the funders.	Assaf-Balut C, 2016, BMJ OPEN DIAB RES CA, V4, DOI DOI 10.1136/BMJDRC-2016-000314.ECOLLECTION2016; Bain E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010443.pub2; Carolan-Olah MC, 2016, COLLEGIAN, V23, P103, DOI 10.1016/j.colegn.2015.01.001; Che L, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3601-1; Dodd JM, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1285; Duran A, 2014, DIABETES CARE, V37, P2442, DOI 10.2337/dc14-0179; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Hernandez-Alonso Pablo, 2016, Nutr Today, V51, P133, DOI 10.1097/NT.0000000000000160; Hernandez-Alonso P, 2014, DIABETES CARE, V37, P3098, DOI 10.2337/dc14-1431; Imamura F, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002087; Izadi V, 2016, NUTRITION, V32, P1092, DOI 10.1016/j.nut.2016.03.006; Kar S, 2016, EUR J OBSTET GYN R B, V198, P40, DOI 10.1016/j.ejogrb.2015.11.033; Koivusalo SB, 2016, DIABETES CARE, V39, P24, DOI 10.2337/dc15-0511; Linnenkamp U, 2014, DIABETES RES CLIN PR, V103, P186, DOI 10.1016/j.diabres.2013.11.004; Luoto R, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001036; Manzano P, 2004, DIABETES CARE, V27, P984, DOI 10.2337/diacare.27.4.984; Poston L, 2015, LANCET DIABETES ENDO, V3, P767, DOI 10.1016/S2213-8587(15)00227-2; Puertollano MA, 2007, BRIT J NUTR, V98, pS54, DOI 10.1017/S0007114507832934; Renault KM, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.09.029; Rogozinska E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115526; Ruiz-Gracia T, 2016, CLIN NUTR, V35, P699, DOI 10.1016/j.clnu.2015.04.017; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Schwingshackl L, 2015, NUTRIENTS, V7, P7651, DOI 10.3390/nu7095356; Simmons D, 2015, DIABETES CARE, V38, P1650, DOI 10.2337/dc15-0360; Smith LA, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-59; Sociedad Espanola de Ginecologia y Obstetricia, PROT AS OBST CONTR P; Song C, 2016, OBES REV, V17, P960, DOI 10.1111/obr.12442; Sun Y, 2016, APPL NURS RES, V30, P125, DOI 10.1016/j.apnr.2015.10.006; Vinter CA, 2011, DIABETES CARE, V34, P2502, DOI 10.2337/dc11-1150; Wang ST, 2015, J MECH DESIGN, V137, DOI 10.1115/1.4030433; Xu J, 2014, SCI WORLD J, DOI 10.1155/2014/926932; Zerbinati C, 2015, CLIN CHIM ACTA, V446, P156, DOI 10.1016/j.cca.2015.04.026; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	35	97	98	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2017	12	10							0185873	10.1371/journal.pone.0185873	http://dx.doi.org/10.1371/journal.pone.0185873			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK0UN	29049303	Green Submitted, Green Published, gold			2023-01-03	WOS:000413195900027
J	Klein, HG; Hrouda, JC; Epstein, JS				Klein, Harvey G.; Hrouda, J. Chris; Epstein, Jay S.			Crisis in the Sustainability of the US Blood System	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSFUSION		[Klein, Harvey G.] NIH, Dept Transfus Med, Bethesda, MD 20892 USA; [Hrouda, J. Chris] Amer Natl Red Cross Biomed Serv, Washington, DC USA; [Epstein, Jay S.] US FDA, Off Blood Res & Review, Ctr Biol Evaluat & Res, Washington, DC 20204 USA	National Institutes of Health (NIH) - USA; American Red Cross; US Food & Drug Administration (FDA)	Klein, HG (corresponding author), NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.	hklein@cc.nih.gov		Epstein, Jay/0000-0003-2293-9062				Bloch EM, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2955; Donohue JM, 2017, JAMA-J AM MED ASSOC, V317, P1415, DOI 10.1001/jama.2017.2826; Ellingson KD, 2017, TRANSFUSION, V57, P1588, DOI 10.1111/trf.14165; Hebert PC, 2014, NEW ENGL J MED, V371, P1459, DOI 10.1056/NEJMe1408976; Klein HG, 2013, NEW ENGL J MED, V368, P199, DOI 10.1056/NEJMp1213134; Kuehnert MJ, 2016, TRANSFUSION, V56, P1669, DOI 10.1111/trf.13673; Mulcahy A., 2017, SUSTAINABLE BLOOD SU; Quillen K, 2014, TRANSFUSION, V54, P1202, DOI 10.1111/trf.12642; Snyder EL, 2015, NEW ENGL J MED, V373, P882, DOI 10.1056/NEJMc1507761	9	46	47	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	2017	377	15					1485	1488		10.1056/NEJMsb1706496	http://dx.doi.org/10.1056/NEJMsb1706496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ4ZP	29020590				2023-01-03	WOS:000412753100016
J	Pasquier, M; Clair, M; Pruvot, E; Hugli, O; Carron, PN				Pasquier, Mathieu; Clair, Mathieu; Pruvot, Etienne; Hugli, Olivier; Carron, Pierre-Nicolas			Carotid Sinus Massage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COMPLICATIONS; SYNCOPE; GUIDELINES; CARE		[Pasquier, Mathieu; Clair, Mathieu; Pruvot, Etienne; Hugli, Olivier; Carron, Pierre-Nicolas] Lausanne Univ Hosp, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Pasquier, M (corresponding author), Lausanne Univ Hosp, Lausanne, Switzerland.		Hugli, Olivier/AAA-7057-2020	Pruvot, Etienne/0000-0003-1386-9285; Hugli, Olivier/0000-0003-2312-1625				[Anonymous], 2009, EUR HEART J, V30, P2631, DOI DOI 10.1093/EURHEARTJ/EHP298; Blomstrom-Lundqvist Carina, 2003, Journal of the American College of Cardiology, V42, P1493, DOI 10.1016/j.jacc.2003.08.013; Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008; Brignole M, 2013, EUROPACE, V15, P1070, DOI 10.1093/europace/eut206; Davies AJ, 1998, AM J CARDIOL, V81, P1256, DOI 10.1016/S0002-9149(98)00130-1; Epstein AE, 2013, J AM COLL CARDIOL, V61, pE6, DOI 10.1016/j.jacc.2012.11.007; MUNRO NC, 1994, J AM GERIATR SOC, V42, P1248, DOI 10.1111/j.1532-5415.1994.tb06505.x; Neumar RW, 2010, CIRCULATION, V122, pS729, DOI 10.1161/CIRCULATIONAHA.110.970988; Krediet CTP, 2011, EUROPACE, V13, P14, DOI 10.1093/europace/euq409; Puggioni E, 2002, AM J CARDIOL, V89, P599, DOI 10.1016/S0002-9149(01)02303-7; SCHWEITZER P, 1985, AM J MED, V78, P645, DOI 10.1016/0002-9343(85)90408-5; Strickberger SA, 2006, CIRCULATION, V113, P316, DOI 10.1161/CIRCULATIONAHA.105.170274; Toorop RJ, 2009, J VASC SURG, V50, P177, DOI 10.1016/j.jvs.2009.03.029; WAXMAN MB, 1980, AM J CARDIOL, V46, P655, DOI 10.1016/0002-9149(80)90517-2	14	11	10	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	2017	377	15					E21	+		10.1056/NEJMvcm1313338	http://dx.doi.org/10.1056/NEJMvcm1313338			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FJ4ZP	29020587	Green Published			2023-01-03	WOS:000412753100001
J	Gotta, V; Baumann, P; Ritz, N; Fuchs, A; Baer, G; Bonhoeffer, JM; Heininger, U; Szinnai, G; Bonhoeffer, J				Gotta, Verena; Baumann, Philipp; Ritz, Nicole; Fuchs, Aline; Baer, Gurli; Bonhoeffer, Jessica M.; Heininger, Ulrich; Szinnai, Gabor; Bonhoeffer, Jan		ProPAED Study Grp	Drivers of antibiotic prescribing in children and adolescents with febrile lower respiratory tract infections	PLOS ONE			English	Article							C-REACTIVE PROTEIN; WHITE BLOOD-CELL; ERYTHROCYTE SEDIMENTATION-RATE; COMMUNITY-ACQUIRED PNEUMONIA; CALCITONIN-I GENE; PNEUMOCOCCAL PNEUMONIA; CLINICAL-FEATURES; LEUKOCYTE COUNT; PROCALCITONIN; BACTERIAL	Background Knowledge of key drivers for antibiotic prescribing in pediatric lower respiratory tract infection (LRTI) could support rational antibiotic use. Thus, we aimed to determine the impact of clinical and laboratory factors on antibiotic prescribing in children and adolescents with febrile LRTI. Methods Pediatric patients from the standard care control group of a randomized controlled trial (ProPAED) investigating procalcitonin guided antibiotic treatment in febrile LRTI were included in a multivariate logistic regression analysis to evaluate the impact of laboratory and clinical factors on antibiotic prescribing. Results The standard care control group of the ProPAED study comprised 165 LRTI patients (median age: 2.7 years, range: 0.1-16), out of which 88 (55%) received antibiotic treatment. Factors significantly associated with antibiotic prescribing in patients with complete clinical and laboratory documentation (n = 158) were C-reactive protein (OR 5.8 for a 10-fold increase, 95% CI 2.2-14.9), white blood count beyond age-dependent reference range (OR 3.9, 95% CI 1.4-11.4), body temperature (OR 1.7 for an increase by 1 degrees C, 95% CI 1.02-2.68), and pleuritic pain (OR 2.8, 95% CI 1.1-7.6). Dyspnea (OR 0.3, 95% CI 0.1-0.7) and wheezing (OR 0.3, 95% CI 0.13-0.95) were inversely associated with antibiotic prescribing. Conclusion Laboratory markers were strong drivers of antibiotic prescribing in children with febrile lower respiratory tract infections, in spite of their known poor prediction of antibiotic need. Building on current guidelines for antibiotic treatment in children with febrile LRTI, a reliable decision algorithm for safe antibiotic withholding considering the laboratory and clinical factors evaluated in this study has the potential to further reduce antibiotic prescribing.	[Gotta, Verena; Ritz, Nicole; Fuchs, Aline] Univ Basel, Childrens Hosp, Dept Pediat Pharmacol & Pharmacometr, Basel, Switzerland; [Baumann, Philipp; Ritz, Nicole; Baer, Gurli; Heininger, Ulrich; Bonhoeffer, Jan] Univ Basel, Childrens Hosp, Dept Pediat Infect Dis & Vaccinol, Basel, Switzerland; [Bonhoeffer, Jessica M.] Univ Basel, Childrens Hosp, Basel, Switzerland; [Szinnai, Gabor] Univ Basel, Childrens Hosp, Dept Pediat Endocrinol & Diabetol, Basel, Switzerland; [Baumann, Philipp] Univ Childrens Hosp Zurich, Dept Intens Care Med & Neonatol, Zurich, Switzerland; [Bonhoeffer, Jessica M.] Univ Childrens Hosp Zurich, Child Dev Ctr, Zurich, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel; University Children's Hospital Zurich; University Children's Hospital Zurich	Baumann, P (corresponding author), Univ Basel, Childrens Hosp, Dept Pediat Infect Dis & Vaccinol, Basel, Switzerland.; Baumann, P (corresponding author), Univ Childrens Hosp Zurich, Dept Intens Care Med & Neonatol, Zurich, Switzerland.	philipp.baumann@kispi.uzh.ch	Ritz, Nicole/G-2924-2015; Ritz, Nicole/L-1452-2019	Ritz, Nicole/0000-0002-1498-1685; Ritz, Nicole/0000-0002-1498-1685; Gotta, Verena/0000-0001-6254-5207				Ahmed MN, 2010, CLIN PEDIATR, V49, P542, DOI 10.1177/0009922809357786; Baer G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068419; Balfour-Lynn IM, 2005, THORAX, V60, P1, DOI 10.1136/thx.2004.030676; Behrman R., 2004, NELSON TXB PEDIAT, V17th ed., P1481; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y; Chen SP, 2013, J CLIN VIROL, V56, P7, DOI 10.1016/j.jcv.2012.08.021; Christ-Crain M, 2007, EUR RESPIR J, V30, P556, DOI 10.1183/09031936.00166106; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC; Davies HD, 1996, PEDIATR INFECT DIS J, V15, P600, DOI 10.1097/00006454-199607000-00008; Domenech VS, 2001, J INVEST MED, V49, P514, DOI 10.2310/6650.2001.33628; Don M, 2009, PEDIATR INT, V51, P91, DOI 10.1111/j.1442-200X.2008.02678.x; Elemraid MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106051; Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003; Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X; Flood RG, 2008, PEDIATR INFECT DIS J, V27, P95, DOI 10.1097/INF.0b013e318157aced; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Horwood J, 2016, BRIT J GEN PRACT, V66, pE207, DOI 10.3399/bjgp16X683821; Jakobsen KA, 2010, SCAND J PRIM HEALTH, V28, P229, DOI 10.3109/02813432.2010.506995; Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2; Koller D, 2013, INFECTION, V41, P121, DOI 10.1007/s15010-012-0302-1; Korppi M, 2004, PEDIATR INT, V46, P545, DOI 10.1111/j.1442-200x.2004.01947.x; Korppi M, 1997, EUR RESPIR J, V10, P1125, DOI 10.1183/09031936.97.10051125; KORPPI M, 1993, SCAND J INFECT DIS, V25, P435, DOI 10.3109/00365549309008524; Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x; Lemaitre C, 2013, PEDIATR INFECT DIS J, V32, P1146, DOI 10.1097/INF.0b013e31829be1bb; Lin Chao-Jen, 2006, Journal of Microbiology Immunology and Infection, V39, P489; Lucas PJ, 2015, SCAND J PRIM HEALTH, V33, P11, DOI 10.3109/02813432.2015.1001942; McDonagh M, 2016, AHRQ PUBLICATION, V163; Moro ML, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-69; Muller B, 2004, CLIN INFECT DIS, V39, P1867, DOI 10.1086/426148; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P484, DOI 10.1097/00006454-199506000-00004; Organization WH, 2001, STAND INT CHEST RAD; Peltola V, 2006, J PEDIATR-US, V149, P721, DOI 10.1016/j.jpeds.2006.08.051; Prat C, 2003, PEDIATR INFECT DIS J, V22, P963, DOI 10.1097/01.inf.0000095197.72976.4f; Schuetz P, 2012, CLIN INFECT DIS, V55, P651, DOI 10.1093/cid/cis464; SHUTTLEWORTH DB, 1971, AM J DIS CHILD, V122, P393, DOI 10.1001/archpedi.1971.02110050063005; Stocker M, 2010, NEONATOLOGY, V97, P165, DOI 10.1159/000241296; Tabain I, 2012, PEDIATR INFECT DIS J, V31, P680, DOI 10.1097/INF.0b013e318256605e; van Buuren S, 2011, J STAT SOFTW, V45, P1; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wexler ID, 2006, PEDIATR PULM, V41, P726, DOI 10.1002/ppul.20383; World Health Organization, 2013, GUIDELINES MANAGEMEN	46	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185197	10.1371/journal.pone.0185197	http://dx.doi.org/10.1371/journal.pone.0185197			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FI4YC	28957358	Green Published, gold, Green Submitted			2023-01-03	WOS:000411985200032
J	Liu, D; Lyu, J; Zhao, HY; An, YZ				Liu, Dan; Lyu, Jie; Zhao, Huiying; An, Youzhong			The influence of analgesic-based sedation protocols on delirium and outcomes in critically ill patients: A randomized controlled trial	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; RISK-FACTORS; POSTOPERATIVE DELIRIUM; REMIFENTANIL; DURATION; PREVALENCE	Objective To investigate the influence of analgesic-based midazolam sedation on delirium and outcomes in critically ill patients and to analyze the risk factors of delirium. Design Single center, prospective randomized controlled trial. Setting A surgical intensive care unit (ICU) in a tertiary care hospital in China. Patients Mechanically ventilated patients requiring sedation. Measurements and main results Patients admitted to the surgical intensive care unit who required sedation and were undergoing mechanical ventilation for longer than 24 hours were randomly divided into three groups: 1) the remifentanil group received remifentanil and midazolam, 2) the fentanyl group received fentanyl and midazolam, and 3) the control group received only midazolam. The analgesic effect, sedation depth, and presence of delirium were evaluated. To compare the effect of different therapies on the occurrence of delirium, days of mechanical ventilation, length of the ICU stay, and 28-day mortality were measured along with the risk factors for delirium. A total of 105 patients were enrolled, and 35 patients were included in each group. Compared to the control group, patients who received remifentanil and fentanyl required less midazolam each day (P = 0.038 and <0.001, respectively). Remifentanil has a significant effect on reducing the occurrence of delirium (P = 0.007). The logistic regression analysis of delirium demonstrated that remifentanil (OR 0.230, 95%Cl 0.0740.711, P = 0.011) is independent protective factors for delirium, and high APACHE II score (OR 1.103, 95%Cl 1.0071.208, P = 0.036) is the independent risk factor for delirium. Conclusion Remifentanil and fentanyl can reduce the amount of midazolam required, and remifentanil could further reduce the occurrence of delirium.	[Liu, Dan; Lyu, Jie; Zhao, Huiying; An, Youzhong] Peking Univ, Peoples Hosp, Dept Crit Care, Beijing, Peoples R China	Peking University	An, YZ (corresponding author), Peking Univ, Peoples Hosp, Dept Crit Care, Beijing, Peoples R China.	bjicu@163.com			Chinese Medical Association of Clinical Medicine Research Fund [2014-Z-15]	Chinese Medical Association of Clinical Medicine Research Fund	This study was supported by a grant from the Chinese Medical Association of Clinical Medicine Research Fund (No.2014-Z-15).	Agarwal V, 2010, J BURN CARE RES, V31, P706, DOI 10.1097/BCR.0b013e3181eebee9; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Flaherty JH, 2007, J AM MED DIR ASSOC, V8, P273, DOI 10.1016/j.jamda.2007.03.006; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Morandi A, 2011, NEUROL CLIN, V29, P749, DOI 10.1016/j.ncl.2011.08.004; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Radtke FM, 2010, J INT MED RES, V38, P1225, DOI 10.1177/147323001003800403; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rotondi AJ, 2002, CRIT CARE MED, V30, P746, DOI 10.1097/00003246-200204000-00004; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Serafim RB, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-51; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Veiga D, 2012, REV BRAS ANESTESIOL, V62, P469, DOI 10.1016/S0034-7094(12)70146-0; Wu Jie, 2013, J MED THEOR PRAC, V26, P2948	23	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184310	10.1371/journal.pone.0184310	http://dx.doi.org/10.1371/journal.pone.0184310			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH0VR	28910303	gold, Green Published, Green Submitted			2023-01-03	WOS:000410859200039
J	Batelaan, NM; Bosman, RC; Muntingh, A; Scholten, WD; Huijbregts, KM; van Balkom, AJLM				Batelaan, Neeltje M.; Bosman, Renske C.; Muntingh, Anna; Scholten, Willemijn D.; Huijbregts, Klaas M.; van Balkom, Anton J. L. M.			Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LONG-TERM TREATMENT; QUALITY-OF-LIFE; GENERALIZED SOCIAL PHOBIA; PANIC DISORDER; DOUBLE-BLIND; IMIPRAMINE THERAPY; PHARMACOLOGICAL-TREATMENT; COURSE TRAJECTORIES; CLINICAL-TRIALS; ACUTE RESPONSE	OBJECTIVES To examine the risk of relapse and time to relapse after discontinuation of antidepressants in patients with anxiety disorder who responded to antidepressants, and to explore whether relapse risk is related to type of anxiety disorder, type of antidepressant, mode of discontinuation, duration of treatment and follow-up, comorbidity, and allowance of psychotherapy. DESIGN Systematic review and meta-analyses of relapse prevention trials. DATA SOURCES PubMed, Cochrane, Embase, and clinical trial registers (from inception to July 2016). STUDY SELECTION Eligible studies included patients with anxiety disorder who responded to antidepressants, randomised patients double blind to either continuing antidepressants or switching to placebo, and compared relapse rates or time to relapse. DATA EXTRACTION Two independent raters selected studies and extracted data. Random effect models were used to estimate odds ratios for relapse, hazard ratios for time to relapse, and relapse prevalence per group. The effect of various categorical and continuous variables was explored with subgroup analyses and meta-regression analyses respectively. Bias was assessed using the Cochrane tool. RESULTS The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year. Across studies, risk of bias was considered low. Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89). Subgroup analyses and meta-regression analyses showed no statistical significance. Time to relapse (n=3002) was shorter when antidepressants were discontinued (summary hazard ratio 3.63, 2.58 to 5.10; n=11 studies). Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group, but prevalence varied considerably across studies, most likely owing to differences in the length of follow-up. Dropout was higher in the placebo group (summary odds ratio 1.31, 1.06 to 1.63; n=27 studies). CONCLUSIONS Up to one year of follow-up, discontinuation of antidepressant treatment results in higher relapse rates among responders compared with treatment continuation. The lack of evidence after a one year period should not be interpreted as explicit advice to discontinue antidepressants after one year. Given the chronicity of anxiety disorders, treatment should be directed by long term considerations, including relapse prevalence, side effects, and patients' preferences.	[Batelaan, Neeltje M.; Bosman, Renske C.; Muntingh, Anna; Scholten, Willemijn D.; Huijbregts, Klaas M.; van Balkom, Anton J. L. M.] Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Psychiat, Amsterdam, Netherlands; [Batelaan, Neeltje M.; Bosman, Renske C.; Muntingh, Anna; Scholten, Willemijn D.; Huijbregts, Klaas M.; van Balkom, Anton J. L. M.] Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Batelaan, Neeltje M.; Muntingh, Anna; Scholten, Willemijn D.; Huijbregts, Klaas M.; van Balkom, Anton J. L. M.] Acad Outpatient Dept Anxiety Disorders, GGZ inGeest, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Batelaan, NM (corresponding author), Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Psychiat, Amsterdam, Netherlands.; Batelaan, NM (corresponding author), Vrije Univ Amsterdam, Med Ctr Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands.	n.batelaan@ggzingeest.nl	Bosman, R.C./K-6519-2019	Bosman, R.C./0000-0002-3143-9345; Batelaan, Neeltje/0000-0001-6444-3781				Allgulander C, 2007, CURR MED RES OPIN, V23, P2543, DOI 10.1185/030079907X226087; Allgulander C, 2006, INT J NEUROPSYCHOPH, V9, P495, DOI 10.1017/S1461145705005973; Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P21; Baldwin DS, 2014, J PSYCHOPHARMACOL, V28, P403, DOI 10.1177/0269881114525674; Baldwin DS, 2012, INT CLIN PSYCHOPHARM, V27, P197, DOI 10.1097/YIC.0b013e3283530ad7; Bandelow B, 2008, WORLD J BIOL PSYCHIA, V9, P248, DOI 10.1080/15622970802465807; Batelaan NM, 2010, ACTA PSYCHIAT SCAND, V122, P56, DOI 10.1111/j.1600-0447.2009.01488.x; Batelaan NM, 2014, J CLIN PSYCHIAT, V75, P985, DOI 10.4088/JCP.13m08837; Borenstein M., 2014, COMPREHENSIVE META A; Borenstein M., 2009, INTRO META ANAL; Bosman RC, 2016, BRIT J GEN PRACT, V66, pE708, DOI 10.3399/bjgp16X686641; Bruce SE, 2005, AM J PSYCHIAT, V162, P1179, DOI 10.1176/appi.ajp.162.6.1179; Choy YJ, 2007, COMPR PSYCHIAT, V48, P419, DOI 10.1016/j.comppsych.2007.04.003; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Davidson J, 2001, AM J PSYCHIAT, V158, P1974, DOI 10.1176/appi.ajp.158.12.1974; Davidson JRT, 2008, EUR NEUROPSYCHOPHARM, V18, P673, DOI 10.1016/j.euroneuro.2008.05.002; Davidson JRT, 2005, J CLIN PSYCHOPHARM, V25, P166, DOI 10.1097/01.jcp.0000155817.21467.6c; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Donovan MR, 2010, J AFFECT DISORDERS, V123, P9, DOI 10.1016/j.jad.2009.06.021; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Fava M, 2006, J CLIN PSYCHIAT, V67, P14; Ferguson JM, 2007, J CLIN PSYCHIAT, V68, P58, DOI 10.4088/JCP.v68n0108; Fineberg NA, 2007, EUR NEUROPSYCHOPHARM, V17, P430, DOI 10.1016/j.euroneuro.2006.11.005; Francois C, 2008, INT J CLIN PRACT, V62, P1693, DOI 10.1111/j.1742-1241.2008.01879.x; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; Gardarsdottir H, 2009, J CLIN PSYCHOPHARM, V29, P69, DOI 10.1097/JCP.0b013e31819302b1; Gardarsdottir H, 2009, AM J EPIDEMIOL, V170, P280, DOI 10.1093/aje/kwp142; Geller DA, 2003, J CHILD ADOL PSYCHOP, V13, pS19, DOI 10.1089/104454603322126313; GlaxoSmithKline, 2008, EXT TRIAL COMP PAR P; GlaxoSmithKline, 2008, LONG TERM TREATM PAR; GlaxoSmithKline, 2008, STUD MAINT EFF SAF P; GlaxoSmithKline, 2008, DOUBL BLIND PLAC CON; Hackett D, 2000, 1 INT FOR MOOD ANX D; Hartung J, 2001, STAT MED, V20, P3875, DOI 10.1002/sim.1009; Hendriks SM, 2014, J AFFECT DISORDERS, V166, P227, DOI 10.1016/j.jad.2014.05.006; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hollander E, 2003, J CLIN PSYCHIAT, V64, P1113, DOI 10.4088/JCP.v64n0919; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Johnson CF, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X658304; Jorm AF, 2002, AUST NZ J PSYCHIAT, V36, P322, DOI 10.1046/j.1440-1614.2002.01023.x; Kamijima K, 2005, INT CLIN PSYCHOPHARM, V20, P265, DOI 10.1097/01.yic.0000171518.25963.63; Karsten J, 2011, BRIT J PSYCHIAT, V198, P206, DOI 10.1192/bjp.bp.110.080572; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359; Koran LM, 2005, J CLIN PSYCHIAT, V66, P515, DOI 10.4088/JCP.v66n0415; Koran LM, 2002, AM J PSYCHIAT, V159, P88, DOI 10.1176/appi.ajp.159.1.88; Lundh A, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000033.pub2, 10.1002/14651858.MR000033.pub3]; Martenyi F, 2002, BRIT J PSYCHIAT, V181, P315, DOI 10.1192/bjp.181.4.315; MAVISSAKALIAN M, 1992, ARCH GEN PSYCHIAT, V49, P318; Mavissakalian M R, 2001, Ann Clin Psychiatry, V13, P63, DOI 10.1023/A:1016699922670; Mavissakalian MR, 1999, ARCH GEN PSYCHIAT, V56, P821, DOI 10.1001/archpsyc.56.9.821; Mavissakalian MT, 2002, J CLIN PSYCHOPHARM, V22, P294, DOI 10.1097/00004714-200206000-00010; Melse JM, 2000, AM J PUBLIC HEALTH, V90, P1241, DOI 10.2105/AJPH.90.8.1241; Michelson D, 1999, BRIT J PSYCHIAT, V174, P213, DOI 10.1192/bjp.174.3.213; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mojtabai R, 2014, J CLIN PSYCHIAT, V75, P169, DOI 10.4088/JCP.13m08443; Montgomery SA, 2005, J CLIN PSYCHIAT, V66, P1270, DOI 10.4088/JCP.v66n1009; National Institute for Health and Care Excellence, 2011, GEN ANX DIS PAN DIS; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Petty DR, 2006, AGE AGEING, V35, P523, DOI 10.1093/ageing/afl023; Rapaport MH, 2001, ACTA PSYCHIAT SCAND, V104, P289, DOI 10.1034/j.1600-0447.2001.00263.x; Review Manager (RevMan), 2014, REV MAN REVMAN; Rhebergen D, 2011, ACTA PSYCHIAT SCAND, V123, P297, DOI 10.1111/j.1600-0447.2011.01677.x; Rickels K, 2010, ARCH GEN PSYCHIAT, V67, P1274, DOI 10.1001/archgenpsychiatry.2010.170; Roest AM, 2015, JAMA PSYCHIAT, V72, P500, DOI 10.1001/jamapsychiatry.2015.15; Romano S, 2001, J CLIN PSYCHOPHARM, V21, P46, DOI 10.1097/00004714-200102000-00009; Saarni SI, 2007, BRIT J PSYCHIAT, V190, P326, DOI 10.1192/bjp.bp.106.025106; Saarni SI, 2006, QUAL LIFE RES, V15, P1403, DOI 10.1007/s11136-006-0020-1; Scholten WD, 2016, J AFFECT DISORDERS, V195, P185, DOI 10.1016/j.jad.2016.02.025; Scholten WD, 2013, J AFFECT DISORDERS, V147, P180, DOI 10.1016/j.jad.2012.10.031; Spinhoven P, 2016, J ANXIETY DISORD, V44, P92, DOI 10.1016/j.janxdis.2016.10.011; Stein DJ, 2012, J CLIN PSYCHIAT, V73, P1002, DOI 10.4088/JCP.11m07493; Stein DJ, 2002, ARCH GEN PSYCHIAT, V59, P1111, DOI 10.1001/archpsyc.59.12.1111; Stein MB, 1996, J CLIN PSYCHOPHARM, V16, P218, DOI 10.1097/00004714-199606000-00005; Sterne JAC, 2011, COCHRANE HDB SYSTEMA; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stocchi F, 2003, J CLIN PSYCHIAT, V64, P250, DOI 10.4088/JCP.v64n0305; Taylor S, 2012, J ANXIETY DISORD, V26, P583, DOI 10.1016/j.janxdis.2012.02.010; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Verbeek-Heida PM, 2006, CHRONIC ILLN, V2, P133, DOI 10.1179/174592006X111003; Walker JR, 2000, J CLIN PSYCHOPHARM, V20, P636, DOI 10.1097/00004714-200012000-00009; Wang CJ, 2013, PILOT STUDY EVALUATE; Wouters H, 2014, PSYCHOL MED, V44, P2301, DOI 10.1017/S0033291713003103	83	35	35	1	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2017	358								j3927	10.1136/bmj.j3927	http://dx.doi.org/10.1136/bmj.j3927			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH6NB	28903922	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000411292600003
J	Eastwood, GL				Eastwood, Gregory L.			What Should I Do When I Hear the Call for Medical Assistance in a Plane?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMMERCIAL AIRLINE FLIGHTS; EMERGENCIES		[Eastwood, Gregory L.] SUNY Upstate Med Univ, Ctr Bioeth & Humanities, 750 E Adams St, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Eastwood, GL (corresponding author), SUNY Upstate Med Univ, Ctr Bioeth & Humanities, 750 E Adams St, Syracuse, NY 13210 USA.	eastwood@upstate.edu						Eastwood Gregory L, 2011, Ann Intern Med, V154, P703, DOI 10.7326/0003-4819-154-10-201105170-00015; Gendreau MA, 2002, NEW ENGL J MED, V346, P1067, DOI 10.1056/NEJMra012774; Mattison MLP, 2011, JAMA-J AM MED ASSOC, V305, P2003, DOI 10.1001/jama.2011.618; Nable JV, 2015, NEW ENGL J MED, V373, P939, DOI 10.1056/NEJMra1409213; Peterson DC, 2013, NEW ENGL J MED, V368, P2075, DOI 10.1056/NEJMoa1212052	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 12	2017	318	10					907	908		10.1001/jama.2017.7187	http://dx.doi.org/10.1001/jama.2017.7187			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG6KJ	28898382				2023-01-03	WOS:000410487100008
J	Zhang, XB; Zhao, YP; Guo, LP; Qiu, ZD; Huang, LQ; Qu, XB				Zhang, Xiaobo; Zhao, Yuping; Guo, Lanping; Qiu, Zhidong; Huang, Luqi; Qu, Xiaobo			Differences in chemical constituents of Artemisia annua L from different geographical regions in China	PLOS ONE			English	Article								Background Daodi-herb is a part of Chinese culture, which has been naturally selected by traditional Chinese medicine clinical practice for many years. Sweet wormwood herb is a kind of Daodiherb, and comes from Artemisia annua L. Artemisinin is a kind of effective antimalarial drug being extracted from A. annua. Because of artemisinin, Sweet wormwood herb earns a reputation. Based on the Pharmacopoeia of the People's Republic of China (PPRC), Sweet wormwood herb can be used to resolve summerheat-heat, and prevent malaria. Besides, it also has other medical efficacies. A. annua, a medicinal plant that is widely distributed in the world contains many kinds of chemical composition. Research has shown that compatibility of artemisinin, scopoletin, arteannuin B and arteannuic acid has antimalarial effect. Compatibility of scopoletin, arteannuin B and arteannuic acid is conducive to resolving summerheatheat. Chemical constituents in A. annua vary significantly according to geographical locations. So, distribution of A. annua may play a key role in the characteristics of efficacy and chemical constituents of Sweet wormwood herb. It is of great significance to study this relationship. Objectives We mainly analyzed the relationship between the chemical constituents (arteannuin B, artemisinin, artemisinic acid, and scopoletin) with special efficacy in A. annua that come from different provinces in china, and analyzed the relationship between chemical constituents and spatial distribution, in order to find out the relationship between efficacy, chemical constituents and distribution. Methods A field survey was carried out to collect A. annua plant samples. A global positioning system (GPS) was used for obtaining geographical coordinates of sampling sites. Chemical constituents in A. annua were determined by liquid chromatography tandem an atmospheric pressure ionization-electrospray mass spectrometry. Relationship between chemical constituents including proportions, correlation analysis (CoA), principal component analysis (PCA) and cluster analysis (ClA) was displayed through Excel and R software version2.3.2 (R), while the one between efficacy, chemical constituents and spatial distribution was presented through ArcGIS10.0, Excel and R software. Results According to the results of CoA, arteannuin B content presented a strong positive correlation with artemisinic acid content (p = 0), and a strong negative correlation with artemisinin content (p = 0). Scopoletin content presented a strong positive correlation with artemisinin content (p = 0), and a strong negative correlation with artemisinic acid content (p = 0). According to the results of PCA, the first two principal components accounted for 81.57% of the total accumulation contribution rate. The contribution of the first principal component is about 45.12%, manly including arteannuin B and artemisinic acid. The contribution of the second principal component is 36.45% of the total, manly including artemisinin and scopoletin. According to the ClA by using the principal component scores, 19 provinces could be divided into two groups. In terms of provinces in group one, the proportions of artemisinin are all higher than 80%. Based on the results of PCA, ClA, percentages and scatter plot analysis, chemical types are defined as "QHYS type", "INT type" and "QHS type." Conclusion As a conclusion, this paper shows the relationship between efficacy, chemical constituents and distribution. Sweet wormwood herb with high arteannuin B and artemisinic acid content, mainly distributes in northern China. Sweet wormwood herb with high artemisinin and scopoletin content has the medical function of preventing malaria, which mainly distributes in southern China. In this paper, it is proved that Sweet wormwood Daodi herb growing in particular geographic regions, has more significant therapeutical effect and higher chemical constituents compared with other same kind of CMM. And also, it has proved the old saying in China that Sweet wormwood Daodi herb which has been used to resolve summerheatheat and prevent malaria, which distributed in central China. But in modern time, Daodi Sweet wormwood herb mainly has been used to extract artemisinin and prevent malaria, so the Daod-region has transferred to the southern China.	[Zhang, Xiaobo; Qiu, Zhidong; Qu, Xiaobo] Changchun Univ Chinese Med, Coll Pharm, Changchun, Jilin, Peoples R China; [Zhang, Xiaobo; Guo, Lanping; Huang, Luqi] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat Med, State Key Lab Breeding Base Dao di Herbs, Beijing, Peoples R China; [Zhao, Yuping] China Acad Chinese Med Sci, Beijing, Peoples R China	Changchun University of Chinese Medicine; China Academy of Chinese Medical Sciences; National Resource Center for Chinese Materia Medica, CACMS; China Academy of Chinese Medical Sciences	Qu, XB (corresponding author), Changchun Univ Chinese Med, Coll Pharm, Changchun, Jilin, Peoples R China.; Huang, LQ (corresponding author), China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat Med, State Key Lab Breeding Base Dao di Herbs, Beijing, Peoples R China.	jack110007@163.com; quxiaobo0727@163.com			Independent topics of the Chinese Academy of traditional Chinese Medicine [zz0708121, 2011zdxk]; Science and technology basic work of science and technology [2013FY114500]; Key project at central government level [2060302]	Independent topics of the Chinese Academy of traditional Chinese Medicine; Science and technology basic work of science and technology; Key project at central government level	This study was supported by the Independent topics of the Chinese Academy of traditional Chinese Medicine (No. zz0708121, 2011zdxk), the Science and technology basic work of science and technology (No. 2013FY114500), and Key project at central government level (No. 2060302). The funders played no role in the design of the study, data collection and analysis or the decision to publish and prepare the manuscript.	Chen KJ, 2009, INTEGRATION MED RECO, P1589; China Association Of traditional Chinese Medicine, 2015, 102015 ZGZYXT CHIN A; Chinese Pharmacopoeia Commission, 2015, CHIN PHARM, P198; Ji Xiao-Guang, 2008, Jishengchong Yu Yixue Kunchong Xuebao, V15, P198; Li LF, 2009, CHINESE J EXPT TRADI, V12, P65; Shi KY, 2007, CHINA PHARM, V10, P25; Wang HongBo, 2011, Drugs and Clinic, V26, P430; Wang Huan, 2015, Zhong Yao Cai, V38, P460; Zhang MX, 2015, SCI TECHNOLOGY IND C, V10, P44; Zhang RS, 2008, CHEM IND FOREST PROD, V28, P84; Zhang Xiao-bo, 2011, Yaoxue Xuebao, V46, P472; [张小波 ZHANG Xiaobo], 2011, [生态学报, Acta Ecologica Sinica], V31, P5299	12	18	19	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2017	12	9							e0183047	10.1371/journal.pone.0183047	http://dx.doi.org/10.1371/journal.pone.0183047			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0PY	28880869	Green Submitted, Green Published, gold			2023-01-03	WOS:000409467200012
J	Han, K; Bose, S; Wang, JH; Lim, SK; Chin, YW; Kim, YM; Choi, HS; Kim, H				Han, Kyungsun; Bose, Shambhunath; Wang, Jing-Hua; Lim, Soo-kyoung; Chin, Young-Won; Kim, Young-Mi; Choi, Han-Seok; Kim, Hojun			In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis	PLOS ONE			English	Article							GUT MICROBIOTA; FLAVONOIDS; ROOT; FXR; RECEPTORS	The radix of Scutellaria baicalensis (SB) is a herb widely used in traditional Chinese medicine to treat metabolic diseases. Several main components, including baicalin and wogonoside, possess anti-dyslipidemia, anti-obesity and anti-diabetic effects. We hypothesized that co-administration of SB extract and metformin exerts a better effect on obesity-induced insulin resistance and lipid metabolism than treatment with metformin alone. We compared the effect of metformin (100 mg/10 mL/kg/day) alone with co-administration of metformin (100 mg/5 mL/kg/day) and SB extract (200 mg/5 mL/kg/day) on Otsuka Long Evans Tokushima Fatty rats, a useful model of type II diabetes with obesity, and used Long-Evans Tokushima Otsuka rats as a control. Weight, fasting glucose, oral glucose tolerance test, intraperitoneal insulin tolerance test, and serum total cholesterol were measured after 12 weeks of drug administration. We observed a synergetic effect of metformin and SB on lowering cholesterol level by excretion of bile acid through feces. We found that this accompanied activation of FXR, CYP7A1 and LDLR genes and repression of HMGCR in the liver. Although there were no significant changes in BSH-active gut microbiota due to high variability, functional prediction with 16S sequences showed increased primary and secondary bile acid biosynthesis in the combination treatment group. Further study is needed to find the specific strains of bacteria which contribute to FXR-related cholesterol and bile acid regulations.	[Han, Kyungsun; Wang, Jing-Hua; Lim, Soo-kyoung; Kim, Hojun] Dongguk Univ, Korean Med, Dept Rehabil Med, Goyang, Gyeonggi Do, South Korea; [Han, Kyungsun] Korea Inst Oriental Med, Clin Res Div, Daejeon, South Korea; [Bose, Shambhunath] Appl Surface Technol Inc, Adv Inst Convergence Technol, 11th Floor,Bldg A, Suwon, South Korea; [Chin, Young-Won; Kim, Young-Mi] Dongguk Univ, Coll Pharm, Goyang, Gyeonggi Do, South Korea; [Choi, Han-Seok] Dongguk Univ, Dept Endocrinol, Goyang, Gyeonggi Do, South Korea	Dongguk University; Korea Institute of Oriental Medicine (KIOM); Dongguk University; Dongguk University	Kim, H (corresponding author), Dongguk Univ, Korean Med, Dept Rehabil Med, Goyang, Gyeonggi Do, South Korea.	kimklar@dongguk.ac.kr	Han, Kyungsun/AAG-1044-2020; Wang, Jing-hua/AAO-2350-2020; Choi, Han Seok/AAG-1493-2019; Kim, Hojun/AAB-8405-2020	Han, Kyungsun/0000-0002-9710-7845; Wang, Jing-hua/0000-0002-2034-7429; Bose, Shambunath/0000-0003-0737-5713; Kim, Hojun/0000-0003-1038-0142; Chin, Young-Won/0000-0001-6964-1779	Convergence of Conventional Medicine and Traditional Korean Medicine R&D program - Ministry of Health and Welfare through the KHIDI (Korea Health Industry Development Institute) [HI14C0558]	Convergence of Conventional Medicine and Traditional Korean Medicine R&D program - Ministry of Health and Welfare through the KHIDI (Korea Health Industry Development Institute)	This work was supported by the grant of Convergence of Conventional Medicine and Traditional Korean Medicine R&D program funded by the Ministry of Health and Welfare through the KHIDI (Korea Health Industry Development Institute, HI14C0558). Author Shambhunath Bose receives a salary from Applied Surface Technology, Inc. The specific roles of this author are articulated in the 'author contributions' section. The funders did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chiang JYL, 2009, J LIPID RES, V50, P1955, DOI 10.1194/jlr.R900010-JLR200; Degirolamo C, 2014, CELL REP, V7, P12, DOI 10.1016/j.celrep.2014.02.032; FDA, 2005, GUID IND EST MAX SAF; Fiorucci S, 2015, TRENDS MOL MED, V21, P702, DOI 10.1016/j.molmed.2015.09.001; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Heo HJ, 2004, J AGR FOOD CHEM, V52, P4128, DOI 10.1021/jf049953x; Horvath CR, 2005, J CHROMATOGR A, V1062, P199, DOI 10.1016/j.chroma.2004.11.030; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Huang WH, 2003, CHEM PHARM BULL, V51, P339; Islam KBMS, 2011, GASTROENTEROLOGY, V141, P1773, DOI 10.1053/j.gastro.2011.07.046; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jung HS, 2012, J ETHNOPHARMACOL, V141, P345, DOI 10.1016/j.jep.2012.02.044; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim EH, 2009, J ETHNOPHARMACOL, V126, P320, DOI 10.1016/j.jep.2009.08.027; Kovacs G, 2004, CHROMATOGRAPHIA, V60, pS81, DOI 10.1365/s10337-004-0266-0; Kroliczewska B, 2011, J ANIM PHYSIOL AN N, V95, P114, DOI 10.1111/j.1439-0396.2010.01033.x; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Li GJ, 2012, PROCEDIA ENVIRON SCI, V12, P1180, DOI 10.1016/j.proenv.2012.01.405; Li HB, 2005, J CHROMATOGR A, V1074, P107, DOI 10.1016/j.chroma.2005.03.088; Lien F, 2014, J CLIN INVEST, V124, P1037, DOI 10.1172/JCI68815; Mazuy C, 2015, CELL MOL LIFE SCI, V72, P1631, DOI 10.1007/s00018-014-1805-y; NAGAI T, 1995, ANTIVIR RES, V26, P11, DOI 10.1016/0166-3542(94)00062-D; Napolitano A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100778; Popescu IR, 2010, FEBS LETT, V584, P2845, DOI 10.1016/j.febslet.2010.04.068; Pu P, MOL CELL ENDOCRINOL; Ridlon JM, 2013, GUT MICROBES, V4, P382, DOI 10.4161/gmic.25723; Ridlon JM, 2006, J LIPID RES, V47, P241, DOI 10.1194/jlr.R500013-JLR200; Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003; Seo MJ, 2014, FOOD CHEM TOXICOL, V67, P57, DOI 10.1016/j.fct.2014.02.009; Song KH, 2013, PHYTOTHER RES, V27, P244, DOI 10.1002/ptr.4691; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Waisundara VY, 2008, AM J CHINESE MED, V36, P517, DOI 10.1142/S0192415X08005953; Wilson ID, 2009, CURR PHARM DESIGN, V15, P1519, DOI 10.2174/138161209788168173; Woudenberg-Vrenken TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071773; Wulffele MG, 2004, J INTERN MED, V256, P1, DOI 10.1111/j.1365-2796.2004.01328.x; Ye F, 2002, J ALTERN COMPLEM MED, V8, P567, DOI 10.1089/107555302320825075; Zhang X, 2015, EURASIP J AUDIO SPEE, DOI 10.1186/s13636-015-0050-0; Zheng Q, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-87; 윤혜진, 2010, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V39, P219	42	33	35	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2017	12	9							e0182467	10.1371/journal.pone.0182467	http://dx.doi.org/10.1371/journal.pone.0182467			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG0EG	28877164	gold, Green Published			2023-01-03	WOS:000409391200014
J	Airan, R				Airan, Raag			Neuromodulation with nanoparticles	SCIENCE			English	Editorial Material							IN-VIVO NEUROSTIMULATION; FOCUSED ULTRASOUND		[Airan, Raag] Stanford Univ, Dept Radiol Neuroimaging & Neurointervent, Palo Alto, CA 94304 USA	Stanford University	Airan, R (corresponding author), Stanford Univ, Dept Radiol Neuroimaging & Neurointervent, Palo Alto, CA 94304 USA.	rairan@stanford.edu		Airan, Raag/0000-0001-5259-5606				Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Airan R. D., 2015, EXPANDING TREATMENT; Airan RD, 2017, NANO LETT, V17, P652, DOI 10.1021/acs.nanolett.6b03517; Airan RD, 2009, NATURE, V458, P1025, DOI 10.1038/nature07926; Deffieux T, 2013, CURR BIOL, V23, P2430, DOI 10.1016/j.cub.2013.10.029; Ellens N. P. K., 2016, MR GUIDED FOCUSED UL; FRY FJ, 1958, SCIENCE, V127, P83, DOI 10.1126/science.127.3289.83; Ghanouni P, 2015, AM J ROENTGENOL, V205, P150, DOI 10.2214/AJR.14.13632; Jorgenson L.A., 2015, PHILOS T R SOC LON B, V370, P214; King RL, 2014, ULTRASOUND MED BIOL, V40, P1512, DOI 10.1016/j.ultrasmedbio.2014.01.020; King RL, 2013, ULTRASOUND MED BIOL, V39, P312, DOI 10.1016/j.ultrasmedbio.2012.09.009; Lee W, 2016, SCI REP-UK, V6, DOI 10.1038/srep34026; Legon W, 2014, NAT NEUROSCI, V17, P322, DOI 10.1038/nn.3620; Menz MD, 2013, J NEUROSCI, V33, P4550, DOI 10.1523/JNEUROSCI.3521-12.2013; Rapoport N, 2016, ADV EXP MED BIOL, V880, P221, DOI 10.1007/978-3-319-22536-4_13; Sassaroli E, 2016, J THER ULTRASOUND, V4, DOI 10.1186/s40349-016-0061-z; Sheeran PS, 2012, CURR PHARM DESIGN, V18, P2152; Ye PP, 2016, ULTRASOUND MED BIOL, V42, P1512, DOI 10.1016/j.ultrasmedbio.2016.02.012	18	20	20	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 4	2017	357	6350							6350	10.1126/science.aao1200	http://dx.doi.org/10.1126/science.aao1200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY5GF	28774921				2023-01-03	WOS:000426854200001
J	Dave, CV; Kesselheim, AS; Fox, ER; Qiu, PH; Hartzema, A				Dave, Chintan V.; Kesselheim, Aaron S.; Fox, Erin R.; Qiu, Peihua; Hartzema, Abraham			High Generic Drug Prices and Market Competition A Retrospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICATION; INDUSTRY	Background: Prices for some generic drugs have increased in recent years, adversely affecting patients who rely on them. Objective: To determine the association between market competition levels and the change in generic drug prices in the United States. Design: Retrospective cohort study. Setting: Prescription claims from commercial health plans between 2008 and 2013. Measurements: The 5.5 years of data were divided into 11 study periods of 6 months each. The Herfindahl-Hirschman Index (HHI)-calculated by summing the squares of individual manufacturers' market shares, with higher values indicating a less competitive market-and average drug prices were estimated for the generic drugs in each period. The HHI value estimated in the baseline period (first half of 2008) was modeled as a fixed covariate. Models estimated price changes over time by level of competition, adjusting for drug shortages, market size, and dosage forms. Results: From 1.08 billion prescription claims, a cohort of 1120 generic drugs was identified. After adjustment, drugs with quadropoly (HHI value of 2500, indicating relatively high levels of competition), duopoly (HHI value of 5000), near-monopoly (HHI value of 8000), and monopoly (HHI value of 10 000) levels of baseline competition were associated with price changes of -31.7% (95% CI, -34.4% to -28.9%), -11.8% (CI, -18.6% to -4.4%), 20.1% (CI, 5.5% to 36.6%), and 47.4% (CI, 25.4% to 73.2%), respectively, over the study period. Limitation: Study findings may not be generalizable to drugs that became generic after 2008. Conclusion: Market competition levels were associated with a change in generic drug prices. Such measurements may be helpful in identifying older prescription drugs at higher risk for price change in the future.	Univ Florida, Gainesville, FL USA; Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; Univ Utah, Salt Lake City, UT USA; [Dave, Chintan V.] 1225 Ctr Dr HPNP 3226, Gainesville, FL 32611 USA; [Kesselheim, Aaron S.] 1620 Tremont St,Suite 3030, Boston, MA 02120 USA; [Fox, Erin R.] 50 North Med Dr,Room A050, Salt Lake City, UT 84132 USA; [Qiu, Peihua] 2004 Mowry Rd,POB 117450, Gainesville, FL 32611 USA; [Hartzema, Abraham] 1225 Ctr Dr,HPNP 4304, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Utah System of Higher Education; University of Utah	Dave, CV (corresponding author), 1225 Ctr Dr HPNP 3226, Gainesville, FL 32611 USA.	chintandave19@gmail.com	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	Dr. Kesselheim's work is funded by the Laura and John Arnold Foundation, with additional support provided by the Engelberg Foundation and the Harvard Program in Therapeutic Science.	Aitken M, 2014, MED USE SHIFTING COS, P51; Alpern JD, 2014, NEW ENGL J MED, V371, P1859, DOI 10.1056/NEJMp1408376; [Anonymous], 2012, COMMUNICATION   0131; Briesacher BA, 2009, AM J MANAG CARE, V15, P450; Fox E, 2009, AM J HEALTH-SYST PH, V66, P798, DOI 10.2146/ajhp080314; Gatesman ML, 2011, NEW ENGL J MED, V365, P1653, DOI 10.1056/NEJMp1109772; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Hershman DL, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju319; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Morton FMS, 1999, RAND J ECON, V30, P421, DOI 10.2307/2556056; Reiffen D, 2005, REV ECON STAT, V87, P37, DOI 10.1162/0034653053327694; Rhoades SA, 1993, FEDERAL RESERVE B, V79, P188; Rockoff Jonathan D., 2015, WALL STREET J; Rosenthal E., 2014, NY TIMES, pA17; Silverman E, 2015, WALL STREET J; The Lancet Oncology, 2015, LANCET ONCOL, V16, P595, DOI DOI 10.1016/S1470-2045; United States Government Accountability Office, 2014, DRUG SHORT PUBL HLTH; US Department of Justice, 2010, HORIZONTAL MERGER GU; Worth Tammy, 2015, Med Econ, V92, P36	19	63	63	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	2017	167	3					145	+		10.7326/M16-1432	http://dx.doi.org/10.7326/M16-1432			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC1XN	28672324				2023-01-03	WOS:000406631400004
J	Luo, HJ; Lin, SX; Wu, SK; Tsai, MW; Lee, SJ				Luo, Hong-Ji; Lin, Shi-Xiang; Wu, Shyi-Kuen; Tsai, Mei-Wun; Lee, Shwn-Jen			Comparison of segmental spinal movement control in adolescents with and without idiopathic scoliosis using modified pressure biofeedback unit	PLOS ONE			English	Article							STABILIZING SYSTEM; ABDOMINAL-MUSCLES; CORE STABILITY; PROPRIOCEPTION; PATHOGENESIS	Background Postural rehabilitation emphasizing on motor control training of segmental spinal movements has been proposed to effectively reduce the scoliotic spinal deformities in adolescent idiopathic scoliosis (AIS). However, information regarding the impairments of segmental spinal movement control involving segmental spinal stabilizers in adolescent idiopathic scoliosis remains limited. Examination of segmental spinal movement control may provide a window for investigating the features of impaired movement control specific to spinal segments that may assist in the development of physiotherapeutic management of AIS. Objectives To compare segmental spinal movement control in adolescents with and without idiopathic scoliosis using modified pressure biofeedback unit. Methods Segmental spinal movement control was assessed in twenty adolescents with idiopathic scoliosis (AISG) and twenty healthy adolescents (CG) using a modified pressure biofeedback unit. Participants performed segmental spinal movements that primarily involved segmental spinal stabilizing muscles with graded and sustained muscle contraction against/off a pressure cuff from baseline to target pressures and then maintained for 1 min. Pressure data during the 1-minute maintenance phase were collected for further analysis. Pressure deviation were calculated and compared between groups. Results The AISG had significantly greater pressure deviations for all segmental spinal movements of cervical, thoracic, and lumbar spine than the CG. Conclusion Pressure biofeedback unit was feasible for assessing segmental spinal movement control in AIS. AISG exhibited poorer ability to grade and sustain muscle activities for local movements of cervical, thoracic, and lumbar spine, suggesting motor control training of segmental spinal movements involving segmental spinal stabilizing muscles on frontal, sagittal, and transverse planes were required.	[Luo, Hong-Ji; Lin, Shi-Xiang; Tsai, Mei-Wun; Lee, Shwn-Jen] Natl Yang Ming Univ, Dept Phys Therapy & Assist Technol, Taipei, Taiwan; [Luo, Hong-Ji; Lee, Shwn-Jen] Natl Yang Ming Univ, Res Ctr Int Classificat Functioning Disabil & Hlt, Taipei, Taiwan; [Wu, Shyi-Kuen] Hungkuang Univ, Dept Phys Therapy, Taichung, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Hungkuang University	Luo, HJ (corresponding author), Natl Yang Ming Univ, Dept Phys Therapy & Assist Technol, Taipei, Taiwan.; Luo, HJ (corresponding author), Natl Yang Ming Univ, Res Ctr Int Classificat Functioning Disabil & Hlt, Taipei, Taiwan.	hjluo@ym.edu.tw						Akuthota V, 2008, CURR SPORT MED REP, V7, P39, DOI 10.1097/01.CSMR.0000308663.13278.69; Asher MA, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-2; Burwell RG, 2016, SCOLIOSIS SPINAL DIS, V11, DOI 10.1186/s13013-016-0063-1; Carlsson H, 2013, MANUAL THER, V18, P103, DOI 10.1016/j.math.2012.08.004; Chattanooga Group Inc, 2005, STAB PRESS BIOF OP I; Cheung J, 2005, EUR SPINE J, V14, P130, DOI 10.1007/s00586-004-0780-7; Chwala W, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/573276; Cobb J, 1948, J BONE JT SURG AM VO, V5, P261; COOK SD, 1986, CLIN ORTHOP RELAT R, P118; Domenech J, 2011, EUR SPINE J, V20, P1069, DOI 10.1007/s00586-011-1776-8; GOLDBERG MS, 1994, SPINE, V19, P1562, DOI 10.1097/00007632-199407001-00004; Gur G, 2017, PROSTHET ORTHOT INT, V41, P303, DOI 10.1177/0309364616664151; Guyot MA, 2016, EUR SPINE J, V25, P3130, DOI 10.1007/s00586-016-4551-z; Hagins M, 1999, J ORTHOP SPORT PHYS, V29, P546, DOI 10.2519/jospt.1999.29.9.546; Hefti F, 2013, J CHILD ORTHOP, V7, P17, DOI 10.1007/s11832-012-0460-9; HERMAN R, 1985, SPINE, V10, P1, DOI 10.1097/00007632-198501000-00001; Hudswell S., 2005, INT J OSTEOPATH MED, V8, P98, DOI [DOI 10.1142/S101370251850004X, DOI 10.1016/J.IJ0SM.2005.07.003]; Iqbal ZA, 2013, J PHYS THER SCI, V25, P657, DOI 10.1589/jpts.25.657; KENNELLY KP, 1993, SPINE, V18, P913, DOI 10.1097/00007632-199306000-00017; Kirkesola G, 2009, J FYSIOTERAPEUTEN, V76, P16; Konieczny MR, 2013, J CHILD ORTHOP, V7, P3, DOI 10.1007/s11832-012-0457-4; Linek P, 2015, J PHYS THER SCI, V27, P465, DOI 10.1589/jpts.27.465; Lombardi G, 2011, ADV CLIN CHEM, V54, P165, DOI 10.1016/B978-0-12-387025-4.00007-8; PANJABI MM, 1992, J SPINAL DISORD, V5, P383, DOI 10.1097/00002517-199212000-00001; Pialasse JP, 2016, J MANIP PHYSIOL THER, V39, P473, DOI 10.1016/j.jmpt.2016.06.001; Pialasse JP, 2015, GAIT POSTURE, V42, P558, DOI 10.1016/j.gaitpost.2015.08.013; Romano M, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-014-0027-2; SHIRADO O, 1995, ARCH PHYS MED REHAB, V76, P621, DOI 10.1016/S0003-9993(95)80630-X; Simoneau M, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-68; SLAGER UT, 1986, DEV MED CHILD NEUROL, V28, P749; Wang WJ, 2011, J PEDIATR ORTHOPED, V31, pS14, DOI 10.1097/BPO.0b013e3181f73c12; WEINSTEIN SL, 1983, J BONE JOINT SURG AM, V65, P447, DOI 10.2106/00004623-198365040-00004; Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3; Weiss HR, 2016, ASIAN SPINE J, V10, P570, DOI 10.4184/asj.2016.10.3.570; Willson JD, 2005, J AM ACAD ORTHOP SUR, V13, P316, DOI 10.5435/00124635-200509000-00005; Yang HS, 2014, BIO-MED MATER ENG, V24, P453, DOI 10.3233/BME-130830; Zapata KA, 2015, PEDIATR PHYS THER, V27, P119, DOI 10.1097/PEP.0000000000000131	37	5	5	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2017	12	7							e0181915	10.1371/journal.pone.0181915	http://dx.doi.org/10.1371/journal.pone.0181915			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC1ED	28753636	Green Submitted, gold, Green Published			2023-01-03	WOS:000406579300033
J	Zhu, YR; Reinach, PS; Zhu, HL; Tan, QF; Zheng, QX; Qu, J; Chen, W				Zhu, Yirui; Reinach, Peter S.; Zhu, Hanlei; Tan, Qiufan; Zheng, Qinxiang; Qu, Jia; Chen, Wei			High-intensity corneal collagen crosslinking with riboflavin and UVA in rat cornea	PLOS ONE			English	Article							IN-VIVO; ENZYMATIC DIGESTION; MOUSE CORNEA; KERATOCONUS; RESISTANCE; IRRADIATION; MICROSCOPY; THICKNESS; KERATITIS; STANDARD	Corneal collagen cross-linking (CXL) halts human corneal ectasias progression by increasing stromal mechanical stiffness. Although some reports describe that this procedure is effective in dealing with some infectious and immunologic corneal thinning diseases, there is a need for more animal models whose corneal thickness more closely resemble those occurring in these patients. To meet this need, we describe here high-intensity protocols that are safe and effective for obtaining CXL in rat corneas. Initially, a range of potentially effective UVA doses were evaluated based on their effectiveness in increasing tissue enzymatic resistance to dissolution. At UVA doses higher than a threshold level of 0.54 J/cm(2), resistance to enzymatic digestion increased relative to that in non-irradiated corneas. Based on the theoretical threshold CXL dose, a CXL regimen was established in which the UVA tissue irradiance was 9 mW/cm(2), which was delivered at doses of either 2.16, 2.7 or 3.24 J/cm(2). Their dose dependent effects were evaluated on ocular surface morphological integrity, keratocyte apoptotic frequency, tissue thickness and endothelial cell layer density. Doses of 2.16 and 2.7 J/cm(2) transiently decreased normal corneal transparency and increased thickness. These effects were fully reversed after 14 days. In contrast, 3.24 J/cm(2) had more irreversible side effects. Three days after treatment, apoptotic frequency in the CXL-2.16 group was lower than that at higher doses. Endothelial cell losses remained evident only in the CXL-3.24 group at 42 days posttreatment. Stromal fiber thickening was evident in all the CXL-treated groups. We determined both the threshold UVA dose using the high-intensity CXL procedure and identified an effective dose range that provides optimal CXL with minimal transient side effects in the rat cornea. These results may help to provide insight into how to improve the CXL outcome in patients afflicted with a severe corneal thinning disease.	[Qu, Jia; Chen, Wei] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China; Wenzhou Med Univ, Hosp Eye, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University	Qu, J; Chen, W (corresponding author), Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China.	13806898805@163.com; chenweimd@hotmail.com	Reinach, Peter/AAI-3582-2021		 [81170820];  [81470605]	; 	This study was funded by the research China (81170820 and 81470605 to Wei Chen).The funders had role in study design, decision to publish and preparation of the manuscript.	Aldahlawi NH, 2016, INVEST OPHTH VIS SCI, V57, P1547, DOI 10.1167/iovs.15-18769; Aldahlawi NH, 2015, J CATARACT REFR SURG, V41, P1989, DOI 10.1016/j.jcrs.2015.10.004; Alio JL, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-47; Angunawela RI, 2009, J CATARACT REFR SURG, V35, P606, DOI 10.1016/j.jcrs.2008.11.050; Bawa G, 2013, BIOMED OPT EXPRESS, V4, P2585, DOI 10.1364/BOE.4.002585; Chen YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep28145; Dhaliwal JS, 2009, CORNEA, V28, P62, DOI 10.1097/ICO.0b013e31818225c3; Ehlers N, 2009, J REFRACT SURG, V25, pS803, DOI 10.3928/1081597X-20090813-08; Gokhale NS, 2010, CORNEA, V29, P117, DOI 10.1097/ICO.0b013e3181a06c31; Hammer A, 2015, INVEST OPHTH VIS SCI, V56, P6581, DOI 10.1167/iovs.15-17426; Hovakimyan M, 2011, CORNEA, V30, P196, DOI 10.1097/ICO.0b013e3181e16d93; Iseli HP, 2008, CORNEA, V27, P590, DOI 10.1097/ICO.0b013e318169d698; JAKUS MA, 1954, AM J OPHTHALMOL, V38, P40, DOI 10.1016/0002-9394(54)90008-2; Kanellopoulos AJ, 2016, CORNEA, V35, P557, DOI 10.1097/ICO.0000000000000758; Kanellopoulos AJ, 2015, BRIT J OPHTHALMOL, V99, P870, DOI 10.1136/bjophthalmol-2014-306411; Kling S, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.1.7; Koller T, 2009, J CATARACT REFR SURG, V35, P1358, DOI 10.1016/j.jcrs.2009.03.035; Kolozsvari BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076333; Lian Y, 2013, INVEST OPHTH VIS SCI, V54, P691, DOI 10.1167/iovs.12-10263; Mazzotta C, 2015, OCUL SURF, V13, P298, DOI 10.1016/j.jtos.2015.04.007; Messmer EM, 2013, CORNEA, V32, P111, DOI 10.1097/ICO.0b013e31824d701b; Rama P, 2009, J CATARACT REFR SURG, V35, P788, DOI 10.1016/j.jcrs.2008.09.035; Schumacher S, 2011, INVEST OPHTH VIS SCI, V52, P9048, DOI 10.1167/iovs.11-7818; Schwartzkopff J, 2010, MOL VIS, V16, P2368; Spadea L, 2010, J REFRACT SURG, V26, P375, DOI 10.3928/1081597X-20100114-03; Spoerl E, 1998, EXP EYE RES, V66, P97, DOI 10.1006/exer.1997.0410; Spoerl E, 2004, CURR EYE RES, V29, P35, DOI 10.1080/02713680490513182; Spoerl E, 2007, CORNEA, V26, P385, DOI 10.1097/ICO.0b013e3180334f78; Spoerl Eberhard, 2011, Open Ophthalmol J, V5, P14, DOI 10.2174/1874364101105010014; TRESELER PA, 1986, TRANSPLANTATION, V41, P248, DOI 10.1097/00007890-198602000-00022; Wang F, 2008, OPHTHALMOLOGICA, V222, P369, DOI 10.1159/000151247; Wang JH, 2009, EYE CONTACT LENS, V35, P44, DOI 10.1097/ICL.0b013e31819579f2; Wollensak G, 2004, CORNEA, V23, P503, DOI 10.1097/01.ico.0000105827.85025.7f; Wollensak G, 2003, J CATARACT REFR SURG, V29, P1786, DOI 10.1016/S0886-3350(03)00343-2; Wollensak G, 2003, J CATARACT REFR SURG, V29, P1780, DOI 10.1016/S0886-3350(03)00407-3; Wollensak G, 2003, AM J OPHTHALMOL, V135, P620, DOI 10.1016/S0002-9394(02)02220-1; Zhang HM, 2013, EXP EYE RES, V115, P255, DOI 10.1016/j.exer.2013.07.025	37	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2017	12	6							e0179580	10.1371/journal.pone.0179580	http://dx.doi.org/10.1371/journal.pone.0179580			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY7CO	28644862	gold, Green Submitted, Green Published			2023-01-03	WOS:000404145100024
J	Pasi, KJ; Rangarajan, S; Georgiev, P; Mant, T; Creagh, MD; Lissitchkov, T; Bevan, D; Austin, S; Hay, CR; Hegemann, I; Kazmi, R; Chowdary, P; Gercheva-Kyuchukova, L; Mamonov, V; Timofeeva, M; Soh, CH; Garg, P; Vaishnaw, A; Akinc, A; Sorensen, B; Ragni, MV				Pasi, K. J.; Rangarajan, S.; Georgiev, P.; Mant, T.; Creagh, M. D.; Lissitchkov, T.; Bevan, D.; Austin, S.; Hay, C. R.; Hegemann, I.; Kazmi, R.; Chowdary, P.; Gercheva-Kyuchukova, L.; Mamonov, V.; Timofeeva, M.; Soh, C. -H.; Garg, P.; Vaishnaw, A.; Akinc, A.; Sorensen, B.; Ragni, M. V.			Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONACOG BETA PEGOL; FACTOR-VIII; INHIBITOR DEVELOPMENT; THROMBIN GENERATION; CLINICAL-TRIALS; FACTOR-IX; PROPHYLAXIS; DEFICIENCY; HEMOSTASIS; CHILDREN	BACKGROUND Current hemophilia treatment involves frequent intravenous infusions of clotting factors, which is associated with variable hemostatic protection, a high treatment burden, and a risk of the development of inhibitory alloantibodies. Fitusiran, an investigational RNA interference (RNAi) therapy that targets antithrombin (encoded by SERPINC1), is in development to address these and other limitations. METHODS In this phase 1 dose-escalation study, we enrolled 4 healthy volunteers and 25 participants with moderate or severe hemophilia A or B who did not have inhibitory alloantibodies. Healthy volunteers received a single subcutaneous injection of fitusiran (at a dose of 0.03 mg per kilogram of body weight) or placebo. The participants with hemophilia received three injections of fitusiran administered either once weekly (at a dose of 0.015, 0.045, or 0.075 mg per kilogram) or once monthly (at a dose of 0.225, 0.45, 0.9, or 1.8 mg per kilogram or a fixed dose of 80 mg). The study objectives were to assess the pharmacokinetic and pharmacodynamic characteristics and safety of fitusiran. RESULTS No thromboembolic events were observed during the study. The most common adverse events were mild injection-site reactions. Plasma levels of fitusiran increased in a dose-dependent manner and showed no accumulation with repeated administration. The monthly regimen induced a dose-dependent mean maximum antithrombin reduction of 70 to 89% from baseline. A reduction in the antithrombin level of more than 75% from baseline resulted in median peak thrombin values at the lower end of the range observed in healthy participants. CONCLUSIONS Once-monthly subcutaneous administration of fitusiran resulted in dose-dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies. (Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT02035605.)	[Pasi, K. J.] Barts & London Queen Marys Sch Med & Dent, Royal London Haemophilia Ctr, London, England; [Mant, T.] NIHR, Biomed Res Ctr, London, England; [Bevan, D.] Kings Coll London, Guys & St Thomas NHS Fdn Trust, London, England; [Austin, S.] St Georges Healthcare NHS Trust Haemophilia Ctr, London, England; [Chowdary, P.] Royal Free Hosp London, London, England; [Rangarajan, S.] Hampshire Hosp NHS Fdn Trust, Haemophilia Haemostasis & Thrombosis Ctr, Basingstoke, Hants, England; [Mant, T.] Quintiles IMS, Reading, Berks, England; [Creagh, M. D.] Royal Cornwall Hosp NHS Trust, Truro, England; [Hay, C. R.] Manchester Royal Infirm, Manchester, Lancs, England; [Kazmi, R.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Georgiev, P.] Univ Multiprofile Hosp Act Treatment Sveti Georgi, Plovdiv, Bulgaria; [Georgiev, P.] Med Univ Plovdiv, Plovdiv, Bulgaria; [Lissitchkov, T.] Univ Hosp Hematol, Sofia, Bulgaria; [Gercheva-Kyuchukova, L.] Univ Hosp St Marina, Dept Hematol, Varna, Bulgaria; [Hegemann, I.] Univ Hosp Zurich, Zurich, Switzerland; [Mamonov, V.] Natl Res Ctr Hematol, Moscow, Russia; [Timofeeva, M.] Res Inst Hematol & Blood Transfus, Kirov, Russia; [Soh, C. -H.; Garg, P.; Vaishnaw, A.; Akinc, A.; Sorensen, B.] Alnylam Pharmaceut, Cambridge, MA USA; [Sorensen, B.] Codiak Biosci, Woburn, MA USA; [Ragni, M. V.] Univ Pittsburgh, Pittsburgh, PA USA; [Ragni, M. V.] Hemophilia Ctr Western Penn, Pittsburgh, PA USA	University of London; Queen Mary University London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; IQVIA; Royal Cornwall Hospital; University of Manchester; University of Southampton; University Hospital Southampton NHS Foundation Trust; Medical University Plovdiv; Medical University Varna; University of Zurich; University Zurich Hospital; Russian Academy of Medical Sciences; National Medical Research Center for Hematology; Kirov Research Institute of Hematology & Blood Transfusiology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pasi, KJ (corresponding author), Royal London Hosp, Haemophilia Ctr, London E1 1BB, England.	k.j.pasi@qmul.ac.uk	Gorodilova, Elena/H-3682-2017; Georgiev, Pencho/AAV-6464-2020; Chowdary, P/I-2623-2012	Gorodilova, Elena/0000-0002-5714-2785; Georgiev, Pencho/0000-0001-5677-6754; Chowdary, P/0000-0002-6690-8586; Rangarajan, Savita/0000-0001-7367-133X; Vettermann, Christian/0000-0003-3794-6441; Laffan, Michael/0000-0002-8268-3268	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT02035605.	Berntorp E, 2003, HAEMOPHILIA, V9, P1, DOI 10.1046/j.1365-2516.9.s1.17.x; Berntorp E, 2012, LANCET, V379, P1447, DOI 10.1016/S0140-6736(11)61139-2; Bolliger D, 2010, THROMB HAEMOSTASIS, V103, P1233, DOI 10.1160/TH09-10-0732; Bolton-Maggs PHB, 2003, LANCET, V361, P1801, DOI 10.1016/S0140-6736(03)13405-8; Dargaud Y, 2005, THROMB HAEMOSTASIS, V93, P475, DOI 10.1160/TH04-10-0706; den Uijl IEM, 2011, HAEMOPHILIA, V17, P41, DOI 10.1111/j.1365-2516.2010.02383.x; DiMichele D, 2007, BRIT J HAEMATOL, V138, P305, DOI 10.1111/j.1365-2141.2007.06657.x; Franchini M, 2009, SEMIN THROMB HEMOST, V35, P307, DOI 10.1055/s-0029-1222609; Ghosh K, 2001, HAEMOPHILIA, V7, P9, DOI 10.1046/j.1365-2516.2001.00455.x; Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752; Gouw SC, 2013, BLOOD, V121, P4046, DOI 10.1182/blood-2012-09-457036; Gringeri A, 2011, J THROMB HAEMOST, V9, P700, DOI 10.1111/j.1538-7836.2011.04214.x; Hemker HC, 2006, THROMB HAEMOSTASIS, V96, P553, DOI 10.1160/TH06-07-0408; Inglesby TV, 1999, HEPATOLOGY, V29, P590, DOI 10.1002/hep.510290219; Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; Mahdi AJ, 2015, BRIT J HAEMATOL, V169, P768, DOI 10.1111/bjh.13360; Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659; Negrier C, 2016, HAEMOPHILIA, V22, P507, DOI 10.1111/hae.12902; NEGRIER C, 1993, BLOOD, V81, P690; NILSSON IM, 1992, J INTERN MED, V232, P25, DOI 10.1111/j.1365-2796.1992.tb00546.x; Oh RC, 2011, AM FAM PHYSICIAN, V84, P1003; Peters RT, 2013, J THROMB HAEMOST, V11, P132, DOI 10.1111/jth.12076; Peyvandi F, 2016, J THROMB HAEMOST, V14, P2095, DOI 10.1111/jth.13491; Peyvandi F, 2016, LANCET, V388, P187, DOI 10.1016/S0140-6736(15)01123-X; Ryan SM, 2008, EXPERT OPIN DRUG DEL, V5, P371, DOI [10.1517/17425247.5.4.371, 10.1517/17425247.5.4.371 ]; Sehgal A, 2015, NAT MED, V21, P492, DOI 10.1038/nm.3847; Shetty S, 2007, BRIT J HAEMATOL, V138, P541, DOI 10.1111/j.1365-2141.2007.06693.x; Skinner MW, 2012, HAEMOPHILIA, V18, P1, DOI 10.1111/j.1365-2516.2012.02822.x; Srivastava A, 2013, HAEMOPHILIA, V19, pE1, DOI 10.1111/j.1365-2516.2012.02909.x; Young G, 2016, HAEMOPHILIA, V22, P25, DOI 10.1111/hae.13028; Young G, 2016, THROMB RES, V141, P69, DOI 10.1016/j.thromres.2016.02.030	32	578	604	13	94	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 31	2017	377	9					819	828		10.1056/NEJMoa1616569	http://dx.doi.org/10.1056/NEJMoa1616569			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF0YG	28691885	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000408626400005
J	Thompson, BT; Chambers, RC; Liu, KD				Thompson, B. Taylor; Chambers, Rachel C.; Liu, Kathleen D.			Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LUNG INJURY; ANGIOTENSIN-CONVERTING ENZYME-2; HIGH-FREQUENCY OSCILLATION; MECHANICAL VENTILATION; BERLIN DEFINITION; HYPOPROTEINEMIC PATIENTS; SARS CORONAVIRUS; CLINICAL-TRIAL; ARDS; PRESSURE	Fifty years ago, Ashbaugh and colleagues described 12 patients with tachypnea, refractory hypoxemia, and diffuse opacities on chest radiographs after infection or trauma.(1) Prominent hyaline membranes were seen lining the alveolar spaces of the lungs in 6 of the 7 patients who died, findings previously thought to be specific for the respiratory distress syndrome of the newborn. Thus, the term adult (later changed to acute) respiratory distress syndrome (ARDS) was proposed. Since ARDS was last reviewed in the Journal, 17 years ago,(2) substantial progress has been made in the care of affected patients and those at risk for the disorder, with reductions in both incidence and mortality. However, ARDS remains a relatively common and lethal or disabling syndrome. In a recent international study involving 29,144 patients,(3) 10% of all patients admitted to the intensive care unit (ICU) and 23% of mechanically ventilated patients had ARDS. Mortality in the subgroup of patients with severe ARDS was 46%. 3 Patients who survive this disorder are at high risk for cognitive decline, depression, post-traumatic stress disorder, and persistent skeletal-muscle weakness.(4,5)	[Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care, Bulfinch Bldg,Suite 148,55 Fruit St, Boston, MA 02114 USA; [Thompson, B. Taylor] Harvard Med Sch, Boston, MA USA; [Chambers, Rachel C.] UCL, Ctr Inflammat & Tissue Repair, London, England; [Chambers, Rachel C.] UCL, Div Med, London, England; [Liu, Kathleen D.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA; [Liu, Kathleen D.] Univ Calif San Francisco, Div Crit Care Med, San Francisco, CA 94143 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of London; University College London; University of London; University College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Thompson, BT (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care, Bulfinch Bldg,Suite 148,55 Fruit St, Boston, MA 02114 USA.	thompson.taylor@mgh.harvard.edu		Chambers, Rachel/0000-0003-1370-9417; Liu, Kathleen/0000-0003-4891-8649	Medical Research Council [G0800265] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; ASHBAUGH DG, 1967, LANCET, V2, P319; Aublanc M, 2017, CURR OPIN CRIT CARE, V23, P24, DOI 10.1097/MCC.0000000000000373; Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bellani G, 2009, CRIT CARE MED, V37, P2216, DOI 10.1097/CCM.0b013e3181aab31f; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Boyle AJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-166; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Christie JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028268; Eisner MD, 2001, AM J RESP CRIT CARE, V164, P231, DOI 10.1164/ajrccm.164.2.2011093; Esteban A, 2004, ANN INTERN MED, V141, P440, DOI 10.7326/0003-4819-141-6-200409210-00009; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gattinoni L, 2016, INTENS CARE MED, V42, P1567, DOI 10.1007/s00134-016-4505-2; Griffiths MJD, 2005, NEW ENGL J MED, V353, P2683, DOI 10.1056/NEJMra051884; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Herasevich V, 2009, INTENS CARE MED, V35, P1018, DOI 10.1007/s00134-009-1460-1; Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT; Huh D, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004249; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; KATZENSTEIN ALA, 1976, AM J PATHOL, V85, P210; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086; Martin GS, 2005, CRIT CARE MED, V33, P1681, DOI 10.1097/01.CCM.0000171539.47006.02; Martin GS, 2002, CRIT CARE MED, V30, P2175, DOI 10.1097/00003246-200210000-00001; Meade MO, 2017, AM J RESP CRIT CARE; Meyer NJ, 2017, LANCET RESP MED, V5, P512, DOI 10.1016/S2213-2600(17)30187-X; Meyer NJ, 2013, SEMIN RESP CRIT CARE, V34, P459, DOI 10.1055/s-0033-1351121; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC; Semler MW, 2016, CRIT CARE MED, V44, P782, DOI 10.1097/CCM.0000000000001555; Shortt K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111953; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Thille AW, 2013, AM J RESP CRIT CARE, V187, P761, DOI 10.1164/rccm.201211-1981OC; Thompson BT, 2016, INTENS CARE MED, V42, P653, DOI 10.1007/s00134-016-4296-5; Vaughan AE, 2015, NATURE, V517, P621, DOI 10.1038/nature14112; Villar J, 2016, CURR OPIN CRIT CARE, V22, P1, DOI 10.1097/MCC.0000000000000266; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wilson JG, 2015, LANCET RESP MED, V3, P24, DOI [10.1016/S2213-2600(14)70291-7, 10.1016/s2213-2600(14)70291-7]; Yadav H, 2017, AM J RESP CRIT CARE, V195, P725, DOI 10.1164/rccm.201609-1767CI; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716	63	829	889	12	204	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 10	2017	377	6					562	572		10.1056/NEJMra1608077	http://dx.doi.org/10.1056/NEJMra1608077			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD0EM	28792873				2023-01-03	WOS:000407212600009
